primaryid$caseid$caseversion$i_f_code$event_dt$mfr_dt$init_fda_dt$fda_dt$rept_cod$auth_num$mfr_num$mfr_sndr$lit_ref$age$age_cod$age_grp$sex$e_sub$wt$wt_cod$rept_dt$to_mfr$occp_cod$reporter_country$occr_country
100115733$10011573$3$F$20130801$20221118$20140314$20221123$EXP$$CA-MERCK-1403CAN005674$MERCK$$75$YR$$M$Y$58.05$KG$20221123$$HP$CA$CA
1002130537$10021305$37$F$20210415$20220928$20140319$20221005$EXP$$PHHY2014CA019281$NOVARTIS$$43$YR$$M$Y$$$20221005$$HP$CA$CA
100234223$10023422$3$F$20120301$20221003$20140320$20221007$EXP$$US-ROCHE-1362929$ROCHE$$67$YR$$F$Y$$$20221007$$LW$US$
100260594$10026059$4$F$20120101$20221124$20140320$20221130$EXP$DE-BFARM-13321363$DE-MYLANLABS-2014S1005326$MYLAN$$63$YR$$M$Y$88$KG$20221130$$HP$DE$DE
100518358$10051835$8$F$20130715$20221125$20140402$20221201$EXP$$CA-ROCHE-1247938$ROCHE$$50$YR$$F$Y$59$KG$20221201$$HP$CA$
100614443$10061444$3$F$$20221123$20140407$20221130$EXP$$EG-ROCHE-1372609$ROCHE$El-Dosouky I, ElHawari S, Emara M. and Hamed E. Types and predictors of interferon/ribavirin induced cardiac complications in the egyptian patients with chronic hepatitis c virus-Abs. no.P1107. Journal of Hepatology 2014 Apr;60 (SUPP 1):S446-7.$$$$$Y$$$20221130$$MD$EG$
1006401873$10064018$73$F$20121201$20221222$20140408$20221226$EXP$$CA-ROCHE-1173339$ROCHE$$71$YR$$F$Y$76$KG$20221226$$HP$CA$
100746869$10074686$9$F$20090714$20221222$20140414$20221230$EXP$$CA-ROCHE-1383185$ROCHE$$52$YR$$M$Y$$$20221230$$HP$CA$CA
100832487$10083248$7$F$20120201$20221108$20140417$20221116$EXP$$CA-ROCHE-1385175$ROCHE$$46$YR$$M$Y$$$20221116$$CN$CA$CA
100900002$10090000$2$F$20140101$20221021$20140421$20221027$EXP$$CA-JNJFOC-20140411796$JOHNSON AND JOHNSON$$54$YR$A$F$Y$57$KG$20221027$$HP$CA$CA
1009456310$10094563$10$F$20130101$20221004$20140422$20221011$PER$$US-PFIZER INC-2014108421$PFIZER$$46$YR$$F$Y$69$KG$20221011$$MD$US$US
101397357$10139735$7$F$20140101$20221008$20140429$20221012$EXP$$BR-SHIRE-BR201401513$TAKEDA$$16$YR$$M$Y$$$20221012$$HP$BR$BR
1014222242$10142222$42$F$20131201$20221216$20140430$20221221$EXP$$CA-ROCHE-1319269$ROCHE$$52$YR$$M$Y$88.2$KG$20221221$$MD$CA$
1015212328$10152123$28$F$20131205$20221115$20140505$20221123$EXP$$CA-ROCHE-1393055$ROCHE$$38$YR$$F$Y$110$KG$20221123$$CN$CA$CA
101530275$10153027$5$F$20131001$20220926$20140505$20221007$EXP$$US-ASTELLAS-2014US004619$ASTELLAS$$65$YR$$F$Y$$$20221007$$CN$US$US
1015648243$10156482$43$F$20121101$20221216$20140507$20221220$EXP$$CA-ROCHE-1162866$ROCHE$$65$YR$$F$Y$63.5$KG$20221220$$HP$CA$
1016133054$10161330$54$F$20120806$20221117$20140509$20221121$EXP$$CA-ROCHE-1113310$ROCHE$$66$YR$$F$Y$69$KG$20221121$$CN$CA$
1017572229$10175722$29$F$20121201$20221011$20140516$20221013$EXP$$CA-ROCHE-1176621$ROCHE$$65$YR$$F$Y$57$KG$20221013$$HP$CA$
101834686$10183468$6$F$20131216$20221003$20140520$20221004$EXP$$FR-SHIRE-ALL1-2014-01294$TAKEDA$$41$YR$$F$Y$61$KG$20221004$$CN$FR$FR
1020049437$10200494$37$F$20120801$20221227$20140528$20221229$EXP$$CA-ROCHE-1112151$ROCHE$$27$YR$$M$Y$80$KG$20221229$$HP$CA$
102151802$10215180$2$F$$20221031$20140603$20221102$EXP$$PHHY2014NL063730$NOVARTIS$Janssen S, Bergmans DCJJ, van Mook WNKA. Oxaliplatin induced multi organ failure: a condition intensivists should be aware of. NETH-J-CRIT-CARE. 2013;17(5):36$70$YR$$F$Y$$$20221102$$HP$NL$NL
102158494$10215849$4$F$20100101$20221130$20140604$20221207$PER$$US-AMGEN-USASP2014040911$AMGEN$$66$YR$E$F$Y$$$20221207$$CN$US$US
102184243$10218424$3$F$20121003$20221213$20140605$20221222$EXP$$FR-JNJFOC-20140600868$JOHNSON AND JOHNSON$$87$YR$E$M$Y$73$KG$20221222$$HP$FR$FR
1023164235$10231642$35$F$20120505$20221128$20140611$20221206$EXP$$PHHY2012CA036601$NOVARTIS$$55$YR$$F$Y$$$20221206$$HP$CA$CA
1023181918$10231819$18$F$20150818$20221109$20140612$20221117$EXP$$CA-ROCHE-1416720$ROCHE$$53$YR$$F$Y$$$20221117$$MD$CA$CA
1023233515$10232335$15$F$20130801$20221003$20140612$20221007$EXP$$PHHY2013CA066835$NOVARTIS$$72$YR$$M$Y$$$20221007$$HP$CA$CA
1023686418$10236864$18$F$20140101$20221007$20140613$20221011$EXP$$US-PFIZER INC-2014161083$PFIZER$$53$YR$$F$Y$$$20221011$$HP$US$US
102404993$10240499$3$F$20120723$20221003$20140617$20221006$EXP$$US-ROCHE-1418124$ROCHE$$61$YR$$F$Y$$$20221006$$LW$US$
1026087144$10260871$44$F$20120818$20221129$20140626$20221201$EXP$$CA-ROCHE-1131745$ROCHE$$57$YR$$F$Y$68$KG$20221201$$CN$CA$
102686218$10268621$8$F$20190319$20221109$20140630$20221111$EXP$$US-PFIZER INC-2014177544$PFIZER$$73$YR$$F$Y$$$20221111$$CN$US$US
1027487980$10274879$80$F$20151125$20221220$20140702$20221222$EXP$$CA-ROCHE-1404692$ROCHE$$46$YR$$M$Y$103$KG$20221222$$HP$CA$
1028518540$10285185$40$F$20140703$20221111$20140708$20221115$EXP$$CA-ROCHE-1267909$ROCHE$$49$YR$$F$Y$79$KG$20221115$$HP$CA$
102951214$10295121$4$F$$20211013$20140710$20221008$PER$$US-PURDUE-USA-2014-0113143$PURDUE$$$$$F$Y$$$20221008$$CN$US$US
1030948610$10309486$10$F$$20221014$20140717$20221121$EXP$$CA-ROCHE-1435384$ROCHE$$72$YR$$M$Y$$$20221121$$MD$CA$CA
103311375$10331137$5$F$20140714$20221103$20140722$20221202$EXP$$JP-AstraZeneca-2014SE52033$ASTRAZENECA$$21539$DY$$F$Y$71$KG$20221202$$MD$JP$
103343176$10334317$6$F$20140710$20221112$20140723$20221117$EXP$$PHHY2014IN087849$NOVARTIS$$35$YR$$F$Y$58$KG$20221117$$CN$IN$IN
103422754$10342275$4$F$$20221120$20140725$20221202$EXP$$FR-JNJFOC-20140709992$JOHNSON AND JOHNSON$$$$$$Y$$$20221202$$MD$FR$FR
103488627$10348862$7$F$20140710$20221205$20140729$20221216$EXP$$US-PFIZER INC-2014204200$PFIZER$$70$YR$$M$Y$90.7$KG$20221216$$MD$US$US
103613677$10361367$7$F$20130701$20221007$20140805$20221013$EXP$$US-ROCHE-1444666$ROCHE$$57$YR$$M$Y$85.352$KG$20221013$$MD$US$
103763213$10376321$3$F$20140523$20221111$20140811$20221121$EXP$SE-MPA-2014-004383$SE-PFIZER INC-2014219900$PFIZER$$91$YR$$F$Y$$$20221121$$MD$SE$SE
103830048$10383004$8$F$20140602$20221221$20140813$20221227$EXP$$US-SA-2014SA082625$SANOFI AVENTIS$$26$YR$A$F$Y$83.9$KG$20221227$$MD$US$US
1039251711$10392517$11$F$20170913$20221213$20140819$20221219$EXP$$PHHY2013AU123443$NOVARTIS$$63$YR$$M$Y$59.4$KG$20221219$$MD$AU$AU
103935282$10393528$2$F$$20221114$20140819$20221123$EXP$$ALCN2014AT004606$ALCON$Diesner SC, Bannert C, Gruber S, Dehlink E, Eiwegger T, Szepfalusi Z. The mydriaticum cyclopentolate induces severe allergy in a 5-year-old child. Klln Padiatr. 2014;226 (4):252-253$$$$$Y$$$20221123$$HP$AT$AT
1040513312$10405133$12$F$20110815$20221219$20140825$20221227$EXP$$CA-ROCHE-1454049$ROCHE$$56$YR$$F$Y$$$20221227$$CN$CA$CA
1041491122$10414911$22$F$20140217$20221117$20140828$20221130$EXP$$PHHY2012CA025137$NOVARTIS$$$$$F$Y$$$20221130$$HP$CA$CA
104249075$10424907$5$F$$20221012$20140902$20221018$PER$$US-JNJFOC-20140827232$JOHNSON AND JOHNSON$$18$YR$A$M$Y$$$20221018$$HP$US$US
104266825$10426682$5$F$20070101$20221107$20140903$20221117$PER$$US-JNJFOC-20140827260$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221117$$LW$US$US
1042881839$10428818$39$F$20140130$20221207$20140904$20221215$EXP$$CA-ROCHE-1457280$ROCHE$$54$YR$$F$Y$85$KG$20221215$$CN$CA$CA
104660044$10466004$4$F$20040423$20221222$20140922$20221227$EXP$$US-ROCHE-1464701$ROCHE$$51$YR$$F$Y$$$20221227$$LW$US$
1046886629$10468866$29$F$20120719$20221017$20140923$20221019$EXP$$CA-ROCHE-1101096$ROCHE$$33$YR$$F$Y$61$KG$20221019$$HP$CA$
104803045$10480304$5$F$20140908$20221004$20140929$20221010$EXP$$US-SHIRE-US201406146$TAKEDA$$52$YR$$F$Y$55.78$KG$20221010$$CN$US$US
1048329111$10483291$11$F$20150402$20221206$20140930$20221209$EXP$$CA-ROCHE-1467535$ROCHE$$52$YR$$F$Y$65$KG$20221209$$MD$CA$CA
1049624415$10496244$15$F$$20221111$20141003$20221117$EXP$$CA-009507513-1410CAN000297$MERCK$unknown. unknown. unknown$78$YR$$F$Y$$$20221117$$HP$CA$CA
105075462$10507546$2$F$$20221208$20141009$20221213$PER$$US-PFIZER INC-2014275038$PFIZER$$$$$F$Y$$$20221213$$CN$US$US
105099892$10509989$2$F$20130703$20221227$20141010$20221230$EXP$$RU-SHIRE-RU201406658$TAKEDA$$5$YR$$M$Y$$$20221230$$MD$RU$RU
105144242$10514424$2$F$20141002$20221115$20141013$20221121$EXP$$CA-JNJFOC-20141001651$JOHNSON AND JOHNSON$$37$YR$A$F$Y$62$KG$20221121$$HP$CA$CA
105154134$10515413$4$F$20120101$20221103$20141014$20221116$EXP$$FR-AUROBINDO-AUR-APL-2014-10735$AUROBINDO$Rabenkogo A, Vigue MG, Jeziorski E. Drug reaction with eosinophilia and systemic symptoms. Arch Pediatr. 2014$9$YR$$F$Y$$$20221116$$HP$FR$FR
1051596715$10515967$15$F$20131024$20221104$20141014$20221110$EXP$$PHHY2013CA024321$NOVARTIS$$70$YR$$M$Y$110.2$KG$20221110$$HP$CA$CA
105160162$10516016$2$F$$20221121$20141014$20221125$EXP$$PHHY2014SI129440$NOVARTIS$Kogoj A. Selective serotonin reuptake inhibitors-induced delirium: A case review. PSYCHIATRIA DANUBINA. 2014;26(3):277-80$86$YR$$M$Y$$$20221125$$HP$SI$SI
1052690053$10526900$53$F$20140701$20221103$20141020$20221107$EXP$$CA-ROCHE-1341517$ROCHE$$75$YR$$M$Y$78$KG$20221107$$CN$CA$
105323424$10532342$4$F$20140101$20221208$20141021$20221212$EXP$$US-PURDUE-USA-2014-0115432$PURDUE$$$$$F$Y$99.773$KG$20221212$$CN$US$US
1053322617$10533226$17$F$20180101$20221208$20141022$20221220$EXP$GB-MHRA-ADR 22718008$GB-Accord-026599$ACCORD$$66$YR$E$M$Y$98.97$KG$20221220$$PH$GB$GB
1054348110$10543481$10$F$20090101$20221014$20141027$20221020$EXP$$US-PFIZER INC-2014290373$PFIZER$$77$YR$$F$Y$59$KG$20221020$$CN$US$US
105559472$10555947$2$F$$20221003$20141030$20221010$EXP$$PHHY2014PL138837$NOVARTIS$Kusztal M, Piotrowski P, Mazanowska O, Misiak B, Kantorska-Janiec M, Boratynska M et al.. Catatonic episode after kidney transplantation. GENERAL HOSPITAL PSYCHIATRY. 2014;36(3):360e3-360e5$21$YR$$F$Y$$$20221010$$HP$PL$PL
105576044$10557604$4$F$$20221130$20141031$20221207$EXP$$CA-MALLINCKRODT-T201403798$SPECGX$$37$YR$$M$Y$122$KG$20221207$$HP$CA$CA
105636858$10563685$8$F$20140916$20161227$20141104$20221021$EXP$$JP-BAYER-2014-158276$BAYER$$55$YR$A$F$Y$64.5$KG$20221021$$MD$JP$JP
105701195$10570119$5$F$20130901$20221101$20141107$20221107$EXP$$CA-ROCHE-1159378$ROCHE$$67$YR$$F$Y$81$KG$20221107$$CN$CA$
105733332$10573333$2$F$$20221212$20141110$20221214$PER$$US-BAYER-2014-164943$BAYER$$$$$F$Y$$$20221214$$CN$US$US
105881184$10588118$4$F$20141106$20221109$20141117$20221114$EXP$$US-SHIRE-US201407776$TAKEDA$$53$YR$$F$Y$$$20221114$$CN$US$US
1058928655$10589286$55$F$20141101$20221018$20141118$20221025$EXP$$CA-ROCHE-1491350$ROCHE$$61$YR$$F$Y$$$20221026$$MD$CA$CA
105912134$10591213$4$F$20141001$20221212$20141118$20221216$EXP$$US-SHIRE-US201407553$TAKEDA$$9$YR$$M$Y$323$KG$20221216$$CN$US$US
105977282$10597728$2$F$20140801$20141113$20141121$20221123$PER$$US-AMGEN-USASP2014088321$AMGEN$$82$YR$E$F$Y$$$20221122$$CN$US$US
1060044427$10600444$27$F$$20221212$20141124$20221222$PER$$CA-AMGEN-CANSP2014090423$AMGEN$$51$YR$A$F$Y$110$KG$20221222$$HP$CA$CA
106022753$10602275$3$F$20131108$20221003$20141124$20221010$EXP$$JP-PFIZER INC-2014318472$PFIZER$Kikuchi, R.. A case of invasive thymoma complicated by tumour lysis syndrome by steroid pulse therapy. The 55th Meeting of the Japan Lung Cancer Society. 2014;54(5):606$72$YR$$F$Y$37$KG$20221010$$MD$JP$JP
106209603$10620960$3$F$$20221216$20141202$20221230$EXP$$DE-RANBAXY-2014RR-89307$RANBAXY$Koschny R, Lutz M, Seckinger J, Schwenger V, Stremmel W, Eisenbach C. Extracorporeal life support and plasmapheresis in a case of severe polyintoxication. J Emerg Med. 2014;47 (5):527-531$21$YR$$F$Y$$$20221230$$MD$DE$DE
1062481015$10624810$15$F$20120220$20221118$20141204$20221125$EXP$$CA-ROCHE-1325548$ROCHE$$15$YR$$M$Y$$$20221125$$CN$CA$CA
106335934$10633593$4$F$19970101$20221116$20141205$20221119$PER$$US-JNJFOC-20141119143$JOHNSON AND JOHNSON$$$$C$M$Y$$$20221119$$LW$US$US
1063710644$10637106$44$F$20140101$20221220$20141208$20221227$EXP$$CA-ROCHE-1504349$ROCHE$$68$YR$$F$Y$95.238$KG$20221227$$HP$CA$CA
106386833$10638683$3$F$20140807$20160413$20141208$20221109$EXP$$JP-BAYER-2014-177858$BAYER$$54$YR$A$M$Y$$$20221109$$MD$JP$JP
1064526734$10645267$34$F$20131231$20221122$20141211$20221124$EXP$$CA-ROCHE-1303094$ROCHE$$47$YR$$F$Y$76.5$KG$20221124$$CN$CA$
1065715210$10657152$10$F$20140701$20220929$20141217$20221001$EXP$$FR-MERCK-1412FRA007081$MERCK$Renard S. Severe Pulmonary Arterial Hypertension in Patients treated for Hepatitis C with Sofosbuvir. CHEST. 2016;149 (3):e69-e73$48$YR$$M$Y$$$20221001$$HP$FR$FR
1067454612$10674546$12$F$20110407$20221008$20141224$20221013$EXP$$FR-SHIRE-FR201409190$TAKEDA$$8$YR$$M$Y$$$20221013$$HP$FR$FR
1068446226$10684462$26$F$20140101$20221108$20141231$20221114$EXP$$PHHY2013CA109032$NOVARTIS$$$$$F$Y$$$20221114$$HP$CA$CA
106876194$10687619$4$F$20080101$20221117$20150102$20221122$EXP$$US-PFIZER INC-2014360643$PFIZER$$21$YR$$M$Y$57$KG$20221122$$CN$US$US
106893282$10689328$2$F$20130415$20220922$20150105$20221004$EXP$$SE-AUROBINDO-AUR-APL-2014-13513$AUROBINDO$$1$MON$$F$Y$$$20221004$$MD$SE$SE
1069613621$10696136$21$F$20140806$20221109$20150107$20221111$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2014-005629$BRISTOL MYERS SQUIBB$Watanabe R, et al. A case of fulminant type 1 diabetes mellitus developed in a patient after use of anti-PD-1 antibody. Folia Endocrinologica Japonica 2015;91(3):865.$74$YR$E$F$Y$42$KG$20221111$$MD$JP$JP
1069770312$10697703$12$F$20140701$20220929$20150108$20221004$EXP$$US-PFIZER INC-2015003827$PFIZER$$64$YR$$M$Y$99.79$KG$20221004$$CN$US$US
107025935$10702593$5$F$20080301$20221006$20150109$20221010$EXP$$CZ-009507513-1501CZE002662$MERCK$Demlova R, Melicharkova K, Rehal Z, Kren L, Oslejskova H, Sterba J et al. Successful use of metronomic vinblastine and fluorothymidine pet imaging for the management of intramedullary spinal cord anaplastic oligoastrocytoma in a child. Current Oncology. 2014;21(6):E790-3$11$YR$$F$Y$$$20221010$$MD$CZ$CZ
1071271830$10712718$30$F$20130916$20220923$20150115$20221001$EXP$$CA-ROCHE-1520634$ROCHE$$44$YR$$F$Y$$$20221001$$MD$CA$CA
107137505$10713750$5$F$20150612$20221206$20150115$20221209$EXP$$US-PFIZER INC-2015011167$PFIZER$$62$YR$$M$Y$113$KG$20221209$$CN$US$US
107330945$10733094$5$F$$20221007$20150123$20221017$EXP$$CA-PFIZER INC-2015026574$PFIZER$$$$$M$Y$$$20221017$$HP$CA$CA
1074197910$10741979$10$F$$20221212$20150127$20221216$EXP$$US-PFIZER INC-2015030234$PFIZER$$62$YR$$F$Y$83.91$KG$20221216$$HP$US$US
107480794$10748079$4$F$$20221201$20150129$20221205$PER$$US-PFIZER INC-2015033492$PFIZER$$62$YR$$F$Y$$$20221205$$MD$US$US
1076503413$10765034$13$F$20080101$20221212$20150205$20221216$EXP$$US-PFIZER INC-2015048780$PFIZER$$62$YR$$F$Y$43.09$KG$20221216$$CN$US$US
107718025$10771802$5$F$20141201$20221021$20150206$20221025$EXP$$PHHY2014CA163869$NOVARTIS$$52$YR$$F$Y$$$20221025$$CN$CA$CA
107770836$10777083$6$F$$20221228$20150209$20221230$PER$$US-PFIZER INC-2015050888$PFIZER$$66$YR$$F$Y$61.23$KG$20221230$$HP$US$US
107971742$10797174$2$F$20111215$20220929$20150216$20221006$EXP$$US-TEVA-483390USA$TEVA$$$$$F$Y$$$20221006$$LW$US$US
108306052$10830605$2$F$$20221202$20150219$20221213$PER$$US-009507513-1502USA004838$MERCK$$$$$F$Y$$$20221213$$MD$US$US
1086958425$10869584$25$F$20131105$20221107$20150226$20221116$EXP$$CA-ROCHE-1544517$ROCHE$$38$YR$$M$Y$65$KG$20221116$$CN$CA$CA
1087204326$10872043$26$F$20150201$20220321$20150226$20221202$EXP$$US-JAZZ-2015-US-002582$JAZZ$$44$YR$$F$Y$$$20221202$$CN$US$US
108720446$10872044$6$F$20140711$20221205$20150226$20221212$PER$$US-JAZZ-2014-US-009109$JAZZ$$61$YR$$M$Y$117.91$KG$20221212$$MD$US$US
108788105$10878810$5$F$20141205$20221220$20150302$20221222$EXP$$US-ABBVIE-15P-163-1352741-00$ABBVIE$$24$YR$$M$Y$$$20221222$$MD$US$US
1088003252$10880032$52$F$20080117$20221024$20150302$20221027$EXP$$PHMT2008CA00492$GLAXOSMITHKLINE$$$$$$Y$$$20221027$$MD$CA$CA
108809815$10880981$5$F$20150127$20221209$20150303$20221216$EXP$$US-PFIZER INC-2015073270$PFIZER$$63$YR$$F$Y$$$20221216$$CN$US$US
108820173$10882017$3$F$20150227$20221019$20150303$20221024$EXP$$CA-PFIZER INC-2015070868$PFIZER$$54$YR$$M$Y$$$20221024$$CN$CA$CA
109165036$10916503$6$F$19820101$20221109$20150311$20221123$EXP$$2015-0731-SPO$ASCEND$$53$YR$$F$Y$75$KG$20221123$$CN$FR$FR
109199792$10919979$2$F$20070101$20221222$20150317$20221227$EXP$$US-ROCHE-1551243$ROCHE$$$$$F$Y$$$20221227$$LW$US$
109325263$10932526$3$F$20130101$20221010$20150320$20221018$PER$$US-JNJFOC-20140814052$JOHNSON AND JOHNSON$$$$$M$Y$$$20221018$$LW$US$US
109337154$10933715$4$F$20030101$20221010$20150320$20221014$PER$$US-JNJFOC-20140814047$JOHNSON AND JOHNSON$$$$C$M$Y$$$20221014$$HP$US$US
109399493$10939949$3$F$20020101$20221012$20150322$20221018$PER$$US-JNJFOC-20140814026$JOHNSON AND JOHNSON$$$$$M$Y$107.6$KG$20221018$$HP$US$US
109436708$10943670$8$F$20041020$20221207$20150322$20221212$EXP$$US-JNJFOC-20141115580$JOHNSON AND JOHNSON$$8$YR$C$M$Y$$$20221212$$HP$US$US
109439923$10943992$3$F$20120205$20221222$20150323$20221228$EXP$$US-ROCHE-1554779$ROCHE$$71$YR$$F$Y$$$20221228$$LW$US$
109460695$10946069$5$F$$20221012$20150322$20221018$PER$$US-JNJFOC-20140814018$JOHNSON AND JOHNSON$$1$DEC$C$M$Y$$$20221018$$HP$US$US
109680228$10968022$8$F$20140307$20221213$20150330$20221219$EXP$$US-JAZZ-2014-US-002347$JAZZ$$56$YR$$M$Y$87.07$KG$20221219$$MD$US$US
109762043$10976204$3$F$20040601$20221019$20150401$20221027$EXP$$US-JNJFOC-20140414401$JOHNSON AND JOHNSON$$12$YR$T$M$Y$$$20221027$$LW$US$US
1098206351$10982063$51$F$20130101$20221221$20150403$20221225$EXP$$CA-ROCHE-1350337$ROCHE$$$$$F$Y$50$KG$20221226$$CN$CA$
109893398$10989339$8$F$20190114$20221129$20150406$20221202$EXP$$US-PFIZER INC-2015113764$PFIZER$$57$YR$$F$Y$113.4$KG$20221202$$CN$US$US
1099047554$10990475$54$F$20150312$20220928$20150406$20221004$EXP$$CA-ROCHE-1551832$ROCHE$$57$YR$$M$Y$84.6$KG$20221004$$HP$CA$
109912044$10991204$4$F$20010101$20221114$20150406$20221125$PER$$US-JNJFOC-20150403986$JOHNSON AND JOHNSON$$1$DEC$C$M$Y$$$20221125$$LW$US$US
1100310630$11003106$30$F$20141226$20221228$20150409$20221230$EXP$$PHHY2014CA170176$NOVARTIS$$61$YR$$M$Y$$$20221230$$HP$CA$CA
1101084316$11010843$16$F$20160708$20221123$20150410$20221130$EXP$$PHHY2014CA055951$NOVARTIS$$45$YR$$M$Y$$$20221130$$MD$CA$CA
110205884$11020588$4$F$$20221013$20150413$20221014$EXP$$CA-ROCHE-1562340$ROCHE$$90$YR$$F$Y$$$20221014$$HP$CA$
1102411311$11024113$11$F$20140101$20221018$20150413$20221025$EXP$$PHHY2014CA064714$NOVARTIS$$68$YR$$M$Y$$$20221025$$HP$CA$CA
110524756$11052475$6$F$$20220929$20150421$20221012$PER$$US-JNJFOC-20150322333$JOHNSON AND JOHNSON$$$$$M$Y$$$20221010$$LW$US$US
110534575$11053457$5$F$20130101$20221107$20150421$20221111$EXP$$US-JNJFOC-20141108721$JOHNSON AND JOHNSON$$24$YR$A$M$Y$$$20221111$$LW$US$US
110579242$11057924$2$F$$20221110$20150423$20221114$EXP$$CA-ROCHE-1567485$ROCHE$$24$YR$$M$Y$$$20221114$$HP$CA$
1106106422$11061064$22$F$$20221021$20150424$20221027$EXP$$CA-ROCHE-1566475$ROCHE$$69$YR$$F$Y$$$20221027$$CN$CA$
1106154321$11061543$21$F$20140101$20221006$20150424$20221018$EXP$$US-PFIZER INC-2015135782$PFIZER$$60$YR$$F$Y$$$20221018$$MD$US$US
1106955816$11069558$16$F$20211001$20220926$20150427$20221003$EXP$$BR-GLAXOSMITHKLINE INC.-BR2015GSK056220$GLAXOSMITHKLINE$$$$$$Y$$$20221003$$CN$BR$BR
1107001411$11070014$11$F$20131127$20221102$20150427$20221108$EXP$$PHHY2013CA139827$NOVARTIS$$64$YR$$F$Y$$$20221108$$HP$CA$CA
1107395118$11073951$18$F$20100703$20201231$20150429$20221004$EXP$$CA-ROCHE-1512211$ROCHE$$52$YR$$M$Y$$$20221004$$CN$CA$CA
1107519838$11075198$38$F$20150211$20221024$20150429$20221102$EXP$$CA-ROCHE-1570320$ROCHE$$43$YR$$F$Y$$$20221102$$CN$CA$CA
110758042$11075804$2$F$$20221114$20150429$20221123$EXP$$JP-ROCHE-1570432$ROCHE$Hoshida Y, Watanabe K, Eguchi G, et al A case of monoclonal-associated PML in patient suffering from duodenal DLBCL treated with rituximab.. Proceedings of The Japanese Society of Pathology 2015 Mar;104 (1):441-.$$$$M$Y$$$20221123$$MD$JP$
1107681228$11076812$28$F$20130122$20221114$20150429$20221118$EXP$$PHHY2013CA007723$NOVARTIS$$66$YR$$M$Y$$$20221118$$HP$CA$CA
1107775736$11077757$36$F$20150416$20221213$20150430$20221220$EXP$$CA-ROCHE-1570993$ROCHE$$67$YR$$F$Y$88.2$KG$20221220$$MD$CA$CA
1108647915$11086479$15$F$20150416$20221027$20150504$20221102$EXP$$CA-ROCHE-1571124$ROCHE$$66$YR$$M$Y$$$20221101$$HP$CA$CA
111092653$11109265$3$F$20060101$20221116$20150513$20221127$PER$$US-JNJFOC-20150506074$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221127$$LW$US$US
111172966$11117296$6$F$20130402$20221013$20150515$20221016$EXP$$PHHY2015AU058774$NOVARTIS$$50$YR$$M$Y$90$KG$20221017$$MD$AU$AU
111398754$11139875$4$F$20140101$20221214$20150527$20221220$PER$$US-PFIZER INC-2015165209$PFIZER$$55$YR$$F$Y$73$KG$20221220$$CN$US$US
111402683$11140268$3$F$$20221107$20150525$20221113$EXP$$US-JNJFOC-20150107078$JOHNSON AND JOHNSON$$31$YR$A$M$Y$$$20221114$$HP$US$US
111405024$11140502$4$F$20090326$20221213$20150525$20221221$PER$$US-JNJFOC-20141117511$JOHNSON AND JOHNSON$$13$YR$T$M$Y$$$20221222$$HP$US$US
111405234$11140523$4$F$20030101$20221108$20150525$20221110$PER$$US-JNJFOC-20140813995$JOHNSON AND JOHNSON$$$$C$M$Y$$$20221110$$HP$US$US
111411202$11141120$2$F$20030101$20221101$20150525$20221103$PER$$US-JNJFOC-20140814041$JOHNSON AND JOHNSON$$$$C$M$Y$$$20221103$$HP$US$US
111411382$11141138$2$F$$20221107$20150525$20221109$PER$$US-JNJFOC-20141001973$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221109$$LW$US$US
1115384211$11153842$11$F$20150901$20221212$20150602$20221220$PER$$CA-AMGEN-CANSP2015052272$AMGEN$$56$YR$A$F$Y$$$20221220$$HP$CA$CA
1115594135$11155941$35$F$20150505$20221006$20150602$20221018$EXP$$NL-SA-2015SA071357$SANOFI AVENTIS$$38$YR$A$F$Y$62$KG$20221018$$HP$NL$NL
1115851226$11158512$26$F$20150101$20221004$20150603$20221014$EXP$$CA-PFIZER INC-2015183008$PFIZER$$60$YR$$F$Y$97$KG$20221014$$CN$CA$CA
111665232$11166523$2$F$20060101$20221101$20150605$20221104$PER$$US-JNJFOC-20150511251$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221104$$LW$US$US
111665242$11166524$2$F$20030101$20221108$20150605$20221111$PER$$US-JNJFOC-20150511292$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221111$$HP$US$US
111666043$11166604$3$F$20100101$20221108$20150605$20221111$PER$$US-JNJFOC-20150511288$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221111$$HP$US$US
111666182$11166618$2$F$20110101$20221012$20150605$20221021$PER$$US-JNJFOC-20150511336$JOHNSON AND JOHNSON$$$$C$M$Y$$$20221021$$HP$US$US
111679973$11167997$3$F$20130620$20221222$20150605$20221227$EXP$$US-ROCHE-1589122$ROCHE$$66$YR$$F$Y$$$20221227$$LW$US$
1117339623$11173396$23$F$20130313$20221019$20150608$20221025$EXP$$PHHY2013CA025650$NOVARTIS$$40$YR$$M$Y$70$KG$20221025$$CN$CA$CA
111765028$11176502$8$F$20141203$20221011$20150610$20221014$EXP$$CA-ROCHE-1591119$ROCHE$$58$YR$$M$Y$128$KG$20221014$$MD$CA$CA
111770694$11177069$4$F$20071215$20220923$20150610$20221005$EXP$$US-ROCHE-1591609$ROCHE$$65$YR$$F$Y$$$20221005$$LW$US$
1117933919$11179339$19$F$$20221202$20150610$20221205$EXP$$CA-ROCHE-1590696$ROCHE$$72$YR$$F$Y$$$20221205$$MD$CA$
1118130018$11181300$18$F$20150122$20221101$20150611$20221107$EXP$$PHHY2015CA012543$NOVARTIS$$63$YR$$M$Y$$$20221107$$CN$CA$CA
1118855212$11188552$12$F$20121227$20221219$20150615$20221228$EXP$$CA-ROCHE-1593339$ROCHE$$62$YR$$F$Y$80$KG$20221228$$MD$CA$CA
1119006911$11190069$11$F$20211027$20221220$20150615$20221223$PER$$US-PFIZER INC-2015196944$PFIZER$$66$YR$$M$Y$$$20221223$$CN$US$US
111941595$11194159$5$F$20150101$20221103$20150616$20221108$EXP$$US-INCYTE CORPORATION-2015IN002663$INCYTE$$$$$$Y$$$20221108$$CN$US$US
111966503$11196650$3$F$$20221003$20150617$20221005$EXP$$US-PFIZER INC-2015198727$PFIZER$$60$YR$$M$Y$$$20221005$$CN$US$US
1119717612$11197176$12$F$20220628$20221025$20150617$20221103$PER$$US-SA-2014SA087746$SANOFI AVENTIS$$29$YR$A$F$Y$52.6$KG$20221103$$MD$US$US
1120064015$11200640$15$F$20150612$20221212$20150618$20221221$EXP$$CA-PFIZER INC-2015202903$PFIZER$$73$YR$$F$Y$$$20221221$$MD$CA$CA
1121096112$11210961$12$F$20150615$20221114$20150623$20221130$PER$$US-BIOMARINAP-US-2015-106664$BIOMARIN$$$$$$Y$$$20221130$$CN$US$US
1121119650$11211196$50$F$20150401$20221024$20150623$20221102$EXP$$CA-ROCHE-1597909$ROCHE$$62$YR$$F$Y$$$20221102$$CN$CA$CA
112113093$11211309$3$F$20150417$20221107$20150623$20221115$EXP$$CA-ROCHE-1597855$ROCHE$$55$YR$$M$Y$$$20221115$$MD$CA$CA
1121349812$11213498$12$F$20150612$20221212$20150623$20221220$PER$$CA-AMGEN-CANSP2015060003$AMGEN$$73$YR$E$F$Y$$$20221220$$HP$CA$CA
1121749410$11217494$10$F$20140717$20221129$20150625$20221206$EXP$$CA-ROCHE-1599129$ROCHE$$59$YR$$F$Y$126.4$KG$20221206$$MD$CA$CA
1123238628$11232386$28$F$20150602$20221121$20150701$20221122$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-041921$BRISTOL MYERS SQUIBB$Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 2017; 89: 1-8.$81$YR$E$M$Y$85$KG$20221122$$MD$JP$JP
1125764511$11257645$11$F$20140919$20221216$20150710$20221223$EXP$$CA-ROCHE-1605988$ROCHE$$38$YR$$F$Y$$$20221223$$CN$CA$CA
112598992$11259899$2$F$20141024$20201007$20150710$20221008$PER$$US-PURDUE-USA-2014-0118622$PURDUE$$0$YR$$F$Y$$$20221008$$CN$US$US
1126087925$11260879$25$F$20210101$20221221$20150710$20221226$EXP$$BR-GLAXOSMITHKLINE-BR2015GSK098504$GLAXOSMITHKLINE$$$$$$Y$$$20221226$$CN$BR$BR
112626725$11262672$5$F$20150612$20211130$20150710$20221008$PER$$US-PURDUE-USA-2015-0124254$PURDUE$$72$YR$$F$Y$$$20221008$$CN$US$US
112654706$11265470$6$F$20150201$20220930$20150713$20221006$EXP$$PT-ABBVIE-15K-130-1422289-00$ABBVIE$$38$YR$$F$Y$$$20221006$$CN$PT$PT
1127535214$11275352$14$F$20140101$20221031$20150716$20221104$EXP$$CA-ROCHE-1455724$ROCHE$$70$YR$$F$Y$$$20221104$$CN$CA$CA
1128678323$11286783$23$F$20150101$20221018$20150721$20221025$EXP$$PHHY2015CA083694$NOVARTIS$$$$$M$Y$$$20221025$$MD$CA$CA
1130269516$11302695$16$F$20150710$20221220$20150723$20221227$EXP$$CA-ROCHE-1612329$ROCHE$$71$YR$$M$Y$$$20221227$$MD$COUNTRY NOT SPECIFIED$CA
1131096039$11310960$39$F$20150914$20221228$20150726$20221230$EXP$$CA-ROCHE-1610105$ROCHE$$47$YR$$F$Y$54$KG$20221230$$HP$CA$
113145096$11314509$6$F$$20221227$20150727$20221229$PER$$US-PFIZER INC-2015237832$PFIZER$$53$YR$$F$Y$91$KG$20221229$$CN$US$US
113153994$11315399$4$F$$20221125$20150728$20221128$EXP$$CA-ROCHE-1611796$ROCHE$$46$YR$$F$Y$73$KG$20221129$$HP$CA$
1132353620$11323536$20$F$20111216$20221107$20150730$20221109$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2015JPN102901$VIIV$$$$$$Y$$$20221109$$MD$JP$JP
1132363620$11323636$20$F$20111216$20221107$20150730$20221109$EXP$$JP-GLAXOSMITHKLINE INC.-JP2015JPN102901$GLAXOSMITHKLINE$$$$$$Y$$$20221109$$MD$JP$JP
113262893$11326289$3$F$$20221123$20150731$20221129$EXP$$AU-Orion Corporation ORION PHARMA-TREX2015-0493$ORION$Watts M, Chan R. Survival versus a fatal outcome in two cases of Anncaliia algerae microsporidial myositis. Neuromuscular Disorders. 2012;22(9-10):855.$66$YR$E$M$Y$$$20221129$$MD$AU$
113276416$11327641$6$F$20140901$20221219$20150731$20221223$EXP$$CA-JNJFOC-20150719488$JOHNSON AND JOHNSON$$50$YR$A$F$Y$74$KG$20221223$$HP$CA$CA
1132997413$11329974$13$F$20121101$20221107$20150803$20221109$EXP$$JP-VIIV HEALTHCARE ULC-JP2015JPN107326$VIIV$$$$$$Y$$$20221109$$MD$JP$JP
1133067913$11330679$13$F$20121101$20221107$20150803$20221109$EXP$$JP-GLAXOSMITHKLINE-JP2015JPN107326$GLAXOSMITHKLINE$$$$$$Y$$$20221109$$MD$JP$JP
113365899$11336589$9$F$20150622$20221205$20150804$20221213$EXP$$IT-PFIZER INC-2015247986$PFIZER$$53$YR$$M$Y$65$KG$20221213$$MD$IT$IT
113624752$11362475$2$F$$20221024$20150810$20221031$EXP$$CA-GLAXOSMITHKLINE-CA2015GSK113983$GLAXOSMITHKLINE$$$$$$Y$$$20221031$$MD$CA$CA
113689332$11368933$2$F$20150101$20221202$20150812$20221207$PER$$US-AMGEN-USASL2015080477$AMGEN$$46$YR$A$F$Y$$$20221207$$CN$US$US
1137703937$11377039$37$F$20150727$20221115$20150813$20221123$EXP$$CO-INCYTE CORPORATION-2015IN003787$INCYTE$$$$$$Y$$$20221123$$CN$CO$CO
113827153$11382715$3$F$20150101$20221117$20150814$20221128$EXP$$US-JAZZ-2015-US-011803$JAZZ$$$$$M$Y$$$20221128$$MD$US$US
113868657$11386865$7$F$20140201$20221111$20150817$20221116$PER$$US-PFIZER INC-2015267334$PFIZER$$60$YR$$F$Y$67$KG$20221116$$CN$US$US
1138896010$11388960$10$F$20220912$20221129$20150817$20221201$EXP$$US-PFIZER INC-2015273572$PFIZER$$69$YR$$F$Y$73$KG$20221201$$CN$US$US
113986072$11398607$2$F$20150804$20221103$20150820$20221118$EXP$$IT-AUROBINDO-AUR-APL-2015-07365$AUROBINDO$$56$YR$$F$Y$$$20221118$$MD$IT$IT
1143790613$11437906$13$F$20150612$20221206$20150831$20221208$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-056744$BRISTOL MYERS SQUIBB$$73$YR$E$F$Y$$$20221208$$MD$CA$CA
1144906030$11449060$30$F$20150502$20220524$20150902$20221123$EXP$$GB-ROCHE-1588876$ROCHE$$43$YR$$F$Y$80.6$KG$20221123$$MD$GB$GB
1146495518$11464955$18$F$20150305$20221219$20150907$20221222$EXP$$CA-ROCHE-1520973$ROCHE$$32$YR$$F$Y$71$KG$20221222$$HP$CA$
1146542812$11465428$12$F$$20221012$20150907$20221013$EXP$$CA-ROCHE-1630210$ROCHE$$54$YR$$M$Y$$$20221013$$HP$CA$
114722818$11472281$8$F$$20221219$20150908$20221222$PER$$US-PFIZER INC-2015283708$PFIZER$$60$YR$$F$Y$90.703$KG$20221222$$CN$US$US
114761366$11476136$6$F$20150515$20221223$20150909$20221226$EXP$$JP-SHIRE-JP201511107AA$TAKEDA$$74$YR$$F$Y$43$KG$20221226$$CN$JP$JP
114854362$11485436$2$F$$20221212$20150909$20221220$EXP$$US-JAZZ-2015-US-000175$JAZZ$$$$$F$Y$$$20221220$$CN$US$US
114880832$11488083$2$F$20150201$20221209$20150909$20221213$EXP$$US-JAZZ-2015-US-003504$JAZZ$$31$YR$$F$Y$$$20221213$$MD$US$US
1149767216$11497672$16$F$$20221201$20150911$20221206$EXP$$CA-INCYTE CORPORATION-2013IN000165$INCYTE$$$$$$Y$$$20221206$$CN$CA$CA
1151945664$11519456$64$F$20150901$20221212$20150918$20221216$PER$$CA-AMGEN-CANSP2015095516$AMGEN$$43$YR$$F$Y$68$KG$20221216$$HP$CA$CA
1152525487$11525254$87$F$$20221220$20150918$20221229$EXP$$CA-PFIZER INC-2015308388$PFIZER$$43$YR$$F$Y$68$KG$20221229$$HP$CA$CA
1152988110$11529881$10$F$20110101$20221212$20150921$20221220$EXP$$CA-PFIZER INC-2015293041$PFIZER$$65$YR$$F$Y$$$20221220$$CN$CA$CA
1153197313$11531973$13$F$20150101$20221128$20150921$20221206$EXP$$CA-PFIZER INC-2015300302$PFIZER$$69$YR$$M$Y$$$20221206$$CN$CA$CA
115334828$11533482$8$F$20140101$20221201$20150921$20221207$EXP$$US-JAZZ-2015-US-013813$JAZZ$$$$$M$Y$$$20221207$$MD$US$US
115334852$11533485$2$F$$20221206$20150921$20221212$EXP$$US-JAZZ-2015-US-013887$JAZZ$$$$$F$Y$$$20221212$$CN$US$US
115411145$11541114$5$F$$20221006$20150923$20221010$PER$$US-PFIZER INC-2015065708$PFIZER$$71$YR$$F$Y$48$KG$20221010$$CN$US$US
115492603$11549260$3$F$20150623$20221216$20150924$20221223$EXP$$US-INCYTE CORPORATION-2015IN002988$INCYTE$$$$$$Y$$$20221223$$CN$US$US
115576017$11557601$7$F$20140121$20221207$20150926$20221212$EXP$$PHHY2013CA121592$NOVARTIS$$63$YR$$F$Y$$$20221212$$HP$CA$CA
1156506845$11565068$45$F$$20221128$20150928$20221201$EXP$$CA-009507513-1509CAN012569$MERCK$$$$$F$Y$97$KG$20221201$$HP$CA$CA
1157420921$11574209$21$F$20140325$20221019$20150930$20221027$EXP$$CA-ROCHE-1639907$ROCHE$$63$YR$$M$Y$89$KG$20221027$$CN$CA$CA
1157787011$11577870$11$F$20150918$20221220$20150930$20221227$EXP$$US-PFIZER INC-2015319862$PFIZER$$17$YR$$M$Y$78$KG$20221227$$CN$US$US
1158070937$11580709$37$F$$20221010$20150930$20221029$EXP$$CA-ABBVIE-15K-028-1471671-00$ABBVIE$$$$$F$Y$$$20221029$$HP$CA$CA
115952949$11595294$9$F$20130101$20221102$20151006$20221108$EXP$$CA-ROCHE-1641632$ROCHE$$49$YR$$M$Y$$$20221108$$CN$CA$CA
1159703019$11597030$19$F$20150801$20221201$20151006$20221208$EXP$$GB-ROCHE-1641219$ROCHE$$73$YR$$F$Y$$$20221208$$HP$GB$GB
115990327$11599032$7$F$$20221018$20151006$20221021$PER$$US-PFIZER INC-2015330789$PFIZER$$70$YR$$F$Y$54$KG$20221021$$CN$US$US
116141494$11614149$4$F$$20221129$20151008$20221205$EXP$$US-JAZZ-2014-US-010846$JAZZ$$$$$F$Y$$$20221205$$CN$US$US
1161812065$11618120$65$F$20150416$20221205$20151010$20221209$EXP$$PHHY2012CA016363$NOVARTIS$$63$YR$$F$Y$$$20221209$$HP$CA$CA
116313906$11631390$6$F$20180829$20221215$20151014$20221223$EXP$$CA-ROCHE-1645569$ROCHE$$50$YR$$F$Y$$$20221223$$MD$CA$CA
116356689$11635668$9$F$20151002$20221005$20151016$20221006$EXP$$US-PFIZER INC-2015341707$PFIZER$$63$YR$$F$Y$97.506$KG$20221006$$HP$US$US
1163606321$11636063$21$F$20151002$20221214$20151016$20221221$EXP$$CA-ROCHE-1646696$ROCHE$$20$YR$$M$Y$$$20221221$$MD$CA$CA
116372803$11637280$3$F$$20221109$20151016$20221112$EXP$$US-SHIRE-US201512542$TAKEDA$$$$$F$Y$$$20221112$$MD$US$US
116506392$11650639$2$F$$20150528$20151021$20221020$PER$$US-NOVOPROD-448531$NOVO NORDISK$$$$$M$Y$$$20221020$$CN$US$US
116592596$11659259$6$F$20150728$20221103$20151026$20221110$EXP$$CA-ROCHE-1648222$ROCHE$$66$YR$$F$Y$$$20221110$$MD$CA$
116612706$11661270$6$F$20150801$20221115$20151026$20221121$EXP$$CA-TAKEDA-2015TUS011190$TAKEDA$$56$YR$$F$Y$$$20221121$$MD$CA$CA
1166243427$11662434$27$F$20150728$20221209$20151027$20221221$EXP$$CA-ROCHE-1650800$ROCHE$$71$YR$$F$Y$$$20221221$$MD$CA$CA
1166352368$11663523$68$F$20151001$20221209$20151027$20221213$EXP$$CA-ROCHE-1649929$ROCHE$$41$YR$$F$Y$85$KG$20221213$$HP$CA$
1166544319$11665443$19$F$20151001$20221012$20151027$20221018$EXP$$US-PFIZER INC-2015356674$PFIZER$$42$YR$$F$Y$64.5$KG$20221018$$HP$US$US
1167242234$11672422$34$F$20151001$20221221$20151028$20221222$EXP$$PHHY2015CA117737$NOVARTIS$$74$YR$$F$Y$$$20221222$$HP$CA$CA
1168069212$11680692$12$F$20150722$20221202$20151029$20221212$EXP$$CA-ROCHE-1650806$ROCHE$$77$YR$$F$Y$$$20221212$$MD$CA$CA
116847947$11684794$7$F$20150101$20221205$20151029$20221207$EXP$$PHHY2015CA138225$NOVARTIS$$36$YR$$M$Y$$$20221207$$CN$CA$CA
116866658$11686665$8$F$20150101$20221122$20151030$20221124$EXP$$US-PFIZER INC-2015365254$PFIZER$$65$YR$$M$Y$$$20221124$$CN$US$US
116876935$11687693$5$F$20150501$20221021$20151030$20221103$EXP$FR-JNJFOC-20151015480$FR-JNJFOC-20151015480$JOHNSON AND JOHNSON$$25$YR$A$M$Y$58$KG$20221103$$MD$FR$FR
1168789254$11687892$54$F$20150101$20221031$20151030$20221107$EXP$$PHHY2015CA139740$NOVARTIS$$$$$F$Y$$$20221107$$CN$CA$CA
1168870915$11688709$15$F$20130101$20221114$20151102$20221123$EXP$$CA-ROCHE-1652828$ROCHE$$54$YR$$M$Y$106$KG$20221123$$MD$CA$CA
1169056711$11690567$11$F$$20221018$20151102$20221020$EXP$$US-PFIZER INC-2015371949$PFIZER$$70$YR$$F$Y$62$KG$20221020$$CN$US$US
1169227552$11692275$52$F$20151011$20221103$20151103$20221107$EXP$$CA-ROCHE-1653795$ROCHE$$45$YR$$F$Y$90$KG$20221107$$HP$CA$
1169545367$11695453$67$F$20150804$20221027$20151104$20221104$EXP$$PHHY2015CA100891$NOVARTIS$$68$YR$$M$Y$$$20221104$$MD$CA$CA
1169665432$11696654$32$F$20160928$20221220$20151104$20221223$EXP$$BR-GLAXOSMITHKLINE-BR2015GSK033029$GLAXOSMITHKLINE$$$$$$Y$$$20221223$$MD$BR$BR
117017308$11701730$8$F$20151020$20221117$20151105$20221121$EXP$$US-PFIZER INC-2015376270$PFIZER$$58$YR$$F$Y$$$20221121$$CN$US$US
117026999$11702699$9$F$20110101$20221209$20151105$20221216$EXP$$US-PFIZER INC-2015371915$PFIZER$$60$YR$$F$Y$54$KG$20221216$$CN$US$US
1171983620$11719836$20$F$20150801$20221124$20151110$20221202$EXP$$CA-ROCHE-1656679$ROCHE$$28$YR$$F$Y$$$20221202$$MD$CA$CA
1172654912$11726549$12$F$20130326$20221004$20151112$20221013$EXP$$CA-ROCHE-1659147$ROCHE$$73$YR$$M$Y$$$20221011$$MD$CA$CA
1172683929$11726839$29$F$20130913$20221201$20151112$20221209$EXP$$CA-ROCHE-1659165$ROCHE$$61$YR$$M$Y$$$20221209$$MD$CA$CA
117353303$11735330$3$F$20150829$20221006$20151113$20221010$EXP$$PHHO2015IE016349$NOVARTIS$$76$YR$$M$Y$85.3$KG$20221010$$MD$IE$IE
117401154$11740115$4$F$20100101$20221128$20151113$20221205$EXP$$US-JAZZ-2015-US-018836$JAZZ$$$$$F$Y$$$20221205$$MD$US$US
117430168$11743016$8$F$20150904$20221003$20151116$20221014$EXP$$CN-PFIZER INC-2015388713$PFIZER$$60$YR$$F$Y$80$KG$20221014$$MD$CN$CN
117431617$11743161$7$F$20140101$20221011$20151116$20221021$EXP$$US-ELI_LILLY_AND_COMPANY-US201511001495$ELI LILLY AND CO$$$$$M$Y$$$20221021$$CN$US$US
117474082$11747408$2$F$20150101$20220929$20151117$20221007$PER$$US-BAYER-2015-465878$BAYER$$60$YR$A$F$Y$$$20221007$$CN$US$US
1174958422$11749584$22$F$20130606$20221003$20151118$20221013$EXP$$CA-ROCHE-1660484$ROCHE$$63$YR$$F$Y$75$KG$20221011$$CN$CA$CA
117496992$11749699$2$F$20081120$20221102$20151118$20221108$EXP$$US-ROCHE-1661922$ROCHE$$48$YR$$F$Y$$$20221108$$MD$US$
117526432$11752643$2$F$$20221111$20151119$20221125$EXP$$US-MACLEODS PHARMACEUTICALS US LTD-MAC2015002161$MACLEODS$Hattab YA, Speredelozzi D, Bajwa O.. Rivaroxaban causing spontanuos splenic rupture.. American Journal of Respiratory and Critical Care Medicine.. 2015;191:A4632$$$$$Y$$$20221125$$MD$US$US
1175728427$11757284$27$F$20130805$20221019$20151120$20221025$EXP$$PHHY2013CA085930$NOVARTIS$$79$YR$$M$Y$$$20221025$$HP$CA$CA
117667363$11766736$3$F$20091004$20221102$20151123$20221108$EXP$$US-ROCHE-1661946$ROCHE$$58$YR$$F$Y$$$20221108$$MD$US$
1177184910$11771849$10$F$20151101$20221208$20151124$20221216$EXP$$US-PFIZER INC-2015398522$PFIZER$$72$YR$$F$Y$$$20221216$$CN$US$US
117749013$11774901$3$F$20130101$20211124$20151124$20221017$EXP$$US-JAZZ-2015-US-019706$JAZZ$$$$$M$Y$$$20221017$$MD$US$US
1178262525$11782625$25$F$20140201$20221122$20151127$20221129$EXP$$CA-ROCHE-1668392$ROCHE$$55$YR$$M$Y$78$KG$20221129$$MD$CA$CA
1178500220$11785002$20$F$20130429$20221109$20151130$20221114$EXP$$CA-ROCHE-1141931$ROCHE$$50$YR$$F$Y$106$KG$20221114$$CN$CA$
117862994$11786299$4$F$$20221006$20151130$20221019$EXP$$US-PFIZER INC-2015401364$PFIZER$Blair, P.. DRESS syndrome presenting after initiation of mycobacterium avium complex osteomyelitis treatment. BMJ Case Reports. 2015;10.1136/bcr-2015-210907$79$YR$$M$Y$$$20221019$$HP$US$US
117876837$11787683$7$F$20150101$20221205$20151130$20221212$EXP$$US-JAZZ-2015-US-020315$JAZZ$$$$$F$Y$$$20221212$$HP$US$US
1178812812$11788128$12$F$20141201$20221212$20151201$20221219$EXP$$CA-ROCHE-1513163$ROCHE$$61$YR$$M$Y$83.9$KG$20221219$$CN$CA$
1178896360$11788963$60$F$20151112$20221206$20151201$20221208$EXP$$PHHY2015CA151030$NOVARTIS$$61$YR$$F$Y$$$20221208$$HP$CA$CA
117915402$11791540$2$F$20151120$20221012$20151201$20221020$EXP$$JP-BAUSCH-BL-2015-028453$BAUSCH AND LOMB$$59$YR$$M$Y$$$20221020$$MD$JP$JP
117917868$11791786$8$F$$20221004$20151201$20221004$EXP$$US-PFIZER INC-2015398901$PFIZER$$56$YR$$F$Y$$$20221004$$CN$US$US
117931714$11793171$4$F$$20220926$20151202$20221003$EXP$$CA-GLAXOSMITHKLINE-CA2014GSK054940$GLAXOSMITHKLINE$$$$$$Y$$$20221003$$CN$CA$CA
118100073$11810007$3$F$20180803$20221027$20151208$20221104$EXP$$CA-ROCHE-1674514$ROCHE$$53$YR$$F$Y$$$20221104$$CN$CA$CA
118129063$11812906$3$F$$20220930$20151209$20221004$EXP$$BR-PFIZER INC-2015411022$PFIZER$$75$YR$$M$Y$67$KG$20221004$$CN$BR$BR
118172843$11817284$3$F$20080101$20221116$20151210$20221121$PER$$US-JNJFOC-20151111235$JOHNSON AND JOHNSON$$$$C$M$Y$$$20221122$$HP$US$US
118175423$11817542$3$F$20080101$20221205$20151210$20221208$PER$$US-JNJFOC-20151110244$JOHNSON AND JOHNSON$$1$DEC$C$M$Y$$$20221208$$LW$US$US
118179684$11817968$4$F$20130101$20221020$20151210$20221102$PER$$US-JNJFOC-20151108020$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221102$$HP$US$US
118181404$11818140$4$F$20040101$20221017$20151210$20221021$PER$$US-JNJFOC-20151106146$JOHNSON AND JOHNSON$$1$DEC$C$M$Y$$$20221021$$LW$US$US
118183087$11818308$7$F$20120101$20220922$20151210$20221003$PER$$US-JNJFOC-20151100778$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221003$$HP$US$US
118187334$11818733$4$F$20100101$20221031$20151210$20221108$PER$$US-JNJFOC-20151113973$JOHNSON AND JOHNSON$$3$DEC$A$M$Y$$$20221108$$HP$US$US
118192197$11819219$7$F$20080101$20221003$20151210$20221012$EXP$$US-JNJFOC-20151114373$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221010$$HP$US$US
118193373$11819337$3$F$20040101$20221221$20151210$20221227$PER$$US-JNJFOC-20150923152$JOHNSON AND JOHNSON$$1$DEC$C$M$Y$$$20221227$$LW$US$US
1182542956$11825429$56$F$20150101$20221109$20151211$20221112$EXP$$CA-ROCHE-1417303$ROCHE$$$$$F$Y$107$KG$20221112$$HP$CA$
1183072018$11830720$18$F$20151202$20221110$20151214$20221118$EXP$$CA-ROCHE-1676032$ROCHE$$61$YR$$F$Y$$$20221118$$MD$CA$CA
118317432$11831743$2$F$$20220927$20151214$20221011$EXP$$US-PFIZER INC-2015435456$PFIZER$Rafferty, E.. Allergy to multiple unrelated drugs containing FD+C no 2: The importance of excipients.. Annals of Allergy, Asthma and Immunology. 2015;115:5(1):A91$11$YR$$M$Y$$$20221011$$HP$US$US
118376622$11837662$2$F$20151123$20220927$20151215$20221003$EXP$$DE-009507513-1512DEU001161$MERCK$$63$YR$$F$Y$$$20221003$$MD$DE$DE
118462142$11846214$2$F$20150801$20221208$20151217$20221212$EXP$DE-BOEHRINGER INGELHEIM GMBH, GERMANY-2015-BI-66253DE$DE-B.I. Pharmaceuticals,Inc./Ridgefield-2015-BI-66253DE$BOEHRINGER INGELHEIM$$97$YR$E$F$Y$49$KG$20221212$$PH$DE$DE
118480743$11848074$3$F$20160801$20221228$20151217$20221230$EXP$$US-JAZZ-2015-US-021584$JAZZ$$25$YR$$M$Y$$$20221230$$MD$US$US
1185237311$11852373$11$F$20150812$20221006$20151218$20221012$EXP$$FR-GILEAD-2015-0186154$GILEAD$$51$YR$A$M$Y$57$KG$20221012$$MD$FR$FR
118587596$11858759$6$F$$20220919$20151222$20221001$EXP$$CA-AUROBINDO-AUR-APL-2015-11455$AUROBINDO$Ashley M. Yu, BHSc and Joel G. DeKoven, MD, MHSc, FRCPC. Occupational Airborne Contact Dermatitis From Proton Pump Inhibitors. Dermatitis. 2015;26 (6):287-90$58$YR$$M$Y$$$20221001$$MD$CA$CA
1186359518$11863595$18$F$20140101$20221021$20151223$20221028$EXP$$PHHY2014CA154360$NOVARTIS$$$$$F$Y$$$20221028$$HP$CA$CA
118696776$11869677$6$F$20150423$20170515$20151228$20221108$EXP$$JP-ROCHE-1660326$ROCHE$Yamazaki O, Tachikawa S, Yamazaki O, Kono J. Skin Disorder Which Developed after Treatment for Advanced Malignant Melanoma Was Switched from Nivolumab to Vemurafenib (Abstract 72-O ). Journal of Environmental Dermatology and Cutaneous Allergology /; Abstracts of the 45th Annual Meeting of the Japanese Society for Dermatoallergology and Contact Dermatitis 2015 Nov;9 (5):452-.$62$YR$$F$Y$46$KG$20221108$$MD$JP$JP
1187110917$11871109$17$F$20141224$20221020$20151228$20221025$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2015JPN180189$VIIV$$$$$$Y$$$20221025$$MD$JP$JP
118782398$11878239$8$F$20151119$20221028$20151230$20221101$EXP$$PHHY2015CA154224$NOVARTIS$$48$YR$$F$Y$$$20221101$$MD$CA$CA
118804154$11880415$4$F$20150909$20221222$20151230$20221223$EXP$$CA-TAKEDA-2015TUS018178$TAKEDA$$59$YR$$F$Y$$$20221223$$CN$CA$CA
118876006$11887600$6$F$20211026$20221211$20160105$20221224$EXP$$GB-AUROBINDO-AUR-APL-2015-11984$AUROBINDO$Jessica Head. A 12-year-old Bella Donna. Archives of Disease in Childhood,. Education and Practice Edition. 2014;99 (5):173-80$12$YR$$F$Y$$$20221224$$MD$GB$GB
118951176$11895117$6$F$20170101$20221201$20160107$20221208$EXP$$US-PFIZER INC-2015442538$PFIZER$$41$YR$$M$Y$113$KG$20221208$$CN$US$US
119053443$11905344$3$F$20120301$20221012$20160109$20221020$PER$$US-JNJFOC-20151222368$JOHNSON AND JOHNSON$$16$YR$T$M$Y$$$20221020$$LW$US$US
119054788$11905478$8$F$$20221221$20160109$20221226$PER$$US-JNJFOC-20151222369$JOHNSON AND JOHNSON$$$$$M$Y$$$20221226$$LW$US$US
1191259921$11912599$21$F$20150101$20210331$20160113$20221214$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-093211$BRISTOL MYERS SQUIBB$$61$YR$A$F$Y$$$20221214$$HP$CA$CA
1191791312$11917913$12$F$20140101$20221208$20160114$20221215$PER$$US-PFIZER INC-2016015258$PFIZER$$46$YR$$F$Y$73$KG$20221215$$CN$US$US
1193375733$11933757$33$F$20140806$20221215$20160121$20221219$EXP$$CA-ROCHE-1434589$ROCHE$$73$YR$$F$Y$87$KG$20221219$$HP$CA$
119338252$11933825$2$F$$20221012$20160121$20221014$EXP$$US-SHIRE-US201600378$TAKEDA$$$$$M$Y$$$20221014$$CN$US$US
1193535521$11935355$21$F$20150401$20221219$20160121$20221223$EXP$$US-PFIZER INC-2016017803$PFIZER$$74$YR$$M$Y$124$KG$20221223$$CN$US$US
1193793114$11937931$14$F$20160217$20221129$20160122$20221206$EXP$$CA-ROCHE-1698822$ROCHE$$42$YR$$M$Y$$$20221206$$HP$CA$CA
119538505$11953850$5$F$20161225$20221114$20160126$20221116$PER$$US-PFIZER INC-2015476213$PFIZER$$41$YR$$F$Y$$$20221116$$HP$US$US
119539343$11953934$3$F$$20221107$20160125$20221107$PER$$US-BIOGEN-2016BI00173051$BIOGEN$$$$$F$Y$$$20221107$$CN$US$US
1196876532$11968765$32$F$20141208$20221212$20160128$20221214$EXP$$CA-ROCHE-1219752$ROCHE$$40$YR$$M$Y$67$KG$20221214$$MD$CA$
119760027$11976002$7$F$20120319$20221026$20160129$20221104$EXP$$CA-ROCHE-1132487$ROCHE$$39$YR$$F$Y$77$KG$20221104$$HP$CA$
119768444$11976844$4$F$$20221018$20160129$20221021$PER$$US-BIOGEN-2016BI00177407$BIOGEN$$$$$M$Y$$$20221021$$CN$US$US
1199484817$11994848$17$F$20151201$20220930$20160203$20221007$EXP$$GB-ROCHE-1677596$ROCHE$$69$YR$$F$Y$$$20221007$$MD$GB$GB
1203751634$12037516$34$F$20150601$20221031$20160208$20221103$EXP$$PHHY2015CA076388$NOVARTIS$$65$YR$$F$Y$$$20221103$$HP$CA$CA
120375559$12037555$9$F$20151224$20221019$20160208$20221031$EXP$$PHHY2016CO015670$NOVARTIS$$38$YR$$F$Y$55$KG$20221031$$CN$CO$CO
1204027945$12040279$45$F$20201127$20221104$20160208$20221108$EXP$$BR-GLAXOSMITHKLINE-BR2015GSK160212$GLAXOSMITHKLINE$$$$$$Y$$$20221108$$MD$BR$BR
120510172$12051017$2$F$20140305$20220913$20160208$20221001$PER$$US-ABBVIE-15P-163-1392790-00$ABBVIE$$45$YR$$F$Y$$$20221001$$HP$US$US
120685052$12068505$2$F$$20221208$20160211$20221213$PER$$US-BIOGEN-2016BI00179440$BIOGEN$$$$$F$Y$$$20221213$$CN$US$US
120723023$12072302$3$F$20090101$20221222$20160212$20221229$EXP$$PHHY2016CR018492$NOVARTIS$$$$$M$Y$$$20221229$$CN$CR$CR
1207531612$12075316$12$F$$20221026$20160212$20221110$EXP$$CA-AUROBINDO-AUR-APL-2016-01463$AUROBINDO$Abidi S, Ursuliak Z, Morrison J, Teehan MD, Tibbo PG, Gardner DM.. Incidence of oculogyric crisis and long-term outcomes with second-generation antipsychotics in a first-episode psychosis program. Journal of Clinical Psychopharmacology. 2015;35(6):715-718$22$YR$$F$Y$$$20221110$$MD$CA$CA
1207853042$12078530$42$F$20150101$20221123$20160216$20221129$EXP$$CA-ROCHE-1711280$ROCHE$$46$YR$$F$Y$$$20221129$$MD$CA$CA
1207965615$12079656$15$F$$20221207$20160216$20221212$EXP$$US-PFIZER INC-2016088306$PFIZER$$62$YR$$F$Y$$$20221212$$HP$US$US
120822789$12082278$9$F$20121205$20221124$20160217$20221128$EXP$$CA-ROCHE-1177020$ROCHE$$54$YR$$F$Y$53$KG$20221128$$CN$CA$
1208261920$12082619$20$F$$20221222$20160217$20221230$EXP$$GB-drreddys-GER/UKI/12/0025687$DR REDDYS$$15$YR$T$F$Y$$$20221230$$MD$GB$GB
120847822$12084782$2$F$$20221006$20160217$20221018$EXP$$DE-PFIZER INC-2016091452$PFIZER$Barthel, D.. Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics. Journal of Rheumatology. 2015;42 (11):2160-2165$17$YR$$F$Y$$$20221018$$MD$DE$DE
120858434$12085843$4$F$20150801$20221024$20160217$20221030$EXP$$BR-BIOGEN-2016BI00190635$BIOGEN$$30$YR$$F$Y$62$KG$20221030$$HP$BR$BR
120914922$12091492$2$F$$20221006$20160218$20221018$EXP$$DE-PFIZER INC-2016091453$PFIZER$Barthel, D.. Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics. Journal of Rheumatology. 2015;42 (11):2160-2165$17$YR$$M$Y$$$20221018$$MD$DE$DE
120968074$12096807$4$F$20140101$20221012$20160220$20221020$EXP$$US-ACORDA-ACO_108922_2015$ACORDA$$$$$F$Y$$$20221020$$MD$US$US
121037492$12103749$2$F$20221212$20221212$20160223$20221215$PER$$US-BIOGEN-2016BI00190216$BIOGEN$$53$YR$$F$Y$$$20221215$$CN$US$US
1211751215$12117512$15$F$20151002$20221130$20160225$20221208$EXP$$CA-ROCHE-1716708$ROCHE$$35$YR$$F$Y$$$20221208$$MD$CA$CA
121182282$12118228$2$F$$20221213$20160226$20221222$PER$$US-AMGEN-USASL2016021584$AMGEN$$55$YR$A$F$Y$$$20221222$$CN$US$US
121210476$12121047$6$F$$20221208$20160226$20221215$PER$$US-PFIZER INC-2016060858$PFIZER$$39$YR$$F$Y$$$20221215$$CN$US$US
1212230538$12122305$38$F$20151219$20221011$20160226$20221014$EXP$$PHHY2015CA172640$NOVARTIS$$61$YR$$F$Y$$$20221014$$CN$CA$CA
121249903$12124990$3$F$20150101$20220930$20160229$20221010$PER$$US-AMGEN-USASL2016023986$AMGEN$$45$YR$A$F$Y$$$20221009$$CN$US$US
121262314$12126231$4$F$20150814$20221025$20160229$20221103$EXP$$CA-009507513-1602CAN010951$MERCK$$47$YR$$F$Y$$$20221103$$PH$CA$CA
121275712$12127571$2$F$$20221221$20160229$20221229$EXP$GB-MHRA-ADR 23357992$GB-PERRIGO-16GB001878$PERRIGO$$$$$$Y$$$20221229$$HP$GB$GB
121283862$12128386$2$F$$20221221$20160229$20221227$EXP$$US-JAZZ-2016-US-003401$JAZZ$$$$$F$Y$$$20221227$$CN$US$US
1213337524$12133375$24$F$$20221212$20160301$20221220$PER$$CA-AMGEN-CANSP2016018438$AMGEN$$65$YR$E$F$Y$$$20221220$$HP$CA$CA
121336525$12133652$5$F$$20221222$20160301$20221229$EXP$GB-MHRA-ADR 23357992$PHHY2016GB024615$NOVARTIS$$4$MON$$$Y$$$20221229$$MD$GB$GB
1213390062$12133900$62$F$20141010$20220924$20160301$20221003$EXP$$CA-ROCHE-1474767$ROCHE$$49$YR$$M$Y$70$KG$20221003$$HP$CA$
121379633$12137963$3$F$$20221215$20160302$20221220$EXP$$GB-AstraZeneca-2016SE19198$ASTRAZENECA$$20$WK$$$Y$$$20221219$$MD$GB$
121389339$12138933$9$F$$20221128$20160302$20221130$EXP$$US-PFIZER INC-2016132391$PFIZER$$68$YR$$F$Y$48$KG$20221130$$CN$US$US
1213946921$12139469$21$F$20121119$20221021$20160303$20221027$EXP$$CA-ROCHE-1162790$ROCHE$$43$YR$$F$Y$63$KG$20221027$$HP$CA$
121453152$12145315$2$F$20151116$20220916$20160304$20221109$EXP$$PHHY2016CA028172$NOVARTIS$$40$YR$$F$Y$$$20221109$$MD$CA$CA
1214630877$12146308$77$F$$20221212$20160304$20221227$EXP$$CA-PFIZER INC-2016130747$PFIZER$$63$YR$$F$Y$$$20221227$$MD$CA$CA
121474823$12147482$3$F$$20221025$20160304$20221031$EXP$$CA-GLAXOSMITHKLINE-CA2016GSK029540$GLAXOSMITHKLINE$$$$$$Y$$$20221031$$PH$CA$CA
121480403$12148040$3$F$20160101$20221005$20160304$20221007$EXP$$CA-TAKEDA-2016TUS003625$TAKEDA$$42$YR$$F$Y$$$20221007$$CN$CA$CA
121532082$12153208$2$F$$20221028$20160305$20221101$PER$$US-BIOGEN-2016BI00194396$BIOGEN$$$$$F$Y$$$20221101$$CN$US$US
121591643$12159164$3$F$$20221130$20160308$20221209$EXP$GB-MHRA-ADR 23357992$GB-APOTEX-2016AP006943$APOTEX$$$$N$$Y$$$20221209$$MD$GB$GB
121611666$12161166$6$F$$20220929$20160308$20221101$EXP$$CA-ABBVIE-10P-163-0641882-00$ABBVIE$$52$YR$$M$Y$$$20221101$$HP$CA$CA
121699232$12169923$2$F$$20221118$20160310$20221123$PER$$PHEH2016US005763$NOVARTIS$Kim S, Chen L, Hebert A, Slopis J, Koenig MK, Patel A. Erythema nodosum in the setting of everolimus use. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2016;AB98$35$YR$$F$Y$$$20221123$$HP$US$US
121701502$12170150$2$F$$20221118$20160311$20221123$PER$$PHEH2016US005686$NOVARTIS$Kim S, Chen L, Hebert A, Slopis J, Koenig MK, Patel A. Erythema nodosum in the setting of everolimus use. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2016;AB98$25$YR$$M$Y$$$20221123$$HP$US$US
1217131112$12171311$12$F$20160101$20221111$20160311$20221114$PER$$US-PFIZER INC-2016108785$PFIZER$$79$YR$$F$Y$73$KG$20221114$$HP$US$US
121758873$12175887$3$F$20150805$20221013$20160314$20221020$EXP$$US-BIOGEN-2015BI154964$BIOGEN$$42$YR$$F$Y$$$20221020$$MD$US$US
121804805$12180480$5$F$$20221003$20160315$20221007$EXP$$GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-016441$BRISTOL MYERS SQUIBB$$84$YR$E$F$Y$$$20221007$$CN$GB$GB
121826693$12182669$3$F$20131012$20221003$20160316$20221006$EXP$$AT-SHIRE-AT201603091$TAKEDA$$68$YR$$M$Y$$$20221006$$MD$AT$AT
121860583$12186058$3$F$$20221130$20160317$20221208$EXP$$JP-ROCHE-1726721$ROCHE$PRIVACY P, Sato K, Sumi M, Kaiume H, Ueki T, Hiroshima Y, Kobayashi H et al Perforated upper gastrointestinal ulcers potentially attributable to mycophenolate mofetil after allogeneic hematopoietic stem cell transplantation. The Japanese Journal of Clinical Hematology 2022;63(10):1402-1408.$46$YR$$M$Y$$$20221208$$MD$JP$JP
1218664123$12186641$23$F$20151201$20221221$20160317$20221228$EXP$$CA-ROCHE-1727203$ROCHE$$11$YR$$F$Y$$$20221228$$MD$CA$CA
121984753$12198475$3$F$20120101$20220926$20160322$20221006$PER$$US-JNJFOC-20160308491$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221006$$LW$US$US
122091106$12209110$6$F$20151201$20221121$20160324$20221125$EXP$$DE-ABBVIE-16K-062-1589815-00$ABBVIE$$60$YR$$M$Y$$$20221125$$MD$DE$DE
1222015118$12220151$18$F$20151020$20221207$20160330$20221214$EXP$$CA-ROCHE-1546279$ROCHE$$60$YR$$M$Y$105$KG$20221214$$HP$CA$
122306663$12230666$3$F$$20221222$20160401$20221229$EXP$$CA-BAXTER-2016BAX016268$BAXTER$$27$YR$$F$Y$$$20221229$$HP$CA$CA
1223243925$12232439$25$F$20160101$20221012$20160401$20221017$EXP$$CA-TAKEDA-2016TUS005281$TAKEDA$$60$YR$$F$Y$$$20221017$$HP$CA$CA
1223244413$12232444$13$F$$20221214$20160401$20221222$PER$$US-PFIZER INC-2016186718$PFIZER$$21$YR$$M$Y$77.11$KG$20221222$$MD$US$US
1223270414$12232704$14$F$20150827$20221118$20160401$20221124$EXP$$CA-TAKEDA-2016TUS004214$TAKEDA$$54$YR$$F$Y$$$20221124$$CN$CA$CA
122367384$12236738$4$F$$20221213$20160405$20221226$EXP$$GB-AUROBINDO-AUR-APL-2016-02203$AUROBINDO$$20$WK$$$Y$$$20221226$$MD$GB$GB
122422523$12242252$3$F$20150825$20190902$20160406$20221017$EXP$$JP-JNJFOC-20150904854$JOHNSON AND JOHNSON$$68$YR$E$F$Y$52$KG$20221017$$MD$JP$JP
122426543$12242654$3$F$20160323$20221107$20160406$20221115$EXP$$US-BIOGEN-2016BI00213721$BIOGEN$$64$YR$$F$Y$$$20221115$$CN$US$US
1224266314$12242663$14$F$20081101$20221118$20160406$20221123$EXP$$US-PFIZER INC-2016015358$PFIZER$$58$YR$$F$Y$81$KG$20221123$$HP$US$US
1224450765$12244507$65$F$20120901$20221220$20160407$20221222$EXP$$CA-ROCHE-1132730$ROCHE$$66$YR$$F$Y$61$KG$20221222$$HP$CA$
122454192$12245419$2$F$20160318$20221014$20160407$20221017$PER$$US-BIOGEN-2016BI00212652$BIOGEN$$67$YR$$F$Y$$$20221017$$CN$US$US
122653124$12265312$4$F$20160301$20221107$20160413$20221110$EXP$$US-SHIRE-US201604300$TAKEDA$$8$YR$$M$Y$22.676$KG$20221110$$CN$US$US
122657786$12265778$6$F$$20221214$20160413$20221221$EXP$$CA-BAXALTA-2016BLT002214$TAKEDA$$27$YR$$F$Y$$$20221221$$HP$CA$CA
122801899$12280189$9$F$20141111$20221113$20160419$20221121$EXP$$CA-ROCHE-1742724$ROCHE$$48$YR$$F$Y$$$20221121$$MD$CA$CA
122808493$12280849$3$F$20160122$20220920$20160419$20221004$EXP$$SE-AUROBINDO-AUR-APL-2016-04852$AUROBINDO$$33$YR$$F$Y$$$20221004$$MD$SE$SE
1228955324$12289553$24$F$20140101$20221213$20160421$20221219$EXP$$PHHY2014CA116710$NOVARTIS$$67$YR$$F$Y$77.098$KG$20221219$$CN$CA$CA
1229013121$12290131$21$F$20210101$20220930$20160421$20221004$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK011740$GLAXOSMITHKLINE$$$$$$Y$$$20221004$$CN$BR$BR
1229416317$12294163$17$F$20121120$20221213$20160422$20221220$EXP$$CA-ROCHE-1745200$ROCHE$$41$YR$$M$Y$122.7$KG$20221220$$CN$CA$CA
123033222$12303322$2$F$$20220926$20160426$20221003$PER$$US-JNJFOC-20160406141$JOHNSON AND JOHNSON$$$$$M$Y$$$20221003$$LW$US$US
123033787$12303378$7$F$20090203$20220929$20160426$20221012$PER$$US-JNJFOC-20160402019$JOHNSON AND JOHNSON$$7$YR$C$M$Y$25.424$KG$20221012$$HP$US$US
123040763$12304076$3$F$20030316$20221116$20160426$20221125$PER$$US-JNJFOC-20160412153$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221125$$HP$US$US
1230456623$12304566$23$F$20150701$20221118$20160426$20221123$EXP$$PHHY2016CA055639$NOVARTIS$$55$YR$$F$Y$$$20221123$$MD$CA$CA
1230619210$12306192$10$F$20160701$20221123$20160426$20221128$EXP$$US-PFIZER INC-2016226395$PFIZER$$57$YR$$M$Y$113$KG$20221128$$CN$US$US
123069373$12306937$3$F$20080301$20221214$20160426$20221221$EXP$$US-JAZZ-JPI-P-003173$JAZZ$$48$YR$$F$Y$$$20221221$$CN$US$US
123088954$12308895$4$F$20140101$20221221$20160427$20221226$EXP$$US-JAZZ-2015-US-011496$JAZZ$$$$$M$Y$$$20221226$$MD$US$US
1231139711$12311397$11$F$20150717$20221026$20160427$20221107$EXP$$DE-INCYTE CORPORATION-2016IN000383$INCYTE$$$$$$Y$$$20221107$$MD$DE$DE
1231249417$12312494$17$F$20090209$20221220$20160428$20221227$PER$$CA-AMGEN-CANSP2016039095$AMGEN$$57$YR$A$M$Y$$$20221227$$HP$CA$CA
123158604$12315860$4$F$20150101$20221209$20160428$20221215$EXP$$US-JAZZ-2016-US-007509$JAZZ$$$$$M$Y$126.98$KG$20221215$$HP$US$US
1232125915$12321259$15$F$20160119$20220906$20160502$20221202$EXP$$GB-ROCHE-1748037$ROCHE$$80$YR$$F$Y$$$20221202$$MD$GB$GB
123214566$12321456$6$F$$20181010$20160502$20221231$PER$$PHEH2016US010509$NOVARTIS$$$$$F$Y$86$KG$20221231$$HP$US$US
1232155510$12321555$10$F$$20221212$20160502$20221220$PER$$CA-AMGEN-CANSP2016054806$AMGEN$$58$YR$A$F$Y$$$20221220$$HP$CA$CA
1232522011$12325220$11$F$20150901$20221201$20160502$20221206$EXP$$CA-DSJP-DSU-2015-130567$DAIICHI$$74$YR$$F$Y$$$20221206$$HP$CA$CA
123255648$12325564$8$F$$20180310$20160503$20221229$EXP$$PHEH2016US010512$NOVARTIS$$$$$$Y$$$20221229$$MD$US$US
123262568$12326256$8$F$$20221121$20160503$20221123$EXP$$CA-ROCHE-1750136$ROCHE$$50$YR$$M$Y$$$20221123$$HP$CA$
1232625826$12326258$26$F$20150801$20221024$20160503$20221102$EXP$$CA-ROCHE-1750044$ROCHE$$34$YR$$M$Y$$$20221101$$CN$CA$CA
1233195424$12331954$24$F$19900101$20221216$20160504$20221227$EXP$$US-PFIZER INC-2016204050$PFIZER$$33$YR$$F$Y$52.154$KG$20221227$$MD$US$US
1233264520$12332645$20$F$20160410$20221216$20160504$20221222$EXP$$US-PFIZER INC-2016230773$PFIZER$$77$YR$$F$Y$58$KG$20221222$$CN$US$US
123356804$12335680$4$F$20160428$20221206$20160505$20221207$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-033720$BRISTOL MYERS SQUIBB$$$$$M$Y$$$20221207$$HP$US$US
123389598$12338959$8$F$20160502$20221208$20160505$20221214$PER$$US-PFIZER INC-2016243931$PFIZER$$59$YR$$F$Y$71.67$KG$20221214$$HP$US$US
123394074$12339407$4$F$20150101$20221012$20160505$20221018$EXP$$US-JAZZ-2015-US-012623$JAZZ$$$$$F$Y$$$20221018$$HP$US$US
123415128$12341512$8$F$$20221013$20160506$20221020$EXP$$PHHY2016CA059634$NOVARTIS$$$$$M$Y$$$20221020$$CN$CA$CA
1234662210$12346622$10$F$20190801$20221220$20160509$20221223$EXP$$US-PFIZER INC-2016150950$PFIZER$$26$YR$$M$Y$$$20221223$$HP$US$US
123483287$12348328$7$F$20150901$20221102$20160509$20221118$EXP$$FR-JNJFOC-20151101884$JOHNSON AND JOHNSON$$31$YR$A$M$Y$52$KG$20221118$$MD$FR$FR
123559386$12355938$6$F$$20221213$20160511$20221215$EXP$$US-JAZZ-2016-US-008484$JAZZ$$$$$F$Y$$$20221215$$CN$US$US
123562423$12356242$3$F$$20221014$20160511$20221021$PER$$US-BIOGEN-2016BI00235995$BIOGEN$$$$$M$Y$$$20221021$$CN$US$US
123565437$12356543$7$F$20160101$20221005$20160511$20221010$EXP$$PHHY2016CA053475$NOVARTIS$$28$YR$$M$Y$$$20221010$$MD$CA$CA
1235836628$12358366$28$F$20131029$20221111$20160512$20221121$EXP$$CA-ROCHE-1756306$ROCHE$$51$YR$$F$Y$$$20221121$$CN$CA$CA
1236543817$12365438$17$F$20140101$20221021$20160512$20221028$EXP$$BR-BIOGEN-2016BI00235292$BIOGEN$$$$$F$Y$69$KG$20221028$$CN$BR$BR
123656032$12365603$2$F$$20221206$20160513$20221213$EXP$$CN-ROCHE-1755331$ROCHE$Fang J, Zhang R, Wang H, Hong M, Wu Q, Nie D, You Y, Zhong Z, Li W, Hu Y and Xia L Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study. Doi: 10.1016/j.leu. Leukemia Research 2016 Jul 01;46:61-8.$$$$$Y$$$20221213$$HP$CN$
123671773$12367177$3$F$$20221107$20160513$20221116$PER$$US-JNJFOC-20160500360$JOHNSON AND JOHNSON$$$$$M$Y$$$20221116$$LW$US$US
1237099728$12370997$28$F$20160101$20221212$20160516$20221222$PER$$CA-AMGEN-CANSP2016061225$AMGEN$$63$YR$A$F$Y$$$20221221$$HP$CA$CA
123711785$12371178$5$F$$20221214$20160516$20221222$PER$$US-PFIZER INC-2016224142$PFIZER$$63$YR$$F$Y$63$KG$20221222$$CN$US$US
123714736$12371473$6$F$20150730$20220706$20160516$20221219$EXP$$US-ROCHE-1756698$ROCHE$$62$YR$$M$Y$72.6$KG$20221219$$MD$US$
123743135$12374313$5$F$20131201$20221215$20160517$20221221$EXP$$US-JAZZ-2015-US-013892$JAZZ$$36$YR$$F$Y$$$20221221$$CN$US$US
1237554632$12375546$32$F$20150101$20221212$20160517$20221222$EXP$$CA-PFIZER INC-2015440794$PFIZER$$42$YR$$F$Y$97$KG$20221222$$MD$CA$CA
1238083419$12380834$19$F$20160401$20221215$20160518$20221222$EXP$$CA-ROCHE-1758483$ROCHE$$23$YR$$F$Y$$$20221222$$MD$CA$CA
1238547412$12385474$12$F$20160101$20221006$20160519$20221012$EXP$$PHHY2016AR068913$NOVARTIS$$69$YR$$F$Y$$$20221012$$CN$AR$AR
123865166$12386516$6$F$$20221031$20160519$20221108$EXP$$US-JAZZ-2015-US-021618$JAZZ$$$$$M$Y$$$20221108$$MD$US$US
1238769511$12387695$11$F$20141201$20221117$20160520$20221121$EXP$$CA-ROCHE-1761274$ROCHE$$45$YR$$F$Y$$$20221121$$CN$COUNTRY NOT SPECIFIED$CA
1239002315$12390023$15$F$20151201$20221103$20160520$20221111$EXP$$US-JAZZ-2016-US-000603$JAZZ$$47$YR$$F$Y$$$20221111$$MD$US$US
1239210611$12392106$11$F$20130617$20221114$20160523$20221121$EXP$$CA-ROCHE-1760131$ROCHE$$40$YR$$F$Y$57$KG$20221121$$HP$CA$CA
1239630314$12396303$14$F$20160514$20221203$20160524$20221209$EXP$$CO-SHIRE-CO201606313$TAKEDA$$3$YR$$M$Y$46$KG$20221209$$HP$CO$CO
123980633$12398063$3$F$20160517$20221213$20160524$20221216$EXP$$US-ROCHE-1762004$ROCHE$$$$$M$Y$$$20221216$$MD$US$
124067318$12406731$8$F$20100101$20221222$20160526$20221226$EXP$$US-JAZZ-2015-US-015583$JAZZ$$$$$M$Y$$$20221226$$CN$US$US
124096415$12409641$5$F$$20221212$20160526$20221222$EXP$$CO-INCYTE CORPORATION-2016IN003124$INCYTE$$$$$$Y$$$20221222$$CN$CO$CO
124111243$12411124$3$F$20210415$20221026$20160527$20221102$EXP$$CA-ROCHE-1764540$ROCHE$$45$YR$$F$Y$$$20221102$$MD$CA$CA
124128583$12412858$3$F$20080101$20221221$20160527$20221227$PER$$US-JAZZ-2016-US-009492$JAZZ$$33$YR$$F$Y$$$20221227$$MD$US$US
1241398810$12413988$10$F$20160101$20221206$20160527$20221213$EXP$$US-JAZZ-2016-US-009575$JAZZ$$$$$F$Y$$$20221213$$MD$US$US
124140502$12414050$2$F$20220714$20220812$20160527$20221026$PER$$US-JAZZ-2015-US-016307$JAZZ$$35$YR$$M$Y$$$20221026$$HP$US$US
124168389$12416838$9$F$$20221201$20160530$20221201$EXP$$US-PFIZER INC-2016280298$PFIZER$$76$YR$$F$Y$$$20221201$$CN$US$US
1241761815$12417618$15$F$20131130$20221024$20160530$20221027$EXP$$PHHY2016CO071682$NOVARTIS$$58$YR$$F$Y$71$KG$20221027$$CN$CO$CO
124207668$12420766$8$F$20130627$20221216$20160531$20221220$EXP$$ES-009507513-1504ESP009226$MERCK$$66$YR$$F$Y$$$20221220$$HP$ES$ES
124253344$12425334$4$F$20160125$20221109$20160601$20221111$EXP$FR-AFSSAPS-PA20160131$FR-B.I. Pharmaceuticals,Inc./Ridgefield-2016-BI-34467FF$BOEHRINGER INGELHEIM$$49$YR$A$M$Y$$$20221111$$HP$FR$FR
1242661011$12426610$11$F$20140528$20221108$20160601$20221115$EXP$$PHHY2013CA144082$NOVARTIS$$83$YR$$F$Y$$$20221115$$HP$CA$CA
124316183$12431618$3$F$20160510$20221027$20160603$20221104$EXP$$US-SHIRE-US201606609$TAKEDA$$24$YR$$M$Y$55$KG$20221104$$HP$US$US
124457012$12445701$2$F$20060101$20220926$20160608$20221006$PER$$US-JNJFOC-20160523024$JOHNSON AND JOHNSON$$1$DEC$C$M$Y$$$20221006$$HP$US$US
124457535$12445753$5$F$$20221019$20160608$20221027$PER$$US-JNJFOC-20160411835$JOHNSON AND JOHNSON$$$$$M$Y$$$20221027$$LW$US$US
124462127$12446212$7$F$$20221126$20160608$20221207$PER$$US-BIOGEN-2016BI00240291$BIOGEN$$$$$F$Y$63.5$KG$20221207$$CN$US$US
124500342$12450034$2$F$$20221024$20160609$20221027$PER$$US-BIOGEN-2016BI00241319$BIOGEN$$$$$F$Y$$$20221027$$CN$US$US
124505682$12450568$2$F$20121001$20221101$20160609$20221114$EXP$IT-MLMSERVICE-20160526-0293587-1$IT-LUPIN PHARMACEUTICALS INC.-2016-02427$LUPIN$Del Casale A, Rapinesi C, Brugnoli R, Girardi P, Sacco M, Giardini M, et al.. Effectiveness of switching from oral ziprasidone to risperidone in a patient with comorbid autistic disorder, profound intellectual disability, gilbert syndrome, and exacerbation of psychosis. Psychiatria Danubina. 2016;28(1):91-94$28$YR$$M$Y$$$20221114$$MD$IT$IT
124604347$12460434$7$F$$20221202$20160613$20221208$EXP$$US-PFIZER INC-2016266871$PFIZER$$72$YR$$F$Y$$$20221208$$CN$US$US
1246649225$12466492$25$F$20120801$20221109$20160615$20221118$EXP$$CA-ROCHE-1775252$ROCHE$$79$YR$$F$Y$$$20221118$$CN$CA$CA
124681188$12468118$8$F$20150901$20221207$20160615$20221212$EXP$$US-PFIZER INC-2016287804$MYLAN$$67$YR$$M$Y$77$KG$20221212$$CN$US$US
124681349$12468134$9$F$20060101$20221221$20160615$20221227$EXP$$US-PFIZER INC-2016297763$PFIZER$$70$YR$$F$Y$56.961$KG$20221227$$MD$US$US
1247755431$12477554$31$F$20151221$20221019$20160617$20221025$EXP$$PHHY2015CA169582$NOVARTIS$$59$YR$$F$Y$$$20221025$$CN$CA$CA
124813377$12481337$7$F$20080101$20221026$20160620$20221031$EXP$$US-BIOGEN-2010BI033734$BIOGEN$$$$$F$Y$93.524$KG$20221031$$CN$US$US
124825915$12482591$5$F$$20221017$20160620$20221021$EXP$$US-ARIAD PHARMACEUTICALS, INC-2016US006617$TAKEDA$$$$$M$Y$79$KG$20221021$$MD$US$US
124828986$12482898$6$F$20150715$20221221$20160620$20221223$EXP$$PHHY2016CO012426$NOVARTIS$$67$YR$$F$Y$67$KG$20221223$$CN$CO$CO
124845626$12484562$6$F$20140901$20221128$20160621$20221205$EXP$$US-JAZZ-2016-US-011104$JAZZ$$41$YR$$F$Y$$$20221205$$MD$US$US
124904574$12490457$4$F$20160101$20221011$20160622$20221018$EXP$$US-JAZZ-2016-US-011165$JAZZ$$$$$F$Y$$$20221018$$CN$US$US
124930793$12493079$3$F$$20220929$20160623$20221012$EXP$$US-PFIZER INC-2016295837$PFIZER$Thind, G.. A case of Takotsubo cardiomyopathy in a patient with anaphylaxis treated with epinephrine. Journal of General Internal Medicine. 2016;31:2(1):S497$58$YR$$F$Y$$$20221012$$MD$US$US
125008673$12500867$3$F$20160530$20221118$20160627$20221123$EXP$$CA-BIOGEN-2016BI00253886$BIOGEN$$42$YR$$M$Y$$$20221123$$MD$CA$CA
1250841710$12508417$10$F$20160702$20221117$20160629$20221123$EXP$$CA-PFIZER INC-2016305222$PFIZER$$71$YR$$M$Y$$$20221123$$CN$CA$CA
1251723525$12517235$25$F$20160101$20221116$20160630$20221124$EXP$$CA-ROCHE-1785228$ROCHE$$68$YR$$F$Y$$$20221124$$CN$CA$CA
125172424$12517242$4$F$$20221115$20160630$20221121$EXP$$AU-PFIZER INC-2970434$PFIZER$Kennedy, B.. Interaction between voriconazole and flucloxacillin during treatment of disseminated Scedosporium apiospermum infection. Journal of Antimicrobial Chemotherapy. 2015;70(7):2171-2173$8$DEC$$M$Y$$$20221121$$HP$AU$AU
125173072$12517307$2$F$$20221114$20160630$20221122$EXP$$CA-AstraZeneca-2016SE68616$ASTRAZENECA$$56$YR$$F$Y$91$KG$20221122$$MD$CA$
1251759423$12517594$23$F$20160205$20221209$20160630$20221216$EXP$$PHHY2016CL088658$NOVARTIS$$$$$F$Y$69.5$KG$20221216$$MD$CL$CL
1252085719$12520857$19$F$20190318$20221219$20160701$20221227$EXP$$US-PFIZER INC-2016320631$PFIZER$$66$YR$$F$Y$120$KG$20221227$$CN$US$US
125216122$12521612$2$F$$20221014$20160701$20221018$EXP$$PHHY2016CA090326$NOVARTIS$$$$$F$Y$$$20221018$$CN$CA$CA
1252758724$12527587$24$F$20121001$20221005$20160705$20221013$EXP$$CA-ROCHE-1786206$ROCHE$$70$YR$$M$Y$$$20221011$$CN$CA$CA
125295212$12529521$2$F$20121201$20221003$20160706$20221028$EXP$SE-ABBVIE-16K-150-1665610-00$SE-ABBVIE-16K-150-1665610-00$ABBVIE$$62$YR$$M$Y$$$20221028$$MD$SE$SE
125321247$12532124$7$F$20160304$20220929$20160706$20221004$EXP$$CA-TAKEDA-2016TUS002594$TAKEDA$$61$YR$$F$Y$$$20221004$$HP$CA$CA
125332002$12533200$2$F$$20200526$20160706$20221008$PER$$US-PURDUE-USA-2015-0127244$PURDUE$$$$$F$Y$$$20221008$$LW$US$US
125377179$12537717$9$F$$20221031$20160707$20221107$EXP$$US-ARIAD PHARMACEUTICALS, INC-2016US006397$TAKEDA$$$$$F$Y$70$KG$20221107$$CN$US$US
125383772$12538377$2$F$20160301$20211028$20160707$20221017$EXP$$US-JAZZ-2016-US-012221$JAZZ$$55$YR$$F$Y$$$20221017$$CN$US$US
125387485$12538748$5$F$20160702$20221108$20160708$20221111$EXP$$FR-ROCHE-1789528$ROCHE$$67$YR$$M$Y$81$KG$20221111$$MD$FR$
125418069$12541806$9$F$20160629$20221121$20160708$20221126$EXP$$JP-BAXALTA-2016BXJ004710$TAKEDA$$67$YR$$M$Y$63$KG$20221126$$CN$JP$JP
125462377$12546237$7$F$20160621$20221007$20160711$20221012$EXP$$CA-TAKEDA-2016TUS011508$TAKEDA$$64$YR$$M$Y$$$20221012$$CN$CA$CA
1254955512$12549555$12$F$20130101$20221205$20160712$20221209$EXP$$US-PFIZER INC-2016335757$PFIZER$$72$YR$$F$Y$59$KG$20221209$$CN$US$US
125497395$12549739$5$F$20160530$20221026$20160712$20221102$EXP$$US-PFIZER INC-2016304153$PFIZER$$71$YR$$F$Y$94.8$KG$20221102$$CN$US$US
125549212$12554921$2$F$$20221121$20160713$20221124$PER$$US-BIOGEN-2016BI00263439$BIOGEN$$$$$F$Y$$$20221124$$CN$US$US
125579983$12557998$3$F$20140101$20220929$20160714$20221026$PER$$US-JAZZ-2016-US-000698$JAZZ$$$$$F$Y$58.957$KG$20221026$$MD$US$US
125595733$12559573$3$F$20150720$20221215$20160715$20221221$EXP$$PHHY2015CA076195$NOVARTIS$$50$YR$$F$Y$$$20221222$$MD$CA$CA
125635877$12563587$7$F$20160707$20221123$20160715$20221129$EXP$$US-JAZZ-2016-US-012720$JAZZ$$50$YR$$M$Y$$$20221129$$MD$US$US
1256496029$12564960$29$F$20150721$20221106$20160718$20221108$EXP$$GB-ROCHE-1657697$ROCHE$$75$YR$$F$Y$$$20221108$$MD$GB$GB
1256922210$12569222$10$F$20161205$20221102$20160719$20221107$EXP$$PHHY2016CO096699$NOVARTIS$$73$YR$$M$Y$80$KG$20221107$$CN$CO$CO
1257115229$12571152$29$F$$20221221$20160719$20221230$EXP$$CA-PFIZER INC-2016324063$PFIZER$$85$YR$$M$Y$$$20221230$$MD$CA$CA
125801184$12580118$4$F$$20180312$20160721$20221228$EXP$$PHHY2016PT099049$NOVARTIS$$$$$$Y$$$20221228$$CN$PT$PT
1258496617$12584966$17$F$20160101$20221116$20160722$20221123$EXP$$BR-TAKEDA-2016TUS012630$TAKEDA$$$$$M$Y$59.5$KG$20221123$$CN$BR$BR
125867747$12586774$7$F$$20221118$20160725$20221122$EXP$$US-PFIZER INC-2016350543$PFIZER$$71$YR$$M$Y$$$20221122$$CN$US$US
1258700620$12587006$20$F$20160401$20220930$20160725$20221007$EXP$$CA-ROCHE-1799664$ROCHE$$60$YR$$F$Y$$$20221007$$CN$CA$CA
125908492$12590849$2$F$20140101$20221202$20160726$20221213$PER$$US-AMGEN-USASL2016094749$AMGEN$$55$YR$A$F$Y$$$20221212$$CN$US$US
1259605213$12596052$13$F$20200201$20221221$20160727$20221228$EXP$$CA-ROCHE-1801131$ROCHE$$46$YR$$F$Y$$$20221228$$CN$CA$CA
125964479$12596447$9$F$20010101$20221221$20160726$20221229$EXP$$US-PFIZER INC-2016320501$PFIZER$$55$YR$$M$Y$108.8$KG$20221229$$HP$US$US
1260155920$12601559$20$F$20141209$20221025$20160728$20221031$EXP$$PHHY2013CA096983$NOVARTIS$$64$YR$$F$Y$$$20221031$$MD$CA$CA
126026383$12602638$3$F$$20221114$20160728$20221117$EXP$$JP-GLAXOSMITHKLINE-JP2016JPN107167$GLAXOSMITHKLINE$$$$$$Y$$$20221117$$MD$JP$JP
1260344212$12603442$12$F$20160720$20221115$20160728$20221123$EXP$$ES-ROCHE-1799367$ROCHE$$75$YR$$F$Y$60$KG$20221123$$MD$ES$
1260584815$12605848$15$F$20140523$20221118$20160729$20221122$EXP$$PHHY2014CA065852$NOVARTIS$$32$YR$$F$Y$$$20221122$$HP$CA$CA
1260602521$12606025$21$F$20160101$20221115$20160729$20221118$EXP$$US-PFIZER INC-2016332106$PFIZER$$76$YR$$F$Y$63$KG$20221118$$CN$US$US
1261389712$12613897$12$F$20160718$20221013$20160802$20221018$PER$$US-PFIZER INC-2016354161$PFIZER$$72$YR$$F$Y$83$KG$20221018$$CN$US$US
126142597$12614259$7$F$20221226$20221227$20160802$20221229$EXP$$US-JAZZ-2016-US-002901$JAZZ$$64$YR$$M$Y$$$20221229$$MD$US$US
1261461516$12614615$16$F$20160101$20221103$20160802$20221111$EXP$$US-PFIZER INC-2016022099$PFIZER$$66$YR$$F$Y$86$KG$20221111$$CN$US$US
1261829811$12618298$11$F$20151016$20221207$20160803$20221213$EXP$$PHHY2015CO136842$NOVARTIS$$40$YR$$M$Y$75$KG$20221213$$CN$CO$CO
1262095310$12620953$10$F$20160322$20220912$20160804$20221006$EXP$$PHHY2016IT104278$NOVARTIS$$15$YR$$M$Y$64.5$KG$20221006$$MD$IT$IT
126218886$12621888$6$F$20160701$20221011$20160804$20221019$EXP$FR-PURDUE PHARMA-GBR-2016-0039405$FR-PURDUE PHARMA-GBR-2016-0039405$PURDUE$$76$YR$$F$Y$$$20221019$$MD$FR$FR
126287463$12628746$3$F$$20221101$20160808$20221114$EXP$CA-MLMSERVICE-20160721-0357315-1$CA-Accord-042925$ACCORD$$39$YR$A$M$Y$$$20221114$$HP$CA$CA
1263897021$12638970$21$F$20160711$20221212$20160809$20221221$EXP$$CL-BIOMARINAP-CL-2016-110693$BIOMARIN$$$$$$Y$$$20221221$$CN$US$CL
126396072$12639607$2$F$20120101$20221004$20160810$20221017$EXP$BE-MLMSERVICE-20160721-0358575-1$BE-Accord-042975$ACCORD$$55$YR$A$M$Y$$$20221017$$MD$BE$BE
126404793$12640479$3$F$20160601$20221121$20160810$20221124$EXP$$FR-PFIZER INC-2016371969$PFIZER$$36$YR$$F$Y$47$KG$20221124$$MD$FR$FR
126409323$12640932$3$F$20160524$20221206$20160810$20221213$EXP$FR-AFSSAPS-NT20161022$FR-GLAXOSMITHKLINE-FR2016GSK114734$GLAXOSMITHKLINE$$$$$$Y$$$20221213$$MD$FR$FR
126415634$12641563$4$F$20160701$20221220$20160810$20221228$PER$$US-PFIZER INC-2016366813$PFIZER$$37$YR$$M$Y$85$KG$20221228$$MD$US$US
126439252$12643925$2$F$20160708$20221108$20160811$20221123$EXP$$IT-AUROBINDO-AUR-APL-2016-09996$AUROBINDO$$33$YR$$F$Y$$$20221123$$MD$IT$IT
1264583516$12645835$16$F$20151218$20221017$20160811$20221024$EXP$$PHHY2016CA007779$NOVARTIS$$45$YR$$M$Y$$$20221024$$MD$CA$CA
126473764$12647376$4$F$20160307$20221107$20160812$20221111$EXP$$PHHY2016CA108699$NOVARTIS$$20$YR$$F$Y$$$20221111$$MD$CA$CA
1264903716$12649037$16$F$20160801$20221019$20160812$20221025$EXP$$PHHY2016IN109563$NOVARTIS$$42$YR$$M$Y$$$20221025$$MD$IN$IN
126518236$12651823$6$F$20150101$20221116$20160815$20221118$EXP$$PHHY2016CA111149$NOVARTIS$$$$$F$Y$$$20221118$$MD$CA$CA
1265259313$12652593$13$F$20160805$20221206$20160815$20221212$EXP$$US-PFIZER INC-2016387053$PFIZER$$72$YR$$M$Y$95.5$KG$20221212$$CN$US$US
126591833$12659183$3$F$$20221110$20160817$20221117$EXP$$PHHY2016CA111169$NOVARTIS$$$$$F$Y$$$20221117$$MD$CA$CA
1266158614$12661586$14$F$20160819$20221102$20160817$20221104$PER$$US-PFIZER INC-2016387665$PFIZER$$62$YR$$F$Y$70$KG$20221104$$MD$US$US
126675208$12667520$8$F$20100101$20221130$20160819$20221206$EXP$$US-PFIZER INC-2016392132$PFIZER$$58$YR$$F$Y$115$KG$20221206$$CN$US$US
126683269$12668326$9$F$20160801$20221207$20160819$20221213$EXP$$PHHY2016CA113655$NOVARTIS$$35$YR$$F$Y$$$20221213$$HP$CA$CA
126708007$12670800$7$F$$20221107$20160822$20221114$EXP$$US-JAZZ-2016-US-006149$JAZZ$$$$$M$Y$$$20221114$$MD$US$US
1267308828$12673088$28$F$20160301$20221128$20160822$20221201$EXP$$PHHY2016CA038348$NOVARTIS$$52$YR$$F$Y$$$20221201$$HP$CA$CA
1267361023$12673610$23$F$20160803$20221101$20160822$20221111$EXP$$GB-ELI_LILLY_AND_COMPANY-GB201608008113$ELI LILLY AND CO$$69$YR$$F$Y$101$KG$20221111$$CN$GB$GB
1267604332$12676043$32$F$$20220718$20160823$20221003$EXP$$CA-SA-2015SA146389$SANOFI AVENTIS$$43$YR$A$F$Y$$$20221003$$MD$CA$CA
1267742711$12677427$11$F$20160803$20221013$20160823$20221017$EXP$GB-MHRA-EYC 00143637$PHHY2016GB112616$NOVARTIS$$69$YR$$F$Y$101$KG$20221017$$PH$GB$GB
126774969$12677496$9$F$20210101$20221124$20160823$20221130$EXP$$CA-PFIZER INC-2016373806$PFIZER$$50$YR$$F$Y$$$20221130$$CN$CA$CA
126785298$12678529$8$F$20160802$20221116$20160823$20221121$EXP$$PHHY2016CA115075$NOVARTIS$$66$YR$$M$Y$$$20221121$$MD$CA$CA
1268190131$12681901$31$F$20160803$20221222$20160824$20221229$EXP$GB-MHRA-EYC 00143637$GB-MYLANLABS-2016M1034603$MYLAN$$69$YR$$F$Y$101$KG$20221229$$PH$GB$GB
1268278111$12682781$11$F$20160803$20221101$20160825$20221114$EXP$$GB-MACLEODS PHARMACEUTICALS US LTD-MAC2016003010$MACLEODS$$$$$$Y$$$20221114$$PH$GB$GB
126843893$12684389$3$F$20160101$20221223$20160825$20221229$EXP$FR-AFSSAPS-RE20160793$FR-VIIV HEALTHCARE LIMITED-FR2016GSK121710$VIIV$$$$$$Y$$$20221229$$MD$FR$FR
126848493$12684849$3$F$20160101$20221223$20160825$20221229$EXP$FR-AFSSAPS-RE20160793$FR-GLAXOSMITHKLINE-FR2016GSK121710$GLAXOSMITHKLINE$$$$$$Y$$$20221229$$MD$FR$FR
1268961213$12689612$13$F$20150401$20221107$20160826$20221109$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2016JPN121032$VIIV$$$$$$Y$$$20221109$$MD$JP$JP
1269022429$12690224$29$F$20160803$20221117$20160826$20221125$EXP$GB-MHRA-EYC 00143637$GB-drreddys-GER/UKI/16/0082539$DR REDDYS$$69$YR$E$F$Y$101$KG$20221125$$PH$GB$GB
126924094$12692409$4$F$20160126$20221221$20160828$20221223$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-006994$BRISTOL MYERS SQUIBB$$53$YR$A$M$Y$$$20221223$$CN$CA$CA
1269299310$12692993$10$F$20160407$20221209$20160829$20221216$EXP$$CA-ROCHE-1821507$ROCHE$$70$YR$$M$Y$77$KG$20221216$$MD$CA$CA
126963186$12696318$6$F$$20221021$20160830$20221101$EXP$$NP-CIPLA LTD.-2016NP17824$CIPLA$Hirachan A., Baral S., Shareef M., Rijal R. and Tibrewala L.. Amlodipine overdose with hypotension and noncardiogenic pulmonary edema. Nepalese Heart Journal. 2016;13 (1):27 to 29$23$YR$$F$Y$$$20221101$$MD$NP$NP
1269705218$12697052$18$F$20160803$20221115$20160830$20221213$EXP$$GB-AUROBINDO-AUR-APL-2016-10627$AUROBINDO$$69$YR$$F$Y$101$KG$20221213$$PH$GB$GB
126984695$12698469$5$F$20080731$20221003$20160830$20221013$PER$$US-JNJFOC-20160709016$JOHNSON AND JOHNSON$$11$YR$C$M$Y$$$20221013$$HP$US$US
126995653$12699565$3$F$20221220$20221220$20160830$20221228$EXP$$US-KAMADA LIMITED-2016US001402$TAKEDA$$69$YR$$M$Y$$$20221228$$CN$US$US
127001772$12700177$2$F$20160811$20221116$20160830$20221122$EXP$$US-SHIRE-US201610863$TAKEDA$$41$YR$$F$Y$134.24$KG$20221122$$HP$US$US
1270337819$12703378$19$F$20140617$20221107$20160831$20221117$EXP$$JP-JNJFOC-20160824209$JOHNSON AND JOHNSON$$62$YR$A$M$Y$$$20221117$$MD$JP$JP
127106412$12710641$2$F$20010101$20221208$20160902$20221215$EXP$$US-SHIRE-US201610636$TAKEDA$$$$$F$Y$91$KG$20221215$$MD$US$US
127116162$12711616$2$F$20160101$20221221$20160902$20221228$EXP$$CR-009507513-1609CRI000234$MERCK$$54$YR$$M$Y$$$20221228$$MD$CR$CR
127145078$12714507$8$F$20160101$20221118$20160905$20221125$EXP$$US-JAZZ-2016-US-008662$JAZZ$$$$$F$Y$$$20221125$$CN$US$US
1271532816$12715328$16$F$$20221005$20160906$20221008$EXP$$CA-ROCHE-1825208$ROCHE$$74$YR$$F$Y$$$20221008$$MD$CA$
1271619613$12716196$13$F$20140701$20221108$20160906$20221114$EXP$$PHHY2014CA097752$NOVARTIS$$$$E$F$Y$68$KG$20221114$$HP$CA$CA
127173267$12717326$7$F$20150807$20221129$20160906$20221212$EXP$$PH-BEH-2015053085$CSL BEHRING$$11$YR$C$M$Y$30$KG$20221212$$HP$US$PH
127208505$12720850$5$F$20140101$20221129$20160907$20221202$EXP$$US-JAZZ-2016-US-016598$JAZZ$$$$$F$Y$$$20221202$$CN$US$US
127219635$12721963$5$F$20160824$20221220$20160907$20221227$PER$$US-PFIZER INC-2016409271$PFIZER$$57$YR$$M$Y$92$KG$20221227$$MD$US$US
127247949$12724794$9$F$20160822$20221208$20160908$20221215$EXP$$AU-PFIZER INC-2016407637$PFIZER$$71$YR$$F$Y$101$KG$20221215$$MD$AU$AU
127255474$12725547$4$F$20160101$20221206$20160908$20221212$EXP$$US-JAZZ-2016-US-016834$JAZZ$$$$$F$Y$$$20221212$$MD$US$US
1272747531$12727475$31$F$20160609$20221125$20160909$20221202$EXP$$CA-ROCHE-1827432$ROCHE$$62$YR$$F$Y$74$KG$20221202$$CN$CA$CA
1272907414$12729074$14$F$20160705$20221202$20160909$20221207$EXP$$CA-TAKEDA-2016TUS012100$TAKEDA$$45$YR$$F$Y$$$20221207$$HP$CA$CA
127319598$12731959$8$F$20150101$20221028$20160912$20221102$EXP$$US-PFIZER INC-2016427778$PFIZER$$72$YR$$F$Y$68.027$KG$20221102$$CN$US$US
1273810627$12738106$27$F$20150414$20221116$20160913$20221123$EXP$$FI-SA-2015SA076433$SANOFI AVENTIS$$42$YR$A$M$Y$91.9$KG$20221123$$MD$FI$FI
127435816$12743581$6$F$20160822$20221215$20160914$20221222$EXP$$JP-INCYTE CORPORATION-2016IN005568$INCYTE$$$$$$Y$$$20221222$$MD$JP$JP
1275802011$12758020$11$F$20160101$20221107$20160919$20221111$EXP$$US-PFIZER INC-2016434097$PFIZER$$83$YR$$F$Y$$$20221111$$CN$US$US
127650047$12765004$7$F$20140801$20221130$20160921$20221208$EXP$$CA-ROCHE-1832465$ROCHE$$51$YR$$M$Y$$$20221208$$MD$CA$CA
127674619$12767461$9$F$$20221206$20160921$20221207$EXP$$US-PFIZER INC-2016422273$PFIZER$$74$YR$$F$Y$59.864$KG$20221207$$MD$US$US
127715263$12771526$3$F$20050424$20221201$20160922$20221209$EXP$$US-BIOGEN-2008BI026805$BIOGEN$$42$YR$$F$Y$$$20221209$$CN$US$US
127726833$12772683$3$F$$20221118$20160922$20221122$EXP$$PHHY2015CA105683$NOVARTIS$$$$$F$Y$$$20221122$$MD$CA$CA
1277328617$12773286$17$F$20160101$20221028$20160922$20221104$EXP$$CA-TAKEDA-2016TUS016639$TAKEDA$$52$YR$$F$Y$$$20221104$$MD$CA$CA
1277437223$12774372$23$F$$20220325$20160923$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-076813$BRISTOL MYERS SQUIBB$$58$YR$A$F$Y$$$20221223$$HP$CA$CA
1277463014$12774630$14$F$20160531$20180626$20160923$20221028$EXP$$PHHY2016US126962$NOVARTIS$$12$YR$$F$Y$53.3$KG$20221028$$MD$US$US
1277830949$12778309$49$F$$20221207$20160926$20221215$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-075856$BRISTOL MYERS SQUIBB$$42$YR$A$F$Y$97$KG$20221215$$HP$CA$CA
1278124222$12781242$22$F$20150101$20221128$20160926$20221205$EXP$$PHHY2015CA109453$NOVARTIS$$65$YR$$F$Y$$$20221205$$CN$CA$CA
127827902$12782790$2$F$20100101$20221205$20160927$20221223$PER$$US-BIOGEN-2016BI00294221$BIOGEN$$$$$F$Y$77.1$KG$20221223$$CN$US$US
1278807624$12788076$24$F$20150729$20221031$20160928$20221111$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-077476$BRISTOL MYERS SQUIBB$$41$YR$A$M$Y$90$KG$20221111$$HP$CA$CA
127891172$12789117$2$F$20160904$20221101$20160928$20221102$PER$$US-SHIRE-US201612229$TAKEDA$$48$YR$$F$Y$$$20221102$$MD$US$US
127900308$12790030$8$F$$20221115$20160928$20221121$EXP$$BR-PFIZER INC-2016448927$PFIZER$$41$YR$$M$Y$$$20221121$$CN$BR$BR
1279156719$12791567$19$F$20160916$20221122$20160929$20221129$EXP$$CA-ROCHE-1835532$ROCHE$$40$YR$$M$Y$$$20221129$$CN$CA$CA
127924905$12792490$5$F$20080201$20220929$20160929$20221012$PER$$US-JNJFOC-20160916929$JOHNSON AND JOHNSON$$8$YR$C$M$Y$$$20221010$$LW$US$US
127966189$12796618$9$F$20160826$20221212$20160929$20221215$EXP$$US-PFIZER INC-2016407480$PFIZER$$42$YR$$F$Y$92$KG$20221215$$MD$US$US
127971963$12797196$3$F$20160801$20221118$20160930$20221123$PER$$US-PFIZER INC-2016456524$PFIZER$$64$YR$$F$Y$49.9$KG$20221123$$HP$US$US
1279748818$12797488$18$F$20140610$20221026$20160930$20221031$EXP$$PHHY2011CA40965$NOVARTIS$$79$YR$$F$Y$$$20221031$$HP$CA$CA
1279856612$12798566$12$F$20120625$20221109$20160930$20221124$EXP$$FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-124801$RANBAXY$Cuny P, Houot M, Ginisty S, Horowicz S, Plassart F, Mentec H et al. Quetiapine and anticholinergic drugs induced ischaemic colitis: A case study. Encephale. 2016;13 Sep:Epub ahead of print$34$YR$$M$Y$$$20221124$$MD$FR$FR
128004404$12800440$4$F$20140101$20221010$20160930$20221014$EXP$$US-JAZZ-2016-US-018638$JAZZ$$$$$F$Y$$$20221014$$CN$US$US
128044032$12804403$2$F$$20160923$20161003$20221003$EXP$$PHHY2016US132664$NOVARTIS$Williams JR, Tenforde MW, Chan JD, Ko A, Graham SM. Safety and clinical response of intraventricular caspofungin for Scedosporium apiospermum complex central nervous system infection. MEDICAL MYCOLOGY CASE REPORTS. 2016;13:1-4$71$YR$$F$Y$$$20221003$$HP$US$US
1280942514$12809425$14$F$20160903$20221004$20161005$20221007$EXP$$CA-TAKEDA-2016TUS017672$TAKEDA$$63$YR$$M$Y$$$20221007$$CN$CA$CA
1282551316$12825513$16$F$20221017$20221026$20161006$20221102$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK144027$GLAXOSMITHKLINE$$$$$$Y$$$20221102$$CN$BR$BR
128268562$12826856$2$F$$20220318$20161006$20221014$PER$$US-INDIVIOR LIMITED-INDV-088194-2016$RECKITT BENCKISER$$$$$M$Y$$$20221014$$CN$US$US
128413273$12841327$3$F$20161005$20221111$20161012$20221114$EXP$$JP-B.I. Pharmaceuticals,Inc./Ridgefield-2016-NB-000137$BOEHRINGER INGELHEIM$$65$YR$E$M$Y$66.4$KG$20221114$$MD$JP$JP
128415612$12841561$2$F$20000711$20221213$20161012$20221219$EXP$$US-JNJFOC-20161006407$JOHNSON AND JOHNSON$$15$YR$T$M$Y$$$20221219$$HP$US$US
1284257851$12842578$51$F$$20221222$20161013$20221227$EXP$$CA-Orion Corporation ORION PHARMA-TREX2016-1958$ORION$$63$YR$A$F$Y$$$20221228$$MD$CA$
128452457$12845245$7$F$20170101$20221019$20161013$20221021$EXP$$CA-TAKEDA-2016TUS013310$TAKEDA$$53$YR$$M$Y$$$20221021$$MD$CA$CA
1284910512$12849105$12$F$20160921$20221116$20161014$20221122$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-084065$BRISTOL MYERS SQUIBB$$86$YR$E$F$Y$78$KG$20221122$$CN$CA$CA
128540802$12854080$2$F$20080101$20220928$20161017$20221006$EXP$$US-JNJFOC-20161009352$JOHNSON AND JOHNSON$$1$DEC$C$M$Y$$$20221006$$HP$US$US
1285693810$12856938$10$F$20160901$20221201$20161018$20221206$PER$$US-PFIZER INC-2016482587$PFIZER$$62$YR$$M$Y$74$KG$20221206$$CN$US$US
128592433$12859243$3$F$20161010$20221031$20161018$20221101$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-085274$BRISTOL MYERS SQUIBB$Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, et al. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell richter transformation of CLL. Blood Advances. 2022; 1-24.doi:10.1182/bloodadvances.2022008790.$$$$M$Y$$$20221102$$MD$US$US
128598976$12859897$6$F$20160725$20221123$20161018$20221123$EXP$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2016-BI-066895$BOEHRINGER INGELHEIM$$90$YR$E$M$Y$70.8$KG$20221123$$MD$US$US
128620415$12862041$5$F$20160829$20170119$20161019$20221211$EXP$$FR-TEVA-704749ACC$TEVA$$71$YR$E$M$Y$$$20221212$$HP$FR$FR
128630377$12863037$7$F$20160901$20221215$20161019$20221221$PER$$US-PFIZER INC-2016487980$PFIZER$$64$YR$$M$Y$90.703$KG$20221221$$HP$US$US
128639229$12863922$9$F$20201231$20221228$20161019$20221230$EXP$$CA-TAKEDA-2016TUS018720$TAKEDA$$49$YR$$F$Y$$$20221230$$CN$CA$CA
128640405$12864040$5$F$20150601$20221024$20161019$20221029$EXP$$US-SHIRE-US201614677$TAKEDA$$44$YR$$F$Y$107.4$KG$20221029$$CN$US$US
128672216$12867221$6$F$20160101$20221212$20161020$20221220$EXP$$US-JAZZ-2016-US-014683$JAZZ$$$$$F$Y$$$20221220$$HP$US$US
128694655$12869465$5$F$20221030$20221215$20161021$20221222$EXP$$PHHY2016CA141723$NOVARTIS$$60$YR$$F$Y$$$20221222$$CN$CA$CA
128702817$12870281$7$F$20151105$20221221$20161021$20221226$EXP$$FR-GLAXOSMITHKLINE-FR2016GSK150405$GLAXOSMITHKLINE$$$$$$Y$$$20221226$$MD$FR$FR
128714059$12871405$9$F$20101124$20221222$20161021$20221223$EXP$$US-NAPPMUNDI-USA-2016-0131102$PURDUE$$70$YR$$M$Y$220$KG$20221223$$CN$US$US
128731326$12873132$6$F$20160531$20161219$20161021$20221031$EXP$$PHHO2016US013356$NOVARTIS$$12$YR$$F$Y$50.1$KG$20221031$$MD$US$US
128754122$12875412$2$F$20081209$20221206$20161024$20221213$EXP$$US-ROCHE-606607$ROCHE$$62$YR$$F$Y$$$20221213$$MD$US$US
1287853810$12878538$10$F$20151120$20221115$20161024$20221116$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-029278$BRISTOL MYERS SQUIBB$Ishii D, et al. A case of renal disorder during nivolumab therapy. The Japanese Journal of Nephrology 2017;59(6):914.$79$YR$E$M$Y$50$KG$20221116$$MD$JP$JP
1287997515$12879975$15$F$20161101$20221123$20161025$20221128$EXP$$US-PFIZER INC-2016495242$PFIZER$$83$YR$$F$Y$72$KG$20221128$$CN$US$US
128803473$12880347$3$F$20160901$20221216$20161025$20221222$EXP$$US-PFIZER INC-2016489834$PFIZER$$65$YR$$F$Y$99.34$KG$20221222$$CN$US$US
128813593$12881359$3$F$20070101$20220926$20161025$20221005$PER$$US-JNJFOC-20150713734$JOHNSON AND JOHNSON$$$$C$M$Y$$$20221005$$HP$US$US
128814264$12881426$4$F$$20220922$20161025$20221002$PER$$US-JNJFOC-20161011983$JOHNSON AND JOHNSON$$$$$M$Y$$$20221002$$HP$US$US
128814453$12881445$3$F$20061001$20220922$20161025$20221003$EXP$$US-JNJFOC-20161011989$JOHNSON AND JOHNSON$$9$YR$C$M$Y$$$20221003$$HP$US$US
128814466$12881446$6$F$20060901$20221020$20161025$20221027$EXP$$US-JNJFOC-20161011990$JOHNSON AND JOHNSON$$21$YR$A$M$Y$128.94$KG$20221027$$HP$US$US
128814504$12881450$4$F$20030301$20221020$20161025$20221028$PER$$US-JNJFOC-20161011992$JOHNSON AND JOHNSON$$18$YR$A$M$Y$$$20221028$$HP$US$US
128815225$12881522$5$F$20061201$20221014$20161025$20221018$PER$$US-JNJFOC-20161012337$JOHNSON AND JOHNSON$$22$YR$A$M$Y$$$20221018$$HP$US$US
128815334$12881533$4$F$20080401$20220922$20161025$20221001$PER$$US-JNJFOC-20161012352$JOHNSON AND JOHNSON$$6$YR$C$M$Y$$$20221001$$HP$US$US
128826632$12882663$2$F$20161005$20221116$20161025$20221121$PER$$US-PFIZER INC-2016495644$PFIZER$$58$YR$$F$Y$$$20221121$$CN$US$US
128890973$12889097$3$F$20220701$20221025$20161027$20221031$EXP$$US-PFIZER INC-2016495265$PFIZER$$58$YR$$F$Y$$$20221031$$CN$US$US
1289195012$12891950$12$F$$20220921$20161028$20221003$EXP$$CA-APOPHARMA INC-2016AP013468$APOTEX$$58$YR$$M$Y$$$20221003$$HP$CA$CA
128946893$12894689$3$F$$20221006$20161028$20221011$EXP$$KR-SA-2016SA192117$SANOFI AVENTIS$Kim H, Bang ES, Lim S-K, Lee JM.. DRESS syndrome and acute generalized exanthematous pustulosis induced by antituberculosis medications and moxifloxacin: Case report.. Int J Clin Pharmacol Ther.. 2016;54(10):808-15.$25$YR$A$F$Y$40$KG$20221011$$PH$KR$KR
128981617$12898161$7$F$20161010$20221206$20161031$20221208$EXP$$CA-TAKEDA-2016TUS019342$TAKEDA$$51$YR$$M$Y$$$20221208$$CN$CA$CA
129015668$12901566$8$F$20161025$20221116$20161102$20221122$EXP$$DE-ROCHE-1848167$ROCHE$$67$YR$$M$Y$$$20221122$$MD$DE$
1290698912$12906989$12$F$20160725$20221223$20161103$20221229$EXP$$PHHY2016CA148830$NOVARTIS$$58$YR$$M$Y$$$20221229$$CN$CA$CA
129082513$12908251$3$F$$20220921$20161103$20221004$EXP$$JP-PFIZER INC-2016511210$PFIZER$Urae, S.. Tumor Lysis-like Syndrome in Eosinophilic Disease of the Lung: A Case Report and Review of the Literature. Internal Medicine. 2016;55 (20):3029-3034$77$YR$$M$Y$$$20221004$$MD$JP$JP
1291173227$12911732$27$F$20180614$20221214$20161104$20221220$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK144075$GLAXOSMITHKLINE$$$$$$Y$$$20221220$$CN$BR$BR
129132333$12913233$3$F$$20220921$20161104$20221004$EXP$$JP-PFIZER INC-2016511338$PFIZER$Yang, S.. Steroid-induced tumor lysis symdrome in a patient with preleukemia. Clinical Nephrology. 2003;59 (3):201-205$32$YR$$M$Y$$$20221004$$MD$TW$TW
129132746$12913274$6$F$20160425$20221129$20161104$20221206$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-035678$BRISTOL MYERS SQUIBB$$69$YR$E$F$Y$$$20221206$$CN$CA$CA
1291330611$12913306$11$F$$20221201$20161104$20221206$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-091788$BRISTOL MYERS SQUIBB$$58$YR$A$F$Y$$$20221206$$MD$CA$CA
1291742713$12917427$13$F$20180101$20220928$20161107$20221012$EXP$$US-PFIZER INC-2016514720$MYLAN$$$$$F$Y$97$KG$20221012$$HP$US$US
129175146$12917514$6$F$20150701$20221206$20161107$20221213$EXP$$PHHY2015CA089817$NOVARTIS$$41$YR$$F$Y$$$20221213$$CN$CA$CA
1292320724$12923207$24$F$20201127$20221124$20161109$20221129$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK044940$GLAXOSMITHKLINE$$$$$$Y$$$20221129$$CN$BR$BR
129235696$12923569$6$F$20160821$20221004$20161108$20221012$EXP$$BR-BIOGEN-2016BI00315184$BIOGEN$$0$YR$$M$Y$2.85$KG$20221012$$CN$BR$BR
129272294$12927229$4$F$20161001$20221206$20161109$20221212$EXP$$US-JAZZ-2016-US-021819$JAZZ$$56$YR$$F$Y$$$20221213$$CN$US$US
1292783615$12927836$15$F$20130417$20221013$20161110$20221020$EXP$$CA-ROCHE-1851729$ROCHE$$49$YR$$F$Y$$$20221020$$CN$CA$CA
1292888834$12928888$34$F$$20220728$20161110$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-091881$BRISTOL MYERS SQUIBB$$55$YR$A$F$Y$$$20221222$$HP$CA$CA
1292888921$12928889$21$F$$20221020$20161110$20221026$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-091709$BRISTOL MYERS SQUIBB$$66$YR$E$F$Y$$$20221026$$MD$CA$CA
129293364$12929336$4$F$20160528$20221229$20161110$20221230$EXP$$FR-009507513-1611FRA003790$MERCK$$79$YR$$M$Y$103.5$KG$20221230$$HP$FR$FR
129301778$12930177$8$F$$20221020$20161110$20221025$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-093180$BRISTOL MYERS SQUIBB$$62$YR$A$F$Y$$$20221025$$CN$CA$CA
129321032$12932103$2$F$20161104$20221006$20161111$20221013$EXP$$ES-ROCHE-1853276$ROCHE$$74$YR$$M$Y$66$KG$20221011$$MD$ES$ES
129402602$12940260$2$F$20160317$20221105$20161115$20221118$EXP$$IT-AUROBINDO-AUR-APL-2016-13847$AUROBINDO$$48$YR$$F$Y$$$20221118$$MD$IT$IT
129431622$12943162$2$F$$20151002$20161115$20221020$PER$$US-NOVOPROD-466507$NOVO NORDISK$$40$YR$$F$Y$$$20221020$$MD$US$US
129432722$12943272$2$F$$20160225$20161115$20221020$PER$$US-NOVOPROD-482415$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
129432752$12943275$2$F$$20160121$20161115$20221020$PER$$US-NOVOPROD-482122$NOVO NORDISK$$60$YR$$F$Y$$$20221020$$CN$US$US
129433102$12943310$2$F$20160716$20160718$20161115$20221020$PER$$US-NOVOPROD-503338$NOVO NORDISK$$86$YR$$F$Y$$$20221020$$CN$US$US
129433212$12943321$2$F$20160701$20160727$20161115$20221020$PER$$US-NOVOPROD-504848$NOVO NORDISK$$58$YR$$F$Y$$$20221020$$CN$US$US
129433222$12943322$2$F$20150101$20160616$20161115$20221020$PER$$US-NOVOPROD-498599$NOVO NORDISK$$71$YR$$F$Y$$$20221020$$MD$US$US
1294337732$12943377$32$F$20220401$20221111$20161115$20221114$EXP$$BR-GLAXOSMITHKLINE-BR2015GSK075816$GLAXOSMITHKLINE$$$$$$Y$$$20221114$$MD$BR$BR
129460879$12946087$9$F$$20221227$20161115$20221230$EXP$$US-JAZZ-2016-US-022236$JAZZ$$$$$M$Y$$$20221230$$MD$US$US
1294773419$12947734$19$F$20150101$20221026$20161117$20221102$EXP$$CA-ROCHE-1854413$ROCHE$$61$YR$$F$Y$141$KG$20221102$$MD$CA$CA
1294979814$12949798$14$F$20150901$20221221$20161117$20221228$EXP$$PHHY2016CA114428$NOVARTIS$$52$YR$$F$Y$$$20221228$$MD$CA$CA
1295427710$12954277$10$F$20160328$20221031$20161118$20221102$EXP$$JP-SHIRE-JP201616794AA$TAKEDA$$0$YR$$F$Y$5.4$KG$20221102$$MD$JP$JP
129565822$12956582$2$F$$20221128$20161118$20221202$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2016-BI-077034$BOEHRINGER INGELHEIM$$40$YR$A$F$Y$94$KG$20221202$$PH$CA$CA
1295753112$12957531$12$F$20111201$20221207$20161118$20221212$EXP$$US-SHIRE-US201617384$TAKEDA$$1$YR$$M$Y$29$KG$20221212$$HP$US$US
129575899$12957589$9$F$20130101$20221020$20161118$20221026$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-093145$BRISTOL MYERS SQUIBB$$49$YR$A$F$Y$$$20221027$$MD$CA$CA
129582968$12958296$8$F$$20221124$20161121$20221227$EXP$$CA-ROCHE-1627311$ROCHE$$40$YR$$F$Y$$$20221227$$MD$CA$
1296415627$12964156$27$F$20160310$20221206$20161122$20221213$EXP$$PHHY2016CA034937$NOVARTIS$$71$YR$$F$Y$$$20221213$$CN$CA$CA
1296897411$12968974$11$F$$20221128$20161123$20221201$PER$$US-PFIZER INC-2016545465$PFIZER$$72$YR$$F$Y$56.689$KG$20221201$$CN$US$US
1296928613$12969286$13$F$20160101$20221221$20161123$20221222$EXP$$PHHY2016CA151435$NOVARTIS$$67$YR$$M$Y$$$20221222$$CN$CA$CA
1297160410$12971604$10$F$20160501$20221027$20161123$20221102$EXP$$US-JAZZ-2016-US-023004$JAZZ$$38$YR$$M$Y$$$20221102$$MD$US$US
129740596$12974059$6$F$20161117$20221012$20161124$20221013$EXP$$FR-ROCHE-1858054$ROCHE$$71$YR$$M$Y$80$KG$20221013$$MD$FR$FR
1297420329$12974203$29$F$20141127$20221222$20161125$20221227$EXP$$CA-ROCHE-1858307$ROCHE$$42$YR$$F$Y$$$20221227$$CN$CA$CA
1297591114$12975911$14$F$20110101$20220928$20161125$20221006$EXP$$GB-MYLANLABS-2016M1035518$MYLAN$$44$YR$$F$Y$114$KG$20221006$$MD$GB$GB
1297671514$12976715$14$F$20200109$20221015$20161128$20221021$EXP$$PHHY2016CA084468$NOVARTIS$$86$YR$$M$Y$$$20221021$$CN$CA$CA
129781427$12978142$7$F$$20221214$20161128$20221222$PER$$US-PFIZER INC-2016448534$PFIZER$$62$YR$$F$Y$$$20221222$$HP$US$US
1297914824$12979148$24$F$20221011$20221026$20161128$20221031$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK087434$GLAXOSMITHKLINE$$$$$$Y$$$20221031$$CN$BR$BR
129816348$12981634$8$F$20190719$20221212$20161129$20221219$EXP$$CA-ROCHE-1860859$ROCHE$$39$YR$$M$Y$$$20221219$$HP$CA$CA
1298165814$12981658$14$F$20160927$20221027$20161129$20221103$EXP$$CA-ROCHE-1860260$ROCHE$$52$YR$$F$Y$$$20221103$$CN$CA$CA
129849016$12984901$6$F$$20221104$20161129$20221108$EXP$$US-PURDUE-USA-2016-0134131$PURDUE$$$$$F$Y$67.59$KG$20221108$$MD$US$US
129879488$12987948$8$F$20160101$20221005$20161130$20221010$EXP$$US-BAXALTA-2016BLT008577$TAKEDA$$$$$F$Y$91$KG$20221010$$HP$US$US
129889867$12988986$7$F$$20221216$20161201$20221221$EXP$$CA-ROCHE-1860198$ROCHE$$$$$M$Y$$$20221221$$HP$CA$
129907712$12990771$2$F$$20221221$20161201$20221230$EXP$$CA-JNJFOC-20161128255$JOHNSON AND JOHNSON$$52$YR$A$F$Y$63.56$KG$20221230$$HP$CA$CA
1299241836$12992418$36$F$20161123$20220930$20161202$20221013$EXP$$CA-ROCHE-1862239$ROCHE$$53$YR$$F$Y$$$20221013$$CN$CA$CA
129925948$12992594$8$F$20161101$20221214$20161202$20221221$PER$$JP-AMGEN-JPNSP2016152588$AMGEN$$47$YR$A$M$Y$85$KG$20221221$$MD$JP$JP
1299455328$12994553$28$F$20160101$20221114$20161202$20221119$EXP$$PHHY2016CA074240$NOVARTIS$$$$$M$Y$$$20221119$$CN$CA$CA
129975195$12997519$5$F$20140212$20221212$20161205$20221215$EXP$$CA-ROCHE-1342887$ROCHE$$63$YR$$F$Y$82.8$KG$20221214$$HP$CA$
1299861416$12998614$16$F$20160614$20221221$20161205$20221227$EXP$$GB-TAKEDA-2016TUS021619$TAKEDA$$$$A$M$Y$$$20221227$$MD$GB$GB
129997106$12999710$6$F$20161116$20221117$20161205$20221121$EXP$$PHHY2016CA166327$NOVARTIS$$32$YR$$M$Y$$$20221121$$CN$CA$CA
130007592$13000759$2$F$20161003$20221105$20161206$20221119$EXP$$IT-AUROBINDO-AUR-APL-2016-14713$AUROBINDO$$51$YR$$F$Y$$$20221119$$MD$IT$IT
1300136918$13001369$18$F$20160101$20220929$20161206$20221001$EXP$$PHHY2016CA114488$NOVARTIS$$$$$F$Y$75$KG$20221001$$CN$CA$CA
130036203$13003620$3$F$20160528$20221221$20161206$20221228$EXP$$FR-ELI_LILLY_AND_COMPANY-FR201611009644$ELI LILLY AND CO$$79$YR$$M$Y$103.5$KG$20221228$$CN$FR$FR
130036768$13003676$8$F$$20221208$20161206$20221208$EXP$$US-PFIZER INC-2015308077$PFIZER$$63$YR$$F$Y$73.8$KG$20221208$$CN$US$US
130040622$13004062$2$F$$20161031$20161206$20221026$PER$$US-JAZZ-2016-US-021669$JAZZ$$$$$M$Y$$$20221026$$HP$US$US
130041264$13004126$4$F$$20221227$20161206$20221229$EXP$$US-JAZZ-2016-US-021749$JAZZ$$$$$F$Y$$$20221229$$HP$US$US
130049454$13004945$4$F$20120625$20221109$20161207$20221121$EXP$FR-MLMSERVICE-20161123-0509896-1$FR-LUPIN PHARMACEUTICALS INC.-2016-05377$LUPIN$Cuny P, Houot M, Ginisty S, Horowicz S, Plassart F, Mentec H et al. Quetiapine and anticholinergic drugs induced ischaemic colitis: A case study. Encephale. 2016$34$YR$$M$Y$$$20221121$$MD$FR$FR
130076682$13007668$2$F$20160818$20220927$20161207$20221003$PER$$US-AMGEN-USASL2016172854$AMGEN$$68$YR$E$F$Y$$$20221003$$CN$US$US
130099103$13009910$3$F$20140720$20221227$20161208$20221230$EXP$$PHHY2014IN084165$NOVARTIS$$34$YR$$F$Y$$$20221230$$CN$IN$IN
1301226122$13012261$22$F$20170823$20221227$20161209$20221230$EXP$$US-PFIZER INC-2016561839$PFIZER$$57$YR$$F$Y$114$KG$20221230$$CN$US$US
130177477$13017747$7$F$$20221107$20161212$20221111$EXP$$US-PFIZER INC-2016564692$PFIZER$$83$YR$$F$Y$$$20221111$$CN$US$US
1302193810$13021938$10$F$20120623$20221103$20161213$20221117$EXP$$FR-AUROBINDO-AUR-APL-2016-15207$AUROBINDO$Cuny P, Houot M, Ginisty S, Horowicz S, Plassart F, Mentec H, Eftekhari  P. et al. Quetiapine and anticholinergic drugs induced ischaemic colitis. A case study Encephale. 2016;43:81-84$34$YR$$M$Y$$$20221117$$MD$FR$FR
1302369512$13023695$12$F$20151222$20221007$20161213$20221013$EXP$$US-PFIZER INC-2016571070$PFIZER$$68$YR$$M$Y$84$KG$20221013$$CN$US$US
1302401114$13024011$14$F$20161101$20211116$20161213$20221212$EXP$$US-PFIZER INC-2016569208$PFIZER$$40$YR$$F$Y$$$20221212$$CN$US$US
130301234$13030123$4$F$$20221107$20161215$20221117$EXP$$PHJP2016JP036265$NOVARTIS$$$$A$M$Y$$$20221117$$MD$JP$JP
1303510110$13035101$10$F$20050201$20221012$20161216$20221018$EXP$$US-PFIZER INC-2016579864$PFIZER$$63$YR$$M$Y$95$KG$20221018$$CN$US$US
130358825$13035882$5$F$20130201$20221006$20161216$20221007$PER$$US-PFIZER INC-2016584425$PFIZER$$60$YR$$F$Y$112$KG$20221007$$CN$US$US
130369477$13036947$7$F$20160101$20221219$20161216$20221223$EXP$$CA-TAKEDA-2016TUS021434$TAKEDA$$48$YR$$F$Y$$$20221223$$CN$CA$CA
1303863515$13038635$15$F$20151228$20221011$20161219$20221019$EXP$$JP-AEGERION PHARMACEUTICAL INC.-AEGR002872$AEGERION$$$$$$Y$$$20221019$$MD$JP$JP
130420884$13042088$4$F$20120601$20221001$20161219$20221004$PER$$US-PFIZER INC-2016584349$PFIZER$$31$YR$$F$Y$111.1$KG$20221004$$LW$US$US
130469199$13046919$9$F$20220101$20221004$20161220$20221010$EXP$$PHHY2016CA172480$NOVARTIS$$60$YR$$M$Y$$$20221010$$CN$CA$CA
130476542$13047654$2$F$20161101$20221117$20161220$20221125$EXP$$US-JAZZ-2016-US-023967$JAZZ$$75$YR$$M$Y$$$20221125$$CN$US$US
130483473$13048347$3$F$20161129$20221129$20161221$20221208$EXP$$JP-TEVA-721834ISR$TEVA$$35$YR$A$F$Y$$$20221208$$MD$JP$JP
1305843511$13058435$11$F$$20221220$20161223$20221230$EXP$$CA-APOTEX-2016AP015741$APOTEX$$73$YR$$F$Y$$$20221230$$MD$CA$CA
130586493$13058649$3$F$20120301$20221005$20161223$20221006$PER$$US-PFIZER INC-2016596189$PFIZER$$42$YR$$F$Y$$$20221006$$LW$US$US
1305905611$13059056$11$F$$20221122$20161223$20221202$EXP$$CA-APOTEX-2016AP015753$APOTEX$$72$YR$$F$Y$$$20221202$$MD$CA$CA
130595802$13059580$2$F$$20221014$20161223$20221017$EXP$$ES-GLAXOSMITHKLINE-ES2016GSK189344$GLAXOSMITHKLINE$Ventura-Ribes O, Machancoses FH, Rosel Remirez JF. Vasculitis after blood pressure monitoring. Reumatol-Clin. 2016;12(4):216-218$80$YR$$M$Y$$$20221017$$HP$ES$ES
130598962$13059896$2$F$20101225$20221003$20161223$20221010$EXP$IT-MINISAL02-387319$IT-MYLANLABS-2016M1056156$MYLAN$Annaloro C, Costa A, Fracchiolla NS, Mometto G, Artuso S, Saporiti G, et al. Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: A case report.. Clinical Case Reports. 2015;3 (7):650-5$55$YR$$M$Y$$$20221010$$HP$IT$IT
130623974$13062397$4$F$20160101$20221214$20161226$20221222$EXP$$CA-TAKEDA-2016TUS022808$TAKEDA$$85$YR$$F$Y$$$20221222$$HP$CA$CA
1306563712$13065637$12$F$20090222$20221205$20161227$20221209$EXP$$US-PFIZER INC-2016595970$PFIZER$$59$YR$$F$Y$73$KG$20221209$$CN$US$US
1307079914$13070799$14$F$20090209$20221227$20161229$20221230$EXP$$CA-Orion Corporation ORION PHARMA-TREX2016-2790$ORION$$57$YR$A$M$Y$$$20221230$$MD$CA$
1307383416$13073834$16$F$20161128$20221213$20161229$20221217$EXP$$CA-TAKEDA-2016TUS023148$TAKEDA$$67$YR$$F$Y$$$20221217$$CN$CA$CA
130748976$13074897$6$F$20161214$20221220$20161230$20221227$PER$$US-PFIZER INC-2016596467$PFIZER$$35$YR$$M$Y$104$KG$20221227$$MD$US$US
130753587$13075358$7$F$20150603$20221006$20161230$20221011$EXP$$US-AstraZeneca-2016SF36386$ASTRAZENECA$$82$YR$$M$Y$83.5$KG$20221011$$LW$US$
1307700011$13077000$11$F$20161206$20221219$20161230$20221230$EXP$$CZ-BIOGEN-2016BI00328821$BIOGEN$$29$YR$$M$Y$$$20221230$$MD$CZ$CZ
130804845$13080484$5$F$$20220929$20170103$20221006$EXP$$CA-PFIZER INC-2016523517$PFIZER$$35$YR$$F$Y$$$20221006$$CN$CA$CA
130810228$13081022$8$F$$20221005$20170103$20221007$PER$$US-PFIZER INC-2016601370$PFIZER$$65$YR$$F$Y$$$20221007$$CN$US$US
1308165710$13081657$10$F$20080101$20221229$20170103$20221230$EXP$$US-PFIZER INC-2016598166$PFIZER$$38$YR$$F$Y$49.9$KG$20221230$$CN$US$US
130846534$13084653$4$F$20160912$20170118$20170104$20221212$EXP$IT-MINISAL02-389561$IT-TEVA-725686ACC$TEVA$$43$YR$A$F$Y$$$20221212$$MD$IT$IT
1308545212$13085452$12$F$$20221208$20170104$20221215$EXP$$US-PFIZER INC-2015269766$PFIZER$$83$YR$$F$Y$55$KG$20221215$$MD$US$US
130877668$13087766$8$F$20100329$20220930$20170105$20221008$EXP$$US-AstraZeneca-2017SE00122$ASTRAZENECA$$18575$DY$$F$Y$113.9$KG$20221008$$LW$US$
130895609$13089560$9$F$20201123$20221129$20170105$20221201$PER$$US-PFIZER INC-2017004247$PFIZER$$66$YR$$M$Y$71$KG$20221201$$CN$US$US
1309076910$13090769$10$F$$20221025$20170106$20221109$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-130668$RANBAXY$$30$YR$$M$Y$$$20221109$$PH$GB$GB
1309116614$13091166$14$F$$20221215$20170106$20221228$EXP$$GB-AUROBINDO-AUR-APL-2016-16077$AUROBINDO$$30$YR$$M$Y$$$20221228$$PH$GB$GB
130939163$13093916$3$F$20221101$20221215$20170106$20221221$EXP$$US-PFIZER INC-2016010159$PFIZER$$62$YR$$F$Y$$$20221221$$HP$US$US
1309437313$13094373$13$F$20181201$20221215$20170106$20221221$EXP$$US-PFIZER INC-2017005477$PFIZER$$63$YR$$F$Y$65.76$KG$20221221$$HP$US$US
130954754$13095475$4$F$$20221010$20170108$20221017$EXP$$GB-MYLANLABS-2017M1000526$MYLAN$$$$$M$Y$$$20221017$$MD$GB$GB
130955484$13095548$4$F$$20221222$20170108$20221227$EXP$$US-BIOGEN-2017BI00338624$BIOGEN$$$$$F$Y$$$20221227$$CN$US$US
1309595312$13095953$12$F$20160226$20221104$20170109$20221110$EXP$$CA-ROCHE-1782427$ROCHE$$$$A$F$Y$123.5$KG$20221110$$MD$CA$CA
130970466$13097046$6$F$20161208$20221212$20170109$20221219$PER$$US-PFIZER INC-2017007183$PFIZER$$65$YR$$F$Y$98$KG$20221219$$CN$US$US
131000368$13100036$8$F$$20221130$20170110$20221205$EXP$$CA-ROCHE-1877137$ROCHE$$69$YR$$F$Y$$$20221205$$MD$CA$
1310187616$13101876$16$F$20170101$20221031$20170110$20221102$EXP$$US-PFIZER INC-2017006260$PFIZER$$72$YR$$F$Y$73.3$KG$20221102$$CN$US$US
131044923$13104492$3$F$$20221212$20170111$20221216$PER$$US-BIOGEN-2017BI00340115$BIOGEN$$$$$F$Y$$$20221216$$CN$US$US
1310615211$13106152$11$F$20161209$20221207$20170111$20221213$PER$$US-PFIZER INC-2017007803$PFIZER$$61$YR$$M$Y$95.25$KG$20221213$$MD$US$US
131070847$13107084$7$F$$20221121$20170111$20221124$EXP$$CA-ROCHE-1789917$ROCHE$$$$$F$Y$$$20221124$$MD$CA$
1310779811$13107798$11$F$20150612$20221220$20170112$20221226$EXP$$CA-Orion Corporation ORION PHARMA-TREX2017-0119$ORION$$73$YR$E$F$Y$$$20221226$$MD$CA$
131095753$13109575$3$F$20070101$20221109$20170112$20221114$EXP$$US-TAKEDA-2017TUS000775$TAKEDA$$$$$$Y$$$20221114$$CN$US$US
131115623$13111562$3$F$$20221118$20170112$20221125$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-000750$BRISTOL MYERS SQUIBB$Reuss JE, Kunk PR, Stowman AM, Gru AA, Slingluff CL, Gaughan EM. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report andamp; review of the literature. Journal for ImmunoTherapy of cancer. 2016; 4(94): 1-6.doi:10.1186/s40425-016-0199-9.$32$YR$A$F$Y$$$20221125$$CN$US$US
1311187019$13111870$19$F$$20221121$20170113$20221122$EXP$$CA-ROCHE-1717236$ROCHE$$$$$F$Y$$$20221122$$MD$CA$
1311312211$13113122$11$F$$20221212$20170113$20221218$PER$$CA-AMGEN-CANSP2017001862$AMGEN$$58$YR$A$F$Y$$$20221218$$MD$CA$CA
1311313323$13113133$23$F$20130101$20221222$20170113$20221228$EXP$$CA-Orion Corporation ORION PHARMA-TREX2016-0862$ORION$$65$YR$E$F$Y$$$20221228$$MD$CA$
131135934$13113593$4$F$$20221213$20170113$20221214$EXP$$US-BIOGEN-2017BI00342151$BIOGEN$$$$$F$Y$$$20221214$$CN$US$US
131155734$13115573$4$F$20160101$20220721$20170114$20221026$PER$$US-JAZZ-2016-US-022692$JAZZ$$$$$F$Y$$$20221026$$CN$US$US
131162183$13116218$3$F$20161214$20221125$20170116$20221206$PER$$GB-AMGEN-GBRSP2016180759$AMGEN$$54$YR$A$F$Y$$$20221205$$CN$GB$GB
1311644513$13116445$13$F$$20220921$20170116$20221006$EXP$$CA-BAUSCH-BL-2017-001069$BAUSCH AND LOMB$$74$YR$$F$Y$$$20221006$$CN$CA$CA
131167729$13116772$9$F$$20221201$20170116$20221202$EXP$$CA-ROCHE-1878330$ROCHE$$57$YR$$F$Y$$$20221202$$MD$CA$
1311681612$13116816$12$F$$20221031$20170116$20221102$PER$$US-PFIZER INC-2017015915$PFIZER$$69$YR$$F$Y$$$20221102$$CN$US$US
131178844$13117884$4$F$20040101$20221012$20170116$20221020$PER$$US-JNJFOC-20170104055$JOHNSON AND JOHNSON$$1$DEC$C$M$Y$$$20221021$$LW$US$US
131178983$13117898$3$F$$20221213$20170116$20221215$EXP$$US-JNJFOC-20170106074$JOHNSON AND JOHNSON$$$$$M$Y$$$20221215$$HP$US$US
131200397$13120039$7$F$20100101$20221018$20170117$20221025$EXP$$US-AstraZeneca-2017SE02375$ASTRAZENECA$$57$YR$$F$Y$42.2$KG$20221025$$LW$US$
1312053711$13120537$11$F$20161201$20221208$20170117$20221213$PER$$US-PFIZER INC-2017013282$PFIZER$$75$YR$$F$Y$$$20221213$$CN$US$US
131205603$13120560$3$F$20140201$20221122$20170117$20221128$PER$$US-PFIZER INC-2017014247$PFIZER$$65$YR$$F$Y$64.853$KG$20221128$$CN$US$US
131215063$13121506$3$F$20161208$20221220$20170117$20221229$EXP$$CA-BIOGEN-2017BI00343393$BIOGEN$$49$YR$$F$Y$$$20221229$$MD$CA$CA
1312164812$13121648$12$F$$20221212$20170117$20221219$EXP$$CA-PFIZER INC-2017017327$PFIZER$$58$YR$$F$Y$$$20221219$$CN$CA$CA
131226566$13122656$6$F$20060101$20221128$20170117$20221206$EXP$$CA-SA-2016SA086812$SANOFI AVENTIS$$50$YR$A$M$Y$$$20221206$$MD$CA$CA
131237885$13123788$5$F$20070101$20221108$20170118$20221111$EXP$$US-AstraZeneca-2017SE03009$ASTRAZENECA$$444$MON$$M$Y$89.8$KG$20221111$$LW$US$
1312599736$13125997$36$F$20170110$20221206$20170118$20221213$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK017485$GLAXOSMITHKLINE$$$$$$Y$$$20221213$$CN$BR$BR
131299688$13129968$8$F$$20221028$20170119$20221101$EXP$$GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-002909$BRISTOL MYERS SQUIBB$$58$YR$A$F$Y$$$20221101$$MD$GB$GB
131307153$13130715$3$F$20150101$20221024$20170119$20221027$PER$$US-JAZZ-2017-US-000387$JAZZ$$$$$F$Y$$$20221027$$CN$US$US
1313143216$13131432$16$F$20170110$20220928$20170119$20221004$EXP$$IE-MYLANLABS-2017M1002906$MYLAN$$44$YR$$M$Y$$$20221004$$MD$IE$IE
131317407$13131740$7$F$20160701$20221215$20170119$20221220$EXP$$US-PFIZER INC-2017024415$PFIZER$$69$YR$$M$Y$$$20221220$$CN$US$US
1313261510$13132615$10$F$$20221218$20170120$20221220$EXP$$CA-Orion Corporation ORION PHARMA-TREX2017-0240$ORION$$58$YR$A$F$Y$$$20221220$$MD$CA$
131352782$13135278$2$F$$20221220$20170120$20221222$EXP$$US-PFIZER INC-2016308561$PFIZER$$67$YR$$F$Y$$$20221222$$CN$US$US
131357277$13135727$7$F$20160101$20221101$20170120$20221108$PER$$US-PFIZER INC-2017020229$PFIZER$$20$YR$$M$Y$113.4$KG$20221108$$CN$US$US
131393333$13139333$3$F$20161201$20221222$20170123$20221230$EXP$$FR-PFIZER INC-2017020968$PFIZER$$72$YR$$F$Y$100$KG$20221230$$MD$FR$FR
131403488$13140348$8$F$20170101$20221219$20170123$20221227$EXP$$US-PFIZER INC-2017030225$PFIZER$$76$YR$$F$Y$$$20221227$$CN$US$US
131422307$13142230$7$F$20161201$20221123$20170124$20221125$EXP$$CA-TAKEDA-2017TUS001307$TAKEDA$$66$YR$$M$Y$122$KG$20221125$$CN$CA$CA
131427527$13142752$7$F$20150420$20221212$20170124$20221219$EXP$$JP-PFIZER INC-2017028174$PFIZER$$31$YR$$F$Y$50$KG$20221219$$MD$JP$JP
1314326411$13143264$11$F$20160101$20221123$20170124$20221130$EXP$$FR-GLAXOSMITHKLINE-FR2016GSK093577$GLAXOSMITHKLINE$$$$$$Y$$$20221130$$HP$FR$FR
1314540416$13145404$16$F$$20221024$20170124$20221027$PER$$US-PFIZER INC-2017029857$PFIZER$$64$YR$$F$Y$$$20221027$$CN$US$US
1314726614$13147266$14$F$$20221206$20170125$20221208$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-005239$BRISTOL MYERS SQUIBB$$49$YR$A$F$Y$73$KG$20221209$$CN$CA$CA
131502044$13150204$4$F$20170119$20221014$20170125$20221020$EXP$$US-SHIRE-US201701265$TAKEDA$$16$YR$$M$Y$$$20221019$$MD$US$US
131531928$13153192$8$F$$20221223$20170126$20221227$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-005886$BRISTOL MYERS SQUIBB$$64$YR$A$F$Y$$$20221228$$CN$CA$CA
1315320010$13153200$10$F$$20221129$20170126$20221201$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-005842$BRISTOL MYERS SQUIBB$$64$YR$A$F$Y$$$20221201$$CN$CA$CA
131537144$13153714$4$F$$20221212$20170126$20221219$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2017-BI-003440$BOEHRINGER INGELHEIM$$85$YR$E$M$Y$$$20221219$$MD$CA$CA
1315500814$13155008$14$F$$20221011$20170126$20221014$EXP$$US-PFIZER INC-2017029933$PFIZER$$75$YR$$F$Y$90.72$KG$20221014$$CN$US$US
131584894$13158489$4$F$20161101$20221218$20170127$20221221$EXP$$CA-TAKEDA-2016TUS021205$TAKEDA$$30$YR$$M$Y$$$20221221$$MD$CA$CA
131588424$13158842$4$F$$20170130$20170127$20221212$EXP$$DE-TEVA-732118GER$TEVA$$79$YR$E$F$Y$50$KG$20221212$$HP$DE$DE
1315892219$13158922$19$F$20070101$20221020$20170127$20221025$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-005391$BRISTOL MYERS SQUIBB$$41$YR$A$F$Y$$$20221025$$HP$CA$CA
131656122$13165612$2$F$$20221129$20170131$20221205$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-004945$BRISTOL MYERS SQUIBB$$67$YR$E$F$Y$$$20221205$$CN$CA$CA
131675254$13167525$4$F$$20221130$20170131$20221205$PER$$US-PFIZER INC-2017040672$PFIZER$$44$YR$$F$Y$$$20221205$$CN$US$US
1316786110$13167861$10$F$$20221207$20170131$20221208$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-005498$BRISTOL MYERS SQUIBB$$59$YR$A$F$Y$58$KG$20221208$$CN$CA$CA
1317870811$13178708$11$F$$20221103$20170202$20221109$EXP$$CA-ROCHE-1886825$ROCHE$$51$YR$$F$Y$$$20221109$$HP$CA$
131790076$13179007$6$F$$20221220$20170202$20221227$PER$$US-PFIZER INC-2017045002$PFIZER$$58$YR$$M$Y$74.84$KG$20221227$$CN$US$US
131795173$13179517$3$F$20150915$20220929$20170202$20221006$EXP$$US-TAKEDA-2017TUS002251$TAKEDA$$24$YR$$F$Y$79.83$KG$20221006$$HP$US$US
131799375$13179937$5$F$20161130$20221222$20170202$20221228$EXP$$US-INCYTE CORPORATION-2017IN000613$INCYTE$$$$$$Y$$$20221228$$CN$US$US
131826877$13182687$7$F$20190801$20221109$20170203$20221111$EXP$$US-PFIZER INC-2017045478$PFIZER$$56$YR$$F$Y$$$20221111$$CN$US$US
131826984$13182698$4$F$20211001$20221208$20170203$20221215$PER$$US-PFIZER INC-2017045712$PFIZER$$64$YR$$F$Y$$$20221215$$CN$US$US
131830144$13183014$4$F$20130401$20221102$20170203$20221107$EXP$$US-009507513-1702USA001550$MERCK$$74$YR$$F$Y$68.027$KG$20221107$$CN$US$US
1318310313$13183103$13$F$20170101$20221020$20170203$20221028$EXP$$CA-TAKEDA-2017TUS002274$TAKEDA$$51$YR$$M$Y$$$20221028$$HP$CA$CA
1318771613$13187716$13$F$20160101$20221020$20170206$20221024$EXP$$US-PFIZER INC-2017047673$PFIZER$$85$YR$$F$Y$51.26$KG$20221024$$CN$US$US
1319115616$13191156$16$F$20161102$20220929$20170207$20221004$EXP$$CA-ROCHE-1889462$ROCHE$$60$YR$$M$Y$$$20221004$$MD$CA$CA
131914403$13191440$3$F$20150301$20221003$20170207$20221011$EXP$$FR-Accord-047915$ACCORD$Yapo Kouadio CG, Hasseine L, Goubaux B, Gari Toussaint M. (Disseminated fungal infection due to Magnusiomyces capitatus in a liver graft patient). J Mycol Med. 2016 Sep 26(3):261-4.$62$YR$A$M$Y$$$20221011$$HP$FR$FR
131932045$13193204$5$F$20170127$20221012$20170207$20221017$EXP$$JP-Eisai Medical Research-EC-2017-024575$EISAI$$73$YR$E$F$Y$59$KG$20221017$$MD$JP$
131943423$13194342$3$F$20161121$20220810$20170207$20221026$PER$$US-JAZZ-2016-US-023752$JAZZ$$31$YR$$M$Y$$$20221026$$HP$US$US
1319527628$13195276$28$F$20160606$20221109$20170208$20221118$EXP$$CA-ROCHE-1889780$ROCHE$$66$YR$$M$Y$85$KG$20221118$$MD$CA$CA
132005322$13200532$2$F$20160201$20221013$20170208$20221020$EXP$$PR-BIOGEN-2017BI00354587$BIOGEN$$55$YR$$F$Y$$$20221020$$CN$PR$PR
1320300811$13203008$11$F$$20220922$20170209$20221003$EXP$$US-PFIZER INC-2017054855$PFIZER$$69$YR$$F$Y$$$20221003$$HP$US$US
132079994$13207999$4$F$$20170220$20170209$20221212$EXP$$ES-TEVA-735074ISR$TEVA$$71$YR$E$F$Y$$$20221212$$HP$ES$ES
132134076$13213407$6$F$20150101$20221129$20170210$20221201$PER$$US-PFIZER INC-2017056695$PFIZER$$63$YR$$F$Y$75$KG$20221201$$HP$US$US
132135254$13213525$4$F$20170121$20221113$20170210$20221123$PER$$US-INCYTE CORPORATION-2017IN000639$INCYTE$$$$$$Y$$$20221123$$CN$US$US
1321461214$13214612$14$F$$20221025$20170210$20221101$EXP$$BE-PFIZER INC-2017059786$PFIZER$Heyrman, B.. A case report of immunosuppression-related Kaposi^s sarcoma after autologous stem cell transplantation. BMC Research Notes. 2016;9:188$61$YR$$M$Y$$$20221101$$HP$BE$BE
132246763$13224676$3$F$$20200520$20170213$20221219$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2017R1-132891$RANBAXY$Alghabra L, Iskandarani M. Spontaneous retroperitoneal haematoma resulting in bowel ischaemia. Br J Surg. 2019;106sup62$69$YR$$M$Y$$$20221219$$MD$GB$GB
1322689610$13226896$10$F$$20221018$20170213$20221020$EXP$$US-PFIZER INC-2017058171$PFIZER$$65$YR$$M$Y$$$20221020$$HP$US$US
132278815$13227881$5$F$20170206$20221222$20170213$20221229$EXP$$GB-MYLANLABS-2017M1007946$MYLAN$$38$YR$$M$Y$$$20221229$$MD$GB$GB
1322794413$13227944$13$F$20130919$20221018$20170213$20221025$EXP$$PHHY2017GB018424$NOVARTIS$$55$YR$$M$Y$$$20221025$$MD$GB$GB
1322882941$13228829$41$F$20130919$20221214$20170213$20221225$PER$US-ASTRAZENECA-2017SE07280$GB-AMGEN-GBRSP2017022053$AMGEN$$55$YR$A$M$Y$$$20221225$$MD$GB$GB
132300859$13230085$9$F$$20221221$20170214$20221227$EXP$$US-PFIZER INC-2017063888$PFIZER$$74$YR$$F$Y$87$KG$20221227$$CN$US$US
132345893$13234589$3$F$$20221027$20170215$20221031$PER$$US-PFIZER INC-2017062345$PFIZER$$62$YR$$F$Y$$$20221031$$MD$US$US
132382382$13238238$2$F$20161201$20221209$20170216$20221219$EXP$$US-SHIRE-US201702379$TAKEDA$$56$YR$$F$Y$48$KG$20221219$$CN$US$US
132387703$13238770$3$F$$20221206$20170216$20221210$EXP$$PHHY2017CA022870$NOVARTIS$$$$A$F$Y$$$20221210$$CN$CA$CA
132447002$13244700$2$F$$20220927$20170216$20221026$PER$$US-JAZZ-2017-US-000341$JAZZ$$$$$M$Y$$$20221026$$MD$US$US
132447379$13244737$9$F$20170101$20221013$20170216$20221026$PER$$US-JAZZ-2017-US-001025$JAZZ$$46$YR$$F$Y$$$20221026$$CN$US$US
132447445$13244744$5$F$20130101$20220809$20170216$20221026$PER$$US-JAZZ-2017-US-000946$JAZZ$$$$$F$Y$102.77$KG$20221026$$HP$US$US
1324667931$13246679$31$F$20130919$20221130$20170217$20221213$EXP$GB-MHRA-ADR 23836748$GB-Accord-048162$ACCORD$$55$YR$A$M$Y$$$20221213$$MD$GB$GB
132535656$13253565$6$F$20161201$20221121$20170220$20221130$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-001926$ACADIA PHARMACEUTICALS$$63$YR$$M$Y$108$KG$20221201$$CN$US$US
132535742$13253574$2$F$$20221205$20170220$20221214$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-001969$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221215$$CN$US$US
1325627411$13256274$11$F$20161013$20221019$20170221$20221025$EXP$$CA-TAKEDA-2015TUS015633$TAKEDA$$25$YR$$F$Y$$$20221025$$HP$CA$CA
132596439$13259643$9$F$20161201$20221017$20170222$20221018$EXP$$US-PFIZER INC-2017077124$PFIZER$$67$YR$$M$Y$79.83$KG$20221018$$CN$US$US
132606723$13260672$3$F$20170208$20221213$20170222$20221221$PER$$JP-Eisai Medical Research-EC-2017-025034$EISAI$$72$YR$E$F$Y$$$20221221$$MD$JP$
132622114$13262211$4$F$$20221121$20170222$20221122$EXP$$CA-ROCHE-1662402$ROCHE$$41$YR$$F$Y$$$20221122$$MD$CA$
132635746$13263574$6$F$20040101$20220915$20170223$20221005$EXP$$FR-ABBVIE-16P-056-1791361-00$ABBVIE$$$$$F$Y$$$20221005$$HP$FR$FR
132642314$13264231$4$F$$20221109$20170223$20221111$PER$$US-PFIZER INC-2017079350$PFIZER$$66$YR$$M$Y$$$20221111$$CN$US$US
1326434415$13264344$15$F$20170101$20221111$20170223$20221117$EXP$$CA-PFIZER INC-2017076339$PFIZER$$63$YR$$F$Y$$$20221117$$CN$CA$CA
1326573912$13265739$12$F$20160707$20221116$20170223$20221120$EXP$$PHHY2016CA100024$NOVARTIS$$77$YR$$F$Y$$$20221121$$HP$CA$CA
1326710920$13267109$20$F$20170101$20221101$20170224$20221115$EXP$GB-MHRA-ADR 23845327$GB-Accord-048413$ACCORD$$82$YR$E$M$Y$50$KG$20221115$$PH$GB$GB
1327603117$13276031$17$F$$20221107$20170228$20221114$EXP$$CA-ROCHE-1898975$ROCHE$$42$YR$$F$Y$97$KG$20221114$$HP$CA$
1327610816$13276108$16$F$20120713$20221107$20170228$20221109$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2015JPN102192$VIIV$$$$$$Y$$$20221109$$MD$JP$JP
1328179114$13281791$14$F$20170101$20221227$20170301$20221229$PER$$US-PFIZER INC-2017086148$PFIZER$$69$YR$$F$Y$67.12$KG$20221229$$HP$US$US
132843414$13284341$4$F$$20221128$20170301$20221209$EXP$$CA-SA-2017SA029762$SANOFI AVENTIS$$40$YR$A$F$Y$$$20221209$$HP$CA$CA
1328785310$13287853$10$F$20170220$20221206$20170302$20221215$PER$$US-PFIZER INC-2016570442$PFIZER$$17$YR$$M$Y$59$KG$20221215$$CN$US$US
132888667$13288866$7$F$$20221021$20170302$20221108$30DAY$$US-PFIZER INC-2017091257$PFIZER$$31$YR$$F$Y$159.4$KG$20221108$$MD$US$US
132891263$13289126$3$F$20170120$20221114$20170302$20221124$PER$$TR-AMGEN-TURSP2017030474$AMGEN$Imre E.; Seker A.; Dilek G. Y.. Urticarial Vasculitis After First Denosumab Injection in an Osteoporotic Woman Diagnosed with Cushing^s Syndrome. Turkish Journal of Endocrinology and Metabolism. 2022;26 (3):181-183$45$YR$A$F$Y$71$KG$20221124$$HP$TR$TR
132984048$13298404$8$F$20140101$20221004$20170306$20221011$EXP$$US-BIOGEN-2017BI00365344$BIOGEN$$$$$F$Y$$$20221011$$CN$US$US
133026733$13302673$3$F$20170223$20221107$20170307$20221120$EXP$$PHHO2017US004465$NOVARTIS$$5$YR$$F$Y$24.2$KG$20221121$$MD$US$US
133036784$13303678$4$F$20170217$20221001$20170307$20221004$EXP$$CO-BAXALTA-2017BLT001601$TAKEDA$$18$YR$$F$Y$46$KG$20221004$$CN$CO$CO
133070782$13307078$2$F$20160301$20221013$20170308$20221021$EXP$$CA-AstraZeneca-2017SE22106$ASTRAZENECA$$24$YR$$M$Y$52.2$KG$20221021$$MD$CA$
133097835$13309783$5$F$$20220922$20170309$20221001$PER$$US-JNJFOC-20170216832$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221001$$HP$US$US
133098364$13309836$4$F$$20221020$20170309$20221103$PER$$US-JNJFOC-20170216980$JOHNSON AND JOHNSON$$$$$M$Y$$$20221103$$LW$US$US
133098524$13309852$4$F$20131114$20220929$20170309$20221013$PER$$US-JNJFOC-20170216800$JOHNSON AND JOHNSON$$10$YR$C$M$Y$$$20221013$$HP$US$US
133098565$13309856$5$F$20070101$20221003$20170309$20221013$PER$$US-JNJFOC-20170216889$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221013$$LW$US$US
133098644$13309864$4$F$$20221006$20170309$20221018$PER$$US-JNJFOC-20170216990$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221018$$LW$US$US
133098874$13309887$4$F$20130701$20221020$20170309$20221028$EXP$$US-JNJFOC-20170216823$JOHNSON AND JOHNSON$$54$YR$A$M$Y$$$20221028$$LW$US$US
133098884$13309888$4$F$19981001$20220922$20170309$20221002$EXP$$US-JNJFOC-20170216981$JOHNSON AND JOHNSON$$11$YR$C$M$Y$$$20221002$$HP$US$US
133099203$13309920$3$F$$20221014$20170309$20221026$PER$$US-JNJFOC-20170216781$JOHNSON AND JOHNSON$$$$$M$Y$$$20221026$$LW$US$US
133099303$13309930$3$F$20020901$20220929$20170309$20221012$PER$$US-JNJFOC-20170216985$JOHNSON AND JOHNSON$$8$YR$C$M$Y$$$20221010$$LW$US$US
133100745$13310074$5$F$20061101$20221121$20170309$20221128$EXP$$US-JNJFOC-20170110056$JOHNSON AND JOHNSON$$5$YR$C$M$Y$$$20221129$$HP$US$US
133101884$13310188$4$F$20160101$20221031$20170309$20221108$PER$$US-JNJFOC-20170201268$JOHNSON AND JOHNSON$$4$DEC$A$M$Y$$$20221108$$LW$US$US
133101954$13310195$4$F$$20221020$20170309$20221030$PER$$US-JNJFOC-20170201260$JOHNSON AND JOHNSON$$$$$M$Y$$$20221030$$LW$US$US
133101975$13310197$5$F$$20220922$20170309$20221003$EXP$$US-JNJFOC-20170201232$JOHNSON AND JOHNSON$$$$$M$Y$$$20221003$$LW$US$US
133102056$13310205$6$F$20170305$20221114$20170309$20221116$PER$$US-JNJFOC-20170201266$JOHNSON AND JOHNSON$$20$YR$A$M$Y$$$20221116$$HP$US$US
133102115$13310211$5$F$20160506$20221031$20170309$20221104$PER$$US-JNJFOC-20170201274$JOHNSON AND JOHNSON$$57$YR$A$M$Y$$$20221104$$HP$US$US
133102145$13310214$5$F$$20221031$20170309$20221102$PER$$US-JNJFOC-20170201276$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221102$$HP$US$US
133102153$13310215$3$F$$20221031$20170309$20221114$PER$$US-JNJFOC-20170201277$JOHNSON AND JOHNSON$$$$$M$Y$$$20221114$$LW$US$US
133102174$13310217$4$F$20120101$20221020$20170309$20221030$PER$$US-JNJFOC-20170201254$JOHNSON AND JOHNSON$$3$DEC$A$M$Y$$$20221030$$HP$US$US
133102244$13310224$4$F$20170305$20221031$20170309$20221103$PER$$US-JNJFOC-20170201270$JOHNSON AND JOHNSON$$46$YR$A$M$Y$$$20221104$$HP$US$US
133102253$13310225$3$F$$20220929$20170309$20221012$PER$$US-JNJFOC-20170201271$JOHNSON AND JOHNSON$$$$$M$Y$$$20221010$$LW$US$US
133102424$13310242$4$F$$20221006$20170309$20221016$PER$$US-JNJFOC-20170201284$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221016$$HP$US$US
133102474$13310247$4$F$$20221006$20170309$20221014$PER$$US-JNJFOC-20170201287$JOHNSON AND JOHNSON$$$$$M$Y$$$20221014$$HP$US$US
133102515$13310251$5$F$$20221006$20170309$20221013$PER$$US-JNJFOC-20170201290$JOHNSON AND JOHNSON$$$$$M$Y$$$20221013$$LW$US$US
133102525$13310252$5$F$$20221006$20170309$20221017$PER$$US-JNJFOC-20170201291$JOHNSON AND JOHNSON$$$$$M$Y$$$20221017$$HP$US$US
133102544$13310254$4$F$$20221006$20170309$20221014$PER$$US-JNJFOC-20170201292$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221014$$HP$US$US
133102576$13310257$6$F$20120401$20221020$20170309$20221028$PER$$US-JNJFOC-20170201406$JOHNSON AND JOHNSON$$26$YR$A$M$Y$$$20221028$$HP$US$US
133102635$13310263$5$F$20010401$20221020$20170309$20221102$PER$$US-JNJFOC-20170201415$JOHNSON AND JOHNSON$$42$YR$A$M$Y$$$20221102$$HP$US$US
133102665$13310266$5$F$$20221006$20170309$20221017$PER$$US-JNJFOC-20170201293$JOHNSON AND JOHNSON$$$$$M$Y$$$20221017$$HP$US$US
133102694$13310269$4$F$20081217$20221020$20170309$20221027$EXP$$US-JNJFOC-20170201297$JOHNSON AND JOHNSON$$18$YR$A$M$Y$$$20221027$$LW$US$US
133103054$13310305$4$F$20080901$20221020$20170309$20221030$PER$$US-JNJFOC-20170201426$JOHNSON AND JOHNSON$$33$YR$A$M$Y$$$20221030$$HP$US$US
133103165$13310316$5$F$20071121$20221020$20170309$20221102$PER$$US-JNJFOC-20170201422$JOHNSON AND JOHNSON$$29$YR$A$M$Y$$$20221102$$HP$US$US
133103246$13310324$6$F$20090601$20220922$20170309$20221002$EXP$$US-JNJFOC-20170201413$JOHNSON AND JOHNSON$$17$YR$T$M$Y$$$20221002$$HP$US$US
133103476$13310347$6$F$20110501$20221014$20170309$20221020$EXP$$US-JNJFOC-20170202573$JOHNSON AND JOHNSON$$26$YR$A$M$Y$$$20221020$$HP$US$US
133103933$13310393$3$F$20110101$20221121$20170309$20221125$EXP$$US-JNJFOC-20170202972$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221125$$LW$US$US
133104224$13310422$4$F$20110601$20221014$20170309$20221020$PER$$US-JNJFOC-20170202640$JOHNSON AND JOHNSON$$27$YR$A$M$Y$$$20221020$$HP$US$US
133106184$13310618$4$F$20090612$20221219$20170309$20221222$PER$$US-JNJFOC-20170118418$JOHNSON AND JOHNSON$$11$YR$C$M$Y$$$20221222$$LW$US$US
133106694$13310669$4$F$$20221205$20170309$20221208$EXP$$US-JNJFOC-20170124442$JOHNSON AND JOHNSON$$$$$M$Y$$$20221209$$LW$US$US
133106884$13310688$4$F$$20220929$20170309$20221012$PER$$US-JNJFOC-20170201256$JOHNSON AND JOHNSON$$$$$M$Y$$$20221009$$LW$US$US
133106915$13310691$5$F$20140101$20221020$20170309$20221030$PER$$US-JNJFOC-20170201264$JOHNSON AND JOHNSON$$6$DEC$A$M$Y$$$20221030$$HP$US$US
133107024$13310702$4$F$$20221006$20170309$20221014$PER$$US-JNJFOC-20170202591$JOHNSON AND JOHNSON$$$$$M$Y$$$20221014$$HP$US$US
133107095$13310709$5$F$20100401$20221014$20170309$20221019$EXP$$US-JNJFOC-20170202568$JOHNSON AND JOHNSON$$21$YR$A$M$Y$$$20221019$$HP$US$US
133107225$13310722$5$F$$20221006$20170309$20221014$PER$$US-JNJFOC-20170202597$JOHNSON AND JOHNSON$$$$$M$Y$$$20221014$$HP$US$US
133107236$13310723$6$F$20030501$20221014$20170309$20221018$EXP$$US-JNJFOC-20170202577$JOHNSON AND JOHNSON$$36$YR$A$M$Y$$$20221018$$HP$US$US
133107256$13310725$6$F$20130814$20221014$20170309$20221025$PER$$US-JNJFOC-20170202580$JOHNSON AND JOHNSON$$25$YR$A$M$Y$$$20221025$$HP$US$US
133107395$13310739$5$F$$20221014$20170309$20221025$PER$$US-JNJFOC-20170202628$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221025$$HP$US$US
133107455$13310745$5$F$20170305$20220922$20170309$20221002$PER$$US-JNJFOC-20170202630$JOHNSON AND JOHNSON$$27$YR$A$M$Y$$$20221002$$HP$US$US
133107566$13310756$6$F$20060201$20221014$20170309$20221021$EXP$$US-JNJFOC-20170202644$JOHNSON AND JOHNSON$$33$YR$A$M$Y$$$20221021$$HP$US$US
133107576$13310757$6$F$20080101$20221014$20170309$20221027$PER$$US-JNJFOC-20170202645$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221027$$HP$US$US
133107824$13310782$4$F$$20221006$20170309$20221013$PER$$US-JNJFOC-20170202625$JOHNSON AND JOHNSON$$$$$M$Y$$$20221013$$LW$US$US
133107834$13310783$4$F$$20221014$20170309$20221025$PER$$US-JNJFOC-20170202626$JOHNSON AND JOHNSON$$$$$M$Y$$$20221025$$HP$US$US
133107855$13310785$5$F$20080101$20221014$20170309$20221020$PER$$US-JNJFOC-20170202627$JOHNSON AND JOHNSON$$41$YR$A$M$Y$$$20221020$$HP$US$US
133107886$13310788$6$F$20100101$20221020$20170309$20221025$PER$$US-JNJFOC-20170202657$JOHNSON AND JOHNSON$$3$DEC$A$M$Y$$$20221025$$HP$US$US
133107947$13310794$7$F$20170305$20221012$20170309$20221018$PER$$US-JNJFOC-20170202612$JOHNSON AND JOHNSON$$24$YR$A$M$Y$$$20221018$$HP$US$US
133107965$13310796$5$F$20070815$20221006$20170309$20221013$PER$$US-JNJFOC-20170202615$JOHNSON AND JOHNSON$$19$YR$A$M$Y$$$20221013$$HP$US$US
133108045$13310804$5$F$20080101$20221014$20170309$20221018$PER$$US-JNJFOC-20170202624$JOHNSON AND JOHNSON$$15$YR$T$M$Y$$$20221018$$HP$US$US
133109024$13310902$4$F$20000101$20221020$20170309$20221026$PER$$US-JNJFOC-20150923148$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221026$$HP$US$US
133109595$13310959$5$F$$20220929$20170309$20221012$PER$$US-JNJFOC-20170213617$JOHNSON AND JOHNSON$$$$$M$Y$$$20221010$$HP$US$US
133109675$13310967$5$F$20140610$20221020$20170309$20221102$PER$$US-JNJFOC-20170213604$JOHNSON AND JOHNSON$$27$YR$A$M$Y$$$20221102$$HP$US$US
133109804$13310980$4$F$$20220929$20170309$20221012$PER$$US-JNJFOC-20170213611$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221011$$LW$US$US
133109905$13310990$5$F$$20221006$20170309$20221013$EXP$$US-JNJFOC-20170213759$JOHNSON AND JOHNSON$$$$$M$Y$$$20221013$$HP$US$US
133109915$13310991$5$F$$20221031$20170309$20221108$PER$$US-JNJFOC-20170213760$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221109$$HP$US$US
133110074$13311007$4$F$20130101$20221014$20170309$20221020$EXP$$US-JNJFOC-20170213645$JOHNSON AND JOHNSON$$2$DEC$A$M$Y$$$20221020$$HP$US$US
133110105$13311010$5$F$$20221014$20170309$20221025$PER$$US-JNJFOC-20170213647$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221025$$HP$US$US
133110205$13311020$5$F$$20221006$20170309$20221013$PER$$US-JNJFOC-20170213616$JOHNSON AND JOHNSON$$$$$M$Y$$$20221013$$HP$US$US
133110235$13311023$5$F$19990507$20221020$20170309$20221027$PER$$US-JNJFOC-20170213648$JOHNSON AND JOHNSON$$41$YR$A$M$Y$$$20221027$$HP$US$US
133110355$13311035$5$F$$20221006$20170309$20221016$PER$$US-JNJFOC-20170213653$JOHNSON AND JOHNSON$$$$$M$Y$$$20221017$$HP$US$US
133110404$13311040$4$F$20130101$20220929$20170309$20221012$PER$$US-JNJFOC-20170213711$JOHNSON AND JOHNSON$$57$YR$A$M$Y$$$20221010$$LW$US$US
133110415$13311041$5$F$20170116$20220929$20170309$20221007$EXP$$US-JNJFOC-20170213734$JOHNSON AND JOHNSON$$27$YR$A$M$Y$$$20221007$$HP$US$US
133110435$13311043$5$F$$20221031$20170309$20221109$PER$$US-JNJFOC-20170213631$JOHNSON AND JOHNSON$$$$$M$Y$$$20221109$$HP$US$US
133110665$13311066$5$F$$20221006$20170309$20221014$PER$$US-JNJFOC-20170213973$JOHNSON AND JOHNSON$$$$$M$Y$$$20221014$$HP$US$US
133110705$13311070$5$F$20170301$20220922$20170309$20221001$PER$$US-JNJFOC-20170213658$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221001$$HP$US$US
133110874$13311087$4$F$$20221020$20170309$20221026$PER$$US-JNJFOC-20170213716$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221026$$LW$US$US
133111144$13311114$4$F$20050101$20221031$20170309$20221110$PER$$US-JNJFOC-20170213633$JOHNSON AND JOHNSON$$20$YR$A$M$Y$$$20221110$$HP$US$US
133111265$13311126$5$F$20170201$20221006$20170309$20221014$PER$$US-JNJFOC-20170213693$JOHNSON AND JOHNSON$$27$YR$A$M$Y$$$20221014$$LW$US$US
133111334$13311133$4$F$20140204$20221014$20170309$20221026$PER$$US-JNJFOC-20170213884$JOHNSON AND JOHNSON$$28$YR$A$M$Y$$$20221026$$LW$US$US
133111385$13311138$5$F$20120101$20220929$20170309$20221012$PER$$US-JNJFOC-20170213724$JOHNSON AND JOHNSON$$4$DEC$A$M$Y$$$20221010$$HP$US$US
133111495$13311149$5$F$$20221014$20170309$20221026$PER$$US-JNJFOC-20170213642$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221026$$HP$US$US
133112035$13311203$5$F$20170306$20220929$20170309$20221007$EXP$$US-JNJFOC-20170213636$JOHNSON AND JOHNSON$$20$YR$A$M$Y$$$20221007$$HP$US$US
133112194$13311219$4$F$$20221006$20170309$20221013$PER$$US-JNJFOC-20170213852$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221014$$LW$US$US
133114242$13311424$2$F$$20220928$20170309$20221007$PER$$US-JNJFOC-20170300750$JOHNSON AND JOHNSON$$$$$M$Y$$$20221007$$LW$US$US
133114543$13311454$3$F$20110922$20221107$20170309$20221115$PER$$US-JNJFOC-20170300759$JOHNSON AND JOHNSON$$16$YR$T$M$Y$$$20221115$$HP$US$US
133115155$13311515$5$F$$20221020$20170309$20221102$PER$$US-JNJFOC-20170216626$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221102$$HP$US$US
133116735$13311673$5$F$20170310$20221006$20170309$20221017$PER$$US-JNJFOC-20170216831$JOHNSON AND JOHNSON$$25$YR$A$M$Y$$$20221017$$HP$US$US
133116785$13311678$5$F$$20221006$20170309$20221018$PER$$US-JNJFOC-20170216805$JOHNSON AND JOHNSON$$$$$M$Y$$$20221018$$HP$US$US
133116823$13311682$3$F$20170101$20221031$20170309$20221109$PER$$US-JNJFOC-20170216658$JOHNSON AND JOHNSON$$30$YR$A$M$Y$$$20221109$$LW$US$US
133116855$13311685$5$F$20090205$20221006$20170309$20221015$PER$$US-JNJFOC-20170216816$JOHNSON AND JOHNSON$$9$YR$C$M$Y$$$20221015$$HP$US$US
133116965$13311696$5$F$20130901$20221006$20170309$20221017$PER$$US-JNJFOC-20170216822$JOHNSON AND JOHNSON$$28$YR$A$M$Y$$$20221017$$LW$US$US
133117324$13311732$4$F$20121109$20220922$20170309$20221001$PER$$US-JNJFOC-20170216815$JOHNSON AND JOHNSON$$12$YR$T$M$Y$$$20221001$$HP$US$US
133117385$13311738$5$F$20170308$20221020$20170309$20221103$PER$$US-JNJFOC-20170216836$JOHNSON AND JOHNSON$$58$YR$A$M$Y$$$20221103$$HP$US$US
133117394$13311739$4$F$$20221031$20170309$20221103$PER$$US-JNJFOC-20170216837$JOHNSON AND JOHNSON$$$$$M$Y$$$20221103$$HP$US$US
133117415$13311741$5$F$$20221006$20170309$20221018$PER$$US-JNJFOC-20170216818$JOHNSON AND JOHNSON$$$$$M$Y$$$20221018$$HP$US$US
133117495$13311749$5$F$20170305$20221014$20170309$20221021$PER$$US-JNJFOC-20170216879$JOHNSON AND JOHNSON$$27$YR$A$M$Y$$$20221021$$HP$US$US
133117584$13311758$4$F$$20221014$20170309$20221026$PER$$US-JNJFOC-20170216780$JOHNSON AND JOHNSON$$$$$M$Y$$$20221026$$LW$US$US
133117604$13311760$4$F$20130201$20220929$20170309$20221012$EXP$$US-JNJFOC-20170216809$JOHNSON AND JOHNSON$$2$DEC$$M$Y$$$20221009$$HP$US$US
133117645$13311764$5$F$$20221014$20170309$20221026$PER$$US-JNJFOC-20170216783$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221026$$HP$US$US
133122166$13312216$6$F$$20221121$20170309$20221124$EXP$$GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-019157$BRISTOL MYERS SQUIBB$$65$YR$E$M$Y$$$20221124$$HP$GB$GB
133148272$13314827$2$F$$20221025$20170309$20221101$EXP$$US-BAXALTA-2017BLT001752$TAKEDA$$$$$M$Y$93$KG$20221101$$HP$US$US
133154696$13315469$6$F$$20221121$20170310$20221123$EXP$$CA-ROCHE-1808080$ROCHE$$64$YR$$F$Y$$$20221123$$HP$CA$
133179788$13317978$8$F$20170303$20221205$20170310$20221208$PER$$US-PFIZER INC-2017104329$PFIZER$$70$YR$$F$Y$$$20221208$$CN$US$US
133197684$13319768$4$F$$20221121$20170310$20221123$PER$$US-BIOGEN-2017BI00369252$BIOGEN$$$$$F$Y$$$20221123$$CN$US$US
133216718$13321671$8$F$20170101$20221222$20170310$20221227$EXP$$US-PFIZER INC-2017095248$PFIZER$$61$YR$$F$Y$$$20221227$$CN$US$US
133217873$13321787$3$F$20170222$20221104$20170310$20221118$EXP$$US-CORCEPT THERAPEUTICS INC.-US-2017CRT000159$CORCEPT$$61$YR$$F$Y$$$20221118$$CN$US$US
1332677614$13326776$14$F$20170224$20221130$20170312$20221206$EXP$$US-SHIRE-US201704221$TAKEDA$$43$YR$$F$Y$$$20221206$$PH$US$US
133341646$13334164$6$F$20081201$20221013$20170313$20221019$EXP$$US-BIOGEN-2008BI033337$BIOGEN$$46$YR$$M$Y$76.272$KG$20221019$$CN$US$US
133361274$13336127$4$F$20060911$20221109$20170315$20221117$EXP$$CA-ROCHE-1562582$ROCHE$$$$A$M$Y$67$KG$20221117$$CN$CA$CA
133404316$13340431$6$F$$20221207$20170316$20221209$PER$$US-PFIZER INC-2017106540$PFIZER$$65$YR$$F$Y$51.701$KG$20221209$$CN$US$US
133410403$13341040$3$F$20170130$20221020$20170316$20221109$EXP$$PL-TAKEDA-2017MPI000816$TAKEDA$$75$YR$$M$Y$90$KG$20221109$$MD$PL$PL
133420836$13342083$6$F$20150101$20221118$20170316$20221124$EXP$$US-ROCHE-1817225$ROCHE$$67$YR$$M$Y$$$20221124$$CN$US$
133427165$13342716$5$F$$20221219$20170316$20221222$EXP$$US-PFIZER INC-2017109378$PFIZER$$72$YR$$F$Y$$$20221222$$CN$US$US
133436492$13343649$2$F$20160101$20221207$20170316$20221213$EXP$$US-JAZZ-2017-US-003225$JAZZ$$$$$F$Y$$$20221213$$CN$US$US
1334444610$13344446$10$F$20170307$20221013$20170317$20221017$EXP$$CN-ROCHE-1903883$ROCHE$$64$YR$$F$Y$48$KG$20221017$$MD$CN$
1334561719$13345617$19$F$20150501$20221228$20170317$20221230$EXP$$GB-ROCHE-1614575$ROCHE$$79$YR$$F$Y$$$20221230$$MD$GB$GB
133464982$13346498$2$F$$20221024$20170317$20221027$EXP$$FR-TAKEDA-2017TUS003359$TAKEDA$$48$YR$$F$Y$$$20221027$$HP$FR$FR
133465025$13346502$5$F$20160130$20220929$20170317$20221004$EXP$$US-TAKEDA-2017TUS005104$TAKEDA$$36$YR$$F$Y$48.526$KG$20221004$$HP$US$US
1335105013$13351050$13$F$20150101$20221128$20170320$20221130$EXP$$US-PFIZER INC-2017107202$PFIZER$$78$YR$$F$Y$73$KG$20221130$$CN$US$US
1335383315$13353833$15$F$20150101$20221228$20170321$20221230$PER$$US-PFIZER INC-2017110744$PFIZER$$63$YR$$F$Y$$$20221230$$CN$US$US
133564493$13356449$3$F$20100101$20221019$20170321$20221021$EXP$$US-TAKEDA-2017TUS005943$TAKEDA$$$$$$Y$$$20221021$$CN$US$US
1335649119$13356491$19$F$20161121$20221012$20170321$20221019$EXP$$DK-SA-2016SA220324$SANOFI AVENTIS$$41$YR$A$F$Y$73$KG$20221019$$HP$DK$DK
1335763314$13357633$14$F$20170301$20220926$20170322$20221004$EXP$$CA-ROCHE-1909497$ROCHE$$44$YR$$F$Y$135$KG$20221004$$CN$CA$CA
133578236$13357823$6$F$$20221013$20170322$20221017$PER$$US-PFIZER INC-2016566868$PFIZER$$73$YR$$F$Y$74.84$KG$20221017$$CN$US$US
133578654$13357865$4$F$20170224$20221214$20170322$20221220$EXP$$US-PFIZER INC-2017077172$PFIZER$$70$YR$$F$Y$$$20221220$$CN$US$US
1335819714$13358197$14$F$$20221215$20170322$20221219$EXP$$AU-ROCHE-1908670$ROCHE$$74$YR$$M$Y$80$KG$20221219$$MD$AU$AU
133583394$13358339$4$F$20170301$20221109$20170322$20221114$EXP$$PHHY2017CA038044$NOVARTIS$$48$YR$$M$Y$$$20221114$$CN$CA$CA
133616822$13361682$2$F$$20221015$20170323$20221029$EXP$$IN-MACLEODS PHARMACEUTICALS US LTD-MAC2017004482$MACLEODS$Nag DS, Samaddar DP, Kant S, Mahanty PR.. Perianesthetic refractory anaphylactic shock with cefuroxime in a patient with history of penicillin allergy on multiple antihypertensive medications.. Revista Brasileira de Anestesiologia.. 2017;67(2):217-220$$$$$Y$$$20221029$$MD$IN$IN
1336401125$13364011$25$F$20170101$20220929$20170323$20221004$EXP$$US-INCYTE CORPORATION-2017IN001912$INCYTE$$$$$$Y$$$20221004$$HP$US$US
133662076$13366207$6$F$20161001$20221227$20170323$20221229$EXP$$US-INCYTE CORPORATION-2016IN006262$INCYTE$$$$$$Y$$$20221229$$HP$US$US
133665444$13366544$4$F$20160101$20221216$20170323$20221221$EXP$$CA-TAKEDA-2017TUS002403$TAKEDA$$26$YR$$F$Y$$$20221221$$CN$CA$CA
133737332$13373733$2$F$$20221004$20170327$20221006$PER$$US-PFIZER INC-2017127522$PFIZER$$58$YR$$M$Y$$$20221006$$HP$US$US
133778742$13377874$2$F$$20221003$20170328$20221012$EXP$$JP-JNJFOC-20170328860$JOHNSON AND JOHNSON$$44$YR$A$M$Y$$$20221011$$MD$JP$JP
133811145$13381114$5$F$$20221025$20170329$20221031$EXP$$US-PFIZER INC-2017132859$PFIZER$$59$YR$$F$Y$52.16$KG$20221031$$MD$US$US
1338203312$13382033$12$F$20160708$20221020$20170329$20221026$EXP$$PHHY2016CA095571$NOVARTIS$$70$YR$$F$Y$$$20221026$$HP$CA$CA
133861053$13386105$3$F$20170317$20221019$20170330$20221028$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-002727$ACADIA PHARMACEUTICALS$$64$YR$$M$Y$$$20221028$$CN$US$US
133868705$13386870$5$F$20130101$20220930$20170330$20221006$PER$$US-PFIZER INC-2017136159$PFIZER$$69$YR$$F$Y$57$KG$20221006$$CN$US$US
133904062$13390406$2$F$20170201$20221121$20170331$20221128$PER$$US-PFIZER INC-2017139331$PFIZER$$55$YR$$F$Y$$$20221128$$CN$US$US
1339079018$13390790$18$F$20160101$20221212$20170331$20221216$EXP$$PHHY2016CA039834$NOVARTIS$$50$YR$$F$Y$$$20221216$$CN$CA$CA
133952935$13395293$5$F$$20221103$20170403$20221108$PER$$US-PFIZER INC-2017141650$PFIZER$$70$YR$$F$Y$$$20221108$$CN$US$US
1339894425$13398944$25$F$20160101$20221102$20170404$20221104$EXP$$PHHY2016CA109964$NOVARTIS$$$$$M$Y$$$20221104$$CN$CA$CA
134033904$13403390$4$F$20080101$20221223$20170404$20221227$EXP$$US-JAZZ-2017-US-004064$JAZZ$$$$$M$Y$$$20221227$$CN$US$US
134058258$13405825$8$F$20170403$20221206$20170405$20221212$PER$$US-PFIZER INC-2017147520$PFIZER$$62$YR$$F$Y$$$20221212$$HP$US$US
134083663$13408366$3$F$20130101$20221116$20170406$20221119$PER$$US-JNJFOC-20170207233$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221119$$HP$US$US
134084083$13408408$3$F$$20221003$20170406$20221013$PER$$US-JNJFOC-20170208481$JOHNSON AND JOHNSON$$$$$M$Y$$$20221013$$LW$US$US
134084824$13408482$4$F$20040101$20221213$20170406$20221214$PER$$US-JNJFOC-20170223643$JOHNSON AND JOHNSON$$13$YR$T$M$Y$$$20221214$$LW$US$US
134085414$13408541$4$F$19980205$20221114$20170406$20221122$PER$$US-JNJFOC-20170224183$JOHNSON AND JOHNSON$$9$YR$C$M$Y$$$20221122$$LW$US$US
134085553$13408555$3$F$20030728$20220928$20170406$20221012$PER$$US-JNJFOC-20170223612$JOHNSON AND JOHNSON$$11$YR$C$M$Y$$$20221010$$LW$US$US
134085563$13408556$3$F$$20221121$20170406$20221130$PER$$US-JNJFOC-20170224754$JOHNSON AND JOHNSON$$$$$M$Y$$$20221130$$HP$US$US
134085935$13408593$5$F$$20221121$20170406$20221129$PER$$US-JNJFOC-20170225229$JOHNSON AND JOHNSON$$$$$M$Y$$$20221130$$LW$US$US
134086183$13408618$3$F$20010501$20221213$20170406$20221222$PER$$US-JNJFOC-20170224206$JOHNSON AND JOHNSON$$5$YR$C$M$Y$$$20221222$$LW$US$US
134086274$13408627$4$F$$20221116$20170406$20221128$PER$$US-JNJFOC-20170225160$JOHNSON AND JOHNSON$$$$$M$Y$$$20221128$$LW$US$US
134088484$13408848$4$F$20020701$20221116$20170406$20221128$PER$$US-JNJFOC-20170224823$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221128$$LW$US$US
134088673$13408867$3$F$20010611$20221221$20170406$20221223$PER$$US-JNJFOC-20170225075$JOHNSON AND JOHNSON$$17$YR$T$M$Y$$$20221223$$LW$US$US
134088853$13408885$3$F$$20220926$20170406$20221003$PER$$US-JNJFOC-20170225486$JOHNSON AND JOHNSON$$$$$M$Y$$$20221003$$LW$US$US
134089053$13408905$3$F$20040109$20221019$20170406$20221027$PER$$US-JNJFOC-20170109079$JOHNSON AND JOHNSON$$6$YR$C$M$Y$$$20221027$$LW$US$US
134089073$13408907$3$F$20050101$20221121$20170406$20221129$PER$$US-JNJFOC-20170109216$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221129$$HP$US$US
134089295$13408929$5$F$20070823$20220926$20170406$20221006$PER$$US-JNJFOC-20170109470$JOHNSON AND JOHNSON$$11$YR$C$M$Y$$$20221006$$HP$US$US
134089463$13408946$3$F$20090101$20221121$20170406$20221201$PER$$US-JNJFOC-20170109743$JOHNSON AND JOHNSON$$1$DEC$C$M$Y$$$20221202$$HP$US$US
134089784$13408978$4$F$20080422$20220926$20170406$20221004$PER$$US-JNJFOC-20170110307$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221004$$LW$US$US
134090063$13409006$3$F$20080101$20221107$20170406$20221110$PER$$US-JNJFOC-20170112677$JOHNSON AND JOHNSON$$1$DEC$C$M$Y$$$20221110$$HP$US$US
134090495$13409049$5$F$20100413$20221207$20170406$20221215$EXP$$US-JNJFOC-20170112929$JOHNSON AND JOHNSON$$13$YR$T$M$Y$$$20221215$$HP$US$US
134090523$13409052$3$F$$20221213$20170406$20221215$PER$$US-JNJFOC-20170112930$JOHNSON AND JOHNSON$$$$$M$Y$$$20221215$$LW$US$US
134090603$13409060$3$F$$20220926$20170406$20221002$PER$$US-JNJFOC-20170113476$JOHNSON AND JOHNSON$$$$$M$Y$$$20221003$$LW$US$US
134090613$13409061$3$F$20060101$20220928$20170406$20221006$EXP$$US-JNJFOC-20170113485$JOHNSON AND JOHNSON$$$$C$M$Y$$$20221007$$LW$US$US
134091823$13409182$3$F$20080320$20221213$20170406$20221215$PER$$US-JNJFOC-20170116633$JOHNSON AND JOHNSON$$6$YR$C$M$Y$$$20221215$$LW$US$US
134091854$13409185$4$F$20070716$20221114$20170406$20221121$PER$$US-JNJFOC-20170116472$JOHNSON AND JOHNSON$$10$YR$C$M$Y$$$20221121$$HP$US$US
134091974$13409197$4$F$$20221207$20170406$20221215$PER$$US-JNJFOC-20170116485$JOHNSON AND JOHNSON$$$$$M$Y$$$20221215$$LW$US$US
134092024$13409202$4$F$$20221121$20170406$20221130$PER$$US-JNJFOC-20170116727$JOHNSON AND JOHNSON$$$$$M$Y$$$20221130$$LW$US$US
134092384$13409238$4$F$20020207$20221207$20170406$20221212$EXP$$US-JNJFOC-20170116487$JOHNSON AND JOHNSON$$3$YR$C$M$Y$$$20221212$$LW$US$US
134092742$13409274$2$F$20020101$20221116$20170406$20221126$PER$$US-JNJFOC-20151100901$JOHNSON AND JOHNSON$$1$DEC$C$M$Y$$$20221126$$LW$US$US
134093184$13409318$4$F$20091230$20221221$20170406$20221227$PER$$US-JNJFOC-20170124612$JOHNSON AND JOHNSON$$13$YR$T$M$Y$$$20221227$$LW$US$US
134094014$13409401$4$F$$20221107$20170406$20221110$PER$$US-JNJFOC-20170124619$JOHNSON AND JOHNSON$$$$$M$Y$$$20221110$$HP$US$US
134094114$13409411$4$F$20110519$20221031$20170406$20221108$PER$$US-JNJFOC-20170124622$JOHNSON AND JOHNSON$$9$YR$C$M$Y$$$20221109$$LW$US$US
134094194$13409419$4$F$20070801$20221116$20170406$20221128$PER$$US-JNJFOC-20170124575$JOHNSON AND JOHNSON$$10$YR$C$M$Y$$$20221128$$HP$US$US
134094304$13409430$4$F$20061205$20221213$20170406$20221220$PER$$US-JNJFOC-20170124641$JOHNSON AND JOHNSON$$5$YR$C$M$Y$$$20221220$$HP$US$US
134094454$13409445$4$F$20030318$20221213$20170406$20221213$PER$$US-JNJFOC-20161005961$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221213$$HP$US$US
134094493$13409449$3$F$20090101$20221012$20170406$20221019$EXP$$US-JNJFOC-20170125907$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221020$$HP$US$US
134094544$13409454$4$F$20070101$20221031$20170406$20221104$PER$$US-JNJFOC-20170126463$JOHNSON AND JOHNSON$$$$C$M$Y$$$20221104$$LW$US$US
134095104$13409510$4$F$20010710$20220928$20170406$20221012$PER$$US-JNJFOC-20170225622$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221009$$HP$US$US
134095154$13409515$4$F$20050506$20221221$20170406$20221227$PER$$US-JNJFOC-20170225851$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221227$$LW$US$US
134095414$13409541$4$F$20050729$20221107$20170406$20221109$PER$$US-JNJFOC-20170127186$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221109$$HP$US$US
134095534$13409553$4$F$20101116$20221228$20170406$20221230$PER$$US-JNJFOC-20170127439$JOHNSON AND JOHNSON$$13$YR$T$M$Y$$$20221230$$LW$US$US
134095874$13409587$4$F$20111101$20221213$20170406$20221214$PER$$US-JNJFOC-20170127374$JOHNSON AND JOHNSON$$12$YR$T$M$Y$$$20221214$$HP$US$US
134097084$13409708$4$F$20001205$20221111$20170406$20221118$PER$$US-JNJFOC-20170224752$JOHNSON AND JOHNSON$$13$YR$T$M$Y$$$20221118$$LW$US$US
134098156$13409815$6$F$$20221122$20170406$20221124$EXP$$US-PFIZER INC-2017071242$PFIZER$$65$YR$$M$Y$$$20221124$$CN$US$US
134099455$13409945$5$F$20121012$20221031$20170406$20221102$EXP$$US-PFIZER INC-2017147004$PFIZER$$50$YR$$M$Y$95.7$KG$20221102$$CN$US$US
134103252$13410325$2$F$$20221213$20170406$20221220$PER$$US-JNJFOC-20170306485$JOHNSON AND JOHNSON$$$$$M$Y$$$20221220$$LW$US$US
134103294$13410329$4$F$20020114$20221129$20170406$20221205$PER$$US-JNJFOC-20170303091$JOHNSON AND JOHNSON$$8$YR$C$M$Y$$$20221205$$LW$US$US
134103402$13410340$2$F$$20221228$20170406$20221230$PER$$US-JNJFOC-20170306467$JOHNSON AND JOHNSON$$$$$M$Y$$$20221230$$LW$US$US
134103632$13410363$2$F$20091001$20221121$20170406$20221130$PER$$US-JNJFOC-20170306612$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221130$$LW$US$US
134103692$13410369$2$F$$20220926$20170406$20221006$PER$$US-JNJFOC-20170306424$JOHNSON AND JOHNSON$$$$$M$Y$$$20221006$$LW$US$US
134103862$13410386$2$F$$20221116$20170406$20221128$PER$$US-JNJFOC-20170306488$JOHNSON AND JOHNSON$$$$$M$Y$$$20221128$$LW$US$US
134104142$13410414$2$F$$20220928$20170406$20221012$PER$$US-JNJFOC-20170306543$JOHNSON AND JOHNSON$$$$$M$Y$$$20221009$$LW$US$US
134104514$13410451$4$F$$20220922$20170406$20221001$PER$$US-JNJFOC-20170226376$JOHNSON AND JOHNSON$$$$$M$Y$$$20221001$$LW$US$US
134104923$13410492$3$F$19990715$20221221$20170406$20221229$PER$$US-JNJFOC-20170227583$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221230$$LW$US$US
134105054$13410505$4$F$$20220928$20170406$20221003$PER$$US-JNJFOC-20170227363$JOHNSON AND JOHNSON$$$$$M$Y$$$20221003$$LW$US$US
134105654$13410565$4$F$20050201$20221114$20170406$20221119$PER$$US-JNJFOC-20170300133$JOHNSON AND JOHNSON$$15$YR$T$M$Y$$$20221119$$LW$US$US
134105664$13410566$4$F$19980520$20221121$20170406$20221130$PER$$US-JNJFOC-20170300134$JOHNSON AND JOHNSON$$4$YR$C$M$Y$$$20221130$$LW$US$US
134105784$13410578$4$F$20050604$20221107$20170406$20221109$PER$$US-JNJFOC-20170300143$JOHNSON AND JOHNSON$$11$YR$C$M$Y$$$20221109$$LW$US$US
134105873$13410587$3$F$20080322$20221219$20170406$20221227$PER$$US-JNJFOC-20170300315$JOHNSON AND JOHNSON$$15$YR$T$M$Y$$$20221227$$LW$US$US
134105903$13410590$3$F$$20220926$20170406$20221003$PER$$US-JNJFOC-20170300463$JOHNSON AND JOHNSON$$$$$M$Y$$$20221003$$LW$US$US
134106494$13410649$4$F$20031106$20220926$20170406$20221004$PER$$US-JNJFOC-20170301290$JOHNSON AND JOHNSON$$6$YR$C$M$Y$$$20221004$$LW$US$US
134106614$13410661$4$F$19990921$20220926$20170406$20221007$PER$$US-JNJFOC-20170300107$JOHNSON AND JOHNSON$$10$YR$C$M$Y$$$20221007$$HP$US$US
134107324$13410732$4$F$20180829$20221219$20170406$20221222$PER$$US-JNJFOC-20170301398$JOHNSON AND JOHNSON$$21$YR$A$M$Y$$$20221222$$LW$US$US
134107364$13410736$4$F$$20221012$20170406$20221020$PER$$US-JNJFOC-20170301417$JOHNSON AND JOHNSON$$$$$M$Y$$$20221021$$LW$US$US
134107733$13410773$3$F$20020205$20221031$20170406$20221109$PER$$US-JNJFOC-20170307893$JOHNSON AND JOHNSON$$11$YR$C$M$Y$$$20221109$$LW$US$US
134107754$13410775$4$F$20100902$20221019$20170406$20221027$PER$$US-JNJFOC-20170307957$JOHNSON AND JOHNSON$$16$YR$T$M$Y$$$20221027$$LW$US$US
134107864$13410786$4$F$20111101$20221121$20170406$20221130$PER$$US-JNJFOC-20170307961$JOHNSON AND JOHNSON$$17$YR$T$M$Y$$$20221130$$HP$US$US
134108364$13410836$4$F$20120224$20221221$20170406$20221228$PER$$US-JNJFOC-20170302025$JOHNSON AND JOHNSON$$15$YR$T$M$Y$$$20221228$$LW$US$US
134108634$13410863$4$F$$20221116$20170406$20221126$PER$$US-JNJFOC-20170301473$JOHNSON AND JOHNSON$$$$$M$Y$$$20221126$$LW$US$US
134108654$13410865$4$F$20040623$20221219$20170406$20221222$PER$$US-JNJFOC-20170301591$JOHNSON AND JOHNSON$$11$YR$C$M$Y$$$20221222$$LW$US$US
134108713$13410871$3$F$$20221114$20170406$20221127$PER$$US-JNJFOC-20170300096$JOHNSON AND JOHNSON$$26$YR$A$M$Y$$$20221128$$LW$US$US
134108794$13410879$4$F$$20221121$20170406$20221130$PER$$US-JNJFOC-20170300097$JOHNSON AND JOHNSON$$$$$M$Y$$$20221130$$LW$US$US
134109114$13410911$4$F$20050518$20220926$20170406$20221006$PER$$US-JNJFOC-20170302243$JOHNSON AND JOHNSON$$8$YR$C$M$Y$$$20221006$$LW$US$US
134109563$13410956$3$F$20001201$20221012$20170406$20221019$PER$$US-JNJFOC-20170304598$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221019$$LW$US$US
134109793$13410979$3$F$20051228$20221219$20170406$20221221$PER$$US-JNJFOC-20170303447$JOHNSON AND JOHNSON$$15$YR$T$M$Y$$$20221221$$LW$US$US
134109944$13410994$4$F$20150810$20221201$20170406$20221205$PER$$US-JNJFOC-20170304013$JOHNSON AND JOHNSON$$24$YR$A$M$Y$$$20221205$$HP$US$US
134110073$13411007$3$F$20161001$20221003$20170406$20221014$PER$$US-JNJFOC-20170304028$JOHNSON AND JOHNSON$$24$YR$A$M$Y$$$20221014$$LW$US$US
134110204$13411020$4$F$20070625$20220928$20170406$20221012$PER$$US-JNJFOC-20170304578$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221010$$LW$US$US
134110584$13411058$4$F$$20221107$20170406$20221109$PER$$US-JNJFOC-20170304459$JOHNSON AND JOHNSON$$$$$M$Y$$$20221109$$LW$US$US
134110714$13411071$4$F$$20221107$20170406$20221110$PER$$US-JNJFOC-20170304478$JOHNSON AND JOHNSON$$$$$M$Y$$$20221111$$LW$US$US
134110862$13411086$2$F$20050101$20221121$20170406$20221130$PER$$US-JNJFOC-20170306753$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221130$$LW$US$US
134111142$13411114$2$F$$20221228$20170406$20221230$PER$$US-JNJFOC-20170306729$JOHNSON AND JOHNSON$$$$$M$Y$$$20221230$$LW$US$US
134111382$13411138$2$F$20120330$20221121$20170406$20221129$PER$$US-JNJFOC-20170306735$JOHNSON AND JOHNSON$$20$YR$A$M$Y$$$20221130$$LW$US$US
134111652$13411165$2$F$$20221114$20170406$20221123$PER$$US-JNJFOC-20170306740$JOHNSON AND JOHNSON$$$$$M$Y$$$20221123$$LW$US$US
134112463$13411246$3$F$20060201$20220928$20170406$20221006$PER$$US-JNJFOC-20170306659$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221006$$LW$US$US
134112603$13411260$3$F$20070101$20221207$20170406$20221213$PER$$US-JNJFOC-20170307189$JOHNSON AND JOHNSON$$13$YR$T$M$Y$$$20221213$$LW$US$US
134112634$13411263$4$F$20020411$20221107$20170406$20221114$EXP$$US-JNJFOC-20170306942$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221115$$LW$US$US
134112754$13411275$4$F$20070817$20221114$20170406$20221123$PER$$US-JNJFOC-20170307030$JOHNSON AND JOHNSON$$11$YR$C$M$Y$$$20221123$$LW$US$US
134112792$13411279$2$F$$20221213$20170406$20221219$PER$$US-JNJFOC-20170306432$JOHNSON AND JOHNSON$$$$$M$Y$$$20221219$$LW$US$US
134112974$13411297$4$F$20100812$20221205$20170406$20221212$PER$$US-JNJFOC-20170307184$JOHNSON AND JOHNSON$$13$YR$T$M$Y$$$20221212$$HP$US$US
134113022$13411302$2$F$$20221114$20170406$20221117$PER$$US-JNJFOC-20170306569$JOHNSON AND JOHNSON$$$$$$Y$$$20221117$$LW$US$US
134113152$13411315$2$F$19980101$20221121$20170406$20221128$PER$$US-JNJFOC-20170306586$JOHNSON AND JOHNSON$$$$$M$Y$$$20221128$$LW$US$US
134113622$13411362$2$F$20111021$20221116$20170406$20221124$PER$$US-JNJFOC-20170304905$JOHNSON AND JOHNSON$$22$YR$A$M$Y$$$20221125$$LW$US$US
134113755$13411375$5$F$20120801$20221111$20170406$20221123$PER$$US-JNJFOC-20170304535$JOHNSON AND JOHNSON$$17$YR$T$M$Y$$$20221123$$LW$US$US
134113794$13411379$4$F$20071010$20221114$20170406$20221123$PER$$US-JNJFOC-20170304310$JOHNSON AND JOHNSON$$10$YR$C$M$Y$$$20221123$$LW$US$US
134113902$13411390$2$F$$20221213$20170406$20221215$PER$$US-JNJFOC-20170304919$JOHNSON AND JOHNSON$$$$$M$Y$$$20221215$$LW$US$US
134114142$13411414$2$F$$20221003$20170406$20221013$PER$$US-JNJFOC-20170304926$JOHNSON AND JOHNSON$$$$$M$Y$$$20221013$$LW$US$US
134114152$13411415$2$F$20000101$20220926$20170406$20221004$PER$$US-JNJFOC-20170304927$JOHNSON AND JOHNSON$$$$$M$Y$$$20221004$$LW$US$US
134114252$13411425$2$F$20061001$20220928$20170406$20221012$PER$$US-JNJFOC-20170304859$JOHNSON AND JOHNSON$$11$YR$C$M$Y$$$20221010$$LW$US$US
134114312$13411431$2$F$$20221012$20170406$20221022$PER$$US-JNJFOC-20170304860$JOHNSON AND JOHNSON$$$$$M$Y$$$20221022$$LW$US$US
134114582$13411458$2$F$$20221205$20170406$20221212$EXP$$US-JNJFOC-20170304896$JOHNSON AND JOHNSON$$$$$M$Y$$$20221213$$LW$US$US
134115123$13411512$3$F$$20221114$20170406$20221119$PER$$US-JNJFOC-20170304979$JOHNSON AND JOHNSON$$$$$M$Y$$$20221119$$LW$US$US
134115232$13411523$2$F$$20221003$20170406$20221013$PER$$US-JNJFOC-20170304964$JOHNSON AND JOHNSON$$$$$M$Y$$$20221013$$LW$US$US
134115242$13411524$2$F$$20221116$20170406$20221128$PER$$US-JNJFOC-20170304965$JOHNSON AND JOHNSON$$$$$M$Y$$$20221128$$LW$US$US
134115252$13411525$2$F$$20221219$20170406$20221223$PER$$US-JNJFOC-20170304982$JOHNSON AND JOHNSON$$$$$M$Y$$$20221223$$LW$US$US
134116263$13411626$3$F$20050131$20221129$20170406$20221206$PER$$US-JNJFOC-20170302957$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221206$$LW$US$US
134116644$13411664$4$F$$20221107$20170406$20221114$PER$$US-JNJFOC-20170303272$JOHNSON AND JOHNSON$$$$$M$Y$$$20221115$$HP$US$US
134116873$13411687$3$F$$20221228$20170406$20221230$PER$$US-JNJFOC-20170303435$JOHNSON AND JOHNSON$$$$$M$Y$$$20221230$$LW$US$US
134117394$13411739$4$F$$20221114$20170406$20221121$PER$$US-JNJFOC-20170304306$JOHNSON AND JOHNSON$$$$$M$Y$$$20221121$$LW$US$US
134117493$13411749$3$F$20040628$20221114$20170406$20221121$PER$$US-JNJFOC-20170303423$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221121$$LW$US$US
134117604$13411760$4$F$$20221114$20170406$20221119$PER$$US-JNJFOC-20170304307$JOHNSON AND JOHNSON$$$$$M$Y$$$20221119$$LW$US$US
134117783$13411778$3$F$20050303$20220926$20170406$20221006$PER$$US-JNJFOC-20170304278$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221006$$LW$US$US
134118172$13411817$2$F$20090501$20221207$20170406$20221216$PER$$US-JNJFOC-20170304872$JOHNSON AND JOHNSON$$14$YR$T$M$Y$$$20221216$$LW$US$US
134118313$13411831$3$F$$20221213$20170406$20221215$PER$$US-JNJFOC-20170304552$JOHNSON AND JOHNSON$$$$$M$Y$$$20221215$$LW$US$US
134118473$13411847$3$F$$20220928$20170406$20221003$PER$$US-JNJFOC-20170304283$JOHNSON AND JOHNSON$$$$$M$Y$$$20221003$$LW$US$US
134118763$13411876$3$F$20080312$20221019$20170406$20221031$PER$$US-JNJFOC-20170304210$JOHNSON AND JOHNSON$$10$YR$C$M$Y$$$20221031$$LW$US$US
134118804$13411880$4$F$$20221121$20170406$20221128$PER$$US-JNJFOC-20170304323$JOHNSON AND JOHNSON$$$$$M$Y$$$20221128$$LW$US$US
134119874$13411987$4$F$20130101$20221228$20170406$20221230$PER$$US-JNJFOC-20170316148$JOHNSON AND JOHNSON$$3$DEC$A$M$Y$$$20221230$$LW$US$US
134119974$13411997$4$F$20070101$20221207$20170406$20221213$PER$$US-JNJFOC-20170316578$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221213$$LW$US$US
134120033$13412003$3$F$$20221114$20170406$20221123$PER$$US-JNJFOC-20170316657$JOHNSON AND JOHNSON$$$$$M$Y$$$20221123$$LW$US$US
134120994$13412099$4$F$$20221207$20170406$20221209$PER$$US-JNJFOC-20170316756$JOHNSON AND JOHNSON$$$$$M$Y$$$20221209$$LW$US$US
134121833$13412183$3$F$20080101$20220921$20170406$20221003$PER$$US-JNJFOC-20170314133$JOHNSON AND JOHNSON$$20$YR$A$M$Y$$$20221003$$HP$US$US
134121943$13412194$3$F$$20221219$20170406$20221222$PER$$US-JNJFOC-20161009028$JOHNSON AND JOHNSON$$$$$M$Y$$$20221222$$LW$US$US
134123064$13412306$4$F$20110521$20221129$20170406$20221206$PER$$US-JNJFOC-20170307964$JOHNSON AND JOHNSON$$12$YR$T$M$Y$$$20221206$$HP$US$US
134123242$13412324$2$F$$20221012$20170406$20221020$PER$$US-JNJFOC-20170308357$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221021$$LW$US$US
134123774$13412377$4$F$$20221012$20170406$20221021$PER$$US-JNJFOC-20170310348$JOHNSON AND JOHNSON$$$$$M$Y$$$20221021$$LW$US$US
134123874$13412387$4$F$$20220926$20170406$20221003$PER$$US-JNJFOC-20170309978$JOHNSON AND JOHNSON$$$$$M$Y$$$20221003$$LW$US$US
134123924$13412392$4$F$20160606$20221019$20170406$20221026$EXP$$US-JNJFOC-20170309959$JOHNSON AND JOHNSON$$28$YR$A$M$Y$$$20221026$$HP$US$US
134124422$13412442$2$F$$20221213$20170406$20221215$PER$$US-JNJFOC-20170308324$JOHNSON AND JOHNSON$$$$$M$Y$$$20221215$$LW$US$US
134124524$13412452$4$F$$20221116$20170406$20221128$PER$$US-JNJFOC-20170308352$JOHNSON AND JOHNSON$$$$$M$Y$$$20221128$$LW$US$US
134124984$13412498$4$F$20020101$20221219$20170406$20221225$PER$$US-JNJFOC-20170309543$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221226$$LW$US$US
134125104$13412510$4$F$20090325$20221019$20170406$20221031$PER$$US-JNJFOC-20170309203$JOHNSON AND JOHNSON$$16$YR$T$M$Y$$$20221031$$LW$US$US
134127504$13412750$4$F$20010510$20220922$20170406$20221001$PER$$US-JNJFOC-20170310766$JOHNSON AND JOHNSON$$4$YR$C$M$Y$$$20221001$$HP$US$US
134127835$13412783$5$F$$20221012$20170406$20221021$PER$$US-JNJFOC-20170312219$JOHNSON AND JOHNSON$$$$$M$Y$$$20221021$$LW$US$US
134128633$13412863$3$F$20070207$20220928$20170406$20221003$PER$$US-JNJFOC-20170312479$JOHNSON AND JOHNSON$$18$YR$A$M$Y$$$20221003$$LW$US$US
134128874$13412887$4$F$$20221021$20170406$20221030$PER$$US-JNJFOC-20170312473$JOHNSON AND JOHNSON$$$$$M$Y$$$20221030$$LW$US$US
134129043$13412904$3$F$20071001$20221006$20170406$20221017$PER$$US-JNJFOC-20161012299$JOHNSON AND JOHNSON$$19$YR$A$M$Y$$$20221017$$HP$US$US
134129764$13412976$4$F$20071119$20221207$20170406$20221213$EXP$$US-JNJFOC-20170312159$JOHNSON AND JOHNSON$$8$YR$C$M$Y$$$20221213$$LW$US$US
134131085$13413108$5$F$20060613$20221111$20170406$20221114$PER$$US-JNJFOC-20170310810$JOHNSON AND JOHNSON$$3$YR$C$M$Y$$$20221114$$LW$US$US
134131233$13413123$3$F$20130401$20221003$20170406$20221014$PER$$US-JNJFOC-20170310918$JOHNSON AND JOHNSON$$12$YR$T$M$Y$$$20221014$$LW$US$US
134131363$13413136$3$F$$20221114$20170406$20221117$PER$$US-JNJFOC-20170311511$JOHNSON AND JOHNSON$$$$$M$Y$$$20221117$$LW$US$US
134132044$13413204$4$F$20060710$20221207$20170406$20221209$PER$$US-JNJFOC-20161015927$JOHNSON AND JOHNSON$$15$YR$T$M$Y$$$20221209$$LW$US$US
134132723$13413272$3$F$20090101$20221205$20170407$20221212$EXP$$US-JAZZ-2017-US-004232$JAZZ$$39$YR$$F$Y$$$20221212$$MD$US$US
134134764$13413476$4$F$20051116$20221012$20170406$20221020$PER$$US-JNJFOC-20170317340$JOHNSON AND JOHNSON$$8$YR$C$M$Y$$$20221020$$HP$US$US
134135873$13413587$3$F$20060801$20221114$20170406$20221124$PER$$US-JNJFOC-20170317752$JOHNSON AND JOHNSON$$11$YR$$M$Y$$$20221124$$LW$US$US
134136574$13413657$4$F$$20221207$20170406$20221209$PER$$US-JNJFOC-20170317860$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221209$$LW$US$US
134137194$13413719$4$F$20090101$20221003$20170406$20221014$PER$$US-JNJFOC-20170313990$JOHNSON AND JOHNSON$$2$DEC$$M$Y$$$20221014$$LW$US$US
134139784$13413978$4$F$20081211$20221121$20170406$20221130$PER$$US-JNJFOC-20170315347$JOHNSON AND JOHNSON$$17$YR$T$M$Y$$$20221130$$LW$US$US
134140074$13414007$4$F$20080101$20221219$20170406$20221227$PER$$US-JNJFOC-20170315349$JOHNSON AND JOHNSON$$20$YR$A$M$Y$$$20221227$$LW$US$US
134140653$13414065$3$F$$20221207$20170406$20221215$PER$$US-JNJFOC-20170318536$JOHNSON AND JOHNSON$$$$$M$Y$$$20221215$$LW$US$US
134142134$13414213$4$F$20090701$20221114$20170406$20221123$PER$$US-JNJFOC-20170319707$JOHNSON AND JOHNSON$$24$YR$A$M$Y$$$20221123$$LW$US$US
134148803$13414880$3$F$20041013$20221219$20170406$20221226$PER$$US-JNJFOC-20170319818$JOHNSON AND JOHNSON$$4$YR$C$M$Y$$$20221226$$LW$US$US
134148964$13414896$4$F$19980101$20221207$20170406$20221209$PER$$US-JNJFOC-20170319804$JOHNSON AND JOHNSON$$$$C$M$Y$$$20221209$$LW$US$US
134155753$13415575$3$F$20170101$20221115$20170407$20221124$PER$$US-JAZZ-2017-US-004199$JAZZ$$$$$M$Y$$$20221124$$CN$US$US
134158524$13415852$4$F$20170101$20221128$20170406$20221203$EXP$$PHHY2017CA047941$NOVARTIS$$$$$M$Y$$$20221203$$CN$CA$CA
134159044$13415904$4$F$20170101$20221207$20170407$20221219$EXP$$US-PFIZER INC-2017149556$PFIZER$$82$YR$$F$Y$$$20221219$$HP$US$US
1341826926$13418269$26$F$20170330$20221118$20170407$20221123$EXP$$CA-TAKEDA-2017TUS007276$TAKEDA$$48$YR$$F$Y$$$20221123$$MD$CA$CA
134191303$13419130$3$F$20110101$20221111$20170407$20221121$EXP$$US-JNJFOC-20170320942$JOHNSON AND JOHNSON$$$$T$M$Y$$$20221122$$LW$US$US
134193864$13419386$4$F$$20221020$20170407$20221102$PER$$US-JNJFOC-20170319591$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221102$$HP$US$US
134194964$13419496$4$F$20080501$20221213$20170407$20221221$PER$$US-JNJFOC-20170323475$JOHNSON AND JOHNSON$$23$YR$A$M$Y$$$20221221$$HP$US$US
134195113$13419511$3$F$20060612$20221221$20170407$20221226$PER$$US-JNJFOC-20170306427$JOHNSON AND JOHNSON$$9$YR$C$M$Y$$$20221227$$LW$US$US
1341979412$13419794$12$F$20170201$20221223$20170407$20221229$EXP$$US-PFIZER INC-2017154081$PFIZER$$57$YR$$F$Y$47$KG$20221229$$CN$US$US
134236044$13423604$4$F$20020101$20221117$20170410$20221129$EXP$$US-ELI_LILLY_AND_COMPANY-US201704001084$ELI LILLY AND CO$$$$$M$Y$$$20221129$$CN$US$US
1342535213$13425352$13$F$20170322$20221114$20170411$20221123$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-002878$ACADIA PHARMACEUTICALS$$63$YR$$F$Y$$$20221124$$CN$US$US
134313025$13431302$5$F$20170113$20221024$20170412$20221027$EXP$$FR-ASTELLAS-2017US013355$ASTELLAS$$76$YR$$M$Y$$$20221027$$MD$FR$FR
134338126$13433812$6$F$20170301$20221214$20170412$20221221$EXP$$FR-SHIRE-FR201706721$TAKEDA$$33$YR$$F$Y$44$KG$20221221$$HP$FR$FR
1344115040$13441150$40$F$20160101$20221024$20170413$20221026$EXP$$PHHY2016CA138250$NOVARTIS$$$$$F$Y$$$20221026$$CN$CA$CA
1344176218$13441762$18$F$20170331$20221004$20170414$20221006$EXP$$CA-TAKEDA-2016TUS022087$TAKEDA$$39$YR$$F$Y$$$20221006$$CN$CA$CA
1344302735$13443027$35$F$$20221108$20170414$20221111$EXP$$US-PFIZER INC-2016508384$MYLAN$$$$$F$Y$$$20221111$$CN$US$US
134479263$13447926$3$F$20110208$20221103$20170417$20221110$EXP$$US-JNJFOC-20170416037$JOHNSON AND JOHNSON$$59$YR$A$M$Y$$$20221110$$LW$US$US
134492628$13449262$8$F$20180416$20221219$20170417$20221227$EXP$$US-PFIZER INC-2017102280$PFIZER$$78$YR$$M$Y$95.25$KG$20221227$$CN$US$US
134516319$13451631$9$F$20170101$20221202$20170418$20221205$EXP$$US-PFIZER INC-2017161562$PFIZER$$76$YR$$F$Y$$$20221205$$CN$US$US
134576587$13457658$7$F$$20221025$20170419$20221101$EXP$$CA-PFIZER INC-2017162130$PFIZER$Boileau, M.. Successful Treatment of Disseminated Anncaliia algerae Microsporidial Infection with Combination Fumagillin and Albendazole. Open Forum Infectious Diseases. 2016;3(3):10.1093/ofid/ofw158$49$YR$$M$Y$$$20221101$$MD$CA$CA
134609012$13460901$2$F$20130429$20221130$20170420$20221205$EXP$$BE-ROCHE-1220316$ROCHE$$42$YR$$F$Y$85.8$KG$20221205$$MD$BE$
1346209010$13462090$10$F$20170125$20221114$20170420$20221121$EXP$$JP-AEGERION PHARMACEUTICAL, INC-AEGR003026$AEGERION$$$$$$Y$$$20221121$$MD$JP$JP
1346262225$13462622$25$F$20170619$20221104$20170420$20221115$EXP$$CA-CELLTRION INC.-2017CA002002$CELLTRION$$$$$$Y$$$20221115$$CN$CA$CA
1346758110$13467581$10$F$20170101$20221219$20170421$20221222$EXP$$US-PFIZER INC-2017038221$PFIZER$$70$YR$$F$Y$54$KG$20221222$$CN$US$US
134809919$13480991$9$F$20170101$20221018$20170425$20221020$EXP$$CA-TAKEDA-2017TUS008390$TAKEDA$$47$YR$$F$Y$$$20221020$$CN$CA$CA
1348445811$13484458$11$F$20160927$20221102$20170426$20221108$EXP$$PHHY2016CA148710$NOVARTIS$$66$YR$$F$Y$$$20221108$$CN$CA$CA
134866394$13486639$4$F$20170401$20221026$20170426$20221028$PER$$US-PFIZER INC-2017180773$PFIZER$$47$YR$$F$Y$50$KG$20221028$$CN$US$US
1349693436$13496934$36$F$20170425$20221104$20170428$20221107$EXP$$DE-B.I. Pharmaceuticals,Inc./Ridgefield-2017-BI-023596$BOEHRINGER INGELHEIM$$65$YR$E$M$Y$90$KG$20221107$$MD$DE$DE
1350002510$13500025$10$F$$20221109$20170501$20221116$EXP$$CA-PFIZER INC-2017188696$PFIZER$Thavendiranathan, P.. Left ventricular dysfunction with trastuzumab therapy: Is primary prevention the best option?. Journal of Clinical Oncology. 2017;35 (8):820-825$51$YR$$F$Y$$$20221116$$HP$CA$CA
1350521712$13505217$12$F$20170101$20221215$20170502$20221226$EXP$$CA-TAKEDA-2017TUS009171$TAKEDA$$51$YR$$F$Y$$$20221226$$CN$CA$CA
135167237$13516723$7$F$20141201$20221209$20170505$20221215$EXP$$US-BIOGEN-2015BI072120$BIOGEN$$62$YR$$F$Y$$$20221215$$CN$US$US
1351680010$13516800$10$F$20110101$20221110$20170505$20221117$EXP$$US-BIOGEN-2012BI010881$BIOGEN$$54$YR$$M$Y$$$20221116$$HP$US$US
135169383$13516938$3$F$$20221115$20170505$20221118$PER$$US-PFIZER INC-2017193055$PFIZER$$63$YR$$M$Y$$$20221118$$HP$US$US
135179163$13517916$3$F$20170425$20221207$20170505$20221209$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-037980$BRISTOL MYERS SQUIBB$$74$YR$E$M$Y$$$20221209$$HP$US$US
1351935913$13519359$13$F$20000101$20221220$20170505$20221229$EXP$$CA-PFIZER INC-2017196797$PFIZER$$58$YR$$F$Y$52$KG$20221229$$CN$CA$CA
135212729$13521272$9$F$$20221020$20170508$20221025$PER$$US-PFIZER INC-2017192842$PFIZER$$69$YR$$F$Y$70$KG$20221025$$CN$US$US
1352437015$13524370$15$F$20170428$20221109$20170508$20221116$EXP$$PHHY2017CA061628$NOVARTIS$$46$YR$$F$Y$$$20221116$$MD$CA$CA
1352576223$13525762$23$F$20161012$20221212$20170509$20221219$EXP$$CA-ROCHE-1931235$ROCHE$$66$YR$$F$Y$$$20221219$$MD$CA$CA
135277513$13527751$3$F$$20221118$20170509$20221123$EXP$$CA-PFIZER INC-2017200671$PFIZER$$29$YR$$F$Y$$$20221123$$CN$CA$CA
135279808$13527980$8$F$20180701$20221108$20170509$20221111$EXP$$US-PFIZER INC-2017199271$PFIZER$$68$YR$$M$Y$91$KG$20221111$$CN$US$US
135316107$13531610$7$F$20170201$20221026$20170510$20221101$EXP$$PHHY2017CA025217$NOVARTIS$$48$YR$$F$Y$$$20221101$$MD$CA$CA
1353323018$13533230$18$F$$20221025$20170510$20221101$EXP$$CA-PFIZER INC-2017199190$PFIZER$Villeneuve, E.. Management of a mixed overdose in the prehospital setting: a case report. Clinical Toxicology. 2017;55 (5):511$71$YR$$F$Y$$$20221101$$HP$CA$CA
1353492724$13534927$24$F$20170101$20221020$20170511$20221031$EXP$$JP-ABBVIE-17K-087-1968634-00$ABBVIE$$$$$F$Y$44$KG$20221031$$MD$JP$JP
1353686735$13536867$35$F$20080101$20221115$20170511$20221122$EXP$$CA-Orion Corporation ORION PHARMA-TREX2017-1374$ORION$$44$YR$A$F$Y$63$KG$20221122$$MD$CA$
135370753$13537075$3$F$20160101$20221120$20170511$20221124$EXP$$CA-Orion Corporation ORION PHARMA-TREX2017-1373$ORION$$29$YR$A$F$Y$$$20221124$$CN$CA$
135389854$13538985$4$F$20040623$20221003$20170512$20221013$PER$$US-JNJFOC-20170416710$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221013$$LW$US$US
135421418$13542141$8$F$$20221025$20170512$20221031$EXP$$CA-BAUSCH-BL-2017-014965$BAUSCH AND LOMB$Villeneuve E, Delisle M, Wang J, Gosselin S. Management of a mixed overdose in the prehospital setting: A case report. Clinical Toxicology. 2017 JAN 01;55(5):511.$71$YR$$F$Y$$$20221031$$HP$CA$CA
135436358$13543635$8$F$20170501$20221031$20170515$20221102$EXP$$KR-ROCHE-1933494$ROCHE$$70$YR$$M$Y$60$KG$20221102$$MD$KR$
135450646$13545064$6$F$20170405$20221223$20170515$20221230$EXP$$JP-009507513-1705JPN000736J$MERCK$Matsumoto K, Wakatuki J, Sakuma D, Kin E, Kobayashi Y, Komata M. WS16-3 Immune-related side effects during the first 5 years of use of immune checkpoint inhibitors. The 60th Annual Meeting of Japan Society of Clinical Oncology. 2022$81$YR$$F$Y$41$KG$20221230$$MD$JP$JP
1354546512$13545465$12$F$20170101$20221209$20170515$20221216$EXP$$US-PFIZER INC-2016460842$PFIZER$$78$YR$$F$Y$59.87$KG$20221216$$CN$US$US
135461403$13546140$3$F$20151023$20170118$20170515$20221208$EXP$$IT-TEVA-2015-29152$TEVA$$49$YR$A$M$Y$$$20221208$$MD$IT$IT
135495299$13549529$9$F$20170430$20221004$20170516$20221014$EXP$$DE-ROCHE-1932235$ROCHE$$72$YR$$M$Y$87$KG$20221014$$MD$DE$
135517933$13551793$3$F$20161201$20221118$20170516$20221123$EXP$$US-BAXALTA-2017BLT004225$TAKEDA$$42$YR$$F$Y$$$20221123$$MD$US$US
135534048$13553404$8$F$20170831$20221115$20170517$20221122$EXP$$CA-ROCHE-1935668$ROCHE$$38$YR$$F$Y$$$20221122$$CN$CA$CA
1355584510$13555845$10$F$20160818$20221212$20170517$20221216$EXP$$CA-TAKEDA-2016TUS015919$TAKEDA$$24$YR$$M$Y$$$20221216$$MD$CA$CA
1355756022$13557560$22$F$20170101$20221114$20170517$20221123$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-002993$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221124$$CN$US$US
1355772815$13557728$15$F$$20221108$20170518$20221111$EXP$$US-PFIZER INC-2017212769$PFIZER$$71$YR$$F$Y$49$KG$20221111$$CN$US$US
135579073$13557907$3$F$20170401$20221014$20170517$20221107$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-003177$ACADIA PHARMACEUTICALS$$73$YR$$M$Y$$$20221107$$CN$US$US
135580163$13558016$3$F$20170201$20221031$20170517$20221124$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-003267$ACADIA PHARMACEUTICALS$$62$YR$$M$Y$$$20221125$$CN$US$US
1355807312$13558073$12$F$20140101$20221122$20170517$20221215$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-002942$ACADIA PHARMACEUTICALS$$$$$F$Y$59$KG$20221216$$CN$US$US
135586332$13558633$2$F$$20221014$20170518$20221021$PER$$US-JAZZ-2017-US-006236$JAZZ$$$$$F$Y$$$20221021$$CN$US$US
135615405$13561540$5$F$$20221025$20170518$20221104$EXP$$CA-LUPIN PHARMACEUTICALS INC.-2017-02331$LUPIN$Villeneuve E, Delisle M, Wang JJ, Gosselin S. Management of a mixed overdose in the prehospital setting: a case report. Clinical Toxicology. 2017;55(5):511$71$YR$$F$Y$$$20221104$$HP$CA$CA
1356231518$13562315$18$F$20150821$20221220$20170519$20221227$EXP$$CA-ROCHE-1936490$ROCHE$$55$YR$$F$Y$$$20221227$$CN$CA$CA
135625496$13562549$6$F$$20221215$20170519$20221226$EXP$$CA-APOTEX-2017AP011966$APOTEX$$64$YR$$M$Y$74$KG$20221226$$MD$CA$CA
135653773$13565377$3$F$20160501$20221024$20170519$20221031$EXP$$US-JAZZ-2017-US-005619$JAZZ$$54$YR$$F$Y$$$20221031$$CN$US$US
135675432$13567543$2$F$$20221207$20170522$20221213$PER$$US-PFIZER INC-2017219941$PFIZER$$64$YR$$F$Y$$$20221213$$CN$US$US
1356828519$13568285$19$F$20150803$20221215$20170522$20221220$EXP$$AU-SA-2015SA169162$SANOFI AVENTIS$$39$YR$A$F$Y$$$20221220$$HP$AU$AU
135708204$13570820$4$F$$20221003$20170523$20221005$EXP$$US-TAKEDA-2017TUS011346$TAKEDA$$$$$$Y$$$20221005$$CN$US$US
135738742$13573874$2$F$20170101$20221207$20170523$20221216$PER$$US-PFIZER INC-2017219840$PFIZER$$64$YR$$F$Y$$$20221216$$CN$US$US
135739157$13573915$7$F$20170106$20221213$20170523$20221220$EXP$$PHJP2017JP001384$NOVARTIS$$48$YR$$M$Y$$$20221220$$MD$JP$JP
135753943$13575394$3$F$$20221024$20170524$20221107$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2017US-141241$RANBAXY$$$$A$M$Y$$$20221107$$CN$US$US
135785608$13578560$8$F$20170501$20221220$20170524$20221223$EXP$$US-JAZZ-2017-US-006083$JAZZ$$71$YR$$M$Y$$$20221223$$CN$US$US
135787922$13578792$2$F$20160101$20220802$20170524$20221026$PER$$US-JAZZ-2017-US-004882$JAZZ$$$$$M$Y$$$20221026$$CN$US$US
135804002$13580400$2$F$20150529$20221117$20170525$20221123$EXP$$US-SHIRE-US201711036$TAKEDA$$46$YR$$F$Y$$$20221123$$HP$US$US
135829905$13582990$5$F$$20221219$20170525$20221222$EXP$$US-JAZZ-2017-US-006284$JAZZ$$$$$M$Y$$$20221222$$CN$US$US
1358505711$13585057$11$F$20150611$20221212$20170526$20221219$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2017JPN076917$VIIV$$$$$$Y$$$20221214$$MD$JP$JP
135876199$13587619$9$F$20170322$20221206$20170526$20221214$EXP$$CA-TAKEDA-2017TUS008487$TAKEDA$$42$YR$$M$Y$$$20221214$$CN$CA$CA
1359000038$13590000$38$F$20130919$20221220$20170529$20221228$EXP$$GB-drreddys-GER/UKI/17/0090884$DR REDDYS$$55$YR$A$M$Y$$$20221228$$MD$GB$GB
135912495$13591249$5$F$20170324$20221118$20170530$20221121$EXP$$US-PFIZER INC-2017127969$PFIZER$$68$YR$$F$Y$$$20221121$$CN$US$US
135923455$13592345$5$F$20111101$20221006$20170530$20221007$PER$$US-PFIZER INC-2017233572$PFIZER$$72$YR$$F$Y$75$KG$20221007$$LW$US$US
135923537$13592353$7$F$20111102$20221006$20170530$20221007$PER$$US-PFIZER INC-2016402029$PFIZER$$60$YR$$F$Y$$$20221007$$LW$US$US
135926288$13592628$8$F$20170501$20221004$20170530$20221007$EXP$$CA-TAKEDA-2017TUS011597$TAKEDA$$19$YR$$F$Y$$$20221007$$CN$CA$CA
1359283810$13592838$10$F$20130919$20221220$20170530$20221229$EXP$GB-MHRA-ADR 23836748$GB-TORRENT-00014939$TORRENT$$55$YR$A$M$Y$$$20221229$$MD$GB$GB
135991773$13599177$3$F$20170521$20221013$20170531$20221019$EXP$$US-ARIAD-2017US008265$TAKEDA$$59$YR$$F$Y$$$20221019$$CN$US$US
1360090413$13600904$13$F$20170521$20221116$20170601$20221118$EXP$$PL-ROCHE-1940860$ROCHE$$56$YR$$F$Y$63$KG$20221118$$MD$PL$
136021315$13602131$5$F$20170207$20221010$20170601$20221013$EXP$$IT-PFIZER INC-2017238938$PFIZER$$13$YR$$M$Y$$$20221013$$MD$IT$IT
1361086621$13610866$21$F$20160804$20221003$20170605$20221005$EXP$$PHHY2017IT021869$NOVARTIS$$13$YR$$M$Y$44$KG$20221005$$MD$IT$IT
136118675$13611867$5$F$$20170620$20170605$20221212$EXP$$ES-TEVA-774045ISR$TEVA$$67$YR$E$F$Y$$$20221212$$MD$ES$ES
136193443$13619344$3$F$20160101$20200627$20170606$20221008$PER$$US-PURDUE-USA-2016-0132275$PURDUE$$59$YR$$F$Y$$$20221008$$CN$US$US
136195624$13619562$4$F$20111101$20221123$20170606$20221130$EXP$$US-JAZZ-2017-US-006353$JAZZ$$27$YR$$M$Y$$$20221130$$MD$US$US
1362375226$13623752$26$F$20171103$20221121$20170608$20221128$EXP$$CA-ROCHE-1946081$ROCHE$$53$YR$$F$Y$90$KG$20221128$$CN$CA$CA
136251504$13625150$4$F$$20220928$20170607$20221012$PER$$US-JNJFOC-20170602495$JOHNSON AND JOHNSON$$$$$M$Y$$$20221010$$LW$US$US
136251904$13625190$4$F$20001109$20220928$20170607$20221007$PER$$US-JNJFOC-20170602379$JOHNSON AND JOHNSON$$12$YR$T$M$Y$$$20221007$$HP$US$US
136270405$13627040$5$F$20151201$20221015$20170607$20221017$PER$$US-PFIZER INC-2017239506$PFIZER$$55$YR$$F$Y$$$20221017$$LW$US$US
136270596$13627059$6$F$20121001$20221001$20170607$20221004$PER$$US-PFIZER INC-2016584463$PFIZER$$58$YR$$F$Y$$$20221004$$LW$US$US
136270673$13627067$3$F$20130201$20221015$20170607$20221017$PER$$US-PFIZER INC-2017239452$PFIZER$$61$YR$$F$Y$$$20221017$$LW$US$US
136287903$13628790$3$F$20120101$20221005$20170607$20221006$PER$$US-PFIZER INC-2016584439$PFIZER$$46$YR$$F$Y$79$KG$20221006$$LW$US$US
136354294$13635429$4$F$$20221122$20170609$20221128$PER$$US-PFIZER INC-2017250307$PFIZER$$53$YR$$F$Y$$$20221128$$CN$US$US
1363703612$13637036$12$F$$20221214$20170609$20221220$EXP$$CA-GLAXOSMITHKLINE-CA2017GSK085504$GLAXOSMITHKLINE$$$$$$Y$$$20221220$$MD$CA$CA
136401705$13640170$5$F$$20221213$20170609$20221219$EXP$$US-BAXALTA-2017BLT005408$TAKEDA$$$$$F$Y$134$KG$20221219$$CN$US$US
136432265$13643226$5$F$20170510$20221208$20170612$20221215$EXP$$CA-TAKEDA-2017TUS012584$TAKEDA$$33$YR$$F$Y$55.329$KG$20221215$$CN$CA$CA
136442425$13644242$5$F$$20221007$20170612$20221012$PER$$US-PFIZER INC-2017252015$PFIZER$$75$YR$$M$Y$113$KG$20221012$$CN$US$US
136461652$13646165$2$F$20170524$20221103$20170613$20221116$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-051724$BRISTOL MYERS SQUIBB$$61$YR$A$F$Y$$$20221116$$CN$US$US
1364725214$13647252$14$F$20161216$20221110$20170613$20221114$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2017JPN088088$VIIV$$$$$$Y$$$20221114$$MD$JP$JP
1365101229$13651012$29$F$20170101$20221109$20170614$20221115$EXP$$US-INCYTE CORPORATION-2017IN004526$INCYTE$$$$$$Y$$$20221115$$CN$US$US
1365103610$13651036$10$F$$20221206$20170614$20221212$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK144065$GLAXOSMITHKLINE$$$$$$Y$$$20221212$$CN$BR$BR
136513203$13651320$3$F$$20221117$20170614$20221122$EXP$$AU-PFIZER INC-2017252504$PFIZER$$44$YR$$M$Y$$$20221122$$MD$AU$AU
136585424$13658542$4$F$20220101$20221207$20170616$20221212$EXP$$US-PFIZER INC-2017164379$PFIZER$$69$YR$$M$Y$$$20221212$$CN$US$US
1365857414$13658574$14$F$$20220927$20170616$20221010$EXP$$GB-GLENMARK PHARMACEUTICALS-2017GMK027851$GLENMARK$$$$$$Y$$$20221010$$PH$GB$GB
1365953730$13659537$30$F$20160101$20221019$20170616$20221026$EXP$$PHHY2014CA049928$NOVARTIS$$$$$F$Y$$$20221026$$HP$CA$CA
136612763$13661276$3$F$20131001$20221221$20170616$20221222$PER$$US-PFIZER INC-2017158441$PFIZER$$59$YR$$F$Y$$$20221222$$LW$US$US
136634412$13663441$2$F$$20221024$20170619$20221027$PER$$US-PFIZER INC-2017261500$PFIZER$$36$YR$$F$Y$$$20221027$$CN$US$US
136677834$13667783$4$F$20170516$20221125$20170620$20221129$EXP$$FR-SHIRE-FR201711214$TAKEDA$$51$YR$$M$Y$53$KG$20221129$$HP$FR$FR
136693863$13669386$3$F$20170401$20170608$20170620$20221209$EXP$$CA-TEVA-764373ACC$TEVA$$31$YR$A$M$Y$$$20221209$$CN$CA$CA
136732318$13673231$8$F$$20221215$20170621$20221221$EXP$$CA-ROCHE-1952034$ROCHE$$60$YR$$F$Y$64$KG$20221221$$HP$CA$
136743692$13674369$2$F$$20221026$20170621$20221102$PER$$US-AMGEN-USASP2017091074$AMGEN$$$$A$F$Y$$$20221102$$CN$US$US
136751873$13675187$3$F$20110104$20220926$20170621$20221004$EXP$$US-AstraZeneca-2017SE62631$ASTRAZENECA$$22692$DY$$F$Y$87.3$KG$20221004$$LW$US$
1367670212$13676702$12$F$20180404$20221003$20170622$20221014$EXP$$US-PFIZER INC-2017270929$MYLAN$$57$YR$$F$Y$100$KG$20221014$$CN$US$US
1368227512$13682275$12$F$$20221009$20170623$20221011$EXP$GB-MHRA-MIDB-CCF9279F-D2CB-42FC-ADF9-3A1581D4A5BD$PHFR2017GB004594$NOVARTIS$$47$YR$$F$Y$$$20221011$$PH$GB$GB
136824972$13682497$2$F$20170525$20221109$20170623$20221118$EXP$$CA-JNJFOC-20170617857$JOHNSON AND JOHNSON$$40$YR$A$M$Y$127.01$KG$20221118$$CN$CA$CA
1368793832$13687938$32$F$20121226$20221020$20170626$20221027$EXP$$CA-ROCHE-1196834$ROCHE$$45$YR$$F$Y$75$KG$20221027$$HP$CA$
1368847913$13688479$13$F$$20221122$20170626$20221205$EXP$$GB-AUROBINDO-AUR-APL-2017-35698$AUROBINDO$$47$YR$$F$Y$$$20221205$$PH$GB$GB
1369684235$13696842$35$F$20160914$20221122$20170628$20221201$EXP$$CO-INCYTE CORPORATION-2017IN005035$INCYTE$$$$$$Y$$$20221201$$CN$CO$CO
136979644$13697964$4$F$$20221219$20170628$20221231$EXP$$CA-APOTEX-2017AP013336$APOTEX$$60$YR$$F$Y$64$KG$20221231$$HP$CA$CA
136992574$13699257$4$F$$20221025$20170628$20221031$EXP$$BE-BAUSCH-BL-2017-019916$BAUSCH AND LOMB$Heyrman B, De Becker A, Schots R. A case report of immunosuppression-related Kaposi^s sarcoma after autologous stem cell transplantation. BMC research notes. 2016;9:1-5. doi:10.1186/s13104-016-1991-9$61$YR$$M$Y$$$20221031$$MD$BE$BE
1370316018$13703160$18$F$20170101$20221212$20170629$20221219$EXP$$US-PFIZER INC-2017142637$PFIZER$$78$YR$$F$Y$$$20221219$$CN$US$US
137043299$13704329$9$F$$20221121$20170630$20221210$EXP$$CA-ROCHE-1955170$ROCHE$$$$$F$Y$70$KG$20221210$$HP$CA$
137048737$13704873$7$F$$20221214$20170630$20221226$EXP$$CA-APOTEX-2017AP013514$APOTEX$$85$YR$$M$Y$$$20221226$$MD$CA$CA
137068084$13706808$4$F$20010501$20221116$20170630$20221128$PER$$US-JNJFOC-20170616667$JOHNSON AND JOHNSON$$10$YR$C$M$Y$$$20221128$$LW$US$US
137076147$13707614$7$F$20150101$20221207$20170630$20221214$EXP$$US-JAZZ-2017-US-008350$JAZZ$$$$$F$Y$$$20221214$$MD$US$US
1370783912$13707839$12$F$$20221123$20170630$20221128$EXP$$US-PFIZER INC-2017284135$PFIZER$$71$YR$$F$Y$$$20221128$$CN$US$US
1371085214$13710852$14$F$20170507$20221115$20170703$20221118$EXP$$TR-ROCHE-1932955$ROCHE$$76$YR$$M$Y$78.3$KG$20221118$$MD$TR$
1371148735$13711487$35$F$20170101$20221214$20170703$20221222$EXP$$CA-CELLTRION INC.-2017CA008553$CELLTRION$$$$$$Y$$$20221222$$CN$CA$CA
137145129$13714512$9$F$20170601$20221116$20170704$20221119$EXP$$PHHY2017CA097764$NOVARTIS$$40$YR$$M$Y$$$20221119$$CN$CA$CA
1371571713$13715717$13$F$$20221013$20170705$20221021$EXP$$CA-JNJFOC-20170625604$JOHNSON AND JOHNSON$$50$YR$A$F$Y$110$KG$20221021$$HP$CA$CA
137168045$13716804$5$F$20220203$20221027$20170705$20221104$EXP$$CA-ROCHE-1959369$ROCHE$$75$YR$$F$Y$$$20221103$$MD$CA$CA
1371742525$13717425$25$F$20161114$20221103$20170705$20221108$EXP$$BR-GLAXOSMITHKLINE-BR2015GSK176439$GLAXOSMITHKLINE$$$$$$Y$$$20221108$$CN$BR$BR
137174472$13717447$2$F$$20221212$20170705$20221219$EXP$$CA-GLAXOSMITHKLINE-CA2017GSK101194$GLAXOSMITHKLINE$$$$$$Y$$$20221219$$MD$CA$CA
1371785211$13717852$11$F$$20221202$20170705$20221207$EXP$$BR-GLAXOSMITHKLINE-BR2017GSK060417$GLAXOSMITHKLINE$$$$$$Y$$$20221207$$CN$BR$BR
137180054$13718005$4$F$20160127$20221220$20170705$20221227$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-083600$BRISTOL MYERS SQUIBB$$76$YR$E$F$Y$73$KG$20221227$$MD$JP$JP
137198107$13719810$7$F$20150501$20221220$20170705$20221228$EXP$$US-JAZZ-2017-US-008485$JAZZ$$49$YR$$F$Y$$$20221228$$HP$US$US
137212426$13721242$6$F$20160228$20221026$20170706$20221102$EXP$$CA-ROCHE-1958977$ROCHE$$65$YR$$F$Y$$$20221102$$MD$CA$CA
1372446910$13724469$10$F$20170501$20221114$20170706$20221117$EXP$$CA-PFIZER INC-2017285010$PFIZER$$61$YR$$F$Y$$$20221117$$CN$CA$CA
137245543$13724554$3$F$20160101$20221207$20170706$20221215$EXP$$US-PFIZER INC-2017288743$PFIZER$$69$YR$$F$Y$66.667$KG$20221215$$CN$US$US
137273677$13727367$7$F$20170113$20221206$20170707$20221214$EXP$$PHHY2016CA109137$NOVARTIS$$78$YR$$F$Y$$$20221214$$CN$CA$CA
1373534710$13735347$10$F$20170101$20221109$20170710$20221115$EXP$$PHHY2017CA100155$NOVARTIS$$$$$M$Y$120$KG$20221115$$CN$CA$CA
1373879924$13738799$24$F$20170601$20221205$20170710$20221213$EXP$$CA-CELLTRION INC.-2017CA008652$CELLTRION$$$$$$Y$$$20221213$$CN$CA$CA
137419374$13741937$4$F$20170622$20221007$20170711$20221011$PER$$US-PFIZER INC-2017298881$PFIZER$$64$YR$$M$Y$$$20221011$$CN$US$US
137457707$13745770$7$F$$20221017$20170712$20221025$EXP$$US-PFIZER INC-2017268709$PFIZER$$9$YR$$M$Y$30$KG$20221025$$HP$US$US
137554058$13755405$8$F$20140424$20221012$20170714$20221014$PER$$US-PFIZER INC-2017305436$PFIZER$$70$YR$$F$Y$$$20221014$$MD$US$US
1375543414$13755434$14$F$20170301$20221209$20170714$20221216$EXP$$US-PFIZER INC-2017306034$PFIZER$$57$YR$$F$Y$$$20221216$$CN$US$US
137554607$13755460$7$F$$20221006$20170714$20221007$PER$$US-PFIZER INC-2017303511$PFIZER$$69$YR$$F$Y$$$20221007$$MD$US$US
137555542$13755554$2$F$20150101$20221122$20170714$20221129$PER$$US-AMGEN-USASL2017104973$AMGEN$$74$YR$E$M$Y$$$20221128$$CN$US$US
137578103$13757810$3$F$$20221017$20170717$20221027$EXP$$CA-ROCHE-1962285$ROCHE$$40$YR$$F$Y$$$20221027$$CN$CA$CA
137578184$13757818$4$F$20140801$20221119$20170717$20221201$EXP$$FR-Accord-053593$ACCORD$Bodard Q, Litrowski N, Carre D, Midhat M, Chenal P, Bravard P.. Mycosis fungoides in a heart transplant recipient.. Ann Dermatol Venereol..2017;144(10):624-8.$68$YR$E$M$Y$$$20221201$$HP$FR$FR
1375930214$13759302$14$F$20151110$20180822$20170717$20221003$EXP$$PHHY2016DE115328$NOVARTIS$$2$YR$$M$Y$12.2$KG$20221003$$MD$DE$DE
137612837$13761283$7$F$20140101$20221012$20170717$20221017$EXP$$PHHY2015CR008160$NOVARTIS$$$$$F$Y$56.7$KG$20221017$$CN$CR$CR
137618042$13761804$2$F$20170201$20221010$20170718$20221013$EXP$FR-AFSSAPS-AM20170810$FR-TAKEDA-2017TUS015034$TAKEDA$$55$YR$$M$Y$72$KG$20221013$$HP$FR$FR
1376235313$13762353$13$F$20170703$20221214$20170718$20221220$EXP$$US-PFIZER INC-2017301253$PFIZER$$59$YR$$M$Y$61$KG$20221220$$CN$US$US
137660856$13766085$6$F$20170630$20221114$20170719$20221124$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-004619$ACADIA PHARMACEUTICALS$$80$YR$$M$Y$$$20221124$$CN$US$US
137679273$13767927$3$F$$20221212$20170719$20221215$PER$$US-PFIZER INC-2017307830$PFIZER$$72$YR$$M$Y$$$20221215$$HP$US$US
137679849$13767984$9$F$20160201$20221214$20170719$20221227$EXP$$IN-INCYTE CORPORATION-2016IN000807$INCYTE$$$$$$Y$$$20221227$$CN$IN$IN
137700023$13770002$3$F$20160917$20220929$20170719$20221003$EXP$$US-TAKEDA-2017TUS015029$TAKEDA$$30$YR$$F$Y$66.667$KG$20221003$$HP$US$US
137728373$13772837$3$F$20170619$20221208$20170720$20221216$EXP$$JP-SHIRE-JP201716085$TAKEDA$$9$YR$$F$Y$$$20221216$$MD$JP$JP
1377312214$13773122$14$F$20170706$20221012$20170720$20221021$PER$$US-INCYTE CORPORATION-2017IN005517$INCYTE$$$$$$Y$$$20221021$$CN$US$US
1377331615$13773316$15$F$20170101$20220930$20170720$20221004$EXP$$CA-PFIZER INC-2017165290$PFIZER$$62$YR$$F$Y$$$20221004$$CN$CA$CA
137754354$13775435$4$F$20170601$20221207$20170720$20221209$EXP$$CA-TAKEDA-2017TUS015054$TAKEDA$$65$YR$$F$Y$$$20221209$$CN$CA$CA
1377743412$13777434$12$F$20160715$20221209$20170721$20221220$EXP$$CA-ROCHE-1964975$ROCHE$$17$YR$$M$Y$$$20221220$$CN$CA$CA
137788618$13778861$8$F$20170929$20221101$20170721$20221103$PER$$US-PFIZER INC-2017316465$PFIZER$$70$YR$$F$Y$66.22$KG$20221103$$HP$US$US
137790453$13779045$3$F$20130101$20220927$20170721$20221010$EXP$$FR-AUROBINDO-AUR-APL-2015-01074$AUROBINDO$Barbara Doudier, Hugues Vencatassin, Sarah Aherfi, Philippe Colsonb. Fatal fulminant hepatitis E associated with autoimmune hepatitis and excessive paracetamol intake in Southeastern France. Journal of Clinical Microbiology. 2014;52(4):1294-1297$77$YR$$F$Y$$$20221010$$HP$FR$FR
137837237$13783723$7$F$$20221121$20170724$20221122$PER$$US-PFIZER INC-2017320556$PFIZER$$69$YR$$F$Y$$$20221122$$HP$US$US
137851605$13785160$5$F$$20221129$20170725$20221202$EXP$$US-ROCHE-1966350$ROCHE$$30$YR$$M$Y$80.812$KG$20221202$$HP$US$
137902963$13790296$3$F$20170101$20170818$20170725$20221027$EXP$$US-VIIV HEALTHCARE LIMITED-US2017113730$VIIV$$$$$F$Y$$$20221027$$PH$US$US
137911163$13791116$3$F$20160527$20221206$20170725$20221215$PER$$US-INCYTE CORPORATION-2017IN003389$INCYTE$$$$$$Y$$$20221215$$CN$US$US
137925767$13792576$7$F$20161129$20221130$20170726$20221204$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2017-BI-041483$BOEHRINGER INGELHEIM$$81$YR$E$M$Y$75$KG$20221204$$HP$ES$ES
1379432715$13794327$15$F$$20221020$20170726$20221024$PER$$US-PFIZER INC-2017241581$PFIZER$$25$YR$$M$Y$$$20221024$$CN$US$US
137953567$13795356$7$F$20190320$20221018$20170726$20221020$EXP$$US-PFIZER INC-2017324138$PFIZER$$65$YR$$F$Y$84$KG$20221020$$HP$US$US
137981064$13798106$4$F$$20221117$20170727$20221118$PER$$US-PFIZER INC-2017324389$PFIZER$$46$YR$$F$Y$$$20221118$$CN$US$US
138024487$13802448$7$F$20170424$20221201$20170728$20221208$EXP$$CA-ROCHE-1967729$ROCHE$$31$YR$$F$Y$$$20221208$$MD$CA$CA
138056073$13805607$3$F$20150511$20221005$20170728$20221007$PER$$US-PFIZER INC-2016584416$PFIZER$$47$YR$$F$Y$84.8$KG$20221007$$LW$US$US
138056185$13805618$5$F$20131101$20221005$20170728$20221006$PER$$US-PFIZER INC-2017053691$PFIZER$$56$YR$$F$Y$104$KG$20221006$$LW$US$US
138060924$13806092$4$F$20160315$20221007$20170728$20221014$EXP$$PHHY2016CA036453$NOVARTIS$$43$YR$$M$Y$$$20221014$$MD$CA$CA
138066333$13806633$3$F$$20221019$20170728$20221019$EXP$$CA-PFIZER INC-2017325722$PFIZER$$49$YR$$F$Y$$$20221019$$CN$CA$CA
138126095$13812609$5$F$20170724$20221114$20170728$20221117$EXP$$PHHY2017CA111503$NOVARTIS$$46$YR$$F$Y$$$20221117$$CN$CA$CA
1381361619$13813616$19$F$20170716$20221102$20170731$20221108$EXP$$CA-ROCHE-1971321$ROCHE$$22$YR$$F$Y$$$20221108$$MD$CA$CA
138154434$13815443$4$F$$20170801$20170731$20221212$EXP$$GB-TEVA-793081ISR$TEVA$$48$YR$A$F$Y$$$20221212$$MD$GB$GB
138159066$13815906$6$F$20141022$20220912$20170731$20221005$EXP$$PHHY2017IT104422$NOVARTIS$$$$$F$Y$10.7$KG$20221005$$MD$IT$IT
138211993$13821199$3$F$20120501$20221005$20170801$20221006$PER$$US-PFIZER INC-2016584472$PFIZER$$48$YR$$F$Y$68$KG$20221006$$LW$US$US
138227253$13822725$3$F$$20221125$20170801$20221130$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-067963$BRISTOL MYERS SQUIBB$Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with Nivolumab therapy. Journal of Cutaneous Pathology. 2017; 44: 381-4.doi:10.1111/cup.12876.$50$YR$A$F$Y$$$20221201$$HP$US$US
1382387614$13823876$14$F$20170717$20221117$20170802$20221121$EXP$$US-PFIZER INC-2017331290$PFIZER$$78$YR$$F$Y$82$KG$20221121$$CN$US$US
1382411511$13824115$11$F$20170601$20221124$20170802$20221202$EXP$$AU-BIOGEN-2017BI00437644$BIOGEN$$30$YR$$F$Y$$$20221202$$CN$AU$AU
138241803$13824180$3$F$20120101$20221004$20170802$20221007$EXP$$US-AstraZeneca-2017SE78104$ASTRAZENECA$$61$YR$$F$Y$78.5$KG$20221007$$LW$US$
138257976$13825797$6$F$20170522$20221021$20170802$20221024$EXP$$PHJP2017JP021551$NOVARTIS$$70$YR$$M$Y$92.7$KG$20221024$$MD$JP$JP
138262686$13826268$6$F$20100101$20221109$20170802$20221117$EXP$$US-EMD Serono-7056049$EMD SERONO INC$$45$YR$A$F$Y$88$KG$20221117$$CN$US$
1382796012$13827960$12$F$$20221220$20170803$20221226$EXP$$CA-Orion Corporation ORION PHARMA-TREX2017-2277$ORION$$56$YR$A$F$Y$$$20221227$$MD$CA$
1383632415$13836324$15$F$20160101$20221109$20170804$20221116$EXP$$PHHY2017BR113598$NOVARTIS$$$$$M$Y$100$KG$20221116$$CN$BR$BR
138415763$13841576$3$F$20170726$20221102$20170807$20221108$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-067594$BRISTOL MYERS SQUIBB$$74$YR$E$M$Y$99$KG$20221109$$HP$US$US
138441075$13844107$5$F$$20221013$20170808$20221106$PER$$US-AMGEN-USASP2017117244$AMGEN$$$$$F$Y$$$20221106$$MD$US$US
138460474$13846047$4$F$$20221003$20170808$20221108$EXP$$US-ROCHE-737962$ROCHE$$$$$F$Y$$$20221108$$MD$US$
1384660216$13846602$16$F$20170529$20221007$20170808$20221008$EXP$$PHHY2017GR116283$NOVARTIS$$13$YR$$M$Y$60$KG$20221008$$MD$GR$GR
138478844$13847884$4$F$20170707$20200407$20170809$20221008$PER$$US-PURDUE-USA-2017-0139866$PURDUE$$$$$F$Y$$$20221008$$CN$US$US
1384976424$13849764$24$F$20170101$20221212$20170809$20221219$EXP$$CA-ROCHE-1976139$ROCHE$$45$YR$$F$Y$85$KG$20221219$$CN$CA$CA
138499738$13849973$8$F$20170701$20221028$20170809$20221104$EXP$$US-ROCHE-1973193$ROCHE$$54$YR$$M$Y$94.432$KG$20221103$$HP$US$
1385082222$13850822$22$F$$20221017$20170809$20221019$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK044952$GLAXOSMITHKLINE$$$$$$Y$$$20221019$$MD$BR$BR
1385138926$13851389$26$F$$20221201$20170809$20221207$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-069714$BRISTOL MYERS SQUIBB$$54$YR$A$F$Y$$$20221207$$CN$CA$CA
138553479$13855347$9$F$20160611$20221128$20170810$20221206$PER$$US-Vifor (International) Inc.-VIT-2017-05244$VIFOR$$86$YR$$F$Y$73.548$KG$20221206$$CN$US$US
138559915$13855991$5$F$20170701$20221031$20170810$20221108$EXP$$US-EMD Serono-8174566$EMD SERONO INC$$76$YR$E$F$Y$$$20221108$$PH$US$
138564634$13856463$4$F$$20221228$20170810$20221230$EXP$$US-JAZZ-2017-US-010131$JAZZ$$$$$F$Y$$$20221230$$CN$US$US
1385764316$13857643$16$F$$20221221$20170811$20221227$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-052306$BRISTOL MYERS SQUIBB$$85$YR$E$M$Y$$$20221227$$MD$CA$CA
138610353$13861035$3$F$$20221031$20170811$20221104$PER$$US-PFIZER INC-2017346776$PFIZER$$64$YR$$F$Y$$$20221104$$CN$US$US
138668264$13866826$4$F$20170601$20221222$20170814$20221229$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-003979$ACADIA PHARMACEUTICALS$$69$YR$$M$Y$$$20221230$$CN$US$US
138670185$13867018$5$F$20180430$20220908$20170814$20221003$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-003808$ACADIA PHARMACEUTICALS$$73$YR$$F$Y$$$20221003$$CN$US$US
138677886$13867788$6$F$20180513$20221004$20170814$20221013$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-003633$ACADIA PHARMACEUTICALS$$42$YR$$F$Y$$$20221014$$CN$US$US
138678762$13867876$2$F$20170401$20220914$20170814$20221006$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-003500$ACADIA PHARMACEUTICALS$$79$YR$$F$Y$$$20221007$$CN$US$US
138679235$13867923$5$F$20170601$20221103$20170814$20221111$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-004312$ACADIA PHARMACEUTICALS$$82$YR$$M$Y$$$20221111$$CN$US$US
138679723$13867972$3$F$$20221216$20170814$20221226$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-004456$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221226$$CN$US$US
138679883$13867988$3$F$$20221215$20170814$20221223$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-004485$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221223$$CN$US$US
138680936$13868093$6$F$20170724$20221007$20170814$20221101$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-004919$ACADIA PHARMACEUTICALS$$75$YR$$F$Y$$$20221101$$CN$US$US
138690014$13869001$4$F$20170510$20220927$20170815$20221004$EXP$$US-TAKEDA-2017TUS016678$TAKEDA$$30$YR$$F$Y$63.5$KG$20221004$$HP$US$US
1386944517$13869445$17$F$20161001$20221102$20170815$20221104$EXP$$GB-PFIZER INC-2017352058$MYLAN$$44$YR$$F$Y$$$20221104$$CN$GB$GB
138701086$13870108$6$F$20170614$20221007$20170815$20221010$EXP$GB-MHRA-EYC 00162837$GB-MYLANLABS-2017M1048814$MYLAN$$39$YR$$F$Y$56$KG$20221010$$CN$GB$GB
138730725$13873072$5$F$20170101$20221002$20170816$20221017$EXP$$GB-AUROBINDO-AUR-APL-2017-38614$AUROBINDO$$39$YR$$F$Y$51$KG$20221017$$CN$GB$GB
1387394518$13873945$18$F$20170612$20221118$20170816$20221124$EXP$$PHHY2017CO102043$NOVARTIS$$57$YR$$M$Y$97$KG$20221124$$CN$CO$CO
138758513$13875851$3$F$$20221222$20170817$20221229$PER$$US-AMGEN-USASP2017122132$AMGEN$$59$YR$A$F$Y$$$20221229$$MD$US$US
1387637910$13876379$10$F$$20221026$20170817$20221031$PER$$US-AMGEN-USASP2017122188$AMGEN$$68$YR$E$F$Y$99.79$KG$20221031$$MD$US$US
138777208$13877720$8$F$20170805$20221129$20170817$20221205$EXP$$PHHY2017MT118533$NOVARTIS$$72$YR$$F$Y$$$20221205$$MD$MT$MT
138805647$13880564$7$F$20160316$20221128$20170818$20221205$EXP$$CA-ROCHE-1743894$ROCHE$$52$YR$$F$Y$$$20221205$$CN$CA$CA
138816473$13881647$3$F$20111201$20221005$20170818$20221006$PER$$US-PFIZER INC-2016584465$PFIZER$$52$YR$$F$Y$98$KG$20221006$$LW$US$US
1388192213$13881922$13$F$20170814$20221023$20170818$20221027$EXP$$VN-ASTELLAS-2017US032784$ASTELLAS$$35$YR$$F$Y$44$KG$20221027$$MD$VN$VN
138824007$13882400$7$F$20170220$20220912$20170818$20221008$EXP$$PHHY2017IT081024$NOVARTIS$$$$$M$Y$50$KG$20221008$$MD$IT$IT
138908193$13890819$3$F$20130101$20221014$20170822$20221019$PER$$US-AMGEN-USASP2017123660$AMGEN$$38$YR$A$F$Y$$$20221019$$HP$US$US
138921482$13892148$2$F$$20221011$20170822$20221026$EXP$$JP-PFIZER INC-2017354669$PFIZER$Naruse, K.. A patent with SGA short stature post Fontan procedure who experienced Protein-losing gastroenteropathy during growth hormone (GH) therapy. The 53rd Chubu Regional Meeting of Japan Pediatric Society. 2017;53rd:53$13$YR$$F$Y$$$20221026$$MD$JP$JP
138927632$13892763$2$F$$20221208$20170822$20221215$EXP$$US-ROCHE-1348333$ROCHE$$72$YR$$M$Y$59.02$KG$20221215$$MD$US$
138956283$13895628$3$F$$20221116$20170823$20221118$PER$$US-PFIZER INC-2017358935$PFIZER$$59$YR$$M$Y$$$20221118$$CN$US$US
1389564415$13895644$15$F$$20221013$20170823$20221017$EXP$$US-PFIZER INC-2016603073$PFIZER$$70$YR$$F$Y$57$KG$20221017$$MD$US$US
138977085$13897708$5$F$20140305$20221003$20170823$20221004$PER$$US-PFIZER INC-2017360446$PFIZER$$66$YR$$F$Y$107$KG$20221004$$LW$US$US
139063625$13906362$5$F$20170710$20191024$20170825$20221101$EXP$$PHHY2017CO108158$NOVARTIS$$75$YR$$M$Y$68$KG$20221101$$CN$CO$CO
139112748$13911274$8$F$$20221212$20170828$20221219$EXP$$CA-GLAXOSMITHKLINE-CA2017GSK130321$GLAXOSMITHKLINE$$$$$$Y$$$20221219$$MD$CA$CA
139124942$13912494$2$F$$20221102$20170828$20221109$PER$$US-INCYTE CORPORATION-2017IN007041$INCYTE$$$$$$Y$$$20221109$$CN$US$US
139125918$13912591$8$F$20160501$20221114$20170828$20221119$EXP$$PHHY2016CA077562$NOVARTIS$$47$YR$$M$Y$$$20221119$$CN$CA$CA
1391742124$13917421$24$F$20161001$20221129$20170829$20221202$EXP$$GB-PURDUE PHARMA-GBR-2017-0048229$PURDUE$$44$YR$$F$Y$$$20221202$$HP$GB$GB
139182179$13918217$9$F$20210510$20220929$20170829$20221007$PER$$US-SA-2017SA040537$SANOFI AVENTIS$$48$YR$A$F$Y$$$20221007$$MD$US$US
139221953$13922195$3$F$$20221109$20170830$20221117$EXP$$IN-SA-2017SA157868$SANOFI AVENTIS$$15$YR$T$M$Y$$$20221117$$MD$IN$IN
139268785$13926878$5$F$20170818$20221021$20170831$20221024$EXP$$GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-076454$BRISTOL MYERS SQUIBB$$72$YR$E$F$Y$108.4$KG$20221024$$MD$GB$GB
139301108$13930110$8$F$20150101$20221108$20170901$20221114$EXP$$US-PFIZER INC-2017379523$MYLAN$$$$$M$Y$$$20221114$$CN$US$US
1393032821$13930328$21$F$20161031$20221020$20170901$20221102$EXP$$PHHY2016CA151784$NOVARTIS$$65$YR$$M$Y$$$20221102$$CN$CA$CA
1393048511$13930485$11$F$20170707$20221018$20170901$20221028$EXP$$IN-INCYTE CORPORATION-2017IN007203$INCYTE$$$$$$Y$$$20221028$$CN$IN$IN
1393173211$13931732$11$F$20170602$20221205$20170904$20221213$EXP$$CA-ROCHE-1986006$ROCHE$$50$YR$$F$Y$90$KG$20221213$$CN$CA$CA
139322145$13932214$5$F$$20221228$20170904$20221229$PER$$US-PFIZER INC-2017379021$PFIZER$$62$YR$$F$Y$$$20221229$$MD$US$US
139347373$13934737$3$F$$20221010$20170905$20221021$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2017US-148873$RANBAXY$$$$$M$Y$$$20221021$$MD$US$US
1393654218$13936542$18$F$20170801$20221013$20170905$20221019$EXP$$US-INCYTE CORPORATION-2017IN007200$INCYTE$$$$$$Y$$$20221019$$CN$US$US
139370253$13937025$3$F$20121001$20221005$20170905$20221006$PER$$US-PFIZER INC-2017379826$PFIZER$$38$YR$$F$Y$$$20221006$$LW$US$US
1393769011$13937690$11$F$20170706$20221202$20170905$20221206$EXP$$US-INCYTE CORPORATION-2017IN006594$INCYTE$$$$$$Y$$$20221206$$CN$US$US
139382473$13938247$3$F$20160101$20221201$20170905$20221209$EXP$$US-JAZZ-2017-US-011327$JAZZ$$50$YR$$F$Y$$$20221209$$MD$US$US
1394052634$13940526$34$F$20150301$20221024$20170906$20221028$EXP$$PHHY2015CA034068$NOVARTIS$$39$YR$$F$Y$$$20221028$$MD$CA$CA
139413876$13941387$6$F$20170101$20221122$20170906$20221125$EXP$$PHHY2017CA019786$NOVARTIS$$50$YR$$M$Y$$$20221125$$CN$CA$CA
139421762$13942176$2$F$20120101$20221122$20170906$20221129$EXP$$US-JAZZ-2017-US-011393$JAZZ$$$$$M$Y$$$20221129$$MD$US$US
139426403$13942640$3$F$20170831$20221221$20170906$20221226$EXP$$US-JAZZ-2017-US-011475$JAZZ$$32$YR$$F$Y$$$20221226$$CN$US$US
139430986$13943098$6$F$20170801$20221122$20170907$20221207$EXP$$CA-UCBSA-2017033656$UCB$$40$YR$$F$Y$$$20221207$$MD$CA$CA
1394656310$13946563$10$F$20170601$20221019$20170907$20221026$EXP$$PHHY2017CA131866$NOVARTIS$$26$YR$$F$Y$$$20221026$$MD$CA$CA
1394916131$13949161$31$F$20170607$20221212$20170908$20221219$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK177634$GLAXOSMITHKLINE$$$$$$Y$$$20221219$$MD$BR$BR
139505022$13950502$2$F$$20221115$20170908$20221121$EXP$$PT-MYLANLABS-2017M1055566$MYLAN$Pereira M, Guerra I.. Clinical case: Acute pancreatitis and lipemia. Clin-Chem-Lab-Med. 2016;54 (10):eA321$41$YR$$F$Y$$$20221121$$HP$PT$PT
139515283$13951528$3$F$20130101$20221122$20170908$20221202$EXP$$US-JAZZ-JPI-P-030318$JAZZ$$$$$F$Y$$$20221202$$MD$US$US
139519135$13951913$5$F$20160525$20221013$20170910$20221017$EXP$$PHHY2016CO080191$NOVARTIS$$61$YR$$F$Y$76$KG$20221017$$CN$CO$CO
139530633$13953063$3$F$$20170828$20170911$20221212$PER$$US-TEVA-796677ACC$TEVA$Latif S, Ohri P, Taxel P. Kyphoplasty complicated by short interval and adjacent multiple vertebral compression fractures: Eight is enough. Endocrine Reviews. 2017;38:.$63$YR$A$F$Y$$$20221212$$MD$US$US
139565924$13956592$4$F$20170817$20221109$20170911$20221109$EXP$$JP-BAYER-2017-169779$BAYER$$69$YR$E$M$Y$55.3$KG$20221109$$MD$JP$JP
1395736413$13957364$13$F$20180329$20221110$20170911$20221116$EXP$$PHHY2017CA132557$NOVARTIS$$57$YR$$F$Y$$$20221117$$CN$CA$CA
139619554$13961955$4$F$$20221129$20170912$20221203$EXP$$PHHY2017CO126665$NOVARTIS$$$$$F$Y$58$KG$20221203$$CN$CO$CO
139630684$13963068$4$F$20170101$20221007$20170913$20221012$PER$$US-PFIZER INC-2017393844$PFIZER$$53$YR$$F$Y$$$20221012$$MD$US$US
1396312812$13963128$12$F$20170801$20221103$20170913$20221111$EXP$$US-PFIZER INC-2017231807$PFIZER$$70$YR$$F$Y$95$KG$20221111$$MD$US$US
1396317813$13963178$13$F$20161201$20221209$20170913$20221213$EXP$$CA-TAKEDA-2017TUS001449$TAKEDA$$53$YR$$M$Y$$$20221213$$CN$CA$CA
139639809$13963980$9$F$20170516$20221005$20170913$20221007$EXP$$JP-ABBVIE-17K-087-1995756-00$ABBVIE$$75$YR$$F$Y$46$KG$20221007$$CN$JP$JP
139669767$13966976$7$F$$20221121$20170914$20221122$EXP$$CA-ROCHE-1992036$ROCHE$$$$$F$Y$$$20221123$$MD$CA$
1396707532$13967075$32$F$20161001$20221220$20170914$20221222$EXP$GB-TEVA-801034ACC$GB-JNJFOC-20170905683$JOHNSON AND JOHNSON$$44$YR$A$F$Y$$$20221222$$HP$GB$GB
139684475$13968447$5$F$20170301$20221018$20170914$20221020$PER$$US-PFIZER INC-2017396906$PFIZER$$66$YR$$F$Y$131.5$KG$20221020$$CN$US$US
1397123126$13971231$26$F$20150101$20221123$20170914$20221129$EXP$$US-ASTELLAS-2017US014871$ASTELLAS$$$$$M$Y$$$20221129$$CN$US$US
139723852$13972385$2$F$20210101$20221108$20170914$20221115$PER$$US-AMGEN-USASL2017137811$AMGEN$$$$A$F$Y$$$20221115$$CN$US$US
139742916$13974291$6$F$$20221107$20170915$20221114$EXP$$DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-082672$BRISTOL MYERS SQUIBB$Pf?hler C. Autoimmune thrombopenia or aggravation of a previously unknown werlhof disease?.$73$YR$E$M$Y$$$20221114$$MD$DE$DE
139751876$13975187$6$F$20170516$20221110$20170915$20221118$EXP$$US-SHIRE-US201720939$TAKEDA$$60$YR$$F$Y$78.912$KG$20221118$$MD$US$US
1397559410$13975594$10$F$20170101$20221006$20170915$20221010$PER$$US-PFIZER INC-2017395067$PFIZER$$86$YR$$F$Y$$$20221010$$HP$US$US
139768756$13976875$6$F$20170805$20221128$20170915$20221203$EXP$$PHHY2017IT133922$NOVARTIS$$51$YR$$F$Y$$$20221203$$MD$IT$IT
139806808$13980680$8$F$$20221130$20170918$20221204$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2017-BI-050658$BOEHRINGER INGELHEIM$$81$YR$E$M$Y$$$20221204$$MD$ES$ES
139813049$13981304$9$F$20180301$20221020$20170918$20221024$PER$$US-PFIZER INC-2017397283$PFIZER$$67$YR$$F$Y$90$KG$20221024$$CN$US$US
139858876$13985887$6$F$$20221221$20170919$20221227$PER$$US-PFIZER INC-2017401395$PFIZER$$72$YR$$F$Y$$$20221227$$MD$US$US
1398623519$13986235$19$F$20161001$20221019$20170919$20221031$EXP$$GB-AUROBINDO-AUR-APL-2017-40140$AUROBINDO$$44$YR$$F$Y$$$20221031$$HP$GB$GB
139866345$13986634$5$F$$20221007$20170919$20221014$EXP$$CA-GLAXOSMITHKLINE-CA2017GSK144375$GLAXOSMITHKLINE$$$$$$Y$$$20221014$$MD$CA$CA
1398766111$13987661$11$F$20180601$20221209$20170919$20221215$EXP$$US-ASTELLAS-2017US036923$ASTELLAS$$79$YR$$M$Y$$$20221215$$CN$US$US
139879677$13987967$7$F$$20221031$20170919$20221104$EXP$$US-PFIZER INC-2017404513$PFIZER$$48$YR$$F$Y$77.11$KG$20221104$$CN$US$US
139900919$13990091$9$F$20170808$20221128$20170920$20221201$EXP$$US-BIOGEN-2017BI00459495$BIOGEN$$47$YR$$F$Y$$$20221201$$CN$US$US
139915524$13991552$4$F$20100601$20221123$20170920$20221129$PER$$US-JNJFOC-20170802244$JOHNSON AND JOHNSON$$9$YR$C$M$Y$$$20221129$$HP$US$US
139915926$13991592$6$F$$20221003$20170920$20221013$PER$$US-JNJFOC-20170802625$JOHNSON AND JOHNSON$$$$$M$Y$$$20221014$$LW$US$US
139915953$13991595$3$F$20060502$20221228$20170920$20221229$PER$$US-JNJFOC-20170803003$JOHNSON AND JOHNSON$$5$YR$C$M$Y$$$20221229$$LW$US$US
139922834$13992283$4$F$20140517$20221107$20170920$20221110$PER$$US-JNJFOC-20170906272$JOHNSON AND JOHNSON$$16$YR$T$M$Y$$$20221110$$LW$US$US
140029609$14002960$9$F$20171212$20221020$20170922$20221025$EXP$$CA-TAKEDA-2017TUS019399$TAKEDA$$51$YR$$M$Y$$$20221025$$CN$CA$CA
140034722$14003472$2$F$$20220922$20170922$20221004$EXP$$PT-AUROBINDO-AUR-APL-2017-40672$AUROBINDO$Pereira M, Guerra I.. Acute pancreatitis and lipemia.. Clinical Chemistry and Laboratory Medicine. 2016;51(10):eA321$41$YR$$F$Y$$$20221004$$HP$PT$PT
140068515$14006851$5$F$$20221123$20170925$20221128$PER$$US-PFIZER INC-2017409298$PFIZER$$60$YR$$F$Y$$$20221128$$MD$US$US
140070265$14007026$5$F$20170701$20221115$20170925$20221125$PER$$US-LUPIN PHARMACEUTICALS INC.-2017-04741$LUPIN$$62$YR$$M$Y$65.76$KG$20221125$$CN$US$US
1400711314$14007113$14$F$$20221205$20170925$20221208$PER$$US-PFIZER INC-2017407271$PFIZER$$50$YR$$M$Y$81.65$KG$20221208$$CN$US$US
140074969$14007496$9$F$20000101$20221215$20170925$20221220$EXP$$US-PFIZER INC-2017409778$PFIZER$$44$YR$$M$Y$88.5$KG$20221220$$CN$US$US
140080678$14008067$8$F$20170801$20221018$20170925$20221021$PER$$US-PFIZER INC-2017411278$PFIZER$$77$YR$$F$Y$73$KG$20221021$$CN$US$US
1400847539$14008475$39$F$$20221118$20170925$20221212$EXP$$PT-PFIZER INC-2017405189$GLAXOSMITHKLINE$$$$$$Y$$$20221212$$HP$PT$PT
140090955$14009095$5$F$20120501$20221005$20170925$20221006$PER$$US-PFIZER INC-2016584504$PFIZER$$40$YR$$F$Y$68.027$KG$20221006$$LW$US$US
140090984$14009098$4$F$20160211$20221001$20170925$20221004$PER$$US-PFIZER INC-2016586541$PFIZER$$47$YR$$F$Y$105$KG$20221004$$LW$US$US
140106347$14010634$7$F$20170831$20221129$20170926$20221202$EXP$$GB-SHIRE-GB201723650$TAKEDA$$61$YR$$F$Y$$$20221202$$MD$GB$GB
140125315$14012531$5$F$20170911$20180118$20170926$20221211$EXP$$DE-TEVA-808038GER$TEVA$$55$YR$A$M$Y$$$20221211$$CN$DE$DE
140128642$14012864$2$F$20170805$20221011$20170926$20221013$EXP$$CA-TAKEDA-2017TUS019690$TAKEDA$$39$YR$$F$Y$$$20221013$$MD$CA$CA
1401401511$14014015$11$F$$20221013$20170926$20221020$PER$$US-AMGEN-USASP2017143522$AMGEN$$66$YR$E$F$Y$66$KG$20221020$$MD$US$US
140141128$14014112$8$F$$20221202$20170927$20221208$EXP$$CA-JNJFOC-20170923187$JOHNSON AND JOHNSON$$38$YR$A$F$Y$66$KG$20221208$$CN$CA$CA
1401530534$14015305$34$F$$20221118$20170927$20221121$EXP$$PT-JNJFOC-20170921376$JOHNSON AND JOHNSON$$23$YR$A$F$Y$102$KG$20221121$$HP$PT$PT
140166943$14016694$3$F$$20221222$20170927$20221227$PER$$US-PFIZER INC-2017416226$PFIZER$$51$YR$$F$Y$$$20221227$$MD$US$US
140182996$14018299$6$F$20150422$20221206$20170928$20221216$PER$$JP-AMGEN-JPNSP2017144345$AMGEN$Yamada R, Murakami A, Kusakabe E, Yamazawa H, Taguchi K, Nishiyama K, et al.. A case of anti-resorptive agents-related osteonecrosis of jaw in a patient with denosumab for multiple metastases to bone from breast cancer and healing after interruption of denosumab. The 14th Ann Met of The Japanese Breast Cancer Society, Chugoku-Shikoku Branch. 2017;83$$$$F$Y$$$20221216$$MD$JP$JP
1402081129$14020811$29$F$$20221118$20170928$20221121$EXP$$PHHY2017PT139841$NOVARTIS$Lopes JB, Cadinha S, Malheiro D, Brosseron L, Moreira D, Silva J. Multiple drug hypersensitivity syndrome to antihistamines, corticosteroids and nonsteroidal anti-inflammatories in a patient with asthma and urticaria. ALLERGY: EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2017;72 (103):219$23$YR$$F$Y$102$KG$20221121$$HP$PT$PT
1402407334$14024073$34$F$20171101$20221214$20170929$20221223$EXP$$CA-CELLTRION INC.-2017CA012918$CELLTRION$$$$$$Y$$$20221223$$CN$CA$CA
140257665$14025766$5$F$20140701$20221001$20170929$20221004$PER$$US-PFIZER INC-2016584462$PFIZER$$67$YR$$F$Y$$$20221004$$LW$US$US
140258075$14025807$5$F$20141001$20221006$20170929$20221007$PER$$US-PFIZER INC-2016584500$PFIZER$$56$YR$$F$Y$93$KG$20221007$$LW$US$US
140263874$14026387$4$F$20170921$20221129$20170929$20221202$EXP$$CA-TAKEDA-2017TUS019872$TAKEDA$$51$YR$$F$Y$$$20221202$$MD$CA$CA
140266275$14026627$5$F$20160101$20221126$20170929$20221206$EXP$$US-ACORDA-ACO_142380_2017$ACORDA$$$$$F$Y$63.5$KG$20221206$$MD$US$US
140274402$14027440$2$F$20220101$20221205$20170929$20221209$EXP$$US-ASTELLAS-2017US038598$ASTELLAS$$$$$M$Y$$$20221209$$CN$US$US
140276768$14027676$8$F$20170401$20221017$20170929$20221019$PER$$US-PFIZER INC-2017419527$PFIZER$$51$YR$$F$Y$55$KG$20221019$$CN$US$US
1403160813$14031608$13$F$20130419$20221214$20171003$20221222$EXP$$CA-ROCHE-2000971$ROCHE$$38$YR$$M$Y$$$20221222$$MD$CA$CA
140324918$14032491$8$F$20170101$20221024$20171003$20221103$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-005614$ACADIA PHARMACEUTICALS$$$$$M$Y$59$KG$20221103$$CN$US$US
140326375$14032637$5$F$$20221010$20171002$20221014$PER$$US-PFIZER INC-2017421865$PFIZER$$68$YR$$F$Y$$$20221014$$MD$US$US
140331062$14033106$2$F$20170901$20221026$20171003$20221031$PER$$US-PFIZER INC-2017424362$PFIZER$$37$YR$$F$Y$83$KG$20221031$$HP$US$US
140331384$14033138$4$F$20110301$20221006$20171003$20221007$PER$$US-PFIZER INC-2016586384$PFIZER$$57$YR$$F$Y$$$20221007$$LW$US$US
1403366322$14033663$22$F$$20221116$20171003$20221130$EXP$$PT-AUROBINDO-AUR-APL-2017-41180$AUROBINDO$Lopes JB, Cadinha S, Malheiro D, Brosseron L, Moreira Da Silva JP.. Multiple drug hypersensitivity syndrome to antihistamines, corticosteroids and nonsteroidal anti-inflammatories in a patient with asthma and urticaria. Allergy:. European Journal of Allergy and Clinical Immunology.. 2017;72(103):219$23$YR$$F$Y$102$KG$20221130$$MD$PT$PT
140341782$14034178$2$F$20161221$20170215$20171003$20221212$PER$$US-TEVA-724836USA$TEVA$$40$YR$A$M$Y$93$KG$20221212$$CN$US$US
140345534$14034553$4$F$20130409$20221005$20171003$20221006$PER$$US-PFIZER INC-2016596185$PFIZER$$65$YR$$F$Y$61$KG$20221006$$LW$US$US
140352984$14035298$4$F$20051010$20220928$20171003$20221004$EXP$$US-PFIZER INC-2017425983$PFIZER$$46$YR$$M$Y$115.67$KG$20221004$$CN$US$US
140368748$14036874$8$F$$20221010$20171004$20221014$PER$$US-AMGEN-USASP2017148397$AMGEN$$72$YR$E$F$Y$74.84$KG$20221014$$MD$US$US
140430193$14043019$3$F$20131201$20221005$20171004$20221006$PER$$US-PFIZER INC-2016596182$PFIZER$$45$YR$$F$Y$54$KG$20221006$$LW$US$US
140456102$14045610$2$F$$20220307$20171005$20221013$PER$$US-INDIVIOR LIMITED-INDV-103505-2017$RECKITT BENCKISER$$$$$F$Y$$$20221013$$CN$US$US
1404664912$14046649$12$F$20170901$20221207$20171005$20221214$EXP$$PHHY2017CA144588$NOVARTIS$$49$YR$$F$Y$$$20221214$$CN$CA$CA
140477603$14047760$3$F$$20221111$20171005$20221114$EXP$$PHHY2017AU144587$NOVARTIS$$$$$F$Y$$$20221114$$MD$AU$AU
140581313$14058131$3$F$$20221213$20171006$20221215$EXP$$US-PFIZER INC-2017428648$PFIZER$Dunkel, I.. Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children^s Oncology Group (COG) trial (ARET0321). Journal of Clinical Oncology. 2017;35 (15 Suppl 1):10506-10506$$$C$$Y$$$20221215$$HP$US$US
140581323$14058132$3$F$$20221213$20171006$20221215$EXP$$US-PFIZER INC-2017428901$PFIZER$Dunkel, I.. Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children^s Oncology Group (COG) trial (ARET0321). Journal of Clinical Oncology. 2017;35 (15 Suppl 1):10506-10506$$$I$$Y$$$20221215$$HP$US$US
140619585$14061958$5$F$20120101$20221006$20171009$20221007$PER$$US-PFIZER INC-2016586545$PFIZER$$55$YR$$F$Y$$$20221007$$LW$US$US
140619996$14061999$6$F$20130101$20221011$20171009$20221012$PER$$US-PFIZER INC-2017419128$PFIZER$$44$YR$$F$Y$$$20221012$$LW$US$US
140620534$14062053$4$F$20150327$20221005$20171009$20221006$PER$$US-PFIZER INC-2016584481$PFIZER$$78$YR$$F$Y$113$KG$20221006$$LW$US$US
140650884$14065088$4$F$20131008$20221118$20171009$20221121$PER$$US-PFIZER INC-2017427387$PFIZER$$48$YR$$F$Y$78$KG$20221121$$LW$US$US
140652023$14065202$3$F$20110801$20221013$20171009$20221014$PER$$US-PFIZER INC-2017427385$PFIZER$$52$YR$$F$Y$$$20221014$$LW$US$US
140675125$14067512$5$F$$20221117$20171010$20221118$EXP$$CA-ROCHE-2004147$ROCHE$$59$YR$$F$Y$$$20221118$$HP$CA$
140680927$14068092$7$F$$20221212$20171010$20221220$PER$$CA-AMGEN-CANSP2017151688$AMGEN$$70$YR$E$M$Y$$$20221220$$HP$CA$CA
1406848613$14068486$13$F$$20221201$20171010$20221205$PER$$US-PFIZER INC-2017430392$PFIZER$$62$YR$$F$Y$$$20221205$$MD$US$US
140688604$14068860$4$F$20140101$20221206$20171010$20221212$PER$$US-PFIZER INC-2017434539$PFIZER$$68$YR$$M$Y$$$20221212$$HP$US$US
1406897031$14068970$31$F$20180326$20221104$20171010$20221115$EXP$$CA-CELLTRION INC.-2017CA013585$CELLTRION$$$$$$Y$$$20221115$$CN$CA$CA
140721067$14072106$7$F$20180312$20221026$20171010$20221103$PER$$US-SA-2017SA160185$SANOFI AVENTIS$$28$YR$A$F$Y$53.5$KG$20221103$$MD$US$US
140725638$14072563$8$F$20220318$20221221$20171011$20221227$EXP$$PHHY2017CA147131$NOVARTIS$$55$YR$$F$Y$$$20221227$$CN$CA$CA
1407420322$14074203$22$F$20170510$20221115$20171011$20221118$EXP$$TR-ROCHE-1938068$ROCHE$$59$YR$$M$Y$58$KG$20221118$$MD$TR$
140752883$14075288$3$F$20160301$20221104$20171011$20221108$PER$$US-PFIZER INC-2017438070$PFIZER$$59$YR$$F$Y$100$KG$20221108$$CN$US$US
140758364$14075836$4$F$20120101$20171011$20171011$20221212$EXP$$GB-TEVA-812988ACC$TEVA$$$$$F$Y$$$20221212$$CN$GB$GB
140758734$14075873$4$F$20151027$20221005$20171011$20221007$PER$$US-PFIZER INC-2016584466$PFIZER$$46$YR$$F$Y$63$KG$20221007$$LW$US$US
140784482$14078448$2$F$$20221019$20171012$20221021$PER$$US-PFIZER INC-2017439244$PFIZER$$60$YR$$F$Y$$$20221021$$HP$US$US
140793434$14079343$4$F$20161124$20220912$20171012$20221006$EXP$$PHHY2017IT148353$NOVARTIS$$12$YR$$F$Y$34.5$KG$20221006$$MD$IT$IT
140797325$14079732$5$F$20120301$20221001$20171012$20221004$PER$$US-PFIZER INC-2016584469$PFIZER$$62$YR$$F$Y$59$KG$20221004$$LW$US$US
140797462$14079746$2$F$20141001$20221003$20171012$20221005$PER$$US-PFIZER INC-2016586544$PFIZER$$69$YR$$F$Y$97$KG$20221005$$LW$US$US
140876295$14087629$5$F$20170601$20221215$20171013$20221221$EXP$$US-JAZZ-2017-US-013346$JAZZ$$10$YR$$F$Y$$$20221221$$HP$US$US
140891056$14089105$6$F$20160901$20221116$20171013$20221119$EXP$$PHHY2016CA150097$NOVARTIS$$44$YR$$F$Y$$$20221119$$CN$CA$CA
1409055611$14090556$11$F$$20191121$20171015$20221109$EXP$$PHEH2017US032775$NOVARTIS$$$$$F$Y$$$20221109$$CN$US$US
1409190337$14091903$37$F$20170731$20221004$20171016$20221011$EXP$$PHHY2017AR151832$NOVARTIS$$44$YR$$M$Y$$$20221011$$CN$AR$AR
140987219$14098721$9$F$20160916$20221208$20171017$20221212$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2017JPN156841$VIIV$$$$$$Y$$$20221212$$MD$JP$JP
140990616$14099061$6$F$20170101$20221217$20171017$20221227$EXP$$CA-PFIZER INC-2017205225$PFIZER$$65$YR$$M$Y$$$20221227$$CN$CA$CA
140996047$14099604$7$F$20170501$20221031$20171017$20221104$EXP$$PHHY2016CA127662$NOVARTIS$$22$YR$$F$Y$$$20221104$$HP$CA$CA
141014174$14101417$4$F$20160101$20221202$20171018$20221209$EXP$$US-PFIZER INC-2017447581$MYLAN$$$$$F$Y$89$KG$20221209$$HP$US$US
1410143518$14101435$18$F$20160101$20220929$20171018$20221003$EXP$$US-PFIZER INC-2017448357$PFIZER$$85$YR$$F$Y$79$KG$20221003$$CN$US$US
1410198213$14101982$13$F$20170101$20221202$20171018$20221207$EXP$$US-PFIZER INC-2017446613$PFIZER$$60$YR$$F$Y$$$20221207$$HP$US$US
141040447$14104044$7$F$$20221013$20171018$20221018$EXP$$PHHY2016CA158111$NOVARTIS$$$$$M$Y$$$20221018$$MD$CA$CA
141065769$14106576$9$F$$20221123$20171019$20221128$PER$$US-PFIZER INC-2017447585$PFIZER$$73$YR$$F$Y$63.5$KG$20221128$$CN$US$US
141088986$14108898$6$F$20120822$20220929$20171019$20221008$EXP$$PL-ABBVIE-17P-129-2134389-00$ABBVIE$Jablonowska E. Progression of coronary artery disease in a HIV-infected patient previously treated for ascending aorta aneurysm.. Kardiochirurgia i Torakochirurgia Polska.. 2017;14 (3):211-213; Marcinkiewicz A. Progression of coronary artery disease in a HIV-infected patient previously treated for ascending aorta aneurysm.. Kardiochirurgia i Torakochirurgia Polska.. 2017;14 (3):211-213; Zwoliski R. Progression of coronary artery disease in a HIV-infected patient previously treated for ascendi...$35$YR$$M$Y$$$20221008$$MD$PL$PL
1411149610$14111496$10$F$20170727$20221202$20171020$20221207$EXP$$CA-TAKEDA-2017TUS021444$TAKEDA$$52$YR$$F$Y$$$20221207$$MD$CA$CA
1411302422$14113024$22$F$20160505$20221027$20171022$20221108$EXP$$PHHY2017CA152629$NOVARTIS$$27$YR$$F$Y$$$20221108$$CN$CA$CA
1411446714$14114467$14$F$20160101$20221113$20171023$20221115$PER$$US-PFIZER INC-2017453141$PFIZER$$72$YR$$F$Y$53$KG$20221115$$CN$US$US
141145609$14114560$9$F$20180101$20221208$20171023$20221213$PER$$US-PFIZER INC-2017118785$PFIZER$$70$YR$$F$Y$82$KG$20221213$$HP$US$US
141151275$14115127$5$F$$20221027$20171023$20221102$EXP$$US-PFIZER INC-2017455015$PFIZER$$83$YR$$F$Y$67.13$KG$20221102$$CN$US$US
141189155$14118915$5$F$$20221021$20171024$20221025$PER$$US-AMGEN-USASP2017158583$AMGEN$$74$YR$E$F$Y$$$20221025$$MD$US$US
141189833$14118983$3$F$20170922$20221129$20171024$20221202$EXP$$US-SHIRE-US201724065$TAKEDA$$60$YR$$M$Y$$$20221202$$MD$US$US
141190905$14119090$5$F$20170501$20221031$20171024$20221108$EXP$$CA-ROCHE-2010731$ROCHE$$22$YR$$F$Y$$$20221107$$HP$CA$CA
141194454$14119445$4$F$$20221104$20171024$20221108$PER$$US-PFIZER INC-2017455586$PFIZER$$66$YR$$F$Y$$$20221108$$MD$US$US
141195794$14119579$4$F$$20221206$20171024$20221209$PER$$US-PFIZER INC-2017455204$PFIZER$$71$YR$$F$Y$$$20221209$$MD$US$US
141217587$14121758$7$F$20120822$20221114$20171024$20221121$EXP$$PL-MYLANLABS-2017M1065817$MYLAN$Zwolinski R, Kamerys J, Jablonowska E, Marcinkiewicz A, Jaszewski R, Krecki R, et al.. Progression of coronary artery disease in a HIV-infected patient previously treated for ascending aorta aneurysm. Kardiochirurgia i Torakochirurgia Polska. 2017;14 (3):211-13$35$YR$$M$Y$$$20221121$$HP$PL$PL
141231576$14123157$6$F$20170725$20221123$20171025$20221129$EXP$$US-ROCHE-1958822$ROCHE$$$$A$F$Y$83.99$KG$20221129$$HP$US$
141243284$14124328$4$F$$20221021$20171025$20221025$PER$$US-PFIZER INC-2017452708$PFIZER$$76$YR$$F$Y$$$20221025$$MD$US$US
141249839$14124983$9$F$20170101$20221007$20171025$20221014$EXP$$CA-TAKEDA-2017TUS012787$TAKEDA$$26$YR$$F$Y$$$20221014$$CN$CA$CA
141259743$14125974$3$F$$20221122$20171025$20221129$EXP$$US-JAZZ-2017-US-013759$JAZZ$$$$$F$Y$$$20221129$$CN$US$US
141268668$14126866$8$F$$20221202$20171025$20221208$PER$$US-AMGEN-USASP2017158588$AMGEN$$68$YR$E$F$Y$$$20221208$$MD$US$US
141274112$14127411$2$F$$20170515$20171026$20221212$PER$$US-TEVA-765967ACC$TEVA$$$$$M$Y$$$20221212$$CN$US$US
141334162$14133416$2$F$20131225$20221013$20171026$20221014$PER$$US-PFIZER INC-2017460494$PFIZER$$58$YR$$F$Y$$$20221014$$LW$US$US
141405059$14140505$9$F$$20221214$20171030$20221219$EXP$$US-PFIZER INC-2017461544$PFIZER$$71$YR$$F$Y$$$20221219$$CN$US$US
141407467$14140746$7$F$$20221107$20171030$20221109$PER$$US-PFIZER INC-2017465703$PFIZER$$66$YR$$F$Y$$$20221109$$MD$US$US
1414134610$14141346$10$F$20170811$20221125$20171030$20221205$EXP$$GB-TEVA-818638ACC$TEVA$$29$YR$A$M$Y$$$20221205$$HP$GB$GB
141420935$14142093$5$F$$20221222$20171030$20221229$PER$$US-AMGEN-USASP2017163353$AMGEN$$70$YR$E$F$Y$$$20221229$$MD$US$US
141448448$14144844$8$F$20140514$20221101$20171031$20221104$EXP$$US-SHIRE-US201726642$TAKEDA$$61$YR$$F$Y$$$20221104$$CN$US$US
141455669$14145566$9$F$20040314$20211231$20171031$20221005$EXP$$GB-BAUSCH-BL-2017-030139$BAUSCH AND LOMB$$66$YR$$M$Y$77.4$KG$20221005$$MD$GB$GB
141461874$14146187$4$F$20171001$20221019$20171031$20221028$EXP$$IT-JNJFOC-20171031905$JOHNSON AND JOHNSON$$66$YR$E$F$Y$$$20221028$$MD$IT$IT
141468655$14146865$5$F$$20220930$20171031$20221005$EXP$$CA-PFIZER INC-2017460118$PFIZER$$59$YR$$F$Y$$$20221005$$CN$CA$CA
141473857$14147385$7$F$20120718$20221117$20171101$20221125$EXP$$US-AstraZeneca-2017SF10090$ASTRAZENECA$$24630$DY$$F$Y$68$KG$20221125$$LW$US$
141481088$14148108$8$F$20170101$20221128$20171101$20221130$EXP$$US-PFIZER INC-2017467374$PFIZER$$94$YR$$F$Y$58$KG$20221130$$CN$US$US
141488275$14148827$5$F$20221004$20221104$20171101$20221111$EXP$$BR-GLAXOSMITHKLINE-BR2017GSK076533$GLAXOSMITHKLINE$$$$$$Y$$$20221111$$CN$BR$BR
141492546$14149254$6$F$20171016$20180208$20171101$20221010$PER$$GB-AMGEN-GBRCT2017160102$AMGEN$$52$YR$A$M$Y$84.5$KG$20221010$$MD$GB$GB
141498325$14149832$5$F$$20221117$20171101$20221121$EXP$$PHHY2017CA158824$NOVARTIS$$$$$F$Y$$$20221121$$MD$CA$CA
141502032$14150203$2$F$$20161222$20171101$20221020$PER$$US-NOVOPROD-524861$NOVO NORDISK$$70$YR$$F$Y$$$20221020$$CN$US$US
141502202$14150220$2$F$$20160908$20171101$20221020$PER$$US-NOVOPROD-510902$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
141502252$14150225$2$F$20160907$20160912$20171101$20221020$PER$$US-NOVOPROD-511668$NOVO NORDISK$$69$YR$$F$Y$$$20221020$$CN$US$US
141502272$14150227$2$F$20150101$20161102$20171101$20221020$PER$$US-NOVOPROD-518555$NOVO NORDISK$$60$YR$$F$Y$$$20221020$$CN$US$US
141502722$14150272$2$F$$20170104$20171101$20221020$PER$$US-NOVOPROD-522980$NOVO NORDISK$$66$YR$$F$Y$$$20221020$$MD$US$US
141502732$14150273$2$F$20160101$20170410$20171101$20221020$PER$$US-NOVOPROD-541174$NOVO NORDISK$$65$YR$$F$Y$$$20221020$$CN$US$US
141502742$14150274$2$F$$20170215$20171101$20221020$PER$$US-NOVOPROD-533141$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
141502752$14150275$2$F$$20170630$20171101$20221020$PER$$US-NOVOPROD-553323$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
141502762$14150276$2$F$$20170801$20171101$20221020$PER$$US-NOVOPROD-557888$NOVO NORDISK$$$$$F$Y$$$20221020$$PH$US$US
141502842$14150284$2$F$20170607$20170609$20171101$20221020$PER$$US-NOVOPROD-550367$NOVO NORDISK$$67$YR$$F$Y$$$20221020$$HP$US$US
141502862$14150286$2$F$$20161217$20171101$20221020$PER$$US-NOVOPROD-524010$NOVO NORDISK$$56$YR$$F$Y$$$20221020$$PH$US$US
141502882$14150288$2$F$$20161206$20171101$20221020$PER$$US-NOVOPROD-522615$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
141502892$14150289$2$F$20170201$20170216$20171101$20221020$PER$$US-NOVOPROD-533317$NOVO NORDISK$$66$YR$$F$Y$$$20221020$$CN$US$US
141502912$14150291$2$F$$20170605$20171101$20221020$PER$$US-NOVOPROD-549595$NOVO NORDISK$$$$E$F$Y$$$20221020$$CN$US$US
141503844$14150384$4$F$$20221117$20171101$20221128$EXP$$US-JAZZ-2017-US-014147$JAZZ$$$$$F$Y$$$20221128$$CN$US$US
141507586$14150758$6$F$$20221123$20171102$20221125$EXP$$CA-ABBVIE-17K-028-2145793-00$ABBVIE$$$$$M$Y$$$20221125$$MD$CA$CA
141575454$14157545$4$F$20171009$20221021$20171103$20221028$EXP$$BR-TAKEDA-2017TUS022779$TAKEDA$$29$YR$$F$Y$75$KG$20221028$$CN$BR$BR
141615294$14161529$4$F$20170915$20221223$20171106$20221230$EXP$$JP-009507513-1710JPN003595J$MERCK$Matsumoto K, Wakatuki J, Sakuma D, Kin E, Kobayashi Y, Komata M. WS16-3 Immune-related side effects during the first 5 years of use of immune checkpoint inhibitors. The 60th Annual Meeting of Japan Society of Clinical Oncology. 2022$58$YR$$M$Y$57$KG$20221230$$MD$JP$JP
1416298558$14162985$58$F$20160929$20221228$20171107$20221230$EXP$$CA-ROCHE-1837378$ROCHE$$58$YR$$F$Y$140$KG$20221230$$CN$CA$
1416514010$14165140$10$F$20190101$20221201$20171107$20221206$EXP$$US-PFIZER INC-2017474236$PFIZER$$58$YR$$M$Y$92.971$KG$20221206$$CN$US$US
141660256$14166025$6$F$20140106$20221208$20171107$20221216$EXP$$JP-MYLANLABS-2013S1024256$MYLAN$$17$YR$$M$Y$39.3$KG$20221216$$MD$JP$JP
141676254$14167625$4$F$20220401$20221004$20171107$20221010$EXP$$US-JAZZ-2017-US-014566$JAZZ$$34$YR$$F$Y$$$20221010$$MD$US$US
1416890311$14168903$11$F$20171101$20221107$20171108$20221109$PER$$US-PFIZER INC-2017474746$PFIZER$$60$YR$$F$Y$$$20221109$$PH$US$US
1416928110$14169281$10$F$20150119$20221221$20171108$20221228$EXP$$PHHY2011CA34112$NOVARTIS$$52$YR$$M$Y$$$20221228$$HP$CA$CA
1416957317$14169573$17$F$20170715$20221223$20171108$20221230$EXP$$PHHY2017CA107620$NOVARTIS$$55$YR$$F$Y$$$20221230$$CN$CA$CA
141715565$14171556$5$F$$20221122$20171108$20221125$PER$$US-BIOGEN-2017BI00478416$BIOGEN$$$$$F$Y$$$20221125$$CN$US$US
1417204311$14172043$11$F$20170116$20221213$20171108$20221220$EXP$$PHHY2017CA009421$NOVARTIS$$56$YR$$F$Y$$$20221220$$CN$CA$CA
141721956$14172195$6$F$20170101$20221020$20171109$20221028$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-005979$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221028$$CN$US$US
141726957$14172695$7$F$20160601$20221207$20171109$20221215$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-005197$ACADIA PHARMACEUTICALS$$76$YR$$M$Y$64$KG$20221216$$CN$US$US
141728412$14172841$2$F$20170701$20220930$20171109$20221024$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-005288$ACADIA PHARMACEUTICALS$$69$YR$$M$Y$$$20221025$$CN$US$US
141730263$14173026$3$F$$20221005$20171109$20221011$PER$$US-AMGEN-USASL2017167815$AMGEN$$68$YR$E$M$Y$$$20221011$$CN$US$US
141730938$14173093$8$F$$20221220$20171109$20221222$EXP$$CA-Orion Corporation ORION PHARMA-TREX2017-3466$ORION$$58$YR$A$F$Y$$$20221222$$MD$CA$
141731986$14173198$6$F$20210101$20221208$20171109$20221216$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-005673$ACADIA PHARMACEUTICALS$$$$$M$Y$123$KG$20221216$$CN$US$US
141742448$14174244$8$F$20161116$20221222$20171109$20221229$EXP$$JP-MYLANLABS-2017M1068472$MYLAN$$18$YR$$F$Y$30.4$KG$20221229$$MD$JP$JP
141747713$14174771$3$F$20111001$20211210$20171109$20221019$PER$$US-ALLERGAN-1716615US$ALLERGAN$$68$YR$$F$Y$$$20221019$$MD$US$US
141759932$14175993$2$F$20170722$20221118$20171109$20221121$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-071340$BRISTOL MYERS SQUIBB$$$$$M$Y$$$20221121$$HP$US$US
141771233$14177123$3$F$$20221117$20171110$20221121$PER$$US-PFIZER INC-2017481323$PFIZER$$58$YR$$F$Y$$$20221121$$CN$US$US
1417714814$14177148$14$F$20170101$20220930$20171110$20221006$EXP$$US-PFIZER INC-2017484503$PFIZER$$80$YR$$F$Y$64$KG$20221006$$CN$US$US
141778675$14177867$5$F$20200901$20221114$20171110$20221208$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-005203$ACADIA PHARMACEUTICALS$$70$YR$$M$Y$$$20221209$$CN$US$US
141782092$14178209$2$F$20170907$20221010$20171110$20221020$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-005758$ACADIA PHARMACEUTICALS$$77$YR$$M$Y$83$KG$20221020$$CN$US$US
141793463$14179346$3$F$20180401$20221101$20171110$20221110$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-006014$ACADIA PHARMACEUTICALS$$83$YR$$M$Y$$$20221111$$CN$US$US
1418295313$14182953$13$F$20211001$20221004$20171113$20221007$EXP$$BR-GLAXOSMITHKLINE-BR2017GSK111501$GLAXOSMITHKLINE$$$$$$Y$$$20221007$$CN$BR$BR
141831116$14183111$6$F$20170101$20221117$20171113$20221122$PER$$US-BIOGEN-2017BI00478420$BIOGEN$$$$$F$Y$$$20221122$$CN$US$US
141865887$14186588$7$F$20171023$20221209$20171114$20221216$EXP$$JP-ABBVIE-17P-087-2162696-00$ABBVIE$$48$YR$$M$Y$$$20221214$$MD$JP$JP
1418942914$14189429$14$F$20171017$20221101$20171115$20221104$EXP$$US-ROCHE-2019577$ROCHE$$58$YR$$F$Y$54.934$KG$20221103$$CN$US$
141911337$14191133$7$F$$20221003$20171115$20221006$EXP$$CA-TAKEDA-2017TUS023263$TAKEDA$$46$YR$$F$Y$$$20221006$$CN$CA$CA
141920425$14192042$5$F$20180101$20220301$20171115$20221012$PER$$US-CELLTRION INC.-2017US014375$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
142055784$14205578$4$F$$20221114$20171120$20221118$EXP$$TR-ALEXION-A201712866$ALEXION$Oruc A, Ayar Y, Aktas N, Yildiz A, Yavuz M, Ersoy A, et al.. Hepatoxicity associated with eculizumab treatment. Nephrology Dialysis Transplantation. 2017;32(Suppl 3):iii137$39$YR$$M$Y$$$20221118$$HP$TR$TR
142063095$14206309$5$F$20171115$20220929$20171120$20221006$PER$$US-JAZZ-2017-US-015228$JAZZ$$64$YR$$F$Y$$$20221006$$CN$US$US
142092174$14209217$4$F$$20221220$20171121$20221229$EXP$$JP-ASTELLAS-2017US047784$ASTELLAS$$35$YR$$M$Y$$$20221229$$MD$JP$JP
142152857$14215285$7$F$20220101$20221005$20171122$20221012$EXP$$PHHY2017CA137159$NOVARTIS$$$$$F$Y$$$20221012$$MD$CA$CA
1421591612$14215916$12$F$20161001$20221013$20171122$20221018$EXP$$PHHY2016CA151751$NOVARTIS$$24$YR$$F$Y$$$20221018$$MD$CA$CA
142189532$14218953$2$F$20080101$20221012$20171123$20221025$PER$$US-JNJFOC-20171012099$JOHNSON AND JOHNSON$$3$DEC$A$M$Y$$$20221025$$LW$US$US
142192744$14219274$4$F$20070101$20221031$20171123$20221108$PER$$US-JNJFOC-20171031358$JOHNSON AND JOHNSON$$17$YR$T$M$Y$$$20221108$$LW$US$US
142192802$14219280$2$F$20010201$20220926$20171123$20221006$PER$$US-JNJFOC-20171031521$JOHNSON AND JOHNSON$$11$YR$C$M$Y$$$20221006$$LW$US$US
142192833$14219283$3$F$$20221219$20171123$20221226$PER$$US-JNJFOC-20171031532$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221226$$LW$US$US
1421982416$14219824$16$F$20171201$20221012$20171123$20221017$EXP$$CA-TAKEDA-2017TUS024098$TAKEDA$$57$YR$$F$Y$$$20221017$$CN$CA$CA
142200043$14220004$3$F$19980211$20221107$20171123$20221110$PER$$US-JNJFOC-20171116664$JOHNSON AND JOHNSON$$12$YR$T$M$Y$$$20221110$$LW$US$US
142200903$14220090$3$F$20030430$20221207$20171123$20221214$PER$$US-JNJFOC-20170923847$JOHNSON AND JOHNSON$$9$YR$C$M$Y$$$20221214$$LW$US$US
142201014$14220101$4$F$$20221207$20171123$20221213$PER$$US-JNJFOC-20170923700$JOHNSON AND JOHNSON$$$$$M$Y$$$20221213$$LW$US$US
142201723$14220172$3$F$20030101$20221213$20171123$20221217$PER$$US-JNJFOC-20171011077$JOHNSON AND JOHNSON$$8$YR$C$M$Y$$$20221217$$LW$US$US
142201814$14220181$4$F$$20220922$20171123$20221004$PER$$US-JNJFOC-20171011309$JOHNSON AND JOHNSON$$$$$M$Y$$$20221004$$LW$US$US
142209283$14220928$3$F$$20221130$20171123$20221206$PER$$US-JNJFOC-20171033455$JOHNSON AND JOHNSON$$$$$M$Y$$$20221206$$LW$US$US
142210782$14221078$2$F$$20221221$20171123$20221226$PER$$US-JNJFOC-20171106330$JOHNSON AND JOHNSON$$$$$M$Y$$$20221226$$LW$US$US
142246522$14224652$2$F$20171102$20221202$20171127$20221206$PER$$US-SHIRE-US201730249$TAKEDA$$10$YR$$M$Y$$$20221206$$HP$US$US
142249133$14224913$3$F$$20221215$20171127$20221219$EXP$$JP-BEH-2017085417$CSL BEHRING$$$$$M$Y$5.5$KG$20221219$$MD$JP$JP
142250215$14225021$5$F$$20221121$20171127$20221124$EXP$$GB-ROCHE-1711532$ROCHE$$$$A$F$Y$$$20221124$$CN$GB$
142271383$14227138$3$F$20171101$20221214$20171127$20221223$EXP$$AU-JNJFOC-20171130563$JOHNSON AND JOHNSON$$58$YR$A$F$Y$$$20221223$$CN$AU$AU
142271614$14227161$4$F$$20171205$20171127$20221209$EXP$$PT-TEVA-2017-PT-826524$TEVA$Duarte A. Rhabdomyolysis as a Rare Clinical Manifestation of Hypothyroidism:About Two Clinical Cases. Review Port Endocrial Diabetes Metab. 2017;12(1):50-59.$49$YR$A$M$Y$$$20221209$$MD$PT$PT
142302723$14230272$3$F$$20220922$20171128$20221007$EXP$$DE-MYLANLABS-2017M1074109$MYLAN$Hoppe J, Holderied A, Schafer H, Schonermarck U, Anders HJ, Fischereder M. Drug-induced cytochrome-P450 induction as therapy for calcineurin inhibitor intoxication. Transpl-Int 2017;30 (Suppl. 4):33 abstr. P30.$54$YR$$M$Y$$$20221007$$HP$DE$DE
142302813$14230281$3$F$$20220922$20171128$20221007$EXP$$DE-MYLANLABS-2017M1074094$MYLAN$Hoppe J, Holderied A, Schafer H, Schonermarck U, Anders HJ, Fischereder M. Drug-induced cytochrome-P450 induction as therapy for calcineurin inhibitor intoxication. Transpl-Int 2017;30 (Suppl. 4):33 abstr. P30.$56$YR$$M$Y$$$20221007$$HP$DE$DE
1423528612$14235286$12$F$20170704$20221206$20171129$20221214$EXP$$GB-ASPEN-GLO2017GB007654$ASPEN$$$$$$Y$$$20221214$$MD$GB$GB
142360524$14236052$4$F$20170101$20221020$20171129$20221025$EXP$$CA-TAKEDA-2017TUS018228$TAKEDA$$35$YR$$F$Y$$$20221025$$CN$CA$CA
142364778$14236477$8$F$$20221104$20171129$20221108$PER$$US-PFIZER INC-2017510314$PFIZER$$72$YR$$F$Y$100$KG$20221108$$HP$US$US
142374203$14237420$3$F$$20221221$20171129$20221230$EXP$$GB-PFIZER INC-2017511602$PFIZER$$53$YR$$F$Y$$$20221230$$MD$GB$GB
1424521513$14245215$13$F$20171128$20221130$20171202$20221204$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2017-BI-064210$BOEHRINGER INGELHEIM$$82$YR$E$F$Y$60$KG$20221204$$MD$ES$ES
142462408$14246240$8$F$20171115$20221022$20171204$20221026$EXP$$TW-ROCHE-2026355$ROCHE$$60$YR$$F$Y$42.6$KG$20221026$$MD$TW$
1424660919$14246609$19$F$$20221212$20171204$20221224$EXP$$GB-AUROBINDO-AUR-APL-2017-43959$AUROBINDO$$85$YR$$M$Y$$$20221224$$MD$GB$GB
142467266$14246726$6$F$$20221128$20171204$20221130$EXP$$US-PFIZER INC-2017514361$PFIZER$$59$YR$$M$Y$$$20221130$$CN$US$US
1424675014$14246750$14$F$20171127$20221025$20171204$20221026$EXP$$US-PFIZER INC-2017514798$PFIZER$$82$YR$$F$Y$73$KG$20221026$$CN$US$US
1424879736$14248797$36$F$20170710$20220912$20171204$20221006$EXP$$PHHY2017FR121490$NOVARTIS$$8$YR$$M$Y$25$KG$20221006$$MD$FR$FR
142493453$14249345$3$F$20170929$20221121$20171204$20221123$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-087839$BRISTOL MYERS SQUIBB$$72$YR$E$M$Y$$$20221123$$HP$US$US
142497429$14249742$9$F$20171024$20221205$20171205$20221208$EXP$$CY-ROCHE-2031101$ROCHE$$66$YR$$F$Y$84$KG$20221208$$MD$CY$CY
142500619$14250061$9$F$20171101$20221130$20171205$20221206$EXP$$CA-TAKEDA-2017TUS023618$TAKEDA$$48$YR$$M$Y$$$20221206$$HP$CA$CA
142515045$14251504$5$F$20171127$20221219$20171205$20221224$EXP$$PHHY2017CA178808$NOVARTIS$$44$YR$$F$Y$$$20221224$$MD$CA$CA
1425234030$14252340$30$F$20170925$20221112$20171205$20221118$EXP$$US-SA-2017SA207805$SANOFI AVENTIS$$62$YR$A$F$Y$59.4$KG$20221118$$MD$US$US
1425529618$14255296$18$F$20170913$20221208$20171206$20221215$EXP$$CA-TAKEDA-2017TUS024863$TAKEDA$$18$YR$$F$Y$$$20221215$$MD$CA$CA
142576832$14257683$2$F$$20221130$20171207$20221208$EXP$$CA-ROCHE-2033051$ROCHE$$62$YR$$M$Y$$$20221208$$CN$CA$CA
142578718$14257871$8$F$$20221109$20171207$20221114$PER$$US-AMGEN-USASP2017180861$AMGEN$$63$YR$A$M$Y$$$20221114$$MD$US$US
142582958$14258295$8$F$$20221109$20171207$20221115$PER$$US-AMGEN-USASP2017180854$AMGEN$$58$YR$A$F$Y$$$20221115$$MD$US$US
142583924$14258392$4$F$$20221111$20171207$20221115$PER$$US-PFIZER INC-2017517099$PFIZER$$38$YR$$F$Y$$$20221115$$MD$US$US
142605762$14260576$2$F$$20221214$20171207$20221220$PER$$US-PFIZER INC-2017521003$PFIZER$$68$YR$$F$Y$$$20221220$$MD$US$US
142632082$14263208$2$F$20170924$20221114$20171208$20221129$EXP$$IT-AUROBINDO-AUR-APL-2017-44070$AUROBINDO$$22$YR$$F$Y$$$20221129$$PH$IT$IT
1426336319$14263363$19$F$20171120$20221124$20171208$20221205$EXP$$CA-PFIZER INC-2017524170$PFIZER$$48$YR$$F$Y$$$20221205$$CN$CA$CA
1426418413$14264184$13$F$20170403$20221223$20171208$20221230$EXP$$PHHY2017GB180222$NOVARTIS$$76$YR$$F$Y$69.9$KG$20221230$$HP$GB$GB
142647992$14264799$2$F$$20221003$20171208$20221013$EXP$$DE-TEVA-2017-DE-830763$TEVA$$54$YR$A$M$Y$$$20221013$$HP$DE$DE
142656688$14265668$8$F$20170403$20221110$20171208$20221117$EXP$$GB-BAUSCH-BL-2017-032426$BAUSCH AND LOMB$$76$YR$$F$Y$69.9$KG$20221117$$HP$GB$GB
142665055$14266505$5$F$20160101$20221013$20171210$20221019$PER$$BR-AMGEN-BRASP2016023746$AMGEN$$44$YR$A$F$Y$60$KG$20221019$$CN$BR$BR
1426665820$14266658$20$F$20170907$20221128$20171211$20221201$EXP$$NL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-112180$BRISTOL MYERS SQUIBB$$68$YR$E$M$Y$71$KG$20221201$$MD$NL$NL
142673184$14267318$4$F$$20221207$20171211$20221213$PER$$US-PFIZER INC-2017526732$PFIZER$$70$YR$$F$Y$$$20221213$$MD$US$US
1426832110$14268321$10$F$20170511$20221021$20171211$20221028$EXP$$PHHY2017CA071454$NOVARTIS$$76$YR$$F$Y$$$20221028$$CN$CA$CA
142688572$14268857$2$F$$20221011$20171211$20221012$PER$$US-PFIZER INC-2017524277$PFIZER$$$$$F$Y$$$20221012$$LW$US$US
1426901210$14269012$10$F$$20221125$20171211$20221202$EXP$$GB-Otsuka-DJ20126363$OTSUKA$$15$YR$$F$Y$$$20221202$$MD$GB$GB
142691846$14269184$6$F$20140101$20221111$20171211$20221114$EXP$$IT-MYLANLABS-2017M1077268$MYLAN$Grosso F, Roveta A, Gallizzi G, Belletti M.. Management of Recurrent Pleura Mesothelioma:Successful Rechallenge with Nintedanib in Combination with Chemotherapy.. Clin. Case Rep.. 2018;6(10):2000-4$53$YR$$M$Y$100$KG$20221114$$MD$IT$IT
1427186711$14271867$11$F$20171101$20221219$20171212$20221228$PER$$US-PFIZER INC-2016155881$PFIZER$$73$YR$$F$Y$91$KG$20221228$$CN$US$US
1427202313$14272023$13$F$$20221007$20171211$20221014$EXP$$CA-OTSUKA-2017_012834$OTSUKA$$22$YR$$F$Y$$$20221014$$HP$CA$CA
142722512$14272251$2$F$$20221003$20171211$20221013$EXP$$DE-TEVA-2017-DE-830764$TEVA$$56$YR$A$M$Y$$$20221013$$HP$DE$DE
142735863$14273586$3$F$$20221030$20171211$20221104$EXP$$FR-OTSUKA-2017_003321$OTSUKA$$48$YR$$F$Y$$$20221104$$MD$FR$FR
1427400921$14274009$21$F$20160614$20221216$20171212$20221230$EXP$$GB-AUROBINDO-AUR-APL-2017-44584$AUROBINDO$$$$A$M$Y$$$20221230$$MD$GB$GB
1427503912$14275039$12$F$$20221030$20171211$20221108$EXP$$GB-OTSUKA-2016_030143$OTSUKA$$30$YR$$M$Y$$$20221108$$PH$GB$GB
142762074$14276207$4$F$$20220925$20171211$20221003$EXP$$GB-Otsuka-DJ20094243$OTSUKA$$$$$F$Y$1.81$KG$20221003$$HP$GB$GB
1427643329$14276433$29$F$20171013$20221027$20171212$20221105$EXP$$CA-CELLTRION INC.-2017CA014614$CELLTRION$$$$$$Y$$$20221106$$CN$CA$CA
142774957$14277495$7$F$$20221006$20171212$20221013$EXP$$GB-SHIRE-GB201732945$TAKEDA$$85$YR$$M$Y$$$20221013$$CN$GB$GB
142777175$14277717$5$F$20160826$20221216$20171212$20221220$EXP$$GB-GALDERMA-GB17012480$GALDERMA$$$$$$Y$$$20221220$$HP$GB$GB
1427871914$14278719$14$F$20171101$20221123$20171212$20221130$EXP$$CA-TAKEDA-2017TUS025270$TAKEDA$$26$YR$$M$Y$$$20221130$$MD$CA$CA
142816912$14281691$2$F$20150709$20221219$20171213$20221227$EXP$$FR-MYLANLABS-2017M1076761$MYLAN$$45$YR$$F$Y$54$KG$20221227$$MD$FR$FR
142825658$14282565$8$F$$20221007$20171213$20221010$EXP$$US-PFIZER INC-2017393431$PFIZER$$69$YR$$F$Y$$$20221010$$HP$US$US
142840805$14284080$5$F$$20221205$20171214$20221209$PER$$US-AMGEN-USASP2017183983$AMGEN$$78$YR$E$F$Y$$$20221208$$MD$US$US
142844039$14284403$9$F$$20221115$20171214$20221117$PER$$US-PFIZER INC-2017534678$PFIZER$$63$YR$$F$Y$$$20221117$$MD$US$US
1428496427$14284964$27$F$20171127$20221116$20171214$20221123$EXP$$PHHY2017DE182835$NOVARTIS$$11$YR$$M$Y$60$KG$20221123$$MD$DE$DE
142859759$14285975$9$F$$20221117$20171214$20221119$EXP$$PHHY2017CA170489$NOVARTIS$$$$$F$Y$$$20221119$$MD$CA$CA
142863712$14286371$2$F$20110801$20221102$20171214$20221110$EXP$$PHHY2017NO180055$NOVARTIS$$$$A$M$Y$$$20221110$$CN$NO$NO
142896024$14289602$4$F$20140101$20221129$20171215$20221202$EXP$$US-AstraZeneca-2017SF27494$ASTRAZENECA$$57$YR$$F$Y$81.6$KG$20221202$$LW$US$
142911234$14291123$4$F$20170101$20221013$20171215$20221017$EXP$$US-PFIZER INC-2017534643$PFIZER$$57$YR$$F$Y$74.512$KG$20221017$$HP$US$US
1429500910$14295009$10$F$$20221207$20171218$20221208$PER$$US-AMGEN-USASP2017183978$AMGEN$$70$YR$E$F$Y$$$20221208$$HP$US$US
142966916$14296691$6$F$20110101$20220930$20171218$20221003$EXP$$US-PFIZER INC-2017536261$PFIZER$$75$YR$$F$Y$$$20221003$$LW$US$US
142973108$14297310$8$F$20170101$20221227$20171218$20221229$EXP$$US-PFIZER INC-2017536717$PFIZER$$66$YR$$F$Y$85.73$KG$20221229$$HP$US$US
142983665$14298366$5$F$20170101$20221212$20171218$20221213$EXP$$PHHY2016CA182630$NOVARTIS$$70$YR$$M$Y$$$20221213$$CN$CA$CA
1430029611$14300296$11$F$$20221214$20171219$20221220$PER$$US-PFIZER INC-2017534888$PFIZER$$64$YR$$F$Y$$$20221220$$MD$US$US
143018454$14301845$4$F$20160419$20221101$20171219$20221104$EXP$$US-PFIZER INC-2017536310$PFIZER$$67$YR$$F$Y$$$20221104$$LW$US$US
143043784$14304378$4$F$$20221205$20171219$20221207$PER$$US-BIOGEN-2017BI00496082$BIOGEN$$$$$F$Y$$$20221207$$CN$US$US
1430640520$14306405$20$F$20171101$20221101$20171220$20221104$EXP$$PHHY2017CO185553$NOVARTIS$$70$YR$$F$Y$58$KG$20221104$$CN$CO$CO
1430727512$14307275$12$F$20161101$20221012$20171220$20221014$EXP$$PHHY2016CA145319$NOVARTIS$$64$YR$$M$Y$$$20221014$$CN$CA$CA
143085666$14308566$6$F$20080301$20221011$20171220$20221024$EXP$$SK-PFIZER INC-2017523755$MYLAN$$$$$F$Y$53$KG$20221024$$MD$SK$SK
143086605$14308660$5$F$20150101$20221010$20171220$20221012$PER$$US-PFIZER INC-2017538048$PFIZER$$52$YR$$F$Y$104$KG$20221012$$LW$US$US
143096543$14309654$3$F$$20221109$20171220$20221114$EXP$$US-PFIZER INC-2017536628$PFIZER$$70$YR$$F$Y$$$20221114$$CN$US$US
143106094$14310609$4$F$$20221031$20171220$20221104$EXP$$SE-MYLANLABS-2017M1079697$MYLAN$Eriksson E, Thorsoon M, Grass J. Hogdos insulin, High dose insulin euglycemia therapy - an important addition to the treatment arsenal in severe toxic myocardial depression. Lakartidningen$51$YR$$F$Y$$$20221104$$HP$SE$SE
143111008$14311100$8$F$20171204$20221006$20171221$20221010$EXP$$JP-ROCHE-2039469$ROCHE$$69$YR$$M$Y$61.2$KG$20221010$$MD$JP$
143125972$14312597$2$F$$20221130$20171221$20221205$PER$$US-PFIZER INC-2017078881$PFIZER$$51$YR$$F$Y$$$20221205$$CN$US$US
143130293$14313029$3$F$20130301$20221013$20171221$20221014$PER$$US-PFIZER INC-2017541307$PFIZER$$76$YR$$F$Y$58.957$KG$20221014$$LW$US$US
143144375$14314437$5$F$20140625$20220926$20171221$20221004$EXP$$US-AstraZeneca-2017SF28535$ASTRAZENECA$$17896$DY$$F$Y$66.2$KG$20221004$$LW$US$
143153027$14315302$7$F$20170101$20221221$20171221$20221223$EXP$$CA-TAKEDA-2017TUS004747$TAKEDA$$59$YR$$M$Y$$$20221223$$HP$CA$CA
143166086$14316608$6$F$$20221110$20171222$20221125$EXP$GB-MHRA-EYC 00150638$GB-MACLEODS PHARMACEUTICALS US LTD-MAC2016004106$MACLEODS$$$$$$Y$$$20221125$$PH$GB$GB
143168007$14316800$7$F$$20221209$20171222$20221214$PER$$US-PFIZER INC-2017542735$PFIZER$$62$YR$$F$Y$$$20221214$$MD$US$US
143173102$14317310$2$F$$20221010$20171222$20221021$EXP$NL-ALKEM LABORATORIES LIMITED-NL-ALKEM-2017-01227$NL-ALKEM LABORATORIES LIMITED-NL-ALKEM-2017-01227$ALKEM$Kampenhout EV, Bolhuis MS, Alffenaar JC, Oswald LM, et al.. Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. Eur Respir J.. 2017;49(3):1-3$25$YR$$F$Y$$$20221021$$MD$NL$NL
1431832718$14318327$18$F$20170712$20220923$20171222$20221005$EXP$$CA-CELLTRION INC.-2017CA017054$CELLTRION$$$$$$Y$$$20221006$$CN$CA$CA
1431951811$14319518$11$F$20170713$20221124$20171222$20221201$EXP$$ES-SA-2017SA150386$SANOFI AVENTIS$$36$YR$A$F$Y$$$20221201$$HP$ES$ES
1432006823$14320068$23$F$20170901$20221108$20171222$20221111$EXP$$US-PFIZER INC-2017541886$PFIZER$$68$YR$$F$Y$75$KG$20221111$$HP$US$US
143212883$14321288$3$F$20150709$20180326$20171223$20221028$EXP$PHHY2017FR193176$PHHY2017FR193176$NOVARTIS$$45$YR$$F$Y$54$KG$20221028$$MD$FR$FR
143212907$14321290$7$F$20170425$20221111$20171223$20221114$EXP$$PHHY2017DE187788$NOVARTIS$$65$YR$$M$Y$90$KG$20221114$$MD$DE$DE
143222949$14322294$9$F$$20221011$20171225$20221026$EXP$$NL-AUROBINDO-AUR-APL-2017-47132$AUROBINDO$Van Kampenhout E, Bolhuis MS, Alffenaar JWC, Oswald LMA, Kerstjens HAM, De Lange WCM et al.. Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.. European Respiratory Journal. 2017;49(3)$25$YR$$F$Y$$$20221026$$MD$NL$NL
143233002$14323300$2$F$$20211118$20171226$20221111$PER$$US-CIPLA LTD.-2017US12215$CIPLA$$41$YR$$F$Y$$$20221111$$PH$US$US
143233164$14323316$4$F$$20180221$20171226$20221209$PER$$US-TEVA-2017-US-836421$TEVA$$$$$$Y$$$20221209$$CN$US$US
1432365622$14323656$22$F$20171001$20221103$20171226$20221108$EXP$$CA-ROCHE-2044455$ROCHE$$28$YR$$F$Y$$$20221107$$MD$CA$CA
143239464$14323946$4$F$20171118$20221115$20171226$20221118$EXP$$TR-ROCHE-2028912$ROCHE$$69$YR$$M$Y$62.5$KG$20221118$$MD$TR$
143254665$14325466$5$F$20170101$20221227$20171226$20221229$EXP$$US-JAZZ-2017-US-017146$JAZZ$$$$$M$Y$$$20221229$$HP$US$US
143259293$14325929$3$F$$20221114$20171226$20221124$EXP$$US-BAUSCH-BL-2017-034806$BAUSCH AND LOMB$Acharya G, Cruz C, Rice T. 5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer. BMJ Case Reports. 2017;.$67$YR$$M$Y$$$20221124$$HP$US$US
143259308$14325930$8$F$$20221021$20171226$20221027$EXP$$GB-BAUSCH-BL-2017-035229$BAUSCH AND LOMB$$30$YR$$M$Y$$$20221027$$PH$GB$GB
1432667513$14326675$13$F$20171204$20220928$20171227$20221004$EXP$$JP-ABBVIE-17K-087-2198372-00$ABBVIE$$74$YR$$M$Y$59$KG$20221004$$MD$JP$JP
1432719212$14327192$12$F$20170301$20221110$20171227$20221117$EXP$$PHHY2017CA040994$NOVARTIS$$52$YR$$M$Y$$$20221117$$MD$CA$CA
143273015$14327301$5$F$$20221219$20171227$20221222$PER$$US-PFIZER INC-2017544657$PFIZER$$66$YR$$F$Y$$$20221222$$HP$US$US
143273435$14327343$5$F$20171201$20221123$20171227$20221129$PER$$US-PFIZER INC-2017544156$PFIZER$$48$YR$$F$Y$$$20221129$$CN$US$US
143276227$14327622$7$F$$20221102$20171227$20221105$EXP$$PHHY2017GB194317$NOVARTIS$$53$YR$$F$Y$$$20221105$$HP$GB$GB
143283563$14328356$3$F$$20221130$20171227$20221202$PER$$US-PFIZER INC-2017547874$PFIZER$$66$YR$$F$Y$$$20221202$$MD$US$US
143283767$14328376$7$F$$20221212$20171227$20221215$PER$$US-PFIZER INC-2017548649$PFIZER$$62$YR$$F$Y$$$20221215$$MD$US$US
1432848031$14328480$31$F$20210301$20221206$20171227$20221213$EXP$$BR-GLAXOSMITHKLINE-BR2017GSK162592$GLAXOSMITHKLINE$$$$$$Y$$$20221213$$CN$BR$BR
1432858015$14328580$15$F$20151110$20221012$20171227$20221024$EXP$DE-EMA-DD-20171213-KUMARNVEVHP-172943$DE-PFIZER INC-2017546144$PFIZER$$34$MON$$M$Y$12.2$KG$20221024$$MD$DE$DE
143295807$14329580$7$F$$20221208$20171227$20221213$EXP$$US-PFIZER INC-2015388221$PFIZER$$64$YR$$F$Y$$$20221213$$MD$US$US
143298493$14329849$3$F$$20221109$20171227$20221114$EXP$$US-SA-2017SA257819$SANOFI AVENTIS$$67$YR$E$M$Y$$$20221114$$HP$US$US
1433140038$14331400$38$F$20170101$20220929$20171228$20221011$EXP$$CA-CELLTRION INC.-2017CA012620$CELLTRION$$$$$$Y$$$20221011$$CN$CA$CA
143318743$14331874$3$F$20170101$20221005$20171228$20221019$PER$$PL-PFM-2017-12696$PIERRE FABRE MEDICAMENT$Bembenek J, Piechal A, Rakowicz M. Zespol Guillain-Barre u chorego z nawrotowym chloniakiem hodgkina. Polski Przeglad Neurologiczny. 2017;13:A130-A131$$$$$Y$$$20221020$$MD$PL$PL
143321348$14332134$8$F$20160316$20221128$20171228$20221201$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2017JPN198663$VIIV$$$$$$Y$$$20221201$$MD$JP$JP
1433213512$14332135$12$F$20161101$20221026$20171228$20221101$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2017JPN198665$VIIV$$$$$$Y$$$20221101$$MD$JP$JP
1433265514$14332655$14$F$20160614$20221219$20171228$20221226$EXP$$BE-SA-2016SA123993$SANOFI AVENTIS$$38$YR$A$M$Y$$$20221226$$MD$BE$BE
1433306212$14333062$12$F$20170203$20221117$20171228$20221121$EXP$$ES-SA-2017SA155725$SANOFI AVENTIS$$54$YR$A$F$Y$90$KG$20221121$$HP$ES$ES
1433331838$14333318$38$F$20171201$20221129$20171228$20221208$EXP$$CA-CELLTRION INC.-2017CA017356$CELLTRION$$$$$$Y$$$20221208$$CN$CA$CA
143335879$14333587$9$F$20170101$20221130$20171228$20221202$EXP$$JP-ABBVIE-17K-087-2186265-00$ABBVIE$$71$YR$$F$Y$$$20221202$$MD$JP$JP
143339688$14333968$8$F$20150706$20221116$20171228$20221124$EXP$$GB-BAUSCH-BL-2017-035501$BAUSCH AND LOMB$$75$YR$$F$Y$81.5$KG$20221124$$HP$GB$GB
143346377$14334637$7$F$20150101$20221003$20171228$20221013$EXP$$PL-ELI_LILLY_AND_COMPANY-PL201712008326$ELI LILLY AND CO$$32$YR$$M$Y$$$20221013$$CN$PL$PL
143363582$14336358$2$F$$20171215$20171229$20221118$EXP$$US-APOTEX-2017AP023880$APOTEX$Toprak M, Katz RB, Ostroff R. Safe Treatment of a Patient With an Ommaya Reservoir With Electroconvulsive Therapy. DOI: 10.1097/YCT.0000000000000427. The Journal of ECT.. 2017;33(4):1-2$58$YR$$F$Y$$$20221118$$HP$US$US
1433650912$14336509$12$F$20120524$20220929$20171229$20221019$EXP$$DE-ABBVIE-17S-062-2201777-00$ABBVIE$$30$YR$$M$Y$$$20221019$$MD$DE$DE
143368592$14336859$2$F$$20221114$20171229$20221120$PER$$PT-AMGEN-PRTSP2017191003$AMGEN$Gravito-soares E.. Fatal colitis associated with active systemic lupus erythematosus complicated by cytomegalovirus superinfection. BMJ. 2017;1-2$47$YR$A$F$Y$$$20221120$$MD$PT$PT
1433806210$14338062$10$F$20171106$20221107$20171229$20221111$EXP$$FR-MYLANLABS-2017M1082885$MYLAN$$50$YR$$M$Y$52$KG$20221111$$MD$FR$FR
1433934518$14339345$18$F$20180118$20221215$20171230$20221228$EXP$$GB-AUROBINDO-AUR-APL-2017-47963$AUROBINDO$$76$YR$$M$Y$69$KG$20221228$$MD$GB$GB
143394286$14339428$6$F$20171129$20221125$20171230$20221209$EXP$$GB-AUROBINDO-AUR-APL-2017-47978$AUROBINDO$$30$YR$$M$Y$81$KG$20221209$$MD$GB$GB
143399922$14339992$2$F$20170403$20220928$20171231$20221008$EXP$$GB-TEVA-2017-GB-836691$TEVA$$76$YR$E$F$Y$$$20221008$$MD$GB$GB
1434359322$14343593$22$F$20171214$20221227$20180102$20221230$EXP$$US-PFIZER INC-2017555069$PFIZER$$77$YR$$F$Y$88$KG$20221230$$HP$US$US
1434557613$14345576$13$F$20170507$20221215$20180103$20221222$EXP$$PHHY2017IN085195$NOVARTIS$$60$YR$$M$Y$$$20221222$$CN$IN$IN
1434765915$14347659$15$F$20170101$20221025$20180103$20221028$PER$$US-PFIZER INC-2017555032$PFIZER$$50$YR$$F$Y$77$KG$20221028$$CN$US$US
143477005$14347700$5$F$$20221028$20180103$20221102$PER$$US-PFIZER INC-2017555194$PFIZER$$70$YR$$M$Y$$$20221102$$CN$US$US
143482897$14348289$7$F$$20221129$20180103$20221202$PER$$US-PFIZER INC-2017553822$PFIZER$$73$YR$$F$Y$73.48$KG$20221202$$CN$US$US
1434974914$14349749$14$F$20171201$20221216$20180104$20221223$EXP$$PHHY2017CA196773$NOVARTIS$$69$YR$$M$Y$$$20221223$$CN$CA$CA
143497619$14349761$9$F$20170101$20221021$20180104$20221028$EXP$$PHHY2017CA101908$NOVARTIS$$$$$M$Y$$$20221028$$CN$CA$CA
1434978416$14349784$16$F$20150101$20221129$20180104$20221205$EXP$$PL-MYLANLABS-2017M1083625$MYLAN$Bembenek J, Piechal A, Rakowicz M.. A patient with guillainbarre syndrome with recurrent hodgkin^s lymphoma.. Polish Neurological Review. 2017;13 (Suppl A):A130-31$32$YR$$M$Y$$$20221205$$HP$PL$PL
143513944$14351394$4$F$$20221130$20180104$20221202$PER$$US-PFIZER INC-2017552948$PFIZER$$65$YR$$M$Y$$$20221202$$CN$US$US
143518824$14351882$4$F$20160118$20221123$20180104$20221129$EXP$$AR-SHIRE-AR201735681$TAKEDA$$$$A$M$Y$$$20221129$$MD$AR$AR
1435237039$14352370$39$F$20171103$20221216$20180104$20221221$EXP$$GB-MYLANLABS-2018M1000507$MYLAN$$73$YR$$F$Y$50$KG$20221221$$PH$GB$GB
1435269911$14352699$11$F$20170101$20221118$20180104$20221121$EXP$$US-PFIZER INC-2017549728$PFIZER$$78$YR$$F$Y$50$KG$20221121$$CN$US$US
143527829$14352782$9$F$20210630$20221118$20180104$20221122$EXP$$US-PFIZER INC-2017551393$PFIZER$$74$YR$$F$Y$61.288$KG$20221122$$CN$US$US
1435354011$14353540$11$F$20160401$20221108$20180105$20221111$EXP$$CA-TAKEDA-2016TUS006034$TAKEDA$$38$YR$$F$Y$$$20221111$$HP$CA$CA
143553422$14355342$2$F$20170101$20221114$20180105$20221129$EXP$$IE-AUROBINDO-AUR-APL-2018-000393$AUROBINDO$$67$YR$$M$Y$$$20221129$$MD$IE$IE
143558992$14355899$2$F$$20221109$20180105$20221111$PER$$US-PFIZER INC-2018005020$PFIZER$$57$YR$$F$Y$86.18$KG$20221111$$CN$US$US
143571082$14357108$2$F$20221006$20221102$20180105$20221104$EXP$$US-SHIRE-US201735284$TAKEDA$$43$YR$$F$Y$$$20221104$$HP$US$US
143607318$14360731$8$F$20171213$20221223$20180106$20221230$EXP$$PHHY2017DE196716$NOVARTIS$$$$E$F$Y$94$KG$20221230$$CN$DE$DE
143609654$14360965$4$F$20170927$20221212$20180107$20221219$EXP$$US-SHIRE-US201732076$TAKEDA$$37$YR$$F$Y$135$KG$20221219$$HP$US$US
143618046$14361804$6$F$20221031$20221107$20180108$20221115$EXP$$US-AstraZeneca-2018SE01490$ASTRAZENECA$$24494$DY$$F$Y$78.9$KG$20221115$$LW$US$
143636052$14363605$2$F$$20221213$20180108$20221219$PER$$US-BIOGEN-2018BI00505518$BIOGEN$$$$$F$Y$$$20221219$$CN$US$US
1436395630$14363956$30$F$20180222$20221214$20180108$20221223$EXP$$CA-CELLTRION INC.-2017CA016524$CELLTRION$$$$$$Y$$$20221223$$MD$CA$CA
1436445111$14364451$11$F$$20221031$20180108$20221107$EXP$$DK-MYLANLABS-2018M1001800$MYLAN$Faaborg L, Niemann I, Ostenfeld E, Hanseen E, Sunde L, Lindegaard J et al.. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.. Acta Oncologica. 2016;55(2):234-239$30$YR$$F$Y$$$20221107$$HP$DK$DK
1436614113$14366141$13$F$20150811$20221111$20180109$20221117$PER$$US-AMGEN-USASP2018001653$AMGEN$$69$YR$E$F$Y$70$KG$20221116$$MD$US$US
1436788037$14367880$37$F$20151225$20221011$20180109$20221017$EXP$$PHHY2015CA111727$NOVARTIS$$27$YR$$F$Y$$$20221017$$CN$CA$CA
143687147$14368714$7$F$20171201$20221102$20180109$20221104$PER$$US-PFIZER INC-2016476864$PFIZER$$76$YR$$F$Y$64$KG$20221104$$CN$US$US
143687613$14368761$3$F$20170208$20221114$20180109$20221117$PER$$US-PFIZER INC-2018003870$PFIZER$$38$YR$$F$Y$$$20221117$$PH$US$US
143694149$14369414$9$F$$20221128$20180109$20221202$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-120164$BRISTOL MYERS SQUIBB$$63$YR$A$F$Y$72$KG$20221202$$MD$CA$CA
143705894$14370589$4$F$$20221214$20180110$20221221$PER$$US-PFIZER INC-2018005170$PFIZER$$43$YR$$F$Y$$$20221221$$CN$US$US
1437062817$14370628$17$F$20150811$20221111$20180110$20221115$EXP$$US-PFIZER INC-2018005394$PFIZER$$69$YR$$F$Y$70$KG$20221115$$MD$US$US
1437455128$14374551$28$F$20171003$20221003$20180111$20221013$EXP$$CA-ROCHE-2053198$ROCHE$$10$YR$$F$Y$$$20221011$$HP$CA$CA
143780624$14378062$4$F$$20221004$20180111$20221007$EXP$$US-TAKEDA-2018TUS000486$TAKEDA$$$$$$Y$$$20221007$$CN$US$US
143799295$14379929$5$F$20220101$20221213$20180112$20221222$EXP$$US-PFIZER INC-2018014288$PFIZER$$78$YR$$F$Y$$$20221222$$CN$US$US
143805123$14380512$3$F$20171015$20220929$20180112$20221003$EXP$$US-PFIZER INC-2018013982$PFIZER$$73$YR$$F$Y$$$20221003$$CN$US$US
1438241913$14382419$13$F$$20221006$20180112$20221013$EXP$$PL-MYLANLABS-2018M1003406$MYLAN$Wojcik-Pedziwiatr M, Michalski M.. A 70-year-old woman with pneumonia, hallucinations and diagnosis of Parkinson?s disease.. LEKARZ RODZINNY.. 2017;5:82-88$70$YR$$F$Y$$$20221013$$HP$PL$PL
143826945$14382694$5$F$20130204$20221024$20180112$20221102$EXP$$US-AstraZeneca-2018SE03261$ASTRAZENECA$$21436$DY$$F$Y$109.8$KG$20221102$$LW$US$
143829684$14382968$4$F$20170501$20180529$20180114$20221220$EXP$$FR-TEVA-2018-FR-846287$TEVA$$75$YR$E$M$Y$$$20221220$$CN$FR$FR
143837594$14383759$4$F$20111109$20221102$20180115$20221110$EXP$$US-AstraZeneca-2018SE03434$ASTRAZENECA$$23842$DY$$F$Y$91.2$KG$20221110$$LW$US$
143839835$14383983$5$F$20120624$20221006$20180115$20221010$EXP$$US-AstraZeneca-2018SE03276$ASTRAZENECA$$11037$DY$$F$Y$149.2$KG$20221010$$LW$US$
143842837$14384283$7$F$20130301$20221202$20180115$20221205$PER$$US-PFIZER INC-2018013284$PFIZER$$69$YR$$F$Y$$$20221205$$LW$US$US
143872566$14387256$6$F$20160914$20221011$20180115$20221018$EXP$$US-Vifor (International) Inc.-VIT-2018-00322$VIFOR$$66$YR$$M$Y$$$20221018$$CN$US$US
143901028$14390102$8$F$$20221104$20180115$20221110$PER$$US-AMGEN-USASP2018005587$AMGEN$$37$YR$A$F$Y$$$20221110$$MD$US$US
143908047$14390804$7$F$20180105$20221014$20180116$20221018$EXP$$JP-ROCHE-2051436$ROCHE$$48$YR$$M$Y$71.4$KG$20221018$$MD$JP$
143910044$14391004$4$F$$20221005$20180116$20221006$PER$$US-PFIZER INC-2018009125$PFIZER$$73$YR$$F$Y$$$20221006$$LW$US$US
143910473$14391047$3$F$20180109$20221219$20180116$20221227$EXP$$US-PFIZER INC-2018015963$PFIZER$$77$YR$$F$Y$$$20221227$$CN$US$US
143916525$14391652$5$F$20151110$20221010$20180116$20221020$EXP$$DE-Rare Disease Therapeutics, Inc.-2040093$NOVA LABORATORIES$$34$MON$$M$Y$12.2$KG$20221020$$MD$DE$DE
1439181116$14391811$16$F$20160301$20221103$20180116$20221110$EXP$$GB-ASPEN-GLO2016GB005993$ASPEN$$$$$$Y$$$20221110$$HP$GB$GB
1439241215$14392412$15$F$$20221006$20180116$20221013$EXP$$PHHY2018PL005683$NOVARTIS$Wojcik-Pedziwiatr M, Michalski M. A 70-year-old woman with pneumonia, hallucinations and diagnosis of Parkinson?s disease. LEKARZ RODZINNY. 2017;5:82-8$70$YR$$F$Y$$$20221013$$HP$PL$PL
143947889$14394788$9$F$$20221118$20180116$20221123$EXP$$BE-PFIZER INC-2017526791$PFIZER$Smets, G.. Posterior reversible encephalopathy syndrome possibly induced by pemetrexed maintenance therapy for lung cancer: a case report and literature review. Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine. 2017;1-7$59$YR$$F$Y$$$20221123$$HP$BE$BE
144005198$14400519$8$F$20170413$20221215$20180117$20221223$EXP$$GB-BAUSCH-BL-2017-035964$BAUSCH AND LOMB$$67$YR$$M$Y$69.4$KG$20221223$$MD$GB$GB
1440061352$14400613$52$F$$20221212$20180117$20221222$PER$$CA-AMGEN-CANSP2017193304$AMGEN$$63$YR$A$F$Y$$$20221222$$HP$CA$CA
144010107$14401010$7$F$20171209$20221220$20180117$20221222$EXP$$CA-TAKEDA-2018TUS001007$TAKEDA$$81$YR$$F$Y$$$20221222$$MD$CA$CA
144020885$14402088$5$F$$20210325$20180117$20221128$EXP$$IN-ROCHE-2053650$ROCHE$Beri S, Shandil A and Garg R Stenotrophomonas maltophilia: An emerging entity for cluster endophthalmitis. The Indian Journal of Ophthalmology 2021;65 (11):1166-71.$57$YR$$F$Y$$$20221128$$HP$IN$
144020955$14402095$5$F$$20210325$20180117$20221129$EXP$$IN-ROCHE-2053653$ROCHE$Beri S, Shandil A, and Garg R Stenotrophomonas maltophilia: An emerging entity for cluster endophthalmitis.. Indian-J-Ophthalmol 2017;65(11):1166-1171.$72$YR$$M$Y$$$20221129$$MD$IN$
144030056$14403005$6$F$20171201$20221121$20180117$20221123$EXP$$US-PFIZER INC-2018020050$PFIZER$$65$YR$$F$Y$104$KG$20221123$$CN$US$US
144033973$14403397$3$F$20130204$20221025$20180117$20221026$EXP$$US-TAKEDA-2018TUS000861$TAKEDA$$$$$$Y$$$20221026$$CN$US$US
144038472$14403847$2$F$20200801$20220926$20180117$20221006$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-007066$ACADIA PHARMACEUTICALS$$70$YR$$M$Y$$$20221006$$CN$US$US
144041349$14404134$9$F$20180101$20221020$20180117$20221024$PER$$US-PFIZER INC-2018020013$PFIZER$$67$YR$$F$Y$46$KG$20221024$$CN$US$US
144042923$14404292$3$F$20150101$20221013$20180117$20221017$EXP$$US-TAKEDA-2018TUS000898$TAKEDA$$$$$$Y$$$20221017$$CN$US$US
144077157$14407715$7$F$20171231$20221008$20180118$20221013$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-000658$BRISTOL MYERS SQUIBB$$73$YR$E$F$Y$66.9$KG$20221014$$HP$US$US
144105658$14410565$8$F$20170801$20220926$20180119$20221002$EXP$$PHHY2018SE004029$NOVARTIS$$$$N$$Y$$$20221002$$MD$SE$SE
144116644$14411664$4$F$20150101$20221013$20180119$20221019$EXP$$US-PFIZER INC-2018024229$PFIZER$$$$$M$Y$$$20221019$$CN$US$US
144125592$14412559$2$F$20170101$20221213$20180119$20221220$PER$$CA-AMGEN-CANSL2015050257$AMGEN$$59$YR$A$F$Y$$$20221220$$CN$CA$CA
1441268446$14412684$46$F$20180101$20221117$20180119$20221125$EXP$$CA-CELLTRION INC.-2018CA017333$CELLTRION$$$$$$Y$$$20221125$$CN$CA$CA
144128614$14412861$4$F$$20221223$20180119$20221227$EXP$$US-JAZZ-2018-US-001273$JAZZ$$$$$F$Y$$$20221227$$CN$US$US
144129312$14412931$2$F$20170501$20221006$20180119$20221018$EXP$DK-DKMA-WBS-0008432$DK-SA-2018SA009733$SANOFI AVENTIS$$27$YR$A$F$Y$42$KG$20221018$$MD$DK$DK
144137404$14413740$4$F$$20180209$20180119$20221208$EXP$$FR-TEVA-2018-FR-846502$TEVA$Heitzmann E, Muller C, Tebacher M, Michel B, Javelot H. Increased QT interval due to antiandrogenic therapy, majorated by psychotropic drugs: About one case. Therapie 2017;72(6):701-703.$78$YR$E$M$Y$$$20221208$$HP$FR$FR
144161317$14416131$7$F$20170801$20220928$20180122$20221003$EXP$SE-UCBSA-2018002372$SE-UCBSA-2018002372$UCB$$$$$$Y$$$20221003$$MD$SE$SE
144165046$14416504$6$F$$20221213$20180122$20221225$EXP$$FR-AUROBINDO-AUR-APL-2018-002434$AUROBINDO$Heitzmann E, Muller C, Tebacher M, Michel B, Javelot H.. Increased QT interval due to antiandrogenic therapy, majorated by psychotropic drugs: About one case. Therapie. 2017;72 (6):701-703$78$YR$$M$Y$$$20221225$$HP$FR$FR
1441680712$14416807$12$F$20171229$20221012$20180122$20221020$EXP$$CA-ROCHE-2049492$ROCHE$$43$YR$$F$Y$$$20221020$$HP$CA$
144169249$14416924$9$F$20170101$20221017$20180122$20221020$EXP$$US-PFIZER INC-2018025001$PFIZER$$57$YR$$F$Y$46.712$KG$20221020$$CN$US$US
144170349$14417034$9$F$$20221103$20180122$20221107$PER$$US-PFIZER INC-2018024662$PFIZER$$67$YR$$F$Y$$$20221107$$MD$US$US
144186822$14418682$2$F$$20170527$20180122$20221209$PER$$US-TEVA-2016-14830$TEVA$$86$YR$E$F$Y$$$20221209$$PH$US$US
1441938832$14419388$32$F$20170901$20221115$20180122$20221121$EXP$$GB-MYLANLABS-2017M1077447$MYLAN$$32$YR$$F$Y$$$20221121$$MD$GB$GB
144209002$14420900$2$F$20150101$20221012$20180122$20221014$EXP$$US-ROCHE-1885432$ROCHE$$80$YR$$F$Y$43.13$KG$20221014$$CN$US$
144217816$14421781$6$F$$20221220$20180122$20221227$PER$$CA-AMGEN-CANSP2018005831$AMGEN$$48$YR$A$F$Y$106$KG$20221227$$PH$CA$CA
144218975$14421897$5$F$$20221103$20180122$20221110$PER$$US-AMGEN-USASP2018006841$AMGEN$$67$YR$E$F$Y$$$20221110$$MD$US$US
1442354112$14423541$12$F$20170101$20221222$20180123$20221228$PER$$US-PFIZER INC-2018027236$PFIZER$$81$YR$$F$Y$52$KG$20221228$$CN$US$US
1442356740$14423567$40$F$$20221027$20180123$20221103$EXP$$US-PFIZER INC-2018026203$PFIZER$$68$YR$$M$Y$86.18$KG$20221103$$MD$US$US
144244787$14424478$7$F$$20221202$20180123$20221207$EXP$$FR-MYLANLABS-2018M1004016$MYLAN$Quaesaet L, Stindel E, Lanternier F, Williams T, Jaffuel S, Moalic E et al. Miltefosine-based regimen as salvage therapy in Lomentospora prolificans bone and joint infection. Medecine et Maladies Infectieuses. 2018;48:63-65$70$YR$$M$Y$$$20221207$$MD$FR$FR
1442690115$14426901$15$F$20170701$20221003$20180123$20221013$EXP$NL-LRB-00254512$NL-TEVA-2018-NL-848285$TEVA$$79$YR$E$M$Y$73$KG$20221013$$CN$NL$NL
144305597$14430559$7$F$20120416$20221004$20180124$20221012$EXP$$US-AstraZeneca-2018SE08506$ASTRAZENECA$$27313$DY$$M$Y$$$20221012$$LW$US$
1443395011$14433950$11$F$$20221003$20180124$20221007$EXP$$PHHY2017NL199683$NOVARTIS$Van Kampenhout E, Bolhuis MS, Alffenaar J-WC, Oswald LMA, Kerstjens HAM, De Lange WCM et al.. Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. EUROPEAN RESPIRATORY JOURNAL. 2017;49(3):1-3$25$YR$$F$Y$$$20221007$$HP$NL$NL
1443858732$14438587$32$F$20170803$20221114$20180125$20221118$EXP$$PHHY2017CA116099$NOVARTIS$$85$YR$$F$Y$$$20221118$$HP$CA$CA
144478567$14447856$7$F$$20221128$20180126$20221202$EXP$$FR-SA-2018SA014262$SANOFI AVENTIS$$62$YR$A$M$Y$$$20221202$$MD$FR$FR
1444863411$14448634$11$F$20170101$20221006$20180126$20221013$EXP$$CA-PFIZER INC-2017317447$PFIZER$$73$YR$$M$Y$$$20221013$$CN$CA$CA
144488598$14448859$8$F$20170413$20221220$20180126$20221230$EXP$$GB-TEVA-2018-GB-850413$TEVA$$67$YR$E$M$Y$69.4$KG$20221230$$MD$GB$GB
144489524$14448952$4$F$$20220927$20180126$20221007$EXP$$FR-MYLANLABS-2018M1004979$MYLAN$Risse J, Vieira M, Beuret F, Petitpain N, Zuily S, Wahl D.. Reversible drug-induced antiphospholipid syndrome.. Lupus.. 2018;27(2):333-335$18$YR$$M$Y$$$20221007$$HP$FR$FR
144490516$14449051$6$F$20170101$20221128$20180126$20221129$EXP$$CA-TAKEDA-2017TUS024839$TAKEDA$$67$YR$$F$Y$$$20221129$$MD$CA$CA
144491883$14449188$3$F$$20221027$20180126$20221102$EXP$$IT-ROCHE-2060825$ROCHE$Ghione P, Cavallo F, Visco C, Chen Z, Castellino A, Tisi MC, Dogliotti I, Nicolosi, M, Boccadoro M, Leonard JP, Vitolo U and Martin P. A retrospective study of RDHAP/ Ox for early progressing follicular lymphoma. Doi; 10.1111/BJH.15057. British Journal of Haematology 2018 Dec;183 (5):828-31.$$$$$Y$$$20221101$$HP$IT$IT
1445052445$14450524$45$F$20170406$20221009$20180129$20221013$EXP$$CA-ROCHE-2061880$ROCHE$$19$YR$$M$Y$$$20221013$$MD$CA$CA
1445361121$14453611$21$F$20200101$20221021$20180129$20221026$EXP$$PHHY2017BR169385$NOVARTIS$$$$$M$Y$67$KG$20221026$$MD$BR$BR
144540165$14454016$5$F$$20221010$20180129$20221021$EXP$$GB-MYLANLABS-2018M1002396$MYLAN$Gonzaga-Lopez A, Munoz-Rodriguez J, Ruiz-Casado A.. Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer.. Ann R Coll Surg Engl.. 2017;99(8):225-6$64$YR$$M$Y$$$20221021$$HP$GB$ES
144541364$14454136$4$F$$20221014$20180129$20221018$EXP$$US-PFIZER INC-2017555973$PFIZER$$70$YR$$F$Y$$$20221018$$CN$US$US
144541932$14454193$2$F$$20210624$20180129$20221219$EXP$$US-GLAXOSMITHKLINE-US2018GSK012354$GLAXOSMITHKLINE$Gleghorn K, Kelly B. Severe cutaneous drug reactions, such as Steven-Johnson syndrome and toxic epidermal necrolysis, in pediatric patients with an emphasis on recently approved medications. 76th Annual Meeting of the American Academy of Dermatology (AAD). 2018$$$$$Y$$$20221219$$MD$US$US
1445587715$14455877$15$F$$20221118$20180130$20221129$EXP$$PT-ROCHE-2058319$ROCHE$PRIVACY P, Cadinha S, Malheiro D, Brosseron L, Moreira Da Silva JP. Multiple drug hypersensitivity syndrome, including antihistamines and corticosteroids, in a patient diagnosed with asthma and chronic urticaria. REVISTA PORTUGUESA DE IMUNOALERGOLOGIA 2017;25 (3):216-217.$23$YR$$F$Y$102$KG$20221129$$HP$COUNTRY NOT SPECIFIED$PT
144568212$14456821$2$F$$20221102$20180130$20221117$EXP$$US-West-Ward Pharmaceuticals Corp.-US-H14001-18-00542$HIKMA$$67$YR$$F$Y$$$20221117$$MD$US$
144575053$14457505$3$F$$20221214$20180130$20221227$PER$$US-PFIZER INC-2018037093$PFIZER$$78$YR$$F$Y$$$20221227$$CN$US$US
144575186$14457518$6$F$$20221130$20180130$20221205$PER$$US-PFIZER INC-2018036988$PFIZER$$68$YR$$F$Y$$$20221205$$MD$US$US
1445770220$14457702$20$F$20171107$20221212$20180130$20221219$EXP$$PHHY2017GB199493$NOVARTIS$$73$YR$$F$Y$50$KG$20221219$$PH$GB$GB
1445851814$14458518$14$F$$20221014$20180130$20221021$EXP$$CA-APOTEX-2018AP005828$APOTEX$$76$YR$$F$Y$$$20221021$$MD$CA$CA
1445886619$14458866$19$F$20120524$20221202$20180130$20221206$EXP$$DE-MYLANLABS-2018M1005245$MYLAN$$30$YR$$M$Y$76$KG$20221206$$MD$DE$DE
144637395$14463739$5$F$20180124$20221216$20180130$20221221$PER$$US-BIOGEN-2018BI00512716$BIOGEN$$68$YR$$F$Y$$$20221221$$CN$US$US
144659274$14465927$4$F$$20221216$20180131$20221230$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2018US-161534$RANBAXY$Defayette A, Perrello A, Brewer T, Picano J, Ahmed S. Enteral baclofen withdrawal managed with intravenous dexmedetomidine: A case report. Am J health Syst Pharm. 2020;Mar 01; 77:352-355$61$YR$$M$Y$$$20221230$$HP$US$US
144663619$14466361$9$F$$20221004$20180131$20221015$EXP$$PL-AUROBINDO-AUR-APL-2018-003673$AUROBINDO$Wojcik-Pedziwiatr M, Michalski M.. A 70-year-old woman with pneumonia, hallucinations and diagnosis of Parkinson?s disease. Lekarz Rodzinny. 2017;82:84-8$70$YR$$F$Y$$$20221015$$MD$PL$PL
144666087$14466608$7$F$20140401$20221123$20180131$20221206$EXP$$US-ACORDA-ACO_137979_2017$ACORDA$$49$YR$$F$Y$55.34$KG$20221206$$MD$US$US
1446725341$14467253$41$F$20140101$20221018$20180131$20221024$EXP$$PHHY2014CA056516$NOVARTIS$$$$$F$Y$$$20221024$$PH$CA$CA
144675923$14467592$3$F$$20221128$20180131$20221205$EXP$$US-ADIENNEP-2018AD000038$ADIENNE PHARMA + BIOTECH$Hashem H, Kumar AR, Mueller I, Babor F, Bredius R, Dalal J, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood 2017 130:24 (2682-2688). Doi:  10.1182/blood-2017-07-798660.$11$YR$$F$Y$$$20221130$$MD$US$
1446968528$14469685$28$F$$20221206$20180131$20221212$EXP$$GB-MYLANLABS-2018M1005349$MYLAN$$44$YR$$M$Y$$$20221212$$HP$GB$GB
144738083$14473808$3$F$$20221012$20180201$20221013$PER$$US-PFIZER INC-2018041827$PFIZER$$62$YR$$F$Y$$$20221013$$HP$US$US
1447381725$14473817$25$F$20170101$20221222$20180201$20221230$EXP$$US-PFIZER INC-2018041621$PFIZER$$68$YR$$F$Y$49$KG$20221230$$CN$US$US
1447501740$14475017$40$F$20170826$20221215$20180201$20221224$EXP$$CA-CELLTRION INC.-2017CA011633$CELLTRION$$$$$$Y$$$20221224$$CN$CA$CA
144754514$14475451$4$F$20180101$20221028$20180201$20221101$PER$$US-PFIZER INC-2018045680$PFIZER$$80$YR$$M$Y$$$20221101$$CN$US$US
144768166$14476816$6$F$$20221024$20180201$20221028$PER$$US-AMGEN-USASP2018013922$AMGEN$$68$YR$E$F$Y$$$20221027$$HP$US$US
144780747$14478074$7$F$20100407$20221117$20180202$20221125$EXP$$US-AstraZeneca-2018SE11774$ASTRAZENECA$$19768$DY$$F$Y$59.4$KG$20221125$$LW$US$
144782794$14478279$4$F$$20180726$20180202$20221220$EXP$$SE-TEVA-2018-SE-850316$TEVA$$30$YR$A$M$Y$$$20221220$$MD$SE$SE
144801012$14480101$2$F$$20221012$20180202$20221015$PER$$US-AMGEN-USASP2018013293$AMGEN$$62$YR$A$F$Y$$$20221015$$HP$US$US
144807565$14480756$5$F$20180101$20221104$20180202$20221109$EXP$$PHHY2018CA014001$NOVARTIS$$53$YR$$M$Y$$$20221109$$HP$CA$CA
1448295038$14482950$38$F$20171222$20221020$20180203$20221020$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-008328$BRISTOL MYERS SQUIBB$$62$YR$A$F$Y$75.74$KG$20221021$$HP$US$US
144843516$14484351$6$F$20100722$20221017$20180205$20221020$EXP$$US-AstraZeneca-2018SE12552$ASTRAZENECA$$23698$DY$$M$Y$104.3$KG$20221020$$LW$US$
1448708629$14487086$29$F$20170731$20221018$20180205$20221026$EXP$$CA-CELLTRION INC.-2017CA010299$CELLTRION$$$$$$Y$$$20221026$$CN$CA$CA
1448755229$14487552$29$F$20180716$20221121$20180205$20221129$EXP$$CA-CELLTRION INC.-2017CA004112$CELLTRION$$$$$$Y$$$20221129$$MD$CA$CA
144881207$14488120$7$F$20171001$20221121$20180205$20221124$EXP$$US-PFIZER INC-2017273721$PFIZER$$57$YR$$F$Y$59$KG$20221124$$CN$US$US
144882112$14488211$2$F$$20220927$20180205$20221007$EXP$$FR-MYLANLABS-2018M1006915$MYLAN$Risse J, Vieira M,  Beuret F, Petitpain N, Zuily S, Wahl D.. Reversible drug-induced antiphospholipid syndrome.. Lupus. 2018;27(2):333-5$$$A$M$Y$$$20221007$$HP$FR$FR
144909348$14490934$8$F$20180126$20221024$20180206$20221026$PER$$US-PFIZER INC-2017229694$PFIZER$$78$YR$$F$Y$72$KG$20221026$$CN$US$US
1449325130$14493251$30$F$20170616$20221219$20180206$20221229$EXP$$CA-CELLTRION INC.-2017CA008080$CELLTRION$$$$$$Y$$$20221229$$CN$CA$CA
1449601314$14496013$14$F$$20221129$20180207$20221208$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-007268$BRISTOL MYERS SQUIBB$$68$YR$E$F$Y$$$20221208$$MD$CA$CA
1449652214$14496522$14$F$20160803$20221122$20180207$20221130$EXP$GB-MHRA-ADR 23595830$GB-TORRENT-00007686$TORRENT$$69$YR$E$F$Y$101$KG$20221130$$MD$GB$GB
144968225$14496822$5$F$20180129$20221205$20180207$20221208$PER$$US-PFIZER INC-2018053031$PFIZER$$76$YR$$F$Y$90.72$KG$20221208$$CN$US$US
1449736919$14497369$19$F$20211201$20221129$20180207$20221205$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK066828$GLAXOSMITHKLINE$$$$$$Y$$$20221205$$MD$BR$BR
145002403$14500240$3$F$20180101$20221213$20180207$20221219$EXP$$US-JAZZ-2018-US-002426$JAZZ$$36$YR$$F$Y$$$20221219$$HP$US$US
1450166939$14501669$39$F$$20221213$20180207$20221216$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-007157$BRISTOL MYERS SQUIBB$$63$YR$A$F$Y$$$20221216$$HP$CA$CA
145021727$14502172$7$F$20121115$20221010$20180208$20221014$EXP$$US-AstraZeneca-2018SE15637$ASTRAZENECA$$22804$DY$$F$Y$108.9$KG$20221014$$LW$US$
145024325$14502432$5$F$20161223$20221117$20180208$20221123$EXP$$CA-TAKEDA-2017TUS000654$TAKEDA$$55$YR$$F$Y$$$20221123$$CN$CA$CA
145027029$14502702$9$F$$20221221$20180208$20221228$EXP$$US-ARIAD PHARMACEUTICALS, INC-2017US008872$TAKEDA$$$$$F$Y$59$KG$20221228$$CN$US$US
145028484$14502848$4$F$$20221116$20180208$20221118$PER$$US-BIOGEN-2018BI00518225$BIOGEN$$$$$F$Y$58.9$KG$20221118$$CN$US$US
145031546$14503154$6$F$20171226$20221116$20180208$20221118$EXP$$US-PFIZER INC-2018054905$PFIZER$$66$YR$$F$Y$83.01$KG$20221118$$CN$US$US
1450608630$14506086$30$F$20171208$20221213$20180208$20221226$EXP$$CA-CELLTRION INC.-2017CA011940$CELLTRION$$$$$$Y$$$20221226$$CN$CA$CA
1450676033$14506760$33$F$20170913$20221124$20180208$20221202$EXP$$PHHY2016CA077754$NOVARTIS$$50$YR$$F$Y$$$20221202$$CN$CA$CA
145073822$14507382$2$F$$20211202$20180208$20221008$PER$$US-PURDUE-USA-2017-0140907$PURDUE$$$$$F$Y$$$20221008$$CN$US$US
145098625$14509862$5$F$$20221021$20180209$20221025$PER$$US-PFIZER INC-2018056457$PFIZER$$77$YR$$F$Y$$$20221025$$MD$US$US
145098745$14509874$5$F$$20221027$20180209$20221031$PER$$US-PFIZER INC-2018057651$PFIZER$$70$YR$$F$Y$$$20221031$$MD$US$US
145102703$14510270$3$F$$20180309$20180209$20221019$EXP$$IE-JNJFOC-20180203321$JOHNSON AND JOHNSON$$73$YR$E$F$Y$44.4$KG$20221019$$MD$IE$IE
1451089110$14510891$10$F$20161201$20221117$20180209$20221122$EXP$$CA-TAKEDA-2016TUS023123$TAKEDA$$44$YR$$M$Y$$$20221122$$HP$CA$CA
1451182314$14511823$14$F$$20221115$20180209$20221117$PER$$US-PFIZER INC-2018056942$PFIZER$$68$YR$$F$Y$$$20221117$$MD$US$US
145119542$14511954$2$F$20170101$20221130$20180209$20221212$EXP$$US-TAKEDA-2018MPI001261$TAKEDA$$58$YR$$M$Y$83$KG$20221212$$MD$US$US
145120034$14512003$4$F$$20180305$20180209$20221209$EXP$$US-TEVA-2018-US-856263$TEVA$$$$$F$Y$$$20221209$$HP$US$US
145142534$14514253$4$F$20180101$20221222$20180209$20221223$EXP$$CA-SHIRE-CA201803915$SERVIER$$$$$$Y$$$20221223$$HP$CA$CA
1451633724$14516337$24$F$$20221124$20180211$20221201$EXP$$CA-ABBVIE-18K-028-2248990-00$ABBVIE$$63$YR$$F$Y$$$20221201$$MD$CA$CA
1451639810$14516398$10$F$$20221115$20180212$20221121$PER$$US-AMGEN-USASP2018018118$AMGEN$$68$YR$E$F$Y$$$20221121$$MD$US$US
145166893$14516689$3$F$$20221121$20180212$20221129$PER$$US-JNJFOC-20180201823$JOHNSON AND JOHNSON$$$$$M$Y$$$20221130$$LW$US$US
145172074$14517207$4$F$20150607$20221021$20180212$20221028$EXP$$US-SHIRE-US201804265$TAKEDA$$39$YR$$F$Y$66.168$KG$20221028$$CN$US$US
145191153$14519115$3$F$$20221019$20180212$20221031$PER$$US-JNJFOC-20180202186$JOHNSON AND JOHNSON$$$$$M$Y$$$20221031$$LW$US$US
145193732$14519373$2$F$20100301$20220928$20180212$20221007$PER$$US-JNJFOC-20180202108$JOHNSON AND JOHNSON$$11$YR$C$M$Y$$$20221007$$LW$US$US
145225068$14522506$8$F$$20221124$20180212$20221129$EXP$$PHHY2017PT200721$NOVARTIS$Gravito-soares E, Gravito-Soares M, Cipriano MA, Amaro P. Fatal colitis associated with active systemic lupus erythematosus complicated by cytomegalovirus superinfection. BRITISH MEDICAL JOURNAL. 2017;1-2$47$YR$$F$Y$$$20221129$$HP$PT$PT
145226804$14522680$4$F$20110117$20221116$20180212$20221119$EXP$$PHHY2018CO020193$NOVARTIS$$53$YR$$F$Y$58$KG$20221119$$CN$CO$CO
145236893$14523689$3$F$$20221202$20180213$20221210$PER$$US-AMGEN-USASP2018018972$AMGEN$$69$YR$E$M$Y$$$20221210$$MD$US$US
145242604$14524260$4$F$$20220926$20180213$20221004$EXP$$US-AstraZeneca-2018SE17018$ASTRAZENECA$$$$$F$Y$140.6$KG$20221004$$LW$US$
145244039$14524403$9$F$$20221214$20180213$20221219$PER$$US-PFIZER INC-2018062204$PFIZER$$52$YR$$M$Y$$$20221219$$MD$US$US
1452600919$14526009$19$F$20180130$20221007$20180213$20221010$EXP$$JP-ROCHE-2070125$ROCHE$$69$YR$$M$Y$65.9$KG$20221010$$MD$JP$
1452632821$14526328$21$F$20180426$20221024$20180213$20221101$EXP$$CA-CELLTRION INC.-2017CA002020$CELLTRION$$$$$$Y$$$20221101$$CN$CA$CA
145271894$14527189$4$F$20060101$20221017$20180213$20221020$EXP$$US-PFIZER INC-2018061139$PFIZER$$59$YR$$F$Y$$$20221020$$LW$US$US
145281596$14528159$6$F$19970101$20221123$20180214$20221124$PER$$US-BIOGEN-2013BI114629$BIOGEN$$$$$F$Y$$$20221124$$CN$US$US
145292932$14529293$2$F$20220929$20221004$20180214$20221006$PER$$US-SHIRE-US201805035$TAKEDA$$69$YR$$F$Y$91.156$KG$20221006$$CN$US$US
145294114$14529411$4$F$$20180209$20180214$20221209$EXP$$US-TEVA-2018-US-859279$TEVA$$$$$M$Y$$$20221209$$MD$US$US
145308238$14530823$8$F$20180101$20221019$20180214$20221024$EXP$$US-PFIZER INC-2018061673$PFIZER$$27$YR$$M$Y$90.72$KG$20221024$$HP$US$US
1453299720$14532997$20$F$20171125$20221021$20180215$20221031$EXP$$CA-ROCHE-2037517$ROCHE$$7$YR$$M$Y$35.5$KG$20221031$$HP$CA$
1453398911$14533989$11$F$20180201$20221227$20180215$20221229$PER$$US-PFIZER INC-2018062283$PFIZER$$75$YR$$F$Y$118$KG$20221229$$CN$US$US
145340465$14534046$5$F$20171001$20221206$20180215$20221212$EXP$$US-PFIZER INC-2018063220$PFIZER$$65$YR$$F$Y$45.36$KG$20221212$$CN$US$US
145349707$14534970$7$F$20150717$20221116$20180215$20221128$EXP$$GB-ASPEN-GLO2015GB010141$ASPEN$$$$$$Y$$$20221128$$HP$GB$GB
145350318$14535031$8$F$20191002$20220930$20180215$20221002$EXP$$PHJP2018JP003345$NOVARTIS$$50$YR$$F$Y$$$20221003$$MD$JP$JP
1453521549$14535215$49$F$20171227$20221011$20180215$20221020$EXP$$CA-CELLTRION INC.-2018CA017660$CELLTRION$$$$$$Y$$$20221020$$CN$CA$CA
1453794813$14537948$13$F$$20221007$20180216$20221013$PER$$US-AMGEN-USASP2018021138$AMGEN$$88$YR$E$F$Y$$$20221013$$MD$US$US
145418982$14541898$2$F$$20221003$20180216$20221013$PER$$US-JNJFOC-20180206421$JOHNSON AND JOHNSON$$$$$M$Y$$$20221013$$LW$US$US
145430023$14543002$3$F$20120101$20221005$20180216$20221007$EXP$$US-TAKEDA-2018TUS004146$TAKEDA$$$$$$Y$$$20221007$$CN$US$US
145430054$14543005$4$F$20130201$20220923$20180216$20221004$EXP$$US-TAKEDA-2018TUS004273$TAKEDA$$$$$$Y$$$20221004$$CN$US$US
145433605$14543360$5$F$20060101$20221017$20180216$20221024$EXP$$US-TAKEDA-2018TUS004230$TAKEDA$$$$$$Y$$$20221024$$CN$US$US
1454426112$14544261$12$F$20170916$20221019$20180216$20221019$EXP$$DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-121037$BRISTOL MYERS SQUIBB$$68$YR$E$M$Y$71$KG$20221019$$HP$DE$DE
145454855$14545485$5$F$$20221212$20180219$20221216$PER$$CA-AMGEN-CANSP2018022155$AMGEN$$67$YR$E$M$Y$$$20221216$$HP$CA$CA
145455057$14545505$7$F$$20221209$20180219$20221221$PER$$US-AMGEN-USASP2018020913$AMGEN$$67$YR$E$M$Y$67$KG$20221220$$CN$US$US
145468344$14546834$4$F$$20221108$20180219$20221110$PER$$US-PFIZER INC-2018065357$PFIZER$$72$YR$$F$Y$$$20221110$$CN$US$US
1454684410$14546844$10$F$20180206$20221216$20180219$20221223$EXP$$US-PFIZER INC-2018065235$PFIZER$$73$YR$$F$Y$77$KG$20221223$$CN$US$US
145469773$14546977$3$F$$20221102$20180219$20221107$EXP$$CA-009507513-1802CAN009207$MERCK$Yu R, Dale S, Yamamura D, Stankus V, Lee C. Daptomycin-nonsusceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus endocarditis. Can J Infect Dis Med Microbiol. 2012;23(2):e48-e50$75$YR$$F$Y$$$20221107$$HP$CA$CA
145469818$14546981$8$F$$20221219$20180219$20221227$EXP$$US-PFIZER INC-2018068998$PFIZER$$66$YR$$F$Y$$$20221227$$CN$US$US
145477992$14547799$2$F$$20180213$20180219$20221208$EXP$$CA-TEVA-2017-CA-836651$TEVA$$$$$$Y$$$20221208$$PH$CA$CA
145490707$14549070$7$F$20171201$20221108$20180219$20221111$PER$$US-PFIZER INC-2018068964$PFIZER$$55$YR$$F$Y$73.03$KG$20221111$$CN$US$US
145498003$14549800$3$F$$20220913$20180219$20221007$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-006156$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221007$$CN$US$US
145498072$14549807$2$F$20171001$20221105$20180219$20221130$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-006142$ACADIA PHARMACEUTICALS$$65$YR$$M$Y$$$20221130$$CN$US$US
145498722$14549872$2$F$20171113$20221031$20180219$20221109$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-006264$ACADIA PHARMACEUTICALS$$73$YR$$M$Y$$$20221110$$CN$US$US
145499402$14549940$2$F$$20221104$20180219$20221114$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-006335$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221114$$CN$US$US
145499968$14549996$8$F$20170101$20220923$20180219$20221003$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-006458$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221003$$CN$US$US
145500434$14550043$4$F$20200201$20221114$20180219$20221123$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-006342$ACADIA PHARMACEUTICALS$$79$YR$$M$Y$$$20221123$$CN$US$US
145502683$14550268$3$F$20220829$20220926$20180219$20221021$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2017-006829$ACADIA PHARMACEUTICALS$$87$YR$$F$Y$$$20221021$$CN$US$US
145505468$14550546$8$F$20210101$20221107$20180219$20221117$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-007192$ACADIA PHARMACEUTICALS$$$$$M$Y$79$KG$20221117$$CN$US$US
145520486$14552048$6$F$20160307$20221021$20180220$20221025$PER$$US-PFIZER INC-2018049626$PFIZER$$55$YR$$F$Y$$$20221025$$LW$US$US
145531419$14553141$9$F$$20221128$20180220$20221208$EXP$$CA-APOTEX-2018AP006524$APOTEX$$61$YR$$F$Y$67$KG$20221208$$HP$CA$CA
145538822$14553882$2$F$20170731$20180205$20180220$20221220$EXP$FR-AFSSAPS-BX20174081$FR-TEVA-2018-FR-856970$TEVA$$73$YR$E$F$Y$68$KG$20221220$$PH$FR$FR
145567032$14556703$2$F$$20221214$20180221$20221219$PER$$US-PFIZER INC-2018073186$PFIZER$$66$YR$$M$Y$90.703$KG$20221219$$CN$US$US
1455747410$14557474$10$F$20210101$20221108$20180221$20221114$EXP$$CA-PFIZER INC-2018058533$PFIZER$$55$YR$$F$Y$$$20221114$$CN$CA$CA
145578515$14557851$5$F$20160501$20221130$20180221$20221202$EXP$$US-PFIZER INC-2017262528$PFIZER$$65$YR$$M$Y$71$KG$20221202$$CN$US$US
1455912610$14559126$10$F$20180208$20221026$20180221$20221102$EXP$$US-PFIZER INC-2018070862$PFIZER$$86$YR$$F$Y$58.97$KG$20221102$$CN$US$US
145595895$14559589$5$F$20180215$20221027$20180221$20221031$EXP$$US-SHIRE-US201806683$TAKEDA$$57$YR$$F$Y$$$20221031$$HP$US$US
1456000916$14560009$16$F$20170202$20221213$20180221$20221217$EXP$$PHHY2017CA018665$NOVARTIS$$47$YR$$F$Y$$$20221217$$CN$CA$CA
145613735$14561373$5$F$20221106$20221117$20180222$20221122$EXP$$US-PFIZER INC-2018074735$PFIZER$$72$YR$$F$Y$81.65$KG$20221122$$HP$US$US
145617986$14561798$6$F$20200114$20221116$20180222$20221123$EXP$$CA-ROCHE-2077557$ROCHE$$70$YR$$F$Y$$$20221123$$CN$CA$CA
1456330815$14563308$15$F$20170728$20221205$20180222$20221210$EXP$$PHHY2017CA113510$NOVARTIS$$61$YR$$M$Y$76$KG$20221210$$CN$CA$CA
145652582$14565258$2$F$$20221207$20180223$20221209$PER$$US-JNJFOC-20180216613$JOHNSON AND JOHNSON$$$$$M$Y$$$20221209$$LW$US$US
145673103$14567310$3$F$$20221003$20180223$20221012$PER$$US-JNJFOC-20180216736$JOHNSON AND JOHNSON$$$$$M$Y$$$20221009$$LW$US$US
145673434$14567343$4$F$20080221$20221116$20180223$20221128$PER$$US-JNJFOC-20180216753$JOHNSON AND JOHNSON$$10$YR$C$M$Y$$$20221128$$LW$US$US
145684063$14568406$3$F$20090417$20221207$20180223$20221212$PER$$US-JNJFOC-20180217396$JOHNSON AND JOHNSON$$9$YR$C$M$Y$$$20221212$$LW$US$US
145695312$14569531$2$F$20130101$20221213$20180224$20221220$PER$$US-JNJFOC-20180216754$JOHNSON AND JOHNSON$$12$YR$T$M$Y$$$20221220$$LW$US$US
1457172012$14571720$12$F$20180220$20221221$20180226$20221228$EXP$$US-PFIZER INC-2018076610$PFIZER$$70$YR$$F$Y$94$KG$20221228$$CN$US$US
145718043$14571804$3$F$$20221011$20180226$20221013$PER$$US-PFIZER INC-2018079147$PFIZER$$57$YR$$F$Y$$$20221013$$MD$US$US
145725993$14572599$3$F$20180101$20221109$20180226$20221111$PER$$US-PFIZER INC-2018078834$PFIZER$$66$YR$$M$Y$123$KG$20221111$$CN$US$US
145764193$14576419$3$F$$20221006$20180227$20221102$PER$$US-TEVA-2018-US-863141$TEVA$$$$$F$Y$$$20221102$$CN$US$US
145780692$14578069$2$F$20171119$20221125$20180227$20221201$EXP$FI-FIMEA-20180202$FI-009507513-1802FIN011193$MERCK$$71$YR$$M$Y$$$20221201$$MD$FI$FI
1457847944$14578479$44$F$20180101$20221101$20180227$20221123$EXP$$CA-CELLTRION INC.-2017CA014453$CELLTRION$$$$$$Y$$$20221123$$CN$CA$CA
1457848037$14578480$37$F$20180101$20221216$20180227$20221226$EXP$$CA-CELLTRION INC.-2018CA018149$CELLTRION$$$$$$Y$$$20221226$$CN$CA$CA
145788396$14578839$6$F$20180120$20221223$20180227$20221229$EXP$$US-PFIZER INC-2018083145$PFIZER$$78$YR$$F$Y$72.57$KG$20221229$$CN$US$US
145791044$14579104$4$F$20171120$20221005$20180227$20221013$EXP$$US-BIOGEN-2018BI00528986$BIOGEN$$42$YR$$M$Y$$$20221013$$HP$US$US
145798632$14579863$2$F$20180210$20221011$20180228$20221013$PER$$US-BIOGEN-2018BI00527308$BIOGEN$$36$YR$$F$Y$$$20221013$$CN$US$US
145810268$14581026$8$F$$20221125$20180228$20221129$PER$$US-PFIZER INC-2018080969$PFIZER$$69$YR$$F$Y$54$KG$20221129$$CN$US$US
145812394$14581239$4$F$20140101$20220927$20180228$20221005$EXP$$US-AstraZeneca-2018SE24251$ASTRAZENECA$$71$YR$$F$Y$81.2$KG$20221005$$LW$US$
145821149$14582114$9$F$$20221122$20180228$20221128$PER$$US-PFIZER INC-2018081329$PFIZER$$66$YR$$F$Y$$$20221128$$HP$US$US
145838399$14583839$9$F$20140101$20221130$20180228$20221207$EXP$$PHHY2014CA022004$NOVARTIS$$54$YR$$M$Y$170$KG$20221207$$CN$CA$CA
1458495132$14584951$32$F$20171101$20221207$20180301$20221216$EXP$GB-MYLANLABS-2018M1008353$GB-TORRENT-00016177$TORRENT$$32$YR$A$F$Y$$$20221216$$MD$GB$GB
1458531252$14585312$52$F$$20221014$20180301$20221019$EXP$$GB-JNJFOC-20180234113$JOHNSON AND JOHNSON$$86$YR$E$F$Y$$$20221019$$HP$GB$GB
145854645$14585464$5$F$$20221025$20180301$20221031$EXP$$US-PFIZER INC-2018081267$PFIZER$$80$YR$$F$Y$$$20221031$$CN$US$US
1458681914$14586819$14$F$20140101$20221214$20180301$20221216$EXP$$US-PFIZER INC-2018085158$PFIZER$$58$YR$$F$Y$86$KG$20221216$$CN$US$US
1458842816$14588428$16$F$20171026$20221102$20180301$20221104$EXP$$PHHY2017CA159357$NOVARTIS$$54$YR$$F$Y$86$KG$20221104$$CN$CA$CA
145896004$14589600$4$F$20170216$20221125$20180302$20221201$EXP$$US-BIOGEN-2018BI00530898$BIOGEN$$27$YR$$F$Y$$$20221201$$CN$US$US
145902399$14590239$9$F$20170123$20221102$20180302$20221110$EXP$$US-PFIZER INC-2018083088$PFIZER$$67$YR$$F$Y$$$20221110$$CN$US$US
1459102113$14591021$13$F$20160101$20221017$20180302$20221020$EXP$$CA-PFIZER INC-2016532697$PFIZER$$57$YR$$F$Y$$$20221020$$CN$CA$CA
1459287532$14592875$32$F$20180103$20221117$20180302$20221124$EXP$$CA-CELLTRION INC.-2018CA017304$CELLTRION$$$$$$Y$$$20221125$$CN$CA$CA
145962562$14596256$2$F$$20221018$20180303$20221027$PER$$US-AMGEN-USASP2018027086$AMGEN$$65$YR$E$F$Y$$$20221026$$CN$US$US
145979306$14597930$6$F$$20221201$20180305$20221206$PER$$US-PFIZER INC-2018085458$PFIZER$$69$YR$$M$Y$$$20221206$$MD$US$US
1459910019$14599100$19$F$20160823$20221110$20180305$20221115$EXP$$CA-TAKEDA-2018TUS004977$TAKEDA$$52$YR$$M$Y$$$20221115$$HP$CA$CA
145994704$14599470$4$F$20220118$20221013$20180305$20221018$EXP$$BR-PFIZER INC-2018087022$PFIZER$$69$YR$$F$Y$$$20221018$$HP$BR$BR
1460003530$14600035$30$F$20180501$20221117$20180305$20221125$EXP$$CA-CELLTRION INC.-2018CA018287$CELLTRION$$$$$$Y$$$20221125$$CN$CA$CA
146024872$14602487$2$F$$20221114$20180306$20221116$PER$$US-PFIZER INC-2018089699$PFIZER$$68$YR$$M$Y$$$20221116$$CN$US$US
146025538$14602553$8$F$20180101$20221124$20180306$20221128$EXP$$US-PFIZER INC-2018092582$PFIZER$$71$YR$$F$Y$64.853$KG$20221128$$CN$US$US
1460423541$14604235$41$F$20170101$20221220$20180306$20221229$EXP$$CA-CELLTRION INC.-2017CA014066$CELLTRION$$$$$$Y$$$20221229$$CN$CA$CA
146043364$14604336$4$F$20180101$20220712$20180306$20221213$PER$$US-AMGEN-USASL2018028889$AMGEN$$$$$F$Y$$$20221213$$CN$US$US
146043624$14604362$4$F$20160407$20221010$20180306$20221018$EXP$$CN-AstraZeneca-2018SE27702$ASTRAZENECA$Liu X, Zhai A, Zhang B. A case report of severe adverse reaction of exenatide: Anaphylactic shock. Medicine 2022;101(39):e30805-.$47$YR$$M$Y$124$KG$20221018$$HP$CN$
1460442831$14604428$31$F$20180222$20221216$20180306$20221226$EXP$$CA-CELLTRION INC.-2018CA018314$CELLTRION$$$$$$Y$$$20221226$$CN$CA$CA
146047156$14604715$6$F$20171118$20221115$20180306$20221118$EXP$$CA-009507513-1803CAN001544$MERCK$$71$YR$$F$Y$57$KG$20221118$$PH$CA$CA
1460493741$14604937$41$F$20170919$20221209$20180306$20221216$EXP$$PHHY2018CA031979$NOVARTIS$$66$YR$$F$Y$$$20221216$$CN$CA$CA
146059233$14605923$3$F$$20221007$20180307$20221014$PER$$US-AMGEN-USASL2018030105$AMGEN$$$$$M$Y$$$20221013$$CN$US$US
146060185$14606018$5$F$20170525$20221130$20180307$20221206$EXP$$CA-ROCHE-2084690$ROCHE$$65$YR$$F$Y$$$20221206$$CN$COUNTRY NOT SPECIFIED$CA
1460652426$14606524$26$F$20180207$20221110$20180307$20221125$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-165261$RANBAXY$$86$YR$$F$Y$$$20221125$$HP$GB$GB
1460670246$14606702$46$F$20180213$20221219$20180307$20221226$EXP$$CA-ROCHE-2075035$ROCHE$$37$YR$$F$Y$$$20221226$$CN$CA$
146069164$14606916$4$F$20120611$20221115$20180307$20221122$EXP$$US-AstraZeneca-2018SE27918$ASTRAZENECA$$22095$DY$$F$Y$78$KG$20221122$$LW$US$
1460707012$14607070$12$F$20160801$20221025$20180307$20221028$EXP$$US-ROCHE-2081802$ROCHE$$33$YR$$F$Y$$$20221028$$CN$US$
1460756433$14607564$33$F$20190717$20221028$20180307$20221102$EXP$$PHHY2018CA036209$NOVARTIS$$43$YR$$F$Y$$$20221102$$CN$CA$CA
1460974941$14609749$41$F$$20221012$20180307$20221021$EXP$$GB-TAKEDA-2018TUS005225$TAKEDA$$53$YR$$M$Y$$$20221021$$HP$CA$CA
146101199$14610119$9$F$20180226$20221202$20180307$20221207$PER$$US-PFIZER INC-2018092189$PFIZER$$78$YR$$F$Y$59$KG$20221207$$CN$US$US
146115083$14611508$3$F$20171102$20220930$20180308$20221014$EXP$$SE-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-165466$RANBAXY$$$$$F$Y$$$20221014$$MD$SE$SE
146116924$14611692$4$F$$20221121$20180308$20221124$EXP$$US-PFIZER INC-2018091693$PFIZER$$63$YR$$F$Y$$$20221124$$CN$US$US
146121765$14612176$5$F$$20221104$20180308$20221111$EXP$$PHHY2018SE035062$NOVARTIS$Chandler RE. Serious neurological adverse events after Ivermectin-do they occur beyond the Indication of onchocerciasis?. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. 2018;98(2):328-82$56$YR$$F$Y$55$KG$20221111$$HP$SE$SE
146122996$14612299$6$F$20171129$20221215$20180308$20221227$EXP$GB-MHRA-INP12070F88-28C6-46F5-BD7B-FB62F61761C4$GB-drreddys-GER/UKI/18/0096623$DR REDDYS$$30$YR$A$M$Y$81$KG$20221227$$MD$GB$GB
1461288818$14612888$18$F$$20220324$20180308$20221128$EXP$$GB-JNJFOC-20180116422$JOHNSON AND JOHNSON$$44$YR$A$M$Y$$$20221128$$CN$GB$GB
1461359641$14613596$41$F$20180101$20221214$20180308$20221222$EXP$$CA-CELLTRION INC.-2018CA018359$CELLTRION$$$$$$Y$$$20221222$$MD$CA$CA
146144674$14614467$4$F$$20210406$20180308$20221012$PER$$US-CELLTRION INC.-2017US010070$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
146148373$14614837$3$F$20141008$20221021$20180308$20221026$EXP$IT-MINISAL02-422135$IT-PFIZER INC-2018093976$PFIZER$$15$YR$$M$Y$78$KG$20221026$$HP$IT$IT
146148627$14614862$7$F$$20220930$20180308$20221003$EXP$$US-PFIZER INC-2018094940$PFIZER$$65$YR$$F$Y$$$20221003$$LW$US$US
146163365$14616336$5$F$$20221208$20180309$20221212$PER$$US-PFIZER INC-2018095559$PFIZER$$69$YR$$M$Y$$$20221212$$CN$US$US
146163429$14616342$9$F$$20221109$20180309$20221111$PER$$US-PFIZER INC-2018096140$PFIZER$$82$YR$$F$Y$$$20221111$$MD$US$US
1461698013$14616980$13$F$$20221118$20180309$20221202$EXP$$GB-AUROBINDO-AUR-APL-2017-48251$AUROBINDO$$22$YR$$F$Y$56$KG$20221202$$MD$GB$GB
1461764426$14617644$26$F$20171215$20220926$20180309$20221003$EXP$$CA-ROCHE-2086120$ROCHE$$44$YR$$F$Y$$$20221003$$CN$CA$
146189996$14618999$6$F$20170929$20221213$20180309$20221221$EXP$$PHJP2018JP005168$NOVARTIS$$70$YR$$M$Y$60$KG$20221221$$MD$JP$JP
146215563$14621556$3$F$20161222$20221111$20180310$20221122$EXP$$IT-AUROBINDO-AUR-APL-2018-012747$AUROBINDO$$46$YR$$F$Y$$$20221122$$MD$IT$IT
146277585$14627758$5$F$20180201$20221103$20180312$20221111$EXP$$CA-PFIZER INC-2018099712$PFIZER$$73$YR$$F$Y$$$20221111$$CN$CA$CA
146296766$14629676$6$F$$20221207$20180313$20221213$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-038174$BRISTOL MYERS SQUIBB$$47$YR$A$F$Y$73$KG$20221213$$HP$CA$CA
1462981013$14629810$13$F$20180228$20221024$20180313$20221026$EXP$$DE-ROCHE-2087412$ROCHE$$43$YR$$F$Y$$$20221026$$CN$DE$
1463001910$14630019$10$F$20221001$20221209$20180313$20221216$EXP$$US-PFIZER INC-2018098171$PFIZER$$61$YR$$M$Y$$$20221216$$MD$US$US
146311404$14631140$4$F$20170914$20221121$20180313$20221128$EXP$$JP-SA-2017SA206584$SANOFI AVENTIS$$60$YR$A$M$Y$64$KG$20221129$$MD$JP$JP
1463138124$14631381$24$F$20180109$20221026$20180313$20221102$EXP$$PHHY2017CA195903$NOVARTIS$$56$YR$$M$Y$$$20221102$$CN$CA$CA
146325786$14632578$6$F$20171101$20221020$20180313$20221021$EXP$$US-ROCHE-2043645$ROCHE$$65$YR$$F$Y$72.64$KG$20221022$$CN$US$
146335769$14633576$9$F$20171001$20221025$20180314$20221027$EXP$$CA-ROCHE-2023946$ROCHE$$34$YR$$M$Y$$$20221027$$MD$CA$
1463360122$14633601$22$F$20080101$20221129$20180314$20221205$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-038682$BRISTOL MYERS SQUIBB$$66$YR$E$F$Y$$$20221205$$MD$CA$CA
146356073$14635607$3$F$20180120$20180403$20180314$20221220$EXP$DE-CADRBFARM-2018021367$DE-TEVA-2018-DE-870594$TEVA$$26$YR$A$F$Y$53$KG$20221220$$CN$DE$DE
146359335$14635933$5$F$19990101$20221227$20180314$20221230$PER$$US-PFIZER INC-2018102759$PFIZER$$46$YR$$F$Y$76.66$KG$20221230$$CN$US$US
146359845$14635984$5$F$20160614$20221221$20180314$20221228$EXP$$PHHY2016GB186243$NOVARTIS$$$$A$M$Y$$$20221228$$MD$GB$GB
146380578$14638057$8$F$$20221208$20180314$20221213$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-058741$BRISTOL MYERS SQUIBB$$40$YR$A$F$Y$$$20221213$$MD$CA$CA
1463807621$14638076$21$F$20170101$20221019$20180314$20221020$EXP$$PHHY2017CA080143$NOVARTIS$$$$$F$Y$$$20221020$$CN$CA$CA
146394054$14639405$4$F$20170124$20221018$20180315$20221021$PER$$US-AMGEN-USASP2018033839$AMGEN$$64$YR$A$F$Y$$$20221021$$HP$US$US
146409862$14640986$2$F$20210101$20221206$20180315$20221212$EXP$$US-PFIZER INC-2018103544$PFIZER$$67$YR$$F$Y$$$20221212$$CN$US$US
146413226$14641322$6$F$20190101$20221202$20180315$20221207$PER$$US-PFIZER INC-2018103114$PFIZER$$57$YR$$F$Y$73.197$KG$20221207$$CN$US$US
1464672938$14646729$38$F$20140216$20221213$20180316$20221216$EXP$$PHHY2014CA045336$NOVARTIS$$65$YR$$F$Y$$$20221216$$HP$CA$CA
1464825330$14648253$30$F$20171215$20221209$20180316$20221219$EXP$$CA-CELLTRION INC.-2018CA017412$CELLTRION$$$$$$Y$$$20221219$$MD$CA$CA
146483053$14648305$3$F$$20221130$20180316$20221202$EXP$$US-PFIZER INC-2018106683$PFIZER$$55$YR$$F$Y$74.83$KG$20221202$$CN$US$US
146484054$14648405$4$F$$20221026$20180316$20221027$EXP$$US-GILEAD-2018-0314410$GILEAD$$63$YR$A$M$Y$$$20221027$$CN$US$US
146487192$14648719$2$F$20170123$20221111$20180316$20221123$EXP$$IT-AUROBINDO-AUR-APL-2018-014649$AUROBINDO$$85$YR$$F$Y$$$20221123$$MD$IT$IT
146496757$14649675$7$F$20160804$20221012$20180316$20221026$EXP$$IT-PFIZER INC-2018103724$PFIZER$$13$YR$$M$Y$44$KG$20221026$$MD$IT$IT
146496867$14649686$7$F$20180214$20221128$20180316$20221201$EXP$$NZ-ROCHE-2083327$ROCHE$$73$YR$$M$Y$82$KG$20221201$$MD$NZ$
146505385$14650538$5$F$20170819$20210122$20180316$20221012$PER$$US-CELLTRION INC.-2017US010782$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
146514844$14651484$4$F$20170124$20221125$20180317$20221201$EXP$$CA-ROCHE-2089314$ROCHE$$64$YR$$F$Y$$$20221201$$CN$CA$CA
146517812$14651781$2$F$20170620$20221114$20180317$20221128$EXP$$IT-AUROBINDO-AUR-APL-2018-014656$AUROBINDO$$76$YR$$F$Y$$$20221128$$MD$IT$IT
1465261410$14652614$10$F$$20220922$20180319$20221003$EXP$$CA-APOTEX-2018AP007741$APOTEX$$44$YR$$M$Y$$$20221003$$HP$CA$CA
146537362$14653736$2$F$20180313$20221114$20180319$20221116$PER$$US-PFIZER INC-2018108329$PFIZER$$61$YR$$F$Y$$$20221116$$HP$US$US
146545333$14654533$3$F$$20201230$20180319$20221012$PER$$US-CELLTRION INC.-2017US012219$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
146545375$14654537$5$F$$20220525$20180319$20221012$PER$$US-CELLTRION INC.-2017US010793$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
146546195$14654619$5$F$$20220218$20180319$20221012$PER$$US-CELLTRION INC.-2017US012468$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
146547044$14654704$4$F$20220128$20220926$20180319$20221012$PER$$US-CELLTRION INC.-2017US014638$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
146547175$14654717$5$F$$20210713$20180319$20221012$PER$$US-CELLTRION INC.-2017US015495$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
146551584$14655158$4$F$$20221020$20180319$20221027$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2018-BI-014441$BOEHRINGER INGELHEIM$$52$YR$A$F$Y$$$20221027$$HP$CA$CA
1465553624$14655536$24$F$20180214$20221124$20180319$20221129$EXP$$ES-SA-2018SA074269$SANOFI AVENTIS$$55$YR$A$F$Y$90$KG$20221129$$MD$ES$ES
1465589911$14655899$11$F$20180309$20221019$20180319$20221021$EXP$$CA-TAKEDA-2018TUS006269$TAKEDA$$58$YR$$F$Y$$$20221021$$CN$CA$CA
146559149$14655914$9$F$$20220927$20180319$20221007$EXP$$CA-GLENMARK PHARMACEUTICALS-2018GMK033302$GLENMARK$$$$$$Y$$$20221007$$MD$CA$CA
146564446$14656444$6$F$$20221116$20180319$20221118$PER$$US-PFIZER INC-2018110171$PFIZER$$60$YR$$F$Y$$$20221118$$MD$US$US
1465657118$14656571$18$F$20171101$20221026$20180319$20221102$EXP$$CA-PFIZER INC-2017485911$PFIZER$$40$YR$$F$Y$$$20221102$$CN$CA$CA
146577282$14657728$2$F$20171005$20180312$20180320$20221012$EXP$$IE-UCBSA-2018002057$UCB$$18$YR$$M$Y$82$KG$20221012$$CN$IE$IE
1465787612$14657876$12$F$$20221103$20180320$20221110$PER$$US-BIOGEN-2017BI00450377$BIOGEN$$$$$M$Y$$$20221110$$CN$US$US
146583623$14658362$3$F$20110707$20220926$20180320$20221004$EXP$$US-AstraZeneca-2018SE33170$ASTRAZENECA$$20924$DY$$F$Y$101.6$KG$20221004$$LW$US$
146584445$14658444$5$F$20170101$20221026$20180320$20221101$EXP$$US-PFIZER INC-2017417872$PFIZER$$59$YR$$F$Y$$$20221101$$HP$US$US
1465877230$14658772$30$F$20180206$20221115$20180320$20221122$EXP$$DE-ROCHE-2071555$ROCHE$$48$YR$$F$Y$$$20221122$$CN$DE$DE
146595773$14659577$3$F$$20220117$20180320$20221012$PER$$US-CELLTRION INC.-2017US017303$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
146595896$14659589$6$F$20170101$20220527$20180320$20221012$PER$$US-CELLTRION INC.-2017US015903$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
146595955$14659595$5$F$$20221031$20180320$20221102$PER$$US-PFIZER INC-2018110140$PFIZER$$61$YR$$F$Y$$$20221102$$HP$US$US
1465980053$14659800$53$F$20180213$20221108$20180320$20221110$EXP$$US-SA-2018SA074660$SANOFI AVENTIS$$34$YR$A$F$Y$77.1$KG$20221110$$HP$US$US
146598098$14659809$8$F$20170805$20221130$20180320$20221208$EXP$$IT-AstraZeneca-2018SE31874$ASTRAZENECA$$51$YR$$F$Y$$$20221208$$MD$IT$
146603096$14660309$6$F$20100101$20221101$20180320$20221104$EXP$$US-PFIZER INC-2018115504$PFIZER$$62$YR$$F$Y$$$20221104$$LW$US$US
146617433$14661743$3$F$$20221027$20180320$20221104$EXP$$CA-ALLERGAN-1814960US$ALLERGAN$Dong V, Dieleman LA. Medication Induced Interstitial Lung Disease In A Patient With Ulcerative Colitis. Journal of the Canadian Association of Gastroenterology. 2018;1(Supplement 1):260-1$$$$M$Y$$$20221104$$MD$CA$CA
146638993$14663899$3$F$$20201207$20180321$20221012$PER$$US-CELLTRION INC.-2018US017294$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
1466414729$14664147$29$F$20160826$20221117$20180321$20221124$EXP$$PHHY2014CA043342$NOVARTIS$$81$YR$$M$Y$$$20221124$$HP$CA$CA
1466415317$14664153$17$F$20170118$20221205$20180321$20221213$EXP$$GB-ALLERGAN-1814947US$ALLERGAN$$$$$F$Y$60.1$KG$20221213$$MD$GB$GB
146646512$14664651$2$F$20180311$20221115$20180321$20221122$PER$$US-TAKEDA-2018TUS006371$TAKEDA$$51$YR$$F$Y$57.596$KG$20221122$$MD$US$US
146654735$14665473$5$F$20110101$20221017$20180321$20221025$EXP$$US-AstraZeneca-2018SE33806$ASTRAZENECA$$44$YR$$M$Y$95.3$KG$20221025$$LW$US$
146654763$14665476$3$F$20080609$20221212$20180321$20221214$EXP$$US-AstraZeneca-2018SE33057$ASTRAZENECA$$19154$DY$$F$Y$$$20221214$$LW$US$
146658302$14665830$2$F$20171110$20221202$20180321$20221215$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-107439$BRISTOL MYERS SQUIBB$$75$YR$E$M$Y$56.599$KG$20221215$$HP$JP$JP
1466702544$14667025$44$F$20180207$20221221$20180322$20221228$EXP$GB-MHRA-EYC 00174086$GB-CIPLA LTD.-2018GB11986$CIPLA$$86$YR$$F$Y$$$20221228$$MD$GB$GB
1466743018$14667430$18$F$20180215$20221206$20180322$20221212$EXP$$DE-ROCHE-2079206$ROCHE$$44$YR$$F$Y$60$KG$20221212$$CN$DE$
146677683$14667768$3$F$20180320$20221109$20180322$20221111$PER$$US-PFIZER INC-2018118570$PFIZER$$65$YR$$F$Y$$$20221111$$HP$US$US
146692157$14669215$7$F$20180101$20221212$20180322$20221218$EXP$$BR-JNJFOC-20180322106$JOHNSON AND JOHNSON$$7$DEC$E$F$Y$62$KG$20221218$$CN$BR$BR
146693054$14669305$4$F$20160111$20220930$20180322$20221003$EXP$$US-PFIZER INC-2018119380$PFIZER$$65$YR$$F$Y$57$KG$20221003$$CN$US$US
146700207$14670020$7$F$20180313$20221209$20180322$20221214$EXP$$US-PFIZER INC-2018118195$PFIZER$$66$YR$$F$Y$69$KG$20221214$$CN$US$US
146708268$14670826$8$F$$20221129$20180322$20221202$PER$$US-PFIZER INC-2018000286$PFIZER$$73$YR$$F$Y$61$KG$20221202$$CN$US$US
146714733$14671473$3$F$20100101$20221020$20180323$20221021$EXP$$US-TAKEDA-2018TUS007090$TAKEDA$$$$$$Y$$$20221021$$CN$US$US
146718593$14671859$3$F$$20221111$20180323$20221114$PER$$US-BIOGEN-2015BI007341$BIOGEN$$$$$F$Y$$$20221114$$CN$US$US
146720594$14672059$4$F$20151201$20220928$20180323$20221001$EXP$$US-TAKEDA-2018TUS007221$TAKEDA$$$$$$Y$$$20221001$$CN$US$US
146721233$14672123$3$F$20140101$20221017$20180323$20221026$EXP$$US-AstraZeneca-2018SE34926$ASTRAZENECA$$58$YR$$F$Y$97.5$KG$20221026$$LW$US$
146721534$14672153$4$F$20121220$20220926$20180323$20221004$EXP$$US-AstraZeneca-2018SE34851$ASTRAZENECA$$21090$DY$$M$Y$72.6$KG$20221004$$LW$US$
146724927$14672492$7$F$$20221117$20180323$20221122$EXP$$US-PFIZER INC-2017469736$PFIZER$$72$YR$$M$Y$$$20221122$$CN$US$US
146726184$14672618$4$F$$20221004$20180323$20221006$PER$$US-PFIZER INC-2018120075$PFIZER$$93$YR$$F$Y$$$20221006$$MD$US$US
1467338534$14673385$34$F$20180207$20221208$20180323$20221222$EXP$$GB-AUROBINDO-AUR-APL-2018-015492$AUROBINDO$$86$YR$$F$Y$$$20221222$$MD$GB$GB
1467551846$14675518$46$F$20180101$20221103$20180323$20221110$EXP$$CA-CELLTRION INC.-2018CA018113$CELLTRION$$$$$$Y$$$20221111$$CN$CA$CA
146769662$14676966$2$F$$20221003$20180324$20221013$PER$$US-JNJFOC-20180316125$JOHNSON AND JOHNSON$$$$$M$Y$$$20221013$$LW$US$US
1467877011$14678770$11$F$$20221221$20180326$20221231$EXP$GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-002909$GB-Accord-064906$ACCORD$$53$YR$A$F$Y$$$20221231$$CN$GB$GB
146788193$14678819$3$F$20140101$20221018$20180326$20221020$EXP$$US-TAKEDA-2018TUS007420$TAKEDA$$$$$$Y$$$20221020$$CN$US$US
146790255$14679025$5$F$20180213$20221220$20180326$20221227$EXP$$PHHY2018IN047426$NOVARTIS$$44$YR$$M$Y$$$20221227$$CN$IN$IN
146792662$14679266$2$F$$20221207$20180326$20221209$PER$$US-PFIZER INC-2018122075$PFIZER$$48$YR$$M$Y$149$KG$20221209$$CN$US$US
146799433$14679943$3$F$20150401$20221010$20180326$20221012$EXP$$US-TAKEDA-2018TUS007394$TAKEDA$$$$$$Y$$$20221012$$CN$US$US
1468024220$14680242$20$F$20171019$20221202$20180326$20221212$EXP$$CA-CELLTRION INC.-2017CA014822$CELLTRION$$$$$$Y$$$20221212$$CN$CA$CA
146808194$14680819$4$F$20090101$20221014$20180326$20221020$EXP$$US-TAKEDA-2018TUS007510$TAKEDA$$$$$$Y$$$20221020$$LW$US$US
1468085339$14680853$39$F$20170801$20221017$20180326$20221025$EXP$$CA-CELLTRION INC.-2017CA011649$CELLTRION$$$$$$Y$$$20221025$$CN$CA$CA
146817186$14681718$6$F$20150401$20221017$20180326$20221020$EXP$$US-PFIZER INC-2018119488$PFIZER$$58$YR$$F$Y$$$20221020$$LW$US$US
1468211619$14682116$19$F$20180311$20221008$20180326$20221014$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-026633$BRISTOL MYERS SQUIBB$$48$YR$A$F$Y$61.4$KG$20221014$$MD$US$US
1468348311$14683483$11$F$20190201$20221110$20180327$20221114$EXP$$US-PFIZER INC-2018125954$PFIZER$$79$YR$$F$Y$79$KG$20221114$$HP$US$US
146834849$14683484$9$F$20171001$20221202$20180327$20221207$PER$$US-PFIZER INC-2018126678$PFIZER$$74$YR$$F$Y$52$KG$20221207$$CN$US$US
146837388$14683738$8$F$20171220$20221129$20180327$20221206$EXP$$PHHY2017CA194354$NOVARTIS$$80$YR$$M$Y$80.9$KG$20221206$$MD$CA$CA
146837567$14683756$7$F$20180514$20221201$20180327$20221208$EXP$$US-AstraZeneca-2018SE34908$ASTRAZENECA$$21622$DY$$M$Y$70.3$KG$20221208$$LW$US$
146844382$14684438$2$F$20171201$20221129$20180327$20221201$EXP$$TW-ROCHE-2096205$ROCHE$$71$YR$$F$Y$$$20221201$$HP$TW$
146851023$14685102$3$F$20140101$20221024$20180327$20221026$EXP$$US-PFIZER INC-2018125360$PFIZER$$58$YR$$F$Y$$$20221026$$CN$US$US
1468565517$14685655$17$F$20180201$20221226$20180327$20221227$EXP$$CA-PFIZER INC-2018115963$PFIZER$$63$YR$$F$Y$$$20221227$$HP$CA$CA
146860959$14686095$9$F$20180201$20221121$20180327$20221122$EXP$$US-PFIZER INC-2018122149$PFIZER$$73$YR$$M$Y$68$KG$20221122$$CN$US$US
146863606$14686360$6$F$20180323$20221110$20180327$20221116$EXP$$US-SHIRE-US201811764$TAKEDA$$58$YR$$F$Y$$$20221116$$MD$US$US
146887584$14688758$4$F$20120501$20221005$20180328$20221006$PER$$US-PFIZER INC-2016584473$PFIZER$$66$YR$$F$Y$$$20221006$$LW$US$US
146888024$14688802$4$F$20160101$20221121$20180328$20221128$EXP$$PHHY2017MX130132$NOVARTIS$$$$$F$Y$57$KG$20221128$$CN$MX$MX
146890348$14689034$8$F$20120524$20221021$20180328$20221102$EXP$$DE-AUROBINDO-AUR-APL-2018-016889$AUROBINDO$$31$YR$$M$Y$76$KG$20221102$$MD$DE$DE
146903616$14690361$6$F$$20221212$20180328$20221214$EXP$$PHHY2018NL045905$NOVARTIS$Witjes B, Zandvliet, Dijkstra, Kors A, Abbink F, Smetsers S et al.. Voriconazole dosing strategies in young children: Challenges and recommendations. ARCHIVES OF DISEASE IN CHILDHOOD. 2017;102 (10)$13$MON$$M$Y$$$20221214$$HP$NL$NL
146904222$14690422$2$F$20170519$20221108$20180328$20221116$EXP$SE-MPA-2017-004231$SE-MYLANLABS-2018M1018160$MYLAN$$70$YR$$F$Y$$$20221116$$MD$SE$SE
146914435$14691443$5$F$20120901$20221110$20180328$20221116$EXP$$US-AstraZeneca-2018SE36309$ASTRAZENECA$$803$MON$$F$Y$123.8$KG$20221116$$LW$US$
146938756$14693875$6$F$20120824$20221004$20180329$20221010$EXP$$US-GLAXOSMITHKLINE-US2018GSK053222$PERRIGO$$60$YR$$M$Y$126.5$KG$20221010$$LW$US$US
146940007$14694000$7$F$$20221206$20180329$20221212$EXP$$US-PFIZER INC-2017467525$PFIZER$$56$YR$$F$Y$$$20221212$$CN$US$US
1469461332$14694613$32$F$20180502$20221031$20180329$20221108$EXP$$CA-CELLTRION INC.-2018CA018914$CELLTRION$$$$$$Y$$$20221108$$CN$CA$CA
146958313$14695831$3$F$$20221219$20180329$20221222$EXP$$US-JAZZ-2018-US-004885$JAZZ$$$$$M$Y$$$20221222$$CN$US$US
146959128$14695912$8$F$20160101$20221026$20180329$20221101$EXP$$CA-TAKEDA-2016TUS018823$TAKEDA$$41$YR$$M$Y$$$20221101$$CN$CA$CA
1469894933$14698949$33$F$20180226$20221228$20180330$20221230$EXP$$DE-ROCHE-2096691$ROCHE$$50$YR$$M$Y$70.9$KG$20221230$$CN$DE$
146993985$14699398$5$F$20160119$20180727$20180330$20221026$EXP$$JP-TEVA-698911ISR$TEVA$$36$YR$A$F$Y$72$KG$20221026$$HP$JP$JP
147002354$14700235$4$F$$20180405$20180330$20221208$EXP$$NL-TEVA-2018-NL-874522$TEVA$$13$MON$I$M$Y$$$20221208$$HP$NL$NL
147039046$14703904$6$F$20170801$20221011$20180402$20221027$PER$$US-PFIZER INC-2018132425$MYLAN$$43$YR$$F$Y$91$KG$20221027$$CN$US$US
147045617$14704561$7$F$$20221031$20180402$20221103$PER$$US-PFIZER INC-2018130721$PFIZER$$74$YR$$F$Y$$$20221103$$CN$US$US
147046203$14704620$3$F$20170706$20180405$20180402$20221020$PER$$NZ-AMGEN-NZLCT2018041493$AMGEN$$24$YR$A$F$Y$$$20221020$$MD$NZ$NZ
147056505$14705650$5$F$20100101$20221006$20180402$20221011$EXP$$US-AstraZeneca-2018SE39740$ASTRAZENECA$$54$YR$$M$Y$117.9$KG$20221011$$LW$US$
147063373$14706337$3$F$20171010$20221214$20180402$20221219$EXP$FR-AFSSAPS-NY20172034$FR-MYLANLABS-2018M1019287$MYLAN$$87$YR$$M$Y$86.3$KG$20221219$$MD$FR$FR
147070552$14707055$2$F$20180101$20221226$20180403$20221228$EXP$FR-AFSSAPS-AN20180318$FR-ABBVIE-18K-056-2306416-00$ABBVIE$$47$YR$$F$Y$57$KG$20221228$$MD$FR$FR
1470742620$14707426$20$F$20180315$20221207$20180403$20221215$EXP$$DE-ROCHE-2098104$ROCHE$$36$YR$$F$Y$$$20221214$$CN$DE$DE
1470787236$14707872$36$F$20190507$20221219$20180403$20221228$EXP$$US-PFIZER INC-2017231089$PFIZER$$63$YR$$F$Y$$$20221228$$CN$US$US
147080046$14708004$6$F$$20221118$20180403$20221123$PER$$US-PFIZER INC-2018132354$PFIZER$$72$YR$$F$Y$$$20221123$$MD$US$US
1470818614$14708186$14$F$20150101$20221031$20180403$20221109$EXP$$PHHY2010CA31063$NOVARTIS$$$$$M$Y$$$20221109$$HP$CA$CA
147084896$14708489$6$F$$20221003$20180403$20221101$EXP$$US-AstraZeneca-2018SE38937$ASTRAZENECA$$$$$M$Y$126.6$KG$20221101$$LW$US$
147089115$14708911$5$F$20171101$20221114$20180403$20221121$EXP$$CA-PFIZER INC-2017524306$PFIZER$$69$YR$$M$Y$76$KG$20221121$$CN$CA$CA
147093236$14709323$6$F$20161130$20221102$20180403$20221110$EXP$$US-AstraZeneca-2018SE39001$ASTRAZENECA$$69$YR$$F$Y$88.9$KG$20221110$$LW$US$
147112587$14711258$7$F$20160101$20221212$20180403$20221219$EXP$$US-PFIZER INC-2018133558$PFIZER$$67$YR$$F$Y$$$20221219$$LW$US$US
147113659$14711365$9$F$20120824$20221011$20180403$20221014$EXP$$US-PFIZER INC-2018133339$PFIZER$$60$YR$$M$Y$$$20221014$$LW$US$US
147130267$14713026$7$F$20161001$20221213$20180404$20221219$EXP$$US-PFIZER INC-2016472583$PFIZER$$79$YR$$M$Y$102$KG$20221219$$CN$US$US
147146003$14714600$3$F$$20221219$20180404$20221229$PER$$US-PFIZER INC-2018135475$PFIZER$$71$YR$$F$Y$65.32$KG$20221229$$CN$US$US
147153172$14715317$2$F$20171119$20221128$20180404$20221208$EXP$FI-FIMEA-20180202$FI-TEVA-2018-FI-876080$TEVA$$71$YR$E$M$Y$$$20221208$$MD$FI$FI
147168512$14716851$2$F$20171001$20221020$20180404$20221022$EXP$$US-SHIRE-US201812210$TAKEDA$$68$YR$$M$Y$$$20221022$$CN$US$US
1471939927$14719399$27$F$20180310$20221123$20180405$20221201$EXP$$DE-ROCHE-2090784$ROCHE$$31$YR$$F$Y$$$20221201$$CN$DE$DE
1471942226$14719422$26$F$20180315$20221223$20180405$20221228$EXP$$DE-ROCHE-2102569$ROCHE$$43$YR$$F$Y$$$20221228$$CN$DE$
147195674$14719567$4$F$$20221110$20180405$20221114$PER$$US-PFIZER INC-2018137781$PFIZER$$75$YR$$F$Y$$$20221114$$HP$US$US
147206243$14720624$3$F$20100101$20221007$20180405$20221011$EXP$$US-TAKEDA-2018TUS008481$TAKEDA$$$$$$Y$$$20221011$$CN$US$US
147236092$14723609$2$F$20151110$20221129$20180405$20221206$EXP$DE-002147023-PHHY2016DE115328$DE-MYLANLABS-2018M1020362$MYLAN$$34$MON$$M$Y$12.2$KG$20221206$$MD$DE$DE
147258334$14725833$4$F$20150701$20221121$20180406$20221125$EXP$$US-TAKEDA-2018TUS008474$TAKEDA$$$$$$Y$$$20221125$$CN$US$US
147258584$14725858$4$F$20150101$20221031$20180406$20221103$EXP$$US-TAKEDA-2018TUS008701$TAKEDA$$$$$$Y$$$20221103$$LW$US$US
147267578$14726757$8$F$20180224$20221010$20180406$20221013$EXP$$PHHY2018DE058976$NOVARTIS$$51$YR$$F$Y$99$KG$20221013$$MD$DE$DE
147301539$14730153$9$F$20100302$20221212$20180406$20221219$EXP$$US-PFIZER INC-2018141165$PFIZER$$47$YR$$M$Y$120$KG$20221219$$LW$US$US
147327977$14732797$7$F$$20221219$20180409$20221227$PER$$US-PFIZER INC-2018140873$PFIZER$$47$YR$$F$Y$$$20221227$$CN$US$US
1473499943$14734999$43$F$20170101$20221206$20180409$20221215$EXP$$CA-CELLTRION INC.-2017CA015610$CELLTRION$$$$$$Y$$$20221215$$MD$CA$CA
147353285$14735328$5$F$20170927$20221107$20180409$20221114$EXP$$JP-BIOGEN-2018BI00551915$BIOGEN$$41$YR$$M$Y$66.3$KG$20221114$$MD$JP$JP
147356519$14735651$9$F$20100101$20221024$20180409$20221026$EXP$$US-PFIZER INC-2018143264$PFIZER$$63$YR$$F$Y$$$20221026$$LW$US$US
147382312$14738231$2$F$20171201$20221006$20180409$20221014$EXP$$US-VERTEX PHARMACEUTICALS-2018-001400$VERTEX$$6$YR$$F$Y$20$KG$20221014$$MD$US$US
147386595$14738659$5$F$20100302$20221208$20180409$20221214$EXP$$US-TAKEDA-2018TUS008946$TAKEDA$$$$$$Y$$$20221214$$CN$US$US
147398037$14739803$7$F$20180227$20221011$20180410$20221014$EXP$$US-PFIZER INC-2018141014$PFIZER$$76$YR$$M$Y$79$KG$20221014$$CN$US$US
147399226$14739922$6$F$$20221213$20180410$20221215$PER$$US-PFIZER INC-2018145712$PFIZER$$72$YR$$F$Y$$$20221215$$CN$US$US
147403192$14740319$2$F$20180328$20221116$20180410$20221117$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-029927$BRISTOL MYERS SQUIBB$$46$YR$A$F$Y$44.9$KG$20221117$$HP$US$US
147403799$14740379$9$F$20180101$20221213$20180410$20221220$EXP$$US-JAZZ-2018-US-004137$JAZZ$$$$$F$Y$67$KG$20221220$$MD$US$US
147404217$14740421$7$F$20180207$20220923$20180410$20221003$EXP$GB-EMA-DD-20180307-PAGRAHARIP-153318$GB-MICRO LABS LIMITED-BB2018-00489$MICRO LABS$$86$YR$E$F$Y$$$20221003$$HP$GB$GB
147416013$14741601$3$F$20180101$20221025$20180410$20221031$EXP$$US-PFIZER INC-2018142318$PFIZER$$63$YR$$F$Y$65.77$KG$20221031$$HP$US$US
147422425$14742242$5$F$20180328$20221018$20180410$20221025$EXP$$PHHY2018CA057860$NOVARTIS$$61$YR$$F$Y$$$20221025$$CN$CA$CA
147426399$14742639$9$F$$20221128$20180410$20221201$PER$$US-BIOGEN-2017BI00486736$BIOGEN$$$$$M$Y$$$20221201$$CN$US$US
147449343$14744934$3$F$$20221222$20180411$20221227$PER$$US-PFIZER INC-2018144085$PFIZER$$64$YR$$F$Y$$$20221227$$MD$US$US
147451385$14745138$5$F$20170705$20221006$20180411$20221014$EXP$$US-ROCHE-1985433$ROCHE$$72$YR$$F$Y$53.6$KG$20221014$$MD$US$
147460163$14746016$3$F$20180101$20221013$20180411$20221019$EXP$$US-ROCHE-2102985$ROCHE$$$$$F$Y$81.72$KG$20221019$$MD$US$
1474607210$14746072$10$F$$20221025$20180411$20221102$EXP$$CA-APOTEX-2018AP009435$APOTEX$$67$YR$$F$Y$$$20221102$$MD$CA$CA
147461889$14746188$9$F$20170923$20221012$20180411$20221014$EXP$$CA-PFIZER INC-2017214689$PFIZER$$67$YR$$M$Y$51$KG$20221014$$CN$CA$CA
147468314$14746831$4$F$$20221125$20180411$20221128$EXP$$CA-ROCHE-2104630$ROCHE$$60$YR$$F$Y$$$20221128$$CN$CA$
147478293$14747829$3$F$20180402$20221114$20180411$20221116$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-031242$BRISTOL MYERS SQUIBB$$52$YR$A$F$Y$$$20221116$$HP$US$US
1475032111$14750321$11$F$20171011$20221125$20180412$20221202$EXP$$CA-ROCHE-2105460$ROCHE$$36$YR$$F$Y$$$20221202$$CN$CA$
147504985$14750498$5$F$20030101$20220927$20180412$20221003$EXP$$BR-BIOGEN-2018BI00553837$BIOGEN$$$$$F$Y$52$KG$20221003$$CN$BR$BR
147510469$14751046$9$F$20170814$20190913$20180412$20221026$EXP$$JP-TEVA-808807ROM$TEVA$$49$YR$A$F$Y$56$KG$20221026$$HP$JP$JP
147515017$14751501$7$F$20170301$20221212$20180412$20221216$EXP$$US-PFIZER INC-2018147654$PFIZER$$67$YR$$F$Y$$$20221216$$LW$US$US
147515806$14751580$6$F$20170101$20221207$20180412$20221220$EXP$$US-GLAXOSMITHKLINE-US2018GSK061921$PERRIGO$$$$$$Y$$$20221220$$CN$US$US
147517775$14751777$5$F$20180115$20221209$20180412$20221215$EXP$$US-JAZZ-2018-US-005826$JAZZ$$50$YR$$F$Y$$$20221215$$MD$US$US
147520544$14752054$4$F$$20221115$20180412$20221116$EXP$$US-PFIZER INC-2018148411$PFIZER$$75$YR$$F$Y$60$KG$20221116$$CN$US$US
1475224219$14752242$19$F$20171220$20220923$20180412$20221006$EXP$$CA-CELLTRION INC.-2017CA017658$CELLTRION$$$$$$Y$$$20221007$$CN$CA$CA
1475229533$14752295$33$F$20170801$20221024$20180412$20221102$EXP$$CA-CELLTRION INC.-2017CA011395$CELLTRION$$$$$$Y$$$20221102$$HP$CA$CA
1475330719$14753307$19$F$20180301$20221121$20180412$20221125$EXP$$PHHY2018CA051472$NOVARTIS$$40$YR$$M$Y$$$20221125$$MD$CA$CA
147539476$14753947$6$F$20170301$20221207$20180412$20221212$EXP$$US-TAKEDA-2018TUS009521$TAKEDA$$$$$$Y$$$20221212$$CN$US$US
147549552$14754955$2$F$20160101$20221028$20180413$20221101$PER$$US-BIOGEN-2018BI00553540$BIOGEN$$$$$F$Y$$$20221101$$CN$US$US
147558407$14755840$7$F$20200201$20221115$20180413$20221116$PER$$US-PFIZER INC-2018150352$PFIZER$$64$YR$$F$Y$48$KG$20221116$$CN$US$US
1475829428$14758294$28$F$20180403$20221216$20180413$20221226$EXP$$CA-CELLTRION INC.-2018CA018698$CELLTRION$$$$$$Y$$$20221226$$CN$CA$CA
1475829631$14758296$31$F$20180101$20221028$20180413$20221108$EXP$$CA-CELLTRION INC.-2018CA019155$CELLTRION$$$$$$Y$$$20221108$$MD$CA$CA
147590154$14759015$4$F$$20221228$20180413$20221230$EXP$$US-JAZZ-2018-US-005943$JAZZ$$$$$M$Y$$$20221230$$CN$US$US
1475947412$14759474$12$F$20180601$20221121$20180413$20221125$EXP$$PHHY2018CA062608$NOVARTIS$$51$YR$$M$Y$$$20221125$$CN$CA$CA
1475956825$14759568$25$F$20181001$20221125$20180413$20221202$EXP$$PHHY2018CA061569$NOVARTIS$$59$YR$$F$Y$$$20221202$$CN$CA$CA
147606027$14760602$7$F$20080101$20220926$20180414$20221004$EXP$$US-AstraZeneca-2018SE44497$ASTRAZENECA$$61$YR$$F$Y$65.8$KG$20221004$$LW$US$
147607443$14760744$3$F$20110101$20221205$20180414$20221210$EXP$$US-TAKEDA-2018TUS009924$TAKEDA$$$$$$Y$$$20221210$$CN$US$US
147627226$14762722$6$F$$20221029$20180416$20221102$EXP$$US-PFIZER INC-2018151193$PFIZER$$74$YR$$F$Y$54$KG$20221102$$CN$US$US
147627484$14762748$4$F$$20221116$20180416$20221121$PER$$US-PFIZER INC-2018153177$PFIZER$$67$YR$$F$Y$$$20221121$$CN$US$US
147634692$14763469$2$F$$20221003$20180416$20221005$PER$$US-PFIZER INC-2018153268$PFIZER$$62$YR$$F$Y$$$20221005$$MD$US$US
147638494$14763849$4$F$$20180604$20180416$20221128$EXP$$CH-ROCHE-2105374$ROCHE$$$$$M$Y$106$KG$20221128$$HP$CH$
1476556335$14765563$35$F$20180207$20221006$20180416$20221011$EXP$GB-MHRA-EYC 00174086$GB-MYLANLABS-2018M1023120$MYLAN$$86$YR$$F$Y$$$20221011$$HP$GB$GB
147656923$14765692$3$F$20161201$20221115$20180416$20221121$EXP$$PL-MYLANLABS-2018M1023163$MYLAN$Magdalena Blonska, Katarzyna Josko, Krystyna Koczynska-Nowacka.. Hypersensitivity to non-steroidal anti-inflammatory drugs in children.. Klinika Pediatryczna.. 25 (4):452-6$4$YR$$M$Y$$$20221121$$HP$PL$PL
147661554$14766155$4$F$20180410$20221202$20180416$20221212$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-034514$BRISTOL MYERS SQUIBB$$78$YR$E$M$Y$41$KG$20221212$$HP$JP$JP
147663819$14766381$9$F$20150215$20221214$20180416$20221221$EXP$$US-INCYTE CORPORATION-2018IN003333$INCYTE$$$$$$Y$$$20221221$$CN$US$US
147668965$14766896$5$F$20180404$20221202$20180417$20221212$EXP$$CO-ROCHE-2107157$ROCHE$$43$YR$$F$Y$69$KG$20221212$$CN$CO$CO
147671418$14767141$8$F$20130101$20221025$20180417$20221027$EXP$BE-EMA-20170220-ISHAEVHP-102440898$BE-ROCHE-2108277$ROCHE$Heyrman B, De Becker A, Schots R. A case report of immunosuppressiohn-related Kaposi^s sarcoma after autologous stem cell transplantation. BMC Research Notes 2016;9:188:1-5.$61$YR$$M$Y$$$20221027$$MD$BE$BE
147679254$14767925$4$F$20110101$20221122$20180417$20221128$EXP$$US-AstraZeneca-2018SE45642$ASTRAZENECA$$81$YR$$M$Y$98.9$KG$20221128$$LW$US$
147687325$14768732$5$F$$20221031$20180417$20221114$EXP$$FR-Ascend Therapeutics-2045859$ASCEND$EMA Ref: 04P-056-0765047-00$29$YR$$F$Y$55$KG$20221114$$HP$FR$FR
1476874782$14768747$82$F$20120101$20221215$20180417$20221220$EXP$$CA-ROCHE-1173899$ROCHE$$$$$F$Y$96$KG$20221220$$CN$CA$
1476955526$14769555$26$F$20171103$20221215$20180417$20221223$EXP$$CA-CELLTRION INC.-2017CA016332$CELLTRION$$$$$$Y$$$20221223$$CN$CA$CA
147697632$14769763$2$F$$20221020$20180417$20221107$EXP$$US-GLAXOSMITHKLINE-US2018GSK065932$GLAXOSMITHKLINE$$$$$$Y$$$20221107$$LW$US$US
147698463$14769846$3$F$$20221012$20180417$20221014$PER$$US-PFIZER INC-2018156925$PFIZER$$67$YR$$F$Y$$$20221014$$CN$US$US
147755165$14775516$5$F$20090604$20221003$20180418$20221007$EXP$$US-AstraZeneca-2018SE46622$ASTRAZENECA$$22511$DY$$M$Y$115.7$KG$20221007$$LW$US$
147755814$14775581$4$F$$20221202$20180418$20221207$EXP$$GR-ROCHE-2106711$ROCHE$Kiapidou S, Sinakos E. Xytiroglou P, Koustiani G, Kaprinis A, Akriviadis E. Exposure to chemotherapeutic agents: an emerging cause of non-cirrhotic portal hypertension.. Annals of Gastroenterology 2017;30:28:-.$49$YR$$M$Y$$$20221207$$MD$GR$GR
147756865$14775686$5$F$20220708$20221012$20180418$20221017$EXP$$US-AstraZeneca-2018SE46465$ASTRAZENECA$$30456$DY$$M$Y$72.6$KG$20221017$$LW$US$
1477692027$14776920$27$F$20140101$20221212$20180419$20221214$EXP$$CA-ROCHE-1412884$ROCHE$$$$$F$Y$$$20221214$$HP$CA$
147788633$14778863$3$F$20150701$20221013$20180419$20221017$EXP$$US-TAKEDA-2018TUS010079$TAKEDA$$$$$$Y$$$20221017$$CN$US$US
147792493$14779249$3$F$$20221013$20180419$20221025$30DAY$$US-APOTEX-2018AP010877$APOTEX$Kaplan FS, Andolina JR, Adamson PC, Teachey DT, Finklestein JZ, Ebb DH, Whitehead B, Jacobs B, Siegel DM, Keen R, Hsiao E, Pignolo RJ. Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.. Bone. 2018;109:276-280$2$YR$$F$Y$$$20221025$$HP$US$US
1477976725$14779767$25$F$20180701$20221228$20180419$20221229$EXP$$US-PFIZER INC-2018159616$PFIZER$$60$YR$$M$Y$76.19$KG$20221229$$HP$US$US
147815129$14781512$9$F$20170126$20221118$20180419$20221125$EXP$$CA-ROCHE-2107638$ROCHE$$34$YR$$F$Y$105$KG$20221125$$MD$CA$CA
147821649$14782164$9$F$20180405$20221209$20180420$20221216$EXP$$JP-ABBVIE-18P-087-2329407-00$ABBVIE$$57$YR$$M$Y$$$20221214$$MD$JP$JP
1478259315$14782593$15$F$20180401$20221110$20180420$20221117$EXP$$CA-ROCHE-2105464$ROCHE$$37$YR$$F$Y$$$20221117$$MD$CA$
147832673$14783267$3$F$20180326$20221115$20180420$20221129$EXP$$IT-AUROBINDO-AUR-APL-2018-020496$AUROBINDO$$37$YR$$F$Y$$$20221129$$MD$IT$IT
1478395117$14783951$17$F$20180101$20221027$20180420$20221031$EXP$$BR-GLAXOSMITHKLINE-BR2017GSK146398$GLAXOSMITHKLINE$$$$$$Y$$$20221031$$MD$BR$BR
147845448$14784544$8$F$20160101$20220930$20180420$20221004$EXP$$US-PFIZER INC-2018163175$PFIZER$$70$YR$$F$Y$64$KG$20221004$$LW$US$US
147852625$14785262$5$F$20100202$20221205$20180421$20221213$EXP$$US-AstraZeneca-2018SE48196$ASTRAZENECA$$24781$DY$$M$Y$91.2$KG$20221213$$LW$US$
147857694$14785769$4$F$20140101$20220930$20180420$20221004$PER$$US-PFIZER INC-2016584490$PFIZER$$58$YR$$F$Y$$$20221004$$LW$US$US
1478676715$14786767$15$F$20180101$20221024$20180420$20221028$EXP$$US-Vifor (International) Inc.-VIT-2018-03607$VIFOR$$71$YR$$M$Y$$$20221028$$HP$US$US
1478740313$14787403$13$F$20180222$20221121$20180421$20221124$EXP$$CA-TAKEDA-2018TUS010395$TAKEDA$$64$YR$$F$Y$$$20221124$$MD$CA$CA
147874974$14787497$4$F$20150501$20221123$20180421$20221208$EXP$$PL-AUROBINDO-AUR-APL-2018-020879$AUROBINDO$Krzysztofiak T, Majewski W.. The influence of hyperbaric pressure on the recurring pain from trigeminal nuralgia after stereotactic radiotherapy.. Pain. 2017;18(2):41-43$39$YR$$$Y$$$20221208$$HP$PL$PL
1478915814$14789158$14$F$20140101$20221215$20180423$20221221$EXP$$PHHY2014CA158244$NOVARTIS$$$$$M$Y$$$20221221$$HP$CA$CA
147892233$14789223$3$F$$20221014$20180423$20221017$EXP$$DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-034911$BRISTOL MYERS SQUIBB$$71$YR$E$M$Y$90$KG$20221017$$MD$DE$DE
147898695$14789869$5$F$$20221216$20180423$20221221$PER$$US-PFIZER INC-2018164942$PFIZER$$86$YR$$F$Y$$$20221221$$MD$US$US
1479403623$14794036$23$F$20180104$20221215$20180423$20221224$EXP$$CA-CELLTRION INC.-2018CA017365$CELLTRION$$$$$$Y$$$20221224$$CN$CA$CA
1479406819$14794068$19$F$20170201$20221212$20180423$20221220$EXP$$CA-CELLTRION INC.-2017CA001878$CELLTRION$$$$$$Y$$$20221220$$MD$CA$CA
147949128$14794912$8$F$20180109$20221115$20180423$20221121$EXP$$DE-SHIRE-DE201801410$TAKEDA$$67$YR$$F$Y$87$KG$20221121$$CN$DE$DE
147950716$14795071$6$F$20060101$20221221$20180423$20221229$EXP$$US-AstraZeneca-2018SE47825$ASTRAZENECA$$52$YR$$M$Y$138.1$KG$20221229$$LW$US$
147980414$14798041$4$F$20130213$20221102$20180424$20221104$EXP$$DE-ROCHE-2112597$ROCHE$$65$YR$$F$Y$80$KG$20221104$$MD$DE$DE
147984066$14798406$6$F$20180101$20221219$20180424$20221227$PER$$US-PFIZER INC-2018165959$PFIZER$$57$YR$$F$Y$68$KG$20221227$$CN$US$US
1480116318$14801163$18$F$20180118$20221202$20180424$20221212$EXP$$CA-CELLTRION INC.-2018CA017682$CELLTRION$$$$$$Y$$$20221212$$CN$CA$CA
148022372$14802237$2$F$$20220516$20180424$20221026$PER$$US-PURDUE-USA-2018-0142636$PURDUE$$$$$F$Y$$$20221027$$CN$US$US
148023193$14802319$3$F$20160611$20221010$20180424$20221011$EXP$$US-NAPPMUNDI-USA-2018-0142890$PURDUE$$24$YR$$M$Y$67.347$KG$20221011$$MD$US$US
148023758$14802375$8$F$20140101$20220915$20180424$20221026$PER$$US-PURDUE PHARMA-USA-2018-0142318$PURDUE$$$$$F$Y$$$20221027$$CN$US$US
148033604$14803360$4$F$$20221019$20180425$20221028$EXP$$PL-JNJFOC-20180414534$JOHNSON AND JOHNSON$Majewski  W, Krzysztofiak T. The influence of hyperbaric pressure on the recurring pain from trigeminal nuralgia after stereotactic radiotherapy. 2017;18 (2):41-43.$39$YR$A$$Y$$$20221028$$HP$PL$PL
148040083$14804008$3$F$20220401$20221013$20180425$20221014$EXP$$US-PFIZER INC-2018167507$PFIZER$$73$YR$$F$Y$41$KG$20221014$$CN$US$US
148041965$14804196$5$F$20180302$20220615$20180425$20221017$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-022003$BRISTOL MYERS SQUIBB$$72$YR$E$F$Y$46$KG$20221017$$MD$JP$JP
1480560925$14805609$25$F$20180101$20221003$20180425$20221005$PER$$US-PFIZER INC-2018168305$PFIZER$$70$YR$$M$Y$91$KG$20221005$$CN$US$US
1480897629$14808976$29$F$20180207$20221024$20180425$20221029$EXP$PHHY2018GB072295$PHHY2018GB072295$NOVARTIS$$86$YR$$F$Y$$$20221029$$HP$GB$GB
148090446$14809044$6$F$$20221202$20180425$20221206$PER$$US-BIOGEN-2018BI00559213$BIOGEN$$$$$F$Y$$$20221206$$CN$US$US
1481568817$14815688$17$F$$20221130$20180426$20221208$PER$$US-PFIZER INC-2016305051$PFIZER$$51$YR$$F$Y$78$KG$20221208$$CN$US$US
148186983$14818698$3$F$20180101$20221101$20180427$20221103$PER$$US-PFIZER INC-2018170159$PFIZER$$66$YR$$F$Y$$$20221103$$MD$US$US
1481955911$14819559$11$F$20180411$20221129$20180427$20221207$EXP$$JP-ABBVIE-18P-087-2337762-00$ABBVIE$$64$YR$$M$Y$$$20221207$$MD$JP$JP
1482068723$14820687$23$F$20161215$20221212$20180427$20221221$EXP$$CA-CELLTRION INC.-2017CA002961$CELLTRION$$$$$$Y$$$20221221$$MD$CA$CA
1482077038$14820770$38$F$20180101$20221128$20180427$20221206$EXP$$CA-CELLTRION INC.-2018CA019461$CELLTRION$$$$$$Y$$$20221207$$MD$CA$CA
148220379$14822037$9$F$20180201$20220930$20180427$20221012$EXP$$GB-AUROBINDO-AUR-APL-2018-017843$AUROBINDO$$72$YR$$M$Y$93.2$KG$20221012$$MD$GB$GB
148243663$14824366$3$F$20040304$20221012$20180429$20221021$PER$$US-JNJFOC-20180424137$JOHNSON AND JOHNSON$$6$YR$C$M$Y$$$20221021$$LW$US$US
148245712$14824571$2$F$$20221107$20180429$20221110$PER$$US-JNJFOC-20170417235$JOHNSON AND JOHNSON$$$$$M$Y$$$20221110$$LW$US$US
148258612$14825861$2$F$$20221108$20180430$20221110$PER$$US-PFIZER INC-2017478113$PFIZER$$62$YR$$M$Y$$$20221110$$CN$US$US
148264124$14826412$4$F$$20221212$20180430$20221215$EXP$$PHHY2018SE068670$NOVARTIS$Lindeman E, Erikson LB, Thorsson M, Nordmark J. High-dose insulin euglycemia therapy in severe toxic myocardial depression- An important addition to the treatment arsenal. LAKARTIDNINGEN (SWEDISH JOURNAL OF MEDICINE). 2018;114:1-5$55$YR$$F$Y$$$20221215$$HP$SE$SE
148265472$14826547$2$F$20171226$20180426$20180430$20221107$EXP$$PHHY2018RO074896$NOVARTIS$$75$YR$$M$Y$$$20221107$$CN$RO$RO
1482824819$14828248$19$F$20200914$20221122$20180430$20221201$EXP$$CA-CELLTRION INC.-2018CA017679$CELLTRION$$$$$$Y$$$20221201$$CN$CA$CA
148289102$14828910$2$F$20180206$20221205$20180430$20221206$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-011948$BRISTOL MYERS SQUIBB$$$$E$M$Y$$$20221206$$HP$US$US
148326076$14832607$6$F$$20221205$20180501$20221213$EXP$$US-GLAXOSMITHKLINE-US2018GSK068188$PERRIGO$$$$$$Y$$$20221213$$MD$US$US
148327083$14832708$3$F$20151001$20221017$20180501$20221018$PER$$US-BIOGEN-2015BI147861$BIOGEN$$52$YR$$F$Y$$$20221018$$CN$US$US
1483342316$14833423$16$F$$20221011$20180501$20221012$EXP$$PHHY2018PL068707$NOVARTIS$Wikiera-Magott I, Fornaiczyk K, Zwolinska D. From body piercing to acute kidney injury - A case report. PEDIATRIA I MEDYCYNA RODZINNA. 2017;13(4):561-6$17$YR$$F$Y$$$20221012$$HP$PL$PL
148358865$14835886$5$F$20171001$20221019$20180502$20221025$PER$$US-AMGEN-USASP2018056480$AMGEN$$66$YR$E$F$Y$$$20221025$$HP$US$US
148360893$14836089$3$F$20170101$20221215$20180502$20221227$PER$$US-PFIZER INC-2018172672$PFIZER$$41$YR$$F$Y$$$20221227$$PH$US$US
1483792933$14837929$33$F$20180101$20221221$20180502$20221229$EXP$$CA-CELLTRION INC.-2018CA019487$CELLTRION$$$$$$Y$$$20221230$$CN$CA$CA
1483815348$14838153$48$F$20151231$20221216$20180502$20221222$EXP$$CA-ROCHE-1696490$ROCHE$$31$YR$$F$Y$178$KG$20221222$$HP$CA$
148382472$14838247$2$F$$20221220$20180502$20221226$EXP$$CA-GLAXOSMITHKLINE-CA2018GSK069739$GLAXOSMITHKLINE$$$$$$Y$$$20221226$$HP$CA$CA
148382627$14838262$7$F$$20221031$20180502$20221111$EXP$$US-GLAXOSMITHKLINE-US2018GSK076610$PERRIGO$$$$$$Y$$$20221111$$CN$US$US
148420947$14842094$7$F$20170101$20221208$20180503$20221214$EXP$$US-JAZZ-2018-US-007141$JAZZ$$$$$F$Y$$$20221214$$MD$US$US
148427008$14842700$8$F$20180101$20221116$20180503$20221125$EXP$$CA-CELLTRION INC.-2018CA019332$CELLTRION$$$$$$Y$$$20221125$$CN$CA$CA
148427934$14842793$4$F$$20221114$20180503$20221116$EXP$$PHHY2017BE198732$NOVARTIS$Smets GJ, Loyson T, Van Paesschen W, Demaerel P, Nackaerts K. Posterior reversible encephalopathy syndrome possibly induced by pemetrexed maintenance therapy for lung cancer: a case report and literature review. ACTA CLINICA BELGICA: INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY MEDICINE. 2017;1-7$59$YR$$F$Y$$$20221116$$HP$BE$BE
148447057$14844705$7$F$$20221213$20180504$20221220$PER$$US-AMGEN-USASP2018059597$AMGEN$$68$YR$E$F$Y$$$20221220$$MD$US$US
148454675$14845467$5$F$20121107$20221103$20180504$20221104$PER$$US-PFIZER INC-2018180547$PFIZER$$41$YR$$F$Y$$$20221104$$LW$US$US
1484937112$14849371$12$F$20180423$20220929$20180504$20221004$EXP$$PHHY2018MX077074$NOVARTIS$$59$YR$$M$Y$$$20221004$$CN$MX$MX
1484952211$14849522$11$F$20170101$20221012$20180504$20221019$EXP$$PHHY2017CA065627$NOVARTIS$$68$YR$$F$Y$$$20221019$$CN$CA$CA
148522562$14852256$2$F$$20221005$20180507$20221006$PER$$US-PFIZER INC-2018097533$PFIZER$$$$A$F$Y$$$20221006$$LW$US$US
148522836$14852283$6$F$$20221108$20180507$20221111$PER$$US-PFIZER INC-2018179634$PFIZER$$64$YR$$F$Y$$$20221111$$MD$US$US
148523423$14852342$3$F$20180401$20221128$20180507$20221129$EXP$$US-PFIZER INC-2018184529$PFIZER$$67$YR$$F$Y$82.55$KG$20221129$$CN$US$US
148528964$14852896$4$F$20140110$20221024$20180507$20221025$PER$$US-PFIZER INC-2017541311$PFIZER$$65$YR$$F$Y$$$20221025$$LW$US$US
148533089$14853308$9$F$20170914$20221212$20180507$20221221$EXP$$CA-009507513-1805CAN000113$MERCK$$85$YR$$F$Y$70$KG$20221221$$MD$CA$CA
1485343239$14853432$39$F$20170123$20221125$20180507$20221205$EXP$$CA-CELLTRION INC.-2017CA000945$CELLTRION$$$$$$Y$$$20221205$$MD$CA$CA
148582053$14858205$3$F$20220927$20221017$20180508$20221027$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-008767$ACADIA PHARMACEUTICALS$$73$YR$$F$Y$$$20221027$$HP$US$US
148589375$14858937$5$F$20140601$20190416$20180508$20221209$EXP$$US-TEVA-2017-US-831445$TEVA$$58$YR$A$F$Y$$$20221209$$LW$US$US
148598039$14859803$9$F$20180401$20221205$20180508$20221205$30DAY$$US-PFIZER INC-2018167245$PFIZER$$24$YR$$F$Y$$$20221205$$CN$US$US
148686606$14868660$6$F$20130823$20221012$20180509$20221013$PER$$US-PFIZER INC-2018034522$PFIZER$$54$YR$$F$Y$$$20221013$$LW$US$US
1486874711$14868747$11$F$20180901$20221004$20180509$20221006$PER$$US-PFIZER INC-2018186931$PFIZER$$70$YR$$F$Y$64$KG$20221006$$MD$US$US
148688242$14868824$2$F$$20221101$20180509$20221103$PER$$US-PFIZER INC-2018186878$PFIZER$$71$YR$$F$Y$$$20221103$$HP$US$US
148711315$14871131$5$F$$20221024$20180509$20221031$EXP$$PHHY2018BE001497$NOVARTIS$$58$YR$$F$Y$$$20221031$$HP$BE$BE
148737788$14873778$8$F$20180401$20221227$20180510$20221229$EXP$$US-JAZZ-2018-US-007429$JAZZ$$44$YR$$F$Y$103.22$KG$20221229$$MD$US$US
1487390210$14873902$10$F$20000101$20221031$20180510$20221103$EXP$$US-BIOGEN-2014BI054571$BIOGEN$$$$$F$Y$$$20221103$$CN$US$US
148742825$14874282$5$F$20180212$20221004$20180510$20221011$EXP$$GR-SA-2018SA129442$SANOFI AVENTIS$$50$YR$A$F$Y$70$KG$20221011$$MD$GR$GR
148761873$14876187$3$F$$20200128$20180510$20221012$PER$$US-CELLTRION INC.-2018US017828$CELLTRION$$$$$$Y$$$20221012$$CN$US$US
148765713$14876571$3$F$$20210311$20180510$20221012$PER$$US-CELLTRION INC.-2018US018001$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
1487927478$14879274$78$F$20171223$20221220$20180511$20221222$EXP$$CA-ROCHE-2020907$ROCHE$$27$YR$$F$Y$76$KG$20221222$$HP$CA$
148794454$14879445$4$F$$20221129$20180511$20221202$PER$$US-PFIZER INC-2017121102$PFIZER$$71$YR$$F$Y$$$20221202$$CN$US$US
148804014$14880401$4$F$20180401$20221025$20180511$20221101$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2018-BI-025298$BOEHRINGER INGELHEIM$$59$YR$A$F$Y$$$20221101$$HP$CA$CA
1488255040$14882550$40$F$20171127$20221122$20180511$20221201$EXP$$CA-CELLTRION INC.-2017CA017395$CELLTRION$$$$$$Y$$$20221201$$CN$CA$CA
148841355$14884135$5$F$20171101$20221123$20180511$20221128$EXP$$DE-SHIRE-DE201816337$TAKEDA$$53$YR$$F$Y$73$KG$20221128$$HP$DE$DE
148842195$14884219$5$F$20010101$20180628$20180511$20221210$EXP$$US-TEVA-2018-US-890269$TEVA$$43$YR$A$F$Y$43$KG$20221210$$CN$US$US
148842948$14884294$8$F$20180318$20221116$20180511$20221118$EXP$$PHHY2018IN006847$NOVARTIS$$69$YR$$M$Y$$$20221118$$CN$IN$IN
148848092$14884809$2$F$$20221020$20180511$20221107$EXP$$US-GLAXOSMITHKLINE-US2018GSK084062$GLAXOSMITHKLINE$$$$$F$Y$$$20221107$$LW$US$US
148850003$14885000$3$F$20160901$20221024$20180511$20221027$EXP$$GB-SA-2018SA125832$SANOFI AVENTIS$$50$YR$A$F$Y$$$20221027$$MD$GB$GB
148865573$14886557$3$F$20180503$20221014$20180512$20221019$EXP$$PHHY2018CA004937$NOVARTIS$$36$YR$$M$Y$$$20221019$$MD$CA$CA
148902219$14890221$9$F$$20221117$20180514$20221121$PER$$US-PFIZER INC-2018192307$PFIZER$$67$YR$$F$Y$$$20221121$$MD$US$US
148902988$14890298$8$F$$20221213$20180514$20221219$EXP$$US-PFIZER INC-2018193315$PFIZER$$63$YR$$F$Y$82$KG$20221219$$CN$US$US
148921699$14892169$9$F$$20221212$20180514$20221219$PER$$US-PFIZER INC-2018193304$PFIZER$$67$YR$$F$Y$$$20221219$$CN$US$US
148930392$14893039$2$F$$20171116$20180514$20221130$EXP$$US-SA-2017SA228971$SANOFI AVENTIS$$43$YR$A$F$Y$$$20221130$$MD$US$US
148931114$14893111$4$F$20161216$20221121$20180514$20221212$PER$$US-BIOGEN-2016BI00332996$BIOGEN$$27$YR$$F$Y$$$20221212$$CN$US$US
148944153$14894415$3$F$20091008$20221111$20180515$20221118$EXP$$US-AstraZeneca-2018SE63055$ASTRAZENECA$$16882$DY$$F$Y$173.3$KG$20221118$$LW$US$
148948827$14894882$7$F$20100101$20221031$20180515$20221109$PER$$US-AMGEN-USASP2018064228$AMGEN$$$$A$F$Y$47.17$KG$20221109$$MD$US$US
1489602817$14896028$17$F$20171121$20221209$20180515$20221212$EXP$$PHHY2017CA174164$NOVARTIS$$71$YR$$M$Y$$$20221212$$CN$CA$CA
148961404$14896140$4$F$20180424$20221020$20180515$20221109$EXP$$HU-TAKEDA-2018MPI005201$TAKEDA$$84$YR$$M$Y$58$KG$20221109$$MD$HU$HU
148962503$14896250$3$F$$20210104$20180515$20221012$PER$$US-CELLTRION INC.-2018US019383$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
148962543$14896254$3$F$$20191118$20180515$20221012$PER$$US-CELLTRION INC.-2018US019223$CELLTRION$$$$$$Y$$$20221012$$HP$US$US
148962674$14896267$4$F$$20200109$20180515$20221012$PER$$US-CELLTRION INC.-2018US019373$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
148963614$14896361$4$F$20190615$20191018$20180515$20221012$PER$$US-CELLTRION INC.-2018US019258$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
148965213$14896521$3$F$$20210208$20180515$20221012$PER$$US-CELLTRION INC.-2018US018857$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
148973253$14897325$3$F$$20200309$20180515$20221012$PER$$US-CELLTRION INC.-2018US017861$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
148973413$14897341$3$F$$20201209$20180515$20221012$PER$$US-CELLTRION INC.-2018US018265$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
1489955513$14899555$13$F$20130905$20221129$20180516$20221202$EXP$$CA-ROCHE-1275094$ROCHE$$60$YR$$F$Y$53.5$KG$20221202$$HP$CA$
1490046523$14900465$23$F$20180813$20221017$20180516$20221022$EXP$$PHHY2018CA004361$NOVARTIS$$57$YR$$M$Y$$$20221022$$MD$CA$CA
149005419$14900541$9$F$20171214$20221121$20180516$20221124$PER$$US-PFIZER INC-2017406967$PFIZER$$10$YR$$M$Y$28.12$KG$20221124$$MD$US$US
149005876$14900587$6$F$20180501$20221212$20180516$20221215$PER$$US-PFIZER INC-2018196856$PFIZER$$68$YR$$F$Y$78.47$KG$20221215$$CN$US$US
149009797$14900979$7$F$20180306$20220926$20180516$20221004$EXP$$JP-GLAXOSMITHKLINE-JP2018JPN082879$GLAXOSMITHKLINE$$$$$$Y$$$20221004$$MD$JP$JP
1490181428$14901814$28$F$20180101$20221104$20180516$20221119$EXP$$CA-CELLTRION INC.-2018CA018622$CELLTRION$$$$$$Y$$$20221119$$CN$CA$CA
1490182340$14901823$40$F$20180326$20221121$20180516$20221129$EXP$$CA-CELLTRION INC.-2018CA019531$CELLTRION$$$$$$Y$$$20221129$$MD$CA$CA
149022797$14902279$7$F$$20221208$20180516$20221216$EXP$$US-SHIRE-US201818256$TAKEDA$$$$$M$Y$63.492$KG$20221216$$MD$US$US
149023133$14902313$3$F$20160413$20221129$20180516$20221205$EXP$$US-SHIRE-US201818012$TAKEDA$$62$YR$$F$Y$80.7$KG$20221205$$HP$US$US
149023193$14902319$3$F$20170613$20221129$20180516$20221207$EXP$$US-SHIRE-US201818450$TAKEDA$$63$YR$$F$Y$80.7$KG$20221207$$HP$US$US
149081902$14908190$2$F$20180101$20221103$20180517$20221109$PER$$US-VERTEX PHARMACEUTICALS-2018-003296$VERTEX$$$$$F$Y$$$20221109$$PH$US$US
149082462$14908246$2$F$20150101$20220929$20180517$20221006$EXP$$IE-ASTELLAS-2018US023224$ASTELLAS$O^Connor C, Farrellb C, Fabrec A, Eatond D, Redmondd K, McSharryb DG, et al. Near-fatal mucormycosis post-double lung transplant presenting as uncontrolled upper gastrointestinal haemorrhage. Medical Mycology Case Reports. 2018;21:30-33$46$YR$$F$Y$$$20221006$$HP$IE$IE
149087714$14908771$4$F$$20221107$20180517$20221109$PER$$US-PFIZER INC-2018201224$PFIZER$$64$YR$$F$Y$$$20221109$$HP$US$US
1491079720$14910797$20$F$20170101$20221206$20180517$20221208$EXP$$CA-TAKEDA-2017TUS020905$TAKEDA$$60$YR$$M$Y$$$20221208$$HP$CA$CA
149121535$14912153$5$F$20150101$20221012$20180518$20221014$PER$$US-PFIZER INC-2018202898$PFIZER$$57$YR$$F$Y$$$20221014$$CN$US$US
1491256424$14912564$24$F$20180425$20220926$20180518$20221003$EXP$$DE-ROCHE-2121572$ROCHE$$40$YR$$F$Y$100$KG$20221003$$CN$DE$DE
149128103$14912810$3$F$$20221011$20180518$20221016$EXP$$US-GLAXOSMITHKLINE-US2018GSK087784$PERRIGO$$$$$$Y$$$20221016$$CN$US$US
149144459$14914445$9$F$20050101$20221202$20180518$20221208$PER$$US-JAZZ-2013-US-001238$JAZZ$$$$$F$Y$50$KG$20221208$$HP$US$US
1491450021$14914500$21$F$20170801$20221227$20180518$20221228$EXP$$US-JAZZ-2018-US-002729$JAZZ$$15$YR$$M$Y$$$20221228$$CN$US$US
149146322$14914632$2$F$$20220901$20180518$20221026$PER$$US-JAZZ-2018-US-006138$JAZZ$$$$$F$Y$94.331$KG$20221026$$CN$US$US
149156644$14915664$4$F$20180507$20220930$20180518$20221005$EXP$$US-SHIRE-US201818633$TAKEDA$$25$YR$$F$Y$70.295$KG$20221005$$HP$US$US
149164738$14916473$8$F$$20221109$20180519$20221123$EXP$$IT-AUROBINDO-AUR-APL-2018-025571$AUROBINDO$Carnovale C, Raschi E, Leonardi L, Moretti U, De Ponti F, Gentili M, et al.. No signal of interactions between influenza vaccines and drugs used for chronic diseases, a case-bycase analysis of the vaccine adverse event reporting system and vigibase. Expert Review Of Vaccines. 2018;17:4:1-19$64$YR$$M$Y$$$20221123$$HP$IT$IT
149186987$14918698$7$F$$20221027$20180521$20221102$EXP$$US-PFIZER INC-2018204418$PFIZER$$64$YR$$M$Y$$$20221102$$MD$US$US
1491885826$14918858$26$F$20170810$20220928$20180521$20221008$EXP$$CA-CELLTRION INC.-2017CA011198$CELLTRION$$$$$$Y$$$20221008$$CN$CA$CA
149192184$14919218$4$F$20180301$20221024$20180521$20221030$EXP$$AU-JNJFOC-20180513143$JOHNSON AND JOHNSON$$42$YR$A$F$Y$$$20221030$$CN$AU$AU
1492008315$14920083$15$F$$20221207$20180521$20221214$EXP$$CA-OTSUKA-2018_011946$OTSUKA$$48$YR$$F$Y$$$20221214$$HP$CA$CA
149203222$14920322$2$F$20100729$20221128$20180521$20221206$EXP$$US-AstraZeneca-2018SE63954$ASTRAZENECA$$17285$DY$$F$Y$74.8$KG$20221206$$LW$US$
149224488$14922448$8$F$$20221208$20180522$20221216$EXP$$US-PFIZER INC-2018207454$PFIZER$$57$YR$$F$Y$91$KG$20221216$$CN$US$US
149234234$14923423$4$F$20130426$20221005$20180522$20221006$PER$$US-PFIZER INC-2016584464$PFIZER$$60$YR$$F$Y$$$20221006$$LW$US$US
149238322$14923832$2$F$20160901$20221015$20180522$20221017$PER$$US-PFIZER INC-2018001469$PFIZER$$48$YR$$F$Y$$$20221017$$LW$US$US
1492395328$14923953$28$F$$20221213$20180522$20221221$EXP$$GB-drreddys-GER/UKI/18/0098799$DR REDDYS$$22$YR$A$F$Y$56$KG$20221221$$MD$GB$GB
149250054$14925005$4$F$20150101$20221028$20180522$20221102$EXP$$US-AstraZeneca-2018SE65775$ASTRAZENECA$$69$YR$$M$Y$124.3$KG$20221102$$LW$US$
149252084$14925208$4$F$20080101$20201207$20180522$20221004$EXP$$US-AstraZeneca-2018SE65521$ASTRAZENECA$$57$YR$$F$Y$$$20221004$$LW$US$
1492544510$14925445$10$F$20180301$20221011$20180522$20221013$EXP$$PHHY2018CA061495$NOVARTIS$$73$YR$$M$Y$$$20221013$$CN$CA$CA
1492678319$14926783$19$F$20180423$20220929$20180523$20221006$EXP$$US-TESARO, INC.-US-2018TSO02208$GLAXOSMITHKLINE$$$$$$Y$$$20221006$$CN$US$US
149271899$14927189$9$F$$20221011$20180523$20221017$EXP$$PHHY2018CA065899$NOVARTIS$$$$$M$Y$$$20221017$$CN$CA$CA
149273938$14927393$8$F$$20221024$20180523$20221027$PER$$US-PFIZER INC-2018209185$PFIZER$$70$YR$$F$Y$$$20221027$$CN$US$US
1492761211$14927612$11$F$20180122$20221122$20180523$20221124$EXP$$US-ROCHE-2126670$ROCHE$$62$YR$$M$Y$103$KG$20221124$$MD$US$
149276858$14927685$8$F$20180101$20221215$20180523$20221216$PER$$US-PFIZER INC-2018208270$PFIZER$$65$YR$$F$Y$$$20221216$$CN$US$US
149277947$14927794$7$F$20180130$20221031$20180523$20221104$EXP$$DE-MYLANLABS-2018M1032349$MYLAN$$$$E$F$Y$79.2$KG$20221104$$MD$DE$DE
149290394$14929039$4$F$20110501$20221003$20180523$20221005$PER$$US-PFIZER INC-2016584471$PFIZER$$39$YR$$F$Y$107$KG$20221005$$LW$US$US
149297962$14929796$2$F$20220501$20221216$20180523$20221223$EXP$$PHHY2018GT017941$NOVARTIS$$89$YR$$F$Y$61.678$KG$20221223$$CN$GT$GT
1492987210$14929872$10$F$20120707$20221130$20180523$20221205$EXP$$US-AstraZeneca-2018SE64044$ASTRAZENECA$$18815$DY$$F$Y$104.3$KG$20221205$$LW$US$
149300627$14930062$7$F$20150101$20221107$20180523$20221111$EXP$$US-TAKEDA-2018TUS017717$TAKEDA$$$$$$Y$$$20221111$$CN$US$US
149302466$14930246$6$F$$20221107$20180523$20221109$PER$$US-PFIZER INC-2018036116$PFIZER$$68$YR$$F$Y$77$KG$20221109$$CN$US$US
149314759$14931475$9$F$$20221121$20180524$20221128$EXP$$CA-APOTEX-2018AP013687$APOTEX$$40$YR$$F$Y$$$20221128$$MD$CA$CA
1493172911$14931729$11$F$20180801$20221219$20180524$20221228$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-007701$ACADIA PHARMACEUTICALS$$73$YR$$M$Y$73$KG$20221229$$CN$US$US
1493174911$14931749$11$F$20180101$20221115$20180524$20221124$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-007333$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221125$$CN$US$US
149318276$14931827$6$F$20190521$20220929$20180524$20221006$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-007437$ACADIA PHARMACEUTICALS$$83$YR$$M$Y$$$20221007$$CN$US$US
149319525$14931952$5$F$20170101$20221013$20180524$20221020$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-007341$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221021$$CN$US$US
149322688$14932268$8$F$20190101$20221020$20180524$20221028$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-008044$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221028$$CN$US$US
149327074$14932707$4$F$20180612$20221110$20180524$20221114$PER$$US-BIOGEN-2018BI00580899$BIOGEN$$42$YR$$F$Y$$$20221114$$CN$US$US
1493506011$14935060$11$F$20170616$20221122$20180524$20221125$EXP$$CA-TAKEDA-2018TUS017743$TAKEDA$$70$YR$$M$Y$$$20221125$$MD$CA$CA
149376847$14937684$7$F$20170818$20221213$20180525$20221219$EXP$$PHHY2017IN166288$NOVARTIS$$65$YR$$F$Y$$$20221219$$CN$IN$IN
149388543$14938854$3$F$20180423$20221031$20180525$20221103$EXP$$US-PFIZER INC-2018213690$PFIZER$$66$YR$$M$Y$90.703$KG$20221103$$HP$US$US
149390962$14939096$2$F$20180301$20221013$20180525$20221017$PER$$US-PFIZER INC-2018213612$PFIZER$$53$YR$$F$Y$$$20221017$$PH$US$US
1493925627$14939256$27$F$20180101$20221107$20180525$20221116$EXP$$CA-CELLTRION INC.-2018CA018642$CELLTRION$$$$$$Y$$$20221116$$CN$CA$CA
149398485$14939848$5$F$$20221026$20180525$20221101$EXP$$US-PFIZER INC-2017324951$PFIZER$$63$YR$$F$Y$$$20221101$$CN$US$US
149404832$14940483$2$F$20171001$20221207$20180525$20221221$EXP$$US-COOPERSURGICAL, INC.-US-2018CPS000068$COOPERSURGICAL$$$$$$Y$$$20221221$$CN$US$US
149418017$14941801$7$F$20170701$20190916$20180527$20221216$EXP$$PHHY2018BE002725$NOVARTIS$$$$$F$Y$$$20221216$$HP$BE$BE
149433622$14943362$2$F$20171122$20221031$20180528$20221111$EXP$FR-EMA-DD-20180515-ISHAEVHP-120655$FR-NOVOPROD-601560$NOVO NORDISK$$29$YR$$F$Y$55$KG$20221111$$MD$FR$FR
1494356925$14943569$25$F$20160501$20220923$20180528$20221003$EXP$$PHHY2016CA078852$NOVARTIS$$47$YR$$F$Y$$$20221003$$CN$CA$CA
149467993$14946799$3$F$20180305$20221103$20180529$20221107$EXP$$GB-ABBVIE-18P-167-2363613-00$ABBVIE$$15$YR$$M$Y$$$20221107$$MD$GB$GB
149473077$14947307$7$F$20150101$20221107$20180529$20221114$EXP$$US-PFIZER INC-2018213868$PFIZER$$69$YR$$M$Y$$$20221114$$CN$US$US
149490415$14949041$5$F$20180101$20221123$20180529$20221128$EXP$$US-PFIZER INC-2018214552$PFIZER$$55$YR$$F$Y$59$KG$20221128$$CN$US$US
149497038$14949703$8$F$20211001$20221222$20180529$20221230$PER$$US-AMGEN-USASP2018071982$AMGEN$$65$YR$E$F$Y$$$20221230$$MD$US$US
1495053412$14950534$12$F$$20221215$20180530$20221221$EXP$$CA-ROCHE-2129535$ROCHE$$$$$M$Y$91.708$KG$20221222$$CN$CA$
149513976$14951397$6$F$20180522$20221103$20180530$20221104$EXP$$PHHO2018IT006651$NOVARTIS$$68$YR$$F$Y$60$KG$20221104$$MD$IT$IT
1495157820$14951578$20$F$20181101$20221220$20180530$20221226$EXP$$CA-ROCHE-2130987$ROCHE$$50$YR$$M$Y$$$20221226$$CN$CA$
1495214414$14952144$14$F$20150502$20221124$20180530$20221129$EXP$$GB-PFIZER INC-2018212467$PFIZER$$43$YR$$F$Y$80.6$KG$20221129$$MD$GB$GB
149523173$14952317$3$F$20180522$20221111$20180530$20221115$PER$$US-PFIZER INC-2018215062$PFIZER$$69$YR$$M$Y$68$KG$20221115$$CN$US$US
149530074$14953007$4$F$$20221206$20180530$20221213$EXP$$US-IMPAX LABORATORIES, INC-2018-IPXL-01795$AMNEAL$$$$$F$Y$$$20221213$$CN$US$US
1495313010$14953130$10$F$20180205$20221004$20180530$20221011$EXP$$GB-BAYER-2018-025888$BAYER$$67$YR$E$M$Y$102.3$KG$20221011$$MD$GB$GB
1495353138$14953531$38$F$20190107$20221024$20180530$20221101$EXP$$CA-CELLTRION INC.-2017CA007602$CELLTRION$$$$$$Y$$$20221101$$CN$CA$CA
149544065$14954406$5$F$20160110$20221123$20180530$20221124$EXP$$PHHY2016DE186820$NOVARTIS$$51$YR$$F$Y$50$KG$20221124$$MD$DE$DE
1495600613$14956006$13$F$$20220404$20180531$20221111$EXP$$CA-SAMSUNG BIOEPIS-SB-2017-04909$SAMSUNG BIOEPIS$$3$YR$C$F$Y$64$KG$20221111$$MD$CA$CA
1495698112$14956981$12$F$20201215$20221216$20180531$20221222$EXP$$US-ROCHE-2095323$ROCHE$$65$YR$$M$Y$$$20221222$$HP$US$
149582912$14958291$2$F$$20221018$20180531$20221026$EXP$$CA-JNJFOC-20180533337$JOHNSON AND JOHNSON$$$$$$Y$$$20221026$$HP$CA$CA
149599885$14959988$5$F$20180424$20221107$20180531$20221115$EXP$$AU-EXELIXIS-CABO-18014266$EXELIXIS$$25$YR$$M$Y$60$KG$20221115$$MD$AU$AU
149612676$14961267$6$F$$20221014$20180601$20221020$EXP$$CA-ROCHE-2130873$ROCHE$Thavendiranathan P, Amir E. Left Ventricular Dysfunction With Trastuzumab Therapy: Is Primary Prevention the Best Option?. DOI: 10.1200/JCO.2016.71.0038. Journal of clinical oncology 2016 Dec 27;35 (8):820-25.$51$YR$$F$Y$$$20221020$$HP$CA$
1496192610$14961926$10$F$20180405$20221205$20180601$20221212$EXP$$DE-ROCHE-2105217$ROCHE$$32$YR$$F$Y$95$KG$20221212$$CN$DE$
149626316$14962631$6$F$$20221128$20180601$20221130$PER$$US-PFIZER INC-2018222989$PFIZER$$70$YR$$F$Y$$$20221130$$MD$US$US
149633208$14963320$8$F$20150101$20221124$20180601$20221128$EXP$$GB-PFIZER INC-2018216266$PFIZER$$47$YR$$F$Y$$$20221128$$MD$GB$GB
1496336426$14963364$26$F$20151203$20221226$20180601$20221229$EXP$$GB-PFIZER INC-2018216449$PFIZER$$67$YR$$F$Y$$$20221229$$MD$GB$GB
149648369$14964836$9$F$20180501$20221025$20180601$20221029$EXP$$PHHY2018CA012257$NOVARTIS$$64$YR$$M$Y$$$20221029$$CN$CA$CA
149675185$14967518$5$F$20180104$20221005$20180604$20221014$EXP$$US-ROCHE-2130820$ROCHE$$61$YR$$M$Y$70.37$KG$20221014$$CN$US$
1496782118$14967821$18$F$20180524$20221122$20180604$20221123$EXP$$US-PFIZER INC-2018222867$PFIZER$$63$YR$$F$Y$136$KG$20221123$$CN$US$US
1496811913$14968119$13$F$20160803$20221007$20180604$20221018$EXP$GB-MHRA-ADR 23595830$GB-Accord-043422$ACCORD$$69$YR$E$F$Y$101$KG$20221018$$PH$GB$GB
149698836$14969883$6$F$20170101$20221214$20180604$20221216$EXP$$CA-TAKEDA-2018TUS018546$TAKEDA$$53$YR$$F$Y$$$20221216$$CN$CA$CA
149709674$14970967$4$F$20120516$20221005$20180604$20221006$PER$$US-PFIZER INC-2016584467$PFIZER$$49$YR$$F$Y$$$20221006$$LW$US$US
149711333$14971133$3$F$20100101$20221026$20180604$20221101$EXP$$US-PFIZER INC-2018227285$PFIZER$$$$$F$Y$$$20221101$$CN$US$US
1497205910$14972059$10$F$20180519$20221017$20180605$20221021$EXP$$CA-ROCHE-2130711$ROCHE$$43$YR$$M$Y$$$20221021$$MD$CA$CA
149737605$14973760$5$F$20170106$20221124$20180605$20221201$EXP$$PHHY2017CA027615$NOVARTIS$$60$YR$$M$Y$$$20221201$$CN$CA$CA
1497752522$14977525$22$F$20171214$20221003$20180606$20221012$EXP$$GB-LUPIN (EUROPE) LIMITED-2018-04121$LUPIN$$$$N$$Y$$$20221012$$MD$GB$GB
149776684$14977668$4$F$20180101$20221010$20180606$20221020$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009036$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221020$$CN$US$US
149797302$14979730$2$F$20130101$20221005$20180606$20221006$PER$$US-PFIZER INC-2017023774$PFIZER$$55$YR$$F$Y$60$KG$20221006$$LW$US$US
1497978410$14979784$10$F$$20221130$20180606$20221202$EXP$$US-PFIZER INC-2018231542$PFIZER$$61$YR$$F$Y$$$20221202$$CN$US$US
149803917$14980391$7$F$20180101$20221028$20180606$20221103$EXP$$CA-TAKEDA-2018TUS003471$TAKEDA$$69$YR$$M$Y$$$20221103$$CN$CA$CA
149807943$14980794$3$F$$20221026$20180606$20221101$EXP$$US-SHIRE-US201819075$TAKEDA$$$$$M$Y$$$20221101$$MD$US$US
149809282$14980928$2$F$20170914$20221116$20180606$20221122$EXP$$PHHY2018GB013581$NOVARTIS$$77$YR$$F$Y$96$KG$20221122$$HP$GB$GB
149811852$14981185$2$F$20180101$20190807$20180606$20221219$PER$$US-Taiho Oncology Inc-EU-2018-00741$TAIHO ONCOLOGY INC$$48$YR$$M$Y$116.8$KG$20221219$$HP$US$US
149824564$14982456$4$F$20110423$20221005$20180607$20221006$PER$$US-PFIZER INC-2016435719$PFIZER$$47$YR$$F$Y$$$20221006$$LW$US$US
1498260513$14982605$13$F$20170101$20221006$20180607$20221010$EXP$$PHHY2017CA188494$NOVARTIS$$$$$F$Y$$$20221010$$CN$CA$CA
149826484$14982648$4$F$$20181004$20180607$20221108$EXP$$PHHY2018JP012332$NOVARTIS$Kuki I, Kawawaki H, Okazaki S, Ehara E, Yoshida Y, Kunihiro N et al.. Efficacy and safety of everolimus in patients younger than 12months with congenital subependymal giant cell astrocytoma. BRAIN AND DEVELOPMENT. 2018;40:415-20$$$$M$Y$$$20221108$$HP$JP$JP
149848854$14984885$4$F$20170909$20221201$20180607$20221206$EXP$$CA-DSJP-DSU-2018-122062$DAIICHI$$58$YR$$F$Y$$$20221206$$CN$CA$CA
149858625$14985862$5$F$20160101$20221115$20180607$20221119$EXP$$PHHY2016CA012996$NOVARTIS$$34$YR$$M$Y$$$20221119$$CN$CA$CA
1498790217$14987902$17$F$$20221031$20180608$20221104$EXP$$GB-MYLANLABS-2018M1033762$MYLAN$$22$YR$$F$Y$56$KG$20221104$$MD$GB$GB
149881182$14988118$2$F$20110201$20221005$20180608$20221006$PER$$US-PFIZER INC-2016596191$PFIZER$$61$YR$$F$Y$$$20221006$$LW$US$US
149881934$14988193$4$F$20180606$20221122$20180608$20221124$EXP$$US-PFIZER INC-2018233757$PFIZER$$41$YR$$F$Y$$$20221124$$HP$US$US
149882072$14988207$2$F$20130401$20221003$20180608$20221004$PER$$US-PFIZER INC-2017053693$PFIZER$$60$YR$$F$Y$$$20221004$$LW$US$US
1498979522$14989795$22$F$20180605$20221014$20180608$20221024$EXP$$CA-CELLTRION INC.-2018CA019070$CELLTRION$$$$$$Y$$$20221024$$CN$CA$CA
149931012$14993101$2$F$$20221020$20180610$20221102$PER$$US-JNJFOC-20170319653$JOHNSON AND JOHNSON$$$$$M$Y$$$20221102$$HP$US$US
149951155$14995115$5$F$$20221020$20180611$20221021$EXP$$CA-ROCHE-2136010$ROCHE$$50$YR$$F$Y$110$KG$20221021$$HP$CA$
149958807$14995880$7$F$20131118$20221110$20180611$20221114$EXP$$DE-MYLANLABS-2018M1011998$MYLAN$$50$YR$$M$Y$74$KG$20221114$$MD$DE$DE
1499627411$14996274$11$F$20170113$20221130$20180611$20221207$EXP$$CA-TAKEDA-2016TUS023400$TAKEDA$$51$YR$$M$Y$75$KG$20221207$$HP$CA$CA
149964712$14996471$2$F$20170306$20221006$20180611$20221017$PER$$US-JNJFOC-20180601653$JOHNSON AND JOHNSON$$28$YR$A$M$Y$$$20221017$$HP$US$US
1499682518$14996825$18$F$20170505$20221206$20180611$20221216$EXP$$CA-PFIZER INC-2017204904$PFIZER$$51$YR$$F$Y$$$20221216$$CN$CA$CA
1499942113$14999421$13$F$20180501$20221118$20180612$20221123$PER$$US-PFIZER INC-2018237424$PFIZER$$93$YR$$F$Y$$$20221123$$CN$US$US
149998738$14999873$8$F$20180401$20221007$20180612$20221012$PER$$US-PFIZER INC-2018233532$PFIZER$$68$YR$$F$Y$$$20221012$$MD$US$US
1500014812$15000148$12$F$20180526$20221010$20180612$20221014$EXP$$FR-ROCHE-2132559$ROCHE$$53$YR$$M$Y$74$KG$20221014$$MD$FR$
1500194912$15001949$12$F$20160901$20221028$20180612$20221103$EXP$$GB-PFIZER INC-2018230482$PFIZER$$50$YR$$F$Y$$$20221103$$MD$GB$GB
1500269923$15002699$23$F$$20221104$20180612$20221109$EXP$$PHHY2018IT017733$NOVARTIS$Carnovale C, Raschi E, Leonardi L, Moretti U, Ponti F, Gentili M et al.. No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase. EXPERT REVIEW OF VACCINES. 2018;17(4):363-81$64$YR$$M$Y$109$KG$20221109$$HP$IT$IT
1500331111$15003311$11$F$20080401$20221202$20180613$20221214$PER$$US-AMGEN-USASP2018078308$AMGEN$$48$YR$A$M$Y$$$20221213$$MD$US$US
150051672$15005167$2$F$$20221118$20180613$20221122$EXP$$CA-GLAXOSMITHKLINE-CA2018GSK104177$GLAXOSMITHKLINE$$$$$$Y$$$20221122$$MD$CA$CA
1500983318$15009833$18$F$$20221017$20180614$20221027$EXP$$CA-APOTEX-2018AP015326$APOTEX$$23$YR$$F$Y$$$20221027$$HP$CA$CA
150109134$15010913$4$F$20180101$20221007$20180614$20221016$EXP$$ES-009507513-1804ESP011263$MERCK$Hu Y, Lu W, Tang B, Zhao Z, An Z. Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study. Frontiers in Oncology. 2022;12:954468$71$YR$$M$Y$87$KG$20221016$$MD$ES$ES
150137863$15013786$3$F$$20221006$20180614$20221007$PER$$US-BIOGEN-2018BI00593711$BIOGEN$$$$$M$Y$$$20221007$$CN$US$US
150144735$15014473$5$F$20161128$20221215$20180615$20221226$EXP$$CA-TAKEDA-2016TUS021409$TAKEDA$$22$YR$$M$Y$$$20221226$$CN$CA$CA
150158983$15015898$3$F$20220901$20221016$20180615$20221025$PER$$US-SA-2018SA157268$SANOFI AVENTIS$$51$YR$A$F$Y$$$20221025$$MD$US$US
1501634310$15016343$10$F$20220730$20221221$20180615$20221230$EXP$$US-SHIRE-US201821651$TAKEDA$$45$YR$$F$Y$62$KG$20221230$$CN$US$US
150180917$15018091$7$F$20180501$20221014$20180615$20221019$EXP$$US-PFIZER INC-2018243469$PFIZER$$10$YR$$M$Y$35.5$KG$20221019$$MD$US$US
150196374$15019637$4$F$20180418$20221220$20180618$20221226$EXP$$FR-ROCHE-2138861$ROCHE$$74$YR$$M$Y$80$KG$20221226$$MD$FR$
1502061812$15020618$12$F$$20221208$20180618$20221222$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-174682$RANBAXY$$22$YR$$F$Y$56$KG$20221222$$MD$GB$GB
150210595$15021059$5$F$20180101$20221212$20180618$20221216$EXP$$US-PFIZER INC-2017193123$PFIZER$$75$YR$$M$Y$$$20221216$$CN$US$US
150277614$15027761$4$F$$20221021$20180619$20221025$PER$$US-PFIZER INC-2018245606$PFIZER$$70$YR$$F$Y$$$20221025$$MD$US$US
150277715$15027771$5$F$20180601$20221214$20180619$20221221$PER$$US-PFIZER INC-2018245766$PFIZER$$63$YR$$M$Y$$$20221221$$HP$US$US
150287185$15028718$5$F$20150701$20221117$20180619$20221122$EXP$$US-TAKEDA-2018TUS019757$TAKEDA$$$$$$Y$$$20221122$$CN$US$US
150300852$15030085$2$F$20171122$20221031$20180619$20221109$EXP$FR-EMA-DD-20180515-ISHAEVHP-120655$FR-TEVA-2018-FR-911683$TEVA$$29$YR$A$F$Y$50$KG$20221109$$HP$FR$FR
150306485$15030648$5$F$20130401$20221207$20180619$20221222$EXP$$FR-GILEAD-2018-0345548$GILEAD$$50$YR$A$M$Y$65$KG$20221222$$MD$FR$FR
150307262$15030726$2$F$20180123$20221012$20180619$20221014$EXP$FR-AFSSAPS-AM20180727$FR-TAKEDA-2018TUS019948$TAKEDA$$31$YR$$M$Y$67$KG$20221014$$HP$FR$FR
1503384010$15033840$10$F$20180515$20221031$20180619$20221108$EXP$$DE-ROCHE-2130154$ROCHE$$47$YR$$F$Y$$$20221108$$CN$DE$
1503390013$15033900$13$F$$20221209$20180620$20221215$EXP$$US-BIOGEN-2018BI00595527$BIOGEN$$$$$F$Y$$$20221215$$CN$US$US
1503487419$15034874$19$F$20170410$20221005$20180620$20221009$EXP$$CA-ROCHE-1919526$ROCHE$$54$YR$$F$Y$$$20221009$$HP$CA$
150355406$15035540$6$F$20150701$20221109$20180620$20221117$EXP$$US-AstraZeneca-2018SE76980$ASTRAZENECA$$575$MON$$F$Y$68.9$KG$20221117$$LW$US$
1503612720$15036127$20$F$20180301$20221219$20180620$20221225$EXP$$CA-CELLTRION INC.-2018CA018983$CELLTRION$$$$$$Y$$$20221226$$MD$CA$CA
1503613712$15036137$12$F$20191028$20221201$20180620$20221205$EXP$$PHHO2018GB003840$NOVARTIS$$64$YR$$M$Y$$$20221205$$MD$GB$GB
1503716116$15037161$16$F$20180418$20221003$20180620$20221007$EXP$$CN-ROCHE-2115397$ROCHE$$61$YR$$M$Y$64.5$KG$20221007$$MD$CN$
150379365$15037936$5$F$$20221006$20180620$20221018$EXP$$RO-MYLANLABS-2018M1032232$MYLAN$Boricean Neacsu G, Scripca O.. Multifocal Choroiditis and Panuveitis ? difficulties in diagnosis and treatment.. Romanian Journal of Ophthalmology. 2017;61 (4):293-298$49$YR$$F$Y$$$20221018$$MD$RO$RO
1504368527$15043685$27$F$20180101$20221109$20180621$20221117$EXP$$CA-CELLTRION INC.-2018CA017322$CELLTRION$$$$$$Y$$$20221117$$CN$CA$CA
150483807$15048380$7$F$20180608$20221119$20180622$20221202$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-057593$BRISTOL MYERS SQUIBB$$65$YR$E$F$Y$43.5$KG$20221202$$MD$JP$JP
1505033017$15050330$17$F$20180111$20221108$20180622$20221110$EXP$$VN-ASTELLAS-2018US004152$ASTELLAS$$50$YR$$M$Y$43$KG$20221110$$MD$VN$VN
150514019$15051401$9$F$20170519$20221128$20180622$20221201$EXP$$JP-LUNDBECK-DKLU2032189$LUNDBECK$$1$YR$I$F$Y$8.54$KG$20221201$$MD$JP$JP
150531219$15053121$9$F$$20221209$20180622$20221214$PER$$US-PFIZER INC-2018247571$PFIZER$$54$YR$$M$Y$$$20221214$$HP$US$US
150572813$15057281$3$F$20170823$20221130$20180624$20221204$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2018-BI-032413$BOEHRINGER INGELHEIM$$43$YR$A$M$Y$$$20221204$$MD$ES$ES
1505728211$15057282$11$F$20170823$20221130$20180624$20221204$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2018-BI-032412$BOEHRINGER INGELHEIM$Villalba-Montaner M, Gavin Sebastian O, Gallardo I, Sancho Val L, Villalba-Montaner M, Fernandez R, et al. A multicenter experience with Idarucizumab ^in real world^ as reversal anticoagulation of Dabigatran. European Haematology Association.$43$YR$A$M$Y$$$20221204$$MD$ES$ES
150574232$15057423$2$F$$20221016$20180625$20221020$EXP$$US-Inventia-000235$INVENTIA HEALTHCARE$US-Inventia-000235-01_Initial Source Document$36$YR$A$M$Y$$$20221020$$MD$US$
1505793627$15057936$27$F$20180601$20221020$20180625$20221030$EXP$$CA-CELLTRION INC.-2018CA020697$CELLTRION$$$$$$Y$$$20221030$$CN$CA$CA
150598495$15059849$5$F$20190712$20221018$20180625$20221026$EXP$$US-SA-2018SA165601$SANOFI AVENTIS$$58$YR$A$F$Y$$$20221026$$MD$US$US
1506004233$15060042$33$F$20180101$20221222$20180625$20221230$EXP$$CA-CELLTRION INC.-2018CA020943$CELLTRION$$$$$$Y$$$20221231$$CN$CA$CA
150621792$15062179$2$F$20150401$20221108$20180625$20221115$EXP$$DE-BIOGEN-2015BI065743$BIOGEN$$44$YR$$F$Y$$$20221115$$CN$DE$DE
1506514215$15065142$15$F$20171113$20221229$20180626$20221230$EXP$$IT-ROCHE-2026263$ROCHE$$67$YR$$F$Y$77$KG$20221230$$MD$IT$IT
150656394$15065639$4$F$$20221202$20180626$20221218$PER$$US-AMGEN-USASP2018084763$AMGEN$$$$A$M$Y$$$20221218$$MD$US$US
150657022$15065702$2$F$20180101$20221121$20180626$20221123$PER$$US-PFIZER INC-2018256662$PFIZER$$68$YR$$F$Y$$$20221123$$HP$US$US
150666398$15066639$8$F$20180611$20221215$20180626$20221222$EXP$$PHHY2018CA024646$NOVARTIS$$57$YR$$F$Y$$$20221222$$CN$CA$CA
1506720911$15067209$11$F$20130101$20221021$20180626$20221022$EXP$$PHHY2017BE013915$NOVARTIS$Heyrman B, De Becker A, Schots R. A case report of immunosuppression-related Kaposi?s sarcoma after autologous stem cell transplantation. BMC RESEARCH NOTES. 2016;9(188):1-5$61$YR$$M$Y$$$20221022$$HP$BE$BE
150674592$15067459$2$F$20180401$20221019$20180626$20221020$EXP$$US-PFIZER INC-2018253499$PFIZER$$86$YR$$M$Y$$$20221020$$PH$US$US
150680973$15068097$3$F$20171015$20221214$20180626$20221219$EXP$$FR-JNJFOC-20180629470$JOHNSON AND JOHNSON$$17$YR$T$M$Y$64.3$KG$20221220$$MD$FR$FR
150749483$15074948$3$F$20170830$20211014$20180627$20221011$EXP$$US-SAOL THERAPEUTICS-2017SAO01802$AMNEAL$$8$YR$$F$Y$37$KG$20221011$$CN$US$US
150753212$15075321$2$F$20180207$20220302$20180627$20221011$EXP$$US-SAOL THERAPEUTICS-2018SAO00187$AMNEAL$$50$YR$$M$Y$$$20221011$$CN$US$US
150753532$15075353$2$F$20171201$20211202$20180627$20221011$EXP$$US-SAOL THERAPEUTICS-2018SAO00399$AMNEAL$$32$YR$$M$Y$$$20221011$$MD$US$US
150805557$15080555$7$F$20170205$20221130$20180628$20221207$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2018-BI-032411$BOEHRINGER INGELHEIM$$67$YR$E$M$Y$76$KG$20221207$$MD$ES$ES
150807346$15080734$6$F$20170411$20221130$20180628$20221208$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2018-BI-032414$BOEHRINGER INGELHEIM$$82$YR$E$F$Y$56$KG$20221208$$MD$ES$ES
1508089311$15080893$11$F$$20221130$20180628$20221208$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2018-BI-032429$BOEHRINGER INGELHEIM$$$$$M$Y$115$KG$20221208$$MD$ES$ES
1508143011$15081430$11$F$20170419$20221130$20180628$20221208$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2018-BI-032426$BOEHRINGER INGELHEIM$$59$YR$A$M$Y$140$KG$20221208$$MD$ES$ES
150814742$15081474$2$F$$20180615$20180628$20221212$EXP$$PHHY2018CN024180$NOVARTIS$Shi TY, Zhang YF, Shi XH, Wen XH, Dong X, Meng J et al.. A rare case of meningoencephalitis by Listeria monocytogenes in systemic lupus erythematosus: case report and review. CLIN RHEUMATOL. 2018;37:271-5$42$YR$$F$Y$$$20221212$$HP$CN$CN
150817918$15081791$8$F$$20221213$20180628$20221220$PER$$US-PFIZER INC-2018258920$PFIZER$$82$YR$$F$Y$$$20221220$$CN$US$US
150825606$15082560$6$F$20180620$20221107$20180628$20221114$EXP$$US-MYLANLABS-2018M1046065$MYLAN$$19$YR$$F$Y$57$KG$20221114$$PH$US$US
150891438$15089143$8$F$20180501$20220913$20180629$20221006$PER$$US-SA-2018SA168416$SANOFI AVENTIS$$35$YR$A$F$Y$$$20221006$$MD$US$US
150939035$15093903$5$F$20170612$20221114$20180629$20221118$EXP$$CA-TAKEDA-2018TUS020977$TAKEDA$$9$YR$$F$Y$$$20221118$$MD$CA$CA
1509544010$15095440$10$F$20100629$20221108$20180702$20221121$EXP$$GB-GILEAD-2018-0347475$GILEAD$$43$YR$A$F$Y$43$KG$20221121$$HP$GB$GB
150959413$15095941$3$F$20130110$20221214$20180702$20221220$EXP$$US-AstraZeneca-2018SE84776$ASTRAZENECA$$21646$DY$$F$Y$104.8$KG$20221220$$LW$US$
150993104$15099310$4$F$20221021$20221026$20180702$20221031$EXP$$US-SHIRE-US201823104$TAKEDA$$63$YR$$F$Y$$$20221031$$HP$US$US
151009363$15100936$3$F$20121001$20221005$20180703$20221006$PER$$US-PFIZER INC-2016584495$PFIZER$$39$YR$$F$Y$$$20221006$$LW$US$US
1510105421$15101054$21$F$20180626$20221013$20180703$20221019$EXP$$PHHY2018CA033930$NOVARTIS$$67$YR$$M$Y$$$20221019$$CN$CA$CA
1510118931$15101189$31$F$20180101$20221214$20180703$20221222$EXP$$CA-CELLTRION INC.-2018CA021050$CELLTRION$$$$$$Y$$$20221222$$CN$CA$CA
151017504$15101750$4$F$$20220926$20180703$20221004$EXP$$CA-APOTEX-2018AP016282$APOTEX$$30$YR$$F$Y$$$20221004$$HP$CA$CA
1510409913$15104099$13$F$20180215$20221114$20180703$20221121$EXP$$PHHY2018NL030250$NOVARTIS$$43$YR$$M$Y$68$KG$20221121$$MD$NL$NL
151048124$15104812$4$F$20150904$20221128$20180703$20221206$EXP$$US-JAZZ-2018-US-010410$JAZZ$$70$YR$$F$Y$$$20221206$$CN$US$US
151052132$15105213$2$F$20180529$20221102$20180704$20221104$PER$$US-SHIRE-US201823292$TAKEDA$$61$YR$$F$Y$$$20221104$$MD$US$US
151058492$15105849$2$F$20180627$20221107$20180704$20221108$PER$$US-SHIRE-US201823407$TAKEDA$$71$YR$$F$Y$$$20221108$$CN$US$US
1510690517$15106905$17$F$20151002$20221209$20180704$20221216$PER$$US-PFIZER INC-2015332728$PFIZER$$33$YR$$M$Y$81$KG$20221216$$CN$US$US
1510737219$15107372$19$F$20180101$20221214$20180704$20221221$EXP$$CA-TAKEDA-2018TUS021103$TAKEDA$$45$YR$$M$Y$$$20221221$$MD$CA$CA
151081138$15108113$8$F$$20220927$20180705$20221012$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2018R1-177226$RANBAXY$$79$YR$$F$Y$$$20221012$$PH$GB$GB
151093845$15109384$5$F$$20220927$20180705$20221008$EXP$$IT-AUROBINDO-AUR-APL-2017-37850$AUROBINDO$Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Caruso C, Quaratino D.. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins.. J-Allergy-Clin-Immunol. 2016;138(1):179-186$45$YR$$F$Y$$$20221008$$MD$IT$IT
151095683$15109568$3$F$$20221212$20180705$20221215$PER$$US-PFIZER INC-2018270452$PFIZER$$62$YR$$F$Y$$$20221215$$CN$US$US
151101817$15110181$7$F$20160901$20221024$20180705$20221101$EXP$$GB-drreddys-GER/UKI/18/0101372$DR REDDYS$$50$YR$A$F$Y$$$20221101$$MD$GB$GB
151115984$15111598$4$F$20160401$20221125$20180705$20221201$EXP$$PHHY2017CA027553$NOVARTIS$$63$YR$$F$Y$$$20221201$$CN$CA$CA
1511322619$15113226$19$F$20171130$20221020$20180706$20221027$EXP$$CA-ROCHE-2043790$ROCHE$$39$YR$$F$Y$$$20221027$$CN$CA$
1511369142$15113691$42$F$20180305$20221228$20180706$20221230$EXP$$DE-ROCHE-2091662$ROCHE$$52$YR$$M$Y$90$KG$20221230$$CN$DE$
1511374710$15113747$10$F$20220101$20221130$20180706$20221206$EXP$$US-PFIZER INC-2017190647$PFIZER$$49$YR$$F$Y$54.43$KG$20221206$$CN$US$US
1511449812$15114498$12$F$20171226$20221212$20180706$20221216$EXP$$US-ROCHE-2144133$ROCHE$$58$YR$$F$Y$70.37$KG$20221216$$CN$US$
151152333$15115233$3$F$20180401$20220919$20180706$20221003$EXP$$US-ALLERGAN-1822839US$ALLERGAN$$$$$F$Y$$$20221003$$MD$US$US
151172637$15117263$7$F$$20221003$20180706$20221010$EXP$$PHHY2018IT030307$NOVARTIS$Invernizzi A, Ricaboni D, Franzetti M, Staurenghi G, McCluskey P, Franzetti F et al.. Bilateral choroiditis as the only sign of persistent Mycobacterium intracellulare infection following haematogenous spread in an immunocompromised patient.. INFECTION. 2018;46(3):423-6$50$YR$$F$Y$$$20221010$$HP$IT$IT
151180237$15118023$7$F$$20221001$20180707$20221013$EXP$$IT-AUROBINDO-AUR-APL-2018-035250$AUROBINDO$Invernizzi A, Ricaboni D,Franzetti M,Staurenghi G,McCluskey P,Franzetti F et al.. Bilateral choroiditis as the only sign of persistent Mycobacterium intracellulare infection following haematogenous spread in an immunocompromised patient. Infection. 2018;46(3):423-426$50$YR$$F$Y$$$20221013$$MD$IT$IT
151194252$15119425$2$F$$20221114$20180709$20221118$EXP$$MX-ROCHE-2151376$ROCHE$Sacks C, Arboine L and Palacios J Left main coronary artery aneurysm. Doi: 10.1056/NEJMicm1708877. New England Journal of Medicine 2018 Jun 07;378 (23):E32-.$49$YR$$M$Y$$$20221118$$MD$MX$
1511981746$15119817$46$F$20170422$20221212$20180709$20221219$EXP$$PHHY2017CA061325$NOVARTIS$$11$YR$$M$Y$$$20221219$$CN$CA$CA
151215972$15121597$2$F$20120625$20221107$20180709$20221109$EXP$$ES-Ipsen Biopharmaceuticals, Inc.-2016-11121$IPSEN$$2$YR$C$M$Y$8.6$KG$20221109$$MD$ES$ES
151223456$15122345$6$F$20180629$20221121$20180709$20221123$PER$$DE-AMGEN-DEUNI2018091060$AMGEN$$71$YR$E$M$Y$96$KG$20221123$$MD$DE$DE
1512362528$15123625$28$F$20180205$20220601$20180710$20221110$EXP$$GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-060524$BRISTOL MYERS SQUIBB$$43$YR$A$F$Y$$$20221110$$CN$GB$GB
151238435$15123843$5$F$$20221025$20180710$20221102$PER$$US-BIOGEN-2018BI00605750$BIOGEN$$$$$F$Y$$$20221102$$CN$US$US
1512401710$15124017$10$F$20170529$20221130$20180710$20221206$EXP$$CA-ROCHE-2151256$ROCHE$$63$YR$$M$Y$97$KG$20221206$$CN$CA$CA
151246206$15124620$6$F$$20221110$20180710$20221114$PER$$US-PFIZER INC-2017527094$PFIZER$$73$YR$$F$Y$77.098$KG$20221114$$CN$US$US
151248016$15124801$6$F$$20221028$20180710$20221103$PER$$US-AMGEN-USASP2018091143$AMGEN$$67$YR$E$F$Y$$$20221103$$HP$US$US
151255157$15125515$7$F$20180622$20221005$20180710$20221007$EXP$$CN-ROCHE-2149937$ROCHE$$53$YR$$F$Y$51.8$KG$20221007$$MD$CN$
151255755$15125575$5$F$20180503$20190325$20180710$20221025$EXP$$JP-009507513-1807JPN000688J$MERCK$$72$YR$$M$Y$39$KG$20221025$$MD$JP$JP
151255806$15125580$6$F$20161225$20221129$20180710$20221208$EXP$$PHHY2016CA042016$NOVARTIS$$52$YR$$M$Y$$$20221208$$CN$CA$CA
151266964$15126696$4$F$20180622$20221125$20180710$20221202$EXP$$GB-PFIZER INC-2018274949$PFIZER$Jones, R.. A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer. Clinical cancer research. 2022;10.1158/1078-0432.CCR-22-2074$50$YR$$M$Y$84.6$KG$20221202$$MD$GB$GB
1512881520$15128815$20$F$20180703$20221013$20180711$20221020$EXP$$DE-ROCHE-2152497$ROCHE$$23$YR$$F$Y$$$20221020$$CN$DE$
151292163$15129216$3$F$20180701$20221007$20180711$20221012$PER$$US-PFIZER INC-2018278534$PFIZER$$66$YR$$F$Y$105$KG$20221012$$HP$US$US
1513064838$15130648$38$F$20180521$20221202$20180711$20221212$EXP$$CA-CELLTRION INC.-2018CA018342$CELLTRION$$$$$$Y$$$20221212$$CN$CA$CA
1513132113$15131321$13$F$20170101$20221102$20180711$20221108$EXP$$US-OTSUKA-2017_021273$OTSUKA$$$$$M$Y$$$20221108$$HP$US$US
1513489323$15134893$23$F$20180605$20221125$20180712$20221205$EXP$$CA-ROCHE-2153780$ROCHE$$63$YR$$F$Y$67$KG$20221205$$CN$CA$CA
1513523121$15135231$21$F$20180401$20221129$20180712$20221208$EXP$$CA-CELLTRION INC.-2018CA019834$CELLTRION$$$$$$Y$$$20221208$$MD$CA$CA
1513530159$15135301$59$F$20210101$20221215$20180712$20221222$EXP$$IL-PFIZER INC-2018276379$PFIZER$$72$YR$$M$Y$$$20221222$$HP$IL$IL
151364952$15136495$2$F$20180201$20221219$20180712$20221228$EXP$FR-AFSSAPS-PP20180442$FR-ELI_LILLY_AND_COMPANY-FR201807001033$ELI LILLY AND CO$$45$YR$$M$Y$47$KG$20221228$$CN$FR$FR
151365295$15136529$5$F$20160401$20220930$20180712$20221004$EXP$$PHHY2016CA052369$NOVARTIS$$60$YR$$F$Y$$$20221004$$CN$CA$CA
151457813$15145781$3$F$20151101$20221102$20180714$20221107$EXP$FI-JNJFOC-20180712947$FI-JNJFOC-20180712947$JOHNSON AND JOHNSON$$63$YR$A$M$Y$$$20221107$$HP$US$US
1514649621$15146496$21$F$20180601$20221012$20180715$20221013$EXP$$PHHY2018CA039195$NOVARTIS$$84$YR$$M$Y$$$20221013$$CN$CA$CA
1514834522$15148345$22$F$20100101$20221209$20180716$20221216$EXP$$US-PFIZER INC-2018284082$PFIZER$$72$YR$$F$Y$$$20221216$$CN$US$US
151487189$15148718$9$F$20170315$20221013$20180716$20221021$EXP$$DE-MYLANLABS-2018M1050463$MYLAN$$78$YR$$F$Y$$$20221021$$HP$DE$DE
151491136$15149113$6$F$20180706$20221208$20180716$20221209$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-065201$BRISTOL MYERS SQUIBB$$79$YR$E$F$Y$57.299$KG$20221209$$HP$US$US
151504172$15150417$2$F$$20220930$20180716$20221012$PER$$CA-PFM-2018-07680$PIERRE FABRE MEDICAMENT$$$$$$Y$$$20221012$$CN$CA$CA
151505573$15150557$3$F$20170911$20221101$20180716$20221109$EXP$$JP-BAUSCH-BL-2018-019193$BAUSCH AND LOMB$$80$YR$$F$Y$42$KG$20221109$$MD$JP$JP
1515102416$15151024$16$F$20180101$20221014$20180716$20221025$PER$$US-SA-2018SA187878$SANOFI AVENTIS$$71$YR$E$F$Y$$$20221025$$CN$US$US
151518334$15151833$4$F$20130601$20221109$20180716$20221116$EXP$$US-BIOGEN-2015BI025434$BIOGEN$$49$YR$$F$Y$$$20221116$$CN$US$US
151522972$15152297$2$F$20180607$20180712$20180717$20221220$EXP$GB-MHRA-TPP34286745C1986023YC1528379332646$GB-TEVA-2018-GB-927040$TEVA$$43$YR$A$F$Y$85$KG$20221220$$HP$GB$GB
151530882$15153088$2$F$$20221101$20180717$20221103$PER$$US-PFIZER INC-2018285799$PFIZER$$69$YR$$F$Y$$$20221103$$HP$US$US
151535076$15153507$6$F$20100427$20221222$20180717$20221223$EXP$$US-AstraZeneca-2018SE90954$ASTRAZENECA$$17018$DY$$M$Y$113.4$KG$20221223$$LW$US$
151552713$15155271$3$F$20120625$20221108$20180717$20221110$EXP$PHHY2018FR047040$PHHY2018FR047040$NOVARTIS$Cuny P, Houot M, Ginisty S, Horowicz S, Plassart F, Mentec H et al.. Quetiapine and anticholinergic drugs induced ischaemic colitis: A case study. ENCEPHALE. 2016;43:81-4$34$YR$$M$Y$$$20221110$$HP$FR$FR
151559753$15155975$3$F$$20221108$20180717$20221111$EXP$$US-SHIRE-US201825418$TAKEDA$$$$$F$Y$$$20221111$$CN$US$US
151571884$15157188$4$F$20180101$20221014$20180718$20221022$EXP$$AU-TEVA-2018-AU-927511$TEVA$$42$YR$A$F$Y$$$20221022$$MD$AU$AU
1515852811$15158528$11$F$20160601$20220608$20180718$20221107$EXP$$PHHY2016GB187021$NOVARTIS$$53$YR$$F$Y$$$20221107$$MD$GB$GB
151585927$15158592$7$F$20180615$20221124$20180718$20221130$EXP$$PHHY2018CO044525$NOVARTIS$$45$YR$$F$Y$60$KG$20221130$$CN$CO$CO
1515990912$15159909$12$F$$20221115$20180718$20221117$PER$$US-PFIZER INC-2018289510$PFIZER$$71$YR$$F$Y$$$20221117$$MD$US$US
151601612$15160161$2$F$20020101$20221012$20180718$20221013$PER$$US-BIOGEN-2016BI00269541$BIOGEN$$$$$F$Y$$$20221013$$CN$US$US
151605126$15160512$6$F$20180616$20221018$20180718$20221024$EXP$$CA-TAKEDA-2018TUS020223$TAKEDA$$21$YR$$F$Y$$$20221024$$MD$CA$CA
151642606$15164260$6$F$$20221222$20180719$20221227$PER$$US-PFIZER INC-2018287690$PFIZER$$62$YR$$F$Y$$$20221227$$CN$US$US
1516474110$15164741$10$F$20190401$20221003$20180719$20221011$PER$$US-SA-2018SA195124$SANOFI AVENTIS$$45$YR$A$M$Y$$$20221011$$MD$US$US
151648502$15164850$2$F$20180531$20221117$20180719$20221121$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-051331$BRISTOL MYERS SQUIBB$$$$E$F$Y$$$20221121$$HP$US$US
1516499524$15164995$24$F$20151110$20221116$20180719$20221124$EXP$$PHHY2016GB187024$NOVARTIS$$67$YR$$F$Y$$$20221124$$MD$GB$GB
151683195$15168319$5$F$20160901$20221024$20180719$20221026$EXP$$PHHY2016GB187015$NOVARTIS$$50$YR$$F$Y$$$20221026$$MD$GB$GB
1517116613$15171166$13$F$20180718$20221122$20180720$20221128$EXP$$US-PFIZER INC-2018291839$PFIZER$$32$YR$$M$Y$78.47$KG$20221128$$HP$US$US
151713715$15171371$5$F$20180301$20221014$20180720$20221019$EXP$$PHHY2018AU046705$NOVARTIS$$43$YR$$F$Y$$$20221019$$MD$AU$AU
151719883$15171988$3$F$20100101$20221024$20180720$20221028$EXP$$US-TAKEDA-2018TUS011327$TAKEDA$$$$$$Y$$$20221028$$HP$US$US
151732657$15173265$7$F$$20221206$20180720$20221213$EXP$$PL-MYLANLABS-2018M1044285$MYLAN$Wikiera-Magott I, Fornalczyk K and Zwolinska D.. From body piercing to acute kidney injury ? a case report.. Pediatr Med Rodz.. 2017;13(4):561?66$17$YR$$F$Y$$$20221213$$MD$PL$PL
1517327525$15173275$25$F$20080101$20221211$20180720$20221222$EXP$$CA-BAUSCH-BL-2018-019816$BAUSCH AND LOMB$$53$YR$$M$Y$$$20221222$$MD$CA$CA
151758162$15175816$2$F$20180702$20221011$20180720$20221013$PER$$US-SHIRE-US201826957$TAKEDA$$26$YR$$F$Y$$$20221013$$MD$US$US
1517922110$15179221$10$F$$20221115$20180723$20221118$PER$$US-AMGEN-USASP2018098518$AMGEN$$71$YR$E$F$Y$$$20221118$$MD$US$US
151795313$15179531$3$F$20191212$20210823$20180723$20221213$EXP$$JP-ROCHE-2158212$ROCHE$$35$YR$$M$Y$$$20221213$$MD$JP$JP
151797578$15179757$8$F$20180111$20221208$20180723$20221212$EXP$$CA-ROCHE-2069964$ROCHE$$20$YR$$F$Y$$$20221212$$CN$CA$
151804706$15180470$6$F$$20221202$20180723$20221206$EXP$$US-PFIZER INC-2018293824$PFIZER$$53$YR$$M$Y$$$20221206$$MD$US$US
1518083223$15180832$23$F$20100629$20221215$20180723$20221228$EXP$$GB-AUROBINDO-AUR-APL-2018-036898$AUROBINDO$$3$MON$$M$Y$$$20221228$$MD$GB$GB
151834512$15183451$2$F$20180317$20221226$20180723$20221228$EXP$$PHHY2018DE026016$NOVARTIS$$76$YR$$M$Y$105$KG$20221228$$MD$DE$DE
151835974$15183597$4$F$$20221004$20180723$20221010$EXP$$US-SHIRE-US201827685$TAKEDA$$$$$F$Y$$$20221010$$CN$US$US
1518385317$15183853$17$F$20180101$20221122$20180723$20221128$EXP$$US-SA-2018SA194712$SANOFI AVENTIS$$46$YR$A$F$Y$$$20221128$$CN$US$US
1518410011$15184100$11$F$$20221208$20180723$20221215$PER$$US-PFIZER INC-2015331180$PFIZER$$64$YR$$M$Y$99$KG$20221215$$CN$US$US
1518524211$15185242$11$F$20180101$20221118$20180723$20221124$EXP$$PHHY2018CO067874$NOVARTIS$$$$$F$Y$60$KG$20221124$$CN$CO$CO
151854162$15185416$2$F$20180709$20221201$20180723$20221210$EXP$$CA-SHIRE-CA201827358$TAKEDA$$56$YR$$F$Y$$$20221210$$CN$CA$CA
151854763$15185476$3$F$$20221129$20180723$20221206$EXP$$US-SHIRE-US201827245$TAKEDA$$$$$M$Y$$$20221206$$CN$US$US
151855688$15185568$8$F$20180708$20221026$20180723$20221027$EXP$$US-SHIRE-US201826841$TAKEDA$$84$YR$$F$Y$$$20221027$$MD$US$US
151881904$15188190$4$F$$20221212$20180724$20221213$PER$$US-AMGEN-USASP2018099089$AMGEN$$68$YR$E$F$Y$$$20221213$$MD$US$US
151885133$15188513$3$F$20180116$20221117$20180724$20221201$EXP$$IT-AUROBINDO-AUR-APL-2018-037237$AUROBINDO$$55$YR$$M$Y$$$20221201$$MD$IT$IT
1518940815$15189408$15$F$20160101$20221212$20180724$20221215$EXP$$CA-TAKEDA-2016TUS013309$TAKEDA$$45$YR$$M$Y$$$20221215$$MD$CA$CA
1519042515$15190425$15$F$20211110$20221110$20180724$20221116$EXP$$US-SHIRE-US201828093$TAKEDA$$29$YR$$F$Y$$$20221116$$CN$US$US
151909698$15190969$8$F$$20221027$20180724$20221029$EXP$$PHHY2018CO054348$NOVARTIS$$$$$F$Y$63$KG$20221029$$CN$CO$CO
151916425$15191642$5$F$20180717$20221019$20180724$20221021$EXP$$CA-TAKEDA-2018TUS022922$TAKEDA$$58$YR$$M$Y$$$20221021$$MD$CA$CA
151917377$15191737$7$F$20050101$20221011$20180724$20221014$EXP$$PHHY2018GB052380$NOVARTIS$Chelaghma N, Oyibo SO. Hyporeninemic hypoaldosteronism in a patient with diabetes mellitus: An unforgettable case report. INTERNATIONAL MEDICAL CASE REPORTS JOURNAL. 2018;11:69-72$58$YR$$M$Y$$$20221014$$HP$GB$GB
151918833$15191883$3$F$$20221212$20180724$20221215$EXP$$PHHY2018SE049955$NOVARTIS$Lindcman E. Hogdos insulin-euglykemiterapivid svar-toxisk myokard depression [Ett viktigt tillskoll I bchandlingsarscnalcn]. LAKARTIDNINGCN. 2017;114$55$YR$$F$Y$$$20221215$$HP$SE$SE
151922152$15192215$2$F$$20221013$20180724$20221017$EXP$$US-SHIRE-US201827699$TAKEDA$$$$$M$Y$$$20221017$$MD$US$US
151933244$15193324$4$F$$20221116$20180725$20221122$EXP$$US-BIOGEN-2018BI00612478$BIOGEN$$$$$F$Y$$$20221122$$CN$US$US
151983194$15198319$4$F$20180101$20221010$20180725$20221017$EXP$$US-JAZZ-2018-US-011349$JAZZ$$$$$F$Y$$$20221017$$CN$US$US
1520044614$15200446$14$F$20180423$20221116$20180726$20221123$EXP$$DE-ROCHE-2126614$ROCHE$$41$YR$$F$Y$54$KG$20221123$$CN$DE$
1520121432$15201214$32$F$20210617$20221019$20180726$20221024$PER$$US-PFIZER INC-2018299647$PFIZER$$53$YR$$F$Y$51.3$KG$20221024$$CN$US$US
1520475521$15204755$21$F$20180601$20221206$20180726$20221213$EXP$$US-SHIRE-US201826554$TAKEDA$$52$YR$$F$Y$109$KG$20221213$$HP$US$US
1520593535$15205935$35$F$20171107$20221216$20180727$20221228$EXP$GB-BAXTER-2017BAX039110$GB-Accord-070062$ACCORD$$73$YR$E$F$Y$50$KG$20221228$$CN$GB$GB
1520648726$15206487$26$F$20180719$20221124$20180727$20221205$EXP$$CA-ROCHE-2160786$ROCHE$$22$YR$$F$Y$$$20221205$$MD$CA$CA
152085256$15208525$6$F$$20221007$20180727$20221014$EXP$$CA-OTSUKA-2018_026645$OTSUKA$$25$YR$$M$Y$$$20221014$$HP$CA$CA
1520935611$15209356$11$F$$20221212$20180727$20221222$PER$$CA-AMGEN-CANSP2018101357$AMGEN$$51$YR$A$F$Y$73$KG$20221222$$HP$CA$CA
152099415$15209941$5$F$20180516$20221219$20180727$20221228$PER$$US-PFIZER INC-2018302514$PFIZER$$56$YR$$F$Y$$$20221228$$PH$US$US
152101084$15210108$4$F$20150901$20221121$20180727$20221124$EXP$$PHHY2018FR054135$NOVARTIS$Guglielmetti L, Barkane L, Le Du D, Marigot-Outtandy D, Robert J, Veziris N et al.. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. EUROPEAN RESPIRATORY JOURNAL. 2018;51(3):1-12$31$YR$$M$Y$52$KG$20221124$$HP$FR$FR
152117683$15211768$3$F$20180207$20221108$20180729$20221114$EXP$$PHHY2018DE054423$NOVARTIS$$76$YR$$M$Y$74$KG$20221114$$MD$DE$DE
152119722$15211972$2$F$$20221031$20180729$20221104$EXP$$US-ROCHE-2160794$ROCHE$$$$A$M$Y$$$20221103$$CN$US$
1521548511$15215485$11$F$$20221212$20180730$20221223$EXP$$CA-PFIZER INC-2018305256$PFIZER$$51$YR$$F$Y$73$KG$20221223$$MD$CA$CA
1521596310$15215963$10$F$20130514$20221020$20180730$20221028$EXP$$US-AstraZeneca-2018SE94894$ASTRAZENECA$$21361$DY$$F$Y$69.4$KG$20221028$$LW$US$
152161687$15216168$7$F$20150501$20221021$20180730$20221027$EXP$$PHHY2018FR054710$NOVARTIS$Guglielmetti L, Barkane L, Le Du D, Marigot-Outtandy D, Robert J, Veziris N et al.. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. EUROPEAN RESPIRATORY JOURNAL. 2018;51(3):1-12$25$YR$$M$Y$58$KG$20221027$$HP$FR$FR
1521877715$15218777$15$F$20180423$20221118$20180731$20221125$EXP$$DE-ROCHE-2153470$ROCHE$$46$YR$$F$Y$$$20221125$$CN$DE$
1522094514$15220945$14$F$20190101$20221021$20180731$20221028$EXP$$PHHY2018CA031760$NOVARTIS$$68$YR$$F$Y$$$20221028$$MD$CA$CA
152213548$15221354$8$F$20170311$20221114$20180731$20221119$EXP$$PHHY2017CA052250$NOVARTIS$$40$YR$$F$Y$$$20221119$$MD$CA$CA
152221628$15222162$8$F$20180701$20221213$20180731$20221215$EXP$$PHHY2018AU056336$NOVARTIS$$3$YR$$F$Y$26.5$KG$20221215$$MD$AU$AU
1522275914$15222759$14$F$20171022$20221212$20180731$20221220$EXP$$CO-SHIRE-CO201730041$TAKEDA$$64$YR$$M$Y$68$KG$20221220$$CN$CO$CO
1522487314$15224873$14$F$20180101$20221012$20180731$20221014$EXP$$CA-TAKEDA-2018TUS023049$TAKEDA$$45$YR$$F$Y$$$20221014$$MD$CA$CA
1522515839$15225158$39$F$20180101$20221111$20180801$20221120$EXP$$CA-CELLTRION INC.-2018CA020447$CELLTRION$$$$$$Y$$$20221121$$CN$CA$CA
152252125$15225212$5$F$20171010$20221213$20180801$20221220$EXP$$JP-ROCHE-2161152$ROCHE$$22$YR$$M$Y$59$KG$20221220$$MD$JP$JP
1522521544$15225215$44$F$20180719$20221005$20180801$20221015$EXP$$CA-CELLTRION INC.-2018CA021617$CELLTRION$$$$$$Y$$$20221015$$CN$CA$CA
152253979$15225397$9$F$20170101$20221208$20180801$20221215$EXP$$CA-TAKEDA-2017TUS019279$TAKEDA$$25$YR$$F$Y$$$20221215$$CN$CA$CA
152256645$15225664$5$F$$20221222$20180801$20221228$PER$$US-AMGEN-USASP2018104037$AMGEN$$73$YR$E$F$Y$$$20221228$$MD$US$US
1522571517$15225715$17$F$20180723$20221212$20180801$20221220$PER$$US-PFIZER INC-2018305349$PFIZER$$65$YR$$F$Y$48.98$KG$20221220$$MD$US$US
152274633$15227463$3$F$20221113$20221118$20180801$20221124$EXP$$US-SHIRE-US201829120$TAKEDA$$73$YR$$M$Y$$$20221124$$CN$US$US
152280432$15228043$2$F$$20221118$20180801$20221123$EXP$$US-SHIRE-US201829386$TAKEDA$$$$$M$Y$$$20221123$$CN$US$US
152283882$15228388$2$F$20151109$20221103$20180801$20221108$EXP$$FI-SSP-2018SA201327AA$SANOFI AVENTIS$Vuorio A, Budowle B, Sajantila A, Laukkala T, Junttila I, Kravik SE, et al.. Duty of notification and aviation safety-A study of fatal aviation accidents in the United States in 2015.. Int J Environ Res Public Health.. 2018;15(6):1-9$63$YR$A$M$Y$$$20221108$$HP$FI$US
152302599$15230259$9$F$20150505$20221013$20180802$20221018$EXP$$CA-ROCHE-2163199$ROCHE$$31$YR$$F$Y$$$20221018$$MD$CA$CA
1523239112$15232391$12$F$20171108$20221129$20180802$20221205$EXP$$PHHY2017CA183462$NOVARTIS$$61$YR$$F$Y$$$20221205$$CN$CA$CA
1523255511$15232555$11$F$20180724$20221117$20180802$20221123$EXP$$PHHY2018CA060023$NOVARTIS$$82$YR$$F$Y$$$20221123$$MD$CA$CA
1523378424$15233784$24$F$20180709$20221219$20180802$20221230$EXP$$BR-GLAXOSMITHKLINE-BR2017GSK169298$GLAXOSMITHKLINE$$$$$$Y$$$20221230$$MD$BR$BR
152361869$15236186$9$F$20180615$20221004$20180803$20221013$EXP$$DE-ROCHE-2161958$ROCHE$$43$YR$$M$Y$71$KG$20221011$$MD$DE$
1523893013$15238930$13$F$$20221019$20180803$20221029$EXP$$US-TEVA-2018-US-934732$TEVA$$58$YR$A$F$Y$$$20221029$$CN$US$US
1523933510$15239335$10$F$20180101$20221208$20180803$20221216$EXP$$CA-TAKEDA-2017TUS025092$TAKEDA$$69$YR$$F$Y$$$20221216$$CN$CA$CA
152393374$15239337$4$F$20171222$20221115$20180803$20221121$EXP$$CA-TAKEDA-2018TUS019033$TAKEDA$$65$YR$$M$Y$$$20221121$$CN$CA$CA
1523952712$15239527$12$F$20170101$20221214$20180803$20221227$PER$$US-PFIZER INC-2017258656$PFIZER$$57$YR$$F$Y$54$KG$20221227$$CN$US$US
152405514$15240551$4$F$$20180727$20180804$20221208$EXP$$GB-TEVA-2018-GB-934632$TEVA$$$$N$M$Y$$$20221208$$CN$GB$GB
152408906$15240890$6$F$20180101$20221014$20180804$20221020$PER$$US-AMGEN-USASP2018104577$AMGEN$$41$YR$A$M$Y$139.7$KG$20221019$$MD$US$US
1524324217$15243242$17$F$20181201$20221221$20180806$20221226$EXP$$CA-ROCHE-2161648$ROCHE$$37$YR$$F$Y$86.26$KG$20221226$$CN$CA$
1524337415$15243374$15$F$20180315$20221114$20180806$20221123$EXP$$BR-SA-2018SA083370$SANOFI AVENTIS$$55$YR$A$F$Y$100$KG$20221123$$MD$BR$BR
152437779$15243777$9$F$20180713$20221014$20180806$20221018$EXP$$JP-ROCHE-2163285$ROCHE$$54$YR$$F$Y$54.3$KG$20221018$$MD$JP$
152447463$15244746$3$F$$20221012$20180806$20221014$EXP$$US-SHIRE-US201829741$TAKEDA$$$$$F$Y$$$20221014$$MD$US$US
152447558$15244755$8$F$20180627$20221121$20180806$20221123$EXP$$US-SHIRE-US201830139$TAKEDA$$47$YR$$M$Y$83$KG$20221123$$MD$US$US
152452463$15245246$3$F$20180201$20221114$20180806$20221116$PER$$US-PFIZER INC-2018313823$PFIZER$$65$YR$$F$Y$$$20221116$$CN$US$US
1524739131$15247391$31$F$20180627$20221130$20180807$20221208$EXP$$CA-ROCHE-2163908$ROCHE$$22$YR$$F$Y$$$20221208$$HP$CA$CA
1524754818$15247548$18$F$20141221$20221214$20180807$20221221$EXP$$CO-ASTELLAS-2017US023151$ASTELLAS$$61$YR$$M$Y$$$20221221$$CN$BR$CO
152489128$15248912$8$F$$20221004$20180807$20221006$PER$$US-PFIZER INC-2018313968$PFIZER$$31$YR$$F$Y$$$20221006$$CN$US$US
152522286$15252228$6$F$20180701$20221123$20180807$20221128$EXP$$US-SHIRE-US201830068$TAKEDA$$41$YR$$F$Y$98$KG$20221128$$HP$US$US
1525346638$15253466$38$F$20180601$20220927$20180808$20221007$EXP$$CA-CELLTRION INC.-2018CA021299$CELLTRION$$$$$$Y$$$20221007$$CN$CA$CA
152535965$15253596$5$F$20180601$20221118$20180808$20221125$EXP$$CA-ROCHE-2165542$ROCHE$$12$YR$$M$Y$$$20221125$$MD$CA$CA
152536347$15253634$7$F$20141001$20221018$20180808$20221027$EXP$$AU-BIOGEN-2014BI117928$BIOGEN$$31$YR$$F$Y$$$20221027$$CN$AU$AU
1525425810$15254258$10$F$20180406$20221129$20180808$20221208$EXP$$CA-CELLTRION INC.-2018CA019226$CELLTRION$$$$$$Y$$$20221208$$CN$CA$CA
152545224$15254522$4$F$$20220930$20180808$20221014$EXP$$IT-MACLEODS PHARMACEUTICALS US LTD-MAC2018016266$MACLEODS$$$$$$Y$$$20221013$$MD$IT$IT
152550993$15255099$3$F$20180401$20221006$20180808$20221017$PER$$FR-AMGEN-FRASP2018108484$AMGEN$$40$YR$A$M$Y$60$KG$20221017$$MD$FR$FR
152564794$15256479$4$F$20180101$20221214$20180808$20221220$PER$$US-PFIZER INC-2018317829$PFIZER$$62$YR$$F$Y$$$20221220$$CN$US$US
152583628$15258362$8$F$$20221114$20180809$20221128$EXP$$GB-AUROBINDO-AUR-APL-2018-040492$AUROBINDO$$21$YR$$M$Y$$$20221128$$MD$GB$GB
152588842$15258884$2$F$20130101$20221123$20180809$20221130$PER$$US-BIOGEN-2014BI074150$BIOGEN$$$$$F$Y$$$20221130$$CN$US$US
152598945$15259894$5$F$20180727$20221111$20180809$20221118$EXP$$DE-SHIRE-DE201829467$TAKEDA$$9$YR$$M$Y$25$KG$20221118$$CN$DE$DE
1526040213$15260402$13$F$20171026$20221209$20180809$20221230$EXP$$JP-ABBVIE-18P-087-2447142-00$ABBVIE$$69$YR$$M$Y$$$20221214$$MD$JP$JP
1526049122$15260491$22$F$20180627$20221208$20180809$20221215$EXP$$PHHY2018CA037910$NOVARTIS$$60$YR$$F$Y$$$20221215$$CN$CA$CA
1526379730$15263797$30$F$20180508$20221128$20180810$20221205$EXP$$DE-ROCHE-2126374$ROCHE$$39$YR$$F$Y$70$KG$20221205$$MD$DE$DE
152653427$15265342$7$F$20180730$20221020$20180810$20221024$EXP$$US-ROCHE-2165713$ROCHE$$61$YR$$M$Y$106.5$KG$20221024$$MD$US$
152653485$15265348$5$F$$20221018$20180810$20221026$PER$$US-INCYTE CORPORATION-2018IN007648$INCYTE$$$$$$Y$$$20221026$$CN$US$US
152680512$15268051$2$F$20130101$20221213$20180812$20221215$PER$$US-JNJFOC-20180800527$JOHNSON AND JOHNSON$$15$YR$T$M$Y$$$20221216$$LW$US$US
1526948512$15269485$12$F$20180701$20221208$20180813$20221212$EXP$$US-ROCHE-2166552$ROCHE$$68$YR$$F$Y$54.48$KG$20221212$$CN$US$
1526972041$15269720$41$F$20180101$20221004$20180813$20221013$EXP$$CA-CELLTRION INC.-2018CA018685$CELLTRION$$$$$$Y$$$20221013$$CN$CA$CA
1526972844$15269728$44$F$20180701$20221115$20180813$20221123$EXP$$CA-CELLTRION INC.-2018CA021612$CELLTRION$$$$$$Y$$$20221124$$CN$CA$CA
1526998818$15269988$18$F$20180101$20221202$20180813$20221207$EXP$$US-PFIZER INC-2018323454$PFIZER$$68$YR$$F$Y$58.957$KG$20221207$$CN$US$US
152709136$15270913$6$F$20201001$20221122$20180813$20221128$PER$$US-PFIZER INC-2018323698$PFIZER$$70$YR$$F$Y$77.11$KG$20221128$$CN$US$US
152714379$15271437$9$F$20180101$20221205$20180813$20221207$PER$$US-PFIZER INC-2018321871$PFIZER$$76$YR$$F$Y$$$20221207$$CN$US$US
1527191113$15271911$13$F$20221207$20221208$20180813$20221215$EXP$$PHHY2018CA066775$NOVARTIS$$50$YR$$F$Y$$$20221215$$CN$CA$CA
152731743$15273174$3$F$20160101$20221118$20180813$20221128$EXP$$IN-MYLANLABS-2018M1061553$MYLAN$Kaur U, Chakrabarti SS, Gambhir IS, Gautam DK. Delayed neuroleptic malignant syndrome associated with the use of low dose risperidone in conjunction with cholinergic. drugs the dangers of polypharmacy in the elderly. Curr. Crug Ther. 2018;13(2):189-192$60$YR$$F$Y$$$20221128$$MD$IN$IN
152732845$15273284$5$F$20170101$20221007$20180813$20221017$EXP$$US-009507513-1808USA002913$MERCK$Hu Y, Lu W, Tang B, Zhao Z, An Z. Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study. Frontiers in Oncology. 2022;12$$$$M$Y$$$20221017$$CN$US$US
152755424$15275542$4$F$$20180821$20180814$20221210$EXP$$US-TEVA-2018-US-940630$TEVA$$$$$F$Y$$$20221210$$CN$US$US
152756883$15275688$3$F$$20221005$20180814$20221019$PER$$US-CELLTRION INC.-2018US021248$CELLTRION$$$$$$Y$$$20221019$$MD$US$US
152756983$15275698$3$F$20220216$20220223$20180814$20221012$PER$$US-CELLTRION INC.-2018US020380$CELLTRION$$$$$$Y$$$20221012$$HP$US$US
152757093$15275709$3$F$$20210621$20180814$20221012$PER$$US-CELLTRION INC.-2018US020247$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
152757373$15275737$3$F$$20200616$20180814$20221012$PER$$US-CELLTRION INC.-2018US019992$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
152757393$15275739$3$F$$20201209$20180814$20221012$PER$$US-CELLTRION INC.-2018US020856$CELLTRION$$$$$$Y$$$20221012$$HP$US$US
152757515$15275751$5$F$$20200825$20180814$20221012$PER$$US-CELLTRION INC.-2018US019959$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
1527627411$15276274$11$F$20170919$20220928$20180814$20221010$EXP$$GB-SA-2017SA220901$SANOFI AVENTIS$$51$YR$A$M$Y$88.9$KG$20221010$$HP$GB$GB
152775664$15277566$4$F$20180528$20180809$20180814$20221208$EXP$NL-LRB-00290564$NL-TEVA-2018-NL-940621$TEVA$$59$YR$A$M$Y$86$KG$20221208$$CN$NL$NL
152794543$15279454$3$F$20180731$20221130$20180815$20221209$EXP$$CA-ROCHE-2170335$ROCHE$$38$YR$$F$Y$$$20221209$$CN$CA$CA
152795155$15279515$5$F$20180101$20221215$20180815$20221222$PER$$US-PFIZER INC-2018323609$PFIZER$$58$YR$$F$Y$$$20221222$$HP$US$US
152795275$15279527$5$F$20180101$20221013$20180815$20221018$EXP$$US-PFIZER INC-2018112582$PFIZER$$72$YR$$M$Y$$$20221018$$HP$US$US
152799377$15279937$7$F$20221023$20221026$20180815$20221102$EXP$$PHHY2017CA072364$NOVARTIS$$58$YR$$F$Y$$$20221102$$CN$CA$CA
1528065511$15280655$11$F$20180701$20221220$20180815$20221221$EXP$$CA-TAKEDA-2018TUS024405$TAKEDA$$37$YR$$M$Y$$$20221221$$CN$CA$CA
1528066212$15280662$12$F$20171101$20221213$20180815$20221216$EXP$$CA-TAKEDA-2017TUS021615$TAKEDA$$36$YR$$M$Y$$$20221216$$MD$CA$CA
1528250628$15282506$28$F$20170629$20221110$20180816$20221118$EXP$$CA-CELLTRION INC.-2018CA021721$CELLTRION$$$$$$Y$$$20221119$$MD$CA$CA
152837744$15283774$4$F$$20221010$20180816$20221017$EXP$PHHY2018IT069648$PHHY2018IT069648$NOVARTIS$Carnovale C, Raschi E, Leonardi L, Moretti U, De Ponti F, Gentili M et al.. No signal of interactions between influenza vaccines and drugs used for chronic diseases: A case-by-case analysis of the vaccine adverse event reporting system and VigiBase. EXPERT REVIEW OF VACCINES. 2018;17(4):363-81$64$YR$$M$Y$$$20221017$$HP$IT$IT
152839232$15283923$2$F$20171101$20221110$20180816$20221118$EXP$$PHHY2017CO174720$NOVARTIS$$32$YR$$F$Y$59$KG$20221118$$CN$CO$CO
152843445$15284344$5$F$$20180817$20180816$20221210$PER$$US-TEVA-2018-US-945059$TEVA$$51$YR$A$F$Y$$$20221210$$CN$US$US
152853428$15285342$8$F$20180101$20221101$20180816$20221110$EXP$$CA-CELLTRION INC.-2018CA020482$CELLTRION$$$$$$Y$$$20221110$$HP$CA$CA
1528647515$15286475$15$F$$20221129$20180816$20221201$EXP$$CA-TAKEDA-2018TUS019093$TAKEDA$$39$YR$$F$Y$$$20221201$$MD$CA$CA
1528733710$15287337$10$F$20180101$20221121$20180817$20221130$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009860$ACADIA PHARMACEUTICALS$$$$$M$Y$85$KG$20221201$$CN$US$US
152873724$15287372$4$F$$20220929$20180817$20221003$EXP$$CA-Orion Corporation ORION PHARMA-TREX2018-2429$ORION$$68$YR$E$F$Y$81$KG$20221003$$HP$CA$
1528861312$15288613$12$F$20210101$20221109$20180817$20221116$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK120527$GLAXOSMITHKLINE$$$$$$Y$$$20221116$$CN$BR$BR
152894772$15289477$2$F$$20221013$20180817$20221017$PER$$US-SHIRE-US201831851$TAKEDA$$$$$M$Y$$$20221017$$HP$US$US
152901018$15290101$8$F$$20221025$20180817$20221101$EXP$$CA-PFIZER INC-2018313245$PFIZER$$68$YR$$M$Y$$$20221101$$CN$CA$CA
152922523$15292252$3$F$20170621$20221117$20180818$20221129$EXP$$IT-AUROBINDO-AUR-APL-2018-041687$AUROBINDO$$87$YR$$F$Y$$$20221129$$MD$IT$IT
152927064$15292706$4$F$20180525$20221110$20180819$20221117$EXP$$PHHY2018US075744$NOVARTIS$$68$YR$$F$Y$$$20221117$$MD$US$US
152941612$15294161$2$F$20180516$20221110$20180820$20221205$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009000$ACADIA PHARMACEUTICALS$$58$YR$$M$Y$$$20221205$$CN$US$US
1529421510$15294215$10$F$20180501$20221201$20180820$20221226$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009151$ACADIA PHARMACEUTICALS$$79$YR$$M$Y$$$20221226$$CN$US$US
152942774$15294277$4$F$$20221010$20180820$20221020$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009088$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221020$$CN$US$US
152943186$15294318$6$F$20180419$20221027$20180820$20221104$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009013$ACADIA PHARMACEUTICALS$$73$YR$$F$Y$$$20221104$$CN$US$US
152944736$15294473$6$F$20180101$20221220$20180820$20221229$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009613$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221230$$CN$US$US
152945223$15294522$3$F$$20220916$20180820$20221011$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009743$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221011$$CN$US$US
152945332$15294533$2$F$20180601$20221220$20180820$20221229$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009294$ACADIA PHARMACEUTICALS$$77$YR$$F$Y$$$20221230$$CN$US$US
152945985$15294598$5$F$20190601$20221101$20180820$20221110$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009403$ACADIA PHARMACEUTICALS$$75$YR$$M$Y$$$20221111$$CN$US$US
152946105$15294610$5$F$20180620$20221115$20180820$20221209$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009391$ACADIA PHARMACEUTICALS$$69$YR$$F$Y$$$20221209$$CN$US$US
152946282$15294628$2$F$20220928$20220927$20180820$20221020$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009429$ACADIA PHARMACEUTICALS$$75$YR$$M$Y$$$20221021$$CN$US$US
152947003$15294700$3$F$20180616$20220929$20180820$20221006$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009547$ACADIA PHARMACEUTICALS$$67$YR$$F$Y$$$20221007$$CN$US$US
152947024$15294702$4$F$20221113$20221116$20180820$20221124$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009250$ACADIA PHARMACEUTICALS$$87$YR$$F$Y$$$20221125$$CN$US$US
152947052$15294705$2$F$$20221107$20180820$20221117$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009535$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221117$$CN$US$US
152950613$15295061$3$F$$20221108$20180820$20221110$PER$$US-PFIZER INC-2018331223$PFIZER$$56$YR$$M$Y$$$20221110$$MD$US$US
1529549013$15295490$13$F$20180407$20221025$20180820$20221028$EXP$$PHHY2018DE005511$NOVARTIS$$4$WK$$F$Y$2$KG$20221028$$MD$DE$DE
1529615310$15296153$10$F$20170101$20221202$20180820$20221207$EXP$$CA-SA-2018SA000739$SANOFI AVENTIS$$61$YR$A$F$Y$67$KG$20221207$$HP$CA$CA
152976136$15297613$6$F$20180720$20221216$20180820$20221216$EXP$$AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-069402$BRISTOL MYERS SQUIBB$$74$YR$E$M$Y$85$KG$20221216$$HP$AU$AU
1529798719$15297987$19$F$20180601$20221202$20180820$20221212$EXP$$CA-CELLTRION INC.-2018CA021736$CELLTRION$$$$$$Y$$$20221212$$CN$CA$CA
152984444$15298444$4$F$20170101$20221117$20180820$20221125$EXP$$US-JAZZ-2018-US-012418$JAZZ$$$$$M$Y$$$20221125$$MD$US$US
1529894949$15298949$49$F$20180620$20221212$20180821$20221220$EXP$$CA-CELLTRION INC.-2018CA021989$CELLTRION$$$$$$Y$$$20221220$$MD$CA$CA
152990064$15299006$4$F$20180806$20221027$20180821$20221104$EXP$$IT-ROCHE-2172007$ROCHE$$56$YR$$F$Y$66$KG$20221103$$MD$IT$
1529904331$15299043$31$F$20180612$20221215$20180821$20221224$EXP$$CA-CELLTRION INC.-2018CA020869$CELLTRION$$$$$$Y$$$20221224$$CN$CA$CA
152995133$15299513$3$F$$20221118$20180821$20221202$EXP$$DK-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-182005$RANBAXY$Abel Mahedi Mohamed H, Nielsen CEN, Schiodt M. Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;Feb; 125(2):157-163$74$YR$$F$Y$$$20221202$$HP$DK$DK
1530013013$15300130$13$F$20180101$20221214$20180821$20221219$EXP$$US-PFIZER INC-2018334526$PFIZER$$87$YR$$M$Y$$$20221219$$HP$US$US
153001723$15300172$3$F$20180809$20221205$20180821$20221209$PER$$US-PFIZER INC-2018335189$PFIZER$$65$YR$$F$Y$$$20221209$$PH$US$US
153003326$15300332$6$F$20180612$20221129$20180821$20221206$EXP$$CA-ROCHE-2172207$ROCHE$$55$YR$$F$Y$$$20221206$$CN$CA$CA
1530162451$15301624$51$F$$20221130$20180821$20221208$EXP$$CA-PFIZER INC-2018332014$PFIZER$Farrell, B.. Managing polypharmacy in a 77-year-old woman with multiple prescribers. CMAJ. 2013;185 (14):10.1503/cmaj.122012$77$YR$$F$Y$$$20221208$$HP$CA$CA
153028426$15302842$6$F$20180203$20221007$20180821$20221010$EXP$$PHHY2018DE075920$NOVARTIS$$$$A$F$Y$70$KG$20221010$$MD$DE$DE
153047118$15304711$8$F$20180504$20221223$20180821$20221228$EXP$$JP-PFIZER INC-2018188353$PFIZER$$77$YR$$F$Y$43.2$KG$20221228$$MD$JP$JP
153061323$15306132$3$F$20180425$20221220$20180822$20221227$PER$$US-PFIZER INC-2018336961$PFIZER$$56$YR$$M$Y$$$20221227$$MD$US$US
153063132$15306313$2$F$20180719$20221109$20180822$20221122$EXP$$AT-ENDO PHARMACEUTICALS INC-2018-040696$ENDO$$70$YR$$M$Y$95$KG$20221122$$CN$AT$AT
153065912$15306591$2$F$20180515$20221219$20180822$20221223$EXP$$CA-GLAXOSMITHKLINE-CA2018GSK138102$GLAXOSMITHKLINE$$$$$$Y$$$20221223$$MD$CA$CA
1530694620$15306946$20$F$20170201$20221214$20180822$20221219$EXP$$PHHY2017CA021725$NOVARTIS$$42$YR$$F$Y$$$20221219$$CN$CA$CA
153071238$15307123$8$F$20180101$20221006$20180822$20221010$EXP$$CA-PFIZER INC-2018194090$PFIZER$$78$YR$$F$Y$$$20221010$$CN$CA$CA
153168499$15316849$9$F$20180222$20221123$20180824$20221201$EXP$$PHHY2018CA031959$NOVARTIS$$21$YR$$F$Y$$$20221201$$CN$CA$CA
153175335$15317533$5$F$20180626$20221007$20180824$20221011$EXP$$BE-B.I. Pharmaceuticals,Inc./Ridgefield-2018-BI-033910$BOEHRINGER INGELHEIM$$63$YR$A$M$Y$62.4$KG$20221011$$MD$BE$BE
153178158$15317815$8$F$$20221216$20180824$20221222$EXP$$US-ARIAD PHARMACEUTICALS, INC-2017US008804$TAKEDA$$$$$M$Y$$$20221222$$HP$US$US
1531796224$15317962$24$F$20171006$20221223$20180824$20221226$EXP$$PHHY2018GB074559$NOVARTIS$$3$MON$$M$Y$$$20221226$$HP$GB$GB
153200694$15320069$4$F$$20221013$20180827$20221017$PER$$US-PFIZER INC-2018340441$PFIZER$$65$YR$$F$Y$68.481$KG$20221017$$MD$US$US
153201245$15320124$5$F$20220201$20221019$20180827$20221025$EXP$$US-PFIZER INC-2018165756$PFIZER$$54$YR$$F$Y$$$20221025$$CN$US$US
153209017$15320901$7$F$$20221125$20180827$20221128$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2018-BI-042807$BOEHRINGER INGELHEIM$$85$YR$E$F$Y$$$20221128$$MD$CA$CA
153217584$15321758$4$F$20171129$20221216$20180827$20221221$EXP$$GB-SA-2018SA232687$SANOFI AVENTIS$$44$YR$A$F$Y$$$20221221$$HP$GB$GB
153222643$15322264$3$F$$20220929$20180827$20221004$EXP$$PHHY2018IT015839$NOVARTIS$Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Caruso C, Quaratino D. Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2016;138(1):179-86$45$YR$$F$Y$$$20221004$$HP$IT$IT
1532274113$15322741$13$F$20170101$20221123$20180827$20221126$EXP$$CA-TAKEDA-2017TUS014686$TAKEDA$$52$YR$$M$Y$$$20221126$$HP$CA$CA
1532384125$15323841$25$F$20180101$20221013$20180828$20221022$EXP$$CA-CELLTRION INC.-2018CA021509$CELLTRION$$$$$$Y$$$20221022$$CN$CA$CA
1532486831$15324868$31$F$20170401$20220930$20180828$20221010$EXP$$CA-CELLTRION INC.-2017CA005101$CELLTRION$$$$$$Y$$$20221010$$CN$CA$CA
1532486939$15324869$39$F$20180619$20221121$20180828$20221129$EXP$$CA-CELLTRION INC.-2018CA020813$CELLTRION$$$$$$Y$$$20221129$$CN$CA$CA
1532641210$15326412$10$F$20190401$20221128$20180828$20221202$PER$$US-SA-2018SA239772$SANOFI AVENTIS$$29$YR$A$F$Y$$$20221202$$MD$US$US
153264182$15326418$2$F$20180816$20221024$20180828$20221026$EXP$$US-SHIRE-US201832744$TAKEDA$$29$YR$$F$Y$$$20221026$$MD$US$US
153277448$15327744$8$F$$20221201$20180828$20221205$EXP$$CA-ROCHE-2176025$ROCHE$$$$$F$Y$$$20221205$$CN$CA$
1532797311$15327973$11$F$$20221202$20180828$20221207$EXP$$CA-ROCHE-2176030$ROCHE$$40$YR$$F$Y$$$20221207$$MD$CA$
153280204$15328020$4$F$20180811$20221124$20180828$20221128$PER$$KR-AMGEN-KORNI2018117529$AMGEN$$55$YR$A$M$Y$72.8$KG$20221127$$MD$KR$KR
153280679$15328067$9$F$20180801$20221215$20180828$20221222$EXP$$PHHY2018CA084138$NOVARTIS$$53$YR$$M$Y$$$20221222$$CN$CA$CA
1532890532$15328905$32$F$20180101$20221215$20180829$20221224$EXP$$CA-CELLTRION INC.-2018CA021662$CELLTRION$$$$$$Y$$$20221224$$MD$CA$CA
153308943$15330894$3$F$20140701$20221011$20180829$20221012$PER$$US-PFIZER INC-2018343743$PFIZER$$62$YR$$F$Y$$$20221012$$LW$US$US
153315026$15331502$6$F$20190712$20221014$20180829$20221020$EXP$$US-TAKEDA-2018TUS025703$TAKEDA$$65$YR$$M$Y$$$20221020$$CN$US$US
153317095$15331709$5$F$20161115$20221025$20180829$20221031$EXP$$PHHY2018DE077811$NOVARTIS$$$$E$F$Y$$$20221031$$MD$DE$DE
153319219$15331921$9$F$$20221227$20180829$20221229$EXP$$US-PFIZER INC-2018345158$PFIZER$$26$YR$$M$Y$$$20221229$$CN$US$US
153319243$15331924$3$F$20171129$20221116$20180829$20221123$EXP$$GB-ELI_LILLY_AND_COMPANY-GB201808011837$ELI LILLY AND CO$$44$YR$$F$Y$$$20221123$$CN$US$GB
153319877$15331987$7$F$20170201$20221006$20180829$20221118$EXP$$PHHY2017MX087931$NOVARTIS$$75$YR$$F$Y$60$KG$20221118$$CN$MX$MX
1533278615$15332786$15$F$$20221018$20180830$20221026$EXP$$DE-BIOGEN-2018BI00625629$BIOGEN$$$$$F$Y$$$20221026$$CN$DE$DE
153339128$15333912$8$F$$20221125$20180830$20221206$EXP$$CA-APOTEX-2018AP019346$APOTEX$$70$YR$$M$Y$$$20221206$$MD$CA$CA
1533441610$15334416$10$F$20180618$20221206$20180830$20221212$EXP$$US-PFIZER INC-2018346432$PFIZER$$65$YR$$M$Y$79$KG$20221212$$MD$US$US
153351784$15335178$4$F$20161213$20221114$20180830$20221124$EXP$ES-JNJFOC-20180825456$ES-JNJFOC-20180825456$JOHNSON AND JOHNSON$$51$YR$A$M$Y$$$20221124$$HP$ES$ES
1533718115$15337181$15$F$20180822$20221019$20180831$20221026$EXP$$CA-ROCHE-2174803$ROCHE$$44$YR$$M$Y$$$20221026$$CN$CA$
1533721813$15337218$13$F$$20221129$20180831$20221205$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-079001$BRISTOL MYERS SQUIBB$$58$YR$A$F$Y$$$20221205$$MD$CA$CA
153392884$15339288$4$F$20090101$20221101$20180831$20221103$EXP$$US-TAKEDA-2018TUS025132$TAKEDA$$$$$$Y$$$20221103$$CN$US$US
1534060717$15340607$17$F$20180828$20221124$20180831$20221202$EXP$$CA-TAKEDA-2018TUS026042$TAKEDA$$88$YR$$F$Y$$$20221202$$CN$CA$CA
153411603$15341160$3$F$20180401$20221011$20180831$20221019$EXP$PHHY2018IT086699$PHHY2018IT086699$NOVARTIS$$70$YR$$M$Y$$$20221019$$MD$IT$IT
153434143$15343414$3$F$$20180824$20180903$20221003$EXP$$JP-009507513-1807JPN000466J$MERCK$Makita H, Hara Y, Otsu S, Nakagawa Y, Fujii A. A case that muscle relaxant involvement was suspected as the cause of delayed awakening after laparoscopic nephrectomy. Summer Seminar in Anesthesiology. 2018$84$YR$$F$Y$50$KG$20221003$$MD$JP$JP
1534351319$15343513$19$F$20180101$20221010$20180903$20221018$EXP$$US-PFIZER INC-2016524113$MYLAN$$$$$F$Y$69.4$KG$20221018$$CN$US$US
1534384817$15343848$17$F$$20221013$20180903$20221025$EXP$$US-GLAXOSMITHKLINE-US2018GSK159053$PERRIGO$$$$$$Y$$$20221025$$CN$US$US
153440092$15344009$2$F$20180716$20221215$20180903$20221221$EXP$$PHHY2018DE086604$NOVARTIS$$80$YR$$F$Y$59$KG$20221221$$MD$DE$DE
1534574348$15345743$48$F$20180101$20221213$20180904$20221222$EXP$$CA-CELLTRION INC.-2018CA020487$CELLTRION$$$$$$Y$$$20221222$$MD$CA$CA
153463063$15346306$3$F$20180809$20221008$20180904$20221018$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-081057$BRISTOL MYERS SQUIBB$$58$YR$A$M$Y$64.9$KG$20221018$$HP$US$US
153464503$15346450$3$F$20170301$20221003$20180904$20221007$PER$$US-PFIZER INC-2018292192$PFIZER$$34$YR$$F$Y$73$KG$20221007$$CN$US$US
1534674733$15346747$33$F$20180808$20221021$20180904$20221028$EXP$$PHHY2018CA042976$NOVARTIS$$43$YR$$F$Y$$$20221028$$CN$CA$CA
1534824313$15348243$13$F$20151116$20221208$20180904$20221220$EXP$$US-GLAXOSMITHKLINE-US2018GSK159249$PERRIGO$$$$$$Y$$$20221220$$CN$US$US
153486837$15348683$7$F$20180717$20221024$20180904$20221025$EXP$$US-ALKERMES INC.-ALK-2018-003878$ALKERMES$$46$YR$$F$Y$43.991$KG$20221025$$MD$US$US
153491012$15349101$2$F$20150101$20221227$20180904$20221229$PER$$US-PFIZER INC-2018350109$PFIZER$$68$YR$$F$Y$$$20221229$$CN$US$US
1534970022$15349700$22$F$20180801$20221109$20180904$20221111$EXP$$CA-TAKEDA-2018TUS021487$TAKEDA$$55$YR$$M$Y$$$20221111$$HP$CA$CA
1535118210$15351182$10$F$20191101$20221209$20180905$20221215$EXP$$US-PFIZER INC-2018358017$MYLAN$$71$YR$$M$Y$96$KG$20221215$$CN$US$US
153522572$15352257$2$F$$20180828$20180905$20221108$EXP$$PT-VIIV HEALTHCARE LIMITED-PT2018160231$VIIV$Coutinho F, Horta M, Rocha E, Vasconcelos C, Araujo A. Merkel Cell carcinoma and the challenge in its approach: a review based on a clinical context of immunosuppression.. Porto Biomedical Journal.. 2018;3:unk$87$YR$$F$Y$$$20221108$$MD$PT$PT
1535265913$15352659$13$F$20200601$20221219$20180905$20221226$EXP$$PHHY2017CA134651$NOVARTIS$$51$YR$$F$Y$$$20221226$$MD$CA$CA
153528162$15352816$2$F$$20180828$20180905$20221108$EXP$$PT-GLAXOSMITHKLINE-PT2018160231$GLAXOSMITHKLINE$Coutinho F, Horta M, Rocha E, Vasconcelos C, Araujo A. Merkel Cell carcinoma and the challenge in its approach: a review based on a clinical context of immunosuppression.. Porto Biomedical Journal.. 2018;3:unk$87$YR$$F$Y$$$20221108$$MD$PT$PT
153536148$15353614$8$F$$20221017$20180905$20221020$EXP$$CA-JAZZ-2017-CA-005108$JAZZ$$5$MON$$F$Y$$$20221020$$HP$CA$CA
1535438335$15354383$35$F$20180101$20221014$20180906$20221024$EXP$$CA-CELLTRION INC.-2018CA018615$CELLTRION$$$$$$Y$$$20221024$$CN$CA$CA
153550878$15355087$8$F$20180701$20221014$20180906$20221019$EXP$$US-PFIZER INC-2018356095$PFIZER$$63$YR$$M$Y$107$KG$20221019$$CN$US$US
153553679$15355367$9$F$20180427$20221208$20180906$20221212$EXP$$DE-ROCHE-2179879$ROCHE$$50$YR$$F$Y$79$KG$20221212$$CN$DE$
153554184$15355418$4$F$20020901$20221203$20180906$20221217$EXP$$DE-AUROBINDO-AUR-APL-2017-04488$AUROBINDO$Schiessl B, Schneider KT, Zimmermann A, Kainer F, Friese K, Oberhoffer R.. Prenatal constriction of the fetal ductus arteriosus--related to maternal pain medication?.. Z Geburtsh Neonatol. 2005;209(2):65-8$$$N$F$Y$2.85$KG$20221217$$MD$DE$DE
153565629$15356562$9$F$20180101$20221219$20180906$20221222$PER$$US-BIOGEN-2018BI00625823$BIOGEN$$$$$F$Y$$$20221222$$CN$US$US
153567327$15356732$7$F$20210101$20221104$20180906$20221111$EXP$$US-PFIZER INC-2018346749$PFIZER$$73$YR$$F$Y$49.9$KG$20221111$$HP$US$US
1535744325$15357443$25$F$20100629$20221004$20180906$20221018$EXP$GB-EMA-DD-20180827-ASHWINIHVP-120514$GB-NOVOPROD-619477$NOVO NORDISK$$43$YR$$F$Y$43$KG$20221018$$HP$GB$GB
1535951912$15359519$12$F$20180528$20221102$20180907$20221109$EXP$$CA-ROCHE-2131663$ROCHE$$33$YR$$F$Y$77.27$KG$20221109$$HP$CA$
153603126$15360312$6$F$$20221214$20180907$20221220$EXP$$US-PFIZER INC-2015308824$MYLAN$$$$$F$Y$$$20221220$$CN$US$US
1536188018$15361880$18$F$20171006$20221125$20180907$20221129$EXP$$PHHY2018GB085930$NOVARTIS$$3$MON$$M$Y$$$20221129$$HP$GB$GB
153622022$15362202$2$F$$20221011$20180907$20221018$EXP$$PL-GLAXOSMITHKLINE-PL2018159487$GLAXOSMITHKLINE$Wikiera-Magott I, Fornalczyk K, Zwolinska D.. From body piercing to acute kidney injury a case report.. PEDIATRIA I MEDYCYNA RODZINNA.. 2017;13(4):561-6$17$YR$$F$Y$$$20221018$$HP$PL$PL
1536302521$15363025$21$F$20171006$20220927$20180907$20221011$EXP$GB-EMA-DD-20180827-KSEVHUMANWT-125137$GB-NOVOPROD-619421$NOVO NORDISK$$3$MON$$M$Y$$$20221011$$HP$GB$GB
1536427213$15364272$13$F$20150325$20221212$20180909$20221219$EXP$$PHHY2017GB204768$NOVARTIS$$49$YR$$F$Y$$$20221219$$MD$GB$GB
153645926$15364592$6$F$20171001$20221101$20180910$20221103$EXP$$CA-ABBVIE-18P-028-2477000-00$ABBVIE$$32$YR$$F$Y$$$20221103$$MD$CA$CA
1536477411$15364774$11$F$$20221130$20180910$20221204$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2018-BI-032422$BOEHRINGER INGELHEIM$$$$E$F$Y$75$KG$20221204$$MD$ES$ES
1536491410$15364914$10$F$20170901$20221128$20180910$20221206$EXP$$CA-ROCHE-2181907$ROCHE$$53$YR$$F$Y$$$20221206$$CN$CA$CA
1536506314$15365063$14$F$20180315$20221110$20180910$20221117$EXP$$DE-ROCHE-2110206$ROCHE$$28$YR$$F$Y$62$KG$20221117$$CN$DE$
153651642$15365164$2$F$$20221115$20180910$20221121$EXP$$US-009507513-1809USA002521$MERCK$$$$$F$Y$$$20221121$$CN$US$US
1536667613$15366676$13$F$$20220921$20180910$20221005$EXP$$CA-GLAXOSMITHKLINE-CA2018GSK140656$GLAXOSMITHKLINE$$$$$$Y$$$20221005$$MD$CA$CA
153678759$15367875$9$F$20171214$20221027$20180910$20221102$EXP$$CA-TAKEDA-2018TUS026561$TAKEDA$$36$YR$$F$Y$$$20221102$$CN$CA$CA
153681566$15368156$6$F$20221107$20221206$20180910$20221210$EXP$$US-SHIRE-US201833949$TAKEDA$$36$YR$$M$Y$95$KG$20221210$$CN$US$US
1536825617$15368256$17$F$$20221028$20180910$20221104$EXP$$PHHY2018CA090852$NOVARTIS$$$$$M$Y$$$20221104$$CN$CA$CA
153696135$15369613$5$F$$20221207$20180911$20221213$PER$$US-PFIZER INC-2018361818$PFIZER$$65$YR$$F$Y$82$KG$20221213$$CN$US$US
1536991026$15369910$26$F$20200724$20221219$20180911$20221227$EXP$$CA-CELLTRION INC.-2018CA021546$CELLTRION$$$$$$Y$$$20221227$$CN$CA$CA
1536994347$15369943$47$F$20180801$20221109$20180911$20221117$EXP$$CA-CELLTRION INC.-2018CA021813$CELLTRION$$$$$$Y$$$20221117$$HP$CA$CA
153723065$15372306$5$F$20180904$20221108$20180911$20221109$EXP$$FR-Eisai Medical Research-EC-2018-044954$EISAI$$72$YR$E$M$Y$72$KG$20221109$$MD$FR$
1537242230$15372422$30$F$20180124$20221011$20180911$20221018$EXP$$PHHY2017CA039769$NOVARTIS$$71$YR$$M$Y$$$20221018$$CN$CA$CA
153729764$15372976$4$F$$20221114$20180912$20221116$EXP$$GB-ROCHE-2182922$ROCHE$$$$E$F$Y$$$20221116$$CN$GB$
153730444$15373044$4$F$20180826$20221118$20180912$20221121$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-083311$BRISTOL MYERS SQUIBB$$74$YR$E$M$Y$90.72$KG$20221121$$HP$US$US
153748183$15374818$3$F$$20221104$20180912$20221108$EXP$$PHHY2018FR091011$NOVARTIS$Sokal A, Elefant E, Leturcq T, Beghin D, Mariette X, Seror R. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. OSTEOPOROSIS INTERNATIONAL. 2018;30(1):221-9$$$N$$Y$$$20221108$$HP$FR$FR
153752942$15375294$2$F$$20221005$20180912$20221011$EXP$$US-SHIRE-US201834697$TAKEDA$$$$$F$Y$$$20221011$$CN$US$US
153765083$15376508$3$F$20180701$20221205$20180912$20221212$EXP$$US-JAZZ-2018-US-013612$JAZZ$$46$YR$$M$Y$88.889$KG$20221212$$MD$US$US
1537670624$15376706$24$F$20190515$20221107$20180913$20221116$EXP$$CA-CELLTRION INC.-2018CA022414$CELLTRION$$$$$$Y$$$20221116$$MD$CA$CA
153771794$15377179$4$F$$20221018$20180913$20221020$EXP$$US-SHIRE-US201835245$TAKEDA$$$$$F$Y$$$20221020$$CN$US$US
153775722$15377572$2$F$20140101$20220929$20180913$20221008$EXP$$US-TEVA-2018-US-953615$TEVA$$39$YR$A$F$Y$52$KG$20221008$$LW$US$US
153786697$15378669$7$F$20180101$20221013$20180913$20221020$EXP$$CA-PFIZER INC-2018369609$PFIZER$$76$YR$$M$Y$$$20221020$$CN$CA$CA
153789508$15378950$8$F$20180909$20221116$20180913$20221118$EXP$$AU-Eisai Medical Research-EC-2018-045011$EISAI$$53$YR$A$M$Y$80$KG$20221118$$MD$AU$
153813967$15381396$7$F$$20220815$20180913$20221005$EXP$$US-ASTELLAS-2018US031071$ASTELLAS$$$$$M$Y$$$20221005$$CN$US$US
153847165$15384716$5$F$$20221128$20180914$20221206$PER$$PHHY2018US097188$NOVARTIS$$$$$F$Y$$$20221206$$CN$US$US
1538536221$15385362$21$F$20170101$20220919$20180914$20221001$EXP$$CA-CELLTRION INC.-2017CA016395$CELLTRION$$$$$$Y$$$20221001$$HP$CA$CA
1538536320$15385363$20$F$20181126$20221221$20180914$20221230$EXP$$CA-CELLTRION INC.-2018CA022467$CELLTRION$$$$$$Y$$$20221231$$MD$CA$CA
153863542$15386354$2$F$$20221017$20180914$20221024$EXP$$PHHY2012ES062473$NOVARTIS$Vecino R, Santiago Garcia B, Baquero-Artigao F, Lopez GL, Garcia C, Munoz G et al.. Tuberculosis in pediatric solid organ and hematopoietic stem cell transplant recipients. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2012;31(7):774-7$3$YR$$M$Y$$$20221024$$HP$ES$ES
153880934$15388093$4$F$$20221105$20180915$20221117$EXP$$PT-AUROBINDO-AUR-APL-2018-045640$AUROBINDO$Coutinho F, Horta M, Rocha E,Vasconcelos C, Araujo A.. Merkel cell carcinoma and the challenge in its approach: a review based on a clinical context of immunosuppression.. Porto Biomed J.. 2018;3(1):1-4$87$YR$$F$Y$$$20221117$$MD$PT$PT
1538875737$15388757$37$F$20150901$20220825$20180916$20221202$EXP$$CA-ROCHE-2182492$ROCHE$$43$YR$$F$Y$97$KG$20221202$$MD$CA$
1539042310$15390423$10$F$20180427$20221206$20180917$20221215$EXP$$CA-ROCHE-2184991$ROCHE$$31$YR$$F$Y$$$20221215$$MD$CA$CA
153904465$15390446$5$F$$20221005$20180917$20221010$EXP$$PHEH2018US037364$NOVARTIS$$$$$F$Y$$$20221010$$CN$US$US
1539046648$15390466$48$F$20161201$20220926$20180917$20221006$EXP$$CA-CELLTRION INC.-2018CA018731$CELLTRION$$$$$$Y$$$20221006$$CN$CA$CA
1539046938$15390469$38$F$20170101$20221219$20180917$20221227$EXP$$CA-CELLTRION INC.-2017CA002981$CELLTRION$$$$$$Y$$$20221227$$CN$CA$CA
153928133$15392813$3$F$20170715$20221102$20180917$20221114$EXP$$DE-PFIZER INC-2018370089$PFIZER$$$$E$F$Y$$$20221114$$MD$DE$DE
153929922$15392992$2$F$$20221024$20180917$20221108$EXP$$TR-MYLANLABS-2018M1066455$MYLAN$Dincer M., Akgun A., Bodur S., Gul H., Tas Torun Y., Bolu A. et,al.. Hyperammonemic encephalopathy without hepatic dysfunction due to treatment with valproate: four cases and a mini review. Psychiatry and clinical psychopharmacology. 2018$38$YR$$F$Y$$$20221108$$HP$TR$TR
1539438840$15394388$40$F$20170601$20221208$20180918$20221219$EXP$$CA-ROCHE-2184987$ROCHE$$64$YR$$F$Y$$$20221219$$MD$CA$CA
153946602$15394660$2$F$20170611$20221010$20180918$20221021$EXP$ES-AEMPS-314648$ES-Accord-072015$ACCORD$$92$YR$E$F$Y$$$20221021$$MD$ES$ES
1539591152$15395911$52$F$20151110$20221128$20180918$20221205$EXP$$GB-MYLANLABS-2018M1066446$MYLAN$$67$YR$$F$Y$$$20221205$$MD$GB$GB
1539632933$15396329$33$F$20160101$20221129$20180918$20221208$EXP$$CA-JNJFOC-20180911207$JOHNSON AND JOHNSON$$54$YR$A$F$Y$76$KG$20221208$$HP$CA$CA
154004122$15400412$2$F$$20180910$20180919$20221104$EXP$$NL-ROCHE-2186839$ROCHE$$45$YR$$F$Y$$$20221103$$HP$NL$NL
1540112317$15401123$17$F$$20221213$20180919$20221215$EXP$$DE-ABBVIE-18K-062-2483634-00$ABBVIE$$63$YR$$F$Y$$$20221215$$HP$CA$CA
154017302$15401730$2$F$20131206$20220930$20180919$20221004$PER$$US-PFIZER INC-2018376276$PFIZER$$62$YR$$F$Y$$$20221004$$LW$US$US
1540173220$15401732$20$F$20180105$20220920$20180919$20221003$EXP$$CA-CELLTRION INC.-2018CA017540$CELLTRION$$$$$$Y$$$20221003$$CN$CA$CA
154017985$15401798$5$F$$20221118$20180919$20221123$EXP$$US-PFIZER INC-2018376843$PFIZER$$72$YR$$F$Y$$$20221123$$CN$US$US
154028402$15402840$2$F$$20221010$20180919$20221014$EXP$$CA-PFIZER INC-2018374183$PFIZER$$65$YR$$F$Y$89$KG$20221014$$HP$CA$CA
154032454$15403245$4$F$20161115$20221024$20180919$20221101$EXP$$DE-PFIZER INC-2018372386$PFIZER$$$$E$F$Y$$$20221101$$MD$DE$DE
1540524817$15405248$17$F$20150325$20221219$20180920$20221221$EXP$$GB-ROCHE-2080942$ROCHE$$49$YR$$F$Y$$$20221222$$MD$GB$GB
154060067$15406006$7$F$$20221205$20180920$20221209$EXP$$US-PFIZER INC-2018351113$PFIZER$$80$YR$$F$Y$71.202$KG$20221209$$MD$US$US
1540779610$15407796$10$F$20150325$20221109$20180920$20221114$EXP$$GB-PFIZER INC-2018374144$PFIZER$$49$YR$$F$Y$$$20221114$$MD$GB$GB
154087732$15408773$2$F$$20220926$20180920$20221003$EXP$$PHHY2018DE098505$NOVARTIS$Hoppe J, Holderied A, Schafer H, Lottspeich C, Vielhauer V, Anders H-J et al.. Drug-induced CYP-induction as therapy for tacrolimus intoxication. TRANSPLANTATION. 2018;102(7):S600$56$YR$$M$Y$$$20221003$$HP$DE$DE
154095504$15409550$4$F$20180101$20221219$20180920$20221223$EXP$$US-TAKEDA-2018TUS027595$TAKEDA$$31$YR$$F$Y$95.238$KG$20221223$$MD$US$US
154101264$15410126$4$F$$20221117$20180921$20221125$EXP$$CZ-AUROBINDO-AUR-APL-2018-025570$AUROBINDO$Horinkova J, Bartecek R, Fedorova S et al.. Electroconvulsive therapy in the treatment of patient with depressive disorder after traumatic brain injury,intracranial bleeding, and polytrauma. Journal of ECT. 2017;33(3):22-4$58$YR$$F$Y$$$20221125$$MD$CZ$CZ
154131219$15413121$9$F$20171124$20220930$20180921$20221006$EXP$$IN-PFIZER INC-2018360606$PFIZER$$62$YR$$F$Y$$$20221006$$CN$IN$IN
154150464$15415046$4$F$20180906$20221216$20180921$20221223$EXP$$JP-009507513-1809JPN001847J$MERCK$Ito K, Kondo Y, Takamizawa S, Enei Y, Imai Y, Inaba H, et al.. O09-5 Experience with pembrolizumab, avelumab and enfortumab vedotin for metastatic urothelial cancer in our hospital. The 72nd Annual Meeting of Central Section of Japanese Urological Association. 174$79$YR$$M$Y$46$KG$20221223$$MD$JP$JP
154154977$15415497$7$F$20180101$20221031$20180922$20221104$EXP$$CA-TAKEDA-2018TUS027828$TAKEDA$$56$YR$$M$Y$$$20221104$$MD$CA$CA
154156183$15415618$3$F$$20221028$20180922$20221102$EXP$$US-SHIRE-US201836319$TAKEDA$$$$$F$Y$$$20221102$$CN$US$US
154157602$15415760$2$F$$20221205$20180922$20221208$PER$$US-JNJFOC-20180912307$JOHNSON AND JOHNSON$$$$$M$Y$$$20221208$$LW$US$US
154158242$15415824$2$F$$20221205$20180922$20221208$PER$$US-JNJFOC-20180912330$JOHNSON AND JOHNSON$$$$$M$Y$$$20221208$$LW$US$US
1541649424$15416494$24$F$20070101$20221128$20180924$20221202$EXP$$PHHY2017CA072370$NOVARTIS$$$$$F$Y$$$20221202$$CN$CA$CA
154171153$15417115$3$F$20150101$20221020$20180924$20221028$PER$$US-AMGEN-USASP2018131049$AMGEN$$62$YR$A$M$Y$$$20221028$$MD$US$US
154190846$15419084$6$F$20180101$20220930$20180924$20221005$EXP$$FR-JAZZ-2018-FR-014047$JAZZ$$$$$$Y$$$20221005$$HP$FR$FR
154200392$15420039$2$F$20180601$20220919$20180924$20221003$EXP$$US-ALLERGAN-1837886US$ALLERGAN$$$$$F$Y$$$20221003$$CN$US$US
154211513$15421151$3$F$$20220104$20180924$20221018$PER$$US-ALLERGAN-1752481US$ALLERGAN$$$$$F$Y$$$20221018$$CN$US$US
1542250234$15422502$34$F$20180222$20221117$20180925$20221125$EXP$$CA-CELLTRION INC.-2017CA003346$CELLTRION$$$$$$Y$$$20221125$$MD$CA$CA
154235846$15423584$6$F$20150101$20221020$20180925$20221031$PER$$US-PFIZER INC-2018379400$PFIZER$$62$YR$$M$Y$$$20221031$$MD$US$US
154264589$15426458$9$F$20180901$20221021$20180925$20221024$EXP$$US-PFIZER INC-2018383407$PFIZER$$71$YR$$F$Y$$$20221024$$HP$US$US
154274887$15427488$7$F$20220129$20221111$20180925$20221121$EXP$$CA-SHIRE-CA201836863$TAKEDA$$28$YR$$M$Y$$$20221121$$HP$CA$CA
154275818$15427581$8$F$20170630$20221114$20180925$20221118$EXP$$PHHY2017CA106692$NOVARTIS$$59$YR$$F$Y$$$20221118$$MD$CA$CA
154281265$15428126$5$F$20180913$20221013$20180926$20221019$EXP$$JP-ALEXION PHARMACEUTICALS INC.-A201812439$ALEXION$$43$YR$$F$Y$$$20221019$$MD$JP$JP
1542893113$15428931$13$F$20180501$20221207$20180926$20221217$EXP$$CA-CELLTRION INC.-2018CA018279$CELLTRION$$$$$$Y$$$20221217$$MD$CA$CA
1542894242$15428942$42$F$20170901$20221215$20180926$20221222$EXP$$CA-CELLTRION INC.-2017CA013003$CELLTRION$$$$$$Y$$$20221223$$CN$CA$CA
1542916212$15429162$12$F$20180601$20221214$20180926$20221219$EXP$$US-PFIZER INC-2018384726$PFIZER$$67$YR$$F$Y$80.74$KG$20221219$$CN$US$US
154294337$15429433$7$F$$20221031$20180926$20221107$EXP$$CA-GLENMARK PHARMACEUTICALS-2018GMK034349$GLENMARK$$$$$$Y$$$20221107$$MD$CA$CA
154298458$15429845$8$F$$20221128$20180926$20221202$EXP$$CA-PFIZER INC-2016303618$PFIZER$$75$YR$$F$Y$$$20221202$$CN$CA$CA
1543068312$15430683$12$F$20160101$20221220$20180926$20221229$EXP$$AU-PFIZER INC-2018381092$PFIZER$$30$YR$$M$Y$$$20221229$$LW$AU$AU
1543074619$15430746$19$F$20180601$20221114$20180926$20221119$EXP$$PHHY2018CA108900$NOVARTIS$$46$YR$$F$Y$$$20221119$$CN$CA$CA
1543101119$15431011$19$F$20150101$20221205$20180926$20221210$EXP$$PHHY2015CA072899$NOVARTIS$$60$YR$$F$Y$$$20221210$$CN$CA$CA
154317356$15431735$6$F$20180101$20221212$20180926$20221216$EXP$$US-PFIZER INC-2018389324$PFIZER$$53$YR$$M$Y$$$20221216$$CN$US$US
154339018$15433901$8$F$20160125$20221031$20180927$20221107$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-018388$BRISTOL MYERS SQUIBB$Asanabe M. The practice of team medical care for immune checkpoint inhibitors.The present situation of cross-disciplinary medical care team-From a nurse^s point of view 2017;17:20-3.$45$YR$A$M$Y$50$KG$20221107$$HP$JP$JP
154342394$15434239$4$F$$20181003$20180927$20221208$EXP$$JP-TEVA-2018-JP-957131$TEVA$Sakata Y, Taga F, Ushigami T, Takeda K, Anzawa K, Nishibu A, et al. A Case of Cutaneous Mycosis Caused by Scedosporium dehoogii on an Immunocompromised Patient. Mycopathol 2018;183(2):465-470.$77$YR$E$M$Y$$$20221208$$HP$JP$JP
154343856$15434385$6$F$20180920$20221019$20180927$20221021$EXP$$AR-ROCHE-2188505$ROCHE$$72$YR$$M$Y$80.8$KG$20221021$$MD$AR$
154345117$15434511$7$F$$20221122$20180927$20221129$EXP$$SK-MYLANLABS-2018M1070023$MYLAN$Lacmanova H, Richter T, Topinkova E.. Indapamide-induced hyponatremia at 83 years old patients.. Geri to Gero. 2018;7 (1):40-3$83$YR$$F$Y$$$20221129$$MD$CZ$CZ
1543466220$15434662$20$F$20180801$20221214$20180927$20221223$EXP$$JP-JNJFOC-20170714850$JOHNSON AND JOHNSON$$63$YR$A$M$Y$$$20221223$$CN$JP$JP
154348675$15434867$5$F$20180829$20221018$20180927$20221028$EXP$$EG-PFIZER INC-2018354074$PFIZER$$60$YR$$M$Y$63$KG$20221028$$PH$EG$EG
154362196$15436219$6$F$20181122$20221202$20180927$20221212$EXP$$US-PFIZER INC-2018388899$MYLAN$$85$YR$$F$Y$76$KG$20221212$$CN$US$US
154379773$15437977$3$F$20130101$20221114$20180928$20221121$EXP$$US-AstraZeneca-2018SF20570$ASTRAZENECA$$66$YR$$M$Y$110.2$KG$20221121$$LW$US$
154380106$15438010$6$F$20180901$20221219$20180928$20221225$EXP$$BR-BIOGEN-2018BI00636348$BIOGEN$$25$YR$$M$Y$65$KG$20221225$$CN$BR$BR
154383696$15438369$6$F$20170101$20221117$20180928$20221124$EXP$$US-BIOGEN-2018BI00636487$BIOGEN$$$$$F$Y$$$20221124$$CN$US$US
154385738$15438573$8$F$20171024$20221209$20180928$20221214$EXP$$JP-ABBVIE-18P-087-2312549-00$ABBVIE$$74$YR$$M$Y$$$20221214$$MD$JP$JP
154388394$15438839$4$F$$20221208$20180928$20221216$PER$$US-AMGEN-USASP2018133697$AMGEN$$45$YR$A$M$Y$$$20221216$$MD$US$US
154478947$15447894$7$F$20170101$20221118$20180928$20221124$EXP$$PHHY2017CA014133$NOVARTIS$$$$$F$Y$105$KG$20221124$$MD$CA$CA
1544995611$15449956$11$F$$20221109$20181001$20221116$EXP$$GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-086169$BRISTOL MYERS SQUIBB$Fadhlillah F, Patil S. Pharmacological and mechanical management of calcium channel blocker toxicity. BMJ Case Reports. 2018; 1-6. doi:10.1136/bcr-2018-225324.$64$YR$A$M$Y$$$20221116$$MD$GB$GB
1545167016$15451670$16$F$20180101$20221122$20181001$20221130$EXP$$JP-UNITED THERAPEUTICS-UNT-2018-014008$UNITED THERAPEUTICS$$$$$M$Y$81.5$KG$20221130$$MD$JP$JP
154521694$15452169$4$F$20161123$20221205$20181001$20221212$EXP$$US-JAZZ-2018-US-013280$JAZZ$$28$YR$$F$Y$$$20221212$$MD$US$US
154524562$15452456$2$F$20170101$20220913$20181001$20221026$PER$$US-JAZZ-2018-US-009961$JAZZ$$$$$F$Y$$$20221026$$CN$US$US
154528253$15452825$3$F$20180913$20221021$20181001$20221025$EXP$$CA-JNJFOC-20180931824$JOHNSON AND JOHNSON$$17$YR$T$F$Y$68$KG$20221025$$HP$CA$CA
154531444$15453144$4$F$20180925$20221128$20181001$20221130$PER$$US-BIOGEN-2018BI00639192$BIOGEN$$33$YR$$F$Y$$$20221130$$CN$US$US
154537252$15453725$2$F$20220801$20220825$20181001$20221005$PER$$PHEH2018US040102$NOVARTIS$$66$YR$$M$Y$$$20221005$$CN$US$US
154541025$15454102$5$F$$20221121$20181002$20221129$EXP$$CA-ROCHE-2189300$ROCHE$$64$YR$$F$Y$$$20221129$$HP$CA$
154551334$15455133$4$F$$20221026$20181002$20221101$EXP$$US-PFIZER INC-2017296843$PFIZER$$80$YR$$F$Y$$$20221101$$CN$US$US
1545644517$15456445$17$F$20180118$20221017$20181002$20221019$EXP$$PHHY2018GB114442$NOVARTIS$$76$YR$$M$Y$69$KG$20221019$$HP$GB$GB
154583026$15458302$6$F$20180914$20221114$20181003$20221116$PER$$US-PFIZER INC-2018338529$PFIZER$$67$YR$$F$Y$$$20221116$$CN$US$US
154585453$15458545$3$F$20180118$20221014$20181003$20221020$EXP$$GB-ABBVIE-18S-167-2506787-00$ABBVIE$$76$YR$$M$Y$$$20221020$$MD$GB$GB
1546053432$15460534$32$F$20160613$20221210$20181003$20221215$EXP$$NO-SAKK-2018SA167682AA$SANOFI AVENTIS$$50$YR$A$F$Y$82$KG$20221215$$HP$NO$NO
154614652$15461465$2$F$20180920$20221107$20181003$20221109$PER$$US-SHIRE-US201837994$TAKEDA$$58$YR$$F$Y$$$20221109$$CN$US$US
1546231222$15462312$22$F$20080615$20221108$20181004$20221122$EXP$$CA-AstraZeneca-2017SE55839$ASTRAZENECA$$44$YR$$F$Y$63$KG$20221122$$MD$CA$
1546312516$15463125$16$F$20180920$20221006$20181004$20221013$EXP$$CA-ROCHE-2194192$ROCHE$$38$YR$$F$Y$$$20221013$$CN$CA$CA
154633163$15463316$3$F$20170101$20221108$20181004$20221115$EXP$$ES-PURDUE-GBR-2018-0059748$PURDUE$$55$YR$$F$Y$$$20221115$$MD$ES$ES
154633853$15463385$3$F$20180131$20221108$20181004$20221116$EXP$$GB-ASTELLAS-2018US042433$ASTELLAS$$76$YR$$M$Y$$$20221116$$HP$GB$GB
154635888$15463588$8$F$20180613$20220927$20181004$20221006$EXP$$BR-EMD Serono-E2B_90060297$EMD SERONO INC$$54$YR$A$F$Y$$$20221006$$CN$BR$
1546363921$15463639$21$F$20180917$20221205$20181004$20221208$EXP$$JP-ROCHE-2190972$ROCHE$$54$YR$$M$Y$62.5$KG$20221208$$MD$JP$
154653212$15465321$2$F$20180204$20221024$20181004$20221031$EXP$$JP-INCYTE CORPORATION-2018IN009788$INCYTE$$$$$$Y$$$20221101$$MD$JP$JP
154654605$15465460$5$F$20221022$20221025$20181004$20221031$EXP$$US-SHIRE-US201838043$TAKEDA$$32$YR$$F$Y$$$20221031$$CN$US$US
154664586$15466458$6$F$20181012$20221108$20181004$20221111$PER$$US-BIOGEN-2018BI00623908$BIOGEN$$51$YR$$F$Y$$$20221111$$CN$US$US
1546722123$15467221$23$F$20180911$20221215$20181005$20221220$EXP$$CA-ROCHE-2184897$ROCHE$$38$YR$$F$Y$$$20221220$$CN$CA$
154675532$15467553$2$F$$20220922$20181005$20221006$EXP$$DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2018R1-186273$RANBAXY$H John, Holderied A, Schafer H, Lottspeich C, Vielhauer V, Hans-Joachim A et al. Drug-induced CYP-Induction as Therapy for Tacrolimus Intoxication. Clin Nephrol Case Stud. 2022;10(1):42-46$54$YR$$M$Y$$$20221006$$MD$DE$DE
154678939$15467893$9$F$20180927$20221012$20181005$20221019$EXP$$CA-ROCHE-2194732$ROCHE$$53$YR$$F$Y$$$20221019$$CN$CA$
154705655$15470565$5$F$20180901$20221129$20181005$20221202$EXP$$US-SHIRE-US201838154$TAKEDA$$34$YR$$F$Y$$$20221202$$HP$US$US
1547057221$15470572$21$F$20160101$20221122$20181005$20221125$EXP$$PHHY2016CA163833$NOVARTIS$$$$$M$Y$$$20221125$$MD$CA$CA
1547058914$15470589$14$F$20180822$20221122$20181005$20221125$EXP$$CA-TAKEDA-2018TUS027388$TAKEDA$$38$YR$$M$Y$$$20221125$$HP$CA$CA
154706794$15470679$4$F$$20221014$20181005$20221018$PER$$US-PFIZER INC-2018397920$PFIZER$$58$YR$$F$Y$$$20221018$$CN$US$US
154740903$15474090$3$F$$20221014$20181008$20221020$EXP$$US-TAKEDA-2018TUS028895$TAKEDA$$$$$M$Y$$$20221020$$CN$US$US
154743649$15474364$9$F$20180301$20221006$20181008$20221010$EXP$$CA-TAKEDA-2018TUS004627$TAKEDA$$53$YR$$M$Y$$$20221010$$CN$CA$CA
154750435$15475043$5$F$20150501$20221212$20181008$20221216$EXP$$FR-MYLANLABS-2018M1074165$MYLAN$Guglielmetti L, Barkane L, Le Du D, Marigot-Outtandy D, Robert J, Veziris N, et al.. Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.. Eur.Resp.J.. 2018;51(3):1-12$25$YR$$M$Y$58$KG$20221216$$MD$FR$FR
154758738$15475873$8$F$20170919$20221012$20181009$20221019$EXP$$PHHY2017CA139939$NOVARTIS$$54$YR$$M$Y$$$20221019$$CN$CA$CA
154761563$15476156$3$F$$20221115$20181009$20221121$EXP$$US-SHIRE-US201838701$TAKEDA$$$$$F$Y$$$20221121$$MD$US$US
154769613$15476961$3$F$$20221122$20181009$20221123$PER$$US-BIOGEN-2018BI00641202$BIOGEN$$$$$F$Y$$$20221123$$CN$US$US
154782322$15478232$2$F$$20221122$20181009$20221129$EXP$$CZ-MYLANLABS-2018M1073750$MYLAN$Lacmanova H, Richter T, Topinkova E.. Indapamidem indukovana hyponatremie u 83 lete pacientky.. Geriatrie A Gerontologie. 2018;1:40-3$83$YR$$F$Y$$$20221129$$MD$CZ$CZ
154795734$15479573$4$F$$20221125$20181009$20221201$EXP$$CA-BAUSCH-BL-2018-027119$BAUSCH AND LOMB$Hohl C, Badke K, Zhao A, Wickham M, Woo S, Sivilotti M, Perry J. Prospective validation of clinical criteria to identify emergency department patients at high risk for adverse drug events. Academic Emergency Medicine. 2018 SEP;25(9):1015-1026. doi:10.1111/acem.13407$73$YR$$M$Y$$$20221201$$MD$CA$CA
154805498$15480549$8$F$20140301$20221012$20181010$20221021$EXP$$US-BIOGEN-2014BI077808$BIOGEN$$66$YR$$F$Y$$$20221021$$CN$US$US
154805843$15480584$3$F$20180806$20221115$20181010$20221116$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-083934$BRISTOL MYERS SQUIBB$$76$YR$E$M$Y$78.5$KG$20221116$$HP$US$US
154825825$15482582$5$F$$20221128$20181010$20221201$EXP$$US-PFIZER INC-2018403971$PFIZER$Idrees, N.. Hemodialysis for treatment of levofloxacin-induced neurotoxicity. Hemodialysis International. 2018;10.1111/hdi.12687$82$YR$$F$Y$67.5$KG$20221201$$HP$US$US
154825865$15482586$5$F$$20221128$20181010$20221201$EXP$$US-PFIZER INC-2018403830$PFIZER$Idrees, N.. Hemodialysis for treatment of levofloxacin-induced neurotoxicity. Hemodialysis International. 2018;10.1111/hdi.12687$82$YR$$F$Y$134$KG$20221201$$HP$US$US
154831407$15483140$7$F$$20221209$20181010$20221214$PER$$US-PFIZER INC-2018404431$PFIZER$$85$YR$$M$Y$$$20221214$$HP$US$US
1548383512$15483835$12$F$20180901$20221003$20181010$20221005$PER$$US-PFIZER INC-2018054936$PFIZER$$81$YR$$F$Y$71$KG$20221005$$CN$US$US
1548419811$15484198$11$F$20160901$20221207$20181010$20221214$EXP$$GB-MYLANLABS-2018M1066442$MYLAN$$50$YR$$F$Y$$$20221214$$MD$GB$GB
154846322$15484632$2$F$20221205$20221208$20181010$20221215$EXP$$US-SHIRE-US201838217$TAKEDA$$76$YR$$F$Y$$$20221215$$CN$US$US
154861942$15486194$2$F$$20221114$20181011$20221123$EXP$$CA-CPL-000710$CADILA$Hohl CM, Badke K, Zhao A, Wickham ME, Woo SA, Sivilotti MLA et al. Prospective Validation of Clinical Criteria to Identify Emergency Department Patients at High Risk for Adverse Drug Events. Academic Emergency Medicine. 2018;25(9):1015-1026$84$YR$E$M$Y$$$20221123$$MD$CA$CA
154862682$15486268$2$F$$20221111$20181011$20221117$EXP$$CA-009507513-1810CAN002067$MERCK$$62$YR$$M$Y$$$20221117$$MD$CA$CA
1548636019$15486360$19$F$20181003$20221117$20181011$20221124$EXP$$CA-ROCHE-2195389$ROCHE$$50$YR$$M$Y$90.8$KG$20221124$$CN$CA$
1548675930$15486759$30$F$20180420$20221006$20181011$20221013$EXP$$CA-ROCHE-2113859$ROCHE$$24$YR$$F$Y$$$20221013$$CN$CA$
154867868$15486786$8$F$20191130$20221115$20181011$20221122$EXP$$CA-ROCHE-2197778$ROCHE$$34$YR$$F$Y$$$20221122$$HP$CA$
1548696024$15486960$24$F$20180801$20221215$20181011$20221224$EXP$$CA-CELLTRION INC.-2018CA021910$CELLTRION$$$$$$Y$$$20221224$$CN$CA$CA
1548696127$15486961$27$F$20180101$20221115$20181011$20221124$EXP$$CA-CELLTRION INC.-2018CA022766$CELLTRION$$$$$$Y$$$20221124$$CN$CA$CA
154885022$15488502$2$F$20120625$20221122$20181011$20221124$EXP$FR-EMA-20161021-PSEVHUMANWTDD-101254839$FR-PURDUE PHARMA-GBR-2018-0060350$PURDUE$Cuny P, Houot M, Ginisty S, Horowicz S, Plassart F, Mentec H et al. Quetiapine and anticholinergic drugs induced ischaemic colitis: A case study. Encephale. 2016;43:81-84$34$YR$$M$Y$$$20221124$$MD$FR$FR
154891893$15489189$3$F$$20221102$20181011$20221104$EXP$$US-PFIZER INC-2018409585$PFIZER$$75$YR$$F$Y$$$20221104$$HP$US$US
154899719$15489971$9$F$$20221119$20181011$20221129$EXP$$CO-INCYTE CORPORATION-2016IN006289$INCYTE$$$$$$Y$$$20221129$$CN$CO$CO
1549019016$15490190$16$F$20180101$20221026$20181011$20221101$EXP$$US-PFIZER INC-2018277896$PFIZER$$60$YR$$F$Y$50$KG$20221101$$CN$US$US
154905096$15490509$6$F$20180130$20221121$20181011$20221123$EXP$$PHHY2018GB122621$NOVARTIS$$76$YR$$M$Y$69$KG$20221123$$PH$GB$GB
154905506$15490550$6$F$20181002$20221107$20181011$20221115$EXP$$PHHO2018IT010967$NOVARTIS$$49$YR$$F$Y$45$KG$20221115$$MD$IT$IT
154908684$15490868$4$F$20171201$20221219$20181011$20221227$PER$$PHEH2018US043044$NOVARTIS$$$$A$F$Y$$$20221227$$HP$US$US
154909143$15490914$3$F$20180610$20221128$20181012$20221212$EXP$$IT-AUROBINDO-AUR-APL-2018-049793$AUROBINDO$$27$YR$$M$Y$$$20221212$$MD$IT$IT
1549133423$15491334$23$F$20180510$20221216$20181012$20221226$EXP$$CA-CELLTRION INC.-2018CA020165$CELLTRION$$$$$$Y$$$20221226$$HP$CA$CA
154919974$15491997$4$F$$20221114$20181012$20221124$EXP$CA-MLMSERVICE-20180925-1392894-1$CA-LUPIN PHARMACEUTICALS INC.-2018-07104$LUPIN$Hohl CM, Badke K, Zhao A, Wickham ME, Woo SA, Sivilotti MLA, et al. Prospective Validation of Clinical Criteria to Identify Emergency Department Patients at High Risk for Adverse Drug Events. Academic Emergency Medicine. 2018;25(9):1015-1027$84$YR$$M$Y$$$20221124$$MD$CA$CA
154944994$15494499$4$F$20180910$20221117$20181012$20221121$EXP$$PT-009507513-1809PRT001357$MERCK$$40$YR$$F$Y$65$KG$20221121$$PH$PT$PT
154947502$15494750$2$F$$20220930$20181012$20221006$EXP$$PHHY2017CA002550$NOVARTIS$$$$$M$Y$$$20221006$$CN$CA$CA
154949915$15494991$5$F$$20221017$20181012$20221020$EXP$$CA-GLAXOSMITHKLINE-CA2016200565$GLAXOSMITHKLINE$$55$YR$$F$Y$$$20221020$$HP$CA$CA
154954002$15495400$2$F$$20221125$20181013$20221209$EXP$$CA-MACLEODS PHARMACEUTICALS US LTD-MAC2018017404$MACLEODS$Hohl CM, Badke K, Zhao A, Wickham ME, Woo SA, Sivilotti MLA et al.. Prospective Validation of Clinical Criteria to Identify Emergency Department Patients at High Risk for Adverse Drug Events.. Academic Emergency Medicine.. 2018;25(9):1015-1026$$$$$Y$$$20221208$$MD$CA$CA
154956926$15495692$6$F$20220101$20221219$20181013$20221226$EXP$$PHHY2018CA122596$NOVARTIS$$51$YR$$F$Y$$$20221226$$CN$CA$CA
1549712223$15497122$23$F$20180702$20221222$20181015$20221228$EXP$$DE-ROCHE-2154800$ROCHE$$35$YR$$F$Y$$$20221228$$CN$DE$DE
154980924$15498092$4$F$20180824$20221223$20181015$20221228$EXP$$US-ROCHE-2185830$ROCHE$$64$YR$$F$Y$$$20221228$$CN$US$
154983157$15498315$7$F$$20221114$20181015$20221128$EXP$$RO-AUROBINDO-AUR-APL-2018-049776$AUROBINDO$Astefanei SM, Cristea A, Zaharie A, Deleanu O.. Another Approach of Resistant Hypertension: What to Do When the Pharmacological Treatment Fails?.. Modern Medicine. 2018;25(3):175-80$42$YR$$F$Y$$$20221128$$MD$RO$RO
154991146$15499114$6$F$20221027$20221109$20181015$20221114$EXP$$US-SHIRE-US201837842$TAKEDA$$68$YR$$F$Y$85$KG$20221114$$CN$US$US
1550108910$15501089$10$F$20170808$20221011$20181015$20221018$EXP$$DE-SHIRE-DE201835447$TAKEDA$$32$YR$$F$Y$65$KG$20221018$$HP$DE$DE
155013467$15501346$7$F$20170316$20221003$20181015$20221008$EXP$$PHHY2017CA042727$NOVARTIS$$73$YR$$F$Y$$$20221008$$MD$CA$CA
155022223$15502222$3$F$20180101$20221214$20181015$20221221$PER$$US-AMGEN INC.-USASP2018118193$AMGEN$$53$YR$A$F$Y$$$20221221$$CN$US$US
155055462$15505546$2$F$$20221003$20181016$20221017$EXP$$RO-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-187804$RANBAXY$Astefanei SM, Cristea AM, Deleanu OC. Another Approach of Resistant Hypertension: What to Do When the Pharmacological Treatment Fails?. Modern Medicine. 2018;25(3):175-180$42$YR$$F$Y$$$20221017$$MD$RO$RO
155056622$15505662$2$F$20150301$20221109$20181016$20221110$EXP$$US-TAKEDA-2018TUS029863$TAKEDA$$$$$$Y$$$20221110$$CN$US$US
1550597018$15505970$18$F$20030101$20221130$20181016$20221202$EXP$$US-PFIZER INC-2018419222$PFIZER$$50$YR$$F$Y$95.71$KG$20221202$$CN$US$US
1550645323$15506453$23$F$20180101$20221122$20181016$20221201$EXP$$CA-CELLTRION INC.-2018CA022247$CELLTRION$$$$$$Y$$$20221201$$MD$CA$CA
155067963$15506796$3$F$20170101$20221117$20181016$20221124$EXP$$US-ROCHE-2195118$ROCHE$$51$YR$$M$Y$129.39$KG$20221124$$CN$US$
155082012$15508201$2$F$20110101$20221205$20181016$20221207$EXP$$US-PFIZER INC-2018156116$PFIZER$$$$$M$Y$$$20221207$$CN$US$US
155082933$15508293$3$F$20180927$20221222$20181016$20221227$EXP$$FR-SA-2018SA282834$SANOFI AVENTIS$$52$YR$A$M$Y$40$KG$20221227$$HP$FR$FR
1550856911$15508569$11$F$$20221004$20181016$20221010$EXP$$GB-MYLANLABS-2018M1075556$MYLAN$$$$$F$Y$97$KG$20221010$$HP$GB$CA
155096637$15509663$7$F$20170428$20221109$20181016$20221121$EXP$$CA-GLAXOSMITHKLINE-CA2017204463$GLAXOSMITHKLINE$$46$YR$$F$Y$$$20221121$$MD$CA$CA
155119423$15511942$3$F$$20221121$20181016$20221123$EXP$$US-TAKEDA-2018TUS029987$TAKEDA$$$$$$Y$$$20221123$$CN$US$US
155150805$15515080$5$F$$20221018$20181017$20221024$PER$$US-AMGEN-USASP2018143430$AMGEN$$72$YR$E$F$Y$$$20221024$$MD$US$US
1551556213$15515562$13$F$20181016$20221220$20181017$20221226$EXP$$CA-ROCHE-2197803$ROCHE$$52$YR$$M$Y$$$20221226$$CN$CA$
1551557236$15515572$36$F$20180628$20221216$20181017$20221221$EXP$$DE-ROCHE-2199160$ROCHE$$35$YR$$F$Y$$$20221221$$CN$DE$
1551577810$15515778$10$F$20160522$20221108$20181017$20221122$EXP$$FR-AUROBINDO-AUR-APL-2018-049422$AUROBINDO$$50$YR$$F$Y$106$KG$20221122$$CN$FR$FR
1551634011$15516340$11$F$20180601$20221220$20181017$20221229$EXP$$CA-CELLTRION INC.-2018CA020225$CELLTRION$$$$$$Y$$$20221230$$CN$CA$CA
155178432$15517843$2$F$20150701$20221013$20181017$20221019$EXP$$US-PFIZER INC-2018163032$PFIZER$$$$$M$Y$$$20221019$$LW$US$US
155180233$15518023$3$F$$20190401$20181017$20221216$EXP$$PHHY2018BR124700$NOVARTIS$$$$E$F$Y$$$20221216$$CN$BR$BR
1551826314$15518263$14$F$20181011$20221013$20181017$20221017$PER$$US-PFIZER INC-2018414579$PFIZER$$63$YR$$F$Y$95$KG$20221017$$MD$US$US
155233382$15523338$2$F$$20221108$20181018$20221110$PER$$US-BIOGEN-2018BI00645898$BIOGEN$$$$$F$Y$$$20221110$$CN$US$US
155241554$15524155$4$F$20060831$20221220$20181019$20221228$EXP$$US-AstraZeneca-2018SF35245$ASTRAZENECA$$29285$DY$$M$Y$88.5$KG$20221228$$LW$US$
155242079$15524207$9$F$20160801$20221107$20181019$20221110$EXP$$US-BIOGEN-2018BI00646037$BIOGEN$$50$YR$$F$Y$$$20221110$$CN$US$US
1552548710$15525487$10$F$20181011$20221130$20181018$20221206$EXP$$GB-MYLANLABS-2018M1077453$MYLAN$$50$YR$$M$Y$$$20221206$$HP$GB$GB
155300563$15530056$3$F$20170901$20221110$20181018$20221111$EXP$$US-TAKEDA-2018TUS029999$TAKEDA$$$$$$Y$$$20221111$$CN$US$US
155314693$15531469$3$F$20150301$20221108$20181019$20221111$EXP$$US-AstraZeneca-2018SF32578$ASTRAZENECA$$690$MON$$F$Y$98.4$KG$20221111$$LW$US$
155321906$15532190$6$F$$20221201$20181019$20221212$PER$$US-PFIZER INC-2018422327$PFIZER$$58$YR$$M$Y$$$20221212$$MD$US$US
155326045$15532604$5$F$20110101$20221206$20181019$20221209$EXP$$US-AstraZeneca-2018SF35144$ASTRAZENECA$$54$YR$$F$Y$53.5$KG$20221209$$LW$US$
155327504$15532750$4$F$$20221205$20181019$20221209$PER$$US-PFIZER INC-2018425584$PFIZER$$73$YR$$F$Y$$$20221209$$MD$US$US
155328244$15532824$4$F$$20221031$20181019$20221104$PER$$US-PFIZER INC-2018417027$GLAXOSMITHKLINE$$$$$M$Y$$$20221104$$MD$US$US
155339443$15533944$3$F$20140224$20221115$20181019$20221121$EXP$$US-AstraZeneca-2018SF35148$ASTRAZENECA$$19300$DY$$F$Y$89.8$KG$20221121$$LW$US$
155339454$15533945$4$F$20131202$20221118$20181019$20221121$EXP$$US-AstraZeneca-2018SF32569$ASTRAZENECA$$22743$DY$$M$Y$89.8$KG$20221121$$LW$US$
155344455$15534445$5$F$20180717$20200106$20181022$20221222$EXP$$TW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-098369$BRISTOL MYERS SQUIBB$$74$YR$E$M$Y$$$20221222$$CN$TW$TW
1553466478$15534664$78$F$20180927$20221222$20181022$20221229$EXP$$DE-ROCHE-2193244$ROCHE$$$$A$F$Y$60$KG$20221229$$CN$DE$
1553493318$15534933$18$F$20211105$20221123$20181022$20221202$EXP$$CA-TAKEDA-2018TUS030178$TAKEDA$$73$YR$$M$Y$$$20221202$$MD$CA$CA
155357462$15535746$2$F$$20221014$20181022$20221018$PER$$US-PFIZER INC-2018422455$PFIZER$$68$YR$$F$Y$$$20221018$$MD$US$US
155358254$15535825$4$F$$20221128$20181022$20221130$PER$$US-PFIZER INC-2018423691$PFIZER$$72$YR$$M$Y$$$20221130$$MD$US$US
155359137$15535913$7$F$$20221026$20181022$20221116$PER$$US-PFIZER INC-2018428162$PFIZER$$61$YR$$F$Y$$$20221116$$CN$US$US
155367212$15536721$2$F$20160101$20221205$20181022$20221207$EXP$$US-PFIZER INC-2018205590$PFIZER$$$$$F$Y$$$20221207$$LW$US$US
155370032$15537003$2$F$20180823$20180824$20181022$20221210$PER$$US-TEVA-2018-US-949653$TEVA$$$$$M$Y$$$20221210$$CN$US$US
155373094$15537309$4$F$$20221201$20181022$20221206$EXP$$IN-PFIZER INC-2018427070$PFIZER$$79$YR$$F$Y$$$20221206$$CN$IN$IN
155377829$15537782$9$F$$20221214$20181022$20221227$EXP$$CA-GLENMARK PHARMACEUTICALS-2018GMK037855$GLENMARK$$$$$$Y$$$20221227$$HP$CA$CA
155378453$15537845$3$F$20180922$20221103$20181022$20221107$EXP$$PHHO2018IT011324$NOVARTIS$$67$YR$$F$Y$70$KG$20221107$$MD$IT$IT
155394874$15539487$4$F$20180401$20220929$20181023$20221011$EXP$FR-AFSSAPS-NY20181736$FR-TEVA-2018-FR-967563$TEVA$$69$YR$E$F$Y$60$KG$20221011$$MD$FR$FR
1553974713$15539747$13$F$20181012$20221128$20181023$20221202$EXP$$CA-ROCHE-2202888$ROCHE$$28$YR$$F$Y$$$20221202$$CN$CA$
1553986810$15539868$10$F$20181013$20221024$20181023$20221028$EXP$$GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-096980$BRISTOL MYERS SQUIBB$$56$YR$A$M$Y$79$KG$20221028$$HP$GB$GB
1553991726$15539917$26$F$20180901$20221117$20181023$20221209$EXP$$FR-ABBVIE-18K-056-2522084-00$ABBVIE$$73$YR$$M$Y$74$KG$20221209$$MD$FR$FR
155407907$15540790$7$F$$20221017$20181023$20221023$EXP$$GB-BIOGEN-2018BI00647943$BIOGEN$$$$$F$Y$$$20221023$$CN$GB$GB
155409793$15540979$3$F$$20221118$20181023$20221121$EXP$$CA-JNJFOC-20181024918$JOHNSON AND JOHNSON$$44$YR$A$F$Y$$$20221121$$HP$CA$CA
155423014$15542301$4$F$20090101$20221014$20181023$20221019$EXP$$US-PFIZER INC-2018125818$PFIZER$$43$YR$$M$Y$$$20221019$$CN$US$US
1554231715$15542317$15$F$$20221004$20181023$20221017$PER$$US-PFIZER INC-2017484076$PFIZER$$59$YR$$F$Y$$$20221017$$CN$US$US
155430686$15543068$6$F$20180101$20221219$20181023$20221227$EXP$$CA-PFIZER INC-2018374743$PFIZER$$54$YR$$F$Y$$$20221227$$CN$CA$CA
155431433$15543143$3$F$20181014$20221108$20181023$20221111$PER$$US-SHIRE-US201840349$TAKEDA$$34$YR$$F$Y$$$20221111$$MD$US$US
1554316435$15543164$35$F$20160101$20221212$20181023$20221227$EXP$$CA-PFIZER INC-2016253265$PFIZER$$65$YR$$F$Y$$$20221227$$CN$CA$CA
1554384912$15543849$12$F$20160517$20221026$20181023$20221031$EXP$$CA-TAKEDA-2016TUS008650$TAKEDA$$13$YR$$F$Y$$$20221031$$CN$CA$CA
155444703$15544470$3$F$20180813$20181018$20181024$20221208$EXP$GB-MHRA-EYC 00184188$GB-TEVA-2018-GB-952316$TEVA$$4$YR$C$M$Y$14.2$KG$20221208$$MD$GB$GB
1554561625$15545616$25$F$20181116$20221202$20181024$20221212$EXP$$CA-CELLTRION INC.-2018CA022134$CELLTRION$$$$$$Y$$$20221212$$CN$CA$CA
1554688610$15546886$10$F$$20221214$20181024$20221223$EXP$$CA-GLENMARK PHARMACEUTICALS-2018GMK037856$GLENMARK$$$$$$Y$$$20221223$$HP$CA$CA
1554691012$15546910$12$F$20220830$20221213$20181024$20221214$EXP$$US-TAKEDA-2018TUS025681$TAKEDA$$63$YR$$F$Y$42.7$KG$20221214$$HP$US$US
1554695422$15546954$22$F$20171009$20221031$20181024$20221109$EXP$$NL-SA-2018SA141172$SANOFI AVENTIS$$47$YR$A$F$Y$76$KG$20221109$$HP$NL$NL
155469666$15546966$6$F$$20221218$20181024$20221226$EXP$$CA-TEVA-2018-CA-967835$TEVA$$76$YR$E$F$Y$$$20221226$$CN$CA$CA
1554732914$15547329$14$F$20181004$20221006$20181024$20221013$EXP$$GB-MYLANLABS-2018M1079272$MYLAN$$18$YR$$M$Y$$$20221013$$MD$GB$GB
155481756$15548175$6$F$20171013$20221024$20181024$20221028$EXP$$CA-TAKEDA-2018TUS013242$TAKEDA$$72$YR$$M$Y$$$20221028$$HP$CA$CA
155494715$15549471$5$F$$20221220$20181025$20221222$PER$$US-PFIZER INC-2018429471$PFIZER$$67$YR$$F$Y$$$20221222$$MD$US$US
1554951612$15549516$12$F$20180101$20221216$20181025$20221222$EXP$$US-PFIZER INC-2018432889$PFIZER$$71$YR$$F$Y$76$KG$20221222$$CN$US$US
155496114$15549611$4$F$20210430$20221026$20181025$20221101$EXP$$US-SHIRE-US201840316$TAKEDA$$79$YR$$F$Y$$$20221101$$CN$US$US
155499344$15549934$4$F$$20221213$20181025$20221215$PER$$US-PFIZER INC-2018435839$PFIZER$$74$YR$$F$Y$$$20221215$$MD$US$US
155513588$15551358$8$F$$20221026$20181025$20221107$EXP$$CA-GLENMARK PHARMACEUTICALS-2018GMK037872$GLENMARK$$$$$$Y$$$20221107$$HP$CA$CA
155513609$15551360$9$F$$20221121$20181025$20221202$EXP$$CA-GLENMARK PHARMACEUTICALS-2018GMK037884$GLENMARK$$$$$$Y$$$20221202$$HP$CA$CA
155516719$15551671$9$F$20200821$20221228$20181025$20221229$EXP$$CA-TAKEDA-2018TUS012453$TAKEDA$$52$YR$$M$Y$$$20221229$$MD$CA$CA
155520823$15552082$3$F$$20221202$20181025$20221206$PER$$US-PFIZER INC-2018428800$PFIZER$$73$YR$$F$Y$$$20221206$$MD$US$US
1555258716$15552587$16$F$20150901$20221212$20181025$20221222$EXP$$CA-PFIZER INC-2015183050$PFIZER$$56$YR$$F$Y$$$20221222$$MD$CA$CA
155530016$15553001$6$F$20171026$20221215$20181026$20221219$EXP$$JP-TAKEDA-2018TJP026707$TAKEDA$Sadamitsu T, Ueda T, Boku E, Tanaka T, Yokoyama T, Yoshimura A. Spontaneous colonic perforation with collagenous colitis in an elderly patient. Clinical Journal of Gastroenterology. 2022;15:1083-7$90$YR$$F$Y$43$KG$20221219$$HP$JP$JP
155542155$15554215$5$F$20200101$20221201$20181026$20221206$PER$$US-PFIZER INC-2018436363$PFIZER$$68$YR$$M$Y$$$20221206$$HP$US$US
155542205$15554220$5$F$$20221130$20181026$20221206$PER$$US-PFIZER INC-2018435984$PFIZER$$68$YR$$F$Y$$$20221206$$MD$US$US
155551688$15555168$8$F$20170301$20221107$20181026$20221110$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2018JPN193652$VIIV$$$$$$Y$$$20221110$$MD$JP$JP
155551697$15555169$7$F$20140912$20221107$20181026$20221110$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2018JPN193647$VIIV$$$$$$Y$$$20221110$$MD$JP$JP
1555543513$15555435$13$F$$20221212$20181026$20221221$EXP$$CA-PFIZER INC-2016241426$PFIZER$$58$YR$$F$Y$$$20221221$$MD$CA$CA
155564992$15556499$2$F$20171207$20221122$20181026$20221130$EXP$$US-AstraZeneca-2018SF37596$ASTRAZENECA$$14325$DY$$M$Y$68$KG$20221130$$LW$US$
155574865$15557486$5$F$20160621$20221104$20181027$20221122$EXP$$CA-ABBVIE-18K-028-2528634-00$ABBVIE$$68$YR$$M$Y$63$KG$20221122$$MD$CA$CA
1555853029$15558530$29$F$$20221212$20181028$20221219$PER$$CA-AMGEN-CANSP2018149419$AMGEN$$59$YR$A$F$Y$68$KG$20221219$$HP$CA$CA
155587564$15558756$4$F$$20221010$20181029$20221013$PER$$US-AMGEN-USASP2018149733$AMGEN$$70$YR$E$F$Y$$$20221012$$HP$US$US
155587648$15558764$8$F$20181018$20221215$20181029$20221220$EXP$$DE-ROCHE-2206440$ROCHE$$38$YR$$F$Y$$$20221220$$CN$DE$
1555968716$15559687$16$F$20181011$20221209$20181029$20221215$EXP$$GB-BAUSCH-BL-2018-029228$BAUSCH AND LOMB$$50$YR$$M$Y$$$20221215$$HP$GB$GB
1555977340$15559773$40$F$20171201$20221005$20181029$20221013$EXP$$PHHY2017CA195895$NOVARTIS$$75$YR$$F$Y$$$20221013$$CN$CA$CA
1555979518$15559795$18$F$20120101$20221017$20181029$20221024$EXP$$PHHY2012CA007523$NOVARTIS$$62$YR$$F$Y$$$20221024$$HP$CA$CA
1555980311$15559803$11$F$20180118$20221111$20181029$20221116$EXP$GB-NOVPHSZ-PHHY2018GB133174$GB-STRIDES ARCOLAB LIMITED-2018SP009261$STRIDES$$76$YR$$M$Y$69$KG$20221116$$MD$GB$GB
155598588$15559858$8$F$$20221017$20181029$20221021$PER$$US-AMGEN-USASP2018148705$AMGEN$$68$YR$E$F$Y$$$20221021$$MD$US$US
155608374$15560837$4$F$$20221025$20181029$20221027$PER$$US-PFIZER INC-2017294631$PFIZER$$41$YR$$F$Y$$$20221027$$MD$US$US
155608598$15560859$8$F$$20221202$20181029$20221206$PER$$US-PFIZER INC-2018438629$PFIZER$$59$YR$$F$Y$$$20221206$$MD$US$US
1556124621$15561246$21$F$$20221121$20181029$20221128$EXP$$CA-GLAXOSMITHKLINE-CA2018194992$GLAXOSMITHKLINE$$$$$$Y$$$20221128$$MD$CA$CA
155613972$15561397$2$F$20120801$20221205$20181029$20221208$EXP$$US-PFIZER INC-2018203409$PFIZER$$$$$M$Y$$$20221208$$CN$US$US
1556174928$15561749$28$F$20210501$20221208$20181029$20221213$EXP$$BR-GLAXOSMITHKLINE-BR2017GSK201070$GLAXOSMITHKLINE$$$$$$Y$$$20221213$$CN$BR$BR
155624466$15562446$6$F$20180101$20221222$20181029$20221230$EXP$$JP-JNJFOC-20181032210$JOHNSON AND JOHNSON$$73$YR$E$M$Y$51.3$KG$20221230$$MD$JP$JP
155624943$15562494$3$F$$20221212$20181029$20221219$PER$$US-PFIZER INC-2018431252$PFIZER$$57$YR$$M$Y$$$20221219$$MD$US$US
1556271810$15562718$10$F$20180101$20220927$20181029$20221003$EXP$$CA-PFIZER INC-2018378704$PFIZER$$36$YR$$F$Y$$$20221003$$MD$CA$CA
1556280312$15562803$12$F$20210101$20221003$20181029$20221005$EXP$$US-SA-2018SA297652$SANOFI AVENTIS$$65$YR$E$F$Y$$$20221005$$MD$US$US
155630123$15563012$3$F$20181019$20221220$20181029$20221229$EXP$$US-SHIRE-US201841702$TAKEDA$$23$YR$$F$Y$122$KG$20221229$$HP$US$US
155640442$15564044$2$F$$20221207$20181030$20221221$EXP$$IN-CIPLA LTD.-2018IN22150$CIPLA$Kumar V.. Fixed Drug Eruption Due to Cetirizine, Levocetirizine, and Hydroxyzine. Dermatol Ther. 2017;30:e12412$21$YR$$M$Y$$$20221221$$HP$US$IN
155642207$15564220$7$F$$20221024$20181030$20221027$PER$$US-AMGEN-USASP2018150332$AMGEN$$61$YR$A$F$Y$$$20221027$$MD$US$US
1556422913$15564229$13$F$20180928$20221215$20181030$20221221$EXP$$DE-ROCHE-2207253$ROCHE$$35$YR$$F$Y$68$KG$20221221$$MD$DE$
1556479211$15564792$11$F$20170101$20221005$20181030$20221007$EXP$$US-PFIZER INC-2018437970$PFIZER$$71$YR$$F$Y$$$20221007$$MD$US$US
155650437$15565043$7$F$20180830$20221205$20181030$20221213$EXP$$DE-ROCHE-2206420$ROCHE$$43$YR$$F$Y$$$20221213$$CN$DE$
155650672$15565067$2$F$$20221128$20181030$20221213$EXP$$US-MACLEODS PHARMACEUTICALS US LTD-MAC2018018123$MACLEODS$Idrees N, Almeqdadi M, Balakrishnan VS, Jaber BL. Hemodialysis for treatment of levofloxacin-induced neurotoxicity. Hemodialysis International. 2018$$$$$Y$$$20221213$$MD$US$US
155651875$15565187$5$F$20170101$20221128$20181030$20221205$PER$$US-SA-2017SA240307$SANOFI AVENTIS$$36$YR$A$F$Y$$$20221205$$MD$US$US
1556560830$15565608$30$F$20180321$20221207$20181030$20221215$EXP$$CA-CELLTRION INC.-2018CA022769$CELLTRION$$$$$$Y$$$20221216$$CN$CA$CA
1556561230$15565612$30$F$20180803$20221026$20181030$20221104$EXP$$CA-CELLTRION INC.-2018CA021365$CELLTRION$$$$$$Y$$$20221104$$MD$CA$CA
155656522$15565652$2$F$$20221128$20181030$20221212$EXP$$US-MACLEODS PHARMACEUTICALS US LTD-MAC2018018127$MACLEODS$Idrees N, Almeqdadi M, Balakrishnan VS, Jaber BL.. Hemodialysis for treatment of levofloxacin-induced neurotoxicity.. Hemodialysis International. 2018$$$$$Y$$$20221212$$MD$US$US
155661022$15566102$2$F$20171001$20180213$20181030$20221020$PER$$US-NOVOPROD-586643$NOVO NORDISK$$82$YR$$F$Y$58.957$KG$20221020$$CN$US$US
155661422$15566142$2$F$20180201$20180301$20181030$20221020$PER$$US-NOVOPROD-588798$NOVO NORDISK$$60$YR$$F$Y$$$20221020$$CN$US$US
155669432$15566943$2$F$20031201$20221219$20181030$20221223$EXP$FI-FIMEA-20181834$FI-OTSUKA-2018_034599$OTSUKA$$21$YR$$F$Y$$$20221223$$CN$FI$FI
1556724816$15567248$16$F$20090209$20221220$20181030$20221229$EXP$$CA-PFIZER INC-2016181292$PFIZER$$57$YR$$M$Y$$$20221229$$MD$CA$CA
155676582$15567658$2$F$$20181025$20181030$20221111$EXP$$FR-SA-2018SA298250$SANOFI AVENTIS$Rousseau G., Palmiere C., Dupont V., Verschoore M., Savary C et al. A diabetic ketoacidosis in a context of hyperglycemia addiction. int. J. Legal Med... 2018;132(3):787-790.$20$YR$A$F$Y$$$20221111$$HP$FR$FR
155686238$15568623$8$F$19970101$20221012$20181031$20221017$EXP$$US-BIOGEN-2018BI00651283$BIOGEN$$$$$F$Y$$$20221017$$MD$US$US
1556892915$15568929$15$F$20170101$20221007$20181031$20221014$EXP$$DE-ROCHE-2207983$ROCHE$$42$YR$$F$Y$$$20221014$$CN$DE$
155698126$15569812$6$F$$20221010$20181031$20221012$PER$$US-PFIZER INC-2018434157$PFIZER$$70$YR$$F$Y$$$20221012$$HP$US$US
155698534$15569853$4$F$$20221213$20181031$20221221$PER$$US-PFIZER INC-2018437614$PFIZER$$66$YR$$M$Y$86$KG$20221221$$CN$US$US
1557367910$15573679$10$F$$20221214$20181101$20221224$EXP$$CA-TEVA-2018-CA-968128$TEVA$$54$YR$A$M$Y$$$20221223$$HP$CA$CA
155737729$15573772$9$F$$20221215$20181101$20221226$PER$$US-AMGEN-USASP2018152304$AMGEN$$72$YR$E$F$Y$$$20221226$$MD$US$US
155739147$15573914$7$F$20180829$20221214$20181101$20221216$EXP$$DE-ROCHE-2194970$ROCHE$$42$YR$$F$Y$$$20221216$$CN$DE$
155743123$15574312$3$F$20180801$20221202$20181101$20221212$PER$$US-SA-2018SA300182$SANOFI AVENTIS$$59$YR$A$F$Y$$$20221212$$CN$US$US
1557482736$15574827$36$F$$20221212$20181101$20221222$EXP$$CA-PFIZER INC-2018445878$PFIZER$$59$YR$$F$Y$68$KG$20221222$$MD$CA$CA
155750222$15575022$2$F$20150201$20220927$20181101$20221010$EXP$$US-MACLEODS PHARMACEUTICALS US LTD-MAC2018018265$MACLEODS$Pinto J, Sheikh I, Pabona JM, Culpepper-Morgan J.. A rare case of metformin associated hepatotoxicity masquerading as autoimmune hepatitis.. American Journal of Gastroenterology.. 2016;111(1):S891$$$$$Y$$$20221010$$MD$US$US
155755142$15575514$2$F$$20221111$20181101$20221121$EXP$$ES-MYLANLABS-2018M1081574$MYLAN$$55$YR$$F$Y$$$20221121$$MD$ES$ES
1557629816$15576298$16$F$20170829$20221205$20181101$20221210$EXP$$PHHY2017CA129996$NOVARTIS$$42$YR$$F$Y$$$20221210$$CN$CA$CA
155764873$15576487$3$F$$20221219$20181101$20221222$PER$$US-PFIZER INC-2018440148$PFIZER$$67$YR$$F$Y$$$20221222$$MD$US$US
155766674$15576667$4$F$$20221216$20181101$20221229$PER$$US-PFIZER INC-2018447696$PFIZER$$74$YR$$M$Y$$$20221229$$HP$US$US
1557718613$15577186$13$F$20181011$20221208$20181102$20221221$EXP$$GB-AUROBINDO-AUR-APL-2018-053021$AUROBINDO$$50$YR$$M$Y$$$20221221$$MD$GB$GB
155775983$15577598$3$F$$20221029$20181102$20221102$EXP$$GB-ROCHE-1817791$ROCHE$$$$$F$Y$$$20221102$$CN$GB$
155778874$15577887$4$F$$20221121$20181102$20221123$PER$$US-PFIZER INC-2018447425$PFIZER$$55$YR$$F$Y$$$20221123$$CN$US$US
1557854227$15578542$27$F$20170928$20221219$20181102$20221229$EXP$$CA-CELLTRION INC.-2017CA012856$CELLTRION$$$$$$Y$$$20221229$$MD$CA$CA
1557953811$15579538$11$F$20180101$20221121$20181102$20221124$EXP$$PHHY2018GB143943$NOVARTIS$$18$YR$$M$Y$$$20221124$$MD$GB$GB
1558030430$15580304$30$F$20180118$20221121$20181102$20221124$EXP$$GB-AstraZeneca-2018SF41959$ASTRAZENECA$$76$YR$$M$Y$69$KG$20221124$$MD$GB$
1558035814$15580358$14$F$20180101$20221020$20181102$20221027$EXP$$CA-TAKEDA-2018TUS031298$TAKEDA$$27$YR$$F$Y$$$20221027$$CN$CA$CA
155831643$15583164$3$F$$20221213$20181103$20221214$PER$$US-Inventia-000252$INVENTIA HEALTHCARE$$$$$F$Y$$$20221214$$CN$US$
155840874$15584087$4$F$20180901$20221111$20181104$20221118$EXP$$US-009507513-1810USA013458$MERCK$$70$YR$$M$Y$$$20221118$$CN$US$US
155846513$15584651$3$F$20181010$20221216$20181102$20221221$EXP$$US-ASTELLAS-2018US046528$ASTELLAS$$56$YR$$M$Y$$$20221221$$CN$US$US
1558476114$15584761$14$F$20180219$20221128$20181105$20221203$EXP$$PHHY2018GB146084$NOVARTIS$$43$YR$$F$Y$$$20221203$$HP$GB$GB
1558505225$15585052$25$F$20181109$20221109$20181102$20221115$EXP$$DE-SHIRE-DE201838632$TAKEDA$$58$YR$$F$Y$79$KG$20221115$$CN$DE$DE
155857127$15585712$7$F$20190101$20221110$20181105$20221114$EXP$$US-PFIZER INC-2018444232$PFIZER$$63$YR$$F$Y$81.65$KG$20221114$$CN$US$US
1558710612$15587106$12$F$20181029$20221026$20181105$20221102$PER$$IL-Eisai Medical Research-EC-2018-047189$EISAI$$61$YR$$F$Y$60$KG$20221102$$MD$IL$
155873932$15587393$2$F$20031201$20221219$20181105$20221226$EXP$FI-FIMEA-20181834$FI-JNJFOC-20181038708$JOHNSON AND JOHNSON$$21$YR$A$F$Y$$$20221226$$CN$FI$FI
155881412$15588141$2$F$20181013$20221026$20181105$20221027$EXP$$US-SHIRE-US201841673$TAKEDA$$75$YR$$M$Y$$$20221027$$HP$US$US
155882615$15588261$5$F$20220929$20221004$20181105$20221011$PER$$US-JAZZ-JPI-P-032141$JAZZ$$73$YR$$F$Y$83.182$KG$20221011$$CN$US$US
155890725$15589072$5$F$20170301$20221004$20181106$20221010$EXP$$CA-TAKEDA-2017TUS008911$TAKEDA$$74$YR$$F$Y$$$20221010$$CN$CA$CA
1558911833$15589118$33$F$20180925$20221213$20181106$20221221$EXP$$CA-CELLTRION INC.-2018CA023137$CELLTRION$$$$$$Y$$$20221221$$CN$CA$CA
1558921530$15589215$30$F$$20221219$20181106$20221226$EXP$$CA-Orion Corporation ORION PHARMA-TREX2018-3173$ORION$$59$YR$A$F$Y$68$KG$20221227$$MD$CA$
1559023923$15590239$23$F$$20221121$20181106$20221125$EXP$$CA-BAUSCH-BL-2018-030153$BAUSCH AND LOMB$$58$YR$$F$Y$$$20221125$$MD$CA$CA
155904962$15590496$2$F$$20221202$20181106$20221214$EXP$$GR-Accord-091683$ACCORD$Kiapidou S, Sinakos E., Chytiroglou P., Koustiani G, Kaprinis A, Akriviadis E. Exposure to chemotherapeutic agents: emerging cause of  non-cirrhotic portal hypertension. 2nd Conference  of Clinical Hepatology, 28-30 September 2018.$49$YR$A$M$Y$$$20221214$$HP$GR$GR
155913077$15591307$7$F$$20221226$20181107$20221228$PER$$US-PFIZER INC-2018444344$PFIZER$$30$YR$$M$Y$$$20221228$$MD$US$US
155914343$15591434$3$F$$20221207$20181107$20221212$PER$$US-PFIZER INC-2018456630$PFIZER$$79$YR$$M$Y$$$20221212$$MD$US$US
155928682$15592868$2$F$20180427$20221003$20181106$20221006$EXP$$IT-MYLANLABS-2018M1082447$MYLAN$$64$YR$$F$Y$62$KG$20221006$$MD$IT$IT
1559317411$15593174$11$F$$20221223$20181107$20221229$PER$$US-PFIZER INC-2018444343$PFIZER$$30$YR$$M$Y$$$20221229$$MD$US$US
1559358730$15593587$30$F$20171001$20221109$20181107$20221118$EXP$$CA-CELLTRION INC.-2017CA015259$CELLTRION$$$$$$Y$$$20221118$$CN$CA$CA
155937623$15593762$3$F$$20221228$20181106$20221229$PER$$US-PFIZER INC-2018454814$PFIZER$$$$E$F$Y$$$20221229$$MD$US$US
155937705$15593770$5$F$$20221213$20181106$20221215$PER$$US-PFIZER INC-2018454792$PFIZER$$67$YR$$F$Y$$$20221215$$MD$US$US
1559407136$15594071$36$F$20180901$20221128$20181107$20221205$EXP$$PHHY2018CA111755$NOVARTIS$$22$YR$$F$Y$$$20221205$$HP$CA$CA
155966025$15596602$5$F$$20221213$20181107$20221222$EXP$$CA-BAUSCH-BL-2018-030118$BAUSCH AND LOMB$$62$YR$$F$Y$$$20221222$$HP$CA$CA
1559704912$15597049$12$F$20181020$20221115$20181108$20221122$EXP$$CA-ROCHE-2208940$ROCHE$$44$YR$$M$Y$$$20221122$$HP$CA$
155970517$15597051$7$F$20181003$20221124$20181108$20221205$EXP$$AU-BIOGEN-2018BI00643907$BIOGEN$$31$YR$$F$Y$$$20221205$$CN$AU$AU
155978244$15597824$4$F$20170108$20221006$20181108$20221014$EXP$$US-AstraZeneca-2018SF43690$ASTRAZENECA$$21635$DY$$M$Y$$$20221014$$LW$US$
155983682$15598368$2$F$20180901$20221227$20181108$20221229$EXP$ES-AEMPS-411193$ES-SAKK-2018SA303965AA$SANOFI AVENTIS$$47$YR$A$M$Y$$$20221229$$MD$ES$ES
155983712$15598371$2$F$$20221212$20181108$20221214$EXP$$US-JAZZ-2018-US-016164$JAZZ$$$$$F$Y$$$20221214$$CN$US$US
1559882710$15598827$10$F$$20221109$20181108$20221116$EXP$$CA-PFIZER INC-2018220210$PFIZER$$27$YR$$F$Y$55$KG$20221116$$CN$CA$CA
155988579$15598857$9$F$$20221202$20181108$20221206$PER$$US-PFIZER INC-2018457551$PFIZER$$66$YR$$M$Y$$$20221206$$HP$US$US
156003143$15600314$3$F$20181031$20221004$20181109$20221004$PER$$US-BIOGEN-2018BI00654085$BIOGEN$$48$YR$$M$Y$$$20221004$$CN$US$US
156008387$15600838$7$F$$20221115$20181109$20221116$EXP$$US-PFIZER INC-2017540462$PFIZER$$75$YR$$F$Y$$$20221116$$MD$US$US
156008858$15600885$8$F$20180509$20221102$20181109$20221107$EXP$$CA-ROCHE-2123224$ROCHE$$37$YR$$F$Y$$$20221107$$CN$CA$
156016182$15601618$2$F$20180801$20221011$20181109$20221021$EXP$$PL-ASPEN-GLO2018PL011117$ASPEN$$$$$$Y$$$20221021$$MD$PL$PL
156021337$15602133$7$F$20180101$20221101$20181109$20221109$EXP$$GB-AstraZeneca-2018SF45599$ASTRAZENECA$$18$YR$$M$Y$$$20221109$$MD$GB$
156025845$15602584$5$F$$20221110$20181109$20221117$PER$$US-SA-2018SA306274$SANOFI AVENTIS$$$$A$F$Y$$$20221118$$MD$US$US
156025914$15602591$4$F$20180101$20221107$20181109$20221114$EXP$$US-SA-2018SA304324$SANOFI AVENTIS$$43$YR$A$M$Y$$$20221114$$MD$US$US
1560460331$15604603$31$F$20181201$20221215$20181110$20221223$EXP$$CA-CELLTRION INC.-2018CA023732$CELLTRION$$$$$$Y$$$20221224$$HP$CA$CA
156059353$15605935$3$F$20181105$20221012$20181112$20221018$EXP$$IT-ROCHE-2211890$ROCHE$$63$YR$$F$Y$$$20221018$$MD$IT$IT
1560603213$15606032$13$F$20181001$20221018$20181112$20221020$EXP$$PHHY2018CA145103$NOVARTIS$$55$YR$$M$Y$$$20221020$$CN$CA$CA
156062979$15606297$9$F$20181001$20221110$20181112$20221125$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-190640$RANBAXY$$50$YR$$M$Y$$$20221125$$HP$GB$GB
1560699115$15606991$15$F$20190401$20221027$20181112$20221102$EXP$$BR-GLAXOSMITHKLINE-BR2017GSK022153$GLAXOSMITHKLINE$$$$$$Y$$$20221102$$HP$BR$BR
156079997$15607999$7$F$20181001$20221221$20181112$20221230$EXP$$GB-TEVA-2018-GB-974182$TEVA$$50$YR$A$M$Y$$$20221230$$HP$GB$GB
156110162$15611016$2$F$20060101$20211028$20181113$20221122$EXP$$US-ROCHE-2141447$ROCHE$Yannuzzi N, Gregori NZ, Rosenfeld PJ, Relhan N, Patel NA, Si N et al.. Endophthalmitis Associated With Intravitreal Injections of Anti-VEGF Agents at a Tertiary Referral Center: In- House and Referred Cases.. OPHTHALMIC SURGERY LASERS AND IMAGING RETINA. 2018;49 (5):313-9.$$$$$Y$$$20221122$$HP$US$US
1561265811$15612658$11$F$20181105$20221118$20181113$20221122$EXP$$JP-ABBVIE-18S-087-2546425-00$ABBVIE$$82$YR$$F$Y$$$20221122$$CN$JP$JP
156128335$15612833$5$F$$20221031$20181113$20221108$EXP$$AU-JNJFOC-20180907256$JOHNSON AND JOHNSON$$72$YR$E$M$Y$$$20221108$$CN$AU$AU
156156664$15615666$4$F$20181001$20221010$20181114$20221018$PER$$US-BIOGEN-2018BI00641766$BIOGEN$$29$YR$$F$Y$$$20221018$$CN$US$US
1561577412$15615774$12$F$$20221124$20181114$20221128$EXP$$CA-ABBVIE-18K-028-2555643-00$ABBVIE$$24$YR$$F$Y$65$KG$20221128$$CN$CA$CA
156178795$15617879$5$F$$20221031$20181114$20221103$PER$$US-PFIZER INC-2018463663$PFIZER$$55$YR$$F$Y$$$20221103$$MD$US$US
156179413$15617941$3$F$$20221227$20181114$20221229$PER$$US-PFIZER INC-2018459486$PFIZER$$63$YR$$F$Y$$$20221229$$MD$US$US
156181132$15618113$2$F$20140801$20221006$20181114$20221007$PER$$US-PFIZER INC-2018465835$PFIZER$$44$YR$$F$Y$92.063$KG$20221007$$LW$US$US
156181476$15618147$6$F$$20221118$20181114$20221122$PER$$US-PFIZER INC-2018459036$PFIZER$$73$YR$$F$Y$$$20221122$$MD$US$US
156181564$15618156$4$F$20181001$20221118$20181114$20221123$EXP$$US-PFIZER INC-2018458506$PFIZER$$71$YR$$F$Y$53.52$KG$20221123$$CN$US$US
156190732$15619073$2$F$$20221130$20181114$20221205$EXP$$GR-SA-2018SA297206$SANOFI AVENTIS$Kiapidou S, Sinakos E, Chytiroglou P, Koustiani G, Kaprinis A, Akrviadis E.. Exposure to chemotherapeutic agents: an emerging cause of non?cirrhotic portal hypertension.. Annals of Gastroenterology.. 2017;30:28$36$YR$A$F$Y$$$20221205$$MD$GR$GR
1561971313$15619713$13$F$20180601$20221206$20181115$20221212$EXP$$DE-ROCHE-2126742$ROCHE$$24$YR$$F$Y$60$KG$20221212$$CN$DE$
156200553$15620055$3$F$$20221104$20181115$20221118$EXP$FR-EMA-DD-20180924-KUMARNVEVHP-115803$FR-Accord-092440$ACCORD$$38$YR$A$M$Y$$$20221118$$HP$FR$FR
1562023913$15620239$13$F$20180119$20221128$20181115$20221205$EXP$$JP-ABBVIE-18P-087-2319797-00$ABBVIE$$$$$$Y$$$20221205$$MD$JP$JP
1562028311$15620283$11$F$20180101$20221108$20181115$20221122$EXP$$GB-AUROBINDO-AUR-APL-2018-054842$AUROBINDO$$18$YR$$M$Y$$$20221122$$MD$GB$GB
156205112$15620511$2$F$20170606$20221116$20181115$20221125$EXP$AT-EMA-DD-20180801-NGEVHPROD-122908$AT-Accord-091842$ACCORD$$$$$M$Y$$$20221125$$MD$AT$AT
1562053738$15620537$38$F$20181031$20221205$20181115$20221215$EXP$$CA-CELLTRION INC.-2018CA023385$CELLTRION$$$$$$Y$$$20221214$$MD$CA$CA
156205502$15620550$2$F$20181004$20181101$20181115$20221003$EXP$$GB-CELLTRION INC.-2018GB023714$CELLTRION$$$$$$Y$$$20221003$$HP$GB$GB
1562122929$15621229$29$F$20170101$20221221$20181115$20221228$EXP$$PHHY2017CA122661$NOVARTIS$$76$YR$$M$Y$$$20221228$$CN$CA$CA
156218076$15621807$6$F$20180101$20221025$20181115$20221027$PER$$US-PFIZER INC-2018456273$PFIZER$$72$YR$$F$Y$69$KG$20221027$$CN$US$US
156220545$15622054$5$F$20170301$20221010$20181115$20221020$PER$$US-PFIZER INC-2018466422$PFIZER$$7$YR$$F$Y$$$20221020$$MD$US$US
156220733$15622073$3$F$20181001$20221222$20181115$20221227$PER$$US-PFIZER INC-2018470554$PFIZER$$59$YR$$F$Y$$$20221227$$PH$US$US
156230242$15623024$2$F$$20211221$20181115$20221026$PER$$US-ALLERGAN-1838731US$ALLERGAN$$$$$F$Y$$$20221026$$MD$US$US
156241438$15624143$8$F$$20220928$20181116$20221004$PER$$US-AMGEN-USASP2018162710$AMGEN$$60$YR$A$M$Y$$$20221004$$CN$US$US
156251049$15625104$9$F$20180115$20221109$20181116$20221119$EXP$$PHHY2018DE154592$NOVARTIS$$63$YR$$F$Y$100$KG$20221119$$MD$DE$DE
156251056$15625105$6$F$20141022$20221129$20181116$20221207$EXP$$PHHY2018DE154594$NOVARTIS$$$$A$F$Y$$$20221207$$CN$DE$DE
156252257$15625225$7$F$20110401$20221219$20181116$20221223$EXP$$PHHY2018DE154593$NOVARTIS$$59$YR$$F$Y$92$KG$20221223$$CN$DE$DE
1562592413$15625924$13$F$20180530$20221101$20181116$20221109$EXP$$CA-CELLTRION INC.-2017CA010462$CELLTRION$$$$$$Y$$$20221110$$HP$CA$CA
1562593729$15625937$29$F$20181102$20221025$20181116$20221103$EXP$$CA-CELLTRION INC.-2018CA023290$CELLTRION$$$$$$Y$$$20221103$$MD$CA$CA
156264676$15626467$6$F$$20221219$20181116$20221229$EXP$$CA-TEVA-2018-CA-976409$TEVA$$61$YR$A$F$Y$67$KG$20221229$$HP$CA$CA
1562675139$15626751$39$F$$20221214$20181116$20221222$EXP$$CA-ABBVIE-18S-028-2552613-00$ABBVIE$$54$YR$$M$Y$$$20221222$$HP$CA$CA
1562713614$15627136$14$F$$20221025$20181116$20221031$EXP$$BR-GLAXOSMITHKLINE-BR2018GSK188262$GLAXOSMITHKLINE$$$$$$Y$$$20221031$$CN$BR$BR
1562767817$15627678$17$F$20180529$20221028$20181116$20221111$EXP$$NL-PFIZER INC-2018471008$PFIZER$Schellekens, K.. UNEXPECTED SEVERE TOXICITY OF CRIZOTINIB IN COMBINATION WITH VINBLASTINE: THE CRISP OPEN-LABEL PHASE 1B TRIAL IN PEDIATRIC PATIENTS WITH ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) (ITCC-053). Pediatric Blood and Cancer. 2022;69 (Supple 5):S321$14$YR$$F$Y$47$KG$20221111$$HP$NL$NL
156281903$15628190$3$F$$20220930$20181116$20221004$PER$$US-PFIZER INC-2018468395$PFIZER$$52$YR$$F$Y$$$20221004$$LW$US$US
156287512$15628751$2$F$$20221007$20181116$20221012$PER$$US-PFIZER INC-2018470178$PFIZER$$79$YR$$M$Y$$$20221012$$MD$US$US
156288752$15628875$2$F$20130601$20221012$20181116$20221013$PER$$US-PFIZER INC-2018471045$PFIZER$$48$YR$$F$Y$$$20221013$$LW$US$US
156294655$15629465$5$F$$20190906$20181117$20221020$PER$$US-CELLTRION INC.-2018US021975$CELLTRION$$$$$$Y$$$20221021$$HP$US$US
156294824$15629482$4$F$20190613$20191007$20181117$20221020$PER$$US-CELLTRION INC.-2018US022602$CELLTRION$$$$$$Y$$$20221021$$MD$US$US
156295392$15629539$2$F$$20220428$20181117$20221012$PER$$US-CELLTRION INC.-2018US023333$CELLTRION$$$$$$Y$$$20221012$$HP$US$US
1563078116$15630781$16$F$20181109$20221118$20181119$20221125$EXP$$DE-ROCHE-2215136$ROCHE$$47$YR$$M$Y$$$20221125$$CN$DE$DE
156309274$15630927$4$F$20181114$20221012$20181119$20221014$EXP$$FR-ROCHE-2216960$ROCHE$$72$YR$$M$Y$83$KG$20221014$$PH$FR$FR
156314293$15631429$3$F$20181105$20221229$20181119$20221230$PER$$US-BIOGEN-2018BI00658456$BIOGEN$$49$YR$$F$Y$$$20221230$$CN$US$US
156315807$15631580$7$F$20170928$20221206$20181119$20221212$EXP$$US-ARIAD PHARMACEUTICALS, INC-2017US009116$TAKEDA$$52$YR$$M$Y$$$20221212$$HP$US$US
156319326$15631932$6$F$$20221123$20181119$20221128$PER$$US-AMGEN-USASP2018163546$AMGEN$$60$YR$A$M$Y$$$20221127$$MD$US$US
156332968$15633296$8$F$$20221114$20181119$20221116$PER$$US-PFIZER INC-2018472814$PFIZER$$79$YR$$F$Y$$$20221116$$MD$US$US
156333343$15633334$3$F$$20221003$20181119$20221013$EXP$$US-UCBSA-2018050387$UCB$$$$$F$Y$$$20221013$$CN$US$US
156339697$15633969$7$F$20171001$20221125$20181119$20221130$EXP$$FR-SA-2018SA020902$SANOFI AVENTIS$$68$YR$E$M$Y$79$KG$20221130$$HP$FR$FR
156342902$15634290$2$F$20180801$20221111$20181119$20221115$PER$$US-PFIZER INC-2018465454$PFIZER$$65$YR$$F$Y$81.65$KG$20221115$$CN$US$US
156345215$15634521$5$F$$20221128$20181119$20221201$EXP$$PHHY2018CA157449$NOVARTIS$$$$$F$Y$$$20221201$$HP$CA$CA
1563475526$15634755$26$F$20181108$20221221$20181119$20221228$EXP$$PHHY2018DE156727$NOVARTIS$$63$YR$$F$Y$66$KG$20221228$$HP$DE$DE
1563532819$15635328$19$F$$20221209$20181120$20221216$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-105928$BRISTOL MYERS SQUIBB$$59$YR$A$F$Y$68$KG$20221216$$CN$CA$CA
156353342$15635334$2$F$$20221207$20181120$20221229$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-010830$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221230$$CN$US$US
156391485$15639148$5$F$20181108$20221116$20181120$20221117$EXP$$ES-TAKEDA-2018MPI016012$TAKEDA$$100$YR$$F$Y$$$20221117$$MD$ES$ES
156394515$15639451$5$F$$20221128$20181120$20221129$PER$$US-PFIZER INC-2018477243$PFIZER$$74$YR$$F$Y$$$20221129$$MD$US$US
156395382$15639538$2$F$20180706$20220630$20181120$20221021$PER$$US-CIPLA LTD.-2018US19953$CIPLA$$$$$F$Y$$$20221021$$CN$US$US
1563997224$15639972$24$F$20180601$20221209$20181120$20221215$EXP$$PHHY2018CA158574$NOVARTIS$$50$YR$$F$Y$$$20221215$$MD$CA$CA
156400383$15640038$3$F$20110618$20221104$20181120$20221107$PER$$US-PFIZER INC-2017556175$PFIZER$$59$YR$$F$Y$$$20221107$$LW$US$US
1564014412$15640144$12$F$$20221012$20181120$20221018$EXP$$GB-SA-2018SA314787$SANOFI AVENTIS$$37$YR$A$M$Y$$$20221018$$HP$GB$GB
1564109111$15641091$11$F$20220424$20221213$20181120$20221219$EXP$$US-SHIRE-US201844242$TAKEDA$$56$YR$$F$Y$74$KG$20221219$$HP$US$US
156420092$15642009$2$F$20181106$20221013$20181121$20221017$EXP$$FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-108288$BRISTOL MYERS SQUIBB$$62$YR$A$M$Y$$$20221017$$HP$FR$FR
1564204710$15642047$10$F$20180413$20221027$20181121$20221031$EXP$$CA-TAKEDA-2017TUS020626$TAKEDA$$34$YR$$M$Y$$$20221031$$CN$CA$CA
1564206116$15642061$16$F$20170301$20221020$20181121$20221027$EXP$$CA-ROCHE-1946076$ROCHE$$39$YR$$F$Y$60$KG$20221027$$CN$CA$CA
1564308136$15643081$36$F$20180101$20221111$20181121$20221121$EXP$$CA-CELLTRION INC.-2018CA018474$CELLTRION$$$$$$Y$$$20221121$$CN$CA$CA
1564309827$15643098$27$F$20180101$20221020$20181121$20221030$EXP$$CA-CELLTRION INC.-2018CA023348$CELLTRION$$$$$$Y$$$20221030$$CN$CA$CA
1564370113$15643701$13$F$$20221020$20181121$20221025$PER$$US-PFIZER INC-2018478926$PFIZER$$57$YR$$F$Y$36$KG$20221025$$CN$US$US
156438505$15643850$5$F$$20221019$20181121$20221021$PER$$US-PFIZER INC-2018477008$PFIZER$$83$YR$$F$Y$$$20221021$$MD$US$US
156444106$15644410$6$F$$20221027$20181121$20221101$PER$$US-PFIZER INC-2018476662$PFIZER$$65$YR$$F$Y$$$20221101$$CN$US$US
156451787$15645178$7$F$20180101$20221129$20181121$20221205$PER$$US-SA-2018SA319063$SANOFI AVENTIS$$55$YR$A$M$Y$$$20221205$$CN$US$US
156452862$15645286$2$F$20160401$20221010$20181121$20221012$PER$$US-PFIZER INC-2018239136$PFIZER$$64$YR$$F$Y$77$KG$20221012$$CN$US$US
156453593$15645359$3$F$$20221102$20181121$20221109$EXP$$US-SHIRE-US201844492$TAKEDA$$$$$F$Y$$$20221109$$MD$US$US
156474062$15647406$2$F$$20181115$20181122$20221007$EXP$$IL-ROCHE-2217081$ROCHE$$$$$M$Y$$$20221007$$MD$IL$
156477367$15647736$7$F$20181115$20221118$20181122$20221128$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-107602$BRISTOL MYERS SQUIBB$$70$YR$E$F$Y$$$20221128$$MD$JP$JP
1564781212$15647812$12$F$20211001$20221128$20181122$20221206$EXP$$US-TAKEDA-2018MPI016032$TAKEDA$$69$YR$$F$Y$$$20221206$$CN$US$US
1564888913$15648889$13$F$20180927$20221116$20181122$20221208$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-010423$ACADIA PHARMACEUTICALS$$78$YR$$M$Y$$$20221209$$CN$US$US
156488974$15648897$4$F$20181001$20221205$20181122$20221215$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-010614$ACADIA PHARMACEUTICALS$$68$YR$$F$Y$$$20221215$$CN$US$US
156489884$15648988$4$F$20180701$20221101$20181122$20221110$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-009838$ACADIA PHARMACEUTICALS$$84$YR$$F$Y$$$20221111$$CN$US$US
156491233$15649123$3$F$20180801$20221128$20181122$20221208$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-010101$ACADIA PHARMACEUTICALS$$76$YR$$M$Y$95$KG$20221208$$CN$US$US
156492112$15649211$2$F$20180101$20221214$20181122$20221222$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-010277$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221223$$CN$US$US
156493983$15649398$3$F$20180101$20220927$20181122$20221020$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-010570$ACADIA PHARMACEUTICALS$$$$$M$Y$66$KG$20221021$$CN$US$US
156494108$15649410$8$F$20180101$20221010$20181122$20221020$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-010561$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221020$$CN$US$US
156498168$15649816$8$F$20180424$20221116$20181123$20221121$EXP$$PHHY2018CA008207$NOVARTIS$$65$YR$$F$Y$$$20221121$$CN$CA$CA
1564998918$15649989$18$F$20181105$20220912$20181123$20221013$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-108807$BRISTOL MYERS SQUIBB$$51$YR$A$F$Y$51.5$KG$20221013$$MD$JP$JP
156504133$15650413$3$F$20180401$20221118$20181123$20221130$EXP$FR-AFSSAPS-NY20181736$FR-Accord-093480$ACCORD$$69$YR$E$F$Y$60$KG$20221130$$MD$FR$FR
1565083714$15650837$14$F$20170207$20221026$20181123$20221102$EXP$$CA-ROCHE-2217380$ROCHE$$74$YR$$F$Y$$$20221102$$MD$CA$CA
156508843$15650884$3$F$20220101$20221214$20181123$20221220$EXP$$US-ROCHE-2219125$ROCHE$$66$YR$$M$Y$99.88$KG$20221220$$CN$US$
156512916$15651291$6$F$20181001$20221109$20181123$20221121$EXP$$CO-GLAXOSMITHKLINE-CO2018211538$GLAXOSMITHKLINE$$$$$$Y$$$20221121$$CN$CO$CO
156515976$15651597$6$F$$20221129$20181123$20221201$PER$$US-PFIZER INC-2018483625$PFIZER$$71$YR$$M$Y$63.5$KG$20221201$$CN$US$US
1565187521$15651875$21$F$$20221108$20181123$20221115$EXP$$BR-GLAXOSMITHKLINE-BR2018GSK210913$GLAXOSMITHKLINE$$$$$$Y$$$20221115$$CN$BR$BR
1565334311$15653343$11$F$20181101$20221107$20181124$20221115$EXP$$CA-ROCHE-2214357$ROCHE$$46$YR$$M$Y$$$20221115$$CN$CA$
1565560727$15655607$27$F$20180918$20220927$20181126$20221007$EXP$$CA-CELLTRION INC.-2018CA022651$CELLTRION$$$$$$Y$$$20221007$$HP$CA$CA
1565561639$15655616$39$F$20181029$20221013$20181126$20221022$EXP$$CA-CELLTRION INC.-2018CA023754$CELLTRION$$$$$$Y$$$20221022$$MD$CA$CA
1565562323$15655623$23$F$20180620$20221118$20181126$20221128$EXP$$CA-CELLTRION INC.-2018CA021238$CELLTRION$$$$$$Y$$$20221128$$CN$CA$CA
156557142$15655714$2$F$$20181115$20181126$20221209$PER$$US-TEVA-2018-US-978048$TEVA$$$$$$Y$$$20221209$$CN$US$US
1565720411$15657204$11$F$$20221104$20181126$20221109$EXP$$PHHY2017CA063817$NOVARTIS$$$$$F$Y$$$20221109$$MD$CA$CA
156580023$15658002$3$F$20180921$20221123$20181126$20221124$EXP$$ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-089690$BRISTOL MYERS SQUIBB$$70$YR$E$M$Y$$$20221124$$HP$ES$ES
156582483$15658248$3$F$$20221107$20181126$20221109$PER$$US-PFIZER INC-2018485105$PFIZER$$59$YR$$M$Y$$$20221109$$HP$US$US
1565830123$15658301$23$F$$20221219$20181126$20221227$EXP$$US-PFIZER INC-2018485086$PFIZER$$64$YR$$F$Y$61$KG$20221227$$CN$US$US
156594575$15659457$5$F$20181109$20221207$20181127$20221209$EXP$$CA-TAKEDA-2017TUS027211$TAKEDA$$84$YR$$M$Y$$$20221209$$HP$CA$CA
156596196$15659619$6$F$$20221212$20181127$20221219$PER$$CA-AMGEN-CANSP2018168313$AMGEN$$$$$F$Y$$$20221219$$HP$CA$CA
1566009116$15660091$16$F$20181127$20221208$20181127$20221215$EXP$$CA-CELLTRION INC.-2018CA024129$CELLTRION$$$$$$Y$$$20221214$$HP$CA$CA
156613966$15661396$6$F$20170801$20221005$20181127$20221011$EXP$$PHHY2015CA121087$NOVARTIS$$72$YR$$M$Y$90$KG$20221011$$MD$CA$CA
156616487$15661648$7$F$20180101$20221028$20181127$20221101$EXP$$CA-TAKEDA-2018TUS000915$TAKEDA$$32$YR$$M$Y$$$20221101$$HP$CA$CA
156623813$15662381$3$F$$20221228$20181127$20221230$EXP$$US-JAZZ-2018-US-017224$JAZZ$$$$$F$Y$$$20221230$$CN$US$US
156640057$15664005$7$F$20171212$20221223$20181128$20221229$EXP$$CA-TAKEDA-2018TUS006976$TAKEDA$$73$YR$$F$Y$$$20221229$$MD$CA$CA
1566446015$15664460$15$F$20181114$20221114$20181128$20221121$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK001620$GLAXOSMITHKLINE$$$$$$Y$$$20221121$$HP$BR$BR
156649869$15664986$9$F$20181112$20221205$20181128$20221207$EXP$$JP-SA-2018SA314512$SANOFI AVENTIS$$24$YR$A$F$Y$$$20221208$$MD$JP$JP
156665223$15666522$3$F$20190101$20221123$20181128$20221128$EXP$$US-ROCHE-2112475$ROCHE$$69$YR$$F$Y$50$KG$20221128$$CN$US$
1566815722$15668157$22$F$$20220918$20181129$20221109$EXP$$CA-ABBVIE-18K-028-2570296-00$ABBVIE$$60$YR$$F$Y$97$KG$20221109$$HP$GB$CA
1566888113$15668881$13$F$20171117$20221021$20181129$20221027$EXP$$CA-TAKEDA-2017TUS022379$TAKEDA$$37$YR$$M$Y$$$20221027$$CN$CA$CA
156691772$15669177$2$F$20180613$20221202$20181129$20221212$PER$$FR-AMGEN-FRACT2018162595$AMGEN$$80$YR$E$M$Y$63$KG$20221212$$MD$FR$FR
1566937738$15669377$38$F$20181009$20221020$20181129$20221030$EXP$$CA-CELLTRION INC.-2018CA022914$CELLTRION$$$$$$Y$$$20221030$$MD$CA$CA
1567023411$15670234$11$F$20181101$20221027$20181129$20221107$PER$$US-SA-2018SA323769$SANOFI AVENTIS$$28$YR$A$M$Y$87.075$KG$20221108$$MD$US$US
156703875$15670387$5$F$$20221117$20181129$20221121$PER$$US-PFIZER INC-2018490958$PFIZER$$66$YR$$F$Y$$$20221121$$MD$US$US
156707534$15670753$4$F$$20221123$20181129$20221128$PER$$US-PFIZER INC-2018488585$PFIZER$$58$YR$$F$Y$$$20221128$$MD$US$US
156709875$15670987$5$F$$20221212$20181129$20221219$PER$$US-PFIZER INC-2018487088$PFIZER$$58$YR$$M$Y$$$20221219$$CN$US$US
156710216$15671021$6$F$20180101$20221104$20181129$20221114$EXP$$US-PFIZER INC-2018487036$PFIZER$$62$YR$$F$Y$54.43$KG$20221114$$CN$US$US
1567229512$15672295$12$F$$20221011$20181129$20221013$EXP$$US-TESARO, INC-US-2017TSO04560$GLAXOSMITHKLINE$$$$$F$Y$$$20221013$$CN$US$US
156737805$15673780$5$F$20180207$20221118$20181129$20221128$EXP$$FR-SHIRE-FR201828929$TAKEDA$$$$A$M$Y$72$KG$20221128$$HP$FR$FR
156747565$15674756$5$F$20140101$20220930$20181130$20221003$PER$$BR-AMGEN-BRASP2014054160$AMGEN$$56$YR$A$F$Y$86$KG$20221003$$CN$BR$BR
156753234$15675323$4$F$$20220228$20181130$20221230$EXP$$US-TEVA-2018-US-982987$TEVA$$31$YR$A$F$Y$$$20221230$$MD$US$US
1567542311$15675423$11$F$20160413$20221006$20181130$20221011$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2017JPN088083$VIIV$$$$$$Y$$$20221011$$MD$JP$JP
1567557112$15675571$12$F$$20220927$20181130$20221007$EXP$$GB-ASPEN-GLO2018GB011876$ASPEN$Keddie S, Bharambe V, Jayakumar A, Shah A, Sanchez V, Adams A et al.. Clinical perspectives into the use of thalidomide for central nervous system tuberculosis.. EUROPEAN JOURNAL OF NEUROLOGY.. 2018;25:(11):1345-51$$$$$Y$$$20221007$$HP$GB$GB
156758767$15675876$7$F$$20221212$20181130$20221221$EXP$$CA-PFIZER INC-2018494620$PFIZER$$$$$F$Y$$$20221221$$MD$CA$CA
156768605$15676860$5$F$$20221220$20181130$20221222$PER$$US-PFIZER INC-2018486539$PFIZER$$82$YR$$F$Y$$$20221222$$MD$US$US
1567690110$15676901$10$F$20181119$20221104$20181130$20221114$EXP$$US-PFIZER INC-2018485639$PFIZER$$68$YR$$M$Y$86$KG$20221114$$CN$US$US
1567763241$15677632$41$F$20170101$20221025$20181130$20221027$EXP$$PHHY2017CA150362$NOVARTIS$$$$$M$Y$$$20221027$$CN$CA$CA
1567784416$15677844$16$F$20111007$20221122$20181130$20221128$EXP$$PHHY2012CA019140$NOVARTIS$$62$YR$$F$Y$$$20221128$$HP$CA$CA
156783375$15678337$5$F$20180101$20221201$20181201$20221207$EXP$$US-BIOGEN-2018BI00664324$BIOGEN$$$$$F$Y$$$20221207$$CN$US$US
156785523$15678552$3$F$20161101$20221205$20181201$20221213$EXP$$PHHY2016CA161278$NOVARTIS$$54$YR$$F$Y$$$20221213$$CN$CA$CA
156793032$15679303$2$F$20180101$20221226$20181203$20221228$EXP$$TN-JNJFOC-20181133067$JOHNSON AND JOHNSON$$53$YR$A$F$Y$$$20221228$$HP$TN$TN
156814076$15681407$6$F$$20221206$20181203$20221212$PER$$US-PFIZER INC-2017458274$PFIZER$$67$YR$$F$Y$68$KG$20221212$$MD$US$US
156818302$15681830$2$F$20170223$20221025$20181203$20221028$EXP$$CA-TAKEDA-2018TUS005674$TAKEDA$$44$YR$$F$Y$$$20221028$$CN$CA$CA
156829812$15682981$2$F$20161105$20221012$20181203$20221014$EXP$IT-MINISAL02-512775$IT-ROCHE-2223581$ROCHE$$63$YR$$F$Y$$$20221014$$MD$IT$IT
1568332838$15683328$38$F$20050101$20220924$20181204$20221004$EXP$$CA-CELLTRION INC.-2018CA024265$CELLTRION$$$$$$Y$$$20221004$$MD$CA$CA
1568401914$15684019$14$F$20180101$20221123$20181204$20221129$EXP$$CA-TAKEDA-2018TUS028881$TAKEDA$$63$YR$$M$Y$$$20221129$$HP$CA$CA
156846597$15684659$7$F$$20221023$20181204$20221102$EXP$$CA-TEVA-2018-CA-981625$TEVA$$70$YR$E$F$Y$$$20221102$$CN$CA$CA
156865953$15686595$3$F$20181123$20221007$20181204$20221011$PER$$US-PFIZER INC-2018490763$PFIZER$$43$YR$$F$Y$$$20221011$$CN$US$US
156871432$15687143$2$F$20181006$20181130$20181204$20221020$EXP$$PHHY2018ES165570$NOVARTIS$$87$YR$$F$Y$40.816$KG$20221020$$MD$ES$ES
1568723514$15687235$14$F$20181121$20221111$20181204$20221121$EXP$$CA-CELLTRION INC.-2018CA023896$CELLTRION$$$$$$Y$$$20221121$$CN$CA$CA
156889047$15688904$7$F$20161020$20221216$20181205$20221222$EXP$$US-ARIAD PHARMACEUTICALS, INC-2017US008743$TAKEDA$$34$YR$$F$Y$$$20221222$$HP$US$US
1568981516$15689815$16$F$20151001$20221104$20181205$20221116$EXP$$GB-ASPEN-GLO2015GB016655$ASPEN$$$$$$Y$$$20221116$$HP$GB$GB
1568988115$15689881$15$F$20150706$20221109$20181205$20221118$EXP$$GB-ASPEN-GLO2015GB016656$ASPEN$$$$$$Y$$$20221118$$HP$GB$GB
1568995146$15689951$46$F$20180101$20220928$20181205$20221010$EXP$$CA-CELLTRION INC.-2018CA020340$CELLTRION$$$$$$Y$$$20221010$$CN$CA$CA
1569037210$15690372$10$F$20180619$20221206$20181205$20221215$PER$$US-PFIZER INC-2018500542$PFIZER$$69$YR$$M$Y$92.99$KG$20221215$$MD$US$US
156925865$15692586$5$F$20120101$20220930$20181206$20221026$PER$$US-PURDUE-USA-2018-0144293$PURDUE$$$$A$F$Y$$$20221027$$CN$US$US
156935442$15693544$2$F$$20221203$20181206$20221217$EXP$$NL-AUROBINDO-AUR-APL-2018-059194$AUROBINDO$Genovese F, Marilli I, Benintende G, Privitera A, Gulino F, Iozza A.I, et al.. Diagnosis and management of fetal ductus arteriosus constriction-closure. Journal of Neonatal-Perinatal Medicine. 2015;8:57-62$$$N$M$Y$$$20221218$$MD$IT$NL
1569475624$15694756$24$F$20181101$20221214$20181206$20221221$EXP$$GB-ELI_LILLY_AND_COMPANY-GB201812000415$ELI LILLY AND CO$$24$YR$$M$Y$$$20221221$$CN$GB$GB
1569533447$15695334$47$F$20190429$20221123$20181206$20221201$EXP$$CA-CELLTRION INC.-2018CA024412$CELLTRION$$$$$$Y$$$20221201$$HP$CA$CA
1569541613$15695416$13$F$20170131$20221223$20181206$20221230$EXP$$CA-TAKEDA-2017TUS002829$TAKEDA$$30$YR$$F$Y$$$20221230$$HP$CA$CA
156959907$15695990$7$F$20200101$20221025$20181206$20221028$EXP$$PHHY2018CA173575$NOVARTIS$$$$$M$Y$$$20221028$$CN$CA$CA
156970843$15697084$3$F$20110101$20221007$20181206$20221010$PER$$US-PFIZER INC-2018497466$PFIZER$$57$YR$$F$Y$$$20221010$$LW$US$US
156980526$15698052$6$F$20180106$20220929$20181207$20221027$30DAY$$US-PFIZER INC-2018007178$PFIZER$$2$YR$$F$Y$13.605$KG$20221027$$MD$US$US
1569826330$15698263$30$F$20180824$20221215$20181207$20221224$EXP$$CA-CELLTRION INC.-2018CA022333$CELLTRION$$$$$$Y$$$20221224$$CN$CA$CA
1569948214$15699482$14$F$20160919$20221006$20181207$20221011$EXP$$PHHY2017CA146049$NOVARTIS$$61$YR$$F$Y$$$20221011$$CN$CA$CA
156995686$15699568$6$F$20180520$20190806$20181207$20221003$EXP$$US-BAYER-2018-223491$BAYER$$35$YR$A$F$Y$$$20221003$$MD$US$US
1570007612$15700076$12$F$20181201$20221006$20181207$20221013$EXP$$US-PFIZER INC-2018497493$PFIZER$$76$YR$$M$Y$86.621$KG$20221013$$CN$US$US
157010884$15701088$4$F$20170523$20221031$20181207$20221104$EXP$$US-SAKK-2018SA332278AA$SANOFI AVENTIS$$54$YR$A$F$Y$$$20221104$$MD$US$US
157013604$15701360$4$F$20120101$20221223$20181207$20221228$EXP$$US-JAZZ-JPI-P-021759$JAZZ$$$$$F$Y$53$KG$20221228$$MD$US$US
157015744$15701574$4$F$$20221221$20181208$20221227$EXP$$CA-TAKEDA-2018TUS034556$TAKEDA$$27$YR$$F$Y$142.3$KG$20221227$$CN$CA$CA
1570343436$15703434$36$F$20180712$20221216$20181210$20221222$EXP$$DE-ROCHE-2168822$ROCHE$$43$YR$$F$Y$116.3$KG$20221222$$CN$DE$DE
1570469610$15704696$10$F$20181130$20221019$20181210$20221021$EXP$$PHHO2018DE012848$NOVARTIS$$71$YR$$M$Y$81$KG$20221021$$MD$DE$DE
157057377$15705737$7$F$$20221019$20181210$20221020$EXP$$PT-UCBSA-2018053578$UCB$$47$YR$$F$Y$$$20221021$$MD$PT$PT
1570727040$15707270$40$F$20180101$20220929$20181210$20221012$EXP$$CA-CELLTRION INC.-2018CA020284$CELLTRION$$$$$$Y$$$20221012$$CN$CA$CA
1570786833$15707868$33$F$20180810$20221129$20181211$20221207$EXP$$DE-ROCHE-2173418$ROCHE$$43$YR$$M$Y$$$20221207$$CN$DE$DE
157082172$15708217$2$F$$20221108$20181211$20221110$PER$$US-PFIZER INC-2018411543$PFIZER$$73$YR$$F$Y$$$20221110$$CN$US$US
157082496$15708249$6$F$$20221027$20181211$20221206$PER$$US-PFIZER INC-2018506709$MYLAN$$$$$M$Y$50$KG$20221206$$MD$US$US
157100033$15710003$3$F$20180830$20221010$20181211$20221013$EXP$$PHHY2018FR176868$NOVARTIS$$42$YR$$F$Y$75$KG$20221013$$MD$FR$FR
157104594$15710459$4$F$20170220$20221020$20181211$20221021$EXP$$PHHY2018DE176511$NOVARTIS$$$$E$F$Y$$$20221021$$MD$DE$DE
157126995$15712699$5$F$20180701$20221212$20181212$20221221$PER$$CA-AMGEN-CANSL2018064398$AMGEN$$70$YR$E$F$Y$75$KG$20221221$$HP$CA$CA
157128374$15712837$4$F$20160412$20221129$20181212$20221207$EXP$$US-AstraZeneca-2018SF59248$ASTRAZENECA$$25205$DY$$F$Y$87.1$KG$20221207$$LW$US$
1571305843$15713058$43$F$20181122$20221216$20181212$20221223$EXP$$DE-ROCHE-2228639$ROCHE$$33$YR$$F$Y$56$KG$20221223$$CN$DE$
157137576$15713757$6$F$$20221019$20181212$20221025$EXP$$PT-SA-2018SA339456$SANOFI AVENTIS$Tavares J., Azevedo J., Carvalho J., Carneiro P., Emidio A., Carreira J et al.. Lyell Syndrome - Reporting A Case Of Shock.1.. Medicina Interna. 2017;23:1$47$YR$A$F$Y$$$20221025$$MD$PT$PT
157142719$15714271$9$F$20181101$20221117$20181212$20221118$EXP$$FR-SHIRE-FR201847680$TAKEDA$$46$YR$$M$Y$66$KG$20221118$$MD$FR$FR
1571449614$15714496$14$F$20211201$20221122$20181212$20221128$PER$$US-PFIZER INC-2018508814$PFIZER$$71$YR$$F$Y$$$20221128$$CN$US$US
1571473018$15714730$18$F$20181101$20221221$20181212$20221230$EXP$$CA-CELLTRION INC.-2018CA024563$CELLTRION$$$$$$Y$$$20221230$$HP$CA$CA
1571473530$15714735$30$F$20181025$20221130$20181212$20221209$EXP$$CA-CELLTRION INC.-2018CA023738$CELLTRION$$$$$$Y$$$20221209$$MD$CA$CA
157147737$15714773$7$F$20181204$20221123$20181212$20221125$EXP$$CN-ROCHE-2226678$ROCHE$$40$YR$$M$Y$52$KG$20221125$$MD$CN$
157148887$15714888$7$F$20090301$20221208$20181212$20221213$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-113697$BRISTOL MYERS SQUIBB$$68$YR$E$F$Y$85$KG$20221213$$MD$CA$CA
157159256$15715925$6$F$$20221027$20181212$20221104$PER$$US-AMGEN-USASP2018177009$AMGEN$$61$YR$A$F$Y$$$20221104$$MD$US$US
157171443$15717144$3$F$20020901$20221205$20181213$20221208$EXP$$GXKR2005DE01112$NOVARTIS$Schiessl B, Schneider KT, Zimmermann A, Kainer F, Friese K, Oberhoffer R. Prenatal constriction of the fetal ductus arteriosus - related to maternal pain medication?. Z GEBURTSHILFE NEONATOL. 2005;209(2):65-8$$$N$$Y$2.9$KG$20221208$$HP$DE$DE
157173665$15717366$5$F$20220101$20221027$20181213$20221104$EXP$$CA-ROCHE-2227633$ROCHE$$28$YR$$F$Y$$$20221104$$MD$CA$CA
157194017$15719401$7$F$20180813$20221109$20181213$20221121$EXP$$PHHY2018DE149237$NOVARTIS$$$$E$F$Y$49$KG$20221121$$MD$DE$DE
157199313$15719931$3$F$20150701$20221010$20181213$20221011$EXP$$US-TAKEDA-2018TUS035543$TAKEDA$$$$$$Y$$$20221011$$CN$US$US
157202909$15720290$9$F$20181204$20221011$20181213$20221017$EXP$$US-SHIRE-US201848004$TAKEDA$$71$YR$$F$Y$82$KG$20221017$$MD$US$US
157203204$15720320$4$F$20181203$20221215$20181213$20221219$EXP$$US-SHIRE-US201847935$TAKEDA$$45$YR$$M$Y$$$20221219$$CN$US$US
157203252$15720325$2$F$$20221219$20181213$20221227$EXP$$US-SHIRE-US201848071$TAKEDA$$$$$F$Y$54$KG$20221227$$PH$US$US
157204208$15720420$8$F$20180705$20221109$20181213$20221117$EXP$$PHHY2018CA048466$NOVARTIS$$52$YR$$F$Y$$$20221117$$MD$CA$CA
157214599$15721459$9$F$20181019$20221019$20181214$20221025$EXP$$DE-ROCHE-2150140$ROCHE$$55$YR$$F$Y$$$20221025$$CN$DE$
1572147121$15721471$21$F$20180530$20221004$20181214$20221013$EXP$$CA-ROCHE-2133198$ROCHE$$39$YR$$F$Y$$$20221012$$HP$CA$CA
1572306314$15723063$14$F$20181105$20221108$20181214$20221115$PER$$US-INCYTE CORPORATION-2018IN011426$INCYTE$$$$$$Y$$$20221116$$CN$US$US
157255687$15725568$7$F$$20221119$20181215$20221202$EXP$PL-EMA-DD-20180207-VSEVHPDD-091531$PL-Accord-096258$ACCORD$$70$YR$E$F$Y$$$20221202$$HP$PL$PL
157258812$15725881$2$F$20021022$20221121$20181216$20221130$PER$$US-JNJFOC-20181205526$JOHNSON AND JOHNSON$$3$YR$C$M$Y$$$20221130$$LW$US$US
1572713220$15727132$20$F$20180502$20221129$20181217$20221207$EXP$$DE-ROCHE-2208865$ROCHE$$25$YR$$F$Y$$$20221207$$CN$DE$
157277466$15727746$6$F$20101101$20221217$20181217$20221223$PER$$US-PFIZER INC-2017111295$PFIZER$$68$YR$$M$Y$$$20221223$$MD$US$US
157277973$15727797$3$F$$20221107$20181217$20221109$PER$$US-PFIZER INC-2018513278$PFIZER$$76$YR$$F$Y$$$20221109$$CN$US$US
1572800927$15728009$27$F$20180101$20221027$20181217$20221104$EXP$$CA-CELLTRION INC.-2018CA023391$CELLTRION$$$$$$Y$$$20221104$$CN$CA$CA
1572801031$15728010$31$F$20181201$20221019$20181217$20221027$EXP$$CA-CELLTRION INC.-2018CA024610$CELLTRION$$$$$$Y$$$20221028$$CN$CA$CA
1572801813$15728018$13$F$20211101$20221123$20181217$20221201$EXP$$CA-CELLTRION INC.-2018CA024612$CELLTRION$$$$$$Y$$$20221201$$HP$CA$CA
157281944$15728194$4$F$20180409$20220930$20181217$20221010$EXP$$DE-ROCHE-2107033$ROCHE$$61$YR$$F$Y$$$20221010$$CN$DE$
1572897527$15728975$27$F$20080101$20220912$20181217$20221006$EXP$$CA-PFIZER INC-2018518605$PFIZER$$44$YR$$F$Y$63$KG$20221006$$MD$CA$CA
157294165$15729416$5$F$$20221007$20181217$20221014$EXP$$US-GLAXOSMITHKLINE-US2018GSK227099$PERRIGO$$$$$F$Y$260$KG$20221014$$CN$US$US
1572965120$15729651$20$F$20150601$20220411$20181217$20221021$EXP$$GB-SA-2018SA335037$SANOFI AVENTIS$$61$YR$A$F$Y$$$20221021$$MD$GB$GB
157309182$15730918$2$F$20181101$20221014$20181217$20221020$EXP$PHHY2018FR186183$PHHY2018FR186183$NOVARTIS$$76$YR$$F$Y$64$KG$20221020$$PH$FR$FR
1573153410$15731534$10$F$20181204$20220907$20181217$20221026$PER$$US-JAZZ-2018-US-018179$JAZZ$$68$YR$$F$Y$$$20221026$$HP$US$US
1573166020$15731660$20$F$20130924$20221221$20181217$20221226$EXP$$PHHY2013CA107770$NOVARTIS$$25$YR$$F$Y$$$20221226$$CN$CA$CA
157317613$15731761$3$F$20150701$20221007$20181217$20221010$EXP$$US-PFIZER INC-2018517472$PFIZER$$$$$F$Y$$$20221010$$HP$US$US
157329167$15732916$7$F$$20221129$20181217$20221201$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-118580$BRISTOL MYERS SQUIBB$Ogata S, et al. Two cases of tumor hemorrhage developed during nivolumab therapy for unresectable recurrent gastric cancer. The 80th Annual Congress of Japan Surgical Association 2018;79:O-86-05.$7$DEC$E$M$Y$$$20221201$$MD$JP$JP
1573329228$15733292$28$F$20180320$20221209$20181218$20221214$EXP$$DE-ROCHE-2097781$ROCHE$$46$YR$$F$Y$$$20221214$$CN$DE$DE
157334834$15733483$4$F$20160201$20221019$20181218$20221024$EXP$$CA-TAKEDA-2016TUS002050$TAKEDA$$43$YR$$M$Y$$$20221024$$CN$US$CA
157338936$15733893$6$F$20170901$20221129$20181218$20221206$PER$$US-PFIZER INC-2018517236$PFIZER$$18$YR$$F$Y$$$20221206$$CN$US$US
157339105$15733910$5$F$$20221228$20181218$20221230$PER$$US-PFIZER INC-2018516943$PFIZER$$66$YR$$F$Y$$$20221230$$CN$US$US
157360864$15736086$4$F$$20201029$20181218$20221104$EXP$$CA-SAMSUNG BIOEPIS-SB-2018-16358$SAMSUNG BIOEPIS$$16$YR$T$F$Y$$$20221104$$HP$CA$CA
157364624$15736462$4$F$20150101$20221220$20181218$20221228$EXP$$CA-PFIZER INC-2018513805$PFIZER$$79$YR$$F$Y$$$20221228$$HP$CA$CA
157378983$15737898$3$F$20160101$20221201$20181219$20221206$EXP$$US-ABBVIE-18K-163-2592549-00$ABBVIE$$$$$F$Y$$$20221206$$CN$US$US
157382992$15738299$2$F$$20221123$20181219$20221209$PER$$US-drreddys-USA/USA/18/0098168$DR REDDYS$$51$YR$A$F$Y$57$KG$20221209$$CN$US$US
1573835942$15738359$42$F$20181125$20221209$20181219$20221215$EXP$$CA-CELLTRION INC.-2018CA024524$CELLTRION$$$$$$Y$$$20221215$$MD$CA$CA
157390235$15739023$5$F$20150101$20221209$20181219$20221214$PER$$US-PFIZER INC-2018518298$PFIZER$$58$YR$$F$Y$118$KG$20221214$$CN$US$US
157391213$15739121$3$F$$20221106$20181219$20221114$EXP$$AU-SAMSUNG BIOEPIS-SB-2018-16468$SAMSUNG BIOEPIS$$66$YR$E$F$Y$$$20221114$$MD$AU$AU
1574043226$15740432$26$F$20200601$20221215$20181219$20221222$EXP$$PHHY2018AR026774$NOVARTIS$$52$YR$$F$Y$$$20221222$$CN$AR$AR
157408245$15740824$5$F$20181102$20221004$20181219$20221007$EXP$$GB-AstraZeneca-2018SF64177$ASTRAZENECA$$61$YR$$F$Y$$$20221007$$MD$GB$
157436625$15743662$5$F$$20221013$20181220$20221017$EXP$$US-PFIZER INC-2017305872$PFIZER$$73$YR$$F$Y$76$KG$20221017$$CN$US$US
157452673$15745267$3$F$20181101$20221017$20181220$20221027$EXP$FR-AFSSAPS-LY20182660$FR-SA-2018SA340726$SANOFI AVENTIS$$76$YR$E$F$Y$64$KG$20221027$$PH$FR$FR
1574950516$15749505$16$F$20180101$20221110$20181221$20221118$EXP$$CA-CELLTRION INC.-2018CA023614$CELLTRION$$$$$$Y$$$20221118$$CN$CA$CA
157513324$15751332$4$F$20160629$20221209$20181221$20221215$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK030883$GLAXOSMITHKLINE$$$$$$Y$$$20221215$$CN$BR$BR
1575279415$15752794$15$F$20170510$20221213$20181221$20221215$EXP$$CA-TAKEDA-2017TUS011849$TAKEDA$$66$YR$$F$Y$$$20221215$$HP$CA$CA
157536909$15753690$9$F$$20220930$20181222$20221003$PER$$US-BIOGEN-2018BI00633054$BIOGEN$$$$$F$Y$$$20221003$$CN$US$US
1575481537$15754815$37$F$20181212$20221114$20181224$20221115$EXP$$DE-ROCHE-2235012$ROCHE$$38$YR$$F$Y$69$KG$20221115$$CN$DE$DE
1575528016$15755280$16$F$20181122$20221124$20181224$20221202$EXP$$PHHY2018CA060279$NOVARTIS$$90$YR$$M$Y$$$20221202$$MD$CA$CA
157554163$15755416$3$F$20181104$20221007$20181224$20221012$EXP$$PHHY2018GR192910$NOVARTIS$$35$YR$$F$Y$$$20221012$$HP$GR$GR
157554837$15755483$7$F$20181101$20221014$20181224$20221020$EXP$$PHHY2018CA053446$NOVARTIS$$64$YR$$M$Y$$$20221020$$MD$CA$CA
157556747$15755674$7$F$$20221031$20181224$20221104$EXP$$US-TAKEDA-2018TUS029744$TAKEDA$$$$$M$Y$$$20221104$$HP$US$US
157571707$15757170$7$F$$20221010$20181224$20221014$EXP$$PHHY2017FR199040$NOVARTIS$Quaesaet L, Stindel E, Lanternier F, Williams T, Jaffuel S, Moalic E et al.. Miltefosine-based regimen as salvage therapy in Lomentospora prolificans bone and joint infection. MEDECINE ET MALADIES INFECTIEUSES. 2018;48:63-5$70$YR$$M$Y$$$20221014$$HP$FR$FR
1575780529$15757805$29$F$20180709$20221201$20181225$20221210$EXP$$CA-CELLTRION INC.-2018CA021158$CELLTRION$$$$$$Y$$$20221210$$MD$CA$CA
1575819427$15758194$27$F$20180710$20221130$20181225$20221208$EXP$$CA-CELLTRION INC.-2018CA021533$CELLTRION$$$$$$Y$$$20221209$$CN$CA$CA
1575819630$15758196$30$F$20180707$20221207$20181225$20221217$EXP$$CA-CELLTRION INC.-2018CA021679$CELLTRION$$$$$$Y$$$20221217$$MD$CA$CA
157591562$15759156$2$F$$20220929$20181226$20221010$EXP$US-MLMSERVICE-20181210-1527721-1$US-LUPIN PHARMACEUTICALS INC.-2018-08944$LUPIN$Ghaly RF, Plesca A, Rana S, Candido KD, Knezevic NN. Gabapentin-related suicide: Myth or fact. Surgical Neurology International. 2018;9(1):210:1-6$28$YR$$M$Y$$$20221010$$MD$US$US
1575939618$15759396$18$F$20180411$20221026$20181226$20221102$EXP$$DE-ROCHE-2113766$ROCHE$$40$YR$$F$Y$$$20221102$$CN$DE$
157594423$15759442$3$F$20221209$20221209$20181226$20221220$EXP$$MX-AstraZeneca-2018SF68895$ASTRAZENECA$$23103$DY$$F$Y$80$KG$20221216$$CN$MX$
1575961312$15759613$12$F$20180101$20221222$20181226$20221230$EXP$$CA-CELLTRION INC.-2018CA021843$CELLTRION$$$$$$Y$$$20221231$$CN$CA$CA
157607984$15760798$4$F$20181213$20221222$20181226$20221227$PER$$US-PFIZER INC-2018527583$PFIZER$$65$YR$$F$Y$$$20221227$$CN$US$US
157608983$15760898$3$F$$20221221$20181226$20221227$PER$$US-PFIZER INC-2018524781$PFIZER$$62$YR$$M$Y$$$20221227$$CN$US$US
1576141320$15761413$20$F$19970101$20221006$20181226$20221018$EXP$FR-EMA-DD-20190108-SANDEVHP-121842$FR-MYLANLABS-2018M1095407$MYLAN$$28$YR$$F$Y$60$KG$20221018$$HP$FR$FR
157617004$15761700$4$F$$20221012$20181226$20221012$EXP$$FR-GLAXOSMITHKLINE-FR2018231686$GLAXOSMITHKLINE$$$$$$Y$$$20221012$$MD$FR$FR
157629293$15762929$3$F$20180101$20221118$20181226$20221129$EXP$$AT-PFIZER INC-2018521806$MYLAN$Rainer, M.. Dementia - A syndromatological chameleon. psychopraxis: neuropraxis. 2018;21:158 - 163$$$E$M$Y$$$20221129$$MD$AT$AT
157632792$15763279$2$F$20180801$20221012$20181227$20221014$EXP$$RU-ROCHE-2235053$ROCHE$$66$YR$$M$Y$63$KG$20221014$$MD$RU$PL
157646945$15764694$5$F$$20221010$20181227$20221018$EXP$$FR-AUROBINDO-AUR-APL-2018-001948$AUROBINDO$Quaesaet, L... Miltefosine-based regimen as salvage therapy in Lomentospora prolificans bone and joint infection.. Med Mal Infect. 2017$70$YR$$M$Y$$$20221018$$MD$FR$FR
157668557$15766855$7$F$20180901$20221215$20181227$20221220$EXP$$US-PFIZER INC-2018360486$PFIZER$$76$YR$$F$Y$61$KG$20221220$$CN$US$US
157671966$15767196$6$F$20181024$20221129$20181227$20221207$EXP$$DE-GILEAD-2018-0381854$GILEAD$$42$YR$A$M$Y$100$KG$20221207$$HP$DE$DE
1576834512$15768345$12$F$20181219$20221021$20181227$20221028$EXP$$PHHY2018CA195193$NOVARTIS$$49$YR$$M$Y$$$20221028$$CN$CA$CA
1576913011$15769130$11$F$20181115$20221028$20181228$20221104$EXP$$US-ROCHE-2233966$ROCHE$$49$YR$$M$Y$90.8$KG$20221103$$CN$US$
157691363$15769136$3$F$20181201$20221127$20181228$20221207$EXP$$PL-TEVA-2018-PL-991737$TEVA$$10$YR$C$M$Y$29.5$KG$20221207$$MD$PL$PL
1576929225$15769292$25$F$20181126$20221215$20181228$20221221$EXP$$DE-ROCHE-2233008$ROCHE$$46$YR$$F$Y$$$20221221$$CN$DE$
1576935932$15769359$32$F$20180917$20221110$20181228$20221118$EXP$$CA-ROCHE-2187617$ROCHE$$43$YR$$F$Y$83.4$KG$20221118$$CN$CA$
1577022120$15770221$20$F$$20221207$20181228$20221213$EXP$$US-PFIZER INC-2018490187$PFIZER$$78$YR$$F$Y$74.84$KG$20221213$$MD$US$US
157703075$15770307$5$F$$20221007$20181228$20221011$PER$$US-PFIZER INC-2018347088$PFIZER$$61$YR$$F$Y$$$20221011$$HP$US$US
1577282113$15772821$13$F$20161216$20221110$20181228$20221117$EXP$$JP-GILEAD-2018-0382301$GILEAD$$31$YR$A$M$Y$$$20221117$$MD$JP$JP
157729294$15772929$4$F$20181210$20221219$20181228$20221227$EXP$$IL-SHIRE-IL201849637$TAKEDA$$57$YR$$M$Y$$$20221227$$MD$IL$IL
157740314$15774031$4$F$20171018$20190422$20181229$20221208$EXP$$JP-TEVA-2018-JP-992967$TEVA$$71$YR$E$F$Y$$$20221208$$MD$JP$JP
1577477320$15774773$20$F$20181031$20221209$20181230$20221215$EXP$$PHHY2018CA146684$NOVARTIS$$65$YR$$M$Y$$$20221215$$CN$CA$CA
157756237$15775623$7$F$20180215$20221108$20181231$20221115$EXP$$US-ROCHE-2234638$ROCHE$$68$YR$$F$Y$68.1$KG$20221115$$CN$US$
1577580929$15775809$29$F$20170701$20221221$20181231$20221230$EXP$$CA-CELLTRION INC.-2017CA011303$CELLTRION$$$$$$Y$$$20221230$$CN$CA$CA
157764006$15776400$6$F$$20221205$20181231$20221214$EXP$$CA-BAYER-2018-242492$BAYER$$63$YR$A$F$Y$$$20221214$$MD$CA$CA
157764757$15776475$7$F$20210709$20221118$20181231$20221124$EXP$$CA-GLAXOSMITHKLINE-CA2018GSK233177$GLAXOSMITHKLINE$$$$$$Y$$$20221124$$MD$CA$CA
1577662113$15776621$13$F$20200729$20221221$20181231$20221227$EXP$$US-PFIZER INC-2017488048$PFIZER$$71$YR$$F$Y$77.6$KG$20221227$$MD$US$US
157767834$15776783$4$F$$20221017$20181231$20221019$PER$$US-PFIZER INC-2018535581$PFIZER$$75$YR$$F$Y$$$20221019$$MD$US$US
157780083$15778008$3$F$20181201$20221207$20181231$20221212$EXP$$US-PFIZER INC-2018535489$PFIZER$$62$YR$$F$Y$$$20221212$$CN$US$US
157784392$15778439$2$F$$20221115$20181231$20221118$EXP$$US-PFIZER INC-2018534217$PFIZER$$69$YR$$F$Y$$$20221118$$CN$US$US
157792024$15779202$4$F$20190307$20221103$20190101$20221107$PER$$US-PFIZER INC-2017369340$PFIZER$$61$YR$$M$Y$111.97$KG$20221107$$PH$US$US
157792884$15779288$4$F$$20221102$20190101$20221104$PER$$US-PFIZER INC-2018537149$PFIZER$$43$YR$$F$Y$$$20221104$$HP$US$US
1578052321$15780523$21$F$20170218$20221222$20190102$20221230$EXP$$CA-CELLTRION INC.-2017CA003138$CELLTRION$$$$$$Y$$$20221231$$CN$CA$CA
1578252128$15782521$28$F$20180828$20221018$20190102$20221021$EXP$$IL-PFIZER INC-2018350729$PFIZER$$45$YR$$M$Y$$$20221021$$HP$IL$IL
157826532$15782653$2$F$$20221214$20190102$20221221$EXP$$US-INCYTE CORPORATION-2017IN002131$INCYTE$$$$$$Y$$$20221221$$CN$US$US
157831069$15783106$9$F$20120101$20221220$20190102$20221227$EXP$$US-PFIZER INC-2019000246$PFIZER$$66$YR$$F$Y$75$KG$20221227$$CN$US$US
157844082$15784408$2$F$$20221102$20190103$20221108$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-122746$BRISTOL MYERS SQUIBB$Zayko MO, Velilla RE, Salah Shurbaji M. Condyloma acuminata presenting as isolated papillary lesions in the prostatic urethra. American Journal of Case Reports. 2018 Dec 22; 19:1522-5.doi:10.12659/AJCR.911682.$62$YR$A$M$Y$$$20221108$$HP$US$US
157846452$15784645$2$F$$20220824$20190103$20221207$EXP$US-MLMSERVICE-20170817-0858834-1$US-ALKEM LABORATORIES LIMITED-US-ALKEM-2018-08996$ALKEM$Villafuerte D, Koch K, Amalakuhan B, Simpson T.. Fatal outcome in a patient with acute interstitial pneumonia despite immunosuppressive therapy.. American Journal of Respiratory and Critical Care Medicine. 2017;195:A3411$58$YR$$M$Y$$$20221206$$HP$US$US
157846522$15784652$2$F$$20220608$20190103$20221207$EXP$$US-ALKEM LABORATORIES LIMITED-US-ALKEM-2018-05191$ALKEM$Liu K and Kia L.. Mycophenolate Mofetil Induced Esophagitis. Clinical Gastroenterology and  Hepatology. 2018;Unk:Unk$65$YR$$F$Y$$$20221206$$MD$US$US
1578478136$15784781$36$F$20180101$20221202$20190103$20221212$EXP$$CA-CELLTRION INC.-2018CA021250$CELLTRION$$$$$$Y$$$20221212$$MD$CA$CA
1578479416$15784794$16$F$20190408$20221018$20190103$20221026$EXP$$CA-CELLTRION INC.-2018CA021700$CELLTRION$$$$$$Y$$$20221026$$HP$CA$CA
157856333$15785633$3$F$$20221215$20190103$20221221$EXP$$US-JAZZ-2018-US-018787$JAZZ$$$$$F$Y$$$20221221$$CN$US$US
1578702414$15787024$14$F$$20221220$20190103$20221227$EXP$$US-TAKEDA-2018TUS036993$TAKEDA$$$$$F$Y$73$KG$20221227$$CN$US$US
157872556$15787255$6$F$$20221005$20190103$20221006$PER$$US-PFIZER INC-2019004026$PFIZER$$71$YR$$F$Y$$$20221006$$CN$US$US
157886035$15788603$5$F$20171008$20221028$20190104$20221109$EXP$$PHHY2019TH000652$NOVARTIS$$58$YR$$F$Y$51$KG$20221109$$MD$TH$TH
157891635$15789163$5$F$$20221202$20190104$20221206$PER$$US-PFIZER INC-2019005304$PFIZER$$63$YR$$M$Y$$$20221206$$HP$US$US
1579072917$15790729$17$F$20181228$20221013$20190104$20221017$EXP$$CA-TAKEDA-2019TUS000239$TAKEDA$$45$YR$$M$Y$$$20221017$$HP$CA$CA
157907903$15790790$3$F$$20221011$20190104$20221015$EXP$$US-SHIRE-US201900036$TAKEDA$$$$$F$Y$$$20221015$$CN$US$US
157913136$15791313$6$F$20220419$20221216$20190104$20221222$EXP$$US-BIOGEN-2019BI00679308$BIOGEN$$51$YR$$F$Y$$$20221222$$CN$US$US
157917712$15791771$2$F$20150101$20221123$20190105$20221130$PER$$US-BIOGEN-2015BI117957$BIOGEN$$$$$F$Y$77.18$KG$20221130$$CN$US$US
157923132$15792313$2$F$$20221104$20190107$20221108$PER$$US-AMGEN-USASP2019000465$AMGEN$$52$YR$$F$Y$$$20221108$$MD$US$US
157926739$15792673$9$F$20190102$20220929$20190107$20221007$EXP$$DE-ROCHE-2240631$ROCHE$$49$YR$$F$Y$$$20221007$$CN$DE$
157938075$15793807$5$F$20180310$20221207$20190107$20221213$EXP$$PHHY2018CA043689$NOVARTIS$$64$YR$$F$Y$$$20221213$$CN$CA$CA
157952766$15795276$6$F$20181218$20221205$20190107$20221207$EXP$$FR-SA-2019SA001925$SANOFI AVENTIS$$73$YR$E$F$Y$54$KG$20221207$$MD$FR$FR
157966676$15796667$6$F$20180523$20221019$20190108$20221021$EXP$$DE-ROCHE-2137306$ROCHE$$49$YR$$F$Y$$$20221021$$CN$DE$
157967394$15796739$4$F$$20221212$20190108$20221222$PER$$US-AMGEN-USASP2019000515$AMGEN$$77$YR$E$F$Y$$$20221221$$HP$US$US
157975862$15797586$2$F$$20190102$20190108$20221213$PER$$US-AMGEN INC.-USASP2019000939$AMGEN$$34$YR$A$F$Y$$$20221212$$HP$US$US
158002423$15800242$3$F$20180101$20221007$20190108$20221014$EXP$$US-BAUSCH-BL-2019-000459$BAUSCH AND LOMB$$74$YR$$F$Y$86.26$KG$20221014$$CN$US$US
1580031519$15800315$19$F$20181201$20221110$20190108$20221116$EXP$$US-JAZZ-2019-US-000075$JAZZ$$45$YR$$F$Y$$$20221116$$MD$US$US
1580075822$15800758$22$F$20190102$20221028$20190109$20221108$EXP$$CA-CELLTRION INC.-2019CA017671$CELLTRION$$$$$$Y$$$20221108$$CN$CA$CA
158015232$15801523$2$F$$20221104$20190109$20221115$EXP$$US-MYLANLABS-2019M1001281$MYLAN$Finch L, Cardonick E. 881: Incidence of childhood hearing loss after in utero exposure to platinum agents. Am-J-Obstet-Gynecol 2019;220 (Suppl.)(1):S573 abstr. 881.$2$MON$$F$Y$$$20221115$$HP$US$US
158015292$15801529$2$F$$20221104$20190109$20221115$EXP$$US-MYLANLABS-2019M1001289$MYLAN$Finch L, Cardonick E. 881: Incidence of childhood hearing loss after in utero exposure to platinum agents. Am-J-Obstet-Gynecol 2019;220 (Suppl.)(1):S573 abstr. 881.$11$YR$$$Y$$$20221115$$HP$US$US
1580277011$15802770$11$F$20181211$20221006$20190109$20221010$EXP$$ES-ROCHE-2228193$ROCHE$$72$YR$$F$Y$70.4$KG$20221010$$MD$ES$
158035613$15803561$3$F$$20221201$20190109$20221206$PER$$US-SUNOVION-2019SUN000045$SUNOVION$$$$$F$Y$$$20221206$$CN$US$US
158037643$15803764$3$F$$20221212$20190109$20221215$PER$$US-PFIZER INC-2019003432$PFIZER$$77$YR$$F$Y$$$20221215$$HP$US$US
158043329$15804332$9$F$20181109$20221128$20190109$20221207$EXP$$FR-SHIRE-FR201900367$TAKEDA$$58$YR$$F$Y$$$20221207$$HP$FR$FR
1580706944$15807069$44$F$20190601$20221211$20190110$20221219$EXP$$IL-PFIZER INC-2018209709$PFIZER$$66$YR$$M$Y$$$20221219$$HP$IL$IL
158071232$15807123$2$F$$20221104$20190110$20221111$EXP$$US-MYLANLABS-2019M1001311$MYLAN$Finch L, Cardonick E. 881: Incidence of childhood hearing loss after in utero exposure to platinum agents. Am-J-Obstet-Gynecol 2019;220 (Suppl.)(1):S573 abstr. 881.$4$YR$$$Y$$$20221111$$HP$US$US
158078994$15807899$4$F$20181221$20221118$20190110$20221128$EXP$$US-TAKEDA-2019TUS000749$TAKEDA$$23$YR$$M$Y$61.3$KG$20221128$$MD$US$US
1580883211$15808832$11$F$20181207$20221125$20190110$20221201$EXP$$DE-ROCHE-2231540$ROCHE$$62$YR$$M$Y$$$20221201$$CN$DE$
1581079215$15810792$15$F$20180101$20221012$20190111$20221018$EXP$$DE-BIOGEN-2018BI00662150$BIOGEN$$$$$F$Y$$$20221018$$CN$DE$DE
1581123723$15811237$23$F$20171204$20221111$20190111$20221121$EXP$$CA-CELLTRION INC.-2017CA017549$CELLTRION$$$$$$Y$$$20221121$$CN$CA$CA
158112567$15811256$7$F$20190110$20221017$20190111$20221018$PER$$US-BIOGEN-2019BI00678513$BIOGEN$$58$YR$$F$Y$$$20221018$$CN$US$US
1581140912$15811409$12$F$$20221021$20190111$20221027$EXP$$CA-ABBVIE-19S-028-2618512-00$ABBVIE$$54$YR$$M$Y$$$20221027$$HP$CA$CA
158115106$15811510$6$F$20190103$20221006$20190111$20221010$PER$$US-PFIZER INC-2018528847$PFIZER$$61$YR$$M$Y$$$20221010$$CN$US$US
158117946$15811794$6$F$20180709$20221108$20190111$20221121$EXP$$CA-ROCHE-2156450$ROCHE$$42$YR$$M$Y$$$20221121$$HP$CA$
158125447$15812544$7$F$20190801$20221102$20190111$20221104$EXP$$US-PFIZER INC-2019014340$PFIZER$$57$YR$$M$Y$$$20221104$$CN$US$US
1581864819$15818648$19$F$20150101$20221129$20190113$20221209$EXP$$PHHY2019DE005383$NOVARTIS$$$$E$F$Y$78$KG$20221209$$MD$DE$DE
1581874910$15818749$10$F$20181001$20221117$20190113$20221123$EXP$$FR-PFIZER INC-2019011377$PFIZER$$43$YR$$F$Y$110$KG$20221123$$MD$FR$FR
1581990312$15819903$12$F$20180629$20221219$20190114$20221227$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-062501$BRISTOL MYERS SQUIBB$$71$YR$E$M$Y$74.3$KG$20221227$$MD$JP$JP
158212433$15821243$3$F$20180101$20221006$20190114$20221018$EXP$$DK-JNJFOC-20190111408$JOHNSON AND JOHNSON$$54$YR$A$M$Y$100$KG$20221018$$CN$DK$DK
1582264414$15822644$14$F$20151126$20221208$20190114$20221215$EXP$$PHHY2015CA103254$NOVARTIS$$59$YR$$M$Y$$$20221215$$MD$CA$CA
158230206$15823020$6$F$$20221205$20190114$20221208$EXP$$US-PFIZER INC-2017395150$PFIZER$$73$YR$$F$Y$$$20221208$$CN$US$US
158233685$15823368$5$F$$20221130$20190114$20221205$PER$$US-PFIZER INC-2019015923$PFIZER$$75$YR$$M$Y$$$20221205$$CN$US$US
158234573$15823457$3$F$$20221220$20190114$20221226$EXP$$US-JAZZ-2019-US-000277$JAZZ$$$$$M$Y$$$20221226$$CN$US$US
158237033$15823703$3$F$$20220929$20190114$20221004$PER$$US-PFIZER INC-2019014035$PFIZER$$70$YR$$M$Y$$$20221004$$CN$US$US
1582373020$15823730$20$F$20190101$20221206$20190114$20221214$EXP$$US-PFIZER INC-2019017920$PFIZER$$80$YR$$F$Y$50$KG$20221214$$MD$US$US
158242313$15824231$3$F$$20221115$20190115$20221123$PER$$US-AMGEN-USASP2019005354$AMGEN$$62$YR$A$F$Y$$$20221123$$MD$US$US
1582474419$15824744$19$F$20181105$20221121$20190115$20221128$EXP$$DE-ROCHE-2241158$ROCHE$$55$YR$$M$Y$88$KG$20221128$$CN$DE$
158255863$15825586$3$F$20181216$20190104$20190115$20221003$EXP$$PHHY2019IT002423$NOVARTIS$$77$YR$$M$Y$$$20221003$$MD$IT$IT
158305544$15830554$4$F$20190103$20221223$20190115$20221230$EXP$$JP-009507513-1901JPN000706J$MERCK$Matsumoto K, Wakatuki J, Sakuma D, Kin E, Kobayashi Y, Komata M. WS16-3 Immune-related side effects during the first 5 years of use of immune checkpoint inhibitors. The 60th Annual Meeting of Japan Society of Clinical Oncology. 2022$76$YR$$F$Y$35$KG$20221230$$MD$JP$JP
158306933$15830693$3$F$20190105$20221130$20190116$20221206$EXP$$CA-ROCHE-2245656$ROCHE$$64$YR$$F$Y$$$20221206$$CN$CA$
158346646$15834664$6$F$20190101$20221007$20190116$20221010$EXP$$PHHY2019TH007462$NOVARTIS$$94$YR$$F$Y$$$20221010$$MD$TH$TH
1583660414$15836604$14$F$20190101$20220930$20190117$20221008$EXP$$CA-ROCHE-2246516$ROCHE$$51$YR$$F$Y$$$20221008$$CN$CA$
158388684$15838868$4$F$$20221116$20190117$20221118$PER$$US-PFIZER INC-2019020047$PFIZER$$62$YR$$F$Y$$$20221118$$MD$US$US
158390557$15839055$7$F$$20221119$20190117$20221125$EXP$$PHHY2016CO133694$NOVARTIS$$$$$M$Y$70$KG$20221125$$CN$CO$CO
158391413$15839141$3$F$20170118$20221027$20190117$20221101$EXP$$DE-PURDUE PHARMA-GBR-2018-0053159$PURDUE$$44$YR$$F$Y$64$KG$20221101$$MD$DE$DE
158396765$15839676$5$F$$20221005$20190117$20221007$EXP$$US-PFIZER INC-2019022339$PFIZER$$78$YR$$F$Y$$$20221007$$CN$US$US
158399219$15839921$9$F$19880101$20221114$20190117$20221116$PER$$US-PFIZER INC-2019019927$PFIZER$$40$YR$$F$Y$$$20221116$$CN$US$US
1584098222$15840982$22$F$20150101$20221212$20190118$20221216$PER$$CA-AMGEN-CANSP2015133922$AMGEN$$42$YR$A$F$Y$96.998$KG$20221216$$HP$CA$CA
158428163$15842816$3$F$20150901$20221128$20190118$20221206$EXP$$US-AstraZeneca-2018SE99601$ASTRAZENECA$$20957$DY$$F$Y$95.3$KG$20221206$$LW$US$
1584338916$15843389$16$F$20181228$20220927$20190118$20221005$EXP$$JP-009507513-1901JPN000567J$MERCK$Yasuda N, Yokoi S, Miyamoto Y, Miyamoto A, Tsuchiya A, Hiraide K, et al.. P34-6 A case in which a pharmacist performed initial screening for immune-related adverse events and intervened in early treatment. The 57th Annual Meeting of the Japan Society of Clinical Oncology. 1371$77$YR$$M$Y$73$KG$20221005$$MD$JP$JP
1584379713$15843797$13$F$20030619$20221128$20190118$20221202$EXP$$DE-MYLANLABS-2019M1003719$MYLAN$Ervens J, Schiffmann L, Berger G, Hoffmeister B, Kahrau S, Buhr HJ.. Colon perforation with acute peritonitis after taking clindamycin and diclofenac following wisdom tooth removal. Journal of Cranio-Maxillofacial Surgery. 2004;32 (5):330-34$16$YR$$F$Y$$$20221202$$MD$DE$DE
158441418$15844141$8$F$20181221$20221117$20190118$20221122$EXP$$PHHO2019US000743$NOVARTIS$$61$YR$$M$Y$96.4$KG$20221122$$MD$US$US
158452095$15845209$5$F$$20221008$20190119$20221019$EXP$RO-EMA-DD-20180403-DPRABHAKAR9P-153704$RO-Accord-102799$ACCORD$$49$YR$A$F$Y$$$20221019$$MD$RO$RO
1584655014$15846550$14$F$20181213$20221220$20190121$20221229$EXP$$CA-CELLTRION INC.-2018CA025160$CELLTRION$$$$$$Y$$$20221230$$CN$CA$CA
1584726314$15847263$14$F$20180613$20221221$20190121$20221227$EXP$$DE-ROCHE-2141062$ROCHE$$50$YR$$F$Y$49$KG$20221228$$CN$DE$DE
158475747$15847574$7$F$20220313$20221101$20190121$20221102$EXP$$CA-ROCHE-2223998$ROCHE$$36$YR$$F$Y$50$KG$20221102$$HP$CA$
1584759312$15847593$12$F$20180509$20221011$20190121$20221017$EXP$$DE-ROCHE-2245668$ROCHE$$44$YR$$F$Y$$$20221017$$CN$DE$
158482228$15848222$8$F$20180101$20221121$20190121$20221130$EXP$GB-EMA-DD-20190107-AGRAHARI_P-095431$GB-TORRENT-00020009$TORRENT$$18$YR$A$M$Y$$$20221130$$MD$GB$GB
158488753$15848875$3$F$20181101$20221109$20190121$20221114$EXP$$US-PFIZER INC-2019025991$PFIZER$$63$YR$$F$Y$$$20221114$$CN$US$US
158494226$15849422$6$F$$20221123$20190121$20221125$EXP$$CA-ABBVIE-19K-028-2633433-00$ABBVIE$$70$YR$$F$Y$$$20221125$$MD$CA$CA
158504833$15850483$3$F$$20221116$20190121$20221122$PER$$US-PFIZER INC-2019024010$PFIZER$$61$YR$$F$Y$64$KG$20221122$$CN$US$US
158508115$15850811$5$F$$20221129$20190121$20221204$PER$$US-AMGEN-USASP2019008012$AMGEN$$52$YR$A$F$Y$$$20221204$$MD$US$US
1585090610$15850906$10$F$20180903$20221004$20190121$20221007$EXP$$KR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-005082$BRISTOL MYERS SQUIBB$$51$YR$A$F$Y$$$20221007$$MD$KR$KR
1585160911$15851609$11$F$20180101$20221028$20190122$20221109$EXP$GB-EMA-DD-20190107-AGRAHARI_P-095431$GB-LUPIN PHARMACEUTICALS INC.-2019-00173$LUPIN$$18$YR$$M$Y$$$20221109$$MD$GB$GB
1585195910$15851959$10$F$20190101$20221202$20190122$20221206$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-004633$BRISTOL MYERS SQUIBB$$74$YR$E$M$Y$60$KG$20221206$$MD$JP$JP
158525805$15852580$5$F$20181217$20221121$20190122$20221123$EXP$$US-SA-2019SA000248$SANOFI AVENTIS$$45$YR$A$F$Y$$$20221123$$MD$US$US
158526105$15852610$5$F$$20221031$20190122$20221103$EXP$$GB-BAYER-2018-201114$BAYER$Keddie S, Bharambe V, Jayakumar A, Shah A, Sanchez V, Adams A.. Clinical perspectives into the use of thalidomide for central nervous system tuberculosis. Eur-J-Neurol. 2018;25(11):1345-51$37$YR$A$M$Y$$$20221103$$HP$GB$GB
158528074$15852807$4$F$20181228$20221019$20190122$20221101$EXP$$PHHY2019DE009445$NOVARTIS$$$$E$F$Y$$$20221101$$MD$DE$DE
158536378$15853637$8$F$20170420$20221212$20190122$20221219$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2018JPN167244$VIIV$$$$$$Y$$$20221214$$MD$JP$JP
1585368111$15853681$11$F$$20221205$20190122$20221212$PER$$US-PFIZER INC-2019027662$PFIZER$$57$YR$$M$Y$79.365$KG$20221212$$MD$US$US
1585544512$15855445$12$F$20190104$20200710$20190122$20221130$PER$$PHEH2019US002874$NOVARTIS$$16$YR$$F$Y$56.6$KG$20221130$$CN$US$US
158554937$15855493$7$F$20181213$20221017$20190122$20221024$EXP$$PHHY2019CA011031$NOVARTIS$$26$YR$$F$Y$$$20221024$$MD$CA$CA
1585637914$15856379$14$F$20180101$20221114$20190123$20221121$EXP$$CA-CELLTRION INC.-2017CA017652$CELLTRION$$$$$$Y$$$20221121$$MD$CA$CA
158566014$15856601$4$F$20181001$20221103$20190123$20221114$EXP$$CA-ROCHE-2249592$ROCHE$$16$YR$$F$Y$$$20221114$$MD$CA$CA
158569988$15856998$8$F$$20220927$20190123$20221001$EXP$$CA-ABBVIE-19K-028-2633351-00$ABBVIE$$$$$M$Y$$$20221001$$CN$CA$CA
158584387$15858438$7$F$$20221208$20190123$20221213$PER$$US-PFIZER INC-2019030150$PFIZER$$82$YR$$F$Y$$$20221213$$CN$US$US
158591563$15859156$3$F$$20221208$20190123$20221216$EXP$$CA-PFIZER INC-2017497021$PFIZER$$63$YR$$M$Y$$$20221216$$MD$CA$CA
158592333$15859233$3$F$$20221114$20190123$20221122$EXP$$US-JAZZ-2018-US-004739$JAZZ$$$$$F$Y$$$20221122$$CN$US$US
158592776$15859277$6$F$$20221004$20190123$20221006$PER$$US-PFIZER INC-2019023692$PFIZER$$68$YR$$F$Y$$$20221006$$MD$US$US
158601103$15860110$3$F$20181221$20221124$20190123$20221129$EXP$$CA-TAKEDA-2019TUS001737$TAKEDA$$69$YR$$M$Y$$$20221129$$MD$CA$CA
158602402$15860240$2$F$20171013$20221024$20190123$20221031$EXP$$CA-TAKEDA-2018TUS033474$TAKEDA$$72$YR$$M$Y$$$20221031$$CN$CA$CA
158605538$15860553$8$F$20180101$20221123$20190123$20221207$EXP$GB-EMA-DD-20190107-AGRAHARI_P-095431$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2019-00644$ALKEM$$18$YR$$M$Y$$$20221207$$CN$GB$GB
158616926$15861692$6$F$$20221107$20190124$20221114$EXP$$US-PFIZER INC-2019029995$PFIZER$$70$YR$$F$Y$77$KG$20221114$$CN$US$US
158639393$15863939$3$F$$20221205$20190124$20221214$EXP$$US-TEVA-2019-US-1001507$TEVA$$2$YR$C$$Y$$$20221214$$HP$US$US
1586455715$15864557$15$F$20180101$20221207$20190124$20221213$EXP$$PHHY2018CA018089$NOVARTIS$$53$YR$$F$Y$$$20221213$$MD$CA$CA
1586490614$15864906$14$F$20150416$20221129$20190124$20221202$EXP$$PHHY2015CA095399$NOVARTIS$$64$YR$$F$Y$$$20221202$$CN$CA$CA
1586559419$15865594$19$F$20190115$20221025$20190125$20221102$EXP$$CA-ROCHE-2249027$ROCHE$$43$YR$$F$Y$$$20221102$$CN$CA$
158656539$15865653$9$F$$20221128$20190125$20221202$EXP$$US-ROCHE-1853249$ROCHE$Andorsky D, Franson P, Mouro J, Li J, Foon K, and Sharman J MAGNIFY: A randomized, phase 3b trial in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) investigating lenalidomide plus rituximab (R2) induction followed by maintenance R2 followed by lenalidomide versus R2 induction.. Journal of Clinical Oncology 2014 May 20;32 (15 S1):-.$$$$$Y$$$20221202$$MD$US$
158659414$15865941$4$F$20180919$20220930$20190125$20221006$EXP$$US-BIOGEN-2019BI00687305$BIOGEN$$56$YR$$F$Y$$$20221006$$CN$US$US
1586636114$15866361$14$F$$20221011$20190125$20221013$EXP$$US-PFIZER INC-2019033104$PFIZER$$68$YR$$F$Y$63.05$KG$20221013$$CN$US$US
158666053$15866605$3$F$$20221018$20190125$20221028$EXP$$US-CIPLA LTD.-2019US00573$CIPLA$$63$YR$$F$Y$$$20221028$$CN$US$US
158671453$15867145$3$F$20170907$20221018$20190125$20221019$EXP$$PHHY2019DE011289$NOVARTIS$$$$E$F$Y$$$20221019$$MD$DE$DE
158673467$15867346$7$F$$20221208$20190125$20221215$EXP$$US-ROCHE-2121467$ROCHE$$77$YR$$M$Y$$$20221215$$MD$US$
158675623$15867562$3$F$20130319$20221005$20190125$20221006$PER$$US-PFIZER INC-2016584417$PFIZER$$61$YR$$F$Y$$$20221006$$LW$US$US
158678653$15867865$3$F$$20220929$20190125$20221003$EXP$$US-PFIZER INC-2019034004$PFIZER$$52$YR$$F$Y$$$20221003$$HP$US$US
158686647$15868664$7$F$20141217$20221107$20190125$20221109$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2017JPN176164$VIIV$$$$$$Y$$$20221109$$MD$JP$JP
158689257$15868925$7$F$20141217$20221107$20190125$20221109$EXP$$JP-GLAXOSMITHKLINE-JP2017JPN176164$GLAXOSMITHKLINE$$$$$$Y$$$20221109$$MD$JP$JP
1587120711$15871207$11$F$20180511$20221215$20190126$20221220$EXP$$CA-TAKEDA-2018TUS017088$TAKEDA$$50$YR$$M$Y$$$20221220$$HP$CA$CA
158712558$15871255$8$F$$20221025$20190126$20221028$EXP$$US-TAKEDA-2019TUS002375$TAKEDA$$$$$F$Y$$$20221028$$MD$US$US
158764883$15876488$3$F$20161126$20221226$20190126$20221231$EXP$$PHHY2019DE013014$NOVARTIS$$$$E$F$Y$$$20221231$$MD$DE$DE
1587757135$15877571$35$F$20180101$20221214$20190128$20221222$EXP$$CA-CELLTRION INC.-2018CA020979$CELLTRION$$$$$$Y$$$20221222$$CN$CA$CA
1587811431$15878114$31$F$20180424$20221006$20190128$20221018$EXP$$CA-CELLTRION INC.-2018CA019397$CELLTRION$$$$$$Y$$$20221018$$MD$CA$CA
158786996$15878699$6$F$20151001$20221024$20190128$20221025$PER$$US-PFIZER INC-2019036808$PFIZER$$54$YR$$F$Y$$$20221025$$LW$US$US
158809795$15880979$5$F$$20221101$20190128$20221104$EXP$$US-PFIZER INC-2019033383$PFIZER$$69$YR$$$Y$$$20221104$$CN$US$US
1588183011$15881830$11$F$20190301$20221017$20190128$20221214$EXP$$US-SA-2019SA021950$SANOFI AVENTIS$$49$YR$A$F$Y$$$20221214$$MD$US$US
158821212$15882121$2$F$20190125$20221018$20190128$20221026$PER$$US-BIOGEN-2019BI00689244$BIOGEN$$6$YR$$F$Y$$$20221026$$CN$US$US
158826155$15882615$5$F$20181218$20221021$20190129$20221026$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-117670$BRISTOL MYERS SQUIBB$$74$YR$E$M$Y$57.6$KG$20221026$$MD$JP$JP
1588478223$15884782$23$F$20190128$20221219$20190129$20221223$EXP$$CA-ROCHE-2255071$ROCHE$$49$YR$$M$Y$$$20221223$$MD$CA$
1588495332$15884953$32$F$20100610$20221214$20190129$20221219$EXP$$GB-MYLANLABS-2019M1007461$MYLAN$$1$DY$$M$Y$3.1$KG$20221219$$HP$GB$GB
158855405$15885540$5$F$20181218$20221212$20190129$20221216$EXP$$FR-PFIZER INC-2019033100$PFIZER$$73$YR$$F$Y$54$KG$20221216$$MD$FR$FR
158857222$15885722$2$F$$20221026$20190129$20221103$EXP$$US-MYLANLABS-2019M1008128$MYLAN$Hao D, Kiss G, Grubb W, Cohen S, Levin D, Sakr A. Spinal Cord Neuromodulation Therapy for Levofloxacin-Reinduced Complex Regional Pain Syndrome and Neurotoxicity: A Case Report. A-A-Pract 2018;11(6):158-159.$43$YR$$F$Y$$$20221103$$MD$US$US
158863864$15886386$4$F$20191002$20221121$20190129$20221128$EXP$$US-SHIRE-US201902774$TAKEDA$$55$YR$$M$Y$$$20221128$$HP$US$US
158868752$15886875$2$F$20180830$20221012$20190129$20221014$EXP$$FR-ROCHE-2252723$ROCHE$$42$YR$$F$Y$75$KG$20221014$$MD$FR$FR
1588698734$15886987$34$F$20180101$20221123$20190130$20221202$EXP$$CA-CELLTRION INC.-2019CA018248$CELLTRION$$$$$$Y$$$20221202$$CN$CA$CA
158879713$15887971$3$F$$20221116$20190130$20221118$EXP$$US-PFIZER INC-2019042071$PFIZER$$70$YR$$F$Y$$$20221118$$CN$US$US
158880726$15888072$6$F$20190328$20221024$20190130$20221028$EXP$$US-PFIZER INC-2019044419$PFIZER$$88$YR$$M$Y$$$20221028$$CN$US$US
1588865315$15888653$15$F$20161127$20221124$20190130$20221130$EXP$$PHHY2016CA164840$NOVARTIS$$72$YR$$M$Y$$$20221130$$CN$CA$CA
158891937$15889193$7$F$20181101$20221215$20190130$20221221$EXP$$JP-Eisai Medical Research-EC-2019-051004$EISAI$Fukumori T. A case of pneumothorax that required regimen change from lenvatinib to sorafenib in the patient with metastases to lung from papillary thyroid cancer. The 62nd Annual Meeting of the Japan Thyroid Association, Program and abstracts. 2019;88-88.$67$YR$E$F$Y$80$KG$20221221$$MD$JP$JP
158894382$15889438$2$F$$20221111$20190130$20221116$PER$$US-TAKEDA-2019TUS003190$TAKEDA$$$$$F$Y$117$KG$20221116$$CN$US$US
158894399$15889439$9$F$20140701$20221013$20190130$20221025$EXP$$CA-OTSUKA-2015_009670$OTSUKA$$1$DY$$M$Y$2$KG$20221025$$MD$CA$CA
158909065$15890906$5$F$20060525$20221006$20190130$20221007$EXP$PHHY2019FR020200$PHHY2019FR020200$NOVARTIS$Mesnage P. Death of a girl at clocheville city: parents complain. LA NOUVELLE REPUBLIQUE. 2016$19$MON$$F$Y$10$KG$20221007$$HP$FR$FR
158934353$15893435$3$F$$20221207$20190130$20221213$PER$$US-AMGEN-USASP2019014288$AMGEN$$61$YR$A$F$Y$$$20221213$$MD$US$US
1589386925$15893869$25$F$20181101$20221123$20190131$20221208$EXP$$GB-AUROBINDO-AUR-APL-2018-060127$AUROBINDO$$27$YR$$M$Y$$$20221208$$MD$GB$GB
1589405912$15894059$12$F$20180531$20221005$20190131$20221021$EXP$$JP-ABBVIE-18K-087-2380083-00$ABBVIE$$65$YR$$F$Y$32$KG$20221021$$CN$JP$JP
158946734$15894673$4$F$$20221227$20190131$20221229$EXP$$US-PFIZER INC-2019044974$PFIZER$$80$YR$$F$Y$$$20221229$$CN$US$US
1589471410$15894714$10$F$20190101$20221215$20190131$20221221$EXP$$US-PFIZER INC-2019037294$PFIZER$$56$YR$$F$Y$75.75$KG$20221221$$CN$US$US
158947614$15894761$4$F$$20221012$20190131$20221014$PER$$US-PFIZER INC-2019043539$PFIZER$$52$YR$$F$Y$$$20221014$$MD$US$US
1589585714$15895857$14$F$20180101$20221122$20190131$20221128$EXP$$US-PFIZER INC-2019045662$PFIZER$$64$YR$$F$Y$77$KG$20221128$$MD$US$US
1589634146$15896341$46$F$20140929$20221104$20190131$20221107$EXP$$PHHY2014CA129860$NOVARTIS$$59$YR$$F$Y$$$20221107$$CN$CA$CA
158964324$15896432$4$F$$20221107$20190131$20221114$EXP$$US-PFIZER INC-2019045021$PFIZER$$71$YR$$F$Y$$$20221114$$CN$US$US
158969133$15896913$3$F$$20221010$20190131$20221017$EXP$$CA-BAUSCH-BL-2019-002598$BAUSCH AND LOMB$$69$YR$$F$Y$$$20221017$$HP$CA$CA
158969512$15896951$2$F$$20190123$20190131$20221130$PER$$PHEH2019US004457$NOVARTIS$$$$$F$Y$$$20221130$$CN$US$US
158975643$15897564$3$F$20200123$20221010$20190131$20221014$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-007013$BRISTOL MYERS SQUIBB$$70$YR$E$F$Y$$$20221014$$CN$US$US
158990438$15899043$8$F$$20221118$20190201$20221125$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK016367$GLAXOSMITHKLINE$$$$$$Y$$$20221125$$MD$CA$CA
158992135$15899213$5$F$20171001$20221227$20190201$20221230$EXP$$US-JAZZ-2019-US-001351$JAZZ$$16$YR$$M$Y$$$20221230$$MD$US$US
158994804$15899480$4$F$20180909$20221104$20190201$20221106$EXP$$PL-ROCHE-2183410$ROCHE$$53$YR$$F$Y$58$KG$20221106$$MD$PL$
158996335$15899633$5$F$$20221101$20190201$20221103$PER$$US-PFIZER INC-2019047557$PFIZER$$73$YR$$F$Y$$$20221103$$MD$US$US
158997072$15899707$2$F$$20221222$20190201$20221227$PER$$US-PFIZER INC-2019047527$PFIZER$$67$YR$$F$Y$$$20221227$$MD$US$US
158997592$15899759$2$F$$20221011$20190201$20221012$PER$$US-PFIZER INC-2019048770$PFIZER$$$$$$Y$$$20221012$$LW$US$US
1589976910$15899769$10$F$$20221101$20190201$20221104$EXP$$US-PFIZER INC-2019045920$PFIZER$$65$YR$$F$Y$86$KG$20221104$$CN$US$US
159002488$15900248$8$F$20181001$20221228$20190201$20221229$EXP$$US-PFIZER INC-2019044281$PFIZER$$69$YR$$F$Y$60$KG$20221229$$CN$US$US
159010215$15901021$5$F$20171229$20221009$20190201$20221012$PER$$US-PFIZER INC-2019048285$PFIZER$$44$YR$$F$Y$96$KG$20221012$$LW$US$US
159025613$15902561$3$F$$20221201$20190201$20221205$EXP$$PHHY2013CA005793$NOVARTIS$$73$YR$$F$Y$$$20221205$$CN$CA$CA
159038396$15903839$6$F$20170101$20221202$20190203$20221206$EXP$$CO-ABBVIE-19K-036-2640767-00$ABBVIE$$$$$F$Y$53$KG$20221206$$CN$CO$CO
159042152$15904215$2$F$20180101$20221223$20190204$20221228$EXP$$BR-EMD Serono-9069317$EMD SERONO INC$$63$YR$A$M$Y$$$20221228$$CN$BR$
1590432711$15904327$11$F$20171110$20221107$20190204$20221108$EXP$$DE-ROCHE-2255094$ROCHE$$60$YR$$M$Y$86$KG$20221108$$MD$DE$
159044656$15904465$6$F$20160901$20221126$20190204$20221208$EXP$GB-EMA-DD-20180507-HJAINP-143207$GB-Accord-105268$ACCORD$$50$YR$A$F$Y$$$20221208$$MD$GB$
1590455823$15904558$23$F$20150420$20221002$20190204$20221012$EXP$GB-EMA-DD-20180425-NSINGHEVHP-174913$GB-Accord-105405$ACCORD$$46$YR$A$F$Y$$$20221012$$HP$GB$GB
1590487919$15904879$19$F$20190109$20221017$20190204$20221025$EXP$$CA-CELLTRION INC.-2019CA018518$CELLTRION$$$$$$Y$$$20221026$$MD$CA$CA
1590571121$15905711$21$F$20180718$20221208$20190204$20221215$EXP$$DE-ROCHE-2171334$ROCHE$$36$YR$$F$Y$$$20221215$$CN$DE$
159059872$15905987$2$F$20201221$20221221$20190204$20221226$EXP$$US-JAZZ-2019-US-000228$JAZZ$$55$YR$$M$Y$$$20221226$$CN$US$US
159069243$15906924$3$F$$20221221$20190204$20221227$PER$$US-PFIZER INC-2016570675$PFIZER$$35$YR$$M$Y$$$20221227$$MD$US$US
1590696012$15906960$12$F$20100601$20221219$20190204$20221227$PER$$US-PFIZER INC-2019051580$PFIZER$$71$YR$$M$Y$104$KG$20221227$$CN$US$US
159071307$15907130$7$F$20180928$20221214$20190204$20221222$PER$$US-PFIZER INC-2019041647$PFIZER$$71$YR$$F$Y$74$KG$20221222$$CN$US$US
159071415$15907141$5$F$$20221117$20190204$20221121$PER$$US-PFIZER INC-2019051400$PFIZER$$67$YR$$F$Y$$$20221121$$MD$US$US
159072609$15907260$9$F$20180101$20221101$20190204$20221103$PER$$US-PFIZER INC-2019046708$PFIZER$$72$YR$$F$Y$65.2$KG$20221103$$MD$US$US
1590726713$15907267$13$F$$20221130$20190204$20221206$PER$$US-PFIZER INC-2019045716$PFIZER$$72$YR$$F$Y$$$20221206$$CN$US$US
159074468$15907446$8$F$20221030$20221107$20190204$20221111$EXP$$US-PFIZER INC-2017037410$PFIZER$$72$YR$$F$Y$48$KG$20221111$$CN$US$US
159080003$15908000$3$F$20160623$20221215$20190204$20221223$EXP$$US-AstraZeneca-2018SF14979$ASTRAZENECA$$25447$DY$$F$Y$59$KG$20221223$$LW$US$
1591700318$15917003$18$F$$20221220$20190205$20221223$EXP$$US-ROCHE-2096482$ROCHE$$$$E$F$Y$$$20221223$$CN$US$
159178674$15917867$4$F$20181201$20221222$20190205$20221227$PER$$US-PFIZER INC-2019043884$PFIZER$$66$YR$$F$Y$127.01$KG$20221227$$CN$US$US
159189813$15918981$3$F$20190124$20200304$20190205$20221115$EXP$$JP-AMICUS-AMI_349AA$AMICUS THERAPEUTICS$$38$YR$$F$Y$41.4$KG$20221115$$MD$JP$JP
159206743$15920674$3$F$19940101$20190124$20190205$20221214$EXP$$PHHY2018FR193178$NOVARTIS$$$$$M$Y$$$20221214$$CN$FR$FR
1592093525$15920935$25$F$20181009$20221031$20190205$20221101$EXP$$PHHY2018CA125337$NOVARTIS$$65$YR$$M$Y$63$KG$20221101$$MD$CA$CA
1592227140$15922271$40$F$20140929$20221104$20190206$20221108$EXP$$CA-ROCHE-2257791$ROCHE$$59$YR$$F$Y$$$20221108$$CN$CA$CA
1592234848$15922348$48$F$20190129$20221209$20190206$20221219$EXP$$CA-CELLTRION INC.-2019CA018486$CELLTRION$$$$$$Y$$$20221219$$MD$CA$CA
1592487726$15924877$26$F$20181011$20221110$20190206$20221116$EXP$$NL-SA-2019SA029467$SANOFI AVENTIS$$33$YR$A$F$Y$68$KG$20221116$$HP$NL$NL
159254544$15925454$4$F$$20221116$20190206$20221121$PER$$US-PFIZER INC-2019053217$PFIZER$$40$YR$$F$Y$$$20221121$$MD$US$US
159255032$15925503$2$F$$20221115$20190206$20221117$PER$$US-PFIZER INC-2019046461$PFIZER$$65$YR$$F$Y$$$20221117$$CN$US$US
159287105$15928710$5$F$$20221031$20190206$20221102$EXP$$US-PFIZER INC-2017240362$PFIZER$$69$YR$$F$Y$$$20221102$$CN$US$US
159287133$15928713$3$F$20200521$20221102$20190206$20221107$EXP$$HR-ALEXION PHARMACEUTICALS INC.-A201901686$ALEXION$Galic S., Csuka D., Zoltan P., Turdic D., Dzepina P., Milosevic D. et al. A case report of a child with sepsis induced multiorgan failure and massive complement consumption treated with a short course of Eculizumab: A case of crosstalk between coagulation and complement?. Medicine. 2019$14$MON$$M$Y$$$20221107$$MD$HR$HR
159290448$15929044$8$F$20110918$20221121$20190206$20221124$EXP$$US-AstraZeneca-2018SF14599$ASTRAZENECA$$18042$DY$$M$Y$$$20221124$$LW$US$
159294585$15929458$5$F$20190108$20221024$20190206$20221031$EXP$$PHHY2019CA028476$NOVARTIS$$45$YR$$M$Y$$$20221031$$CN$CA$CA
159304075$15930407$5$F$$20221215$20190207$20221219$EXP$$CA-ABBVIE-19K-028-2655633-00$ABBVIE$$65$YR$$F$Y$$$20221219$$HP$CA$CA
1593073810$15930738$10$F$$20221123$20190207$20221206$EXP$$CA-ABBVIE-19K-028-2655654-00$ABBVIE$$70$YR$$F$Y$$$20221206$$CN$CA$CA
159315235$15931523$5$F$20140117$20221005$20190207$20221013$EXP$$US-AstraZeneca-2018SF14134$ASTRAZENECA$$19362$DY$$F$Y$86.2$KG$20221013$$LW$US$
1593204447$15932044$47$F$$20221124$20190207$20221206$EXP$$CA-ABBVIE-19K-028-2651975-00$ABBVIE$$44$YR$$F$Y$97$KG$20221206$$HP$CA$CA
159322162$15932216$2$F$$20221018$20190207$20221020$PER$$US-PFIZER INC-2019058301$PFIZER$$46$YR$$F$Y$$$20221020$$CN$US$US
159322522$15932252$2$F$$20221207$20190207$20221213$PER$$US-PFIZER INC-2019056001$PFIZER$$58$YR$$F$Y$$$20221213$$CN$US$US
159324556$15932455$6$F$20180914$20221205$20190207$20221205$EXP$$KR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-116846$BRISTOL MYERS SQUIBB$$47$YR$A$F$Y$42$KG$20221205$$MD$KR$KR
1593246013$15932460$13$F$20220711$20221208$20190207$20221212$EXP$$US-PFIZER INC-2019023402$PFIZER$$79$YR$$F$Y$68$KG$20221212$$CN$US$US
159328104$15932810$4$F$$20221101$20190207$20221104$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK019011$GLAXOSMITHKLINE$$$$$$Y$$$20221104$$MD$CA$CA
159330954$15933095$4$F$20181123$20221228$20190207$20221229$EXP$$US-KYOWAKIRIN-2019BKK000349$KYOWA$$$$$$Y$$$20221229$$HP$US$US
159336698$15933669$8$F$20140205$20221019$20190207$20221027$EXP$$CA-AstraZeneca-2019SE21320$ASTRAZENECA$$65$YR$$M$Y$88$KG$20221027$$MD$CA$
1593436814$15934368$14$F$$20220811$20190207$20221012$EXP$$CA-ABBVIE-19K-028-2655903-00$ABBVIE$$42$YR$$F$Y$$$20221012$$MD$CA$CA
159344215$15934421$5$F$20170301$20221219$20190207$20221227$EXP$$US-AstraZeneca-2018SF13721$ASTRAZENECA$$811$MON$$F$Y$95.3$KG$20221227$$LW$US$
159349005$15934900$5$F$20170301$20221220$20190207$20221224$EXP$$US-TAKEDA-2019TUS004555$TAKEDA$$$$$$Y$$$20221224$$CN$US$US
159355646$15935564$6$F$20180201$20221119$20190208$20221202$EXP$GB-EMA-DD-20180528-KHAREEVHP-094504$GB-Accord-105428$ACCORD$$72$YR$E$M$Y$93.2$KG$20221202$$MD$GB$GB
159359784$15935978$4$F$$20221109$20190208$20221114$EXP$$US-ROCHE-2064837$ROCHE$$$$E$M$Y$$$20221114$$MD$US$
159360672$15936067$2$F$20181209$20221201$20190208$20221216$EXP$$IT-AUROBINDO-AUR-APL-2019-006196$AUROBINDO$$48$YR$$F$Y$$$20221216$$PH$IT$IT
159361664$15936166$4$F$20181201$20221118$20190208$20221121$EXP$$US-TAKEDA-2019TUS004254$TAKEDA$$64$YR$$F$Y$86$KG$20221121$$MD$US$US
159369349$15936934$9$F$$20221130$20190208$20221206$EXP$$CA-Orion Corporation ORION PHARMA-TREX2019-0392$ORION$$18$YR$A$F$Y$70$KG$20221206$$HP$CA$
159390974$15939097$4$F$$20221018$20190208$20221020$PER$$US-PFIZER INC-2019056761$PFIZER$$73$YR$$F$Y$$$20221020$$CN$US$US
159395017$15939501$7$F$20050617$20221031$20190208$20221108$EXP$$US-AstraZeneca-2018SF22327$ASTRAZENECA$$12635$DY$$F$Y$65.8$KG$20221108$$LW$US$
159395718$15939571$8$F$20100607$20221103$20190208$20221109$EXP$$US-AstraZeneca-2018SF34894$ASTRAZENECA$$26734$DY$$F$Y$86.9$KG$20221109$$LW$US$
1593970210$15939702$10$F$$20221213$20190208$20221216$EXP$$CA-ABBVIE-19K-028-2658260-00$ABBVIE$$56$YR$$F$Y$$$20221216$$HP$CA$CA
159412963$15941296$3$F$20220327$20221018$20190208$20221020$EXP$$US-TAKEDA-2019TUS004693$TAKEDA$$$$$$Y$$$20221020$$CN$US$US
159415623$15941562$3$F$$20221206$20190208$20221214$EXP$$US-AstraZeneca-2018SF65590$ASTRAZENECA$$$$$F$Y$82.1$KG$20221214$$LW$US$
1594220112$15942201$12$F$20190124$20221222$20190210$20221230$EXP$$CA-CELLTRION INC.-2019CA018555$CELLTRION$$$$$$Y$$$20221231$$HP$CA$CA
159432492$15943249$2$F$20061215$20221003$20190210$20221013$PER$$US-JNJFOC-20190139844$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221013$$LW$US$US
159437587$15943758$7$F$$20221026$20190210$20221101$PER$$US-AMGEN-USASP2019021260$AMGEN$$74$YR$E$F$Y$$$20221101$$HP$US$US
1594435627$15944356$27$F$20181009$20221031$20190211$20221102$EXP$$CA-ROCHE-2260729$ROCHE$$65$YR$$M$Y$63$KG$20221102$$MD$CA$CA
159445364$15944536$4$F$20181101$20221209$20190211$20221219$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-010772$ACADIA PHARMACEUTICALS$$78$YR$$M$Y$$$20221219$$CN$US$US
159445673$15944567$3$F$20181114$20221220$20190211$20221229$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-010815$ACADIA PHARMACEUTICALS$$73$YR$$F$Y$$$20221230$$CN$US$US
159445863$15944586$3$F$20180101$20221026$20190211$20221103$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-010781$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221104$$MD$US$US
159446669$15944666$9$F$20180101$20221005$20190211$20221028$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-011075$ACADIA PHARMACEUTICALS$$77$YR$$F$Y$$$20221028$$CN$US$US
159447803$15944780$3$F$20181201$20221220$20190211$20221229$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-011244$ACADIA PHARMACEUTICALS$$80$YR$$M$Y$$$20221230$$CN$US$US
159451186$15945118$6$F$20180101$20221119$20190211$20221128$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-011301$ACADIA PHARMACEUTICALS$$$$$F$Y$64$KG$20221129$$CN$US$US
159451954$15945195$4$F$20181201$20221103$20190211$20221111$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-011452$ACADIA PHARMACEUTICALS$$70$YR$$F$Y$$$20221111$$CN$US$US
159452702$15945270$2$F$20180101$20220920$20190211$20221014$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2018-011238$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221014$$MD$US$US
159453457$15945345$7$F$20190115$20220927$20190211$20221007$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-011471$ACADIA PHARMACEUTICALS$$68$YR$$M$Y$$$20221007$$CN$US$US
159453603$15945360$3$F$20190101$20221004$20190211$20221027$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-011420$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221028$$CN$US$US
159453774$15945377$4$F$20190101$20221027$20190211$20221103$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-011540$ACADIA PHARMACEUTICALS$$82$YR$$M$Y$148$KG$20221104$$CN$US$US
1594640810$15946408$10$F$20190101$20221110$20190211$20221117$EXP$$PHHY2017CA178348$NOVARTIS$$40$YR$$F$Y$$$20221117$$CN$CA$CA
159466553$15946655$3$F$20180101$20221031$20190211$20221111$EXP$$CA-PFIZER INC-2018186127$PFIZER$$58$YR$$F$Y$$$20221111$$MD$CA$CA
159471692$15947169$2$F$$20221006$20190211$20221010$PER$$US-PFIZER INC-2019056983$PFIZER$$57$YR$$M$Y$$$20221010$$CN$US$US
159474513$15947451$3$F$20140701$20221004$20190211$20221012$EXP$$US-AstraZeneca-2019SE11630$ASTRAZENECA$$860$MON$$F$Y$81.6$KG$20221012$$LW$US$
159474673$15947467$3$F$$20221018$20190211$20221019$PER$$US-PFIZER INC-2019062481$PFIZER$$68$YR$$M$Y$$$20221019$$CN$US$US
159476332$15947633$2$F$20180830$20221007$20190212$20221019$EXP$$FR-AUROBINDO-AUR-APL-2019-007340$AUROBINDO$$42$YR$$F$Y$75$KG$20221019$$MD$FR$FR
159491894$15949189$4$F$20181218$20221010$20190211$20221017$EXP$$PHHY2019DE031938$NOVARTIS$$67$YR$$M$Y$$$20221017$$MD$DE$DE
1595024410$15950244$10$F$20180227$20221215$20190212$20221227$EXP$$PHHY2018CA036004$NOVARTIS$$45$YR$$M$Y$$$20221227$$CN$CA$CA
159504152$15950415$2$F$$20221021$20190212$20221029$EXP$$US-drreddys-USA/USA/19/0107617$DR REDDYS$Hao D, Sakr A, Kiss G, Grubb W, Cohen S, Levin D. Spinal Cord Neuromodulation Therapy for Levofloxacin-Reinduced Complex Regional Pain Syndrome and Neurotoxicity. A Case Report. A and A practice. 2018;11(6):158-59.$43$YR$A$F$Y$$$20221029$$MD$US$US
1595055014$15950550$14$F$$20221213$20190212$20221220$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK024159$GLAXOSMITHKLINE$$$$$$Y$$$20221220$$MD$CA$CA
159514875$15951487$5$F$20090801$20221206$20190211$20221214$EXP$$US-AstraZeneca-2018SF13962$ASTRAZENECA$$520$MON$$F$Y$123.4$KG$20221214$$LW$US$
159516556$15951655$6$F$20180101$20221227$20190211$20221230$EXP$$US-PFIZER INC-2019051083$PFIZER$$77$YR$$F$Y$$$20221230$$CN$US$US
159525482$15952548$2$F$20151001$20221021$20190211$20221025$PER$$US-TEVA-2019-US-1009232$TEVA$$54$YR$A$F$Y$$$20221025$$LW$US$US
159526005$15952600$5$F$20181127$20221111$20190212$20221115$PER$$US-PFIZER INC-2019059193$PFIZER$$70$YR$$F$Y$$$20221115$$CN$US$US
159530445$15953044$5$F$20190101$20221107$20190211$20221115$PER$$US-VERTEX PHARMACEUTICALS-2019-000292$VERTEX$$63$YR$$M$Y$$$20221115$$HP$US$US
159531949$15953194$9$F$20181124$20221114$20190212$20221121$EXP$$DE-ROCHE-2263565$ROCHE$$30$YR$$F$Y$55$KG$20221121$$MD$DE$
159539492$15953949$2$F$$20221117$20190213$20221201$EXP$$CZ-AUROBINDO-AUR-APL-2019-007158$AUROBINDO$Havrda M.. Patient with mild reductions in glomerular filtration.. POSTGRADUALNI MEDICINA.. 2017;4:392-398$77$YR$$M$Y$$$20221201$$MD$CZ$CZ
159540526$15954052$6$F$$20221208$20190212$20221214$EXP$$US-PFIZER INC-2019057924$PFIZER$$52$YR$$M$Y$79.38$KG$20221214$$CN$US$US
159542613$15954261$3$F$20180101$20220929$20190213$20221006$PER$$US-TAKEDA-2019TUS003781$TAKEDA$$$$$M$Y$$$20221006$$MD$US$US
1595475713$15954757$13$F$20181201$20221128$20190213$20221202$EXP$$CA-ROCHE-2260685$ROCHE$$48$YR$$M$Y$$$20221202$$CN$CA$
159551925$15955192$5$F$20221206$20221214$20190213$20221220$PER$$US-PFIZER INC-2018445667$PFIZER$$85$YR$$M$Y$$$20221220$$CN$US$US
159554179$15955417$9$F$20140101$20220922$20190213$20221003$EXP$$CA-CELLTRION INC.-2019CA018619$CELLTRION$$$$$$Y$$$20221003$$HP$CA$CA
159555302$15955530$2$F$20190201$20221109$20190213$20221118$PER$$FR-AMGEN-FRACT2019019978$AMGEN$$57$YR$A$M$Y$60$KG$20221118$$MD$FR$FR
159555982$15955598$2$F$20181101$20221031$20190213$20221102$EXP$DK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-012266$DK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-012266$BRISTOL MYERS SQUIBB$$70$YR$E$F$Y$$$20221102$$MD$DK$DK
159564239$15956423$9$F$$20221216$20190213$20221221$EXP$$US-PFIZER INC-2019060114$PFIZER$$66$YR$$M$Y$$$20221221$$CN$US$US
159572857$15957285$7$F$20181017$20221031$20190213$20221108$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-013302$BRISTOL MYERS SQUIBB$$63$YR$A$F$Y$63.3$KG$20221109$$MD$JP$JP
159575536$15957553$6$F$20120101$20221114$20190213$20221118$EXP$$US-AstraZeneca-2018SF64656$ASTRAZENECA$$68$YR$$F$Y$72.6$KG$20221118$$LW$US$
159587072$15958707$2$F$$20210909$20190213$20221008$PER$$US-PURDUE-USA-2018-0144894$PURDUE$$$$$F$Y$$$20221008$$CN$US$US
159589268$15958926$8$F$$20220930$20190214$20221013$EXP$$PT-AUROBINDO-AUR-APL-2019-004795$AUROBINDO$Oliveira.V, Chaves.J.. Seizure control with add-on eslicarbizepine in two patients with Dravet syndrome.. Epilepsia.. 2018;59 (3):S114-S115$20$YR$$M$Y$$$20221013$$HP$PT$PT
1595903812$15959038$12$F$20220501$20221020$20190214$20221022$EXP$$PHEH2019US006275$NOVARTIS$$59$YR$$F$Y$$$20221022$$CN$US$US
1595936920$15959369$20$F$20180822$20221229$20190214$20221230$EXP$$DE-ROCHE-2176591$ROCHE$$49$YR$$F$Y$78$KG$20221230$$MD$DE$DE
1595952219$15959522$19$F$20180118$20221118$20190214$20221130$EXP$GB-MHRA-ADR 24319901$GB-Accord-106227$ACCORD$$76$YR$E$M$Y$69$KG$20221130$$HP$GB$GB
159595763$15959576$3$F$$20221119$20190214$20221202$EXP$IT-EMA-DD-20180620-AJEVHP-124211$IT-Accord-107098$ACCORD$$64$YR$A$M$Y$$$20221202$$HP$IT$IT
159607842$15960784$2$F$$20221019$20190214$20221031$PER$$US-JNJFOC-20190139661$JOHNSON AND JOHNSON$$$$C$M$Y$$$20221031$$LW$US$US
159614532$15961453$2$F$20190207$20221013$20190214$20221021$PER$$US-VERTEX PHARMACEUTICALS-2019-001268$VERTEX$$22$YR$$M$Y$$$20221021$$CN$US$US
1596152511$15961525$11$F$20190123$20220929$20190214$20221004$EXP$$PHHY2019CA020132$NOVARTIS$$57$YR$$F$Y$$$20221004$$CN$CA$CA
159634005$15963400$5$F$20190208$20221117$20190214$20221121$EXP$$CA-ROCHE-2264621$ROCHE$$52$YR$$F$Y$$$20221121$$MD$CA$
159637575$15963757$5$F$20150409$20221208$20190214$20221216$EXP$$US-JAZZ-2019-US-002029$JAZZ$$45$YR$$F$Y$$$20221216$$HP$US$US
159637582$15963758$2$F$20190122$20221216$20190214$20221226$EXP$$JP-009507513-1901JPN002544J$MERCK$Ito K, Kondo Y, Takamizawa S, Enei Y, Imai Y, Inaba H, et al.. O09-5 Experience with pembrolizumab, avelumab and enfortumab vedotin for metastatic urothelial cancer in our hospital. The 72nd Annual Meeting of Central Section of Japanese Urological Association. 174$51$YR$$M$Y$$$20221226$$MD$JP$JP
1596485426$15964854$26$F$20180101$20221103$20190215$20221114$EXP$$CA-CELLTRION INC.-2018CA020850$CELLTRION$$$$$$Y$$$20221114$$CN$CA$CA
1596565212$15965652$12$F$20161101$20221201$20190215$20221207$EXP$$CA-TAKEDA-2016TUS023477$TAKEDA$$44$YR$$F$Y$$$20221207$$MD$CA$CA
159659292$15965929$2$F$$20221202$20190215$20221207$PER$$US-PFIZER INC-2019067131$PFIZER$$74$YR$$F$Y$$$20221207$$CN$US$US
159662344$15966234$4$F$20190121$20221215$20190215$20221226$EXP$GB-MHRA-EYC 00193692$GB-TEVA-2019-GB-1012051$TEVA$$56$YR$A$F$Y$80$KG$20221226$$MD$GB$GB
159665144$15966514$4$F$20150101$20221007$20190215$20221011$EXP$$US-TAKEDA-2019TUS005846$TAKEDA$$$$$$Y$$$20221011$$CN$US$US
159675832$15967583$2$F$20190204$20221018$20190215$20221025$EXP$$CA-JNJFOC-20190211538$JOHNSON AND JOHNSON$$60$YR$A$F$Y$$$20221026$$HP$CA$CA
159687172$15968717$2$F$$20221117$20190215$20221121$EXP$$US-PFIZER INC-2019064814$PFIZER$$52$YR$$M$Y$$$20221121$$HP$US$US
1596908511$15969085$11$F$20170215$20221024$20190215$20221103$EXP$$DE-JNJFOC-20190209453$JOHNSON AND JOHNSON$$65$YR$E$F$Y$$$20221103$$MD$DE$DE
159704505$15970450$5$F$20190201$20221214$20190215$20221220$EXP$$US-JAZZ-2019-US-002159$JAZZ$$45$YR$$F$Y$$$20221220$$HP$US$US
159706057$15970605$7$F$$20221017$20190215$20221021$EXP$$US-SHIRE-US201905184$TAKEDA$$$$$F$Y$252$KG$20221021$$MD$US$US
1597127116$15971271$16$F$20150427$20221017$20190215$20221020$EXP$$PHHY2015CA052243$NOVARTIS$$72$YR$$F$Y$$$20221020$$MD$CA$CA
159745186$15974518$6$F$20160608$20221128$20190218$20221130$EXP$$JP-GLAXOSMITHKLINE-JP2017JPN199483$GLAXOSMITHKLINE$$$$$$Y$$$20221130$$MD$JP$JP
159751773$15975177$3$F$20180831$20200630$20190218$20221020$PER$$US-CELLTRION INC.-2018US024167$CELLTRION$$$$$$Y$$$20221021$$MD$US$US
159753444$15975344$4$F$$20200103$20190218$20221012$PER$$US-CELLTRION INC.-2018US023755$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
159753503$15975350$3$F$20190114$20191007$20190218$20221012$PER$$US-CELLTRION INC.-2019US018068$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
159755504$15975550$4$F$20181022$20210831$20190218$20221020$PER$$US-CELLTRION INC.-2018US024750$CELLTRION$$$$$$Y$$$20221021$$HP$US$US
159758623$15975862$3$F$$20200217$20190218$20221021$PER$$US-CELLTRION INC.-2019US017563$CELLTRION$$$$$$Y$$$20221021$$MD$US$US
159759794$15975979$4$F$20220125$20221216$20190218$20221223$EXP$$PHHY2018CA055604$NOVARTIS$$57$YR$$M$Y$$$20221223$$MD$CA$CA
159761966$15976196$6$F$$20221115$20190218$20221117$PER$$US-PFIZER INC-2019060629$PFIZER$$77$YR$$F$Y$$$20221117$$MD$US$US
159762589$15976258$9$F$$20221114$20190218$20221116$EXP$$US-PFIZER INC-2019062245$PFIZER$$75$YR$$M$Y$108.8$KG$20221116$$CN$US$US
159762842$15976284$2$F$$20221007$20190218$20221010$PER$$US-PFIZER INC-2019070256$PFIZER$$$$$$Y$$$20221010$$LW$US$US
159763337$15976333$7$F$$20221226$20190218$20221228$PER$$US-PFIZER INC-2019069196$PFIZER$$67$YR$$F$Y$$$20221228$$MD$US$US
1597850810$15978508$10$F$$20221206$20190219$20221213$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-013850$BRISTOL MYERS SQUIBB$$40$YR$A$F$Y$$$20221213$$CN$CA$CA
1597990210$15979902$10$F$20190101$20221202$20190219$20221212$EXP$$CA-CELLTRION INC.-2019CA018765$CELLTRION$$$$$$Y$$$20221212$$MD$CA$CA
1598361115$15983611$15$F$20181122$20221216$20190220$20221222$EXP$$DE-ROCHE-2229092$ROCHE$$37$YR$$F$Y$$$20221222$$CN$DE$
159836132$15983613$2$F$20181231$20221202$20190220$20221216$EXP$$IT-AUROBINDO-AUR-APL-2019-008392$AUROBINDO$$59$YR$$F$Y$$$20221216$$PH$IT$IT
159875348$15987534$8$F$20150129$20221212$20190220$20221216$EXP$$US-PFIZER INC-2019073848$MYLAN$$71$YR$$M$Y$$$20221216$$CN$US$US
159875384$15987538$4$F$$20221101$20190220$20221104$EXP$$PHHY2019GB039534$NOVARTIS$$$$$M$Y$$$20221104$$CN$GB$GB
159877688$15987768$8$F$20150101$20221207$20190220$20221214$EXP$$US-PFIZER INC-2019063056$PFIZER$$72$YR$$F$Y$95$KG$20221214$$CN$US$US
1598864012$15988640$12$F$20190901$20221118$20190221$20221124$EXP$$CA-ROCHE-2264595$ROCHE$$31$YR$$F$Y$$$20221124$$HP$CA$
159886628$15988662$8$F$20150504$20221208$20190221$20221220$EXP$GB-EMA-DD-20180712-NGEVHPROD-123416$GB-Accord-108096$ACCORD$$79$YR$E$F$Y$$$20221220$$MD$GB$GB
159889195$15988919$5$F$20180419$20221114$20190221$20221116$EXP$$DE-ROCHE-2118102$ROCHE$$49$YR$$F$Y$58$KG$20221116$$CN$DE$DE
159894082$15989408$2$F$$20221219$20190221$20221229$EXP$$HR-TEVA-2019-HR-1014449$TEVA$$40$YR$A$F$Y$$$20221229$$HP$HR$HR
159894884$15989488$4$F$$20221214$20190221$20221222$PER$$US-PFIZER INC-2019068903$PFIZER$$49$YR$$F$Y$$$20221222$$CN$US$US
159899513$15989951$3$F$$20221201$20190221$20221205$PER$$US-PFIZER INC-2019068702$PFIZER$$65$YR$$F$Y$$$20221205$$CN$US$US
159918212$15991821$2$F$$20221130$20190221$20221202$EXP$$US-AstraZeneca-2019SE30118$ASTRAZENECA$$$$$$Y$$$20221202$$LW$US$
1599189735$15991897$35$F$20180101$20221019$20190221$20221028$EXP$$US-PFIZER INC-2019068478$PFIZER$$76$YR$$F$Y$70$KG$20221028$$MD$US$US
159921086$15992108$6$F$20130906$20221205$20190221$20221213$EXP$$US-AstraZeneca-2018SF21255$ASTRAZENECA$$20478$DY$$M$Y$93.9$KG$20221213$$LW$US$
159922338$15992233$8$F$20130103$20221121$20190221$20221124$EXP$$US-AstraZeneca-2018SF64674$ASTRAZENECA$$23922$DY$$F$Y$$$20221124$$LW$US$
159926774$15992677$4$F$20210810$20221012$20190221$20221018$EXP$$CA-SHIRE-CA201905659$TAKEDA$$69$YR$$F$Y$$$20221018$$CN$CA$CA
159927265$15992726$5$F$20171125$20221031$20190221$20221107$EXP$$DE-PFIZER INC-2018368006$PFIZER$$$$E$F$Y$$$20221107$$MD$DE$DE
159932814$15993281$4$F$20190208$20221006$20190222$20221013$EXP$$PHHY2019CA033482$NOVARTIS$$59$YR$$M$Y$$$20221013$$CN$CA$CA
1599388741$15993887$41$F$20190409$20221220$20190222$20221228$EXP$$CA-CELLTRION INC.-2019CA018843$CELLTRION$$$$$$Y$$$20221228$$HP$CA$CA
1599401615$15994016$15$F$20181122$20221129$20190222$20221206$EXP$$CA-TAKEDA-2018TUS033911$TAKEDA$$50$YR$$M$Y$$$20221206$$CN$CA$CA
1599420734$15994207$34$F$20180625$20221130$20190222$20221209$EXP$$CA-CELLTRION INC.-2018CA023873$CELLTRION$$$$$$Y$$$20221210$$MD$CA$CA
159944164$15994416$4$F$$20221026$20190222$20221031$PER$$US-BIOGEN-2019BI00684369$BIOGEN$$$$$F$Y$$$20221031$$CN$US$US
1599469214$15994692$14$F$20170127$20221021$20190222$20221102$EXP$$PHHY2017CA027401$NOVARTIS$$55$YR$$M$Y$$$20221102$$HP$CA$CA
1599493017$15994930$17$F$20181016$20210823$20190222$20221018$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106229$BRISTOL MYERS SQUIBB$$69$YR$E$M$Y$59.4$KG$20221018$$MD$JP$JP
1599554316$15995543$16$F$20180208$20220929$20190222$20221003$EXP$$PHHY2017CA111935$NOVARTIS$$50$YR$$F$Y$130$KG$20221003$$CN$CA$CA
159955622$15995562$2$F$$20221102$20190222$20221107$EXP$$CA-009507513-1902CAN008361$MERCK$$$$$$Y$$$20221107$$CN$CA$CA
159956853$15995685$3$F$20190215$20221005$20190222$20221010$PER$$US-SHIRE-US201906007$TAKEDA$$5$YR$$F$Y$20.5$KG$20221010$$HP$US$US
159971653$15997165$3$F$$20221227$20190222$20221230$PER$$US-BIOGEN-2019BI00700578$BIOGEN$$$$$F$Y$$$20221230$$CN$US$US
159973944$15997394$4$F$$20221205$20190222$20221212$EXP$$US-JAZZ-2019-US-002449$JAZZ$$$$$F$Y$$$20221212$$HP$US$US
159975536$15997553$6$F$20190206$20221012$20190222$20221020$PER$$DE-SEATTLE GENETICS-2019SGN00366$SEATTLE GENETICS$$$$A$F$Y$$$20221020$$MD$DE$DE
1599769314$15997693$14$F$$20221103$20190222$20221108$PER$$PHEH2019US007896$NOVARTIS$$$$$F$Y$$$20221109$$CN$US$US
159982947$15998294$7$F$20120101$20221115$20190223$20221118$EXP$$US-TAKEDA-2019TUS009185$TAKEDA$$$$$$Y$$$20221118$$CN$US$US
159993322$15999332$2$F$$20221107$20190225$20221110$PER$$US-PFIZER INC-2019078748$PFIZER$$55$YR$$F$Y$$$20221110$$HP$US$US
159994049$15999404$9$F$20190201$20221011$20190225$20221014$EXP$$US-PFIZER INC-2019079862$PFIZER$$66$YR$$F$Y$71.669$KG$20221014$$CN$US$US
159995126$15999512$6$F$20150901$20221114$20190225$20221115$EXP$$US-PFIZER INC-2019084697$PFIZER$$78$YR$$F$Y$$$20221115$$LW$US$US
159997725$15999772$5$F$$20221020$20190225$20221024$PER$$US-PFIZER INC-2019081408$PFIZER$$79$YR$$F$Y$$$20221024$$CN$US$US
1600061418$16000614$18$F$$20221207$20190225$20221213$EXP$$US-PFIZER INC-2019076848$PFIZER$$72$YR$$F$Y$68.04$KG$20221213$$CN$US$US
160009093$16000909$3$F$20170915$20221128$20190225$20221205$EXP$$PHHY2018FR125217$NOVARTIS$$74$YR$$F$Y$90$KG$20221205$$MD$FR$FR
160014366$16001436$6$F$20150626$20221109$20190225$20221121$EXP$$GB-ALLERGAN-1907036US$ALLERGAN$$$$$F$Y$$$20221121$$MD$GB$GB
160015707$16001570$7$F$20130101$20221219$20190225$20221228$EXP$$US-AstraZeneca-2018SF64993$ASTRAZENECA$$79$YR$$F$Y$68.9$KG$20221228$$LW$US$
160017018$16001701$8$F$$20221209$20190225$20221215$PER$$US-PFIZER INC-2019080617$PFIZER$$79$YR$$F$Y$$$20221215$$CN$US$US
1600238950$16002389$50$F$20190211$20221202$20190225$20221212$EXP$$CA-CELLTRION INC.-2019CA018940$CELLTRION$$$$$$Y$$$20221212$$CN$CA$CA
1600343831$16003438$31$F$20190101$20221201$20190226$20221210$EXP$$CA-CELLTRION INC.-2019CA018883$CELLTRION$$$$$$Y$$$20221210$$CN$CA$CA
160035425$16003542$5$F$$20221019$20190226$20221025$EXP$$CA-009507513-1902CAN008297$MERCK$$81$YR$$M$Y$$$20221025$$HP$CA$CA
160041793$16004179$3$F$$20221014$20190226$20221019$EXP$$CA-Orion Corporation ORION PHARMA-TREX2019-0531$ORION$$60$YR$A$M$Y$$$20221019$$HP$CA$
1600432210$16004322$10$F$20190101$20221205$20190226$20221213$EXP$$CA-ROCHE-2267315$ROCHE$$37$YR$$M$Y$$$20221213$$CN$CA$
160044346$16004434$6$F$20170101$20221101$20190226$20221107$EXP$$US-ROCHE-2269859$ROCHE$$37$YR$$F$Y$96.248$KG$20221107$$CN$US$
1600451521$16004515$21$F$20181201$20221110$20190226$20221118$EXP$$CA-ROCHE-2266633$ROCHE$$27$YR$$F$Y$$$20221118$$CN$CA$
1600523134$16005231$34$F$20030101$20221213$20190226$20221220$EXP$$US-PFIZER INC-2019073145$MYLAN$$$$$F$Y$81.65$KG$20221220$$CN$US$US
160070288$16007028$8$F$20151201$20221208$20190226$20221209$EXP$$PHHY2019GB041338$NOVARTIS$$69$YR$$F$Y$$$20221209$$MD$GB$GB
160072702$16007270$2$F$$20221102$20190226$20221109$EXP$$PHHY2019CA042484$NOVARTIS$$$$$$Y$$$20221109$$CN$CA$CA
160078756$16007875$6$F$$20221012$20190226$20221014$EXP$$JP-PFIZER INC-2019078250$PFIZER$$71$YR$$M$Y$$$20221014$$MD$JP$JP
160079023$16007902$3$F$20170621$20221117$20190226$20221122$EXP$$PHHY2019GB043007$NOVARTIS$$$$A$F$Y$109$KG$20221122$$HP$GB$GB
160083884$16008388$4$F$20180901$20221004$20190225$20221006$PER$$US-BIOGEN-2019BI00699921$BIOGEN$$60$YR$$F$Y$$$20221006$$CN$US$US
160101374$16010137$4$F$20190201$20221124$20190227$20221219$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-011926$ACADIA PHARMACEUTICALS$$68$YR$$M$Y$$$20221219$$CN$US$US
1601045627$16010456$27$F$20190308$20221124$20190227$20221202$EXP$$CA-CELLTRION INC.-2019CA018945$CELLTRION$$$$$$Y$$$20221202$$MD$CA$CA
160105984$16010598$4$F$20130222$20221212$20190225$20221216$PER$$US-PFIZER INC-2018512353$PFIZER$$51$YR$$F$Y$77$KG$20221216$$LW$US$US
160108218$16010821$8$F$20190206$20221207$20190227$20221215$EXP$$CA-ROCHE-2262889$ROCHE$$43$YR$$M$Y$$$20221215$$HP$CA$
160110577$16011057$7$F$20180208$20221130$20190227$20221207$EXP$$JP-ABBVIE-19P-087-2682524-00$ABBVIE$$46$YR$$M$Y$$$20221207$$MD$JP$JP
160113894$16011389$4$F$20161115$20221031$20190227$20221107$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-106401$BRISTOL MYERS SQUIBB$$48$YR$A$F$Y$76$KG$20221107$$HP$JP$JP
1601147010$16011470$10$F$20181225$20221213$20190227$20221227$PER$$JP-AMGEN-JPNSP2019028422$AMGEN$$76$YR$E$F$Y$39.1$KG$20221227$$MD$JP$JP
1601179918$16011799$18$F$20190320$20221212$20190227$20221219$EXP$$PHHY2019CA031716$NOVARTIS$$75$YR$$F$Y$$$20221219$$MD$CA$CA
160128292$16012829$2$F$$20221027$20190227$20221103$EXP$$PHHY2018CA197655$NOVARTIS$$$$$M$Y$$$20221103$$CN$CA$CA
160129029$16012902$9$F$20190217$20221017$20190227$20221020$EXP$$PHHY2019CA041355$NOVARTIS$$71$YR$$F$Y$$$20221020$$MD$CA$CA
160129135$16012913$5$F$20190201$20221109$20190227$20221115$EXP$$US-ROCHE-2159435$ROCHE$$70$YR$$F$Y$68.1$KG$20221115$$CN$US$
160142925$16014292$5$F$20220101$20221220$20190227$20221220$EXP$$US-PFIZER INC-2019014029$PFIZER$$59$YR$$M$Y$$$20221220$$CN$US$US
1601437014$16014370$14$F$20160323$20221007$20190227$20221010$EXP$$PHHY2019GB041230$NOVARTIS$$78$YR$$F$Y$$$20221010$$HP$GB$GB
160145314$16014531$4$F$20050101$20221121$20190227$20221123$EXP$$US-TAKEDA-2019TUS010410$TAKEDA$$$$$$Y$$$20221123$$CN$US$US
160149136$16014913$6$F$$20190915$20190227$20221210$EXP$$CA-TEVA-2019-CA-1016206$TEVA$$45$YR$A$F$Y$$$20221210$$HP$CA$CA
160153027$16015302$7$F$20180501$20221114$20190228$20221122$EXP$$DE-ROCHE-2130664$ROCHE$$54$YR$$F$Y$$$20221122$$CN$DE$
160154293$16015429$3$F$20190201$20221109$20190228$20221114$PER$$US-BIOGEN-2019BI00701472$BIOGEN$$49$YR$$F$Y$$$20221114$$CN$US$US
1601550526$16015505$26$F$20161025$20221201$20190228$20221210$EXP$$CA-CELLTRION INC.-2017CA001884$CELLTRION$$$$$$Y$$$20221210$$CN$CA$CA
160164342$16016434$2$F$20221201$20221205$20190228$20221216$PER$$US-ELI_LILLY_AND_COMPANY-US201902012588$ELI LILLY AND CO$$73$YR$$M$Y$$$20221216$$CN$US$US
1601673411$16016734$11$F$20190215$20221012$20190228$20221024$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019378$BRISTOL MYERS SQUIBB$$74$YR$E$M$Y$86$KG$20221024$$MD$JP$JP
160168559$16016855$9$F$20180701$20221208$20190228$20221215$PER$$US-PFIZER INC-2019087019$PFIZER$$81$YR$$F$Y$$$20221215$$CN$US$US
160168725$16016872$5$F$$20221213$20190228$20221219$PER$$US-PFIZER INC-2019084029$PFIZER$$61$YR$$M$Y$$$20221219$$CN$US$US
160174877$16017487$7$F$20211118$20221103$20190228$20221110$EXP$$PHHY2019AR043082$NOVARTIS$$53$YR$$M$Y$$$20221110$$CN$AR$AR
160184015$16018401$5$F$20130103$20221121$20190228$20221123$EXP$$US-TAKEDA-2019TUS010672$TAKEDA$$$$$$Y$$$20221123$$CN$US$US
160187038$16018703$8$F$20120101$20221115$20190228$20221122$EXP$$US-GLAXOSMITHKLINE-US2019GSK035582$PERRIGO$$$$$$Y$$$20221122$$CN$US$US
160187685$16018768$5$F$20140101$20221102$20190228$20221104$EXP$$US-AstraZeneca-2018SF26233$ASTRAZENECA$$90$YR$$F$Y$47.6$KG$20221104$$LW$US$
1602019719$16020197$19$F$20170928$20221122$20190228$20221130$EXP$$CA-CELLTRION INC.-2017CA013511$CELLTRION$$$$$$Y$$$20221201$$CN$CA$CA
1602044718$16020447$18$F$$20221128$20190301$20221212$EXP$$GB-AUROBINDO-AUR-APL-2019-010130$AUROBINDO$$$$A$M$Y$$$20221212$$HP$GB$GB
160208228$16020822$8$F$20190219$20221216$20190301$20221229$EXP$$JP-GLAXOSMITHKLINE-JP2019JPN034033$GLAXOSMITHKLINE$$$$$$Y$$$20221229$$MD$JP$JP
1602083530$16020835$30$F$20150918$20221221$20190301$20221229$EXP$$CA-CELLTRION INC.-2018CA021661$CELLTRION$$$$$$Y$$$20221230$$HP$CA$CA
160214209$16021420$9$F$20160101$20221201$20190301$20221212$PER$$GB-AMGEN-GBRSP2019029352$AMGEN$$60$YR$A$F$Y$$$20221211$$HP$GB$GB
160220402$16022040$2$F$20040506$20221013$20190301$20221021$EXP$$CA-JNJFOC-20190240880$JOHNSON AND JOHNSON$$23$YR$A$F$Y$$$20221021$$PH$CA$CA
1602253014$16022530$14$F$$20221130$20190301$20221216$EXP$$CA-AUROBINDO-AUR-APL-2019-009916$AUROBINDO$$40$YR$$M$Y$$$20221216$$HP$CA$CA
1602399610$16023996$10$F$$20221121$20190301$20221205$EXP$$US-GLAXOSMITHKLINE-US2019GSK037390$PERRIGO$$$$$$Y$$$20221205$$CN$US$US
160250537$16025053$7$F$20190222$20221115$20190301$20221122$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-020938$BRISTOL MYERS SQUIBB$$84$YR$E$M$Y$48$KG$20221122$$HP$US$US
160268442$16026844$2$F$20040421$20221013$20190303$20221021$EXP$$CA-JNJFOC-20190241512$JOHNSON AND JOHNSON$$79$YR$E$M$Y$$$20221021$$PH$CA$CA
160277714$16027771$4$F$20190201$20221216$20190304$20221226$EXP$$JP-009507513-1902JPN002445J$MERCK$Ito K, Kondo Y, Takamizawa S, Enei Y, Imai Y, Inaba H, et al.. O09-5 Experience with pembrolizumab, avelumab and enfortumab vedotin for metastatic urothelial cancer in our hospital. The 72nd Annual Meeting of Central Section of Japanese Urological Association. 174$64$YR$$M$Y$$$20221226$$MD$JP$JP
160285436$16028543$6$F$20190101$20221221$20190304$20221226$EXP$$DE-ROCHE-2271569$ROCHE$$45$YR$$F$Y$$$20221226$$CN$DE$
1602866112$16028661$12$F$20190201$20221227$20190304$20221229$EXP$$CA-TAKEDA-2018TUS030643$TAKEDA$$28$YR$$F$Y$$$20221229$$HP$CA$CA
160296667$16029666$7$F$20190204$20221019$20190304$20221027$EXP$$CA-ROCHE-2178920$ROCHE$$51$YR$$F$Y$89$KG$20221028$$HP$CA$
1602989912$16029899$12$F$20170626$20221114$20190304$20221118$EXP$$PHHY2017CA091565$NOVARTIS$$46$YR$$M$Y$$$20221118$$CN$CA$CA
160302417$16030241$7$F$$20221006$20190304$20221013$EXP$$US-GLAXOSMITHKLINE-US2019GSK037544$PERRIGO$$$$$F$Y$133.56$KG$20221013$$CN$US$US
160332452$16033245$2$F$20040626$20221013$20190305$20221019$EXP$$CA-JNJFOC-20190242040$JOHNSON AND JOHNSON$$18$YR$A$F$Y$$$20221019$$PH$CA$CA
160332502$16033250$2$F$20040722$20221013$20190305$20221020$EXP$$CA-JNJFOC-20190241656$JOHNSON AND JOHNSON$$19$YR$A$M$Y$73$KG$20221020$$HP$CA$CA
160337453$16033745$3$F$20040604$20221013$20190305$20221020$EXP$$CA-JNJFOC-20190300155$JOHNSON AND JOHNSON$$15$YR$T$F$Y$$$20221020$$HP$CA$CA
160344374$16034437$4$F$$20221222$20190305$20221227$EXP$$US-PFIZER INC-2019091886$PFIZER$$55$YR$$F$Y$$$20221227$$CN$US$US
160344904$16034490$4$F$$20221003$20190305$20221005$PER$$US-PFIZER INC-2019082934$PFIZER$$62$YR$$F$Y$$$20221005$$MD$US$US
160347906$16034790$6$F$20180130$20221111$20190305$20221119$EXP$$JP-ABBVIE-19P-087-2691159-00$ABBVIE$$45$YR$$M$Y$$$20221119$$MD$JP$JP
160356605$16035660$5$F$$20221222$20190305$20221230$EXP$$US-PFIZER INC-2019091701$PFIZER$$67$YR$$F$Y$$$20221230$$CN$US$US
160380504$16038050$4$F$$20221214$20190305$20221220$EXP$$US-AstraZeneca-2018SF27075$ASTRAZENECA$$$$$M$Y$68$KG$20221216$$LW$US$
1603895034$16038950$34$F$$20221010$20190306$20221128$EXP$$CA-ABBVIE-19K-028-2688707-00$ABBVIE$$$$E$F$Y$$$20221128$$HP$CA$CA
160390097$16039009$7$F$20150416$20221108$20190306$20221110$EXP$$PHHY2019GB042527$NOVARTIS$$65$YR$$F$Y$$$20221110$$MD$GB$GB
160394882$16039488$2$F$20040312$20221013$20190306$20221021$EXP$$CA-JNJFOC-20190240539$JOHNSON AND JOHNSON$$19$YR$A$F$Y$64$KG$20221021$$PH$CA$CA
160395322$16039532$2$F$20031126$20221013$20190306$20221024$EXP$$CA-JNJFOC-20190240118$JOHNSON AND JOHNSON$$12$YR$T$F$Y$$$20221024$$HP$CA$CA
160395752$16039575$2$F$20040511$20221013$20190306$20221024$EXP$$CA-JNJFOC-20190241401$JOHNSON AND JOHNSON$$15$YR$T$F$Y$50$KG$20221024$$HP$CA$CA
160402805$16040280$5$F$$20221122$20190306$20221201$EXP$$US-ROCHE-2277083$ROCHE$O^Connell C, Kropf P, Punwani N, Rogers D, Sposto R and Gronbaek K Phase I results of a multicenter clinical trial combining guadecitabine, a DNA methyltransferase inhibitor, with atezolizumab, an immune checkpoint inhibitor, in patients with relapsed or refractory myelodysplastic syndrome or chronic myelomonocytic. Blood 2018 Nov;132 (SUP1):1811-.$$$$$Y$$$20221201$$HP$US$
160402932$16040293$2$F$20040718$20221013$20190306$20221024$EXP$$CA-JNJFOC-20190241868$JOHNSON AND JOHNSON$$16$YR$T$F$Y$$$20221024$$PH$CA$CA
160403933$16040393$3$F$20180301$20221227$20190306$20221228$EXP$DK-DKMA-WBS-0021594$DK-B.I. Pharmaceuticals,Inc./Ridgefield-2019-12-000768$BOEHRINGER INGELHEIM$$44$YR$A$M$Y$97$KG$20221228$$MD$DK$DK
160404049$16040404$9$F$20180920$20221102$20190306$20221109$EXP$$JP-ABBVIE-18P-087-2565882-00$ABBVIE$$66$YR$$M$Y$61.3$KG$20221109$$MD$JP$JP
1604092912$16040929$12$F$20190220$20221206$20190306$20221212$EXP$$PHHY2019CA049894$NOVARTIS$$52$YR$$F$Y$$$20221212$$MD$CA$CA
160421894$16042189$4$F$20170101$20221208$20190306$20221213$EXP$$ES-SA-2019SA060107$SANOFI AVENTIS$Martin Garcia C, Sierra Pacho M, Moreno Rodilla E, Callejo Melgosa AM, Martinez Alonso JC, Fernandez Colino T, et al.. Successful Bendamustine Desensitization for a Delayed-Type Hypersensitivity Reaction.. J Investig Allergol Clin Immunol.. 2019;29(1):68-9$28$YR$A$M$Y$$$20221213$$HP$ES$ES
1604225720$16042257$20$F$20180731$20220317$20190306$20221216$EXP$$DE-ROCHE-2248869$ROCHE$$42$YR$$F$Y$50$KG$20221216$$MD$DE$
160428402$16042840$2$F$20040526$20221013$20190306$20221024$EXP$$CA-JNJFOC-20190240453$JOHNSON AND JOHNSON$$51$YR$A$F$Y$91$KG$20221024$$HP$CA$CA
1604332615$16043326$15$F$20190107$20221214$20190306$20221222$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-022282$BRISTOL MYERS SQUIBB$$76$YR$E$M$Y$$$20221222$$MD$JP$JP
160433492$16043349$2$F$$20200922$20190306$20221018$EXP$$US-JNJFOC-20190240641$JOHNSON AND JOHNSON$$$$$$Y$$$20221018$$CN$US$US
160446964$16044696$4$F$20181215$20221123$20190306$20221129$EXP$$PHHY2018CA195232$NOVARTIS$$46$YR$$F$Y$$$20221129$$CN$CA$CA
160449062$16044906$2$F$20040621$20221013$20190307$20221020$EXP$$CA-JNJFOC-20190240730$JOHNSON AND JOHNSON$$20$YR$A$M$Y$$$20221020$$HP$CA$CA
1604571911$16045719$11$F$20160101$20221115$20190307$20221117$EXP$$CA-ROCHE-1551878$ROCHE$$$$$F$Y$52$KG$20221117$$HP$CA$
1604592527$16045925$27$F$20190311$20220929$20190307$20221010$EXP$$CA-CELLTRION INC.-2019CA019169$CELLTRION$$$$$$Y$$$20221010$$CN$CA$CA
1604629612$16046296$12$F$20170803$20221002$20190307$20221004$EXP$$CA-TAKEDA-2019TUS011597$TAKEDA$$40$YR$$M$Y$$$20221004$$CN$CA$CA
160463722$16046372$2$F$19990101$20221013$20190307$20221021$EXP$$CA-JNJFOC-20190300746$JOHNSON AND JOHNSON$$$$$M$Y$$$20221021$$CN$CA$CA
160465444$16046544$4$F$$20221128$20190307$20221206$EXP$$PHEH2019US010117$NOVARTIS$$$$$M$Y$$$20221206$$CN$US$US
1604665310$16046653$10$F$20190301$20221128$20190307$20221205$EXP$$DE-ROCHE-2278394$ROCHE$$58$YR$$F$Y$53$KG$20221205$$CN$DE$
160468088$16046808$8$F$20180901$20221101$20190307$20221103$EXP$$US-PFIZER INC-2019091417$PFIZER$$67$YR$$M$Y$90$KG$20221103$$CN$US$US
160476884$16047688$4$F$$20221122$20190307$20221124$EXP$$US-PFIZER INC-2019098521$PFIZER$$62$YR$$F$Y$$$20221124$$CN$US$US
160480762$16048076$2$F$20040506$20221013$20190307$20221024$EXP$$CA-JNJFOC-20190241897$JOHNSON AND JOHNSON$$17$YR$T$F$Y$$$20221024$$PH$CA$CA
160480936$16048093$6$F$$20221117$20190307$20221122$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK041244$GLAXOSMITHKLINE$$$$$$Y$$$20221122$$MD$CA$CA
160482957$16048295$7$F$$20221117$20190307$20221121$EXP$$US-PFIZER INC-2019100655$PFIZER$$80$YR$$F$Y$$$20221121$$CN$US$US
160485123$16048512$3$F$20150101$20221109$20190307$20221117$EXP$$US-AstraZeneca-2019SE36610$ASTRAZENECA$$89$YR$$F$Y$49.9$KG$20221117$$LW$US$
160486673$16048667$3$F$20201019$20221206$20190307$20221212$PER$$US-SA-2019SA062757$SANOFI AVENTIS$$48$YR$A$F$Y$$$20221212$$MD$US$US
160488194$16048819$4$F$20180330$20221207$20190307$20221213$EXP$$PHJP2019JP002665$NOVARTIS$$70$YR$$M$Y$62.3$KG$20221213$$MD$JP$JP
160496882$16049688$2$F$$20221216$20190307$20221221$EXP$$US-BIOGEN-2019BI00705192$BIOGEN$$$$$M$Y$$$20221221$$CN$US$US
160501722$16050172$2$F$20040609$20221013$20190308$20221025$EXP$$CA-JNJFOC-20190241877$JOHNSON AND JOHNSON$$20$YR$A$F$Y$$$20221025$$HP$CA$CA
160502683$16050268$3$F$20140801$20221011$20190308$20221022$EXP$$FR-AUROBINDO-AUR-APL-2017-36721$AUROBINDO$Bodard Q, Litrowski N, Carre D, Midhat M, Chenal P, Bravard P. Mycosis fungoides in a heart transplant recipient. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE. 2017;144(10):624-8$68$YR$$M$Y$$$20221022$$MD$FR$FR
160505912$16050591$2$F$20040717$20221013$20190308$20221021$EXP$$CA-JNJFOC-20190300412$JOHNSON AND JOHNSON$$15$YR$T$F$Y$$$20221021$$PH$CA$CA
1605090410$16050904$10$F$20160101$20221220$20190308$20221229$PER$$US-PFIZER INC-2019100565$PFIZER$$58$YR$$F$Y$$$20221229$$MD$US$US
160509852$16050985$2$F$20181226$20220706$20190308$20221220$EXP$$US-ROCHE-2242265$ROCHE$$64$YR$$F$Y$76$KG$20221220$$MD$US$
160522753$16052275$3$F$$20221207$20190308$20221208$EXP$$US-PFIZER INC-2019101468$PFIZER$$$$A$M$Y$79$KG$20221208$$LW$US$US
1605411411$16054114$11$F$$20221028$20190308$20221111$EXP$$CA-Ascend Therapeutics-2063780$ASCEND$Patient no : UNKNOWN Study identification for EudraCT:$60$YR$$F$Y$$$20221111$$HP$CA$CA
1605439221$16054392$21$F$20181018$20221124$20190309$20221202$EXP$$CA-CELLTRION INC.-2017CA017541$CELLTRION$$$$$$Y$$$20221202$$HP$CA$CA
160548492$16054849$2$F$20040225$20221013$20190310$20221019$EXP$$CA-JNJFOC-20190240199$JOHNSON AND JOHNSON$$11$YR$C$F$Y$$$20221019$$PH$CA$CA
160548502$16054850$2$F$20040614$20221013$20190310$20221020$EXP$$CA-JNJFOC-20190240604$JOHNSON AND JOHNSON$$18$YR$A$M$Y$$$20221020$$PH$CA$CA
160552406$16055240$6$F$20190301$20221109$20190311$20221115$EXP$$CA-ROCHE-2278210$ROCHE$$52$YR$$F$Y$$$20221115$$CN$CA$
1605668314$16056683$14$F$20181201$20221216$20190311$20221221$EXP$$PHHY2018CA123301$NOVARTIS$$45$YR$$F$Y$$$20221221$$MD$CA$CA
160567956$16056795$6$F$20190306$20221219$20190311$20221224$EXP$$PHHY2019IN051428$NOVARTIS$$38$YR$$F$Y$$$20221224$$CN$IN$IN
1605784312$16057843$12$F$20150721$20221109$20190311$20221114$EXP$$GB-PFIZER INC-2019098055$PFIZER$$75$YR$$F$Y$$$20221114$$MD$GB$GB
1605863114$16058631$14$F$20190101$20221006$20190311$20221011$EXP$$CA-TAKEDA-2019TUS012325$TAKEDA$$44$YR$$F$Y$$$20221011$$CN$CA$CA
160589306$16058930$6$F$20190215$20221010$20190311$20221012$PER$$US-PFIZER INC-2016445366$PFIZER$$20$YR$$M$Y$$$20221012$$HP$US$US
160595924$16059592$4$F$20190301$20221007$20190311$20221011$EXP$$US-SHIRE-US201907648$TAKEDA$$73$YR$$F$Y$$$20221011$$HP$US$US
1605982514$16059825$14$F$20190319$20221012$20190311$20221021$EXP$$CA-CELLTRION INC.-2019CA019149$CELLTRION$$$$$$Y$$$20221021$$MD$CA$CA
160599827$16059982$7$F$20190218$20221206$20190312$20221215$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-012101$ACADIA PHARMACEUTICALS$$76$YR$$F$Y$$$20221216$$CN$US$US
160600273$16060027$3$F$20190101$20221107$20190312$20221117$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-012108$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221117$$CN$US$US
1606074339$16060743$39$F$20180129$20221219$20190312$20221227$EXP$$CA-CELLTRION INC.-2018CA017918$CELLTRION$$$$$$Y$$$20221227$$CN$CA$CA
160616299$16061629$9$F$$20221219$20190312$20221229$PER$$US-PFIZER INC-2019103205$PFIZER$$81$YR$$F$Y$$$20221229$$CN$US$US
160617196$16061719$6$F$20190301$20221227$20190312$20221229$EXP$$US-PFIZER INC-2019102089$PFIZER$$68$YR$$F$Y$$$20221229$$CN$US$US
1606179111$16061791$11$F$$20221006$20190312$20221010$PER$$US-PFIZER INC-2019080339$PFIZER$$65$YR$$F$Y$$$20221010$$MD$US$US
1606205714$16062057$14$F$20181224$20221026$20190312$20221102$EXP$$DE-ROCHE-2278493$ROCHE$$$$A$F$Y$$$20221102$$CN$DE$
160631272$16063127$2$F$$20221213$20190312$20221220$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-009871$BOEHRINGER INGELHEIM$$75$YR$E$M$Y$$$20221220$$MD$CA$CA
1606318517$16063185$17$F$20190127$20221129$20190312$20221202$EXP$$AU-SA-2019SA065102$SANOFI AVENTIS$$23$YR$A$F$Y$50$KG$20221202$$HP$AU$AU
160632672$16063267$2$F$20170715$20221018$20190312$20221020$EXP$$DE-MYLANLABS-2019M1021636$MYLAN$$$$A$F$Y$$$20221020$$MD$DE$DE
160632712$16063271$2$F$20171029$20221021$20190312$20221031$EXP$$DE-MYLANLABS-2019M1021596$MYLAN$$$$A$F$Y$$$20221031$$MD$DE$DE
160635162$16063516$2$F$$20221025$20190312$20221104$EXP$GB-MHRA-MIDB-53BA12AF-5BF1-4A35-A156-D63B22C3399A$GB-TEVA-2019-GB-1022066$TEVA$$50$YR$A$M$Y$$$20221104$$PH$GB$GB
160641903$16064190$3$F$20161115$20221011$20190312$20221021$EXP$$DE-MYLANLABS-2019M1022423$MYLAN$$$$E$F$Y$$$20221021$$MD$DE$DE
1606610518$16066105$18$F$20220622$20221207$20190313$20221213$EXP$$CA-TAKEDA-2019TUS013355$TAKEDA$$68$YR$$F$Y$$$20221213$$HP$CA$CA
160663238$16066323$8$F$$20221205$20190313$20221208$EXP$$US-PFIZER INC-2019100680$PFIZER$$68$YR$$F$Y$$$20221208$$CN$US$US
160669395$16066939$5$F$$20221226$20190313$20221229$EXP$$PT-MYLANLABS-2019M1022795$MYLAN$Coutinho F, Horta M, Rocha E, Vasconcelos C, Araujo A. Merkel cell carcinoma and the challenge in its approach: a review based on a clinical context of immunosuppression.. Porto Biomed J. 2018;3(1):1-4$87$YR$$F$Y$$$20221229$$MD$PT$PT
160679143$16067914$3$F$20170715$20221010$20190313$20221017$EXP$$DE-MYLANLABS-2019M1023037$MYLAN$$$$E$F$Y$$$20221017$$MD$DE$DE
160684409$16068440$9$F$$20221117$20190313$20221128$EXP$$US-JAZZ-2018-US-003746$JAZZ$$$$$M$Y$$$20221128$$MD$US$US
160704524$16070452$4$F$20180101$20220927$20190314$20221011$EXP$$CZ-AUROBINDO-AUR-APL-2019-013168$AUROBINDO$Kunova A., Heller S., Karetova D., Prochazka P., Lindner J.. Acute aortic dissection type B (summary completed with casuistic).. Postgradualni medicina.. 2019;1:27-32$50$YR$$M$Y$$$20221011$$MD$CZ$CZ
160707619$16070761$9$F$20190228$20221213$20190314$20221220$EXP$$CA-ROCHE-2278182$ROCHE$$39$YR$$F$Y$$$20221220$$HP$CA$
160707995$16070799$5$F$20171129$20221222$20190314$20221231$EXP$GB-EMA-DD-20181008-KSEVHUMANWT-173419$GB-Accord-112541$ACCORD$$44$YR$A$F$Y$$$20221231$$CN$GB$GB
1607132614$16071326$14$F$20181208$20221215$20190314$20221221$EXP$$US-PFIZER INC-2018505951$PFIZER$$74$YR$$F$Y$64$KG$20221221$$CN$US$US
160713406$16071340$6$F$$20221012$20190314$20221020$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-05930$SAMSUNG BIOEPIS$$82$YR$E$M$Y$84$KG$20221020$$MD$CA$CA
160714604$16071460$4$F$$20221117$20190314$20221121$PER$$US-PFIZER INC-2019111199$PFIZER$$63$YR$$F$Y$$$20221121$$MD$US$US
1607168810$16071688$10$F$$20221021$20190314$20221102$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-05827$SAMSUNG BIOEPIS$$51$YR$A$F$Y$94$KG$20221102$$CN$CA$CA
1607203610$16072036$10$F$20180522$20221226$20190314$20221229$EXP$$JP-ABBVIE-18P-087-2484893-00$ABBVIE$$59$YR$$M$Y$61$KG$20221229$$PH$JP$JP
160736565$16073656$5$F$$20221102$20190314$20221111$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-05971$SAMSUNG BIOEPIS$$57$YR$A$M$Y$112$KG$20221111$$HP$CA$CA
160737278$16073727$8$F$$20221017$20190314$20221026$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-05871$SAMSUNG BIOEPIS$$27$YR$A$F$Y$70$KG$20221026$$CN$CA$CA
160746039$16074603$9$F$20190306$20220929$20190314$20221006$EXP$$CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-024052$BRISTOL MYERS SQUIBB$$69$YR$E$M$Y$78$KG$20221006$$HP$CN$CN
160746509$16074650$9$F$20181009$20221107$20190314$20221111$EXP$$CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-007755$BRISTOL MYERS SQUIBB$$67$YR$E$M$Y$74$KG$20221111$$HP$CL$CL
1607495617$16074956$17$F$20171117$20221219$20190315$20221227$EXP$$CA-CELLTRION INC.-2017CA016759$CELLTRION$$$$$$Y$$$20221227$$CN$CA$CA
1607507732$16075077$32$F$20190101$20221221$20190315$20221229$EXP$$CA-CELLTRION INC.-2019CA019352$CELLTRION$$$$$$Y$$$20221230$$CN$CA$CA
160752762$16075276$2$F$20180223$20221201$20190315$20221216$EXP$$IT-AUROBINDO-AUR-APL-2019-012611$AUROBINDO$$78$YR$$F$Y$$$20221216$$MD$IT$IT
160754397$16075439$7$F$$20221026$20190315$20221109$EXP$$CA-AUROBINDO-AUR-APL-2019-012890$AUROBINDO$$59$YR$$F$Y$97$KG$20221109$$MD$CA$CA
160757923$16075792$3$F$20180713$20221021$20190315$20221026$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-070816$BRISTOL MYERS SQUIBB$$62$YR$A$F$Y$87.7$KG$20221026$$HP$US$US
160758063$16075806$3$F$$20221201$20190315$20221203$EXP$$FR-ROCHE-2280899$ROCHE$Sokal A, Sokal A; Elefant E; Leturcq T; Beghin D; Mariette X; Seror R. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study.. Osteoporosis International. 2019;30(1):221-229.$$$N$$Y$$$20221203$$HP$FR$FR
160759497$16075949$7$F$20190101$20221018$20190315$20221026$EXP$$BR-BIOGEN-2019BI00699507$BIOGEN$$$$$F$Y$80$KG$20221026$$HP$BR$BR
1607623913$16076239$13$F$$20221028$20190315$20221102$PER$$US-PFIZER INC-2019100613$PFIZER$$62$YR$$F$Y$$$20221102$$CN$US$US
160762657$16076265$7$F$$20221130$20190315$20221206$PER$$US-PFIZER INC-2019024393$PFIZER$$84$YR$$F$Y$$$20221206$$MD$US$US
160763133$16076313$3$F$$20221110$20190315$20221114$PER$$US-PFIZER INC-2019105534$PFIZER$$57$YR$$F$Y$117.9$KG$20221114$$CN$US$US
1607637317$16076373$17$F$20180401$20221220$20190315$20221228$EXP$$US-PFIZER INC-2019106933$PFIZER$$73$YR$$F$Y$74.84$KG$20221228$$CN$US$US
160764406$16076440$6$F$20190101$20221027$20190315$20221102$PER$$US-PFIZER INC-2019107200$PFIZER$$64$YR$$M$Y$72.57$KG$20221102$$CN$US$US
160778342$16077834$2$F$$20200922$20190315$20221018$EXP$$US-JNJFOC-20190316837$JOHNSON AND JOHNSON$$$$$M$Y$$$20221018$$CN$US$US
160789922$16078992$2$F$$20221118$20190315$20221124$EXP$$TR-AstraZeneca-2019SE39425$ASTRAZENECA$Seker A. EXENATIDE WORSENS DEPRESSION AND CAUSES SUICIDAL IDEATION RELAPSE: A CASE REPORT. 27th Congress of the European Psychiatric Association (EPA) 2019;E-PP0311.$14$YR$$M$Y$$$20221124$$HP$TR$
160794633$16079463$3$F$20190326$20221212$20190315$20221220$EXP$$US-SHIRE-US201908237$TAKEDA$$58$YR$$F$Y$$$20221220$$HP$US$US
160798406$16079840$6$F$$20221209$20190315$20221215$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-06154$SAMSUNG BIOEPIS$$47$YR$A$F$Y$76$KG$20221215$$CN$CA$CA
1607985410$16079854$10$F$$20221011$20190315$20221018$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-05830$SAMSUNG BIOEPIS$$62$YR$A$F$Y$72$KG$20221018$$MD$CA$CA
160798708$16079870$8$F$$20221129$20190315$20221207$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-06204$SAMSUNG BIOEPIS$$62$YR$A$M$Y$62$KG$20221207$$HP$CA$CA
160798845$16079884$5$F$$20221018$20190315$20221026$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-05912$SAMSUNG BIOEPIS$$35$YR$A$F$Y$$$20221026$$MD$CA$CA
160798987$16079898$7$F$$20221003$20190315$20221011$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-06227$SAMSUNG BIOEPIS$$61$YR$A$M$Y$60$KG$20221011$$CN$CA$CA
1607993110$16079931$10$F$$20221213$20190315$20221219$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-06016$SAMSUNG BIOEPIS$$53$YR$A$M$Y$67$KG$20221220$$MD$CA$CA
1608044814$16080448$14$F$20190218$20221030$20190315$20221115$EXP$$JP-ABBVIE-19S-087-2705373-00$ABBVIE$$68$YR$$M$Y$57$KG$20221115$$MD$JP$JP
1608178112$16081781$12$F$20180901$20221114$20190316$20221115$EXP$$PHHY2019FR055349$NOVARTIS$$73$YR$$M$Y$74$KG$20221115$$MD$FR$FR
160818546$16081854$6$F$$20220929$20190316$20221006$EXP$$CA-009507513-1903CAN006481$MERCK$Alshaikh OM, Asa SL, Mete 0, Ezzat SZ. An Institutional Experience of Pituitary Carcinomas in a 15 year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors (PitNETs). Endocrine Reviews. 2018;2(1):39$23$YR$$F$Y$$$20221006$$MD$CA$CA
160818622$16081862$2$F$$20220929$20190317$20221006$EXP$$CA-009507513-1903CAN006510$MERCK$$65$YR$$F$Y$$$20221006$$CN$CA$CA
160821588$16082158$8$F$$20221121$20190317$20221128$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-06048$SAMSUNG BIOEPIS$$53$YR$A$F$Y$120$KG$20221128$$HP$CA$CA
160821738$16082173$8$F$$20221028$20190317$20221108$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-06086$SAMSUNG BIOEPIS$$77$YR$E$M$Y$61$KG$20221108$$MD$CA$CA
160822393$16082239$3$F$20040220$20221012$20190317$20221019$PER$$US-JNJFOC-20190239276$JOHNSON AND JOHNSON$$31$YR$A$M$Y$93.978$KG$20221019$$CN$US$US
1608296033$16082960$33$F$20180614$20221024$20190318$20221102$EXP$$CA-ROCHE-2148014$ROCHE$$27$YR$$M$Y$68.6$KG$20221031$$CN$CA$
160839702$16083970$2$F$$20221007$20190318$20221019$EXP$$US-PFIZER INC-2019117292$MYLAN$$$$$M$Y$$$20221019$$MD$US$US
160844534$16084453$4$F$$20221220$20190318$20221226$EXP$$CA-GLAXOSMITHKLINE-CA2018GSK178040$GLAXOSMITHKLINE$$$$$$Y$$$20221226$$MD$CA$CA
160868267$16086826$7$F$$20221128$20190318$20221206$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-05975$SAMSUNG BIOEPIS$$65$YR$E$F$Y$86$KG$20221206$$MD$CA$CA
160869585$16086958$5$F$$20221016$20190318$20221020$EXP$$GB-MYLANLABS-2018M1022013$MYLAN$$$$$M$Y$$$20221020$$MD$GB$GB
160870098$16087009$8$F$$20220929$20190318$20221006$EXP$$CA-009507513-1903CAN006484$MERCK$$$$A$M$Y$$$20221006$$CN$CA$CA
160874672$16087467$2$F$$20220929$20190319$20221003$EXP$$CA-009507513-1903CAN006527$MERCK$$58$YR$$F$Y$$$20221003$$HP$CA$CA
160885292$16088529$2$F$20190124$20221028$20190319$20221101$PER$$US-PFIZER INC-2019107845$PFIZER$$59$YR$$F$Y$$$20221101$$PH$US$US
160890968$16089096$8$F$$20221128$20190319$20221209$EXP$$CA-ALLERGAN-1911618US$ALLERGAN$$$$$F$Y$$$20221209$$HP$CA$CA
160908905$16090890$5$F$20180101$20221130$20190319$20221202$EXP$$US-PFIZER INC-2019111184$PFIZER$$59$YR$$M$Y$97$KG$20221202$$CN$US$US
160930585$16093058$5$F$$20220929$20190320$20221003$EXP$$CA-009507513-1903CAN006459$MERCK$$26$YR$$F$Y$$$20221003$$HP$CA$CA
160932022$16093202$2$F$20160928$20221130$20190320$20221213$EXP$AT-EMA-DD-20181107-KUMARVN_P-110545$AT-Accord-113500$ACCORD$$65$YR$A$M$Y$56$KG$20221213$$MD$AT$AT
1609334541$16093345$41$F$20190306$20221129$20190320$20221208$EXP$$CA-CELLTRION INC.-2019CA017984$CELLTRION$$$$$$Y$$$20221208$$MD$CA$CA
160947253$16094725$3$F$$20221221$20190320$20221229$PER$$US-AMGEN-USASP2019041729$AMGEN$$65$YR$E$F$Y$$$20221229$$MD$US$US
160954294$16095429$4$F$$20221110$20190320$20221115$EXP$$CA-PFIZER INC-2019110613$PFIZER$$74$YR$$F$Y$$$20221115$$HP$CA$CA
160954587$16095458$7$F$$20220929$20190320$20221007$EXP$$CA-009507513-1903CAN006571$MERCK$$$$$$Y$$$20221007$$MD$CA$CA
160963756$16096375$6$F$$20221012$20190320$20221019$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-06173$SAMSUNG BIOEPIS$$35$YR$A$M$Y$74$KG$20221019$$CN$CA$CA
160976206$16097620$6$F$20190225$20221107$20190320$20221111$EXP$$US-SHIRE-US201908857$TAKEDA$$50$YR$$M$Y$62$KG$20221111$$CN$US$US
1609796811$16097968$11$F$20180125$20221220$20190320$20221227$EXP$$PHHY2018CA026946$NOVARTIS$$74$YR$$F$Y$$$20221227$$CN$CA$CA
1609813543$16098135$43$F$20190726$20221219$20190320$20221227$EXP$$CA-CELLTRION INC.-2019CA019470$CELLTRION$$$$$$Y$$$20221228$$CN$CA$CA
1609893820$16098938$20$F$20200518$20221110$20190321$20221110$EXP$$US-PFIZER INC-2019118803$PFIZER$$25$YR$$M$Y$$$20221110$$HP$US$US
160989703$16098970$3$F$$20221117$20190321$20221122$PER$$US-PFIZER INC-2019118725$PFIZER$$66$YR$$F$Y$$$20221122$$PH$US$US
160992608$16099260$8$F$20140917$20221110$20190321$20221116$EXP$$PHHY2014CA040423$NOVARTIS$$66$YR$$F$Y$$$20221116$$HP$CA$CA
161001433$16100143$3$F$20190101$20221006$20190321$20221011$EXP$$CA-PFIZER INC-2018465189$PFIZER$$61$YR$$F$Y$$$20221011$$MD$CA$CA
161004553$16100455$3$F$20190101$20221110$20190321$20221116$PER$$US-PFIZER INC-2019119902$PFIZER$$59$YR$$F$Y$$$20221116$$CN$US$US
161005066$16100506$6$F$20201101$20221130$20190321$20221202$PER$$US-PFIZER INC-2019118269$PFIZER$$36$YR$$F$Y$$$20221202$$CN$US$US
1610088213$16100882$13$F$20200409$20221218$20190321$20221223$EXP$$CA-TAKEDA-2019TUS015415$TAKEDA$$62$YR$$F$Y$$$20221223$$CN$CA$CA
1610114414$16101144$14$F$20190208$20220929$20190321$20221004$EXP$$CA-TAKEDA-2019TUS015880$TAKEDA$$53$YR$$F$Y$$$20221004$$CN$CA$CA
161030734$16103073$4$F$20170101$20221203$20190322$20221217$EXP$$ES-AUROBINDO-AUR-APL-2019-014505$AUROBINDO$Martin Garcia C, Sierra Pacho M, Moreno Rodilla E, Callejo Melgosa AM, Martinez Alonso JC, Fernandez Colino T, et al.. Successful Bendamustine Desensitization for a Delayed-Type Hypersensitivity Reaction.. J Investig Allergol Clin Immunol.. 2019;29(1):68-9$28$YR$$M$Y$$$20221217$$HP$ES$ES
1610321016$16103210$16$F$20151021$20221018$20190322$20221031$EXP$$GB-MACLEODS PHARMACEUTICALS US LTD-MAC2019020516$MACLEODS$$$$$$Y$$$20221031$$MD$GB$GB
161032694$16103269$4$F$20180101$20221102$20190322$20221104$EXP$$US-BIOGEN-2019BI00714115$BIOGEN$$$$$F$Y$$$20221104$$CN$US$US
1610440825$16104408$25$F$20161010$20221011$20190322$20221019$EXP$GB-EMA-DD-20190311-kumarsingh_a-170148$GB-TORRENT-00020586$TORRENT$$26$YR$A$F$Y$$$20221019$$MD$GB$GB
1610451815$16104518$15$F$20180901$20221115$20190322$20221123$EXP$$FR-AUROBINDO-AUR-APL-2019-014551$AUROBINDO$$73$YR$$M$Y$74$KG$20221123$$MD$FR$FR
161045388$16104538$8$F$20190301$20221124$20190322$20221201$EXP$$DE-ROCHE-2288237$ROCHE$$60$YR$$M$Y$$$20221201$$CN$DE$
161055512$16105551$2$F$20190101$20221212$20190322$20221216$PER$$US-VERTEX PHARMACEUTICALS-2019-002402$VERTEX$$$$$F$Y$$$20221216$$HP$US$US
161066108$16106610$8$F$20180601$20221018$20190322$20221020$PER$$US-PFIZER INC-2019119777$PFIZER$$41$YR$$F$Y$$$20221020$$HP$US$US
161071953$16107195$3$F$20160407$20221113$20190322$20221116$EXP$$PHHY2016IL063714$NOVARTIS$$51$YR$$F$Y$$$20221116$$HP$IL$IL
161083162$16108316$2$F$20180501$20221019$20190322$20221026$EXP$$PHHY2019GB064854$NOVARTIS$$38$YR$$M$Y$$$20221026$$CN$GB$GB
161085082$16108508$2$F$20190319$20221111$20190323$20221122$EXP$$US-SHIRE-US201909515$TAKEDA$$38$YR$$F$Y$$$20221122$$HP$US$US
1610977932$16109779$32$F$20161110$20221213$20190325$20221227$EXP$$GB-AUROBINDO-AUR-APL-2019-015183$AUROBINDO$$26$YR$$F$Y$$$20221227$$MD$GB$GB
1611001810$16110018$10$F$20130502$20221114$20190325$20221122$EXP$$CA-ROCHE-2286334$ROCHE$$35$YR$$F$Y$$$20221122$$MD$CA$CA
161109049$16110904$9$F$20190201$20221121$20190325$20221205$EXP$$CA-TAKEDA-2019TUS005447$TAKEDA$$80$YR$$M$Y$$$20221205$$CN$CA$CA
1611250316$16112503$16$F$20190401$20221012$20190325$20221014$EXP$$US-PFIZER INC-2018093406$PFIZER$$68$YR$$F$Y$$$20221014$$CN$US$US
161125907$16112590$7$F$$20221116$20190325$20221128$EXP$$US-TEVA-2019-US-1029867$TEVA$$72$YR$E$F$Y$$$20221126$$CN$US$US
161128189$16112818$9$F$20180101$20221222$20190325$20221226$EXP$$US-JAZZ-2019-US-003948$JAZZ$$$$$M$Y$$$20221226$$HP$US$US
161129843$16112984$3$F$19840801$20190325$20190325$20221129$EXP$$PHHY2019GB067014$NOVARTIS$Davies S. Secondary leukemia with a translocation. CANCER GENET CYTOGENET. 1988;31:271-4$24$YR$$F$Y$$$20221129$$HP$GB$GB
161133162$16113316$2$F$$20221207$20190325$20221214$PER$$US-PFIZER INC-2019123621$PFIZER$$82$YR$$F$Y$58.97$KG$20221214$$CN$US$US
161134585$16113458$5$F$20190127$20221205$20190325$20221208$EXP$$US-PFIZER INC-2019125495$PFIZER$$61$YR$$F$Y$88.889$KG$20221208$$CN$US$US
1611469810$16114698$10$F$20180201$20221116$20190325$20221122$EXP$$CA-TAKEDA-2019TUS015579$TAKEDA$$44$YR$$F$Y$$$20221122$$CN$CA$CA
1611551427$16115514$27$F$20180101$20221122$20190325$20221201$EXP$$CA-CELLTRION INC.-2018CA022277$CELLTRION$$$$$$Y$$$20221201$$HP$CA$CA
161163352$16116335$2$F$20180601$20190318$20190326$20221111$PER$$US-AMGEN-USASP2019043306$AMGEN$$79$YR$E$F$Y$$$20221110$$CN$US$US
161167603$16116760$3$F$$20221215$20190326$20221227$EXP$$US-drreddys-USA/USA/19/0108882$DR REDDYS$Pace M. Axillary artery dissection after ultrasound-guided infraclavicular brachial plexus block: A case report. A and A Practice. 2018;11(1):19-21. doi:DOI: 10.1213/XAA.0000000000000725$52$YR$A$M$Y$63$KG$20221227$$MD$US$US
161170243$16117024$3$F$$20221215$20190326$20221227$PER$$US-PFIZER INC-2019124975$PFIZER$$61$YR$$F$Y$$$20221227$$HP$US$US
161172322$16117232$2$F$$20221003$20190326$20221013$EXP$$CA-ROCHE-2286954$ROCHE$$39$YR$$F$Y$69$KG$20221012$$CN$CA$CA
1611741110$16117411$10$F$$20221130$20190326$20221206$EXP$$US-PFIZER INC-2018473157$MYLAN$$$$$M$Y$$$20221206$$CN$US$US
161178572$16117857$2$F$$20221012$20190326$20221019$PER$$US-SA-2019SA077126$SANOFI AVENTIS$$$$A$F$Y$$$20221019$$MD$US$US
161179507$16117950$7$F$20190301$20221130$20190326$20221207$EXP$$CA-TAKEDA-2019TUS003652$TAKEDA$$78$YR$$M$Y$$$20221207$$CN$CA$CA
1611834215$16118342$15$F$20190101$20221028$20190326$20221103$EXP$$FR-PFIZER INC-2019105208$PFIZER$$67$YR$$F$Y$70.4$KG$20221103$$MD$FR$FR
161200433$16120043$3$F$$20221101$20190326$20221103$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-030092$BRISTOL MYERS SQUIBB$$74$YR$E$F$Y$$$20221103$$MD$JP$JP
161200604$16120060$4$F$20170226$20220927$20190326$20221003$EXP$$JP-GILEAD-2019-0398622$GILEAD$$54$YR$A$M$Y$$$20221003$$MD$JP$JP
161202057$16120205$7$F$$20221114$20190326$20221117$EXP$$US-SHIRE-US201909165$TAKEDA$$$$$F$Y$90.703$KG$20221117$$HP$US$US
161203407$16120340$7$F$$20220926$20190326$20221003$EXP$$PHHY2019CA062039$NOVARTIS$$60$YR$$F$Y$$$20221003$$MD$CA$CA
1612064333$16120643$33$F$20180814$20221119$20190327$20221202$EXP$$DE-AUROBINDO-AUR-APL-2018-053445$AUROBINDO$$74$YR$$F$Y$82$KG$20221203$$MD$DE$DE
1612206224$16122062$24$F$20190318$20221125$20190327$20221130$EXP$$US-PFIZER INC-2019127333$PFIZER$$67$YR$$F$Y$72.57$KG$20221130$$PH$US$US
1612230317$16122303$17$F$20161010$20221005$20190327$20221018$EXP$$GB-MACLEODS PHARMACEUTICALS US LTD-MAC2019020575$MACLEODS$$$$$$Y$$$20221017$$HP$GB$GB
161226577$16122657$7$F$20190307$20221221$20190327$20221222$EXP$$CA-ROCHE-2291082$ROCHE$$49$YR$$F$Y$$$20221222$$CN$CA$
1612312326$16123123$26$F$$20221103$20190327$20221109$EXP$$CA-APOTEX-2019AP009858$APOTEX$$58$YR$$F$Y$$$20221109$$MD$CA$CA
161233193$16123319$3$F$$20221215$20190327$20221227$EXP$$US-PFIZER INC-2019126091$PFIZER$Pace, M.. Axillary artery dissection after ultrasound-guided infraclavicular brachial plexus block: A case report. A + A Practice. 2018;11(1):19-21$52$YR$$M$Y$63$KG$20221227$$MD$US$US
161240274$16124027$4$F$20150301$20221017$20190327$20221020$EXP$$US-TAKEDA-2019TUS016654$TAKEDA$$$$$$Y$$$20221020$$CN$US$US
1612429015$16124290$15$F$20190220$20221007$20190327$20221008$EXP$$PHHY2019DE061810$NOVARTIS$$69$YR$$F$Y$62$KG$20221008$$MD$DE$DE
161250906$16125090$6$F$$20221108$20190327$20221109$PER$$US-PFIZER INC-2019127231$PFIZER$$62$YR$$F$Y$$$20221109$$CN$US$US
161259842$16125984$2$F$20190209$20221028$20190328$20221102$EXP$$US-ROCHE-2264792$ROCHE$$38$YR$$M$Y$$$20221102$$MD$US$
161270777$16127077$7$F$20190201$20221104$20190328$20221104$EXP$$PL-ROCHE-2288547$ROCHE$$53$YR$$F$Y$65$KG$20221104$$MD$PL$
161272692$16127269$2$F$20190326$20221130$20190328$20221208$PER$$US-BAYER-2019-060423$BAYER$$34$YR$A$F$Y$$$20221208$$PH$US$US
1612950816$16129508$16$F$20190311$20221128$20190328$20221202$EXP$$CA-TAKEDA-2019TUS017936$TAKEDA$$77$YR$$M$Y$$$20221202$$HP$CA$CA
1613038910$16130389$10$F$20180301$20221221$20190328$20221227$EXP$$PHHY2018CA044169$NOVARTIS$$53$YR$$M$Y$$$20221227$$CN$CA$CA
161308113$16130811$3$F$$20221207$20190328$20221213$EXP$$IE-WHANIN PHARM. CO., LTD.-2019M1027853$MYLAN$$$$A$M$Y$$$20221213$$PH$IE$IE
1613147715$16131477$15$F$20190101$20221028$20190328$20221104$PER$$FR-AMGEN-FRANI2019038611$AMGEN$$67$YR$E$F$Y$70.4$KG$20221103$$MD$FR$FR
161326742$16132674$2$F$20190319$20221103$20190329$20221109$EXP$$US-EMD Serono-9081832$EMD SERONO INC$$72$YR$E$F$Y$$$20221109$$HP$US$
161330574$16133057$4$F$$20221129$20190329$20221201$EXP$$US-PFIZER INC-2019124986$PFIZER$$83$YR$$F$Y$$$20221201$$MD$US$US
1613323819$16133238$19$F$20190314$20221205$20190329$20221215$PER$$JP-AMGEN-JPNSP2019047457$AMGEN$$79$YR$E$M$Y$58.4$KG$20221215$$MD$JP$JP
161341605$16134160$5$F$20190206$20221219$20190329$20221226$EXP$$CA-TAKEDA-2019TUS017496$TAKEDA$$41$YR$$M$Y$$$20221226$$CN$CA$CA
161349635$16134963$5$F$20150904$20220927$20190329$20221007$EXP$$JP-JNJFOC-20190332839$JOHNSON AND JOHNSON$$57$YR$A$M$Y$$$20221007$$MD$JP$JP
161352497$16135249$7$F$20150904$20220927$20190329$20221003$EXP$$JP-JNJFOC-20190335454$JOHNSON AND JOHNSON$$57$YR$A$M$Y$$$20221003$$MD$JP$JP
161364055$16136405$5$F$20210922$20221011$20190329$20221017$EXP$$US-SHIRE-US201909698$TAKEDA$$89$YR$$F$Y$$$20221017$$HP$US$US
161364086$16136408$6$F$$20221116$20190329$20221121$EXP$$US-SHIRE-US201910014$TAKEDA$$$$$F$Y$93$KG$20221121$$HP$US$US
161374182$16137418$2$F$20190312$20221202$20190330$20221216$EXP$$IT-AUROBINDO-AUR-APL-2019-015619$AUROBINDO$$63$YR$$F$Y$$$20221217$$PH$IT$IT
1613832312$16138323$12$F$20180814$20221205$20190401$20221219$PER$$JP-AMGEN-JPNSP2019047456$AMGEN$$72$YR$E$M$Y$50$KG$20221219$$MD$JP$JP
161394452$16139445$2$F$$20221209$20190401$20221214$PER$$US-BIOGEN-2019BI00700333$BIOGEN$$$$$F$Y$$$20221214$$CN$US$US
161405763$16140576$3$F$$20221011$20190401$20221018$EXP$$FR-MYLANLABS-2019M1024880$MYLAN$Camus V, Dubois S, Lepretre S, Jardin F, Tilly H. Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient. Clinical Case Reports. 2018;6 (8):1418-1421$38$YR$$M$Y$$$20221018$$HP$FR$FR
161406033$16140603$3$F$$20220926$20190401$20221010$EXP$$ES-ASTELLAS-2019US013154$ASTELLAS$Sadyrbaeva-Dolgova s. Multiple drugs Nephrogenic diabetes insipidus: case report.. Reactions weekly. 2019;1761:258:Unknown$39$YR$$M$Y$$$20221010$$CN$ES$ES
161421025$16142102$5$F$20181213$20221012$20190401$20221020$PER$$US-SA-2019SA084553$SANOFI AVENTIS$$61$YR$A$F$Y$$$20221020$$MD$US$US
1614255640$16142556$40$F$20150601$20221124$20190401$20221128$EXP$$GB-MYLANLABS-2019M1028945$MYLAN$$58$YR$$F$Y$$$20221128$$MD$GB$GB
161425948$16142594$8$F$$20221206$20190401$20221213$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-037726$BRISTOL MYERS SQUIBB$$72$YR$E$F$Y$$$20221213$$CN$CA$CA
161429583$16142958$3$F$$20221202$20190401$20221208$EXP$$US-JAZZ-2019-US-004463$JAZZ$$$$$F$Y$$$20221208$$HP$US$US
161437905$16143790$5$F$$20221117$20190401$20221121$EXP$$US-SHIRE-US201910074$TAKEDA$$$$$F$Y$$$20221121$$MD$US$US
161438143$16143814$3$F$20190318$20221214$20190401$20221219$EXP$$US-SHIRE-US201910432$TAKEDA$$63$YR$$F$Y$$$20221219$$CN$US$US
161444219$16144421$9$F$$20221012$20190401$20221016$PER$$US-AMGEN-USASP2019050924$AMGEN$$63$YR$A$F$Y$$$20221016$$CN$US$US
161445622$16144562$2$F$$20221122$20190402$20221129$EXP$$PHHY2019CA068037$NOVARTIS$$77$YR$$M$Y$$$20221129$$MD$CA$CA
1614466613$16144666$13$F$20190101$20221102$20190402$20221110$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-012373$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221111$$CN$US$US
161450607$16145060$7$F$20190301$20221005$20190402$20221011$EXP$$US-JAZZ-2019-US-004415$JAZZ$$41$YR$$F$Y$$$20221011$$MD$US$US
1614616810$16146168$10$F$20180101$20221118$20190402$20221128$EXP$$US-ROCHE-2193176$ROCHE$$65$YR$$F$Y$92.162$KG$20221128$$CN$US$
161463183$16146318$3$F$20190323$20221010$20190402$20221012$PER$$US-PFIZER INC-2019136663$PFIZER$$66$YR$$F$Y$$$20221012$$PH$US$US
1614761012$16147610$12$F$20190306$20221213$20190402$20221216$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-030393$BRISTOL MYERS SQUIBB$$76$YR$E$F$Y$55.1$KG$20221216$$MD$JP$JP
161480774$16148077$4$F$20150301$20221026$20190402$20221103$EXP$$US-PFIZER INC-2019141248$PFIZER$$67$YR$$F$Y$$$20221103$$HP$US$US
1614812910$16148129$10$F$$20221202$20190402$20221207$PER$$US-PFIZER INC-2019136625$PFIZER$$74$YR$$F$Y$55.79$KG$20221207$$HP$US$US
161488873$16148887$3$F$$20221031$20190402$20221114$EXP$$JP-ALLERGAN-1914291US$ALLERGAN$Unknown. Title not provided. 73rd Annual Congress of Japan Clinical Ophthalmology$$$$F$Y$$$20221114$$MD$JP$JP
161497372$16149737$2$F$$20221129$20190402$20221205$EXP$$DE-MYLANLABS-2019M1028438$MYLAN$Hoppe J, Holderied A, Schafer H, Lottspeich C, Vielhauer V, Anders H-J et al.. Drug-induced CYP-induction as therapy for tacrolimus intoxication. Transplantation. 2018;102(7):S600$56$YR$$M$Y$$$20221205$$HP$DE$DE
161502144$16150214$4$F$20150301$20221011$20190402$20221014$EXP$$US-AstraZeneca-2019SE47282$ASTRAZENECA$$812$MON$$F$Y$81.6$KG$20221014$$LW$US$
1615208713$16152087$13$F$20181214$20221221$20190403$20221230$PER$$JP-AMGEN-JPNSP2019050127$AMGEN$$67$YR$E$F$Y$62.7$KG$20221230$$MD$JP$JP
161526023$16152602$3$F$20190201$20221116$20190403$20221123$EXP$$CA-ROCHE-2291877$ROCHE$$50$YR$$M$Y$69$KG$20221123$$CN$CA$
161532028$16153202$8$F$20180101$20221020$20190403$20221027$EXP$$CA-ROCHE-2296136$ROCHE$$$$$F$Y$$$20221027$$CN$CA$
1615368219$16153682$19$F$20180101$20221102$20190403$20221104$EXP$$GB-ROCHE-2271800$ROCHE$$66$YR$$M$Y$98.972$KG$20221104$$PH$GB$GB
1615394213$16153942$13$F$$20221215$20190403$20221221$PER$$US-PFIZER INC-2019141368$PFIZER$$67$YR$$F$Y$$$20221221$$CN$US$US
161539515$16153951$5$F$20190731$20221114$20190403$20221116$EXP$$US-PFIZER INC-2019142132$PFIZER$$68$YR$$F$Y$83.91$KG$20221116$$CN$US$US
161539866$16153986$6$F$20180101$20221110$20190403$20221114$EXP$$US-PFIZER INC-2019128948$PFIZER$$74$YR$$F$Y$56.68$KG$20221114$$CN$US$US
161546322$16154632$2$F$20150720$20190324$20190403$20221220$EXP$$DE-TEVA-2019-DE-1031155$TEVA$$76$YR$E$F$Y$$$20221220$$MD$DE$DE
161564742$16156474$2$F$$20221101$20190404$20221107$PER$$US-AMGEN-USASP2019052063$AMGEN$$70$YR$E$M$Y$$$20221107$$MD$US$US
161566336$16156633$6$F$$20221107$20190404$20221110$EXP$$US-TAKEDA-2019TUS018912$TAKEDA$$$$$M$Y$$$20221110$$CN$US$US
161568388$16156838$8$F$20220201$20221215$20190404$20221220$EXP$$PHHY2019CA043807$NOVARTIS$$61$YR$$M$Y$$$20221220$$MD$CA$CA
161575315$16157531$5$F$$20221027$20190404$20221031$PER$$US-PFIZER INC-2019144453$PFIZER$$69$YR$$F$Y$$$20221031$$HP$US$US
161575546$16157554$6$F$$20221212$20190404$20221219$PER$$US-PFIZER INC-2019142648$PFIZER$$75$YR$$F$Y$$$20221219$$CN$US$US
1615875711$16158757$11$F$20170812$20221221$20190404$20221223$EXP$$JP-ABBVIE-19K-087-2729673-00$ABBVIE$H Uedono ,A Tsuda ,N Ueno , et al.. [CASE REPORT] Seronegative Full-house Nephropathy with Crohn^s Disease. Internal Medicine. 2022; 61 (23) 3553-3558$28$YR$$F$Y$46$KG$20221223$$MD$JP$JP
161589045$16158904$5$F$$20221121$20190404$20221124$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK059937$GLAXOSMITHKLINE$$$$$$Y$$$20221124$$MD$CA$CA
161595905$16159590$5$F$$20221214$20190404$20221221$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK052972$GLAXOSMITHKLINE$$$$$$Y$$$20221221$$MD$CA$CA
161605802$16160580$2$F$$20221006$20190405$20221013$EXP$$CA-ROCHE-2296138$ROCHE$$$$$M$Y$$$20221011$$MD$CA$
161606954$16160695$4$F$20180926$20221101$20190405$20221108$EXP$$CA-ROCHE-2192263$ROCHE$$46$YR$$M$Y$$$20221108$$CN$CA$
1616162824$16161628$24$F$20180614$20221124$20190405$20221202$EXP$$CA-CELLTRION INC.-2018CA021079$CELLTRION$$$$$$Y$$$20221202$$MD$CA$CA
161621284$16162128$4$F$20100621$20221107$20190405$20221110$PER$$US-JNJFOC-20190336252$JOHNSON AND JOHNSON$$10$YR$C$M$Y$$$20221110$$LW$US$US
1616260014$16162600$14$F$20190401$20221125$20190405$20221128$EXP$$AU-ROCHE-2296452$ROCHE$$71$YR$$M$Y$90.7$KG$20221128$$MD$AU$
161627196$16162719$6$F$$20221212$20190405$20221216$EXP$$CA-TAKEDA-2019TUS019083$TAKEDA$$21$YR$$F$Y$66$KG$20221216$$HP$CA$CA
161627383$16162738$3$F$$20221031$20190405$20221107$PER$$US-SHIRE-US201911153$TAKEDA$$$$$F$Y$$$20221107$$MD$US$US
161629023$16162902$3$F$20190226$20221014$20190405$20221018$EXP$$CZ-ROCHE-2274663$ROCHE$$65$YR$$M$Y$95$KG$20221018$$MD$CZ$
161635566$16163556$6$F$20190301$20221024$20190405$20221026$EXP$$CA-ROCHE-2297958$ROCHE$$23$YR$$F$Y$$$20221026$$CN$CA$
1616363212$16163632$12$F$20210301$20221222$20190405$20221229$EXP$$US-INCYTE CORPORATION-2019IN003206$INCYTE$$$$$$Y$$$20221229$$MD$US$US
161639094$16163909$4$F$20040218$20220926$20190405$20221006$PER$$US-JNJFOC-20190336448$JOHNSON AND JOHNSON$$5$YR$C$M$Y$$$20221006$$LW$US$US
161654783$16165478$3$F$20070101$20221130$20190405$20221208$EXP$$US-AstraZeneca-2019SE50641$ASTRAZENECA$$55$YR$$M$Y$140.6$KG$20221208$$LW$US$
1616612424$16166124$24$F$20151201$20221119$20190406$20221202$EXP$GB-EMA-DD20190219GANGALS192526$GB-Accord-117948$ACCORD$$69$YR$E$F$Y$$$20221202$$MD$GB$GB
161680927$16168092$7$F$$20221103$20190408$20221107$PER$$US-PFIZER INC-2018411228$PFIZER$$54$YR$$F$Y$$$20221107$$MD$US$US
161681463$16168146$3$F$20150201$20220930$20190408$20221004$PER$$US-PFIZER INC-2019149053$PFIZER$$49$YR$$F$Y$$$20221004$$LW$US$US
161681997$16168199$7$F$$20221122$20190408$20221128$PER$$US-PFIZER INC-2019151274$PFIZER$$72$YR$$F$Y$$$20221128$$CN$US$US
161684428$16168442$8$F$20190326$20221108$20190408$20221115$EXP$$BR-GLAXOSMITHKLINE-BR2019GSK062064$GLAXOSMITHKLINE$$$$$$Y$$$20221115$$MD$BR$BR
161702346$16170234$6$F$20181031$20221220$20190408$20221224$EXP$$PT-JNJFOC-20190409387$JOHNSON AND JOHNSON$$43$YR$A$M$Y$42$KG$20221224$$MD$PT$PT
161714146$16171414$6$F$20210808$20221201$20190408$20221207$EXP$$US-SHIRE-US201910935$TAKEDA$$61$YR$$F$Y$77$KG$20221207$$HP$US$US
161716384$16171638$4$F$$20221017$20190408$20221028$EXP$$IE-ELI_LILLY_AND_COMPANY-IE201904001243$ELI LILLY AND CO$$$$$M$Y$$$20221028$$CN$IE$IE
161734814$16173481$4$F$20190330$20221219$20190409$20221223$EXP$$CA-ROCHE-2296156$ROCHE$$47$YR$$F$Y$$$20221223$$CN$CA$
161741044$16174104$4$F$20080101$20221114$20190409$20221122$EXP$$US-AstraZeneca-2019SE11962$ASTRAZENECA$$50$YR$$M$Y$97.5$KG$20221122$$LW$US$
1617415519$16174155$19$F$20190217$20221108$20190409$20221115$EXP$$US-PFIZER INC-2019144118$MYLAN$$60$YR$$F$Y$44$KG$20221115$$CN$US$US
1617476226$16174762$26$F$20180101$20221206$20190409$20221215$EXP$$CA-CELLTRION INC.-2018CA023892$CELLTRION$$$$$$Y$$$20221215$$CN$CA$CA
161760294$16176029$4$F$$20221010$20190409$20221011$EXP$$US-TAKEDA-2019TUS019537$TAKEDA$$$$$M$Y$$$20221011$$CN$US$US
1617654814$16176548$14$F$20170101$20221114$20190409$20221118$EXP$$PHHY2017CA174786$NOVARTIS$$70$YR$$M$Y$$$20221118$$CN$CA$CA
161776735$16177673$5$F$20180814$20221215$20190410$20221228$EXP$$DE-AUROBINDO-AUR-APL-2018-049438$AUROBINDO$$68$YR$$F$Y$63$KG$20221228$$MD$DE$DE
161778658$16177865$8$F$20190304$20221105$20190410$20221118$EXP$$FR-AUROBINDO-AUR-APL-2019-018637$AUROBINDO$$67$YR$$F$Y$70.4$KG$20221118$$MD$FR$FR
161778665$16177866$5$F$$20221110$20190410$20221115$EXP$$CA-009507513-1904CAN003850$MERCK$$24$YR$$F$Y$73$KG$20221115$$HP$CA$CA
161782263$16178226$3$F$$20221128$20190410$20221205$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-035660$BRISTOL MYERS SQUIBB$Chan NC, Eikelboom JW. How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. Blood. 2019; 1-30. doi:10.1182/blood-2019-01-846048.$75$YR$E$F$Y$$$20221205$$MD$CA$CA
161784593$16178459$3$F$20180715$20221123$20190410$20221201$EXP$$US-UCBSA-2019013866$UCB$$34$YR$$F$Y$72.58$KG$20221201$$HP$US$US
1617861332$16178613$32$F$20180802$20221124$20190410$20221209$EXP$$PHHY2018CA066991$NOVARTIS$$53$YR$$F$Y$$$20221209$$CN$CA$CA
161794333$16179433$3$F$$20221219$20190410$20221222$EXP$$US-PFIZER INC-2019151115$PFIZER$$78$YR$$F$Y$$$20221222$$CN$US$US
1617977011$16179770$11$F$20180831$20220929$20190410$20221003$EXP$$CN-ROCHE-2297509$ROCHE$$63$YR$$F$Y$72$KG$20221003$$MD$CN$
161802114$16180211$4$F$$20200414$20190410$20221212$PER$$US-TEVA-2019-US-1034339$TEVA$$62$YR$A$F$Y$59$KG$20221212$$CN$US$US
161802987$16180298$7$F$$20221110$20190410$20221116$EXP$$CA-009507513-1904CAN003813$MERCK$$76$YR$$F$Y$$$20221116$$CN$CA$CA
161811459$16181145$9$F$20190220$20220927$20190410$20221003$EXP$$JP-DSJP-DSJ-2019-106925AA$DAIICHI$$71$YR$$M$Y$77$KG$20221003$$MD$JP$JP
1618292518$16182925$18$F$20190101$20221012$20190411$20221019$EXP$$CA-ROCHE-2301920$ROCHE$$$$$M$Y$$$20221019$$MD$CA$
1618379810$16183798$10$F$$20221122$20190411$20221128$EXP$$US-TAKEDA-2019TUS004590$TAKEDA$$$$$F$Y$$$20221128$$CN$US$US
161838575$16183857$5$F$$20221107$20190411$20221109$EXP$$PHHY2018CA001371$NOVARTIS$$$$$M$Y$$$20221109$$HP$CA$CA
161842472$16184247$2$F$20190328$20221011$20190411$20221014$EXP$$CA-PFIZER INC-2019151375$PFIZER$$27$YR$$F$Y$$$20221014$$CN$CA$CA
1618657921$16186579$21$F$20170101$20221107$20190411$20221114$EXP$$PHHY2017CA008718$NOVARTIS$$$$$F$Y$$$20221114$$CN$CA$CA
1618736433$16187364$33$F$20180724$20221017$20190412$20221025$EXP$$CA-CELLTRION INC.-2018CA021724$CELLTRION$$$$$$Y$$$20221025$$CN$CA$CA
1618842913$16188429$13$F$20190220$20221010$20190412$20221018$EXP$$DE-AUROBINDO-AUR-APL-2019-018854$AUROBINDO$$69$YR$$F$Y$62$KG$20221018$$MD$DE$DE
161895226$16189522$6$F$$20221102$20190412$20221103$PER$$US-PFIZER INC-2019156521$PFIZER$$72$YR$$F$Y$$$20221103$$HP$US$US
161895543$16189554$3$F$$20221130$20190412$20221202$EXP$$US-PFIZER INC-2019155993$PFIZER$$75$YR$$M$Y$$$20221202$$MD$US$US
1619009918$16190099$18$F$20190322$20221207$20190412$20221212$EXP$$DE-ROCHE-2302794$ROCHE$$33$YR$$M$Y$$$20221212$$CN$DE$
161902442$16190244$2$F$$20221027$20190412$20221031$PER$$US-PFIZER INC-2019149396$PFIZER$$56$YR$$F$Y$$$20221031$$HP$US$US
161909244$16190924$4$F$20190401$20221205$20190412$20221208$EXP$$JP-BIOGEN-2019BI00724550$BIOGEN$$48$YR$$F$Y$$$20221208$$MD$JP$JP
161913035$16191303$5$F$20221121$20221122$20190412$20221128$EXP$$CA-PFIZER INC-2019153563$PFIZER$$73$YR$$F$Y$$$20221128$$CN$CA$CA
161913486$16191348$6$F$$20221128$20190412$20221208$EXP$$CA-PFIZER INC-2019157164$PFIZER$Chan, N.. How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. Blood. 2019;133(21):2269-2278$75$YR$$F$Y$$$20221208$$MD$CA$CA
161916365$16191636$5$F$20190403$20221019$20190412$20221029$EXP$$US-SA-2019SA100983$SANOFI AVENTIS$$59$YR$A$F$Y$$$20221029$$MD$US$US
161920469$16192046$9$F$20180201$20221003$20190412$20221007$EXP$$PHHY2019PL082623$NOVARTIS$Masajtis-Zagajewska A, Holub T, Nowicki M. Different clinical course of atypical hemolytic uremic syndrome -a description of a series of clinical cases. PRZEGLAD LEKARSKI. 2018;12(75):606-10$23$YR$$F$Y$65$KG$20221007$$HP$PL$PL
161934219$16193421$9$F$$20221110$20190413$20221117$EXP$$CA-009507513-1904CAN003774$MERCK$$66$YR$$M$Y$$$20221117$$HP$CA$CA
161939985$16193998$5$F$20181004$20221105$20190413$20221111$EXP$$PHHY2019CH016383$NOVARTIS$$78$YR$$F$Y$61.8$KG$20221111$$MD$CH$CH
161969655$16196965$5$F$$20221214$20190415$20221219$EXP$$US-PFIZER INC-2019153122$PFIZER$$65$YR$$F$Y$66$KG$20221219$$CN$US$US
161993219$16199321$9$F$$20221122$20190415$20221125$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK062135$GLAXOSMITHKLINE$$$$$$Y$$$20221125$$MD$CA$CA
161994715$16199471$5$F$20200701$20221010$20190415$20221014$EXP$$US-SHIRE-US201905194$TAKEDA$$44$YR$$M$Y$59.864$KG$20221014$$HP$US$US
162000754$16200075$4$F$20180301$20221103$20190415$20221110$PER$$US-SA-2018SA126183$SANOFI AVENTIS$$50$YR$A$F$Y$$$20221110$$MD$US$US
162003158$16200315$8$F$20190207$20220928$20190416$20221007$PER$$JP-AMGEN-JPNSP2019059637$AMGEN$$71$YR$E$M$Y$73$KG$20221007$$MD$JP$JP
1620139312$16201393$12$F$20190222$20221206$20190416$20221215$EXP$$DE-ROCHE-2276118$ROCHE$$57$YR$$F$Y$$$20221215$$CN$DE$
1620149315$16201493$15$F$20190402$20221118$20190416$20221128$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-034904$BRISTOL MYERS SQUIBB$$48$YR$A$M$Y$67.2$KG$20221128$$MD$JP$JP
162027562$16202756$2$F$20170520$20221011$20190416$20221012$PER$$US-PFIZER INC-2019158719$PFIZER$$52$YR$$F$Y$$$20221012$$LW$US$US
162034467$16203446$7$F$20190201$20221025$20190416$20221031$EXP$$US-PFIZER INC-2019160345$PFIZER$$77$YR$$M$Y$$$20221031$$CN$US$US
162037485$16203748$5$F$20190101$20190617$20190416$20221201$EXP$$US-PARI RESPIRATORY EQUIPMENT, INC.-2019PAR00026$PARI RESPIRATORY EQUIPMENT$$$$$M$Y$16$KG$20190702$$CN$US$US
162038064$16203806$4$F$20150928$20221005$20190416$20221007$PER$$US-GILEAD-2019-0402307$GILEAD$$52$YR$A$M$Y$$$20221007$$LW$US$US
162038925$16203892$5$F$20150401$20221025$20190416$20221028$PER$$US-GILEAD-2019-0402371$GILEAD$$53$YR$A$M$Y$$$20221028$$LW$US$US
162039628$16203962$8$F$$20221020$20190416$20221028$EXP$$CA-TITAN PHARMACEUTICALS-2019TAN00015$TITAN PHARMACEUTICALS$$2$DY$$M$Y$3$KG$20221027$$CN$CA$CA
162041905$16204190$5$F$20120101$20221027$20190416$20221103$EXP$$US-GILEAD-2019-0402421$GILEAD$$$$A$M$Y$$$20221102$$LW$US$US
162046032$16204603$2$F$20181217$20221025$20190416$20221031$EXP$$DE-JNJFOC-20181227960$JOHNSON AND JOHNSON$$62$YR$A$M$Y$110$KG$20221031$$MD$DE$DE
162049463$16204946$3$F$$20221102$20190416$20221109$EXP$$US-TAKEDA-2019TUS022126$TAKEDA$$$$$M$Y$$$20221109$$CN$US$US
162064336$16206433$6$F$20180424$20221003$20190417$20221009$EXP$$JP-ROCHE-2304978$ROCHE$Yamabe T, Naniwa T, Kimura S, et al. Four cases of macrophage activation syndrome diagnosed after relapse accompanied by serious liver disorder and disseminated intravascular coagulation during tocilizumab therapy for adult-onset Still^s disease.. Proceedings of the 63rd Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology; 14-17 APR 2019, Kyoto-city, Kyoto; 2019. 2019;:813-.$42$YR$$F$Y$53$KG$20221009$$HP$JP$JP
162064506$16206450$6$F$20180925$20221003$20190417$20221010$EXP$$JP-ROCHE-2305013$ROCHE$Yamabe T, Naniwa T, Kimura S, et al Four cases of macrophage activation syndrome diagnosed after relapse accompanied by serious liver disorder and disseminated intravascular coagulation during tocilizumab therapy for adult-onset Still^s disease.. Proceedings of the 63rd Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology; 14-17 APR 2019, Kyoto-city, Kyoto; 2019. 2019;:813-.$80$YR$$F$Y$42$KG$20221010$$HP$JP$JP
162064606$16206460$6$F$20130614$20221003$20190417$20221007$EXP$$JP-ROCHE-2304939$ROCHE$Yamabe T, Naniwa T, Kimura S, et al. Four cases of macrophage activation syndrome diagnosed after relapse accompanied by serious liver disorder and disseminated intravascular coagulation during tocilizumab therapy for adult-onset Still^s disease.. Proceedings of the 63rd Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology; 2019, Kyoto-city, Kyoto 2019;:813-.$56$YR$$F$Y$55$KG$20221007$$HP$JP$JP
162084285$16208428$5$F$20130101$20221025$20190417$20221028$EXP$$US-GILEAD-2019-0402595$GILEAD$$$$A$M$Y$$$20221028$$LW$US$US
162086895$16208689$5$F$20110723$20221026$20190417$20221102$EXP$$US-GILEAD-2019-0402599$GILEAD$$29$YR$A$M$Y$$$20221101$$LW$US$US
1621003311$16210033$11$F$20190315$20220928$20190417$20221003$EXP$$PHHY2019CA063326$NOVARTIS$$57$YR$$F$Y$$$20221003$$CN$CA$CA
162100383$16210038$3$F$$20221005$20190417$20221012$EXP$$PHHY2018DO135766$NOVARTIS$$$$$F$Y$$$20221012$$CN$DO$DO
162102022$16210202$2$F$20190401$20221227$20190418$20221229$EXP$$US-SHIRE-US201912683$TAKEDA$$44$YR$$F$Y$86$KG$20221229$$HP$US$US
1621060931$16210609$31$F$20180712$20221006$20190418$20221018$EXP$$CA-CELLTRION INC.-2018CA021609$CELLTRION$$$$$$Y$$$20221018$$CN$CA$CA
162125554$16212555$4$F$$20221107$20190418$20221114$EXP$$US-PFIZER INC-2019164568$PFIZER$$78$YR$$M$Y$$$20221114$$CN$US$US
162131524$16213152$4$F$20140101$20221101$20190418$20221107$EXP$$US-GILEAD-2019-0402588$GILEAD$$$$A$M$Y$$$20221107$$LW$US$US
1621371116$16213711$16$F$$20221111$20190418$20221115$EXP$$US-PFIZER INC-2018486636$PFIZER$$69$YR$$M$Y$74.84$KG$20221115$$MD$US$US
162140304$16214030$4$F$$20221223$20190418$20221226$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK059003$GLAXOSMITHKLINE$$$$$$Y$$$20221226$$MD$CA$CA
162141669$16214166$9$F$$20221212$20190418$20221217$EXP$$CA-TAKEDA-2019TUS022246$TAKEDA$$39$YR$$M$Y$$$20221217$$CN$CA$CA
162145895$16214589$5$F$20220606$20221024$20190418$20221028$EXP$$US-SHIRE-US201912618$TAKEDA$$15$YR$$M$Y$$$20221028$$HP$US$US
1621537836$16215378$36$F$20180612$20221202$20190419$20221212$EXP$$CA-CELLTRION INC.-2018CA020116$CELLTRION$$$$$$Y$$$20221212$$MD$CA$CA
1621540410$16215404$10$F$20190201$20221003$20190419$20221010$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-037780$BRISTOL MYERS SQUIBB$Akiyama T, Kishino K, Furukawa E, Konno Y, Takei K, Akiyama K, et al. Nivolumab-induced autoimmune haemolytic anaemia. Japanese Journal of Transfusion and Cell Therapy. 2022; 68(4): 486-90.$63$YR$A$M$Y$81$KG$20221010$$MD$JP$JP
1621689914$16216899$14$F$20171214$20221005$20190419$20221012$EXP$$GB-GLAXOSMITHKLINE-GB2019GSK071356$GLAXOSMITHKLINE$$$$$$Y$$$20221012$$MD$GB$GB
1621706214$16217062$14$F$20171214$20221005$20190419$20221012$EXP$$GB-VIIV HEALTHCARE LIMITED-GB2019GSK071356$VIIV$$$$$$Y$$$20221012$$MD$GB$GB
162179372$16217937$2$F$20170423$20220930$20190419$20221004$EXP$$US-TAKEDA-2019TUS023366$TAKEDA$$$$$$Y$$$20221004$$CN$US$US
162179659$16217965$9$F$20190901$20221129$20190419$20221201$PER$$US-PFIZER INC-2019166336$PFIZER$$83$YR$$F$Y$77.551$KG$20221201$$CN$US$US
162188773$16218877$3$F$$20221103$20190419$20221104$EXP$$US-GLAXOSMITHKLINE-US2019GSK071419$GLAXOSMITHKLINE$$$$$M$Y$$$20221104$$MD$US$US
1621979351$16219793$51$F$20190101$20221202$20190420$20221217$EXP$$CA-CELLTRION INC.-2019CA019178$CELLTRION$$$$$$Y$$$20221217$$MD$CA$CA
162207022$16220702$2$F$20120101$20221213$20190421$20221221$PER$$US-JNJFOC-20190413437$JOHNSON AND JOHNSON$$12$YR$T$M$Y$$$20221221$$LW$US$US
1622189414$16221894$14$F$20171225$20221007$20190422$20221013$EXP$$US-SA-2018SA077204$SANOFI AVENTIS$$71$YR$E$F$Y$68.04$KG$20221013$$MD$US$US
1622202731$16222027$31$F$20150101$20221130$20190422$20221212$EXP$GB-EMA-DD20181127N9C8J7154750$GB-Accord-123715$ACCORD$$61$YR$A$F$Y$$$20221212$$MD$GB$GB
162226512$16222651$2$F$$20221108$20190422$20221110$PER$$US-PFIZER INC-2019166505$PFIZER$$61$YR$$M$Y$$$20221110$$HP$US$US
162230633$16223063$3$F$20190404$20220929$20190422$20221007$PER$$US-SA-2019SA109589$SANOFI AVENTIS$$4$YR$C$M$Y$$$20221007$$MD$US$US
1622478010$16224780$10$F$$20221209$20190422$20221215$EXP$$FR-PFIZER INC-2019169286$PFIZER$Massard, C.. Keynote-365 cohort b:Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2019;37 (Supp 7):10.1200/JCO.2019.37.7_suppl.17$$$$M$Y$$$20221215$$HP$FR$FR
1622479010$16224790$10$F$$20221209$20190422$20221215$EXP$$FR-PFIZER INC-2019169230$PFIZER$Massard, C.. Keynote-365 cohort b:Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2019;37 (Suppl 7):10.1200/JCO.2019.37.7_suppl.17$$$$M$Y$$$20221215$$HP$FR$FR
162248593$16224859$3$F$$20220926$20190422$20221003$EXP$$CA-BAYER-2019-074414$BAYER$$47$YR$A$F$Y$95$KG$20221003$$HP$CA$CA
162249843$16224984$3$F$20060101$20221012$20190422$20221020$EXP$$US-AstraZeneca-2019SE56530$ASTRAZENECA$$50$YR$$M$Y$59$KG$20221020$$LW$US$
162250662$16225066$2$F$20130101$20220306$20190422$20221130$EXP$$GB-JNJFOC-20190417076$JOHNSON AND JOHNSON$$59$YR$A$M$Y$$$20221130$$CN$GB$GB
162251348$16225134$8$F$20200401$20221128$20190422$20221205$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK065206$GLAXOSMITHKLINE$$$$$$Y$$$20221205$$MD$CA$CA
1622574415$16225744$15$F$20160128$20221122$20190422$20221128$EXP$$PHHY2011CA110502$NOVARTIS$$52$YR$$F$Y$$$20221128$$HP$CA$CA
1622656823$16226568$23$F$20190107$20221014$20190423$20221027$EXP$$GB-AUROBINDO-AUR-APL-2019-021893$AUROBINDO$$4$MON$$F$Y$3.43$KG$20221027$$MD$GB$GB
162270177$16227017$7$F$$20221014$20190423$20221028$EXP$$CA-APOTEX-2019AP012171$APOTEX$$52$YR$$F$Y$$$20221028$$HP$CA$CA
1622762432$16227624$32$F$20180201$20221003$20190423$20221012$EXP$$CA-MYLANLABS-2019M1034910$MYLAN$$61$YR$$M$Y$$$20221012$$MD$CA$CA
162276544$16227654$4$F$$20221115$20190423$20221117$EXP$$US-PFIZER INC-2019144373$PFIZER$$53$YR$$F$Y$$$20221117$$MD$US$US
162289447$16228944$7$F$20130101$20221026$20190423$20221103$EXP$$US-PFIZER INC-2019167136$PFIZER$$46$YR$$M$Y$63.5$KG$20221103$$CN$US$US
162297395$16229739$5$F$20140701$20221003$20190423$20221005$PER$$US-GILEAD-2019-0402644$GILEAD$$51$YR$A$M$Y$$$20221005$$LW$US$US
162304288$16230428$8$F$20190301$20221125$20190423$20221202$EXP$$PHHY2019GB088308$NOVARTIS$$55$YR$$M$Y$$$20221202$$PH$GB$GB
162304543$16230454$3$F$20150501$20190426$20190423$20221122$EXP$$PHHY2019IT091302$NOVARTIS$Dionisi V, Bellarosa C, Cardano R, Rizzini EL, Ghedini P, Morganti AG et al. Use of radium-223 dichloride in patients with osteonecrosis of the jaw induced by zoledronic acid: report of 2 cases. CLINICAL GENITOURINARY CANCER. 2019;1-6$79$YR$$M$Y$$$20221122$$HP$IT$IT
162304842$16230484$2$F$20170601$20221003$20190423$20221006$EXP$$CA-TAKEDA-2017TUS012807$TAKEDA$$68$YR$$F$Y$$$20221006$$CN$CA$CA
162307425$16230742$5$F$20080327$20221017$20190423$20221025$EXP$$US-AstraZeneca-2019SE58725$ASTRAZENECA$$22481$DY$$F$Y$94.8$KG$20221025$$LW$US$
1623213421$16232134$21$F$20180417$20221005$20190424$20221015$EXP$$CA-CELLTRION INC.-2018CA019845$CELLTRION$$$$$$Y$$$20221015$$CN$CA$CA
162324333$16232433$3$F$$20221014$20190424$20221021$EXP$$CA-APOTEX-2019AP012280$APOTEX$$66$YR$$F$Y$$$20221021$$MD$CA$CA
162324867$16232486$7$F$20190401$20221221$20190424$20221227$EXP$$CA-TAKEDA-2019TUS012343$TAKEDA$$79$YR$$F$Y$$$20221227$$HP$CA$CA
1623254338$16232543$38$F$20190115$20221220$20190424$20221226$EXP$$CH-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-002252$BOEHRINGER INGELHEIM$$78$YR$E$M$Y$68$KG$20221226$$CN$CH$CH
162336992$16233699$2$F$$20221219$20190424$20221222$PER$$US-JNJFOC-20190413640$JOHNSON AND JOHNSON$$$$$M$Y$$$20221222$$LW$US$US
162351393$16235139$3$F$$20220726$20190424$20221005$PER$$US-SHIRE-US201913395$TAKEDA$$$$$M$Y$$$20221005$$HP$US$US
162354416$16235441$6$F$20180622$20221114$20190424$20221117$EXP$$US-AstraZeneca-2019SE10343$ASTRAZENECA$$27417$DY$$F$Y$81.2$KG$20221117$$LW$US$
1623584048$16235840$48$F$20180501$20220912$20190424$20221002$EXP$$CA-CELLTRION INC.-2018CA018603$CELLTRION$$$$$$Y$$$20221003$$CN$CA$CA
1623624430$16236244$30$F$20190314$20221027$20190425$20221111$EXP$$DE-AUROBINDO-AUR-APL-2019-018189$AUROBINDO$$$$A$F$Y$98$KG$20221111$$MD$DE$DE
162369173$16236917$3$F$20190410$20221222$20190425$20221223$EXP$$CA-ROCHE-2305370$ROCHE$$49$YR$$F$Y$$$20221223$$CN$CA$
162374546$16237454$6$F$20170901$20221208$20190425$20221221$EXP$$US-GLAXOSMITHKLINE-US2019GSK074666$PERRIGO$$$$$$Y$$$20221221$$MD$US$US
162384187$16238418$7$F$20181003$20221007$20190425$20221011$EXP$$PHHY2018CA119453$NOVARTIS$$50$YR$$F$Y$$$20221011$$CN$CA$CA
162388325$16238832$5$F$20090101$20221031$20190425$20221102$EXP$$US-TAKEDA-2019TUS024602$TAKEDA$$$$$$Y$$$20221102$$CN$US$US
1623886314$16238863$14$F$20190405$20220929$20190425$20221004$EXP$$US-ROCHE-2299664$ROCHE$$77$YR$$F$Y$57.8$KG$20221004$$MD$US$
162395056$16239505$6$F$20190101$20221013$20190425$20221018$EXP$$US-PFIZER INC-2019171886$PFIZER$$53$YR$$F$Y$$$20221018$$HP$US$US
162397002$16239700$2$F$$20221205$20190425$20221209$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK068107$GLAXOSMITHKLINE$$$$$$Y$$$20221209$$MD$CA$CA
162409317$16240931$7$F$20190201$20221114$20190425$20221117$EXP$$PHHY2019CA051896$NOVARTIS$$52$YR$$F$Y$$$20221117$$MD$CA$CA
1624117412$16241174$12$F$20170601$20221121$20190425$20221125$EXP$$US-ABBVIE-19P-163-2752746-00$ABBVIE$$16$YR$$F$Y$$$20221125$$MD$US$US
1624225628$16242256$28$F$20190416$20221116$20190426$20221123$EXP$$US-SA-2019SA113045$SANOFI AVENTIS$$61$YR$A$M$Y$$$20221123$$MD$US$US
1624235119$16242351$19$F$$20221117$20190426$20221128$EXP$$CA-TEVA-2019-CA-1041136$TEVA$$77$YR$E$F$Y$$$20221126$$HP$CA$CA
162437434$16243743$4$F$20191001$20221005$20190426$20221007$PER$$US-PFIZER INC-2019176317$PFIZER$$69$YR$$F$Y$77.11$KG$20221007$$CN$US$US
162438354$16243835$4$F$20090101$20221031$20190426$20221104$EXP$$US-PFIZER INC-2019181319$PFIZER$$50$YR$$F$Y$$$20221104$$HP$US$US
1624451714$16244517$14$F$$20221101$20190426$20221110$EXP$$CA-APOTEX-2017AP009547$APOTEX$$51$YR$$F$Y$110$KG$20221110$$MD$CA$CA
162452139$16245213$9$F$19800101$20220929$20190426$20221004$PER$$US-PFIZER INC-2018207247$PFIZER$$31$YR$$F$Y$60.78$KG$20221004$$CN$US$US
162453673$16245367$3$F$20190101$20221219$20190426$20221226$EXP$$BR-BIOGEN-2019BI00729128$BIOGEN$$25$YR$$M$Y$$$20221226$$CN$BR$BR
162471218$16247121$8$F$20180322$20221122$20190427$20221130$EXP$$DE-ROCHE-2129945$ROCHE$$42$YR$$F$Y$$$20221130$$CN$DE$
162471283$16247128$3$F$20100101$20221007$20190427$20221011$EXP$$US-TAKEDA-2019TUS024345$TAKEDA$$$$$$Y$$$20221011$$CN$US$US
162508752$16250875$2$F$$20221211$20190429$20221220$EXP$$GB-OTSUKA-2019_014787$OTSUKA$Horgan C, Kanellopoulos A, Paneesha S, Kishore B, Lovell R, Nikolou E. A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid  leukemia, following relapse 18 months post allogeneic stem cell transplant. Hematology Reports. 2019;11:7800$68$YR$$F$Y$$$20221220$$HP$GB$GB
162509802$16250980$2$F$20120705$20221005$20190429$20221006$PER$$US-PFIZER INC-2016584432$PFIZER$$70$YR$$F$Y$$$20221006$$LW$US$US
1625120521$16251205$21$F$20190101$20221221$20190429$20221227$EXP$$US-PFIZER INC-2019176767$PFIZER$$83$YR$$F$Y$63$KG$20221227$$CN$US$US
162518659$16251865$9$F$20190101$20221216$20190429$20221223$EXP$$CA-PFIZER INC-2019041269$PFIZER$$38$YR$$F$Y$$$20221223$$CN$CA$CA
1625335923$16253359$23$F$20180710$20221221$20190429$20221229$EXP$$CA-CELLTRION INC.-2018CA020124$CELLTRION$$$$$$Y$$$20221230$$HP$CA$CA
162553167$16255316$7$F$20180101$20221102$20190430$20221104$EXP$$CA-TAKEDA-2018TUS022374$TAKEDA$$37$YR$$F$Y$$$20221104$$CN$CA$CA
162562876$16256287$6$F$$20221219$20190430$20221222$EXP$$US-PFIZER INC-2019182747$PFIZER$Tseng, S.. INFLAMMATION AND MULTI-ORGAN DYSFUNCTION IN A RECENT PEDIATRIC HEART TRANSPLANT RECIPIENT. Journal of the American College of Cardiology. 2019;73 (9):2730$17$YR$$M$Y$$$20221222$$HP$US$US
1625804811$16258048$11$F$20171218$20221124$20190430$20221130$EXP$$CA-TAKEDA-2018TUS000383$TAKEDA$$57$YR$$M$Y$$$20221130$$CN$CA$CA
162594846$16259484$6$F$$20221126$20190501$20221205$EXP$$JP-ASTELLAS-2019JP007814$ASTELLAS$$31$YR$$F$Y$$$20221205$$CN$JP$JP
1625990719$16259907$19$F$20190321$20221101$20190501$20221109$EXP$$CA-CELLTRION INC.-2019CA019993$CELLTRION$$$$$$Y$$$20221110$$MD$CA$CA
162601434$16260143$4$F$$20221219$20190501$20221222$EXP$$US-PFIZER INC-2019185359$PFIZER$$70$YR$$F$Y$$$20221222$$HP$US$US
162614554$16261455$4$F$$20221113$20190501$20221116$EXP$$CA-PFIZER INC-2019180994$PFIZER$$32$YR$$F$Y$$$20221116$$CN$CA$CA
162614994$16261499$4$F$$20221123$20190501$20221203$EXP$$CA-TEVA-2019-CA-1042426$TEVA$$73$YR$E$F$Y$$$20221203$$HP$CA$CA
162625995$16262599$5$F$20181203$20221130$20190502$20221206$EXP$$CA-TAKEDA-2019TUS000338$TAKEDA$$44$YR$$F$Y$$$20221206$$MD$CA$CA
162636234$16263623$4$F$20190408$20221206$20190502$20221216$EXP$$AU-009507513-1905AUS000335$MERCK$$70$YR$$M$Y$84$KG$20221216$$HP$AU$AU
162641722$16264172$2$F$$20221018$20190502$20221026$PER$$CA-IGSA-SR10008248$GRIFOLS$$3$YR$$F$Y$64$KG$20221026$$HP$CA$CA
162643016$16264301$6$F$20190401$20221129$20190502$20221130$EXP$$CA-ROCHE-2311256$ROCHE$$38$YR$$F$Y$$$20221130$$CN$CA$
1626433812$16264338$12$F$20190301$20221018$20190502$20221027$EXP$$GB-ASPEN-GLO2019GB004102$ASPEN$$$$$$Y$$$20221027$$HP$GB$GB
162645566$16264556$6$F$$20221114$20190502$20221117$EXP$$US-TAKEDA-2019TUS026981$TAKEDA$$$$$$Y$$$20221117$$CN$US$US
1626464427$16264644$27$F$$20221222$20190502$20221229$EXP$$US-PFIZER INC-2019184100$PFIZER$$75$YR$$F$Y$$$20221229$$CN$US$US
162646727$16264672$7$F$$20221103$20190502$20221104$EXP$$US-PFIZER INC-2019183756$PFIZER$$61$YR$$M$Y$$$20221104$$HP$US$US
162646876$16264687$6$F$$20221130$20190502$20221206$PER$$US-PFIZER INC-2019186469$PFIZER$$71$YR$$F$Y$$$20221206$$MD$US$US
1626522820$16265228$20$F$20190101$20221214$20190502$20221224$PER$$NL-AMGEN-NLDSL2019066683$AMGEN$$70$YR$E$F$Y$$$20221224$$MD$NL$NL
162653762$16265376$2$F$$20221017$20190502$20221025$PER$$US-SA-2019SA118668$SANOFI AVENTIS$$64$YR$A$F$Y$$$20221025$$MD$US$US
162660537$16266053$7$F$$20221122$20190502$20221201$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK076212$GLAXOSMITHKLINE$$$$$$Y$$$20221201$$MD$CA$CA
162660663$16266066$3$F$$20221019$20190502$20221026$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK076641$GLAXOSMITHKLINE$$$$$$Y$$$20221026$$HP$CA$CA
162674704$16267470$4$F$20190430$20221102$20190503$20221113$PER$$JP-BEH-2019102034$CSL BEHRING$$15$YR$T$M$Y$62$KG$20221113$$HP$JP$JP
162677042$16267704$2$F$$20221019$20190503$20221031$PER$$US-JNJFOC-20190434199$JOHNSON AND JOHNSON$$$$$M$Y$$$20221031$$LW$US$US
162685302$16268530$2$F$20110310$20221221$20190503$20221227$PER$$US-JNJFOC-20190434214$JOHNSON AND JOHNSON$$12$YR$T$M$Y$$$20221227$$LW$US$US
162695824$16269582$4$F$$20221117$20190503$20221122$PER$$US-PFIZER INC-2018491385$PFIZER$$53$YR$$F$Y$$$20221122$$CN$US$US
162700692$16270069$2$F$20180830$20221130$20190503$20221206$EXP$$FR-MYLANLABS-2019M1041837$MYLAN$$42$YR$$F$Y$75$KG$20221206$$MD$FR$FR
162704914$16270491$4$F$20190307$20221021$20190503$20221028$EXP$$CA-Ipsen Biopharmaceuticals, Inc.-2019-03944$IPSEN$$65$YR$E$F$Y$$$20221028$$HP$CA$CA
162705026$16270502$6$F$20130808$20221207$20190503$20221212$PER$$US-GILEAD-2019-0405255$GILEAD$$48$YR$A$M$Y$$$20221212$$LW$US$US
162712222$16271222$2$F$20140901$20221005$20190503$20221006$PER$$US-PFIZER INC-2016584436$PFIZER$$57$YR$$F$Y$98.866$KG$20221006$$LW$US$US
162744103$16274410$3$F$20190324$20190412$20190506$20221220$PER$$US-TEVA-2019-US-1039592$TEVA$$42$YR$A$F$Y$83$KG$20221220$$CN$US$US
162745845$16274584$5$F$20180801$20221108$20190504$20221114$EXP$$PHHY2018CO129253$NOVARTIS$$52$YR$$F$Y$45$KG$20221114$$CN$CO$CO
162757516$16275751$6$F$$20221130$20190506$20221207$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK080005$GLAXOSMITHKLINE$$$$$$Y$$$20221207$$HP$CA$CA
162765365$16276536$5$F$20020101$20221101$20190506$20221104$EXP$$US-PFIZER INC-2019191405$PFIZER$$37$YR$$M$Y$$$20221104$$LW$US$US
1627662510$16276625$10$F$$20221026$20190506$20221101$PER$$US-PFIZER INC-2019184708$PFIZER$$61$YR$$F$Y$$$20221101$$HP$US$US
162766904$16276690$4$F$$20221206$20190506$20221212$PER$$US-PFIZER INC-2019188315$PFIZER$$65$YR$$F$Y$$$20221212$$CN$US$US
1627694213$16276942$13$F$20190408$20221212$20190506$20221220$PER$$US-PFIZER INC-2019185847$PFIZER$$63$YR$$F$Y$122.45$KG$20221220$$CN$US$US
162771053$16277105$3$F$$20221123$20190506$20221128$PER$$US-PFIZER INC-2019189065$PFIZER$$71$YR$$F$Y$$$20221128$$CN$US$US
162780215$16278021$5$F$20181217$20221222$20190506$20221230$EXP$$JP-PFIZER INC-2019181747$PFIZER$$75$YR$$F$Y$54.7$KG$20221230$$MD$JP$JP
162783157$16278315$7$F$20190205$20221201$20190506$20221208$EXP$$CA-TAKEDA-2019TUS012194$TAKEDA$$43$YR$$F$Y$$$20221208$$CN$CA$CA
162783543$16278354$3$F$20130101$20221006$20190506$20221014$EXP$$US-AstraZeneca-2019SE61557$ASTRAZENECA$$34$YR$$F$Y$65.8$KG$20221014$$LW$US$
1627851310$16278513$10$F$20190101$20221129$20190506$20221202$EXP$$US-INCYTE CORPORATION-2019IN004341$INCYTE$$$$$$Y$$$20221202$$CN$US$US
1627895614$16278956$14$F$20190524$20221202$20190506$20221209$EXP$$PHHY2018CA004055$NOVARTIS$$60$YR$$M$Y$$$20221209$$MD$CA$CA
162790443$16279044$3$F$$20221205$20190506$20221212$EXP$$US-JAZZ-2019-US-005106$JAZZ$$$$$F$Y$$$20221212$$MD$US$US
162793548$16279354$8$F$20190412$20221216$20190507$20221223$EXP$$CA-TAKEDA-2019TUS027794$TAKEDA$$81$YR$$M$Y$$$20221223$$MD$CA$CA
1627989818$16279898$18$F$20190301$20221122$20190507$20221129$EXP$$CA-ROCHE-2313701$ROCHE$$84$YR$$F$Y$59$KG$20221129$$MD$CA$CA
1628028431$16280284$31$F$$20221222$20190507$20221226$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK078216$GLAXOSMITHKLINE$$$$$$Y$$$20221226$$MD$CA$CA
162814435$16281443$5$F$$20221123$20190507$20221128$PER$$US-PFIZER INC-2019187908$PFIZER$$80$YR$$F$Y$81.633$KG$20221128$$HP$US$US
162814554$16281455$4$F$$20221123$20190507$20221124$PER$$US-PFIZER INC-2019187928$PFIZER$$80$YR$$F$Y$81.65$KG$20221124$$HP$US$US
162814804$16281480$4$F$$20221109$20190507$20221114$EXP$$US-PFIZER INC-2019188409$PFIZER$$61$YR$$M$Y$104.31$KG$20221114$$CN$US$US
162816094$16281609$4$F$20150102$20221117$20190507$20221122$EXP$$US-PFIZER INC-2019191375$PFIZER$$46$YR$$M$Y$$$20221122$$LW$US$US
162819346$16281934$6$F$20090101$20221220$20190507$20221221$EXP$$US-PFIZER INC-2019189421$PFIZER$$44$YR$$F$Y$$$20221221$$LW$US$US
162822187$16282218$7$F$20010101$20221011$20190507$20221018$EXP$$US-PFIZER INC-2018176937$PFIZER$$34$YR$$M$Y$$$20221018$$LW$US$US
162831515$16283151$5$F$20170822$20221109$20190507$20221114$EXP$$US-PFIZER INC-2019184728$PFIZER$$77$YR$$F$Y$$$20221114$$CN$US$US
162831993$16283199$3$F$20100101$20221212$20190507$20221220$EXP$$US-AstraZeneca-2019SE62586$ASTRAZENECA$$64$YR$$M$Y$105.2$KG$20221220$$LW$US$
1628343911$16283439$11$F$$20221017$20190507$20221025$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK079995$GLAXOSMITHKLINE$$$$$$Y$$$20221025$$MD$CA$CA
162835233$16283523$3$F$20080716$20221212$20190507$20221220$EXP$$US-AstraZeneca-2019SE62684$ASTRAZENECA$$19254$DY$$F$Y$59.4$KG$20221215$$LW$US$
1628433718$16284337$18$F$20171117$20221104$20190508$20221115$EXP$$CA-CELLTRION INC.-2017CA017476$CELLTRION$$$$$$Y$$$20221115$$CN$CA$CA
162847585$16284758$5$F$20190501$20221109$20190508$20221111$EXP$$JP-ABBVIE-19S-087-2773121-00$ABBVIE$$68$YR$$M$Y$$$20221111$$MD$JP$JP
162847837$16284783$7$F$$20221219$20190508$20221223$EXP$$US-ALEXION PHARMACEUTICALS INC.-A201906645$ALEXION$$$$E$F$Y$$$20221223$$CN$US$US
162849563$16284956$3$F$20180831$20221215$20190508$20221223$EXP$$US-AstraZeneca-2019SE59898$ASTRAZENECA$$25701$DY$$F$Y$74.8$KG$20221223$$LW$US$
1628497115$16284971$15$F$20181012$20221114$20190508$20221121$EXP$$DE-ROCHE-2239868$ROCHE$$32$YR$$F$Y$49$KG$20221121$$CN$DE$
162851373$16285137$3$F$20160318$20221004$20190508$20221012$EXP$$US-AstraZeneca-2018SF00046$ASTRAZENECA$$25199$DY$$M$Y$86.6$KG$20221012$$LW$US$
1628675011$16286750$11$F$20190429$20221206$20190508$20221207$EXP$$PHHO2019US004866$NOVARTIS$$70$YR$$M$Y$$$20221207$$MD$US$US
162868127$16286812$7$F$20190404$20221104$20190508$20221114$EXP$$CA-TAKEDA-2019TUS027348$TAKEDA$$49$YR$$M$Y$$$20221114$$MD$CA$CA
162876875$16287687$5$F$20020101$20221024$20190508$20221102$EXP$$US-AstraZeneca-2019SE62696$ASTRAZENECA$$37$YR$$M$Y$86.2$KG$20221102$$LW$US$
162882342$16288234$2$F$20160618$20221116$20190508$20221117$EXP$PHHY2019GB104937$PHHY2019GB104937$NOVARTIS$$33$YR$$M$Y$$$20221117$$HP$GB$GB
162886874$16288687$4$F$20190101$20221019$20190509$20221028$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-012732$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221028$$CN$US$US
162887214$16288721$4$F$20190101$20221213$20190509$20221221$EXP$$US-TAKEDA-2019TUS028178$TAKEDA$$71$YR$$M$Y$$$20221221$$HP$US$US
162897613$16289761$3$F$20150722$20221005$20190509$20221013$EXP$$US-AstraZeneca-2019SE63169$ASTRAZENECA$$26678$DY$$F$Y$98$KG$20221013$$LW$US$
162900332$16290033$2$F$$20220926$20190509$20221004$EXP$$CA-BAYER-2019-087608$BAYER$$73$YR$E$F$Y$99$KG$20221004$$HP$CA$CA
162904634$16290463$4$F$20150101$20221128$20190509$20221213$EXP$$US-GLAXOSMITHKLINE-US2019GSK081785$GLAXOSMITHKLINE$$$$$F$Y$95.238$KG$20221213$$MD$US$US
162910879$16291087$9$F$$20221107$20190509$20221114$EXP$$US-PFIZER INC-2019195255$PFIZER$$57$YR$$F$Y$$$20221114$$CN$US$US
162913422$16291342$2$F$20180907$20221003$20190509$20221004$EXP$FR-AFSSAPS-NT20190454$FR-PFIZER INC-2019193993$PFIZER$$33$YR$$F$Y$$$20221004$$MD$FR$FR
1629159812$16291598$12$F$$20221109$20190509$20221121$EXP$$CA-GLAXOSMITHKLINE-CA2019080821$GLAXOSMITHKLINE$$$$$M$Y$$$20221121$$MD$CA$CA
1629166622$16291666$22$F$20190403$20221114$20190509$20221122$EXP$$CA-TAKEDA-2019TUS008469$TAKEDA$$60$YR$$F$Y$$$20221122$$MD$CA$CA
162918126$16291812$6$F$$20221219$20190509$20221228$EXP$$CA-BAYER-2019-087631$BAYER$$44$YR$A$F$Y$63$KG$20221228$$MD$CA$CA
1629213714$16292137$14$F$20190402$20221219$20190509$20221222$EXP$$FR-ABBVIE-19K-056-2752982-00$ABBVIE$$84$YR$$F$Y$78$KG$20221222$$MD$FR$FR
162921926$16292192$6$F$20190201$20221114$20190509$20221121$EXP$$DK-ALLERGAN-1918916US$ALLERGAN$$$$$M$Y$74$KG$20221121$$MD$DK$DK
162923753$16292375$3$F$20140101$20221206$20190509$20221215$EXP$$US-AstraZeneca-2019SE65340$ASTRAZENECA$$50$YR$$F$Y$92.5$KG$20221215$$LW$US$
162923763$16292376$3$F$20060101$20221003$20190509$20221011$EXP$$US-AstraZeneca-2019SE63143$ASTRAZENECA$$46$YR$$F$Y$$$20221011$$LW$US$
162923774$16292377$4$F$20130101$20221213$20190509$20221221$EXP$$US-AstraZeneca-2019SE62738$ASTRAZENECA$$63$YR$$M$Y$102.5$KG$20221221$$LW$US$
162924043$16292404$3$F$20070904$20221213$20190509$20221220$EXP$$US-AstraZeneca-2019SE66909$ASTRAZENECA$$18090$DY$$F$Y$$$20221216$$LW$US$
162924053$16292405$3$F$20100421$20221031$20190509$20221107$EXP$$US-AstraZeneca-2019SE65157$ASTRAZENECA$$24146$DY$$F$Y$63.5$KG$20221107$$LW$US$
1629243410$16292434$10$F$20190101$20221108$20190509$20221114$EXP$$US-PFIZER INC-2019196798$PFIZER$$63$YR$$M$Y$125$KG$20221114$$CN$US$US
1629615133$16296151$33$F$20160629$20221018$20190509$20221025$EXP$$PHHY2016CA077409$NOVARTIS$$68$YR$$M$Y$$$20221025$$CN$CA$CA
162962225$16296222$5$F$20190401$20221115$20190510$20221117$PER$$US-PFIZER INC-2019199122$PFIZER$$67$YR$$F$Y$$$20221117$$CN$US$US
162967989$16296798$9$F$20190220$20221122$20190510$20221201$PER$$JP-AMGEN-JPNSP2019071586$AMGEN$$54$YR$A$F$Y$70.5$KG$20221130$$MD$JP$JP
162968473$16296847$3$F$20190420$20221111$20190510$20221116$EXP$$US-Horizon-PRO-0098-2019$HORIZON THERAPEUTICS$$$$$$Y$$$20221116$$CN$US$US
162975049$16297504$9$F$$20221017$20190510$20221020$EXP$$US-PFIZER INC-2019199478$PFIZER$$75$YR$$F$Y$$$20221020$$CN$US$US
163001504$16300150$4$F$20100101$20221115$20190510$20221123$EXP$$US-AstraZeneca-2019SE64904$ASTRAZENECA$$58$YR$$F$Y$$$20221123$$LW$US$
163003665$16300366$5$F$20151001$20221031$20190510$20221104$EXP$$US-AstraZeneca-2019SE65940$ASTRAZENECA$$696$MON$$F$Y$136.1$KG$20221104$$LW$US$
1630166412$16301664$12$F$$20221112$20190511$20221127$EXP$$CA-TEVA-2019-CA-1046238$TEVA$$58$YR$A$F$Y$$$20221125$$MD$CA$CA
163019663$16301966$3$F$20101231$20221110$20190512$20221117$EXP$$PHHY2011CA03040$NOVARTIS$$53$YR$$F$Y$$$20221117$$CN$CA$CA
163019927$16301992$7$F$20190501$20221214$20190512$20221221$EXP$$PHHY2019CA107206$NOVARTIS$$20$YR$$F$Y$$$20221221$$CN$CA$CA
163042563$16304256$3$F$20170601$20221027$20190513$20221103$EXP$$DE-MYLANLABS-2019M1045795$MYLAN$$66$YR$$M$Y$$$20221103$$LW$DE$DE
163052212$16305221$2$F$20180101$20221118$20190513$20221128$EXP$$AT-MYLANLABS-2019M1044133$MYLAN$Rainer M.. Dementia - A syndromatological chameleon.. psychopraxis: neuropraxis.. 2018;21:158-163$$$E$M$Y$$$20221128$$MD$AT$AT
163057735$16305773$5$F$20140101$20221025$20190513$20221102$EXP$$US-AstraZeneca-2019SE65615$ASTRAZENECA$$62$YR$$F$Y$87.5$KG$20221102$$LW$US$
163058643$16305864$3$F$20140101$20221103$20190513$20221111$EXP$$US-AstraZeneca-2019SE65290$ASTRAZENECA$$50$YR$$F$Y$$$20221111$$LW$US$
163065675$16306567$5$F$20020101$20221005$20190513$20221010$EXP$$US-AstraZeneca-2019SE63759$ASTRAZENECA$$42$YR$$F$Y$136.1$KG$20221010$$LW$US$
163067504$16306750$4$F$20130831$20221005$20190513$20221013$EXP$$US-AstraZeneca-2019SE66031$ASTRAZENECA$$16535$DY$$F$Y$$$20221013$$LW$US$
163067953$16306795$3$F$20140430$20221205$20190513$20221209$EXP$$US-AstraZeneca-2019SE66059$ASTRAZENECA$$18280$DY$$F$Y$59$KG$20221209$$LW$US$
163069405$16306940$5$F$$20221201$20190513$20221208$EXP$$US-JAZZ-2019-US-006522$JAZZ$$$$$F$Y$$$20221208$$MD$US$US
163082223$16308222$3$F$20140101$20220926$20190514$20221005$EXP$$US-AstraZeneca-2019SE66873$ASTRAZENECA$$74$YR$$F$Y$74.8$KG$20221005$$LW$US$
163091673$16309167$3$F$20181219$20220927$20190514$20221003$EXP$$US-PFIZER INC-2018535942$PFIZER$$58$YR$$F$Y$$$20221003$$HP$US$US
163096415$16309641$5$F$20020101$20221101$20190514$20221107$EXP$$US-TAKEDA-2019TUS029316$TAKEDA$$$$$$Y$$$20221107$$CN$US$US
163101365$16310136$5$F$20190429$20221222$20190514$20221228$EXP$$DE-ROCHE-2242981$ROCHE$$57$YR$$F$Y$$$20221228$$CN$DE$
1631015113$16310151$13$F$20180523$20221128$20190514$20221202$EXP$$CA-ROCHE-2130233$ROCHE$$34$YR$$F$Y$$$20221202$$CN$CA$
163105843$16310584$3$F$20070419$20221031$20190514$20221109$EXP$$US-AstraZeneca-2019SE67490$ASTRAZENECA$$24648$DY$$F$Y$72.6$KG$20221109$$LW$US$
163106624$16310662$4$F$20090101$20221213$20190514$20221215$EXP$$US-TAKEDA-2019TUS029405$TAKEDA$$$$$$Y$$$20221215$$CN$US$US
163111005$16311100$5$F$$20221213$20190514$20221221$EXP$$US-GLAXOSMITHKLINE-US2019GSK082695$PERRIGO$$$$$$Y$$$20221221$$CN$US$US
1631112221$16311122$21$F$20190101$20221027$20190514$20221103$EXP$$PHHY2019CA077093$NOVARTIS$$$$$F$Y$96.7$KG$20221103$$CN$CA$CA
163115732$16311573$2$F$$20221202$20190514$20221212$EXP$$US-SHIRE-US201911488AA$TAKEDA$$$$$F$Y$47$KG$20221212$$MD$US$US
1631178115$16311781$15$F$20190409$20221222$20190514$20221227$EXP$$PHHY2017CA070109$NOVARTIS$$67$YR$$F$Y$$$20221227$$CN$CA$CA
1631237215$16312372$15$F$20190528$20221025$20190515$20221028$EXP$$CA-TAKEDA-2019TUS028408$TAKEDA$$58$YR$$M$Y$$$20221028$$CN$CA$CA
1631250910$16312509$10$F$20181022$20221202$20190515$20221206$PER$$JP-AMGEN-JPNSP2019074298$AMGEN$$78$YR$E$F$Y$38.1$KG$20221205$$MD$JP$JP
163127614$16312761$4$F$$20221017$20190515$20221019$EXP$$US-ROCHE-2315480$ROCHE$Chu G, Salzman J Hyperammonemia after capecitabine associated with occult impairment of the urea cycle. DOI: 10.1002/cam4.2036. Cancer medicine NLM (Medline) 2019 Apr 11;8:1996-2004.$67$YR$$F$Y$$$20221019$$HP$US$
1631284919$16312849$19$F$20160722$20220110$20190515$20221207$EXP$$PHHY2016DE143742$NOVARTIS$$64$YR$$M$Y$69$KG$20221207$$MD$DE$DE
1631302515$16313025$15$F$20170501$20221213$20190515$20221220$EXP$$CA-ROCHE-2318618$ROCHE$$54$YR$$F$Y$$$20221220$$CN$CA$CA
163138182$16313818$2$F$20121201$20221005$20190515$20221006$PER$$US-PFIZER INC-2019202140$PFIZER$$65$YR$$F$Y$$$20221006$$LW$US$US
163138802$16313880$2$F$20220701$20221003$20190515$20221005$PER$$US-PFIZER INC-2019204332$PFIZER$$57$YR$$F$Y$$$20221005$$CN$US$US
163139058$16313905$8$F$20190312$20221215$20190515$20221221$30DAY$$US-PFIZER INC-2019203031$PFIZER$$63$YR$$F$Y$58.51$KG$20221221$$CN$US$US
163144144$16314414$4$F$20190501$20221128$20190515$20221201$EXP$$CA-ROCHE-2319242$ROCHE$$58$YR$$M$Y$$$20221201$$CN$CA$
163163679$16316367$9$F$$20221220$20190515$20221222$EXP$$CA-TAKEDA-2019TUS000696$TAKEDA$$50$YR$$F$Y$$$20221222$$CN$CA$CA
1631691633$16316916$33$F$20180925$20221121$20190515$20221129$EXP$$CA-CELLTRION INC.-2018CA023092$CELLTRION$$$$$$Y$$$20221129$$CN$CA$CA
163175563$16317556$3$F$20190322$20191017$20190516$20221012$EXP$$US-CELLTRION INC.-2019US019995$CELLTRION$$$$$$Y$$$20221012$$HP$US$US
163176837$16317683$7$F$20190404$20221019$20190516$20221021$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-046147$BRISTOL MYERS SQUIBB$$71$YR$E$M$Y$65$KG$20221021$$MD$JP$JP
163178725$16317872$5$F$$20221014$20190516$20221017$PER$$US-BIOGEN-2019BI00736261$BIOGEN$$$$$M$Y$$$20221017$$CN$US$US
163202119$16320211$9$F$20200301$20221213$20190516$20221219$EXP$$US-PFIZER INC-2019208886$PFIZER$$71$YR$$F$Y$44$KG$20221219$$HP$US$US
163203007$16320300$7$F$20040101$20221109$20190516$20221111$PER$$US-PFIZER INC-2018531148$PFIZER$$61$YR$$F$Y$$$20221111$$MD$US$US
163205245$16320524$5$F$20190301$20221003$20190516$20221005$EXP$$US-PFIZER INC-2019204795$PFIZER$$70$YR$$F$Y$70.748$KG$20221005$$CN$US$US
163206929$16320692$9$F$20190501$20221019$20190516$20221024$EXP$$PHHY2019CA111105$NOVARTIS$$63$YR$$F$Y$$$20221024$$MD$CA$CA
1632071310$16320713$10$F$20180101$20221110$20190516$20221118$EXP$$US-BAUSCH-BL-2019-013298$BAUSCH AND LOMB$$36$YR$$M$Y$99.88$KG$20221118$$CN$US$US
1632107011$16321070$11$F$$20221213$20190516$20221219$EXP$$US-PFIZER INC-2019208177$PFIZER$$72$YR$$F$Y$$$20221219$$CN$US$US
1632218511$16322185$11$F$20170101$20221011$20190516$20221014$EXP$$US-PFIZER INC-2019205677$PFIZER$$74$YR$$F$Y$58.957$KG$20221014$$MD$US$US
1632257312$16322573$12$F$20180301$20220929$20190516$20221006$EXP$$US-TAKEDA-2019TUS014254$TAKEDA$$69$YR$$M$Y$123$KG$20221006$$CN$US$US
163226172$16322617$2$F$20190427$20221124$20190516$20221130$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-046696$BRISTOL MYERS SQUIBB$$72$YR$E$M$Y$61$KG$20221130$$HP$JP$JP
163226513$16322651$3$F$20110101$20221115$20190516$20221117$EXP$$US-TAKEDA-2019TUS030641$TAKEDA$$$$$$Y$$$20221117$$CN$US$US
163227952$16322795$2$F$$20221020$20190516$20221021$EXP$$US-KYOWAKIRIN-2019BKK001871$KYOWA$$$$$$Y$$$20221021$$CN$US$US
1632282714$16322827$14$F$$20221025$20190516$20221101$PER$$AR-AMGEN-ARGSL2019047426$AMGEN$$69$YR$E$F$Y$$$20221101$$CN$AR$AR
163232943$16323294$3$F$20190514$20221109$20190517$20221111$EXP$$US-SHIRE-US201916033$TAKEDA$$76$YR$$F$Y$$$20221111$$HP$US$US
163234373$16323437$3$F$20220914$20221103$20190517$20221128$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-012844$ACADIA PHARMACEUTICALS$$84$YR$$M$Y$$$20221128$$CN$US$US
163234703$16323470$3$F$20080327$20221017$20190517$20221018$EXP$$US-TAKEDA-2019TUS030397$TAKEDA$$$$$$Y$$$20221018$$CN$US$US
163234863$16323486$3$F$$20200407$20190517$20221012$PER$$US-CELLTRION INC.-2019US018612$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
1632354724$16323547$24$F$20190131$20221219$20190517$20221223$EXP$$DE-ROCHE-2267069$ROCHE$$57$YR$$M$Y$$$20221223$$CN$DE$
163238573$16323857$3$F$20140101$20221006$20190517$20221010$EXP$$US-TAKEDA-2019TUS030096$TAKEDA$$$$$$Y$$$20221010$$CN$US$US
163240513$16324051$3$F$20190204$20200121$20190517$20221012$PER$$US-CELLTRION INC.-2019US018609$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
163243762$16324376$2$F$20190422$20221206$20190517$20221220$EXP$$IT-AUROBINDO-AUR-APL-2019-027026$AUROBINDO$$30$YR$$F$Y$$$20221220$$MD$IT$IT
1632504825$16325048$25$F$20190424$20221205$20190517$20221215$EXP$$CA-CELLTRION INC.-2019CA019782$CELLTRION$$$$$$Y$$$20221214$$CN$CA$CA
1632522527$16325225$27$F$20180101$20220930$20190517$20221010$EXP$$CA-CELLTRION INC.-2018CA024843$CELLTRION$$$$$$Y$$$20221010$$CN$CA$CA
163258824$16325882$4$F$$20210603$20190517$20221209$EXP$$US-PFIZER INC-2019205584$PFIZER$$75$YR$$M$Y$$$20221209$$HP$US$US
1632594812$16325948$12$F$20181221$20221205$20190517$20221219$PER$$JP-AMGEN-JPNSP2019077663$AMGEN$$68$YR$E$F$Y$40$KG$20221219$$MD$JP$JP
163263467$16326346$7$F$20181027$20221027$20190517$20221103$EXP$$GB-PFIZER INC-2019211267$PFIZER$$39$YR$$M$Y$91$KG$20221103$$CN$GB$GB
163281074$16328107$4$F$20130628$20221007$20190518$20221011$EXP$$US-TAKEDA-2019TUS030709$TAKEDA$$$$$$Y$$$20221011$$CN$US$US
1632814323$16328143$23$F$20180712$20221119$20190518$20221203$EXP$$DE-AUROBINDO-AUR-APL-2019-027522$AUROBINDO$$43$YR$$F$Y$116.3$KG$20221203$$CN$DE$DE
163298635$16329863$5$F$20180221$20221118$20190520$20221201$PER$$JP-AMGEN-JPNCT2019078177$AMGEN$$80$YR$E$M$Y$$$20221201$$MD$JP$JP
163304395$16330439$5$F$$20221212$20190520$20221219$PER$$CA-AMGEN-CANSP2019077526$AMGEN$$70$YR$E$F$Y$$$20221219$$HP$CA$CA
163304425$16330442$5$F$$20221212$20190520$20221218$PER$$CA-AMGEN-CANSP2019077665$AMGEN$$$$$F$Y$$$20221218$$MD$CA$CA
163306885$16330688$5$F$$20221111$20190520$20221116$EXP$$US-TAKEDA-2019TUS030737$TAKEDA$$$$$$Y$$$20221116$$CN$US$US
163310033$16331003$3$F$20181101$20221207$20190520$20221216$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-011869$ACADIA PHARMACEUTICALS$$66$YR$$M$Y$$$20221216$$CN$US$US
163313668$16331366$8$F$20190101$20221107$20190520$20221117$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-011981$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221117$$CN$US$US
163316952$16331695$2$F$20190301$20221012$20190520$20221020$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-012231$ACADIA PHARMACEUTICALS$$85$YR$$F$Y$$$20221021$$CN$US$US
1633171812$16331718$12$F$20190603$20221212$20190520$20221222$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-012245$ACADIA PHARMACEUTICALS$$76$YR$$M$Y$$$20221222$$CN$US$US
163319965$16331996$5$F$20190101$20221026$20190520$20221117$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-012527$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221118$$CN$US$US
163320953$16332095$3$F$20190401$20221221$20190520$20221229$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-012612$ACADIA PHARMACEUTICALS$$61$YR$$M$Y$$$20221230$$HP$US$US
163322075$16332207$5$F$$20221202$20190520$20221207$EXP$$US-PFIZER INC-2019212977$PFIZER$$70$YR$$F$Y$$$20221207$$CN$US$US
163323673$16332367$3$F$$20221129$20190520$20221201$PER$$US-PFIZER INC-2019207542$PFIZER$$55$YR$$M$Y$$$20221201$$CN$US$US
1633264812$16332648$12$F$20190101$20221108$20190520$20221110$PER$$US-PFIZER INC-2019210972$PFIZER$$66$YR$$F$Y$$$20221110$$CN$US$US
163327893$16332789$3$F$$20221220$20190520$20221227$PER$$US-PFIZER INC-2019211556$PFIZER$$76$YR$$F$Y$47.63$KG$20221227$$CN$US$US
163328096$16332809$6$F$$20221129$20190520$20221201$PER$$US-PFIZER INC-2019211724$PFIZER$$81$YR$$F$Y$$$20221201$$MD$US$US
163331323$16333132$3$F$19920101$20221213$20190520$20221219$EXP$$US-TAKEDA-2019TUS031211$TAKEDA$$$$$$Y$$$20221219$$CN$US$US
163331416$16333141$6$F$$20221216$20190520$20221228$PER$$US-PFIZER INC-2019209431$PFIZER$$71$YR$$F$Y$$$20221228$$CN$US$US
163338483$16333848$3$F$$20221031$20190520$20221101$EXP$$US-TAKEDA-2019TUS030713$TAKEDA$$$$$$Y$$$20221101$$CN$US$US
163341354$16334135$4$F$20110812$20221102$20190520$20221107$EXP$$US-TAKEDA-2019TUS030662$TAKEDA$$$$$$Y$$$20221107$$CN$US$US
163348453$16334845$3$F$$20221117$20190520$20221125$EXP$$US-JAZZ-2019-US-006762$JAZZ$$$$$F$Y$$$20221125$$HP$US$US
1633528539$16335285$39$F$20181105$20221202$20190521$20221212$EXP$$CA-CELLTRION INC.-2018CA023907$CELLTRION$$$$$$Y$$$20221212$$HP$CA$CA
163359437$16335943$7$F$20221020$20221221$20190521$20221228$EXP$$US-SHIRE-US201916431$TAKEDA$$45$YR$$F$Y$$$20221228$$HP$US$US
163374054$16337405$4$F$$20221129$20190521$20221206$EXP$$US-PFIZER INC-2019212646$PFIZER$Gutierrez, G.. Shall we try angiotensin II (Too)? Treatment of refractory shock due to co-ingestion of amlodipine and benazepril: A case report. Journal of Medical Toxicology. 2019;15 (2):62$57$YR$$M$Y$$$20221206$$HP$US$US
163385614$16338561$4$F$20180822$20221007$20190521$20221011$PER$$DE-AMGEN-DEUNI2019077630$AMGEN$$79$YR$E$F$Y$77$KG$20221011$$MD$DE$DE
163386733$16338673$3$F$20190424$20221222$20190521$20221227$PER$$DE-AMGEN-DEUNI2019077621$AMGEN$$67$YR$E$M$Y$85$KG$20221226$$MD$DE$DE
163390354$16339035$4$F$20170907$20221103$20190521$20221107$EXP$$US-TAKEDA-2019TUS030325$TAKEDA$$$$$$Y$$$20221107$$CN$US$US
1634008517$16340085$17$F$20181121$20220909$20190522$20221003$EXP$$CA-CELLTRION INC.-2018CA023742$CELLTRION$$$$$$Y$$$20221004$$MD$CA$CA
1634036122$16340361$22$F$20190101$20221018$20190522$20221026$EXP$$CA-CELLTRION INC.-2019CA021288$CELLTRION$$$$$$Y$$$20221026$$CN$CA$CA
163408897$16340889$7$F$$20221205$20190522$20221219$EXP$$CA-AUROBINDO-AUR-APL-2019-027485$AUROBINDO$$23$YR$$F$Y$$$20221219$$HP$CA$CA
163408995$16340899$5$F$$20221205$20190522$20221218$EXP$$CA-AUROBINDO-AUR-APL-2019-027458$AUROBINDO$$20$YR$$M$Y$$$20221218$$HP$CA$CA
163417884$16341788$4$F$20190201$20221220$20190522$20221228$EXP$$DE-ROCHE-2270829$ROCHE$$48$YR$$F$Y$$$20221228$$CN$DE$
163419054$16341905$4$F$20180101$20221107$20190522$20221111$EXP$$US-GILEAD-2019-0409083$GILEAD$$37$YR$A$F$Y$$$20221111$$LW$US$US
163421593$16342159$3$F$20130101$20221025$20190522$20221028$PER$$US-GILEAD-2019-0409046$GILEAD$$53$YR$A$M$Y$$$20221028$$LW$US$US
163429355$16342935$5$F$19991101$20221104$20190522$20221108$EXP$$US-TAKEDA-2019TUS031634$TAKEDA$$$$$$Y$$$20221108$$CN$US$US
163438605$16343860$5$F$$20221212$20190522$20221220$EXP$$CA-PFIZER INC-2019217974$PFIZER$$$$$F$Y$$$20221220$$CN$CA$CA
163440535$16344053$5$F$20190407$20221031$20190522$20221104$PER$$DE-AMGEN-DEUNI2019077675$AMGEN$$70$YR$E$M$Y$92$KG$20221103$$MD$DE$DE
1634405612$16344056$12$F$20190225$20221212$20190522$20221215$EXP$$FR-ABBVIE-19K-056-2713273-00$ABBVIE$$79$YR$$M$Y$74$KG$20221215$$MD$FR$FR
163441754$16344175$4$F$$20221011$20190522$20221017$EXP$$US-TAKEDA-2019TUS031530$TAKEDA$$$$$$Y$$$20221017$$CN$US$US
163444033$16344403$3$F$$20221117$20190522$20221122$EXP$$US-PFIZER INC-2019211887$PFIZER$$74$YR$$F$Y$63.5$KG$20221122$$CN$US$US
163445003$16344500$3$F$$20221018$20190522$20221020$PER$$US-PFIZER INC-2019217492$PFIZER$$67$YR$$M$Y$$$20221020$$CN$US$US
163462355$16346235$5$F$$20221129$20190523$20221214$EXP$$CA-AUROBINDO-AUR-APL-2019-027597$AUROBINDO$$54$YR$$M$Y$$$20221214$$HP$CA$CA
163462933$16346293$3$F$$20221020$20190523$20221024$PER$$US-PFIZER INC-2019212053$PFIZER$$66$YR$$F$Y$$$20221024$$MD$US$US
163463833$16346383$3$F$20080101$20221214$20190523$20221221$EXP$$US-TAKEDA-2019TUS031315$TAKEDA$$$$$$Y$$$20221221$$CN$US$US
1634652814$16346528$14$F$20180822$20221228$20190523$20221230$EXP$$PHHY2019DE114978$NOVARTIS$$49$YR$$F$Y$78$KG$20221230$$MD$DE$DE
163467825$16346782$5$F$20170317$20221011$20190523$20221017$EXP$$US-TAKEDA-2019TUS031682$TAKEDA$$$$$$Y$$$20221017$$CN$US$US
1634717315$16347173$15$F$20190501$20221115$20190523$20221119$EXP$$PHHY2019CA113991$NOVARTIS$$36$YR$$M$Y$$$20221119$$HP$CA$CA
163475623$16347562$3$F$20060101$20221213$20190523$20221219$EXP$$US-TAKEDA-2019TUS031352$TAKEDA$$$$$$Y$$$20221219$$CN$US$US
1634766815$16347668$15$F$20181001$20221215$20190523$20221222$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-114352$BRISTOL MYERS SQUIBB$$75$YR$E$M$Y$$$20221222$$MD$JP$JP
163478012$16347801$2$F$20180901$20221124$20190523$20221130$EXP$FR-AFSSAPS-AN20181011$FR-MYLANLABS-2019M1047185$MYLAN$$73$YR$$M$Y$$$20221130$$MD$FR$FR
163482464$16348246$4$F$20110101$20221206$20190523$20221216$EXP$$US-TAKEDA-2019TUS031317$TAKEDA$$$$$$Y$$$20221216$$CN$US$US
163489459$16348945$9$F$20181001$20221108$20190523$20221111$EXP$$FR-SHIRE-FR201915968$TAKEDA$$$$A$F$Y$46$KG$20221111$$HP$FR$FR
163496526$16349652$6$F$$20221123$20190523$20221128$EXP$$US-PFIZER INC-2019218245$PFIZER$$78$YR$$F$Y$$$20221128$$CN$US$US
163496602$16349660$2$F$$20221110$20190523$20221115$EXP$$JP-PFIZER INC-2019208165$PFIZER$$$$$F$Y$$$20221115$$PH$JP$JP
163500273$16350027$3$F$20140101$20221207$20190523$20221209$EXP$$US-TAKEDA-2019TUS031203$TAKEDA$$$$$$Y$$$20221209$$CN$US$US
1635059218$16350592$18$F$20181124$20221205$20190524$20221213$PER$$JP-AMGEN-JPNSP2019080110$AMGEN$$74$YR$E$F$Y$47.1$KG$20221213$$MD$JP$JP
1635138016$16351380$16$F$20180531$20221111$20190524$20221118$EXP$$DE-ROCHE-2232459$ROCHE$$53$YR$$F$Y$78$KG$20221118$$CN$DE$
1635149916$16351499$16$F$20181027$20221113$20190524$20221117$EXP$$GB-BAUSCH-BL-2019-015127$BAUSCH AND LOMB$$39$YR$$M$Y$91$KG$20221117$$CN$GB$GB
163515212$16351521$2$F$20150301$20221026$20190524$20221031$EXP$$US-TAKEDA-2019TUS031209$TAKEDA$$$$$$Y$$$20221031$$CN$US$US
163522603$16352260$3$F$$20221218$20190524$20221221$EXP$$CA-Orion Corporation ORION PHARMA-TREX2019-1549$ORION$$$$$F$Y$$$20221221$$MD$CA$
163522796$16352279$6$F$20140801$20221117$20190524$20221118$EXP$$US-PFIZER INC-2019223203$PFIZER$$67$YR$$M$Y$$$20221118$$LW$US$US
163523052$16352305$2$F$19981121$20190515$20190524$20221209$EXP$$DE-TEVA-2019-DE-1053159$TEVA$$45$YR$A$M$Y$88$KG$20221209$$MD$DE$DE
163524103$16352410$3$F$20190418$20221102$20190524$20221105$EXP$$DE-ROCHE-2324933$ROCHE$$36$YR$$F$Y$$$20221105$$CN$DE$
163529693$16352969$3$F$$20221006$20190524$20221007$EXP$$US-PFIZER INC-2019216673$PFIZER$$71$YR$$M$Y$$$20221007$$CN$US$US
163531264$16353126$4$F$$20221028$20190524$20221102$EXP$$US-PFIZER INC-2019221423$PFIZER$$86$YR$$F$Y$$$20221102$$CN$US$US
1635365427$16353654$27$F$20190221$20221206$20190524$20221221$PER$$JP-AMGEN-JPNSP2019053070$AMGEN$$76$YR$E$M$Y$61.7$KG$20221221$$MD$JP$JP
1635366619$16353666$19$F$20180608$20221205$20190524$20221213$PER$$JP-AMGEN-JPNSP2019080214$AMGEN$$61$YR$A$F$Y$63$KG$20221213$$MD$JP$JP
163541333$16354133$3$F$$20221007$20190524$20221011$PER$$US-PFIZER INC-2019219022$PFIZER$$66$YR$$F$Y$$$20221011$$CN$US$US
163547274$16354727$4$F$$20221123$20190524$20221205$EXP$$CA-AstraZeneca-2019SE77251$ASTRAZENECA$$18$YR$$F$Y$63$KG$20221205$$MD$CA$
1635606334$16356063$34$F$20181001$20221128$20190526$20221208$EXP$$CA-CELLTRION INC.-2018CA023094$CELLTRION$$$$$$Y$$$20221208$$MD$CA$CA
1635643213$16356432$13$F$20190410$20221014$20190527$20221021$PER$$JP-AMGEN-JPNSP2019080570$AMGEN$$78$YR$E$M$Y$58$KG$20221021$$MD$JP$JP
1635645415$16356454$15$F$20180827$20221205$20190527$20221212$PER$$JP-AMGEN-JPNSP2019082210$AMGEN$$68$YR$E$M$Y$63$KG$20221211$$MD$JP$JP
163570975$16357097$5$F$$20221123$20190527$20221206$EXP$$US-CIPLA LTD.-2019US03979$CIPLA$Gutierrez GC, Dayton C, Smedley L, Saikumar H, Everett C, Rodriguez A et al.. Shall we try angiotensin II (Too)? Treatment of refractory shock due to co-ingestion of amlodipine and benazepril: A case report. Journal of Medical Toxicology. 2019;15 (2):62$57$YR$$M$Y$$$20221206$$PH$US$US
163571655$16357165$5$F$20160101$20221128$20190527$20221201$PER$$US-AMGEN-USASP2019080002$AMGEN$$61$YR$A$F$Y$$$20221130$$HP$US$US
163579297$16357929$7$F$20120101$20221220$20190527$20221227$EXP$$US-GILEAD-2019-0409536$GILEAD$$$$A$F$Y$$$20221227$$LW$US$US
163582855$16358285$5$F$20140101$20221205$20190527$20221213$EXP$$US-TAKEDA-2019TUS032776$TAKEDA$$$$$$Y$$$20221213$$CN$US$US
1635840117$16358401$17$F$$20220927$20190527$20221006$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-049379$BRISTOL MYERS SQUIBB$$47$YR$A$F$Y$95$KG$20221006$$MD$CA$CA
163584406$16358440$6$F$20170317$20221013$20190527$20221014$EXP$$US-PFIZER INC-2019223627$PFIZER$$45$YR$$F$Y$$$20221014$$LW$US$US
163586056$16358605$6$F$20190514$20221107$20190527$20221206$EXP$$JP-009507513-1905JPN001534J$MERCK$Hirotsu Y, Nakatsuji T, Takahashi T, Komatsu H, Matsumoto Y, Yasui H, et al.. IIIP-109-6 A case of fulminant type 1 diabetes mellitus thought to be caused by pembrolizumab.. Journal of the Japan Diabetes Society. The 63rd Annual Meeting. 2020;63:S322$85$YR$$F$Y$55$KG$20221206$$MD$JP$JP
163587283$16358728$3$F$$20221207$20190527$20221214$PER$$US-SHIRE-US201917049$TAKEDA$$$$$F$Y$$$20221214$$HP$US$US
163604284$16360428$4$F$$20221207$20190528$20221220$EXP$$US-GLAXOSMITHKLINE-US2019GSK093822$PERRIGO$$$$$$Y$$$20221220$$MD$US$US
163604954$16360495$4$F$$20221124$20190528$20221129$EXP$$CA-Orion Corporation ORION PHARMA-TREX2019-0427$ORION$$53$YR$A$F$Y$$$20221129$$PH$CA$
163609756$16360975$6$F$20171020$20221006$20190528$20221017$EXP$$DE-MYLANLABS-2019M1049484$MYLAN$$79$YR$$M$Y$$$20221017$$MD$DE$DE
1636190315$16361903$15$F$20190410$20221114$20190528$20221206$EXP$$US-INCYTE CORPORATION-2019IN003802$INCYTE$$$$$$Y$$$20221206$$CN$US$US
163635263$16363526$3$F$20190501$20221003$20190528$20221004$EXP$$PHHY2019CA122385$NOVARTIS$$46$YR$$M$Y$$$20221004$$CN$CA$CA
163641822$16364182$2$F$$20221215$20190528$20221221$EXP$$PHHY2019CA120293$NOVARTIS$Andelfinger G, Marquis C, Raboisson MJ, Karalis A, Waldmuller S, Wiegand G et al.. Treatment of RIT1-associated cardiomyopathy with trametinib: Initial results in two patients. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY$$$N$$Y$4.49$KG$20221221$$HP$CA$CA
163642676$16364267$6$F$$20221130$20190528$20221207$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-023481$BOEHRINGER INGELHEIM$Lanzas I, Montaner M, Fernandez R, Gallardo I, Sancho Val L, Quinones B, et al. A MULTICENTER EXPERIENCE WITH IDARUCIZUMAB ^IN REAL WORLD^ AS REVERSAL ANTICOAGULATION OF DABIGATRAN. -. 2019 Oct;$93$YR$E$F$Y$$$20221208$$MD$ES$ES
1636456042$16364560$42$F$20190201$20220920$20190528$20221003$EXP$$CA-CELLTRION INC.-2019CA018404$CELLTRION$$$$$$Y$$$20221004$$MD$CA$CA
163649682$16364968$2$F$$20221108$20190529$20221122$EXP$$US-Unichem Pharmaceuticals (USA) Inc-UCM201905-000175$UNICHEM$$57$YR$A$M$Y$$$20221122$$HP$US$
1636512636$16365126$36$F$20190101$20221121$20190529$20221129$EXP$$CA-CELLTRION INC.-2019CA021466$CELLTRION$$$$$$Y$$$20221129$$HP$CA$CA
163655063$16365506$3$F$$20221115$20190529$20221126$EXP$$US-Accord-129735$ACCORD$Gutierrez GC, Dayton C, Attridge RL, Smedley L, Saikumar H, Everett C et al. Angiotensin II Use in Treatment of Refractory Shock Due to Benazepril and Amlodipine Toxic Ingestion. Journal of pharmacy practice. 2022: 8971900221137389.$57$YR$A$M$Y$$$20221126$$PH$US$US
163666314$16366631$4$F$20180101$20220928$20190529$20221003$EXP$$US-ROCHE-2309506$ROCHE$$$$$M$Y$68.1$KG$20221003$$CN$US$
163676055$16367605$5$F$$20221219$20190529$20221222$EXP$$US-PFIZER INC-2016511264$PFIZER$$66$YR$$F$Y$$$20221222$$CN$US$US
163698386$16369838$6$F$20180416$20221209$20190530$20221216$EXP$$JP-ABBVIE-19P-087-2801490-00$ABBVIE$$88$YR$$M$Y$$$20221214$$MD$JP$JP
1636991744$16369917$44$F$20190320$20221207$20190530$20221215$EXP$$CA-CELLTRION INC.-2019CA019965$CELLTRION$$$$$$Y$$$20221216$$HP$CA$CA
163701504$16370150$4$F$$20221219$20190530$20221222$PER$$US-AMGEN-USASP2019084912$AMGEN$$68$YR$E$F$Y$$$20221222$$CN$US$US
163701967$16370196$7$F$20170206$20221208$20190530$20221213$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2017JPN199674$VIIV$$$$$$Y$$$20221213$$MD$JP$JP
1637090816$16370908$16$F$20180822$20221125$20190530$20221210$EXP$$DE-AUROBINDO-AUR-APL-2019-029932$AUROBINDO$$49$YR$$F$Y$78$KG$20221210$$MD$DE$DE
163711775$16371177$5$F$20181024$20221117$20190530$20221122$EXP$$IL-ROCHE-2327289$ROCHE$$65$YR$$F$Y$75$KG$20221122$$MD$IL$
163729473$16372947$3$F$$20221103$20190530$20221129$EXP$$PHHY2019SE124613$NOVARTIS$$50$YR$$F$Y$$$20221129$$MD$SE$SE
163730604$16373060$4$F$20140101$20221205$20190530$20221206$EXP$$US-PFIZER INC-2019232548$PFIZER$$57$YR$$M$Y$$$20221206$$LW$US$US
163732486$16373248$6$F$20200201$20221103$20190530$20221109$EXP$$US-SA-2018SA332750$SANOFI AVENTIS$$67$YR$E$F$Y$$$20221109$$MD$US$US
163736313$16373631$3$F$$20221006$20190530$20221014$PER$$US-SA-2019SA145544$SANOFI AVENTIS$$39$YR$A$M$Y$$$20221014$$MD$US$US
163739832$16373983$2$F$20161214$20220930$20190530$20221006$EXP$$BE-TAKEDA-2018TUS036368$TAKEDA$Devos, Timothy, Havelange et.al. Real-life outcomes of ponatinib treatment in patients with chronic myeloid leukemia (CML) or philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL): 5-year-data from a Belgian registry. HemaSphere. 2022;6:S3:1139-1140$72$YR$$F$Y$$$20221006$$MD$BE$BE
163741327$16374132$7$F$20190514$20221227$20190530$20221229$EXP$$US-SHIRE-US201917377$TAKEDA$$20$YR$$M$Y$$$20221229$$CN$US$US
163755574$16375557$4$F$20190101$20190711$20190531$20221212$EXP$$US-TEVA-2019-US-1056771$TEVA$$$$$F$Y$$$20221212$$HP$US$US
163758655$16375865$5$F$$20221209$20190531$20221219$PER$$US-AMGEN-USASP2019085243$AMGEN$$$$A$F$Y$$$20221219$$CN$US$US
163763662$16376366$2$F$20180201$20221129$20190531$20221201$EXP$$US-ROCHE-2322867$ROCHE$$38$YR$$F$Y$65.83$KG$20221202$$CN$US$
163764894$16376489$4$F$$20221118$20190531$20221130$EXP$$FR-AUROBINDO-AUR-APL-2019-030146$AUROBINDO$Prescrire. Rep?rage d^une surdose de parac?tamol par autom?dication. [Identification of a paracetamol overdose through self-medication ].. Prescrire. 2013;33(356):472$$$$F$Y$$$20221130$$MD$FR$FR
163765962$16376596$2$F$20090107$20190523$20190531$20221212$EXP$DE-BFARM-19005529$DE-TEVA-2019-DE-1056169$TEVA$$70$YR$E$M$Y$$$20221212$$MD$DE$DE
1637700711$16377007$11$F$$20221018$20190531$20221020$EXP$$US-PFIZER INC-2019232393$PFIZER$$66$YR$$F$Y$$$20221020$$CN$US$US
163775553$16377555$3$F$20190501$20221110$20190531$20221114$PER$$US-PFIZER INC-2019234681$PFIZER$$33$YR$$F$Y$$$20221114$$CN$US$US
163789875$16378987$5$F$20180307$20221223$20190531$20221230$EXP$$JP-JNJFOC-20190541231$JOHNSON AND JOHNSON$$33$YR$A$M$Y$$$20221230$$MD$JP$JP
163793834$16379383$4$F$$20221208$20190531$20221213$PER$$US-PFIZER INC-2019232880$PFIZER$$65$YR$$F$Y$$$20221213$$CN$US$US
1638013310$16380133$10$F$20180630$20221125$20190601$20221208$EXP$$DE-AUROBINDO-AUR-APL-2018-039386$AUROBINDO$$$$A$F$Y$114$KG$20221208$$MD$DE$DE
163802737$16380273$7$F$20190405$20221021$20190601$20221103$EXP$$DE-AUROBINDO-AUR-APL-2019-023233$AUROBINDO$$$$A$F$Y$61$KG$20221103$$MD$DE$DE
163806932$16380693$2$F$$20221205$20190601$20221206$PER$$US-JNJFOC-20190528270$JOHNSON AND JOHNSON$$$$$M$Y$$$20221207$$LW$US$US
163810673$16381067$3$F$20120524$20221010$20190602$20221012$EXP$$PHHY2019DE120628$NOVARTIS$$30$YR$$M$Y$76$KG$20221012$$MD$DE$DE
163810742$16381074$2$F$$20221125$20190602$20221130$EXP$$GB-BIOGEN-2019BI00744879$BIOGEN$$$$$F$Y$$$20221130$$CN$GB$GB
163812608$16381260$8$F$$20221213$20190603$20221214$EXP$$CA-ABBVIE-19K-028-2805084-00$ABBVIE$$$$$F$Y$$$20221214$$HP$CA$CA
163814272$16381427$2$F$20160101$20221124$20190603$20221206$EXP$$DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-19-03683$HIKMA$$60$YR$$M$Y$$$20221206$$MD$DE$
1638318718$16383187$18$F$20190101$20221025$20190603$20221025$EXP$$CA-PFIZER INC-2019207599$PFIZER$$44$YR$$F$Y$$$20221025$$CN$CA$CA
163832222$16383222$2$F$$20221005$20190603$20221006$PER$$US-PFIZER INC-2016584489$PFIZER$$67$YR$$F$Y$$$20221006$$LW$US$US
163832962$16383296$2$F$$20221024$20190603$20221026$PER$$US-PFIZER INC-2019230051$PFIZER$$66$YR$$M$Y$98.43$KG$20221026$$CN$US$US
163840726$16384072$6$F$20160101$20221130$20190603$20221213$EXP$$DE-Accord-130810$ACCORD$Peitsch WK. Apremilast in a patient with psoriasis and mantle cell lymphoma under maintenance treatment with rituximab. Journal of the German Society of Dermatology. 2019;17(3):330-332$60$YR$$M$Y$$$20221213$$MD$DE$DE
163841686$16384168$6$F$$20221010$20190603$20221017$EXP$$AU-PFIZER INC-2019219939$MYLAN$$58$YR$$F$Y$$$20221017$$CN$AU$AU
1638441517$16384415$17$F$20150325$20221218$20190603$20221227$EXP$$GB-MYLANLABS-2019M1051183$MYLAN$$49$YR$$F$Y$$$20221227$$MD$GB$GB
1638445814$16384458$14$F$20190306$20221205$20190603$20221209$EXP$$CA-TAKEDA-2019TUS030138$TAKEDA$$40$YR$$F$Y$$$20221209$$CN$CA$CA
1638628010$16386280$10$F$20190101$20221218$20190603$20221220$EXP$$CA-TAKEDA-2019TUS033301$TAKEDA$$69$YR$$M$Y$$$20221220$$CN$CA$CA
1638639944$16386399$44$F$20190101$20221222$20190603$20221230$EXP$$CA-CELLTRION INC.-2019CA020778$CELLTRION$$$$$$Y$$$20221231$$MD$CA$CA
1638642328$16386423$28$F$20190101$20221025$20190603$20221103$EXP$$CA-CELLTRION INC.-2019CA020095$CELLTRION$$$$$$Y$$$20221103$$CN$CA$CA
163866404$16386640$4$F$20190201$20221209$20190604$20221214$EXP$$DK-CELLTRION INC.-2019DK021242$CELLTRION$$$$$$Y$$$20221215$$MD$DK$DK
1638803221$16388032$21$F$$20221026$20190604$20221108$EXP$$CA-AUROBINDO-AUR-APL-2019-030631$AUROBINDO$$43$YR$$F$Y$68$KG$20221108$$MD$CA$CA
163884702$16388470$2$F$$20221107$20190604$20221110$PER$$US-PFIZER INC-2019238266$PFIZER$$56$YR$$$Y$$$20221110$$CN$US$US
163886327$16388632$7$F$$20221121$20190604$20221123$PER$$US-PFIZER INC-2019234166$PFIZER$$77$YR$$M$Y$$$20221123$$MD$US$US
1638879411$16388794$11$F$$20220824$20190604$20221123$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-051033$BRISTOL MYERS SQUIBB$$43$YR$A$F$Y$97$KG$20221124$$HP$CA$CA
163905543$16390554$3$F$20200130$20200217$20190604$20221130$PER$$PHEH2019US023341$NOVARTIS$$60$YR$$F$Y$$$20221130$$CN$US$US
163918574$16391857$4$F$20180301$20221227$20190605$20221229$EXP$$PT-GILEAD-2019-0411578$GILEAD$$49$YR$A$M$Y$80$KG$20221229$$MD$PT$PT
163930745$16393074$5$F$$20221123$20190605$20221207$EXP$$US-MACLEODS PHARMACEUTICALS US LTD-MAC2019021537$MACLEODS$Gutierrez GC, Dayton C, Attridge RL, Smedley L, Saikumar H, Everett C etal.. Angiotensin II Use in Treatment of Refractory Shock Due to Benazepril and Amlodipine Toxic Ingestion. Journal of Pharmacy Practice. 2022;0(0):1-4$$$$$Y$$$20221207$$PH$US$US
163930823$16393082$3$F$20190219$20221012$20190605$20221018$EXP$$US-ROCHE-2327973$ROCHE$$44$YR$$F$Y$$$20221018$$CN$US$
163964764$16396476$4$F$20181001$20221116$20190605$20221118$EXP$$PT-ABBVIE-19K-130-2806285-00$ABBVIE$$32$YR$$F$Y$$$20221118$$CN$PT$PT
163965512$16396551$2$F$$20220912$20190606$20221219$PER$$US-AMGEN-USASP2019088488$AMGEN$$78$YR$E$F$Y$$$20221219$$CN$US$US
163966524$16396652$4$F$$20221020$20190606$20221026$PER$$US-AMGEN-USASP2019089330$AMGEN$$65$YR$E$F$Y$$$20221026$$MD$US$US
1639672330$16396723$30$F$20190501$20221115$20190606$20221124$EXP$$CA-CELLTRION INC.-2019CA021493$CELLTRION$$$$$$Y$$$20221124$$CN$CA$CA
163967952$16396795$2$F$20160101$20221124$20190606$20221201$EXP$$DE-BAXTER-2019BAX010931$BAXTER$Ludwig-peitsch WK.Apremilast in a patient with psoriasis and mantle cell lymphoma under maintenance treatment with rituximab.Journal of the german society of dermatology 2019;17(3):330-332.DOI:10.1111/ddg.13771$60$YR$$M$Y$$$20221201$$MD$DE$DE
163968027$16396802$7$F$20171201$20221123$20190606$20221202$EXP$$BR-EMD Serono-9094538$EMD SERONO INC$$32$YR$A$F$Y$$$20221202$$HP$BR$
163969812$16396981$2$F$$20221124$20190606$20221209$EXP$$DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-209773$RANBAXY$Peitsch WK. Apremilast bei einem Patienten mit Psoriasis und Mantelzelllymphom unter Erhaltungstherapie mit Rituximab. J Dtsch Dermatol Ges. 2019;17(3):330-332$60$YR$$M$Y$$$20221209$$MD$DE$DE
163970343$16397034$3$F$$20221129$20190606$20221216$EXP$$US-AUROBINDO-AUR-APL-2019-031531$AUROBINDO$Gutierrez G, Dayton C, Smedley L, Saikumar H, Everett C, Rodriguez A et al. Shall we try angiotensin II (Too)? Treatment of refractory shock due to co-ingestion of amlodipine and benazepril: A case report. Journal of Medical Toxicology. 2019;15(2):62$57$YR$$M$Y$$$20221214$$HP$US$US
163975282$16397528$2$F$20190602$20190603$20190606$20221211$PER$$US-AMGEN-USASP2019089030$AMGEN$$65$YR$E$F$Y$$$20221211$$CN$US$US
163985635$16398563$5$F$20180301$20221117$20190606$20221118$EXP$$US-PFIZER INC-2019242213$PFIZER$$56$YR$$M$Y$$$20221118$$LW$US$US
163991854$16399185$4$F$$20221118$20190606$20221122$EXP$$CA-TAKEDA-2018TUS032138$TAKEDA$$39$YR$$M$Y$$$20221122$$CN$CA$CA
164004834$16400483$4$F$20190401$20220211$20190606$20221130$EXP$GB-MHRA-EYC 00199723$GB-JNJFOC-20190533358$JOHNSON AND JOHNSON$$64$YR$A$F$Y$73$KG$20221130$$HP$GB$GB
164005216$16400521$6$F$20180101$20221024$20190606$20221107$EXP$$CA-Osmotica_Pharmaceutical_US_LLC-POI0573201900220$OSMOTICA$$60$YR$A$F$Y$$$20221107$$HP$CA$CA
1640177620$16401776$20$F$20190509$20221128$20190606$20221208$EXP$$CA-CELLTRION INC.-2019CA021586$CELLTRION$$$$$$Y$$$20221208$$MD$CA$CA
164021033$16402103$3$F$20190302$20190529$20190607$20221018$EXP$$CH-TEVA-2019-CH-1059783$TEVA$$73$YR$E$F$Y$81$KG$20221018$$MD$CH$CH
164022045$16402204$5$F$20121201$20221017$20190607$20221025$EXP$$US-AstraZeneca-2018SF14888$ASTRAZENECA$$21271$DY$$M$Y$$$20221025$$LW$US$
164031308$16403130$8$F$20190401$20221209$20190607$20221219$EXP$$PHHY2018CO072743$NOVARTIS$$15$YR$$F$Y$$$20221219$$CN$CO$CO
1640315113$16403151$13$F$20190101$20221222$20190607$20221228$EXP$$CA-ROCHE-2329495$ROCHE$$$$$F$Y$$$20221228$$CN$CA$
1640338011$16403380$11$F$20170615$20221028$20190607$20221103$EXP$$PHHY2017CA138216$NOVARTIS$$68$YR$$F$Y$69.4$KG$20221103$$MD$CA$CA
1640432414$16404324$14$F$20220101$20221221$20190607$20221227$EXP$$US-PFIZER INC-2019236267$PFIZER$$87$YR$$M$Y$66.44$KG$20221227$$CN$US$US
164053969$16405396$9$F$20210228$20221221$20190607$20221226$EXP$$US-SA-2019SA155233$SANOFI AVENTIS$$10$YR$C$M$Y$$$20221226$$MD$US$US
164054842$16405484$2$F$20010101$20221005$20190607$20221010$EXP$$US-TAKEDA-2019TUS018395$TAKEDA$$$$$$Y$$$20221010$$CN$US$US
1640558821$16405588$21$F$20190313$20221211$20190607$20221220$EXP$$CA-PFIZER INC-2019126325$PFIZER$$28$YR$$F$Y$$$20221220$$CN$CA$CA
164060535$16406053$5$F$$20221020$20190607$20221024$PER$$US-PFIZER INC-2019239049$PFIZER$$65$YR$$F$Y$$$20221024$$MD$US$US
1640673214$16406732$14$F$20050101$20221125$20190607$20221202$EXP$$PHHY2019DE131179$NOVARTIS$$$$A$M$Y$$$20221202$$CN$DE$DE
164067373$16406737$3$F$20190201$20221005$20190607$20221011$EXP$$PHHY2019CA131959$NOVARTIS$$54$YR$$F$Y$$$20221012$$MD$CA$CA
164077142$16407714$2$F$$20221003$20190609$20221010$EXP$$PHHY2019ES132191$NOVARTIS$Prieto LM, Santiago B, del Rosal T, Carazo B, Jimenez AB, Perez-Gorricho B et al.. Linezolid-containing Treatment Regimens for Tuberculosis in Children. THE PEDIATRIC INFECTIOUS DISEASE JOURNAL. 2019;38(3):263-7$3$YR$$M$Y$$$20221010$$HP$ES$ES
1640794610$16407946$10$F$20170329$20221117$20190610$20221123$EXP$$CA-ROCHE-2331251$ROCHE$$62$YR$$F$Y$93$KG$20221123$$MD$CA$CA
164088529$16408852$9$F$20180115$20221024$20190610$20221025$EXP$$PHHY2018CA016510$NOVARTIS$$53$YR$$M$Y$$$20221025$$CN$CA$CA
164091927$16409192$7$F$20160101$20221124$20190610$20221208$EXP$$DE-AUROBINDO-AUR-APL-2019-021267$AUROBINDO$Ludwig-Peitsch W. Apremilast in a patient with psoriasis and mantle cell lymphoma under maintenance treatment with rituximab. Journal of the German Society of Dermatology. 2019;17 (3):330-332$60$YR$$M$Y$$$20221208$$MD$DE$DE
1641096413$16410964$13$F$20180503$20220926$20190610$20221018$EXP$$DE-GLAXOSMITHKLINE-DE2019101591$GLAXOSMITHKLINE$$$$$$Y$$$20221018$$MD$DE$DE
164112615$16411261$5$F$20151116$20221213$20190610$20221220$EXP$$US-AstraZeneca-2018SF34851$ASTRAZENECA$$20411$DY$$F$Y$64.9$KG$20221216$$LW$US$
164117537$16411753$7$F$20191203$20221219$20190610$20221222$EXP$$US-SHIRE-US201918588$TAKEDA$$66$YR$$M$Y$$$20221222$$CN$US$US
164117974$16411797$4$F$$20221129$20190610$20221201$PER$$US-PFIZER INC-2019248512$PFIZER$$68$YR$$M$Y$$$20221201$$HP$US$US
164117993$16411799$3$F$$20221219$20190610$20221222$PER$$US-PFIZER INC-2019236851$PFIZER$$67$YR$$F$Y$$$20221222$$HP$US$US
164127687$16412768$7$F$20180613$20221220$20190611$20221227$EXP$$CA-ROCHE-2334612$ROCHE$$42$YR$$F$Y$$$20221227$$MD$CA$CA
164133305$16413330$5$F$20160901$20221205$20190611$20221213$EXP$$US-AstraZeneca-2018SF14939$ASTRAZENECA$$641$MON$$M$Y$145.2$KG$20221213$$LW$US$
164133505$16413350$5$F$20180301$20221031$20190611$20221104$EXP$$US-AstraZeneca-2018SF65039$ASTRAZENECA$$20528$DY$$M$Y$127$KG$20221104$$LW$US$
164136392$16413639$2$F$20190301$20221020$20190611$20221027$EXP$$CA-ABBVIE-19K-028-2814360-00$ABBVIE$$73$YR$$F$Y$$$20221027$$CN$CA$CA
164139679$16413967$9$F$20170101$20221129$20190611$20221201$EXP$$CA-TAKEDA-2017TUS019637$TAKEDA$$40$YR$$F$Y$$$20221201$$CN$CA$CA
164143597$16414359$7$F$20180101$20220927$20190611$20221006$EXP$$CA-TAKEDA-2018TUS006952$TAKEDA$$54$YR$$F$Y$$$20221006$$CN$CA$CA
1641673810$16416738$10$F$$20221130$20190611$20221205$EXP$$BR-GLAXOSMITHKLINE-BR2019GSK102514$GLAXOSMITHKLINE$$$$$$Y$$$20221205$$HP$BR$BR
164169163$16416916$3$F$$20221115$20190611$20221117$PER$$US-BIOGEN-2019BI00731658$BIOGEN$$$$$M$Y$$$20221117$$CN$US$US
164171673$16417167$3$F$20170101$20221020$20190611$20221022$EXP$$PHHY2019MX134046$NOVARTIS$$$$$F$Y$59$KG$20221022$$CN$MX$MX
164171983$16417198$3$F$20190101$20221129$20190611$20221202$EXP$$US-PFIZER INC-2019249928$PFIZER$$63$YR$$F$Y$$$20221202$$HP$US$US
164173458$16417345$8$F$20190101$20200917$20190611$20221130$PER$$US-AMGEN INC.-USASP2019090250$AMGEN$$68$YR$E$F$Y$$$20221130$$CN$US$US
164173538$16417353$8$F$20170830$20221130$20190611$20221207$EXP$$DE-JNJFOC-20190610744$JOHNSON AND JOHNSON$$5$DEC$A$M$Y$$$20221207$$MD$DE$DE
164175826$16417582$6$F$20210101$20221205$20190611$20221209$EXP$$US-PFIZER INC-2015463050$PFIZER$$45$YR$$M$Y$$$20221209$$CN$US$US
1641799911$16417999$11$F$20190411$20221219$20190611$20221226$EXP$$CA-TAKEDA-2019TUS009095$TAKEDA$$54$YR$$M$Y$$$20221226$$CN$CA$CA
164182644$16418264$4$F$$20221129$20190612$20221214$EXP$$CA-AUROBINDO-AUR-APL-2019-031939$AUROBINDO$$25$YR$$F$Y$50$KG$20221214$$HP$CA$CA
1641850528$16418505$28$F$20180301$20221216$20190612$20221226$EXP$$CA-CELLTRION INC.-2018CA019337$CELLTRION$$$$$$Y$$$20221226$$CN$CA$CA
164189226$16418922$6$F$20181222$20221007$20190612$20221014$PER$$JP-AMGEN-JPNSP2019090492$AMGEN$$53$YR$A$M$Y$60$KG$20221014$$MD$JP$JP
164208357$16420835$7$F$20180101$20221208$20190612$20221227$EXP$$PHHY2018CA197201$NOVARTIS$$37$YR$$F$Y$$$20221227$$MD$CA$CA
164217194$16421719$4$F$$20221106$20190612$20221116$EXP$$FR-JNJFOC-20190609400$JOHNSON AND JOHNSON$$$$$$Y$$$20221116$$MD$FR$FR
164223882$16422388$2$F$20161215$20221027$20190612$20221101$EXP$$DE-MYLANLABS-2019M1054016$MYLAN$$$$A$F$Y$$$20221101$$MD$DE$DE
164232134$16423213$4$F$20010101$20221011$20190612$20221017$EXP$$US-TAKEDA-2019TUS029237$TAKEDA$$$$$$Y$$$20221017$$LW$US$US
1642321610$16423216$10$F$20190521$20221216$20190612$20221222$EXP$$US-SHIRE-US201918462$TAKEDA$$68$YR$$F$Y$60$KG$20221222$$HP$US$US
164237722$16423772$2$F$$20190606$20190613$20221012$PER$$US-009507513-1906USA002990$MERCK$$$$$M$Y$$$20221012$$MD$US$US
1642428231$16424282$31$F$20160829$20221012$20190613$20221019$EXP$$PHHY2016CA116021$NOVARTIS$$48$YR$$F$Y$$$20221019$$CN$CA$CA
164256753$16425675$3$F$20171218$20221214$20190613$20221220$PER$$US-PFIZER INC-2017508397$PFIZER$$40$YR$$F$Y$64$KG$20221220$$CN$US$US
1642768216$16427682$16$F$20210310$20221214$20190613$20221221$EXP$$BR-GLAXOSMITHKLINE-BR2019GSK103510$GLAXOSMITHKLINE$$$$$$Y$$$20221221$$MD$BR$BR
164281854$16428185$4$F$20151101$20221214$20190613$20221219$EXP$$US-TAKEDA-2019TUS037592$TAKEDA$$$$$$Y$$$20221219$$CN$US$US
164288143$16428814$3$F$20220201$20220930$20190613$20221003$PER$$PHEH2019US025210$NOVARTIS$$30$YR$$M$Y$$$20221003$$CN$US$US
164292153$16429215$3$F$20190610$20221123$20190614$20221130$EXP$$US-SHIRE-US201919229$TAKEDA$$87$YR$$F$Y$$$20221130$$MD$US$US
164294532$16429453$2$F$$20221002$20190614$20221010$PER$$US-AMGEN-USASP2019092477$AMGEN$$66$YR$E$F$Y$$$20221010$$CN$US$US
164301335$16430133$5$F$20170530$20221007$20190614$20221019$PER$$JP-AMGEN-JPNCT2019094510$AMGEN$$86$YR$E$F$Y$$$20221017$$MD$JP$JP
164310766$16431076$6$F$20120601$20221101$20190614$20221104$EXP$$US-PFIZER INC-2019252135$PFIZER$$58$YR$$M$Y$70$KG$20221104$$HP$US$US
164312143$16431214$3$F$20170130$20221227$20190614$20221229$EXP$CY-EMA-DD-20180220-SGALIPALLIP-110632$CY-MYLANLABS-2019M1055091$MYLAN$$36$YR$$F$Y$64$KG$20221229$$MD$CY$CY
164313823$16431382$3$F$20180822$20221014$20190614$20221018$EXP$$DE-PFIZER INC-2019248948$PFIZER$$79$YR$$F$Y$77$KG$20221018$$MD$DE$DE
164314808$16431480$8$F$$20221121$20190614$20221128$PER$$US-PFIZER INC-2017082990$PFIZER$$21$YR$$M$Y$125$KG$20221128$$MD$US$US
164318113$16431811$3$F$20050419$20220926$20190614$20221007$PER$$US-JNJFOC-20151104876$JOHNSON AND JOHNSON$$9$YR$C$M$Y$$$20221007$$LW$US$US
164320243$16432024$3$F$20050101$20220929$20190614$20221007$PER$$US-JNJFOC-20151100791$JOHNSON AND JOHNSON$$$$C$M$Y$$$20221007$$HP$US$US
1643270521$16432705$21$F$20181003$20221209$20190614$20221222$PER$$JP-AMGEN-JPNSP2019090583$AMGEN$$60$YR$A$F$Y$59.3$KG$20221222$$MD$JP$JP
164337953$16433795$3$F$20070101$20221014$20190614$20221020$PER$$US-JNJFOC-20151100811$JOHNSON AND JOHNSON$$4$DEC$A$M$Y$$$20221020$$HP$US$US
164358313$16435831$3$F$20190424$20221017$20190614$20221026$EXP$FR-AFSSAPS-AM20190908$FR-SA-2019SA153187$SANOFI AVENTIS$$59$YR$A$M$Y$60$KG$20221026$$MD$FR$FR
164384179$16438417$9$F$$20221205$20190617$20221218$EXP$$CA-AUROBINDO-AUR-APL-2019-033193$AUROBINDO$$$$$F$Y$$$20221218$$HP$CA$CA
164384192$16438419$2$F$$20221026$20190617$20221110$EXP$$CA-AUROBINDO-AUR-APL-2019-033254$AUROBINDO$$23$YR$$F$Y$$$20221110$$HP$CA$CA
1643937612$16439376$12$F$$20221205$20190617$20221214$EXP$$US-SHIRE-US201919349$TAKEDA$$$$$F$Y$$$20221214$$CN$US$US
164394737$16439473$7$F$$20221221$20190617$20221227$PER$$US-PFIZER INC-2019256392$PFIZER$$76$YR$$M$Y$$$20221227$$HP$US$US
1643950914$16439509$14$F$20200101$20221130$20190617$20221205$EXP$$US-PFIZER INC-2019251641$PFIZER$$69$YR$$F$Y$65.77$KG$20221205$$CN$US$US
164400098$16440009$8$F$$20221214$20190617$20221228$EXP$E2B_02373859$CA-ASSERTIO THERAPEUTICS, INC.-CA-2019DEP000563$ASSERTIO THERAPEUTICS$$43$YR$$F$Y$68$KG$20221228$$MD$CA$CA
164402222$16440222$2$F$20160101$20220926$20190617$20221004$EXP$$US-VERTEX PHARMACEUTICALS-2019-005458$VERTEX$$$$$M$Y$33$KG$20221004$$HP$US$US
164423892$16442389$2$F$20170214$20221011$20190617$20221020$EXP$$DE-MYLANLABS-2019M1055595$MYLAN$$$$E$F$Y$$$20221020$$MD$DE$DE
1644253018$16442530$18$F$20160601$20221206$20190617$20221214$EXP$$US-PFIZER INC-2016177750$MYLAN$$40$YR$$M$Y$110$KG$20221214$$CN$US$US
164436876$16443687$6$F$$20221101$20190618$20221104$PER$$US-BIOGEN-2019BI00751843$BIOGEN$$$$$F$Y$$$20221104$$CN$US$US
164438003$16443800$3$F$20190424$20221019$20190618$20221029$EXP$FR-AFSSAPS-AM20190908$FR-TEVA-2019-FR-1063283$TEVA$$59$YR$A$M$Y$60$KG$20221029$$MD$FR$FR
164446889$16444688$9$F$20181103$20221227$20190618$20221230$EXP$$PHHY2018EE181633$NOVARTIS$$39$YR$$M$Y$$$20221230$$MD$EE$EE
1644490618$16444906$18$F$20140101$20221017$20190618$20221020$EXP$$US-PFIZER INC-2019258954$PFIZER$$70$YR$$F$Y$68.95$KG$20221020$$CN$US$US
164455352$16445535$2$F$20171027$20221031$20190618$20221104$PER$$US-PFIZER INC-2019258792$PFIZER$$53$YR$$F$Y$$$20221104$$MD$US$US
164457586$16445758$6$F$20190401$20190617$20190618$20221201$EXP$$US-PARI RESPIRATORY EQUIPMENT, INC.-2019PAR00049$PARI RESPIRATORY EQUIPMENT$$8$YR$$F$Y$27.211$KG$20190702$$CN$US$US
164470283$16447028$3$F$$20221012$20190618$20221017$EXP$$US-SHIRE-US201919351$TAKEDA$$$$$F$Y$33.379$KG$20221017$$CN$US$US
1644838611$16448386$11$F$20181001$20221011$20190619$20221015$EXP$$FR-ABBVIE-19K-056-2820223-00$ABBVIE$$64$YR$$F$Y$52$KG$20221015$$MD$FR$FR
164497407$16449740$7$F$20181116$20220409$20190619$20221213$EXP$$JP-ABBVIE-19P-087-2824127-00$ABBVIE$$61$YR$$M$Y$$$20221213$$MD$JP$JP
164510613$16451061$3$F$20181001$20221108$20190619$20221110$PER$$US-PFIZER INC-2019154769$PFIZER$$48$YR$$F$Y$$$20221110$$HP$US$US
164513414$16451341$4$F$$20221209$20190619$20221213$PER$$US-PFIZER INC-2019254582$PFIZER$$63$YR$$F$Y$70.31$KG$20221213$$CN$US$US
164513674$16451367$4$F$$20221111$20190619$20221115$PER$$PR-PFIZER INC-2019260570$PFIZER$$57$YR$$F$Y$$$20221115$$MD$PR$PR
164513963$16451396$3$F$$20221213$20190619$20221215$PER$$US-PFIZER INC-2019260230$PFIZER$$47$YR$$F$Y$$$20221215$$HP$US$US
164513992$16451399$2$F$$20221123$20190619$20221128$PER$$US-PFIZER INC-2019260572$PFIZER$$50$YR$$F$Y$$$20221128$$HP$US$US
1645168717$16451687$17$F$20190101$20221216$20190619$20221227$PER$$US-Eisai Medical Research-EC-2019-056095$EISAI$$78$YR$E$F$Y$$$20221227$$CN$US$
1645204318$16452043$18$F$20150420$20221115$20190619$20221123$EXP$$GB-MYLANLABS-2019M1056318$MYLAN$$46$YR$$F$Y$$$20221123$$HP$GB$GB
164523036$16452303$6$F$20190604$20221115$20190619$20221129$EXP$$US-MYLANLABS-2019M1056031$MYLAN$$30$YR$$M$Y$64.9$KG$20221129$$CN$US$US
1645336313$16453363$13$F$20190603$20221227$20190619$20221230$EXP$$US-SA-2019SA163329$SANOFI AVENTIS$$16$YR$T$M$Y$$$20221230$$MD$US$US
1645413432$16454134$32$F$20181107$20221215$20190620$20221224$EXP$$CA-CELLTRION INC.-2018CA023923$CELLTRION$$$$$$Y$$$20221224$$CN$CA$CA
1645445526$16454455$26$F$20181203$20221103$20190620$20221115$EXP$$CA-CELLTRION INC.-2018CA020119$CELLTRION$$$$$$Y$$$20221115$$MD$CA$CA
164546315$16454631$5$F$$20221017$20190619$20221024$EXP$$CA-BAUSCH-BL-2019-017539$BAUSCH AND LOMB$$62$YR$$F$Y$$$20221024$$CN$CA$CA
1645470722$16454707$22$F$20211119$20221129$20190619$20221206$EXP$$PHEH2019US025339$NOVARTIS$$82$YR$$M$Y$54.871$KG$20221206$$MD$US$US
1645527723$16455277$23$F$20190101$20221209$20190620$20221219$EXP$$CA-CELLTRION INC.-2019CA019833$CELLTRION$$$$$$Y$$$20221219$$MD$CA$CA
164556344$16455634$4$F$20100101$20221117$20190620$20221125$EXP$$US-AstraZeneca-2018SF26648$ASTRAZENECA$$59$YR$$F$Y$99.8$KG$20221125$$LW$US$
164575873$16457587$3$F$20170115$20221027$20190620$20221103$EXP$$DE-MYLANLABS-2019M1056608$MYLAN$$$$E$M$Y$$$20221103$$MD$DE$DE
164577574$16457757$4$F$$20221024$20190620$20221026$PER$$US-PFIZER INC-2019262683$PFIZER$$65$YR$$F$Y$$$20221026$$MD$US$US
164583522$16458352$2$F$$20221024$20190620$20221101$EXP$$GB-CLOVIS ONCOLOGY-CLO-2019-000995$CLOVIS ONCOLOGY$$$$$$Y$$$20221101$$MD$GB$GB
164601057$16460105$7$F$20190603$20220929$20190620$20221003$EXP$$US-SHIRE-US201920074$TAKEDA$$50$YR$$F$Y$$$20221003$$HP$US$US
1646095518$16460955$18$F$20190306$20221128$20190621$20221130$EXP$$FR-ABBVIE-19K-056-2823088-00$ABBVIE$$67$YR$$M$Y$66$KG$20221130$$MD$FR$FR
164613634$16461363$4$F$$20221101$20190620$20221108$PER$$US-JAZZ-2019-US-008238$JAZZ$$$$$F$Y$$$20221108$$MD$US$US
164615455$16461545$5$F$20190117$20221021$20190621$20221031$EXP$$GB-CELLTRION INC.-2019GB020083$CELLTRION$$$$$$Y$$$20221031$$MD$GB$GB
1646167951$16461679$51$F$20190101$20220926$20190621$20221008$EXP$$CA-CELLTRION INC.-2019CA020018$CELLTRION$$$$$$Y$$$20221008$$CN$CA$CA
1646205528$16462055$28$F$20190101$20221115$20190621$20221123$EXP$$CA-CELLTRION INC.-2019CA019748$CELLTRION$$$$$$Y$$$20221123$$CN$CA$CA
1646268924$16462689$24$F$20210425$20221228$20190621$20221229$EXP$$CA-ROCHE-2341004$ROCHE$$59$YR$$M$Y$$$20221229$$CN$CA$
164637888$16463788$8$F$20221117$20221206$20190621$20221215$PER$$US-PFIZER INC-2019267737$PFIZER$$54$YR$$M$Y$$$20221215$$CN$US$US
164642114$16464211$4$F$20190428$20221117$20190621$20221123$EXP$$US-SHIRE-US201920030$TAKEDA$$64$YR$$F$Y$$$20221123$$CN$US$US
164644502$16464450$2$F$$20220929$20190621$20221006$EXP$$CA-APOTEX-2019AP016623$APOTEX$$41$YR$$F$Y$$$20221006$$HP$CA$CA
164645894$16464589$4$F$20190101$20221109$20190621$20221116$EXP$$JP-AstraZeneca-2019SE64731$ASTRAZENECA$$40$YR$$M$Y$92$KG$20221116$$MD$JP$
164650417$16465041$7$F$20181218$20221108$20190621$20221115$EXP$$US-Vifor (International) Inc.-VIT-2019-06147$VIFOR$$72$YR$$M$Y$$$20221115$$CN$US$US
164651473$16465147$3$F$$20221129$20190621$20221202$EXP$$CA-PFIZER INC-2019264628$PFIZER$$77$YR$$F$Y$$$20221202$$HP$CA$CA
164656676$16465667$6$F$20220526$20221005$20190621$20221006$EXP$$PHHY2019CA143135$NOVARTIS$$74$YR$$M$Y$$$20221006$$CN$CA$CA
164660266$16466026$6$F$20190509$20221125$20190621$20221230$PER$$US-ACORDA-ACO_158669_2019$ACORDA$$60$YR$$F$Y$57.596$KG$20221230$$CN$US$US
164660774$16466077$4$F$20190507$20220728$20190621$20221230$PER$$US-ACORDA-ACO_158926_2019$ACORDA$$81$YR$$M$Y$89.796$KG$20221230$$CN$US$US
164660914$16466091$4$F$20190501$20220623$20190621$20221230$PER$$US-ACORDA-ACO_159085_2019$ACORDA$$68$YR$$F$Y$$$20221230$$CN$US$US
164661259$16466125$9$F$20201101$20220607$20190621$20221230$PER$$US-ACORDA-ACO_159213_2019$ACORDA$$74$YR$$M$Y$87.075$KG$20221230$$CN$US$US
164669573$16466957$3$F$20211013$20221024$20190624$20221027$EXP$$US-SHIRE-US201920012$TAKEDA$$52$YR$$F$Y$$$20221027$$HP$US$US
164676458$16467645$8$F$20190622$20221107$20190624$20221110$EXP$$JP-ABBVIE-19S-087-2830677-00$ABBVIE$$69$YR$$M$Y$58$KG$20221110$$MD$JP$JP
164681069$16468106$9$F$20190529$20221021$20190624$20221031$EXP$$DE-AUROBINDO-AUR-APL-2019-035533$AUROBINDO$$$$A$F$Y$85$KG$20221101$$MD$DE$DE
1646828210$16468282$10$F$20160901$20221206$20190624$20221212$EXP$$US-GLAXOSMITHKLINE-US2019GSK112632$PERRIGO$$$$$$Y$$$20221212$$CN$US$US
164685533$16468553$3$F$$20221211$20190624$20221222$EXP$GB-EMA-DD-20190516-AGRAHARI_P-181349$GB-Accord-134190$ACCORD$$68$YR$E$F$Y$$$20221222$$HP$GB$GB
164688606$16468860$6$F$$20221101$20190624$20221104$PER$$US-PFIZER INC-2018163416$PFIZER$$22$YR$$F$Y$$$20221104$$MD$US$US
164688675$16468867$5$F$20211201$20221021$20190624$20221024$EXP$$US-PFIZER INC-2019268000$PFIZER$$72$YR$$M$Y$$$20221024$$HP$US$US
164698102$16469810$2$F$$20221119$20190624$20221125$PER$$US-SA-2019SA169032$SANOFI AVENTIS$$33$YR$A$M$Y$$$20221125$$MD$US$US
164712962$16471296$2$F$20190612$20221227$20190624$20221230$PER$$US-SA-2019SA170999$SANOFI AVENTIS$$15$YR$T$M$Y$$$20221230$$MD$US$US
164738608$16473860$8$F$20180722$20221206$20190625$20221210$EXP$$PHHY2018CA063309$NOVARTIS$$50$YR$$F$Y$$$20221210$$CN$CA$CA
1647386313$16473863$13$F$20161106$20221107$20190625$20221110$EXP$$PHHY2019DE138765$NOVARTIS$$62$YR$$M$Y$$$20221110$$MD$DE$DE
1647393511$16473935$11$F$20190328$20221118$20190625$20221125$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-057668$BRISTOL MYERS SQUIBB$$69$YR$E$M$Y$66$KG$20221125$$MD$JP$JP
1647393914$16473939$14$F$20190628$20221216$20190625$20221223$EXP$$PHEH2019US026090$NOVARTIS$$57$YR$$F$Y$48.98$KG$20221223$$CN$US$US
164740952$16474095$2$F$$20221213$20190625$20221216$PER$$US-PFIZER INC-2019270202$PFIZER$$34$YR$$F$Y$$$20221216$$HP$US$US
1647411210$16474112$10$F$20171201$20221125$20190625$20221129$PER$$US-PFIZER INC-2018057750$PFIZER$$11$YR$$F$Y$$$20221129$$HP$US$US
1647411416$16474114$16$F$20190331$20221108$20190625$20221111$PER$$US-PFIZER INC-2019270132$PFIZER$$80$YR$$F$Y$64$KG$20221111$$CN$US$US
164754059$16475405$9$F$20190401$20221223$20190625$20221230$EXP$$PHHY2019CO145017$NOVARTIS$$54$YR$$F$Y$55$KG$20221230$$CN$CO$CO
164765974$16476597$4$F$$20221026$20190626$20221031$EXP$$PT-MYLANLABS-2019M1058283$MYLAN$Oliveira V, Chaves J... Seizure control with add-on eslicarbizepine in two patients with Dravet syndrome. Epilepsia. 2018;59 (3):S114-S115$24$YR$$M$Y$$$20221031$$HP$PT$PT
164769593$16476959$3$F$$20221129$20190626$20221205$EXP$$CA-Orion Corporation ORION PHARMA-TREX2019-1975$ORION$$77$YR$E$F$Y$$$20221205$$HP$CA$
164779426$16477942$6$F$$20221028$20190626$20221107$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-15547$SAMSUNG BIOEPIS$$20$YR$A$M$Y$65$KG$20221107$$HP$CA$CA
164779455$16477945$5$F$$20221020$20190626$20221028$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-15605$SAMSUNG BIOEPIS$$55$YR$A$F$Y$112$KG$20221028$$HP$CA$CA
164779516$16477951$6$F$$20221003$20190626$20221011$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-15755$SAMSUNG BIOEPIS$$59$YR$A$M$Y$71$KG$20221011$$HP$CA$CA
164779564$16477956$4$F$$20221021$20190626$20221031$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-15843$SAMSUNG BIOEPIS$$$$$M$Y$$$20221031$$CN$CA$CA
1647836710$16478367$10$F$20190611$20220928$20190626$20221003$EXP$$IN-PFIZER INC-2017265096$PFIZER$$55$YR$$F$Y$$$20221003$$CN$IN$IN
164786984$16478698$4$F$20170401$20220929$20190626$20221003$EXP$$PHHY2019AU143332$NOVARTIS$$49$YR$$F$Y$$$20221003$$MD$AU$AU
164789883$16478988$3$F$20170506$20221031$20190626$20221107$EXP$$DE-MYLANLABS-2019M1057743$MYLAN$$65$YR$$M$Y$$$20221107$$MD$DE$DE
1648015110$16480151$10$F$20180105$20221128$20190626$20221129$EXP$$CA-TAKEDA-2016TUS021628$TAKEDA$$42$YR$$M$Y$$$20221129$$HP$CA$CA
1648059332$16480593$32$F$20150101$20221103$20190626$20221114$EXP$$US-PFIZER INC-2019260541$PFIZER$$53$YR$$F$Y$113$KG$20221114$$CN$US$US
1648101227$16481012$27$F$20190606$20221012$20190626$20221021$EXP$$CA-SHIRE-CA201919300$TAKEDA$$58$YR$$M$Y$63$KG$20221021$$CN$CA$CA
1648119613$16481196$13$F$20180127$20221104$20190626$20221119$EXP$$CA-CELLTRION INC.-2018CA017983$CELLTRION$$$$$$Y$$$20221119$$CN$CA$CA
1648272210$16482722$10$F$20220610$20221103$20190627$20221108$EXP$$CA-TAKEDA-2019TUS028105$TAKEDA$$66$YR$$F$Y$$$20221108$$HP$CA$CA
164831367$16483136$7$F$20190117$20221209$20190627$20221213$EXP$$JP-ABBVIE-19P-087-2834827-00$ABBVIE$$73$YR$$M$Y$$$20221213$$MD$JP$JP
1648356112$16483561$12$F$20220101$20221212$20190627$20221219$EXP$$US-PFIZER INC-2018230052$PFIZER$$76$YR$$F$Y$62.14$KG$20221219$$CN$US$US
1648436512$16484365$12$F$20160101$20221103$20190627$20221114$EXP$$PHHY2016CA124384$NOVARTIS$$$$$F$Y$$$20221114$$CN$CA$CA
164852542$16485254$2$F$20101205$20190621$20190627$20221219$EXP$$PHHY2019GB143607$NOVARTIS$$19$YR$$F$Y$$$20221219$$MD$GB$GB
164872124$16487212$4$F$$20190730$20190627$20221212$EXP$$US-TEVA-2019-US-1067965$TEVA$$60$YR$A$$Y$$$20221212$$HP$US$US
164921548$16492154$8$F$$20221003$20190628$20221011$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-15866$SAMSUNG BIOEPIS$$60$YR$A$F$Y$72$KG$20221011$$HP$CA$CA
164921938$16492193$8$F$$20221202$20190628$20221212$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-15606$SAMSUNG BIOEPIS$$58$YR$A$M$Y$96$KG$20221212$$MD$CA$CA
164922154$16492215$4$F$$20221130$20190628$20221208$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-15796$SAMSUNG BIOEPIS$$$$$M$Y$53$KG$20221208$$CN$CA$CA
164933717$16493371$7$F$20190606$20221215$20190628$20221220$EXP$$US-SA-2019SA175742$SANOFI AVENTIS$$44$YR$A$M$Y$$$20221220$$MD$US$US
1649355311$16493553$11$F$20190118$20220919$20190628$20221001$EXP$$DE-AUROBINDO-AUR-APL-2019-036703$AUROBINDO$$$$E$F$Y$63$KG$20221001$$MD$DE$DE
164936262$16493626$2$F$20190301$20220216$20190628$20221013$PER$$US-INDIVIOR LIMITED-INDV-118646-2019$RECKITT BENCKISER$$40$YR$$M$Y$$$20221013$$CN$US$US
164937215$16493721$5$F$20190910$20221206$20190628$20221209$EXP$$US-JAZZ-2019-US-008798$JAZZ$$45$YR$$M$Y$$$20221209$$MD$US$US
164947029$16494702$9$F$20190430$20221017$20190628$20221019$EXP$$DE-Eisai Medical Research-EC-2019-055892$EISAI$$64$YR$A$M$Y$60$KG$20221019$$MD$DE$
164953296$16495329$6$F$$20200203$20190628$20221213$PER$$PHEH2019US027230$NOVARTIS$$$$$F$Y$$$20221213$$HP$US$US
1649665112$16496651$12$F$20191201$20221123$20190628$20221129$EXP$$US-SA-2019SA175793$SANOFI AVENTIS$$59$YR$A$F$Y$$$20221130$$MD$US$US
164967885$16496788$5$F$20130103$20221121$20190628$20221128$EXP$$US-PFIZER INC-2019094103$PFIZER$$$$A$F$Y$$$20221128$$MD$US$US
164969023$16496902$3$F$$20221121$20190628$20221124$EXP$$US-INCYTE CORPORATION-2019IN006365$INCYTE$$$$$$Y$$$20221124$$CN$US$US
164977839$16497783$9$F$20220701$20221125$20190628$20221202$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR110915$GLAXOSMITHKLINE$$$$$$Y$$$20221202$$MD$CA$CA
164978518$16497851$8$F$20190605$20221021$20190628$20221025$EXP$$US-PFIZER INC-2019265512$PFIZER$$74$YR$$F$Y$85$KG$20221025$$CN$US$US
164984313$16498431$3$F$20190416$20221206$20190629$20221221$EXP$$IT-AUROBINDO-AUR-APL-2019-036110$AUROBINDO$$50$YR$$F$Y$$$20221221$$PH$IT$IT
164990792$16499079$2$F$20190211$20221209$20190701$20221214$PER$$DE-AMGEN-DEUNI2019102983$AMGEN$$62$YR$A$F$Y$58$KG$20221214$$MD$DE$DE
165022827$16502282$7$F$$20221019$20190701$20221021$PER$$US-PFIZER INC-2018483402$PFIZER$$61$YR$$M$Y$$$20221021$$MD$US$US
1650267111$16502671$11$F$$20221017$20190701$20221027$EXP$$CA-APOTEX-2019AP017128$APOTEX$$32$YR$$F$Y$$$20221027$$HP$CA$CA
165067138$16506713$8$F$20190612$20221111$20190701$20221118$EXP$$US-SHIRE-US201921056$TAKEDA$$38$YR$$F$Y$67$KG$20221118$$MD$US$US
165072389$16507238$9$F$20190601$20221205$20190701$20221208$EXP$$US-PFIZER INC-2019273483$PFIZER$$61$YR$$F$Y$71.973$KG$20221208$$CN$US$US
165078386$16507838$6$F$20190608$20221222$20190701$20221228$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK117252$GLAXOSMITHKLINE$$$$$$Y$$$20221228$$CN$BR$BR
1650915834$16509158$34$F$20180525$20221116$20190702$20221126$PER$$GB-AMGEN-GBRNI2018173425$AMGEN$$58$YR$A$F$Y$$$20221126$$MD$GB$GB
1650951110$16509511$10$F$20190219$20221129$20190702$20221201$EXP$$ES-GLAXOSMITHKLINE-ES2019GSK057780$GLAXOSMITHKLINE$$$$$$Y$$$20221201$$MD$ES$ES
1651007628$16510076$28$F$$20221003$20190701$20221007$EXP$$PHHY2018CO158317$NOVARTIS$$$$$F$Y$59$KG$20221007$$CN$CO$CO
1651019414$16510194$14$F$20190101$20221018$20190702$20221022$EXP$$JP-ABBVIE-19S-087-2815373-00$ABBVIE$Yokota R, Kawamura M, Nakamura S. B-26 A case (program) of a 70-year-old male patient with Parkinson^s disease who developed Oculogyric crisis after LCIG introduction. The 231st Kanto and Koshinetsu branch meeting of Japanese Society of Neurology. 2019 Dec 07; #7-#7.$70$YR$$M$Y$62$KG$20221022$$MD$JP$JP
165126577$16512657$7$F$$20221124$20190701$20221129$EXP$$PT-MYLANLABS-2019M1060171$MYLAN$Oliveira V, Chaves J. Seizure control with add-on eslicarbizepine in two patients with Dravet syndrome. Epilepsia. 2018;59 (3):S114-S115$20$YR$$M$Y$$$20221129$$HP$PT$PT
165129123$16512912$3$F$20170307$20221115$20190701$20221117$EXP$$DE-MYLANLABS-2019M1060178$MYLAN$$78$YR$$F$Y$$$20221117$$MD$DE$DE
1651329019$16513290$19$F$20160623$20221221$20190701$20221227$EXP$$PHHY2016CA090447$NOVARTIS$$28$YR$$F$Y$$$20221227$$MD$CA$CA
165142665$16514266$5$F$$20221104$20190702$20221114$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-16302$SAMSUNG BIOEPIS$$19$YR$A$M$Y$105$KG$20221114$$CN$CA$CA
165148535$16514853$5$F$20190101$20221201$20190702$20221206$EXP$$US-PFIZER INC-2018477176$PFIZER$$71$YR$$F$Y$$$20221206$$CN$US$US
165177928$16517792$8$F$$20221121$20190702$20221201$EXP$$CO-INCYTE CORPORATION-2018IN007751$INCYTE$$$$$$Y$$$20221201$$CN$CO$CO
165183038$16518303$8$F$$20221215$20190702$20221221$PER$$US-PFIZER INC-2019278575$PFIZER$$72$YR$$M$Y$$$20221221$$PH$US$US
165184156$16518415$6$F$$20221021$20190702$20221025$PER$$US-PFIZER INC-2019281421$PFIZER$$50$YR$$F$Y$$$20221025$$HP$US$US
1652084434$16520844$34$F$20160722$20221214$20190702$20221216$EXP$$GB-MYLANLABS-2019M1061731$MYLAN$$33$YR$$F$Y$$$20221216$$MD$GB$GB
1652241910$16522419$10$F$$20221104$20190703$20221110$EXP$$US-PFIZER INC-2019280984$PFIZER$$61$YR$$F$Y$$$20221110$$CN$US$US
1652298717$16522987$17$F$20180101$20221215$20190703$20221224$EXP$$CA-CELLTRION INC.-2018CA023475$CELLTRION$$$$$$Y$$$20221224$$CN$CA$CA
165231105$16523110$5$F$20190614$20221222$20190702$20221227$EXP$$ES-ABBVIE-19P-144-2835448-00$ABBVIE$$74$YR$$F$Y$$$20221227$$MD$ES$ES
165241914$16524191$4$F$$20220923$20190703$20221003$EXP$$CA-APOTEX-2019AP017287$APOTEX$$73$YR$$F$Y$81$KG$20221003$$HP$CA$CA
165249856$16524985$6$F$20130826$20221107$20190703$20221114$EXP$$JP-JNJFOC-20190701533$JOHNSON AND JOHNSON$$66$YR$E$F$Y$$$20221114$$MD$JP$JP
1652624113$16526241$13$F$20190626$20221031$20190703$20221116$EXP$$US-SA-2019SA178400$SANOFI AVENTIS$$40$YR$A$M$Y$$$20221116$$MD$US$US
165267334$16526733$4$F$$20221109$20190704$20221121$EXP$E2B_01805151$CA-APOTEX-2019AP017405$APOTEX$$68$YR$$M$Y$$$20221121$$HP$CA$CA
165268694$16526869$4$F$20180305$20221027$20190703$20221102$PER$$PHHY2018US048139$NOVARTIS$$64$YR$$F$Y$58.1$KG$20221102$$HP$US$US
165270872$16527087$2$F$$20221003$20190703$20221005$PER$$US-PFIZER INC-2019286164$PFIZER$$56$YR$$F$Y$$$20221005$$HP$US$US
165272584$16527258$4$F$20190619$20221028$20190703$20221101$EXP$$US-SA-2019SA129838$SANOFI AVENTIS$$14$YR$T$M$Y$$$20221101$$MD$US$US
165273612$16527361$2$F$$20221109$20190704$20221118$EXP$$CA-APOTEX-2019AP017343$APOTEX$$67$YR$$M$Y$$$20221118$$MD$CA$CA
1652766613$16527666$13$F$20170929$20221110$20190703$20221117$EXP$$JP-GILEAD-2018-0382287$GILEAD$$31$YR$A$M$Y$$$20221117$$MD$JP$JP
165280108$16528010$8$F$20190509$20221104$20190704$20221104$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-063509$BRISTOL MYERS SQUIBB$$67$YR$E$F$Y$$$20221104$$MD$JP$JP
165283972$16528397$2$F$$20221003$20190704$20221013$EXP$$US-TEVA-2019-US-1070384$TEVA$$19$MON$I$F$Y$$$20221013$$HP$US$US
165283983$16528398$3$F$$20221018$20190704$20221028$EXP$$US-TEVA-2019-US-1070383$TEVA$$5$YR$C$F$Y$$$20221028$$HP$US$US
165298763$16529876$3$F$$20221013$20190704$20221018$EXP$$US-GW PHARMA-201906USGW2225$JAZZ$$$$$M$Y$$$20221018$$HP$US$US
1653016823$16530168$23$F$20180101$20221206$20190704$20221215$EXP$$CA-CELLTRION INC.-2018CA017850$CELLTRION$$$$$$Y$$$20221215$$CN$CA$CA
165305864$16530586$4$F$20201111$20221128$20190704$20221130$EXP$$CA-TAKEDA-2019TUS040732$TAKEDA$$22$YR$$F$Y$$$20221130$$CN$CA$CA
1653094311$16530943$11$F$20180101$20221011$20190704$20221017$EXP$$PHHY2018CA072313$NOVARTIS$$$$$F$Y$$$20221017$$CN$CA$CA
165309688$16530968$8$F$$20221226$20190705$20221230$EXP$$IN-PFIZER INC-2018302438$PFIZER$$82$YR$$F$Y$$$20221230$$CN$IN$IN
165311962$16531196$2$F$$20221202$20190705$20221209$PER$$US-AMGEN-USASP2019106370$AMGEN$$72$YR$E$F$Y$$$20221209$$HP$US$US
165315702$16531570$2$F$20190101$20221104$20190705$20221108$EXP$$US-KYOWAKIRIN-2019BKK010416$KYOWA$$$$$$Y$$$20221108$$HP$US$US
1653166412$16531664$12$F$20190101$20221110$20190704$20221110$EXP$$AU-009507513-1906AUS011608$MERCK$$21$YR$$M$Y$60$KG$20221110$$HP$AU$AU
165320393$16532039$3$F$$20221215$20190705$20221222$PER$$US-INCYTE CORPORATION-2019IN006494$INCYTE$$$$$$Y$$$20221222$$CN$US$US
165326727$16532672$7$F$20161027$20221104$20190704$20221114$EXP$$CA-ROCHE-1994734$ROCHE$$79$YR$$F$Y$51$KG$20221114$$CN$CA$CA
165331943$16533194$3$F$$20221109$20190704$20221116$EXP$$CA-APOTEX-2019AP017401$APOTEX$$68$YR$$M$Y$$$20221116$$HP$CA$CA
165334495$16533449$5$F$20181001$20221109$20190704$20221115$EXP$$PHHY2018CO051727$NOVARTIS$$53$YR$$F$Y$70$KG$20221115$$CN$CO$CO
1653353219$16533532$19$F$$20221221$20190705$20221227$EXP$$US-PFIZER INC-2019285743$PFIZER$$70$YR$$F$Y$62.6$KG$20221227$$CN$US$US
165337143$16533714$3$F$$20221109$20190704$20221117$EXP$$CA-APOTEX-2019AP017407$APOTEX$$68$YR$$F$Y$$$20221117$$MD$CA$CA
165346213$16534621$3$F$20190101$20221018$20190705$20221028$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-013242$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221028$$CN$US$US
165352642$16535264$2$F$20100308$20220926$20190705$20221004$EXP$$US-AstraZeneca-2019SE94715$ASTRAZENECA$$20376$DY$$F$Y$56.2$KG$20221004$$LW$US$
1653543816$16535438$16$F$20181120$20221026$20190705$20221104$EXP$$US-ROCHE-2343876$ROCHE$$65$YR$$F$Y$72.64$KG$20221104$$CN$US$
1653551914$16535519$14$F$20190201$20221025$20190705$20221031$PER$$US-PFIZER INC-2019282842$PFIZER$$66$YR$$F$Y$79.38$KG$20221031$$HP$US$US
165355213$16535521$3$F$$20221221$20190705$20221227$PER$$US-PFIZER INC-2019285775$PFIZER$$70$YR$$F$Y$62.6$KG$20221227$$CN$US$US
1653559711$16535597$11$F$$20221219$20190705$20221228$PER$$US-PFIZER INC-2019281370$PFIZER$$18$YR$$M$Y$$$20221228$$HP$US$US
165356943$16535694$3$F$20140310$20221013$20190705$20221014$PER$$US-PFIZER INC-2019283455$PFIZER$$51$YR$$F$Y$54$KG$20221014$$LW$US$US
165363059$16536305$9$F$$20221004$20190705$20221005$PER$$US-PFIZER INC-2018108142$PFIZER$$57$YR$$F$Y$$$20221005$$MD$US$US
165365222$16536522$2$F$$20221206$20190706$20221219$EXP$$IE-AUROBINDO-AUR-APL-2019-037715$AUROBINDO$$38$YR$$F$Y$$$20221219$$MD$IE$IE
165366577$16536657$7$F$$20221117$20190706$20221127$EXP$$CA-TEVA-2019-CA-1071549$TEVA$$26$YR$A$F$Y$80$KG$20221126$$HP$CA$CA
1653741316$16537413$16$F$20180116$20221130$20190707$20221215$EXP$$JP-ABBVIE-18K-087-2232775-00$ABBVIE$Okajima M, Fujioka S, Komorita S, et al. A case of treatment-resistant dyskinesia during levodopa-carbidopa intestinal gel treatment. The 228th Kyushu Region Meeting of the Japanese Society of Neurology. 2019 Dec 07; 18-18.; Komorita S, Nishida A, Mishima T, et al. Optimal dose of levodopa-carbidopa intestinal gel in the treatment of diphasic dyskinesia and freezing of gait. Rinsho Shinkeigaku (Clin Neurol). 2021;$58$YR$$M$Y$52$KG$20221215$$MD$JP$JP
1653828620$16538286$20$F$20210101$20221101$20190708$20221110$EXP$$CA-CELLTRION INC.-2019CA022047$CELLTRION$$$$$$Y$$$20221110$$MD$CA$CA
1653906330$16539063$30$F$20190703$20221117$20190708$20221124$EXP$$PHHY2019CA155399$NOVARTIS$$50$YR$$F$Y$$$20221124$$CN$CA$CA
165392605$16539260$5$F$20190101$20221012$20190708$20221018$EXP$$DE-ROCHE-2348859$ROCHE$Heger J, Eichenauer D, Kasper P, Boll B, Shimabukuro-Vornhagen A, and Kochanek M Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy. European Journal of Haematology 2019;103 (3):268-71.$$$$F$Y$70$KG$20221018$$HP$DE$DE
1653962030$16539620$30$F$20161110$20221205$20190708$20221209$EXP$$GB-MYLANLABS-2016M1049014$MYLAN$$26$YR$$F$Y$$$20221209$$HP$GB$GB
165396497$16539649$7$F$20190601$20221221$20190708$20221228$EXP$$US-ROCHE-2346267$ROCHE$$52$YR$$F$Y$79.45$KG$20221228$$MD$US$
165398962$16539896$2$F$20190501$20221212$20190708$20221219$PER$$US-PFIZER INC-2019288218$PFIZER$$71$YR$$F$Y$80.272$KG$20221219$$CN$US$US
165399752$16539975$2$F$$20221202$20190708$20221207$PER$$US-PFIZER INC-2019283309$PFIZER$$72$YR$$F$Y$$$20221207$$HP$US$US
1654121013$16541210$13$F$20190325$20221125$20190708$20221202$EXP$$CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-034418$BRISTOL MYERS SQUIBB$$79$YR$E$M$Y$88$KG$20221202$$HP$CL$CL
1654184122$16541841$22$F$19960101$20221102$20190708$20221111$EXP$$US-JNJFOC-20190635771$JOHNSON AND JOHNSON$$72$YR$E$M$Y$61.29$KG$20221111$$CN$US$US
1654285528$16542855$28$F$20190508$20221027$20190709$20221102$EXP$$IE-ROCHE-2317974$ROCHE$$67$YR$$F$Y$75$KG$20221101$$MD$IE$
1654288928$16542889$28$F$20191009$20221222$20190709$20221230$EXP$$CA-CELLTRION INC.-2019CA019741$CELLTRION$$$$$$Y$$$20221231$$CN$CA$CA
165431473$16543147$3$F$$20221207$20190709$20221209$EXP$$US-ROCHE-2350792$ROCHE$$72$YR$$F$Y$$$20221209$$CN$US$
165439397$16543939$7$F$20180101$20221101$20190709$20221107$EXP$$US-ROCHE-2346733$ROCHE$$57$YR$$F$Y$61.29$KG$20221107$$CN$US$
165440669$16544066$9$F$$20221104$20190709$20221114$PER$$US-INCYTE CORPORATION-2019IN005521$INCYTE$$$$$$Y$$$20221115$$CN$US$US
165443498$16544349$8$F$20170831$20220912$20190709$20221005$EXP$$PHHY2018FR048485$NOVARTIS$$4$YR$$M$Y$18.2$KG$20221005$$MD$FR$FR
165446922$16544692$2$F$20171026$20221013$20190709$20221021$EXP$$DE-MYLANLABS-2019M1061888$MYLAN$$$$E$F$Y$$$20221021$$MD$DE$DE
165446942$16544694$2$F$20171015$20221011$20190709$20221018$EXP$$DE-MYLANLABS-2019M1061942$MYLAN$$$$E$F$Y$$$20221018$$MD$DE$DE
165446992$16544699$2$F$20171015$20221014$20190709$20221018$EXP$$DE-MYLANLABS-2019M1061959$MYLAN$$$$E$F$Y$$$20221018$$MD$DE$DE
165458222$16545822$2$F$20170615$20221006$20190709$20221013$EXP$$DE-MYLANLABS-2019M1062926$MYLAN$$$$E$M$Y$$$20221013$$MD$DE$DE
165458355$16545835$5$F$20190625$20221201$20190709$20221206$PER$$US-SHIRE-US201921789$TAKEDA$$36$YR$$F$Y$$$20221206$$HP$US$US
165492914$16549291$4$F$20190427$20221115$20190709$20221120$EXP$$PHJP2019JP006227$NOVARTIS$$23$YR$$F$Y$80.7$KG$20221121$$MD$JP$JP
165498486$16549848$6$F$20190101$20210324$20190710$20221208$EXP$$US-BEH-2019103933$CSL BEHRING$$55$YR$A$F$Y$$$20221208$$HP$US$US
1655138711$16551387$11$F$20210630$20221004$20190710$20221010$EXP$$PHEH2019US028686$NOVARTIS$$74$YR$$F$Y$52.16$KG$20221010$$CN$US$US
165522605$16552260$5$F$$20221010$20190710$20221012$PER$$US-PFIZER INC-2019289706$PFIZER$$68$YR$$F$Y$$$20221012$$CN$US$US
1655254112$16552541$12$F$$20221202$20190710$20221207$EXP$$US-PFIZER INC-2019290646$PFIZER$$79$YR$$F$Y$$$20221207$$CN$US$US
165525819$16552581$9$F$$20221222$20190710$20221227$EXP$$US-PFIZER INC-2019283173$PFIZER$$73$YR$$M$Y$83.46$KG$20221227$$CN$US$US
165525824$16552582$4$F$20190101$20221129$20190710$20221202$PER$$US-PFIZER INC-2019292069$PFIZER$$72$YR$$F$Y$$$20221202$$HP$US$US
165548174$16554817$4$F$20060209$20221215$20190710$20221219$EXP$$US-TAKEDA-2019TUS042422$TAKEDA$$$$$$Y$$$20221219$$CN$US$US
1655579429$16555794$29$F$20190121$20221215$20190710$20221222$EXP$GB-MHRA-EYC 00193692$GB-MYLANLABS-2019M1063640$MYLAN$$56$YR$$F$Y$80$KG$20221222$$MD$GB$GB
165558502$16555850$2$F$20161129$20221013$20190710$20221021$EXP$$DE-MYLANLABS-2019M1062761$MYLAN$$$$E$F$Y$$$20221021$$MD$DE$DE
1655585912$16555859$12$F$20221001$20221124$20190710$20221125$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK106932$GLAXOSMITHKLINE$$$$$$Y$$$20221125$$MD$BR$BR
165558782$16555878$2$F$20170907$20221010$20190710$20221019$EXP$$DE-MYLANLABS-2019M1062766$MYLAN$$$$E$F$Y$$$20221019$$MD$DE$DE
1655652116$16556521$16$F$20190516$20221003$20190711$20221012$EXP$$CA-CELLTRION INC.-2019CA021455$CELLTRION$$$$$$Y$$$20221013$$CN$CA$CA
165569715$16556971$5$F$20181119$20221122$20190711$20221125$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-067016$BRISTOL MYERS SQUIBB$$$$$M$Y$60.2$KG$20221125$$MD$JP$JP
165571214$16557121$4$F$$20221107$20190711$20221114$PER$$US-SHIRE-US201922234$TAKEDA$$$$$M$Y$$$20221114$$CN$US$US
165572464$16557246$4$F$20180113$20221108$20190711$20221111$EXP$$DE-MYLANLABS-2019M1063120$MYLAN$$$$E$F$Y$$$20221111$$MD$DE$DE
1655725216$16557252$16$F$20200623$20221125$20190711$20221205$EXP$$CA-CELLTRION INC.-2019CA022653$CELLTRION$$$$$$Y$$$20221205$$MD$CA$CA
165574245$16557424$5$F$20181119$20221122$20190711$20221130$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-065423$BRISTOL MYERS SQUIBB$$68$YR$E$M$Y$60$KG$20221130$$MD$JP$JP
165575236$16557523$6$F$20190108$20221011$20190711$20221021$EXP$$JP-CELLTRION INC.-2019JP020717$CELLTRION$$$$$$Y$$$20221021$$HP$JP$JP
165583972$16558397$2$F$$20221208$20190711$20221222$EXP$$CA-AUROBINDO-AUR-APL-2019-038642$AUROBINDO$$51$YR$$F$Y$$$20221222$$HP$CA$CA
165585293$16558529$3$F$20190201$20221219$20190711$20221227$PER$$PHEH2019US028849$NOVARTIS$$$$A$F$Y$$$20221227$$HP$US$US
165585523$16558552$3$F$20200101$20221209$20190711$20221216$EXP$$CA-PFIZER INC-2019294509$PFIZER$$58$YR$$F$Y$$$20221216$$CN$CA$CA
165597323$16559732$3$F$20191006$20221026$20190711$20221102$EXP$$US-PFIZER INC-2019292834$PFIZER$$71$YR$$F$Y$70.31$KG$20221102$$CN$US$US
165607115$16560711$5$F$$20221207$20190711$20221212$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-17714$SAMSUNG BIOEPIS$$67$YR$E$F$Y$85$KG$20221212$$CN$CA$CA
1656091010$16560910$10$F$$20221018$20190711$20221026$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-17663$SAMSUNG BIOEPIS$$47$YR$A$M$Y$87$KG$20221026$$HP$CA$CA
1656317220$16563172$20$F$20190101$20221031$20190711$20221108$EXP$$DE-CELLTRION INC.-2019DE022709$CELLTRION$Heger JM, Eichenauer DA, Kasper P, Boll B, Shimabukuro-Vornhagen A, Kochanek M.. Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy.. European Journal of Haematology. 2019;1-4$$$$$Y$$$20221108$$HP$DE$DE
1656321812$16563218$12$F$20190614$20221122$20190711$20221201$PER$$JP-AMGEN-JPNCT2019109673$AMGEN$$76$YR$E$M$Y$$$20221201$$MD$JP$JP
165632268$16563226$8$F$$20221019$20190711$20221028$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-17918$SAMSUNG BIOEPIS$$62$YR$A$F$Y$78$KG$20221028$$MD$CA$CA
1656334324$16563343$24$F$20181214$20221017$20190711$20221025$EXP$$CA-CELLTRION INC.-2018CA024961$CELLTRION$$$$$$Y$$$20221025$$CN$CA$CA
165633943$16563394$3$F$20190319$20221129$20190712$20221208$EXP$$US-BIOGEN-2019BI00759676$BIOGEN$$58$YR$$M$Y$$$20221208$$CN$US$US
1656404516$16564045$16$F$20180728$20221202$20190712$20221209$PER$$JP-AMGEN-JPNSP2019099850$AMGEN$$69$YR$E$M$Y$64.4$KG$20221209$$MD$JP$JP
165641087$16564108$7$F$$20221011$20190712$20221019$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-17770$SAMSUNG BIOEPIS$$64$YR$A$F$Y$68$KG$20221019$$CN$CA$CA
165646523$16564652$3$F$20190426$20221206$20190712$20221221$EXP$$IT-AUROBINDO-AUR-APL-2019-039855$AUROBINDO$$40$YR$$F$Y$$$20221221$$PH$IT$IT
165659517$16565951$7$F$20190701$20221109$20190712$20221114$EXP$$CA-TAKEDA-2019TUS042270$TAKEDA$$48$YR$$M$Y$$$20221114$$MD$CA$CA
165664902$16566490$2$F$$20221026$20190712$20221101$EXP$$US-PFIZER INC-2019292649$PFIZER$$71$YR$$F$Y$70.31$KG$20221101$$CN$US$US
165673362$16567336$2$F$20180720$20221011$20190712$20221019$PER$$US-SHIRE-US201922566$TAKEDA$$66$YR$$F$Y$34$KG$20221019$$MD$US$US
165682626$16568262$6$F$20160301$20221031$20190712$20221106$EXP$$BR-BIOGEN-2019BI00761536$BIOGEN$$27$YR$$F$Y$72$KG$20221106$$HP$BR$BR
165683933$16568393$3$F$$20221118$20190712$20221125$EXP$$US-SHIRE-US201922565$TAKEDA$$$$$F$Y$104.31$KG$20221125$$CN$US$US
165685552$16568555$2$F$20190101$20221108$20190712$20221115$EXP$$PHHY2019CO147393$NOVARTIS$$$$$M$Y$66$KG$20221115$$CN$CO$CO
165714162$16571416$2$F$20180830$20221202$20190715$20221205$EXP$$FR-MYLANLABS-2019M1064111$MYLAN$$42$YR$$F$Y$75$KG$20221205$$MD$FR$FR
1657169621$16571696$21$F$20220124$20221123$20190715$20221128$EXP$$IN-PFIZER INC-2019111745$PFIZER$$48$YR$$F$Y$77$KG$20221128$$CN$IN$IN
165719928$16571992$8$F$20040930$20221025$20190715$20221101$EXP$$US-PFIZER INC-2019296460$PFIZER$$65$YR$$F$Y$58.97$KG$20221101$$CN$US$US
1657234912$16572349$12$F$20190630$20221213$20190715$20221215$EXP$$PHJP2019JP008703$NOVARTIS$$4$YR$$F$Y$18.7$KG$20221215$$MD$JP$JP
165728492$16572849$2$F$20221106$20221206$20190715$20221209$EXP$$US-JAZZ-2019-US-009599$JAZZ$$38$YR$$F$Y$$$20221209$$CN$US$US
165732013$16573201$3$F$20181218$20221010$20190715$20221018$EXP$$DE-MYLANLABS-2019M1064968$MYLAN$$67$YR$$M$Y$$$20221018$$MD$DE$DE
165750376$16575037$6$F$20180101$20221003$20190715$20221004$EXP$$PHHY2019FR161146$NOVARTIS$$75$YR$$M$Y$72$KG$20221004$$HP$FR$FR
165761937$16576193$7$F$$20220930$20190716$20221010$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-17719$SAMSUNG BIOEPIS$$25$YR$A$F$Y$76$KG$20221010$$MD$CA$CA
165778395$16577839$5$F$20190606$20221206$20190716$20221212$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-067765$BRISTOL MYERS SQUIBB$$51$YR$A$M$Y$53.7$KG$20221212$$MD$JP$JP
1657801610$16578016$10$F$20190801$20221206$20190716$20221212$EXP$$US-PFIZER INC-2019297066$PFIZER$$71$YR$$F$Y$73$KG$20221212$$CN$US$US
165781623$16578162$3$F$$20221221$20190716$20221227$PER$$US-PFIZER INC-2019301383$PFIZER$$$$$F$Y$$$20221227$$MD$US$US
165783134$16578313$4$F$20080701$20221214$20190716$20221219$EXP$$US-TAKEDA-2019TUS043592$TAKEDA$$$$$$Y$$$20221219$$CN$US$US
165787465$16578746$5$F$20170101$20221024$20190716$20221031$PER$$US-Eisai Medical Research-EC-2017-030131$EISAI$$64$YR$A$M$Y$$$20221031$$CN$US$
165819764$16581976$4$F$20190101$20200519$20190717$20221115$PER$$US-AMGEN-USASP2019111298$AMGEN$$80$YR$E$F$Y$$$20221114$$CN$US$US
165826746$16582674$6$F$20190601$20221212$20190717$20221215$EXP$$CA-BIOGEN-2019BI00763382$BIOGEN$$55$YR$$F$Y$$$20221215$$HP$CA$CA
165836299$16583629$9$F$20210101$20221027$20190717$20221031$PER$$US-PFIZER INC-2019299604$PFIZER$$73$YR$$F$Y$$$20221031$$HP$US$US
1658426010$16584260$10$F$20030101$20221107$20190717$20221114$EXP$$GB-PFIZER INC-2011207736$PFIZER$$31$YR$$F$Y$63.5$KG$20221114$$MD$GB$GB
165844555$16584455$5$F$20150810$20221219$20190717$20221227$EXP$$GB-ASPEN-GLO2016GB012390$ASPEN$$$$$$Y$$$20221227$$HP$GB$GB
1658461412$16584614$12$F$20170811$20221114$20190717$20221122$EXP$$IT-AEGERION PHARMACEUTICAL, INC-AEGR004386$AEGERION$$$$$$Y$$$20221122$$MD$IT$IT
1658488016$16584880$16$F$20190528$20221003$20190717$20221007$EXP$$PHHO2019GB007274$NOVARTIS$$5$YR$$M$Y$21$KG$20221007$$MD$GB$GB
1658605112$16586051$12$F$$20200605$20190717$20221209$EXP$$CO-INCYTE CORPORATION-2019IN007036$INCYTE$$$$$$Y$$$20221209$$CN$CO$CO
165876455$16587645$5$F$20220721$20221109$20190717$20221116$EXP$$BR-GLAXOSMITHKLINE-BR2019AMR124454$GLAXOSMITHKLINE$$$$$$Y$$$20221116$$CN$BR$BR
165894139$16589413$9$F$20190619$20221116$20190718$20221121$EXP$$DE-ROCHE-2343272$ROCHE$$67$YR$$M$Y$75$KG$20221121$$MD$DE$
1659185813$16591858$13$F$20190712$20221021$20190718$20221024$EXP$$US-PFIZER INC-2019307099$PFIZER$$56$YR$$F$Y$$$20221024$$CN$US$US
1659214427$16592144$27$F$20190101$20221006$20190718$20221012$EXP$$US-TESAROUBC-2019-TSO02339-US$GLAXOSMITHKLINE$$$$$$Y$$$20221012$$HP$US$US
165952012$16595201$2$F$20180401$20221221$20190718$20221227$EXP$$FR-BIOGEN-2019BI00761130$BIOGEN$$$$A$F$Y$$$20221227$$CN$FR$FR
165958718$16595871$8$F$20180101$20221222$20190719$20221223$EXP$$SE-ABBVIE-19K-150-2855444-00$ABBVIE$$$$$F$Y$80$KG$20221223$$HP$SE$SE
165962765$16596276$5$F$20180901$20221102$20190719$20221109$EXP$$PHHY2018CA123018$NOVARTIS$$53$YR$$F$Y$$$20221109$$CN$CA$CA
165965479$16596547$9$F$20160610$20221117$20190719$20221121$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2017JPN142447$VIIV$$$$$$Y$$$20221121$$MD$JP$JP
165994662$16599466$2$F$20171214$20221017$20190719$20221025$EXP$$DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-006605$BRISTOL MYERS SQUIBB$$56$YR$A$M$Y$$$20221025$$HP$DE$DE
165999188$16599918$8$F$20190413$20221112$20190720$20221130$EXP$$RU-ABBVIE-19K-251-2856668-00$ABBVIE$$61$YR$$M$Y$78$KG$20221130$$MD$RU$RU
165999972$16599997$2$F$20190715$20221215$20190720$20221219$PER$$US-SHIRE-US201923323$TAKEDA$$43$YR$$M$Y$$$20221219$$HP$US$US
1660071311$16600713$11$F$20190902$20221122$20190719$20221124$EXP$$US-PFIZER INC-2019307236$PFIZER$$79$YR$$F$Y$82$KG$20221124$$HP$US$US
166010284$16601028$4$F$20190705$20221110$20190719$20221117$EXP$$US-VERTEX PHARMACEUTICALS-2019-006535$VERTEX$$30$YR$$M$Y$$$20221117$$HP$US$US
166017475$16601747$5$F$$20221110$20190719$20221117$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR127715$GLAXOSMITHKLINE$$$$$$Y$$$20221117$$MD$CA$CA
166062802$16606280$2$F$20190710$20190726$20190721$20221206$PER$$US-AMGEN-USASP2019115564$AMGEN$$60$YR$A$M$Y$$$20221206$$CN$US$US
1660649410$16606494$10$F$20190701$20221021$20190722$20221028$EXP$$US-BIOGEN-2019BI00763401$BIOGEN$$47$YR$$M$Y$$$20221028$$CN$US$US
166076342$16607634$2$F$$20221003$20190722$20221013$EXP$$CA-TEVA-2019-CA-1079610$TEVA$$$$$M$Y$$$20221013$$CN$CA$CA
1660912310$16609123$10$F$$20221101$20190722$20221110$EXP$$CA-APOTEX-2019AP018499$APOTEX$$65$YR$$F$Y$$$20221110$$MD$CA$CA
166099878$16609987$8$F$20190319$20220927$20190722$20221003$EXP$$JP-GILEAD-2019-0419212$GILEAD$$41$YR$A$M$Y$$$20221003$$MD$JP$JP
166114294$16611429$4$F$20150801$20221007$20190722$20221010$PER$$US-PFIZER INC-2019048721$PFIZER$$65$YR$$F$Y$$$20221010$$LW$US$US
1661363945$16613639$45$F$20190701$20221205$20190723$20221215$EXP$$CA-CELLTRION INC.-2019CA022790$CELLTRION$$$$$$Y$$$20221215$$MD$CA$CA
1661364027$16613640$27$F$20190628$20220921$20190723$20221002$EXP$$CA-CELLTRION INC.-2019CA022824$CELLTRION$$$$$$Y$$$20221003$$MD$CA$CA
166137438$16613743$8$F$20180718$20221216$20190723$20221221$EXP$$DE-ROCHE-2183928$ROCHE$$39$YR$$F$Y$62$KG$20221221$$MD$DE$
166145327$16614532$7$F$$20221115$20190723$20221121$PER$$US-PFIZER INC-2019310959$PFIZER$$71$YR$$F$Y$$$20221121$$HP$US$US
166145775$16614577$5$F$$20221227$20190723$20221230$EXP$$US-PFIZER INC-2019310825$PFIZER$$84$YR$$F$Y$56.7$KG$20221230$$CN$US$US
166146163$16614616$3$F$20180101$20220930$20190723$20221007$EXP$$FR-AUROBINDO-AUR-APL-2019-042696$AUROBINDO$$75$YR$$M$Y$72$KG$20221007$$HP$FR$FR
166147255$16614725$5$F$20190101$20221125$20190723$20221130$PER$$US-PFIZER INC-2019312687$PFIZER$$54$YR$$F$Y$$$20221130$$HP$US$US
1661486413$16614864$13$F$$20221122$20190723$20221130$EXP$$US-PFIZER INC-2019311646$PFIZER$$48$YR$$F$Y$$$20221130$$CN$US$US
166148946$16614894$6$F$20110101$20221104$20190723$20221108$EXP$$US-GILEAD-2019-0419390$GILEAD$$53$YR$A$M$Y$$$20221107$$LW$US$US
166154355$16615435$5$F$$20220926$20190723$20221008$EXP$$ES-AUROBINDO-AUR-APL-2019-043267$AUROBINDO$Sadyrbaeva-Dolgova S, Cancela-diaz B, Jimenz-morales A, Sanchez-argaiz M. Nephrogenic diabetes insipidus induced by liposomal amphotericin b: A case report. European Journal of Hospital Pharmacy - Science and Practice. 2019;26(1):A106abstr. 4CPS-082$39$YR$$M$Y$$$20221008$$HP$ES$ES
166163476$16616347$6$F$20180704$20221223$20190723$20221227$EXP$$GB-MYLANLABS-2019M1068313$MYLAN$$57$YR$$F$Y$$$20221227$$MD$GB$GB
166189266$16618926$6$F$20190101$20221221$20190723$20221227$EXP$$US-PFIZER INC-2019309944$PFIZER$$56$YR$$F$Y$127$KG$20221227$$CN$US$US
166202482$16620248$2$F$$20221018$20190723$20221027$EXP$$BE-JNJFOC-20190715951$JOHNSON AND JOHNSON$$$$$$Y$$$20221027$$HP$BE$BE
1662350711$16623507$11$F$20190224$20221013$20190724$20221017$EXP$$DE-ROCHE-2354095$ROCHE$$47$YR$$M$Y$$$20221017$$CN$DE$
166235743$16623574$3$F$$20221223$20190724$20221229$EXP$$US-ASTELLAS-2018US053141$ASTELLAS$$$$$M$Y$$$20221229$$CN$US$US
166244435$16624443$5$F$20080508$20221006$20190724$20221012$EXP$$US-GILEAD-2019-0419475$GILEAD$$23$YR$A$M$Y$$$20221011$$LW$US$US
1662446025$16624460$25$F$20190710$20221031$20190724$20221107$EXP$$DE-ROCHE-2355980$ROCHE$$34$YR$$F$Y$$$20221107$$CN$DE$DE
166245232$16624523$2$F$20190714$20221014$20190724$20221017$EXP$$US-KYOWAKIRIN-2019BKK011474$KYOWA$$$$$$Y$$$20221017$$HP$US$US
166251734$16625173$4$F$$20221128$20190724$20221130$PER$$US-PFIZER INC-2019312402$PFIZER$$44$YR$$F$Y$$$20221130$$CN$US$US
1662541010$16625410$10$F$20200205$20221117$20190724$20221121$EXP$$US-PFIZER INC-2019313310$PFIZER$$69$YR$$M$Y$75.283$KG$20221121$$CN$US$US
166255723$16625572$3$F$20220124$20221024$20190724$20221031$EXP$$CA-TAKEDA-2017MPI006451$TAKEDA$$70$YR$$M$Y$$$20221031$$CN$CA$CA
166271833$16627183$3$F$20160916$20221208$20190724$20221220$EXP$$US-AstraZeneca-2019SE10713$ASTRAZENECA$$12535$DY$$M$Y$136.1$KG$20221216$$LW$US$
1662878723$16628787$23$F$20180401$20221202$20190725$20221212$EXP$$CA-CELLTRION INC.-2018CA018020$CELLTRION$$$$$$Y$$$20221212$$CN$CA$CA
1663029426$16630294$26$F$20190420$20221114$20190725$20221116$EXP$$DE-PURDUE PHARMA-GBR-2019-0068421$PURDUE$$47$YR$$F$Y$61$KG$20221116$$MD$DE$DE
166309489$16630948$9$F$$20221024$20190725$20221029$EXP$$PHHY2018CO055420$NOVARTIS$$$$$F$Y$67$KG$20221029$$CN$CO$CO
166312885$16631288$5$F$$20220915$20190725$20221006$EXP$$CA-SHIRE-CA201923310$TAKEDA$$$$$$Y$$$20221006$$CN$CA$CA
1663141319$16631413$19$F$20160323$20221007$20190725$20221010$EXP$$GB-MYLANLABS-2019M1069544$MYLAN$$78$YR$$F$Y$$$20221010$$MD$GB$GB
1663200711$16632007$11$F$$20221128$20190725$20221130$EXP$$US-PFIZER INC-2019317494$PFIZER$$67$YR$$F$Y$$$20221130$$CN$US$US
1663289014$16632890$14$F$20181201$20221021$20190725$20221025$PER$$US-PFIZER INC-2018402431$PFIZER$$54$YR$$F$Y$92$KG$20221025$$HP$US$US
1663402421$16634024$21$F$20180705$20221101$20190725$20221110$EXP$$CA-CELLTRION INC.-2018CA021351$CELLTRION$$$$$$Y$$$20221110$$MD$CA$CA
1663440525$16634405$25$F$20190318$20221209$20190726$20221219$EXP$$CA-CELLTRION INC.-2019CA020003$CELLTRION$$$$$$Y$$$20221219$$MD$CA$CA
166351226$16635122$6$F$20141219$20221219$20190726$20221221$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2017JPN160693$VIIV$$$$$$Y$$$20221221$$MD$JP$JP
166351446$16635144$6$F$20141219$20221219$20190726$20221221$EXP$$JP-GLAXOSMITHKLINE-JP2017JPN160693$GLAXOSMITHKLINE$$$$$$Y$$$20221221$$MD$JP$JP
166360736$16636073$6$F$20190328$20221027$20190726$20221031$PER$$US-PFIZER INC-2019151560$PFIZER$$61$YR$$M$Y$92$KG$20221031$$HP$US$US
166364723$16636472$3$F$$20221121$20190726$20221128$PER$$US-PFIZER INC-2019317598$PFIZER$$70$YR$$F$Y$$$20221128$$MD$US$US
166379766$16637976$6$F$20140617$20221107$20190726$20221116$EXP$$JP-JNJFOC-20190735146$JOHNSON AND JOHNSON$$62$YR$A$M$Y$$$20221116$$MD$JP$JP
166389615$16638961$5$F$20100604$20221129$20190726$20221202$EXP$$US-GILEAD-2019-0419915$GILEAD$$63$YR$A$M$Y$$$20221202$$LW$US$US
166390212$16639021$2$F$20190529$20221031$20190726$20221103$EXP$PHHY2019IT168236$PHHY2019IT168236$NOVARTIS$Barbieri MA, Sorbara EE, Cicala G, Santoro V, Cutroneo PM,Franchina T, et al.. Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Databas. DRUGS-REAL-WORLD-OUTC. 2022;9(1):91-107$74$YR$$F$Y$$$20221103$$HP$IT$IT
1664154236$16641542$36$F$20161010$20221213$20190729$20221222$EXP$GB-EMA-DD-20190311-KUMARSINGH_A-170148$GB-Accord-124546$ACCORD$$26$YR$A$F$Y$$$20221222$$HP$GB$GB
1664222810$16642228$10$F$20190101$20221028$20190729$20221102$EXP$$CA-PFIZER INC-2019239098$PFIZER$$64$YR$$M$Y$$$20221102$$CN$CA$CA
166425004$16642500$4$F$20160101$20221026$20190729$20221031$EXP$$US-GILEAD-2019-0419935$GILEAD$$$$A$M$Y$$$20221030$$LW$US$US
166431328$16643132$8$F$$20221031$20190729$20221103$EXP$$US-PFIZER INC-2019320724$PFIZER$$80$YR$$F$Y$$$20221103$$CN$US$US
166438945$16643894$5$F$20140101$20221025$20190729$20221028$EXP$$US-GILEAD-2019-0419932$GILEAD$$71$YR$E$M$Y$$$20221027$$LW$US$US
1664423725$16644237$25$F$20200923$20221103$20190729$20221109$EXP$$PHEH2019US031389$NOVARTIS$$62$YR$$F$Y$112$KG$20221109$$CN$US$US
166443324$16644332$4$F$20180626$20221011$20190729$20221020$EXP$$DE-MYLANLABS-2019M1068002$MYLAN$$$$A$F$Y$$$20221020$$MD$DE$DE
166445703$16644570$3$F$20221029$20221107$20190729$20221111$EXP$$CA-GILEAD-2019-0420529$GILEAD$$65$YR$E$M$Y$$$20221111$$PH$CA$CA
166455382$16645538$2$F$$20190723$20190730$20221111$PER$$US-AMGEN-USASL2019118521$AMGEN$$$$$F$Y$$$20221111$$CN$US$US
1664563425$16645634$25$F$20200425$20221216$20190730$20221227$PER$$JP-AMGEN-JPNSP2019120520$AMGEN$$82$YR$E$M$Y$55.3$KG$20221227$$MD$JP$JP
166456692$16645669$2$F$$20190723$20190730$20221111$PER$$US-AMGEN-USASL2019118460$AMGEN$$$$$M$Y$$$20221111$$CN$US$US
1664579113$16645791$13$F$20180928$20221202$20190730$20221211$EXP$$FR-ABBVIE-18K-056-2528056-00$ABBVIE$$64$YR$$M$Y$76$KG$20221211$$MD$FR$FR
166458219$16645821$9$F$$20221205$20190730$20221213$EXP$$CA-ROCHE-2363680$ROCHE$$$$$M$Y$$$20221213$$HP$CA$
166473142$16647314$2$F$20111201$20221005$20190730$20221006$PER$$US-PFIZER INC-2016584418$PFIZER$$67$YR$$F$Y$$$20221006$$LW$US$US
166473416$16647341$6$F$20190527$20221223$20190730$20221230$EXP$$JP-009507513-1907JPN002952J$MERCK$Matsumoto K, Wakatuki J, Sakuma D, Kin E, Kobayashi Y, Komata M. WS16-3 Immune-related side effects during the first 5 years of use of immune checkpoint inhibitors. The 60th Annual Meeting of Japan Society of Clinical Oncology. 2022$67$YR$$M$Y$40$KG$20221230$$MD$JP$JP
166476654$16647665$4$F$$20221102$20190730$20221103$PER$$US-PFIZER INC-2019322283$PFIZER$$75$YR$$F$Y$$$20221103$$MD$US$US
1664898118$16648981$18$F$20190721$20221223$20190730$20221227$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-072687$BRISTOL MYERS SQUIBB$$35$YR$A$M$Y$86$KG$20221227$$MD$JP$JP
166493275$16649327$5$F$20220815$20221121$20190730$20221122$EXP$$US-PFIZER INC-2019325371$PFIZER$$80$YR$$M$Y$85.714$KG$20221122$$CN$US$US
1664974638$16649746$38$F$20180101$20221202$20190730$20221212$EXP$$CA-CELLTRION INC.-2018CA017401$CELLTRION$$$$$$Y$$$20221212$$MD$CA$CA
166498257$16649825$7$F$20180101$20221028$20190730$20221105$EXP$$JP-UNITED THERAPEUTICS-UNT-2018-014473$UNITED THERAPEUTICS$$$$$F$Y$47$KG$20221105$$MD$JP$JP
1665017033$16650170$33$F$20190101$20221205$20190731$20221213$EXP$$CA-CELLTRION INC.-2019CA020445$CELLTRION$$$$$$Y$$$20221213$$MD$CA$CA
166504314$16650431$4$F$20191201$20221121$20190731$20221128$EXP$$US-ROCHE-2359934$ROCHE$$60$YR$$F$Y$90.8$KG$20221128$$CN$US$
1665077712$16650777$12$F$20190601$20221122$20190731$20221130$PER$$JP-AMGEN-JPNSP2019119493$AMGEN$$53$YR$A$F$Y$49.9$KG$20221129$$MD$JP$JP
166521875$16652187$5$F$20130101$20211119$20190731$20221130$EXP$$GB-JNJFOC-20190732991$JOHNSON AND JOHNSON$$$$$F$Y$$$20221201$$CN$GB$GB
166524902$16652490$2$F$$20221214$20190731$20221216$EXP$$US-SHIRE-US201924614$TAKEDA$$$$$M$Y$$$20221216$$CN$US$US
166528236$16652823$6$F$20190606$20221129$20190731$20221205$PER$$US-SHIRE-US201924611$TAKEDA$$80$YR$$F$Y$$$20221205$$MD$US$US
1665369320$16653693$20$F$20190524$20220928$20190731$20221010$EXP$$AR-INCYTE CORPORATION-2019IN007480$INCYTE$$$$$$Y$$$20221010$$CN$AR$AR
166540365$16654036$5$F$$20221205$20190731$20221215$EXP$$CZ-JNJFOC-20190736034$JOHNSON AND JOHNSON$$59$YR$A$F$Y$$$20221216$$MD$CZ$CZ
166540743$16654074$3$F$20190101$20221017$20190731$20221025$PER$$US-SA-2019SA123849$SANOFI AVENTIS$$76$YR$E$F$Y$$$20221025$$MD$US$US
166552737$16655273$7$F$20150101$20220927$20190801$20221011$EXP$$CZ-AUROBINDO-AUR-APL-2019-044527$AUROBINDO$Kamasova, M. Fixed triple combination therapy of antihypertensive drugs in common clinical practice. Farmakoter Revue. 2019;4(3):400-02$54$YR$$F$Y$$$20221011$$MD$CZ$CZ
166560646$16656064$6$F$20220408$20221107$20190801$20221110$EXP$$US-SHIRE-US201924762$TAKEDA$$76$YR$$F$Y$$$20221110$$HP$US$US
166564634$16656463$4$F$$20221201$20190801$20221202$EXP$$US-PFIZER INC-2019325408$PFIZER$$66$YR$$F$Y$$$20221202$$CN$US$US
166571083$16657108$3$F$$20221110$20190801$20221114$EXP$$CA-009507513-1907CAN016767$MERCK$$66$YR$$F$Y$$$20221114$$MD$CA$CA
166580044$16658004$4$F$$20221205$20190801$20221213$EXP$$CA-BAYER-2019-139374$BAYER$$65$YR$E$F$Y$$$20221213$$HP$CA$CA
166585716$16658571$6$F$20180101$20221121$20190801$20221129$EXP$$CZ-MYLANLABS-2019M1071854$MYLAN$Kunova A., Heller S., Karetova D., Prochazka P., Lindner J.. Acute aortic dissection type B (summary completed with casuistic).. Postgradualni medicina. 2019;21:27-32$50$YR$$M$Y$$$20221129$$MD$CZ$CZ
166590645$16659064$5$F$20190301$20220926$20190801$20221006$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-066993$BRISTOL MYERS SQUIBB$Kubo T, Hino A, Fukushima K, Shimomura Y, Kurashige M, Kusakabe S, et al. Nivolumab-induced systemic lymphadenopathy occurring during treatment of malignant melanoma: A case report. International Journal of Hematology. 2022 Feb 24; 116(2): 302-6. 10.1007/s12185-022-03312-0$57$YR$A$M$Y$$$20221006$$MD$JP$JP
166592713$16659271$3$F$$20221115$20190802$20221118$PER$$US-AMGEN-USASP2019123403$AMGEN$$66$YR$E$F$Y$$$20221118$$MD$US$US
1665952914$16659529$14$F$20180615$20221005$20190802$20221009$EXP$$DE-ROCHE-2143622$ROCHE$$52$YR$$F$Y$$$20221009$$CN$DE$
166601494$16660149$4$F$20150528$20221024$20190802$20221027$EXP$$JP-KYOWAKIRIN-2019AKK012250$KYOWA$$$$$$Y$$$20221027$$HP$JP$JP
166611073$16661107$3$F$20221213$20221219$20190802$20221228$30DAY$$US-PFIZER INC-2019330319$PFIZER$$8$YR$$F$Y$$$20221228$$CN$US$US
166614916$16661491$6$F$$20221019$20190802$20221020$PER$$US-PFIZER INC-2019329217$PFIZER$$70$YR$$F$Y$94.3$KG$20221020$$CN$US$US
166617592$16661759$2$F$20180901$20221028$20190802$20221104$EXP$$JP-AstraZeneca-2018SF44107$ASTRAZENECA$Fujiwara K.. The second Pneumonitis Management Academy. 2019;$57$YR$$M$Y$$$20221104$$MD$JP$
1666183219$16661832$19$F$$20221117$20190802$20221129$EXP$$US-PFIZER INC-2019313322$MYLAN$$$$$M$Y$119$KG$20221129$$CN$US$US
166633343$16663334$3$F$20190726$20221020$20190802$20221025$EXP$$US-ASTELLAS-2019US027170$ASTELLAS$$66$YR$$M$Y$$$20221025$$CN$US$US
166641715$16664171$5$F$$20221121$20190802$20221123$EXP$$US-PFIZER INC-2019329356$PFIZER$$66$YR$$F$Y$78$KG$20221123$$HP$US$US
166646832$16664683$2$F$20190521$20221207$20190803$20221221$EXP$$IT-AUROBINDO-AUR-APL-2019-044584$AUROBINDO$$49$YR$$F$Y$$$20221221$$PH$IT$IT
1666588522$16665885$22$F$20190401$20221214$20190804$20221222$EXP$$CA-CELLTRION INC.-2018CA025312$CELLTRION$$$$$$Y$$$20221222$$CN$CA$CA
166694547$16669454$7$F$20190703$20221202$20190805$20221208$EXP$$JP-PFIZER INC-2019270425$PFIZER$$75$YR$$F$Y$59$KG$20221208$$MD$JP$JP
166695173$16669517$3$F$20060101$20221110$20190805$20221117$EXP$$FR-MYLANLABS-2017M1024468$MYLAN$Mazzola A, Minh M, Charlotte F, Hdiji A, Bernard D, Wendum D, Calmus Y and Conti F.. Chronic hepatitis E viral infection after liver transplantation: a regression of fibrosis following antiviral therapy. Transplantation. 2017;101 (9):2083-7$57$YR$$M$Y$$$20221117$$MD$FR$FR
166699624$16669962$4$F$20190101$20221111$20190805$20221123$EXP$$US-ASTELLAS-2019US006931$ASTELLAS$$$$$M$Y$$$20221123$$CN$US$US
166702392$16670239$2$F$$20221123$20190805$20221130$PER$$US-BIOMARINAP-US-2019-124931$BIOMARIN$$$$$$Y$$$20221130$$CN$US$US
1667142817$16671428$17$F$20180701$20220929$20190806$20221020$EXP$$CA-CELLTRION INC.-2018CA019774$CELLTRION$$$$$$Y$$$20221020$$MD$CA$CA
166726112$16672611$2$F$20180329$20221207$20190806$20221209$PER$$JP-BEH-2019105142$CSL BEHRING$$9$YR$C$M$Y$23$KG$20221209$$MD$JP$JP
1667309610$16673096$10$F$$20221220$20190806$20221227$EXP$$US-PFIZER INC-2018211378$PFIZER$$84$YR$$F$Y$$$20221227$$CN$US$US
1667362215$16673622$15$F$20170901$20221208$20190806$20221212$EXP$$CA-PFIZER INC-2017067275$PFIZER$$80$YR$$M$Y$$$20221212$$CN$CA$CA
166753604$16675360$4$F$$20221020$20190806$20221027$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-031834$BOEHRINGER INGELHEIM$$62$YR$A$F$Y$$$20221027$$MD$CA$CA
166753633$16675363$3$F$20190717$20221031$20190806$20221104$EXP$$US-VERTEX PHARMACEUTICALS-2019-007191$VERTEX$$49$YR$$M$Y$$$20221104$$MD$US$US
166756897$16675689$7$F$20181220$20221227$20190806$20221230$EXP$$PHHY2019DE022006$NOVARTIS$$66$YR$$F$Y$$$20221230$$MD$DE$DE
1667582748$16675827$48$F$20190101$20221123$20190806$20221202$EXP$$CA-CELLTRION INC.-2019CA022380$CELLTRION$$$$$$Y$$$20221202$$CN$CA$CA
166760454$16676045$4$F$20220826$20221011$20190807$20221012$PER$$US-BIOGEN-2019BI00770682$BIOGEN$$53$YR$$F$Y$$$20221012$$CN$US$US
1667618213$16676182$13$F$20180601$20221227$20190807$20221229$EXP$$US-JAZZ-2019-US-010445$JAZZ$$66$YR$$F$Y$70.2$KG$20221229$$MD$US$US
166774682$16677468$2$F$20190727$20190801$20190807$20221213$PER$$US-AMGEN INC.-USASP2019124203$AMGEN$$35$YR$A$F$Y$$$20221213$$CN$US$US
166778492$16677849$2$F$$20221003$20190807$20221014$PER$$US-JNJFOC-20190803043$JOHNSON AND JOHNSON$$$$$M$Y$$$20221014$$LW$US$US
166785818$16678581$8$F$$20221005$20190807$20221020$EXP$$DE-MYLANLABS-2019M1072975$MYLAN$$$$$M$Y$130$KG$20221020$$CN$DE$DE
166786364$16678636$4$F$20190601$20220929$20190807$20221009$EXP$$US-ROCHE-2364359$ROCHE$$56$YR$$F$Y$95.34$KG$20221009$$CN$US$
1667954312$16679543$12$F$20190801$20221026$20190807$20221107$EXP$$CO-INCYTE CORPORATION-2019IN002427$INCYTE$$$$$$Y$$$20221107$$CN$CO$CO
1667969113$16679691$13$F$$20221208$20190807$20221208$EXP$$US-PFIZER INC-2019335382$PFIZER$$73$YR$$F$Y$57$KG$20221208$$CN$US$US
166799363$16679936$3$F$20190501$20221024$20190807$20221027$EXP$$US-SHIRE-US201924704$TAKEDA$$34$YR$$F$Y$$$20221027$$HP$US$US
1668002822$16680028$22$F$20180101$20221116$20190807$20221123$EXP$$PHHY2018CA157745$NOVARTIS$$$$$F$Y$$$20221123$$MD$CA$CA
166802014$16680201$4$F$$20211019$20190807$20221216$EXP$$PHHY2019JP181511$NOVARTIS$Fukai R, Takahashi K, Abe H, Higashiyama Y, Doi H, Takeuchi H et al.. Non-traumatic acute epidural hematoma in multiple sclerosis treated with fingolimod. FRONTIERS IN NEUROLOGY. 2019;10:1-4$27$YR$$F$Y$$$20221216$$HP$JP$JP
1668109723$16681097$23$F$20190701$20221221$20190808$20221230$EXP$$CA-CELLTRION INC.-2019CA023484$CELLTRION$$$$$$Y$$$20221230$$MD$CA$CA
166814894$16681489$4$F$$20221206$20190808$20221208$EXP$$CA-SA-2019SA210548$SANOFI AVENTIS$$$$A$F$Y$$$20221208$$CN$CA$CA
1668168319$16681683$19$F$20180308$20221116$20190808$20221123$EXP$$DE-ROCHE-2242179$ROCHE$$31$YR$$F$Y$70$KG$20221123$$CN$DE$
1668186012$16681860$12$F$20190308$20221003$20190808$20221007$EXP$$US-SA-2019SA213778$SANOFI AVENTIS$$19$YR$A$M$Y$$$20221007$$MD$US$US
166822526$16682252$6$F$20190315$20221114$20190808$20221121$EXP$$JP-ROCHE-2372278$ROCHE$$$$A$F$Y$$$20221121$$MD$JP$JP
166826916$16682691$6$F$$20221011$20190808$20221019$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-21860$SAMSUNG BIOEPIS$$54$YR$A$F$Y$74$KG$20221019$$MD$CA$CA
166834048$16683404$8$F$$20221104$20190808$20221113$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-21244$SAMSUNG BIOEPIS$$48$YR$A$F$Y$110$KG$20221114$$HP$CA$CA
166834227$16683422$7$F$$20221216$20190808$20221222$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-21883$SAMSUNG BIOEPIS$$25$YR$A$M$Y$81$KG$20221222$$CN$CA$CA
166834412$16683441$2$F$$20221212$20190808$20221217$PER$$US-ELI_LILLY_AND_COMPANY-US201908002448$ELI LILLY AND CO$$$$$F$Y$$$20221217$$CN$US$US
166834945$16683494$5$F$$20221213$20190808$20221220$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-032186$BOEHRINGER INGELHEIM$$60$YR$A$F$Y$$$20221220$$HP$CA$CA
166844155$16684415$5$F$$20221017$20190808$20221026$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-21326$SAMSUNG BIOEPIS$$33$YR$A$F$Y$122$KG$20221026$$HP$CA$CA
166845996$16684599$6$F$$20221111$20190808$20221118$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-22301$SAMSUNG BIOEPIS$$56$YR$A$F$Y$68$KG$20221118$$HP$CA$CA
166847746$16684774$6$F$$20221104$20190808$20221114$EXP$$US-PFIZER INC-2019335284$PFIZER$$62$YR$$M$Y$$$20221114$$CN$US$US
166849914$16684991$4$F$$20221205$20190808$20221208$EXP$$US-PFIZER INC-2019339983$PFIZER$$68$YR$$F$Y$$$20221208$$HP$US$US
166851952$16685195$2$F$$20190731$20190808$20221220$EXP$$PHHY2019IR179456$NOVARTIS$Mohammadian M, Butt S. Symptomatic central nervous system tuberculoma, a case report in the United States and literature review. IDCASES. 2019;17:1-4$69$YR$$M$Y$$$20221220$$HP$IR$IR
166853848$16685384$8$F$20190603$20221202$20190809$20221214$EXP$$RU-ABBVIE-19K-251-2883023-00$ABBVIE$$78$YR$$F$Y$50$KG$20221214$$MD$RU$RU
166873403$16687340$3$F$20190801$20221211$20190809$20221221$EXP$$GB-ASPEN-GLO2019GB007814$ASPEN$$$$$$Y$$$20221221$$CN$GB$GB
166874687$16687468$7$F$20190604$20221214$20190809$20221221$EXP$$US-PFIZER INC-2019341413$PFIZER$$78$YR$$F$Y$108$KG$20221221$$CN$US$US
166875163$16687516$3$F$20220101$20221026$20190809$20221102$EXP$$US-PFIZER INC-2019338141$PFIZER$$56$YR$$F$Y$$$20221102$$HP$US$US
1668778016$16687780$16$F$$20221019$20190809$20221024$EXP$$US-PFIZER INC-2019328293$PFIZER$$74$YR$$F$Y$65.77$KG$20221024$$CN$US$US
1668812112$16688121$12$F$20200101$20221118$20190809$20221125$EXP$$PHHY2019CL183733$NOVARTIS$$$$$F$Y$$$20221125$$CN$CL$CL
166882997$16688299$7$F$20190726$20221031$20190809$20221104$EXP$$US-PFIZER INC-2019337483$PFIZER$$80$YR$$F$Y$86.18$KG$20221104$$PH$US$US
166887152$16688715$2$F$20190716$20211206$20190809$20221008$PER$$US-PURDUE-USA-2019-0147750$PURDUE$$63$YR$$M$Y$$$20221008$$CN$US$US
166888746$16688874$6$F$$20221012$20190809$20221021$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-21896$SAMSUNG BIOEPIS$$61$YR$A$F$Y$84$KG$20221021$$HP$CA$CA
166888757$16688875$7$F$$20221006$20190809$20221012$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-21920$SAMSUNG BIOEPIS$$51$YR$A$M$Y$93$KG$20221012$$HP$CA$CA
166892982$16689298$2$F$20180701$20221208$20190809$20221215$EXP$$CA-TAKEDA-2018TUS022103$TAKEDA$$64$YR$$M$Y$$$20221215$$MD$CA$CA
166894574$16689457$4$F$$20221102$20190809$20221103$PER$$US-PFIZER INC-2019344100$PFIZER$$52$YR$$F$Y$$$20221103$$LW$US$US
1669045913$16690459$13$F$20190806$20221108$20190810$20221111$EXP$$CA-TAKEDA-2019TUS036872$TAKEDA$$50$YR$$F$Y$$$20221111$$MD$CA$CA
166909104$16690910$4$F$$20221215$20190812$20221219$EXP$$CA-ROCHE-2369617$ROCHE$$7$YR$$F$Y$28$KG$20221219$$HP$CA$
166916995$16691699$5$F$$20221014$20190812$20221021$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-21419$SAMSUNG BIOEPIS$$55$YR$A$F$Y$$$20221021$$HP$CA$CA
166917616$16691761$6$F$$20221219$20190812$20221226$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-21328$SAMSUNG BIOEPIS$$20$YR$A$F$Y$40$KG$20221226$$MD$CA$CA
166917885$16691788$5$F$$20221215$20190812$20221224$EXP$$CZ-JNJFOC-20190804428$JOHNSON AND JOHNSON$$35$YR$A$M$Y$$$20221224$$MD$CZ$CZ
1669193610$16691936$10$F$20190717$20221227$20190812$20221229$PER$$US-BIOGEN-2019BI00773466$BIOGEN$$53$YR$$F$Y$$$20221229$$CN$US$US
166920039$16692003$9$F$$20221209$20190812$20221215$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-21393$SAMSUNG BIOEPIS$$31$YR$A$M$Y$85$KG$20221215$$CN$CA$CA
1669224314$16692243$14$F$20180901$20221219$20190812$20221227$EXP$$FR-MYLANLABS-2019M1074536$MYLAN$$73$YR$$M$Y$74$KG$20221227$$MD$FR$FR
166923829$16692382$9$F$$20221109$20190812$20221111$PER$$US-PFIZER INC-2019339801$PFIZER$$76$YR$$F$Y$61$KG$20221111$$CN$US$US
166924525$16692452$5$F$20140101$20221221$20190812$20221229$PER$$US-PFIZER INC-2019341501$PFIZER$$72$YR$$F$Y$81.65$KG$20221229$$CN$US$US
1669253314$16692533$14$F$$20221109$20190812$20221114$EXP$$US-PFIZER INC-2019339262$PFIZER$$64$YR$$M$Y$119.75$KG$20221114$$CN$US$US
166928984$16692898$4$F$$20221010$20190812$20221014$EXP$$US-PFIZER INC-2019343830$PFIZER$$70$YR$$M$Y$$$20221014$$CN$US$US
166939914$16693991$4$F$20200101$20221216$20190812$20221222$PER$$US-SA-2019SA220898$SANOFI AVENTIS$$$$A$M$Y$89.3$KG$20221222$$MD$US$US
166940772$16694077$2$F$$20221104$20190812$20221110$EXP$$KR-GLAXOSMITHKLINE-KR2019141317$GLAXOSMITHKLINE$$$$$$Y$$$20221110$$CN$KR$KR
1669445617$16694456$17$F$20170901$20221107$20190812$20221111$EXP$$GB-OTSUKA-2019_028851$OTSUKA$$32$YR$$F$Y$$$20221111$$MD$GB$GB
166946462$16694646$2$F$$20221017$20190812$20221020$EXP$$US-SHIRE-US201925178$TAKEDA$$$$$F$Y$$$20221020$$CN$US$US
1669554325$16695543$25$F$20180713$20221102$20190813$20221108$EXP$$CA-ROCHE-2372247$ROCHE$$34$YR$$F$Y$$$20221108$$MD$CA$CA
166960782$16696078$2$F$20190807$20221006$20190813$20221018$EXP$$CA-drreddys-USA/CAN/19/0113013$DR REDDYS$$70$YR$E$F$Y$$$20221018$$HP$CA$CA
166969582$16696958$2$F$$20221207$20190813$20221215$EXP$$US-PFIZER INC-2019341866$PFIZER$$27$YR$$F$Y$$$20221215$$CN$US$US
166975487$16697548$7$F$20190804$20221130$20190813$20221207$EXP$$PHEH2019US033495$NOVARTIS$$36$YR$$F$Y$$$20221207$$HP$US$US
166979448$16697944$8$F$20190708$20221006$20190813$20221010$EXP$$JP-PFIZER INC-2019341728$PFIZER$$76$YR$$F$Y$$$20221010$$MD$JP$JP
166982926$16698292$6$F$$20221223$20190813$20221226$EXP$$US-JAZZ-2019-US-010945$JAZZ$$$$$M$Y$$$20221226$$HP$US$US
166986395$16698639$5$F$20190209$20221108$20190813$20221109$EXP$$DE-GILEAD-2019-0407326$GILEAD$$68$YR$E$M$Y$$$20221109$$MD$DE$DE
166992789$16699278$9$F$20190215$20221017$20190813$20221022$EXP$$PHHY2019DE188191$NOVARTIS$$$$E$F$Y$78$KG$20221022$$MD$DE$DE
167008145$16700814$5$F$20190721$20221031$20190814$20221107$PER$$CA-AMGEN-CANNI2019129700$AMGEN$$35$YR$A$F$Y$$$20221106$$PH$CA$CA
1670100624$16701006$24$F$20190301$20221202$20190814$20221206$EXP$$US-TESARO-2019-TSO01640-US$GLAXOSMITHKLINE$$$$$$Y$$$20221206$$HP$US$US
167012683$16701268$3$F$$20221223$20190814$20221230$EXP$$US-BIOGEN-2019BI00772313$BIOGEN$$$$$F$Y$$$20221230$$HP$US$US
1670148821$16701488$21$F$20161010$20220922$20190814$20221007$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-203076$RANBAXY$$26$YR$$F$Y$$$20221007$$PH$GB$GB
167017478$16701747$8$F$20190805$20221025$20190814$20221101$EXP$$CA-PFIZER INC-2019345151$PFIZER$$55$YR$$F$Y$65$KG$20221101$$CN$CA$CA
167021713$16702171$3$F$$20221217$20190814$20221231$EXP$$DE-AUROBINDO-AUR-APL-2019-051902$AUROBINDO$Anderson N, Borlak J. Hepatobiliary events in migraine therapy with herbs-the case of petadolex, a petasites hybridus extract. Journal of Clinical Medicine. 2019;8(5):652$34$YR$$F$Y$$$20221231$$HP$DE$DE
167021952$16702195$2$F$$20220926$20190814$20221004$EXP$$PHHY2019DE186333$NOVARTIS$$72$YR$$M$Y$$$20221004$$PH$DE$DE
1670282733$16702827$33$F$$20221213$20190814$20221221$EXP$$CA-ABBVIE-19K-028-2888402-00$ABBVIE$$43$YR$$F$Y$$$20221221$$HP$CA$CA
1670366510$16703665$10$F$20190701$20221214$20190814$20221220$EXP$$US-PFIZER INC-2019348387$PFIZER$$58$YR$$M$Y$$$20221220$$CN$US$US
167039952$16703995$2$F$$20221110$20190814$20221115$EXP$$PHHY2019CA187172$NOVARTIS$$$$$F$Y$$$20221115$$MD$CA$CA
1670401335$16704013$35$F$20170215$20221017$20190814$20221028$EXP$$CA-ROCHE-2374570$ROCHE$$32$YR$$F$Y$$$20221029$$CN$CA$CA
167040296$16704029$6$F$20121227$20221018$20190814$20221026$EXP$$US-AstraZeneca-2019SF13949$ASTRAZENECA$$22487$DY$$F$Y$101.2$KG$20221026$$CN$US$
167042042$16704204$2$F$$20190808$20190814$20221220$EXP$NL-LRB-00344736$NL-TEVA-2019-NL-1091076$TEVA$$$$$F$Y$82$KG$20221220$$CN$NL$NL
167046764$16704676$4$F$20180101$20221128$20190814$20221130$EXP$$US-PFIZER INC-2019018613$PFIZER$$68$YR$$M$Y$83.91$KG$20221130$$CN$US$US
167046944$16704694$4$F$$20221215$20190814$20221221$EXP$$US-JAZZ-2019-US-011149$JAZZ$$$$$M$Y$$$20221221$$MD$US$US
1670494010$16704940$10$F$20180704$20221017$20190814$20221025$EXP$$CA-CELLTRION INC.-2018CA021411$CELLTRION$$$$$$Y$$$20221025$$CN$CA$CA
1670494314$16704943$14$F$20190227$20221020$20190814$20221030$EXP$$CA-CELLTRION INC.-2019CA019664$CELLTRION$$$$$$Y$$$20221030$$CN$CA$CA
1670495515$16704955$15$F$20190501$20221103$20190814$20221111$EXP$$CA-CELLTRION INC.-2019CA021326$CELLTRION$$$$$$Y$$$20221111$$CN$CA$CA
167051143$16705114$3$F$20181112$20221031$20190815$20221108$PER$$JP-AMGEN-JPNCT2019129901$AMGEN$$70$YR$E$M$Y$$$20221107$$MD$JP$JP
1670514433$16705144$33$F$20171001$20221129$20190815$20221208$EXP$$CA-CELLTRION INC.-2017CA014893$CELLTRION$$$$$$Y$$$20221208$$CN$CA$CA
1670780512$16707805$12$F$20160401$20221206$20190815$20221213$EXP$$US-PFIZER INC-2018360182$PFIZER$$67$YR$$M$Y$107$KG$20221213$$CN$US$US
167078863$16707886$3$F$$20221028$20190815$20221103$EXP$$CA-PFIZER INC-2019345260$PFIZER$$53$YR$$F$Y$$$20221103$$CN$CA$CA
167087058$16708705$8$F$20190606$20221118$20190816$20221125$EXP$$JP-ASTELLAS-2019JP017433$ASTELLAS$$82$YR$$F$Y$33$KG$20221125$$CN$JP$JP
167098765$16709876$5$F$$20221025$20190816$20221026$EXP$$US-PFIZER INC-2019346371$PFIZER$$80$YR$$F$Y$$$20221026$$CN$US$US
1671091022$16710910$22$F$20190801$20221219$20190816$20221230$EXP$$GB-PFIZER INC-2019347198$PFIZER$$84$YR$$M$Y$$$20221230$$HP$GB$GB
167122972$16712297$2$F$20190729$20221224$20190816$20221228$EXP$$US-SA-2019SA213860$SANOFI AVENTIS$$49$YR$A$F$Y$$$20221228$$CN$US$US
1671261612$16712616$12$F$20161018$20221215$20190816$20221221$EXP$$PHHY2016CA002947$NOVARTIS$$51$YR$$F$Y$$$20221221$$MD$CA$CA
167133156$16713315$6$F$20160101$20221129$20190818$20221204$EXP$$BR-BIOGEN-2019BI00774808$BIOGEN$$$$$F$Y$$$20221204$$CN$BR$BR
167151834$16715183$4$F$20150101$20221118$20190819$20221201$EXP$CZ-EMA-DD-20190806-KUMARSINGH_A-114917$CZ-Accord-151935$ACCORD$$54$YR$$F$Y$$$20221201$$HP$CZ$CZ
167155766$16715576$6$F$$20221220$20190819$20221227$PER$$US-PFIZER INC-2019351800$PFIZER$$84$YR$$F$Y$$$20221227$$MD$US$US
1671565610$16715656$10$F$$20221219$20190819$20221223$EXP$$BR-GLAXOSMITHKLINE-BR2019GSK094333$GLAXOSMITHKLINE$$$$$$Y$$$20221223$$HP$BR$BR
1671592214$16715922$14$F$$20221011$20190819$20221014$EXP$CA-HEALTHCANVIG-000714873$CA-SUNOVION-2018SUN004352$SUNOVION$$23$YR$$F$Y$$$20221014$$HP$CA$CA
167166472$16716647$2$F$$20221219$20190819$20221222$EXP$$PHHY2019DE189372$NOVARTIS$Anderson N, Borlak J. Hepatobiliary events in migraine therapy with herbsthe case of petadolex, a petasites hybridus extract. JOURNAL OF CLINICAL MEDICINE. 2019;8 (5):652$34$YR$$F$Y$$$20221222$$HP$DE$DE
167167529$16716752$9$F$20190730$20221012$20190819$20221014$EXP$$GB-ROCHE-2372961$ROCHE$$71$YR$$M$Y$63.4$KG$20221014$$MD$GB$
1671681617$16716816$17$F$20190818$20221004$20190819$20221012$EXP$$JP-JNJFOC-20190820111$JOHNSON AND JOHNSON$$57$YR$A$M$Y$$$20221011$$CN$JP$JP
1671772810$16717728$10$F$$20221011$20190819$20221017$EXP$CA-HEALTHCANVIG-02498042$CA-SUNOVION-2019SUN003373$SUNOVION$$32$YR$$F$Y$$$20221017$$HP$CA$CA
167177419$16717741$9$F$$20221011$20190819$20221017$EXP$$CA-SUNOVION-2018SUN000530$SUNOVION$$32$YR$$M$Y$$$20221017$$CN$CA$CA
1671881030$16718810$30$F$20190101$20220920$20190820$20221001$EXP$$CA-CELLTRION INC.-2019CA021409$CELLTRION$$$$$$Y$$$20221001$$CN$CA$CA
167217334$16721733$4$F$20190809$20221216$20190820$20221223$EXP$$CA-TAKEDA-2019TUS046643$TAKEDA$$60$YR$$M$Y$$$20221223$$CN$CA$CA
167220178$16722017$8$F$$20221012$20190820$20221017$EXP$$CA-OTSUKA-2019_029651$OTSUKA$$32$YR$$F$Y$$$20221017$$HP$CA$CA
1672263241$16722632$41$F$20190101$20221111$20190820$20221115$EXP$$CA-CELLTRION INC.-2019CA021328$CELLTRION$$$$$$Y$$$20221115$$MD$CA$CA
167227322$16722732$2$F$$20190815$20190821$20221229$PER$$US-AMGEN-USASP2019133322$AMGEN$$$$A$F$Y$$$20221229$$CN$US$US
167235664$16723566$4$F$20191101$20221012$20190821$20221024$EXP$$AU-009507513-1908AUS007145$MERCK$$49$YR$$M$Y$$$20221024$$MD$AU$AU
1672406018$16724060$18$F$20190720$20220930$20190821$20221007$EXP$$PHHY2018CA180772$NOVARTIS$$73$YR$$F$Y$$$20221007$$CN$CA$CA
1672418110$16724181$10$F$20190808$20221115$20190821$20221117$EXP$$TR-ROCHE-2383671$ROCHE$$78$YR$$F$Y$86$KG$20221117$$MD$TR$
1672482011$16724820$11$F$20180808$20221207$20190821$20221219$EXP$$US-ROCHE-2376004$ROCHE$$62$YR$$F$Y$63.56$KG$20221219$$CN$US$
167272848$16727284$8$F$20150615$20221114$20190822$20221123$PER$$US-SA-2015SA087855$SANOFI AVENTIS$$20$YR$A$F$Y$71.2$KG$20221123$$MD$US$US
1672804310$16728043$10$F$$20221130$20190822$20221216$EXP$$CA-AUROBINDO-AUR-APL-2019-054000$AUROBINDO$$53$YR$$F$Y$60$KG$20221216$$HP$CA$CA
167280973$16728097$3$F$$20221205$20190822$20221218$EXP$$CA-AUROBINDO-AUR-APL-2019-053922$AUROBINDO$$32$YR$$F$Y$$$20221218$$HP$CA$CA
167280985$16728098$5$F$$20221221$20190822$20221230$EXP$$CA-AUROBINDO-AUR-APL-2019-054044$AUROBINDO$$89$YR$$F$Y$$$20221230$$HP$CA$CA
167281454$16728145$4$F$$20221121$20190822$20221201$EXP$$CA-GLENMARK PHARMACEUTICALS-2019GMK042719$GLENMARK$$$$$$Y$$$20221201$$CN$CA$CA
167290562$16729056$2$F$20190701$20221025$20190822$20221102$EXP$$PHHY2019CA186374$NOVARTIS$$78$YR$$F$Y$$$20221102$$CN$CA$CA
167298262$16729826$2$F$$20190814$20190822$20221122$EXP$$PHHY2019SA192414$NOVARTIS$Alsuhaibani M, Felimban G, Shoukri M, Alosaimi A, Almohaizeie A, AlHajjar S. Safety and tolerability of moxifloxacin for the treatment of disseminated BCGitis in children. INTERNATIONAL JOURNAL OF PEDIATRICS AND ADOLESCENT MEDICINE. 2019;6:47-50$3$YR$$M$Y$$$20221122$$HP$SA$SA
167298572$16729857$2$F$$20221206$20190822$20221214$EXP$$US-PFIZER INC-2019359640$PFIZER$$56$YR$$F$Y$$$20221214$$HP$US$US
1673023912$16730239$12$F$20190430$20221021$20190822$20221031$PER$$JP-AMGEN-JPNSP2019132188$AMGEN$$69$YR$E$F$Y$53.6$KG$20221031$$MD$JP$JP
1673025016$16730250$16$F$20190511$20221021$20190822$20221027$PER$$JP-AMGEN-JPNSP2019132297$AMGEN$$81$YR$E$F$Y$55.7$KG$20221027$$MD$JP$JP
167304155$16730415$5$F$20190101$20221101$20190822$20221129$PER$$US-TEVA-2019-US-1094635$TEVA$$67$YR$E$M$Y$$$20221129$$CN$US$US
167305147$16730514$7$F$20181022$20221025$20190822$20221103$EXP$$DE-PFIZER INC-2019358569$PFIZER$$$$E$M$Y$$$20221103$$MD$DE$DE
167309196$16730919$6$F$$20221202$20190822$20221209$PER$$US-INCYTE CORPORATION-2019IN008324$INCYTE$$$$$$Y$$$20221209$$CN$US$US
167325432$16732543$2$F$$20221219$20190823$20221227$EXP$$PHHY2019AU189391$NOVARTIS$$42$YR$$F$Y$94$KG$20221227$$MD$AU$AU
167330874$16733087$4$F$$20221025$20190823$20221104$EXP$$CA-GLENMARK PHARMACEUTICALS-2019GMK042726$GLENMARK$$$$$$Y$$$20221104$$HP$CA$CA
1673349913$16733499$13$F$20190429$20220930$20190823$20221012$EXP$$DE-AUROBINDO-AUR-APL-2019-032480$AUROBINDO$$$$A$F$Y$58.5$KG$20221012$$MD$DE$DE
1673361510$16733615$10$F$20190710$20221107$20190823$20221122$EXP$$DE-AUROBINDO-AUR-APL-2019-055434$AUROBINDO$$$$E$F$Y$66$KG$20221122$$MD$DE$DE
167347564$16734756$4$F$$20221207$20190823$20221220$EXP$$CA-AUROBINDO-AUR-APL-2019-055308$AUROBINDO$$63$YR$$F$Y$$$20221220$$HP$CA$CA
167355109$16735510$9$F$$20221213$20190823$20221219$EXP$$US-PFIZER INC-2019334513$PFIZER$$70$YR$$F$Y$$$20221219$$CN$US$US
1673573812$16735738$12$F$$20221025$20190823$20221028$PER$$US-PFIZER INC-2019361936$PFIZER$$65$YR$$F$Y$$$20221028$$CN$US$US
167358689$16735868$9$F$$20221227$20190823$20221229$EXP$$US-PFIZER INC-2019360210$PFIZER$$82$YR$$F$Y$$$20221229$$CN$US$US
167363807$16736380$7$F$$20221011$20190823$20221018$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-23769$SAMSUNG BIOEPIS$$28$YR$A$F$Y$82$KG$20221018$$HP$CA$CA
167380324$16738032$4$F$20180201$20221202$20190824$20221209$EXP$$PHHY2018DE087559$NOVARTIS$$$$A$F$Y$$$20221209$$MD$DE$DE
167380813$16738081$3$F$20190601$20221206$20190824$20221208$EXP$$PHHY2019GB193759$NOVARTIS$$37$YR$$F$Y$$$20221208$$MD$GB$GB
167383344$16738334$4$F$$20221216$20190825$20221226$EXP$$FR-EXELIXIS-CABO-19023252$EXELIXIS$$65$YR$$M$Y$$$20221226$$MD$FR$FR
167383766$16738376$6$F$$20221220$20190825$20221229$PER$$CA-AMGEN-CANNI2019136568$AMGEN$$$$A$F$Y$$$20221229$$HP$CA$CA
167388922$16738892$2$F$$20221026$20190826$20221101$EXP$$PR-ABBVIE-19K-131-2899655-00$ABBVIE$$$$A$F$Y$75$KG$20221101$$CN$PR$PR
1673913019$16739130$19$F$20190101$20221018$20190826$20221027$EXP$$JP-ABBVIE-19K-087-2899192-00$ABBVIE$$73$YR$$M$Y$39$KG$20221027$$CN$JP$JP
167404894$16740489$4$F$20190101$20221024$20190826$20221026$PER$$US-PFIZER INC-2019104923$PFIZER$$66$YR$$F$Y$$$20221026$$HP$US$US
1674085766$16740857$66$F$$20221124$20190826$20221129$EXP$$US-PFIZER INC-2019363980$PFIZER$$65$YR$$F$Y$59.87$KG$20221129$$CN$US$US
167415325$16741532$5$F$$20221011$20190826$20221014$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-080379$BRISTOL MYERS SQUIBB$$52$YR$A$M$Y$$$20221014$$HP$CA$CA
167420492$16742049$2$F$20190701$20190818$20190826$20221220$EXP$GB-MHRA-EYC 00205068$GB-TEVA-2019-GB-1096224$TEVA$$81$YR$E$F$Y$$$20221220$$PH$GB$GB
167427095$16742709$5$F$20190508$20221129$20190826$20221212$EXP$GB-MHRA-ADR 24407011$GB-BEH-2019105943$CSL BEHRING$$29$YR$A$M$Y$$$20221212$$HP$GB$GB
167439734$16743973$4$F$20190101$20221115$20190827$20221121$EXP$$US-SA-2019SA238580$SANOFI AVENTIS$$21$YR$A$F$Y$77$KG$20221121$$MD$US$US
167441697$16744169$7$F$$20221003$20190827$20221010$EXP$$PHHY2019PL194521$NOVARTIS$Tarasewicz A, Gebka A, Serkies-Minuth E, Raczynska D, Slizien M, Debska-Slizien A. Jednostronna neuropatia nerwu wzrokowego w przebiegu terapii takrolimusem u chorego po przeszczepieniu nerki [Unilateral neuropathy of optic nerve during tacrolimus therapy in a kidney transplant patient]. NEPHROLOGICAL FORUM [FORUM NEFROLOGICZNE]. 2019;12(2):101-5$34$YR$$M$Y$$$20221010$$HP$PL$PL
167442933$16744293$3$F$$20221008$20190827$20221008$PER$$PHEH2019US035459$NOVARTIS$$$$$F$Y$$$20221008$$CN$US$US
167444539$16744453$9$F$20190918$20221222$20190827$20221229$EXP$$US-ASTELLAS-2019US008234$ASTELLAS$$72$YR$$M$Y$$$20221229$$CN$US$US
167451395$16745139$5$F$20121212$20221223$20190827$20221228$PER$$US-PFIZER INC-2019367400$PFIZER$$54$YR$$F$Y$$$20221228$$MD$US$US
167451726$16745172$6$F$20190101$20221222$20190827$20221227$EXP$$US-PFIZER INC-2018445511$PFIZER$$63$YR$$F$Y$95.25$KG$20221227$$MD$US$US
1674518214$16745182$14$F$$20221014$20190827$20221018$PER$$US-PFIZER INC-2019363313$PFIZER$$79$YR$$F$Y$52.16$KG$20221018$$CN$US$US
167458266$16745826$6$F$20190527$20221102$20190827$20221104$EXP$$CA-TAKEDA-2019TUS010255$TAKEDA$$25$YR$$F$Y$$$20221104$$CN$CA$CA
167479876$16747987$6$F$20190418$20221104$20190827$20221111$EXP$$BR-ABBVIE-19P-020-2757132-00$ABBVIE$$62$YR$$F$Y$$$20221111$$MD$BR$BR
1674909035$16749090$35$F$20170713$20221129$20190828$20221207$EXP$$CA-CELLTRION INC.-2018CA024994$CELLTRION$$$$$$Y$$$20221208$$CN$CA$CA
167498243$16749824$3$F$$20221012$20190828$20221018$EXP$$PHJP2019JP010906$NOVARTIS$Inoue S, Nakagawa R, Inuzuka R, Hirata Y, Urata S, Nakano K et al. A Neonate Successfully Treated with Everolimus: Our Use Experiences against Cardiac Rhabdomyoma with the High-grade Left Ventricular Outflow Tract Stenosis. The 7th General Meeting of Japanese Society of Tuberous Sclerosis/The 76th Hokur. 15$7$DY$$M$Y$$$20221018$$HP$JP$JP
167498259$16749825$9$F$20190203$20221012$20190828$20221018$EXP$$PHHY2018CA041441$NOVARTIS$$27$YR$$F$Y$$$20221018$$CN$CA$CA
167500502$16750050$2$F$20190101$20190808$20190828$20221229$PER$$US-AMGEN-USASP2019127852$AMGEN$$39$YR$A$F$Y$$$20221229$$CN$US$US
167501538$16750153$8$F$$20221215$20190828$20221222$PER$$US-PFIZER INC-2017254763$PFIZER$$11$YR$$M$Y$$$20221222$$CN$US$US
167503176$16750317$6$F$20190801$20221209$20190828$20221219$EXP$$GB-ASPEN-GLO2019GB008885$ASPEN$$$$$$Y$$$20221219$$CN$GB$GB
167517664$16751766$4$F$$20221121$20190828$20221122$PER$$US-PFIZER INC-2019369661$PFIZER$$62$YR$$M$Y$$$20221122$$CN$US$US
167518375$16751837$5$F$20190820$20221004$20190828$20221006$EXP$$CA-JNJFOC-20190832912$JOHNSON AND JOHNSON$$34$YR$A$M$Y$74$KG$20221006$$HP$CA$CA
1675198521$16751985$21$F$20181010$20221121$20190828$20221128$EXP$$PHHY2019DE073814$NOVARTIS$$57$YR$$F$Y$88$KG$20221128$$MD$DE$DE
167522087$16752208$7$F$20190801$20221205$20190828$20221209$EXP$GB-EMA-DD-20190821-BANAVALLI_M-132339$GB-GLAXOSMITHKLINE-GB2019155232$GLAXOSMITHKLINE$$$$$$Y$$$20221209$$MD$GB$GB
167522646$16752264$6$F$20190301$20221214$20190828$20221221$EXP$$CA-GLAXOSMITHKLINE-CA2019GSK057411$GLAXOSMITHKLINE$$$$$$Y$$$20221221$$MD$CA$CA
167524113$16752411$3$F$20220829$20221107$20190828$20221111$EXP$$US-SHIRE-US201927782$TAKEDA$$37$YR$$F$Y$66$KG$20221111$$CN$US$US
1675330437$16753304$37$F$20190101$20221021$20190829$20221101$EXP$$CA-CELLTRION INC.-2019CA020259$CELLTRION$$$$$$Y$$$20221101$$MD$CA$CA
167533392$16753339$2$F$20190801$20221220$20190829$20221228$EXP$$GB-ASPEN-GLO2019GB008781$ASPEN$$$$$$Y$$$20221228$$CN$GB$GB
167535746$16753574$6$F$20190801$20221216$20190829$20221220$EXP$GB-EMA-DD-20190821-BANAVALLI_M-132339$GB-BAXTER-2019BAX017004$BAXTER$$89$YR$$M$Y$$$20221220$$HP$GB$GB
167538396$16753839$6$F$20190101$20221121$20190829$20221205$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-219172$RANBAXY$$$$E$F$Y$$$20221205$$CN$US$US
1675445111$16754451$11$F$$20221122$20190829$20221124$EXP$$US-PFIZER INC-2019368412$PFIZER$$71$YR$$F$Y$66.213$KG$20221124$$MD$US$US
167545168$16754516$8$F$20190825$20221220$20190829$20221227$EXP$$PR-PFIZER INC-2019368502$PFIZER$$70$YR$$F$Y$$$20221227$$HP$PR$PR
167557067$16755706$7$F$20180919$20221118$20190829$20221122$EXP$$JP-JNJFOC-20190712767$JOHNSON AND JOHNSON$$64$YR$A$F$Y$55.5$KG$20221122$$MD$JP$JP
1675583210$16755832$10$F$20210110$20221024$20190829$20221027$EXP$$CA-TAKEDA-2019TUS049907$TAKEDA$$78$YR$$F$Y$$$20221027$$CN$CA$CA
167563226$16756322$6$F$20190826$20221111$20190829$20221115$EXP$$BR-ROCHE-2395900$ROCHE$$57$YR$$M$Y$71.1$KG$20221115$$MD$BR$
1675644811$16756448$11$F$20190101$20221005$20190829$20221012$EXP$$PHHY2019CA131489$NOVARTIS$$$$$F$Y$$$20221012$$CN$CA$CA
167564806$16756480$6$F$20190727$20221103$20190829$20221111$EXP$$DE-AstraZeneca-2019SF19796$ASTRAZENECA$$$$E$F$Y$67.2$KG$20221111$$MD$DE$
167565166$16756516$6$F$20190412$20220318$20190829$20221026$PER$$FR-JAZZ-2019-FR-012126$JAZZ$$$$$$Y$$$20221026$$MD$FR$FR
1675696720$16756967$20$F$20190329$20221005$20190829$20221009$EXP$$CA-ROCHE-2297121$ROCHE$$46$YR$$F$Y$$$20221009$$CN$CA$
167571966$16757196$6$F$20190201$20221114$20190829$20221128$EXP$$JP-LUNDBECK-DKLU3003247$LUNDBECK$$4$YR$C$F$Y$13.7$KG$20221128$$MD$JP$JP
167578113$16757811$3$F$20221114$20221205$20190830$20221209$PER$$US-BIOGEN-2019BI00780557$BIOGEN$$65$YR$$F$Y$$$20221209$$CN$US$US
167581893$16758189$3$F$20180430$20221026$20190830$20221103$EXP$$US-GILEAD-2019-0425695$GILEAD$$46$YR$A$M$Y$$$20221103$$LW$US$US
167588493$16758849$3$F$20170101$20221003$20190830$20221012$EXP$$RO-Accord-152842$ACCORD$Mihaila RG, Sandu M. Liver infarction in a patient with clostridium difficile colitis. A possible connection? Journal of Gastrointestinal and Liver Diseases. 2019;28(2):245-246.$66$YR$E$F$Y$78$KG$20221012$$MD$RO$RO
1675890430$16758904$30$F$20190201$20221125$20190830$20221205$EXP$$CA-CELLTRION INC.-2019CA019160$CELLTRION$$$$$$Y$$$20221205$$CN$CA$CA
167591994$16759199$4$F$20190701$20221024$20190830$20221028$EXP$$US-ROCHE-2389664$ROCHE$$58$YR$$F$Y$52.21$KG$20221028$$CN$US$
167594653$16759465$3$F$20190801$20221117$20190830$20221124$EXP$$US-GW PHARMA-201908USGW3042$JAZZ$$$$$$Y$$$20221124$$CN$US$US
167598904$16759890$4$F$20190809$20221005$20190830$20221011$EXP$$GB-SHIRE-GB201928105$TAKEDA$$6$YR$$M$Y$$$20221011$$HP$GB$GB
167603108$16760310$8$F$$20221205$20190830$20221208$EXP$$US-PFIZER INC-2019371895$PFIZER$$68$YR$$F$Y$$$20221208$$HP$US$US
167604304$16760430$4$F$$20221116$20190830$20221121$PER$$US-PFIZER INC-2019374171$PFIZER$$65$YR$$F$Y$$$20221121$$MD$US$US
167605444$16760544$4$F$$20221219$20190830$20221227$PER$$US-PFIZER INC-2019374430$PFIZER$$68$YR$$F$Y$$$20221227$$MD$US$US
167617155$16761715$5$F$20190808$20221003$20190830$20221010$EXP$$US-SA-2019SA239615$SANOFI AVENTIS$$12$YR$T$M$Y$$$20221010$$MD$US$US
167621304$16762130$4$F$20190201$20200205$20190830$20221207$EXP$$PHJP2019JP003274$NOVARTIS$Takashima Y, Nanjo S, Nakayama Y,Mihara H, Fujinami H, and Yasuda I. Colitis Ulcerative in a Patient on Secukinumab. The 10th Annual Meeting of Japanese Society for Inflammatory Bowel Disease progr. 2019;105$45$YR$$M$Y$69.8$KG$20221207$$MD$JP$JP
167623228$16762322$8$F$20190801$20221203$20190831$20221217$EXP$$GB-AUROBINDO-AUR-APL-2019-057230$AUROBINDO$$89$YR$$M$Y$$$20221217$$MD$GB$GB
1676291435$16762914$35$F$20191010$20221123$20190902$20221217$EXP$$CA-CELLTRION INC.-2019CA024180$CELLTRION$$$$$$Y$$$20221217$$MD$CA$CA
1676301815$16763018$15$F$20190201$20221025$20190902$20221102$EXP$$US-EMD Serono-9113254$EMD SERONO INC$$45$YR$A$F$Y$$$20221102$$CN$US$
1676582912$16765829$12$F$20190730$20221006$20190903$20221018$EXP$$NL-ABBVIE-17K-114-2095144-00$ABBVIE$$73$YR$$F$Y$$$20221018$$CN$NL$NL
167659364$16765936$4$F$20090319$20221128$20190903$20221130$EXP$$US-GILEAD-2019-0425746$GILEAD$$48$YR$A$F$Y$$$20221130$$LW$US$US
167661082$16766108$2$F$$20221201$20190903$20221202$EXP$$FR-ROCHE-2393092$ROCHE$$$$$M$Y$$$20221202$$MD$FR$
1676620921$16766209$21$F$20190801$20221001$20190903$20221005$EXP$$IN-PFIZER INC-2019352041$PFIZER$$70$YR$$M$Y$66$KG$20221005$$CN$IN$IN
1676662017$16766620$17$F$20181029$20221019$20190903$20221028$EXP$$CA-ROCHE-2395456$ROCHE$$74$YR$$F$Y$$$20221028$$MD$CA$CA
167667693$16766769$3$F$$20221017$20190903$20221021$PER$$US-PFIZER INC-2019373177$PFIZER$$73$YR$$M$Y$$$20221021$$CN$US$US
167668517$16766851$7$F$$20221003$20190903$20221208$EXP$$US-PFIZER INC-2019374923$PFIZER$$63$YR$$F$Y$133.81$KG$20221208$$CN$US$US
167669213$16766921$3$F$$20221026$20190903$20221028$PER$$US-PFIZER INC-2019373852$PFIZER$$74$YR$$F$Y$$$20221028$$CN$US$US
167671715$16767171$5$F$$20221207$20190903$20221212$PER$$US-PFIZER INC-2019375624$PFIZER$$54$YR$$M$Y$$$20221212$$HP$US$US
167673014$16767301$4$F$$20221207$20190903$20221215$EXP$$US-PFIZER INC-2019377268$PFIZER$$80$YR$$F$Y$$$20221215$$CN$US$US
167690962$16769096$2$F$$20221006$20190903$20221012$EXP$$US-JNJFOC-20190828457$JOHNSON AND JOHNSON$$$$$M$Y$$$20221012$$HP$US$US
1676954627$16769546$27$F$20190414$20221201$20190903$20221210$EXP$$CA-CELLTRION INC.-2019CA024158$CELLTRION$$$$$$Y$$$20221210$$HP$CA$CA
1677005337$16770053$37$F$20151218$20221228$20190904$20221230$EXP$$CA-ROCHE-1686800$ROCHE$$65$YR$$M$Y$83$KG$20221230$$HP$CA$
1677005740$16770057$40$F$20190101$20221208$20190904$20221221$EXP$$CA-CELLTRION INC.-2019CA022375$CELLTRION$$$$$$Y$$$20221221$$CN$CA$CA
167704115$16770411$5$F$20160101$20221128$20190904$20221130$EXP$$US-GILEAD-2019-0425766$GILEAD$$42$YR$A$M$Y$$$20221130$$LW$US$US
167704555$16770455$5$F$20190728$20191003$20190904$20221130$PER$$PHEH2019US036043$NOVARTIS$$65$YR$$F$Y$57$KG$20221130$$MD$US$US
167719825$16771982$5$F$20190601$20220929$20190904$20221003$EXP$$US-PFIZER INC-2019374507$PFIZER$$74$YR$$F$Y$54.43$KG$20221003$$CN$US$US
1677328215$16773282$15$F$20210424$20221219$20190904$20221222$EXP$$BR-GLAXOSMITHKLINE-BR2018GSK235496$GLAXOSMITHKLINE$$$$$$Y$$$20221222$$MD$BR$BR
167735382$16773538$2$F$$20221026$20190904$20221031$EXP$$US-SHIRE-US201928424$TAKEDA$$$$$F$Y$$$20221031$$CN$US$US
167735677$16773567$7$F$$20221226$20190904$20221229$EXP$$CA-BAUSCH-BL-2019-025025$BAUSCH AND LOMB$$53$YR$$F$Y$60$KG$20221229$$CN$CA$CA
167737055$16773705$5$F$20190101$20221003$20190904$20221007$EXP$$JP-ALEXION PHARMACEUTICALS INC.-A201913077$ALEXION$$55$YR$$M$Y$67$KG$20221007$$MD$JP$JP
167737199$16773719$9$F$20160101$20221220$20190904$20221227$EXP$$PHHY2019CO088811$NOVARTIS$$$$$F$Y$71$KG$20221227$$CN$CO$CO
167739232$16773923$2$F$20190822$20221013$20190904$20221018$EXP$$DE-BIOGEN-2019BI00779916$BIOGEN$$67$YR$$F$Y$$$20221018$$CN$DE$DE
167750874$16775087$4$F$20110601$20221117$20190905$20221122$EXP$$US-GILEAD-2019-0426512$GILEAD$$51$YR$A$M$Y$$$20221122$$LW$US$US
167759378$16775937$8$F$20190201$20221104$20190905$20221114$EXP$$US-PFIZER INC-2019143091$PFIZER$$64$YR$$F$Y$104.31$KG$20221114$$HP$US$US
167762718$16776271$8$F$20190101$20221103$20190905$20221107$PER$$US-PFIZER INC-2019382578$PFIZER$$41$YR$$F$Y$$$20221107$$HP$US$US
167767815$16776781$5$F$$20221020$20190905$20221101$EXP$$CA-PFIZER INC-2019372202$PFIZER$$54$YR$$F$Y$56$KG$20221101$$HP$CA$CA
1677739121$16777391$21$F$20191025$20221218$20190905$20221223$EXP$$PHEH2019US035985$NOVARTIS$$53$YR$$F$Y$63.497$KG$20221223$$CN$US$US
167774393$16777439$3$F$20100514$20221215$20190905$20221220$EXP$$US-AstraZeneca-2019SF26384$ASTRAZENECA$$14569$DY$$F$Y$81.6$KG$20221220$$LW$US$
167776922$16777692$2$F$$20221003$20190905$20221010$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR158105$GLAXOSMITHKLINE$$$$$F$Y$$$20221010$$MD$CA$CA
167779982$16777998$2$F$$20221130$20190905$20221208$PER$$US-TAKEDA-2019TUS050680$TAKEDA$$$$$F$Y$73$KG$20221208$$CN$US$US
167782043$16778204$3$F$$20221017$20190905$20221019$EXP$$CA-ABBVIE-19K-028-2911804-00$ABBVIE$$$$$F$Y$$$20221019$$CN$CA$CA
167787584$16778758$4$F$$20221028$20190906$20221102$EXP$$CA-Orion Corporation ORION PHARMA-TREX2019-3228$ORION$$54$YR$A$F$Y$56$KG$20221102$$HP$CA$
1677958712$16779587$12$F$20220101$20221104$20190906$20221114$EXP$$US-PFIZER INC-2018524894$PFIZER$$62$YR$$F$Y$$$20221114$$CN$US$US
167796403$16779640$3$F$20190801$20221221$20190906$20221230$EXP$GB-EMA-DD-20190821-BANAVALLI_M-132339$GB-TEVA-2019-GB-1102626$TEVA$$89$YR$E$M$Y$$$20221230$$CN$GB$GB
167799242$16779924$2$F$$20220923$20190906$20221007$EXP$$ES-MACLEODS PHARMACEUTICALS US LTD-MAC2019022800$MACLEODS$$$$$$Y$$$20221006$$HP$ES$ES
167803175$16780317$5$F$20190821$20221018$20190906$20221027$PER$$US-VERTEX PHARMACEUTICALS-2019-008426$VERTEX$$3$YR$$M$Y$14$KG$20221027$$MD$US$US
167808655$16780865$5$F$20190101$20220929$20190906$20221011$EXP$$US-AMICUS THERAPEUTICS, INC.-AMI_544$AMICUS THERAPEUTICS$$$$$F$Y$105.22$KG$20221011$$CN$US$US
167814136$16781413$6$F$20090922$20221219$20190906$20221222$EXP$$US-AstraZeneca-2019SF26407$ASTRAZENECA$$20112$DY$$M$Y$90.7$KG$20221222$$LW$US$
1678159212$16781592$12$F$20190704$20221121$20190906$20221128$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-070899$BRISTOL MYERS SQUIBB$Mizukoshi E. Management of immune-related adverse events (irAEs) with immune checkpoint inhibitors (ICIs). Japan Digestive Disease Week 2019. 2019;$54$YR$A$M$Y$58$KG$20221128$$MD$JP$JP
1678298618$16782986$18$F$20190702$20221026$20190906$20221028$EXP$$CA-TAKEDA-2018TUS032885$TAKEDA$$42$YR$$F$Y$$$20221028$$CN$CA$CA
1678379215$16783792$15$F$20190409$20221110$20190908$20221124$EXP$$DE-AUROBINDO-AUR-APL-2019-058637$AUROBINDO$$62$YR$$F$Y$85.8$KG$20221124$$MD$DE$DE
1678410037$16784100$37$F$20190826$20221025$20190909$20221103$EXP$$CA-CELLTRION INC.-2019CA024125$CELLTRION$$$$$$Y$$$20221103$$MD$CA$CA
1678537211$16785372$11$F$20190820$20221219$20190909$20221222$EXP$$PHHY2019AU208485$NOVARTIS$$8$YR$$M$Y$34.2$KG$20221222$$MD$AU$AU
1678555417$16785554$17$F$20190101$20221223$20190909$20221229$EXP$$US-PFIZER INC-2019384470$PFIZER$$91$YR$$F$Y$70$KG$20221229$$CN$US$US
1678560016$16785600$16$F$20180901$20221020$20190909$20221024$PER$$US-PFIZER INC-2016400160$PFIZER$$71$YR$$F$Y$60$KG$20221024$$HP$US$US
167856137$16785613$7$F$20221101$20221128$20190909$20221201$PER$$US-PFIZER INC-2019386974$PFIZER$$60$YR$$F$Y$53.07$KG$20221201$$CN$US$US
167861442$16786144$2$F$$20221011$20190909$20221017$EXP$$CA-PFIZER INC-2019385923$PFIZER$$45$YR$$M$Y$81.179$KG$20221017$$MD$CA$CA
167863539$16786353$9$F$20190828$20221206$20190909$20221207$EXP$$PHHO2019IT008751$NOVARTIS$$74$YR$$M$Y$97$KG$20221207$$MD$IT$IT
167864514$16786451$4$F$20190822$20191004$20190909$20221201$PER$$PHEH2019US036365$NOVARTIS$$68$YR$$F$Y$60.78$KG$20221201$$MD$US$US
167875348$16787534$8$F$20030101$20221017$20190909$20221025$EXP$GB-MHRA-EYC 00070456$GB-BAUSCH-BL-2019-024636$BAUSCH AND LOMB$$31$YR$$F$Y$63.5$KG$20221025$$MD$GB$GB
1678842012$16788420$12$F$20190823$20221021$20190910$20221025$EXP$$DE-ROCHE-2395875$ROCHE$$36$YR$$F$Y$53$KG$20221025$$MD$DE$DE
167887838$16788783$8$F$$20220913$20190910$20221007$PER$$CA-AMGEN-CANSP2019146248$AMGEN$$60$YR$A$F$Y$$$20221006$$HP$CA$CA
167888413$16788841$3$F$$20221216$20190910$20221230$EXP$$IT-AUROBINDO-AUR-APL-2019-059331$AUROBINDO$Hadjistilianou D. Retinoblastoma: From diagnosis to treatment. Ocular oncology meeting. 2019$12$MON$$M$Y$$$20221230$$MD$IT$IT
167898266$16789826$6$F$20100101$20221012$20190910$20221019$EXP$$CR-ROCHE-1526158$ROCHE$$17$YR$$F$Y$56.7$KG$20221019$$CN$CR$CR
1679022221$16790222$21$F$20190722$20221114$20190910$20221120$EXP$$PHHY2019DE186078$NOVARTIS$$$$E$F$Y$66$KG$20221121$$MD$DE$DE
1679049214$16790492$14$F$20150801$20221115$20190910$20221117$PER$$US-PFIZER INC-2019385677$PFIZER$$65$YR$$M$Y$57.61$KG$20221117$$CN$US$US
167911942$16791194$2$F$20181205$20221026$20190910$20221107$EXP$$US-PERRIGO-18US014774$PADAGIS$$$$$$Y$$$20221107$$CN$US$US
167918822$16791882$2$F$20190424$20220926$20190910$20221001$EXP$$GB-ABBVIE-19P-167-2850174-00$ABBVIE$$49$YR$$M$Y$$$20221001$$MD$GB$GB
167922984$16792298$4$F$$20221115$20190910$20221121$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-087227$BRISTOL MYERS SQUIBB$$$$$$Y$$$20221121$$PH$JP$JP
167928373$16792837$3$F$$20190913$20190910$20221206$PER$$US-AMGEN-USASP2019145027$AMGEN$$$$E$F$Y$$$20221205$$MD$US$US
1679302036$16793020$36$F$$20221206$20190911$20221214$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-087087$BRISTOL MYERS SQUIBB$$81$YR$E$F$Y$$$20221214$$HP$CA$CA
167931494$16793149$4$F$20190801$20221127$20190911$20221213$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-220454$RANBAXY$$89$YR$$M$Y$$$20221213$$CN$GB$GB
1679378912$16793789$12$F$$20221212$20190911$20221220$PER$$CA-AMGEN-CANSP2018056893$AMGEN$$63$YR$A$F$Y$$$20221220$$HP$CA$CA
167948187$16794818$7$F$20190731$20221202$20190911$20221207$PER$$US-PFIZER INC-2019334973$PFIZER$$58$YR$$F$Y$88$KG$20221207$$HP$US$US
1679490518$16794905$18$F$$20221220$20190911$20221228$EXP$$US-PFIZER INC-2019387533$PFIZER$$53$YR$$F$Y$67.13$KG$20221228$$CN$US$US
1679682410$16796824$10$F$20190101$20221004$20190911$20221007$EXP$$FR-GILEAD-2019-0427632$GILEAD$$$$$$Y$$$20221007$$MD$FR$FR
167970983$16797098$3$F$20161215$20221117$20190911$20221124$EXP$$PHHY2016CA181099$NOVARTIS$$54$YR$$F$Y$$$20221124$$CN$CA$CA
1679712933$16797129$33$F$20191016$20221215$20190911$20221224$EXP$$CA-CELLTRION INC.-2019CA023311$CELLTRION$$$$$$Y$$$20221224$$MD$CA$CA
167973053$16797305$3$F$20190807$20221012$20190912$20221017$EXP$$US-SHIRE-US201929613$TAKEDA$$33$YR$$F$Y$$$20221017$$MD$US$US
167982244$16798224$4$F$20190730$20221209$20190912$20221213$EXP$$CA-TAKEDA-2019TUS051857$TAKEDA$$5$YR$$F$Y$$$20221213$$CN$CA$CA
1679871210$16798712$10$F$20190812$20221208$20190912$20221219$PER$$JP-AMGEN-JPNSP2019145867$AMGEN$$69$YR$E$M$Y$67$KG$20221218$$MD$JP$JP
1679947516$16799475$16$F$$20221007$20190912$20221014$EXP$$CA-PFIZER INC-2019392601$PFIZER$$60$YR$$F$Y$$$20221014$$MD$CA$CA
167996142$16799614$2$F$20170101$20221006$20190912$20221013$EXP$FR-AFSSAPS-NY20182180$FR-BAYER-2018-235000$BAYER$$38$YR$A$F$Y$65$KG$20221013$$CN$FR$FR
168011164$16801116$4$F$20190906$20221105$20190912$20221111$EXP$$PHHY2019IN211394$NOVARTIS$$73$YR$$F$Y$$$20221111$$CN$IN$IN
168018893$16801889$3$F$20190808$20221114$20190912$20221119$EXP$$PHHY2019CA210736$NOVARTIS$$46$YR$$M$Y$$$20221119$$MD$CA$CA
1680191210$16801912$10$F$20190625$20221003$20190912$20221005$EXP$$JP-ROCHE-2400290$ROCHE$Omura S, Yamabe T, Ohmura SI, Uehara K and Naniwa T Macrophage activation syndrome in patients with adult onset Stills disease under tocilizumab treatment. A single center observational study, Doi: 10.1080/14397595.2021.1899565. Modern rheumatology 2022;32 (1):169-76.$18$YR$$F$Y$59$KG$20221005$$MD$JP$JP
168020527$16802052$7$F$20150107$20221202$20190912$20221205$EXP$$JP-SHIRE-JP201929372AA$TAKEDA$$$$$$Y$$$20221205$$CN$JP$JP
168024173$16802417$3$F$20190830$20221207$20190912$20221216$PER$$US-BIOGEN-2019BI00783947$BIOGEN$$47$YR$$M$Y$$$20221216$$CN$US$US
168028964$16802896$4$F$20180730$20181205$20190913$20221221$EXP$$PHHY2018DE103623$NOVARTIS$$54$YR$$F$Y$68$KG$20221221$$MD$DE$DE
1680320112$16803201$12$F$20190321$20221117$20190913$20221125$EXP$$CA-CELLTRION INC.-2019CA020451$CELLTRION$$$$$$Y$$$20221125$$MD$CA$CA
1680393922$16803939$22$F$$20221017$20190913$20221021$EXP$$CA-JNJFOC-20190905109$JOHNSON AND JOHNSON$$53$YR$A$M$Y$$$20221021$$MD$CA$CA
1680436519$16804365$19$F$$20221220$20190913$20221228$PER$$US-PFIZER INC-2019092332$PFIZER$$14$YR$$F$Y$50$KG$20221228$$MD$US$US
168046186$16804618$6$F$20190312$20221006$20190913$20221013$EXP$$US-ROCHE-2286557$ROCHE$$44$YR$$F$Y$117.3$KG$20221012$$MD$US$
1680467710$16804677$10$F$$20221028$20190913$20221103$PER$$US-PFIZER INC-2019320435$PFIZER$$57$YR$$M$Y$91.3$KG$20221103$$CN$US$US
168047544$16804754$4$F$$20221128$20190913$20221212$EXP$$PL-AUROBINDO-AUR-APL-2019-059998$AUROBINDO$Koprowicz P, Wlodarczyk J, Kurpesa M, Kasprzak DJ, Rechcinski T. Amiodarone-thyroid-arrhythmia. Difficult cooperation between endocrinologist and cardiologist. A patient with amiodarone-induced thyroid disturbances. FOLIA CARDIOLOGICA EXCERPTA. 2019;14(3):294-7$85$YR$$M$Y$$$20221212$$MD$PL$PL
1680496614$16804966$14$F$20110305$20220929$20190913$20221003$EXP$$PHHY2019GB210231$NOVARTIS$$4$DY$$M$Y$2.855$KG$20221003$$MD$GB$GB
1680617525$16806175$25$F$20190831$20221025$20190913$20221028$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-086177$BRISTOL MYERS SQUIBB$$68$YR$E$M$Y$$$20221028$$HP$CA$CA
168068038$16806803$8$F$$20221216$20190913$20221230$EXP$$CA-Ascend Therapeutics US, LLC-2074452$ASCEND$(1909CAN0011986) HA Canada (Agency no. E2B 02464087)$$$$F$Y$$$20221230$$MD$CA$CA
1680701639$16807016$39$F$20190711$20221031$20190913$20221104$EXP$$AR-MYLANLABS-2019M1067437$MYLAN$$56$YR$$M$Y$$$20221104$$HP$AR$AR
168072598$16807259$8$F$$20221219$20190913$20221228$EXP$$CA-PFIZER INC-2019394537$PFIZER$$4$YR$$M$Y$$$20221228$$HP$CA$CA
1680761720$16807617$20$F$20190731$20221028$20190914$20221102$EXP$$US-ROCHE-2369790$ROCHE$$75$YR$$F$Y$55.1$KG$20221102$$MD$US$
1680787510$16807875$10$F$20110305$20220930$20190915$20221001$EXP$$PHHY2019GB210254$NOVARTIS$$4$DY$$M$Y$2.85$KG$20221001$$HP$GB$GB
168089653$16808965$3$F$$20190828$20190916$20221130$EXP$$PHEH2019US038124$NOVARTIS$$$$$F$Y$$$20221130$$CN$US$US
168090525$16809052$5$F$$20221005$20190916$20221010$PER$$PHEH2019US037907$NOVARTIS$$$$$F$Y$$$20221010$$CN$US$US
168093703$16809370$3$F$20160101$20221212$20190916$20221219$EXP$$BR-BIOGEN-2019BI00784917$BIOGEN$$$$$M$Y$62$KG$20221219$$CN$BR$BR
168100658$16810065$8$F$20190901$20221118$20190916$20221123$PER$$US-PFIZER INC-2019394301$PFIZER$$63$YR$$F$Y$$$20221123$$PH$US$US
168108193$16810819$3$F$$20221219$20190916$20221222$EXP$$CA-PFIZER INC-2019396335$PFIZER$$4$YR$$M$Y$$$20221222$$HP$CA$CA
168119165$16811916$5$F$20190904$20221122$20190916$20221128$EXP$$UA-ABBVIE-19P-269-2919181-00$ABBVIE$$46$YR$$F$Y$$$20221128$$MD$UA$UA
168120343$16812034$3$F$20090610$20191213$20190916$20221008$PER$$US-NAPPMUNDI-USA-2019-0148228$PURDUE$$52$YR$$M$Y$112.47$KG$20221008$$MD$US$US
168122174$16812217$4$F$$20221201$20190916$20221205$EXP$$PL-SA-2019SA255979$SANOFI AVENTIS$$79$YR$E$M$Y$$$20221205$$MD$PL$PL
168122418$16812241$8$F$20180504$20221213$20190916$20221219$EXP$$CA-PFIZER INC-2018343750$PFIZER$$72$YR$$M$Y$$$20221219$$CN$CA$CA
168124786$16812478$6$F$20180801$20221219$20190916$20221222$EXP$$JP-GILEAD-2019-0428408$GILEAD$$71$YR$E$M$Y$$$20221222$$MD$JP$JP
1681322621$16813226$21$F$20170112$20221220$20190916$20221226$EXP$$PHHY2017CA006479$NOVARTIS$$67$YR$$M$Y$$$20221227$$HP$CA$CA
168134444$16813444$4$F$20190816$20220925$20190917$20221027$PER$$US-ALEXION PHARMACEUTICALS INC.-A201913655$ALEXION$$54$YR$$F$Y$92$KG$20221027$$MD$US$US
1681353315$16813533$15$F$20201103$20221208$20190917$20221213$EXP$$CA-TAKEDA-2019TUS052257$TAKEDA$$77$YR$$F$Y$$$20221213$$CN$CA$CA
1681354128$16813541$28$F$20180920$20221109$20190917$20221118$EXP$$CA-CELLTRION INC.-2018CA023014$CELLTRION$$$$$$Y$$$20221118$$CN$CA$CA
168147759$16814775$9$F$20190822$20221101$20190917$20221106$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-084127$BRISTOL MYERS SQUIBB$$69$YR$E$M$Y$$$20221107$$MD$JP$JP
168147833$16814783$3$F$$20221207$20190917$20221210$EXP$$CA-ABBVIE-19K-028-2924089-00$ABBVIE$$$$$M$Y$$$20221210$$CN$CA$CA
168148826$16814882$6$F$$20221013$20190917$20221013$PER$$US-PFIZER INC-2019396544$PFIZER$$46$YR$$M$Y$$$20221013$$HP$US$US
1681532518$16815325$18$F$$20221121$20190917$20221124$EXP$$CA-JNJFOC-20190913993$JOHNSON AND JOHNSON$$$$$F$Y$$$20221124$$HP$CA$CA
1681549110$16815491$10$F$20190830$20221102$20190917$20221104$EXP$$CA-ROCHE-2407517$ROCHE$$84$YR$$F$Y$$$20221104$$HP$CA$CA
168160213$16816021$3$F$20190101$20221011$20190917$20221013$EXP$$US-KYOWAKIRIN-2019BKK014433$KYOWA$$$$$$Y$$$20221013$$CN$US$US
168162492$16816249$2$F$$20220929$20190917$20221007$EXP$$PHHY2019CA214592$NOVARTIS$$80$YR$$F$Y$$$20221007$$CN$CA$CA
168163499$16816349$9$F$20210412$20221104$20190917$20221111$EXP$$BR-GLAXOSMITHKLINE-BR2018GSK067759$GLAXOSMITHKLINE$$$$$$Y$$$20221111$$HP$BR$BR
168173604$16817360$4$F$20190506$20221103$20190917$20221108$EXP$$DE-EXELIXIS-XL18419021456$EXELIXIS$$$$$$Y$$$20221108$$MD$DE$DE
168178384$16817838$4$F$$20221130$20190917$20221207$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-102366$BOEHRINGER INGELHEIM$Moreno M, Sebastian O, Calvo J, Rebollo M, Amarilla I, Fernandez N. Real world use of idarucizumab for dabigatran reversal in Aragon (Spain). Journal of Thrombosis and Haemostasis.$$$$M$Y$$$20221208$$MD$ES$ES
168180653$16818065$3$F$$20221010$20190917$20221013$EXP$$CA-PFIZER INC-2019390234$PFIZER$$61$YR$$F$Y$$$20221013$$HP$CA$CA
168186667$16818666$7$F$$20221010$20190917$20221017$EXP$$CA-GLAXOSMITHKLINE-CA2019166866$GLAXOSMITHKLINE$$$$$$Y$$$20221017$$MD$CA$CA
1681867315$16818673$15$F$20200731$20221011$20190917$20221013$EXP$$BR-GLAXOSMITHKLINE-BR2019GSK003150$GLAXOSMITHKLINE$$$$$$Y$$$20221013$$MD$BR$BR
168193103$16819310$3$F$20190827$20221216$20190917$20221221$EXP$IT-MINISAL02-573023$IT-MYLANLABS-2019M1087735$MYLAN$$8$MON$$M$Y$4.8$KG$20221221$$MD$IT$IT
168193123$16819312$3$F$20190828$20221216$20190917$20221219$EXP$IT-MINISAL02-573030$IT-MYLANLABS-2019M1087740$MYLAN$$41$YR$$M$Y$$$20221219$$MD$IT$IT
168193133$16819313$3$F$20190830$20221216$20190917$20221221$EXP$IT-MINISAL02-573016$IT-MYLANLABS-2019M1087737$MYLAN$$15$YR$$M$Y$$$20221221$$MD$IT$IT
1681984718$16819847$18$F$20090508$20221110$20190917$20221115$EXP$$PHHY2018CA073479$NOVARTIS$$66$YR$$M$Y$$$20221115$$CN$CA$CA
168200164$16820016$4$F$20190911$20190925$20190918$20221202$PER$$US-AMGEN-USASP2019150826$AMGEN$$63$YR$A$M$Y$$$20221202$$HP$US$US
1682123612$16821236$12$F$20190101$20221021$20190918$20221026$EXP$$JP-ABBVIE-19K-087-2929767-00$ABBVIE$$52$YR$$F$Y$59$KG$20221026$$MD$JP$JP
168218422$16821842$2$F$$20221130$20190918$20221205$EXP$$CA-PFIZER INC-2019397046$PFIZER$$72$YR$$M$Y$$$20221205$$CN$CA$CA
168221637$16822163$7$F$$20221201$20190918$20221206$PER$$US-PFIZER INC-2019398190$PFIZER$$72$YR$$F$Y$$$20221206$$CN$US$US
168227622$16822762$2$F$20150807$20221201$20190918$20221205$EXP$$US-JNJFOC-20190915836$JOHNSON AND JOHNSON$$54$YR$A$M$Y$$$20221205$$HP$US$US
168232187$16823218$7$F$$20221019$20190918$20221028$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-27258$SAMSUNG BIOEPIS$$67$YR$E$M$Y$97$KG$20221028$$HP$CA$CA
1682405612$16824056$12$F$20190805$20221008$20190918$20221027$EXP$$JP-009507513-1908JPN001334J$MERCK$Kato C. 10 A case of cholangitis sclerosing caused by pembrolizumab with difficulty in treatment. The 156th Regular Meeting of the Medical Society of Toho University [assembly. 2$54$YR$$M$Y$64$KG$20221027$$MD$JP$JP
168240893$16824089$3$F$$20221018$20190918$20221025$EXP$$FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-090005$BRISTOL MYERS SQUIBB$Jhel A, Cugnet-anceau C, Vigouroux C, Legeay AL, Dalle S, Harou O, et al. Acquired generalized lipodystrophy: A new cause of Anti-PD-1 immune-related diabetes. Diabetes Care. 2019 Aug 21; 1-3.doi:10.2337/dc18-2535.$62$YR$A$F$Y$$$20221025$$HP$FR$FR
168243304$16824330$4$F$20180919$20221206$20190918$20221208$EXP$$DE-SHIRE-DE201929993$TAKEDA$$83$YR$$F$Y$$$20221208$$HP$DE$DE
1682450330$16824503$30$F$20110305$20221125$20190918$20221201$EXP$$GB-BAUSCH-BL-2019-025890$BAUSCH AND LOMB$$4$DY$$M$Y$2.855$KG$20221201$$MD$GB$GB
168249752$16824975$2$F$$20221126$20190919$20221209$EXP$$PL-MACLEODS PHARMACEUTICALS US LTD-MAC2019022946$MACLEODS$$$$$$Y$$$20221209$$MD$PL$PL
1682512316$16825123$16$F$20180326$20221216$20190919$20221226$EXP$$CA-CELLTRION INC.-2018CA019407$CELLTRION$$$$$$Y$$$20221226$$CN$CA$CA
168253173$16825317$3$F$20171106$20221011$20190919$20221021$EXP$$FR-CELLTRION INC.-2017FR017348$CELLTRION$$$$$$Y$$$20221021$$CN$FR$FR
1682540126$16825401$26$F$20191220$20221212$20190919$20221219$EXP$$CA-CELLTRION INC.-2019CA024859$CELLTRION$$$$$$Y$$$20221220$$HP$CA$CA
168259105$16825910$5$F$$20221013$20190919$20221021$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-27392$SAMSUNG BIOEPIS$$67$YR$E$M$Y$87$KG$20221021$$MD$CA$CA
168272688$16827268$8$F$20180830$20221025$20190919$20221029$EXP$$ES-ABBVIE-19K-144-2929980-00$ABBVIE$$64$YR$$F$Y$$$20221029$$MD$ES$ES
1682750210$16827502$10$F$20191001$20221207$20190919$20221215$EXP$$US-PFIZER INC-2019116220$PFIZER$$69$YR$$M$Y$82.55$KG$20221215$$CN$US$US
1682773014$16827730$14$F$20200225$20221219$20190919$20221227$EXP$$US-PFIZER INC-2019401855$PFIZER$$67$YR$$M$Y$73.48$KG$20221227$$CN$US$US
168281558$16828155$8$F$$20221201$20190919$20221208$EXP$$PL-PFIZER INC-2019396851$PFIZER$Koprowicz, P.. Amiodarone - thyroid - arrhythmia. Difficult cooperation between endocrinologist and cardiologist. A patient with amiodarone-induced thyroid disturbances.. FOLIA CARDIOLOGICA EXCERPTA. 2019;14(3):294-297$85$YR$$M$Y$$$20221208$$MD$PL$PL
168284319$16828431$9$F$20190701$20221219$20190919$20221226$EXP$$JP-JNJFOC-20190918111$JOHNSON AND JOHNSON$$71$YR$E$M$Y$71.9$KG$20221227$$MD$JP$JP
1683013913$16830139$13$F$20190101$20221117$20190919$20221125$EXP$$CA-CELLTRION INC.-2019CA023409$CELLTRION$$$$$$Y$$$20221125$$CN$CA$CA
168302763$16830276$3$F$20220901$20221012$20190920$20221017$EXP$$US-ROCHE-2406449$ROCHE$$84$YR$$F$Y$63.56$KG$20221017$$CN$US$
1683043018$16830430$18$F$20171114$20221220$20190920$20221228$EXP$$CA-CELLTRION INC.-2017CA016341$CELLTRION$$$$$$Y$$$20221228$$CN$CA$CA
168305785$16830578$5$F$$20221125$20190920$20221205$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-27295$SAMSUNG BIOEPIS$$51$YR$A$F$Y$63$KG$20221205$$HP$CA$CA
168311932$16831193$2$F$$20221130$20190920$20221206$EXP$$CA-Orion Corporation ORION PHARMA-TREX2019-3504$ORION$$72$YR$E$M$Y$$$20221206$$MD$CA$
168316624$16831662$4$F$$20221128$20190920$20221206$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-27394$SAMSUNG BIOEPIS$$48$YR$A$M$Y$90$KG$20221206$$CN$CA$CA
168317457$16831745$7$F$20180723$20221006$20190920$20221010$EXP$$US-ROCHE-2407941$ROCHE$$77$YR$$M$Y$83.3$KG$20221010$$MD$US$
1683181217$16831812$17$F$20180828$20221117$20190920$20221124$EXP$$CA-ROCHE-2177467$ROCHE$$46$YR$$M$Y$$$20221124$$HP$CA$
168318586$16831858$6$F$20190801$20221019$20190920$20221025$EXP$$PHHO2019GB008825$NOVARTIS$$50$YR$$F$Y$$$20221025$$MD$GB$GB
168329697$16832969$7$F$$20221006$20190920$20221012$EXP$$US-JAZZ-2019-US-012962$JAZZ$$$$$F$Y$57.143$KG$20221012$$MD$US$US
168340254$16834025$4$F$$20221117$20190920$20221121$PER$$US-PFIZER INC-2019406065$PFIZER$$73$YR$$F$Y$$$20221121$$MD$US$US
168342889$16834288$9$F$20170101$20221021$20190920$20221024$EXP$$US-PFIZER INC-2019404521$PFIZER$$78$YR$$F$Y$$$20221024$$CN$US$US
168343579$16834357$9$F$20170101$20221214$20190920$20221219$EXP$$BR-BIOGEN-2019BI00757716$BIOGEN$$$$$F$Y$54$KG$20221219$$CN$BR$BR
1683571511$16835715$11$F$$20221011$20190920$20221017$EXP$$CA-GLAXOSMITHKLINE-CA2019168899$GLAXOSMITHKLINE$$$$$$Y$$$20221017$$HP$CA$CA
168360754$16836075$4$F$20190911$20221121$20190921$20221130$PER$$US-SHIRE-US201930904$TAKEDA$$40$YR$$F$Y$92$KG$20221130$$CN$US$US
1683621339$16836213$39$F$20190911$20221214$20190921$20221228$EXP$$CA-CELLTRION INC.-2019CA024236$CELLTRION$$$$$$Y$$$20221228$$MD$CA$CA
1683647117$16836471$17$F$20211201$20221213$20190921$20221227$EXP$$GB-AUROBINDO-AUR-APL-2019-061027$AUROBINDO$$52$YR$$M$Y$$$20221227$$MD$GB$GB
168381945$16838194$5$F$20190907$20221115$20190923$20221117$EXP$$US-ROCHE-2407852$ROCHE$$71$YR$$F$Y$67.9$KG$20221117$$MD$US$
1683880511$16838805$11$F$20171106$20221109$20190923$20221114$EXP$$PHHY2017CA165821$NOVARTIS$$57$YR$$F$Y$$$20221114$$CN$CA$CA
168395537$16839553$7$F$$20221115$20190923$20221117$PER$$US-PFIZER INC-2019407501$PFIZER$$40$YR$$F$Y$$$20221117$$CN$US$US
168398973$16839897$3$F$20190916$20221208$20190923$20221228$PER$$US-AMGEN-USASP2019154140$AMGEN$$85$YR$E$F$Y$$$20221228$$CN$US$US
168401129$16840112$9$F$20211201$20221129$20190923$20221206$EXP$GB-SA-2019SA243296$GB-PERRIGO-19GB011035$PERRIGO$$52$YR$$M$Y$$$20221206$$HP$GB$GB
168404362$16840436$2$F$$20220915$20190923$20221004$PER$$US-BIOMARINAP-US-2019-125696$BIOMARIN$$$$$$Y$$$20221004$$CN$US$US
1684096414$16840964$14$F$20190101$20220928$20190923$20221004$EXP$$CA-PFIZER INC-2019339330$PFIZER$$44$YR$$F$Y$$$20221004$$HP$CA$CA
168410142$16841014$2$F$20150114$20221024$20190923$20221102$EXP$$AU-TAKEDA-2019TUS053539$TAKEDA$$48$YR$$F$Y$66$KG$20221102$$MD$AU$AU
168410353$16841035$3$F$20210809$20221108$20190923$20221114$PER$$US-SA-2019SA257515$SANOFI AVENTIS$$73$YR$E$F$Y$$$20221114$$MD$US$US
168413595$16841359$5$F$20190901$20221117$20190923$20221122$EXP$$PHHY2019CA218351$NOVARTIS$$34$YR$$M$Y$$$20221122$$HP$CA$CA
1684140026$16841400$26$F$20190101$20221102$20190923$20221107$EXP$$US-GLAXOSMITHKLINE-2019-TSO01817-US$GLAXOSMITHKLINE$$$$$$Y$$$20221107$$MD$US$US
168420407$16842040$7$F$$20220617$20190923$20221006$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-27131$SAMSUNG BIOEPIS$$64$YR$A$F$Y$$$20221006$$CN$CA$CA
1684238928$16842389$28$F$20180912$20221017$20190924$20221025$EXP$$CA-CELLTRION INC.-2018CA021828$CELLTRION$$$$$$Y$$$20221025$$MD$CA$CA
1684243530$16842435$30$F$20180101$20221013$20190924$20221022$EXP$$CA-CELLTRION INC.-2018CA021107$CELLTRION$$$$$$Y$$$20221022$$CN$CA$CA
168442444$16844244$4$F$$20220929$20190924$20221003$EXP$$CA-ROCHE-2407372$ROCHE$$41$YR$$F$Y$77$KG$20221003$$HP$CA$
168446562$16844656$2$F$20050101$20221031$20190924$20221107$EXP$$US-JAZZ-2019-US-013134$JAZZ$$$$$F$Y$$$20221107$$MD$US$US
168449417$16844941$7$F$$20221207$20190924$20221214$EXP$$US-PFIZER INC-2019409206$PFIZER$$82$YR$$M$Y$79.365$KG$20221214$$CN$US$US
168451945$16845194$5$F$20190101$20221220$20190924$20221228$EXP$$US-PFIZER INC-2019408004$PFIZER$$65$YR$$M$Y$82$KG$20221228$$CN$US$US
1684589217$16845892$17$F$20140527$20221209$20190924$20221216$EXP$$PHHY2011CA48114$NOVARTIS$$60$YR$$F$Y$$$20221216$$HP$CA$CA
168463408$16846340$8$F$20190319$20221006$20190924$20221013$EXP$$PHHY2019CA064982$NOVARTIS$$55$YR$$F$Y$$$20221013$$CN$CA$CA
168464414$16846441$4$F$20190705$20221116$20190924$20221118$EXP$$US-GLAXOSMITHKLINE-2019-TSO02416-US$GLAXOSMITHKLINE$$$$$$Y$$$20221118$$MD$US$US
168464466$16846446$6$F$20190405$20220929$20190924$20221005$EXP$US-ROCHE-2299664/EU-EC-10003966592$US-TESAROUBC-2019-TSO01552-US$GLAXOSMITHKLINE$$$$$$Y$$$20221005$$MD$US$US
168467789$16846778$9$F$20190515$20221214$20190924$20221221$EXP$$PHHY2019DE220486$NOVARTIS$$6$YR$$F$Y$19.3$KG$20221221$$MD$DE$DE
168474957$16847495$7$F$20190501$20220526$20190924$20221230$PER$$US-ACORDA-ACO_159688_2019$ACORDA$$82$YR$$F$Y$58.957$KG$20221230$$CN$US$US
168475184$16847518$4$F$$20221220$20190924$20221230$PER$$US-ACORDA-ACO_159628_2019$ACORDA$$$$$F$Y$49.887$KG$20221230$$CN$US$US
168477012$16847701$2$F$$20221005$20190924$20221230$PER$$US-ACORDA-ACO_160956_2019$ACORDA$$$$$F$Y$$$20221230$$CN$US$US
168478256$16847825$6$F$20190724$20220419$20190924$20221230$PER$$US-ACORDA-ACO_160279_2019$ACORDA$$62$YR$$M$Y$$$20221230$$CN$US$US
1684833928$16848339$28$F$20190107$20221121$20190925$20221201$EXP$$GB-LUPIN PHARMACEUTICALS INC.-2019-06097$LUPIN$$4$MON$$F$Y$3.43$KG$20221201$$HP$GB$GB
168488015$16848801$5$F$20190220$20220929$20190925$20221004$EXP$$CA-TAKEDA-2019TUS010933$TAKEDA$$54$YR$$M$Y$$$20221004$$CN$CA$CA
1685361811$16853618$11$F$$20221003$20190926$20221011$PER$$IT-AMGEN-ITASP2019156992$AMGEN$Cerchione C. ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALI DOM I DE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET. Clinical Lymphoma Myeloma and Leukemia. 2022;22:S426-S427$$$$$Y$$$20221011$$HP$IT$IT
1685403025$16854030$25$F$$20221214$20190926$20221222$EXP$GB-MHRA-ADR 24431064$GB-drreddys-GER/UKI/19/0114321$DR REDDYS$$$$A$M$Y$$$20221223$$HP$GB$GB
168547464$16854746$4$F$20110101$20221220$20190926$20221227$EXP$$US-GILEAD-2019-0429522$GILEAD$$51$YR$A$F$Y$69.841$KG$20221227$$LW$US$US
168560775$16856077$5$F$$20221219$20190926$20221229$EXP$$US-GILEAD-2019-0429414$GILEAD$$55$YR$A$F$Y$$$20221229$$LW$US$US
1685623810$16856238$10$F$20190831$20221220$20190926$20221227$EXP$$US-PFIZER INC-2019413833$PFIZER$$47$YR$$M$Y$92.971$KG$20221227$$CN$US$US
168563532$16856353$2$F$20170328$20221107$20190926$20221109$EXP$$CA-TAKEDA-2017TUS004228$TAKEDA$$19$YR$$M$Y$$$20221109$$HP$CA$CA
1685649559$16856495$59$F$20190101$20221115$20190926$20221115$EXP$$IL-PFIZER INC-2019118031$PFIZER$$84$YR$$M$Y$75$KG$20221115$$HP$IL$IL
168573433$16857343$3$F$$20220929$20190926$20221010$EXP$$CA-PFIZER INC-2019410534$PFIZER$$52$YR$$F$Y$$$20221010$$HP$CA$CA
168574512$16857451$2$F$$20221103$20190926$20221107$PER$$US-SHIRE-US201931693$TAKEDA$$$$$F$Y$$$20221107$$HP$US$US
168603559$16860355$9$F$20181203$20221011$20190927$20221014$EXP$$PHHY2018CA197951$NOVARTIS$$61$YR$$F$Y$138$KG$20221014$$MD$CA$CA
168606035$16860603$5$F$20190907$20221104$20190927$20221109$PER$$ZA-AMGEN-ZAFSP2019150936$AMGEN$$43$YR$A$F$Y$78.9$KG$20221108$$CN$ZA$ZA
1686119931$16861199$31$F$20190101$20221219$20190927$20221227$EXP$$CA-CELLTRION INC.-2019CA024374$CELLTRION$$$$$$Y$$$20221227$$CN$CA$CA
168613964$16861396$4$F$20190101$20221206$20190927$20221208$PER$$US-AMGEN-USASP2019157125$AMGEN$$38$YR$A$F$Y$88.435$KG$20221207$$HP$US$US
168614763$16861476$3$F$20160217$20221207$20190927$20221208$EXP$$GB-MYLANLABS-2019M1089220$MYLAN$$49$YR$$F$Y$$$20221208$$MD$GB$GB
168623152$16862315$2$F$20190816$20221207$20190927$20221221$EXP$$IT-AUROBINDO-AUR-APL-2019-062811$AUROBINDO$$54$YR$$F$Y$$$20221221$$PH$IT$IT
168623884$16862388$4$F$$20221123$20190927$20221128$PER$$US-PFIZER INC-2019417840$PFIZER$$38$YR$$F$Y$$$20221128$$HP$US$US
168635626$16863562$6$F$20190101$20221125$20190927$20221208$EXP$$CA-INTERCEPT-PM2019001670$INTERCEPT PHARMACEUTICALS$$$$$F$Y$$$20221208$$CN$CA$CA
168635902$16863590$2$F$$20190924$20190927$20221020$EXP$$PHHY2019CA224575$NOVARTIS$$$$$F$Y$$$20221020$$HP$CA$CA
1686367427$16863674$27$F$20190101$20221028$20190927$20221102$EXP$$US-GLAXOSMITHKLINE-US2019TSO170263$GLAXOSMITHKLINE$$$$$$Y$$$20221102$$CN$US$US
168646914$16864691$4$F$20190209$20221114$20190929$20221118$EXP$$PHHY2019DE221035$NOVARTIS$$68$YR$$M$Y$$$20221118$$MD$DE$DE
1686644712$16866447$12$F$$20221014$20190930$20221018$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK138459$GLAXOSMITHKLINE$$$$$$Y$$$20221018$$MD$BR$BR
1686686214$16866862$14$F$20190927$20221214$20190930$20221217$EXP$$SE-ABBVIE-19K-150-2943690-00$ABBVIE$$64$YR$$M$Y$84$KG$20221217$$HP$SE$SE
1686688710$16866887$10$F$$20221214$20190930$20221226$EXP$GB-MHRA-ADR 24378536$GB-Accord-118241$ACCORD$$$$A$M$Y$$$20221226$$CN$GB$GB
168670403$16867040$3$F$$20211126$20190930$20221003$PER$$US-AUROBINDO-AUR-APL-2019-024127$AUROBINDO$$$$$F$Y$$$20221003$$PH$US$US
168679865$16867986$5$F$20190601$20221214$20190930$20221220$EXP$$JP-ABBVIE-19P-087-2945044-00$ABBVIE$$61$YR$$M$Y$41$KG$20221220$$MD$JP$JP
168682175$16868217$5$F$$20221018$20190930$20221020$PER$$US-PFIZER INC-2019419427$PFIZER$$49$YR$$F$Y$$$20221020$$MD$US$US
1686848820$16868488$20$F$20190801$20221003$20190930$20221007$EXP$$US-INCYTE CORPORATION-2019IN009709$INCYTE$$$$$$Y$$$20221007$$CN$US$US
168689735$16868973$5$F$20190821$20210716$20190930$20221017$EXP$$PL-JNJFOC-20190903355$JOHNSON AND JOHNSON$$41$YR$A$F$Y$69$KG$20221017$$MD$PL$PL
168720302$16872030$2$F$$20221017$20191001$20221025$EXP$$IE-AUROBINDO-AUR-APL-2019-063613$AUROBINDO$$$$$M$Y$$$20221025$$MD$IE$IE
168727009$16872700$9$F$20190704$20221126$20191001$20221129$EXP$$AT-ROCHE-2415586$ROCHE$$67$YR$$F$Y$89$KG$20221129$$MD$AT$
168731662$16873166$2$F$$20190920$20191001$20221031$PER$$US-UCBSA-2019040610$UCB$Kairamkonda S, Arya K, Gabriel G, Veerapandiyan A. A challenging case of intractable seizures in a pediatric patient with anti-GAD65 encephalitis. 71st Annual Meeting of the American Academy of Neurology, AAN 2019. United States. Neurology. 2019;92(15 Suppl 1)$13$YR$$F$Y$$$20221031$$MD$US$US
168732626$16873262$6$F$$20221220$20191001$20221229$PER$$US-PFIZER INC-2019301396$PFIZER$$15$YR$$M$Y$$$20221229$$PH$US$US
168734205$16873420$5$F$$20221212$20191001$20221219$PER$$US-PFIZER INC-2019421404$PFIZER$$61$YR$$$Y$$$20221219$$CN$US$US
1687381022$16873810$22$F$20181027$20221027$20191001$20221101$EXP$$GB-MYLANLABS-2019M1091765$MYLAN$$39$YR$$M$Y$91$KG$20221101$$CN$GB$GB
1687393820$16873938$20$F$20190618$20221123$20191001$20221129$EXP$$DE-ROCHE-2348096$ROCHE$$51$YR$$F$Y$$$20221129$$CN$DE$DE
168742673$16874267$3$F$20120101$20221028$20191001$20221031$EXP$$US-TAKEDA-2019TUS054697$TAKEDA$$$$$$Y$$$20221031$$CN$US$US
1687426817$16874268$17$F$$20221017$20191001$20221025$EXP$$GB-BAUSCH-BL-2019-055878$BAUSCH AND LOMB$$$$A$F$Y$$$20221025$$PH$GB$GB
168748809$16874880$9$F$20191219$20221114$20191001$20221118$EXP$$CA-TAKEDA-2019TUS054596$TAKEDA$$67$YR$$F$Y$$$20221118$$CN$CA$CA
1687550010$16875500$10$F$20190101$20221010$20191002$20221019$EXP$$CA-CELLTRION INC.-2019CA019915$CELLTRION$$$$$$Y$$$20221019$$CN$CA$CA
168755353$16875535$3$F$20161031$20221202$20191002$20221213$PER$$JP-AMGEN-JPNSP2016153931$AMGEN$$60$YR$A$F$Y$$$20221213$$MD$JP$JP
168755455$16875545$5$F$20180501$20221109$20191002$20221117$EXP$$US-AstraZeneca-2019SF36611$ASTRAZENECA$$750$MON$$M$Y$77.1$KG$20221117$$LW$US$
168755764$16875576$4$F$20130101$20221031$20191002$20221108$EXP$$US-AstraZeneca-2019SF36478$ASTRAZENECA$$59$YR$$F$Y$76.2$KG$20221108$$LW$US$
168756202$16875620$2$F$20190101$20221121$20191002$20221124$EXP$$US-GW PHARMA-201907USGW2475$JAZZ$$$$$M$Y$$$20221124$$CN$US$US
1687609945$16876099$45$F$20190326$20221219$20191002$20221226$EXP$$US-SA-2019SA031718$SANOFI AVENTIS$$44$YR$A$M$Y$116.1$KG$20221226$$MD$US$US
1687638610$16876386$10$F$20191008$20221006$20191002$20221010$EXP$$CA-TAKEDA-2019TUS054504$TAKEDA$$56$YR$$M$Y$$$20221010$$MD$CA$CA
168774493$16877449$3$F$$20221120$20191002$20221123$EXP$$US-PFIZER INC-2019421419$PFIZER$$64$YR$$M$Y$$$20221123$$HP$US$US
168779386$16877938$6$F$$20221012$20191002$20221020$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-28742$SAMSUNG BIOEPIS$$33$YR$A$M$Y$157$KG$20221020$$HP$CA$CA
168780364$16878036$4$F$20161201$20221018$20191002$20221020$EXP$$US-TAKEDA-2019TUS054828$TAKEDA$$$$$$Y$$$20221019$$CN$US$US
1687924712$16879247$12$F$20190101$20221223$20191003$20221229$EXP$$JP-ABBVIE-19K-087-2925623-00$ABBVIE$$75$YR$$F$Y$53$KG$20221229$$CN$JP$JP
168792879$16879287$9$F$$20221209$20191003$20221214$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-28745$SAMSUNG BIOEPIS$$19$YR$A$F$Y$67$KG$20221214$$HP$CA$CA
168793066$16879306$6$F$20160101$20221107$20191003$20221114$EXP$$DE-BIOGEN-2016BI00291086$BIOGEN$$$$$F$Y$61$KG$20221114$$CN$DE$DE
1687931218$16879312$18$F$20190101$20221209$20191003$20221219$EXP$$CA-CELLTRION INC.-2019CA025270$CELLTRION$$$$$$Y$$$20221219$$CN$CA$CA
168795105$16879510$5$F$20190131$20221017$20191003$20221022$EXP$$PHHY2018CA145967$NOVARTIS$$60$YR$$F$Y$$$20221022$$CN$CA$CA
1687967415$16879674$15$F$$20221212$20191003$20221220$EXP$$CA-Noden Pharma DAC-NOD-2019-000161$NODEN PHARMA$$65$YR$E$F$Y$69$KG$20221220$$HP$CA$
168801873$16880187$3$F$$20220927$20191003$20221007$EXP$$PL-TEVA-2019-PL-1112626$TEVA$$34$YR$A$M$Y$$$20221007$$HP$PL$PL
168804344$16880434$4$F$$20221212$20191003$20221216$EXP$$NL-PFIZER INC-2019411676$PFIZER$Van Wezel, E.. Sofosbuvir add-on to ribavirin treatment for chronic hepatitis e virus infection in solid organ transplant recipients does not result in sustained virological response. Open Forum Infectious Diseases. 2019;6 (8):1-4$52$YR$$F$Y$$$20221216$$HP$NL$NL
1688093623$16880936$23$F$$20221114$20191003$20221116$EXP$$US-PFIZER INC-2019426277$PFIZER$$80$YR$$F$Y$63$KG$20221116$$CN$US$US
168809456$16880945$6$F$20190101$20221205$20191003$20221209$PER$$US-PFIZER INC-2019424168$PFIZER$$59$YR$$F$Y$$$20221209$$PH$US$US
168809726$16880972$6$F$$20221206$20191003$20221213$PER$$US-PFIZER INC-2019424019$PFIZER$$72$YR$$M$Y$81.64$KG$20221213$$CN$US$US
168820464$16882046$4$F$20180706$20221122$20191003$20221129$EXP$$JP-BIOGEN-2019BI00789866$BIOGEN$$43$YR$$M$Y$$$20221129$$MD$JP$JP
168821147$16882114$7$F$20180823$20221018$20191003$20221021$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2019JPN178266$VIIV$$$$$$Y$$$20221021$$MD$JP$JP
168824512$16882451$2$F$20110601$20221005$20191003$20221026$PER$$US-JAZZ-JPI-P-017525$JAZZ$$10$YR$$F$Y$$$20221026$$HP$US$US
168825354$16882535$4$F$$20221017$20191003$20221024$EXP$$CA-BAUSCH-BL-2019-055729$BAUSCH AND LOMB$$60$YR$$F$Y$61$KG$20221024$$CN$CA$CA
1688282130$16882821$30$F$20190919$20221123$20191003$20221227$EXP$$CA-CELLTRION INC.-2019CA025254$CELLTRION$$$$$$Y$$$20221227$$CN$CA$CA
1688291410$16882914$10$F$20190101$20221110$20191004$20221117$EXP$$CA-TAKEDA-2019TUS044590$TAKEDA$$32$YR$$M$Y$$$20221117$$CN$CA$CA
168834794$16883479$4$F$20180827$20220706$20191004$20221219$EXP$$US-ROCHE-2428714$ROCHE$$75$YR$$F$Y$75$KG$20221220$$MD$US$
168844708$16884470$8$F$$20221129$20191004$20221207$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-28738$SAMSUNG BIOEPIS$$41$YR$A$F$Y$78$KG$20221207$$CN$CA$CA
1688451510$16884515$10$F$20181109$20221206$20191004$20221212$EXP$$US-ROCHE-2222984$ROCHE$$52$YR$$F$Y$80.6$KG$20221212$$MD$US$
168847823$16884782$3$F$$20220927$20191004$20221006$EXP$$US-JNJFOC-20190939546$JOHNSON AND JOHNSON$$32$YR$A$M$Y$$$20221006$$HP$US$US
1688543711$16885437$11$F$20190823$20221108$20191004$20221110$EXP$$AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-085513$BRISTOL MYERS SQUIBB$$69$YR$E$M$Y$$$20221110$$HP$AU$AU
168865597$16886559$7$F$20190101$20221020$20191004$20221101$PER$$US-SA-2019SA240146$SANOFI AVENTIS$$57$YR$A$F$Y$52.154$KG$20221101$$MD$US$US
1688672054$16886720$54$F$$20220621$20191004$20221021$EXP$$CA-ABBVIE-19K-028-2946845-00$ABBVIE$$44$YR$$F$Y$$$20221021$$HP$CA$CA
1688675013$16886750$13$F$20170531$20221116$20191004$20221122$EXP$$CA-TAKEDA-2019TUS027610$TAKEDA$$65$YR$$F$Y$$$20221122$$CN$CA$CA
1688691636$16886916$36$F$20210901$20221201$20191004$20221205$EXP$$US-GLAXOSMITHKLINE-US2019TSO170833$GLAXOSMITHKLINE$$$$$$Y$$$20221205$$CN$US$US
168875405$16887540$5$F$20190105$20220706$20191005$20221220$EXP$$US-ROCHE-2247883$ROCHE$$64$YR$$F$Y$57.2$KG$20221220$$MD$US$
168887358$16888735$8$F$$20221031$20191007$20221109$EXP$$ES-CELLTRION INC.-2019ES025393$CELLTRION$Cancio-Suarez RM, Diaz BI, Gonzalez-Garcia A. Progressive multifocal leukoencephalopathy in the course of combined therapy with bendamustine and rituximab.. MED CLIN (BARC). 2019;S0025-7753(19):30523-8$$$$$Y$$$20221109$$HP$ES$ES
168890844$16889084$4$F$20190101$20221206$20191007$20221211$EXP$$JP-SA-2019SA260384$SANOFI AVENTIS$$77$YR$E$M$Y$$$20221212$$MD$JP$JP
168903385$16890338$5$F$20220606$20220928$20191007$20221004$EXP$$US-SHIRE-US201932559$TAKEDA$$40$YR$$F$Y$$$20221004$$CN$US$US
168903702$16890370$2$F$20190915$20220921$20191007$20221001$EXP$$FR-AUROBINDO-AUR-APL-2019-064635$AUROBINDO$$48$YR$$M$Y$$$20221001$$PH$FR$FR
168904964$16890496$4$F$20160701$20220930$20191007$20221005$EXP$$US-TAKEDA-2019TUS055558$TAKEDA$$$$$$Y$$$20221005$$CN$US$US
168906454$16890645$4$F$$20221219$20191007$20221229$PER$$US-PFIZER INC-2019428242$PFIZER$$65$YR$$F$Y$$$20221229$$CN$US$US
1689295033$16892950$33$F$20180517$20221017$20191007$20221026$EXP$$CA-CELLTRION INC.-2018CA020229$CELLTRION$$$$$$Y$$$20221026$$CN$CA$CA
1689315717$16893157$17$F$20190906$20221206$20191008$20221212$EXP$$CA-ROCHE-2412851$ROCHE$$42$YR$$F$Y$107.2$KG$20221212$$CN$CA$
1689319018$16893190$18$F$20190903$20220929$20191008$20221003$EXP$$CA-TAKEDA-2019TUS051010$TAKEDA$$30$YR$$M$Y$$$20221003$$MD$CA$CA
1689349516$16893495$16$F$20190809$20221207$20191008$20221209$EXP$$DE-ROCHE-2358101$ROCHE$$49$YR$$F$Y$$$20221209$$CN$DE$
1689384714$16893847$14$F$20190101$20221118$20191008$20221123$EXP$$US-PFIZER INC-2019428836$PFIZER$$55$YR$$F$Y$60$KG$20221123$$CN$US$US
168948663$16894866$3$F$$20221210$20191008$20221216$EXP$$US-INDIVIOR US-INDV-119444-2019$RECKITT BENCKISER$$$$$$Y$$$20221216$$CN$US$US
168949144$16894914$4$F$$20220304$20191008$20221013$PER$$US-INDIVIOR US-INDV-120215-2019$RECKITT BENCKISER$$$$$M$Y$$$20221013$$CN$US$US
168961114$16896111$4$F$20170301$20221212$20191008$20221219$EXP$$FR-MYLANLABS-2019M1092949$MYLAN$$64$YR$$F$Y$74$KG$20221219$$HP$FR$FR
168972219$16897221$9$F$20220316$20221011$20191009$20221017$EXP$$US-SHIRE-US201933061$TAKEDA$$57$YR$$M$Y$91$KG$20221017$$HP$US$US
168972532$16897253$2$F$$20220706$20191009$20221219$EXP$$US-ROCHE-2428692$ROCHE$$70$YR$$F$Y$$$20221220$$MD$US$
168976508$16897650$8$F$20190301$20221115$20191009$20221122$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-096760$BRISTOL MYERS SQUIBB$$66$YR$E$M$Y$66.6$KG$20221122$$MD$JP$JP
168977848$16897784$8$F$20190917$20221118$20191009$20221202$EXP$$DE-AUROBINDO-AUR-APL-2019-065071$AUROBINDO$$$$A$F$Y$51$KG$20221202$$MD$DE$DE
168981673$16898167$3$F$20190822$20221213$20191009$20221223$PER$$GB-AMGEN-GBRSP2019162731$AMGEN$$47$YR$A$F$Y$$$20221223$$HP$GB$GB
168983749$16898374$9$F$$20221004$20191009$20221010$EXP$$CA-ROCHE-2422844$ROCHE$$60$YR$$F$Y$78$KG$20221010$$MD$CA$
168984283$16898428$3$F$$20221018$20191009$20221020$EXP$$CA-PFIZER INC-2019428244$PFIZER$$53$YR$$F$Y$67$KG$20221020$$HP$CA$CA
168989026$16898902$6$F$20180101$20221011$20191009$20221014$EXP$$US-PFIZER INC-2019430600$PFIZER$$77$YR$$F$Y$64$KG$20221014$$CN$US$US
168989123$16898912$3$F$$20221010$20191009$20221012$PER$$US-PFIZER INC-2019431630$PFIZER$$66$YR$$F$Y$$$20221012$$MD$US$US
168990402$16899040$2$F$20101205$20221218$20191009$20221222$EXP$$GB-MYLANLABS-2019M1093997$MYLAN$$19$YR$$F$Y$$$20221222$$MD$GB$GB
168993102$16899310$2$F$20181107$20191003$20191009$20221026$EXP$$JP-TEVA-2019-JP-006554J$TEVA$$77$YR$E$M$Y$75$KG$20221026$$MD$JP$JP
168997985$16899798$5$F$$20221011$20191009$20221018$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR178680$GLAXOSMITHKLINE$$$$$$Y$$$20221018$$HP$CA$CA
1690044715$16900447$15$F$$20221102$20191009$20221104$EXP$$US-PFIZER INC-2019436539$PFIZER$$64$YR$$F$Y$52.109$KG$20221104$$CN$US$US
1690191212$16901912$12$F$20190101$20221214$20191010$20221215$EXP$$JP-ABBVIE-19K-087-2937519-00$ABBVIE$$81$YR$$F$Y$42$KG$20221215$$CN$JP$JP
169019459$16901945$9$F$20190326$20221006$20191010$20221013$EXP$$US-ROCHE-2296103$ROCHE$$77$YR$$M$Y$80.4$KG$20221012$$MD$US$
169019543$16901954$3$F$20190101$20221107$20191010$20221114$EXP$$PR-ABBVIE-19K-131-2824076-00$ABBVIE$$51$YR$$F$Y$55.79$KG$20221114$$CN$PR$PR
1690195918$16901959$18$F$20221019$20221102$20191010$20221108$EXP$$US-SHIRE-US201933339$TAKEDA$$56$YR$$F$Y$63.49$KG$20221108$$HP$US$US
1690287429$16902874$29$F$20120202$20221025$20191010$20221107$EXP$$AU-TASMAN PHARMA, INC.-2019TSM00106$TASMAN PHARMA$$$$A$F$Y$$$20221107$$HP$AU$AU
1690309625$16903096$25$F$20180928$20221129$20191010$20221207$EXP$$CA-ROCHE-2190496$ROCHE$$58$YR$$F$Y$$$20221207$$CN$CA$
169031435$16903143$5$F$20180727$20221006$20191010$20221013$EXP$$US-ROCHE-2171648$ROCHE$$66$YR$$M$Y$91.8$KG$20221013$$MD$US$
169034455$16903445$5$F$20161001$20221110$20191010$20221116$PER$$US-PFIZER INC-2019433072$PFIZER$$22$YR$$M$Y$$$20221116$$HP$US$US
1690366322$16903663$22$F$20190828$20221214$20191010$20221222$30DAY$$US-PFIZER INC-2017245995$PFIZER$$35$YR$$F$Y$66$KG$20221222$$CN$US$US
169043817$16904381$7$F$20190704$20221202$20191010$20221212$PER$$AT-AMGEN-AUTNI2019165404$AMGEN$$67$YR$E$F$Y$89$KG$20221212$$MD$AT$AT
169046716$16904671$6$F$$20221018$20191010$20221027$EXP$$AU-JNJFOC-20190939378$JOHNSON AND JOHNSON$$38$YR$A$F$Y$$$20221027$$HP$AU$AU
169052243$16905224$3$F$$20221108$20191010$20221114$EXP$$US-SHIRE-US201933506$TAKEDA$$$$$F$Y$129$KG$20221114$$HP$US$US
169052277$16905227$7$F$$20221208$20191010$20221216$EXP$$US-SHIRE-US201933099$TAKEDA$$$$$F$Y$96$KG$20221216$$HP$US$US
1690553317$16905533$17$F$20170901$20221207$20191010$20221220$EXP$$GB-ELI_LILLY_AND_COMPANY-GB201802002156$ELI LILLY AND CO$$32$YR$$F$Y$$$20221220$$CN$GB$GB
169059442$16905944$2$F$$20221011$20191010$20221014$PER$$US-TEVA-2019-US-1119668$TEVA$$$$$F$Y$$$20221014$$LW$US$US
1690610334$16906103$34$F$20181123$20221111$20191010$20221121$EXP$$CA-CELLTRION INC.-2018CA024375$CELLTRION$$$$$$Y$$$20221121$$HP$CA$CA
1690637615$16906376$15$F$20181213$20221118$20191011$20221129$EXP$$FR-ABBVIE-19K-056-2956791-00$ABBVIE$$66$YR$$F$Y$$$20221129$$MD$FR$FR
1690714910$16907149$10$F$20221115$20221209$20191011$20221219$EXP$$US-SHIRE-US201933389$TAKEDA$$81$YR$$F$Y$90$KG$20221219$$HP$US$US
169072813$16907281$3$F$20190101$20221012$20191011$20221122$EXP$$US-ABBVIE-19K-163-2957728-00$ABBVIE$$$$$M$Y$$$20221122$$CN$US$US
169073867$16907386$7$F$20190609$20221116$20191011$20221126$EXP$NL-LRB-00351135$NL-TEVA-2019-NL-1119422$TEVA$$50$YR$A$M$Y$96$KG$20221125$$CN$NL$NL
169076532$16907653$2$F$$20221115$20191011$20221117$PER$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-095158$BRISTOL MYERS SQUIBB$$39$YR$A$F$Y$$$20221117$$CN$US$US
1690792117$16907921$17$F$20190101$20220928$20191011$20221013$EXP$$IL-ABBVIE-19K-082-2955109-00$ABBVIE$$59$YR$$M$Y$73$KG$20221013$$MD$IL$IL
1690804010$16908040$10$F$20190101$20220920$20191011$20221103$EXP$$IL-ABBVIE-19K-082-2956727-00$ABBVIE$$86$YR$$F$Y$60$KG$20221103$$MD$IL$IL
169080984$16908098$4$F$20190924$20221027$20191011$20221031$PER$$FR-AMGEN-FRACT2019163040$AMGEN$$72$YR$E$F$Y$86$KG$20221031$$MD$FR$FR
169087532$16908753$2$F$20180710$20220706$20191011$20221218$EXP$$US-ROCHE-2427087$ROCHE$$28$YR$$M$Y$95.9$KG$20221219$$MD$US$
169087647$16908764$7$F$$20221027$20191011$20221103$EXP$$US-SHIRE-US201933341$TAKEDA$$$$$F$Y$108$KG$20221103$$HP$US$US
169096707$16909670$7$F$20030101$20221027$20191011$20221103$EXP$$FR-OTSUKA-2018_030883$OTSUKA$$$$$M$Y$$$20221103$$CN$FR$FR
1690967310$16909673$10$F$$20221213$20191011$20221219$EXP$$US-SHIRE-US201933546$TAKEDA$$$$$F$Y$250$KG$20221219$$HP$US$US
169107979$16910797$9$F$20211208$20221031$20191012$20221108$EXP$$US-SHIRE-US201933720$TAKEDA$$59$YR$$F$Y$73$KG$20221108$$HP$US$US
169110109$16911010$9$F$$20221010$20191012$20221021$EXP$GB-MHRA-ADR 24378536$GB-CPL-000906$CADILA$$$$A$M$Y$$$20221021$$CN$GB$GB
169110373$16911037$3$F$20110101$20221212$20191012$20221223$EXP$$NL-Accord-157130$ACCORD$van Wezel EM, de Bruijne J, Damman K, Bijmolen M, van den Berg AP, Verschuuren?EAM, et al, Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response. Open Forum Infect Dis. 2019 Aug 1;6(8).$52$YR$A$F$Y$$$20221223$$HP$NL$NL
169116422$16911642$2$F$$20221206$20191013$20221220$EXP$$IE-AUROBINDO-AUR-APL-2019-065967$AUROBINDO$$$$$M$Y$$$20221220$$MD$IE$IE
169116585$16911658$5$F$20150220$20220926$20191013$20221007$EXP$$FR-AUROBINDO-AUR-APL-2019-065845$AUROBINDO$$3$DY$$F$Y$2.27$KG$20221007$$MD$FR$FR
1691209532$16912095$32$F$20170616$20221012$20191014$20221021$EXP$$CA-CELLTRION INC.-2018CA018692$CELLTRION$$$$$$Y$$$20221021$$CN$CA$CA
169121783$16912178$3$F$20190401$20221110$20191014$20221114$EXP$$DE-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-106430$BOEHRINGER INGELHEIM$$42$YR$A$M$Y$$$20221115$$MD$DE$DE
169122853$16912285$3$F$20170101$20221028$20191014$20221111$EXP$$ES-AUROBINDO-AUR-APL-2018-009225$AUROBINDO$Lombardero PM, Santos ML, Velaz Suarez MA. Mortal toxicity to capecitabine in a patient without the *2A mutation of the dihydropyrimidine dehydrogenase gene.. Casos Clinicos Rev. OFILILAPHAR.. 2019;29(3):231-233$67$YR$$M$Y$66$KG$20221112$$PH$ES$ES
1691258611$16912586$11$F$$20221121$20191014$20221128$EXP$$BR-GLAXOSMITHKLINE-BR2018GSK225808$GLAXOSMITHKLINE$$$$$$Y$$$20221128$$CN$BR$BR
169127672$16912767$2$F$20191003$20191004$20191014$20221230$PER$$US-AMGEN-USASP2019165693$AMGEN$$79$YR$E$F$Y$$$20221229$$PH$US$US
169132885$16913288$5$F$$20221124$20191014$20221201$EXP$$CA-ROCHE-2429230$ROCHE$$$$$F$Y$$$20221201$$MD$CA$
169140234$16914023$4$F$$20221011$20191014$20221013$PER$$US-PFIZER INC-2019440552$PFIZER$$69$YR$$F$Y$$$20221013$$CN$US$US
169142047$16914204$7$F$$20221213$20191014$20221215$PER$$US-PFIZER INC-2019440094$PFIZER$$79$YR$$F$Y$$$20221215$$MD$US$US
1691464715$16914647$15$F$20191001$20221206$20191014$20221214$EXP$$US-SHIRE-US201933714$TAKEDA$$52$YR$$F$Y$57$KG$20221214$$HP$US$US
169148003$16914800$3$F$$20220706$20191014$20221216$EXP$$US-ROCHE-2430502$ROCHE$$48$YR$$F$Y$$$20221216$$MD$US$
169156043$16915604$3$F$20190101$20221012$20191014$20221014$EXP$$GB-BAUSCH-BL-2019-057515$BAUSCH AND LOMB$$$$$M$Y$$$20221014$$CN$GB$GB
169160028$16916002$8$F$20191115$20221115$20191014$20221117$EXP$$US-SHIRE-US201934289$TAKEDA$$51$YR$$F$Y$$$20221117$$CN$US$US
169165275$16916527$5$F$20190909$20221118$20191014$20221124$EXP$$US-BIOGEN-2019BI00795102$BIOGEN$$40$YR$$M$Y$$$20221124$$CN$US$US
1691661732$16916617$32$F$20181101$20221214$20191014$20221223$EXP$$CA-CELLTRION INC.-2018CA023489$CELLTRION$$$$$$Y$$$20221223$$MD$CA$CA
169166372$16916637$2$F$$20221114$20191014$20221116$PER$$US-SHIRE-US201934116$TAKEDA$$$$$M$Y$73$KG$20221116$$HP$US$US
169172685$16917268$5$F$20190930$20221207$20191015$20221213$EXP$$IT-AUROBINDO-AUR-APL-2019-066224$AUROBINDO$$48$YR$$M$Y$$$20221213$$MD$IT$IT
1691744819$16917448$19$F$20210930$20221226$20191015$20221228$EXP$$BR-GLAXOSMITHKLINE-BR2018GSK224019$GLAXOSMITHKLINE$$$$$$Y$$$20221228$$MD$BR$BR
1691763611$16917636$11$F$20170505$20221213$20191015$20221217$EXP$$CA-TAKEDA-2017TUS009559$TAKEDA$$60$YR$$M$Y$$$20221217$$HP$CA$CA
169177052$16917705$2$F$20190101$20221201$20191015$20221215$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-223532$RANBAXY$$$$E$F$Y$$$20221215$$PH$US$US
169180108$16918010$8$F$$20221102$20191015$20221104$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR130612$GLAXOSMITHKLINE$$$$$$Y$$$20221104$$MD$CA$CA
169183593$16918359$3$F$$20221121$20191015$20221122$PER$$US-SHIRE-US201933260$TAKEDA$$$$$F$Y$$$20221122$$HP$US$US
169185063$16918506$3$F$20190925$20221202$20191015$20221205$EXP$$JP-PFIZER INC-2019435948$PFIZER$$17$MON$$M$Y$$$20221205$$PH$JP$JP
1691878415$16918784$15$F$$20221026$20191015$20221031$EXP$GB-MHRA-ADR 24431064$GB-MYLANLABS-2019M1096139$MYLAN$$$$A$M$Y$$$20221031$$CN$GB$GB
169188272$16918827$2$F$$20190930$20191015$20221130$PER$$NVSC2019US001177$NOVARTIS$$$$$F$Y$$$20221130$$CN$US$US
169189497$16918949$7$F$20210220$20221013$20191015$20221017$EXP$$US-PFIZER INC-2019064045$PFIZER$$77$YR$$F$Y$$$20221017$$CN$US$US
169189544$16918954$4$F$20191109$20221221$20191015$20221230$PER$$US-PFIZER INC-2019441052$PFIZER$$66$YR$$F$Y$66.667$KG$20221230$$CN$US$US
169190415$16919041$5$F$$20221215$20191015$20221220$EXP$$US-PFIZER INC-2019441729$PFIZER$$63$YR$$F$Y$$$20221220$$HP$US$US
1691905518$16919055$18$F$20180201$20220713$20191015$20221013$EXP$$PHHY2018CA089256$NOVARTIS$$71$YR$$F$Y$$$20221013$$MD$CA$CA
169191085$16919108$5$F$20190902$20221014$20191015$20221021$EXP$$PHHY2019CA227772$NOVARTIS$$72$YR$$M$Y$$$20221021$$MD$CA$CA
169192966$16919296$6$F$20220101$20221110$20191015$20221114$EXP$$US-PFIZER INC-2019444870$PFIZER$$80$YR$$M$Y$$$20221114$$CN$US$US
1691933419$16919334$19$F$20190101$20221114$20191015$20221122$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-097328$BRISTOL MYERS SQUIBB$Shiori A, Kubo T, Sugawara T, Shinkawa T, Kurisu T, Hasegawa T et al. Ipilimumab plus nivolumab induced fatal hepatitis fulminant despite the significant efficacy. Proceedings of the JapaneseSociety of Pathology. 2022; 111(1): 358.$58$YR$A$M$Y$63.5$KG$20221122$$MD$JP$JP
169193584$16919358$4$F$20190601$20221124$20191015$20221128$PER$$US-PFIZER INC-2019444409$PFIZER$$80$YR$$M$Y$70.295$KG$20221128$$CN$US$US
169201522$16920152$2$F$$20220706$20191015$20221216$EXP$$US-ROCHE-2430265$ROCHE$$51$YR$$F$Y$$$20221216$$MD$US$
169203273$16920327$3$F$$20221209$20191015$20221215$EXP$$CA-PFIZER INC-2019442627$PFIZER$$53$YR$$M$Y$69$KG$20221215$$HP$CA$CA
169217603$16921760$3$F$$20221121$20191015$20221124$EXP$$US-SHIRE-US201932451$TAKEDA$$$$$F$Y$$$20221124$$CN$US$US
169218136$16921813$6$F$$20221207$20191015$20221213$PER$$US-SHIRE-US201934792$TAKEDA$$$$$F$Y$46.71$KG$20221213$$HP$US$US
169219162$16921916$2$F$20190408$20221122$20191015$20221125$EXP$$NVSC2019AT001900$NOVARTIS$$$$A$F$Y$$$20221125$$MD$AT$AT
169220573$16922057$3$F$20190918$20221220$20191015$20221228$EXP$$NVSC2019NL001668$NOVARTIS$$77$YR$$M$Y$$$20221228$$HP$NL$NL
1692208823$16922088$23$F$20170701$20221202$20191015$20221212$EXP$$CA-CELLTRION INC.-2017CA010220$CELLTRION$$$$$$Y$$$20221212$$CN$CA$CA
1692221743$16922217$43$F$20190101$20221202$20191015$20221212$EXP$$CA-CELLTRION INC.-2019CA023664$CELLTRION$$$$$$Y$$$20221212$$CN$CA$CA
169229434$16922943$4$F$20190731$20221202$20191016$20221230$EXP$$GB-ABBVIE-19P-167-2964858-00$ABBVIE$$31$YR$$F$Y$$$20221214$$MD$GB$GB
169232694$16923269$4$F$$20221209$20191016$20221219$PER$$US-AMGEN-USASP2019171092$AMGEN$$85$YR$E$M$Y$$$20221219$$HP$US$US
169238062$16923806$2$F$20190807$20191231$20191016$20221229$EXP$$IE-SAMSUNG BIOEPIS-SB-2019-30443$SAMSUNG BIOEPIS$$50$YR$A$F$Y$111.8$KG$20221229$$HP$IE$IE
169244572$16924457$2$F$20190227$20221107$20191016$20221110$EXP$$US-ASTELLAS-2019US008833$ASTELLAS$$58$YR$$M$Y$$$20221110$$MD$US$US
169246687$16924668$7$F$20191001$20221004$20191016$20221007$EXP$$US-PFIZER INC-2019126883$PFIZER$$60$YR$$M$Y$105.2$KG$20221007$$HP$US$US
169250215$16925021$5$F$$20221208$20191016$20221214$PER$$US-PFIZER INC-2019448146$PFIZER$$77$YR$$F$Y$$$20221214$$MD$US$US
169256707$16925670$7$F$20191005$20221201$20191016$20221206$EXP$$US-SA-2019SA285435$SANOFI AVENTIS$$26$YR$A$M$Y$$$20221206$$MD$US$US
169261555$16926155$5$F$20191003$20221201$20191016$20221209$EXP$$US-SHIRE-US201934355$TAKEDA$$38$YR$$F$Y$$$20221209$$MD$US$US
169261579$16926157$9$F$20190101$20221124$20191016$20221130$EXP$$US-SHIRE-US201934174$TAKEDA$$51$YR$$M$Y$79$KG$20221130$$HP$US$US
169261869$16926186$9$F$20190825$20221011$20191016$20221018$EXP$$US-TAKEDA-2019TUS056489$TAKEDA$$45$YR$$M$Y$79$KG$20221018$$PH$US$US
169264114$16926411$4$F$20190101$20221004$20191016$20221007$EXP$$NVSC2019CA004846$NOVARTIS$$$$$F$Y$$$20221007$$HP$CA$CA
169264187$16926418$7$F$20190930$20221117$20191016$20221122$PER$$NVSC2019US001797$NOVARTIS$$39$YR$$F$Y$$$20221122$$CN$US$US
169275986$16927598$6$F$20191009$20221220$20191016$20221226$EXP$$US-SHIRE-US201934057$TAKEDA$$12$YR$$F$Y$51.2$KG$20221226$$CN$US$US
1692782129$16927821$29$F$20191001$20221128$20191017$20221210$EXP$$CA-CELLTRION INC.-2019CA024764$CELLTRION$$$$$$Y$$$20221210$$MD$CA$CA
169283033$16928303$3$F$20130101$20221111$20191017$20221120$EXP$$US-BIOGEN-2019BI00796163$BIOGEN$$$$$F$Y$$$20221120$$CN$US$US
169285177$16928517$7$F$$20221217$20191017$20221231$EXP$$RO-AUROBINDO-AUR-APL-2019-067305$AUROBINDO$S?ndulescu O, Streinu-Cercel A, Oan? AA, Streinu-Cercel A. Repeated systemic infections unveiling a silent colon cancer. Romanian Archives of Microbiology and Immunology. 2018;77(4):301-304$72$YR$$F$Y$$$20221231$$MD$RO$RO
169290095$16929009$5$F$20181001$20221018$20191017$20221024$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2019JPN187001$VIIV$$$$$$Y$$$20221024$$MD$JP$JP
169290574$16929057$4$F$20120822$20220921$20191017$20221001$EXP$$PL-AUROBINDO-AUR-APL-2018-001975$AUROBINDO$Zwolinski R, Kamerys J, Jablonowska E, Marcinkiewicz A, Jaszewski R, Krecki R, et al. Progression of coronary artery disease in a HIV-infected patient previously treated for ascending aorta aneurysm. Kardiochirurgia i Torakochirurgia Polska. 2017;14(3):211-13$35$YR$$M$Y$$$20221001$$MD$PL$PL
169290956$16929095$6$F$20190129$20221116$20191017$20221122$EXP$$NVSC2019CA003496$NOVARTIS$$63$YR$$F$Y$$$20221122$$MD$CA$CA
169304452$16930445$2$F$20221221$20221221$20191017$20221230$PER$$US-PFIZER INC-2019447905$PFIZER$$68$YR$$F$Y$$$20221230$$CN$US$US
169306564$16930656$4$F$$20221026$20191017$20221028$PER$$US-PFIZER INC-2019447701$PFIZER$$69$YR$$F$Y$$$20221028$$HP$US$US
169318786$16931878$6$F$$20221221$20191017$20221226$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR184975$GLAXOSMITHKLINE$$$$$$Y$$$20221226$$MD$CA$CA
169320013$16932001$3$F$20170101$20221103$20191017$20221108$EXP$$ES-ROCHE-2430727$ROCHE$Lombardero P, Santos M and Velaz S Mortal toxicity to capecitabine in a patient without the 2A mutation of the dihydropyrimidine dehydrogenase gene. Casos Clinicos Rev. OFILILAPHAR 2019;29 (3):231-3.$67$YR$$M$Y$66$KG$20221108$$HP$ES$ES
169323822$16932382$2$F$$20221201$20191017$20221208$PER$$US-TEVA-2019-US-1123181$TEVA$$$$$F$Y$$$20221208$$LW$US$US
169324432$16932443$2$F$$20220302$20191017$20221010$EXP$$US-ROCHE-2212240$ROCHE$$$$$M$Y$$$20221010$$CN$US$
1693278428$16932784$28$F$20190101$20221110$20191018$20221119$EXP$$CA-CELLTRION INC.-2019CA021050$CELLTRION$$$$$$Y$$$20221119$$CN$CA$CA
169334552$16933455$2$F$$20221024$20191018$20221026$EXP$$US-KYOWAKIRIN-2019BKK003196$KYOWA$$$$$$Y$$$20221026$$CN$US$US
169335225$16933522$5$F$20190325$20221202$20191018$20221206$EXP$$US-KYOWAKIRIN-2019BKK005147$KYOWA$$$$$$Y$$$20221206$$HP$US$US
169336093$16933609$3$F$20170101$20221121$20191018$20221125$EXP$ES-AEMPS-324672$ES-SA-2018SA183738$SANOFI AVENTIS$$67$YR$E$M$Y$66$KG$20221125$$HP$ES$ES
169340654$16934065$4$F$$20221213$20191018$20221219$EXP$$US-SHIRE-US201935328$TAKEDA$$$$$F$Y$113$KG$20221219$$HP$US$US
169346098$16934609$8$F$20191010$20221022$20191018$20221031$EXP$$US-TAKEDA-2019TUS057281$TAKEDA$$48$YR$$F$Y$$$20221031$$CN$US$US
169347682$16934768$2$F$20190901$20191013$20191018$20221214$EXP$$NVSC2019EG004420$NOVARTIS$$$$$M$Y$$$20221214$$MD$EG$EG
169350077$16935007$7$F$20181016$20221216$20191018$20221221$EXP$$US-PFIZER INC-2019448111$PFIZER$$61$YR$$M$Y$107.48$KG$20221221$$CN$US$US
169358604$16935860$4$F$20181016$20221110$20191018$20221115$EXP$$FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-097641$BRISTOL MYERS SQUIBB$$59$YR$A$M$Y$$$20221115$$HP$FR$FR
169359566$16935956$6$F$20220215$20220928$20191018$20221005$EXP$$US-SHIRE-US201933778$TAKEDA$$56$YR$$F$Y$$$20221005$$CN$US$US
169369262$16936926$2$F$20190727$20221110$20191018$20221117$EXP$$NVSC2019CO001762$NOVARTIS$$42$YR$$F$Y$52$KG$20221117$$CN$CO$CO
1693723215$16937232$15$F$20220925$20221206$20191019$20221208$EXP$$US-ROCHE-2445426$ROCHE$$$$A$F$Y$$$20221208$$CN$US$
1693843016$16938430$16$F$20200412$20221107$20191019$20221111$EXP$$NVSC2019US005699$NOVARTIS$$38$YR$$F$Y$68.027$KG$20221111$$CN$US$US
169388928$16938892$8$F$20180131$20221213$20191020$20221220$EXP$$PHHY2018CA019630$NOVARTIS$$47$YR$$F$Y$$$20221220$$CN$CA$CA
169389106$16938910$6$F$20170201$20221118$20191020$20221125$EXP$$PHHY2017CA043595$NOVARTIS$$56$YR$$F$Y$$$20221125$$PH$CA$CA
169390672$16939067$2$F$$20221124$20191020$20221128$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-108533$BOEHRINGER INGELHEIM$$64$YR$A$M$Y$$$20221128$$HP$CA$CA
1693907913$16939079$13$F$20190812$20221213$20191020$20221221$EXP$$CA-CELLTRION INC.-2019CA024113$CELLTRION$$$$$$Y$$$20221221$$HP$CA$CA
1693978613$16939786$13$F$$20221020$20191021$20221026$EXP$$BR-GLAXOSMITHKLINE-BR2019AMR187717$GLAXOSMITHKLINE$$$$$$Y$$$20221026$$CN$BR$BR
1694002520$16940025$20$F$20190818$20221129$20191021$20221130$EXP$$CN-ROCHE-2444246$ROCHE$$54$YR$$F$Y$46.5$KG$20221130$$MD$CN$
169402394$16940239$4$F$20220921$20221011$20191021$20221014$EXP$$US-SHIRE-US201934625$TAKEDA$$49$YR$$F$Y$$$20221014$$CN$US$US
169406372$16940637$2$F$$20220929$20191021$20221004$EXP$$NVSC2019TR009388$NOVARTIS$Tunakan Dalgic C, Alkaya Balkan M, Yuceyar N, Mete Gokmen EN. Successful desensitisation with alemtuzumab in a relapse remitting multiple sclerosis case. ALLERGY. 2019;74:742$40$YR$$F$Y$$$20221004$$HP$TR$TR
169407052$16940705$2$F$$20220916$20191021$20221004$EXP$$UA-GLAXOSMITHKLINE-UA2019EME185684$GLAXOSMITHKLINE$Tomicheva A. Comorbid patient in gastroenterology: touches to clinical profile. Health of Ukraine MEDICAL JOURNAL. 2019;51$$$$$Y$$$20221004$$HP$UA$UA
169408606$16940860$6$F$20190912$20220921$20191021$20221004$EXP$$US-AMNEAL PHARMACEUTICALS-2019-AMRX-02213$AMNEAL$$51$YR$$F$Y$$$20221004$$CN$US$US
1694089910$16940899$10$F$$20221009$20191021$20221229$EXP$GB-MHRA-ADR 24378536$GB-TORRENT-00020358$TORRENT$$$$A$M$Y$$$20221229$$HP$GB$GB
169413373$16941337$3$F$20190902$20200107$20191021$20221215$EXP$$NVSC2019FR010248$NOVARTIS$$73$YR$$M$Y$$$20221214$$MD$FR$FR
169414316$16941431$6$F$20191009$20221206$20191021$20221209$EXP$$US-SHIRE-US201934219$TAKEDA$$6$YR$$M$Y$$$20221209$$MD$US$US
1694143319$16941433$19$F$20190906$20221104$20191021$20221109$EXP$$US-SHIRE-US201934148$TAKEDA$$28$YR$$M$Y$$$20221109$$CN$US$US
169422396$16942239$6$F$20190101$20220927$20191021$20221006$PER$$US-SA-2019SA290450$SANOFI AVENTIS$$16$YR$T$M$Y$$$20221006$$CN$US$US
169430628$16943062$8$F$20180720$20210702$20191021$20221006$EXP$$PHJP2018JP018965$NOVARTIS$$31$YR$$F$Y$$$20221006$$MD$JP$JP
169436004$16943600$4$F$$20221219$20191022$20221222$EXP$$US-CIPLA LTD.-2019US06931$CIPLA$Chauhan S, Chawla M, Lee R.. Massive hemoptysis in a patient with gastric adenocarcinoma: a case of radiation recall injury after 40 years. Chest. 2019;156(4):A2127$59$YR$$M$Y$$$20221223$$HP$US$US
169436334$16943633$4$F$20191010$20221207$20191022$20221221$EXP$$IT-AUROBINDO-AUR-APL-2019-068005$AUROBINDO$$32$YR$$F$Y$$$20221221$$MD$IT$IT
1694385522$16943855$22$F$20181001$20221024$20191022$20221031$EXP$$DE-ROCHE-2442808$ROCHE$$$$A$M$Y$94$KG$20221031$$CN$DE$
169440727$16944072$7$F$20191005$20221128$20191022$20221202$EXP$$US-ROCHE-2448488$ROCHE$$74$YR$$M$Y$$$20221202$$CN$US$
1694412723$16944127$23$F$$20221109$20191022$20221110$EXP$$US-SHIRE-US201935456$TAKEDA$$$$$M$Y$125$KG$20221110$$CN$US$US
169442389$16944238$9$F$$20221026$20191022$20221031$EXP$$US-SHIRE-US201935446$TAKEDA$$$$$F$Y$$$20221031$$CN$US$US
169442653$16944265$3$F$20190315$20221006$20191022$20221020$EXP$$US-CIPLA LTD.-2019US06918$CIPLA$$23$YR$$F$Y$$$20221020$$HP$US$US
169450049$16945004$9$F$20190804$20221115$20191022$20221122$EXP$$DE-ROCHE-2437281$ROCHE$$47$YR$$F$Y$53$KG$20221122$$MD$DE$DE
169450312$16945031$2$F$20190806$20221109$20191022$20221111$EXP$$JP-PFIZER INC-2019383018$PFIZER$$44$YR$$F$Y$49.3$KG$20221111$$MD$JP$JP
169451694$16945169$4$F$$20221130$20191022$20221206$EXP$$CA-PFIZER INC-2019449544$PFIZER$$59$YR$$F$Y$77$KG$20221206$$HP$CA$CA
1694532011$16945320$11$F$$20221011$20191022$20221013$EXP$$US-GLAXOSMITHKLINE-US-2017TSO04560$GLAXOSMITHKLINE$$$$$$Y$$$20221013$$CN$US$US
1694550510$16945505$10$F$$20221221$20191022$20221229$EXP$$US-PFIZER INC-2019455558$PFIZER$$75$YR$$M$Y$$$20221229$$CN$US$US
1694588527$16945885$27$F$20190918$20221108$20191022$20221110$EXP$$BR-ROCHE-2430912$ROCHE$$53$YR$$F$Y$56$KG$20221110$$MD$BR$
1694593913$16945939$13$F$20190921$20221010$20191022$20221021$EXP$$US-PFIZER INC-2019456361$MYLAN$$69$YR$$F$Y$$$20221021$$CN$US$US
169460593$16946059$3$F$$20221024$20191022$20221026$PER$$US-PFIZER INC-2019448161$PFIZER$$67$YR$$F$Y$$$20221026$$MD$US$US
169463132$16946313$2$F$$20191009$20191022$20221201$EXP$$NVSC2019KZ012442$NOVARTIS$$70$YR$$M$Y$$$20221201$$MD$KZ$KZ
169463542$16946354$2$F$$20221128$20191022$20221130$EXP$$US-SHIRE-US201934936$TAKEDA$$$$$F$Y$$$20221130$$CN$US$US
169466625$16946662$5$F$$20221202$20191022$20221207$EXP$$US-PFIZER INC-2019452914$PFIZER$$65$YR$$F$Y$$$20221207$$CN$US$US
169466936$16946693$6$F$20080101$20221123$20191022$20221128$EXP$$US-PFIZER INC-2019450706$PFIZER$$70$YR$$F$Y$83.46$KG$20221128$$CN$US$US
169467143$16946714$3$F$$20221128$20191022$20221130$PER$$US-PFIZER INC-2019452853$PFIZER$$73$YR$$F$Y$$$20221130$$CN$US$US
169467785$16946778$5$F$20211201$20221128$20191022$20221130$EXP$$US-PFIZER INC-2019457191$PFIZER$$43$YR$$F$Y$$$20221130$$HP$US$US
1694684210$16946842$10$F$20220801$20221024$20191022$20221101$PER$$US-INCYTE CORPORATION-2019IN010222$INCYTE$$$$$$Y$$$20221101$$HP$US$US
169471876$16947187$6$F$20190810$20221020$20191022$20221026$EXP$$NVSC2019CZ011544$NOVARTIS$$52$YR$$M$Y$93$KG$20221026$$MD$CZ$CZ
1694729514$16947295$14$F$20180601$20221207$20191022$20221214$EXP$$NVSC2019CA011653$NOVARTIS$$64$YR$$F$Y$108.9$KG$20221214$$MD$CA$CA
169473382$16947338$2$F$$20221206$20191022$20221212$PER$$US-SHIRE-US201935670$TAKEDA$$$$$F$Y$73$KG$20221212$$HP$US$US
169473658$16947365$8$F$20191017$20221031$20191022$20221108$EXP$$CA-SHIRE-CA201935657$TAKEDA$$47$YR$$M$Y$$$20221108$$CN$CA$CA
1694737033$16947370$33$F$20191007$20221219$20191022$20221226$EXP$$IE-SHIRE-IE201934321$TAKEDA$$35$YR$$F$Y$$$20221226$$CN$IE$IE
169476572$16947657$2$F$$20221005$20191022$20221006$PER$$US-PFIZER INC-2019456550$PFIZER$$$$$$Y$$$20221006$$LW$US$US
169476973$16947697$3$F$$20221005$20191022$20221006$PER$$US-PFIZER INC-2019456544$PFIZER$$$$A$F$Y$$$20221006$$LW$US$US
169477265$16947726$5$F$$20221011$20191022$20221017$PER$$US-PFIZER INC-2019457168$PFIZER$$62$YR$$M$Y$64.399$KG$20221017$$CN$US$US
1694836426$16948364$26$F$20190705$20221027$20191022$20221105$EXP$$CA-CELLTRION INC.-2019CA023079$CELLTRION$$$$$$Y$$$20221105$$CN$CA$CA
169494692$16949469$2$F$20190101$20221118$20191023$20221124$EXP$$AU-Orion Corporation ORION PHARMA-TREX2019-4571$ORION$$74$YR$E$F$Y$75.01$KG$20221124$$MD$AU$
1694977917$16949779$17$F$20200103$20221117$20191023$20221123$EXP$$US-SHIRE-US201935634$TAKEDA$$77$YR$$F$Y$99$KG$20221123$$HP$US$US
169498514$16949851$4$F$20190420$20220930$20191023$20221005$EXP$$DE-GLAXOSMITHKLINE-DE2019GSK191190$GLAXOSMITHKLINE$$$$$$Y$$$20221005$$MD$DE$DE
169499252$16949925$2$F$$20191017$20191023$20221209$PER$$US-TEVA-2019-US-1126689$TEVA$$$$$$Y$$$20221209$$MD$US$US
169501542$16950154$2$F$$20221123$20191023$20221205$EXP$$GB-LUPIN PHARMACEUTICALS INC.-2019-06787$LUPIN$Carr DF, Wang CW, Bellon T, Ressel L, Nwikue G, Shrivastava V, et al. Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. British Journal of Dermatology. 2019;181(1):166-174$57$YR$$M$Y$$$20221205$$HP$GB$GB
169501974$16950197$4$F$$20221025$20191023$20221027$PER$$US-PFIZER INC-2019454385$PFIZER$$72$YR$$F$Y$$$20221027$$MD$US$US
169502194$16950219$4$F$$20221215$20191023$20221215$PER$$US-PFIZER INC-2019455352$PFIZER$$72$YR$$$Y$$$20221215$$HP$US$US
169502708$16950270$8$F$20220101$20221020$20191023$20221024$EXP$$US-PFIZER INC-2019456265$PFIZER$$74$YR$$F$Y$$$20221024$$HP$US$US
1695027913$16950279$13$F$$20221220$20191023$20221227$PER$$US-PFIZER INC-2019457378$PFIZER$$77$YR$$F$Y$$$20221227$$PH$US$US
169508915$16950891$5$F$20190101$20221026$20191023$20221102$EXP$$CA-PFIZER INC-2019436102$PFIZER$$45$YR$$F$Y$$$20221102$$HP$CA$CA
169512453$16951245$3$F$20190101$20220919$20191023$20221004$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-222674$RANBAXY$$$$A$F$Y$$$20221004$$CN$US$US
1695178610$16951786$10$F$20200401$20221012$20191023$20221017$EXP$$US-SHIRE-US201935440$TAKEDA$$74$YR$$F$Y$$$20221017$$HP$US$US
169522648$16952264$8$F$$20221021$20191023$20221028$EXP$$PHHY2018CA187144$NOVARTIS$$$$$F$Y$$$20221028$$CN$CA$CA
169528644$16952864$4$F$20190101$20191101$20191023$20221229$PER$$US-AMGEN INC.-USASP2019173808$AMGEN$$43$YR$A$F$Y$$$20221229$$PH$US$US
169529112$16952911$2$F$20171213$20191008$20191023$20221209$EXP$$NVSC2019LV004745$NOVARTIS$$$$$$Y$$$20221209$$MD$LV$LV
169529904$16952990$4$F$$20221004$20191023$20221013$EXP$$NVSC2019UA012961$NOVARTIS$Tomicheva A. Comorbid patient in gastroenterology: touches to clinical profile. HEALTH OF UKRAINE MEDICAL JOURNAL. 2019;51$58$YR$$M$Y$$$20221013$$HP$UA$UA
1695329913$16953299$13$F$20180101$20221114$20191023$20221117$EXP$$PHHY2017CA090130$NOVARTIS$$$$$F$Y$$$20221117$$CN$CA$CA
169533312$16953331$2$F$$20190923$20191023$20221008$PER$$US-NAPPMUNDI-USA-2019-0148476$PURDUE$$$$$F$Y$$$20221008$$CN$US$US
1695335216$16953352$16$F$20190101$20221206$20191023$20221210$EXP$$CA-TAKEDA-2019TUS058822$TAKEDA$$49$YR$$M$Y$$$20221210$$MD$CA$CA
169541876$16954187$6$F$20170126$20221108$20191023$20221109$PER$$US-BIOGEN-2014BI120019$BIOGEN$$18$YR$$M$Y$$$20221109$$CN$US$US
1695454739$16954547$39$F$20181005$20221215$20191023$20221224$EXP$$CA-CELLTRION INC.-2018CA024331$CELLTRION$$$$$$Y$$$20221224$$CN$CA$CA
1695454933$16954549$33$F$20190101$20221212$20191023$20221220$EXP$$CA-CELLTRION INC.-2019CA024603$CELLTRION$$$$$$Y$$$20221220$$CN$CA$CA
169551293$16955129$3$F$20191001$20221212$20191024$20221213$EXP$FR-AFSSAPS-NT20191218$FR-ABBVIE-19K-056-2971864-00$ABBVIE$$52$YR$$F$Y$73$KG$20221213$$MD$FR$FR
169554086$16955408$6$F$20200301$20221124$20191024$20221201$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR186675$GLAXOSMITHKLINE$$$$$$Y$$$20221201$$MD$CA$CA
1695551411$16955514$11$F$20190328$20221214$20191024$20221220$EXP$$CA-ROCHE-2295088$ROCHE$$47$YR$$F$Y$$$20221220$$CN$CA$
1695558513$16955585$13$F$20180101$20221201$20191024$20221205$EXP$$US-PFIZER INC-2019457463$PFIZER$$89$YR$$F$Y$54.422$KG$20221205$$HP$US$US
1695563218$16955632$18$F$$20221005$20191024$20221007$EXP$$US-PFIZER INC-2019458377$PFIZER$$29$YR$$F$Y$68$KG$20221007$$HP$US$US
169556672$16955667$2$F$$20221228$20191024$20221230$PER$$US-PFIZER INC-2019459403$PFIZER$$46$YR$$F$Y$$$20221230$$HP$US$US
169559549$16955954$9$F$20191012$20221115$20191024$20221116$EXP$$NVSC2019AU012863$NOVARTIS$$53$YR$$F$Y$76.7$KG$20221117$$MD$AU$AU
169561428$16956142$8$F$20190920$20221207$20191024$20221216$EXP$$US-PFIZER INC-2019454735$PFIZER$$72$YR$$F$Y$78.005$KG$20221216$$CN$US$US
169570334$16957033$4$F$20191013$20221114$20191024$20221207$EXP$$JP-AstraZeneca-2019SF49107$ASTRAZENECA$$72$YR$$F$Y$$$20221208$$MD$JP$
169570794$16957079$4$F$$20221018$20191024$20221024$EXP$$NVSC2019GB013920$NOVARTIS$Fulham J, Plucinski M. Stoma formation after lymphoproliferative disorders and immunosuppression therapy. BRITISH JOURNAL OF NURSING. 2018;27(22):S20-6$31$YR$$M$Y$$$20221024$$HP$GB$GB
169577362$16957736$2$F$20191001$20221102$20191024$20221109$EXP$$US-VERTEX PHARMACEUTICALS-2019-010264$VERTEX$$35$YR$$F$Y$$$20221109$$HP$US$US
169585374$16958537$4$F$20190101$20221005$20191024$20221011$EXP$$JP-GILEAD-2019-0433777$GILEAD$Hamamoto K, Ishikawa T, Sasaki R, Iwamoto T, Takami T, Sakaida I. SP3-22 A patient with decompensated cirrhosis caused by hepatitis C virus whose hepatic function dramatically improved by combination therapy with BRTO/PSE. Kanzo/The 56th Annual Meeting of the Japan Society of Hepatology. 2020;61:(S1)A278$59$YR$A$M$Y$$$20221011$$MD$JP$JP
169589326$16958932$6$F$20170504$20221213$20191024$20221222$EXP$$IN-INCYTE CORPORATION-2017IN004811$INCYTE$$$$$$Y$$$20221222$$CN$IN$IN
169599462$16959946$2$F$20191217$20221206$20191025$20221214$EXP$$CA-TAKEDA-2019TUS059822$TAKEDA$$64$YR$$M$Y$$$20221214$$MD$CA$CA
169602854$16960285$4$F$$20221201$20191025$20221206$PER$$US-PFIZER INC-2019459208$PFIZER$$39$YR$$F$Y$$$20221206$$HP$US$US
1696032610$16960326$10$F$20190910$20221121$20191025$20221123$PER$$US-PFIZER INC-2019458667$PFIZER$$62$YR$$F$Y$67$KG$20221123$$CN$US$US
169604046$16960404$6$F$20191013$20221123$20191025$20221130$EXP$$US-SHIRE-US201935291$TAKEDA$$43$YR$$M$Y$87$KG$20221130$$MD$US$US
1696048618$16960486$18$F$20191011$20221121$20191025$20221129$EXP$$CA-CELLTRION INC.-2019CA025818$CELLTRION$$$$$$Y$$$20221129$$CN$CA$CA
169609569$16960956$9$F$20191018$20221116$20191025$20221123$EXP$$US-SHIRE-US201936275$TAKEDA$$57$YR$$F$Y$70$KG$20221123$$HP$US$US
169615822$16961582$2$F$$20221102$20191025$20221104$EXP$$CA-PFIZER INC-2019458063$PFIZER$$93$YR$$M$Y$$$20221104$$PH$CA$CA
169615973$16961597$3$F$20160101$20221102$20191025$20221107$EXP$$CA-PFIZER INC-2019458033$PFIZER$$38$YR$$F$Y$$$20221107$$CN$CA$CA
1696169216$16961692$16$F$$20221013$20191025$20221019$EXP$$US-PFIZER INC-2018436535$MYLAN$$$$$F$Y$84$KG$20221019$$CN$US$US
169620072$16962007$2$F$$20221003$20191025$20221010$EXP$$US-SHIRE-US201935636$TAKEDA$$$$$M$Y$104$KG$20221010$$HP$US$US
169620494$16962049$4$F$20191001$20221014$20191025$20221019$EXP$$US-SHIRE-US201934913$TAKEDA$$68$YR$$F$Y$73.48$KG$20221019$$HP$US$US
1696225714$16962257$14$F$20190926$20221025$20191025$20221028$EXP$$US-ALNYLAM PHARMACEUTICALS, INC.-ALN-2019-000799$ALNYLAM PHARMACEUTICALS$$$$$$Y$$$20221028$$MD$US$US
169623222$16962322$2$F$$20190812$20191025$20221020$PER$$US-NOVOPROD-680096$NOVO NORDISK$$57$YR$$F$Y$$$20221020$$CN$US$US
169623232$16962323$2$F$$20190625$20191025$20221020$PER$$US-NOVOPROD-670770$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
169623272$16962327$2$F$$20190529$20191025$20221020$PER$$US-NOVOPROD-666383$NOVO NORDISK$$63$YR$$F$Y$$$20221020$$CN$US$US
169623292$16962329$2$F$$20190325$20191025$20221020$PER$$US-NOVOPROD-653292$NOVO NORDISK$$77$YR$$F$Y$$$20221020$$CN$US$US
169623312$16962331$2$F$$20190325$20191025$20221020$PER$MSB 2019-06044$US-NOVOPROD-654811$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
169623332$16962333$2$F$$20190123$20191025$20221020$PER$$US-NOVOPROD-644224$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
169623362$16962336$2$F$$20190109$20191025$20221020$PER$$US-NOVOPROD-642237$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
169623382$16962338$2$F$20190218$20190218$20191025$20221020$PER$$US-NOVOPROD-652176$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
169623402$16962340$2$F$20180801$20190506$20191025$20221020$PER$US-NOVOPROD-649955$US-NOVOPROD-649955$NOVO NORDISK$$67$YR$$F$Y$$$20221020$$MD$US$US
169623422$16962342$2$F$$20190315$20191025$20221020$PER$$US-NOVOPROD-653359$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
169623432$16962343$2$F$$20190826$20191025$20221020$PER$$US-NOVOPROD-682578$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
169623442$16962344$2$F$$20181227$20191025$20221020$PER$$US-NOVOPROD-640495$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
169623502$16962350$2$F$20190101$20190625$20191025$20221020$PER$$US-NOVOPROD-671097$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
169623522$16962352$2$F$20180101$20190111$20191025$20221020$PER$$US-NOVOPROD-642827$NOVO NORDISK$$72$YR$$F$Y$$$20221020$$CN$US$US
169623542$16962354$2$F$$20190529$20191025$20221020$PER$$US-NOVOPROD-666382$NOVO NORDISK$$$$$F$Y$$$20221020$$CN$US$US
169627192$16962719$2$F$$20191021$20191025$20221207$EXP$$NVSC2019TR013384$NOVARTIS$$$$$$Y$$$20221207$$MD$TR$TR
169629514$16962951$4$F$20190924$20221107$20191025$20221114$EXP$$CA-JNJFOC-20191025952$JOHNSON AND JOHNSON$$58$YR$A$F$Y$$$20221114$$HP$CA$CA
169632944$16963294$4$F$20180724$20221123$20191025$20221129$EXP$$CA-PFIZER INC-2018317876$PFIZER$$79$YR$$F$Y$$$20221129$$MD$CA$CA
169638546$16963854$6$F$$20221219$20191026$20221226$EXP$$US-SHIRE-US201936129$TAKEDA$$$$$M$Y$72$KG$20221226$$CN$US$US
169646182$16964618$2$F$20190801$20191023$20191028$20221130$PER$$US-AMGEN-USASP2019177195$AMGEN$$98$YR$E$F$Y$$$20221130$$CN$US$US
1696499222$16964992$22$F$20160604$20221212$20191028$20221219$EXP$$BR-GLAXOSMITHKLINE-BR2015GSK062465$GLAXOSMITHKLINE$$$$$$Y$$$20221219$$MD$BR$BR
1696600320$16966003$20$F$20180701$20221222$20191028$20221222$EXP$$US-PFIZER INC-2019461491$PFIZER$$60$YR$$M$Y$82.55$KG$20221222$$CN$US$US
169661182$16966118$2$F$20190101$20220929$20191028$20221003$EXP$$US-KYOWAKIRIN-2019BKK016607$KYOWA$$$$$$Y$$$20221003$$HP$US$US
169661785$16966178$5$F$$20221116$20191028$20221121$PER$$US-PFIZER INC-2019464974$PFIZER$$67$YR$$F$Y$$$20221121$$HP$US$US
169664984$16966498$4$F$20160301$20220927$20191028$20221003$EXP$$PHHY2016CA058494$NOVARTIS$$39$YR$$F$Y$$$20221003$$MD$CA$CA
169678024$16967802$4$F$20190501$20221111$20191028$20221118$EXP$$CZ-BIOGEN-2019BI00799198$BIOGEN$$24$YR$$F$Y$$$20221118$$MD$CZ$CZ
1696825237$16968252$37$F$20191015$20221212$20191028$20221219$EXP$$CA-CELLTRION INC.-2019CA025922$CELLTRION$$$$$$Y$$$20221220$$MD$CA$CA
169694465$16969446$5$F$20190101$20221026$20191029$20221102$EXP$$CA-PFIZER INC-2019231983$PFIZER$$67$YR$$F$Y$$$20221102$$HP$CA$CA
169698103$16969810$3$F$20190924$20221014$20191029$20221021$EXP$FR-AFSSAPS-MP20191337$FR-TAKEDA-2019TUS060175$TAKEDA$Rocanieres P, Lamure S, Geny C, Faillie JL, Hillaire-Buys D, Bres V et al. Parkinsonian patients requiring proteasome inhibitors for multiple myeloma: exceptional circumstances call for extra caution. Journal of Parkinson^s Disease. 2022$68$YR$$M$Y$$$20221021$$HP$FR$FR
169698329$16969832$9$F$20191022$20220928$20191029$20221003$EXP$$US-SHIRE-US201936239$TAKEDA$$68$YR$$F$Y$63$KG$20221003$$HP$US$US
1697002214$16970022$14$F$20220414$20221007$20191029$20221012$EXP$$NVSC2019US017773$NOVARTIS$$74$YR$$M$Y$67.356$KG$20221012$$CN$US$US
169704543$16970454$3$F$20180601$20221223$20191029$20221228$PER$$US-PFIZER INC-2019464867$PFIZER$$75$YR$$F$Y$84$KG$20221228$$CN$US$US
1697148918$16971489$18$F$20191004$20221220$20191029$20221229$EXP$$NVSC2019DE017286$NOVARTIS$$$$E$F$Y$56$KG$20221229$$MD$DE$DE
169720273$16972027$3$F$20120101$20210204$20191029$20221008$PER$$US-PURDUE PHARMA-USA-2019-0148908$PURDUE$$18$YR$$M$Y$$$20221008$$CN$US$US
169722764$16972276$4$F$$20221020$20191029$20221101$EXP$$CA-BEH-2019108411$CSL BEHRING$$62$YR$A$F$Y$$$20221101$$CN$CA$CA
1697236210$16972362$10$F$20190401$20221119$20191029$20221124$EXP$$FR-ABBVIE-19K-056-2977469-00$ABBVIE$$66$YR$$M$Y$117$KG$20221124$$MD$FR$FR
1697245410$16972454$10$F$20190519$20221122$20191029$20221125$EXP$$FR-ABBVIE-19K-056-2976437-00$ABBVIE$$81$YR$$M$Y$69$KG$20221125$$MD$FR$FR
169727418$16972741$8$F$20210605$20221110$20191030$20221116$EXP$$US-SHIRE-US201935967$TAKEDA$$17$YR$$F$Y$43.99$KG$20221116$$CN$US$US
169731323$16973132$3$F$20160101$20221102$20191030$20221107$EXP$$CA-Orion Corporation ORION PHARMA-TREX2019-4811$ORION$$38$YR$A$F$Y$$$20221107$$MD$CA$
169745813$16974581$3$F$20190507$20191021$20191030$20221012$PER$$US-CELLTRION INC.-2019US022669$CELLTRION$$$$$$Y$$$20221012$$HP$US$US
169745883$16974588$3$F$20190325$20191113$20191030$20221012$PER$$US-CELLTRION INC.-2019US021499$CELLTRION$$$$$$Y$$$20221012$$HP$US$US
169746843$16974684$3$F$$20191025$20191030$20221012$EXP$$US-CELLTRION INC.-2019US021853$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
169746913$16974691$3$F$20190704$20190913$20191030$20221012$EXP$$US-CELLTRION INC.-2019US020792$CELLTRION$$$$$$Y$$$20221012$$HP$US$US
169746953$16974695$3$F$20190425$20191127$20191030$20221012$EXP$$US-CELLTRION INC.-2019US024138$CELLTRION$$$$$$Y$$$20221012$$CN$US$US
1697469810$16974698$10$F$20190327$20221111$20191030$20221121$EXP$$CA-CELLTRION INC.-2019CA020192$CELLTRION$$$$$$Y$$$20221121$$MD$CA$CA
169747013$16974701$3$F$$20191007$20191030$20221012$PER$$US-CELLTRION INC.-2019US023812$CELLTRION$$$$$$Y$$$20221012$$CN$US$US
169747033$16974703$3$F$20190401$20190920$20191030$20221012$PER$$US-CELLTRION INC.-2019US022634$CELLTRION$$$$$$Y$$$20221012$$HP$US$US
169747133$16974713$3$F$20190402$20191127$20191030$20221013$PER$$US-CELLTRION INC.-2019US025815$CELLTRION$$$$$$Y$$$20221013$$HP$US$US
1697473112$16974731$12$F$20190428$20221122$20191030$20221207$EXP$$FR-ABBVIE-19K-056-2977950-00$ABBVIE$$68$YR$$M$Y$111$KG$20221207$$MD$FR$FR
169748124$16974812$4$F$$20221102$20191030$20221103$PER$$US-PFIZER INC-2019470595$PFIZER$$61$YR$$F$Y$$$20221103$$MD$US$US
169757114$16975711$4$F$20191018$20221004$20191030$20221007$EXP$$US-SA-2019SA299596$SANOFI AVENTIS$$23$YR$A$M$Y$$$20221007$$MD$US$US
169763434$16976343$4$F$20180201$20221212$20191030$20221215$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR195163$GLAXOSMITHKLINE$$$$$$Y$$$20221215$$MD$CA$CA
169770426$16977042$6$F$20190221$20221118$20191030$20221124$EXP$$FR-ABBVIE-19K-056-2977463-00$ABBVIE$$54$YR$$M$Y$77$KG$20221124$$MD$FR$FR
169771103$16977110$3$F$20191001$20201012$20191030$20221213$PER$$US-AMGEN INC.-USASP2019178159$AMGEN$$74$YR$E$F$Y$$$20221213$$CN$US$US
1697730919$16977309$19$F$20190620$20221212$20191031$20221219$EXP$$CA-TAKEDA-2019TUS038200$TAKEDA$$57$YR$$M$Y$$$20221219$$CN$CA$CA
169779544$16977954$4$F$20191024$20191203$20191031$20221209$PER$$US-AMGEN-USASP2019178086$AMGEN$$54$YR$A$M$Y$$$20221209$$HP$US$US
169780753$16978075$3$F$$20221128$20191031$20221205$EXP$$US-SHIRE-US201936664$TAKEDA$$$$$F$Y$35$KG$20221205$$HP$US$US
169784256$16978425$6$F$20190504$20221108$20191031$20221111$EXP$$PHHY2019CA112034$NOVARTIS$$56$YR$$M$Y$$$20221111$$CN$CA$CA
1697931810$16979318$10$F$20200614$20221220$20191031$20221227$PER$$US-PFIZER INC-2019468150$PFIZER$$75$YR$$F$Y$95.193$KG$20221227$$CN$US$US
1697935919$16979359$19$F$20191009$20221028$20191031$20221108$EXP$$CA-ROCHE-2447688$ROCHE$$38$YR$$F$Y$73$KG$20221108$$CN$CA$
169794762$16979476$2$F$20191001$20221205$20191031$20221206$EXP$FR-AFSSAPS-NT20191218$FR-JNJFOC-20191036841$JOHNSON AND JOHNSON$$52$YR$A$F$Y$73$KG$20221206$$MD$FR$FR
1697954729$16979547$29$F$20190101$20221220$20191031$20221229$EXP$$CA-CELLTRION INC.-2019CA022083$CELLTRION$$$$$$Y$$$20221229$$CN$CA$CA
169799864$16979986$4$F$20200625$20221117$20191031$20221123$EXP$$CA-TAKEDA-2019TUS061007$TAKEDA$$40$YR$$M$Y$$$20221123$$MD$CA$CA
169811424$16981142$4$F$20190902$20221108$20191031$20221115$EXP$$GT-ABBVIE-19P-069-2976928-00$ABBVIE$$54$YR$$F$Y$$$20221115$$MD$GT$GT
169815253$16981525$3$F$$20190920$20191101$20221012$PER$$US-CELLTRION INC.-2019US021456$CELLTRION$$$$$$Y$$$20221012$$HP$US$US
169815263$16981526$3$F$$20190909$20191101$20221012$PER$$US-CELLTRION INC.-2019US021482$CELLTRION$Alfaro-Cruz L., Schady D., Kellermayer R.. Giant cell [granulomatous] gastritis in left-sided paediatric ulcerative colitis. J-Crohn^s-Colitis. 2019;13 (3):396-397$$$$$Y$$$20221012$$HP$US$US
169815553$16981555$3$F$$20200319$20191101$20221012$PER$$US-CELLTRION INC.-2019US023377$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
169815562$16981556$2$F$$20211203$20191101$20221012$PER$$US-CELLTRION INC.-2019US022862$CELLTRION$$$$$$Y$$$20221012$$MD$US$US
169815583$16981558$3$F$20190101$20191004$20191101$20221012$EXP$$US-CELLTRION INC.-2019US022938$CELLTRION$$$$$$Y$$$20221012$$HP$US$US
169815633$16981563$3$F$$20191125$20191101$20221012$PER$$US-CELLTRION INC.-2019US023340$CELLTRION$$$$$$Y$$$20221012$$HP$US$US
169815673$16981567$3$F$20180801$20191114$20191101$20221012$PER$$US-CELLTRION INC.-2019US022797$CELLTRION$$$$$$Y$$$20221012$$CN$US$US
169818825$16981882$5$F$$20221019$20191101$20221025$EXP$$CA-Orion Corporation ORION PHARMA-TREX2019-4884$ORION$$66$YR$E$F$Y$$$20221025$$HP$CA$
169821836$16982183$6$F$20191008$20221209$20191101$20221215$EXP$$JP-ABBVIE-19P-087-2987142-00$ABBVIE$$68$YR$$M$Y$$$20221215$$HP$JP$JP
169826173$16982617$3$F$20191025$20191119$20191101$20221214$PER$$US-AMGEN-USASP2019178880$AMGEN$$82$YR$E$M$Y$129.71$KG$20221213$$HP$US$US
1698274816$16982748$16$F$20181219$20221207$20191101$20221214$EXP$$ES-JNJFOC-20191046486$JOHNSON AND JOHNSON$$61$YR$A$F$Y$92.5$KG$20221215$$MD$ES$ES
169831747$16983174$7$F$20190510$20221209$20191101$20221213$EXP$$JP-ABBVIE-19P-087-2987175-00$ABBVIE$$69$YR$$M$Y$68.4$KG$20221213$$MD$JP$JP
169834905$16983490$5$F$20181001$20221004$20191101$20221007$EXP$$JP-Eisai Medical Research-EC-2019-064499$EISAI$$78$YR$E$F$Y$53$KG$20221007$$MD$JP$
169837255$16983725$5$F$20191011$20221205$20191101$20221206$EXP$$JP-SHIRE-JP201936960AA$TAKEDA$$9$YR$$F$Y$21.9$KG$20221206$$CN$JP$JP
1698690325$16986903$25$F$20190729$20221122$20191104$20221130$EXP$$CA-CELLTRION INC.-2019CA023615$CELLTRION$$$$$$Y$$$20221201$$CN$CA$CA
169869217$16986921$7$F$20180416$20220930$20191102$20221012$EXP$$DE-AUROBINDO-AUR-APL-2018-025940$AUROBINDO$$$$E$F$Y$75$KG$20221012$$MD$DE$DE
169873519$16987351$9$F$20180501$20221114$20191102$20221117$EXP$$PHHY2018CA052227$NOVARTIS$$46$YR$$M$Y$$$20221117$$MD$CA$CA
169874275$16987427$5$F$20220927$20221104$20191102$20221109$EXP$$US-SHIRE-US201936164$TAKEDA$$73$YR$$F$Y$55.782$KG$20221109$$HP$US$US
1698762414$16987624$14$F$$20221031$20191104$20221104$EXP$$US-SHIRE-US201937040$TAKEDA$$$$$F$Y$98$KG$20221104$$CN$US$US
1698784015$16987840$15$F$20190821$20221006$20191104$20221017$EXP$$CA-CELLTRION INC.-2019CA021069$CELLTRION$$$$$$Y$$$20221018$$MD$CA$CA
169880909$16988090$9$F$$20221205$20191104$20221212$EXP$$US-SHIRE-US201936998$TAKEDA$$$$$F$Y$22$KG$20221212$$CN$US$US
169883166$16988316$6$F$$20221104$20191104$20221108$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR199180$GLAXOSMITHKLINE$$$$$$Y$$$20221108$$MD$CA$CA
169894746$16989474$6$F$$20221108$20191104$20221110$PER$$US-PFIZER INC-2019475919$PFIZER$$68$YR$$F$Y$$$20221110$$MD$US$US
169894804$16989480$4$F$$20221104$20191104$20221108$PER$$US-PFIZER INC-2019475907$PFIZER$$74$YR$$F$Y$$$20221108$$MD$US$US
169910179$16991017$9$F$20191001$20221003$20191104$20221005$EXP$$IN-PFIZER INC-2019459214$PFIZER$$42$YR$$F$Y$$$20221005$$CN$IN$IN
169911366$16991136$6$F$$20221117$20191104$20221122$EXP$$US-SHIRE-US201937402$TAKEDA$$$$$F$Y$$$20221122$$CN$US$US
1699136619$16991366$19$F$20190101$20221209$20191104$20221217$PER$$US-DSJP-DSU-2019-142830$DAIICHI$$$$$M$Y$$$20221217$$CN$US$US
169916165$16991616$5$F$20191030$20221017$20191104$20221024$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-105439$BRISTOL MYERS SQUIBB$$73$YR$E$M$Y$122$KG$20221024$$HP$US$US
169929016$16992901$6$F$20220426$20221108$20191105$20221115$EXP$$NVSC2019CA023159$NOVARTIS$$66$YR$$F$Y$$$20221115$$MD$CA$CA
169942334$16994233$4$F$20191022$20200113$20191105$20221123$PER$$NVSC2019US024557$NOVARTIS$$85$YR$$M$Y$76.8$KG$20221123$$CN$US$US
169944862$16994486$2$F$20190801$20220926$20191105$20221004$EXP$FR-AFSSAPS-NY20191729$FR-SA-2019SA300059$SANOFI AVENTIS$$48$YR$A$M$Y$77.5$KG$20221004$$MD$FR$FR
169951204$16995120$4$F$$20221104$20191105$20221108$PER$$US-PFIZER INC-2019473108$PFIZER$$76$YR$$M$Y$$$20221108$$CN$US$US
1699530616$16995306$16$F$20200302$20221219$20191105$20221228$EXP$$US-SHIRE-US201936135$TAKEDA$$70$YR$$F$Y$70$KG$20221228$$HP$US$US
169955787$16995578$7$F$20190301$20221006$20191105$20221010$PER$$US-PFIZER INC-2019472691$PFIZER$$65$YR$$M$Y$$$20221010$$CN$US$US
169960886$16996088$6$F$$20221114$20191105$20221116$PER$$US-PFIZER INC-2019474729$PFIZER$$79$YR$$F$Y$$$20221116$$HP$US$US
169961415$16996141$5$F$$20221201$20191105$20221205$PER$$US-PFIZER INC-2019478837$PFIZER$$76$YR$$F$Y$$$20221205$$MD$US$US
169962964$16996296$4$F$$20221020$20191105$20221024$EXP$$CA-PFIZER INC-2019476386$PFIZER$$56$YR$$F$Y$64$KG$20221024$$HP$CA$CA
169967304$16996730$4$F$$20221019$20191105$20221021$PER$$US-PFIZER INC-2019479725$PFIZER$$65$YR$$F$Y$$$20221021$$MD$US$US
1699698018$16996980$18$F$20171108$20221102$20191106$20221111$EXP$$CA-CELLTRION INC.-2017CA017532$CELLTRION$$$$$$Y$$$20221111$$MD$CA$CA
169972246$16997224$6$F$$20221026$20191106$20221101$PER$$US-AMGEN-USASP2019182357$AMGEN$$72$YR$E$F$Y$$$20221101$$MD$US$US
169989252$16998925$2$F$20160901$20221213$20191106$20221228$EXP$NL-002147023-PHHY2019NL211876$NL-ALKEM LABORATORIES LIMITED-NL-ALKEM-2019-09199$ALKEM$Van Wezel EM, De Bruijne J, Damman K, Bijmolen M, et al.. Sofosbuvir add-on to ribavirin treatment for chronic hepatitis e virus infection in solid organ transplant recipients does not result in sustained virological response.. Open Forum Infectious Diseases. 2019;6(8):ofz346$52$YR$$F$Y$$$20221228$$MD$NL$NL
169999082$16999908$2$F$$20221109$20191106$20221116$PER$$US-VERTEX PHARMACEUTICALS-2019-010617$VERTEX$$$$$F$Y$$$20221116$$HP$US$US
170000343$17000034$3$F$$20221214$20191106$20221216$EXP$$US-SHIRE-US201937305$TAKEDA$$$$$M$Y$$$20221216$$MD$US$US
170005276$17000527$6$F$20191001$20221110$20191106$20221117$EXP$$PHHY2018CA096398$NOVARTIS$$55$YR$$F$Y$$$20221117$$CN$CA$CA
170006759$17000675$9$F$20150301$20221117$20191106$20221124$EXP$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-111491$BOEHRINGER INGELHEIM$$68$YR$E$M$Y$$$20221124$$CN$US$US
1700153510$17001535$10$F$20190101$20221003$20191106$20221011$PER$$US-DSJP-DSU-2019-141002$DAIICHI$$$$$F$Y$$$20221011$$CN$US$US
170018183$17001818$3$F$$20221121$20191106$20221128$EXP$$CA-AstraZeneca-2019SF55776$ASTRAZENECA$$68$YR$$F$Y$$$20221128$$MD$CA$
1700307114$17003071$14$F$20191007$20221028$20191107$20221104$EXP$$US-SHIRE-US201937017$TAKEDA$$29$YR$$F$Y$98$KG$20221104$$CN$US$US
170035866$17003586$6$F$20170801$20221018$20191107$20221020$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2018JPN170314$VIIV$$$$$$Y$$$20221020$$MD$JP$JP
170037816$17003781$6$F$$20221020$20191107$20221107$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-103663$BRISTOL MYERS SQUIBB$$42$YR$A$F$Y$$$20221107$$HP$CA$CA
170039464$17003946$4$F$20191009$20221130$20191107$20221202$EXP$FR-AFSSAPS-AN20191211$FR-PFIZER INC-2019478062$PFIZER$$58$YR$$M$Y$88.7$KG$20221202$$MD$FR$FR
170041582$17004158$2$F$20191029$20221103$20191107$20221109$PER$$US-VERTEX PHARMACEUTICALS-2019-010663$VERTEX$$30$YR$$F$Y$$$20221109$$HP$US$US
1700432410$17004324$10$F$20191027$20221027$20191107$20221110$EXP$$JP-PFIZER INC-2019481418$PFIZER$$7$YR$$M$Y$20$KG$20221110$$MD$JP$JP
170045988$17004598$8$F$20190101$20221122$20191107$20221128$EXP$$CA-PFIZER INC-2019262838$PFIZER$$53$YR$$M$Y$$$20221128$$CN$CA$CA
170046494$17004649$4$F$$20221017$20191107$20221019$PER$$US-PFIZER INC-2019481244$PFIZER$$65$YR$$F$Y$$$20221019$$CN$US$US
170046916$17004691$6$F$20191201$20221101$20191107$20221104$EXP$$US-PFIZER INC-2019481599$PFIZER$$71$YR$$F$Y$101$KG$20221104$$CN$US$US
170049083$17004908$3$F$20181201$20221011$20191107$20221013$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-104689$BRISTOL MYERS SQUIBB$$74$YR$E$F$Y$45$KG$20221014$$MD$JP$JP
170058614$17005861$4$F$20190101$20221025$20191107$20221028$EXP$$US-PFIZER INC-2019132680$PFIZER$$57$YR$$M$Y$$$20221028$$HP$US$US
170059225$17005922$5$F$20190701$20221221$20191107$20221229$PER$$US-SA-2019SA306457$SANOFI AVENTIS$$27$YR$A$F$Y$$$20221229$$MD$US$US
1700711331$17007113$31$F$20190420$20221114$20191107$20221128$EXP$$DE-AUROBINDO-AUR-APL-2019-027518$AUROBINDO$$47$YR$$F$Y$61$KG$20221128$$MD$DE$DE
170071992$17007199$2$F$20161021$20191015$20191107$20221215$EXP$$PHHY2017FR165129$NOVARTIS$$15$YR$$M$Y$47$KG$20221214$$MD$FR$FR
170074533$17007453$3$F$$20221207$20191108$20221221$PER$$US-AMGEN-USASP2019184244$AMGEN$$70$YR$E$F$Y$$$20221221$$MD$US$US
1700794911$17007949$11$F$$20221115$20191108$20221121$EXP$$US-SHIRE-US201937923$TAKEDA$$$$$F$Y$122$KG$20221121$$CN$US$US
170080934$17008093$4$F$$20221020$20191108$20221026$EXP$$CA-Orion Corporation ORION PHARMA-TREX2019-5211$ORION$$56$YR$A$F$Y$64$KG$20221026$$HP$CA$
1700835821$17008358$21$F$$20221212$20191108$20221216$EXP$$US-SHIRE-US201937990$TAKEDA$$$$$F$Y$60$KG$20221216$$HP$US$US
170084672$17008467$2$F$20191007$20220913$20191108$20221012$PER$$US-009507513-1910USA008717$MERCK$$$$$$Y$$$20221012$$CN$US$US
170086735$17008673$5$F$20191025$20221021$20191108$20221025$EXP$$US-SHIRE-US201937654$TAKEDA$$65$YR$$M$Y$132.8$KG$20221025$$CN$US$US
170087273$17008727$3$F$$20221102$20191108$20221102$EXP$$CA-ROCHE-2454297$ROCHE$$39$YR$$F$Y$$$20221102$$CN$CA$
170088365$17008836$5$F$20191017$20221113$20191108$20221121$EXP$$HU-SA-2019SA305576$SANOFI AVENTIS$$30$YR$A$F$Y$$$20221121$$HP$HU$HU
1700964331$17009643$31$F$20190701$20221201$20191108$20221210$EXP$$CA-CELLTRION INC.-2019CA025206$CELLTRION$$$$$$Y$$$20221210$$HP$CA$CA
170097252$17009725$2$F$20190828$20191029$20191108$20221031$PER$$US-UCBSA-2019046177$UCB$$$$$M$Y$$$20221031$$CN$US$US
1701016214$17010162$14$F$20180503$20221104$20191108$20221109$EXP$$DE-MYLANLABS-2019M1106223$MYLAN$$50$YR$$F$Y$$$20221109$$MD$DE$DE
170101973$17010197$3$F$$20221209$20191108$20221216$PER$$US-PFIZER INC-2019484741$PFIZER$$66$YR$$M$Y$$$20221216$$CN$US$US
170102974$17010297$4$F$$20221108$20191108$20221114$PER$$US-PFIZER INC-2019484711$PFIZER$$71$YR$$M$Y$$$20221114$$MD$US$US
1701036810$17010368$10$F$20190825$20221021$20191108$20221025$EXP$$CN-ROCHE-2408103$ROCHE$$69$YR$$M$Y$59$KG$20221025$$MD$CN$
170118274$17011827$4$F$20201218$20221221$20191108$20221229$EXP$$US-SHIRE-US201936813$TAKEDA$$32$YR$$M$Y$66$KG$20221229$$HP$US$US
170125867$17012586$7$F$20191001$20221011$20191109$20221012$PER$$US-BIOGEN-2019BI00805143$BIOGEN$$51$YR$$F$Y$$$20221012$$CN$US$US
170129624$17012962$4$F$20221209$20221209$20191109$20221216$EXP$$US-SHIRE-US201937689$TAKEDA$$60$YR$$F$Y$115$KG$20221216$$CN$US$US
170138622$17013862$2$F$20190806$20221207$20191111$20221221$EXP$$IT-AUROBINDO-AUR-APL-2019-070800$AUROBINDO$$44$YR$$F$Y$$$20221221$$MD$IT$IT
170144142$17014414$2$F$$20191106$20191111$20221213$EXP$$FR-Orion Corporation ORION PHARMA-19_00007422$ORION$Ibranosyan M, Beraud L. The clinical presentation of Legionella arthritis reveals the mode of infection and the bacterial species. case report and literature review. BMC infectious diseases.. 2019 OCT 21;19(1):864.$56$YR$A$F$Y$$$20221213$$MD$FR$
170157224$17015722$4$F$20181101$20221219$20191111$20221223$EXP$$JP-TEVA-2019-JP-1067553$TEVA$$54$YR$A$F$Y$55$KG$20221223$$HP$JP$JP
170163897$17016389$7$F$20190601$20221012$20191111$20221018$EXP$$PHHY2019CA137206$NOVARTIS$$59$YR$$M$Y$$$20221018$$CN$CA$CA
170164854$17016485$4$F$$20221228$20191111$20221229$PER$$US-PFIZER INC-2019484233$PFIZER$$73$YR$$F$Y$$$20221229$$MD$US$US
170166393$17016639$3$F$$20221201$20191111$20221206$PER$$US-PFIZER INC-2019488151$PFIZER$$79$YR$$F$Y$$$20221206$$CN$US$US
1701691628$17016916$28$F$20150101$20221124$20191111$20221129$EXP$$GB-PFIZER INC-2019477443$PFIZER$$45$YR$$F$Y$80$KG$20221129$$MD$GB$GB
170169726$17016972$6$F$$20221103$20191111$20221108$EXP$$CA-ROCHE-2450348$ROCHE$$50$YR$$M$Y$101$KG$20221108$$HP$CA$
170180095$17018009$5$F$20190101$20221122$20191111$20221124$EXP$$US-PFIZER INC-2019485778$PFIZER$$72$YR$$F$Y$65.77$KG$20221124$$CN$US$US
170181649$17018164$9$F$20210501$20221101$20191111$20221104$EXP$$US-SHIRE-US201937006$TAKEDA$$76$YR$$F$Y$62$KG$20221104$$CN$US$US
170191116$17019111$6$F$20190912$20221125$20191112$20221207$EXP$$CA-TAKEDA-2019TUS052586$TAKEDA$$60$YR$$M$Y$$$20221207$$HP$CA$CA
170199477$17019947$7$F$$20220930$20191112$20221012$EXP$$GB-AUROBINDO-AUR-APL-2019-071831$AUROBINDO$Fu L, Santhanakrishnan K, Al-Aloul M, Jones NP, Steeples LR. Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches. Ocul Immunol Inflamm. 2019;17:1-7$55$YR$$M$Y$$$20221012$$MD$GB$GB
170201172$17020117$2$F$20191009$20221119$20191112$20221202$EXP$FR-AFSSAPS-AN20191211$FR-Accord-160580$ACCORD$$58$YR$$M$Y$88.7$KG$20221203$$MD$FR$FR
170202213$17020221$3$F$$20221108$20191112$20221115$EXP$$US-JAZZ-2019-US-014990$JAZZ$$$$$F$Y$$$20221115$$CN$US$US
1702028524$17020285$24$F$$20221017$20191112$20221021$EXP$$CA-TAKEDA-2019TUS063470$TAKEDA$$56$YR$$M$Y$$$20221021$$HP$CA$CA
170210373$17021037$3$F$$20221201$20191112$20221208$EXP$$CA-PFIZER INC-2019484155$PFIZER$$54$YR$$F$Y$67$KG$20221208$$HP$CA$CA
170212043$17021204$3$F$20190424$20221011$20191112$20221019$EXP$FR-AFSSAPS-AM20190908$FR-MYLANLABS-2019M1106893$MYLAN$$59$YR$$M$Y$60$KG$20221019$$MD$FR$FR
170213874$17021387$4$F$20170101$20221202$20191112$20221205$PER$$US-PFIZER INC-2019366450$PFIZER$$62$YR$$F$Y$$$20221205$$LW$US$US
170214766$17021476$6$F$$20221014$20191112$20221018$PER$$US-PFIZER INC-2019485539$PFIZER$$68$YR$$F$Y$$$20221018$$MD$US$US
1702150312$17021503$12$F$$20221213$20191112$20221220$EXP$$US-PFIZER INC-2019486279$PFIZER$$46$YR$$F$Y$$$20221220$$CN$US$US
170215234$17021523$4$F$$20221213$20191112$20221220$PER$$US-PFIZER INC-2019486614$PFIZER$$68$YR$$M$Y$90.703$KG$20221220$$CN$US$US
170218312$17021831$2$F$20191009$20221011$20191112$20221025$EXP$FR-AFSSAPS-AN20191211$FR-JNJFOC-20191104515$JOHNSON AND JOHNSON$$58$YR$A$M$Y$88.7$KG$20221025$$MD$FR$FR
170220593$17022059$3$F$20190901$20221201$20191112$20221208$EXP$$US-JAZZ-2019-US-013509$JAZZ$$53$YR$$F$Y$$$20221208$$CN$US$US
170229152$17022915$2$F$20191108$20221031$20191112$20221101$EXP$$US-SHIRE-US201938663$TAKEDA$$8$YR$$F$Y$$$20221101$$HP$US$US
1702341711$17023417$11$F$20190521$20221114$20191112$20221124$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-096166$BRISTOL MYERS SQUIBB$Kakuda M, et al. A case of headache and marked pituitary enlargement after initiation of nivolumab and ipilimumab. The 20th Meeting of Kanto-Koshinetsu Branch of the Japan Endocrine 2019:84.$40$YR$A$F$Y$54$KG$20221124$$MD$JP$JP
170237455$17023745$5$F$20191019$20200420$20191113$20221130$PER$$NVSC2019US012617$NOVARTIS$$43$YR$$F$Y$$$20221130$$CN$US$US
170257863$17025786$3$F$$20221025$20191113$20221026$PER$$US-PFIZER INC-2019488090$PFIZER$$63$YR$$M$Y$90.703$KG$20221026$$CN$US$US
170259542$17025954$2$F$$20221110$20191113$20221116$EXP$$JP-PFIZER INC-2019485180$PFIZER$$$$$$Y$$$20221116$$PH$JP$JP
170259742$17025974$2$F$$20221020$20191113$20221025$EXP$$CA-ROCHE-2462044$ROCHE$$67$YR$$M$Y$$$20221025$$HP$CA$
170262404$17026240$4$F$$20221227$20191113$20221229$EXP$$US-PFIZER INC-2019489527$PFIZER$$71$YR$$F$Y$56.689$KG$20221229$$CN$US$US
170262559$17026255$9$F$20190729$20221212$20191113$20221221$EXP$$FR-NOVOPROD-694841$NOVO NORDISK$$67$YR$$F$Y$90$KG$20221221$$MD$FR$FR
170267183$17026718$3$F$$20221202$20191113$20221209$EXP$$NVSC2019CA031843$NOVARTIS$$39$YR$$M$Y$$$20221209$$CN$CA$CA
1702733810$17027338$10$F$20221105$20221214$20191113$20221220$EXP$$IN-PFIZER INC-2018043942$PFIZER$$61$YR$$F$Y$$$20221220$$CN$IN$IN
170273967$17027396$7$F$$20221028$20191113$20221105$PER$$NVSC2019US032786$NOVARTIS$$$$$M$Y$$$20221105$$CN$US$US
1702798515$17027985$15$F$20220114$20221221$20191113$20221230$EXP$$US-SHIRE-US201938023$TAKEDA$$59$YR$$F$Y$68$KG$20221230$$CN$US$US
170279874$17027987$4$F$$20221024$20191113$20221028$EXP$$US-SHIRE-US201937376$TAKEDA$$$$$F$Y$45.351$KG$20221028$$HP$US$US
1702801110$17028011$10$F$20190726$20221202$20191113$20221216$EXP$$DE-SHIRE-DE201924751$TAKEDA$$73$YR$$F$Y$79.819$KG$20221216$$CN$DE$DE
1702813310$17028133$10$F$$20221003$20191113$20221011$EXP$$CZ-MYLANLABS-2019M1108209$MYLAN$Hubenak J.. Trazodone once-daily in depression. PSYCHIATRIE PRO PRAXI. 2019;20 (3):133-5$67$YR$$F$Y$78$KG$20221011$$MD$CZ$CZ
1702832025$17028320$25$F$$20221219$20191113$20221226$EXP$$CA-BAUSCH-BL-2019-061339$BAUSCH AND LOMB$$71$YR$$F$Y$69$KG$20221226$$CN$CA$CA
170291575$17029157$5$F$20191031$20221019$20191114$20221021$EXP$$CN-ROCHE-2463553$ROCHE$$29$YR$$M$Y$82$KG$20221021$$MD$CN$
170297103$17029710$3$F$$20221205$20191114$20221209$PER$$US-BIOGEN-2019BI00806718$BIOGEN$$$$$F$Y$$$20221209$$CN$US$US
170298972$17029897$2$F$20190101$20221205$20191114$20221213$EXP$$HR-009507513-1903HRV007055$MERCK$$64$YR$$F$Y$84$KG$20221213$$MD$HR$HR
1703116819$17031168$19$F$20190801$20221101$20191114$20221107$EXP$$US-GLAXOSMITHKLINE-2019-TSO02991-US$GLAXOSMITHKLINE$$$$$$Y$$$20221107$$HP$US$US
170311773$17031177$3$F$19740101$20221014$20191114$20221018$EXP$$US-PFIZER INC-2018455098$PFIZER$$38$YR$$F$Y$72.562$KG$20221018$$CN$US$US
170311893$17031189$3$F$$20221107$20191114$20221109$PER$$US-PFIZER INC-2019487605$PFIZER$$70$YR$$F$Y$$$20221109$$MD$US$US
1703124214$17031242$14$F$$20221212$20191114$20221215$PER$$US-PFIZER INC-2019446983$PFIZER$$67$YR$$F$Y$74.84$KG$20221215$$CN$US$US
170313815$17031381$5$F$20191026$20221014$20191114$20221018$EXP$$US-PFIZER INC-2019490246$PFIZER$$64$YR$$F$Y$90.703$KG$20221018$$HP$US$US
170314745$17031474$5$F$$20221228$20191114$20221230$PER$$US-PFIZER INC-2019490285$PFIZER$$87$YR$$F$Y$$$20221230$$HP$US$US
170316716$17031671$6$F$$20221221$20191114$20221227$PER$$US-PFIZER INC-2019493903$PFIZER$$65$YR$$F$Y$$$20221227$$MD$US$US
170320908$17032090$8$F$20191003$20221111$20191114$20221117$EXP$$AT-SHIRE-AT201934212$TAKEDA$$40$YR$$M$Y$84.81$KG$20221117$$CN$AT$AT
1703216018$17032160$18$F$20181018$20221021$20191114$20221101$EXP$$CA-CELLTRION INC.-2018CA023682$CELLTRION$$$$$$Y$$$20221101$$CN$CA$CA
1703261811$17032618$11$F$20191102$20220930$20191114$20221003$EXP$$NVSC2019ES026569$NOVARTIS$$75$YR$$M$Y$70$KG$20221003$$MD$ES$ES
170326577$17032657$7$F$$20221109$20191114$20221115$EXP$$CA-AstraZeneca-2019SF62239$ASTRAZENECA$$74$YR$$F$Y$$$20221115$$MD$CA$
1703279512$17032795$12$F$$20221227$20191114$20221229$EXP$$US-TAKEDA-2019TUS064835$TAKEDA$$$$$F$Y$73$KG$20221229$$HP$US$US
1703379111$17033791$11$F$20190225$20221121$20191114$20221126$PER$$US-ABBVIE-19P-163-2996478-00$ABBVIE$$18$YR$$F$Y$$$20221126$$MD$US$US
170342503$17034250$3$F$20190501$20221208$20191114$20221214$PER$$US-ABBVIE-19K-163-2957574-00$ABBVIE$$68$YR$$M$Y$83.915$KG$20221214$$CN$US$US
170343594$17034359$4$F$20190523$20221121$20191115$20221127$EXP$$US-ABBVIE-19P-163-2998420-00$ABBVIE$$18$YR$$F$Y$$$20221127$$MD$US$US
170361743$17036174$3$F$$20221202$20191115$20221207$EXP$$CA-ROCHE-2172763$ROCHE$$47$YR$$F$Y$73$KG$20221207$$HP$CA$
170361888$17036188$8$F$$20221017$20191115$20221031$EXP$$AU-TAKEDA-2019TUS060008$TAKEDA$$$$$M$Y$$$20221031$$CN$AU$AU
170367494$17036749$4$F$$20221201$20191115$20221205$EXP$$CA-PFIZER INC-2019494100$PFIZER$$72$YR$$M$Y$$$20221205$$CN$CA$CA
1703692134$17036921$34$F$20180802$20221204$20191115$20221212$EXP$$IL-PFIZER INC-2018312739$PFIZER$$62$YR$$M$Y$$$20221212$$HP$IL$IL
170371434$17037143$4$F$20170911$20221109$20191115$20221115$EXP$$CA-AstraZeneca-2019SF62225$ASTRAZENECA$$64$YR$$M$Y$$$20221115$$MD$CA$
170372474$17037247$4$F$$20221117$20191115$20221121$PER$$US-PFIZER INC-2019493449$PFIZER$$68$YR$$F$Y$$$20221121$$MD$US$US
1703756311$17037563$11$F$20190701$20221128$20191115$20221201$EXP$$NVSC2019CO009471$NOVARTIS$$6$YR$$F$Y$25$KG$20221201$$CN$CO$CO
170377676$17037767$6$F$$20221216$20191115$20221223$EXP$$US-PFIZER INC-2019494624$PFIZER$$73$YR$$F$Y$98.88$KG$20221223$$CN$US$US
170384432$17038443$2$F$20191101$20191114$20191115$20221012$PER$$US-BAYER-2019-206528$BAYER$$59$YR$A$F$Y$$$20221012$$CN$US$US
1703866314$17038663$14$F$20191001$20221202$20191115$20221207$EXP$$NVSC2019CA023085$NOVARTIS$$51$YR$$F$Y$$$20221207$$CN$CA$CA
170388194$17038819$4$F$20191113$20220816$20191115$20221206$PER$$NVSC2019US037298$NOVARTIS$$27$YR$$M$Y$$$20221207$$CN$US$US
170394733$17039473$3$F$$20191101$20191115$20221201$EXP$$US-SAMSUNG BIOEPIS-SB-2019-33400$SAMSUNG BIOEPIS$$$$$$Y$$$20221201$$CN$US$US
170395667$17039566$7$F$20191011$20221006$20191115$20221017$EXP$$US-ROCHE-2459754$ROCHE$$65$YR$$M$Y$77.1$KG$20221017$$MD$US$
1704002644$17040026$44$F$$20221017$20191116$20221109$EXP$$CA-ABBVIE-19K-028-3002083-00$ABBVIE$$43$YR$$F$Y$$$20221109$$HP$CA$CA
170402642$17040264$2$F$20151020$20191008$20191116$20221215$EXP$$PHHY2018DE065721$NOVARTIS$$0$YR$$F$Y$$$20221214$$MD$DE$DE
170412698$17041269$8$F$$20221221$20191118$20221228$EXP$$US-SHIRE-US201939380$TAKEDA$$$$$F$Y$86$KG$20221228$$HP$US$US
170413157$17041315$7$F$20220101$20221209$20191118$20221213$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-107361$BRISTOL MYERS SQUIBB$$63$YR$A$F$Y$64.86$KG$20221213$$HP$CA$CA
170419322$17041932$2$F$$20221020$20191118$20221025$EXP$$GB-ROCHE-2468565$ROCHE$J F, Plucinski M. Stoma formation after lymphoproliferative disorders and immunosuppression therapy. British Journal of Nursing 2018;27(22):S20-S26.$42$YR$$F$Y$$$20221025$$HP$GB$GB
170421304$17042130$4$F$20180928$20221014$20191118$20221026$EXP$$BR-SA-2019SA093324$SANOFI AVENTIS$$36$YR$A$F$Y$60$KG$20221026$$MD$BR$BR
170424575$17042457$5$F$20161106$20221115$20191118$20221117$EXP$$US-PFIZER INC-2018114120$PFIZER$$64$YR$$F$Y$79.38$KG$20221117$$HP$US$US
170430383$17043038$3$F$$20221024$20191118$20221102$EXP$$RU-PFIZER INC-2019390393$PFIZER$$$$$F$Y$$$20221102$$MD$RU$RU
1704313410$17043134$10$F$$20221101$20191118$20221104$EXP$$US-PFIZER INC-2019493328$PFIZER$$60$YR$$M$Y$129.73$KG$20221104$$MD$US$US
170432577$17043257$7$F$20180323$20221130$20191118$20221208$EXP$$PHHY2018CA055667$NOVARTIS$$50$YR$$M$Y$$$20221208$$CN$CA$CA
1704425114$17044251$14$F$$20221114$20191118$20221121$PER$$IT-AMGEN-ITASP2019187917$AMGEN$Musuraca G. CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA ^ROLE OF BENDAMUSTINEBORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS^ ERA. Tumori. 2022;108 (4):146-147$$$$$Y$$$20221121$$HP$IT$IT
170460512$17046051$2$F$$20220930$20191119$20221007$EXP$$JP-ASTELLAS-2019JP026091$ASTELLAS$Ijiri N, Sato M, Konoeda C, Nagayama K, Nakajima J. Basiliximab for early perioperative transplant-associated thrombotic microangiopathy after lung transplantation: a case report. Surgical Case Reports. 2022;8(1):1-4$58$YR$$F$Y$$$20221007$$CN$JP$JP
170460752$17046075$2$F$20190512$20221213$20191119$20221225$EXP$$IT-AUROBINDO-AUR-APL-2019-073154$AUROBINDO$$68$YR$$F$Y$$$20221225$$MD$IT$IT
170465106$17046510$6$F$$20221026$20191119$20221109$EXP$$CA-AUROBINDO-AUR-APL-2019-072797$AUROBINDO$$83$YR$$F$Y$$$20221109$$HP$CA$CA
170475477$17047547$7$F$20191020$20220927$20191119$20221007$EXP$$JP-ELI_LILLY_AND_COMPANY-JP201911003446$ELI LILLY AND CO$$58$YR$$F$Y$$$20221007$$CN$JP$JP
170476288$17047628$8$F$20191001$20221205$20191119$20221208$EXP$$PHHY2019CA194163$NOVARTIS$$64$YR$$F$Y$70$KG$20221208$$CN$CA$CA
170479803$17047980$3$F$20140101$20221019$20191119$20221021$EXP$$GB-Rare Disease Therapeutics, Inc.-2076994$NOVA LABORATORIES$Stoma formation after lymphoproliferative disorders and immunosuppression therapy. ?Fulham J, Plucinski M.. ?Br-J-Nurs. 2018;27(22):S20-S26.$31$YR$$M$Y$$$20221021$$HP$GB$GB
170480292$17048029$2$F$$20221001$20191119$20221005$PER$$US-PFIZER INC-2019494354$PFIZER$$52$YR$$F$Y$$$20221005$$HP$US$US
170480776$17048077$6$F$20191201$20221128$20191119$20221130$PER$$US-PFIZER INC-2019494688$PFIZER$$65$YR$$F$Y$$$20221130$$HP$US$US
170480995$17048099$5$F$20170201$20221004$20191119$20221006$PER$$US-PFIZER INC-2019494818$PFIZER$$94$YR$$F$Y$52.154$KG$20221006$$CN$US$US
170483805$17048380$5$F$$20221221$20191119$20221227$PER$$US-PFIZER INC-2019497757$PFIZER$$65$YR$$F$Y$49$KG$20221227$$CN$US$US
170484589$17048458$9$F$$20221209$20191119$20221215$PER$$US-PFIZER INC-2018335867$PFIZER$$57$YR$$F$Y$73$KG$20221215$$CN$US$US
170497192$17049719$2$F$20190218$20221007$20191119$20221010$PER$$DE-AMGEN-DEUNI2019190567$AMGEN$$79$YR$E$F$Y$77$KG$20221010$$MD$DE$DE
1704996126$17049961$26$F$20210813$20221014$20191119$20221018$EXP$$US-SHIRE-US201938480$TAKEDA$$58$YR$$F$Y$75.74$KG$20221018$$CN$US$US
170499953$17049995$3$F$20190101$20221213$20191119$20221219$EXP$$US-PFIZER INC-2019365382$PFIZER$$81$YR$$F$Y$$$20221219$$CN$US$US
170506457$17050645$7$F$20210120$20221129$20191119$20221203$EXP$$PHHY2019CA143351$NOVARTIS$$53$YR$$F$Y$$$20221203$$CN$CA$CA
1705138125$17051381$25$F$20170101$20221024$20191120$20221101$EXP$$CA-CELLTRION INC.-2017CA011436$CELLTRION$$$$$$Y$$$20221101$$CN$CA$CA
170524078$17052407$8$F$20190101$20220930$20191120$20221007$EXP$$NVSC2019CO041409$NOVARTIS$$$$$F$Y$45$KG$20221007$$CN$CO$CO
170530968$17053096$8$F$$20220929$20191120$20221003$PER$$US-PFIZER INC-2019495947$PFIZER$$73$YR$$F$Y$$$20221003$$CN$US$US
1705339612$17053396$12$F$$20221010$20191120$20221014$PER$$US-PFIZER INC-2017232025$PFIZER$$64$YR$$F$Y$$$20221014$$CN$US$US
170540827$17054082$7$F$20161021$20221220$20191120$20221227$EXP$$US-PFIZER INC-2019503746$PFIZER$$75$YR$$F$Y$62.132$KG$20221227$$CN$US$US
170540923$17054092$3$F$$20221028$20191120$20221102$EXP$$US-PFIZER INC-2019467317$PFIZER$$79$YR$$F$Y$$$20221102$$CN$US$US
1705458417$17054584$17$F$20190101$20221202$20191120$20221208$EXP$$US-PFIZER INC-2019499305$PFIZER$$44$YR$$M$Y$85.28$KG$20221208$$CN$US$US
170554732$17055473$2$F$$20221219$20191120$20221221$EXP$$CA-PFIZER INC-2019495347$PFIZER$$25$MON$$F$Y$$$20221221$$HP$CA$CA
170554832$17055483$2$F$$20221219$20191120$20221222$EXP$$CA-PFIZER INC-2019495315$PFIZER$$$$$$Y$$$20221222$$HP$CA$CA
1705562724$17055627$24$F$20180511$20221121$20191120$20221129$EXP$$CA-CELLTRION INC.-2018CA020177$CELLTRION$$$$$$Y$$$20221129$$CN$CA$CA
1705563022$17055630$22$F$20180228$20221216$20191120$20221226$EXP$$CA-CELLTRION INC.-2018CA018822$CELLTRION$$$$$$Y$$$20221226$$CN$CA$CA
170565445$17056544$5$F$$20221229$20191121$20221230$PER$$US-BIOGEN-2019BI00804437$BIOGEN$$$$$F$Y$$$20221230$$CN$US$US
170574132$17057413$2$F$$20221213$20191121$20221228$EXP$$TR-ALKEM LABORATORIES LIMITED-TR-ALKEM-2019-09758$ALKEM$Schmidt E, Herzog S, Brocker EB, Zillikens D, et al.. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with Rituximab. Br J Dermatol.. 2005;153(2):449-451$14$YR$$M$Y$40$KG$20221228$$HP$TR$TR
170583885$17058388$5$F$20190827$20221122$20191121$20221124$EXP$$DE-ROCHE-2453217$ROCHE$$53$YR$$M$Y$$$20221124$$CN$DE$
170589133$17058913$3$F$20220101$20221026$20191121$20221101$PER$$US-PFIZER INC-2019499353$PFIZER$$63$YR$$F$Y$$$20221101$$HP$US$US
1705901811$17059018$11$F$20190801$20221017$20191121$20221110$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-110415$BRISTOL MYERS SQUIBB$$83$YR$E$M$Y$$$20221110$$MD$JP$JP
170595969$17059596$9$F$20191101$20221121$20191121$20221124$EXP$$US-SA-2019SA320449$SANOFI AVENTIS$$30$YR$A$M$Y$$$20221124$$MD$US$US
170598522$17059852$2$F$20190326$20191115$20191121$20221130$EXP$$PL-BAYER-2019-209124$BAYER$$46$YR$A$F$Y$$$20221130$$MD$PL$PL
170614574$17061457$4$F$20140201$20221003$20191121$20221004$PER$$US-PFIZER INC-2019386388$PFIZER$$52$YR$$F$Y$$$20221004$$LW$US$US
1706184015$17061840$15$F$$20221212$20191121$20221219$EXP$$US-SHIRE-US201939676$TAKEDA$$$$$F$Y$61$KG$20221219$$HP$US$US
170618955$17061895$5$F$20191031$20200116$20191121$20221230$PER$$US-AMGEN-USASP2019192388$AMGEN$$29$YR$A$F$Y$$$20221230$$CN$US$US
1706211018$17062110$18$F$20211201$20220922$20191122$20221007$EXP$$GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-228367$RANBAXY$$$$A$M$Y$$$20221007$$CN$GB$GB
170621522$17062152$2$F$$20221212$20191122$20221214$PER$$US-SHIRE-US201935006$TAKEDA$$$$$F$Y$57$KG$20221214$$HP$US$US
1706231612$17062316$12$F$20190701$20220929$20191122$20221006$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-092524$BRISTOL MYERS SQUIBB$$60$YR$A$M$Y$57.6$KG$20221006$$MD$JP$JP
170623336$17062333$6$F$$20221221$20191122$20221227$PER$$US-AMGEN-USASP2019193456$AMGEN$$65$YR$E$F$Y$$$20221227$$MD$US$US
170624604$17062460$4$F$$20221014$20191122$20221021$EXP$$GB-ASPEN-GLO2019GB012118$ASPEN$Horgan C, Kanellopoulos A, Paneesha S, Kishore B, Lovell R, Nikolousis E.. A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant.. Hematology Reports. 2019;11:7800$$$$$Y$$$20221021$$HP$GB$GB
170628045$17062804$5$F$20190319$20221219$20191122$20221223$EXP$$CN-ROCHE-2055588$ROCHE$$61$YR$$F$Y$68$KG$20221223$$CN$CN$
170628473$17062847$3$F$$20221214$20191122$20221229$EXP$$CA-APOTEX-2019AP024849$APOTEX$$61$YR$$F$Y$70$KG$20221229$$HP$CA$CA
170640973$17064097$3$F$20190101$20221220$20191122$20221227$EXP$$CA-PFIZER INC-2019053949$PFIZER$$64$YR$$M$Y$$$20221227$$CN$CA$CA
170642818$17064281$8$F$$20221213$20191122$20221216$PER$$US-PFIZER INC-2019313619$PFIZER$$78$YR$$F$Y$72.57$KG$20221216$$CN$US$US
1706461812$17064618$12$F$20191101$20221130$20191122$20221206$PER$$US-PFIZER INC-2019505060$PFIZER$$76$YR$$F$Y$44.45$KG$20221206$$CN$US$US
170651584$17065158$4$F$20190101$20221209$20191122$20221216$PER$$US-BIOGEN-2019BI00803909$BIOGEN$$$$$F$Y$$$20221216$$CN$US$US
170653496$17065349$6$F$20211105$20221010$20191122$20221014$EXP$$US-SAKK-2019SA151125AA$SANOFI AVENTIS$$40$YR$A$M$Y$$$20221014$$MD$US$US
1706542210$17065422$10$F$20160920$20221121$20191122$20221128$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK027013$GLAXOSMITHKLINE$$$$$$Y$$$20221128$$CN$BR$BR
170660172$17066017$2$F$20091013$20211110$20191122$20221116$PER$$US-PERRIGO-19US002912$PERRIGO$$53$YR$$M$Y$79.365$KG$20221116$$CN$US$US
170660377$17066037$7$F$20181120$20221028$20191122$20221104$EXP$$US-ROCHE-2465366$ROCHE$$67$YR$$F$Y$50.848$KG$20221104$$CN$US$
170668674$17066867$4$F$$20221101$20191122$20221104$EXP$$US-PFIZER INC-2019436168$PFIZER$$78$YR$$F$Y$49.887$KG$20221104$$CN$US$US
170670997$17067099$7$F$$20221205$20191122$20221210$EXP$$US-SHIRE-US201938992$TAKEDA$$$$$F$Y$87$KG$20221210$$CN$US$US
170679232$17067923$2$F$20191018$20191105$20191122$20221130$PER$$NVSC2019US035368$NOVARTIS$$$$$M$Y$$$20221130$$HP$US$US
1706816413$17068164$13$F$20200910$20221026$20191122$20221102$EXP$$NVSC2019US043709$NOVARTIS$$35$YR$$F$Y$145.13$KG$20221102$$CN$US$US
1706842913$17068429$13$F$20211201$20221221$20191123$20221229$EXP$GB-EMA-DD-20191031-SAHU_K-125923$GB-Accord-161764$ACCORD$$52$YR$A$M$Y$$$20221229$$CN$GB$GB
170685712$17068571$2$F$$20191113$20191123$20221008$PER$$US-NAPPMUNDI-USA-2019-0149102$PURDUE$$$$$M$Y$$$20221008$$CN$US$US
1706903922$17069039$22$F$20190101$20221212$20191124$20221220$EXP$$CA-CELLTRION INC.-2019CA019786$CELLTRION$$$$$$Y$$$20221220$$CN$CA$CA
170697907$17069790$7$F$20181106$20221125$20191125$20221130$EXP$$FR-ABBVIE-19K-056-2964348-00$ABBVIE$$82$YR$$M$Y$78$KG$20221130$$MD$FR$FR
170702449$17070244$9$F$$20221207$20191125$20221212$EXP$$CA-ROCHE-2472550$ROCHE$$61$YR$$F$Y$70$KG$20221212$$HP$CA$
1707038214$17070382$14$F$$20221121$20191125$20221201$EXP$$CA-GLENMARK PHARMACEUTICALS-2019GMK044466$GLENMARK$$$$$$Y$$$20221201$$HP$CA$CA
170705274$17070527$4$F$$20221206$20191125$20221209$EXP$$US-PFIZER INC-2016102380$PFIZER$$66$YR$$F$Y$77.11$KG$20221209$$CN$US$US
170705753$17070575$3$F$$20221011$20191125$20221014$EXP$$US-PFIZER INC-2019504012$PFIZER$$65$YR$$F$Y$$$20221014$$CN$US$US
170708918$17070891$8$F$20180101$20221115$20191125$20221117$PER$$US-PFIZER INC-2017521061$PFIZER$$37$YR$$M$Y$$$20221117$$MD$US$US
170717652$17071765$2$F$$20221121$20191125$20221201$EXP$$CA-PFIZER INC-2019506115$PFIZER$$69$YR$$F$Y$52$KG$20221201$$MD$CA$CA
170719912$17071991$2$F$20191107$20221025$20191125$20221101$PER$$US-JAZZ-2019-US-015957$JAZZ$$30$YR$$F$Y$$$20221101$$CN$US$US
170722834$17072283$4$F$$20221107$20191125$20221111$PER$$US-SHIRE-US201940577$TAKEDA$$$$$M$Y$90.703$KG$20221111$$CN$US$US
1707248410$17072484$10$F$20110510$20221122$20191125$20221124$EXP$$PHHY2017CA070663$NOVARTIS$$77$YR$$F$Y$$$20221125$$CN$CA$CA
170727747$17072774$7$F$20191017$20210409$20191125$20221111$EXP$$NVSC2019BR027924$NOVARTIS$$48$YR$$M$Y$84$KG$20221111$$CN$BR$BR
170735529$17073552$9$F$20181120$20221208$20191126$20221216$EXP$$CA-ROCHE-2155735$ROCHE$$71$YR$$F$Y$$$20221216$$MD$CA$
170736553$17073655$3$F$20120101$20221003$20191126$20221011$EXP$$US-AstraZeneca-2019SF65593$ASTRAZENECA$$54$YR$$F$Y$70.8$KG$20221011$$LW$US$
1707400210$17074002$10$F$20180719$20220926$20191126$20221007$EXP$$DE-AUROBINDO-AUR-APL-2019-074127$AUROBINDO$$52$YR$$M$Y$$$20221007$$MD$DE$DE
170752026$17075202$6$F$20191114$20221004$20191126$20221006$EXP$$US-ROCHE-2478307$ROCHE$$64$YR$$F$Y$78$KG$20221006$$MD$US$
1707553315$17075533$15$F$20180101$20221118$20191126$20221122$PER$$US-PFIZER INC-2018182949$PFIZER$$45$YR$$F$Y$66$KG$20221122$$MD$US$US
170755354$17075535$4$F$$20221214$20191126$20221221$PER$$US-PFIZER INC-2019507284$PFIZER$$87$YR$$F$Y$48$KG$20221221$$CN$US$US
170756837$17075683$7$F$$20221031$20191126$20221103$PER$$US-PFIZER INC-2019509511$PFIZER$$58$YR$$F$Y$$$20221103$$MD$US$US
170757213$17075721$3$F$$20221220$20191126$20221230$EXP$$CA-APOTEX-2019AP025200$APOTEX$$39$YR$$F$Y$$$20221230$$HP$CA$CA
170758134$17075813$4$F$20191106$20221003$20191126$20221012$EXP$$ES-JNJFOC-20191129159$JOHNSON AND JOHNSON$$62$YR$A$M$Y$84$KG$20221008$$MD$ES$ES
170760846$17076084$6$F$20191029$20221010$20191126$20221018$EXP$$FR-PFIZER INC-2019497248$PFIZER$$47$YR$$F$Y$96$KG$20221018$$MD$FR$FR
170773584$17077358$4$F$$20221004$20191126$20221010$PER$$US-AMGEN-USASP2019195516$AMGEN$$85$YR$E$F$Y$$$20221010$$MD$US$US
1707853135$17078531$35$F$20191101$20221121$20191126$20221128$EXP$$CA-CELLTRION INC.-2019CA026646$CELLTRION$$$$$$Y$$$20221129$$CN$CA$CA
1708040114$17080401$14$F$$20221221$20191127$20221228$EXP$$US-SHIRE-US201939737$TAKEDA$$$$$F$Y$71$KG$20221228$$HP$US$US
1708094110$17080941$10$F$20170801$20221025$20191127$20221026$EXP$$CA-PFIZER INC-2017243485$PFIZER$$56$YR$$F$Y$$$20221026$$MD$CA$CA
170820497$17082049$7$F$$20221027$20191127$20221101$EXP$$FR-MYLANLABS-2019M1114992$MYLAN$Gregorie M.. Drug-drug interaction in older patients living with HIV.. Lett Infectiologue. 2019;34 (5):212-7$58$YR$$F$Y$$$20221101$$HP$FR$FR
170821658$17082165$8$F$20190901$20221018$20191127$20221024$EXP$$NVSC2019AT005963$NOVARTIS$$$$A$F$Y$$$20221024$$MD$AT$AT
170821984$17082198$4$F$20220601$20221123$20191127$20221130$EXP$$PHHY2019CA030053$NOVARTIS$$66$YR$$F$Y$$$20221130$$MD$CA$CA
1708226218$17082262$18$F$20190808$20221021$20191127$20221026$EXP$$PHHY2019CA033702$NOVARTIS$$36$YR$$F$Y$$$20221026$$CN$CA$CA
170823875$17082387$5$F$$20221223$20191127$20221228$PER$$US-PFIZER INC-2019512237$PFIZER$$68$YR$$F$Y$100$KG$20221228$$CN$US$US
170823964$17082396$4$F$$20221011$20191127$20221012$PER$$US-PFIZER INC-2019511403$PFIZER$$66$YR$$M$Y$$$20221012$$HP$US$US
170828044$17082804$4$F$20190101$20221207$20191127$20221219$PER$$US-TAKEDA-2019TUS066833$TAKEDA$$$$$M$Y$$$20221219$$HP$US$US
1708284910$17082849$10$F$20170101$20221219$20191127$20221221$EXP$$US-PFIZER INC-2019511168$PFIZER$Narang, A.. Severe Late-Onset Acute Cellular Rejection in a Pediatric Patient With Isolated Small Intestinal Transplant Rescued With Aggressive Immunosuppressive Approach: A Case Report. Transplantation Proceedings. 2019;51 (9):3181-3185$20$YR$$F$Y$$$20221221$$MD$US$US
170828736$17082873$6$F$20180930$20221124$20191127$20221128$EXP$$FR-MYLANLABS-2019M1116342$MYLAN$$75$YR$$M$Y$72$KG$20221128$$HP$FR$FR
170829038$17082903$8$F$20221109$20221110$20191127$20221116$EXP$$PHHY2018CA079536$NOVARTIS$$68$YR$$M$Y$$$20221116$$CN$CA$CA
170830347$17083034$7$F$20190626$20221125$20191127$20221130$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-111757$BRISTOL MYERS SQUIBB$$36$YR$A$F$Y$64.5$KG$20221130$$MD$JP$JP
170835643$17083564$3$F$20190610$20221206$20191127$20221209$EXP$$GB-ABBVIE-19K-167-3014065-00$ABBVIE$$57$YR$$M$Y$$$20221209$$HP$GB$GB
170836033$17083603$3$F$$20221201$20191127$20221205$PER$$US-BIOGEN-2019BI00809257$BIOGEN$$$$$M$Y$$$20221205$$CN$US$US
170837247$17083724$7$F$20190101$20221116$20191127$20221123$PER$$US-VERTEX PHARMACEUTICALS-2019-011757$VERTEX$$$$$F$Y$$$20221123$$CN$US$US
170837883$17083788$3$F$20191007$20221124$20191127$20221128$EXP$$PHHY2018CA005801$NOVARTIS$$50$YR$$F$Y$$$20221129$$MD$CA$CA
1708419516$17084195$16$F$20190101$20221031$20191127$20221107$EXP$$CA-BAUSCH-BL-2019-062680$BAUSCH AND LOMB$$55$YR$$F$Y$83.99$KG$20221107$$CN$CA$CA
170843585$17084358$5$F$$20221220$20191127$20221226$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR150815$GLAXOSMITHKLINE$$$$$$Y$$$20221226$$HP$CA$CA
170852962$17085296$2$F$$20191121$20191128$20221102$EXP$$US-JNJFOC-20191138362$JOHNSON AND JOHNSON$$$$$$Y$$$20221102$$CN$US$US
170856332$17085633$2$F$20191113$20221031$20191128$20221105$EXP$$NVSC2019CA045157$NOVARTIS$$72$YR$$M$Y$$$20221105$$CN$CA$CA
170857162$17085716$2$F$$20221207$20191128$20221221$EXP$$SG-ALKEM LABORATORIES LIMITED-SG-ALKEM-2018-11523$ALKEM$Yip L, Dart RC and Graham K.. Olanzapine toxicity in a toddler.. Pediatrics.. 1998;102(6):1494$30$MON$$M$Y$13.5$KG$20221221$$HP$SG$SG
170857222$17085722$2$F$$20221207$20191128$20221221$EXP$$SG-ALKEM LABORATORIES LIMITED-SG-ALKEM-2018-11521$ALKEM$Catalano G, Cooper DS, Catalano MC and Butera AS.. Olanzapine overdose in an 18-month-old child. J Child Adolesc Psychopharmacol.. 1999;9:267-271$18$MON$$M$Y$11$KG$20221221$$HP$SG$SG
170871555$17087155$5$F$$20221202$20191128$20221209$EXP$$US-SHIRE-US201941001$TAKEDA$$$$$F$Y$86.16$KG$20221209$$MD$US$US
170872105$17087210$5$F$20190101$20221026$20191128$20221102$EXP$$US-UNITED THERAPEUTICS-UNT-2019-018507$UNITED THERAPEUTICS$$$$$M$Y$127.44$KG$20221102$$MD$US$US
170873609$17087360$9$F$20191201$20221128$20191128$20221201$EXP$$US-PFIZER INC-2019515420$PFIZER$$81$YR$$F$Y$63.492$KG$20221201$$CN$US$US
170881514$17088151$4$F$20190101$20221006$20191128$20221011$EXP$$US-PFIZER INC-2019512329$PFIZER$$75$YR$$F$Y$$$20221011$$CN$US$US
170882627$17088262$7$F$20180419$20220929$20191128$20221005$EXP$$CA-TAKEDA-2019TUS067458$TAKEDA$$64$YR$$F$Y$$$20221005$$MD$CA$CA
170883917$17088391$7$F$$20221102$20191128$20221119$EXP$$CA-ROCHE-2475266$ROCHE$$54$YR$$F$Y$90$KG$20221119$$HP$CA$
170884369$17088436$9$F$20190722$20221026$20191128$20221101$EXP$$NVSJ2019JP004363$NOVARTIS$$43$YR$$F$Y$$$20221101$$MD$JP$JP
170885035$17088503$5$F$20180101$20221121$20191128$20221129$EXP$$PHHY2017CA158369$NOVARTIS$$39$YR$$F$Y$$$20221129$$CN$CA$CA
1708892813$17088928$13$F$$20221207$20191128$20221215$EXP$$US-SHIRE-US201939950$TAKEDA$$$$$F$Y$107$KG$20221215$$MD$US$US
170889364$17088936$4$F$$20221004$20191128$20221010$EXP$$US-SHIRE-US201939861$TAKEDA$$$$$F$Y$57.596$KG$20221010$$CN$US$US
170889527$17088952$7$F$20191112$20221129$20191128$20221205$EXP$$US-SHIRE-US201940293$TAKEDA$$67$YR$$F$Y$53$KG$20221205$$HP$US$US
170893106$17089310$6$F$$20221018$20191128$20221024$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-113883$BRISTOL MYERS SQUIBB$$40$YR$A$M$Y$$$20221024$$MD$JP$JP
170893835$17089383$5$F$$20221120$20191128$20221123$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR211430$GLAXOSMITHKLINE$$$$$$Y$$$20221123$$MD$CA$CA
170894095$17089409$5$F$20220601$20221205$20191128$20221219$PER$$AU-TOLMAR, INC.-19AU000929$TOLMAR$$90$YR$$M$Y$$$20221219$$HP$AU$AU
1708942411$17089424$11$F$20190101$20221219$20191128$20221226$EXP$$GB-JAZZ-2019-US-016237$JAZZ$$$$$M$Y$$$20221226$$CN$US$US
170913392$17091339$2$F$$20221028$20191129$20221101$PER$$US-SHIRE-US201941114$TAKEDA$$$$$F$Y$83.9$KG$20221101$$HP$US$US
170926144$17092614$4$F$$20221013$20191129$20221021$EXP$$CA-APOTEX-2019AP025442$APOTEX$$53$YR$$F$Y$$$20221021$$HP$CA$CA
1709321630$17093216$30$F$20190101$20221031$20191129$20221108$EXP$$CA-CELLTRION INC.-2019CA026882$CELLTRION$$$$$$Y$$$20221108$$CN$CA$CA
170933992$17093399$2$F$$20191122$20191129$20221110$EXP$$NVSC2019FR050374$NOVARTIS$Arcani R, Venton G, Colle J, Suchon P, Ivanov V, Mercier C et al.. Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone. EUROPEAN JOURNAL OF HAEMATOLOGY. 2019;103:385-92$50$YR$$F$Y$$$20221110$$HP$FR$FR
170937344$17093734$4$F$20180214$20221116$20191129$20221124$EXP$$PHHY2018CA031316$NOVARTIS$$27$YR$$F$Y$$$20221124$$CN$CA$CA
170941035$17094103$5$F$20181106$20221209$20191129$20221213$EXP$$JP-ABBVIE-19P-087-3175520-00$ABBVIE$$76$YR$$M$Y$$$20221213$$MD$JP$JP
1709439729$17094397$29$F$20200108$20221213$20191129$20221221$EXP$$CA-CELLTRION INC.-2019CA021786$CELLTRION$$$$$$Y$$$20221221$$MD$CA$CA
170944003$17094400$3$F$$20221205$20191129$20221208$EXP$$AU-SHIRE-AU201941242$TAKEDA$$$$$F$Y$$$20221208$$HP$AU$AU
1709474212$17094742$12$F$20190801$20221207$20191130$20221215$EXP$$CA-TAKEDA-2019TUS050123$TAKEDA$$47$YR$$F$Y$$$20221215$$HP$CA$CA
170956048$17095604$8$F$$20221007$20191201$20221014$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-35058$SAMSUNG BIOEPIS$$78$YR$E$F$Y$68$KG$20221014$$HP$CA$CA
170959472$17095947$2$F$20190610$20221206$20191202$20221216$PER$$GB-AMGEN-GBRSP2019197207$AMGEN$$57$YR$A$M$Y$$$20221216$$HP$GB$GB
170977513$17097751$3$F$20191101$20221219$20191202$20221224$EXP$$NVSC2019CA054222$NOVARTIS$$$$A$M$Y$$$20221224$$CN$CA$CA
1709843110$17098431$10$F$20190701$20221027$20191202$20221102$PER$$US-PFIZER INC-2019434176$PFIZER$$72$YR$$F$Y$59$KG$20221102$$CN$US$US
170993775$17099377$5$F$$20221220$20191202$20221227$PER$$US-PFIZER INC-2019516160$PFIZER$$63$YR$$F$Y$$$20221227$$MD$US$US
170994004$17099400$4$F$20190101$20221117$20191202$20221122$PER$$US-PFIZER INC-2019516665$PFIZER$$75$YR$$M$Y$$$20221122$$HP$US$US
170994025$17099402$5$F$$20221128$20191202$20221129$EXP$$US-PFIZER INC-2019515720$PFIZER$$68$YR$$M$Y$$$20221129$$MD$US$US
1709944410$17099444$10$F$$20221220$20191202$20221228$EXP$$US-PFIZER INC-2019515805$PFIZER$$73$YR$$M$Y$$$20221228$$CN$US$US
170994925$17099492$5$F$20191110$20221213$20191202$20221219$PER$$US-PFIZER INC-2019516593$PFIZER$$65$YR$$M$Y$80.29$KG$20221219$$CN$US$US
170997846$17099784$6$F$20120101$20221009$20191202$20221011$PER$$US-PFIZER INC-2019519975$PFIZER$$57$YR$$F$Y$$$20221011$$LW$US$US
171005792$17100579$2$F$$20221102$20191202$20221107$PER$$US-JNJFOC-20191142253$JOHNSON AND JOHNSON$$$$$M$Y$$$20221107$$LW$US$US
171008162$17100816$2$F$$20221221$20191202$20221227$PER$$US-JNJFOC-20191140098$JOHNSON AND JOHNSON$$$$$M$Y$$$20221227$$LW$US$US
171008172$17100817$2$F$$20221121$20191202$20221129$PER$$US-JNJFOC-20191140140$JOHNSON AND JOHNSON$$$$$M$Y$$$20221129$$LW$US$US
171008383$17100838$3$F$20100101$20220926$20191202$20221005$PER$$US-JNJFOC-20191140297$JOHNSON AND JOHNSON$$10$YR$C$M$Y$$$20221005$$LW$US$US
1710092517$17100925$17$F$20200101$20221013$20191202$20221019$PER$$US-SA-2019SA330863$SANOFI AVENTIS$$60$YR$A$F$Y$$$20221019$$MD$US$US
171014863$17101486$3$F$$20221003$20191202$20221012$EXP$$PL-MYLANLABS-2019M1116144$MYLAN$Siejko A, Kuzma-Mroczkowska E, Panczyk-Tomaszewska M. Trudnosci w leczeniu dziecka ze steroidozaleznym idiopatycznym zespolem nerczycowym.. PRZEGLAD LEKARSKI. 2019;76 (5):295-298$10$YR$$M$Y$$$20221012$$HP$PL$PL
171017336$17101733$6$F$20211105$20221103$20191202$20221107$EXP$$US-SHIRE-US201940437$TAKEDA$$69$YR$$M$Y$80.2$KG$20221107$$CN$US$US
171024948$17102494$8$F$20190917$20221115$20191202$20221117$EXP$$PHHY2019DE218305$NOVARTIS$$$$A$F$Y$51$KG$20221117$$MD$DE$DE
171026453$17102645$3$F$$20220930$20191202$20221005$PER$$NVSC2019US003492$NOVARTIS$$$$$F$Y$$$20221005$$CN$US$US
1710361814$17103618$14$F$20190509$20221102$20191203$20221108$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-115267$BRISTOL MYERS SQUIBB$Yoshikawa S, et al. A case of pancreatic immune-related adverse event which formed multiple pancreatic necrosis and pancreatic fistula. Pancreas. 2022; 37(3): A501-2.$68$YR$E$M$Y$$$20221108$$MD$JP$JP
1710374566$17103745$66$F$$20221031$20191203$20221107$EXP$GB-LICONSA-2019-006355$GB-STRIDES ARCOLAB LIMITED-2019SP012208$STRIDES$$7$YR$$M$Y$$$20221107$$MD$GB$GB
1710504512$17105045$12$F$20191121$20221031$20191203$20221109$EXP$$CA-TAKEDA-2019TUS062830$TAKEDA$$17$YR$$F$Y$$$20221109$$CN$CA$CA
171064665$17106466$5$F$20210701$20221004$20191203$20221006$PER$$US-PFIZER INC-2019520837$PFIZER$$61$YR$$F$Y$61.224$KG$20221006$$CN$US$US
171064972$17106497$2$F$$20221031$20191203$20221103$PER$$US-PFIZER INC-2019520921$PFIZER$$66$YR$$F$Y$$$20221103$$HP$US$US
171066082$17106608$2$F$$20221219$20191203$20221230$PER$$US-PFIZER INC-2019520234$PFIZER$$58$YR$$F$Y$$$20221230$$HP$US$US
171073187$17107318$7$F$20221001$20221108$20191203$20221114$EXP$$US-PFIZER INC-2019518169$PFIZER$$72$YR$$F$Y$$$20221114$$CN$US$US
171075283$17107528$3$F$$20220923$20191203$20221006$EXP$$PL-PFIZER INC-2019515342$PFIZER$Kryszczyszyn-musialik, K.. Hodgkin^s lymphoma with multifocal Staphylococcus aureus infection in a 29-years-old male - a case study. Onkologia w Praktyce Klinicznej - Edukacja. 2019;5 (4):280-285$29$YR$$M$Y$$$20221006$$MD$PL$PL
171079993$17107999$3$F$20191126$20221118$20191203$20221130$EXP$$CN-ELI_LILLY_AND_COMPANY-CN201911013898$ELI LILLY AND CO$$85$YR$$M$Y$82.5$KG$20221130$$CN$CN$CN
171080662$17108066$2$F$$20221121$20191203$20221205$EXP$$CA-MAYNE PHARMA-2019MYN000850$MAYNE$$$$$$Y$$$20221205$$MD$CA$CA
171088032$17108803$2$F$20191015$20220929$20191204$20221004$EXP$ES-AEMPS-566235$ES-SA-2019SA328684$SANOFI AVENTIS$$48$YR$A$M$Y$$$20221004$$MD$ES$ES
1710904216$17109042$16$F$20180101$20221214$20191203$20221223$EXP$$CA-CELLTRION INC.-2018CA023082$CELLTRION$$$$$$Y$$$20221223$$CN$CA$CA
171090913$17109091$3$F$$20221130$20191204$20221202$PER$$US-BIOGEN-2014BI028102$BIOGEN$$$$$F$Y$$$20221202$$CN$US$US
171106874$17110687$4$F$$20221222$20191204$20221230$PER$$US-PFIZER INC-2019524403$PFIZER$$70$YR$$F$Y$$$20221230$$CN$US$US
171108568$17110856$8$F$20191218$20221223$20191204$20221229$EXP$$NVSC2019CA057381$NOVARTIS$$67$YR$$F$Y$$$20221229$$CN$CA$CA
171113723$17111372$3$F$$20201208$20191204$20221117$EXP$$JP-INCYTE CORPORATION-2019IN012201$INCYTE$$$$$$Y$$$20221117$$MD$JP$JP
171118423$17111842$3$F$20191122$20221024$20191204$20221101$PER$$US-SA-2019SA332091$SANOFI AVENTIS$$49$YR$A$F$Y$$$20221101$$MD$US$US
171120602$17112060$2$F$$20221205$20191204$20221219$EXP$$CO-INCYTE CORPORATION-2019IN011459$INCYTE$$$$$$Y$$$20221219$$CN$CO$CO
171128393$17112839$3$F$20191107$20191126$20191204$20221201$EXP$$NVSC2019US051148$NOVARTIS$$74$YR$$F$Y$$$20221201$$CN$US$US
171128558$17112855$8$F$20190101$20221104$20191204$20221110$EXP$$NVSC2019DE053908$NOVARTIS$$69$YR$$M$Y$105$KG$20221110$$CN$DE$DE
171131125$17113112$5$F$$20221220$20191204$20221229$PER$$US-AMGEN-USASP2019200993$AMGEN$$66$YR$E$F$Y$$$20221228$$CN$US$US
1711315724$17113157$24$F$20171221$20221212$20191204$20221219$EXP$$CA-CELLTRION INC.-2017CA017456$CELLTRION$$$$$$Y$$$20221219$$MD$CA$CA
1711376918$17113769$18$F$20190318$20221129$20191205$20221207$EXP$$CA-CELLTRION INC.-2018CA024353$CELLTRION$$$$$$Y$$$20221208$$CN$CA$CA
1711377021$17113770$21$F$20180327$20221116$20191205$20221123$EXP$$CA-CELLTRION INC.-2018CA019352$CELLTRION$$$$$$Y$$$20221123$$CN$CA$CA
171139876$17113987$6$F$$20210428$20191205$20221125$EXP$$US-ROCHE-2491782$ROCHE$Barnes A, Iyer M, Rathbun S, Yeh S, Bergstrom C and Hubbar G Management of a cluster of endophthalmitis cases due to nutritionally variant streptococcus following intravitreal bevacizumab. Investigative Ophthalmology and Visual Science 2019 Jul;60 (9):-.$85$YR$$M$Y$$$20221125$$HP$US$
171140026$17114002$6$F$$20210428$20191205$20221129$EXP$$US-ROCHE-2491790$ROCHE$Barnes A, Iyer M, Rathbun S, Yeh S, Bergstrom C and Hubbar G Management of a cluster of endophthalmitis cases due to nutritionally variant streptococcus following intravitreal bevacizumab. Investigative Ophthalmology and Visual Science 2019 Jul;60 (9):-.$62$YR$$F$Y$$$20221129$$HP$US$
171140036$17114003$6$F$$20210428$20191205$20221128$EXP$$US-ROCHE-2491787$ROCHE$Barnes A, Iyer M, Rathbun S, Yeh S, Bergstrom C and Hubbar G Management of a cluster of endophthalmitis cases due to nutritionally variant streptococcus following intravitreal bevacizumab.. Investigative Ophthalmology and Visual Science 2019 Jul;60 (9):-.$84$YR$$M$Y$$$20221128$$HP$US$
171140046$17114004$6$F$$20210428$20191205$20221125$EXP$$US-ROCHE-2490359$ROCHE$Barnes A, Iyer M, Rathbun S, Yeh S, Bergstrom C and Hubbar G Management of a cluster of endophthalmitis cases due to nutritionally variant streptococcus following intravitreal bevacizumab. Investigative Ophthalmology and Visual Science 2019 Jul;60 (9):-.$74$YR$$F$Y$$$20221125$$HP$US$
171153002$17115300$2$F$$20221205$20191205$20221209$EXP$$US-GW PHARMA-201910USGW3755$JAZZ$$$$$$Y$$$20221209$$CN$US$US
1711544114$17115441$14$F$20120206$20221123$20191205$20221129$EXP$$PHHY2017CO043126$NOVARTIS$$61$YR$$F$Y$69$KG$20221129$$CN$CO$CO
171155663$17115566$3$F$20190101$20221103$20191205$20221108$EXP$$CA-TAKEDA-2019TUS068841$TAKEDA$$69$YR$$M$Y$$$20221108$$CN$CA$CA
171158944$17115894$4$F$$20221121$20191205$20221123$PER$$US-PFIZER INC-2019496099$PFIZER$$73$YR$$F$Y$65.76$KG$20221123$$CN$US$US
1711627213$17116272$13$F$19880101$20221010$20191205$20221014$EXP$$US-PFIZER INC-2019155957$PFIZER$$67$YR$$F$Y$62.6$KG$20221014$$CN$US$US
171164078$17116407$8$F$20150101$20221121$20191205$20221201$EXP$$CZ-MYLANLABS-2019M1118705$MYLAN$Kamasova, M.. Fixed triple combination therapy of antihypertensive drugs in common clinical practice.. Farmakoter Revue. 2019;4(3):400-402$54$YR$$F$Y$$$20221201$$HP$CZ$CZ
171178585$17117858$5$F$20190801$20221115$20191205$20221123$PER$$CA-TOLMAR, INC.-19CA000841$TOLMAR$$68$YR$$M$Y$$$20221123$$CN$CA$CA
171182984$17118298$4$F$$20221114$20191205$20221124$EXP$$US-JAZZ-2019-US-016795$JAZZ$$$$$M$Y$$$20221124$$HP$US$US
171187862$17118786$2$F$20170428$20221115$20191206$20221123$EXP$$DE-CIPLA LTD.-2019DE07858$CIPLA$$55$YR$$F$Y$$$20221123$$MD$DE$DE
171194352$17119435$2$F$20190901$20191128$20191206$20221220$PER$$US-TEVA-2019-US-1147965$TEVA$$82$YR$E$F$Y$68.1$KG$20221220$$CN$US$US
171194694$17119469$4$F$20190101$20200207$20191206$20221209$PER$$US-AMGEN-USASP2019202615$AMGEN$$72$YR$E$F$Y$$$20221209$$CN$US$US
1712004318$17120043$18$F$20190901$20221025$20191206$20221102$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-116594$BRISTOL MYERS SQUIBB$Nakayama S, et al. A case of pure red cell aplasia developing during nivolumab/ipilimumab therapy for renal cancer. The 243rd Kansai Regional Meeting of The Japanese Urological Association 2020:8.$54$YR$A$F$Y$49$KG$20221103$$MD$JP$JP
171200966$17120096$6$F$20210108$20221208$20191206$20221217$EXP$$US-SHIRE-US201942043$TAKEDA$$51$YR$$F$Y$113$KG$20221217$$MD$US$US
171214195$17121419$5$F$20190701$20221011$20191206$20221021$EXP$FR-AFSSAPS-CN20190930$FR-MYLANLABS-2019M1119289$MYLAN$$54$YR$$M$Y$87.5$KG$20221021$$MD$FR$FR
171216016$17121601$6$F$20190101$20221220$20191206$20221227$EXP$$PHHY2014CH103912$NOVARTIS$$$$A$F$Y$$$20221227$$PH$CH$CH
171218753$17121875$3$F$$20221102$20191206$20221104$EXP$$US-PFIZER INC-2019523415$PFIZER$$66$YR$$F$Y$$$20221104$$CN$US$US
171224412$17122441$2$F$20190101$20221116$20191206$20221122$EXP$$DE-PFIZER INC-2019521885$PFIZER$$$$$F$Y$$$20221122$$MD$DE$DE
171229506$17122950$6$F$$20220927$20191206$20221003$EXP$$CA-TAKEDA-2018TUS024344$TAKEDA$$60$YR$$F$Y$$$20221003$$CN$CA$CA
171229954$17122995$4$F$20180101$20221101$20191206$20221104$EXP$$PHHY2018CA004736$NOVARTIS$$$$$F$Y$$$20221104$$HP$CA$CA
171233712$17123371$2$F$$20221212$20191206$20221216$EXP$$US-JAZZ-2019-US-016907$JAZZ$$$$$F$Y$$$20221216$$MD$US$US
171239526$17123952$6$F$20191222$20221013$20191206$20221019$EXP$$US-INCYTE CORPORATION-2019IN010860$INCYTE$$$$$$Y$$$20221019$$MD$US$US
171248322$17124832$2$F$20190101$20221207$20191206$20221213$EXP$$US-ARBOR PHARMACEUTICALS, LLC-US-2019ARB001651$ARBOR$$$$$M$Y$$$20221213$$CN$US$US
1712531433$17125314$33$F$20191130$20221017$20191207$20221025$EXP$$CA-CELLTRION INC.-2019CA026525$CELLTRION$$$$$$Y$$$20221026$$MD$CA$CA
171253658$17125365$8$F$20190927$20221017$20191207$20221027$EXP$$DE-AUROBINDO-AUR-APL-2019-103592$AUROBINDO$$85$YR$$F$Y$55$KG$20221027$$MD$DE$DE
171273743$17127374$3$F$20140128$20221110$20191209$20221124$EXP$$SE-AUROBINDO-AUR-APL-2019-103782$AUROBINDO$$71$YR$$F$Y$$$20221124$$HP$SE$SE
171275875$17127587$5$F$$20221004$20191209$20221015$EXP$GB-EMA-DD-20191118-SAHU_K-153115$GB-Accord-163401$ACCORD$$55$YR$A$M$Y$$$20221015$$MD$GB$GB
171285544$17128554$4$F$20191128$20220930$20191209$20221012$EXP$$CH-ELI_LILLY_AND_COMPANY-CH201912001659$ELI LILLY AND CO$$66$YR$$F$Y$$$20221012$$CN$CH$CH
171287682$17128768$2$F$20190101$20221103$20191209$20221115$EXP$$CA-ABBVIE-19K-028-3184052-00$ABBVIE$$$$$F$Y$$$20221108$$CN$CA$CA
1712923511$17129235$11$F$20170801$20221003$20191209$20221010$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-095931$BRISTOL MYERS SQUIBB$$73$YR$E$F$Y$52.1$KG$20221010$$MD$JP$JP
171293867$17129386$7$F$$20221219$20191209$20221222$EXP$$US-PFIZER INC-2019528123$PFIZER$$75$YR$$F$Y$74.83$KG$20221222$$CN$US$US
171294882$17129488$2$F$$20221123$20191209$20221128$PER$$US-PFIZER INC-2019527560$PFIZER$$59$YR$$F$Y$$$20221128$$MD$US$US
171294935$17129493$5$F$20190101$20221107$20191209$20221114$EXP$$US-PFIZER INC-2019527142$PFIZER$$69$YR$$F$Y$56.689$KG$20221114$$CN$US$US
171295195$17129519$5$F$$20221027$20191209$20221031$PER$$US-PFIZER INC-2019528979$PFIZER$$82$YR$$F$Y$$$20221031$$CN$US$US
171297869$17129786$9$F$$20221215$20191209$20221222$EXP$$US-TAKEDA-2019TUS062985$TAKEDA$$$$$F$Y$$$20221222$$CN$US$US
171303483$17130348$3$F$20190807$20221020$20191209$20221101$PER$$AU-TOLMAR, INC.-19AU001054$TOLMAR$$71$YR$$M$Y$$$20221031$$HP$AU$AU
171304895$17130489$5$F$$20221212$20191209$20221219$EXP$$US-SHIRE-US201941247$TAKEDA$$$$$F$Y$83$KG$20221219$$CN$US$US
1713049713$17130497$13$F$20200103$20221111$20191209$20221121$EXP$$US-SHIRE-US201941934$TAKEDA$$66$YR$$F$Y$54$KG$20221121$$CN$US$US
1713056518$17130565$18$F$20191124$20221011$20191209$20221013$EXP$$CN-ROCHE-2484890$ROCHE$$63$YR$$F$Y$45$KG$20221013$$MD$CN$
171306624$17130662$4$F$20191126$20221110$20191209$20221116$EXP$$JP-009507513-1912JPN000582J$MERCK$Hori N, Oishi M, Hamasaki A, Mizuno K, Yamamura M, Onodera M. P14-5 Two cases of BRAF mutation positive and MSI-H unresectable advanced recurrent large intestine carcinoma in which pembrolizumab showed significant effect. The 60th Annual Meeting of Japan Society of Clinical Oncology. 2022;1333$70$YR$$F$Y$$$20221116$$MD$JP$JP
171308906$17130890$6$F$20190101$20221215$20191209$20221215$PER$$US-PFIZER INC-2019527089$PFIZER$$7$YR$$M$Y$46.2$KG$20221215$$HP$US$US
171312242$17131224$2$F$$20221219$20191209$20221221$EXP$RO-FMX-PRM-05-LIT$NVSC2019RO049911$NOVARTIS$Sandulescu O, Streinu-Cercel A, Oana AA. Repeated systemic infections unveiling a silent colon cancer. ROMANIAN ARCHIVES OF MICROBIOLOGY AND IMMUNOLOGY. 2018;77(4):301-4$72$YR$$F$Y$$$20221221$$HP$RO$RO
171329452$17132945$2$F$20190101$20191203$20191210$20221202$EXP$$SG-ABBVIE-19P-141-3184343-00$ABBVIE$$$$$M$Y$$$20221202$$MD$SG$SG
1713336819$17133368$19$F$20190730$20221208$20191210$20221208$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-118263$BRISTOL MYERS SQUIBB$$60$YR$A$F$Y$52.5$KG$20221209$$MD$JP$JP
1713402027$17134020$27$F$$20221123$20191210$20221206$EXP$$GB-AUROBINDO-AUR-APL-2019-103963$AUROBINDO$$7$YR$$M$Y$$$20221206$$MD$GB$GB
171343072$17134307$2$F$20191204$20191204$20191210$20221129$PER$$US-AMGEN INC.-USASP2019203855$AMGEN$$$$A$F$Y$$$20221129$$PH$US$US
171350235$17135023$5$F$$20221025$20191210$20221102$EXP$$DE-Noden Pharma DAC-NOD-2019-000188$NODEN PHARMA$$74$YR$E$F$Y$$$20221101$$MD$DE$
171352002$17135200$2$F$$20221013$20191210$20221020$EXP$$DE-Noden Pharma DAC-NOD-2019-000187$NODEN PHARMA$$81$YR$E$F$Y$$$20221020$$MD$DE$
1713574029$17135740$29$F$$20221212$20191210$20221229$EXP$$CA-PFIZER INC-2019532008$GLAXOSMITHKLINE$$$$$$Y$$$20221229$$MD$CA$CA
171359573$17135957$3$F$20190101$20221024$20191210$20221026$EXP$$US-PFIZER INC-2019397247$PFIZER$Rubin, D.. Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. Alimentary Pharmacology and Therapeutics. 2021;1-9$73$YR$$M$Y$$$20221026$$HP$US$US
171371762$17137176$2$F$20190420$20221115$20191210$20221117$EXP$$FR-PFIZER INC-2019369394$PFIZER$$80$YR$$F$Y$64$KG$20221117$$MD$FR$FR
1713734319$17137343$19$F$20181110$20221221$20191210$20221230$EXP$$CA-CELLTRION INC.-2018CA024006$CELLTRION$$$$$$Y$$$20221230$$HP$CA$CA
171381772$17138177$2$F$20190601$20220118$20191211$20221013$PER$$US-AUROBINDO-AUR-APL-2019-072052$AUROBINDO$$77$YR$$F$Y$$$20221013$$CN$US$US
1713940011$17139400$11$F$20170101$20221104$20191211$20221107$PER$$US-GILEAD-2019-0441931$GILEAD$$$$A$M$Y$$$20221107$$LW$US$US
171396618$17139661$8$F$20191029$20221206$20191211$20221208$EXP$$US-ROCHE-2491783$ROCHE$$65$YR$$F$Y$84.9$KG$20221208$$MD$US$
171402304$17140230$4$F$20191101$20221125$20191211$20221203$EXP$$NVSC2019CO062042$NOVARTIS$$35$YR$$F$Y$61$KG$20221203$$CN$CO$CO
171406745$17140674$5$F$20151101$20201112$20191211$20221021$EXP$$NVSC2019HU062621$NOVARTIS$$33$YR$$F$Y$$$20221021$$MD$HU$HU
171410554$17141055$4$F$$20221205$20191211$20221207$PER$$US-PFIZER INC-2019534021$PFIZER$$69$YR$$F$Y$$$20221207$$HP$US$US
171413218$17141321$8$F$20190710$20221116$20191211$20221122$EXP$$ES-SA-2019SA206290$SANOFI AVENTIS$$29$YR$A$F$Y$47$KG$20221122$$HP$ES$ES
171415412$17141541$2$F$$20221025$20191211$20221028$EXP$$HU-UCBSA-2019052628$UCB$$60$YR$$F$Y$$$20221028$$HP$HU$HU
1714168811$17141688$11$F$20190101$20221026$20191211$20221101$EXP$$US-SA-2019SA338671$SANOFI AVENTIS$$42$YR$A$F$Y$$$20221101$$MD$US$US
171418529$17141852$9$F$20141023$20221006$20191211$20221011$EXP$$PHHY2014CA140784$NOVARTIS$$30$YR$$M$Y$$$20221011$$HP$CA$CA
171422274$17142227$4$F$20190916$20221027$20191211$20221101$EXP$$FR-PFIZER INC-2019532211$PFIZER$$74$YR$$F$Y$90$KG$20221101$$MD$FR$FR
171422766$17142276$6$F$$20221003$20191211$20221006$EXP$$US-SHIRE-US201942257$TAKEDA$$$$$M$Y$80.7$KG$20221006$$HP$US$US
171423047$17142304$7$F$20191022$20221017$20191211$20221024$EXP$$US-INCYTE CORPORATION-2019IN010824$INCYTE$$$$$$Y$$$20221024$$CN$US$US
1714370814$17143708$14$F$$20221212$20191212$20221216$PER$$US-PFIZER INC-2019532617$PFIZER$$67$YR$$F$Y$$$20221216$$CN$US$US
1714372410$17143724$10$F$$20221207$20191212$20221215$PER$$US-PFIZER INC-2019513711$PFIZER$$77$YR$$F$Y$$$20221215$$MD$US$US
171439084$17143908$4$F$20191001$20220930$20191211$20221006$EXP$$DE-ABBVIE-19K-062-3186580-00$ABBVIE$$79$YR$$M$Y$72$KG$20221006$$MD$DE$DE
171441674$17144167$4$F$20191101$20200225$20191211$20221102$EXP$$NVSJ2019JP004958$NOVARTIS$$$$$F$Y$$$20221102$$MD$JP$JP
171444994$17144499$4$F$20191023$20221103$20191212$20221110$EXP$$US-BIOGEN-2019BI00813908$BIOGEN$$40$YR$$F$Y$$$20221110$$HP$US$US
171449605$17144960$5$F$20190529$20221219$20191212$20221226$PER$$US-SA-2019SA342026$SANOFI AVENTIS$$35$YR$A$F$Y$$$20221226$$MD$US$US
171450558$17145055$8$F$20190101$20221007$20191212$20221013$EXP$$NL-ABBVIE-19S-114-2776898-00$ABBVIE$$$$$F$Y$54$KG$20221013$$HP$NL$NL
1714532715$17145327$15$F$20170626$20221021$20191212$20221102$EXP$$PHHY2017CA097050$NOVARTIS$$80$YR$$M$Y$56$KG$20221102$$HP$CA$CA
171464695$17146469$5$F$20190228$20221110$20191212$20221115$EXP$$NVSC2019CH064100$NOVARTIS$$$$A$F$Y$$$20221115$$CN$CH$CH
171466105$17146610$5$F$20191209$20221226$20191212$20221230$EXP$$US-BIOGEN-2019BI00816977$BIOGEN$$37$YR$$F$Y$$$20221230$$CN$US$US
171473636$17147363$6$F$$20221122$20191212$20221126$EXP$$US-SHIRE-US201942634$TAKEDA$$$$$M$Y$$$20221126$$MD$US$US
1714737113$17147371$13$F$20200201$20221219$20191212$20221226$EXP$$US-SHIRE-US201941710$TAKEDA$$14$YR$$F$Y$95$KG$20221226$$HP$US$US
171481675$17148167$5$F$$20221011$20191212$20221013$PER$$NVSC2019US013118$NOVARTIS$$$$$M$Y$$$20221013$$CN$US$US
1714917112$17149171$12$F$$20221010$20191213$20221012$EXP$$US-SHIRE-US201943176$TAKEDA$$$$$F$Y$$$20221012$$CN$US$US
171501315$17150131$5$F$20191101$20220923$20191213$20221003$EXP$$PHHY2019CA075887$NOVARTIS$$64$YR$$F$Y$$$20221003$$CN$CA$CA
171510738$17151073$8$F$$20221214$20191213$20221220$EXP$$BR-GLAXOSMITHKLINE-BR2019AMR113919$GLAXOSMITHKLINE$$$$$$Y$$$20221220$$CN$BR$BR
171512359$17151235$9$F$$20221216$20191213$20221221$EXP$$US-PFIZER INC-2019536050$PFIZER$$61$YR$$F$Y$102$KG$20221221$$CN$US$US
171512377$17151237$7$F$$20221209$20191213$20221214$PER$$US-PFIZER INC-2019536995$PFIZER$$78$YR$$F$Y$$$20221214$$HP$US$US
171513145$17151314$5$F$$20221220$20191213$20221227$PER$$US-PFIZER INC-2019537033$PFIZER$$83$YR$$F$Y$$$20221227$$CN$US$US
171513434$17151343$4$F$$20221206$20191213$20221209$EXP$$US-PFIZER INC-2019539245$PFIZER$$65$YR$$F$Y$$$20221209$$CN$US$US
1715141018$17151410$18$F$20191207$20221116$20191213$20221121$EXP$$JP-ROCHE-2494706$ROCHE$$68$YR$$M$Y$71.2$KG$20221121$$MD$JP$
171525955$17152595$5$F$$20221006$20191213$20221010$EXP$$PHHY2018CA039120$NOVARTIS$$$$$F$Y$$$20221010$$CN$CA$CA
171529697$17152969$7$F$20181022$20221214$20191213$20221220$EXP$$DE-MYLANLABS-2019M1122702$MYLAN$$$$E$M$Y$$$20221220$$MD$DE$DE
171530417$17153041$7$F$20171220$20221219$20191213$20221227$EXP$$DE-MYLANLABS-2019M1122799$MYLAN$$$$A$F$Y$$$20221227$$MD$DE$DE
171531583$17153158$3$F$20180803$20221117$20191213$20221121$EXP$$US-INCYTE CORPORATION-2019IN012182$INCYTE$$$$$$Y$$$20221122$$CN$US$US
1715396140$17153961$40$F$20190101$20221103$20191213$20221112$EXP$$CA-CELLTRION INC.-2019CA026944$CELLTRION$$$$$$Y$$$20221112$$MD$CA$CA
1715397915$17153979$15$F$20181119$20221026$20191213$20221103$EXP$$CA-CELLTRION INC.-2018CA024369$CELLTRION$$$$$$Y$$$20221104$$CN$CA$CA
171545962$17154596$2$F$$20221025$20191214$20221101$EXP$$CA-JNJFOC-20191215082$JOHNSON AND JOHNSON$$$$$F$Y$$$20221101$$HP$CA$CA
171547075$17154707$5$F$$20221215$20191214$20221222$EXP$$US-SHIRE-US201943102$TAKEDA$$$$$F$Y$79$KG$20221222$$HP$US$US
171548055$17154805$5$F$20220123$20221003$20191214$20221010$EXP$$US-TAKEDA-2019TUS070484$TAKEDA$$72$YR$$F$Y$64$KG$20221010$$MD$US$US
171552662$17155266$2$F$$20221010$20191215$20221014$EXP$$US-BIOGEN-2019BI00816864$BIOGEN$$$$$F$Y$$$20221014$$CN$US$US
171555115$17155511$5$F$20181220$20221021$20191215$20221024$EXP$$DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-118573$BRISTOL MYERS SQUIBB$$59$YR$A$F$Y$$$20221024$$MD$DE$DE
171558564$17155856$4$F$20191128$20221005$20191215$20221016$EXP$$JP-ROCHE-2495576$ROCHE$$49$YR$$M$Y$67$KG$20221016$$MD$JP$JP
1715669822$17156698$22$F$$20221004$20191216$20221010$EXP$$GB-AUROBINDO-AUR-APL-2019-104872$AUROBINDO$$7$YR$$M$Y$$$20221010$$PH$GB$GB
171571093$17157109$3$F$20190704$20221118$20191216$20221201$EXP$DE-EMA-DD-20191203-SHUKLA_V-112242$DE-Accord-164949$ACCORD$$67$YR$$F$Y$85$KG$20221201$$MD$DE$DE
171573467$17157346$7$F$$20221026$20191216$20221101$EXP$$US-SHIRE-US201942858$TAKEDA$$$$$F$Y$96.14$KG$20221101$$HP$US$US
171573712$17157371$2$F$20180901$20221129$20191216$20221205$EXP$$PHHY2018IN106354$NOVARTIS$$57$YR$$M$Y$74$KG$20221205$$CN$IN$IN
1715744814$17157448$14$F$20190807$20221108$20191216$20221116$EXP$$DE-ROCHE-2428584$ROCHE$$43$YR$$F$Y$$$20221116$$CN$DE$
171579593$17157959$3$F$20191120$20200311$20191216$20221201$EXP$$NVSC2019US040138$NOVARTIS$$76$YR$$M$Y$74.842$KG$20221201$$CN$US$US
171583297$17158329$7$F$20210101$20221115$20191216$20221117$EXP$$US-PFIZER INC-2019539903$PFIZER$$60$YR$$F$Y$$$20221117$$CN$US$US
171588242$17158824$2$F$$20191206$20191216$20221130$EXP$$NVSC2019US065528$NOVARTIS$$$$$F$Y$$$20221130$$CN$US$US
1715923161$17159231$61$F$20151101$20221117$20191216$20221122$EXP$$GB-MYLANLABS-2019M1117808$MYLAN$$59$YR$$M$Y$62$KG$20221122$$MD$GB$GB
171593402$17159340$2$F$$20221025$20191216$20221031$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR225827$GLAXOSMITHKLINE$$$$$$Y$$$20221031$$CN$CA$CA
171593462$17159346$2$F$20190902$20221014$20191216$20221025$EXP$$CA-GLAXOSMITHKLINE-CA2019226677$GLAXOSMITHKLINE$$72$YR$$M$Y$$$20221025$$MD$CA$CA
171596478$17159647$8$F$$20221206$20191216$20221208$EXP$$US-PFIZER INC-2019540233$PFIZER$$75$YR$$F$Y$$$20221208$$CN$US$US
171600056$17160005$6$F$20220626$20221025$20191216$20221101$PER$$US-SA-2019SA344746$SANOFI AVENTIS$$71$YR$E$F$Y$$$20221101$$HP$US$US
1716021115$17160211$15$F$20191209$20221013$20191216$20221020$PER$$CA-Eisai Medical Research-EC-2019-067106$EISAI$$64$YR$A$F$Y$83.8$KG$20221020$$MD$CA$
171603175$17160317$5$F$$20221004$20191216$20221006$EXP$$US-PFIZER INC-2019447892$PFIZER$$73$YR$$F$Y$$$20221006$$CN$US$US
171605085$17160508$5$F$20190101$20221206$20191216$20221212$EXP$$US-SHIRE-US201943134$TAKEDA$$$$$M$Y$77$KG$20221212$$CN$US$US
171605452$17160545$2$F$20190101$20220322$20191216$20221213$EXP$$US-AMNEAL PHARMACEUTICALS-2019-IPXL-01196$AMNEAL$$$$$F$Y$65$KG$20221213$$CN$US$US
171607732$17160773$2$F$$20221118$20191216$20221124$EXP$$CA-TAKEDA-2019TUS069626$TAKEDA$$72$YR$$F$Y$$$20221124$$MD$CA$CA
1716079913$17160799$13$F$20190430$20221006$20191216$20221008$EXP$$PHHY2019CO104382$NOVARTIS$$80$YR$$F$Y$65$KG$20221008$$CN$CO$CO
171608053$17160805$3$F$$20191211$20191216$20221201$EXP$$NVSC2019US068641$NOVARTIS$$$$$M$Y$$$20221201$$CN$US$US
171614344$17161434$4$F$20180710$20221124$20191216$20221130$EXP$$JP-ALEXION-A201808933$ALEXION$$8$YR$$F$Y$10.9$KG$20221130$$MD$JP$JP
171615142$17161514$2$F$20190704$20220929$20191216$20221004$EXP$$DE-SA-2019SA341856$SANOFI AVENTIS$$67$YR$E$F$Y$85$KG$20221004$$HP$DE$DE
1716156013$17161560$13$F$20191118$20221221$20191216$20221223$EXP$$IL-ABBVIE-19K-082-3190296-00$ABBVIE$$88$YR$$F$Y$58.5$KG$20221223$$MD$IL$IL
1716175915$17161759$15$F$20190407$20221130$20191217$20221207$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-081801$BRISTOL MYERS SQUIBB$$72$YR$E$M$Y$66$KG$20221207$$MD$JP$JP
1716180610$17161806$10$F$20191022$20221017$20191217$20221025$EXP$$NVSC2019US066918$NOVARTIS$$77$YR$$F$Y$$$20221025$$CN$US$US
1716232324$17162323$24$F$20170901$20221207$20191217$20221221$EXP$GB-EMA-DD-20190930-SHUKLA_V-102108$GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2019-08687$ALKEM$$32$YR$$F$Y$$$20221221$$MD$GB$GB
1716286312$17162863$12$F$20180117$20221014$20191217$20221024$EXP$$CA-CELLTRION INC.-2018CA017715$CELLTRION$$$$$$Y$$$20221024$$CN$CA$CA
171635074$17163507$4$F$$20221207$20191217$20221216$PER$$US-AMGEN-USASP2019208286$AMGEN$$74$YR$E$F$Y$$$20221215$$HP$US$US
171635142$17163514$2$F$20220307$20221018$20191217$20221025$EXP$$US-AstraZeneca-2019SF82582$ASTRAZENECA$$22687$DY$$F$Y$78$KG$20221025$$LW$US$
171638152$17163815$2$F$20060907$20220926$20191217$20221007$PER$$US-JNJFOC-20191226877$JOHNSON AND JOHNSON$$6$YR$C$M$Y$$$20221007$$LW$US$US
1716434034$17164340$34$F$20190101$20221026$20191217$20221105$EXP$$CA-CELLTRION INC.-2019CA027317$CELLTRION$$$$$$Y$$$20221105$$CN$CA$CA
171645234$17164523$4$F$20190701$20221129$20191217$20221201$EXP$$US-PFIZER INC-2019539517$PFIZER$$76$YR$$F$Y$82.494$KG$20221201$$CN$US$US
1716527938$17165279$38$F$20190314$20221018$20191217$20221024$EXP$$IL-PFIZER INC-2018434483$PFIZER$$73$YR$$M$Y$$$20221024$$HP$IL$IL
171653476$17165347$6$F$20200101$20221205$20191217$20221208$EXP$$US-PFIZER INC-2018352742$PFIZER$$74$YR$$F$Y$55.329$KG$20221208$$CN$US$US
171655177$17165517$7$F$$20221114$20191217$20221122$EXP$$CA-AstraZeneca-2019SF79182$ASTRAZENECA$$32$YR$$M$Y$$$20221122$$MD$CA$
171657813$17165781$3$F$$20220930$20191217$20221003$EXP$$US-PFIZER INC-2019544058$PFIZER$$78$YR$$M$Y$$$20221003$$CN$US$US
1716624612$17166246$12$F$20191206$20221025$20191217$20221027$EXP$$NVSC2019PL063245$NOVARTIS$$56$YR$$F$Y$78.4$KG$20221027$$MD$PL$PL
171669505$17166950$5$F$20190101$20221031$20191217$20221107$EXP$$US-JAZZ-2019-US-015281$JAZZ$$$$$F$Y$$$20221107$$CN$US$US
1716787511$17167875$11$F$20181201$20221128$20191218$20221212$EXP$$CA-ROCHE-2499007$ROCHE$$32$YR$$F$Y$58$KG$20221212$$HP$CA$
171694905$17169490$5$F$20191209$20221115$20191218$20221118$EXP$$NVSC2019SG067712$NOVARTIS$$58$YR$$F$Y$49.9$KG$20221118$$MD$SG$SG
171695454$17169545$4$F$20191202$20221019$20191218$20221026$EXP$$US-VERTEX PHARMACEUTICALS-2019-012679$VERTEX$$25$YR$$M$Y$$$20221026$$MD$US$US
171697702$17169770$2$F$$20221111$20191218$20221114$PER$$US-JNJFOC-20191227036$JOHNSON AND JOHNSON$$$$$M$Y$$$20221114$$LW$US$US
171697849$17169784$9$F$20030101$20221020$20191218$20221024$PER$$US-PFIZER INC-2019401101$PFIZER$$55$YR$$F$Y$74.39$KG$20221024$$MD$US$US
171703212$17170321$2$F$$20221202$20191218$20221209$EXP$$US-JNJFOC-20191218066$JOHNSON AND JOHNSON$$11$YR$C$M$Y$44.038$KG$20221209$$CN$US$US
171708875$17170887$5$F$20180116$20221202$20191218$20221209$EXP$$DE-ROCHE-2325379$ROCHE$$35$YR$$F$Y$$$20221209$$CN$DE$
171714754$17171475$4$F$20190901$20221102$20191218$20221117$PER$$AU-TOLMAR, INC.-19AU001076$TOLMAR$$80$YR$$M$Y$$$20221117$$HP$AU$AU
171716432$17171643$2$F$20191120$20221006$20191218$20221012$EXP$$CA-JNJFOC-20191217449$JOHNSON AND JOHNSON$$82$YR$E$F$Y$$$20221010$$HP$CA$CA
1717256313$17172563$13$F$20191210$20221001$20191218$20221005$EXP$$IN-PFIZER INC-2019096696$PFIZER$$69$YR$$F$Y$63.3$KG$20221005$$CN$IN$IN
171730052$17173005$2$F$20180621$20221229$20191219$20221230$EXP$$DE-ROCHE-2496926$ROCHE$$59$YR$$M$Y$$$20221230$$MD$DE$
1717309426$17173094$26$F$$20221216$20191219$20221220$EXP$$US-SHIRE-US201943636$TAKEDA$$$$$M$Y$53$KG$20221220$$HP$US$US
171731057$17173105$7$F$20190925$20221209$20191218$20221216$EXP$$PHHY2019BR225919$NOVARTIS$$59$YR$$F$Y$$$20221216$$CN$BR$BR
171734184$17173418$4$F$$20221227$20191218$20221229$EXP$$US-TAKEDA-2019TUS070636$TAKEDA$$$$$F$Y$$$20221229$$CN$US$US
171740416$17174041$6$F$20221107$20221107$20191219$20221114$EXP$$US-PFIZER INC-2019546631$PFIZER$$50$YR$$F$Y$84$KG$20221114$$CN$US$US
171740537$17174053$7$F$$20221212$20191219$20221214$PER$$US-PFIZER INC-2019542449$PFIZER$$77$YR$$F$Y$54.43$KG$20221214$$CN$US$US
171742967$17174296$7$F$20211104$20221209$20191219$20221215$EXP$$US-SHIRE-US201943406$TAKEDA$$60$YR$$F$Y$50$KG$20221215$$HP$US$US
1717471916$17174719$16$F$20190925$20221121$20191219$20221123$EXP$$PHHY2019DE227733$NOVARTIS$$$$A$F$Y$103$KG$20221123$$MD$DE$DE
171749134$17174913$4$F$$20221027$20191219$20221101$EXP$$PL-MYLANLABS-2019M1125098$MYLAN$Tarasewicz, A.. Unilateral neuropathy of optic nerve during tacrolimus therapy in a kidney transplant patient.. FORUM NEFROLOGICZNE. 2019;2:101-5$34$YR$$M$Y$$$20221101$$MD$PL$PL
171756212$17175621$2$F$$20221025$20191219$20221102$EXP$$CA-UCBSA-2019054444$UCB$$$$$F$Y$$$20221102$$HP$CA$CA
171757172$17175717$2$F$20130909$20221114$20191219$20221118$EXP$$PHHY2013CA101417$NOVARTIS$$36$YR$$F$Y$$$20221118$$MD$CA$CA
171765878$17176587$8$F$20190722$20221220$20191219$20221229$EXP$$DE-MYLANLABS-2019M1124969$MYLAN$$$$E$F$Y$65$KG$20221229$$MD$DE$DE
1717668217$17176682$17$F$$20221110$20191219$20221114$EXP$$US-SHIRE-US201943764$TAKEDA$$$$$F$Y$48$KG$20221114$$HP$US$US
171767386$17176738$6$F$$20221215$20191219$20221219$EXP$$US-SHIRE-US201943674$TAKEDA$$$$$F$Y$$$20221219$$MD$US$US
1717748111$17177481$11$F$20191030$20221129$20191219$20221206$EXP$$BR-GLAXOSMITHKLINE-BR2017GSK050809$GLAXOSMITHKLINE$$$$$$Y$$$20221206$$CN$BR$BR
171777282$17177728$2$F$20190925$20221220$20191219$20221230$EXP$$US-COOPERSURGICAL, INC.-US-2019CPS003213$COOPERSURGICAL$$33$YR$$F$Y$69.388$KG$20221230$$HP$US$US
171784212$17178421$2$F$20140128$20221117$20191219$20221127$EXP$SE-EMA-DD-20191126-AGRAHARI_P-112208$SE-TEVA-2019-SE-1153415$TEVA$$71$YR$E$F$Y$$$20221126$$HP$SE$SE
1718074030$17180740$30$F$20181008$20221019$20191220$20221027$EXP$$GB-ASPEN-GLO2019GB013478$ASPEN$$$$$$Y$$$20221027$$MD$GB$GB
1718087716$17180877$16$F$20191024$20221117$20191219$20221123$EXP$$JP-ALNYLAM PHARMACEUTICALS, INC.-ALN-2019-000826$ALNYLAM PHARMACEUTICALS$$$$$$Y$$$20221123$$MD$JP$JP
171812264$17181226$4$F$$20221027$20191220$20221101$EXP$$US-SHIRE-US201944181$TAKEDA$$$$$M$Y$113.3$KG$20221101$$HP$US$US
171834273$17183427$3$F$$20220706$20191220$20221216$EXP$$US-ROCHE-2499866$ROCHE$$81$YR$$M$Y$$$20221216$$MD$US$
171838532$17183853$2$F$$20191213$20191220$20221108$EXP$$CO-Vifor (International) Inc.-VIT-2019-17052$VIFOR$$$$$F$Y$$$20221108$$CN$CO$CO
171843712$17184371$2$F$$20221025$20191220$20221107$EXP$$CA-GLAXOSMITHKLINE-CA2019232012$GLAXOSMITHKLINE$$$$$F$Y$$$20221107$$HP$CA$CA
171844045$17184404$5$F$$20221207$20191220$20221213$PER$$US-PFIZER INC-2019547247$PFIZER$$41$YR$$F$Y$74.84$KG$20221213$$CN$US$US
171845046$17184504$6$F$$20221026$20191220$20221028$PER$$US-PFIZER INC-2019152032$PFIZER$$77$YR$$F$Y$$$20221028$$MD$US$US
171845767$17184576$7$F$20170721$20221103$20191220$20221108$PER$$US-PFIZER INC-2019547075$PFIZER$$72$YR$$F$Y$63.492$KG$20221108$$CN$US$US
1718482811$17184828$11$F$20191101$20221026$20191220$20221102$PER$$US-BIOGEN-2019BI00818732$BIOGEN$$45$YR$$F$Y$$$20221102$$CN$US$US
171849442$17184944$2$F$$20221117$20191220$20221123$EXP$$ES-MYLANLABS-2019M1125753$MYLAN$Sadyrbaeva-Dolgova S, Cancela-Diez B, Sanchez-Argaiz M, Jimenez-Morales A. Nephrogenic diabetes insipidus induced by liposomal amphotericin b: A case report.. European Journal of Hospital Pharmacy - Science and Practice. 2019;26 (Suppl. 1):A:4CPS-082$39$YR$$M$Y$$$20221123$$HP$ES$ES
171854973$17185497$3$F$$20220111$20191220$20221216$PER$$US-MALLINCKRODT-T201903955$SPECGX$$$$$F$Y$115$KG$20221216$$CN$US$US
171855855$17185585$5$F$20220311$20221109$20191220$20221114$PER$$NVSC2019US075680$NOVARTIS$$66$YR$$F$Y$$$20221114$$CN$US$US
171860952$17186095$2$F$$20221017$20191220$20221021$EXP$$DE-JNJFOC-20191221502$JOHNSON AND JOHNSON$$55$YR$A$F$Y$$$20221021$$MD$DE$DE
1718749012$17187490$12$F$20221215$20221228$20191220$20221230$PER$$NVSC2019US027703$NOVARTIS$$66$YR$$F$Y$$$20221230$$CN$US$US
1718756215$17187562$15$F$20211020$20221110$20191220$20221116$EXP$$US-SHIRE-US201944249$TAKEDA$$20$YR$$M$Y$42.993$KG$20221116$$HP$US$US
171877992$17187799$2$F$20190101$20221123$20191221$20221206$EXP$$DE-AUROBINDO-AUR-APL-2019-105754$AUROBINDO$$$$$F$Y$$$20221206$$MD$DE$DE
171878186$17187818$6$F$$20221027$20191221$20221102$PER$$PK-AMGEN-PAKSP2019211859$AMGEN$$35$YR$A$F$Y$72$KG$20221101$$CN$PK$PK
1718788111$17187881$11$F$20201107$20221128$20191221$20221201$EXP$$US-SHIRE-US201943847$TAKEDA$$69$YR$$F$Y$55$KG$20221201$$HP$US$US
171882703$17188270$3$F$$20221025$20191221$20221110$EXP$$NVSC2019CA076669$NOVARTIS$$$$$F$Y$$$20221110$$HP$CA$CA
171891402$17189140$2$F$$20221128$20191223$20221212$EXP$$US-AUROBINDO-AUR-APL-2019-104980$AUROBINDO$Villalba AA, Haq M, Zhang C, Thakkar J.. Amoxicillin/Clavulanic Acid-Induced Agranulocytosis: A Case Report and Review of the Literature.. Case Reports in Hematology.. 2019$49$YR$$M$Y$$$20221212$$MD$US$US
171895033$17189503$3$F$20150101$20221205$20191223$20221213$EXP$$GB-BIOGEN-2017BI00377579$BIOGEN$$$$$M$Y$$$20221213$$CN$GB$GB
171897608$17189760$8$F$20190912$20221123$20191223$20221128$EXP$$IT-ROCHE-2489290$ROCHE$$63$YR$$M$Y$82$KG$20221128$$MD$IT$
171906135$17190613$5$F$$20221104$20191223$20221111$EXP$$CA-GLAXOSMITHKLINE-CA2018GSK121814$GLAXOSMITHKLINE$$$$$$Y$$$20221111$$MD$CA$CA
171914502$17191450$2$F$$20221004$20191223$20221006$PER$$US-PFIZER INC-2019548866$PFIZER$$78$YR$$F$Y$$$20221006$$CN$US$US
1719214811$17192148$11$F$20210201$20221202$20191223$20221207$EXP$$US-SHIRE-US201943966$TAKEDA$$94$YR$$F$Y$53$KG$20221207$$CN$US$US
1719240946$17192409$46$F$20191015$20221221$20191223$20221230$EXP$$CA-CELLTRION INC.-2019CA025241$CELLTRION$$$$$$Y$$$20221230$$MD$CA$CA
1719246426$17192464$26$F$$20221226$20191223$20221231$PER$$US-AMGEN-USASP2019210482$AMGEN$Capra; M.. UPDATED PROGRESSION-FREE SURVIVALAND DEPTH OF RESPONSE IN IKEMA, A RANDOMIZED PHASE 3 TRIAL OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA. Hematology, Transfusion and Cell Therapy. 2022;44 (s2):S249$$$$$Y$$$20221231$$HP$US$US
171925503$17192550$3$F$$20221018$20191223$20221028$EXP$$PT-AstraZeneca-2019SF82896$ASTRAZENECA$Varandas AC, Mesquita M, Marques ML, Alives M. Rinite Uma Fam?lia de Patologias: Rinossinusite cronica com polipose nasal. Jornal do Medico 2019;102:26-27.$20$YR$$M$Y$$$20221028$$MD$PT$
171932572$17193257$2$F$20191112$20221129$20191223$20221202$EXP$$US-SHIRE-US201944414$TAKEDA$$16$YR$$M$Y$$$20221202$$CN$US$US
1719325912$17193259$12$F$20200401$20221130$20191223$20221208$EXP$$DE-SHIRE-DE201944441$TAKEDA$$81$YR$$F$Y$85$KG$20221208$$HP$DE$DE
1719352811$17193528$11$F$$20221226$20191223$20221230$EXP$$CA-BAUSCH-BL-2019-065992$BAUSCH AND LOMB$$76$YR$$F$Y$$$20221230$$CN$CA$CA
171936172$17193617$2$F$$20221202$20191223$20221208$EXP$$ZA-JNJFOC-20191227750$JOHNSON AND JOHNSON$$$$$M$Y$$$20221208$$CN$ZA$ZA
171938086$17193808$6$F$20171220$20221111$20191223$20221118$EXP$$DE-SAMSUNG BIOEPIS-SB-2019-38299$SAMSUNG BIOEPIS$$$$A$F$Y$$$20221118$$MD$DE$DE
171943242$17194324$2$F$$20221013$20191224$20221023$EXP$$DE-AUROBINDO-AUR-APL-2019-106698$AUROBINDO$$55$YR$$F$Y$$$20221023$$MD$DE$DE
171947272$17194727$2$F$$20220706$20191224$20221220$EXP$$US-ROCHE-2506335$ROCHE$$57$YR$$F$Y$$$20221220$$MD$US$
1719519712$17195197$12$F$$20221128$20191224$20221130$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-121179$BRISTOL MYERS SQUIBB$$72$YR$E$M$Y$$$20221130$$CN$CA$CA
171956512$17195651$2$F$$20221206$20191224$20221211$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-121415$BRISTOL MYERS SQUIBB$$73$YR$E$F$Y$101$KG$20221212$$CN$CA$CA
171960745$17196074$5$F$$20221111$20191224$20221115$EXP$$US-PFIZER INC-2019550890$PFIZER$$25$YR$$M$Y$$$20221115$$MD$US$US
171961652$17196165$2$F$20191101$20221010$20191224$20221019$EXP$$NL-TOLMAR, INC.-19NL001160$TOLMAR$$82$YR$$M$Y$$$20221019$$HP$NL$NL
171966245$17196624$5$F$$20221108$20191224$20221111$EXP$$PHHY2019CO093386$NOVARTIS$$$$$M$Y$60$KG$20221111$$CN$CO$CO
171966603$17196660$3$F$$20221114$20191224$20221117$EXP$$CA-PFIZER INC-2019549933$PFIZER$$51$YR$$F$Y$60$KG$20221117$$HP$CA$CA
171966692$17196669$2$F$$20221114$20191224$20221117$EXP$$CA-PFIZER INC-2019549295$PFIZER$$33$YR$$F$Y$$$20221117$$HP$CA$CA
171966812$17196681$2$F$$20221114$20191224$20221117$EXP$$CA-PFIZER INC-2019551135$PFIZER$$60$YR$$F$Y$61$KG$20221117$$HP$CA$CA
171968548$17196854$8$F$$20221031$20191224$20221103$PER$$US-BIOGEN-2019BI00810593$BIOGEN$$$$$M$Y$$$20221103$$CN$US$US
171973263$17197326$3$F$$20221202$20191224$20221205$EXP$$NVSC2019ES072256$NOVARTIS$Mas-Serrano M, Garcia-Pastor A, Tornero-Molina P, Vazquez-Alen P, Palacios-Mendoza MA, Gil-Nunez AC. Treatment of alteplase-induced orolingual angioedema by means of icatibant. REV NEUROL. 2019;69(6):261-2$55$YR$$M$Y$70$KG$20221205$$HP$ES$ES
171975035$17197503$5$F$$20221201$20191224$20221215$PER$$AU-TOLMAR, INC.-19AU000949$TOLMAR$$$$$M$Y$$$20221215$$HP$AU$AU
171975566$17197556$6$F$$20221215$20191224$20221221$EXP$$US-SHIRE-US201943808$TAKEDA$$$$$M$Y$72$KG$20221221$$HP$US$US
171978223$17197822$3$F$20111115$20221215$20191224$20221220$EXP$$US-JAZZ-2019-US-017825$JAZZ$$40$YR$$F$Y$$$20221220$$HP$US$US
1719794110$17197941$10$F$20180401$20221001$20191225$20221013$EXP$$FR-AUROBINDO-AUR-APL-2019-072692$AUROBINDO$$54$YR$$M$Y$70$KG$20221013$$MD$FR$FR
1719892924$17198929$24$F$20200101$20221104$20191225$20221110$EXP$$NVSC2019CA077102$NOVARTIS$$72$YR$$M$Y$$$20221110$$CN$CA$CA
1719940415$17199404$15$F$20191217$20221110$20191226$20221116$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-121782$BRISTOL MYERS SQUIBB$$65$YR$E$M$Y$58.5$KG$20221117$$MD$JP$JP
171996053$17199605$3$F$$20221123$20191226$20221215$EXP$$CA-ABBVIE-19K-028-3205516-00$ABBVIE$$73$YR$$F$Y$$$20221215$$CN$CA$CA
172003462$17200346$2$F$$20221010$20191226$20221020$EXP$$DE-AUROBINDO-AUR-APL-2019-107343$AUROBINDO$$65$YR$$F$Y$$$20221020$$MD$DE$DE
172006744$17200674$4$F$20180101$20221101$20191226$20221114$EXP$PT-EMA-DD-20191212-KUMARSINGH-A-101305$PT-Accord-167417$ACCORD$$67$YR$E$F$Y$$$20221114$$MD$PT$PT
1720105333$17201053$33$F$20100610$20221226$20191226$20221229$EXP$$PHHY2013GB058488$NOVARTIS$$1$DY$$M$Y$3.1$KG$20221229$$HP$GB$GB
172013002$17201300$2$F$$20221013$20191226$20221020$EXP$DE-BFARM-19014362$DE-SA-2019SA352106$SANOFI AVENTIS$$62$YR$A$M$Y$$$20221020$$MD$DE$DE
172017359$17201735$9$F$$20221110$20191226$20221114$EXP$$US-PFIZER INC-2019552271$PFIZER$$85$YR$$F$Y$68.02$KG$20221114$$CN$US$US
1720206417$17202064$17$F$20190502$20221128$20191226$20221201$EXP$$DE-ROCHE-2452624$ROCHE$$$$A$F$Y$$$20221201$$CN$DE$
172023327$17202332$7$F$$20221116$20191226$20221123$PER$$US-PFIZER INC-2019551266$PFIZER$$64$YR$$F$Y$$$20221123$$CN$US$US
1720241313$17202413$13$F$20220401$20221213$20191226$20221222$EXP$$US-SHIRE-US201944732$TAKEDA$$78$YR$$F$Y$50$KG$20221222$$HP$US$US
1720269324$17202693$24$F$20150727$20221115$20191226$20221118$EXP$$PHHY2015CO093258$NOVARTIS$$61$YR$$F$Y$64$KG$20221118$$CN$CO$CO
172028815$17202881$5$F$$20221108$20191226$20221109$PER$$US-PFIZER INC-2019551060$PFIZER$$32$YR$$F$Y$$$20221109$$HP$US$US
172029264$17202926$4$F$$20221227$20191226$20221227$PER$$US-PFIZER INC-2019551447$PFIZER$$64$YR$$M$Y$$$20221227$$MD$US$US
172030265$17203026$5$F$20131231$20221206$20191226$20221214$EXP$$US-AstraZeneca-2019SF85249$ASTRAZENECA$$18551$DY$$M$Y$95.3$KG$20221214$$LW$US$
172036077$17203607$7$F$20191218$20221115$20191226$20221121$EXP$$NVSC2019SG075815$NOVARTIS$$58$YR$$F$Y$49.9$KG$20221121$$MD$SG$SG
172036492$17203649$2$F$$20221012$20191226$20221014$EXP$$DE-JNJFOC-20191231232$JOHNSON AND JOHNSON$$73$YR$E$M$Y$$$20221014$$MD$DE$DE
172036652$17203665$2$F$$20221125$20191226$20221205$EXP$$CA-ELI_LILLY_AND_COMPANY-CA201912010117$ELI LILLY AND CO$$15$YR$$M$Y$127$KG$20221205$$CN$IN$CA
172036762$17203676$2$F$20191009$20221012$20191226$20221017$EXP$$DE-JNJFOC-20191230325$JOHNSON AND JOHNSON$$62$YR$A$M$Y$$$20221017$$MD$DE$DE
1720465019$17204650$19$F$20190813$20221215$20191226$20221224$EXP$$CA-CELLTRION INC.-2019CA024108$CELLTRION$$$$$$Y$$$20221224$$CN$CA$CA
172054963$17205496$3$F$20190307$20221206$20191227$20221212$EXP$$US-ROCHE-2506349$ROCHE$$59$YR$$M$Y$84$KG$20221212$$MD$US$
172057882$17205788$2$F$$20221122$20191227$20221202$EXP$US-STRIDES ARCOLAB LIMITED-2019SP011188$US-STRIDES ARCOLAB LIMITED-2019SP011188$STRIDES$Sanchez-Valenzuela M, Carrillo-Martin I, Garcia-Saucedo J, Motoa G, Gonzalez-Estrada A.. Excipients aside, anaphylaxis to corticosteroids is a real thing.. Annals of Allergy, Asthma and Immunology. 2019;123(Suppl.)(5):S67-S68$67$YR$$F$Y$$$20221202$$HP$US$US
172061964$17206196$4$F$$20221024$20191227$20221027$PER$$US-AMGEN-USASP2019214377$AMGEN$$65$YR$E$F$Y$$$20221027$$MD$US$US
172067264$17206726$4$F$$20221205$20191227$20221218$EXP$$CA-AUROBINDO-AUR-APL-2019-010059$AUROBINDO$$32$YR$$M$Y$$$20221218$$HP$CA$CA
172071488$17207148$8$F$20190830$20221018$20191227$20221020$EXP$$NVSC2019CA054670$NOVARTIS$$43$YR$$M$Y$$$20221020$$MD$CA$CA
172072136$17207213$6$F$20210609$20221222$20191227$20221229$EXP$$NVSC2019CO004510$NOVARTIS$$47$YR$$M$Y$71$KG$20221229$$CN$CO$CO
172073455$17207345$5$F$20191015$20200316$20191227$20221220$EXP$BE-FAMHP-DHH-N2019-73670$BE-TEVA-2019-BE-1157701$TEVA$$88$YR$E$M$Y$57.4$KG$20221220$$PH$BE$BE
172077867$17207786$7$F$20191201$20221110$20191227$20221121$PER$$US-VERTEX PHARMACEUTICALS-2019-013186$VERTEX$$53$YR$$F$Y$66$KG$20221121$$MD$US$US
172079943$17207994$3$F$$20221021$20191227$20221102$EXP$$CA-PFIZER INC-2019554322$MYLAN$$63$YR$$F$Y$$$20221102$$HP$CA$CA
172083197$17208319$7$F$20191224$20221209$20191227$20221216$EXP$$JP-ALNYLAM PHARMACEUTICALS, INC.-ALN-2019-001010$ALNYLAM PHARMACEUTICALS$$$$$$Y$$$20221216$$MD$JP$JP
172085133$17208513$3$F$$20220511$20191227$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-120996$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20221222$$HP$CA$CA
172085254$17208525$4$F$$20220923$20191227$20221004$EXP$$CA-APOTEX-2019AP026448$APOTEX$$58$YR$$F$Y$81$KG$20221004$$HP$CA$CA
172085795$17208579$5$F$20200101$20221020$20191227$20221024$EXP$$US-PFIZER INC-2019552917$PFIZER$$72$YR$$F$Y$109.59$KG$20221024$$CN$US$US
172086537$17208653$7$F$$20221125$20191227$20221202$EXP$$US-SHIRE-US201945175$TAKEDA$$$$$F$Y$45.81$KG$20221202$$CN$US$US
172088817$17208881$7$F$20190101$20221223$20191227$20221229$EXP$$PHHY2019CA073784$NOVARTIS$$74$YR$$F$Y$$$20221229$$CN$CA$CA
172089304$17208930$4$F$20150101$20221007$20191227$20221011$EXP$$US-TAKEDA-2019TUS073648$TAKEDA$$$$$$Y$$$20221011$$CN$US$US
1720918024$17209180$24$F$20191115$20221107$20191227$20221116$EXP$$CA-CELLTRION INC.-2019CA025904$CELLTRION$$$$$$Y$$$20221116$$MD$CA$CA
172096342$17209634$2$F$$20221021$20191227$20221101$PER$$US-SA-2019SA359323$SANOFI AVENTIS$$61$YR$A$F$Y$$$20221101$$MD$US$US
172097564$17209756$4$F$20180820$20201016$20191227$20221028$EXP$$NVSJ2019JP005564$NOVARTIS$$63$YR$$F$Y$$$20221028$$MD$JP$JP
172102572$17210257$2$F$$20211109$20191227$20221013$PER$$US-Indivior Limited-INDV-122475-2019$RECKITT BENCKISER$$$$$M$Y$$$20221013$$HP$US$US
172104572$17210457$2$F$20190726$20221027$20191227$20221028$EXP$$DE-ANIPHARMA-2019-DE-000188$ANI$$89$YR$$F$Y$$$20221028$$MD$DE$DE
1721065311$17210653$11$F$20191215$20221107$20191227$20221114$EXP$$US-SA-2019SA358958$SANOFI AVENTIS$$28$YR$A$M$Y$$$20221114$$MD$US$US
172107053$17210705$3$F$20191001$20221026$20191227$20221103$EXP$$CA-VERTEX PHARMACEUTICALS-2019-011736$VERTEX$$19$YR$$M$Y$$$20221103$$MD$CA$CA
172108698$17210869$8$F$20190701$20221212$20191227$20221216$EXP$$US-JAZZ-2019-US-017882$JAZZ$$35$YR$$F$Y$$$20221216$$MD$US$US
1721141713$17211417$13$F$20180801$20221024$20191228$20221101$EXP$$PHHY2018CA051394$NOVARTIS$$70$YR$$M$Y$78$KG$20221101$$CN$CA$CA
1721245811$17212458$11$F$20191128$20221107$20191230$20221109$EXP$$US-SHIRE-US201945053$TAKEDA$$64$YR$$M$Y$295$KG$20221109$$CN$US$US
172125472$17212547$2$F$$20221124$20191230$20221206$EXP$$CA-LUPIN PHARMACEUTICALS INC.-2019-08605$LUPIN$McLennan JD. Deprescribing in a Youth with an Intellectual Disability, Autism, Behavioural Problems, and Medication-Related Obesity: A Case Study. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2019;28(3):141-146$15$YR$$M$Y$127$KG$20221206$$MD$CA$CA
1721283414$17212834$14$F$$20221107$20191230$20221110$EXP$$US-SHIRE-US201945192$TAKEDA$$$$$F$Y$75$KG$20221110$$HP$US$US
172131424$17213142$4$F$$20191224$20191230$20221111$EXP$$NVSC2019US081271$NOVARTIS$$$$$M$Y$$$20221111$$CN$US$US
1721350515$17213505$15$F$20200204$20221206$20191230$20221209$EXP$$US-PFIZER INC-2019448951$PFIZER$$60$YR$$F$Y$80.29$KG$20221209$$HP$US$US
172139175$17213917$5$F$$20221108$20191230$20221111$PER$$US-PFIZER INC-2019554920$PFIZER$$53$YR$$F$Y$$$20221111$$CN$US$US
172139773$17213977$3$F$20191220$20221202$20191230$20221207$PER$$US-PFIZER INC-2019555292$PFIZER$$67$YR$$F$Y$$$20221207$$HP$US$US
1721490017$17214900$17$F$20210121$20221219$20191230$20221227$EXP$$CA-CELLTRION INC.-2019CA025825$CELLTRION$$$$$$Y$$$20221227$$HP$CA$CA
1721511918$17215119$18$F$20191108$20221018$20191230$20221027$EXP$$CA-CELLTRION INC.-2019CA027597$CELLTRION$$$$$$Y$$$20221027$$MD$CA$CA
1721558710$17215587$10$F$$20221004$20191230$20221011$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-39411$SAMSUNG BIOEPIS$$70$YR$E$F$Y$$$20221011$$HP$CA$CA
172161623$17216162$3$F$20190819$20221014$20191230$20221018$EXP$$JP-PFIZER INC-2019531014$PFIZER$$53$YR$$F$Y$$$20221018$$MD$JP$JP
172162455$17216245$5$F$20191217$20200227$20191230$20221130$PER$$NVSC2019US076541$NOVARTIS$$72$YR$$F$Y$$$20221130$$MD$US$US
172163643$17216364$3$F$20191116$20200205$20191230$20221130$PER$$NVSC2019US059447$NOVARTIS$$74$YR$$M$Y$$$20221130$$MD$US$US
172165208$17216520$8$F$$20221026$20191230$20221110$EXP$$CA-AUROBINDO-AUR-APL-2019-107050$AUROBINDO$$59$YR$$F$Y$$$20221110$$MD$CA$CA
172171122$17217112$2$F$$20221007$20191231$20221021$EXP$$NO-ALKEM LABORATORIES LIMITED-NO-ALKEM-2019-11027$ALKEM$Nordmo E, Aronsen L, Wasland K, Smabrekke L, et al.. Severe apnea in an infant exposed to Lamotrigine in breast milk. Ann Pharmacother.. 2009;43(11):1893-1897$17$DY$$$Y$$$20221021$$HP$NO$NO
172174435$17217443$5$F$$20221216$20191231$20221224$EXP$$US-SHIRE-US201944922$TAKEDA$$$$$M$Y$52$KG$20221224$$HP$US$US
172176146$17217614$6$F$20191230$20221012$20191231$20221026$EXP$$US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-125249$BRISTOL MYERS SQUIBB$$84$YR$E$F$Y$68.94$KG$20221026$$CN$US$US
172176214$17217621$4$F$20190101$20221215$20191231$20221223$EXP$$GB-TEVA-2019-GB-1159517$TEVA$$$$$M$Y$$$20221223$$CN$GB$GB
172177903$17217790$3$F$20130101$20220926$20191231$20221004$EXP$$US-AstraZeneca-2019SF88683$ASTRAZENECA$$41$YR$$F$Y$45.8$KG$20221004$$LW$US$
172181344$17218134$4$F$20190101$20221017$20191231$20221024$EXP$$FR-VIIV HEALTHCARE LIMITED-FR2019GSK237496$VIIV$$20$WK$$$Y$$$20221024$$MD$FR$FR
172181493$17218149$3$F$20190325$20220915$20191231$20221001$EXP$$BE-ABBVIE-19K-013-3215032-00$ABBVIE$$74$YR$$M$Y$$$20221001$$MD$BE$BE
172181635$17218163$5$F$$20221108$20191231$20221110$EXP$$CA-ROCHE-2503010$ROCHE$$81$YR$$M$Y$$$20221110$$HP$CA$
172188552$17218855$2$F$$20221017$20191231$20221020$EXP$$US-PFIZER INC-2019507880$PFIZER$$60$YR$$M$Y$129.2$KG$20221020$$CN$US$US
172190936$17219093$6$F$$20221004$20191231$20221011$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-39541$SAMSUNG BIOEPIS$$46$YR$A$F$Y$79$KG$20221011$$HP$CA$CA
172191044$17219104$4$F$$20221125$20191231$20221206$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-39558$SAMSUNG BIOEPIS$$45$YR$A$M$Y$63$KG$20221206$$MD$CA$CA
1721920511$17219205$11$F$20200901$20221025$20191231$20221101$EXP$$CA-SHIRE-CA201944362$TAKEDA$$61$YR$$F$Y$$$20221101$$CN$CA$CA
172195012$17219501$2$F$$20220929$20191231$20221003$PER$$US-PFIZER INC-2019561103$PFIZER$$74$YR$$F$Y$$$20221003$$CN$US$US
172197223$17219722$3$F$20191117$20221102$20191231$20221109$EXP$$NVSC2019FR081048$NOVARTIS$$64$YR$$M$Y$$$20221109$$MD$FR$FR
172197697$17219769$7$F$$20220929$20191231$20221005$EXP$$US-SHIRE-US201945039$TAKEDA$$$$$F$Y$66$KG$20221005$$HP$US$US
172197747$17219774$7$F$20190101$20221222$20191231$20221228$EXP$$US-PFIZER INC-2019546603$PFIZER$$58$YR$$F$Y$$$20221228$$HP$US$US
172197778$17219777$8$F$$20221028$20191231$20221103$EXP$$NVSC2019CO013487$NOVARTIS$$$$$F$Y$62$KG$20221103$$CN$CO$CO
1722125110$17221251$10$F$$20221226$20191231$20221230$EXP$$CA-BAUSCH-BL-2019-066183$BAUSCH AND LOMB$$53$YR$$F$Y$$$20221230$$CN$CA$CA
172214439$17221443$9$F$$20221205$20200101$20221218$EXP$$CA-AUROBINDO-AUR-APL-2019-106389$AUROBINDO$McLennan JD.. Deprescribing in a Youth with an Intellectual Disability, Autism, Behavioural Problems, and Medication-Related Obesity:A Case Study. Journal of the Canadian Academy of Child + Adolescent Psychiatry. 2019;28(3):141-146$15$YR$$M$Y$127$KG$20221218$$MD$CA$CA
172216314$17221631$4$F$$20221013$20200101$20221021$EXP$$FR-Accord-167847$ACCORD$Gregoire M. Drug-drug interactions in older patients living with HIV. La Lettre de l^infectiologue, XXXIV (5), pp.212-217, Sep-Oct 2019.$58$YR$A$F$Y$$$20221021$$MD$FR$FR
172217498$17221749$8$F$$20221027$20200101$20221110$EXP$$PT-AUROBINDO-AUR-APL-2019-104534$AUROBINDO$Varandas AC, Mesquita M, Marques ML, Alives M. Uma familia de patologias. RINITE. 2019;13 (8)$20$YR$$M$Y$$$20221110$$MD$PT$PT
172217747$17221774$7$F$$20221201$20200101$20221216$EXP$$CA-AUROBINDO-AUR-APL-2019-107105$AUROBINDO$$73$YR$$F$Y$101$KG$20221216$$MD$CA$CA
1722187618$17221876$18$F$20181217$20221129$20200101$20221207$EXP$$DE-ROCHE-2239412$ROCHE$$53$YR$$F$Y$$$20221207$$CN$DE$
172219053$17221905$3$F$20080701$20221006$20200101$20221014$EXP$$US-AstraZeneca-2019SF90267$ASTRAZENECA$$689$MON$$F$Y$127.9$KG$20221014$$CN$US$
172221317$17222131$7$F$$20221130$20200101$20221206$EXP$$CA-AstraZeneca-2019SF89058$ASTRAZENECA$$74$YR$$M$Y$$$20221206$$MD$CA$
172221822$17222182$2$F$$20221020$20200101$20221030$EXP$$DE-TEVA-2019-DE-1158897$TEVA$$74$YR$E$F$Y$$$20221030$$MD$DE$DE
172222322$17222232$2$F$$20221020$20200101$20221030$EXP$$DE-TEVA-2019-DE-1158902$TEVA$$81$YR$E$F$Y$$$20221030$$MD$DE$DE
172226289$17222628$9$F$20190110$20220309$20200102$20221215$EXP$$JP-ROCHE-2285206$ROCHE$PRIVACY P, Chikasawa Y, Yamaguchi T, Amano K. Current status of emicizumab using in clinical practice based on medical experience at Tokyo Medical University. Journal of Bone and Mineral Metabolism. The Japanese Journal of Thrombosis and H 2022;33:14-22.$47$YR$$M$Y$85$KG$20221215$$MD$JP$JP
1722306716$17223067$16$F$20180411$20221020$20200102$20221030$EXP$$CA-CELLTRION INC.-2018CA018988$CELLTRION$$$$$$Y$$$20221030$$CN$CA$CA
172232496$17223249$6$F$$20221024$20200102$20221031$EXP$$US-SHIRE-US201945267$TAKEDA$$$$$F$Y$70.295$KG$20221031$$CN$US$US
172235235$17223523$5$F$20190901$20221108$20200102$20221115$EXP$$US-ROCHE-2507709$ROCHE$$51$YR$$F$Y$76.272$KG$20221115$$CN$US$
172237012$17223701$2$F$20180101$20221018$20200102$20221029$EXP$NL-EMA-DD-20191213-BANAVALLI_M-133650$NL-Accord-168030$ACCORD$$44$YR$A$F$Y$$$20221029$$HP$NL$NL
1722394215$17223942$15$F$20190830$20221122$20200102$20221129$EXP$$CA-ROCHE-2510155$ROCHE$$46$YR$$M$Y$$$20221129$$CN$CA$CA
172247023$17224702$3$F$20181220$20221030$20200102$20221109$EXP$$DE-TEVA-2019-DE-1160243$TEVA$$59$YR$A$F$Y$$$20221109$$MD$DE$DE
172254804$17225480$4$F$20140905$20221011$20200102$20221017$EXP$$US-AstraZeneca-2020SE00144$ASTRAZENECA$$16325$DY$$F$Y$78.9$KG$20221017$$LW$US$
172255822$17225582$2$F$$20221018$20200102$20221019$PER$$US-SHIRE-US201945383$TAKEDA$$$$$M$Y$102.04$KG$20221019$$CN$US$US
172256825$17225682$5$F$20190101$20221205$20200102$20221210$EXP$$CA-TAKEDA-2019TUS074330$TAKEDA$$58$YR$$M$Y$$$20221210$$CN$CA$CA
172257268$17225726$8$F$$20221121$20200102$20221128$EXP$$CA-PFIZER INC-2019561814$PFIZER$$33$YR$$F$Y$51$KG$20221128$$HP$CA$CA
172261116$17226111$6$F$20180720$20200221$20200102$20221022$EXP$$CA-INTERCEPT-PMOCA2018001237$INTERCEPT PHARMACEUTICALS$$46$YR$$F$Y$$$20221022$$CN$CA$CA
172264732$17226473$2$F$20180830$20221024$20200102$20221031$PER$$US-INCYTE CORPORATION-2019IN013022$INCYTE$$$$$$Y$$$20221031$$CN$US$US
172265272$17226527$2$F$$20221011$20200102$20221014$EXP$$CA-TAKEDA-2020TUS000087$TAKEDA$$74$YR$$F$Y$$$20221014$$MD$CA$CA
172268822$17226882$2$F$20190101$20200113$20200102$20221222$PER$$US-AMGEN-USASL2019185282$AMGEN$$75$YR$E$F$Y$$$20221222$$CN$US$US
172269068$17226906$8$F$20200117$20221123$20200102$20221129$EXP$$US-SHIRE-US201945195$TAKEDA$$58$YR$$F$Y$71$KG$20221129$$HP$US$US
1722753920$17227539$20$F$20191212$20221213$20200103$20221221$EXP$$CA-CELLTRION INC.-2019CA027829$CELLTRION$$$$$$Y$$$20221221$$HP$CA$CA
172275438$17227543$8$F$20200101$20221221$20200103$20221227$EXP$$US-ROCHE-2510104$ROCHE$$52$YR$$M$Y$72.64$KG$20221227$$CN$US$
172276734$17227673$4$F$$20221208$20200103$20221222$EXP$$PT-AUROBINDO-AUR-APL-2019-109453$AUROBINDO$Santa C, Ferreira C, Sangalho I, Coutinho IA, Gouveia J, Carvalho JC, et al. Rinossinusite cr?nica com e sem polipose nasal (Chronic rhinosinusitis with and without nasal polyposis). Revista Portuguesa Imunoalergologia. 2022;30(3):207-221$20$YR$$M$Y$$$20221222$$MD$PT$PT
1722777911$17227779$11$F$$20221212$20200103$20221220$PER$$US-AMGEN-USASP2019217874$AMGEN$$63$YR$A$F$Y$$$20221219$$MD$US$US
172278873$17227887$3$F$20090813$20221010$20200103$20221018$EXP$$US-AstraZeneca-2020SE00375$ASTRAZENECA$$22582$DY$$F$Y$86.2$KG$20221018$$CN$US$
172280322$17228032$2$F$$20221020$20200103$20221030$EXP$$DE-TEVA-2019-DE-1159873$TEVA$$94$YR$E$F$Y$$$20221030$$MD$DE$DE
172282852$17228285$2$F$20181029$20221205$20200103$20221207$EXP$$GB-ROCHE-2345203$ROCHE$$74$YR$$F$Y$$$20221207$$MD$GB$
1722833314$17228333$14$F$20200113$20221130$20200103$20221206$EXP$$US-SHIRE-US201945601$TAKEDA$$75$YR$$M$Y$97.95$KG$20221206$$HP$US$US
172289782$17228978$2$F$20190726$20221020$20200103$20221030$EXP$$DE-TEVA-2019-DE-1160013$TEVA$$89$YR$E$F$Y$$$20221030$$MD$DE$DE
172295843$17229584$3$F$20221013$20221018$20200103$20221020$EXP$$CA-TAKEDA-2020TUS000094$TAKEDA$$38$YR$$M$Y$$$20221020$$CN$CA$CA
172300009$17230000$9$F$20120101$20221205$20200103$20221212$EXP$$CA-MYLANLABS-2020M1000184$MYLAN$$24$YR$$F$Y$$$20221212$$CN$CA$CA
172300517$17230051$7$F$20160217$20221129$20200103$20221207$EXP$$CA-MYLANLABS-2020M1000146$MYLAN$$42$YR$$M$Y$$$20221207$$HP$CA$CA
1723030616$17230306$16$F$20180101$20221010$20200103$20221013$EXP$$US-PFIZER INC-2020002121$PFIZER$$67$YR$$M$Y$$$20221013$$CN$US$US
172306142$17230614$2$F$20000307$20221219$20200103$20221226$PER$$US-JNJFOC-20200103960$JOHNSON AND JOHNSON$$9$YR$C$M$Y$$$20221226$$LW$US$US
172307082$17230708$2$F$20040101$20221114$20200103$20221125$PER$$US-JNJFOC-20200103360$JOHNSON AND JOHNSON$$17$YR$T$M$Y$$$20221125$$LW$US$US
172307422$17230742$2$F$$20221019$20200103$20221027$PER$$US-JNJFOC-20200103213$JOHNSON AND JOHNSON$$$$$M$Y$$$20221027$$LW$US$US
172308359$17230835$9$F$20210514$20221215$20200103$20221223$EXP$$US-SHIRE-US201945486$TAKEDA$$33$YR$$F$Y$91$KG$20221223$$HP$US$US
172310367$17231036$7$F$$20221228$20200103$20221230$PER$$US-PFIZER INC-2019346130$PFIZER$$80$YR$$F$Y$$$20221230$$HP$US$US
172310564$17231056$4$F$$20221020$20200103$20221024$EXP$$US-PFIZER INC-2018389083$PFIZER$$73$YR$$F$Y$$$20221024$$CN$US$US
172313173$17231317$3$F$$20221213$20200103$20221221$PER$$US-PFIZER INC-2019561332$PFIZER$$47$YR$$F$Y$$$20221221$$CN$US$US
172313467$17231346$7$F$20200101$20221122$20200103$20221123$EXP$$US-PFIZER INC-2019561626$PFIZER$$48$YR$$F$Y$$$20221123$$CN$US$US
172315456$17231545$6$F$20220101$20221109$20200103$20221115$EXP$$US-PFIZER INC-2019560575$PFIZER$$64$YR$$F$Y$$$20221115$$MD$US$US
172317112$17231711$2$F$$20221006$20200103$20221007$PER$$US-PFIZER INC-2020002184$PFIZER$$70$YR$$M$Y$$$20221007$$CN$US$US
172318623$17231862$3$F$$20221004$20200103$20221005$EXP$$US-PFIZER INC-2020001669$PFIZER$$85$YR$$F$Y$$$20221005$$CN$US$US
172318652$17231865$2$F$$20221014$20200103$20221017$PER$$US-PFIZER INC-2020002055$PFIZER$$73$YR$$M$Y$$$20221017$$MD$US$US
1723198020$17231980$20$F$20190901$20221228$20200103$20221229$EXP$$US-GLAXOSMITHKLINE-US2019TSO170527$GLAXOSMITHKLINE$$$$$$Y$$$20221229$$CN$US$US
1723213114$17232131$14$F$20150101$20221220$20200103$20221228$EXP$$US-PFIZER INC-2020001486$PFIZER$$80$YR$$F$Y$69.841$KG$20221228$$CN$US$US
172324728$17232472$8$F$20201105$20221221$20200103$20221228$EXP$$US-SHIRE-US201945055$TAKEDA$$64$YR$$F$Y$98$KG$20221228$$HP$US$US
172324733$17232473$3$F$$20221219$20200103$20221222$PER$$US-PFIZER INC-2019471971$PFIZER$$64$YR$$F$Y$$$20221222$$CN$US$US
1723282111$17232821$11$F$$20221226$20200103$20221230$EXP$$CA-BAUSCH-BL-2019-066666$BAUSCH AND LOMB$$72$YR$$M$Y$$$20221230$$CN$CA$CA
172329058$17232905$8$F$20191118$20221229$20200103$20221231$EXP$$NVSC2019US084689$NOVARTIS$$73$YR$$F$Y$$$20221231$$CN$US$US
172333733$17233373$3$F$$20221013$20200104$20221026$EXP$$DE-AUROBINDO-AUR-APL-2020-000954$AUROBINDO$$81$YR$$F$Y$$$20221026$$MD$DE$DE
172337815$17233781$5$F$20191201$20220928$20200106$20221006$EXP$$US-BIOGEN-2019BI00804933$BIOGEN$$28$YR$$M$Y$$$20221006$$CN$US$US
1723486311$17234863$11$F$20180601$20221215$20200106$20221221$EXP$$DE-ROCHE-2151250$ROCHE$$47$YR$$F$Y$$$20221221$$CN$DE$
172352396$17235239$6$F$20190619$20221223$20200106$20221227$EXP$$CO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-103064$BRISTOL MYERS SQUIBB$$69$YR$E$F$Y$57$KG$20221227$$HP$CO$CO
1723530050$17235300$50$F$20190101$20221214$20200106$20221223$EXP$$CA-CELLTRION INC.-2019CA024862$CELLTRION$$$$$$Y$$$20221223$$MD$CA$CA
172354127$17235412$7$F$$20221124$20200106$20221128$EXP$$CA-ROCHE-2508236$ROCHE$$51$YR$$F$Y$73$KG$20221128$$HP$CA$
1723655911$17236559$11$F$20190716$20221208$20200106$20221215$EXP$$PHHY2019CA169072$NOVARTIS$$75$YR$$M$Y$$$20221215$$CN$CA$CA
172367065$17236706$5$F$20191127$20221215$20200106$20221219$EXP$$NVSC2020US000917$NOVARTIS$$61$YR$$F$Y$70.3$KG$20221219$$MD$US$US
172368295$17236829$5$F$$20221010$20200106$20221020$EXP$$CA-PFIZER INC-2019561414$MYLAN$$61$YR$$F$Y$122$KG$20221020$$HP$CA$CA
172369584$17236958$4$F$$20221024$20200106$20221028$EXP$$BR-PFIZER INC-2020003001$PFIZER$Rubin, D.. Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. Alimentary Pharmacology and Therapeutics. 2021;1-9$47$YR$$F$Y$93$KG$20221028$$MD$BR$BR
172370763$17237076$3$F$20160615$20221013$20200106$20221014$PER$$US-PFIZER INC-2020000482$PFIZER$$69$YR$$F$Y$$$20221014$$MD$US$US
172373706$17237370$6$F$$20221205$20200106$20221209$PER$$US-PFIZER INC-2020003358$PFIZER$$41$YR$$F$Y$$$20221209$$HP$US$US
172373724$17237372$4$F$$20221103$20200106$20221113$EXP$$US-PFIZER INC-2020002940$PFIZER$$65$YR$$M$Y$89.796$KG$20221113$$CN$US$US
172374792$17237479$2$F$20190918$20221207$20200106$20221211$EXP$ES-AEMPS-574711$ES-JNJFOC-20191248692$JOHNSON AND JOHNSON$$82$YR$E$F$Y$$$20221212$$PH$ES$ES
172377825$17237782$5$F$20150220$20221118$20200106$20221128$EXP$$FR-MYLANLABS-2020M1001492$MYLAN$$$$$F$Y$2.27$KG$20221128$$HP$FR$FR
172378908$17237890$8$F$$20221114$20200106$20221118$EXP$$CA-AstraZeneca-2020SE01450$ASTRAZENECA$$69$YR$$F$Y$$$20221118$$MD$CA$
172382213$17238221$3$F$$20221121$20200106$20221123$EXP$$US-PFIZER INC-2020001886$PFIZER$$64$YR$$M$Y$$$20221123$$CN$US$US
172382615$17238261$5$F$20191224$20221011$20200106$20221013$EXP$$FR-GLAXOSMITHKLINE-FR2019TSO237680$GLAXOSMITHKLINE$$$$$$Y$$$20221013$$MD$FR$FR
172383066$17238306$6$F$$20221110$20200106$20221117$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-40376$SAMSUNG BIOEPIS$$59$YR$A$F$Y$67$KG$20221117$$CN$CA$CA
1723848420$17238484$20$F$20141201$20221007$20200106$20221013$EXP$$PHHY2018CA047605$NOVARTIS$$67$YR$$M$Y$$$20221013$$CN$CA$CA
1723911322$17239113$22$F$20201123$20221202$20200106$20221210$EXP$$US-SHIRE-US202000150$TAKEDA$$55$YR$$F$Y$63$KG$20221210$$MD$US$US
172392152$17239215$2$F$$20200106$20200106$20221008$PER$$US-NAPPMUNDI-USA-2019-0149504$PURDUE$$$$$$Y$$$20221008$$CN$US$US
1723966233$17239662$33$F$20190821$20221205$20200106$20221215$EXP$$CA-CELLTRION INC.-2019CA024019$CELLTRION$$$$$$Y$$$20221215$$MD$CA$CA
172398933$17239893$3$F$$20221203$20200106$20221218$EXP$$GB-AUROBINDO-AUR-APL-2020-000124$AUROBINDO$$7$YR$$M$Y$$$20221218$$PH$GB$GB
172399742$17239974$2$F$$20221017$20200107$20221027$EXP$$DE-TEVA-2019-DE-1161202$TEVA$$73$YR$E$M$Y$$$20221027$$MD$DE$DE
1724034910$17240349$10$F$20180920$20221010$20200107$20221013$EXP$$DE-ROCHE-2454676$ROCHE$$40$YR$$F$Y$$$20221013$$CN$DE$DE
172405427$17240542$7$F$$20221121$20200107$20221128$EXP$$CA-Orion Corporation ORION PHARMA-TREX2020-0041$ORION$$33$YR$A$F$Y$51$KG$20221128$$HP$CA$
1724068320$17240683$20$F$20140101$20221213$20200107$20221228$EXP$$CA-ABBVIE-20K-028-3221180-00$ABBVIE$$46$YR$$M$Y$$$20221228$$MD$CA$CA
172407839$17240783$9$F$20190801$20220914$20200107$20221020$EXP$$FR-ABBVIE-20K-056-3219772-00$ABBVIE$$74$YR$$M$Y$73$KG$20221020$$MD$FR$FR
172409098$17240909$8$F$20160816$20221227$20200107$20221230$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK120535$GLAXOSMITHKLINE$$$$$$Y$$$20221230$$MD$BR$BR
172414232$17241423$2$F$$20221017$20200107$20221027$EXP$$DE-TEVA-2019-DE-1162360$TEVA$$65$YR$E$F$Y$$$20221027$$MD$DE$DE
172415825$17241582$5$F$20191226$20221213$20200107$20221221$EXP$$US-ELI_LILLY_AND_COMPANY-US201912013204$ELI LILLY AND CO$$73$YR$$F$Y$$$20221221$$CN$US$US
1724161613$17241616$13$F$20180918$20221023$20200107$20221101$EXP$$CA-CELLTRION INC.-2018CA020719$CELLTRION$$$$$$Y$$$20221101$$CN$CA$CA
172416827$17241682$7$F$$20221128$20200107$20221129$EXP$$US-PFIZER INC-2020003617$PFIZER$$68$YR$$F$Y$$$20221129$$CN$US$US
172418323$17241832$3$F$$20221122$20200107$20221128$EXP$$BR-PFIZER INC-2020004613$PFIZER$$$$$F$Y$$$20221128$$CN$BR$BR
1724197610$17241976$10$F$20191229$20221202$20200107$20221206$EXP$$NVSC2019GR083398$NOVARTIS$$71$YR$$M$Y$109$KG$20221206$$MD$GR$GR
172423745$17242374$5$F$$20221121$20200107$20221124$EXP$$US-PFIZER INC-2020002573$PFIZER$Burke, M.. Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). Blood. 2019;134 (Supp 1):3873$$$$$Y$$$20221124$$MD$US$US
1724268012$17242680$12$F$20190101$20221027$20200107$20221103$PER$$US-VERTEX PHARMACEUTICALS-2019-013786$VERTEX$$$$$F$Y$50$KG$20221103$$HP$US$US
172427315$17242731$5$F$$20221121$20200107$20221123$EXP$$US-PFIZER INC-2020001470$PFIZER$Burke, M.. Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). Blood. 2019;134 (Supp 1):3873$$$C$$Y$$$20221123$$MD$US$US
172427884$17242788$4$F$$20221130$20200107$20221206$EXP$$CA-PFIZER INC-2019563118$PFIZER$$48$YR$$M$Y$$$20221206$$HP$CA$CA
1724284713$17242847$13$F$20210531$20221122$20200107$20221128$EXP$$US-SHIRE-US202000116$TAKEDA$$82$YR$$F$Y$75$KG$20221128$$HP$US$US
1724352514$17243525$14$F$20191101$20221130$20200107$20221207$EXP$$DE-SHIRE-DE202000119$TAKEDA$$43$YR$$F$Y$114.29$KG$20221207$$CN$DE$DE
1724352717$17243527$17$F$20200102$20221227$20200107$20221229$EXP$$US-SHIRE-US202000215$TAKEDA$$51$YR$$M$Y$$$20221229$$CN$US$US
172443585$17244358$5$F$20050101$20221209$20200107$20221212$EXP$$US-GILEAD-2019-0444948$GILEAD$$$$A$M$Y$$$20221212$$LW$US$US
172443744$17244374$4$F$20130918$20221219$20200107$20221221$EXP$$US-GILEAD-2019-0444926$GILEAD$$58$YR$A$M$Y$$$20221221$$LW$US$US
172443794$17244379$4$F$20070101$20221209$20200107$20221214$EXP$$US-GILEAD-2020-0445051$GILEAD$$59$YR$A$M$Y$140.59$KG$20221214$$LW$US$US
172443963$17244396$3$F$20150101$20221207$20200107$20221212$EXP$$US-GILEAD-2019-0444952$GILEAD$$$$A$M$Y$$$20221212$$LW$US$US
172444084$17244408$4$F$20160101$20221207$20200107$20221208$EXP$$US-GILEAD-2019-0444956$GILEAD$$57$YR$A$F$Y$$$20221208$$LW$US$US
172444777$17244477$7$F$20130101$20221209$20200107$20221214$EXP$$US-GILEAD-2020-0445071$GILEAD$$36$YR$A$F$Y$$$20221214$$LW$US$US
172449709$17244970$9$F$$20221129$20200108$20221230$PER$$NVSC2020US002062$NOVARTIS$$$$$M$Y$$$20221230$$CN$US$US
172451919$17245191$9$F$$20221027$20200108$20221102$PER$$US-AMGEN-USASP2020001561$AMGEN$$65$YR$E$M$Y$$$20221102$$MD$US$US
1724530125$17245301$25$F$20171101$20221203$20200108$20221217$EXP$$GB-AUROBINDO-AUR-APL-2020-000773$AUROBINDO$$$$E$M$Y$$$20221217$$MD$GB$GB
1724597328$17245973$28$F$20200101$20221222$20200108$20221230$EXP$$US-SHIRE-US202000231$TAKEDA$$42$YR$$F$Y$154$KG$20221230$$MD$US$US
172461692$17246169$2$F$$20200102$20200108$20221031$PER$$US-UCBSA-2020000298$UCB$$$$$M$Y$$$20221031$$CN$US$US
1724671312$17246713$12$F$$20221216$20200108$20221222$PER$$US-PFIZER INC-2019518683$PFIZER$$79$YR$$$Y$$$20221222$$MD$US$US
1724682310$17246823$10$F$20050101$20221007$20200108$20221013$PER$$US-PFIZER INC-2016505756$PFIZER$$55$YR$$F$Y$81.65$KG$20221013$$MD$US$US
1724685610$17246856$10$F$20210101$20221228$20200108$20221229$EXP$$US-PFIZER INC-2020005279$PFIZER$$72$YR$$F$Y$79$KG$20221229$$CN$US$US
172481442$17248144$2$F$$20221118$20200108$20221129$EXP$$DE-drreddys-GER/GER/19/0117858$DR REDDYS$$55$YR$A$F$Y$$$20221129$$MD$DE$DE
172482962$17248296$2$F$20191117$20221216$20200108$20221219$EXP$$CA-ABBVIE-20K-028-3224432-00$ABBVIE$$79$YR$$M$Y$81$KG$20221219$$CN$CA$CA
172486875$17248687$5$F$20180201$20221206$20200108$20221215$EXP$$IE-JNJFOC-20190225378$JOHNSON AND JOHNSON$$69$YR$E$F$Y$85$KG$20221216$$HP$IE$IE
172487994$17248799$4$F$20160301$20221115$20200108$20221117$EXP$$US-SA-2020SA002557$SANOFI AVENTIS$$45$YR$A$F$Y$$$20221117$$CN$US$US
172488547$17248854$7$F$$20221028$20200108$20221107$EXP$$CO-INCYTE CORPORATION-2019IN011796$INCYTE$$$$$$Y$$$20221108$$CN$CO$CO
172489853$17248985$3$F$20120221$20220330$20200108$20221226$PER$$US-COLLEGIUM PHARMACEUTICAL, INC.-US-2019COL000368$COLLEGIUM PHARMACEUTICAL$$65$YR$$M$Y$$$20221226$$MD$US$US
172492803$17249280$3$F$$20221214$20200108$20221220$PER$$US-AMGEN-USASP2020002335$AMGEN$$58$YR$A$F$Y$$$20221220$$CN$US$US
1724961215$17249612$15$F$20180118$20221011$20200108$20221020$EXP$$CA-CELLTRION INC.-2017CA011724$CELLTRION$$$$$$Y$$$20221020$$MD$CA$CA
172500854$17250085$4$F$$20221130$20200109$20221207$EXP$$CA-Orion Corporation ORION PHARMA-TREX2020-0145$ORION$$48$YR$A$M$Y$$$20221207$$HP$CA$
172502482$17250248$2$F$$20221020$20200109$20221025$EXP$$CA-PFIZER INC-2020004854$PFIZER$$68$YR$$F$Y$$$20221025$$HP$CA$CA
172504076$17250407$6$F$20191031$20221026$20200109$20221107$EXP$$BE-ASPEN-GLO2019BE013906$ASPEN$$$$$$Y$$$20221107$$MD$BE$BE
172504704$17250470$4$F$20160301$20221007$20200109$20221014$EXP$$BR-BIOGEN-2020BI00824100$BIOGEN$$44$YR$$F$Y$60$KG$20221014$$CN$BR$BR
1725063218$17250632$18$F$20191115$20221028$20200109$20221104$EXP$$DE-ROCHE-2491834$ROCHE$$44$YR$$F$Y$$$20221103$$CN$DE$
172507316$17250731$6$F$20200201$20221006$20200109$20221102$PER$$US-KARYOPHARM-2019KPT001039$KARYOPHARM THERAPEUTICS$$$$$$Y$$$20221102$$CN$US$US
172510243$17251024$3$F$$20221103$20200109$20221108$PER$$NVSC2020US002520$NOVARTIS$$$$$M$Y$$$20221108$$HP$US$US
172517583$17251758$3$F$20190903$20221126$20200109$20221201$EXP$$BG-TAKEDA-2020TUS001103$TAKEDA$$64$YR$$M$Y$$$20221201$$CN$BG$BG
172517863$17251786$3$F$20210101$20221110$20200109$20221114$PER$$US-SHIRE-US202000256$TAKEDA$$$$$F$Y$$$20221114$$CN$US$US
172518095$17251809$5$F$20190101$20221111$20200109$20221114$EXP$$US-PFIZER INC-2020007442$PFIZER$$61$YR$$F$Y$90.26$KG$20221114$$CN$US$US
172519375$17251937$5$F$$20221121$20200109$20221123$EXP$$US-PFIZER INC-2020002771$PFIZER$Burke, M.. Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia. Blood. 2019;134 (Supp 1):3873$$$$$Y$$$20221123$$MD$US$US
172519435$17251943$5$F$$20221121$20200109$20221123$EXP$$US-PFIZER INC-2020002772$PFIZER$Burke, M.. Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia. Blood. 2019;134 (Supp 1):3873$$$$$Y$$$20221123$$MD$US$US
172521547$17252154$7$F$$20221013$20200109$20221017$PER$$US-PFIZER INC-2019543712$PFIZER$$65$YR$$$Y$$$20221017$$CN$US$US
172521668$17252166$8$F$20200101$20221130$20200109$20221205$EXP$$US-PFIZER INC-2020009019$PFIZER$$61$YR$$M$Y$$$20221205$$HP$US$US
172534529$17253452$9$F$20190101$20221128$20200109$20221130$EXP$$FR-MYLANLABS-2020M1002051$MYLAN$$20$WK$$$Y$$$20221130$$MD$FR$FR
172535746$17253574$6$F$$20221118$20200109$20221129$EXP$$US-TAKEDA-2017TUS002008$TAKEDA$$$$$F$Y$104$KG$20221129$$CN$US$US
1725373826$17253738$26$F$20210421$20221130$20200109$20221206$EXP$$US-SHIRE-US202000327$TAKEDA$$75$YR$$F$Y$60.771$KG$20221206$$MD$US$US
172549326$17254932$6$F$20180101$20221213$20200109$20221226$EXP$$US-TAKEDA-2018TUS002831$TAKEDA$$$$$F$Y$51$KG$20221226$$PH$US$US
1725496312$17254963$12$F$20220203$20221201$20200109$20221205$PER$$NVSC2020US003740$NOVARTIS$$86$YR$$F$Y$$$20221205$$CN$US$US
172552722$17255272$2$F$20190101$20221123$20200110$20221215$PER$$US-PRINSTON PHARMACEUTICAL INC.-2019PRN00913$PRINSTON PHARMACEUTICAL$$37$YR$$F$Y$74.83$KG$20221202$$CN$US$US
172558162$17255816$2$F$20190325$20200107$20200110$20221003$PER$$DE-AMGEN-DEUNI2019054609$AMGEN$$79$YR$E$F$Y$65$KG$20221003$$MD$DE$DE
172559462$17255946$2$F$$20191229$20200110$20221108$EXP$$US-JNJFOC-20200100921$JOHNSON AND JOHNSON$$3$YR$C$F$Y$$$20221108$$CN$US$US
172571715$17257171$5$F$20191101$20221222$20200110$20221229$EXP$$NVSC2019CA042899$NOVARTIS$$67$YR$$M$Y$$$20221229$$MD$CA$CA
172573148$17257314$8$F$20191223$20221027$20200110$20221102$EXP$$US-PFIZER INC-2020009993$PFIZER$$76$YR$$F$Y$74.03$KG$20221102$$CN$US$US
172573859$17257385$9$F$$20221201$20200110$20221206$PER$$US-PFIZER INC-2020011317$PFIZER$$69$YR$$F$Y$74.8$KG$20221206$$MD$US$US
172581222$17258122$2$F$20150801$20221024$20200110$20221103$EXP$$JP-INCYTE CORPORATION-2019IN013254$INCYTE$$$$$$Y$$$20221104$$MD$JP$JP
172586515$17258651$5$F$20180101$20221031$20200110$20221107$EXP$$PT-MYLANLABS-2020M1002549$MYLAN$Bibi M, Cruz I, Guimaraes F, Ferro A, et al. Miopatia Aguda Grave pela Associacao de Antibioticos e Estatina. 25? Congresso Nacional de Medicina Interna.. Doencas Endocrinas e Metabolicas. 2019$67$YR$$F$Y$$$20221107$$HP$PT$PT
1725994013$17259940$13$F$$20220926$20200111$20221011$EXP$$LT-AUROBINDO-AUR-APL-2020-001762$AUROBINDO$Kunigeliene A, Alekna D, Guzevicius M. A clinical case: Treatment of a patient with schizophrenia and kidney transplant. Health Sciences in Eastern Europe. 2019;29(6):132-5$32$YR$$M$Y$$$20221011$$MD$LT$LT
172600225$17260022$5$F$$20200109$20200111$20221201$EXP$$NVSC2020US005195$NOVARTIS$$$$$F$Y$$$20221201$$HP$US$US
1726004316$17260043$16$F$20171101$20221203$20200111$20221215$EXP$GB-EMA-20191231-AUTODUP-30637000$GB-Accord-169101$ACCORD$$$$E$M$Y$$$20221215$$MD$GB$GB
172601008$17260100$8$F$20221110$20221116$20200111$20221121$EXP$$US-SHIRE-US202000863$TAKEDA$$42$YR$$F$Y$83$KG$20221121$$HP$US$US
172601554$17260155$4$F$$20221021$20200111$20221102$EXP$$CA-APOTEX-2020AP005002$APOTEX$$$$$$Y$$$20221102$$HP$CA$CA
172603295$17260329$5$F$$20221213$20200112$20221219$PER$$US-AMGEN-USASP2020003815$AMGEN$$51$YR$A$F$Y$$$20221219$$MD$US$US
172603304$17260330$4$F$$20221202$20200112$20221209$PER$$US-AMGEN-USASP2020003372$AMGEN$$58$YR$A$F$Y$$$20221209$$CN$US$US
1726079015$17260790$15$F$20190101$20221115$20200113$20221123$EXP$$CA-CELLTRION INC.-2019CA018473$CELLTRION$$$$$$Y$$$20221123$$MD$CA$CA
172611096$17261109$6$F$20200103$20221104$20200113$20221114$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000023$ACADIA PHARMACEUTICALS$$76$YR$$F$Y$$$20221114$$CN$US$US
172615422$17261542$2$F$20180723$20200107$20200113$20221003$PER$$DE-AMGEN-DEUNI2018181916$AMGEN$$56$YR$A$F$Y$56$KG$20221002$$MD$DE$DE
1726168331$17261683$31$F$20190101$20221114$20200113$20221121$EXP$$CA-CELLTRION INC.-2019CA022979$CELLTRION$$$$$$Y$$$20221121$$CN$CA$CA
172622662$17262266$2$F$$20221207$20200113$20221222$PER$$US-SHIRE-US202000986$TAKEDA$$$$$M$Y$12.24$KG$20221222$$CN$US$US
172622735$17262273$5$F$$20221011$20200113$20221020$EXP$GR-EMA-20150317-AUTODUP-407976$GR-MYLANLABS-2020M1002412$MYLAN$Moschou B, Metallinou D, Maniati K, Kapeni E, Nuktari G.. Septicaemia and meningitis from Pantoea agglomerans in full-term neonate.. Proceedings of the 5th panhellenic neonatology congress.. 2014;AA44:10-11$$$N$$Y$3.06$KG$20221020$$HP$GR$GR
172624345$17262434$5$F$$20221212$20200113$20221215$PER$$US-PFIZER INC-2018440225$PFIZER$$77$YR$$F$Y$$$20221215$$CN$US$US
172624547$17262454$7$F$$20221108$20200113$20221114$EXP$$US-PFIZER INC-2019549290$PFIZER$$50$YR$$F$Y$$$20221114$$HP$US$US
172625185$17262518$5$F$$20221214$20200113$20221219$EXP$$NVSC2020US005275$NOVARTIS$$$$$F$Y$$$20221219$$CN$US$US
172625493$17262549$3$F$20190101$20221228$20200113$20221230$PER$$US-PFIZER INC-2020015095$PFIZER$$58$YR$$F$Y$$$20221230$$CN$US$US
172625938$17262593$8$F$20200326$20221129$20200113$20221206$EXP$$CA-TAKEDA-2019TUS050505$TAKEDA$$63$YR$$F$Y$$$20221206$$CN$CA$CA
1726317310$17263173$10$F$20191127$20221213$20200113$20221221$EXP$$CA-TAKEDA-2019TUS053901$TAKEDA$$57$YR$$F$Y$$$20221221$$MD$CA$CA
172634904$17263490$4$F$$20221212$20200113$20221219$EXP$$US-PFIZER INC-2020011382$PFIZER$$$$$M$Y$$$20221219$$LW$US$US
172637972$17263797$2$F$$20221031$20200113$20221104$PER$$CZ-AMGEN-CZESP2020003784$AMGEN$Radocha J.. Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. Cancers. 2022;14:5165$$$$$Y$$$20221104$$HP$CZ$CZ
172642244$17264224$4$F$19910101$20221118$20200113$20221123$EXP$$US-TAKEDA-2020TUS001602$TAKEDA$$$$$$Y$$$20221123$$CN$US$US
172647774$17264777$4$F$20140101$20221017$20200113$20221021$EXP$$US-TAKEDA-2020TUS001716$TAKEDA$$$$$$Y$$$20221021$$CN$US$US
172649344$17264934$4$F$20191206$20221222$20200113$20221226$EXP$$US-JAZZ-2020-US-000338$JAZZ$$37$YR$$F$Y$$$20221226$$MD$US$US
172651642$17265164$2$F$$20221018$20200113$20221025$PER$$US-AMGEN-USASP2020003985$AMGEN$Ailawadhi S. Phase I Trial of lbrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2019;134 (1)$$$$$Y$$$20221025$$MD$US$US
1726526612$17265266$12$F$20191218$20221114$20200114$20221118$EXP$$US-SHIRE-US202000867$TAKEDA$$78$YR$$F$Y$63$KG$20221118$$HP$US$US
172653285$17265328$5$F$$20221121$20200114$20221121$EXP$$CA-ROCHE-2515630$ROCHE$$$$$M$Y$$$20221121$$MD$CA$
172653666$17265366$6$F$$20221028$20200114$20221104$EXP$$US-SHIRE-US202000780$TAKEDA$$$$$M$Y$86$KG$20221104$$MD$US$US
172656897$17265689$7$F$20190101$20221012$20200114$20221016$PER$$BR-AMGEN-BRASP2019202959$AMGEN$$64$YR$A$F$Y$61$KG$20221016$$CN$BR$BR
172659642$17265964$2$F$$20221018$20200114$20221025$PER$$US-AMGEN-USASP2020003980$AMGEN$Ailawadhi S. Phase I Trial of lbrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2019;134 (1)$$$$$Y$$$20221025$$MD$US$US
172671452$17267145$2$F$$20200109$20200114$20221130$EXP$$NVSC2020US004801$NOVARTIS$$$$$F$Y$$$20221130$$CN$US$US
172676217$17267621$7$F$20191201$20221216$20200114$20221221$EXP$$US-PFIZER INC-2020015148$PFIZER$$55$YR$$F$Y$$$20221221$$HP$US$US
172676624$17267662$4$F$$20221017$20200114$20221019$PER$$US-PFIZER INC-2020016524$PFIZER$$68$YR$$F$Y$81.633$KG$20221019$$CN$US$US
172696746$17269674$6$F$20170201$20221123$20200114$20221129$EXP$$DE-SHIRE-DE202000711$TAKEDA$$$$A$M$Y$49$KG$20221129$$HP$DE$DE
172698943$17269894$3$F$20140101$20221017$20200114$20221018$EXP$$US-PFIZER INC-2020016139$PFIZER$$45$YR$$F$Y$$$20221018$$LW$US$US
172703754$17270375$4$F$20180423$20221019$20200114$20221025$EXP$$PHHY2018CA074366$NOVARTIS$$54$YR$$M$Y$$$20221025$$CN$CA$CA
1727078220$17270782$20$F$20221130$20221214$20200115$20221219$EXP$$US-SHIRE-US202000909$TAKEDA$$67$YR$$F$Y$58.05$KG$20221219$$CN$US$US
172709949$17270994$9$F$$20221018$20200115$20221025$EXP$$US-SHIRE-US202000941$TAKEDA$$$$$M$Y$104$KG$20221025$$CN$US$US
172710229$17271022$9$F$20170828$20221011$20200115$20221026$EXP$$US-SA-2019SA127547$SANOFI AVENTIS$$20$YR$A$F$Y$$$20221026$$MD$US$US
172710492$17271049$2$F$$20221018$20200115$20221025$PER$$US-AMGEN-USASP2020003969$AMGEN$Ailawadhi S. Phase I Trial of lbrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2019;134 (1)$$$$$Y$$$20221025$$MD$US$US
172710895$17271089$5$F$20200106$20221107$20200115$20221110$EXP$$US-SHIRE-US202000864$TAKEDA$$51$YR$$F$Y$79.365$KG$20221110$$HP$US$US
172712822$17271282$2$F$$20221018$20200115$20221025$PER$$US-AMGEN-USASP2020003981$AMGEN$Ailawadhi S.. Phase I Trial of lbrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2019;134 (1)$$$$$Y$$$20221025$$MD$US$US
172715592$17271559$2$F$$20221018$20200115$20221025$PER$$US-AMGEN-USASP2020003982$AMGEN$Ailawadhi S.. Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2019;134 (1)$$$$$Y$$$20221025$$MD$US$US
172715602$17271560$2$F$$20221018$20200115$20221025$PER$$US-AMGEN-USASP2020003984$AMGEN$Ailawadhi S. Phase I Trial of lbrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2019;134 (1)$$$$$Y$$$20221025$$MD$US$US
172719322$17271932$2$F$$20221018$20200115$20221025$PER$$US-AMGEN-USASP2020003983$AMGEN$Ailawadhi S.. Phase I Trial of lbrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2019;134 (1)$$$$$Y$$$20221025$$MD$US$US
172721003$17272100$3$F$20190101$20221221$20200115$20221227$EXP$$US-PFIZER INC-2019149582$PFIZER$$63$YR$$F$Y$104$KG$20221227$$HP$US$US
172721025$17272102$5$F$$20221206$20200115$20221209$EXP$$US-PFIZER INC-2019281268$PFIZER$$33$YR$$F$Y$55.34$KG$20221209$$MD$US$US
172721234$17272123$4$F$20150101$20221017$20200115$20221020$EXP$$US-PFIZER INC-2020016133$PFIZER$$45$YR$$F$Y$$$20221020$$LW$US$US
172725774$17272577$4$F$20180101$20221122$20200115$20221206$EXP$$EG-BAYER-2019-205035$BAYER$$42$YR$A$F$Y$$$20221206$$CN$EG$EG
172726733$17272673$3$F$$20221202$20200115$20221206$PER$$US-PFIZER INC-2018511948$PFIZER$$63$YR$$F$Y$$$20221206$$MD$US$US
172730147$17273014$7$F$$20221024$20200115$20221026$EXP$$US-PFIZER INC-2020017107$PFIZER$$41$YR$$M$Y$$$20221026$$CN$US$US
172732468$17273246$8$F$20190101$20221021$20200115$20221028$EXP$$JP-Eisai Medical Research-EC-2020-068229$EISAI$Kuroda T, Watanabe E. A case of pseudocirrhosis caused by administration of eribulin after CDK4/6 inhibitor. Lecture.$$$E$F$Y$$$20221028$$MD$JP$
172736437$17273643$7$F$20211130$20221014$20200115$20221020$EXP$$US-SHIRE-US202000939$TAKEDA$$77$YR$$F$Y$55$KG$20221019$$CN$US$US
172744545$17274454$5$F$20221123$20221123$20200115$20221201$EXP$$US-TAKEDA-2020TUS001598$TAKEDA$$69$YR$$F$Y$77.605$KG$20221201$$HP$US$US
1727561225$17275612$25$F$20181023$20221026$20200116$20221103$EXP$$CA-CELLTRION INC.-2018CA023762$CELLTRION$$$$$$Y$$$20221104$$CN$CA$CA
172757674$17275767$4$F$20200107$20221115$20200116$20221118$EXP$$US-SHIRE-US202001534$TAKEDA$$35$YR$$M$Y$$$20221118$$PH$US$US
172758158$17275815$8$F$20191201$20221026$20200116$20221104$PER$$US-AMGEN-USASP2020003550$AMGEN$Chen, DY. Durable melanoma control following disseminated talimogene laherparepvec herpetic infection. JAAD Case reports. 2022;29:131-133$96$YR$E$F$Y$$$20221104$$MD$US$US
172758873$17275887$3$F$20191114$20221110$20200116$20221122$EXP$$FR-AUROBINDO-AUR-APL-2020-002035$AUROBINDO$$13$YR$$M$Y$$$20221122$$MD$FR$FR
172765972$17276597$2$F$$20200113$20200116$20221124$EXP$$NVSC2020US007416$NOVARTIS$$$$$M$Y$$$20221124$$HP$US$US
172772475$17277247$5$F$20200109$20220930$20200116$20221003$EXP$$ES-JNJFOC-20200116288$JOHNSON AND JOHNSON$$70$YR$E$F$Y$84.7$KG$20221003$$MD$ES$ES
172775292$17277529$2$F$$20220929$20200116$20221012$PER$$US-ELI_LILLY_AND_COMPANY-US202001007025$ELI LILLY AND CO$$83$YR$$F$Y$$$20221012$$CN$US$US
1727785045$17277850$45$F$20190101$20221208$20200116$20221216$EXP$$PHHY2019CA181510$NOVARTIS$$56$YR$$M$Y$$$20221216$$CN$CA$CA
172781543$17278154$3$F$20151001$20221108$20200116$20221111$EXP$$US-INCYTE CORPORATION-2020IN000262$INCYTE$$$$$$Y$$$20221111$$CN$US$US
172783584$17278358$4$F$$20220927$20200116$20221004$PER$$US-INCYTE CORPORATION-2020IN000234$INCYTE$$$$$$Y$$$20221004$$CN$US$US
172784102$17278410$2$F$20190801$20221114$20200116$20221116$EXP$FR-AFSSAPS-NY20191729$FR-MYLANLABS-2020M1004521$MYLAN$$48$YR$$M$Y$77.5$KG$20221116$$MD$FR$FR
1727848511$17278485$11$F$20190730$20221112$20200116$20221116$EXP$$IN-PFIZER INC-2020019644$PFIZER$$35$YR$$M$Y$63.5$KG$20221116$$CN$IN$IN
172784864$17278486$4$F$20220901$20221123$20200116$20221124$EXP$$US-PFIZER INC-2020019787$PFIZER$$76$YR$$M$Y$$$20221124$$CN$US$US
172784945$17278494$5$F$19910101$20221205$20200116$20221206$EXP$$US-PFIZER INC-2020019157$PFIZER$$20$YR$$M$Y$$$20221206$$LW$US$US
172785056$17278505$6$F$20200101$20221124$20200116$20221202$EXP$$US-PFIZER INC-2020021298$MYLAN$$60$YR$$M$Y$79$KG$20221202$$HP$US$US
172796252$17279625$2$F$$20200115$20200116$20221201$PER$$NVSC2020US010304$NOVARTIS$$$$$F$Y$$$20221201$$CN$US$US
1727971929$17279719$29$F$20200107$20221109$20200116$20221118$EXP$$CA-CELLTRION INC.-2019CA026794$CELLTRION$$$$$$Y$$$20221118$$CN$CA$CA
172800807$17280080$7$F$20191123$20221027$20200117$20221104$EXP$$CA-CELLTRION INC.-2019CA025824$CELLTRION$$$$$$Y$$$20221105$$MD$CA$CA
172802306$17280230$6$F$$20221203$20200117$20221208$EXP$$US-ROCHE-2523313$ROCHE$$82$YR$$M$Y$$$20221208$$CN$US$
1728024211$17280242$11$F$20211209$20221114$20200117$20221116$EXP$$US-SHIRE-US202001435$TAKEDA$$68$YR$$F$Y$98$KG$20221116$$CN$US$US
172804276$17280427$6$F$20200612$20221215$20200117$20221220$PER$$US-SHIRE-US202000988$TAKEDA$$50$YR$$M$Y$75$KG$20221220$$CN$US$US
1728219218$17282192$18$F$20191209$20221201$20200117$20221209$EXP$$CA-ROCHE-2522555$ROCHE$$55$YR$$F$Y$$$20221209$$CN$CA$CA
1728222014$17282220$14$F$20190101$20221219$20200117$20221226$EXP$$CA-ROCHE-2522590$ROCHE$$38$YR$$F$Y$$$20221226$$CN$CA$CA
1728269614$17282696$14$F$20191101$20221206$20200117$20221210$EXP$$US-SHIRE-US202001296$TAKEDA$$70$YR$$F$Y$70.295$KG$20221210$$CN$US$US
172827522$17282752$2$F$20191101$20200113$20200117$20221124$EXP$$NVSC2019AZ064116$NOVARTIS$$27$YR$$M$Y$$$20221124$$MD$AZ$AZ
172831849$17283184$9$F$$20221221$20200117$20221230$PER$$US-PFIZER INC-2018148522$PFIZER$$41$YR$$F$Y$82$KG$20221230$$MD$US$US
172832216$17283221$6$F$20200102$20221109$20200117$20221111$PER$$US-PFIZER INC-2020019606$PFIZER$$69$YR$$F$Y$77.098$KG$20221111$$CN$US$US
172832673$17283267$3$F$$20221221$20200117$20221227$PER$$US-PFIZER INC-2020020780$PFIZER$$36$YR$$F$Y$88.889$KG$20221227$$MD$US$US
1728327014$17283270$14$F$20200114$20221205$20200117$20221208$EXP$$US-PFIZER INC-2020022774$PFIZER$$48$YR$$F$Y$$$20221208$$HP$US$US
1728388611$17283886$11$F$$20221121$20200117$20221129$EXP$$CA-CELLTRION INC.-2020CA017835$CELLTRION$$$$$$Y$$$20221129$$CN$CA$CA
172842233$17284223$3$F$20160101$20221123$20200117$20221130$EXP$$PHHY2016CA158001$NOVARTIS$$$$$F$Y$$$20221130$$CN$CA$CA
172842665$17284266$5$F$20170316$20221121$20200117$20221129$EXP$$CA-AstraZeneca-2020SE05042$ASTRAZENECA$$50$YR$$F$Y$$$20221129$$MD$CA$
172851376$17285137$6$F$20191101$20221005$20200117$20221012$EXP$$ES-JNJFOC-20200124756$JOHNSON AND JOHNSON$$58$YR$A$M$Y$59$KG$20221010$$MD$ES$ES
172851962$17285196$2$F$20190901$20221011$20200117$20221019$EXP$DK-DKMA-WBS-0023586$DK-MYLANLABS-2020M1004728$MYLAN$$62$YR$$F$Y$$$20221019$$MD$DK$DK
1728609023$17286090$23$F$20180118$20220930$20200118$20221011$EXP$$GB-AUROBINDO-AUR-APL-2018-057945$AUROBINDO$$76$YR$$M$Y$69$KG$20221011$$MD$GB$GB
172864903$17286490$3$F$$20220926$20200119$20221007$EXP$$CA-JNJFOC-20200117320$JOHNSON AND JOHNSON$$60$YR$A$F$Y$$$20221007$$MD$CA$CA
1728665730$17286657$30$F$20191129$20221124$20200119$20221203$EXP$$CA-CELLTRION INC.-2019CA028016$CELLTRION$$$$$$Y$$$20221203$$MD$CA$CA
1728673036$17286730$36$F$20191213$20221220$20200119$20221230$EXP$$CA-CELLTRION INC.-2020CA017731$CELLTRION$$$$$$Y$$$20221230$$HP$CA$CA
172876493$17287649$3$F$$20221129$20200120$20221208$EXP$$CA-ABBVIE-20K-028-3238834-00$ABBVIE$$74$YR$$M$Y$$$20221208$$HP$CA$CA
172883905$17288390$5$F$20190101$20221102$20200120$20221103$EXP$$US-PFIZER INC-2018091581$PFIZER$$64$YR$$M$Y$117.9$KG$20221103$$CN$US$US
172886987$17288698$7$F$20211001$20221006$20200120$20221008$EXP$$DE-ROCHE-2519590$ROCHE$$28$YR$$F$Y$50$KG$20221008$$MD$DE$
172891057$17289105$7$F$20210101$20221207$20200120$20221214$EXP$$US-PFIZER INC-2020024902$PFIZER$$73$YR$$F$Y$$$20221214$$CN$US$US
172891086$17289108$6$F$$20221019$20200120$20221021$EXP$$US-PFIZER INC-2020024918$PFIZER$$91$YR$$F$Y$$$20221021$$CN$US$US
172891688$17289168$8$F$$20221123$20200120$20221130$EXP$$US-TAKEDA-2020TUS003777$TAKEDA$$$$$M$Y$$$20221130$$CN$US$US
172892912$17289291$2$F$20190101$20221107$20200120$20221118$EXP$$FR-ELI_LILLY_AND_COMPANY-FR201907009859$ELI LILLY AND CO$$72$YR$$M$Y$$$20221118$$CN$DE$FR
172896456$17289645$6$F$20180314$20221021$20200120$20221031$EXP$$FR-MYLANLABS-2020M1005214$MYLAN$$54$YR$$M$Y$70$KG$20221031$$MD$FR$FR
1728967813$17289678$13$F$20221205$20221219$20200120$20221224$EXP$$US-SHIRE-US202001340$TAKEDA$$74$YR$$F$Y$102$KG$20221224$$HP$US$US
1728968117$17289681$17$F$20191229$20221216$20200120$20221222$EXP$$US-SHIRE-US202001714$TAKEDA$$17$YR$$M$Y$$$20221222$$HP$US$US
172901249$17290124$9$F$20190801$20221212$20200120$20221216$EXP$$CO-TAKEDA-2019TUS049387$TAKEDA$$30$YR$$F$Y$68$KG$20221216$$HP$CO$CO
1729051210$17290512$10$F$20160901$20221020$20200121$20221027$EXP$$GB-ROCHE-1845223$ROCHE$$50$YR$$F$Y$$$20221027$$MD$GB$GB
1729120129$17291201$29$F$20191015$20221220$20200121$20221228$EXP$$CA-CELLTRION INC.-2019CA025942$CELLTRION$$$$$$Y$$$20221228$$CN$CA$CA
172912963$17291296$3$F$20180101$20221008$20200121$20221010$PER$$US-GILEAD-2020-0447098$GILEAD$$31$YR$A$M$Y$$$20221010$$LW$US$US
172928383$17292838$3$F$$20221011$20200121$20221021$EXP$FR-EMA-DD-20200110-KUMARVN_P-105945$FR-Accord-170214$ACCORD$$38$YR$A$F$Y$$$20221021$$HP$FR$FR
172929885$17292988$5$F$20211001$20221221$20200121$20221228$EXP$$US-PFIZER INC-2019421384$PFIZER$$66$YR$$F$Y$108.86$KG$20221228$$CN$US$US
172930486$17293048$6$F$20170301$20221213$20200121$20221219$EXP$$PHHY2017CA048441$NOVARTIS$$30$YR$$M$Y$$$20221219$$MD$CA$CA
1729309218$17293092$18$F$20190101$20221214$20200121$20221222$EXP$$CA-CELLTRION INC.-2019CA017860$CELLTRION$$$$$$Y$$$20221222$$CN$CA$CA
172944095$17294409$5$F$20160901$20221007$20200121$20221011$EXP$$US-GILEAD-2020-0447109$GILEAD$$53$YR$A$M$Y$80.726$KG$20221011$$LW$US$US
172947894$17294789$4$F$20191227$20200228$20200121$20221020$EXP$$NVSJ2019JP006644$NOVARTIS$$$$$F$Y$$$20221020$$MD$JP$JP
172948202$17294820$2$F$$20200115$20200121$20221111$EXP$$NVSC2020GR012691$NOVARTIS$Apostolakopoulou L, Armenis G, Tentolouris V, Mavridis Th, Strataki E, Tzanetakos D et al.. Longitudinal myelitis in a patient with psoriasis under secukinumab. 2019$45$YR$$M$Y$$$20221111$$HP$GR$GR
172951913$17295191$3$F$$20221025$20200121$20221027$PER$$US-PFIZER INC-2020025753$PFIZER$$76$YR$$F$Y$$$20221027$$CN$US$US
1729521911$17295219$11$F$$20221110$20200121$20221114$EXP$$US-PFIZER INC-2020024834$PFIZER$$54$YR$$F$Y$$$20221114$$MD$US$US
1729522712$17295227$12$F$$20221005$20200121$20221007$EXP$$US-PFIZER INC-2020024926$PFIZER$$71$YR$$F$Y$66$KG$20221007$$CN$US$US
172952479$17295247$9$F$20160101$20221117$20200121$20221122$EXP$$US-PFIZER INC-2020025165$PFIZER$$59$YR$$M$Y$$$20221122$$HP$US$US
172952912$17295291$2$F$$20221128$20200121$20221202$EXP$$US-PFIZER INC-2020025807$PFIZER$$84$YR$$M$Y$64.41$KG$20221202$$CN$US$US
172959397$17295939$7$F$20200401$20221115$20200122$20221118$EXP$$CA-ABBVIE-20K-028-3234155-00$ABBVIE$$72$YR$$M$Y$$$20221118$$MD$CA$CA
172969425$17296942$5$F$20220101$20221222$20200122$20221229$EXP$$CA-ROCHE-2526128$ROCHE$$44$YR$$F$Y$$$20221229$$CN$CA$CA
1729699816$17296998$16$F$$20221107$20200121$20221116$EXP$$CA-JNJFOC-20200116985$JOHNSON AND JOHNSON$$23$YR$A$F$Y$$$20221117$$HP$CA$CA
1729700112$17297001$12$F$$20221019$20200121$20221027$EXP$$CA-JNJFOC-20200118152$JOHNSON AND JOHNSON$$32$YR$A$F$Y$$$20221027$$HP$CA$CA
1729726323$17297263$23$F$20200108$20221111$20200122$20221121$EXP$$CA-CELLTRION INC.-2019CA025455$CELLTRION$$$$$$Y$$$20221121$$MD$CA$CA
172974214$17297421$4$F$20190101$20221222$20200122$20221226$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2020JPN010786$VIIV$$$$$$Y$$$20221226$$MD$JP$JP
172974424$17297442$4$F$20200101$20221013$20200121$20221019$EXP$$NVSC2020CA014573$NOVARTIS$$32$YR$$F$Y$$$20221019$$MD$CA$CA
172975264$17297526$4$F$20191211$20220405$20200122$20221223$EXP$$US-Horizon-ACT-0020-2020$HORIZON THERAPEUTICS$$$$$$Y$$$20221223$$MD$US$US
172975887$17297588$7$F$$20221107$20200121$20221114$EXP$$CA-JNJFOC-20200116972$JOHNSON AND JOHNSON$$25$YR$A$M$Y$$$20221114$$HP$CA$CA
1729767423$17297674$23$F$20151201$20221220$20200121$20221222$EXP$$PHHY2015CA170994$NOVARTIS$$57$YR$$F$Y$$$20221222$$CN$CA$CA
172979518$17297951$8$F$20190101$20221207$20200121$20221214$EXP$$US-PFIZER INC-2019467124$PFIZER$$73$YR$$F$Y$54$KG$20221214$$CN$US$US
1729803811$17298038$11$F$$20221212$20200121$20221221$EXP$$CA-TAKEDA-2020TUS003290$TAKEDA$$66$YR$$M$Y$$$20221221$$CN$CA$CA
172983575$17298357$5$F$$20221109$20200122$20221114$EXP$$NVSJ2020JP000592$NOVARTIS$Kawakubo N, Hishiki T, Arakawa A. Three cases of surgical resection for pneumothorax/tumour bronchial fistula due to metastases of osteosarcoma to lung. S-PIC (PEDIATRIC SURGERY AND PEDIATRIC INTENSIVE CARE) 2019 PROGRAM/ABSTRACTS FO. 2019;165$18$YR$$F$Y$$$20221114$$HP$JP$JP
172983653$17298365$3$F$$20200407$20200122$20221213$EXP$$NVSC2020US007753$NOVARTIS$$$$$F$Y$$$20221213$$CN$US$US
172984096$17298409$6$F$20200101$20221114$20200121$20221123$EXP$$US-VERTEX PHARMACEUTICALS-2020-000591$VERTEX$$12$YR$$M$Y$$$20221123$$MD$US$US
172986276$17298627$6$F$$20221201$20200122$20221205$PER$$US-BIOGEN-2020BI00828119$BIOGEN$$$$$F$Y$$$20221205$$CN$US$US
172986927$17298692$7$F$20191129$20221117$20200122$20221124$EXP$$NVSC2020DE012660$NOVARTIS$$$$A$F$Y$46$KG$20221124$$HP$DE$DE
172989086$17298908$6$F$$20221017$20200121$20221020$EXP$$US-PFIZER INC-2020022641$PFIZER$$74$YR$$F$Y$97$KG$20221020$$CN$US$US
172990774$17299077$4$F$$20221109$20200121$20221115$EXP$$NVSJ2020JP000591$NOVARTIS$Kawakubo N, Hishiki T, Arakawa A, Nakajima M. Three cases of surgical resection for pneumothorax/tumour bronchial fistula due to metastases of osteosarcoma to lung. S-PIC (PEDIATRIC SURGERY?PEDIATRIC INTENSIVE CARE) 2019 PROGRAM/ABSTRACTS FOR TH. 2019;165$11$YR$$F$Y$$$20221115$$HP$JP$JP
172992653$17299265$3$F$20190101$20221205$20200121$20221213$PER$$US-TAKEDA-2020TUS003386$TAKEDA$$$$$M$Y$88$KG$20221213$$MD$US$US
173006862$17300686$2$F$$20221010$20200122$20221013$EXP$$US-ALLERGAN-2000182US$ALLERGAN$$$$$F$Y$$$20221013$$HP$US$US
173007859$17300785$9$F$$20221214$20200122$20221221$EXP$$CA-JNJFOC-20200124582$JOHNSON AND JOHNSON$$76$YR$E$F$Y$$$20221221$$CN$CA$CA
173009033$17300903$3$F$20211112$20221110$20200122$20221115$PER$$US-PFIZER INC-2020027759$PFIZER$$70$YR$$F$Y$$$20221115$$CN$US$US
173010855$17301085$5$F$20140501$20221205$20200122$20221208$PER$$US-PFIZER INC-2020028341$PFIZER$$59$YR$$F$Y$205$KG$20221208$$CN$US$US
1730111415$17301114$15$F$$20221111$20200122$20221116$PER$$US-PFIZER INC-2020030255$PFIZER$$87$YR$$F$Y$61.23$KG$20221116$$MD$US$US
173011227$17301122$7$F$20200103$20221020$20200122$20221101$EXP$$US-PFIZER INC-2020011017$PFIZER$$57$YR$$F$Y$86$KG$20221101$$CN$US$US
173012626$17301262$6$F$20180101$20221028$20200122$20221104$EXP$$PHHY2018CA014341$NOVARTIS$$$$$M$Y$$$20221104$$CN$CA$CA
173014062$17301406$2$F$$20221129$20200122$20221207$EXP$$FR-MYLANLABS-2020M1002520$MYLAN$Attal M, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019;394(10214):2096-2107.$57$YR$$M$Y$$$20221207$$MD$FR$FR
173014072$17301407$2$F$$20221129$20200122$20221208$EXP$$FR-MYLANLABS-2020M1002524$MYLAN$Attal M, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019;394(10214):2096-2107.$76$YR$$M$Y$$$20221208$$MD$FR$FR
173014082$17301408$2$F$$20221129$20200122$20221209$EXP$$FR-MYLANLABS-2020M1002523$MYLAN$Attal M, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019;394(10214):2096-2107.$68$YR$$M$Y$$$20221209$$MD$FR$FR
173015104$17301510$4$F$$20221229$20200122$20221230$PER$$NVSC2020US015572$NOVARTIS$$$$$F$Y$$$20221230$$CN$US$US
1730154537$17301545$37$F$$20221205$20200122$20221214$EXP$$US-SHIRE-US202002077$TAKEDA$$$$$F$Y$109$KG$20221214$$HP$US$US
173019064$17301906$4$F$20191216$20221025$20200122$20221031$EXP$$US-VERTEX PHARMACEUTICALS-2019-013334$VERTEX$$35$YR$$F$Y$83$KG$20221031$$MD$US$US
173024242$17302424$2$F$$20200121$20200122$20221124$EXP$$NVSC2020US015808$NOVARTIS$$$$$M$Y$$$20221124$$CN$US$US
173030985$17303098$5$F$$20221014$20200122$20221018$PER$$US-PFIZER INC-2020032006$PFIZER$$75$YR$$M$Y$$$20221018$$CN$US$US
1730486111$17304861$11$F$$20221026$20200123$20221103$EXP$$US-PFIZER INC-2019149638$PFIZER$$68$YR$$F$Y$$$20221103$$MD$US$US
173049086$17304908$6$F$$20221019$20200123$20221024$PER$$US-PFIZER INC-2020029555$PFIZER$$78$YR$$F$Y$$$20221024$$CN$US$US
173049186$17304918$6$F$20190101$20221221$20200123$20221227$PER$$US-PFIZER INC-2020008919$PFIZER$$36$YR$$F$Y$104.3$KG$20221227$$CN$US$US
173049205$17304920$5$F$20210201$20221024$20200123$20221026$EXP$$US-PFIZER INC-2020029963$PFIZER$$75$YR$$F$Y$$$20221026$$CN$US$US
173050128$17305012$8$F$$20221108$20200123$20221114$PER$$US-PFIZER INC-2020022448$PFIZER$$53$YR$$F$Y$95.25$KG$20221114$$CN$US$US
173050652$17305065$2$F$$20221121$20200123$20221202$EXP$$CA-TAKEDA-2020TUS004386$TAKEDA$$65$YR$$F$Y$$$20221202$$HP$CA$CA
173052496$17305249$6$F$$20221111$20200123$20221115$EXP$$US-PFIZER INC-2020031979$PFIZER$$64$YR$$F$Y$$$20221115$$HP$US$US
173057284$17305728$4$F$20221109$20221109$20200123$20221116$PER$$NVSC2020US017006$NOVARTIS$$60$YR$$M$Y$$$20221116$$CN$US$US
173060167$17306016$7$F$$20220902$20200123$20221215$PER$$NVSC2020US016291$NOVARTIS$$$$$F$Y$$$20221215$$CN$US$US
173061376$17306137$6$F$20191101$20221123$20200123$20221128$EXP$$US-PFIZER INC-2020024829$PFIZER$$62$YR$$F$Y$$$20221128$$CN$US$US
1730673612$17306736$12$F$20191027$20221004$20200123$20221013$EXP$$NVSC2020US015670$NOVARTIS$$19$YR$$M$Y$$$20221013$$MD$US$US
1730700518$17307005$18$F$$20221026$20200123$20221109$EXP$$CA-AUROBINDO-AUR-APL-2020-003529$AUROBINDO$$44$YR$$F$Y$97$KG$20221109$$MD$CA$CA
1730775715$17307757$15$F$20180116$20221111$20200123$20221123$EXP$$BR-GLAXOSMITHKLINE-BR2016GSK112839$GLAXOSMITHKLINE$$$$$$Y$$$20221123$$MD$BR$BR
1730776611$17307766$11$F$$20221212$20200123$20221219$EXP$$CA-GLAXOSMITHKLINE-CA2020AMR008683$GLAXOSMITHKLINE$$$$$$Y$$$20221219$$MD$CA$CA
173086613$17308661$3$F$$20221006$20200123$20221010$EXP$$US-REGENERON PHARMACEUTICALS, INC.-2020-13117$REGENERON$$$$$F$Y$$$20221010$$CN$US$US
1730946114$17309461$14$F$20200701$20221216$20200123$20221221$EXP$$US-ROCHE-2428021$ROCHE$$46$YR$$M$Y$$$20221221$$CN$US$
173137022$17313702$2$F$$20191114$20200124$20221117$EXP$$JP-ROCHE-2501354$ROCHE$$$$$F$Y$$$20221117$$MD$JP$JP
173139238$17313923$8$F$$20221214$20200124$20221221$EXP$$US-SHIRE-US202002370$TAKEDA$$$$$F$Y$63$KG$20221221$$HP$US$US
173140338$17314033$8$F$$20221011$20200124$20221018$EXP$$CA-GLAXOSMITHKLINE-CA2019AMR223877$GLAXOSMITHKLINE$$$$$$Y$$$20221018$$MD$CA$CA
173140423$17314042$3$F$20191101$20221005$20200124$20221012$EXP$$GB-GLAXOSMITHKLINE-GB2020EME011793$GLAXOSMITHKLINE$$$$$$Y$$$20221012$$HP$GB$GB
173153516$17315351$6$F$20200101$20220923$20200124$20221003$EXP$$US-VERTEX PHARMACEUTICALS-2020-001002$VERTEX$$$$$F$Y$68$KG$20221003$$MD$US$US
173156073$17315607$3$F$20210101$20221111$20200124$20221122$PER$$US-SA-2020SA017376$SANOFI AVENTIS$$62$YR$A$F$Y$$$20221122$$MD$US$US
173157734$17315773$4$F$20200101$20221101$20200124$20221109$PER$$US-SA-2020SA017137$SANOFI AVENTIS$$48$YR$A$F$Y$$$20221109$$MD$US$US
173158158$17315815$8$F$$20220927$20200124$20221003$PER$$US-PFIZER INC-2020030061$PFIZER$$67$YR$$$Y$$$20221003$$HP$US$US
1731591611$17315916$11$F$$20221216$20200124$20221222$EXP$$US-PFIZER INC-2018520926$PFIZER$$72$YR$$F$Y$119.29$KG$20221222$$MD$US$US
173161745$17316174$5$F$20200101$20221103$20200124$20221104$EXP$$US-PFIZER INC-2020029458$PFIZER$$94$YR$$F$Y$$$20221104$$CN$US$US
173168642$17316864$2$F$20190801$20220929$20200124$20221003$EXP$$DE-PFIZER INC-2019405299$PFIZER$$67$YR$$F$Y$54$KG$20221003$$CN$DE$DE
1731720632$17317206$32$F$$20221209$20200124$20221217$EXP$$US-SHIRE-US202001903$TAKEDA$$$$$F$Y$57.596$KG$20221217$$HP$US$US
1731726343$17317263$43$F$20191030$20221024$20200124$20221031$EXP$$US-SHIRE-US201935296$TAKEDA$$86$YR$$F$Y$68$KG$20221031$$HP$US$US
173178963$17317896$3$F$20220517$20221011$20200124$20221012$PER$$NVSC2020US018204$NOVARTIS$$26$YR$$M$Y$$$20221012$$CN$US$US
173182824$17318282$4$F$20200108$20220930$20200124$20221004$EXP$$IT-PFIZER INC-2020030343$PFIZER$$8$YR$$F$Y$$$20221004$$MD$IT$IT
1731844115$17318441$15$F$20120101$20221123$20200124$20221128$EXP$$PHHY2019CA102821$NOVARTIS$$41$YR$$F$Y$87$KG$20221128$$MD$CA$CA
173185202$17318520$2$F$20190529$20221114$20200124$20221118$EXP$$US-ABBVIE-19P-163-3147267-00$ABBVIE$$75$YR$$F$Y$$$20221118$$MD$US$US
173186435$17318643$5$F$20190101$20221125$20200124$20221130$EXP$$BR-BIOGEN-2020BI00829529$BIOGEN$$$$$F$Y$48$KG$20221130$$CN$BR$BR
173186677$17318667$7$F$20191214$20221031$20200124$20221107$EXP$$US-VERTEX PHARMACEUTICALS-2020-000166$VERTEX$$25$YR$$M$Y$66$KG$20221107$$MD$US$US
173186784$17318678$4$F$20191126$20221014$20200124$20221018$EXP$$US-PFIZER INC-2020032771$PFIZER$$74$YR$$F$Y$72.562$KG$20221018$$CN$US$US
173189183$17318918$3$F$$20221201$20200124$20221207$EXP$$US-JAZZ-2020-US-001065$JAZZ$$$$$F$Y$$$20221207$$CN$US$US
173193645$17319364$5$F$$20221205$20200124$20221212$PER$$NL-AMGEN-NLDSP2020011618$AMGEN$Houdt W. J. V.. Talimogene laherparepvec monotherapy for head and neck melanoma patients. Melanoma Research. 2022;1-5$$$$$Y$$$20221212$$MD$NL$NL
173219196$17321919$6$F$20220203$20221021$20200127$20221028$EXP$$US-ACORDA-ACO_159682_2019$ACORDA$$71$YR$$F$Y$$$20221028$$CN$US$US
173222285$17322228$5$F$20180801$20221208$20200127$20221216$PER$$US-AMGEN-USASP2020012197$AMGEN$$70$YR$E$F$Y$$$20221216$$MD$US$US
1732293231$17322932$31$F$20200106$20221216$20200127$20221222$EXP$$CA-ROCHE-2521131$ROCHE$$48$YR$$M$Y$$$20221222$$CN$CA$
173237804$17323780$4$F$20150301$20221208$20200127$20221215$EXP$$US-BIOGEN-2015BI044525$BIOGEN$$54$YR$$F$Y$$$20221215$$CN$US$US
173240855$17324085$5$F$$20200123$20200127$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-005924$BRISTOL MYERS SQUIBB$$58$YR$A$M$Y$$$20221222$$HP$CA$CA
173240979$17324097$9$F$20210101$20221213$20200127$20221220$EXP$$BR-GLAXOSMITHKLINE-BR2020AMR012597$GLAXOSMITHKLINE$$$$$$Y$$$20221220$$CN$BR$BR
1732521514$17325215$14$F$20180201$20221220$20200127$20221227$EXP$$US-PFIZER INC-2020031985$PFIZER$$71$YR$$F$Y$65.76$KG$20221227$$MD$US$US
173258114$17325811$4$F$$20221024$20200127$20221026$EXP$$US-PFIZER INC-2020036855$PFIZER$$80$YR$$F$Y$$$20221026$$CN$US$US
1732598411$17325984$11$F$20190101$20221129$20200127$20221206$EXP$$US-VERTEX PHARMACEUTICALS-2019-013607$VERTEX$$$$$F$Y$91$KG$20221206$$MD$US$US
173262385$17326238$5$F$$20221130$20200127$20221205$PER$$US-PFIZER INC-2020034375$PFIZER$$70$YR$$M$Y$$$20221205$$CN$US$US
173263863$17326386$3$F$$20221114$20200127$20221116$PER$$US-PFIZER INC-2020033129$PFIZER$$71$YR$$F$Y$$$20221116$$CN$US$US
173264086$17326408$6$F$$20221122$20200127$20221124$PER$$US-PFIZER INC-2020034753$PFIZER$$61$YR$$F$Y$$$20221124$$MD$US$US
173264283$17326428$3$F$$20221223$20200127$20221227$PER$$US-PFIZER INC-2020036619$PFIZER$$61$YR$$F$Y$$$20221227$$HP$US$US
173265493$17326549$3$F$$20221011$20200127$20221019$EXP$$ALC2020CA000613$ALCON$$70$YR$$M$Y$$$20221019$$CN$CA$CA
173266432$17326643$2$F$20190701$20221212$20200127$20221219$EXP$FR-AFSSAPS-TS20191312$FR-PFIZER INC-2020029045$PFIZER$$50$YR$$M$Y$91$KG$20221219$$MD$FR$FR
173273062$17327306$2$F$$20200110$20200127$20221026$EXP$$NVSJ2020JP000661$NOVARTIS$$$$$$Y$$$20221026$$MD$JP$JP
173275075$17327507$5$F$20190101$20221026$20200127$20221027$EXP$$JP-SHIRE-JP202002887AA$TAKEDA$$$$$M$Y$45.2$KG$20221027$$CN$JP$JP
1732786710$17327867$10$F$20190101$20221213$20200127$20221219$EXP$$PHHY2019CA011353$NOVARTIS$$53$YR$$F$Y$$$20221219$$CN$CA$CA
173303783$17330378$3$F$$20221220$20200128$20221223$PER$$US-SA-2020SA014879$SANOFI AVENTIS$$43$YR$A$F$Y$$$20221223$$CN$US$US
173307393$17330739$3$F$20190905$20220914$20200128$20221017$PER$$CO-TOLMAR, INC.-19CO000182$TOLMAR$$84$YR$$M$Y$$$20221017$$HP$CO$CO
173311152$17331115$2$F$20190101$20221213$20200128$20221216$EXP$$US-GW PHARMA-202001USGW00288$JAZZ$$$$$$Y$$$20221216$$CN$US$US
173318902$17331890$2$F$$20200114$20200128$20221031$PER$$US-UCBSA-2020003860$UCB$Schreiber JM, Tochen L, Brown M, Evans S, Ball LJ, Bumbut A, et al. A multi-disciplinary clinic for SCN8A-related epilepsy. Epilepsy Research. 2020;159$1$YR$$F$Y$$$20221031$$MD$US$US
1733203537$17332035$37$F$20191120$20221018$20200127$20221027$EXP$$CA-CELLTRION INC.-2019CA027203$CELLTRION$$$$$$Y$$$20221027$$CN$CA$CA
173322992$17332299$2$F$$20221214$20200128$20221222$EXP$$CA-SHIRE-CA202002543$TAKEDA$$$$$$Y$$$20221222$$CN$CA$CA
173328584$17332858$4$F$20200123$20220224$20200128$20221026$EXP$$US-GLAXOSMITHKLINE-US2020TSO014358$GLAXOSMITHKLINE$$41$YR$$F$Y$$$20221026$$MD$US$US
173331207$17333120$7$F$$20221108$20200128$20221111$PER$$US-AMGEN-USASP2020012486$AMGEN$$68$YR$E$F$Y$$$20221111$$MD$US$US
173332167$17333216$7$F$20191220$20221214$20200128$20221220$EXP$$MX-ROCHE-2531379$ROCHE$$49$YR$$F$Y$57$KG$20221220$$CN$MX$
173335142$17333514$2$F$20221001$20221212$20200128$20221215$EXP$FR-AFSSAPS-MA20200052$FR-PURDUE-GBR-2020-0074631$PURDUE$$42$YR$$M$Y$$$20221215$$PH$FR$FR
173337024$17333702$4$F$20140201$20221128$20200128$20221130$EXP$FR-AFSSAPS-NY20200105$FR-ABBVIE-20K-056-3251787-00$ABBVIE$$45$YR$$F$Y$78$KG$20221130$$MD$FR$FR
173345783$17334578$3$F$20070601$20221103$20200128$20221107$PER$$US-JNJFOC-20200143102$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221107$$LW$US$US
173346362$17334636$2$F$20040101$20220926$20200128$20221006$PER$$US-JNJFOC-20200143457$JOHNSON AND JOHNSON$$1$DEC$C$M$Y$$$20221006$$LW$US$US
1733492111$17334921$11$F$$20221212$20200128$20221219$EXP$$CA-GLAXOSMITHKLINE-CA2020AMR012159$GLAXOSMITHKLINE$$$$$$Y$$$20221219$$MD$CA$CA
173349534$17334953$4$F$$20221104$20200128$20221109$EXP$$CA-GLAXOSMITHKLINE-CA2020AMR003146$GLAXOSMITHKLINE$$$$$$Y$$$20221109$$MD$CA$CA
173352824$17335282$4$F$20180101$20221021$20200128$20221027$EXP$$US-JAZZ-2020-US-001201$JAZZ$$$$$M$Y$$$20221027$$CN$US$US
173353478$17335347$8$F$$20221206$20200128$20221213$EXP$$BR-GLAXOSMITHKLINE-BR2018GSK215886$GLAXOSMITHKLINE$$$$$$Y$$$20221213$$CN$BR$BR
173361865$17336186$5$F$$20221201$20200129$20221213$EXP$$CA-Orion Corporation ORION PHARMA-TREX2020-0525$ORION$$57$YR$A$M$Y$$$20221213$$HP$CA$
173363572$17336357$2$F$$20220928$20200128$20221007$PER$$US-JNJFOC-20200143087$JOHNSON AND JOHNSON$$$$$M$Y$$$20221007$$LW$US$US
173363582$17336358$2$F$$20221130$20200128$20221207$PER$$US-JNJFOC-20200143105$JOHNSON AND JOHNSON$$$$$M$Y$$$20221207$$LW$US$US
1733660221$17336602$21$F$20200109$20221118$20200129$20221124$EXP$$NVSC2020IE013187$NOVARTIS$$54$YR$$F$Y$64.2$KG$20221124$$MD$IE$IE
173368262$17336826$2$F$$20200114$20200129$20221031$PER$$US-UCBSA-2020003862$UCB$Schreiber JM, Tochen L, Brown M, Evans S, Ball LJ, Bumbut A, et al. A multi-disciplinary clinic for SCN8A-related epilepsy. Epilepsy Research. 2020;159$11$YR$$M$Y$$$20221031$$MD$US$US
173369296$17336929$6$F$$20221004$20200128$20221013$EXP$$PT-PFIZER INC-2020030830$PFIZER$Matos, A.. Henoch-schonlein purpura in adult-a diagnostic and therapeutic challenge. REVISTA ONLINE DE CASOS CLINICOS EM MEDICINA INTERNA (RCCMI). 2019;1-3$72$YR$$M$Y$$$20221013$$HP$PT$PT
173370126$17337012$6$F$20180101$20221104$20200128$20221114$EXP$$US-PFIZER INC-2020036817$PFIZER$$75$YR$$F$Y$102.04$KG$20221114$$CN$US$US
173370185$17337018$5$F$20191226$20221017$20200128$20221020$PER$$US-PFIZER INC-2020038814$PFIZER$$53$YR$$F$Y$$$20221020$$HP$US$US
173370454$17337045$4$F$20180621$20221209$20200129$20221216$EXP$$PHHY2018CA033855$NOVARTIS$$75$YR$$F$Y$$$20221216$$CN$CA$CA
173371512$17337151$2$F$20190806$20200125$20200129$20221104$EXP$$NVSC2020RO020670$NOVARTIS$$59$YR$$M$Y$$$20221104$$CN$RO$RO
1733784512$17337845$12$F$$20221115$20200129$20221122$EXP$$GB-GLAXOSMITHKLINE-GB2020011881$GLAXOSMITHKLINE$$7$YR$$M$Y$$$20221122$$MD$GB$GB
173378713$17337871$3$F$$20221123$20200129$20221203$EXP$$CA-TEVA-2020-CA-1176269$TEVA$$53$YR$A$F$Y$$$20221203$$CN$CA$CA
1733836612$17338366$12$F$20160609$20221125$20200129$20221201$EXP$$PHHY2016CA082637$NOVARTIS$$62$YR$$F$Y$$$20221201$$MD$CA$CA
1733894213$17338942$13$F$20190515$20221006$20200129$20221012$EXP$$NVSJ2020JP000775$NOVARTIS$$3$YR$$M$Y$13.7$KG$20221012$$MD$JP$JP
173390632$17339063$2$F$$20221228$20200129$20221230$PER$$US-JNJFOC-20200143188$JOHNSON AND JOHNSON$$$$$M$Y$$$20221230$$LW$US$US
173390796$17339079$6$F$20200122$20221117$20200129$20221122$EXP$$US-SA-2019SA174831$SANOFI AVENTIS$$4$YR$C$M$Y$$$20221122$$MD$US$US
173399128$17339912$8$F$$20221129$20200129$20221202$EXP$$US-AMNEAL PHARMACEUTICALS-2020-AMRX-00178$AMNEAL$$$$$M$Y$104.3$KG$20221202$$MD$US$US
173401808$17340180$8$F$$20221003$20200129$20221008$EXP$$GXKR2008GB07781$NOVARTIS$Furse R, Green C, Mee A. Carcinoid Syndrome Unmasked by Fluoxetine, a Selective Serotonin Reuptake Inhibitor. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY. 2008;6:e27-8$55$YR$$M$Y$$$20221008$$HP$GB$GB
1734035221$17340352$21$F$20190703$20221216$20200129$20221222$EXP$$US-GLAXOSMITHKLINE-2019-TSO02447-US$GLAXOSMITHKLINE$$$$$$Y$$$20221222$$MD$US$US
173413554$17341355$4$F$20200118$20221126$20200129$20221206$EXP$$BG-TAKEDA-2020TUS005257$TAKEDA$$33$YR$$F$Y$$$20221206$$CN$BG$BG
1734312211$17343122$11$F$20200728$20221220$20200129$20221230$EXP$$US-VERTEX PHARMACEUTICALS-2020-001238$VERTEX$$12$YR$$M$Y$53$KG$20221230$$MD$US$US
173457657$17345765$7$F$20200120$20221215$20200129$20221221$EXP$$UA-BAYER-2020-012156$BAYER$$$$A$M$Y$77$KG$20221221$$MD$UA$UA
173458532$17345853$2$F$20180318$20221102$20200129$20221110$EXP$$JP-BIOGEN-2020BI00832124$BIOGEN$$51$YR$$F$Y$45.6$KG$20221110$$MD$JP$JP
1734605312$17346053$12$F$20180501$20221217$20200129$20221222$EXP$$CO-TAKEDA-2018TUS017346$TAKEDA$$61$YR$$F$Y$68$KG$20221222$$HP$CO$CO
173463774$17346377$4$F$$20221101$20200129$20221107$PER$$US-AMGEN-USASP2020014494$AMGEN$$67$YR$E$F$Y$$$20221107$$CN$US$US
173465613$17346561$3$F$$20200124$20200130$20221213$PER$$NVSC2020US020394$NOVARTIS$$71$YR$$F$Y$$$20221213$$HP$US$US
1734668928$17346689$28$F$20190101$20221010$20200130$20221011$EXP$$NVSC2020US022180$NOVARTIS$$$$$F$Y$$$20221011$$CN$US$US
173474132$17347413$2$F$$20221007$20200130$20221014$EXP$$NVSC2019CA075890$NOVARTIS$$$$$F$Y$70$KG$20221014$$CN$CA$CA
173474818$17347481$8$F$$20221011$20200130$20221018$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-006919$BRISTOL MYERS SQUIBB$$59$YR$A$M$Y$$$20221018$$MD$JP$JP
173475502$17347550$2$F$20200101$20221018$20200130$20221026$PER$$US-VERTEX PHARMACEUTICALS-2020-001301$VERTEX$$31$YR$$M$Y$$$20221026$$HP$US$US
1734818914$17348189$14$F$20160101$20221123$20200130$20221128$EXP$$US-PFIZER INC-2020039215$PFIZER$$65$YR$$F$Y$82$KG$20221128$$CN$US$US
173482156$17348215$6$F$20191220$20221019$20200130$20221021$PER$$US-PFIZER INC-2020039889$PFIZER$$65$YR$$F$Y$90.703$KG$20221021$$CN$US$US
173482484$17348248$4$F$20191201$20221220$20200130$20221227$EXP$$US-PFIZER INC-2020039887$PFIZER$$58$YR$$F$Y$59.864$KG$20221227$$HP$US$US
173493094$17349309$4$F$20191001$20221129$20200130$20221209$PER$$JP-AMGEN-JPNSP2020014610$AMGEN$$$$$$Y$$$20221208$$MD$JP$JP
1734972316$17349723$16$F$20180508$20221006$20200130$20221020$EXP$$DE-PFIZER INC-2019154747$MYLAN$$39$YR$$F$Y$70$KG$20221020$$MD$DE$DE
173500913$17350091$3$F$20190604$20221212$20200130$20221218$EXP$$GB-BIOGEN-2019BI00751558$BIOGEN$$70$YR$$M$Y$$$20221218$$CN$GB$GB
173501748$17350174$8$F$20191201$20221117$20200130$20221124$EXP$$CA-BAUSCH-BL-2020-001386$BAUSCH AND LOMB$$50$YR$$M$Y$$$20221124$$CN$CA$CA
173503688$17350368$8$F$20190901$20221214$20200130$20221221$EXP$$AT-MYLANLABS-2020M1010555$MYLAN$$$$A$F$Y$$$20221221$$MD$AT$AT
173509413$17350941$3$F$$20221017$20200130$20221029$EXP$$US-drreddys-USA/USA/20/0119044$DR REDDYS$Newsome A, Taylor A, Garner S. Therapeutic Anticoagulation With an Ultra-Low Concentration Argatroban-Based Purge Solution for Percutaneous Ventricular Assist Device in Patient With Heparin-Induced Thrombocytopenia. Hospital Pharmacy. 2019;UNKNOWN:1-6. doi:10.1177/0018578719888905$68$YR$E$M$Y$$$20221029$$PH$US$US
173509566$17350956$6$F$20200126$20221116$20200130$20221118$EXP$$JP-PFIZER INC-2020043997$PFIZER$$48$YR$$F$Y$44.3$KG$20221118$$MD$JP$JP
1735101110$17351011$10$F$20200122$20221005$20200130$20221008$EXP$$NVSC2020JP018338$NOVARTIS$$47$YR$$F$Y$64.2$KG$20221008$$MD$JP$JP
173511383$17351138$3$F$$20221223$20200130$20221227$EXP$GB-EMA-DD-20200117-ZAVIOUR_N-164821$GB-STRIDES ARCOLAB LIMITED-2020SP000855$STRIDES$$20$WK$$$Y$$$20221228$$MD$GB$GB
173511678$17351167$8$F$20221004$20221013$20200130$20221018$EXP$$US-SHIRE-US202003357$TAKEDA$$55$YR$$F$Y$98.866$KG$20221018$$CN$US$US
173516857$17351685$7$F$20191027$20221018$20200130$20221021$EXP$$US-PFIZER INC-2020039732$PFIZER$$19$YR$$M$Y$103.5$KG$20221021$$MD$US$US
173521344$17352134$4$F$$20200224$20200130$20221210$EXP$$US-TEVA-2020-US-1175590$TEVA$Chaucer B, Stone A, Davis RM, Aulakh BS. Fatal chemotherapy-induced mucositis. Am-J-Respir-Crit-Care-Med 2019;199(9): (plus poster) abstr. A4827.$60$YR$A$F$Y$$$20221210$$HP$US$US
1735338410$17353384$10$F$20191206$20221219$20200131$20221223$EXP$$DE-ROCHE-2528579$ROCHE$$28$YR$$F$Y$81$KG$20221223$$MD$DE$
1735410617$17354106$17$F$20200115$20221219$20200131$20221223$EXP$$CA-ROCHE-2534441$ROCHE$$38$YR$$F$Y$$$20221223$$CN$CA$CA
173558623$17355862$3$F$$20221125$20200131$20221205$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-02852$SAMSUNG BIOEPIS$$18$YR$A$M$Y$60$KG$20221205$$CN$CA$CA
173563689$17356368$9$F$$20221122$20200131$20221128$EXP$$US-SHIRE-US202003090$TAKEDA$$$$$F$Y$75.737$KG$20221128$$HP$US$US
1735636911$17356369$11$F$20221201$20221222$20200131$20221230$EXP$$US-SHIRE-US202003207$TAKEDA$$72$YR$$M$Y$73$KG$20221230$$MD$US$US
1735662313$17356623$13$F$20210601$20221011$20200131$20221017$EXP$$US-SHIRE-US202003292$TAKEDA$$19$YR$$F$Y$48$KG$20221017$$CN$US$US
173569534$17356953$4$F$$20221104$20200131$20221108$PER$$US-PFIZER INC-2020042227$PFIZER$$$$$F$Y$$$20221108$$HP$US$US
173574694$17357469$4$F$20190502$20221114$20200131$20221122$EXP$$JP-LUNDBECK-DKLU3008104$LUNDBECK$$11$MON$I$F$Y$7.08$KG$20221122$$HP$JP$JP
173574924$17357492$4$F$$20221004$20200131$20221012$EXP$$PT-TAKEDA-2020TEU001095$TAKEDA$Matos AS, Pais JP, Cambao AR, Nascimento A, Guerra D. Henoch-schonlein purpura in adult-a diagnostic and therapeutic challenge. Portuguese Society of Internal Medicine. 2019;1-3$72$YR$$M$Y$$$20221012$$HP$PT$PT
1735832711$17358327$11$F$20200310$20221003$20200201$20221007$EXP$$US-SHIRE-US202003319$TAKEDA$$60$YR$$F$Y$82$KG$20221007$$HP$US$US
173588869$17358886$9$F$20200810$20221222$20200202$20221230$EXP$$US-SHIRE-US202003388$TAKEDA$$71$YR$$F$Y$77$KG$20221230$$CN$US$US
173588907$17358890$7$F$20210613$20220928$20200202$20221004$EXP$$NVSC2020IL023723$NOVARTIS$$49$YR$$F$Y$$$20221004$$HP$IL$IL
173588987$17358898$7$F$20210906$20221216$20200202$20221224$EXP$$US-SHIRE-US202003314$TAKEDA$$62$YR$$F$Y$54$KG$20221224$$CN$US$US
173592659$17359265$9$F$20200128$20221021$20200203$20221030$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-007781$BRISTOL MYERS SQUIBB$$65$YR$E$M$Y$$$20221031$$MD$JP$JP
173593472$17359347$2$F$$20221109$20200203$20221118$PER$$US-AMGEN-USASP2020015688$AMGEN$Clark R. O.; Donigian S.; Whiteway S. et al.. Malignant Giant Cell Tumor of Bone With a KRAS G12V Mutation. Journal of Pediatric Hematology/Oncology. 2022;44 (1):e268-e271$24$YR$A$M$Y$$$20221118$$MD$US$US
173594256$17359425$6$F$20191129$20221115$20200203$20221118$EXP$$TR-ROCHE-2524659$ROCHE$$62$YR$$M$Y$59$KG$20221118$$MD$TR$
1735947110$17359471$10$F$20191104$20221114$20200203$20221117$EXP$$DE-ABBVIE-20K-062-3259942-00$ABBVIE$$70$YR$$M$Y$90$KG$20221117$$MD$DE$DE
173595103$17359510$3$F$20200126$20221201$20200203$20221208$EXP$$JP-ALEXION PHARMACEUTICALS INC.-A202001115$ALEXION$$26$YR$$F$Y$$$20221208$$MD$JP$JP
1735980310$17359803$10$F$20210101$20221121$20200203$20221128$EXP$$US-SHIRE-US202003739$TAKEDA$$18$YR$$M$Y$76.644$KG$20221128$$CN$US$US
1736021823$17360218$23$F$20190624$20221207$20200203$20221219$PER$$JP-AMGEN-JPNSP2019109964$AMGEN$$53$YR$A$F$Y$43.7$KG$20221219$$MD$JP$JP
173616223$17361622$3$F$20190601$20220929$20200203$20221005$EXP$$US-SA-2020SA026500$SANOFI AVENTIS$$72$YR$E$M$Y$$$20221006$$CN$US$US
173618647$17361864$7$F$20200123$20221027$20200203$20221108$EXP$$JP-PFIZER INC-2020041706$PFIZER$$14$YR$$M$Y$32$KG$20221108$$MD$JP$JP
1736204216$17362042$16$F$20190501$20221129$20200203$20221201$EXP$$US-PFIZER INC-2020044804$PFIZER$$71$YR$$F$Y$86.18$KG$20221201$$CN$US$US
173620798$17362079$8$F$20190401$20221208$20200203$20221215$EXP$$CA-ROCHE-2538349$ROCHE$$71$YR$$M$Y$87$KG$20221215$$MD$CA$CA
173623427$17362342$7$F$20210520$20221130$20200203$20221209$EXP$$US-SHIRE-US202003413$TAKEDA$$64$YR$$F$Y$72.11$KG$20221209$$CN$US$US
173624086$17362408$6$F$20191113$20221104$20200203$20221109$EXP$$ES-SHIRE-ES202003902$TAKEDA$$7$YR$$M$Y$24$KG$20221109$$HP$ES$ES
173625003$17362500$3$F$$20220927$20200203$20221003$EXP$$ES-GLAXOSMITHKLINE-ES2019157039$GLAXOSMITHKLINE$Sadyrbaeva-Dolgova S. Nephrogenic diabetes insipidus induced by liposomal amphotericin b. A case report. EJHP-SP. 2019;26 (Suppl. 1):A106$$$$$Y$$$20221003$$PH$ES$ES
173625735$17362573$5$F$$20221107$20200203$20221111$PER$$US-PFIZER INC-2020041654$PFIZER$$64$YR$$F$Y$$$20221111$$CN$US$US
1736308011$17363080$11$F$20200114$20221109$20200203$20221109$EXP$$NVSC2020MY016963$NOVARTIS$$61$YR$$M$Y$51.1$KG$20221109$$MD$MY$MY
173633722$17363372$2$F$20191205$20221123$20200203$20221128$EXP$$DE-BAUSCH-BL-2020-002565$BAUSCH AND LOMB$$70$YR$$M$Y$$$20221128$$MD$DE$DE
173634806$17363480$6$F$20190327$20221121$20200203$20221205$EXP$$US-JUBILANT CADISTA PHARMACEUTICALS-2019JUB00272$JUBILANT$$61$YR$$M$Y$77.098$KG$20221205$$CN$US$US
173640613$17364061$3$F$20221219$20221219$20200204$20221227$EXP$$US-TAKEDA-2020TUS005565$TAKEDA$$65$YR$$F$Y$$$20221227$$MD$US$US
173640705$17364070$5$F$$20221130$20200204$20221206$PER$$US-AMGEN-USASP2020016609$AMGEN$$68$YR$E$F$Y$$$20221205$$MD$US$US
173644474$17364447$4$F$20191201$20221128$20200204$20221208$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000293$ACADIA PHARMACEUTICALS$$80$YR$$F$Y$$$20221208$$CN$US$US
1736501613$17365016$13$F$20190816$20221125$20200204$20221209$EXP$$DE-AUROBINDO-AUR-APL-2020-004698$AUROBINDO$$54$YR$$F$Y$100$KG$20221209$$CN$DE$DE
173657673$17365767$3$F$20200125$20221126$20200204$20221130$EXP$$BG-TAKEDA-2020TUS005688$TAKEDA$$51$YR$$F$Y$$$20221130$$CN$BG$BG
173660153$17366015$3$F$20200118$20221103$20200204$20221107$EXP$$GB-KARYOPHARM THERAPEUTICS, INC.-2020KPT000083$KARYOPHARM THERAPEUTICS$$81$YR$$F$Y$64.9$KG$20221107$$MD$GB$GB
1736618910$17366189$10$F$$20221025$20200204$20221031$EXP$$US-PFIZER INC-2020047923$PFIZER$$71$YR$$F$Y$$$20221031$$CN$US$US
173661903$17366190$3$F$$20221106$20200204$20221108$PER$$US-PFIZER INC-2020043844$PFIZER$$54$YR$$F$Y$$$20221108$$CN$US$US
173662197$17366219$7$F$$20221219$20200204$20221222$PER$$US-PFIZER INC-2020042410$PFIZER$$48$YR$$F$Y$50$KG$20221222$$CN$US$US
173665856$17366585$6$F$20191227$20221108$20200204$20221114$EXP$$US-PFIZER INC-2020044883$PFIZER$$84$YR$$F$Y$86$KG$20221114$$CN$US$US
173670323$17367032$3$F$20191201$20221028$20200204$20221104$EXP$$BR-JNJFOC-20200137428$JOHNSON AND JOHNSON$$20$YR$A$M$Y$65$KG$20221104$$CN$BR$BR
1736705013$17367050$13$F$20191112$20220922$20200204$20221006$EXP$DE-002147023-NVSC2019DE060731 (DE-002147023-NVSC2019DE060731)$DE-IBIGEN-2020.08147$ISTITUTO BICHIMICO ITALIANO GIOVANNI LORENZINI (IBIGEN)$$63$YR$$F$Y$73$KG$20220822$$HP$DE$
1736718410$17367184$10$F$20200101$20221223$20200204$20221229$EXP$$US-PFIZER INC-2020044415$PFIZER$$75$YR$$M$Y$$$20221229$$HP$US$US
173672685$17367268$5$F$20191121$20221025$20200204$20221101$EXP$$ES-Taiho Oncology  Inc-IM-2019-00684$TAIHO ONCOLOGY INC$$84$YR$E$M$Y$64.3$KG$20221101$$MD$ES$ES
173674442$17367444$2$F$$20221129$20200204$20221202$PER$$US-JNJFOC-20200203354$JOHNSON AND JOHNSON$$$$$M$Y$$$20221202$$LW$US$US
173674622$17367462$2$F$$20221121$20200204$20221124$PER$$US-JNJFOC-20200203015$JOHNSON AND JOHNSON$$$$$M$Y$$$20221124$$LW$US$US
173675482$17367548$2$F$$20221202$20200204$20221212$EXP$$CA-Allegis Pharmaceuticals, LLC-APL202001-000013$ALLEGIS PHARMACEUTICALS$$72$YR$E$M$Y$$$20221210$$CN$CA$
173675862$17367586$2$F$$20220926$20200204$20221004$EXP$$IN-SHIRE-IN202003418$TAKEDA$Parida A, Bhat, et.al. An unusual case of human intravenous immunoglobulin induced erythema multiforme in a child. INDIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY. 62:201$4$YR$$F$Y$$$20221004$$HP$IN$IN
173679754$17367975$4$F$20200130$20221201$20200204$20221207$PER$$NVSC2020US028679$NOVARTIS$$23$YR$$F$Y$$$20221207$$CN$US$US
173696472$17369647$2$F$20190801$20221114$20200204$20221121$EXP$$BE-ABBVIE-20K-013-3262704-00$ABBVIE$$67$YR$$M$Y$$$20221121$$MD$BE$BE
1736984612$17369846$12$F$20200101$20221110$20200205$20221114$EXP$$US-DSJP-DSU-2020-103633$DAIICHI$$32$YR$$M$Y$$$20221114$$CN$US$US
173701713$17370171$3$F$$20200128$20200205$20221212$EXP$$NVSC2020US022918$NOVARTIS$$$$$F$Y$$$20221212$$MD$US$US
173703086$17370308$6$F$20190101$20221107$20200205$20221110$EXP$$JP-UCBSA-2020004974$UCB$Narita H, Tsuboi Y. A case of rhabdomyolysis with disseminated erythema-type drug eruption. The Nishinihon journal of dermatology, Organ magazine of Western Japan Division. 2019;81 (6):529$68$YR$$F$Y$$$20221110$$MD$JP$JP
173704083$17370408$3$F$$20221013$20200205$20221023$PER$$ES-AMGEN-ESPSP2020016426$AMGEN$Gonzalez-quevedo D.; Perez-del-rio V.; Moriel-garceso D. et al.. A 2-year follow-up of a novel Fracture Liaison Service: can we reduce the mortality in elderly hip fracture patients? A prospective cohort study. Osteoporosis International. 2022;33 (8):1695-1702$$$$$Y$$$20221023$$HP$ES$ES
173706094$17370609$4$F$20200101$20221103$20200205$20221110$EXP$$US-SA-2020SA029459$SANOFI AVENTIS$$56$YR$A$F$Y$$$20221110$$CN$US$US
1737076341$17370763$41$F$20200129$20221215$20200205$20221221$EXP$$US-SHIRE-US202004220$TAKEDA$$3$YR$$M$Y$$$20221221$$MD$US$US
173714243$17371424$3$F$$20200203$20200205$20221212$PER$$NVSC2020US029041$NOVARTIS$$$$$M$Y$$$20221212$$CN$US$US
1737154710$17371547$10$F$$20221227$20200205$20221229$EXP$$US-PFIZER INC-2020042059$PFIZER$$70$YR$$F$Y$66.68$KG$20221229$$HP$US$US
173716245$17371624$5$F$$20221011$20200205$20221013$EXP$$NVSC2020US030087$NOVARTIS$$$$$F$Y$$$20221013$$CN$US$US
173719042$17371904$2$F$20110101$20221221$20200205$20221227$PER$$US-JNJFOC-20200203050$JOHNSON AND JOHNSON$$10$YR$C$M$Y$$$20221227$$LW$US$US
1737222311$17372223$11$F$$20221017$20200205$20221020$EXP$$CA-TAKEDA-2019TUS074322$TAKEDA$$59$YR$$F$Y$$$20221019$$CN$CA$CA
1737231113$17372311$13$F$20191101$20221115$20200205$20221121$EXP$$CA-TAKEDA-2020TUS004702$TAKEDA$$61$YR$$F$Y$$$20221121$$HP$CA$CA
1737275419$17372754$19$F$20180315$20221216$20200205$20221222$EXP$$DE-MYLANLABS-2020M1012929$MYLAN$$63$YR$$F$Y$$$20221222$$CN$DE$DE
173732856$17373285$6$F$$20221123$20200205$20221130$EXP$$US-SHIRE-US202004073$TAKEDA$$$$$F$Y$122.5$KG$20221130$$CN$US$US
1737363136$17373631$36$F$20190101$20221221$20200206$20221229$EXP$$CA-CELLTRION INC.-2019CA026726$CELLTRION$$$$$$Y$$$20221229$$MD$CA$CA
173737052$17373705$2$F$$20221220$20200206$20221227$EXP$$CA-ROCHE-2543800$ROCHE$$17$YR$$M$Y$$$20221227$$CN$CA$CA
173739212$17373921$2$F$20080101$20220921$20200205$20221001$PER$$US-JNJFOC-20200204647$JOHNSON AND JOHNSON$$8$YR$C$M$Y$$$20221001$$LW$US$US
173744284$17374428$4$F$$20221212$20200205$20221219$EXP$$US-PFIZER INC-2020048680$PFIZER$$70$YR$$F$Y$$$20221219$$CN$US$US
1737445322$17374453$22$F$20050101$20221206$20200205$20221208$EXP$$US-PFIZER INC-2020047798$PFIZER$$47$YR$$F$Y$81.65$KG$20221208$$CN$US$US
1737465711$17374657$11$F$$20221031$20200205$20221102$PER$$US-PFIZER INC-2020052652$PFIZER$$57$YR$$F$Y$$$20221102$$MD$US$US
173752722$17375272$2$F$$20221027$20200205$20221102$EXP$$US-PFIZER INC-2020045028$PFIZER$$54$YR$$F$Y$$$20221102$$CN$US$US
173753042$17375304$2$F$$20221128$20200205$20221202$EXP$$PL-MYLANLABS-2020M1012749$MYLAN$Kryszczyszyn-musialik, K.. Hodgkin^s lymphoma with multifocal Staphylococcus aureus infection in a 29-years-old male - a case study.. Onkologia w Praktyce Klinicznej - Edukacja.. 2019;5 (4):280-285$29$YR$$M$Y$$$20221202$$MD$PL$PL
173754403$17375440$3$F$20200120$20221006$20200205$20221013$PER$$FR-AMGEN-FRACT2020014715$AMGEN$$52$YR$A$M$Y$69$KG$20221013$$MD$FR$FR
173758734$17375873$4$F$$20221222$20200206$20221227$PER$$US-BIOGEN-2020BI00835941$BIOGEN$$$$$F$Y$$$20221227$$CN$US$US
1737609510$17376095$10$F$20200103$20221004$20200206$20221010$EXP$$US-SHIRE-US202004144$TAKEDA$$68$YR$$F$Y$75$KG$20221010$$MD$US$US
173768493$17376849$3$F$20200124$20221128$20200206$20221129$PER$$US-JNJFOC-20200143117$JOHNSON AND JOHNSON$$58$YR$A$F$Y$77.18$KG$20221129$$HP$US$US
173771376$17377137$6$F$$20221222$20200206$20221227$PER$$US-PFIZER INC-2020054612$PFIZER$$69$YR$$F$Y$$$20221227$$MD$US$US
173773552$17377355$2$F$$20221208$20200206$20221214$EXP$$US-PFIZER INC-2018190640$PFIZER$$70$YR$$M$Y$$$20221214$$CN$US$US
173773707$17377370$7$F$$20221203$20200206$20221208$EXP$$US-PFIZER INC-2020052181$PFIZER$$79$YR$$M$Y$104.3$KG$20221208$$CN$US$US
1737739210$17377392$10$F$$20221207$20200206$20221212$EXP$$US-PFIZER INC-2020050680$PFIZER$$75$YR$$F$Y$88.45$KG$20221212$$CN$US$US
173792712$17379271$2$F$$20221216$20200206$20221223$EXP$$CA-GLAXOSMITHKLINE-CA2020AMR018999$GLAXOSMITHKLINE$$$$$$Y$$$20221223$$MD$CA$CA
173848182$17384818$2$F$$20221010$20200206$20221013$EXP$$CA-BAUSCH-BL-2020-003444$BAUSCH AND LOMB$$59$YR$$F$Y$$$20221013$$MD$CA$CA
173863293$17386329$3$F$20200115$20220930$20200206$20221010$PER$$FR-AMGEN-FRANI2020014917$AMGEN$$62$YR$A$M$Y$55$KG$20221010$$MD$FR$FR
173864012$17386401$2$F$$20221219$20200206$20221222$EXP$$CA-PFIZER INC-2020052451$PFIZER$$60$YR$$F$Y$$$20221222$$CN$CA$CA
173865465$17386546$5$F$$20221021$20200206$20221031$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-03485$SAMSUNG BIOEPIS$$44$YR$A$M$Y$90$KG$20221031$$MD$CA$CA
173865556$17386555$6$F$$20221006$20200206$20221013$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-03486$SAMSUNG BIOEPIS$$67$YR$E$M$Y$76$KG$20221013$$MD$CA$CA
173870625$17387062$5$F$$20221012$20200206$20221014$EXP$$US-PFIZER INC-2020046285$PFIZER$$51$YR$$M$Y$$$20221014$$CN$US$US
1738840017$17388400$17$F$20200805$20221214$20200206$20221222$EXP$$US-SHIRE-US202003705$TAKEDA$$72$YR$$F$Y$82$KG$20221222$$HP$US$US
173884484$17388448$4$F$20200124$20221010$20200206$20221018$EXP$$US-SHIRE-US202003914$TAKEDA$$51$YR$$F$Y$$$20221018$$CN$US$US
173886353$17388635$3$F$$20221116$20200207$20221121$PER$$US-PFIZER INC-2020053494$PFIZER$$71$YR$$F$Y$42.1$KG$20221121$$MD$US$US
173889225$17388922$5$F$$20221030$20200207$20221103$PER$$US-PFIZER INC-2020053082$PFIZER$$49$YR$$F$Y$$$20221103$$CN$US$US
173889292$17388929$2$F$$20221010$20200207$20221014$EXP$$US-PFIZER INC-2020051073$PFIZER$$73$YR$$F$Y$$$20221014$$CN$US$US
173891816$17389181$6$F$20210806$20221004$20200206$20221010$EXP$$NVSC2020US024561$NOVARTIS$$73$YR$$F$Y$51.701$KG$20221010$$CN$US$US
173905766$17390576$6$F$20200101$20221114$20200207$20221117$EXP$$US-BIOGEN-2020BI00835159$BIOGEN$$63$YR$$F$Y$56.75$KG$20221117$$CN$US$US
173906829$17390682$9$F$$20221227$20200207$20221230$EXP$$US-SHIRE-US202004225$TAKEDA$$$$$M$Y$125$KG$20221230$$CN$US$US
1739068510$17390685$10$F$20220728$20221215$20200207$20221220$EXP$$US-SHIRE-US202004184$TAKEDA$$74$YR$$F$Y$55$KG$20221220$$HP$US$US
173907914$17390791$4$F$20221007$20221025$20200207$20221027$EXP$$US-SHIRE-US202004669$TAKEDA$$30$YR$$M$Y$$$20221027$$PH$US$US
173907974$17390797$4$F$$20210202$20200207$20221006$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-235616$RANBAXY$$$$$F$Y$$$20221006$$CN$US$US
1739088212$17390882$12$F$$20221212$20200207$20221221$EXP$$CA-PFIZER INC-2018169790$PFIZER$$63$YR$$F$Y$$$20221221$$HP$CA$CA
173908956$17390895$6$F$20160803$20221201$20200207$20221202$EXP$FR-AFSSAPS-NY20200105$FR-TAKEDA-2020TUS007476$TAKEDA$$45$YR$$F$Y$78$KG$20221202$$HP$FR$FR
1739101038$17391010$38$F$$20221211$20200207$20221219$EXP$GB-EMA-DD-20200116-ZAVIOUR_N-155806$GB-drreddys-GER/UKI/20/0119153$DR REDDYS$$47$YR$A$F$Y$$$20221219$$PH$GB$GB
173912002$17391200$2$F$20190701$20221109$20200207$20221115$EXP$$DK-ALLERGAN-2005008US$ALLERGAN$$$$$F$Y$50$KG$20221115$$CN$DK$DK
1739122120$17391221$20$F$20170801$20221122$20200207$20221130$EXP$$CA-JNJFOC-20170826218$JOHNSON AND JOHNSON$$40$YR$A$F$Y$$$20221130$$MD$CA$CA
173916303$17391630$3$F$20170101$20221121$20200207$20221201$EXP$$NO-CELLTRION INC.-2020NO018498$CELLTRION$$$$$$Y$$$20221201$$MD$NO$NO
173917396$17391739$6$F$20220901$20220923$20200207$20221003$EXP$$US-SHIRE-US202004040$TAKEDA$$43$YR$$F$Y$47$KG$20221003$$CN$US$US
173918893$17391889$3$F$$20221025$20200207$20221031$EXP$$FR-UCBSA-2020005344$UCB$$71$YR$$M$Y$$$20221031$$MD$FR$FR
1739250616$17392506$16$F$20191227$20221202$20200207$20221209$EXP$$CA-ROCHE-2515343$ROCHE$$41$YR$$F$Y$$$20221209$$CN$CA$
173925169$17392516$9$F$20190510$20220927$20200207$20221003$EXP$$JP-ROCHE-2329919$ROCHE$$57$YR$$M$Y$67$KG$20221003$$MD$JP$JP
173932862$17393286$2$F$20180730$20200204$20200208$20221019$PER$$AR-AMGEN-ARGSP2020021079$AMGEN$$27$YR$A$F$Y$$$20221017$$CN$AR$AR
173934063$17393406$3$F$20200101$20221019$20200208$20221020$EXP$$US-ROCHE-2543309$ROCHE$$68$YR$$F$Y$$$20221020$$CN$US$
1739349510$17393495$10$F$20191218$20221020$20200208$20221025$EXP$$CA-TAKEDA-2020TUS005498$TAKEDA$$69$YR$$F$Y$$$20221025$$MD$CA$CA
173936429$17393642$9$F$$20221120$20200209$20221125$EXP$$US-SHIRE-US202004662$TAKEDA$$$$$F$Y$113$KG$20221125$$HP$US$US
1739377319$17393773$19$F$20200107$20221116$20200209$20221124$EXP$$CA-CELLTRION INC.-2020CA017870$CELLTRION$$$$$$Y$$$20221125$$HP$CA$CA
173944263$17394426$3$F$20200124$20220923$20200210$20221001$EXP$$US-SHIRE-US201937572$TAKEDA$$43$YR$$F$Y$56$KG$20221001$$HP$US$US
1739475011$17394750$11$F$20191205$20221128$20200210$20221207$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010529$BRISTOL MYERS SQUIBB$$46$YR$A$F$Y$51.6$KG$20221207$$MD$JP$JP
173965385$17396538$5$F$$20221011$20200210$20221013$PER$$US-PFIZER INC-2020056709$PFIZER$$66$YR$$F$Y$$$20221013$$MD$US$US
173966876$17396687$6$F$20221026$20221031$20200210$20221102$EXP$$US-PFIZER INC-2020052747$PFIZER$$74$YR$$M$Y$$$20221102$$MD$US$US
173967606$17396760$6$F$20150101$20221221$20200210$20221227$EXP$$US-PFIZER INC-2020055269$PFIZER$$57$YR$$F$Y$$$20221227$$HP$US$US
173968945$17396894$5$F$20200113$20221019$20200210$20221025$EXP$$NVSC2020CA033218$NOVARTIS$$81$YR$$M$Y$$$20221025$$CN$CA$CA
173969925$17396992$5$F$$20221111$20200210$20221116$EXP$$US-TAKEDA-2020TUS005766$TAKEDA$$$$$F$Y$58.957$KG$20221116$$MD$US$US
173971664$17397166$4$F$$20221205$20200210$20221212$EXP$$DE-MYLANLABS-2020M1013822$MYLAN$$74$YR$$F$Y$$$20221212$$MD$DE$DE
173975703$17397570$3$F$$20221111$20200210$20221118$EXP$$NVSC2020US034163$NOVARTIS$$$$$F$Y$$$20221118$$CN$US$US
1739772610$17397726$10$F$20221209$20221220$20200210$20221227$EXP$$US-SHIRE-US202003911$TAKEDA$$77$YR$$F$Y$70$KG$20221227$$HP$US$US
173979212$17397921$2$F$$20221101$20200210$20221111$EXP$$US-TEVA-2020-US-1181356$TEVA$$52$YR$A$F$Y$$$20221111$$CN$US$US
173989242$17398924$2$F$20200128$20221130$20200210$20221206$PER$$US-SHIRE-US202004250$TAKEDA$$49$YR$$M$Y$97$KG$20221206$$CN$US$US
173994473$17399447$3$F$20191008$20221214$20200211$20221219$EXP$$US-ROCHE-2454141$ROCHE$$7$YR$$M$Y$28$KG$20221219$$MD$US$
173996382$17399638$2$F$$20221021$20200211$20221026$PER$$US-SHIRE-US202005119$TAKEDA$$$$$M$Y$81.633$KG$20221026$$HP$US$US
174007379$17400737$9$F$$20221104$20200211$20221109$PER$$NVSC2020US035931$NOVARTIS$$$$$F$Y$49.89$KG$20221109$$CN$US$US
1740089714$17400897$14$F$20200101$20221212$20200211$20221219$EXP$$NVSC2020US033420$NOVARTIS$$60$YR$$F$Y$$$20221219$$CN$US$US
174011995$17401199$5$F$20181124$20220929$20200211$20221003$EXP$$US-TAKEDA-2020TUS006788$TAKEDA$$0$YR$$F$Y$2.589$KG$20221003$$HP$US$US
174013702$17401370$2$F$20191031$20221116$20200211$20221125$EXP$GB-JNJFOC-20200209260$GB-TAKEDA-2020TUS008927$TAKEDA$$75$YR$$F$Y$$$20221125$$MD$GB$GB
174014675$17401467$5$F$20221101$20221122$20200211$20221129$EXP$$NVSC2019CA018247$NOVARTIS$$61$YR$$F$Y$$$20221129$$CN$CA$CA
174015996$17401599$6$F$20220415$20221125$20200208$20221130$EXP$$US-SHIRE-US202003989$TAKEDA$$40$YR$$F$Y$68$KG$20221130$$HP$US$US
174019184$17401918$4$F$20050101$20221117$20200211$20221122$EXP$$US-PFIZER INC-2020061019$PFIZER$$66$YR$$F$Y$$$20221122$$LW$US$US
174021328$17402132$8$F$$20221214$20200211$20221222$PER$$US-PFIZER INC-2020058477$PFIZER$$62$YR$$F$Y$$$20221222$$CN$US$US
174022555$17402255$5$F$20191025$20221018$20200211$20221031$EXP$$US-Hikma Pharmaceuticals USA Inc.-US-H14001-20-00484$HIKMA$$19$YR$$M$Y$103.55$KG$20221031$$MD$US$US
174024173$17402417$3$F$20190801$20221018$20200211$20221028$PER$$US-SA-2020SA034899$SANOFI AVENTIS$$59$YR$A$F$Y$$$20221028$$CN$US$US
174025018$17402501$8$F$20200201$20221228$20200211$20221229$EXP$$US-PFIZER INC-2020058370$PFIZER$$73$YR$$F$Y$107.94$KG$20221229$$CN$US$US
174028092$17402809$2$F$$20221028$20200211$20221101$PER$$US-PFIZER INC-2020055072$PFIZER$$64$YR$$F$Y$79.365$KG$20221101$$CN$US$US
174028685$17402868$5$F$$20221220$20200211$20221227$EXP$$US-PFIZER INC-2020058581$PFIZER$$76$YR$$F$Y$$$20221227$$CN$US$US
174029277$17402927$7$F$20200101$20221108$20200211$20221213$EXP$$US-ABBVIE-20K-163-3268754-00$ABBVIE$$69$YR$$M$Y$112.49$KG$20221213$$CN$US$US
174029802$17402980$2$F$20190726$20221205$20200211$20221212$EXP$$DE-MYLANLABS-2020M1014721$MYLAN$$89$YR$$F$Y$$$20221212$$MD$DE$DE
174031034$17403103$4$F$20180606$20221222$20200211$20221228$EXP$$CA-TAKEDA-2018TUS009200$TAKEDA$$61$YR$$F$Y$$$20221228$$CN$CA$CA
174032163$17403216$3$F$20130101$20221014$20200211$20221024$EXP$$US-PFIZER INC-2020057304$MYLAN$$$$$M$Y$81$KG$20221024$$CN$US$US
174032252$17403225$2$F$$20200205$20200211$20221208$EXP$$NVSC2020TR033357$NOVARTIS$Karaca O, Pinar HU. Is high dose lumbar erector spinae plane block safe?. JOURNAL OF CLINICAL ANESTHESIA. 2020;62:1-2$58$YR$$F$Y$$$20221208$$HP$TR$TR
174033522$17403352$2$F$$20221107$20200211$20221114$EXP$$CA-PFIZER INC-2020055789$PFIZER$$70$YR$$M$Y$$$20221114$$CN$CA$CA
174033724$17403372$4$F$$20221004$20200211$20221007$PER$$NVSC2020US035872$NOVARTIS$$$$$M$Y$$$20221007$$CN$US$US
174035043$17403504$3$F$20140101$20221201$20200211$20221208$EXP$$US-TEVA-2020-US-1181603$TEVA$$55$YR$A$F$Y$$$20221208$$LW$US$US
174038873$17403887$3$F$$20221215$20200211$20221222$PER$$US-AMGEN-USASP2020023291$AMGEN$$60$YR$A$F$Y$$$20221222$$MD$US$US
174039767$17403976$7$F$$20221214$20200211$20221219$EXP$$US-SHIRE-US202004317$TAKEDA$$$$$F$Y$53$KG$20221219$$CN$US$US
174042032$17404203$2$F$20190101$20200201$20200211$20221209$EXP$$US-TEVA-2020-US-1183563$TEVA$$$$$$Y$$$20221209$$CN$US$US
174048345$17404834$5$F$$20221108$20200211$20221110$EXP$$JP-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-007042$BOEHRINGER INGELHEIM$$27$YR$A$M$Y$63.1$KG$20221110$$MD$JP$JP
174055842$17405584$2$F$$20221130$20200212$20221205$PER$$US-SHIRE-US202005457$TAKEDA$$$$$M$Y$76$KG$20221205$$HP$US$US
1740609418$17406094$18$F$$20221109$20200212$20221114$EXP$$US-SHIRE-US202005342$TAKEDA$$$$$F$Y$74$KG$20221114$$HP$US$US
1740700110$17407001$10$F$20210720$20221011$20200212$20221017$EXP$$US-SHIRE-US202005386$TAKEDA$$76$YR$$F$Y$84$KG$20221017$$HP$US$US
174070576$17407057$6$F$20200126$20221026$20200212$20221103$EXP$$US-SHIRE-US202005033$TAKEDA$$42$YR$$F$Y$95$KG$20221103$$MD$US$US
174070623$17407062$3$F$$20221202$20200212$20221207$EXP$$DE-MYLANLABS-2020M1015447$MYLAN$$73$YR$$M$Y$$$20221207$$MD$DE$DE
174076563$17407656$3$F$20090101$20221025$20200212$20221027$EXP$$NVSC2020BE036994$NOVARTIS$Vieujean S, Moens A, Rothfuss K, Savarino E, Vavricka S, Reenaers C et al.. Pneumocystis jirovecii pneumonia in IBD patients treated with immunomodulator(s). JOURNAL OF CROHN^S AND COLITIS. 2019;13(1):S468-9$71$YR$$M$Y$$$20221027$$HP$BE$BE
174078982$17407898$2$F$$20221202$20200212$20221207$EXP$$US-PFIZER INC-2017488304$PFIZER$$71$YR$$F$Y$78.912$KG$20221207$$CN$US$US
174084764$17408476$4$F$$20221201$20200212$20221208$EXP$$CA-PFIZER INC-2020056767$PFIZER$$31$YR$$F$Y$46$KG$20221208$$HP$CA$CA
174086662$17408666$2$F$20200201$20221105$20200212$20221115$EXP$$US-VERTEX PHARMACEUTICALS-2020-002560$VERTEX$$48$YR$$F$Y$$$20221115$$HP$US$US
174087406$17408740$6$F$20200201$20221206$20200212$20221208$EXP$$NVSC2020JP028745$NOVARTIS$$60$YR$$M$Y$92.5$KG$20221208$$MD$JP$JP
174087554$17408755$4$F$20221207$20221222$20200212$20221229$EXP$$NVSC2020US032609$NOVARTIS$$21$YR$$F$Y$$$20221229$$CN$US$US
174094628$17409462$8$F$$20221111$20200212$20221118$EXP$$GR-ROCHE-2528781$ROCHE$$$$A$F$Y$60$KG$20221118$$CN$GR$GR
174094762$17409476$2$F$$20221107$20200212$20221114$EXP$$CA-PFIZER INC-2020058515$PFIZER$$$$$F$Y$$$20221114$$MD$CA$CA
174094795$17409479$5$F$$20221018$20200212$20221020$EXP$$US-PFIZER INC-2020060758$PFIZER$$65$YR$$F$Y$$$20221020$$CN$US$US
174094806$17409480$6$F$$20221221$20200212$20221229$EXP$$CA-PFIZER INC-2020058185$PFIZER$$$$A$M$Y$$$20221229$$MD$CA$CA
174095734$17409573$4$F$20221109$20221128$20200212$20221205$EXP$$US-SHIRE-US202004527$TAKEDA$$75$YR$$F$Y$79$KG$20221205$$CN$US$US
1740998812$17409988$12$F$20200101$20221130$20200212$20221207$EXP$$CA-PFIZER INC-2020025886$PFIZER$$63$YR$$F$Y$$$20221207$$MD$CA$CA
174104793$17410479$3$F$20090601$20200309$20200212$20221008$PER$$US-NAPPMUNDI-USA-2020-0149903$PURDUE$$24$YR$$M$Y$$$20221008$$CN$US$US
174108074$17410807$4$F$20191201$20221004$20200212$20221005$PER$$US-PFIZER INC-2020062917$PFIZER$$62$YR$$F$Y$$$20221005$$HP$US$US
174108163$17410816$3$F$$20221105$20200212$20221108$PER$$US-PFIZER INC-2020061557$PFIZER$$66$YR$$$Y$50.8$KG$20221108$$CN$US$US
174108212$17410821$2$F$$20221206$20200212$20221208$PER$$US-PFIZER INC-2020062905$PFIZER$$61$YR$$F$Y$$$20221208$$CN$US$US
174110587$17411058$7$F$$20221102$20200212$20221111$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-03985$SAMSUNG BIOEPIS$$55$YR$A$F$Y$73$KG$20221111$$CN$CA$CA
174110596$17411059$6$F$$20221209$20200212$20221216$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-03950$SAMSUNG BIOEPIS$$41$YR$A$F$Y$88$KG$20221216$$HP$CA$CA
174110657$17411065$7$F$$20221108$20200212$20221115$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-03974$SAMSUNG BIOEPIS$$65$YR$E$M$Y$73$KG$20221115$$HP$CA$CA
174110983$17411098$3$F$$20221206$20200212$20221213$EXP$$US-JAZZ-2020-US-001834$JAZZ$$$$$F$Y$$$20221213$$HP$US$US
174113959$17411395$9$F$20200101$20221206$20200212$20221213$EXP$$CA-BAUSCH-BL-2020-004328$BAUSCH AND LOMB$$54$YR$$M$Y$$$20221213$$CN$CA$CA
174123158$17412315$8$F$20160119$20221011$20200213$20221021$EXP$GB-EMA-DD-20200205-PRABHAKAR_D-142804$GB-Accord-172272$ACCORD$$80$YR$E$F$Y$$$20221021$$MD$GB$GB
1741233110$17412331$10$F$20190415$20221019$20200213$20221025$EXP$$AT-ROCHE-2307899$ROCHE$$53$YR$$F$Y$70$KG$20221025$$MD$AT$
1741324322$17413243$22$F$20200423$20221111$20200213$20221121$EXP$$CA-CELLTRION INC.-2020CA019039$CELLTRION$$$$$$Y$$$20221121$$HP$CA$CA
174132655$17413265$5$F$$20221120$20200213$20221128$EXP$$CA-GLAXOSMITHKLINE-CA2018GSK109730$GLAXOSMITHKLINE$$$$$$Y$$$20221128$$MD$CA$CA
174141308$17414130$8$F$20200101$20221128$20200213$20221130$PER$$US-PFIZER INC-2020039284$PFIZER$$66$YR$$F$Y$66$KG$20221130$$HP$US$US
174141543$17414154$3$F$20211104$20221025$20200213$20221107$EXP$$US-TAKEDA-2020TUS008918$TAKEDA$$69$YR$$M$Y$$$20221107$$CN$US$US
174148633$17414863$3$F$20210801$20221026$20200213$20221031$EXP$$US-SHIRE-US202005669$TAKEDA$$53$YR$$F$Y$80.726$KG$20221031$$CN$US$US
174149656$17414965$6$F$20191226$20221028$20200213$20221104$EXP$$CA-TAKEDA-2020TUS001368$TAKEDA$$82$YR$$M$Y$$$20221104$$HP$CA$CA
174149954$17414995$4$F$20151101$20221215$20200213$20221221$EXP$$HU-MYLANLABS-2020M1015809$MYLAN$$33$YR$$F$Y$$$20221221$$MD$HU$HU
174151164$17415116$4$F$$20221018$20200213$20221021$EXP$$CA-PFIZER INC-2020058152$PFIZER$$68$YR$$F$Y$$$20221021$$HP$CA$CA
174152204$17415220$4$F$20190101$20221206$20200213$20221215$EXP$$PHHY2019CA049536$NOVARTIS$$63$YR$$F$Y$$$20221214$$CN$CA$CA
1741551217$17415512$17$F$$20221020$20200213$20221025$EXP$$US-SHIRE-US202005065$TAKEDA$$$$$F$Y$86$KG$20221025$$HP$US$US
174172353$17417235$3$F$$20221222$20200214$20221229$EXP$$NVSC2020CA039448$NOVARTIS$$$$A$F$Y$$$20221229$$CN$CA$CA
174177414$17417741$4$F$$20221020$20200214$20221021$EXP$$CA-ROCHE-2547886$ROCHE$$49$YR$$F$Y$$$20221021$$HP$CA$
1741811328$17418113$28$F$20200122$20221208$20200214$20221222$EXP$$DE-AUROBINDO-AUR-APL-2020-007406$AUROBINDO$$72$YR$$F$Y$65.2$KG$20221222$$MD$DE$DE
174181443$17418144$3$F$$20221018$20200214$20221020$EXP$$CA-PFIZER INC-2020062964$PFIZER$$44$YR$$F$Y$$$20221020$$HP$CA$CA
174182842$17418284$2$F$$20221003$20200213$20221017$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-236497$RANBAXY$$$$$F$Y$$$20221017$$CN$US$US
174184283$17418428$3$F$20200201$20200217$20200214$20221215$PER$$US-AMGEN-USASP2020023957$AMGEN$$55$YR$A$M$Y$$$20221213$$MD$US$US
174187645$17418764$5$F$$20221201$20200214$20221209$EXP$$CA-Orion Corporation ORION PHARMA-TREX2020-0847$ORION$$31$YR$A$F$Y$46$KG$20221209$$HP$CA$
174187676$17418767$6$F$20200113$20221228$20200214$20221230$EXP$$CA-TAKEDA-2019TUS001027$TAKEDA$$55$YR$$F$Y$$$20221230$$CN$CA$CA
174187747$17418774$7$F$20080101$20221129$20200211$20221209$EXP$$US-GLAXOSMITHKLINE-US2020GSK021406$PERRIGO$$$$$$Y$$$20221209$$MD$US$US
1741915412$17419154$12$F$19991101$20221212$20200214$20221219$EXP$$US-PFIZER INC-2020067583$PFIZER$$42$YR$$M$Y$$$20221219$$LW$US$US
174193092$17419309$2$F$20170527$20221118$20200214$20221122$EXP$$CA-TAKEDA-2018TUS008914$TAKEDA$$37$YR$$M$Y$$$20221122$$MD$CA$CA
174194982$17419498$2$F$$20221202$20200214$20221208$EXP$$DE-MYLANLABS-2020M1016073$MYLAN$$65$YR$$F$Y$$$20221208$$MD$DE$DE
174195874$17419587$4$F$$20221128$20200214$20221130$EXP$$FR-MYLANLABS-2020M1016222$MYLAN$Mangin M, Lienhart A, Gouraud A, Roux S, Hodique F, Balme B, et, al.. Deux cas d^hemophilie A acquise associee a une pemphigoide bulleuse traitee par omalizumab:coincidence ou effet secondaire (abstract number P044).. JDP. 2019;A:158-A159$64$YR$$M$Y$$$20221130$$MD$FR$FR
174196402$17419640$2$F$$20221107$20200214$20221114$EXP$$CA-Orion Corporation ORION PHARMA-TREX2020-0840$ORION$$$$$F$Y$$$20221114$$MD$CA$
174196435$17419643$5$F$$20221223$20200214$20221228$EXP$$CA-Orion Corporation ORION PHARMA-TREX2020-0838$ORION$$$$A$M$Y$$$20221228$$MD$CA$
174200477$17420047$7$F$20200207$20221114$20200214$20221121$EXP$$US-SHIRE-US202005403$TAKEDA$$37$YR$$F$Y$$$20221121$$MD$US$US
174201178$17420117$8$F$20221020$20221025$20200214$20221028$EXP$$US-SHIRE-US202005813$TAKEDA$$33$YR$$M$Y$102$KG$20221028$$MD$US$US
174207027$17420702$7$F$20210315$20221215$20200214$20221227$PER$$US-PFIZER INC-2018168385$PFIZER$$68$YR$$F$Y$54.43$KG$20221227$$CN$US$US
174207523$17420752$3$F$$20221221$20200214$20221229$EXP$$US-PFIZER INC-2020066668$PFIZER$$71$YR$$M$Y$$$20221229$$HP$US$US
174207634$17420763$4$F$$20221114$20200214$20221116$PER$$US-PFIZER INC-2020066118$PFIZER$$72$YR$$M$Y$72.57$KG$20221116$$CN$US$US
174208343$17420834$3$F$20151201$20221201$20200214$20221208$PER$$US-TEVA-2020-US-1184049$TEVA$$55$YR$A$F$Y$81.72$KG$20221208$$LW$US$US
1742089514$17420895$14$F$20200716$20221110$20200214$20221114$EXP$$US-PFIZER INC-2020008704$PFIZER$$79$YR$$F$Y$63.5$KG$20221114$$CN$US$US
174208976$17420897$6$F$$20221209$20200214$20221219$EXP$$CA-PFIZER INC-2020062991$PFIZER$$73$YR$$F$Y$$$20221219$$HP$CA$CA
174212626$17421262$6$F$20210301$20221221$20200214$20221229$EXP$$NVSC2019GB031704$NOVARTIS$$$$A$F$Y$$$20221229$$MD$GB$GB
1742231010$17422310$10$F$$20221219$20200214$20221227$EXP$$US-SHIRE-US202005691$TAKEDA$$$$$F$Y$88$KG$20221227$$MD$US$US
1742249831$17422498$31$F$20191217$20221130$20200215$20221209$EXP$$CA-CELLTRION INC.-2019CA024164$CELLTRION$$$$$$Y$$$20221210$$CN$CA$CA
174227803$17422780$3$F$20200207$20221026$20200215$20221102$EXP$$CA-ROCHE-2548610$ROCHE$$33$YR$$F$Y$$$20221102$$CN$CA$
174228652$17422865$2$F$$20191028$20200215$20221024$EXP$$NVSJ2019JP002760$NOVARTIS$$$$$$Y$$$20221024$$PH$JP$JP
1742300021$17423000$21$F$20181001$20221018$20200216$20221019$EXP$$US-BIOGEN-2020BI00838554$BIOGEN$$49$YR$$F$Y$64.922$KG$20221019$$CN$US$US
174230022$17423002$2$F$$20200203$20200216$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-009209$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20221222$$MD$CA$CA
1742356331$17423563$31$F$20200212$20221122$20200217$20221125$EXP$$US-SHIRE-US202006022$TAKEDA$$54$YR$$F$Y$52$KG$20221125$$HP$US$US
174236362$17423636$2$F$$20221115$20200217$20221118$PER$$US-SHIRE-US202006031$TAKEDA$$$$$M$Y$82.993$KG$20221118$$HP$US$US
1742420528$17424205$28$F$20190810$20221201$20200217$20221210$EXP$$CA-CELLTRION INC.-2019CA023386$CELLTRION$$$$$$Y$$$20221210$$MD$CA$CA
174242518$17424251$8$F$$20220920$20200217$20221005$EXP$$PT-CELLTRION INC.-2020PT018908$CELLTRION$Matos AS, Pais JP, Cambao AR, Nascimento A, Guerra D. Henoch-schonlein purpura in adult-a diagnostic and therapeutic challenge.. REVISTA ONLINE DE CASOS CLINICOS EM MEDICINA INTERNA (RCCMI). 2019;1-3$$$$$Y$$$20221005$$HP$PT$PT
1742444421$17424444$21$F$$20221125$20200217$20221210$EXP$$CA-ROCHE-2543750$ROCHE$$59$YR$$F$Y$68$KG$20221210$$MD$CA$
174245972$17424597$2$F$$20221004$20200217$20221013$PER$$US-INCYTE CORPORATION-2020IN001359$INCYTE$$$$$$Y$$$20221013$$CN$US$US
174247098$17424709$8$F$$20221121$20200217$20221202$EXP$$CA-GLENMARK PHARMACEUTICALS-2020GMK046089$GLENMARK$$$$$$Y$$$20221202$$HP$CA$CA
174248183$17424818$3$F$$20221212$20200217$20221226$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-236900$RANBAXY$Saffaei D, Lovett S, Rech MA. New-Onset Seizure in Patient Medicated With Bupropion for Smoking Cessation: A Case Report. J Emerg Med. 2020;58(3):e145-e147$66$YR$$F$Y$$$20221227$$HP$US$US
174248203$17424820$3$F$$20221102$20200217$20221117$EXP$$NO-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-236935$RANBAXY$Lao YE , Molden E , Kringen MK , Annexstad EJ , Saeverud HA , Jacobsen D , Hovda KE. Fatal liver failure after therapeutic doses of paracetamol in a patient with Duchenne muscular dystrophy and atypical pharmacogenetic profile of drug-metabolizing enzymes. Basic Clin Pharmacol Toxicol. 2020;127 (1):47-51$30$YR$$M$Y$50$KG$20221117$$HP$NO$NO
1742484517$17424845$17$F$20200101$20221014$20200217$20221021$EXP$$NVSC2020AR039743$NOVARTIS$$45$YR$$M$Y$$$20221021$$CN$AR$AR
174253802$17425380$2$F$$20200206$20200218$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010671$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20221222$$HP$CA$CA
174256364$17425636$4$F$$20221018$20200218$20221025$EXP$$CA-Orion Corporation ORION PHARMA-TREX2020-0877$ORION$$68$YR$E$F$Y$$$20221025$$HP$CA$
174258064$17425806$4$F$20140101$20221003$20200217$20221004$EXP$$US-PFIZER INC-2020069061$PFIZER$$58$YR$$F$Y$$$20221004$$LW$US$US
174263304$17426330$4$F$20200327$20221014$20200218$20221019$PER$$NVSC2020US037695$NOVARTIS$$40$YR$$F$Y$$$20221019$$CN$US$US
174266259$17426625$9$F$20200206$20221005$20200217$20221008$EXP$$CA-ROCHE-2550557$ROCHE$$52$YR$$F$Y$$$20221008$$CN$CA$
174266358$17426635$8$F$20200220$20221102$20200217$20221107$EXP$$US-PFIZER INC-2020067899$PFIZER$$79$YR$$F$Y$72.562$KG$20221107$$MD$US$US
174269582$17426958$2$F$$20221019$20200218$20221028$EXP$$BR-BIOGEN-2019BI00774807$BIOGEN$$$$$F$Y$60$KG$20221028$$CN$BR$BR
174272308$17427230$8$F$20190101$20221215$20200217$20221222$EXP$$CA-ROCHE-2545743$ROCHE$$$$$M$Y$$$20221222$$CN$CA$
174273542$17427354$2$F$$20221107$20200217$20221110$EXP$$US-SHIRE-US202005861$TAKEDA$$$$$F$Y$$$20221110$$CN$US$US
1742776616$17427766$16$F$20180101$20221024$20200217$20221029$EXP$$PHHY2018CA049036$NOVARTIS$$$$$M$Y$$$20221029$$CN$CA$CA
174278552$17427855$2$F$$20221202$20200217$20221208$PER$$US-SHIRE-US202005792$TAKEDA$$$$$F$Y$57$KG$20221208$$HP$US$US
1742792611$17427926$11$F$20211214$20221118$20200217$20221125$EXP$$US-SHIRE-US202005385$TAKEDA$$46$YR$$F$Y$66$KG$20221125$$CN$US$US
174280613$17428061$3$F$20110730$20221101$20200217$20221114$EXP$$ES-SHIRE-ALL1-2013-08062$TAKEDA$$41$YR$$M$Y$$$20221114$$HP$ES$ES
174282743$17428274$3$F$20191212$20221019$20200217$20221107$PER$$CO-TOLMAR, INC.-19CO019662$TOLMAR$$78$YR$$M$Y$$$20221107$$HP$CO$CO
174287372$17428737$2$F$$20220920$20200217$20221003$EXP$E2B_02854790$CA-ASSERTIO THERAPEUTICS, INC.-CA-2020DEP000099$ASSERTIO THERAPEUTICS$$42$YR$$F$Y$126$KG$20221003$$HP$CA$CA
174288175$17428817$5$F$20171220$20221018$20200217$20221027$EXP$$PHHY2018DE048317$NOVARTIS$$$$A$F$Y$$$20221027$$MD$DE$DE
1742889330$17428893$30$F$20220529$20221215$20200218$20221224$EXP$$US-SHIRE-US202006248$TAKEDA$$62$YR$$F$Y$99$KG$20221224$$HP$US$US
174289624$17428962$4$F$20200129$20221221$20200217$20221228$EXP$$US-BIOGEN-2020BI00835053$BIOGEN$$58$YR$$F$Y$66.284$KG$20221228$$CN$US$US
1742914811$17429148$11$F$20221114$20221207$20200218$20221216$EXP$$US-SHIRE-US202006283$TAKEDA$$55$YR$$F$Y$84$KG$20221216$$CN$US$US
174293973$17429397$3$F$$20221010$20200218$20221015$EXP$$CA-ABBVIE-20K-028-3272487-00$ABBVIE$$55$YR$$F$Y$$$20221015$$HP$CA$CA
174297553$17429755$3$F$20160701$20220930$20200218$20221003$EXP$$US-PFIZER INC-2019435521$PFIZER$$60$YR$$F$Y$$$20221003$$CN$US$US
174297936$17429793$6$F$$20221215$20200218$20221220$EXP$$US-PFIZER INC-2020066436$PFIZER$$67$YR$$$Y$$$20221220$$CN$US$US
174299536$17429953$6$F$$20221212$20200218$20221219$EXP$$US-PFIZER INC-2020068611$PFIZER$$61$YR$$F$Y$$$20221219$$CN$US$US
174299763$17429976$3$F$20191231$20221013$20200218$20221018$EXP$$US-PFIZER INC-2020069020$PFIZER$$61$YR$$F$Y$$$20221018$$HP$US$US
174300425$17430042$5$F$20190101$20220930$20200218$20221004$PER$$US-PFIZER INC-2018444294$PFIZER$$26$YR$$M$Y$76.76$KG$20221004$$MD$US$US
174302043$17430204$3$F$$20221103$20200218$20221104$PER$$US-PFIZER INC-2020068066$PFIZER$$74$YR$$F$Y$$$20221104$$CN$US$US
174302333$17430233$3$F$$20221101$20200218$20221103$PER$$US-PFIZER INC-2020069429$PFIZER$$63$YR$$F$Y$$$20221103$$HP$US$US
174304705$17430470$5$F$$20221203$20200218$20221208$EXP$$US-PFIZER INC-2020058399$PFIZER$$77$YR$$F$Y$$$20221208$$CN$US$US
174308632$17430863$2$F$20180101$20221118$20200218$20221123$EXP$$CA-PFIZER INC-2018147722$PFIZER$$38$YR$$M$Y$$$20221123$$CN$CA$CA
1743094731$17430947$31$F$20220110$20221205$20200218$20221212$EXP$$US-SHIRE-US202006242$TAKEDA$$60$YR$$F$Y$74$KG$20221212$$HP$US$US
1743138833$17431388$33$F$20220428$20221117$20200218$20221128$PER$$US-PFIZER INC-2020072404$PFIZER$$87$YR$$F$Y$56.25$KG$20221128$$CN$US$US
174316362$17431636$2$F$20181001$20201002$20200218$20221229$EXP$$PHHY2018ZA022091$NOVARTIS$$56$YR$$F$Y$$$20221229$$CN$ZA$ZA
1743264510$17432645$10$F$20200205$20221115$20200218$20221122$EXP$$DK-SEATTLE GENETICS-2020SGN01081$SEATTLE GENETICS$$41$YR$$F$Y$57$KG$20221122$$MD$DK$DK
1743313926$17433139$26$F$20160707$20221220$20200219$20221228$PER$$CA-AMGEN-CANSP2016091942$AMGEN$$43$YR$A$F$Y$96$KG$20221228$$HP$CA$CA
174334413$17433441$3$F$20191001$20221219$20200219$20221223$EXP$$CA-ROCHE-2443334$ROCHE$$34$YR$$M$Y$$$20221223$$CN$CA$
174336175$17433617$5$F$20200204$20221110$20200219$20221111$EXP$$FR-GLAXOSMITHKLINE-FR2020GSK024104$GLAXOSMITHKLINE$$$$$$Y$$$20221111$$MD$FR$FR
174336802$17433680$2$F$$20221116$20200219$20221124$EXP$$PT-AMCo Ltd-GSH201709-005533$ADVANZ PHARMA$$$$$$Y$$$20221124$$HP$PT$PT
174339696$17433969$6$F$20160901$20221026$20200219$20221028$EXP$$US-GILEAD-2020-0451415$GILEAD$$66$YR$E$M$Y$111.1$KG$20221027$$LW$US$US
174342473$17434247$3$F$$20221026$20200219$20221028$PER$$US-PFIZER INC-2020055409$PFIZER$$$$$$Y$$$20221028$$CN$US$US
174342937$17434293$7$F$$20221121$20200219$20221122$EXP$$US-PFIZER INC-2020073619$PFIZER$$76$YR$$F$Y$$$20221122$$CN$US$US
1743454914$17434549$14$F$20200106$20221117$20200219$20221123$EXP$$IN-PFIZER INC-2020021101$PFIZER$$74$YR$$F$Y$84.2$KG$20221123$$CN$IN$IN
1743464613$17434646$13$F$20181213$20221124$20200219$20221129$EXP$$GB-MYLANLABS-2020M1016716$MYLAN$$$$N$M$Y$$$20221129$$MD$GB$GB
1743465918$17434659$18$F$20191214$20221013$20200219$20221025$EXP$$CA-CELLTRION INC.-2019CA027013$CELLTRION$$$$$$Y$$$20221025$$MD$CA$CA
174347663$17434766$3$F$20190801$20221020$20200219$20221025$EXP$$CO-TAKEDA-2019TUS047500$TAKEDA$$56$YR$$M$Y$72$KG$20221025$$HP$CO$CO
174348422$17434842$2$F$20140128$20221114$20200219$20221115$EXP$SE-EMA-DD-20191126-AGRAHARI_P-112208$NVSC2020SE043422$NOVARTIS$$71$YR$$F$Y$$$20221115$$HP$SE$SE
174348556$17434855$6$F$20200101$20221014$20200219$20221021$EXP$$NVSC2020CA042837$NOVARTIS$$$$$M$Y$$$20221021$$CN$CA$CA
174349629$17434962$9$F$20190813$20221123$20200219$20221128$EXP$$CA-TAKEDA-2019TUS058296$TAKEDA$$29$YR$$F$Y$$$20221128$$CN$CA$CA
1743506015$17435060$15$F$20191125$20221220$20200219$20221223$EXP$$DE-ROCHE-2513695$ROCHE$$27$YR$$F$Y$$$20221223$$CN$DE$
1743527915$17435279$15$F$20191115$20221125$20200219$20221202$EXP$$NVSC2019DE066721$NOVARTIS$$$$A$F$Y$58$KG$20221202$$MD$DE$DE
174354032$17435403$2$F$20190514$20220930$20200219$20221004$EXP$$US-TAKEDA-2020TUS009722$TAKEDA$$0$YR$$F$Y$2.44$KG$20221004$$HP$US$US
174359664$17435966$4$F$20200101$20221104$20200219$20221109$EXP$$CA-BAUSCH-BL-2020-005014$BAUSCH AND LOMB$$70$YR$$M$Y$$$20221109$$CN$CA$CA
174360094$17436009$4$F$20160501$20220721$20200219$20221227$EXP$$US-GILEAD-2020-0451432$GILEAD$$60$YR$A$F$Y$$$20221227$$LW$US$US
1743615017$17436150$17$F$20190901$20221207$20200219$20221212$EXP$$DE-SHIRE-DE201932395$TAKEDA$$$$A$M$Y$85$KG$20221212$$HP$DE$DE
174361826$17436182$6$F$20190507$20221102$20200219$20221111$EXP$$DE-JNJFOC-20190736936$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221111$$MD$DE$DE
174366373$17436637$3$F$20180403$20220929$20200219$20221005$EXP$$US-TAKEDA-2020TUS009725$TAKEDA$$0$YR$$F$Y$3.32$KG$20221005$$HP$US$US
174367402$17436740$2$F$20171212$20221121$20200219$20221129$PER$$US-SA-2020SA035251$SANOFI AVENTIS$$59$YR$A$M$Y$$$20221129$$MD$US$US
174368705$17436870$5$F$20180125$20221012$20200219$20221017$EXP$$CA-TAKEDA-2020TUS007933$TAKEDA$$27$YR$$F$Y$$$20221017$$CN$CA$CA
174369882$17436988$2$F$$20221205$20200219$20221212$EXP$$US-JAZZ-2020-US-002336$JAZZ$$$$$F$Y$$$20221212$$CN$US$US
174370982$17437098$2$F$$20221107$20200219$20221109$PER$$US-JNJFOC-20200227400$JOHNSON AND JOHNSON$$10$YR$C$M$Y$$$20221109$$LW$US$US
174373968$17437396$8$F$20191202$20221108$20200219$20221114$EXP$$DE-ABBVIE-20K-062-3282520-00$ABBVIE$$60$YR$$M$Y$113$KG$20221114$$MD$DE$DE
174376124$17437612$4$F$20190625$20221209$20200219$20221217$EXP$$KR-TAKEDA-2020TUS010540$TAKEDA$$26$YR$$M$Y$$$20221217$$MD$KR$KR
174376633$17437663$3$F$20201227$20221228$20200219$20221229$PER$$NVSC2020US045774$NOVARTIS$$61$YR$$M$Y$$$20221229$$HP$US$US
1743808914$17438089$14$F$20100610$20221013$20200220$20221023$EXP$$GB-AUROBINDO-AUR-APL-2020-008750$AUROBINDO$$1$DY$$M$Y$3.1$KG$20221023$$MD$GB$GB
174381662$17438166$2$F$20200101$20221226$20200220$20221229$PER$$US-SHIRE-US202006431$TAKEDA$$30$YR$$M$Y$$$20221229$$MD$US$US
1743828913$17438289$13$F$$20221007$20200220$20221013$EXP$$US-SHIRE-US202006415$TAKEDA$$$$$F$Y$88$KG$20221013$$HP$US$US
1743953011$17439530$11$F$20191223$20221213$20200220$20221215$EXP$$GB-ROCHE-2549653$ROCHE$$38$YR$$M$Y$$$20221215$$MD$GB$
174397816$17439781$6$F$$20221216$20200220$20221224$EXP$$US-SHIRE-US202006678$TAKEDA$$$$$F$Y$125$KG$20221224$$CN$US$US
174399685$17439968$5$F$$20221123$20200220$20221123$PER$$US-PFIZER INC-2020074680$PFIZER$$69$YR$$F$Y$52.16$KG$20221123$$HP$US$US
174399773$17439977$3$F$$20221019$20200220$20221021$PER$$US-PFIZER INC-2020075659$PFIZER$$48$YR$$M$Y$$$20221021$$MD$US$US
1744003217$17440032$17$F$20180101$20221221$20200220$20221229$EXP$$US-PFIZER INC-2020073893$PFIZER$$74$YR$$M$Y$81.633$KG$20221229$$CN$US$US
174400388$17440038$8$F$$20221104$20200220$20221108$PER$$US-PFIZER INC-2019352043$PFIZER$$63$YR$$F$Y$74$KG$20221108$$HP$US$US
174400524$17440052$4$F$$20221019$20200220$20221020$EXP$$US-PFIZER INC-2018159245$PFIZER$$60$YR$$M$Y$$$20221020$$MD$US$US
174402582$17440258$2$F$$20221020$20200220$20221024$PER$$US-PFIZER INC-2020074861$PFIZER$$73$YR$$M$Y$$$20221024$$CN$US$US
1744076416$17440764$16$F$20200123$20221128$20200220$20221202$EXP$$IN-PFIZER INC-2020071864$PFIZER$$70$YR$$F$Y$50.1$KG$20221202$$CN$IN$IN
174414318$17441431$8$F$$20221026$20200220$20221031$EXP$$US-PFIZER INC-2020075770$PFIZER$$74$YR$$F$Y$$$20221031$$CN$US$US
1744190621$17441906$21$F$20080101$20221025$20200220$20221104$EXP$$CA-ALLERGAN-1761788US$ALLERGAN$$$$$M$Y$$$20221104$$MD$CA$CA
174419569$17441956$9$F$20200211$20221018$20200220$20221020$EXP$$US-SHIRE-US202006374$TAKEDA$$70$YR$$M$Y$$$20221020$$PH$US$US
1744200220$17442002$20$F$20220512$20221215$20200220$20221223$EXP$$CA-SHIRE-CA202006208$TAKEDA$$49$YR$$F$Y$80$KG$20221223$$HP$CA$CA
174422004$17442200$4$F$$20221027$20200220$20221031$PER$$US-PFIZER INC-2018135776$PFIZER$$65$YR$$F$Y$77.098$KG$20221031$$CN$US$US
1744266813$17442668$13$F$20200722$20221212$20200220$20221217$EXP$$CA-TAKEDA-2020TUS010311$TAKEDA$$85$YR$$F$Y$$$20221217$$MD$CA$CA
174427695$17442769$5$F$$20200505$20200220$20221013$PER$$US-CELLTRION INC.-2020US019556$CELLTRION$$$$$$Y$$$20221013$$CN$US$US
174431527$17443152$7$F$20191011$20220930$20200221$20221010$EXP$$DE-AUROBINDO-AUR-APL-2020-008950$AUROBINDO$$$$E$F$Y$64$KG$20221010$$MD$DE$DE
1744472811$17444728$11$F$20191223$20221118$20200221$20221122$EXP$$GR-009507513-2002GRC006773$MERCK$$$$A$F$Y$60$KG$20221122$$MD$GR$GR
174448813$17444881$3$F$$20221017$20200221$20221027$EXP$$DE-TEVA-2020-DE-1189586$TEVA$$73$YR$E$F$Y$73$KG$20221028$$PH$DE$DE
174449862$17444986$2$F$$20221017$20200221$20221027$EXP$$DE-TEVA-2020-DE-1189100$TEVA$$81$YR$E$M$Y$$$20221027$$MD$DE$DE
174451448$17445144$8$F$20200219$20221101$20200221$20221104$PER$$US-PFIZER INC-2020076687$PFIZER$$65$YR$$M$Y$$$20221104$$CN$US$US
174451715$17445171$5$F$$20221122$20200221$20221128$PER$$US-PFIZER INC-2020077259$PFIZER$$69$YR$$F$Y$$$20221128$$HP$US$US
174454062$17445406$2$F$$20221108$20200221$20221116$EXP$$NVSC2020DE043040$NOVARTIS$$27$YR$$F$Y$79.5$KG$20221116$$MD$DE$DE
1744585211$17445852$11$F$$20221111$20200221$20221121$EXP$$GR-BEH-2020113354$CSL BEHRING$$$$A$F$Y$60$KG$20221121$$CN$GR$GR
174461856$17446185$6$F$20181115$20221102$20200221$20221107$EXP$$PHHY2018CA198027$NOVARTIS$$48$YR$$F$Y$$$20221107$$MD$CA$CA
174465353$17446535$3$F$20160801$20221006$20200221$20221012$EXP$$BR-BIOGEN-2017BI00386327$BIOGEN$$50$YR$$F$Y$70$KG$20221012$$CN$BR$BR
1744666510$17446665$10$F$20201111$20221114$20200221$20221118$EXP$$US-SHIRE-US202006619$TAKEDA$$56$YR$$F$Y$99$KG$20221118$$CN$US$US
174468346$17446834$6$F$20200117$20221202$20200221$20221209$EXP$$CA-TAKEDA-2020TUS003962$TAKEDA$$75$YR$$F$Y$$$20221209$$MD$CA$CA
174470262$17447026$2$F$20190707$20221030$20200221$20221101$EXP$FR-AFSSAPS-NT20200045$FR-BAUSCH-BL-2020-005459$BAUSCH AND LOMB$$67$YR$$F$Y$77$KG$20221101$$MD$FR$FR
1744728412$17447284$12$F$20200201$20221123$20200221$20221129$EXP$$CA-PFIZER INC-2019453993$PFIZER$$29$YR$$F$Y$$$20221129$$CN$CA$CA
174472953$17447295$3$F$20190801$20221108$20200221$20221110$EXP$$PHHY2019CA190540$NOVARTIS$$56$YR$$M$Y$$$20221110$$CN$CA$CA
1744734623$17447346$23$F$20200817$20221219$20200221$20221224$EXP$$NVSC2020US047767$NOVARTIS$$22$YR$$F$Y$81.633$KG$20221224$$PH$US$US
174474264$17447426$4$F$$20221212$20200221$20221216$EXP$$US-PFIZER INC-2020076725$PFIZER$$60$YR$$M$Y$$$20221216$$CN$US$US
174475822$17447582$2$F$$20221116$20200221$20221118$PER$$NVSC2020US049203$NOVARTIS$$$$$M$Y$$$20221118$$CN$US$US
174476316$17447631$6$F$20221128$20221207$20200221$20221213$EXP$$US-SHIRE-US202006854$TAKEDA$$72$YR$$F$Y$70$KG$20221213$$HP$US$US
174480272$17448027$2$F$$20221119$20200222$20221202$EXP$DE-BFARM-20001442$DE-Accord-173459$ACCORD$$89$YR$E$F$Y$$$20221202$$PH$DE$DE
174480592$17448059$2$F$$20221119$20200222$20221202$EXP$DE-BFARM-20001390$DE-Accord-173258$ACCORD$$81$YR$E$M$Y$$$20221202$$MD$DE$DE
174481186$17448118$6$F$$20221103$20200222$20221108$PER$$NVSC2020US049184$NOVARTIS$$$$$M$Y$$$20221108$$CN$US$US
174487092$17448709$2$F$$20221110$20200224$20221123$EXP$$DE-drreddys-GER/GER/20/0119818$DR REDDYS$$89$YR$E$F$Y$$$20221123$$PH$DE$DE
174487402$17448740$2$F$$20221017$20200224$20221027$EXP$$DE-TEVA-2020-DE-1189864$TEVA$$89$YR$E$F$Y$$$20221028$$PH$DE$DE
174488556$17448855$6$F$20180101$20220929$20200224$20221005$EXP$$NL-ABBVIE-20K-114-3233918-00$ABBVIE$$$$$F$Y$$$20221005$$CN$NL$NL
174490982$17449098$2$F$$20221110$20200224$20221123$EXP$$DE-drreddys-GER/GER/20/0119833$DR REDDYS$$80$YR$E$M$Y$70$KG$20221123$$PH$DE$DE
174492582$17449258$2$F$20191027$20221010$20200224$20221021$EXP$DE-ADRED-04330-01$DE-NOVOPROD-712747$NOVO NORDISK$$86$YR$$M$Y$$$20221021$$MD$DE$DE
174498462$17449846$2$F$$20221119$20200224$20221202$EXP$DE-BFARM-20001480$DE-Accord-173415$ACCORD$$80$YR$E$M$Y$70$KG$20221203$$PH$DE$DE
174500252$17450025$2$F$$20221119$20200224$20221202$EXP$DE-BFARM-20001649$DE-Accord-173669$ACCORD$$70$YR$E$M$Y$72$KG$20221202$$PH$DE$DE
174509795$17450979$5$F$20190118$20220930$20200224$20221011$PER$$CA-TOLMAR, INC.-19CA019774$TOLMAR$$67$YR$$M$Y$$$20221011$$CN$CA$CA
174513513$17451351$3$F$$20221128$20200224$20221130$EXP$$US-PFIZER INC-2020079419$PFIZER$$58$YR$$F$Y$$$20221130$$HP$US$US
174513578$17451357$8$F$20221001$20221026$20200224$20221101$EXP$$US-PFIZER INC-2020017315$PFIZER$$73$YR$$F$Y$$$20221101$$HP$US$US
174514762$17451476$2$F$$20221103$20200224$20221110$PER$$US-SA-2020SA043211$SANOFI AVENTIS$$$$A$F$Y$$$20221110$$MD$US$US
174515554$17451555$4$F$$20221107$20200224$20221114$EXP$$US-PFIZER INC-2020080420$PFIZER$$68$YR$$F$Y$$$20221114$$CN$US$US
174516322$17451632$2$F$$20221010$20200224$20221017$EXP$$DE-GLAXOSMITHKLINE-DE2020027578$GLAXOSMITHKLINE$$82$YR$$M$Y$$$20221017$$MD$DE$DE
174524126$17452412$6$F$20140101$20221212$20200224$20221219$EXP$$US-PFIZER INC-2020080279$PFIZER$$50$YR$$F$Y$$$20221219$$LW$US$US
1745245114$17452451$14$F$20200210$20221109$20200224$20221116$PER$$DE-Eisai Medical Research-EC-2020-070145$EISAI$$73$YR$E$M$Y$83$KG$20221116$$MD$DE$
174528193$17452819$3$F$$20221110$20200224$20221119$EXP$$CA-SHIRE-CA202005705$TAKEDA$$52$YR$$F$Y$$$20221119$$HP$CA$CA
174528212$17452821$2$F$20200210$20221013$20200224$20221017$EXP$$US-SHIRE-US202006373$TAKEDA$$12$YR$$M$Y$$$20221017$$CN$US$US
174528617$17452861$7$F$20221019$20221026$20200224$20221101$EXP$$US-SHIRE-US202006702$TAKEDA$$80$YR$$M$Y$99.773$KG$20221101$$CN$US$US
174528969$17452896$9$F$20200215$20221020$20200224$20221025$EXP$$US-SHIRE-US202006805$TAKEDA$$33$YR$$M$Y$82.993$KG$20221025$$HP$US$US
174534503$17453450$3$F$20190601$20221130$20200224$20221207$EXP$$FR-ABBVIE-20K-056-3290799-00$ABBVIE$$77$YR$$M$Y$$$20221207$$MD$FR$FR
1745361413$17453614$13$F$20200218$20221104$20200224$20221109$EXP$$CA-Eisai Medical Research-EC-2020-070610$EISAI$$70$YR$E$F$Y$56.5$KG$20221109$$MD$CA$
174545207$17454520$7$F$$20221129$20200225$20221205$EXP$$US-SHIRE-US202007102$TAKEDA$$$$$M$Y$58.957$KG$20221205$$CN$US$US
1745456916$17454569$16$F$20201205$20221212$20200225$20221220$EXP$$US-SHIRE-US202007104$TAKEDA$$42$YR$$F$Y$52$KG$20221220$$MD$US$US
174547828$17454782$8$F$20200210$20221221$20200225$20221227$EXP$$US-SA-2020SA047561$SANOFI AVENTIS$$18$YR$A$M$Y$$$20221227$$MD$US$US
174555152$17455515$2$F$$20221017$20200225$20221027$EXP$$DE-TEVA-2020-DE-1191439$TEVA$$70$YR$E$M$Y$72$KG$20221027$$PH$DE$DE
174555292$17455529$2$F$$20221010$20200225$20221018$EXP$$DE-AUROBINDO-AUR-APL-2020-009190$AUROBINDO$$82$YR$$M$Y$$$20221018$$MD$DE$DE
1745557025$17455570$25$F$20200118$20221214$20200225$20221222$EXP$$CA-CELLTRION INC.-2019CA027691$CELLTRION$$$$$$Y$$$20221222$$HP$CA$CA
1745559531$17455595$31$F$20190928$20221205$20200225$20221215$EXP$$CA-CELLTRION INC.-2019CA025209$CELLTRION$$$$$$Y$$$20221214$$MD$CA$CA
1745560013$17455600$13$F$20200210$20221212$20200225$20221220$EXP$$CA-CELLTRION INC.-2020CA019361$CELLTRION$$$$$$Y$$$20221220$$HP$CA$CA
174556067$17455606$7$F$20190425$20221118$20200225$20221128$EXP$$CA-CELLTRION INC.-2019CA021302$CELLTRION$$$$$$Y$$$20221128$$CN$CA$CA
1745561612$17455616$12$F$20200709$20221104$20200225$20221115$EXP$$CA-CELLTRION INC.-2020CA019390$CELLTRION$$$$$$Y$$$20221115$$PH$CA$CA
174559523$17455952$3$F$20200218$20200302$20200225$20221213$PER$$US-AMGEN INC.-USASP2020030220$AMGEN$$56$YR$A$F$Y$$$20221213$$CN$US$US
174560123$17456012$3$F$20200206$20221209$20200225$20221215$EXP$$CA-TAKEDA-2020TUS010895$TAKEDA$$52$YR$$M$Y$$$20221215$$CN$CA$CA
174563106$17456310$6$F$$20221202$20200225$20221212$EXP$$DE-PFIZER INC-2020082670$PFIZER$$80$YR$$M$Y$70$KG$20221212$$PH$DE$DE
174564283$17456428$3$F$$20220930$20200225$20221004$EXP$$US-PFIZER INC-2020079457$PFIZER$$70$YR$$M$Y$$$20221004$$HP$US$US
174564714$17456471$4$F$$20221121$20200225$20221123$PER$$US-PFIZER INC-2020081755$PFIZER$$70$YR$$F$Y$$$20221123$$CN$US$US
174565072$17456507$2$F$$20221202$20200225$20221208$PER$$US-PFIZER INC-2020080899$PFIZER$$66$YR$$F$Y$$$20221208$$CN$US$US
174566154$17456615$4$F$$20221011$20200225$20221014$EXP$$US-PFIZER INC-2020081983$PFIZER$$65$YR$$F$Y$$$20221014$$LW$US$US
174569804$17456980$4$F$20200201$20221129$20200225$20221201$EXP$$US-SA-2020SA042280$SANOFI AVENTIS$$47$YR$A$F$Y$104$KG$20221201$$CN$US$US
174574972$17457497$2$F$$20221012$20200225$20221016$EXP$$DE-JNJFOC-20200227653$JOHNSON AND JOHNSON$$89$YR$E$F$Y$$$20221016$$PH$DE$DE
174575547$17457554$7$F$$20221021$20200225$20221027$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-014461$BRISTOL MYERS SQUIBB$$64$YR$A$F$Y$$$20221027$$HP$CA$CA
174577265$17457726$5$F$$20221012$20200225$20221018$EXP$$NVSC2020CA048924$NOVARTIS$$$$$F$Y$$$20221018$$CN$CA$CA
174578092$17457809$2$F$$20221021$20200225$20221031$PER$$ES-AMGEN-ESPSP2020029392$AMGEN$$66$YR$E$M$Y$$$20221031$$MD$ES$ES
174594253$17459425$3$F$20191204$20221128$20200226$20221201$EXP$$CA-ROCHE-2557922$ROCHE$$44$YR$$F$Y$$$20221201$$CN$CA$CA
1745943910$17459439$10$F$20200201$20220923$20200225$20221008$EXP$$CA-CELLTRION INC.-2019CA022980$CELLTRION$$$$$$Y$$$20221008$$HP$CA$CA
1745999515$17459995$15$F$20181101$20221019$20200225$20221027$EXP$$CA-CELLTRION INC.-2019CA020763$CELLTRION$$$$$$Y$$$20221028$$CN$CA$CA
174600262$17460026$2$F$$20221007$20200225$20221013$EXP$$CA-TAKEDA-2020TUS010881$TAKEDA$$38$YR$$M$Y$$$20221013$$CN$CA$CA
174600634$17460063$4$F$20200201$20221005$20200226$20221014$EXP$$CA-ROCHE-2556382$ROCHE$$$$E$M$Y$$$20221014$$CN$CA$CA
1746014410$17460144$10$F$$20221207$20200226$20221214$EXP$$US-PFIZER INC-2020080122$PFIZER$$66$YR$$F$Y$$$20221214$$CN$US$US
1746022230$17460222$30$F$20200101$20221124$20200225$20221202$EXP$$CA-CELLTRION INC.-2019CA028238$CELLTRION$$$$$$Y$$$20221202$$HP$CA$CA
174603897$17460389$7$F$$20221205$20200226$20221212$EXP$$US-PFIZER INC-2019074680$PFIZER$$57$YR$$M$Y$$$20221212$$CN$US$US
174605053$17460505$3$F$$20221013$20200225$20221017$EXP$$DE-ROCHE-2553794$ROCHE$$73$YR$$F$Y$73$KG$20221017$$PH$DE$DE
174606435$17460643$5$F$$20221110$20200226$20221117$PER$$GR-AMGEN-GRCSP2020028536$AMGEN$$$$A$F$Y$60$KG$20221117$$CN$GR$GR
174606804$17460680$4$F$20191201$20221219$20200226$20221230$PER$$US-VERTEX PHARMACEUTICALS-2020-003569$VERTEX$$29$YR$$F$Y$$$20221230$$PH$US$US
174614228$17461422$8$F$20200207$20200429$20200226$20221201$EXP$$NVSC2020US048271$NOVARTIS$$77$YR$$F$Y$$$20221201$$MD$US$US
174617368$17461736$8$F$20160101$20221207$20200226$20221213$EXP$$CA-TAKEDA-2016TUS018955$TAKEDA$$22$YR$$M$Y$$$20221213$$MD$CA$CA
1746227614$17462276$14$F$20200304$20221026$20200226$20221101$EXP$$CA-TAKEDA-2019TUS052916$TAKEDA$$64$YR$$M$Y$$$20221101$$MD$CA$CA
174623666$17462366$6$F$$20221004$20200226$20221006$EXP$$US-PFIZER INC-2020084975$PFIZER$$74$YR$$F$Y$$$20221006$$CN$US$US
1746238511$17462385$11$F$20190101$20221208$20200226$20221212$EXP$$JP-ABBVIE-19K-087-2935316-00$ABBVIE$$73$YR$$F$Y$42$KG$20221212$$MD$JP$JP
174624392$17462439$2$F$$20221010$20200226$20221017$EXP$$DE-AUROBINDO-AUR-APL-2020-009276$AUROBINDO$$80$YR$$M$Y$70$KG$20221017$$PH$DE$DE
174626492$17462649$2$F$$20221110$20200226$20221121$EXP$$DE-drreddys-GER/GER/20/0119915$DR REDDYS$$70$YR$E$M$Y$72$KG$20221121$$PH$DE$DE
1746349216$17463492$16$F$20180613$20221202$20200226$20221207$EXP$$DE-MYLANLABS-2020M1020608$MYLAN$$70$YR$$M$Y$$$20221207$$MD$DE$DE
174638973$17463897$3$F$$20221018$20200226$20221020$EXP$$CA-JNJFOC-20200227521$JOHNSON AND JOHNSON$$58$YR$A$F$Y$118.9$KG$20221020$$HP$CA$CA
174640368$17464036$8$F$$20221021$20200226$20221027$EXP$$CA-TAKEDA-2019TUS025669$TAKEDA$$47$YR$$F$Y$$$20221027$$HP$CA$CA
174640609$17464060$9$F$20220101$20221215$20200226$20221220$EXP$$US-PFIZER INC-2020085167$PFIZER$$63$YR$$F$Y$$$20221220$$CN$US$US
174640934$17464093$4$F$$20200623$20200226$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-014320$BRISTOL MYERS SQUIBB$$50$YR$A$F$Y$$$20221222$$CN$CA$CA
174642942$17464294$2$F$20191031$20221201$20200226$20221213$EXP$$GB-ASPEN-GLO2020GB001891$ASPEN$$$$$$Y$$$20221213$$MD$GB$GB
174650672$17465067$2$F$20140501$20220913$20200226$20221026$PER$$US-JAZZ-2014-US-011139$JAZZ$$49$YR$$M$Y$68.027$KG$20221026$$MD$US$US
174652843$17465284$3$F$20190808$20221013$20200227$20221020$EXP$DE-ADRED-04123-01$DE-PFIZER INC-2020082950$PFIZER$$89$YR$$F$Y$$$20221020$$PH$DE$DE
174653037$17465303$7$F$$20221017$20200227$20221019$EXP$$CA-ROCHE-2551540$ROCHE$$65$YR$$M$Y$88$KG$20221019$$HP$CA$
174654777$17465477$7$F$$20221102$20200226$20221107$EXP$$US-SHIRE-US202007393$TAKEDA$$$$$F$Y$43$KG$20221107$$CN$US$US
174657642$17465764$2$F$$20221010$20200227$20221019$EXP$$DE-AUROBINDO-AUR-APL-2020-009278$AUROBINDO$$89$YR$$F$Y$$$20221019$$PH$DE$DE
1746590414$17465904$14$F$20200101$20221005$20200227$20221015$EXP$$CA-CELLTRION INC.-2019CA027877$CELLTRION$$$$$$Y$$$20221015$$MD$CA$CA
174663202$17466320$2$F$$20221010$20200227$20221021$EXP$DE-ADRED-04363-01$DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2020-00423$ALKEM$$82$YR$$M$Y$$$20221021$$MD$DE$DE
174666706$17466670$6$F$$20221028$20200227$20221104$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-06298$SAMSUNG BIOEPIS$$22$YR$A$F$Y$56$KG$20221104$$MD$CA$CA
174666755$17466675$5$F$$20221128$20200227$20221207$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-06206$SAMSUNG BIOEPIS$$63$YR$A$F$Y$81$KG$20221207$$HP$CA$CA
174667135$17466713$5$F$$20221020$20200227$20221031$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-06449$SAMSUNG BIOEPIS$$31$YR$A$M$Y$108$KG$20221031$$HP$CA$CA
174667532$17466753$2$F$$20220930$20200227$20221007$EXP$$NVSC2020FR051016$NOVARTIS$Bastos S, Masmoudi W, Hebert V, Duval-modeste AB. Metastatic squamous cell carcinoma in a renal transplant patient with history of transplant rejection: efficacy of nivolumab therapy. ANNALES DE DERMATOLOGIE ET VENEREOLOGIE. 2019$59$YR$$M$Y$$$20221007$$HP$FR$FR
174668474$17466847$4$F$20190728$20221012$20200227$20221014$EXP$$JP-Eisai Medical Research-EC-2020-069742$EISAI$$69$YR$E$M$Y$69$KG$20221014$$MD$JP$
174673464$17467346$4$F$$20221115$20200227$20221117$PER$$US-PFIZER INC-2020087955$PFIZER$$53$YR$$F$Y$$$20221117$$HP$US$US
174673518$17467351$8$F$20200901$20221117$20200227$20221122$PER$$US-PFIZER INC-2019021913$PFIZER$$67$YR$$F$Y$$$20221122$$CN$US$US
174674374$17467437$4$F$$20221127$20200227$20221130$PER$$US-PFIZER INC-2020086579$PFIZER$$61$YR$$M$Y$$$20221130$$HP$US$US
174676103$17467610$3$F$$20221018$20200227$20221028$EXP$DE-ADRED-04364-01$DE-TORRENT-00016830$TORRENT$$81$YR$E$M$Y$$$20221028$$MD$DE$DE
174676152$17467615$2$F$$20221010$20200227$20221018$EXP$DE-ADRED-04123-01$DE-TORRENT-00016837$TORRENT$$89$YR$E$F$Y$$$20221018$$PH$DE$DE
174676254$17467625$4$F$$20221023$20200227$20221101$EXP$DE-ADRED-04162-01$DE-TORRENT-00016848$TORRENT$$80$YR$E$M$Y$70$KG$20221101$$PH$DE$DE
174678398$17467839$8$F$20191201$20221017$20200227$20221027$PER$$US-VERTEX PHARMACEUTICALS-2020-003490$VERTEX$$24$YR$$F$Y$76$KG$20221027$$MD$US$US
174679403$17467940$3$F$20200214$20221103$20200227$20221107$EXP$$KR-ROCHE-2554178$ROCHE$$62$YR$$F$Y$69.5$KG$20221107$$MD$KR$
174679432$17467943$2$F$$20191021$20200227$20221102$EXP$$NVSJ2019JP001933$NOVARTIS$$$$$$Y$$$20221102$$PH$JP$JP
174680672$17468067$2$F$$20190708$20200227$20221130$PER$$PHEH2019US028644$NOVARTIS$$$$$F$Y$$$20221130$$HP$US$US
174685325$17468532$5$F$$20221110$20200227$20221114$EXP$$FR-MYLANLABS-2020M1021304$MYLAN$Valette C, Ofaiche J, Severino M, Mazereeuw-Hautier J... Fatal outcome of Netherton syndrome due to excessive use of topical corticosteroids in an adult patient. Annales de dermatologie et de venereologie. 2019;S0151-9638 (19):30313-8$38$YR$$F$Y$$$20221114$$HP$FR$FR
1746937114$17469371$14$F$20160330$20221021$20200227$20221026$EXP$$PHHY2014CA003762$NOVARTIS$$43$YR$$F$Y$$$20221026$$CN$CA$CA
174697772$17469777$2$F$20191031$20221128$20200227$20221207$EXP$$GB-BAUSCH-BL-2020-004920$BAUSCH AND LOMB$$75$YR$$F$Y$$$20221207$$MD$GB$GB
174702415$17470241$5$F$$20221205$20200227$20221208$EXP$$US-PFIZER INC-2020084929$PFIZER$$$$A$F$Y$$$20221208$$HP$US$US
1747087512$17470875$12$F$20190101$20221202$20200227$20221212$EXP$$CA-CELLTRION INC.-2019CA018853$CELLTRION$$$$$$Y$$$20221212$$CN$CA$CA
174711864$17471186$4$F$$20221025$20200227$20221028$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-017127$BRISTOL MYERS SQUIBB$Maesaka F, et al. A case of metastatic renal cell carcinoma with complete response status following single-agent therapy with nivolumab. The 243rd Kansai regional meeting of the Japanese Urological Association 2020;7.$70$YR$E$M$Y$$$20221028$$MD$JP$JP
174712679$17471267$9$F$20190202$20221119$20200227$20221203$EXP$$DE-AUROBINDO-AUR-APL-2020-009581$AUROBINDO$$$$A$F$Y$100$KG$20221203$$MD$DE$DE
174716978$17471697$8$F$20190808$20220919$20200228$20221027$EXP$$IL-ABBVIE-19K-082-3001148-00$ABBVIE$$83$YR$$F$Y$50$KG$20221026$$MD$IL$IL
174720295$17472029$5$F$20161228$20221212$20200228$20221214$EXP$$US-009507513-1812USA007452$MERCK$$$$$M$Y$$$20221214$$HP$US$US
1747207732$17472077$32$F$20191120$20221208$20200228$20221221$EXP$$CA-CELLTRION INC.-2019CA027171$CELLTRION$$$$$$Y$$$20221221$$MD$CA$CA
174723824$17472382$4$F$$20221018$20200228$20221030$EXP$$US-drreddys-USA/USA/20/0120124$DR REDDYS$Essrani R, Mehmood A, Ravi S. Famotidine-induced hypomagnesemia leading to hypocalcemia. Am J Gastroenterol. 2019;114:S1498-9. doi:10.14309/01.ajg.0000600388.59140.a4.$55$YR$A$F$Y$$$20221031$$MD$US$US
174732343$17473234$3$F$$20221117$20200228$20221122$EXP$$US-PFIZER INC-2020086301$PFIZER$$$$$F$Y$$$20221122$$LW$US$US
174732402$17473240$2$F$$20221011$20200228$20221014$EXP$$US-PFIZER INC-2020086415$PFIZER$$$$$$Y$$$20221014$$LW$US$US
1747328920$17473289$20$F$20200215$20221205$20200228$20221214$EXP$$CA-CELLTRION INC.-2020CA018641$CELLTRION$$$$$$Y$$$20221214$$MD$CA$CA
174748284$17474828$4$F$$20221020$20200228$20221022$PER$$NVSC2020US056925$NOVARTIS$$$$$M$Y$$$20221022$$CN$US$US
174751965$17475196$5$F$$20221031$20200228$20221108$EXP$$US-TEVA-2020-US-1189056$TEVA$$63$YR$A$F$Y$$$20221109$$CN$US$US
174752709$17475270$9$F$$20221216$20200228$20221227$PER$$US-PFIZER INC-2020043442$PFIZER$$54$YR$$M$Y$$$20221227$$HP$US$US
1747530314$17475303$14$F$$20221221$20200228$20221227$PER$$US-PFIZER INC-2015100286$PFIZER$$74$YR$$F$Y$63$KG$20221227$$CN$US$US
174754664$17475466$4$F$20200301$20221103$20200228$20221107$PER$$US-PFIZER INC-2020088891$PFIZER$$64$YR$$F$Y$$$20221107$$HP$US$US
174755048$17475504$8$F$20221129$20221219$20200228$20221227$EXP$$US-PFIZER INC-2020088290$PFIZER$$72$YR$$M$Y$$$20221227$$HP$US$US
174756105$17475610$5$F$$20221129$20200228$20221202$PER$$US-PFIZER INC-2020089760$PFIZER$$66$YR$$F$Y$$$20221202$$MD$US$US
174758347$17475834$7$F$20200101$20221201$20200228$20221206$EXP$$US-PFIZER INC-2020086636$PFIZER$$66$YR$$F$Y$$$20221206$$HP$US$US
174763694$17476369$4$F$20190913$20221019$20200228$20221101$EXP$$ES-JNJFOC-20190919818$JOHNSON AND JOHNSON$$62$YR$A$F$Y$60.4$KG$20221101$$MD$ES$ES
174769026$17476902$6$F$20190101$20221209$20200228$20221216$EXP$$CA-JNJFOC-20191024135$JOHNSON AND JOHNSON$$53$YR$A$F$Y$82$KG$20221216$$HP$CA$CA
1747710913$17477109$13$F$20190131$20221130$20200228$20221208$EXP$$DE-JNJFOC-20190608550$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221209$$MD$DE$DE
174772044$17477204$4$F$$20221014$20200229$20221020$EXP$$NVSC2020US058255$NOVARTIS$$$$$F$Y$$$20221020$$CN$US$US
174773855$17477385$5$F$$20221212$20200229$20221216$PER$$NVSC2020US057199$NOVARTIS$$$$$F$Y$$$20221216$$CN$US$US
174776066$17477606$6$F$20180201$20221124$20200228$20221130$EXP$GB-EMA-DD-20180528-KHAREEVHP-094504$GB-MYLANLABS-2020M1021400$MYLAN$$72$YR$$M$Y$93.2$KG$20221130$$MD$GB$GB
174778626$17477862$6$F$$20221013$20200229$20221025$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-06545$SAMSUNG BIOEPIS$$18$YR$A$F$Y$61$KG$20221025$$MD$CA$CA
174779124$17477912$4$F$20150201$20221220$20200228$20221223$EXP$$US-GILEAD-2020-0452908$GILEAD$$58$YR$A$F$Y$$$20221223$$LW$US$US
174781077$17478107$7$F$$20221117$20200228$20221205$PER$$US-SA-2020SA049957$SANOFI AVENTIS$$53$YR$A$F$Y$63.04$KG$20221205$$MD$US$US
174782664$17478266$4$F$$20221205$20200228$20221212$EXP$$CA-PFIZER INC-2020073322$PFIZER$$61$YR$$F$Y$$$20221212$$HP$CA$CA
174786812$17478681$2$F$20191208$20200217$20200228$20221019$EXP$$NVSC2020IT054410$NOVARTIS$$63$YR$$F$Y$$$20221019$$HP$IT$IT
174788802$17478880$2$F$20190701$20221017$20200229$20221020$EXP$$NVSC2020DE052832$NOVARTIS$$68$YR$$F$Y$93$KG$20221020$$MD$DE$DE
1747893816$17478938$16$F$20191112$20221111$20200228$20221114$EXP$$DE-MYLANLABS-2020M1013314$MYLAN$$63$YR$$F$Y$73$KG$20221114$$MD$DE$DE
174790824$17479082$4$F$$20221023$20200229$20221101$EXP$DE-ADRED-04116-01$DE-TORRENT-00016871$TORRENT$$70$YR$E$M$Y$72$KG$20221101$$PH$DE$DE
174792114$17479211$4$F$$20220929$20200228$20221007$EXP$$GB-JNJFOC-20191225731$JOHNSON AND JOHNSON$$$$A$M$Y$$$20221007$$CN$GB$GB
174792224$17479222$4$F$20191201$20221018$20200228$20221021$EXP$$GB-JNJFOC-20191246893$JOHNSON AND JOHNSON$$62$YR$A$F$Y$$$20221021$$CN$GB$GB
174794199$17479419$9$F$20170328$20221118$20200228$20221124$EXP$$JP-BAUSCH-BL-2019-060755$BAUSCH AND LOMB$$75$YR$$M$Y$$$20221124$$MD$JP$JP
174801597$17480159$7$F$$20220927$20200228$20221006$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-06409$SAMSUNG BIOEPIS$$59$YR$A$F$Y$41$KG$20221006$$HP$CA$CA
1748021213$17480212$13$F$$20221221$20200228$20221227$EXP$$NVSC2020GB050186$NOVARTIS$$7$YR$$M$Y$$$20221227$$HP$GB$GB
174803333$17480333$3$F$20180312$20221217$20200228$20221221$EXP$$CA-TAKEDA-2018TUS029240$TAKEDA$$33$YR$$M$Y$$$20221221$$CN$CA$CA
174804354$17480435$4$F$$20221125$20200229$20221205$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-06763$SAMSUNG BIOEPIS$$28$YR$A$M$Y$64$KG$20221205$$MD$CA$CA
174804445$17480444$5$F$$20221102$20200229$20221111$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-06945$SAMSUNG BIOEPIS$$47$YR$A$F$Y$57$KG$20221111$$MD$CA$CA
1748054620$17480546$20$F$$20221215$20200301$20221221$EXP$$US-SHIRE-US202007886$TAKEDA$$$$$F$Y$49$KG$20221221$$HP$US$US
174806784$17480678$4$F$$20221215$20200301$20221222$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-06764$SAMSUNG BIOEPIS$$42$YR$A$M$Y$74$KG$20221222$$CN$CA$CA
174807282$17480728$2$F$20200101$20221124$20200301$20221129$EXP$$AR-ABBVIE-20K-007-3299161-00$ABBVIE$$57$YR$$F$Y$$$20221129$$CN$AR$AR
1748084425$17480844$25$F$20181212$20221118$20200301$20221127$EXP$$CA-CELLTRION INC.-2018CA025151$CELLTRION$$$$$$Y$$$20221128$$CN$CA$CA
174813254$17481325$4$F$20180101$20220922$20200302$20221006$EXP$$DE-AUROBINDO-AUR-APL-2020-010102$AUROBINDO$$54$YR$$M$Y$78$KG$20221006$$LW$DE$DE
174813586$17481358$6$F$20200101$20221227$20200302$20221229$PER$$US-DSJP-DSU-2020-105921$DAIICHI$$$$$M$Y$$$20221229$$CN$US$US
174816543$17481654$3$F$20200101$20221020$20200302$20221027$EXP$$FR-AUROBINDO-AUR-APL-2020-010579$AUROBINDO$$62$YR$$F$Y$$$20221027$$MD$FR$FR
174816995$17481699$5$F$20200101$20221003$20200302$20221006$EXP$$US-SHIRE-US202007982$TAKEDA$$50$YR$$F$Y$113$KG$20221006$$CN$US$US
174824502$17482450$2$F$20190101$20221125$20200302$20221129$EXP$$NVSC2020DE054538$NOVARTIS$$$$$F$Y$$$20221129$$MD$DE$DE
174825192$17482519$2$F$$20221011$20200302$20221018$EXP$DE-ADRED-04364-01$DE-PFIZER INC-2020084385$PFIZER$$81$YR$$M$Y$$$20221018$$MD$DE$DE
174828056$17482805$6$F$$20221124$20200302$20221129$EXP$$IN-PFIZER INC-2020051232$PFIZER$$68$YR$$F$Y$$$20221129$$CN$IN$IN
174829423$17482942$3$F$$20221209$20200302$20221213$PER$$US-PFIZER INC-2018065737$PFIZER$$65$YR$$M$Y$74$KG$20221213$$CN$US$US
174830753$17483075$3$F$$20221201$20200302$20221206$PER$$US-PFIZER INC-2020090905$PFIZER$$62$YR$$F$Y$$$20221206$$MD$US$US
174831246$17483124$6$F$$20221226$20200302$20221228$PER$$US-PFIZER INC-2020089861$PFIZER$$31$YR$$M$Y$$$20221228$$MD$US$US
174831672$17483167$2$F$$20221011$20200302$20221012$PER$$US-PFIZER INC-2020092055$PFIZER$$$$$$Y$$$20221012$$LW$US$US
174838564$17483856$4$F$$20221013$20200302$20221013$PER$$US-PFIZER INC-2020089936$PFIZER$$14$YR$$M$Y$$$20221013$$HP$US$US
174839154$17483915$4$F$20150101$20221025$20200302$20221028$EXP$$US-AstraZeneca-2020SE29221$ASTRAZENECA$$71$YR$$M$Y$120$KG$20221028$$LW$US$
174839634$17483963$4$F$$20221129$20200302$20221207$EXP$$NVSC2020JP058868$NOVARTIS$Iwashita S, Hashiguchi H, Okubo A, Yoneda M, Takai S. Pain relief of arthroscopic rotator cuff repair by nerve block. JOURNAL OF NIPPON MEDICAL SCHOOL. 2020;87(2):87-91$$$A$$Y$$$20221207$$HP$JP$JP
174842973$17484297$3$F$20190101$20220929$20200302$20221011$PER$$AU-TOLMAR, INC.-19AU019828$TOLMAR$$$$$M$Y$$$20221011$$HP$AU$AU
174846745$17484674$5$F$$20220929$20200302$20221006$EXP$$NVSC2020CA058057$NOVARTIS$$$$$F$Y$$$20221006$$CN$CA$CA
174847977$17484797$7$F$20191230$20220422$20200302$20221110$EXP$$JP-JAZZ-2020-JP-002971$JAZZ$$59$YR$$M$Y$47.5$KG$20221110$$MD$JP$JP
174849162$17484916$2$F$20200113$20221111$20200302$20221115$EXP$$IT-PFIZER INC-2020066657$PFIZER$$67$YR$$F$Y$$$20221115$$MD$IT$IT
174850327$17485032$7$F$20191223$20221116$20200302$20221124$EXP$$GR-SHIRE-GR202006953$TAKEDA$$60$YR$$F$Y$60$KG$20221124$$CN$GR$GR
174850605$17485060$5$F$20200402$20221028$20200302$20221101$EXP$$US-SHIRE-US202008013$TAKEDA$$19$YR$$M$Y$$$20221101$$PH$US$US
1748509812$17485098$12$F$20190611$20221124$20200302$20221130$EXP$$IT-SHIRE-IT201919957$TAKEDA$$47$YR$$M$Y$61$KG$20221130$$HP$IT$IT
1748548317$17485483$17$F$20200418$20221220$20200302$20221229$EXP$$CA-CELLTRION INC.-2020CA019839$CELLTRION$$$$$$Y$$$20221229$$HP$CA$CA
174857683$17485768$3$F$20200128$20221116$20200303$20221123$EXP$$CA-ROCHE-2560472$ROCHE$$79$YR$$F$Y$$$20221123$$MD$CA$CA
1748594244$17485942$44$F$20190807$20221205$20200303$20221215$EXP$$CA-CELLTRION INC.-2019CA023896$CELLTRION$$$$$$Y$$$20221215$$CN$CA$CA
174862584$17486258$4$F$20200101$20221027$20200303$20221104$EXP$FR-AFSSAPS-AN20200182$FR-TEVA-2020-FR-1193729$TEVA$$62$YR$A$F$Y$$$20221104$$MD$FR$FR
1748653111$17486531$11$F$20110305$20221111$20200303$20221116$EXP$GB-EMA-DD-20190913-NEGI_N-110827$GB-SAKK-2019SA262115AA$SANOFI AVENTIS$$4$DY$N$M$Y$2.855$KG$20221116$$MD$GB$GB
1748687731$17486877$31$F$20200616$20221209$20200303$20221219$EXP$$US-SHIRE-US202004154$TAKEDA$$61$YR$$F$Y$74.83$KG$20221219$$HP$US$US
174878342$17487834$2$F$$20221207$20200303$20221213$EXP$$US-PFIZER INC-2020093376$MYLAN$$$$$$Y$$$20221213$$CN$US$US
1748795811$17487958$11$F$$20221101$20200303$20221104$EXP$$US-PFIZER INC-2020094058$PFIZER$$76$YR$$M$Y$$$20221104$$CN$US$US
174880489$17488048$9$F$20220215$20221115$20200303$20221117$EXP$$US-PFIZER INC-2019112044$PFIZER$$74$YR$$F$Y$104.33$KG$20221117$$CN$US$US
174880789$17488078$9$F$$20221206$20200303$20221209$PER$$US-PFIZER INC-2020093678$PFIZER$$80$YR$$F$Y$$$20221209$$CN$US$US
1748815811$17488158$11$F$$20221115$20200303$20221117$EXP$$US-PFIZER INC-2020093883$PFIZER$$79$YR$$F$Y$$$20221117$$CN$US$US
174881966$17488196$6$F$20190101$20221223$20200303$20221229$EXP$$NVSC2020CO045786$NOVARTIS$$$$$F$Y$108$KG$20221229$$CN$CO$CO
1748831718$17488317$18$F$20200522$20220427$20200303$20221202$EXP$$NVSC2020CR059107$NOVARTIS$$39$YR$$F$Y$$$20221202$$CN$CR$CR
174883406$17488340$6$F$$20221227$20200303$20221229$EXP$$NVSC2020US056319$NOVARTIS$$$$$F$Y$$$20221229$$CN$US$US
174883475$17488347$5$F$20190606$20221026$20200303$20221028$EXP$$NVSC2020DE057080$NOVARTIS$$59$YR$$F$Y$60$KG$20221028$$HP$DE$DE
174893722$17489372$2$F$$20200226$20200303$20221130$PER$$NVSC2020US055908$NOVARTIS$$$$$F$Y$$$20221130$$CN$US$US
174895206$17489520$6$F$20191214$20221130$20200303$20221203$EXP$$NVSC2020CA059767$NOVARTIS$$59$YR$$F$Y$43$KG$20221203$$MD$CA$CA
1749076215$17490762$15$F$$20221028$20200304$20221103$EXP$$US-SHIRE-US202008287$TAKEDA$$$$$F$Y$55$KG$20221103$$CN$US$US
174907959$17490795$9$F$$20221003$20200304$20221010$PER$$US-AMGEN-USASP2020035984$AMGEN$$42$YR$A$F$Y$$$20221010$$HP$US$US
174908844$17490884$4$F$20110101$20221123$20200304$20221129$EXP$$US-BIOGEN-2020BI00843523$BIOGEN$$$$$F$Y$$$20221129$$CN$US$US
1749089520$17490895$20$F$20131022$20221207$20200303$20221213$EXP$$PHHY2013CA123018$NOVARTIS$$42$YR$$F$Y$$$20221213$$CN$CA$CA
174911074$17491107$4$F$$20221003$20200303$20221005$PER$$US-PFIZER INC-2020094052$PFIZER$$62$YR$$M$Y$$$20221005$$PH$US$US
174911915$17491191$5$F$$20221018$20200304$20221101$EXP$$US-AUROBINDO-AUR-APL-2020-010227$AUROBINDO$Essrani R, Mehmood A, Kirshan Ravi SJ.. Famotidine-induced hypomagnesemia leading to hypocalcemia. American Journal of Gastroenterology. 2019;114:S1498-S1499$55$YR$$F$Y$$$20221101$$MD$US$US
1749173314$17491733$14$F$20191115$20221203$20200304$20221216$EXP$$DE-AUROBINDO-AUR-APL-2020-010340$AUROBINDO$$$$A$F$Y$58$KG$20221216$$MD$DE$DE
174932052$17493205$2$F$20190120$20221115$20200303$20221125$EXP$$US-AMNEAL PHARMACEUTICALS-2019-IPXL-00339$AMNEAL$$74$YR$$M$Y$$$20221125$$CN$US$US
1749336914$17493369$14$F$20180918$20221020$20200304$20221030$EXP$$CA-CELLTRION INC.-2018CA022279$CELLTRION$$$$$$Y$$$20221030$$MD$CA$CA
174933852$17493385$2$F$20190301$20221117$20200303$20221127$EXP$$US-AMNEAL PHARMACEUTICALS-2019-IPXL-00726$AMNEAL$$78$YR$$M$Y$69$KG$20221128$$CN$US$US
1749408923$17494089$23$F$20190528$20221109$20200304$20221118$EXP$$CA-CELLTRION INC.-2019CA021921$CELLTRION$$$$$$Y$$$20221118$$HP$CA$CA
174941515$17494151$5$F$20190820$20220902$20200303$20221006$EXP$$US-AMNEAL PHARMACEUTICALS-2019-IPXL-01708$AMNEAL$$71$YR$$F$Y$61.224$KG$20221006$$CN$US$US
174957136$17495713$6$F$$20221012$20200303$20221020$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-06922$SAMSUNG BIOEPIS$$48$YR$A$F$Y$50$KG$20221020$$MD$CA$CA
174958944$17495894$4$F$20190901$20221004$20200304$20221010$EXP$$NVSC2020IN060311$NOVARTIS$$68$YR$$F$Y$50$KG$20221010$$CN$IN$IN
174959497$17495949$7$F$20200101$20221028$20200304$20221102$PER$$US-PFIZER INC-2020074293$PFIZER$$65$YR$$M$Y$79.38$KG$20221102$$PH$US$US
174960118$17496011$8$F$20191217$20221212$20200303$20221215$EXP$$IL-ABBVIE-20K-082-3300762-00$ABBVIE$$80$YR$$M$Y$$$20221215$$MD$IL$IL
174961085$17496108$5$F$20200101$20221116$20200304$20221121$EXP$$US-PFIZER INC-2020095812$PFIZER$$70$YR$$F$Y$115$KG$20221121$$CN$US$US
174964164$17496416$4$F$20170101$20221206$20200303$20221208$EXP$$US-TAKEDA-2020TUS012445$TAKEDA$$$$$$Y$$$20221208$$LW$US$US
174970062$17497006$2$F$$20221118$20200304$20221128$EXP$$GR-MYLANLABS-2020M1022395$MYLAN$Klavdianou O, Venkateswaran N., Kondylis G., Kosmidis I., Palioura S. Bilateral spontaneous corneal perforations in a patient with follicular dendritic cell sarcoma and distant history of paraneoplastic pemphigus.. 52nd Panhellenic Congress of Opthalmology.. 2019;19:19$73$YR$$F$Y$$$20221128$$MD$GR$GR
174983173$17498317$3$F$$20221115$20200304$20221116$PER$$NVSC2020US061094$NOVARTIS$$$$$F$Y$$$20221116$$CN$US$US
174985967$17498596$7$F$20200225$20221212$20200304$20221215$EXP$$US-SHIRE-US202008189$TAKEDA$$21$YR$$M$Y$$$20221215$$PH$US$US
174986376$17498637$6$F$20180717$20221223$20200304$20221227$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-069194$BRISTOL MYERS SQUIBB$$73$YR$E$F$Y$$$20221227$$MD$JP$JP
174987257$17498725$7$F$$20221114$20200305$20221116$PER$$NVSC2020US062188$NOVARTIS$$$$$M$Y$$$20221116$$CN$US$US
174987422$17498742$2$F$$20221214$20200304$20221221$EXP$$NVSC2020GB062707$NOVARTIS$$$$A$F$Y$$$20221221$$CN$GB$GB
174993813$17499381$3$F$$20221228$20200305$20221230$EXP$$PL-JNJFOC-20200242832$JOHNSON AND JOHNSON$$58$YR$A$F$Y$$$20221230$$MD$PL$PL
1749976823$17499768$23$F$20200107$20221221$20200304$20221230$EXP$$CA-CELLTRION INC.-2019CA027723$CELLTRION$$$$$$Y$$$20221230$$MD$CA$CA
174998757$17499875$7$F$20220925$20221207$20200305$20221210$EXP$$US-KAMADA LIMITED-2020US001233$TAKEDA$$59$YR$$F$Y$77.551$KG$20221210$$CN$US$US
175002737$17500273$7$F$20180701$20221128$20200305$20221201$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2018JPN152698$VIIV$$$$$$Y$$$20221201$$MD$JP$JP
1750085317$17500853$17$F$20200116$20221118$20200305$20221201$EXP$$CA-CELLTRION INC.-2020CA019771$CELLTRION$$$$$$Y$$$20221201$$HP$CA$CA
175008822$17500882$2$F$$20221014$20200305$20221018$EXP$$DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-20-50689$HIKMA$$82$YR$$M$Y$$$20221018$$MD$DE$DE
1750106511$17501065$11$F$$20221220$20200305$20221226$EXP$$CA-GLAXOSMITHKLINE-CA2020AMR037509$GLAXOSMITHKLINE$$$$$$Y$$$20221226$$MD$CA$CA
175012267$17501226$7$F$20200201$20221103$20200305$20221110$EXP$$CA-PFIZER INC-2019194324$PFIZER$$36$YR$$F$Y$$$20221110$$MD$CA$CA
175014193$17501419$3$F$$20221026$20200305$20221101$EXP$$PT-MYLANLABS-2020M1022571$MYLAN$Matos AS, Pais JP, Cambao AR, Nascimento A, Guerra D.. Henoch-schonlein purpura in adult-a diagnostic and therapeutic challenge.. REVISTA ONLINE DE CASOS CL?NICOS EM MEDICINA INTERNA (RCCMI). 2019;1-3$72$YR$$M$Y$$$20221101$$HP$PT$PT
175017477$17501747$7$F$$20221012$20200305$20221017$PER$$US-PFIZER INC-2020097879$PFIZER$$66$YR$$M$Y$$$20221017$$CN$US$US
175017575$17501757$5$F$20200229$20221209$20200305$20221214$EXP$$US-PFIZER INC-2020096540$PFIZER$$74$YR$$F$Y$86$KG$20221214$$CN$US$US
175018076$17501807$6$F$$20221103$20200305$20221108$PER$$US-PFIZER INC-2020098676$PFIZER$$85$YR$$F$Y$50.794$KG$20221108$$CN$US$US
175018402$17501840$2$F$$20221011$20200305$20221020$EXP$$DE-GLENMARK PHARMACEUTICALS-2020GMK046400$GLENMARK$$$$$$Y$$$20221020$$PH$DE$DE
175044736$17504473$6$F$$20221213$20200305$20221219$EXP$$GR-MYLANLABS-2020M1023392$MYLAN$Alexiou D, Zisis Ch, Zormpas P, Karalis, Mylonas S, Aggelis N, et al.. Presentation of a case of Hemophagocytic syndrome on the ground of a possible common varied immunodeficiency.. Anosia.. 2019;15(2)$72$YR$$M$Y$$$20221219$$MD$GR$GR
175045734$17504573$4$F$$20221122$20200305$20221128$PER$$US-PFIZER INC-2020098507$PFIZER$$81$YR$$F$Y$$$20221128$$CN$US$US
175050903$17505090$3$F$20180324$20221124$20200305$20221130$EXP$FR-AFSSAPS-PB20200146$FR-009507513-2002FRA010154$MERCK$Raphalen JH, Marcais A, Parize P, Pilmis B, Lillo-Lelouet A, Lamhaut L, et al.. Is caspofungin efficient to treat invasive candidiasis requiring continuous veno-venous hemofiltration? A case report. Therapies. 2021;527:4$44$YR$$F$Y$68.5$KG$20221130$$HP$FR$FR
175055224$17505522$4$F$20130302$20200420$20200305$20221008$PER$$US-PURDUE PHARMA-USA-2020-0150169$PURDUE$$29$YR$$M$Y$58.957$KG$20221008$$CN$US$US
175061022$17506102$2$F$20110730$20221108$20200305$20221111$EXP$$ES-PFIZER INC-2020095164$PFIZER$$41$YR$$M$Y$$$20221111$$MD$ES$ES
175065174$17506517$4$F$20201029$20221212$20200305$20221216$PER$$US-ROCHE-2468012$ROCHE$$61$YR$$F$Y$$$20221216$$CN$US$US
1750763213$17507632$13$F$20201018$20221007$20200306$20221012$EXP$$US-TAKEDA-2020TUS012218$TAKEDA$$82$YR$$M$Y$84$KG$20221012$$MD$US$US
1750772820$17507728$20$F$20190711$20221215$20200305$20221224$EXP$$CA-CELLTRION INC.-2019CA022395$CELLTRION$$$$$$Y$$$20221224$$MD$CA$CA
175078926$17507892$6$F$20150209$20221213$20200306$20221221$EXP$$US-AstraZeneca-2018SF65392$ASTRAZENECA$$19591$DY$$F$Y$95.3$KG$20221221$$LW$US$
1750801411$17508014$11$F$20170927$20221216$20200305$20221224$EXP$$US-SHIRE-US202008443$TAKEDA$$32$YR$$F$Y$106$KG$20221224$$HP$US$US
175080832$17508083$2$F$$20221014$20200305$20221027$EXP$$DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-239425$RANBAXY$$80$YR$$M$Y$70$KG$20221028$$PH$DE$DE
175082087$17508208$7$F$20161001$20221026$20200305$20221104$PER$$JP-AMGEN-JPNCT2017019840$AMGEN$$81$YR$E$F$Y$$$20221103$$MD$JP$JP
175082734$17508273$4$F$$20221201$20200305$20221206$EXP$$US-SHIRE-US202008535$TAKEDA$$$$$F$Y$73$KG$20221206$$CN$US$US
1750832122$17508321$22$F$20200203$20221214$20200306$20221222$EXP$$CA-CELLTRION INC.-2020CA019223$CELLTRION$$$$$$Y$$$20221223$$HP$CA$CA
175086764$17508676$4$F$$20221007$20200306$20221011$EXP$$US-SHIRE-US202008685$TAKEDA$$$$$F$Y$46.25$KG$20221011$$HP$US$US
175087722$17508772$2$F$$20221202$20200306$20221212$PER$$US-JNJFOC-20200307201$JOHNSON AND JOHNSON$$82$YR$E$M$Y$$$20221212$$CN$US$US
175088284$17508828$4$F$$20221108$20200306$20221114$EXP$$US-PFIZER INC-2020099150$PFIZER$$73$YR$$F$Y$$$20221114$$CN$US$US
175094074$17509407$4$F$20210501$20221004$20200306$20221012$PER$$US-SA-2020SA058125$SANOFI AVENTIS$$58$YR$A$F$Y$$$20221012$$MD$US$US
175095594$17509559$4$F$20200101$20221116$20200306$20221124$EXP$$JP-JNJFOC-20200303194$JOHNSON AND JOHNSON$$46$YR$A$M$Y$$$20221124$$MD$JP$JP
175100113$17510011$3$F$$20221107$20200306$20221109$PER$$US-PFIZER INC-2020100060$PFIZER$$62$YR$$F$Y$$$20221109$$HP$US$US
175100744$17510074$4$F$20200101$20221115$20200306$20221117$PER$$US-PFIZER INC-2020098218$PFIZER$$38$YR$$F$Y$$$20221117$$HP$US$US
175101084$17510108$4$F$$20221114$20200306$20221116$PER$$US-PFIZER INC-2020099761$PFIZER$$75$YR$$F$Y$$$20221116$$MD$US$US
175101124$17510112$4$F$$20221107$20200306$20221110$PER$$US-PFIZER INC-2019369958$PFIZER$$41$YR$$M$Y$103.4$KG$20221110$$MD$US$US
175102555$17510255$5$F$$20221102$20200306$20221107$PER$$US-PFIZER INC-2020100763$PFIZER$$52$YR$$F$Y$$$20221107$$CN$US$US
175103006$17510300$6$F$$20221221$20200306$20221227$EXP$$CA-ASTELLAS-2020US008540$ASTELLAS$$23$MON$$F$Y$$$20221227$$CN$CA$CA
175107285$17510728$5$F$$20221121$20200306$20221128$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-07207$SAMSUNG BIOEPIS$$35$YR$A$M$Y$207$KG$20221128$$MD$CA$CA
175110633$17511063$3$F$20200101$20221104$20200306$20221205$PER$$US-HARMONY BIOSCIENCES-2020HMY00013$HARMONY BIOSCIENCES$$53$YR$$F$Y$71.882$KG$20221202$$CN$US$US
175112214$17511221$4$F$20191025$20220929$20200306$20221003$EXP$$FR-PFIZER INC-2020097093$PFIZER$$75$YR$$M$Y$74$KG$20221003$$MD$FR$FR
175114883$17511488$3$F$20200302$20221014$20200306$20221019$EXP$$NVSC2020CA063520$NOVARTIS$$70$YR$$F$Y$$$20221019$$CN$CA$CA
175117272$17511727$2$F$$20221010$20200308$20221014$EXP$$NVSC2020DE061427$NOVARTIS$$59$YR$$F$Y$$$20221014$$MD$DE$DE
175141895$17514189$5$F$20130101$20220930$20200306$20221012$EXP$$PT-AUROBINDO-AUR-APL-2020-010731$AUROBINDO$Santiago LG, Morgado FJ, Baptista MS, Goncalo M. Hypersensitivity to antibiotics in drug reaction with eosinophilia and systemic symptoms (DRESS) from other culprits. Contact Dermatitis. 2020;82(5):290-296$25$YR$$M$Y$$$20221012$$MD$PT$PT
1751449219$17514492$19$F$$20221117$20200307$20221123$EXP$$US-SHIRE-US202008621$TAKEDA$$$$$F$Y$78$KG$20221123$$HP$US$US
175146335$17514633$5$F$$20221125$20200309$20221202$EXP$$AT-009507513-1904AUT011511$MERCK$Bohn JP, Willenbacher W, Oberacher H, Steurer M.. Pomalidomide in primary intraocular lymphoma (PIOL). Oncology Research and Treatment. 2018;Suppl 4:51$$$$F$Y$$$20221202$$HP$AT$AT
175148645$17514864$5$F$$20221003$20200309$20221010$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-07274$SAMSUNG BIOEPIS$$46$YR$A$F$Y$164$KG$20221010$$MD$CA$CA
175151383$17515138$3$F$$20200301$20200309$20221212$PER$$NVSC2020US061642$NOVARTIS$$$$$F$Y$$$20221212$$CN$US$US
175152532$17515253$2$F$20200216$20220930$20200309$20221009$EXP$FR-AFSSAPS-GR20200315$FR-ROCHE-2562866$ROCHE$$21$YR$$M$Y$68$KG$20221009$$MD$FR$FR
1751569039$17515690$39$F$20200101$20221212$20200309$20221220$EXP$$CA-CELLTRION INC.-2020CA019621$CELLTRION$$$$$$Y$$$20221220$$MD$CA$CA
175159098$17515909$8$F$20170601$20221128$20200309$20221202$EXP$$JP-GILEAD-2018-0359565$GILEAD$$41$YR$A$M$Y$$$20221202$$MD$JP$JP
175161847$17516184$7$F$$20221110$20200309$20221116$EXP$$US-PFIZER INC-2020101159$PFIZER$$72$YR$$M$Y$64$KG$20221116$$CN$US$US
175162734$17516273$4$F$20220801$20221122$20200309$20221125$EXP$$US-KYOWAKIRIN-2020BKK003462$KYOWA$$$$$$Y$$$20221125$$HP$US$US
1751658413$17516584$13$F$20191101$20221115$20200309$20221122$PER$$US-VERTEX PHARMACEUTICALS-2020-001871$VERTEX$$44$YR$$F$Y$66$KG$20221122$$MD$US$US
175165922$17516592$2$F$$20221028$20200309$20221107$EXP$$CA-JNJFOC-20200236591$JOHNSON AND JOHNSON$$82$YR$E$M$Y$$$20221107$$PH$CA$CA
175169317$17516931$7$F$20160119$20221011$20200309$20221020$EXP$$GB-MYLANLABS-2020M1023547$MYLAN$$80$YR$$F$Y$$$20221020$$MD$GB$GB
1751703910$17517039$10$F$$20221014$20200309$20221019$EXP$$CA-JNJFOC-20200243785$JOHNSON AND JOHNSON$$$$$F$Y$79$KG$20221019$$HP$CA$CA
175174943$17517494$3$F$$20221202$20200309$20221206$PER$$US-SA-2020SA059830$SANOFI AVENTIS$$66$YR$E$F$Y$$$20221206$$MD$US$US
175180313$17518031$3$F$20191208$20221213$20200309$20221221$EXP$IT-MINISAL02-601547$IT-MYLANLABS-2020M1023984$MYLAN$$63$YR$$F$Y$$$20221221$$HP$IT$IT
175180552$17518055$2$F$20200101$20221105$20200309$20221110$EXP$$CA-JNJFOC-20200216768$JOHNSON AND JOHNSON$$61$YR$A$F$Y$$$20221110$$CN$CA$CA
175184556$17518455$6$F$20191122$20221208$20200309$20221212$PER$$KR-AMGEN-KORNI2020021376$AMGEN$$57$YR$A$M$Y$53.1$KG$20221212$$MD$KR$KR
1751888714$17518887$14$F$$20221206$20200309$20221209$EXP$$US-PFIZER INC-2020103707$PFIZER$$71$YR$$M$Y$89.342$KG$20221209$$CN$US$US
175190583$17519058$3$F$$20221107$20200310$20221115$EXP$$US-AstraZeneca-2020SE31960$ASTRAZENECA$$$$$F$Y$72.1$KG$20221115$$LW$US$
175194108$17519410$8$F$20200301$20221021$20200309$20221025$EXP$$US-SHIRE-US202008684$TAKEDA$$88$YR$$F$Y$55.782$KG$20221025$$CN$US$US
1751990515$17519905$15$F$20181113$20221206$20200310$20221214$EXP$$NVSJ2020JP002771$NOVARTIS$$26$YR$$F$Y$59.6$KG$20221214$$MD$JP$JP
1752073114$17520731$14$F$20200413$20221102$20200310$20221104$EXP$$US-PFIZER INC-2020103777$PFIZER$$61$YR$$F$Y$57.15$KG$20221104$$CN$US$US
175212752$17521275$2$F$20200108$20221130$20200310$20221202$EXP$$IT-MYLANLABS-2020M1024767$MYLAN$$8$YR$$F$Y$$$20221202$$MD$IT$IT
175215764$17521576$4$F$20200201$20220930$20200310$20221007$EXP$$CA-JNJFOC-20200242723$JOHNSON AND JOHNSON$$28$YR$A$F$Y$55$KG$20221007$$HP$CA$CA
175224084$17522408$4$F$$20221029$20200310$20221103$EXP$$NVSC2020IN067488$NOVARTIS$$45$YR$$M$Y$$$20221103$$CN$IN$IN
175224253$17522425$3$F$20190205$20221003$20200310$20221005$EXP$$JP-BIOGEN-2019BI00820022$BIOGEN$$38$YR$$F$Y$$$20221005$$MD$JP$JP
175236399$17523639$9$F$$20221212$20200310$20221215$PER$$US-PFIZER INC-2019562556$PFIZER$$63$YR$$F$Y$$$20221215$$MD$US$US
175246503$17524650$3$F$$20221107$20200310$20221110$EXP$$PL-UCBSA-2020006967$UCB$$25$YR$$F$Y$$$20221110$$MD$PL$PL
1752546513$17525465$13$F$20200128$20221024$20200311$20221027$EXP$$CA-ROCHE-2561197$ROCHE$$47$YR$$F$Y$$$20221027$$CN$CA$CA
175257333$17525733$3$F$$20220916$20200311$20221003$PER$$US-drreddys-USA/USA/20/0120297$DR REDDYS$$48$YR$A$F$Y$90$KG$20221003$$MD$US$US
175261986$17526198$6$F$$20221017$20200310$20221026$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-07602$SAMSUNG BIOEPIS$$24$YR$A$M$Y$63$KG$20221026$$CN$CA$CA
175269504$17526950$4$F$$20221110$20200311$20221114$EXP$$US-PFIZER INC-2020106204$PFIZER$$73$YR$$F$Y$$$20221114$$CN$US$US
175269933$17526993$3$F$$20221015$20200311$20221029$EXP$$JP-MACLEODS PHARMACEUTICALS US LTD-MAC2020025512$MACLEODS$Katsuta M, Asahina A, Shiohara T.. Multiple Fixed Drug Eruption Mimicking Parapsoriasis en Plaque in a Patient with Hepatitis C Virus Infection. Case Reports in Dermatology. 2020;12(1):25-32$$$$$Y$$$20221029$$MD$JP$JP
175270627$17527062$7$F$20200730$20221214$20200311$20221227$PER$$US-PFIZER INC-2020106082$PFIZER$$68$YR$$F$Y$$$20221227$$CN$US$US
175271727$17527172$7$F$$20221123$20200310$20221130$EXP$$NVSC2020US068311$NOVARTIS$$$$$F$Y$$$20221130$$CN$US$US
175272944$17527294$4$F$$20221219$20200311$20221227$EXP$$US-PFIZER INC-2018050568$PFIZER$$63$YR$$M$Y$$$20221227$$CN$US$US
175275173$17527517$3$F$20150128$20221006$20200311$20221011$EXP$$CA-JNJFOC-20200243642$JOHNSON AND JOHNSON$$39$YR$A$F$Y$108$KG$20221011$$CN$CA$CA
175277946$17527794$6$F$20200101$20221103$20200311$20221104$EXP$$US-KYOWAKIRIN-2020BKK003559$KYOWA$$$$$$Y$$$20221104$$PH$US$US
175279633$17527963$3$F$20200101$20221027$20200311$20221111$EXP$$FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-240177$RANBAXY$$62$YR$$F$Y$$$20221111$$MD$FR$FR
175281624$17528162$4$F$20191216$20221007$20200311$20221013$EXP$$NVSC2019CA086278$NOVARTIS$$73$YR$$F$Y$$$20221013$$CN$CA$CA
1752818411$17528184$11$F$20190101$20221116$20200311$20221118$EXP$$PHHY2019CA069815$NOVARTIS$$$$$M$Y$$$20221118$$CN$CA$CA
175286753$17528675$3$F$$20221207$20200312$20221222$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-239816$RANBAXY$Jiang M, Wasserlauf J, Knight BP, Verma N. Increased Capture Threshold in permanent His-bundle pacing associated with flecainide. Pacing Clin Electrophysiol. 2020;43(4):36-363$64$YR$$M$Y$$$20221222$$MD$US$US
175291164$17529116$4$F$$20221025$20200311$20221027$EXP$$CA-JNJFOC-20200244252$JOHNSON AND JOHNSON$$57$YR$A$M$Y$$$20221027$$CN$CA$CA
175294866$17529486$6$F$20200202$20221111$20200312$20221120$EXP$$US-BIOGEN-2020BI00847228$BIOGEN$$52$YR$$F$Y$$$20221120$$CN$US$US
1752949537$17529495$37$F$20080101$20221211$20200311$20221216$EXP$$GB-MYLANLABS-2020M1026187$MYLAN$$53$YR$$M$Y$$$20221216$$HP$GB$GB
175297682$17529768$2$F$20180329$20221011$20200311$20221019$EXP$$DE-MYLANLABS-2020M1025840$MYLAN$$$$A$F$Y$$$20221019$$MD$DE$DE
175302209$17530220$9$F$$20221118$20200312$20221124$EXP$$US-SHIRE-US202009017$TAKEDA$$$$$F$Y$60$KG$20221124$$HP$US$US
1753106223$17531062$23$F$20200525$20221222$20200312$20221227$EXP$$US-SHIRE-US202009193$TAKEDA$$64$YR$$F$Y$105.22$KG$20221227$$HP$US$US
1753128613$17531286$13$F$20201128$20221121$20200312$20221127$EXP$$US-SHIRE-US202009264$TAKEDA$$65$YR$$F$Y$75$KG$20221127$$CN$US$US
175314986$17531498$6$F$$20221222$20200312$20221226$EXP$CA-NOVARTIS PHARMA AG-02446272, 02424027$CA-GLAXOSMITHKLINE-CA2020044221$GLAXOSMITHKLINE$$65$YR$$F$Y$$$20221226$$HP$CA$CA
175320353$17532035$3$F$$20221122$20200312$20221128$EXP$$AT-PFIZER INC-2020103392$PFIZER$Bohn, J.. Pomalidomide in primary intraocular lymphoma. Leukemia and Lymphoma. 2019;60 (6):1584-1586$67$YR$$F$Y$$$20221128$$HP$AT$AT
175321013$17532101$3$F$$20221207$20200311$20221209$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-019980$BRISTOL MYERS SQUIBB$$72$YR$E$F$Y$$$20221209$$HP$CA$CA
1753215729$17532157$29$F$20200520$20221220$20200312$20221229$EXP$$CA-CELLTRION INC.-2020CA020072$CELLTRION$$$$$$Y$$$20221230$$MD$CA$CA
175325848$17532584$8$F$$20221101$20200312$20221108$EXP$$US-SHIRE-US202009196$TAKEDA$$$$$M$Y$116$KG$20221108$$CN$US$US
175326423$17532642$3$F$20200226$20200317$20200312$20221011$EXP$$US-KYOWAKIRIN-2020BKK003557$KYOWA$$$$$$Y$$$20221011$$HP$US$US
175326642$17532664$2$F$$20221011$20200312$20221012$PER$$US-PFIZER INC-2020102832$PFIZER$$$$$$Y$$$20221012$$LW$US$US
175326674$17532667$4$F$20141027$20221011$20200312$20221012$PER$$US-PFIZER INC-2020102878$PFIZER$$59$YR$$F$Y$$$20221012$$LW$US$US
175326682$17532668$2$F$$20221011$20200312$20221012$PER$$US-PFIZER INC-2020102742$PFIZER$$$$$$Y$$$20221012$$LW$US$US
175326752$17532675$2$F$$20221011$20200312$20221012$PER$$US-PFIZER INC-2020102844$PFIZER$$$$$$Y$$$20221012$$LW$US$US
175327099$17532709$9$F$$20221128$20200312$20221205$PER$$US-PFIZER INC-2020107437$PFIZER$$66$YR$$F$Y$92.08$KG$20221205$$CN$US$US
175327634$17532763$4$F$20200310$20221103$20200312$20221107$PER$$US-PFIZER INC-2020107051$PFIZER$$74$YR$$F$Y$$$20221107$$CN$US$US
175327803$17532780$3$F$20200309$20221005$20200312$20221007$PER$$US-PFIZER INC-2020107028$PFIZER$$70$YR$$F$Y$79.38$KG$20221007$$CN$US$US
175336863$17533686$3$F$$20221021$20200312$20221028$EXP$$PHHY2019CA162532$NOVARTIS$$$$$M$Y$$$20221028$$CN$CA$CA
175338138$17533813$8$F$$20220928$20200312$20221004$EXP$$NVSC2020CA069732$NOVARTIS$$69$YR$$F$Y$$$20221004$$HP$CA$CA
175338332$17533833$2$F$20181101$20221011$20200312$20221020$EXP$$DE-MYLANLABS-2019M1122712$MYLAN$$$$A$F$Y$$$20221020$$MD$DE$DE
1753392826$17533928$26$F$$20221213$20200312$20221221$EXP$$US-SHIRE-US202009402$TAKEDA$$$$$F$Y$45$KG$20221221$$HP$US$US
1753547619$17535476$19$F$20180723$20221122$20200313$20221201$EXP$$CA-CELLTRION INC.-2018CA021871$CELLTRION$$$$$$Y$$$20221201$$CN$CA$CA
1753557531$17535575$31$F$20181220$20221201$20200313$20221210$EXP$$CA-CELLTRION INC.-2018CA025126$CELLTRION$$$$$$Y$$$20221210$$MD$CA$CA
175356192$17535619$2$F$$20200306$20200313$20221205$PER$$NVSC2020US067511$NOVARTIS$Aguirre-Alarcon A, Spaliaras J, Straker T. Use of high flow nasal cannula in a gravid patient with laryngotracheitis undergoing direct laryngoscopy. TRENDS IN ANAESTHESIA  AND CRITICAL CARE. 2020;30:e72$25$YR$$F$Y$$$20221205$$HP$US$US
1753562142$17535621$42$F$20200102$20221202$20200313$20221212$EXP$$CA-CELLTRION INC.-2020CA017805$CELLTRION$$$$$$Y$$$20221212$$HP$CA$CA
175360875$17536087$5$F$$20221014$20200313$20221021$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-08977$SAMSUNG BIOEPIS$$27$YR$A$F$Y$48$KG$20221021$$CN$CA$CA
175361772$17536177$2$F$20190921$20221010$20200313$20221018$PER$$DE-LUPIN PHARMACEUTICALS INC.-2020-00847$LUPIN$$48$YR$$M$Y$84$KG$20221018$$PH$DE$DE
1753643630$17536436$30$F$20191003$20221124$20200313$20221202$EXP$$CA-CELLTRION INC.-2019CA025554$CELLTRION$$$$$$Y$$$20221202$$MD$CA$CA
175365767$17536576$7$F$20191107$20221031$20200313$20221031$PER$$US-BIOGEN-2019BI00806624$BIOGEN$$51$YR$$M$Y$$$20221031$$CN$US$US
1753689011$17536890$11$F$20200204$20221116$20200313$20221119$EXP$$NVSC2020CO021662$NOVARTIS$$61$YR$$F$Y$68$KG$20221119$$CN$CO$CO
175369712$17536971$2$F$20191211$20221113$20200313$20221126$EXP$ES-AEMPS-605561$ES-Axellia-003034$XELLIA PHARMACEUTICALS$Bellon T, Lerma V, Guijarro J, Ramirez E, Martinez C, Escudero C. et al. LTT and HLA testing as diagnostic tools in Spanish vancomycin-induced DRESS cases: A case-control study. Front Pharmacol. 2022 Oct 20;13: 959321$12$YR$T$F$Y$37$KG$20221126$$HP$ES$ES
175371432$17537143$2$F$$20200122$20200313$20221006$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-235601$RANBAXY$$$$$F$Y$$$20221006$$CN$US$US
175371762$17537176$2$F$$20191211$20200313$20221006$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-231308$RANBAXY$$$$$F$Y$$$20221006$$CN$US$US
175372012$17537201$2$F$$20191216$20200313$20221006$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2019R1-231570$RANBAXY$$$$$F$Y$$$20221006$$CN$US$US
175372552$17537255$2$F$20200121$20200127$20200313$20221006$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-235665$RANBAXY$$55$YR$A$F$Y$$$20221006$$CN$US$US
175378568$17537856$8$F$20200730$20221117$20200313$20221124$EXP$$US-SHIRE-US202009326$TAKEDA$$56$YR$$M$Y$82$KG$20221124$$CN$US$US
175387402$17538740$2$F$$20200310$20200313$20221027$PER$$NVSC2020US071956$NOVARTIS$Herbert KA, Sheppard SM. Not your typical dyspnea of pregnancy: A case report of transcatheter valve-in-valve replacement during pregnancy. A AND A PRACTICE. 2019;12(6):202-4$30$YR$$F$Y$$$20221027$$HP$US$US
175391324$17539132$4$F$20201001$20221219$20200313$20221229$PER$$US-PFIZER INC-2020109155$PFIZER$$74$YR$$F$Y$70.3$KG$20221229$$CN$US$US
175394614$17539461$4$F$$20221028$20200313$20221101$PER$$US-PFIZER INC-2020109348$PFIZER$$61$YR$$F$Y$$$20221101$$MD$US$US
175394926$17539492$6$F$20191001$20221005$20200313$20221007$EXP$$US-PFIZER INC-2020108934$PFIZER$$64$YR$$F$Y$$$20221007$$CN$US$US
175395464$17539546$4$F$20130101$20221025$20200313$20221102$EXP$$US-GILEAD-2020-0454581$GILEAD$$53$YR$A$M$Y$$$20221102$$LW$US$US
175400608$17540060$8$F$20191203$20221118$20200313$20221128$EXP$$AT-EMD Serono-9126529$EMD SERONO INC$$45$YR$A$F$Y$49$KG$20221128$$MD$AT$
175400896$17540089$6$F$20210616$20221121$20200313$20221125$EXP$$US-SA-2020SA062730$SANOFI AVENTIS$$24$YR$A$M$Y$$$20221125$$MD$US$US
1754099113$17540991$13$F$20191119$20221125$20200314$20221205$EXP$$CA-CELLTRION INC.-2019CA026380$CELLTRION$$$$$$Y$$$20221205$$MD$CA$CA
175413867$17541386$7$F$$20220923$20200313$20221222$PER$$NVSC2020US068260$NOVARTIS$$$$$F$Y$$$20221222$$CN$US$US
175415212$17541521$2$F$$20221107$20200313$20221108$EXP$$US-PURDUE-USA-2020-0150291$PURDUE$$$$$F$Y$$$20221108$$CN$US$US
175421262$17542126$2$F$$20221010$20200313$20221013$EXP$$PL-ALLERGAN-2011808US$ALLERGAN$Siwek M,  Woron J, Gorostowicz A, Wordliczek J. Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders. Pharmacological reports. 2020;ePub ahead of print$$$$F$Y$$$20221013$$MD$PL$PL
1754221026$17542210$26$F$20180511$20221101$20200314$20221109$EXP$$CA-CELLTRION INC.-2018CA020139$CELLTRION$$$$$$Y$$$20221109$$CN$CA$CA
175422216$17542221$6$F$20200101$20221118$20200313$20221124$PER$$US-ABBVIE-19K-163-3193854-00$ABBVIE$$76$YR$$F$Y$58.966$KG$20221124$$CN$US$US
175422347$17542234$7$F$20160901$20221114$20200313$20221116$EXP$$FR-EXELIXIS-CABO-18028059$EXELIXIS$$54$YR$$M$Y$55$KG$20221116$$MD$FR$FR
1754239015$17542390$15$F$20210630$20221202$20200314$20221209$EXP$$US-SHIRE-US202009519$TAKEDA$$48$YR$$F$Y$67$KG$20221209$$MD$US$US
175423966$17542396$6$F$20200101$20221117$20200314$20221125$EXP$$CA-TAKEDA-2020TUS013737$TAKEDA$$67$YR$$M$Y$$$20221125$$MD$CA$CA
175425214$17542521$4$F$$20221209$20200314$20221220$PER$$US-AMGEN-USASP2020041547$AMGEN$$65$YR$E$F$Y$$$20221220$$MD$US$US
1754280116$17542801$16$F$20200201$20221124$20200315$20221202$EXP$$CA-CELLTRION INC.-2020CA020353$CELLTRION$$$$$$Y$$$20221202$$CN$CA$CA
175431623$17543162$3$F$20200225$20221213$20200316$20221226$EXP$$IT-AUROBINDO-AUR-APL-2020-012329$AUROBINDO$$31$YR$$M$Y$$$20221226$$MD$IT$IT
175435169$17543516$9$F$20190207$20221004$20200316$20221014$EXP$$BE-ASPEN-GLO2020BE002507$ASPEN$$$$$$Y$$$20221014$$MD$BE$BE
175435239$17543523$9$F$20200203$20220920$20200316$20221003$EXP$$CA-CELLTRION INC.-2020CA019261$CELLTRION$$$$$$Y$$$20221003$$HP$CA$CA
175436582$17543658$2$F$$20221017$20200316$20221027$EXP$$DE-TEVA-2020-DE-1201625$TEVA$$76$YR$E$M$Y$53$KG$20221028$$MD$DE$DE
1754384011$17543840$11$F$20220331$20221206$20200316$20221209$EXP$$US-KAMADA LIMITED-2020US001501$TAKEDA$$62$YR$$M$Y$93$KG$20221209$$HP$US$US
175439602$17543960$2$F$$20221017$20200316$20221027$EXP$$DE-TEVA-2020-DE-1200385$TEVA$$79$YR$E$F$Y$$$20221027$$MD$DE$DE
175440947$17544094$7$F$$20220929$20200316$20221005$EXP$$LT-ROCHE-2564778$ROCHE$Kunigeeliene A, Kunigeeliene A, Alekna D, Guzevicius M. A case report: treatment of a patient with schizophrenia and a kindney transplant.. Sveikatos mokslai/ Health Sciences In Eastern Europe. 2019;29(6):132-135.$32$YR$$M$Y$$$20221005$$MD$LT$LT
175441835$17544183$5$F$20190606$20221029$20200316$20221112$EXP$$DE-AUROBINDO-AUR-APL-2020-012583$AUROBINDO$$59$YR$$F$Y$60$KG$20221112$$HP$DE$DE
1754434510$17544345$10$F$20210916$20221214$20200316$20221221$EXP$$US-SHIRE-US202009983$TAKEDA$$68$YR$$F$Y$92$KG$20221221$$HP$US$US
175445106$17544510$6$F$$20221128$20200316$20221203$EXP$$NVSC2020PT072602$NOVARTIS$Varandas AC, Mesquita M, Marques ML, Alives M. Cronic rinossinusite with nasal polipose [Chronic rhinosinusitis with nasal polypose]. JORNAL DO MEDICO. 2019;102$20$YR$$M$Y$$$20221203$$HP$PT$PT
175445609$17544560$9$F$20200227$20221130$20200316$20221202$EXP$$US-PFIZER INC-2020109206$PFIZER$$68$YR$$F$Y$82$KG$20221202$$CN$US$US
175446067$17544606$7$F$20220725$20221130$20200316$20221205$EXP$$US-SHIRE-US202009790$TAKEDA$$67$YR$$F$Y$94.331$KG$20221205$$HP$US$US
175446872$17544687$2$F$$20221119$20200316$20221202$EXP$DE-BFARM-20002553$DE-Accord-175721$ACCORD$$80$YR$E$M$Y$$$20221202$$MD$DE$DE
175447542$17544754$2$F$$20221119$20200316$20221202$EXP$DE-BFARM-20002594$DE-Accord-175899$ACCORD$$79$YR$E$F$Y$$$20221202$$MD$DE$DE
175447627$17544762$7$F$$20221014$20200316$20221219$PER$$US-PFIZER INC-2020112730$PFIZER$$76$YR$$F$Y$$$20221219$$MD$US$US
175447812$17544781$2$F$$20221119$20200316$20221202$EXP$DE-BFARM-20002595$DE-Accord-175873$ACCORD$$76$YR$E$M$Y$53$KG$20221202$$MD$DE$DE
175450915$17545091$5$F$20180615$20221219$20200316$20221227$EXP$$DE-MYLANLABS-2020M1026397$MYLAN$$$$A$F$Y$$$20221227$$MD$DE$DE
175451377$17545137$7$F$$20221206$20200316$20221212$EXP$$US-SHIRE-US202009963$TAKEDA$$$$$F$Y$75$KG$20221212$$HP$US$US
175452155$17545215$5$F$$20221010$20200316$20221014$EXP$$US-PFIZER INC-2020110865$PFIZER$$66$YR$$F$Y$$$20221014$$CN$US$US
175452373$17545237$3$F$20181123$20221010$20200316$20221017$EXP$$DE-MYLANLABS-2020M1026425$MYLAN$$$$A$F$Y$$$20221017$$MD$DE$DE
175456722$17545672$2$F$20190101$20221030$20200316$20221111$EXP$$JP-ELI_LILLY_AND_COMPANY-JP202003001594$ELI LILLY AND CO$Matsuo M, et al..Delayed pharyngocutaneous fistula caused by molecular targeted therapy: a case report.Journal of Medical Case Reports 2022;16(1):1-5.$64$YR$$M$Y$$$20221111$$MD$JP$JP
175458022$17545802$2$F$$20221202$20200316$20221209$EXP$$DE-MYLANLABS-2020M1026562$MYLAN$$89$YR$$F$Y$$$20221209$$PH$DE$DE
175458707$17545870$7$F$20191223$20221108$20200316$20221115$EXP$$GR-MYLANLABS-2020M1026906$MYLAN$$$$A$F$Y$60$KG$20221115$$MD$GR$GR
175459269$17545926$9$F$20200101$20221220$20200316$20221228$EXP$$US-PFIZER INC-2020111346$PFIZER$$70$YR$$F$Y$$$20221228$$HP$US$US
175462395$17546239$5$F$20190502$20221202$20200316$20221207$EXP$$CA-TAKEDA-2020TUS013979$TAKEDA$$53$YR$$M$Y$$$20221207$$CN$CA$CA
1754650610$17546506$10$F$$20221108$20200316$20221110$EXP$$US-SHIRE-US202009532$TAKEDA$$$$$F$Y$52.154$KG$20221110$$CN$US$US
175465113$17546511$3$F$$20221212$20200316$20221215$EXP$$CA-TAKEDA-2020TUS013699$TAKEDA$$83$YR$$F$Y$$$20221215$$CN$CA$CA
175467766$17546776$6$F$20200101$20221026$20200316$20221107$PER$$US-SA-2020SA065172$SANOFI AVENTIS$$52$YR$A$F$Y$$$20221108$$MD$US$US
1754694613$17546946$13$F$$20221115$20200316$20221119$EXP$$US-SHIRE-US202009945$TAKEDA$$$$$F$Y$50$KG$20221119$$MD$US$US
175470582$17547058$2$F$$20221014$20200316$20221019$EXP$$DE-DSJP-DSE-2020-108376$DAIICHI$$71$YR$$F$Y$69$KG$20221019$$PH$DE$DE
175470593$17547059$3$F$$20221130$20200316$20221209$EXP$$NVSJ2020JP000577$NOVARTIS$Yoshida T, Hayata E, Nakata M, Oji A, Umemura N, Nagasaki S, et al.. A Case of Perinatal Management Performed by Multi-professional Collaboration for a Pregnant Woman, Complicated with Mental Disability Induced by Methylphenidate Abuse. Tokyo Journal of Obstetrics and Gynecology/The 390th Annual Meeting of The Japan. 2019;68(4):579$35$YR$$F$Y$$$20221209$$HP$JP$JP
175482664$17548266$4$F$$20221208$20200317$20221222$EXP$$PT-AUROBINDO-AUR-APL-2020-009437$AUROBINDO$Palhinha A, Lobato M, Romeira AM, Leiria-Pinto P.. Anaphylaxis to beta-lactams - when tolerance does not exclude allergy. Revista Portuguesa de Imunoalergologia. 2019;27(1):55$49$YR$$M$Y$$$20221222$$MD$PT$PT
175489077$17548907$7$F$20190101$20221201$20200317$20221205$PER$$US-BIOGEN-2019BI00700516$BIOGEN$$31$YR$$M$Y$$$20221205$$CN$US$US
1754890914$17548909$14$F$$20221209$20200317$20221221$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-08574$SAMSUNG BIOEPIS$$53$YR$A$F$Y$$$20221221$$CN$CA$CA
175490778$17549077$8$F$20200101$20221109$20200317$20221116$EXP$$CA-ROCHE-2564340$ROCHE$$42$YR$$F$Y$$$20221116$$CN$CA$
1754916816$17549168$16$F$20220326$20221116$20200317$20221123$EXP$$US-SHIRE-US202009602$TAKEDA$$9$YR$$F$Y$49.88$KG$20221123$$HP$US$US
175496983$17549698$3$F$20190103$20221118$20200317$20221125$EXP$$CA-TAKEDA-2019TUS048079$TAKEDA$$50$YR$$F$Y$$$20221125$$CN$CA$CA
175499618$17549961$8$F$20220101$20221107$20200317$20221110$EXP$$US-PFIZER INC-2020115295$PFIZER$$77$YR$$F$Y$$$20221110$$CN$US$US
175501022$17550102$2$F$$20221223$20200317$20221230$EXP$$US-TAKEDA-2020TUS014524$TAKEDA$$$$$F$Y$$$20221230$$HP$US$US
175505813$17550581$3$F$$20221206$20200317$20221212$EXP$$US-PFIZER INC-2020114617$PFIZER$$61$YR$$F$Y$81.65$KG$20221212$$CN$US$US
175505833$17550583$3$F$$20221219$20200317$20221222$PER$$US-PFIZER INC-2018452012$PFIZER$$78$YR$$F$Y$$$20221222$$CN$US$US
175507012$17550701$2$F$$20221013$20200317$20221020$EXP$$DE-B.I. Pharmaceuticals,Inc./Ridgefield-2020-12-013634$BOEHRINGER INGELHEIM$$71$YR$E$F$Y$69$KG$20221020$$PH$DE$DE
1755108430$17551084$30$F$$20221213$20200317$20221221$EXP$$US-SHIRE-US202009671$TAKEDA$$$$$F$Y$31$KG$20221221$$CN$US$US
175513822$17551382$2$F$$20221103$20200317$20221108$EXP$$US-PFIZER INC-2020113317$PFIZER$$56$YR$$F$Y$$$20221108$$HP$US$US
175514999$17551499$9$F$20220118$20220307$20200317$20221121$EXP$$NVSC2020US077023$NOVARTIS$$49$YR$$F$Y$$$20221121$$CN$US$US
1755173617$17551736$17$F$20170320$20221209$20200317$20221223$EXP$$PHHY2017CA043518$NOVARTIS$$47$YR$$F$Y$$$20221223$$PH$CA$CA
1755193818$17551938$18$F$20190101$20221031$20200317$20221108$EXP$$US-JAZZ-2020-US-000283$JAZZ$$$$$F$Y$60.798$KG$20221108$$HP$US$US
175524863$17552486$3$F$20200307$20200415$20200317$20221130$PER$$NVSC2020US070760$NOVARTIS$$80$YR$$M$Y$$$20221130$$MD$US$US
175527232$17552723$2$F$$20221011$20200318$20221020$EXP$$DE-AUROBINDO-AUR-APL-2020-013340$AUROBINDO$$71$YR$$F$Y$69$KG$20221020$$PH$DE$DE
175529202$17552920$2$F$20110912$20200313$20200317$20221024$EXP$$NVSC2020ES074525$NOVARTIS$$67$YR$$$Y$$$20221024$$MD$ES$ES
175529522$17552952$2$F$20190906$20221102$20200318$20221104$EXP$$FR-ROCHE-2565302$ROCHE$$77$YR$$M$Y$81$KG$20221104$$MD$FR$
175538333$17553833$3$F$20200305$20221212$20200317$20221220$PER$$US-INCYTE CORPORATION-2020IN002298$INCYTE$$$$$$Y$$$20221220$$CN$US$US
175540764$17554076$4$F$$20200608$20200318$20221212$EXP$$US-TEVA-2020-US-1204103$TEVA$$49$YR$A$F$Y$$$20221212$$MD$US$US
1755410411$17554104$11$F$20180301$20221222$20200318$20221231$EXP$$CA-CELLTRION INC.-2018CA019777$CELLTRION$$$$$$Y$$$20221231$$CN$CA$CA
175542398$17554239$8$F$$20221110$20200318$20221117$EXP$$CA-BIOGEN-2020BI00848675$BIOGEN$$$$$M$Y$$$20221117$$CN$CA$CA
175543964$17554396$4$F$$20221206$20200318$20221209$EXP$$US-SHIRE-US202010016$TAKEDA$$$$$F$Y$95$KG$20221209$$HP$US$US
175544912$17554491$2$F$$20221110$20200318$20221122$EXP$$DE-drreddys-GER/GER/20/0120784$DR REDDYS$$79$YR$E$F$Y$$$20221122$$MD$DE$DE
175547282$17554728$2$F$$20221119$20200318$20221203$EXP$DE-BFARM-20002681$DE-Accord-175893$ACCORD$$71$YR$E$F$Y$69$KG$20221203$$PH$DE$DE
175549305$17554930$5$F$20220704$20221108$20200318$20221114$EXP$$US-PFIZER INC-2020115207$PFIZER$$59$YR$$F$Y$86.18$KG$20221114$$CN$US$US
175553493$17555349$3$F$20200101$20221025$20200318$20221102$EXP$$US-VERTEX PHARMACEUTICALS-2020-005484$VERTEX$$34$YR$$M$Y$$$20221102$$MD$US$US
175555146$17555514$6$F$20120101$20221220$20200318$20221227$EXP$$CA-Orion Corporation ORION PHARMA-TREX2020-1412$ORION$$40$YR$A$F$Y$$$20221228$$MD$CA$
175556213$17555621$3$F$$20221212$20200318$20221219$EXP$$CA-PFIZER INC-2020114752$PFIZER$$83$YR$$F$Y$$$20221219$$HP$CA$CA
175556524$17555652$4$F$$20221017$20200318$20221021$EXP$$CA-PFIZER INC-2020114852$PFIZER$$48$YR$$M$Y$120$KG$20221021$$HP$CA$CA
175558822$17555882$2$F$$20221013$20200318$20221020$EXP$$TR-BAYER-2020-045714$BAYER$$$$$F$Y$$$20221020$$CN$TR$TR
1755596524$17555965$24$F$20200130$20221207$20200316$20221222$PER$$JP-AMGEN-JPNSP2020041741$AMGEN$$67$YR$E$F$Y$61$KG$20221222$$MD$JP$JP
1755597210$17555972$10$F$20190211$20221202$20200318$20221206$EXP$$DE-MYLANLABS-2020M1027307$MYLAN$$$$A$F$Y$67$KG$20221206$$MD$DE$DE
175560752$17556075$2$F$$20221202$20200318$20221209$EXP$$DE-MYLANLABS-2020M1027340$MYLAN$$70$YR$$M$Y$72$KG$20221209$$PH$DE$DE
175563153$17556315$3$F$20180101$20221208$20200318$20221214$EXP$$CZ-ROCHE-2566448$ROCHE$Reporter known to licensee. Porod prvniho ditete po transplantaci delohy v Ceske republice - sexualni, reprodukcni a eticke souvislosti. Sexuologia.. 2019;19(2):15-19.$33$YR$$F$Y$$$20221214$$MD$CZ$CZ
1755666314$17556663$14$F$20200313$20221107$20200318$20221111$EXP$$US-SHIRE-US202010202$TAKEDA$$62$YR$$F$Y$52.608$KG$20221111$$HP$US$US
175570125$17557012$5$F$20180412$20221214$20200318$20221216$EXP$$CA-TAKEDA-2018TUS006482$TAKEDA$$22$YR$$F$Y$$$20221216$$HP$CA$CA
1755701312$17557013$12$F$20200227$20221018$20200318$20221020$EXP$$BE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-020480$BRISTOL MYERS SQUIBB$$83$YR$E$M$Y$$$20221020$$HP$BE$BE
175570184$17557018$4$F$20200101$20220919$20200318$20221003$EXP$$US-ALLERGAN-2011746US$ALLERGAN$$$$$F$Y$54.48$KG$20221003$$MD$US$US
1755710611$17557106$11$F$20200304$20221206$20200318$20221210$EXP$$US-SHIRE-US202010024$TAKEDA$$16$YR$$M$Y$$$20221210$$PH$US$US
175571207$17557120$7$F$20200224$20221213$20200318$20221216$EXP$$US-SHIRE-US202010019$TAKEDA$$25$YR$$M$Y$$$20221216$$PH$US$US
1755731823$17557318$23$F$20220210$20221208$20200318$20221219$EXP$$US-SHIRE-US202009716$TAKEDA$$78$YR$$F$Y$98$KG$20221219$$CN$US$US
175573215$17557321$5$F$20120607$20221024$20200318$20221026$EXP$$US-AstraZeneca-2020SE38242$ASTRAZENECA$$20601$DY$$M$Y$86.2$KG$20221026$$LW$US$
175575028$17557502$8$F$20190101$20221104$20200318$20221109$EXP$$CA-TAKEDA-2019TUS011824$TAKEDA$$45$YR$$M$Y$$$20221109$$HP$CA$CA
1755770522$17557705$22$F$20200930$20221208$20200319$20221221$EXP$$CA-CELLTRION INC.-2019CA023393$CELLTRION$$$$$$Y$$$20221221$$CN$CA$CA
175579226$17557922$6$F$20210831$20221202$20200318$20221208$EXP$$US-SHIRE-US202010326$TAKEDA$$38$YR$$F$Y$62.6$KG$20221208$$CN$US$US
175584484$17558448$4$F$$20221207$20200318$20221212$EXP$$US-PFIZER INC-2020116596$PFIZER$$73$YR$$M$Y$$$20221212$$CN$US$US
175586612$17558661$2$F$$20221207$20200319$20221209$PER$$US-BIOGEN-2020BI00851064$BIOGEN$$$$$F$Y$$$20221209$$CN$US$US
175589037$17558903$7$F$20210101$20220923$20200319$20221003$EXP$$CO-ROCHE-2554415$ROCHE$$73$YR$$F$Y$78$KG$20221003$$CN$CO$CO
1755891512$17558915$12$F$20170706$20221117$20200319$20221125$EXP$$CA-CELLTRION INC.-2017CA009470$CELLTRION$$$$$$Y$$$20221125$$HP$CA$CA
1755894812$17558948$12$F$20140501$20221208$20200318$20221214$EXP$$US-SHIRE-US202010147$TAKEDA$$59$YR$$M$Y$107$KG$20221214$$HP$US$US
1755903322$17559033$22$F$20200101$20221212$20200319$20221220$EXP$$CA-CELLTRION INC.-2019CA025446$CELLTRION$$$$$$Y$$$20221220$$MD$CA$CA
175592166$17559216$6$F$$20221129$20200319$20221205$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021540$BRISTOL MYERS SQUIBB$$40$YR$A$M$Y$$$20221205$$HP$CA$CA
1755922611$17559226$11$F$20220615$20221219$20200319$20221229$EXP$$US-SHIRE-US202010188$TAKEDA$$64$YR$$F$Y$75$KG$20221229$$HP$US$US
1755938613$17559386$13$F$20200224$20221213$20200319$20221216$EXP$$GB-ROCHE-2559355$ROCHE$$76$YR$$F$Y$$$20221216$$MD$GB$GB
175593947$17559394$7$F$20200301$20220927$20200319$20221003$EXP$$US-SHIRE-US202010420$TAKEDA$$70$YR$$F$Y$72$KG$20221003$$CN$US$US
175598332$17559833$2$F$$20221006$20200319$20221010$EXP$DK-DKMA-WBS-0024856$DK-SA-2020SA067439$SANOFI AVENTIS$$36$YR$A$M$Y$$$20221010$$LW$DK$DK
175600005$17560000$5$F$20221117$20221122$20200319$20221128$EXP$$US-SHIRE-US202010390$TAKEDA$$63$YR$$F$Y$95.238$KG$20221128$$HP$US$US
175606722$17560672$2$F$$20200311$20200319$20221220$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021576$BRISTOL MYERS SQUIBB$$53$YR$A$F$Y$$$20221221$$CN$CA$CA
175610062$17561006$2$F$$20221103$20200319$20221114$EXP$$US-PFIZER INC-2020117655$PFIZER$$69$YR$$M$Y$81.65$KG$20221114$$CN$US$US
175610984$17561098$4$F$20221124$20221128$20200319$20221201$EXP$$US-SHIRE-US202009773$TAKEDA$$36$YR$$M$Y$$$20221201$$CN$US$US
1756114713$17561147$13$F$20200311$20221110$20200319$20221114$EXP$$US-SHIRE-US202010098$TAKEDA$$47$YR$$M$Y$$$20221114$$PH$US$US
175617113$17561711$3$F$$20200923$20200319$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-022131$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20221222$$CN$CA$CA
1756241212$17562412$12$F$20221117$20221117$20200319$20221121$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-000736$BOEHRINGER INGELHEIM$$80$YR$E$F$Y$$$20221121$$CN$CA$CA
175625807$17562580$7$F$20190801$20221208$20200319$20221219$EXP$$DE-SHIRE-DE202010385$TAKEDA$$23$YR$$M$Y$82.993$KG$20221219$$HP$DE$DE
175626426$17562642$6$F$20220324$20221005$20200319$20221011$PER$$NVSC2020US077905$NOVARTIS$$51$YR$$F$Y$$$20221011$$HP$US$US
1756265815$17562658$15$F$20220509$20221101$20200319$20221110$EXP$$IE-JNJFOC-20200219269$JOHNSON AND JOHNSON$$82$YR$E$M$Y$$$20221111$$HP$IE$IE
175626864$17562686$4$F$20200122$20200312$20200319$20221201$EXP$$NVSC2020US073261$NOVARTIS$$74$YR$$F$Y$70.31$KG$20221201$$MD$US$US
1756297730$17562977$30$F$$20221214$20200319$20221216$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-014608$BOEHRINGER INGELHEIM$$77$YR$E$F$Y$$$20221216$$CN$CA$CA
175630682$17563068$2$F$$20220927$20200320$20221004$EXP$$FR-CELLTRION INC.-2020FR020679$CELLTRION$$$$$$Y$$$20221005$$MD$FR$FR
1756309926$17563099$26$F$20191201$20221222$20200319$20221229$EXP$$CA-BAUSCH-BL-2019-064621$BAUSCH AND LOMB$$50$YR$$F$Y$104.42$KG$20221229$$CN$CA$CA
175631359$17563135$9$F$20190920$20221220$20200319$20221227$EXP$$JP-BAUSCH-BL-2020-008202$BAUSCH AND LOMB$$62$YR$$M$Y$68.7$KG$20221227$$$COUNTRY NOT SPECIFIED$JP
175635853$17563585$3$F$$20220927$20200319$20221004$EXP$$US-ELI_LILLY_AND_COMPANY-US202003008554$ELI LILLY AND CO$$$$$M$Y$$$20221004$$MD$US$US
175639078$17563907$8$F$20211225$20221129$20200320$20221202$EXP$$US-SHIRE-US202010611$TAKEDA$$76$YR$$M$Y$104$KG$20221202$$HP$US$US
1756392822$17563928$22$F$20200101$20221017$20200320$20221021$EXP$$US-SHIRE-US202010587$TAKEDA$$56$YR$$F$Y$157$KG$20221021$$HP$US$US
1756406911$17564069$11$F$20200201$20221115$20200320$20221123$EXP$$US-BIOGEN-2020BI00849686$BIOGEN$$58$YR$$F$Y$$$20221123$$MD$US$US
175640788$17564078$8$F$$20221109$20200320$20221114$EXP$$US-SHIRE-US202010397$TAKEDA$$$$$M$Y$80$KG$20221114$$CN$US$US
175641012$17564101$2$F$20200211$20221213$20200320$20221227$EXP$$IT-AUROBINDO-AUR-APL-2020-013905$AUROBINDO$$$$$F$Y$$$20221227$$MD$IT$IT
175642035$17564203$5$F$20200323$20221111$20200320$20221115$PER$$NVSC2020US078033$NOVARTIS$$22$YR$$F$Y$$$20221115$$CN$US$US
1756434026$17564340$26$F$20200407$20221213$20200320$20221220$EXP$$US-SHIRE-US202010640$TAKEDA$$56$YR$$F$Y$104$KG$20221220$$HP$US$US
175643972$17564397$2$F$$20221014$20200320$20221020$EXP$$DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-20-50885$HIKMA$$76$YR$$M$Y$53$KG$20221020$$MD$DE$DE
175645965$17564596$5$F$20190501$20221222$20200320$20221228$EXP$$DE-ROCHE-2362638$ROCHE$$$$$F$Y$$$20221228$$CN$DE$
1756461810$17564618$10$F$20200129$20220920$20200320$20221008$EXP$$IL-ABBVIE-20K-082-3292782-00$ABBVIE$$68$YR$$F$Y$73$KG$20221008$$MD$IL$IL
175646664$17564666$4$F$$20221214$20200320$20221219$PER$$US-SHIRE-US202010580$TAKEDA$$$$$F$Y$59$KG$20221219$$CN$US$US
1756503313$17565033$13$F$20200612$20221017$20200320$20221020$EXP$$US-SHIRE-US202010008$TAKEDA$$60$YR$$M$Y$93$KG$20221019$$CN$US$US
175651264$17565126$4$F$$20221111$20200320$20221114$EXP$$NVSJ2020JP003398$NOVARTIS$Akagi Y, Kato T, Hosoi H, Kobata H, Tamura S, Sonoki T, et al.. A Case of Steroid-Resistant TAFRO Syndrome Successfully Treated with Cyclosporine and Rituximab. THE JOURNAL OF THE WAKAYAMA MEDICAL SOCIETY. 2019;70:170$48$YR$$F$Y$$$20221114$$HP$JP$JP
175654217$17565421$7$F$20210101$20221115$20200320$20221122$EXP$$US-PFIZER INC-2020119611$PFIZER$$59$YR$$F$Y$$$20221122$$HP$US$US
1756553412$17565534$12$F$$20221107$20200320$20221114$PER$$US-PFIZER INC-2020120628$PFIZER$$62$YR$$M$Y$$$20221114$$CN$US$US
175655747$17565574$7$F$$20221216$20200320$20221221$EXP$$US-PFIZER INC-2020119555$PFIZER$$73$YR$$F$Y$$$20221221$$CN$US$US
175657533$17565753$3$F$20200101$20221024$20200320$20221028$EXP$FR-AFSSAPS-AN20200182$FR-MYLANLABS-2020M1028671$MYLAN$$62$YR$$F$Y$$$20221028$$MD$FR$FR
175657542$17565754$2$F$$20221003$20200320$20221011$EXP$DK-DKMA-WBS-0024750$DK-MYLANLABS-2020M1028655$MYLAN$$44$YR$$F$Y$298$KG$20221011$$MD$DK$DK
175660309$17566030$9$F$20200104$20221115$20200320$20221121$EXP$$US-SHIRE-US202010612$TAKEDA$$43$YR$$F$Y$74$KG$20221121$$HP$US$US
175663423$17566342$3$F$$20221013$20200320$20221021$EXP$$CA-OTSUKA-2020_007562$OTSUKA$$$$$M$Y$$$20221021$$HP$CA$CA
175664138$17566413$8$F$20191016$20221025$20200320$20221028$PER$$US-BIOGEN-2020BI00851618$BIOGEN$$66$YR$$F$Y$$$20221028$$CN$US$US
175669585$17566958$5$F$20190815$20220930$20200320$20221007$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-023857$BRISTOL MYERS SQUIBB$$76$YR$E$M$Y$46.5$KG$20221007$$MD$JP$JP
175671126$17567112$6$F$20200302$20221007$20200320$20221012$EXP$$CA-JNJFOC-20200318495$JOHNSON AND JOHNSON$$7$YR$C$F$Y$20.6$KG$20221012$$HP$CA$CA
175671152$17567115$2$F$20191101$20221123$20200320$20221129$EXP$$US-VERTEX PHARMACEUTICALS-2020-004977$VERTEX$$33$YR$$M$Y$$$20221129$$PH$US$US
175672008$17567200$8$F$20200330$20221215$20200320$20221222$EXP$$US-SHIRE-US202004849$TAKEDA$$50$YR$$F$Y$74.8$KG$20221222$$MD$US$US
175679122$17567912$2$F$$20221223$20200320$20221227$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-022607$BRISTOL MYERS SQUIBB$$67$YR$E$F$Y$$$20221227$$MD$CA$CA
175679663$17567966$3$F$$20221207$20200320$20221214$EXP$$PT-PERRIGO-20PT004036$PERRIGO$Palhinha A, Lobato M, Romeira AM, Leiria-Pinto P.. Anaphylaxis to beta-lactams - when tolerance does not exclude allergy.. Revista Portuguesa de Imunoalergologia.. 2019;27(1):55$49$YR$$M$Y$$$20221214$$MD$PT$PT
175680872$17568087$2$F$$20200313$20200320$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-022579$BRISTOL MYERS SQUIBB$$56$YR$A$F$Y$$$20221222$$HP$CA$CA
175682387$17568238$7$F$20220401$20221209$20200320$20221214$EXP$$US-PFIZER INC-2020120891$PFIZER$$54$YR$$F$Y$$$20221214$$HP$US$US
175686192$17568619$2$F$$20221014$20200320$20221026$EXP$$DE-GLENMARK PHARMACEUTICALS-2020GMK046618$GLENMARK$$$$$$Y$$$20221026$$PH$DE$DE
175691704$17569170$4$F$$20221115$20200322$20221119$EXP$$NVSC2020US080500$NOVARTIS$$$$$F$Y$$$20221119$$CN$US$US
1756929317$17569293$17$F$20200308$20221129$20200322$20221205$EXP$$US-SHIRE-US202010799$TAKEDA$$48$YR$$F$Y$79.819$KG$20221205$$CN$US$US
1756935411$17569354$11$F$20210326$20221108$20200322$20221110$EXP$$US-SHIRE-US202010763$TAKEDA$$29$YR$$M$Y$$$20221110$$CN$US$US
1756935719$17569357$19$F$20200227$20221019$20200322$20221024$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-023612$BRISTOL MYERS SQUIBB$Kawashima Y, Taniguchi Y, Shimokawa T, Takiguchi Y, Misumi T, Nakamura A, et al. A randomized phase II/ III trial of nivolumab versus nivolumab plus docetaxel for previously treated advanced or recurrent non-small cell lung cancer: TORG1630. Journal of Clinical Oncology. 2022; 40(16(S1)):9030$55$YR$A$M$Y$71.8$KG$20221024$$MD$JP$JP
175695686$17569568$6$F$20200313$20221208$20200323$20221210$EXP$$US-SHIRE-US202010877$TAKEDA$$33$YR$$M$Y$$$20221210$$CN$US$US
175696502$17569650$2$F$$20200313$20200323$20221221$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-022575$BRISTOL MYERS SQUIBB$$54$YR$A$F$Y$$$20221221$$CN$CA$CA
175697697$17569769$7$F$$20220923$20200323$20221006$EXP$$FR-ROCHE-2568757$ROCHE$Mangin M, Mangin M, Lienhart A, Gouraud A, Roux S, Hodique F, Balme B et al. Deux cas d^hemophilie A acquise associee a une pemphigoide bulleuse traitee par omalizumab : coincidence ou effet secondaire. JDP 2019;A:158-9.$64$YR$$M$Y$$$20221006$$HP$FR$FR
175702593$17570259$3$F$$20200928$20200323$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-023559$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20221222$$MD$CA$CA
175705833$17570583$3$F$20220901$20221006$20200323$20221014$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000908$ACADIA PHARMACEUTICALS$$74$YR$$F$Y$$$20221014$$CN$US$US
1757070014$17570700$14$F$20190110$20221206$20200323$20221214$EXP$$NVSJ2020JP003571$NOVARTIS$$8$YR$$F$Y$27.8$KG$20221214$$MD$JP$JP
175707862$17570786$2$F$20190701$20221212$20200323$20221219$EXP$FR-AFSSAPS-TS20191312$NVSC2020FR075429$NOVARTIS$$50$YR$$M$Y$91$KG$20221219$$MD$FR$FR
175708362$17570836$2$F$$20221017$20200323$20221020$EXP$$DE-BAYER-2020-044140$BAYER$$71$YR$E$F$Y$69$KG$20221020$$PH$DE$DE
175709086$17570908$6$F$$20221221$20200323$20221226$EXP$$NVSC2020US076405$NOVARTIS$$$$$F$Y$$$20221226$$CN$US$US
175711532$17571153$2$F$$20221101$20200323$20221104$EXP$$US-PFIZER INC-2020120316$PFIZER$$40$YR$$F$Y$$$20221104$$HP$US$US
1757156910$17571569$10$F$20191211$20221019$20200323$20221021$EXP$$CA-TAKEDA-2019TUS074209$TAKEDA$$31$YR$$F$Y$$$20221021$$CN$CA$CA
1757189815$17571898$15$F$20201103$20221215$20200323$20221224$EXP$$US-SHIRE-US202010884$TAKEDA$$67$YR$$F$Y$68$KG$20221224$$MD$US$US
175719234$17571923$4$F$20191029$20221220$20200323$20221227$EXP$$JP-JNJFOC-20200321354$JOHNSON AND JOHNSON$$72$YR$E$F$Y$66.2$KG$20221227$$MD$JP$JP
1757205524$17572055$24$F$20191125$20221223$20200323$20221228$EXP$$GB-MYLANLABS-2019M1116157$MYLAN$$60$YR$$M$Y$$$20221228$$MD$GB$GB
175723402$17572340$2$F$$20221020$20200323$20221026$EXP$$CA-PFIZER INC-2020118822$PFIZER$$54$YR$$M$Y$83$KG$20221026$$CN$CA$CA
175724947$17572494$7$F$20200305$20221128$20200323$20221128$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-023931$BRISTOL MYERS SQUIBB$$68$YR$E$M$Y$83.2$KG$20221128$$MD$JP$JP
175725382$17572538$2$F$$20220928$20200323$20221003$EXP$$NVSC2020CA081050$NOVARTIS$$53$YR$$M$Y$$$20221003$$CN$CA$CA
1757255513$17572555$13$F$$20221122$20200323$20221129$EXP$$US-SHIRE-US202010741$TAKEDA$$$$$F$Y$$$20221129$$MD$US$US
175726827$17572682$7$F$20200101$20221012$20200323$20221019$PER$$US-SA-2020SA067845$SANOFI AVENTIS$$17$YR$T$F$Y$$$20221019$$MD$US$US
1757279210$17572792$10$F$20200226$20221214$20200323$20221222$EXP$$US-SHIRE-US202010404$TAKEDA$$48$YR$$M$Y$$$20221222$$MD$US$US
175728346$17572834$6$F$20200314$20221202$20200323$20221206$EXP$$US-SHIRE-US202010734$TAKEDA$$53$YR$$M$Y$$$20221206$$PH$US$US
1757308815$17573088$15$F$20161117$20221222$20200323$20221227$EXP$$CA-TAKEDA-2019TUS026181$TAKEDA$$74$YR$$M$Y$$$20221227$$CN$CA$CA
1757410318$17574103$18$F$20200311$20221130$20200323$20221207$EXP$$NVSC2020DE082129$NOVARTIS$$$$E$F$Y$75$KG$20221207$$HP$DE$DE
175742802$17574280$2$F$20220101$20221025$20200324$20221103$EXP$$US-BEH-2020114703$CSL BEHRING$$$$A$F$Y$$$20221103$$HP$US$US
175743257$17574325$7$F$$20221021$20200324$20221028$EXP$$NVSC2020US081956$NOVARTIS$$$$$F$Y$70.3$KG$20221028$$CN$US$US
1757486111$17574861$11$F$20190401$20221013$20200324$20221017$EXP$$DE-ROCHE-2393556$ROCHE$$43$YR$$F$Y$$$20221017$$CN$DE$
175749123$17574912$3$F$$20221101$20200324$20221102$EXP$$US-ROCHE-2567884$ROCHE$$$$$M$Y$$$20221102$$CN$US$
175749883$17574988$3$F$$20221129$20200324$20221205$EXP$$US-SHIRE-US202010924$TAKEDA$$$$$M$Y$79$KG$20221205$$HP$US$US
175749947$17574994$7$F$$20221214$20200324$20221216$EXP$$CA-TAKEDA-2020TUS005439$TAKEDA$$42$YR$$M$Y$$$20221216$$CN$CA$CA
175750203$17575020$3$F$20180601$20221017$20200324$20221021$EXP$$US-GILEAD-2020-0455875$GILEAD$$32$YR$A$M$Y$83.9$KG$20221021$$LW$US$US
175751142$17575114$2$F$$20221213$20200324$20221216$EXP$$NVSC2020US072768$NOVARTIS$$67$YR$$M$Y$$$20221216$$CN$US$US
175753733$17575373$3$F$20200306$20221012$20200324$20221021$EXP$$GB-TAKEDA-2020TUS015490$TAKEDA$$78$YR$$M$Y$78.6$KG$20221021$$HP$GB$GB
175755776$17575577$6$F$20200218$20221026$20200324$20221028$EXP$$US-GW PHARMA-202003USGW01108$JAZZ$$$$$$Y$$$20221028$$MD$US$US
175758025$17575802$5$F$20220219$20221215$20200324$20221219$EXP$$CA-ROCHE-2570242$ROCHE$$41$YR$$M$Y$$$20221219$$CN$CA$
1757585514$17575855$14$F$20190924$20221202$20200324$20221208$EXP$$NVSC2019CA014604$NOVARTIS$$52$YR$$M$Y$$$20221208$$CN$CA$CA
175758563$17575856$3$F$$20221019$20200324$20221029$EXP$DE-ADRED-04458-01$DE-TORRENT-00016996$TORRENT$$71$YR$E$F$Y$69$KG$20221029$$PH$DE$DE
175759249$17575924$9$F$20200306$20221213$20200324$20221220$PER$$NVSC2020US082282$NOVARTIS$$61$YR$$F$Y$$$20221220$$CN$US$US
175759505$17575950$5$F$20200101$20221003$20200324$20221011$PER$$US-VERTEX PHARMACEUTICALS-2020-002661$VERTEX$$$$$F$Y$$$20221011$$MD$US$US
175762082$17576208$2$F$$20221014$20200324$20221019$EXP$$DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-20-50881$HIKMA$$57$YR$$F$Y$$$20221019$$MD$DE$DE
175763732$17576373$2$F$20191229$20220107$20200324$20221230$PER$$US-ACORDA-ACO_163079_2019$ACORDA$$80$YR$$M$Y$$$20221230$$CN$US$US
175765584$17576558$4$F$20220831$20220901$20200324$20221230$PER$$US-ACORDA-ACO_163084_2019$ACORDA$$68$YR$$F$Y$$$20221230$$CN$US$US
175766522$17576652$2$F$$20221201$20200324$20221230$PER$$US-ACORDA-ACO_163750_2020$ACORDA$$$$$F$Y$$$20221230$$CN$US$US
175766962$17576696$2$F$$20221220$20200324$20221230$PER$$US-ACORDA-ACO_163910_2020$ACORDA$$$$$F$Y$$$20221230$$CN$US$US
175767762$17576776$2$F$$20220510$20200324$20221230$PER$$US-ACORDA-ACO_163086_2019$ACORDA$$$$$F$Y$81.633$KG$20221230$$CN$US$US
175771313$17577131$3$F$$20221003$20200324$20221010$EXP$$NVSC2020CA082147$NOVARTIS$$61$YR$$M$Y$$$20221010$$CN$CA$CA
1757766914$17577669$14$F$$20221102$20200324$20221109$EXP$$US-SHIRE-US202010474$TAKEDA$$$$$F$Y$68$KG$20221109$$MD$US$US
175777519$17577751$9$F$$20220929$20200324$20221004$EXP$$US-SHIRE-US202011024$TAKEDA$$$$$M$Y$103$KG$20221004$$MD$US$US
175782102$17578210$2$F$20030201$20221122$20200324$20221123$EXP$$US-NAPPMUNDI-USA-2020-0150475$PURDUE$$79$YR$$F$Y$$$20221123$$CN$US$US
1757846018$17578460$18$F$20200312$20221220$20200324$20221229$EXP$$CA-CELLTRION INC.-2020CA020670$CELLTRION$$$$$$Y$$$20221229$$HP$CA$CA
1757896512$17578965$12$F$20200214$20221107$20200324$20221114$EXP$$GB-PFIZER INC-2020121801$PFIZER$$65$YR$$F$Y$80$KG$20221114$$MD$GB$GB
175790569$17579056$9$F$20200311$20221205$20200325$20221212$EXP$$CA-ROCHE-2568628$ROCHE$$49$YR$$F$Y$$$20221212$$CN$CA$
1757916930$17579169$30$F$20190509$20221202$20200325$20221212$EXP$$CA-CELLTRION INC.-2019CA021569$CELLTRION$$$$$$Y$$$20221212$$CN$CA$CA
175799455$17579945$5$F$$20221206$20200325$20221213$EXP$$US-SHIRE-US202011109$TAKEDA$$$$$F$Y$67$KG$20221213$$MD$US$US
1758022925$17580229$25$F$$20221025$20200325$20221101$EXP$$CA-BIOVITRUM-2020CA1335$BIOVITRUM$$52$YR$$F$Y$$$20221101$$HP$CA$CA
175803092$17580309$2$F$$20200318$20200325$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-023667$BRISTOL MYERS SQUIBB$$61$YR$A$F$Y$$$20221222$$HP$CA$CA
175805112$17580511$2$F$$20221219$20200325$20221227$EXP$$PT-MYLANLABS-2020M1030259$MYLAN$Valido RB, Pedro F, Filipa C, Pedro F.. Severe Catatonia Following Quetiapine Abrupt Withdrawal.. 28th annual congress of the European Psychiatric Association(EPA). 2020;63 (Suppl. 1):663$66$YR$$F$Y$$$20221227$$HP$PT$PT
175806903$17580690$3$F$$20200430$20200325$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-023759$BRISTOL MYERS SQUIBB$$61$YR$A$F$Y$$$20221222$$MD$CA$CA
175808022$17580802$2$F$20190801$20221108$20200325$20221121$EXP$FR-AFSSAPS-AM20200368$FR-Accord-176974$ACCORD$$66$YR$E$F$Y$65$KG$20221121$$MD$FR$FR
175809983$17580998$3$F$$20221208$20200325$20221215$PER$$US-PFIZER INC-2018249815$PFIZER$$69$YR$$F$Y$$$20221215$$CN$US$US
1758115519$17581155$19$F$20200301$20221130$20200325$20221206$EXP$$US-SHIRE-US202011080$TAKEDA$$45$YR$$F$Y$83$KG$20221206$$HP$US$US
175811696$17581169$6$F$20200101$20221103$20200325$20221107$EXP$$NVSC2020CA043083$NOVARTIS$$$$$F$Y$$$20221107$$CN$CA$CA
175815734$17581573$4$F$$20221020$20200325$20221028$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-09689$SAMSUNG BIOEPIS$$30$YR$A$F$Y$81$KG$20221028$$HP$CA$CA
1758184310$17581843$10$F$$20221020$20200325$20221025$EXP$$US-SHIRE-US202011174$TAKEDA$$$$$M$Y$89$KG$20221025$$CN$US$US
175819293$17581929$3$F$$20221004$20200325$20221012$EXP$$US-SHIRE-US202011219$TAKEDA$$$$$F$Y$68$KG$20221012$$CN$US$US
175819647$17581964$7$F$20220726$20221212$20200325$20221219$EXP$$US-SHIRE-US202011222$TAKEDA$$51$YR$$F$Y$70$KG$20221219$$CN$US$US
175828693$17582869$3$F$20191201$20221025$20200325$20221109$PER$$US-INCYTE CORPORATION-2020IN001791$INCYTE$$$$$$Y$$$20221110$$CN$US$US
175830814$17583081$4$F$20200310$20220929$20200325$20221006$EXP$$CA-TAKEDA-2020TUS015002$TAKEDA$$34$YR$$F$Y$$$20221006$$CN$CA$CA
175835793$17583579$3$F$$20221020$20200326$20221027$EXP$$CA-Orion Corporation ORION PHARMA-TREX2020-1499$ORION$$54$YR$A$M$Y$83$KG$20221027$$HP$CA$
1758366819$17583668$19$F$20191227$20221212$20200326$20221220$EXP$$CA-CELLTRION INC.-2019CA028085$CELLTRION$$$$$$Y$$$20221220$$HP$CA$CA
1758391515$17583915$15$F$20201214$20221221$20200326$20221229$EXP$$US-SHIRE-US202011251$TAKEDA$$52$YR$$F$Y$68$KG$20221229$$CN$US$US
175839362$17583936$2$F$20190801$20220922$20200326$20221001$EXP$FR-AFSSAPS-AM20200368$FR-TEVA-2020-FR-1209074$TEVA$$66$YR$E$F$Y$65$KG$20221001$$MD$FR$FR
175841982$17584198$2$F$$20200320$20200326$20221007$EXP$$NVSC2020CA082980$NOVARTIS$$$$$M$Y$$$20221007$$CN$CA$CA
1758421414$17584214$14$F$20180702$20221205$20200326$20221212$EXP$$NVSC2020DE081374$NOVARTIS$$35$YR$$F$Y$$$20221212$$CN$DE$DE
175843863$17584386$3$F$20151201$20221009$20200326$20221011$PER$$US-PFIZER INC-2020123309$PFIZER$$30$YR$$F$Y$125$KG$20221011$$LW$US$US
175846028$17584602$8$F$20180401$20221221$20200326$20221227$EXP$$NVSC2020DE081384$NOVARTIS$$53$YR$$M$Y$$$20221227$$MD$DE$DE
1758460310$17584603$10$F$$20221028$20200326$20221103$EXP$$US-SHIRE-US202011250$TAKEDA$$$$$M$Y$90$KG$20221103$$CN$US$US
175847042$17584704$2$F$$20200323$20200326$20221013$EXP$$NVSC2020CA082875$NOVARTIS$$6$MON$$F$Y$7$KG$20221013$$HP$CA$CA
175848384$17584838$4$F$20220101$20221213$20200326$20221220$PER$$US-PFIZER INC-2020128359$PFIZER$$50$YR$$F$Y$$$20221220$$HP$US$US
175848444$17584844$4$F$20190801$20221107$20200326$20221114$EXP$FR-AFSSAPS-AM20200368$FR-PFIZER INC-2020126938$PFIZER$$66$YR$$F$Y$65$KG$20221114$$MD$FR$FR
175848796$17584879$6$F$20180101$20221103$20200326$20221109$EXP$$US-ABBVIE-20P-163-3336069-00$ABBVIE$$$$$M$Y$$$20221109$$CN$US$US
175859613$17585961$3$F$$20221205$20200326$20221212$EXP$$DE-MYLANLABS-2020M1031677$MYLAN$$71$YR$$F$Y$69$KG$20221212$$PH$DE$DE
175866438$17586643$8$F$20200311$20221221$20200326$20221229$EXP$$US-SHIRE-US202010691$TAKEDA$$25$YR$$F$Y$82$KG$20221229$$CN$US$US
175866673$17586667$3$F$20200215$20221130$20200326$20221202$EXP$$US-SHIRE-US202010926$TAKEDA$$25$YR$$M$Y$$$20221202$$PH$US$US
175869875$17586987$5$F$20171101$20221016$20200326$20221025$PER$$US-SA-2020SA072678$SANOFI AVENTIS$$57$YR$A$F$Y$$$20221025$$MD$US$US
175870862$17587086$2$F$$20200319$20200326$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-024299$BRISTOL MYERS SQUIBB$$56$YR$A$F$Y$$$20221222$$HP$CA$CA
175871155$17587115$5$F$$20221005$20200326$20221011$EXP$$NVSC2020CO085247$NOVARTIS$$$$$F$Y$$$20221011$$CN$CO$CO
175871313$17587131$3$F$$20221202$20200326$20221207$EXP$$DE-MYLANLABS-2020M1031784$MYLAN$$79$YR$$F$Y$$$20221207$$MD$DE$DE
175872362$17587236$2$F$$20221116$20200326$20221124$EXP$$US-JAZZ-2017-US-011479$JAZZ$$$$$F$Y$$$20221124$$MD$US$US
175875077$17587507$7$F$20200825$20221013$20200326$20221027$PER$$NVSC2020US083248$NOVARTIS$$50$YR$$F$Y$$$20221027$$CN$US$US
1758769216$17587692$16$F$20200101$20220930$20200327$20221006$EXP$$DE-ABBVIE-20K-062-3331220-00$ABBVIE$$78$YR$$F$Y$70$KG$20221006$$MD$DE$DE
1758778510$17587785$10$F$20191216$20220918$20200327$20221021$EXP$$IL-ABBVIE-20K-082-3337576-00$ABBVIE$$75$YR$$M$Y$80.2$KG$20221021$$MD$IL$US
175884205$17588420$5$F$20200301$20221116$20200327$20221122$EXP$$JP-ALEXION PHARMACEUTICALS INC.-A202003942$ALEXION$$86$YR$$F$Y$$$20221122$$MD$JP$JP
175885852$17588585$2$F$20180101$20221216$20200327$20221222$EXP$$BR-BIOGEN-2020BI00854418$BIOGEN$$$$$F$Y$52$KG$20221222$$CN$BR$BR
1758904622$17589046$22$F$20200128$20221115$20200327$20221121$EXP$$CA-CELLTRION INC.-2020CA019029$CELLTRION$$$$$$Y$$$20221122$$HP$CA$CA
175899753$17589975$3$F$$20221205$20200327$20221220$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-241736$RANBAXY$Jennifer J, Ashour S, Fuller L. Iron pill-induced duodenitis: A distinct pattern of duodenal mucosal injury in a patient with a duodenal mass. Pathol Res Pract. 2020;May;216(5):152916(1-4)$$$$F$Y$$$20221220$$HP$US$US
175902062$17590206$2$F$$20221114$20200327$20221124$EXP$$DE-drreddys-GER/GER/20/0120910$DR REDDYS$$71$YR$E$F$Y$69$KG$20221124$$PH$DE$DE
175910243$17591024$3$F$20170101$20221011$20200327$20221014$EXP$$US-PFIZER INC-2020127757$PFIZER$$67$YR$$F$Y$$$20221014$$LW$US$US
175910602$17591060$2$F$20200107$20221101$20200327$20221104$EXP$$US-PFIZER INC-2020128251$PFIZER$$67$YR$$F$Y$$$20221104$$CN$US$US
175913127$17591312$7$F$$20221102$20200327$20221104$PER$$US-PFIZER INC-2020129173$PFIZER$$69$YR$$M$Y$$$20221104$$HP$US$US
175913149$17591314$9$F$20170101$20221027$20200327$20221102$EXP$$IN-PFIZER INC-2017393435$PFIZER$$57$YR$$M$Y$68$KG$20221102$$CN$IN$IN
175932213$17593221$3$F$$20221111$20200327$20221116$EXP$$GB-MYLANLABS-2020M1032652$MYLAN$Gundogmus, I.. Firstepisode psychosis induced by pregabalin withdrawal: a case report.. Psychiatry Clin Psychopharmacol.. 2018;28(4):461-3$20$YR$$M$Y$$$20221116$$HP$GB$GB
175932414$17593241$4$F$$20221219$20200327$20221227$EXP$$PT-MYLANLABS-2020M1026749$MYLAN$Palhinha A, Lobato M, Romeira AM, Leiria-Pinto P.. Anaphylaxis to beta-lactams - when tolerance does not exclude allergy.. Portuguese Journal of Immunoallergology. 2019;27(S1):55$49$YR$$M$Y$$$20221227$$HP$PT$PT
1759336210$17593362$10$F$$20221215$20200327$20221222$EXP$$US-SHIRE-US202007902$TAKEDA$$$$$M$Y$116$KG$20221222$$HP$US$US
1759351711$17593517$11$F$20211101$20221118$20200327$20221122$EXP$$US-PFIZER INC-2020075570$PFIZER$$85$YR$$F$Y$$$20221122$$HP$US$US
175935263$17593526$3$F$20200101$20221012$20200327$20221013$PER$$US-PFIZER INC-2020127456$PFIZER$$64$YR$$F$Y$$$20221013$$HP$US$US
175944234$17594423$4$F$20200212$20200616$20200327$20221123$EXP$$NVSC2020US084255$NOVARTIS$$28$YR$$F$Y$93$KG$20221123$$MD$US$US
175948787$17594878$7$F$20200319$20221222$20200328$20221228$EXP$$NVSC2020US082118$NOVARTIS$$83$YR$$M$Y$91$KG$20221228$$MD$US$US
1759505610$17595056$10$F$20200415$20221109$20200328$20221114$EXP$$US-SHIRE-US202011591$TAKEDA$$56$YR$$F$Y$63$KG$20221114$$CN$US$US
175950816$17595081$6$F$$20221216$20200328$20221224$EXP$$US-SHIRE-US202011520$TAKEDA$$$$$F$Y$65$KG$20221224$$CN$US$US
175951194$17595119$4$F$20200314$20200410$20200328$20221202$PER$$US-AMGEN INC.-USASP2020046277$AMGEN$$53$YR$A$F$Y$$$20221202$$CN$US$US
175953524$17595352$4$F$20150101$20220928$20200329$20221006$EXP$$DE-BIOGEN-2020BI00853796$BIOGEN$$$$$F$Y$$$20221006$$CN$DE$DE
175959873$17595987$3$F$$20220926$20200329$20221010$EXP$$DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-241756$RANBAXY$Mohr A, Langan EA, Terheyden P. Sequential Immune Checkpoint Inhibition in the Therapy of Merkel Cell Carcinoma. Aktuel Dermatol. 2020;46(1):45-49$67$YR$$M$Y$$$20221010$$HP$DE$DE
1759601413$17596014$13$F$20190301$20221130$20200330$20221205$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-025938$BRISTOL MYERS SQUIBB$$64$YR$A$M$Y$$$20221205$$PH$JP$JP
175974053$17597405$3$F$$20221221$20200330$20221229$EXP$$CA-SA-2020SA068772$SANOFI AVENTIS$$$$A$M$Y$$$20221229$$MD$CA$CA
175978314$17597831$4$F$$20221219$20200330$20221227$PER$$US-PFIZER INC-2019043752$PFIZER$$45$YR$$F$Y$$$20221227$$MD$US$US
175978714$17597871$4$F$$20221107$20200330$20221114$EXP$$US-PFIZER INC-2020126822$PFIZER$$62$YR$$F$Y$$$20221114$$CN$US$US
175980316$17598031$6$F$$20221216$20200330$20221221$EXP$$US-PFIZER INC-2020129435$PFIZER$$67$YR$$M$Y$$$20221221$$CN$US$US
175980692$17598069$2$F$$20221012$20200330$20221014$PER$$US-PFIZER INC-2020129408$PFIZER$$55$YR$$F$Y$$$20221014$$HP$US$US
175983826$17598382$6$F$$20221102$20200330$20221106$EXP$$US-ROCHE-2569859$ROCHE$$91$YR$$M$Y$$$20221107$$CN$US$
1759903510$17599035$10$F$20210101$20221215$20200330$20221228$EXP$$CA-PFIZER INC-2018311183$PFIZER$$58$YR$$F$Y$83.447$KG$20221228$$CN$CA$CA
175994554$17599455$4$F$$20221031$20200330$20221107$EXP$$ES-MYLANLABS-2020M1033120$MYLAN$Lopez-Marina V, Rama Martinez T, Pizarro Romero G, Alcolea Garcia R, Costa Bardaji N.. Pancytopenia secondary to methotrexate poisoning in an elderly patient. SEMERGEN SOCIEDAD ESPANOLA DE MEDICINA RURAL Y GENERALISTA. 2019;45(6):29-31$71$YR$$M$Y$$$20221107$$HP$ES$ES
175995082$17599508$2$F$20070101$20220928$20200330$20221012$PER$$US-JNJFOC-20200340192$JOHNSON AND JOHNSON$$7$YR$C$M$Y$$$20221010$$LW$US$US
175995695$17599569$5$F$20191130$20221111$20200330$20221116$PER$$JP-AMGEN-JPNSP2020049866$AMGEN$$73$YR$E$M$Y$58.7$KG$20221115$$MD$JP$JP
175996036$17599603$6$F$20200303$20220104$20200330$20221023$PER$$NVSC2020US072640$NOVARTIS$$3$YR$$M$Y$$$20221023$$CN$US$US
175996822$17599682$2$F$$20221110$20200330$20221115$EXP$$GB-MYLANLABS-2020M1032351$MYLAN$Storrar NPF, Mathur A, Johnson PRE, Roddie PH.. Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide and lenalidomide-containing regimens. Br J Haematol.$$$$M$Y$$$20221115$$HP$GB$GB
175999084$17599908$4$F$20190101$20221220$20200330$20221228$EXP$$US-PFIZER INC-2020130005$PFIZER$$72$YR$$F$Y$71.655$KG$20221228$$HP$US$US
175999496$17599949$6$F$20200320$20221121$20200330$20221124$EXP$$US-SHIRE-US202011240$TAKEDA$$54$YR$$M$Y$$$20221124$$PH$US$US
176000398$17600039$8$F$20191023$20221216$20200330$20221220$EXP$$JP-SHIRE-JP202011378AA$TAKEDA$$1$YR$$M$Y$$$20221220$$MD$JP$JP
176003077$17600307$7$F$$20221128$20200330$20221206$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10269$SAMSUNG BIOEPIS$$66$YR$E$M$Y$82$KG$20221206$$MD$CA$CA
176003553$17600355$3$F$20191012$20221202$20200330$20221212$EXP$$FR-SA-2020SA076147$SANOFI AVENTIS$$72$YR$E$F$Y$40$KG$20221212$$HP$FR$FR
176007385$17600738$5$F$$20221021$20200330$20221025$EXP$$US-PFIZER INC-2020125233$PFIZER$$75$YR$$F$Y$$$20221025$$CN$US$US
1760139011$17601390$11$F$20200324$20221111$20200331$20221115$EXP$$US-SHIRE-US202011861$TAKEDA$$4$YR$$M$Y$$$20221115$$PH$US$US
176023422$17602342$2$F$20180101$20220920$20200330$20221003$EXP$$TH-009507513-2003THA009757$MERCK$Tajarernmuang P, Fiset PO, Routy JP, Beaudoin S. Intractable pleural effusion in Kaposi sarcoma following antiretroviral therapy in a Caucasian female infected with HIV. BMJ Case Reports. 2020;13 (2)$57$YR$$F$Y$$$20221003$$HP$TH$CA
176024053$17602405$3$F$$20220818$20200331$20221207$PER$$NVSC2020US083907$NOVARTIS$$$$$M$Y$$$20221207$$CN$US$US
176024667$17602466$7$F$$20220927$20200331$20221006$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-09842$SAMSUNG BIOEPIS$$60$YR$A$F$Y$60$KG$20221006$$HP$CA$CA
176031459$17603145$9$F$20190409$20220927$20200331$20221007$EXP$$CA-CELLTRION INC.-2019CA020042$CELLTRION$$$$$$Y$$$20221007$$MD$CA$CA
1760396322$17603963$22$F$20201002$20221215$20200331$20221220$EXP$$US-SHIRE-US202011706$TAKEDA$$63$YR$$F$Y$39.9$KG$20221220$$MD$US$US
176044384$17604438$4$F$$20221101$20200331$20221104$PER$$US-PFIZER INC-2019062198$PFIZER$$61$YR$$M$Y$$$20221104$$MD$US$US
176045303$17604530$3$F$20200320$20221014$20200331$20221019$EXP$$CA-PFIZER INC-2020133329$PFIZER$$56$YR$$F$Y$$$20221019$$MD$CA$CA
1760458019$17604580$19$F$20160101$20221014$20200331$20221019$EXP$$US-PFIZER INC-2017438951$PFIZER$$77$YR$$F$Y$95.25$KG$20221019$$CN$US$US
176045848$17604584$8$F$20200101$20221213$20200331$20221219$EXP$$US-PFIZER INC-2020128868$PFIZER$$64$YR$$M$Y$$$20221219$$HP$US$US
176046474$17604647$4$F$$20221104$20200331$20221108$PER$$US-PFIZER INC-2020047833$PFIZER$$62$YR$$F$Y$$$20221108$$CN$US$US
176048775$17604877$5$F$$20221104$20200331$20221114$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10473$SAMSUNG BIOEPIS$$69$YR$E$M$Y$97$KG$20221114$$CN$CA$CA
176053396$17605339$6$F$$20221006$20200331$20221011$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-09847$SAMSUNG BIOEPIS$$70$YR$E$F$Y$96$KG$20221011$$MD$CA$CA
1760551911$17605519$11$F$20200101$20221124$20200331$20221201$PER$$US-SA-2020SA079476$SANOFI AVENTIS$$37$YR$A$M$Y$$$20221201$$MD$US$US
176057995$17605799$5$F$$20221028$20200331$20221104$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10592$SAMSUNG BIOEPIS$$59$YR$A$F$Y$47$KG$20221104$$CN$CA$CA
176058816$17605881$6$F$20191201$20221201$20200331$20221208$EXP$$NVSC2020CO048553$NOVARTIS$$43$YR$$F$Y$92$KG$20221208$$CN$CO$CO
176065097$17606509$7$F$$20221122$20200331$20221201$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10543$SAMSUNG BIOEPIS$$34$YR$A$F$Y$70$KG$20221202$$HP$CA$CA
176065466$17606546$6$F$20190408$20221209$20200331$20221219$EXP$$CA-SHIRE-CA202011056$TAKEDA$$$$A$M$Y$79$KG$20221219$$CN$CA$CA
176065845$17606584$5$F$$20221125$20200331$20221205$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10547$SAMSUNG BIOEPIS$$27$YR$A$M$Y$102$KG$20221205$$HP$CA$CA
176065968$17606596$8$F$$20221108$20200331$20221115$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10961$SAMSUNG BIOEPIS$$42$YR$A$F$Y$68$KG$20221115$$MD$CA$CA
176078113$17607811$3$F$$20221003$20200401$20221013$EXP$$CA-ROCHE-2573567$ROCHE$$61$YR$$M$Y$$$20221013$$CN$CA$CA
176079665$17607966$5$F$$20221014$20200331$20221021$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-09673$SAMSUNG BIOEPIS$$49$YR$A$M$Y$100$KG$20221021$$HP$CA$CA
1760803220$17608032$20$F$20200224$20221221$20200331$20221230$PER$$GB-AMGEN-GBRNI2020044379$AMGEN$$76$YR$E$F$Y$$$20221230$$MD$GB$GB
176085429$17608542$9$F$20190101$20220928$20200331$20221017$EXP$$IL-ABBVIE-19K-082-2851420-00$ABBVIE$$80$YR$$M$Y$68$KG$20221017$$MD$IL$IL
176089513$17608951$3$F$$20221108$20200401$20221117$EXP$$US-SA-2020SA079538$SANOFI AVENTIS$$14$YR$T$M$Y$48.073$KG$20221117$$MD$US$US
176090452$17609045$2$F$20191030$20221010$20200401$20221019$EXP$$DE-AUROBINDO-AUR-APL-2020-015994$AUROBINDO$$$$A$F$Y$72.4$KG$20221019$$MD$DE$DE
1760913421$17609134$21$F$$20221202$20200401$20221209$EXP$$US-SHIRE-US202011949$TAKEDA$$$$$M$Y$107$KG$20221209$$HP$US$US
176093884$17609388$4$F$20200301$20221019$20200401$20221025$EXP$$NVSC2020CA086933$NOVARTIS$$83$YR$$M$Y$$$20221025$$CN$CA$CA
176094156$17609415$6$F$20200201$20221124$20200401$20221201$EXP$$NVSC2020BR074362$NOVARTIS$$37$YR$$F$Y$61$KG$20221201$$CN$BR$BR
176094275$17609427$5$F$20191001$20221020$20200401$20221024$EXP$$NVSC2019CA034498$NOVARTIS$$43$YR$$F$Y$$$20221024$$CN$CA$CA
176103963$17610396$3$F$20200301$20221206$20200401$20221209$PER$$US-PFIZER INC-2020129481$PFIZER$$77$YR$$M$Y$83.91$KG$20221209$$CN$US$US
176104284$17610428$4$F$$20221028$20200401$20221103$PER$$US-PFIZER INC-2020131951$PFIZER$$64$YR$$F$Y$$$20221103$$PH$US$US
176105014$17610501$4$F$$20221018$20200401$20221021$EXP$$US-PFIZER INC-2020088321$PFIZER$$52$YR$$F$Y$$$20221021$$HP$US$US
1761105410$17611054$10$F$20200219$20221104$20200401$20221110$PER$$US-VERTEX PHARMACEUTICALS-2020-005255$VERTEX$$20$YR$$M$Y$48$KG$20221110$$HP$US$US
176113955$17611395$5$F$20190522$20221220$20200401$20221224$PER$$JP-AMGEN-JPNNI2020047195$AMGEN$$59$YR$A$F$Y$$$20221224$$MD$JP$JP
1761181811$17611818$11$F$20200108$20221102$20200401$20221109$EXP$$NVSC2020CA086610$NOVARTIS$$24$YR$$F$Y$73$KG$20221109$$MD$CA$CA
176119802$17611980$2$F$$20221130$20200401$20221208$EXP$$PHHY2018CA159978$NOVARTIS$$$$$M$Y$$$20221208$$CN$CA$CA
176125704$17612570$4$F$20180101$20221121$20200401$20221201$EXP$$PHHY2018CA076534$NOVARTIS$$$$$M$Y$$$20221201$$CN$CA$CA
176142485$17614248$5$F$20220109$20221202$20200402$20221208$EXP$$NVSC2020US086364$NOVARTIS$$38$YR$$F$Y$133$KG$20221208$$CN$US$US
176142632$17614263$2$F$$20220922$20200402$20221007$EXP$$DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-242240$RANBAXY$Vossen D, Nehls V. A patient with inflammatory arthralgia, paraesthesia and atrial fibrillation. Z Rheumatol. 2020;79(1):78-82$61$YR$$M$Y$$$20221007$$MD$DE$DE
1761431811$17614318$11$F$$20221128$20200402$20221209$PER$$NVSC2020US083676$NOVARTIS$$$$$F$Y$$$20221209$$CN$US$US
1761448411$17614484$11$F$20210401$20221004$20200402$20221012$EXP$$CA-CELLTRION INC.-2020CA019806$CELLTRION$$$$$$Y$$$20221013$$MD$CA$CA
176151833$17615183$3$F$$20221123$20200402$20221128$PER$$US-PFIZER INC-2020133936$PFIZER$$57$YR$$M$Y$$$20221128$$CN$US$US
176153425$17615342$5$F$20190504$20221202$20200402$20221213$PER$$JP-AMGEN-JPNSP2020052334$AMGEN$$58$YR$A$M$Y$75.4$KG$20221212$$MD$JP$JP
176154173$17615417$3$F$$20221014$20200402$20221018$EXP$$US-PFIZER INC-2020137529$PFIZER$$43$YR$$$Y$$$20221018$$CN$US$US
1761548314$17615483$14$F$20190308$20221202$20200402$20221212$PER$$JP-AMGEN-JPNSP2019076666$AMGEN$$40$YR$A$M$Y$103.4$KG$20221212$$MD$JP$JP
176168788$17616878$8$F$$20221219$20200402$20221224$EXP$$US-SHIRE-US202008931$TAKEDA$$$$$F$Y$59$KG$20221224$$HP$US$US
176169024$17616902$4$F$20200303$20221011$20200402$20221012$PER$$NVSC2020US088917$NOVARTIS$$14$YR$$F$Y$$$20221012$$CN$US$US
176169628$17616962$8$F$20200823$20221019$20200402$20221026$EXP$$US-SHIRE-US202012054$TAKEDA$$32$YR$$M$Y$132$KG$20221026$$HP$US$US
176171836$17617183$6$F$$20221227$20200402$20221230$EXP$$US-PFIZER INC-2020136817$PFIZER$$75$YR$$$Y$$$20221230$$CN$US$US
176178668$17617866$8$F$$20221006$20200402$20221012$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10347$SAMSUNG BIOEPIS$$40$YR$A$F$Y$45$KG$20221012$$HP$CA$CA
176178854$17617885$4$F$$20221216$20200402$20221226$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10690$SAMSUNG BIOEPIS$$30$YR$A$M$Y$83$KG$20221226$$MD$CA$CA
1761858318$17618583$18$F$20160323$20221007$20200402$20221019$PER$$GB-AMGEN-GBRSP2019117813$AMGEN$$78$YR$E$F$Y$$$20221017$$MD$GB$GB
176188893$17618889$3$F$20190501$20221017$20200402$20221019$EXP$$NVSC2020ES069703$NOVARTIS$Valdivielso CE, Palomares M, Aguirre P. Crohn^s disease in patients treated with etanercept. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. 2020;112(1):80-1$39$YR$$M$Y$$$20221019$$HP$ES$ES
176190303$17619030$3$F$$20221101$20200402$20221107$EXP$$US-TAKEDA-2020TUS016785$TAKEDA$$$$$M$Y$83$KG$20221107$$HP$US$US
1762006326$17620063$26$F$20200101$20221209$20200403$20221219$EXP$$CA-CELLTRION INC.-2020CA021104$CELLTRION$$$$$$Y$$$20221219$$HP$CA$CA
176202232$17620223$2$F$$20200214$20200403$20221223$PER$$US-AMGEN INC.-USASP2020047543$AMGEN$$$$$$Y$$$20221222$$CN$US$US
176212713$17621271$3$F$$20221025$20200403$20221101$EXP$$AU-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-026804$BRISTOL MYERS SQUIBB$$34$YR$A$F$Y$$$20221102$$HP$AU$AU
176219868$17621986$8$F$20200318$20221210$20200403$20221215$EXP$$US-VIIV HEALTHCARE LIMITED-US2020GSK058128$VIIV$$$$$$Y$$$20221215$$MD$US$US
176224474$17622447$4$F$20200201$20220929$20200403$20221011$PER$$NL-TOLMAR, INC.-20NL020830$TOLMAR$$59$YR$$M$Y$$$20221011$$HP$NL$NL
1762267115$17622671$15$F$20210122$20221222$20200403$20221230$EXP$$US-SHIRE-US202012166$TAKEDA$$72$YR$$F$Y$68$KG$20221230$$HP$US$US
176228215$17622821$5$F$$20221012$20200403$20221014$PER$$US-PFIZER INC-2020136641$PFIZER$$56$YR$$F$Y$$$20221014$$CN$US$US
1762291810$17622918$10$F$$20221017$20200403$20221020$PER$$US-PFIZER INC-2020137849$PFIZER$$66$YR$$F$Y$$$20221020$$CN$US$US
1762338213$17623382$13$F$20200811$20221007$20200403$20221014$EXP$$US-SHIRE-US202008310$TAKEDA$$63$YR$$F$Y$72$KG$20221014$$HP$US$US
176235406$17623540$6$F$$20221013$20200403$20221020$EXP$$CA-JNJFOC-20200340132$JOHNSON AND JOHNSON$$42$YR$A$F$Y$$$20221020$$HP$CA$CA
176242065$17624206$5$F$$20221028$20200403$20221107$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11003$SAMSUNG BIOEPIS$$75$YR$E$M$Y$78$KG$20221107$$MD$CA$CA
176242145$17624214$5$F$$20221209$20200403$20221213$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10756$SAMSUNG BIOEPIS$$49$YR$A$F$Y$83$KG$20221213$$HP$CA$CA
176243813$17624381$3$F$$20221107$20200403$20221108$EXP$$US-NAPPMUNDI-USA-2020-0150782$PURDUE$$$$A$M$Y$$$20221108$$CN$US$US
176245885$17624588$5$F$$20221202$20200403$20221212$PER$$US-VERTEX PHARMACEUTICALS-2020-007038$VERTEX$$$$$F$Y$$$20221212$$PH$US$US
176246992$17624699$2$F$$20221205$20200403$20221219$EXP$$CA-Ascend Therapeutics US, LLC-2082303$ASCEND$$57$YR$$F$Y$$$20221219$$HP$CA$CA
176253032$17625303$2$F$20200215$20221220$20200403$20221223$EXP$$US-JAZZ-2020-US-004635$JAZZ$$31$YR$$F$Y$$$20221223$$CN$US$US
1762538720$17625387$20$F$20220808$20221115$20200403$20221122$EXP$$US-SHIRE-US202012189$TAKEDA$$52$YR$$F$Y$87.982$KG$20221122$$HP$US$US
176255098$17625509$8$F$$20221117$20200404$20221125$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10766$SAMSUNG BIOEPIS$$22$YR$A$M$Y$90$KG$20221125$$MD$CA$CA
176257035$17625703$5$F$$20221014$20200404$20221021$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10740$SAMSUNG BIOEPIS$$26$YR$A$F$Y$57$KG$20221021$$CN$CA$CA
176266636$17626663$6$F$$20221017$20200405$20221026$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10539$SAMSUNG BIOEPIS$$47$YR$A$M$Y$92$KG$20221026$$HP$CA$CA
176267426$17626742$6$F$$20221114$20200405$20221121$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10973$SAMSUNG BIOEPIS$$42$YR$A$F$Y$96$KG$20221121$$CN$CA$CA
176267465$17626746$5$F$$20221104$20200405$20221114$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10975$SAMSUNG BIOEPIS$$63$YR$A$F$Y$56$KG$20221114$$MD$CA$CA
1762803824$17628038$24$F$20200107$20221205$20200405$20221214$EXP$$CA-CELLTRION INC.-2019CA027800$CELLTRION$$$$$$Y$$$20221214$$MD$CA$CA
176283962$17628396$2$F$$20220928$20200406$20221003$PER$$US-GLAXOSMITHKLINE-US2020058364$GLAXOSMITHKLINE$$$$$M$Y$$$20221003$$CN$US$US
1762896819$17628968$19$F$$20220929$20200406$20221003$EXP$$US-GLAXOSMITHKLINE-US2020AMR057933$GLAXOSMITHKLINE$$$$$$Y$$$20221003$$CN$US$US
176295272$17629527$2$F$$20221011$20200406$20221014$EXP$$DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-028286$BRISTOL MYERS SQUIBB$$75$YR$E$M$Y$$$20221014$$MD$DE$DE
176295432$17629543$2$F$$20221104$20200406$20221115$EXP$$SG-APOTEX-2020AP009419$APOTEX$$65$YR$$F$Y$$$20221115$$CN$SG$KR
176295494$17629549$4$F$$20221118$20200406$20221122$PER$$US-PFIZER INC-2020134185$PFIZER$$69$YR$$F$Y$$$20221122$$CN$US$US
1762964210$17629642$10$F$20200301$20221116$20200406$20221122$EXP$$US-PFIZER INC-2020139793$PFIZER$$67$YR$$F$Y$105.23$KG$20221122$$CN$US$US
176302502$17630250$2$F$$20220928$20200406$20221005$EXP$$NVSC2020CA091422$NOVARTIS$$59$YR$$F$Y$$$20221005$$CN$CA$CA
1763034511$17630345$11$F$20191101$20221223$20200406$20221230$EXP$$NVSC2019AR057677$NOVARTIS$$60$YR$$F$Y$$$20221230$$CN$AR$AR
176308404$17630840$4$F$20151201$20220929$20200406$20221004$EXP$$US-SA-2020SA085096$SANOFI AVENTIS$$62$YR$A$M$Y$$$20221004$$MD$US$US
176312144$17631214$4$F$20200331$20221111$20200406$20221114$PER$$US-Eisai Medical Research-EC-2020-072724$EISAI$$9$YR$C$M$Y$28.2$KG$20221114$$MD$US$
176312518$17631251$8$F$20170101$20221222$20200406$20221227$EXP$$CA-TAKEDA-2017TUS015424$TAKEDA$$63$YR$$F$Y$$$20221227$$CN$CA$CA
176313106$17631310$6$F$$20221216$20200406$20221222$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10954$SAMSUNG BIOEPIS$$53$YR$A$F$Y$47$KG$20221222$$MD$CA$CA
176314794$17631479$4$F$20191220$20221115$20200406$20221123$PER$$US-VERTEX PHARMACEUTICALS-2020-006718$VERTEX$$12$YR$$M$Y$$$20221123$$MD$US$US
176316588$17631658$8$F$$20221121$20200406$20221126$EXP$$US-SHIRE-US202012480$TAKEDA$$$$$F$Y$95$KG$20221126$$HP$US$US
176318106$17631810$6$F$$20221003$20200406$20221008$EXP$$US-SHIRE-US202012476$TAKEDA$$$$$F$Y$78$KG$20221008$$HP$US$US
176320474$17632047$4$F$$20221011$20200406$20221013$PER$$US-PFIZER INC-2020142441$PFIZER$$59$YR$$F$Y$$$20221013$$HP$US$US
1763224418$17632244$18$F$20150526$20221201$20200406$20221206$EXP$$PHHY2015CA077176$NOVARTIS$$$$$M$Y$$$20221206$$CN$CA$CA
176325996$17632599$6$F$20190411$20221026$20200406$20221104$EXP$$GB-PUMA BIOTECHNOLOGY, LTD.-2019GB008756$PUMA BIOTECHNOLOGY$$$$$$Y$$$20221104$$MD$GB$GB
176327426$17632742$6$F$20200315$20221130$20200406$20221202$EXP$$US-SHIRE-US202012336$TAKEDA$$10$YR$$M$Y$$$20221202$$MD$US$US
1763278010$17632780$10$F$20200101$20221019$20200406$20221025$EXP$$US-PFIZER INC-2020140616$PFIZER$$79$YR$$F$Y$114.76$KG$20221025$$CN$US$US
176328638$17632863$8$F$20200321$20221103$20200406$20221109$EXP$$US-SA-2020SA044634$SANOFI AVENTIS$$40$YR$A$F$Y$$$20221109$$MD$US$US
176333494$17633349$4$F$$20221020$20200406$20221028$EXP$$CA-TITAN PHARMACEUTICALS-2020TAN00015$TITAN PHARMACEUTICALS$$$$$M$Y$2$KG$20221027$$CN$CA$CA
1763352112$17633521$12$F$20160701$20221121$20200406$20221124$EXP$$PHHY2016CA113144$NOVARTIS$$51$YR$$F$Y$$$20221125$$CN$CA$CA
176341218$17634121$8$F$20190101$20221124$20200406$20221201$EXP$$CA-PFIZER INC-2019082183$PFIZER$$39$YR$$F$Y$$$20221201$$CN$CA$CA
1763508519$17635085$19$F$20200306$20221122$20200407$20221129$EXP$$GB-ABBVIE-20K-167-3334062-00$ABBVIE$$78$YR$$M$Y$78.6$KG$20221129$$HP$GB$GB
176353526$17635352$6$F$$20221114$20200406$20221121$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-10688$SAMSUNG BIOEPIS$$61$YR$A$M$Y$83$KG$20221121$$CN$CA$CA
176354032$17635403$2$F$20160501$20221107$20200407$20221117$EXP$FR-AFSSAPS-AN20200375$FR-TERSERA THERAPEUTICS LLC-2020TRS000834$TERSERA THERAPEUTICS$$$$$$Y$$$20221117$$MD$FR$FR
176356303$17635630$3$F$20141101$20200402$20200406$20221020$EXP$$US-009507513-2004USA001289$MERCK$Lipson EJ, Naqvi FF, Loss MJ, Schollenberger MD, Pardoll DW, Moore Jr J, et al. Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection. American journal of transplantation : official journal of the American Society. 2020$57$YR$$F$Y$$$20221020$$MD$US$US
176356632$17635663$2$F$$20221003$20200407$20221013$EXP$$CA-ROCHE-2576502$ROCHE$$26$YR$$F$Y$$$20221012$$CN$CA$CA
176357452$17635745$2$F$20110401$20221214$20200407$20221221$EXP$$US-EMD Serono-9155789$EMD SERONO INC$$29$YR$A$M$Y$78$KG$20221221$$CN$US$
176358048$17635804$8$F$$20221010$20200407$20221014$EXP$$PL-GLAXOSMITHKLINE-PL2020GSK059906$GLAXOSMITHKLINE$$$$$$Y$$$20221014$$MD$PL$PL
176361429$17636142$9$F$$20221129$20200407$20221202$EXP$$CA-009507513-2004CAN001312$MERCK$unknown. unknown. unknown$56$YR$$F$Y$$$20221202$$MD$CA$CA
176366342$17636634$2$F$$20221109$20200407$20221111$PER$$US-PFIZER INC-2020140115$PFIZER$$75$YR$$F$Y$$$20221111$$CN$US$US
176374828$17637482$8$F$$20221208$20200407$20221216$EXP$$US-PFIZER INC-2020140005$PFIZER$$75$YR$$F$Y$$$20221216$$HP$US$US
176375223$17637522$3$F$$20221128$20200407$20221202$EXP$$CA-009507513-2004CAN001310$MERCK$$46$YR$$F$Y$73$KG$20221202$$HP$CA$CA
176382797$17638279$7$F$20200306$20221014$20200407$20221026$EXP$$GB-ASPEN-GLO2020GB003586$ASPEN$$$$$$Y$$$20221026$$HP$GB$GB
176386259$17638625$9$F$$20221115$20200407$20221126$EXP$$CA-TEVA-2020-CA-1219098$TEVA$$53$YR$A$F$Y$60$KG$20221125$$HP$CA$CA
176390432$17639043$2$F$$20220929$20200407$20221005$EXP$$JP-OTSUKA-2020_008730$OTSUKA$Suzuki S, Hoshino K, Yoshida K, Nishioka M, Momoki K, Ota T, et al.. A case of pulmonary arterial hypertension developed during maintenance therapy for pinealoblastoma. The 26th Meeting for Japanese Society of Pediatric Pulmonary Circulation. 2020;00(00):18$13$YR$$M$Y$$$20221005$$MD$JP$JP
176391033$17639103$3$F$$20221116$20200407$20221121$PER$$US-PFIZER INC-2020143573$PFIZER$$69$YR$$M$Y$$$20221121$$CN$US$US
1763915816$17639158$16$F$20200321$20221020$20200407$20221025$EXP$$JP-ROCHE-2574487$ROCHE$$59$YR$$M$Y$91.6$KG$20221025$$MD$JP$
176394052$17639405$2$F$20170105$20221116$20200407$20221123$PER$$US-JNJFOC-20200404225$JOHNSON AND JOHNSON$$29$YR$A$M$Y$$$20221124$$LW$US$US
176394345$17639434$5$F$$20221215$20200407$20221220$EXP$$US-PFIZER INC-2020119114$PFIZER$$58$YR$$F$Y$$$20221220$$CN$US$US
1763958515$17639585$15$F$20200307$20221213$20200407$20221220$EXP$$US-SHIRE-US202012392$TAKEDA$$70$YR$$F$Y$86$KG$20221220$$HP$US$US
176395927$17639592$7$F$$20221011$20200407$20221018$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11074$SAMSUNG BIOEPIS$$40$YR$A$F$Y$84$KG$20221018$$HP$CA$CA
176396023$17639602$3$F$20191229$20221024$20200407$20221029$EXP$$US-SHIRE-US202012617$TAKEDA$$6$YR$$M$Y$$$20221029$$CN$US$US
176397745$17639774$5$F$$20220930$20200407$20221010$EXP$$US-SHIRE-US202012654$TAKEDA$$$$$F$Y$23$KG$20221010$$MD$US$US
176402276$17640227$6$F$$20221125$20200407$20221205$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11235$SAMSUNG BIOEPIS$$74$YR$E$M$Y$101$KG$20221205$$MD$CA$CA
176405257$17640525$7$F$20180701$20221019$20200408$20221030$EXP$$DE-AUROBINDO-AUR-APL-2020-016665$AUROBINDO$$$$E$F$Y$61$KG$20221031$$MD$DE$DE
1764098516$17640985$16$F$$20221202$20200407$20221210$EXP$$US-SHIRE-US202012645$TAKEDA$$$$$F$Y$103$KG$20221210$$HP$US$US
1764108218$17641082$18$F$20201201$20221020$20200407$20221027$EXP$$US-SHIRE-US202012468$TAKEDA$$57$YR$$F$Y$113$KG$20221027$$HP$US$US
176415762$17641576$2$F$$20200307$20200407$20221007$EXP$$NVSC2020US093328$NOVARTIS$Malek AE, Viola GM, Seiler GT, Szvalb D. Disseminated Nocardia farcinica infection in immunocompromised patient. INFECTION$72$YR$$F$Y$$$20221007$$HP$US$US
176419744$17641974$4$F$$20221118$20200407$20221123$PER$$US-AMGEN-USASP2020056425$AMGEN$$69$YR$E$F$Y$$$20221123$$CN$US$US
176441016$17644101$6$F$$20221011$20200408$20221019$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11079$SAMSUNG BIOEPIS$$37$YR$A$M$Y$132$KG$20221019$$HP$CA$CA
176442055$17644205$5$F$$20221221$20200408$20221227$PER$$US-PFIZER INC-2017533307$PFIZER$$59$YR$$M$Y$$$20221227$$HP$US$US
176443688$17644368$8$F$$20221013$20200408$20221017$PER$$US-PFIZER INC-2020144147$PFIZER$$68$YR$$F$Y$$$20221017$$CN$US$US
176453022$17645302$2$F$20200324$20220929$20200408$20221003$EXP$$US-ROCHE-2576771$ROCHE$$74$YR$$F$Y$$$20221003$$HP$US$
1764585616$17645856$16$F$20210825$20221130$20200408$20221213$PER$$NVSC2020US091669$NOVARTIS$$39$YR$$F$Y$$$20221214$$CN$US$US
176458653$17645865$3$F$$20221026$20200408$20221101$EXP$$US-SHIRE-US202012672$TAKEDA$$$$$F$Y$81$KG$20221101$$HP$US$US
1764592110$17645921$10$F$20191009$20221214$20200408$20221227$PER$$JP-AMGEN-JPNSP2020056607$AMGEN$$50$YR$A$M$Y$61$KG$20221227$$MD$JP$JP
1764593011$17645930$11$F$20200226$20220930$20200408$20221003$EXP$$NVSC2020US092924$NOVARTIS$$29$YR$$F$Y$63.946$KG$20221003$$CN$US$US
176462983$17646298$3$F$$20221109$20200408$20221116$EXP$$US-SA-2020SA088009$SANOFI AVENTIS$$67$YR$E$M$Y$$$20221116$$MD$US$US
176462993$17646299$3$F$$20221109$20200408$20221117$EXP$$US-SA-2020SA088066$SANOFI AVENTIS$$64$YR$A$M$Y$$$20221117$$MD$US$US
176463004$17646300$4$F$$20221109$20200408$20221117$EXP$$US-SA-2020SA088144$SANOFI AVENTIS$$59$YR$A$F$Y$$$20221117$$MD$US$US
176463014$17646301$4$F$$20221109$20200408$20221116$EXP$$US-SA-2020SA088179$SANOFI AVENTIS$$40$YR$A$F$Y$$$20221116$$MD$US$US
176464785$17646478$5$F$$20221017$20200408$20221018$PER$$NVSC2020US093115$NOVARTIS$$$$$M$Y$$$20221018$$CN$US$US
176467954$17646795$4$F$$20221104$20200408$20221110$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029509$BRISTOL MYERS SQUIBB$$69$YR$E$M$Y$$$20221110$$CN$JP$JP
176469057$17646905$7$F$20200922$20221206$20200409$20221212$EXP$$US-SHIRE-US202012717$TAKEDA$$38$YR$$F$Y$99$KG$20221212$$CN$US$US
176470127$17647012$7$F$$20221221$20200408$20221226$EXP$$US-TAKEDA-2020TUS017512$TAKEDA$$$$$M$Y$$$20221226$$CN$US$US
1764703017$17647030$17$F$20200220$20221201$20200409$20221210$EXP$$CA-CELLTRION INC.-2020CA019888$CELLTRION$$$$$$Y$$$20221210$$HP$CA$CA
176471464$17647146$4$F$$20221006$20200408$20221012$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11184$SAMSUNG BIOEPIS$$35$YR$A$M$Y$83$KG$20221012$$MD$CA$CA
176471926$17647192$6$F$$20221129$20200409$20221205$EXP$$US-SHIRE-US202012756$TAKEDA$$$$$M$Y$112.9$KG$20221205$$CN$US$US
1764723115$17647231$15$F$20200408$20221208$20200408$20221221$EXP$$DE-AUROBINDO-AUR-APL-2020-016912$AUROBINDO$$81$YR$$F$Y$75$KG$20221221$$MD$DE$DE
176476492$17647649$2$F$20191201$20221205$20200409$20221209$EXP$$US-BIOGEN-2020BI00860387$BIOGEN$$54$YR$$F$Y$$$20221209$$CN$US$US
176476932$17647693$2$F$$20220924$20200408$20221003$EXP$$CA-GLAXOSMITHKLINE-CA2020AMR060772$GLAXOSMITHKLINE$$$$$$Y$$$20221003$$MD$CA$CA
176477547$17647754$7$F$$20221123$20200409$20221130$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11218$SAMSUNG BIOEPIS$$79$YR$E$F$Y$72$KG$20221130$$CN$CA$CA
176478316$17647831$6$F$$20221121$20200408$20221125$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11185$SAMSUNG BIOEPIS$$61$YR$A$F$Y$91$KG$20221125$$HP$CA$CA
176478487$17647848$7$F$$20221125$20200408$20221206$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11254$SAMSUNG BIOEPIS$$34$YR$A$F$Y$93$KG$20221206$$HP$CA$CA
176486062$17648606$2$F$$20200408$20200409$20221220$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029670$BRISTOL MYERS SQUIBB$$56$YR$A$F$Y$$$20221221$$HP$CA$CA
176486564$17648656$4$F$20090101$20221011$20200408$20221013$EXP$$US-NAPPMUNDI-USA-2020-0151151$PURDUE$$$$$F$Y$$$20221013$$CN$US$US
176489235$17648923$5$F$$20221208$20200408$20221214$EXP$$US-SHIRE-US202012812$TAKEDA$$$$$F$Y$$$20221214$$MD$US$US
176489864$17648986$4$F$20191210$20200406$20200409$20221210$EXP$$NL-TEVA-2020-NL-1215914$TEVA$$19$YR$A$M$Y$75$KG$20221210$$CN$NL$NL
176490335$17649033$5$F$$20221012$20200408$20221020$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11154$SAMSUNG BIOEPIS$$62$YR$A$M$Y$109$KG$20221020$$HP$CA$CA
176491476$17649147$6$F$20170101$20220927$20200408$20221002$EXP$$PHHY2017CA116024$NOVARTIS$$$$$M$Y$$$20221002$$HP$CA$CA
176492924$17649292$4$F$$20221109$20200409$20221116$EXP$$US-SA-2020SA088064$SANOFI AVENTIS$$58$YR$A$M$Y$$$20221116$$MD$US$US
176492954$17649295$4$F$$20221109$20200409$20221117$EXP$$US-SA-2020SA088101$SANOFI AVENTIS$$72$YR$E$M$Y$$$20221117$$MD$US$US
176493174$17649317$4$F$$20221109$20200409$20221116$EXP$$US-SA-2020SA088065$SANOFI AVENTIS$$77$YR$E$F$Y$$$20221116$$MD$US$US
176499254$17649925$4$F$$20221010$20200409$20221014$EXP$$US-PFIZER INC-2020148537$PFIZER$$63$YR$$F$Y$$$20221014$$MD$US$US
176507363$17650736$3$F$$20221222$20200408$20221229$EXP$$US-TAKEDA-2020TUS017581$TAKEDA$$$$$M$Y$$$20221229$$MD$US$US
176508005$17650800$5$F$20200331$20221214$20200408$20221222$PER$$US-JAZZ-2020-US-004753$JAZZ$$56$YR$$F$Y$$$20221222$$HP$US$US
176508128$17650812$8$F$20191214$20221121$20200409$20221128$EXP$$NVSC2020GB095058$NOVARTIS$$36$YR$$F$Y$$$20221128$$HP$GB$GB
176509126$17650912$6$F$20180419$20221207$20200409$20221214$EXP$$CA-PFIZER INC-2018200664$MYLAN$$77$YR$$F$Y$$$20221214$$CN$CA$CA
176509802$17650980$2$F$$20221017$20200408$20221020$EXP$DE-ADRED-04235-01$DE-DSJP-DSE-2020-111060$DAIICHI$$80$YR$$M$Y$83$KG$20221020$$PH$DE$DE
176509822$17650982$2$F$20200108$20221010$20200408$20221013$EXP$DE-ADRED-02443-02$DE-DSJP-DSE-2020-111061$DAIICHI$$81$YR$$M$Y$$$20221013$$MD$DE$DE
176512194$17651219$4$F$20191202$20221110$20200409$20221117$PER$$JP-AMGEN-JPNSP2020057314$AMGEN$$62$YR$A$M$Y$84.5$KG$20221116$$MD$JP$JP
176512783$17651278$3$F$$20221015$20200409$20221018$EXP$$US-KYOWAKIRIN-2020BKK005404$KYOWA$$$$$$Y$$$20221018$$HP$US$US
176513062$17651306$2$F$$20200408$20200409$20221221$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029788$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20221221$$HP$CA$CA
176514397$17651439$7$F$20180801$20220808$20200409$20221110$EXP$DE-BFARM-20003581$DE-TORRENT-00017169$TORRENT$$68$YR$E$M$Y$77$KG$20221110$$MD$DE$DE
176516243$17651624$3$F$20160101$20221202$20200409$20221212$EXP$$DE-TEVA-2020-DE-1221791$TEVA$$73$YR$E$F$Y$75$KG$20221212$$LW$DE$DE
176518198$17651819$8$F$20180726$20221026$20200409$20221028$EXP$$CA-TAKEDA-2018TUS027814$TAKEDA$$81$YR$$M$Y$$$20221028$$CN$CA$CA
176518473$17651847$3$F$20190221$20221123$20200409$20221128$EXP$$PHHY2017CA099526$NOVARTIS$$51$YR$$F$Y$$$20221128$$MD$CA$CA
176518543$17651854$3$F$20200101$20221011$20200409$20221018$EXP$$NVSC2020US095486$NOVARTIS$$$$A$M$Y$$$20221018$$MD$US$US
176520215$17652021$5$F$20191011$20221216$20200409$20221220$EXP$$FR-PFIZER INC-2020147136$PFIZER$$83$YR$$F$Y$52$KG$20221220$$MD$FR$FR
176521065$17652106$5$F$$20221012$20200409$20221018$EXP$$CA-AstraZeneca-2020SE48846$ASTRAZENECA$$56$YR$$F$Y$80$KG$20221018$$MD$CA$
1765258016$17652580$16$F$20200828$20221205$20200409$20221214$EXP$$US-SHIRE-US202012842$TAKEDA$$70$YR$$F$Y$88$KG$20221214$$CN$US$US
176526623$17652662$3$F$20200101$20221220$20200409$20221222$EXP$$US-PFIZER INC-2020121159$PFIZER$$30$YR$$M$Y$70$KG$20221222$$CN$US$US
176528756$17652875$6$F$$20221122$20200409$20221128$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11639$SAMSUNG BIOEPIS$$57$YR$A$F$Y$82$KG$20221128$$HP$CA$CA
1765289515$17652895$15$F$19960610$20221027$20200409$20221031$PER$$US-BIOGEN-2020BI00861349$BIOGEN$$40$YR$$F$Y$$$20221031$$CN$US$US
176529305$17652930$5$F$$20220927$20200409$20221003$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11698$SAMSUNG BIOEPIS$$23$YR$A$M$Y$66$KG$20221003$$HP$CA$CA
176530335$17653033$5$F$$20221125$20200409$20221206$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11691$SAMSUNG BIOEPIS$$35$YR$A$M$Y$94$KG$20221206$$HP$CA$CA
176530435$17653043$5$F$$20221110$20200409$20221117$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11729$SAMSUNG BIOEPIS$$68$YR$E$M$Y$76$KG$20221117$$MD$CA$CA
176531784$17653178$4$F$$20221102$20200409$20221105$EXP$$NVSC2020US096407$NOVARTIS$$$$$F$Y$$$20221105$$CN$US$US
176535182$17653518$2$F$$20220928$20200409$20221005$EXP$$NVSC2020CA096583$NOVARTIS$$66$YR$$F$Y$$$20221005$$CN$CA$CA
176538362$17653836$2$F$20200108$20221008$20200410$20221018$EXP$$DE-MACLEODS PHARMACEUTICALS US LTD-MAC2020026095$MACLEODS$$$$$$Y$$$20221018$$MD$DE$DE
176540308$17654030$8$F$$20221215$20200410$20221222$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-15952$SAMSUNG BIOEPIS$$65$YR$E$M$Y$99$KG$20221222$$HP$CA$CA
176546692$17654669$2$F$$20221018$20200410$20221028$EXP$$DE-TEVA-2020-DE-1221695$TEVA$$57$YR$A$F$Y$$$20221028$$MD$DE$DE
176546743$17654674$3$F$$20221130$20200410$20221207$EXP$$CA-SPECGX-T202000719$SPECGX$$62$YR$$F$Y$$$20221207$$MD$CA$CA
176547364$17654736$4$F$$20221222$20200410$20221227$PER$$NVSC2020US097332$NOVARTIS$$$$$F$Y$$$20221227$$CN$US$US
176547747$17654774$7$F$20190906$20221220$20200410$20221223$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-029775$BRISTOL MYERS SQUIBB$Sugi S, et al.. A case of immune-related lung disorder and liver disorder after 2 courses of nivolumab + ipilimumab therapy. Annual Meeting of Japanese Society of Pharmaceutical oncology in 2020 (cancelled 2020:P-209.$8$DEC$E$F$Y$$$20221223$$HP$JP$JP
1765556210$17655562$10$F$20170101$20221213$20200410$20221220$PER$$US-PFIZER INC-2017524750$PFIZER$$57$YR$$F$Y$86.18$KG$20221220$$CN$US$US
176559146$17655914$6$F$$20221103$20200410$20221114$EXP$$US-PFIZER INC-2020146745$PFIZER$$75$YR$$F$Y$$$20221114$$CN$US$US
176563489$17656348$9$F$$20221017$20200410$20221028$EXP$$CA-ROCHE-2579781$ROCHE$$54$YR$$F$Y$$$20221028$$CN$CA$CA
176564496$17656449$6$F$$20221207$20200410$20221212$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11534$SAMSUNG BIOEPIS$$58$YR$A$F$Y$68$KG$20221212$$HP$CA$CA
176564745$17656474$5$F$$20221108$20200410$20221115$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11626$SAMSUNG BIOEPIS$$23$YR$A$M$Y$73$KG$20221115$$CN$CA$CA
176568785$17656878$5$F$$20221017$20200410$20221018$EXP$$US-PFIZER INC-2020147841$PFIZER$$65$YR$$F$Y$$$20221018$$CN$US$US
176569017$17656901$7$F$$20221220$20200410$20221228$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11502$SAMSUNG BIOEPIS$$43$YR$A$M$Y$89$KG$20221228$$HP$CA$CA
1765720210$17657202$10$F$20190509$20221021$20200410$20221027$EXP$$FR-ABBVIE-20K-056-3359557-00$ABBVIE$$69$YR$$M$Y$59$KG$20221027$$MD$FR$FR
176572484$17657248$4$F$20190318$20221013$20200410$20221017$EXP$$PHHY2019BR094341$NOVARTIS$$39$YR$$F$Y$$$20221017$$CN$BR$BR
176573704$17657370$4$F$20200406$20221107$20200410$20221110$EXP$$US-SHIRE-US202013053$TAKEDA$$7$YR$$M$Y$$$20221110$$PH$US$US
176575803$17657580$3$F$$20221014$20200410$20221024$EXP$$DE-BAXTER-2020BAX007604$BAXTER$$44$YR$$M$Y$$$20221021$$MD$DE$DE
1765763020$17657630$20$F$20181220$20221017$20200411$20221021$EXP$$DE-ROCHE-2248497$ROCHE$$58$YR$$F$Y$$$20221021$$CN$DE$
1765763227$17657632$27$F$20190924$20221013$20200411$20221022$EXP$$CA-CELLTRION INC.-2019CA023746$CELLTRION$$$$$$Y$$$20221022$$MD$CA$CA
176576602$17657660$2$F$20200108$20221013$20200411$20221020$EXP$$DE-SA-2020SA092894$SANOFI AVENTIS$$81$YR$E$M$Y$$$20221020$$MD$DE$DE
1765767912$17657679$12$F$20200401$20220921$20200411$20221004$EXP$$CA-CELLTRION INC.-2020CA021353$CELLTRION$$$$$$Y$$$20221004$$HP$CA$CA
1765783215$17657832$15$F$20210702$20221114$20200411$20221119$EXP$$US-SHIRE-US202012882$TAKEDA$$23$YR$$F$Y$61$KG$20221119$$PH$US$US
176578403$17657840$3$F$20171209$20220927$20200411$20221004$PER$$PHHY2018US057903$NOVARTIS$$55$YR$$F$Y$54$KG$20221004$$MD$US$US
1765787115$17657871$15$F$20210616$20221114$20200411$20221121$EXP$$US-SHIRE-US202012915$TAKEDA$$71$YR$$M$Y$105.99$KG$20221121$$CN$US$US
176579926$17657992$6$F$$20221104$20200411$20221111$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-12189$SAMSUNG BIOEPIS$$47$YR$A$F$Y$101$KG$20221111$$MD$CA$CA
176582986$17658298$6$F$$20221101$20200412$20221109$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-12094$SAMSUNG BIOEPIS$$40$YR$A$F$Y$71$KG$20221109$$MD$CA$CA
176583186$17658318$6$F$$20221129$20200412$20221207$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11537$SAMSUNG BIOEPIS$$27$YR$A$M$Y$61$KG$20221207$$HP$CA$CA
176583225$17658322$5$F$$20221028$20200412$20221107$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-12098$SAMSUNG BIOEPIS$$47$YR$A$F$Y$40$KG$20221107$$HP$CA$CA
176583867$17658386$7$F$20200223$20221109$20200412$20221117$EXP$$DE-ABBVIE-20K-062-3351926-00$ABBVIE$$77$YR$$F$Y$55$KG$20221117$$MD$DE$DE
176584618$17658461$8$F$$20221011$20200412$20221014$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-12136$SAMSUNG BIOEPIS$$70$YR$E$M$Y$108$KG$20221014$$MD$CA$CA
176584646$17658464$6$F$$20221010$20200412$20221013$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-12134$SAMSUNG BIOEPIS$$53$YR$A$M$Y$76$KG$20221013$$HP$CA$CA
176584654$17658465$4$F$$20221213$20200412$20221216$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-12105$SAMSUNG BIOEPIS$$76$YR$E$F$Y$53$KG$20221216$$HP$CA$CA
176593372$17659337$2$F$$20221020$20200413$20221030$EXP$$DE-TEVA-2020-DE-1221914$TEVA$$80$YR$E$M$Y$83$KG$20221030$$PH$DE$DE
176594619$17659461$9$F$$20221207$20200413$20221212$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11725$SAMSUNG BIOEPIS$$19$YR$A$M$Y$102$KG$20221212$$CN$CA$CA
176599026$17659902$6$F$20190723$20221206$20200413$20221212$EXP$$US-ROCHE-2447058$ROCHE$$49$YR$$M$Y$64.6$KG$20221212$$MD$US$
1766026815$17660268$15$F$$20221107$20200413$20221110$PER$$US-PFIZER INC-2020146675$PFIZER$$70$YR$$F$Y$$$20221110$$CN$US$US
176602945$17660294$5$F$20220101$20221212$20200413$20221219$PER$$US-PFIZER INC-2020147063$PFIZER$$76$YR$$F$Y$$$20221219$$CN$US$US
176603103$17660310$3$F$$20221031$20200413$20221103$PER$$US-PFIZER INC-2020147855$PFIZER$$72$YR$$F$Y$$$20221103$$CN$US$US
176603167$17660316$7$F$$20221219$20200413$20221229$PER$$US-PFIZER INC-2019545282$PFIZER$$80$YR$$M$Y$73.48$KG$20221229$$CN$US$US
1766033915$17660339$15$F$$20221227$20200413$20221230$EXP$$US-PFIZER INC-2019268231$PFIZER$$76$YR$$F$Y$58.06$KG$20221230$$CN$US$US
176603655$17660365$5$F$$20221103$20200413$20221113$EXP$$US-PFIZER INC-2020147595$PFIZER$$57$YR$$F$Y$$$20221113$$CN$US$US
176603863$17660386$3$F$$20221219$20200413$20221221$PER$$US-PFIZER INC-2020149062$PFIZER$$45$YR$$F$Y$$$20221221$$HP$US$US
176603957$17660395$7$F$20200501$20221107$20200413$20221114$EXP$$US-PFIZER INC-2020148725$PFIZER$$44$YR$$M$Y$$$20221114$$CN$US$US
176608108$17660810$8$F$20190901$20221202$20200413$20221210$EXP$$NVSC2019CA023579$NOVARTIS$$63$YR$$M$Y$$$20221210$$CN$CA$CA
176612489$17661248$9$F$20210512$20221018$20200413$20221021$EXP$$US-PFIZER INC-2020148670$PFIZER$$51$YR$$F$Y$$$20221021$$HP$US$US
176616943$17661694$3$F$$20221013$20200413$20221021$EXP$DE-ADRED-04767-01$DE-BAUSCH-BL-2020-010723$BAUSCH AND LOMB$$44$YR$$M$Y$$$20221021$$MD$DE$DE
176617842$17661784$2$F$$20200408$20200413$20221007$EXP$$NVSC2020CA096914$NOVARTIS$$$$$F$Y$$$20221007$$HP$CA$CA
1766189426$17661894$26$F$20200923$20221114$20200413$20221122$EXP$$US-SHIRE-US202013186$TAKEDA$$47$YR$$F$Y$70$KG$20221122$$HP$US$US
176619447$17661944$7$F$20200210$20221216$20200413$20221221$PER$$US-BIOGEN-2020BI00839410$BIOGEN$$29$YR$$M$Y$$$20221221$$CN$US$US
176619597$17661959$7$F$20210115$20221205$20200413$20221214$PER$$JP-AMGEN-JPNSP2020058898$AMGEN$$56$YR$A$M$Y$68.5$KG$20221214$$MD$JP$JP
176621823$17662182$3$F$20200323$20221130$20200413$20221205$EXP$$IT-ROCHE-2577499$ROCHE$$$$$$Y$$$20221205$$MD$IT$
176625205$17662520$5$F$$20221216$20200413$20221226$PER$$US-AMGEN-USASP2020060168$AMGEN$$61$YR$A$M$Y$$$20221226$$MD$US$US
176625407$17662540$7$F$$20221012$20200413$20221021$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11923$SAMSUNG BIOEPIS$$48$YR$A$F$Y$46$KG$20221021$$HP$CA$CA
176625514$17662551$4$F$$20221209$20200413$20221217$EXP$$US-SHIRE-US202013164$TAKEDA$$$$$F$Y$94$KG$20221217$$HP$US$US
176626683$17662668$3$F$20191012$20221215$20200413$20221220$EXP$$FR-PFIZER INC-2020146861$PFIZER$$72$YR$$F$Y$40$KG$20221220$$MD$FR$FR
176629412$17662941$2$F$20190801$20190813$20200413$20221220$PER$$US-AMGEN INC.-USASP2019218908$AMGEN$$$$$F$Y$$$20221219$$CN$US$US
176629553$17662955$3$F$$20221129$20200413$20221205$EXP$$NVSC2020CA097327$NOVARTIS$$56$YR$$F$Y$81$KG$20221205$$HP$CA$CA
176631157$17663115$7$F$20160128$20221219$20200413$20221223$EXP$$CA-BAUSCH-BL-2020-010296$BAUSCH AND LOMB$$52$YR$$F$Y$$$20221223$$CN$CA$CA
176636132$17663613$2$F$$20221010$20200414$20221021$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-243090$RANBAXY$Tsujimoto S-I, Shirai R, Utano T, Osumi T, Shioda Y, Kiyotani C, et al. Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation. Int J Hematol. 2020;111(3):463-466$$$C$$Y$$$20221021$$HP$JP$JP
1766383713$17663837$13$F$20200117$20221018$20200414$20221026$EXP$$US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-US-006429$BOEHRINGER INGELHEIM$$65$YR$E$F$Y$$$20221026$$CN$US$US
176641526$17664152$6$F$20200131$20221214$20200414$20221216$EXP$$JP-ROCHE-2543920$ROCHE$$54$YR$$F$Y$48.6$KG$20221216$$MD$JP$
1766426726$17664267$26$F$20191118$20221220$20200414$20221230$EXP$$CA-CELLTRION INC.-2019CA027213$CELLTRION$$$$$$Y$$$20221230$$HP$CA$CA
176646846$17664684$6$F$20200328$20221008$20200414$20221018$PER$$CA-TOLMAR, INC.-20CA020857$TOLMAR$$71$YR$$M$Y$$$20221018$$CN$CA$CA
176648306$17664830$6$F$20200101$20221102$20200414$20221104$PER$$US-PFIZER INC-2020151456$PFIZER$$31$YR$$F$Y$$$20221104$$HP$US$US
176648738$17664873$8$F$20221009$20221222$20200414$20221229$EXP$$US-PFIZER INC-2020143729$PFIZER$$59$YR$$F$Y$73.48$KG$20221229$$CN$US$US
1766510815$17665108$15$F$20150101$20221024$20200414$20221028$EXP$$US-PFIZER INC-2020067483$PFIZER$$65$YR$$F$Y$71.21$KG$20221028$$HP$US$US
176651332$17665133$2$F$$20221031$20200414$20221104$EXP$$US-PFIZER INC-2020151079$PFIZER$$62$YR$$F$Y$93.878$KG$20221104$$HP$US$US
176654618$17665461$8$F$20200301$20221017$20200414$20221020$PER$$US-VERTEX PHARMACEUTICALS-2020-008397$VERTEX$$29$YR$$F$Y$52$KG$20221020$$MD$US$US
176655385$17665538$5$F$$20221216$20200414$20221222$PER$$US-PFIZER INC-2020154065$PFIZER$$66$YR$$F$Y$$$20221222$$MD$US$US
176661335$17666133$5$F$20200311$20221206$20200414$20221209$PER$$US-PFIZER INC-2020151609$PFIZER$$65$YR$$F$Y$131.52$KG$20221209$$CN$US$US
1766616320$17666163$20$F$20200327$20221125$20200414$20221129$EXP$$DK-ROCHE-2576915$ROCHE$$49$YR$$F$Y$62$KG$20221129$$MD$DK$
176663163$17666316$3$F$20191114$20221104$20200414$20221109$EXP$FR-AFSSAPS-LY20192121$NVSC2020FR099064$NOVARTIS$$13$YR$$M$Y$$$20221109$$MD$FR$FR
176663204$17666320$4$F$20200401$20221108$20200414$20221121$PER$$US-SA-2020SA094756$SANOFI AVENTIS$$16$YR$T$M$Y$$$20221121$$MD$US$US
176667935$17666793$5$F$20190917$20221130$20200414$20221207$EXP$$CA-ROCHE-2420326$ROCHE$$54$YR$$M$Y$$$20221207$$CN$CA$
176669126$17666912$6$F$$20221031$20200414$20221107$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11921$SAMSUNG BIOEPIS$$20$YR$A$M$Y$81$KG$20221107$$HP$CA$CA
176669572$17666957$2$F$20190801$20221107$20200414$20221109$EXP$FR-AFSSAPS-AM20200368$FR-MYLANLABS-2020M1037613$MYLAN$$66$YR$$F$Y$65$KG$20221109$$MD$FR$FR
176669962$17666996$2$F$20191205$20221208$20200414$20221212$EXP$$KR-ROCHE-2499090$ROCHE$$79$YR$$M$Y$78.8$KG$20221212$$MD$KR$
1766706214$17667062$14$F$$20220914$20200414$20221013$EXP$$CA-AstraZeneca-2020SE49789$ASTRAZENECA$$78$YR$$F$Y$93$KG$20221013$$MD$CA$
1766711713$17667117$13$F$$20220928$20200414$20221005$EXP$$NVSC2020CA098733$NOVARTIS$$59$YR$$F$Y$68$KG$20221005$$HP$CA$CA
176672004$17667200$4$F$$20221122$20200414$20221130$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-12195$SAMSUNG BIOEPIS$$46$YR$A$M$Y$80$KG$20221130$$HP$CA$CA
1766735510$17667355$10$F$20001107$20221212$20200414$20221219$EXP$$US-PERRIGO-20US005045$PERRIGO$$$$$$Y$$$20221219$$MD$US$US
176674104$17667410$4$F$20130628$20221007$20200414$20221014$EXP$$US-PERRIGO-20US005073$PERRIGO$$63$YR$$F$Y$$$20221014$$MD$US$US
176674426$17667442$6$F$$20220930$20200414$20221007$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-12211$SAMSUNG BIOEPIS$$21$YR$A$M$Y$68$KG$20221007$$HP$CA$CA
176674774$17667477$4$F$$20221130$20200414$20221202$EXP$$US-PFIZER INC-2020137647$PFIZER$$60$YR$$F$Y$$$20221202$$CN$US$US
176686122$17668612$2$F$20140403$20220929$20200415$20221006$EXP$$US-BIOGEN-2014BI033576$BIOGEN$$53$YR$$F$Y$$$20221006$$CN$US$US
176686332$17668633$2$F$$20221031$20200415$20221102$EXP$$US-ROCHE-2581158$ROCHE$$42$YR$$F$Y$$$20221102$$CN$US$
176686792$17668679$2$F$20200108$20221010$20200415$20221020$EXP$$DE-AUROBINDO-AUR-APL-2020-018320$AUROBINDO$$81$YR$$M$Y$$$20221020$$MD$DE$DE
176691053$17669105$3$F$20200326$20221130$20200415$20221201$EXP$$PR-ABBVIE-20K-131-3341535-00$ABBVIE$$43$YR$$F$Y$92.532$KG$20221201$$CN$PR$PR
176692488$17669248$8$F$20200114$20220928$20200415$20221004$EXP$$DE-ROCHE-2531723$ROCHE$$54$YR$$F$Y$$$20221004$$CN$DE$
1766934113$17669341$13$F$20211007$20221101$20200415$20221109$EXP$$US-SHIRE-US202013358$TAKEDA$$51$YR$$F$Y$77$KG$20221109$$CN$US$US
176697095$17669709$5$F$$20221125$20200415$20221201$EXP$$US-SHIRE-US202013377$TAKEDA$$$$$F$Y$73.92$KG$20221201$$HP$US$US
176699552$17669955$2$F$$20221007$20200415$20221011$PER$$US-PFIZER INC-2017536259$PFIZER$$63$YR$$F$Y$85$KG$20221011$$CN$US$US
176700444$17670044$4$F$$20221121$20200415$20221123$PER$$US-PFIZER INC-2020154317$PFIZER$$79$YR$$F$Y$$$20221123$$MD$US$US
176703969$17670396$9$F$$20221123$20200415$20221130$EXP$$US-SHIRE-US202013328$TAKEDA$$$$$F$Y$86$KG$20221130$$CN$US$US
1767072213$17670722$13$F$20200101$20221005$20200415$20221007$EXP$$US-SA-2020SA096126$SANOFI AVENTIS$$67$YR$E$F$Y$$$20221007$$MD$US$US
176710575$17671057$5$F$$20221121$20200415$20221128$EXP$$CA-APOTEX-2020AP009843$APOTEX$$51$YR$$F$Y$73$KG$20221128$$HP$CA$CA
176715744$17671574$4$F$$20221130$20200415$20221206$EXP$$CA-PFIZER INC-2020153317$PFIZER$$49$YR$$F$Y$$$20221206$$HP$CA$CA
176718916$17671891$6$F$$20220927$20200415$20221004$EXP$$CA-APOTEX-2020AP009942$APOTEX$$42$YR$$F$Y$126$KG$20221004$$HP$CA$CA
176723355$17672335$5$F$20191024$20221101$20200415$20221116$EXP$$US-UNITED THERAPEUTICS-UNT-2019-019732$UNITED THERAPEUTICS$$61$YR$$M$Y$146.03$KG$20221116$$MD$US$US
176724406$17672440$6$F$$20221027$20200415$20221101$EXP$$US-SHIRE-US202013320$TAKEDA$$$$$F$Y$59$KG$20221101$$HP$US$US
176727309$17672730$9$F$20200306$20221108$20200415$20221110$EXP$$US-SHIRE-US202013489$TAKEDA$$83$YR$$F$Y$$$20221110$$CN$US$US
176731412$17673141$2$F$$20200414$20200416$20221221$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-031084$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20221221$$MD$CA$CA
176740055$17674005$5$F$20200604$20221101$20200415$20221111$EXP$$DE-CELLTRION INC.-2020DE021464$CELLTRION$$$$$$Y$$$20221111$$MD$DE$DE
176743963$17674396$3$F$20200407$20221005$20200416$20221013$PER$$US-AMGEN-USASP2020060934$AMGEN$$78$YR$E$F$Y$$$20221012$$HP$US$US
176744593$17674459$3$F$$20200414$20200416$20221017$PER$$US-AMGEN-USASL2020057205$AMGEN$$$$$F$Y$$$20221017$$CN$US$US
1767506810$17675068$10$F$20210124$20221130$20200416$20221208$EXP$$US-SHIRE-US202013475$TAKEDA$$63$YR$$F$Y$68$KG$20221208$$HP$US$US
176752422$17675242$2$F$$20221222$20200416$20221229$EXP$$NVSC2020GB101968$NOVARTIS$$$$A$F$Y$$$20221229$$CN$GB$GB
176756477$17675647$7$F$20200414$20221213$20200416$20221219$EXP$$US-TAKEDA-2020TUS018607$TAKEDA$$66$YR$$F$Y$$$20221219$$CN$US$US
1767608514$17676085$14$F$20200301$20221205$20200416$20221208$EXP$$US-SHIRE-US202013369$TAKEDA$$37$YR$$M$Y$$$20221208$$CN$US$US
176761853$17676185$3$F$20160812$20221103$20200416$20221107$EXP$$CA-TAKEDA-2018TUS009460$TAKEDA$$27$YR$$M$Y$$$20221107$$HP$CA$CA
1767625312$17676253$12$F$20200413$20221215$20200416$20221221$EXP$$AR-PFIZER INC-2020156271$PFIZER$$64$YR$$M$Y$72$KG$20221221$$MD$AR$AR
176763526$17676352$6$F$$20221013$20200416$20221021$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-12855$SAMSUNG BIOEPIS$$63$YR$A$M$Y$88$KG$20221021$$CN$CA$CA
176766594$17676659$4$F$20170104$20221222$20200416$20221229$EXP$$CY-MYLANLABS-2020M1037832$MYLAN$$68$YR$$F$Y$64$KG$20221229$$MD$CY$CY
176766924$17676692$4$F$$20221201$20200416$20221210$EXP$$CA-ABBVIE-20K-028-3366850-00$ABBVIE$$$$$F$Y$$$20221210$$HP$CA$CA
1767676510$17676765$10$F$20200521$20221121$20200416$20221125$EXP$$CA-GLAXOSMITHKLINE-CA2020AMR063821$GLAXOSMITHKLINE$$$$$$Y$$$20221125$$PH$CA$CA
176777587$17677758$7$F$20190506$20221020$20200416$20221027$EXP$$CA-TAKEDA-2019TUS028622$TAKEDA$$21$YR$$M$Y$$$20221027$$HP$CA$CA
1767809411$17678094$11$F$20200401$20221128$20200417$20221205$EXP$$CA-ROCHE-2583552$ROCHE$$48$YR$$F$Y$$$20221205$$MD$CA$CA
176782184$17678218$4$F$$20221130$20200417$20221207$EXP$$CA-Orion Corporation ORION PHARMA-TREX2020-1791$ORION$$49$YR$A$F$Y$$$20221207$$HP$CA$
1767841811$17678418$11$F$$20221108$20200417$20221114$EXP$$US-SHIRE-US202013618$TAKEDA$$$$$F$Y$56$KG$20221114$$HP$US$US
176785119$17678511$9$F$20200316$20221208$20200417$20221212$EXP$$US-ROCHE-2582092$ROCHE$$83$YR$$M$Y$55.4$KG$20221212$$MD$US$
176794648$17679464$8$F$$20221122$20200417$20221128$EXP$CA-GLAXOSMITHKLINE-CA2020AMR065962$CA-GLAXOSMITHKLINE-CA2020AMR065962$GLAXOSMITHKLINE$$$$$$Y$$$20221128$$MD$CA$CA
1767963516$17679635$16$F$$20221214$20200417$20221222$EXP$$NVSC2020US101240$NOVARTIS$$$$$F$Y$58.05$KG$20221222$$CN$US$US
176797974$17679797$4$F$$20221027$20200417$20221104$PER$$NVSC2020US101412$NOVARTIS$$$$$F$Y$50.34$KG$20221104$$CN$US$US
176802514$17680251$4$F$20191101$20221114$20200417$20221118$PER$$NVSC2020US100307$NOVARTIS$$30$YR$$F$Y$$$20221118$$CN$US$US
1768026914$17680269$14$F$20200328$20221104$20200417$20221111$EXP$$US-SHIRE-US202013544$TAKEDA$$53$YR$$F$Y$63.946$KG$20221111$$CN$US$US
176802903$17680290$3$F$$20221108$20200417$20221114$EXP$$US-SHIRE-US202000750$TAKEDA$$$$$F$Y$$$20221114$$HP$US$US
1768064015$17680640$15$F$$20221212$20200417$20221220$EXP$$US-SHIRE-US202013753$TAKEDA$$$$$F$Y$53.96$KG$20221220$$CN$US$US
176810199$17681019$9$F$$20221130$20200417$20221206$EXP$$CA-AstraZeneca-2019SE56192$ASTRAZENECA$$61$YR$$F$Y$70$KG$20221206$$MD$CA$
176811526$17681152$6$F$20190810$20221215$20200417$20221220$EXP$$DE-MYLANLABS-2020M1038277$MYLAN$$$$A$F$Y$$$20221220$$CN$DE$DE
1768122815$17681228$15$F$20210902$20221122$20200417$20221128$EXP$$US-SHIRE-US202013749$TAKEDA$$51$YR$$F$Y$86$KG$20221128$$MD$US$US
176817942$17681794$2$F$$20200415$20200417$20221111$PER$$US-AMGEN-USASP2020062647$AMGEN$$85$YR$E$F$Y$$$20221111$$CN$US$US
176820162$17682016$2$F$$20221011$20200418$20221020$EXP$$DE-AUROBINDO-AUR-APL-2020-018466$AUROBINDO$$44$YR$$M$Y$$$20221020$$MD$DE$DE
176820816$17682081$6$F$20221215$20221216$20200418$20221227$EXP$$US-SHIRE-US202013756$TAKEDA$$79$YR$$F$Y$44$KG$20221227$$HP$US$US
176822363$17682236$3$F$20200119$20221214$20200418$20221227$EXP$$IT-AUROBINDO-AUR-APL-2020-019097$AUROBINDO$$16$YR$$F$Y$$$20221227$$MD$IT$IT
176824117$17682411$7$F$$20221111$20200418$20221118$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-12993$SAMSUNG BIOEPIS$$21$YR$A$M$Y$75$KG$20221118$$CN$CA$CA
176824412$17682441$2$F$20180916$20200514$20200418$20221008$PER$$US-NAPPMUNDI-USA-2020-0149956$PURDUE$$58$YR$$F$Y$$$20221008$$CN$US$US
176825897$17682589$7$F$$20221128$20200418$20221206$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-13535$SAMSUNG BIOEPIS$$28$YR$A$F$Y$127$KG$20221206$$CN$CA$CA
176827992$17682799$2$F$$20200413$20200419$20221011$PER$$US-GILEAD-2020-0458994$GILEAD$$38$YR$A$F$Y$78.005$KG$20221011$$CN$US$US
176828222$17682822$2$F$$20200415$20200419$20221221$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-031408$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20221221$$HP$CA$CA
176828778$17682877$8$F$20171120$20221205$20200420$20221214$EXP$$CA-CELLTRION INC.-2017CA016747$CELLTRION$$$$$$Y$$$20221215$$HP$CA$CA
176832222$17683222$2$F$20190601$20221110$20200420$20221123$EXP$$DE-drreddys-GER/GER/20/0122045$DR REDDYS$$44$YR$A$F$Y$68$KG$20221123$$MD$DE$DE
176834432$17683443$2$F$$20200414$20200420$20221221$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-031020$BRISTOL MYERS SQUIBB$$54$YR$A$F$Y$$$20221221$$HP$CA$CA
1768363812$17683638$12$F$20100210$20221018$20200420$20221026$EXP$$US-PERRIGO-19US017030$PERRIGO$$$$$$Y$$$20221026$$MD$US$US
176838592$17683859$2$F$20200108$20221010$20200420$20221019$EXP$DE-ADRED-02443-02$DE-TORRENT-00017301$TORRENT$$81$YR$E$M$Y$$$20221019$$MD$DE$DE
176844087$17684408$7$F$20190705$20220926$20200420$20221007$EXP$$JP-ELI_LILLY_AND_COMPANY-JP202004005999$ELI LILLY AND CO$$15$YR$$F$Y$68$KG$20221007$$CN$JP$JP
1768463818$17684638$18$F$20210829$20221214$20200420$20221219$EXP$$US-SHIRE-US202013771$TAKEDA$$25$YR$$M$Y$$$20221219$$CN$US$US
176847713$17684771$3$F$20200412$20221102$20200420$20221102$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-030897$BRISTOL MYERS SQUIBB$$53$YR$A$M$Y$151.1$KG$20221102$$MD$JP$JP
176847905$17684790$5$F$$20221123$20200420$20221130$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-13375$SAMSUNG BIOEPIS$$65$YR$E$M$Y$62$KG$20221130$$MD$CA$CA
176847913$17684791$3$F$$20221222$20200420$20221230$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-13063$SAMSUNG BIOEPIS$$30$YR$A$F$Y$55$KG$20221230$$CN$CA$CA
176847937$17684793$7$F$$20221115$20200420$20221123$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-13438$SAMSUNG BIOEPIS$$66$YR$E$M$Y$99$KG$20221123$$HP$CA$CA
176849785$17684978$5$F$20180401$20221011$20200420$20221018$EXP$$PHHY2018CA076806$NOVARTIS$$46$YR$$M$Y$$$20221018$$CN$CA$CA
176852613$17685261$3$F$$20221122$20200420$20221130$PER$$US-SA-2020SA100155$SANOFI AVENTIS$$18$YR$A$F$Y$$$20221130$$MD$US$US
176852742$17685274$2$F$$20221115$20200420$20221121$EXP$$LB-JNJFOC-20200412888$JOHNSON AND JOHNSON$$$$$M$Y$$$20221121$$MD$LB$LB
176855764$17685576$4$F$$20221010$20200420$20221017$EXP$$US-SHIRE-US202013914$TAKEDA$$$$$F$Y$72$KG$20221017$$HP$US$US
176857846$17685784$6$F$$20221108$20200420$20221115$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-13372$SAMSUNG BIOEPIS$$60$YR$A$F$Y$75$KG$20221115$$HP$CA$CA
176858178$17685817$8$F$$20221108$20200420$20221116$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-12809$SAMSUNG BIOEPIS$$25$YR$A$M$Y$70$KG$20221116$$MD$CA$CA
176858505$17685850$5$F$$20221007$20200420$20221013$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-13054$SAMSUNG BIOEPIS$$42$YR$A$F$Y$100$KG$20221013$$HP$CA$CA
176866452$17686645$2$F$20190601$20221010$20200420$20221019$EXP$$DE-AUROBINDO-AUR-APL-2020-019401$AUROBINDO$$44$YR$$F$Y$68$KG$20221019$$MD$DE$DE
176866712$17686671$2$F$$20200415$20200420$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-031449$BRISTOL MYERS SQUIBB$$41$YR$A$M$Y$90$KG$20221222$$HP$CA$CA
1768674830$17686748$30$F$20200116$20221013$20200421$20221025$EXP$$CA-CELLTRION INC.-2019CA027021$CELLTRION$$$$$$Y$$$20221025$$MD$CA$CA
176869898$17686989$8$F$20200212$20221201$20200421$20221204$EXP$$CA-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-008222$BOEHRINGER INGELHEIM$$79$YR$E$M$Y$$$20221205$$CN$CA$CA
176871812$17687181$2$F$20200101$20221012$20200421$20221021$EXP$$JP-BIOGEN-2020BI00865654$BIOGEN$$$$$M$Y$55.5$KG$20221021$$MD$JP$JP
176872493$17687249$3$F$$20221212$20200421$20221227$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-243798$RANBAXY$Gary M.Vilke, YahiaAkeely, Lucia C.Lin. Sequential Drug-Induced Severe Hyponatremia in a Minimally symtomatic 81 year old female. Int. J. Emerg. Med. 2020;58(3):e137-e140$81$YR$$F$Y$62.5$KG$20221227$$MD$US$US
1768734610$17687346$10$F$20181101$20221108$20200421$20221109$EXP$$JP-SA-2019SA175010$SANOFI AVENTIS$$41$YR$A$M$Y$62$KG$20221110$$MD$JP$JP
176879783$17687978$3$F$$20221023$20200421$20221102$EXP$DE-ADRED-04767-01$DE-TORRENT-00017334$TORRENT$$44$YR$A$M$Y$$$20221102$$MD$DE$DE
1768822114$17688221$14$F$20190101$20221004$20200421$20221007$EXP$$PHHY2019CA169685$NOVARTIS$$$$$F$Y$96.4$KG$20221007$$CN$CA$CA
176882363$17688236$3$F$20200407$20221125$20200421$20221129$EXP$$GB-MYLANLABS-2020M1039285$MYLAN$$71$YR$$M$Y$$$20221129$$PH$GB$GB
176884013$17688401$3$F$$20221010$20200421$20221012$PER$$US-SHIRE-US202014019$TAKEDA$$$$$M$Y$77$KG$20221012$$CN$US$US
176887228$17688722$8$F$20220507$20221005$20200421$20221010$EXP$$US-TAKEDA-2020TUS018752$TAKEDA$$59$YR$$M$Y$108$KG$20221010$$MD$US$US
176889484$17688948$4$F$$20221104$20200421$20221109$EXP$$US-SHIRE-US202013888$TAKEDA$$$$$M$Y$88$KG$20221109$$CN$US$US
176890744$17689074$4$F$20200419$20221128$20200421$20221202$EXP$$DE-SHIRE-DE202013953$TAKEDA$$51$YR$$F$Y$90$KG$20221202$$HP$DE$DE
1768917611$17689176$11$F$$20221212$20200421$20221219$EXP$$US-SHIRE-US202014037$TAKEDA$$$$$F$Y$61$KG$20221219$$CN$US$US
176894332$17689433$2$F$$20221102$20200421$20221115$EXP$$US-INSMED, INC.-US-INS-20-00416$INSMED$$$$$F$Y$$$20221115$$CN$US$US
1768957210$17689572$10$F$20170101$20221025$20200421$20221030$EXP$$PHHY2017CA170575$NOVARTIS$$$$$F$Y$$$20221031$$CN$CA$CA
176897692$17689769$2$F$$20221221$20200421$20221229$EXP$$US-AstraZeneca-2020SE50900$ASTRAZENECA$$$$$F$Y$64$KG$20221229$$CN$US$
1768991719$17689917$19$F$20190101$20221019$20200421$20221021$EXP$$CA-TAKEDA-2019TUS070406$TAKEDA$$58$YR$$F$Y$$$20221021$$MD$CA$CA
176901004$17690100$4$F$$20200414$20200421$20221210$PER$$US-TEVA-2020-US-1225222$TEVA$$$$$F$Y$$$20221210$$CN$US$US
176901834$17690183$4$F$20191003$20221111$20200421$20221121$EXP$$JP-009507513-2004JPN001327J$MERCK$$81$YR$$F$Y$57$KG$20221121$$MD$JP$JP
176902412$17690241$2$F$20191004$20191004$20200421$20221101$PER$$US-PARATEK PHARMACEUTICALS, INC.-2020PTK00019$PARATEK PHARMACEUTICALS$$15$YR$$M$Y$$$20221031$$CN$US$US
176902517$17690251$7$F$20190101$20221129$20200421$20221206$EXP$$PHHY2019US103982$NOVARTIS$$$$$M$Y$$$20221206$$CN$US$US
176903402$17690340$2$F$20200301$20200414$20200421$20221011$PER$$US-GILEAD-2020-0459219$GILEAD$$33$YR$A$F$Y$103.4$KG$20221011$$CN$US$US
176903645$17690364$5$F$$20221122$20200421$20221201$EXP$$NVSC2020CA102983$NOVARTIS$$55$YR$$F$Y$$$20221201$$CN$CA$CA
1769053913$17690539$13$F$20150521$20221101$20200421$20221107$EXP$$PHHY2015CA063455$NOVARTIS$$49$YR$$M$Y$$$20221107$$MD$CA$CA
176906192$17690619$2$F$$20221017$20200421$20221027$EXP$$DE-TEVA-2020-DE-1225633$TEVA$$44$YR$A$F$Y$68$KG$20221028$$PH$DE$DE
176906749$17690674$9$F$20190101$20221001$20200421$20221010$EXP$$FR-AUROBINDO-AUR-APL-2020-019797$AUROBINDO$$20$WK$$$Y$$$20221010$$MD$FR$FR
176908662$17690866$2$F$20200108$20221014$20200422$20221028$EXP$$DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-244665$RANBAXY$$81$YR$$M$Y$$$20221028$$MD$DE$DE
176912988$17691298$8$F$20200319$20221207$20200422$20221214$EXP$$FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-026341$BRISTOL MYERS SQUIBB$$74$YR$E$F$Y$66$KG$20221214$$HP$FR$FR
176920256$17692025$6$F$$20221223$20200422$20221230$EXP$$GB-TAKEDA-2020TUS019264$TAKEDA$$$$$M$Y$$$20221230$$HP$GB$GB
1769212211$17692122$11$F$$20221124$20200422$20221124$EXP$$US-PFIZER INC-2019340317$PFIZER$$$$A$F$Y$93.44$KG$20221124$$MD$US$US
176922792$17692279$2$F$$20221012$20200422$20221014$PER$$US-PFIZER INC-2020158231$PFIZER$$70$YR$$F$Y$$$20221014$$CN$US$US
176925962$17692596$2$F$20200403$20221220$20200422$20221222$PER$$US-SHIRE-US202014086$TAKEDA$$58$YR$$M$Y$90$KG$20221222$$HP$US$US
176927682$17692768$2$F$20190601$20221010$20200422$20221020$EXP$$DE-LUPIN PHARMACEUTICALS INC.-2020-01718$LUPIN$$44$YR$$F$Y$68$KG$20221020$$MD$DE$DE
176929168$17692916$8$F$20200827$20221123$20200422$20221128$EXP$$NVSC2020US107034$NOVARTIS$$37$YR$$F$Y$84.998$KG$20221128$$CN$US$US
1769356632$17693566$32$F$20200408$20221215$20200422$20221222$EXP$$US-SHIRE-US202013982$TAKEDA$$8$YR$$M$Y$$$20221222$$MD$US$US
176936364$17693636$4$F$20200412$20221122$20200422$20221124$EXP$$US-SHIRE-US202014229$TAKEDA$$8$YR$$M$Y$$$20221124$$PH$US$US
176938383$17693838$3$F$$20200615$20200422$20221008$PER$$US-NAPPMUNDI-USA-2020-0151808$PURDUE$$$$$M$Y$$$20221008$$CN$US$US
176938443$17693844$3$F$$20200615$20200422$20221008$PER$$US-PURDUE PHARMA-USA-2020-0151807$PURDUE$$$$$F$Y$$$20221008$$CN$US$US
176941377$17694137$7$F$$20221102$20200422$20221111$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-13434$SAMSUNG BIOEPIS$$22$YR$A$F$Y$91$KG$20221111$$HP$CA$CA
176941417$17694141$7$F$$20221214$20200422$20221221$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-13473$SAMSUNG BIOEPIS$$62$YR$A$M$Y$106$KG$20221221$$MD$CA$CA
176945838$17694583$8$F$20200101$20221007$20200422$20221014$EXP$$US-PFIZER INC-2020133769$PFIZER$$60$YR$$F$Y$99.79$KG$20221014$$CN$US$US
176945853$17694585$3$F$$20221123$20200422$20221128$EXP$$CA-PFIZER INC-2019053224$PFIZER$$53$YR$$F$Y$$$20221128$$CN$CA$CA
176954094$17695409$4$F$$20221102$20200422$20221107$EXP$$US-BIOGEN-2020BI00865484$BIOGEN$$$$$F$Y$$$20221107$$PH$US$US
176955373$17695537$3$F$20190925$20220929$20200422$20221001$EXP$$JP-ABBVIE-20K-087-3372172-00$ABBVIE$$55$YR$$F$Y$58$KG$20221001$$MD$JP$JP
176955982$17695598$2$F$$20200625$20200422$20221008$PER$$US-NAPPMUNDI-USA-2020-0151437$PURDUE$$$$$M$Y$$$20221008$$CN$US$US
176956232$17695623$2$F$20040601$20200421$20200422$20221008$PER$$US-NAPPMUNDI-USA-2020-0151676$PURDUE$$39$YR$$M$Y$$$20221008$$CN$US$US
176956563$17695656$3$F$$20220601$20200423$20221026$PER$$US-PURDUE-USA-2020-0149697$PURDUE$$$$$F$Y$$$20221027$$CN$US$US
176956753$17695675$3$F$$20220601$20200423$20221026$PER$$US-PURDUE-USA-2020-0149696$PURDUE$$$$$F$Y$$$20221027$$CN$US$US
176957243$17695724$3$F$$20200527$20200422$20221008$PER$$US-NAPPMUNDI-USA-2020-0151427$PURDUE$$$$$M$Y$$$20221008$$CN$US$US
176958732$17695873$2$F$20170301$20200421$20200423$20221008$PER$$US-NAPPMUNDI-USA-2020-0150122$PURDUE$$$$$$Y$$$20221008$$CN$US$US
176959392$17695939$2$F$20020429$20201130$20200422$20221008$PER$$US-NAPPMUNDI-USA-2002-0002069$PURDUE$$29$YR$$F$Y$104.31$KG$20221008$$CN$US$US
176959992$17695999$2$F$20190601$20221015$20200423$20221021$EXP$$DE-HETERO-HET2020DE00432$HETERO$$44$YR$$F$Y$68$KG$20221021$$MD$DE$DE
176961152$17696115$2$F$$20210526$20200422$20221008$PER$$US-NAPPMUNDI-USA-2019-0149032$PURDUE$$$$$M$Y$$$20221008$$CN$US$US
176961624$17696162$4$F$20180101$20221215$20200423$20221216$EXP$$US-PURDUE PHARMA-USA-2020-0151000$PURDUE$$$$$F$Y$$$20221216$$CN$US$US
1769631036$17696310$36$F$20200420$20220921$20200423$20221007$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-032828$BRISTOL MYERS SQUIBB$$59$YR$A$M$Y$69.6$KG$20221007$$MD$JP$JP
176963852$17696385$2$F$19950101$20200526$20200423$20221008$PER$$US-PURDUE-USA-2020-0150489$PURDUE$$$$$M$Y$$$20221008$$CN$US$US
176964428$17696442$8$F$20200419$20221109$20200423$20221114$EXP$$DE-ABBVIE-20K-062-3375244-00$ABBVIE$$77$YR$$F$Y$55$KG$20221114$$MD$DE$DE
176965062$17696506$2$F$20110101$20200713$20200423$20221008$PER$$US-NAPPMUNDI-USA-2020-0150632$PURDUE$$$$$M$Y$$$20221008$$CN$US$US
176966372$17696637$2$F$20050101$20200624$20200423$20221008$PER$$US-NAPPMUNDI-USA-2020-0151009$PURDUE$$$$$F$Y$$$20221008$$CN$US$US
176968243$17696824$3$F$$20221129$20200423$20221202$EXP$$CA-ROCHE-2585673$ROCHE$$53$YR$$F$Y$$$20221202$$HP$CA$
176969285$17696928$5$F$20190214$20221020$20200423$20221028$EXP$$JP-BAUSCH-BL-2020-012061$BAUSCH AND LOMB$$37$YR$$M$Y$71.8$KG$20221028$$MD$JP$JP
176969708$17696970$8$F$20200625$20221122$20200423$20221129$PER$$NVSC2020US108429$NOVARTIS$$17$YR$$M$Y$$$20221129$$HP$US$US
176972274$17697227$4$F$$20221223$20200423$20221228$EXP$$GB-VIIV HEALTHCARE LIMITED-GB2020EME069114$VIIV$$$$$$Y$$$20221228$$PH$GB$GB
176972414$17697241$4$F$$20221223$20200423$20221228$EXP$$GB-GLAXOSMITHKLINE-GB2020EME069114$GLAXOSMITHKLINE$$$$$$Y$$$20221228$$PH$GB$GB
176973106$17697310$6$F$20200417$20221021$20200423$20221030$EXP$$US-UNITED THERAPEUTICS-UNT-2020-006000$UNITED THERAPEUTICS$$63$YR$$M$Y$107.03$KG$20221030$$PH$US$US
1769735410$17697354$10$F$20181213$20221031$20200423$20221103$EXP$$CA-TAKEDA-2018TUS024534$TAKEDA$$62$YR$$F$Y$$$20221103$$HP$CA$CA
176976602$17697660$2$F$20190601$20221010$20200423$20221019$EXP$DE-ADRED-04239-01$DE-TORRENT-00017390$TORRENT$$44$YR$A$F$Y$68$KG$20221019$$MD$DE$DE
176977238$17697723$8$F$$20221114$20200423$20221117$EXP$$US-SHIRE-US202014171$TAKEDA$$$$$F$Y$52$KG$20221117$$CN$US$US
176983238$17698323$8$F$$20221207$20200423$20221215$EXP$$US-PFIZER INC-2018393088$PFIZER$$71$YR$$F$Y$$$20221215$$CN$US$US
176983559$17698355$9$F$$20221130$20200423$20221205$PER$$US-PFIZER INC-2020163264$PFIZER$$84$YR$$F$Y$$$20221205$$MD$US$US
176984645$17698464$5$F$$20221129$20200423$20221207$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-13514$SAMSUNG BIOEPIS$$43$YR$A$M$Y$90$KG$20221207$$CN$CA$CA
176987954$17698795$4$F$$20221214$20200423$20221219$EXP$$NVSC2020GR107983$NOVARTIS$Thodou E, Befani M, Triantafyllidis G, Choreftaki T, Kanellis G, Giannakoulas N. Hodgkin lymphoma mimicking inflammatory breast carcinoma: A rare case with diagnostic challenge and novel treatment. CASE REPORTS IN HEMATOLOGY. 2019;1-6$57$YR$$F$Y$$$20221220$$HP$GR$GR
1769936911$17699369$11$F$$20221123$20200423$20221128$PER$$US-PFIZER INC-2020160735$PFIZER$$67$YR$$F$Y$$$20221128$$CN$US$US
1769941017$17699410$17$F$$20221202$20200423$20221207$EXP$$CA-PFIZER INC-2020159862$PFIZER$$59$YR$$F$Y$115$KG$20221207$$CN$CA$CA
176995778$17699577$8$F$$20221110$20200423$20221115$EXP$$CA-TAKEDA-2020TUS019455$TAKEDA$$63$YR$$F$Y$$$20221115$$CN$CA$CA
177001544$17700154$4$F$20200228$20221028$20200423$20221102$EXP$$CA-PFIZER INC-2019133476$PFIZER$$77$YR$$F$Y$$$20221102$$CN$CA$CA
177003754$17700375$4$F$20130101$20221114$20200423$20221116$EXP$$US-TAKEDA-2020TUS019640$TAKEDA$$$$$$Y$$$20221116$$CN$US$US
177010085$17701008$5$F$20090101$20221122$20200423$20221123$EXP$$US-GILEAD-2020-0460557$GILEAD$$31$YR$A$F$Y$$$20221123$$LW$US$US
1770125822$17701258$22$F$20180901$20221206$20200424$20221215$EXP$$CA-CELLTRION INC.-2018CA022761$CELLTRION$$$$$$Y$$$20221214$$CN$CA$CA
177012853$17701285$3$F$$20220928$20200424$20221013$EXP$$FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-244571$RANBAXY$Bodard Q, Carre D, Chenal P, Zarnitsky C, Midhat M, Litrowski N. Drug-induced Sweet^s syndrome related to hydroxychloroquine: About 2 cases. Rev Med Interne. 2020;41(4):289-292(CA101)$31$YR$$$Y$$$20221013$$HP$FR$FR
177012993$17701299$3$F$$20220928$20200424$20221013$EXP$$FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-244572$RANBAXY$Bodard Q, Carre D, Chenal P, Zarnitsky C, Midhat M, Litrowski N. Drug-induced Sweet^s syndrome related to hydroxychloroquine: About 2 cases. Rev Med Interne. 2020;41(4):289-292$42$YR$$$Y$$$20221013$$HP$FR$FR
1770148118$17701481$18$F$20191224$20221206$20200424$20221215$EXP$$CA-CELLTRION INC.-2019CA028127$CELLTRION$$$$$$Y$$$20221215$$HP$CA$CA
177015643$17701564$3$F$20190101$20221025$20200423$20221029$EXP$$SE-ABBVIE-19K-150-3201967-00$ABBVIE$$$$$M$Y$$$20221029$$HP$SE$SE
177016893$17701689$3$F$$20221116$20200423$20221118$EXP$$US-009507513-2004USA006685$MERCK$$$$$F$Y$$$20221118$$MD$US$US
1770176311$17701763$11$F$20200416$20221018$20200423$20221021$EXP$$US-SHIRE-US202014033$TAKEDA$$70$YR$$M$Y$$$20221021$$HP$US$US
177029142$17702914$2$F$$20221025$20200423$20221101$EXP$$US-JAZZ-2019-US-013634$JAZZ$$$$$F$Y$$$20221101$$CN$US$US
177029923$17702992$3$F$$20221130$20200424$20221208$EXP$$US-BIOGEN-2020BI00865022$BIOGEN$$$$$F$Y$$$20221208$$CN$US$US
177032004$17703200$4$F$20200204$20221010$20200424$20221013$EXP$$IT-ROCHE-2583281$ROCHE$$51$YR$$M$Y$82$KG$20221013$$MD$IT$
177033022$17703302$2$F$$20221004$20200424$20221010$EXP$$CA-ROCHE-1985837$ROCHE$$38$YR$$M$Y$$$20221010$$HP$CA$
177033322$17703332$2$F$$20200422$20200423$20221221$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-033240$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20221222$$HP$CA$CA
177035532$17703553$2$F$20180323$20221025$20200424$20221030$EXP$$NVSC2020FR110110$NOVARTIS$$67$YR$$F$Y$71$KG$20221031$$MD$FR$FR
177043238$17704323$8$F$20191123$20221019$20200424$20221024$EXP$$IL-ABBVIE-20K-082-3216923-00$ABBVIE$$74$YR$$M$Y$95$KG$20221024$$MD$IL$IL
177043592$17704359$2$F$20170101$20221219$20200424$20221229$EXP$FR-AFSSAPS-AM20200495$FR-TEVA-2020-FR-1226234$TEVA$$37$YR$A$F$Y$57$KG$20221229$$MD$FR$FR
177044584$17704458$4$F$20170101$20200901$20200424$20221228$EXP$$US-GILEAD-2020-0459960$GILEAD$$$$A$F$Y$108.84$KG$20221228$$LW$US$US
177047216$17704721$6$F$$20221111$20200424$20221121$PER$$US-SA-2020SA103218$SANOFI AVENTIS$$55$YR$A$M$Y$$$20221121$$CN$US$US
177049493$17704949$3$F$20120401$20221227$20200424$20221231$EXP$$NVSC2020ES110216$NOVARTIS$$49$YR$$F$Y$69$KG$20221231$$MD$ES$ES
177051675$17705167$5$F$20200101$20221129$20200424$20221201$PER$$US-PFIZER INC-2019280655$PFIZER$$83$YR$$F$Y$$$20221201$$CN$US$US
177052123$17705212$3$F$$20221209$20200424$20221216$PER$$US-PFIZER INC-2019466172$PFIZER$$60$YR$$F$Y$$$20221216$$CN$US$US
1770542612$17705426$12$F$$20221123$20200424$20221219$EXP$$GB-VIIV HEALTHCARE LIMITED-GB2012001032$VIIV$$$$$$Y$$$20221219$$MD$GB$GB
1770543112$17705431$12$F$$20221123$20200424$20221219$EXP$$GB-GLAXOSMITHKLINE-GB2012001032$GLAXOSMITHKLINE$$$$$$Y$$$20221219$$MD$GB$GB
177054783$17705478$3$F$20160101$20221013$20200424$20221017$EXP$$US-TAKEDA-2020TUS019719$TAKEDA$$$$$$Y$$$20221017$$CN$US$US
177056565$17705656$5$F$$20221102$20200424$20221111$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-14472$SAMSUNG BIOEPIS$$24$YR$A$F$Y$60$KG$20221111$$MD$CA$CA
1770575910$17705759$10$F$20200713$20221108$20200424$20221114$EXP$$CA-PFIZER INC-2019546763$PFIZER$$81$YR$$F$Y$50$KG$20221114$$CN$CA$CA
177058716$17705871$6$F$$20221020$20200424$20221025$EXP$$US-SHIRE-US202013841$TAKEDA$$$$$M$Y$80$KG$20221025$$HP$US$US
177059008$17705900$8$F$20190904$20221018$20200424$20221031$EXP$$EC-BIOMARINAP-EC-2020-129764$BIOMARIN$$$$$$Y$$$20221031$$CN$US$EC
177059045$17705904$5$F$20200519$20221216$20200424$20221223$EXP$$US-SHIRE-US202014305$TAKEDA$$47$YR$$M$Y$$$20221223$$CN$US$US
177061277$17706127$7$F$20190426$20221130$20200424$20221207$EXP$$DE-JNJFOC-20191210641$JOHNSON AND JOHNSON$$4$DEC$A$F$Y$$$20221208$$MD$DE$DE
177061846$17706184$6$F$$20221025$20200424$20221102$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-13617$SAMSUNG BIOEPIS$$54$YR$A$F$Y$50$KG$20221102$$HP$CA$CA
177062665$17706266$5$F$$20221109$20200424$20221111$PER$$US-PFIZER INC-2020164475$PFIZER$$63$YR$$F$Y$$$20221111$$MD$US$US
1770679912$17706799$12$F$20200101$20221227$20200424$20221231$PER$$US-AMGEN-USASP2020066501$AMGEN$$80$YR$E$M$Y$86$KG$20221231$$CN$US$US
177068747$17706874$7$F$20180503$20221101$20200424$20221108$EXP$$PHHY2018CA007687$NOVARTIS$$44$YR$$F$Y$$$20221108$$CN$CA$CA
1770698314$17706983$14$F$20190816$20221128$20200424$20221205$EXP$$NVSC2020DE108248$NOVARTIS$$54$YR$$F$Y$100$KG$20221205$$CN$DE$DE
177071225$17707122$5$F$20190101$20221103$20200424$20221111$EXP$$US-BIOGEN-2019BI00768143$BIOGEN$$$$$F$Y$$$20221111$$HP$US$US
177073034$17707303$4$F$20090101$20220930$20200424$20221005$EXP$$US-TAKEDA-2020TUS019724$TAKEDA$$$$$$Y$$$20221005$$CN$US$US
177079479$17707947$9$F$20191201$20221210$20200425$20221213$EXP$$FR-ROCHE-2572252$ROCHE$$52$YR$$M$Y$89$KG$20221213$$MD$FR$
177080562$17708056$2$F$20200108$20221119$20200425$20221202$EXP$DE-BFARM-20004303$DE-Accord-179625$ACCORD$$81$YR$E$M$Y$$$20221202$$MD$DE$DE
177082812$17708281$2$F$20200301$20221207$20200426$20221209$PER$$US-BIOGEN-2020BI00867470$BIOGEN$$54$YR$$F$Y$$$20221209$$CN$US$US
1770840622$17708406$22$F$20190926$20220929$20200426$20221003$EXP$$PHHY2019AR173414$NOVARTIS$$82$YR$$F$Y$$$20221003$$CN$AR$AR
177084642$17708464$2$F$$20221119$20200426$20221202$EXP$DE-BFARM-20004259$DE-Accord-179622$ACCORD$$57$YR$A$F$Y$$$20221202$$MD$DE$DE
177091508$17709150$8$F$20121113$20221214$20200426$20221220$EXP$$PHHY2013CA072971$NOVARTIS$$47$YR$$F$Y$$$20221220$$MD$CA$CA
177093136$17709313$6$F$$20221110$20200426$20221117$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-13608$SAMSUNG BIOEPIS$$45$YR$A$F$Y$82$KG$20221117$$MD$CA$CA
1770951321$17709513$21$F$20200219$20221117$20200427$20221125$EXP$$CA-CELLTRION INC.-2020CA019593$CELLTRION$$$$$$Y$$$20221125$$HP$CA$CA
177097966$17709796$6$F$20200305$20221018$20200427$20221020$EXP$$US-ROCHE-2564390$ROCHE$$64$YR$$F$Y$54.48$KG$20221020$$CN$US$
177106984$17710698$4$F$20200101$20221017$20200427$20221020$EXP$$US-PFIZER INC-2020160845$PFIZER$$77$YR$$F$Y$$$20221020$$CN$US$US
177107093$17710709$3$F$$20221013$20200427$20221017$PER$$US-PFIZER INC-2020161986$PFIZER$$72$YR$$M$Y$$$20221017$$CN$US$US
177107495$17710749$5$F$20180222$20221011$20200427$20221021$EXP$$SK-MYLANLABS-2020M1040162$MYLAN$Michalova jr R, Mankova A, Jezikova A, Vnucak M, Granak K, Staskova K et al.. Pregnancy in a patient with newly diagnosed systemic lupus erythematosus: a case report. Internal Medicine. 2017;63 (5 supp 1)$$$N$F$Y$1.3$KG$20221021$$HP$SK$SK
1771108123$17711081$23$F$$20221104$20200427$20221114$EXP$$US-PFIZER INC-2020164578$PFIZER$$73$YR$$F$Y$$$20221114$$CN$US$US
177111474$17711147$4$F$$20221214$20200427$20221219$PER$$US-PFIZER INC-2020164802$PFIZER$$71$YR$$F$Y$$$20221219$$CN$US$US
177113662$17711366$2$F$20190418$20221206$20200427$20221214$EXP$$US-PFIZER INC-2020166525$PFIZER$$59$YR$$F$Y$82.55$KG$20221214$$CN$US$US
177115194$17711519$4$F$20140101$20221010$20200427$20221012$EXP$$US-GILEAD-2020-0461387$GILEAD$$61$YR$A$F$Y$$$20221012$$LW$US$US
177120963$17712096$3$F$20200402$20221007$20200427$20221012$EXP$$US-SHIRE-US202014496$TAKEDA$$59$YR$$M$Y$$$20221012$$CN$US$US
1771214713$17712147$13$F$20200731$20221003$20200427$20221007$EXP$$US-SHIRE-US202014616$TAKEDA$$62$YR$$M$Y$74$KG$20221007$$CN$US$US
1771289540$17712895$40$F$20220501$20221220$20200427$20221227$EXP$$US-SHIRE-US202014494$TAKEDA$$44$YR$$F$Y$79$KG$20221227$$HP$US$US
1771370313$17713703$13$F$20200420$20221121$20200427$20221129$EXP$$US-SHIRE-US202014090$TAKEDA$$62$YR$$F$Y$$$20221129$$MD$US$US
1771405514$17714055$14$F$20200116$20221220$20200427$20221228$EXP$$NVSC2020DE033689$NOVARTIS$$$$A$F$Y$69$KG$20221228$$MD$DE$DE
177144032$17714403$2$F$$20221017$20200427$20221019$PER$$US-PFIZER INC-2020167704$PFIZER$$78$YR$$F$Y$$$20221019$$CN$US$US
177144055$17714405$5$F$20210706$20221130$20200427$20221205$PER$$US-PFIZER INC-2020166334$PFIZER$$79$YR$$F$Y$$$20221205$$CN$US$US
177144566$17714456$6$F$$20221102$20200427$20221104$PER$$US-PFIZER INC-2020169111$PFIZER$$75$YR$$F$Y$$$20221104$$MD$US$US
177154197$17715419$7$F$20200415$20220930$20200427$20221007$EXP$$FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-032550$BRISTOL MYERS SQUIBB$$73$YR$E$F$Y$57$KG$20221007$$HP$FR$FR
177154364$17715436$4$F$20200301$20221031$20200427$20221104$EXP$$US-PFIZER INC-2020054089$PFIZER$$27$YR$$F$Y$$$20221104$$MD$US$US
1771575913$17715759$13$F$20200313$20221006$20200427$20221018$EXP$$CA-CELLTRION INC.-2020CA019642$CELLTRION$$$$$$Y$$$20221018$$MD$CA$CA
1771614519$17716145$19$F$20190601$20221111$20200428$20221125$EXP$$CA-CELLTRION INC.-2019CA026792$CELLTRION$$$$$$Y$$$20221125$$HP$CA$CA
1771632815$17716328$15$F$20190501$20221116$20200428$20221123$EXP$$DE-ROCHE-2588771$ROCHE$$42$YR$$F$Y$$$20221123$$CN$DE$
177166636$17716663$6$F$20090716$20221007$20200428$20221012$EXP$$US-GILEAD-2020-0461267$GILEAD$$54$YR$A$M$Y$$$20221012$$LW$US$US
177171097$17717109$7$F$20220901$20221213$20200428$20221219$PER$$US-PFIZER INC-2020029529$PFIZER$$51$YR$$F$Y$$$20221219$$HP$US$US
177172892$17717289$2$F$20190601$20221014$20200428$20221024$EXP$$DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-20-51214$HIKMA$$44$YR$$F$Y$68$KG$20221024$$MD$DE$DE
177172974$17717297$4$F$20150101$20221025$20200428$20221028$EXP$$US-AstraZeneca-2020SE54726$ASTRAZENECA$$68$YR$$F$Y$98$KG$20221028$$LW$US$
177173514$17717351$4$F$$20221209$20200428$20221213$PER$$US-PFIZER INC-2020163065$PFIZER$$75$YR$$F$Y$$$20221213$$CN$US$US
177173569$17717356$9$F$20200101$20221104$20200428$20221110$EXP$$US-PFIZER INC-2020167259$PFIZER$$46$YR$$F$Y$112.01$KG$20221110$$HP$US$US
1771754620$17717546$20$F$$20221115$20200428$20221116$EXP$$FR-TAKEDA-2020TJP008380$TAKEDA$Laloui K, Tafat A, Razafimbelo H, Goby-Riemon AC, Rabus MT, Rwabihama JP.. About a case of microscopic colitis under lansoprazole.. Soins-Gerontologie. 2020;25(141):47-48$86$YR$$F$Y$43.68$KG$20221116$$HP$FR$FR
177175624$17717562$4$F$$20221117$20200428$20221121$EXP$$US-KYOWAKIRIN-2020BKK006519$KYOWA$$$$$$Y$$$20221121$$HP$US$US
177176324$17717632$4$F$20200101$20220923$20200428$20221005$EXP$$BR-ABBVIE-20K-020-3379337-00$ABBVIE$$76$YR$$F$Y$70$KG$20221005$$CN$BR$BR
177177747$17717774$7$F$$20221202$20200428$20221212$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-14584$SAMSUNG BIOEPIS$$55$YR$A$M$Y$81$KG$20221212$$CN$CA$CA
1771783922$17717839$22$F$20150720$20221026$20200428$20221031$EXP$$PHHY2015CA085384$NOVARTIS$$76$YR$$M$Y$$$20221031$$HP$CA$CA
1771784921$17717849$21$F$20190706$20221219$20200428$20221222$EXP$$NVSC2019CO054686$NOVARTIS$$6$YR$$F$Y$$$20221222$$CN$CO$CO
177180022$17718002$2$F$$20221119$20200428$20221202$EXP$DE-BFARM-20004281$DE-Accord-179672$ACCORD$$85$YR$E$M$Y$$$20221202$$MD$DE$DE
177180194$17718019$4$F$20180501$20220824$20200428$20221028$EXP$$GB-OTSUKA-2018_023534$OTSUKA$$58$YR$$F$Y$79.8$KG$20221028$$MD$GB$GB
177182864$17718286$4$F$20190101$20221028$20200428$20221102$EXP$$CA-PFIZER INC-2019450205$PFIZER$$71$YR$$F$Y$$$20221102$$HP$CA$CA
1771890711$17718907$11$F$20210416$20221128$20200428$20221202$EXP$$US-SHIRE-US202014621$TAKEDA$$78$YR$$F$Y$61.224$KG$20221202$$CN$US$US
1771891710$17718917$10$F$20200101$20221021$20200428$20221027$EXP$$BR-SHIRE-BR202014057$TAKEDA$$5$YR$$M$Y$39$KG$20221027$$CN$BR$BR
1771894315$17718943$15$F$20220424$20221205$20200428$20221212$EXP$$US-SHIRE-US202014625$TAKEDA$$46$YR$$F$Y$72$KG$20221212$$HP$US$US
1771907921$17719079$21$F$20190815$20221206$20200428$20221215$EXP$$PHHY2019CA194329$NOVARTIS$$70$YR$$M$Y$$$20221215$$CN$CA$CA
177191394$17719139$4$F$$20221102$20200428$20221111$EXP$$US-PFIZER INC-2020171069$PFIZER$$77$YR$$F$Y$$$20221111$$CN$US$US
177194776$17719477$6$F$20180801$20221019$20200428$20221025$EXP$$US-GILEAD-2020-0462168$GILEAD$$32$YR$A$M$Y$$$20221024$$LW$US$US
177195573$17719557$3$F$20200421$20221115$20200428$20221123$EXP$$JP-ALLERGAN-2016959US$ALLERGAN$$$$$M$Y$$$20221123$$MD$JP$JP
177195975$17719597$5$F$20160101$20221117$20200428$20221123$EXP$$US-TAKEDA-2020TUS020417$TAKEDA$$$$$$Y$$$20221123$$CN$US$US
177196323$17719632$3$F$20200108$20221010$20200428$20221011$EXP$$NVSC2020IT113524$NOVARTIS$$8$YR$$F$Y$$$20221011$$MD$IT$IT
177197084$17719708$4$F$$20221107$20200428$20221115$EXP$$US-AstraZeneca-2020SE53588$ASTRAZENECA$$$$$M$Y$74.8$KG$20221115$$CN$US$
1772019837$17720198$37$F$20181008$20221118$20200428$20221120$EXP$$NVSC2020GB061360$NOVARTIS$$74$YR$$M$Y$$$20221121$$MD$IE$IE
177202998$17720299$8$F$20140312$20221101$20200428$20221106$EXP$$PHHY2014CA035505$NOVARTIS$$72$YR$$M$Y$$$20221107$$HP$CA$CA
177204412$17720441$2$F$$20200422$20200428$20221011$PER$$US-GILEAD-2020-0460805$GILEAD$$68$YR$E$F$Y$84.4$KG$20221011$$CN$US$US
177204809$17720480$9$F$20200201$20221207$20200428$20221214$EXP$$CA-TAKEDA-2020TUS012473$TAKEDA$$22$YR$$M$Y$$$20221214$$MD$CA$CA
177208733$17720873$3$F$20190101$20221207$20200428$20221220$EXP$$US-AstraZeneca-2020SE54463$ASTRAZENECA$$42$YR$$F$Y$80.3$KG$20221215$$LW$US$
177222664$17722266$4$F$$20221103$20200429$20221104$EXP$$CA-ROCHE-2588247$ROCHE$$42$YR$$F$Y$106$KG$20221104$$CN$CA$
177223392$17722339$2$F$20200108$20221031$20200429$20221107$EXP$$NVSC2020BR007725$NOVARTIS$$42$YR$$F$Y$$$20221107$$CN$BR$BR
177223718$17722371$8$F$20200101$20221004$20200429$20221006$PER$$US-PFIZER INC-2020171635$PFIZER$$70$YR$$F$Y$58.059$KG$20221006$$CN$US$US
177223842$17722384$2$F$$20221209$20200429$20221216$PER$$US-PFIZER INC-2020170219$PFIZER$$76$YR$$F$Y$$$20221216$$CN$US$US
177224037$17722403$7$F$20200422$20221207$20200429$20221213$PER$$US-PFIZER INC-2020167785$PFIZER$$65$YR$$F$Y$85.73$KG$20221213$$CN$US$US
177228363$17722836$3$F$$20221130$20200429$20221205$EXP$$CA-BAUSCH-BL-2020-012539$BAUSCH AND LOMB$$57$YR$$F$Y$$$20221205$$HP$CA$CA
177232413$17723241$3$F$20221115$20221115$20200429$20221117$PER$$NVSC2020US114967$NOVARTIS$$17$YR$$M$Y$$$20221117$$HP$US$US
177236275$17723627$5$F$$20221117$20200429$20221125$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-14169$SAMSUNG BIOEPIS$$60$YR$A$F$Y$65$KG$20221125$$MD$CA$CA
177238257$17723825$7$F$$20221027$20200429$20221108$PER$$US-SA-2020SA110390$SANOFI AVENTIS$$62$YR$A$M$Y$$$20221108$$CN$US$US
177238872$17723887$2$F$$20221020$20200429$20221024$EXP$$US-PFIZER INC-2020171981$PFIZER$$52$YR$$M$Y$$$20221024$$HP$US$US
177239019$17723901$9$F$20200101$20221004$20200429$20221007$EXP$$CA-PFIZER INC-2020127554$PFIZER$$62$YR$$M$Y$$$20221007$$CN$CA$CA
1772408113$17724081$13$F$20221208$20221207$20200429$20221217$EXP$$US-SHIRE-US202014810$TAKEDA$$60$YR$$F$Y$78$KG$20221217$$MD$US$US
177245452$17724545$2$F$$20200419$20200429$20221031$PER$$US-UCBSA-2020017631$UCB$Santoro JD, Filippakis A, Chitnis T. Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis. Epilepsy and Behavior Reports. 2019;12$19$YR$$F$Y$$$20221031$$MD$US$US
177245525$17724552$5$F$$20221207$20200429$20221212$EXP$$CA-SAMSUNG BIOEPIS-SB-2019-05817$SAMSUNG BIOEPIS$$59$YR$A$F$Y$104$KG$20221212$$MD$CA$CA
177251048$17725104$8$F$20180731$20221219$20200429$20221226$EXP$$NVSC2020DE113525$NOVARTIS$$42$YR$$F$Y$50$KG$20221226$$MD$DE$DE
177254377$17725437$7$F$20180213$20221129$20200429$20221130$EXP$$PHHY2017CA142206$NOVARTIS$$31$YR$$F$Y$$$20221130$$MD$CA$CA
177254817$17725481$7$F$$20220927$20200429$20221003$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-14238$SAMSUNG BIOEPIS$$21$YR$A$F$Y$77$KG$20221003$$HP$CA$CA
177254886$17725488$6$F$$20221013$20200429$20221021$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-14321$SAMSUNG BIOEPIS$$24$YR$A$M$Y$89$KG$20221021$$HP$CA$CA
1772556610$17725566$10$F$20200106$20221111$20200429$20221115$EXP$$DE-MYLANLABS-2020M1042273$MYLAN$$$$E$F$Y$93$KG$20221115$$MD$DE$DE
177256167$17725616$7$F$20220701$20221125$20200429$20221202$EXP$$CA-SHIRE-CA202008364$TAKEDA$$66$YR$$F$Y$70$KG$20221202$$CN$CA$CA
177256274$17725627$4$F$20200426$20221026$20200429$20221101$EXP$$US-SHIRE-US202014753$TAKEDA$$9$YR$$M$Y$$$20221101$$HP$US$US
177258233$17725823$3$F$$20221123$20200429$20221130$EXP$$CA-BAUSCH-BL-2020-012807$BAUSCH AND LOMB$$$$$$Y$$$20221130$$HP$CA$CA
1772594026$17725940$26$F$20200506$20221125$20200429$20221129$EXP$$NVSC2020CA115612$NOVARTIS$$71$YR$$F$Y$$$20221129$$CN$CA$CA
177260296$17726029$6$F$20191001$20221214$20200429$20221219$EXP$$NVSC2019CO066833$NOVARTIS$$12$YR$$F$Y$53$KG$20221219$$CN$CO$CO
1772622510$17726225$10$F$20191202$20221114$20200429$20221128$EXP$$DE-AUROBINDO-AUR-APL-2020-020829$AUROBINDO$$$$A$F$Y$100.8$KG$20221128$$MD$DE$DE
1772631520$17726315$20$F$20190701$20221109$20200430$20221117$EXP$$AU-BIOGEN-2019BI00805716$BIOGEN$$25$YR$$F$Y$65$KG$20221116$$HP$AU$AU
177263652$17726365$2$F$$20220926$20200430$20221011$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-244910$RANBAXY$Sandhu J, Wang C, Fakih M.. Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2020;Feb; 18(2):116-119$58$YR$$M$Y$$$20221011$$MD$US$US
1772640215$17726402$15$F$20221031$20221202$20200430$20221209$EXP$$US-SHIRE-US202014935$TAKEDA$$60$YR$$F$Y$71$KG$20221209$$HP$US$US
177265794$17726579$4$F$20140101$20221011$20200430$20221013$EXP$$US-TAKEDA-2020TUS020557$TAKEDA$$$$$$Y$$$20221013$$CN$US$US
177269353$17726935$3$F$$20221007$20200430$20221021$PER$$US-drreddys-USA/USA/20/0122356$DR REDDYS$$61$YR$A$F$Y$56.25$KG$20221021$$CN$US$US
177269926$17726992$6$F$$20221019$20200430$20221028$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-14273$SAMSUNG BIOEPIS$$47$YR$A$F$Y$$$20221028$$HP$CA$CA
177270412$17727041$2$F$20160101$20221021$20200430$20221028$EXP$$DE-BIOGEN-2019BI00794420$BIOGEN$$$$$F$Y$$$20221028$$CN$DE$DE
177271535$17727153$5$F$$20221130$20200430$20221207$EXP$$CA-GLAXOSMITHKLINE-CA2020GSK073370$GLAXOSMITHKLINE$$$$$$Y$$$20221207$$HP$CA$CA
177272054$17727205$4$F$$20221103$20200430$20221108$EXP$$CA-ROCHE-2587582$ROCHE$$64$YR$$F$Y$$$20221107$$MD$CA$
177277005$17727700$5$F$20200424$20221110$20200430$20221118$EXP$$NVSC2020US116129$NOVARTIS$$66$YR$$F$Y$$$20221118$$CN$US$US
177278029$17727802$9$F$20220601$20221202$20200430$20221212$EXP$$US-SHIRE-US202014958$TAKEDA$$60$YR$$F$Y$118$KG$20221212$$CN$US$US
177278365$17727836$5$F$$20221010$20200430$20221012$PER$$US-PFIZER INC-2020173254$PFIZER$$85$YR$$F$Y$$$20221012$$CN$US$US
177278524$17727852$4$F$$20221102$20200430$20221107$PER$$US-PFIZER INC-2020170817$PFIZER$$80$YR$$F$Y$64.41$KG$20221107$$CN$US$US
177279193$17727919$3$F$20190212$20221213$20200430$20221219$EXP$$US-ASTELLAS-2019US001577$ASTELLAS$$77$YR$$M$Y$$$20221219$$MD$US$US
177279484$17727948$4$F$$20221104$20200430$20221114$EXP$$US-PFIZER INC-2020168609$PFIZER$$69$YR$$F$Y$$$20221114$$CN$US$US
1772821421$17728214$21$F$20200417$20221219$20200430$20221222$EXP$$NVSC2020US107963$NOVARTIS$$36$YR$$F$Y$123.83$KG$20221222$$HP$US$US
177284824$17728482$4$F$20190101$20221028$20200430$20221102$EXP$$CA-PFIZER INC-2019231700$PFIZER$$65$YR$$M$Y$$$20221102$$CN$CA$CA
177285863$17728586$3$F$20190425$20221110$20200430$20221118$EXP$$BE-ABBVIE-19K-013-3146235-00$ABBVIE$$68$YR$$M$Y$180$KG$20221118$$MD$BE$BE
177287193$17728719$3$F$$20221116$20200430$20221123$EXP$$NVSC2020TR116058$NOVARTIS$Aktas H, Yilmaz OE, Ertugrul G, Terzi E. Intramuscular diclofenac is a cause of Nicolau Syndrome in obese women: An observational study of consecutive ten patients. DERMATOLOGIC THERAPY. 2020;33(3):1-3$45$YR$$F$Y$$$20221123$$HP$TR$TR
177287212$17728721$2$F$$20221219$20200430$20221224$EXP$$NVSC2020CA116541$NOVARTIS$$$$$F$Y$$$20221224$$MD$CA$CA
177290016$17729001$6$F$20190901$20221025$20200430$20221031$EXP$$DE-BIOGEN-2019BI00807679$BIOGEN$$32$YR$$F$Y$$$20221031$$CN$DE$DE
177291283$17729128$3$F$$20221116$20200430$20221118$EXP$$NVSC2020TR116076$NOVARTIS$Aktas H, Y?lmaz OE, Ertugrul G, Terzi E. Intramuscular diclofenac is a cause of Nicolau Syndrome in obese women: An observational study of consecutive ten patients. DERMATOLOGIC THERAPY. 2020;33(3):1-3$56$YR$$F$Y$$$20221118$$HP$TR$TR
177291313$17729131$3$F$$20221116$20200430$20221121$EXP$$NVSC2020TR116303$NOVARTIS$Aktas H, Yilmaz OE, Ertugrul G, Terzi E. Intramuscular diclofenac is a cause of Nicolau Syndrome in obese women: An observational study of consecutive ten patients. DERMATOLOGIC THERAPY. 2020;33(3):1-3$50$YR$$F$Y$$$20221121$$HP$TR$TR
177291493$17729149$3$F$$20221116$20200430$20221121$EXP$$NVSC2020TR116047$NOVARTIS$Aktas H, Yilmaz OE, Ertugrul G, Terzi E. Intramuscular diclofenac is a cause of Nicolau Syndrome in obese women: An observational study of consecutive ten patients. DERMATOLOGIC THERAPY. 2020;33(3):1-3$60$YR$$F$Y$$$20221121$$HP$TR$TR
177291553$17729155$3$F$$20221116$20200430$20221118$EXP$$NVSC2020TR116075$NOVARTIS$Aktas H, Yilmaz OE, Ertugrul G, Terzi E. Intramuscular diclofenac is a cause of Nicolau Syndrome in obese women: An observational study of consecutive ten patients. DERMATOLOGIC THERAPY. 2020;33(3):1-3$51$YR$$F$Y$$$20221118$$HP$TR$TR
177293597$17729359$7$F$20190531$20221220$20200430$20221226$EXP$$JP-ABBVIE-20P-087-3385377-00$ABBVIE$$74$YR$$M$Y$41.6$KG$20221226$$MD$JP$JP
177294273$17729427$3$F$$20221116$20200430$20221121$EXP$$NVSC2020TR116073$NOVARTIS$Aktas H, Y?lmaz OE, Ertugrul G, Terzi E. Intramuscular diclofenac is a cause of Nicolau Syndrome in obese women: An observational study of consecutive ten patients. DERMATOLOGIC THERAPY. 2020;33(3):1-3$64$YR$$F$Y$$$20221121$$HP$TR$TR
177294283$17729428$3$F$$20221116$20200430$20221118$EXP$$NVSC2020TR115979$NOVARTIS$Aktas H, Yilmaz OE, Ertugrul G, Terzi E. Intramuscular diclofenac is a cause of Nicolau Syndrome in obese women: An observational study of consecutive ten patients. DERMATOLOGIC THERAPY. 2020;33(3):1-3$55$YR$$F$Y$$$20221118$$HP$TR$TR
177295223$17729522$3$F$$20221116$20200430$20221121$EXP$$NVSC2020TR116140$NOVARTIS$Aktas H, Y?lmaz OE, Ertugrul G, Terzi E. Intramuscular diclofenac is a cause of Nicolau Syndrome in obese women: An observational study of consecutive ten patients. DERMATOLOGIC THERAPY. 2020;33(3):1-3$62$YR$$F$Y$$$20221121$$HP$TR$TR
1772972634$17729726$34$F$20160218$20220927$20200430$20221005$EXP$$PHHY2016CA187545$NOVARTIS$$53$YR$$F$Y$$$20221005$$CN$CA$CA
177297544$17729754$4$F$$20221110$20200430$20221117$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-14499$SAMSUNG BIOEPIS$$67$YR$E$F$Y$103$KG$20221117$$HP$CA$CA
177298032$17729803$2$F$$20221031$20200430$20221104$EXP$$CA-PFIZER INC-2020173000$PFIZER$$$$$F$Y$$$20221104$$HP$CA$CA
177299412$17729941$2$F$$20200424$20200430$20221006$PER$$US-GILEAD-2020-0461476$GILEAD$$42$YR$A$F$Y$$$20221006$$CN$US$US
177303265$17730326$5$F$20221101$20221214$20200430$20221215$PER$$US-PFIZER INC-2020110096$PFIZER$$72$YR$$F$Y$88.449$KG$20221215$$MD$US$US
177303303$17730330$3$F$$20220929$20200430$20221003$PER$$US-PFIZER INC-2020172737$PFIZER$$44$YR$$M$Y$$$20221003$$HP$US$US
177303357$17730335$7$F$$20221018$20200430$20221021$PER$$US-PFIZER INC-2019164373$PFIZER$$55$YR$$F$Y$92.08$KG$20221021$$CN$US$US
177303716$17730371$6$F$$20221219$20200430$20221227$EXP$$US-PFIZER INC-2020174816$PFIZER$$83$YR$$F$Y$$$20221227$$HP$US$US
1773038920$17730389$20$F$20190912$20221105$20200430$20221111$EXP$$PHHY2019CL210984$NOVARTIS$$66$YR$$F$Y$$$20221111$$HP$CL$CL
177305383$17730538$3$F$$20221116$20200430$20221118$EXP$$NVSC2020TR116069$NOVARTIS$Aktas H, Yilmaz OE, Ertugrul G, Terzi E. Intramuscular diclofenac is a cause of Nicolau Syndrome in obese women: An observational study of consecutive ten patients. DERMATOLOGIC THERAPY. 2020;33(3):1-3$53$YR$$F$Y$$$20221118$$HP$TR$TR
177305482$17730548$2$F$$20221116$20200430$20221118$EXP$$NVSC2020TR116306$NOVARTIS$Aktas H, Yimaz OE, Ertugrul G, Terzi E. Intramuscular diclofenac is a cause of Nicolau Syndrome in obese women: An observational study of consecutive ten patients. DERMATOLOGIC THERAPY. 2020;33(3):1-3$65$YR$$F$Y$$$20221118$$HP$TR$TR
177305579$17730557$9$F$20180501$20221108$20200430$20221115$EXP$$PHHY2018CA017295$NOVARTIS$$46$YR$$F$Y$$$20221115$$CN$CA$CA
177307054$17730705$4$F$20200320$20221208$20200430$20221216$EXP$$US-PFIZER INC-2020170626$PFIZER$$85$YR$$M$Y$68.95$KG$20221216$$CN$US$US
177307302$17730730$2$F$20200108$20221202$20200430$20221208$EXP$$DE-MYLANLABS-2020M1042457$MYLAN$$81$YR$$M$Y$$$20221208$$MD$DE$DE
177307382$17730738$2$F$$20221205$20200430$20221213$EXP$$DE-MYLANLABS-2020M1042459$MYLAN$$80$YR$$M$Y$83$KG$20221213$$PH$DE$DE
1773075110$17730751$10$F$$20221123$20200430$20221129$EXP$$NVSC2020CA113431$NOVARTIS$$$$$F$Y$$$20221129$$HP$CA$CA
1773075636$17730756$36$F$20160218$20220927$20200430$20221005$EXP$$PHHY2016CA005296$NOVARTIS$$53$YR$$F$Y$$$20221005$$CN$CA$CA
1773163517$17731635$17$F$20211101$20221214$20200501$20221221$EXP$$US-GLAXOSMITHKLINE-US2020AMR073551$GLAXOSMITHKLINE$$$$$$Y$$$20221221$$CN$US$US
177317099$17731709$9$F$20050816$20221208$20200501$20221215$EXP$$US-SHIRE-US202015048$TAKEDA$$56$YR$$M$Y$75$KG$20221215$$CN$US$US
177317952$17731795$2$F$20190601$20221014$20200501$20221027$EXP$$DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-245730$RANBAXY$$44$YR$$F$Y$68$KG$20221028$$MD$DE$DE
177337752$17733775$2$F$20200201$20221206$20200501$20221215$EXP$$JP-ROCHE-2593109$ROCHE$$80$YR$$F$Y$$$20221215$$MD$JP$JP
177341087$17734108$7$F$20220101$20221011$20200501$20221013$PER$$US-PFIZER INC-2020175757$PFIZER$$82$YR$$M$Y$$$20221013$$CN$US$US
177341545$17734154$5$F$20210201$20221110$20200501$20221114$PER$$US-PFIZER INC-2020174982$PFIZER$$63$YR$$F$Y$$$20221114$$HP$US$US
177342242$17734224$2$F$$20220926$20200501$20221003$EXP$$US-PERRIGO-20US005750$PERRIGO$$$$$F$Y$95.7$KG$20221003$$MD$US$US
177344582$17734458$2$F$$20180622$20200501$20221102$EXP$$NVSC2018CO003674$NOVARTIS$$$$$M$Y$$$20221102$$CN$CO$CO
177345953$17734595$3$F$$20221116$20200501$20221123$EXP$$NVSC2020US113854$NOVARTIS$$$$$F$Y$$$20221123$$CN$US$US
177350099$17735009$9$F$20190425$20221110$20200501$20221115$EXP$$US-SHIRE-US202014781$TAKEDA$$80$YR$$F$Y$55.33$KG$20221115$$MD$US$US
177352032$17735203$2$F$$20200429$20200501$20221011$PER$$US-GILEAD-2020-0462942$GILEAD$$72$YR$E$F$Y$$$20221011$$CN$US$US
177357714$17735771$4$F$$20221123$20200501$20221129$EXP$$CA-BAUSCH-BL-2020-012871$BAUSCH AND LOMB$$65$YR$$F$Y$$$20221129$$CN$CA$CA
177362688$17736268$8$F$$20221028$20200501$20221028$PER$$NVSC2020US118109$NOVARTIS$$$$$M$Y$$$20221029$$CN$US$US
177369127$17736912$7$F$$20221208$20200502$20221212$EXP$$CA-ROCHE-2587799$ROCHE$$61$YR$$F$Y$67$KG$20221212$$HP$CA$
177372463$17737246$3$F$20160101$20221003$20200503$20221004$EXP$$US-TAKEDA-2020TUS020965$TAKEDA$$$$$$Y$$$20221004$$CN$US$US
177373132$17737313$2$F$$20221031$20200503$20221104$EXP$$CA-PFIZER INC-2020173222$PFIZER$$79$YR$$M$Y$65$KG$20221104$$PH$CA$CA
177373213$17737321$3$F$$20221212$20200503$20221227$EXP$$DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-245843$RANBAXY$Alsayed AH. Paediatric extensiv cerebral venous sinus thrombosis with benign course. Fortschr Neurol Psychiatr. 2020;88(3):194-197$14$YR$$F$Y$50$KG$20221227$$HP$DE$DE
1773948720$17739487$20$F$20200101$20221123$20200504$20221202$EXP$$CA-CELLTRION INC.-2020CA020583$CELLTRION$$$$$$Y$$$20221202$$HP$CA$CA
177394889$17739488$9$F$20190201$20221202$20200504$20221212$EXP$$CA-CELLTRION INC.-2019CA028163$CELLTRION$$$$$$Y$$$20221212$$MD$CA$CA
177396702$17739670$2$F$20220701$20221116$20200504$20221118$PER$$US-SHIRE-US202015288$TAKEDA$$52$YR$$F$Y$$$20221118$$CN$US$US
177397293$17739729$3$F$$20221208$20200504$20221223$EXP$$IE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-245411$RANBAXY$Murphy R, McGuinness D, Hallahan B. Pregabalin-induced sexual disinhibition. Ir J Psychol Med. 2020;37(1):55-58$27$YR$$M$Y$$$20221223$$HP$IE$IE
1773995116$17739951$16$F$20220107$20221214$20200504$20221221$EXP$$US-SHIRE-US202015265$TAKEDA$$47$YR$$F$Y$82$KG$20221221$$MD$US$US
1774015911$17740159$11$F$20200101$20221215$20200504$20221221$EXP$$US-PFIZER INC-2020133636$PFIZER$$56$YR$$M$Y$$$20221221$$HP$US$US
177403754$17740375$4$F$$20221114$20200504$20221121$EXP$$DE-JNJFOC-20200435612$JOHNSON AND JOHNSON$$$$$M$Y$$$20221121$$CN$DE$DE
177409033$17740903$3$F$20190925$20221214$20200504$20221221$EXP$$NVSC2020CA119419$NOVARTIS$$$$E$M$Y$$$20221221$$MD$CA$CA
177409646$17740964$6$F$20210101$20221216$20200504$20221221$EXP$$US-PFIZER INC-2020177341$PFIZER$$66$YR$$F$Y$$$20221221$$HP$US$US
177410139$17741013$9$F$20180101$20221012$20200504$20221018$EXP$$PHHY2017CA147088$NOVARTIS$$$$$F$Y$$$20221018$$MD$CA$CA
177410406$17741040$6$F$$20221017$20200504$20221020$EXP$$PHHY2018CH039854$NOVARTIS$$$$A$F$Y$$$20221020$$CN$CH$CH
177411777$17741177$7$F$20210630$20221116$20200504$20221117$PER$$NVSC2020US117379$NOVARTIS$$36$YR$$F$Y$110$KG$20221117$$CN$US$US
1774164111$17741641$11$F$20220101$20221109$20200504$20221114$EXP$$US-SHIRE-US202015177$TAKEDA$$49$YR$$F$Y$91$KG$20221114$$HP$US$US
177416493$17741649$3$F$20200420$20221026$20200504$20221101$EXP$$US-SHIRE-US202015224$TAKEDA$$38$YR$$M$Y$$$20221101$$MD$US$US
177417882$17741788$2$F$20171016$20221018$20200504$20221021$EXP$FR-AFSSAPS-NT20200427$FR-PFIZER INC-2020171250$PFIZER$$32$YR$$M$Y$$$20221021$$MD$FR$FR
1774198914$17741989$14$F$20200424$20221006$20200504$20221012$EXP$$US-SHIRE-US202015262$TAKEDA$$58$YR$$F$Y$49$KG$20221012$$HP$US$US
177420643$17742064$3$F$20190101$20210329$20200504$20221102$EXP$$NVSC2020DE119531$NOVARTIS$$$$A$M$Y$67$KG$20221102$$CN$DE$DE
1774206917$17742069$17$F$20200101$20221108$20200504$20221114$EXP$$US-DSJP-DSU-2020-112655$DAIICHI$$$$$F$Y$$$20221114$$MD$US$US
177420753$17742075$3$F$$20221006$20200504$20221014$EXP$$NL-MYLANLABS-2020M1043771$MYLAN$Workum JD, Janssen SHV, Touw HRW.. Considerations in Neuromuscular Blockade in the ICU: A Case Report and Review of the Literature.. Hindawi Case Reports in Critical Care.. 2020;8780979:1-4.$76$YR$$F$Y$$$20221014$$MD$NL$NL
177420925$17742092$5$F$$20221014$20200504$20221019$EXP$$NVSC2020CA118886$NOVARTIS$$51$YR$$M$Y$$$20221019$$HP$CA$CA
177424533$17742453$3$F$$20221031$20200504$20221108$EXP$$CA-PFIZER INC-2020174093$PFIZER$$32$YR$$F$Y$$$20221108$$HP$CA$CA
177424682$17742468$2$F$$20221128$20200505$20221213$EXP$$NL-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-245310$RANBAXY$Oude Munnink T, Van Der Meer A, De Haan J, Touw D, Van Kruchten M. Reversible Impaired Methotrexate Clearance after Platinum-Based Chemotherapy for Osteosarcoma. Ther Drug Monit. 2019;Dec;41(6):693-695$18$YR$$M$Y$$$20221213$$HP$NL$NL
177436717$17743671$7$F$20200423$20221206$20200505$20221215$EXP$$JP-ROCHE-2593531$ROCHE$$80$YR$$F$Y$$$20221215$$CN$JP$JP
177439102$17743910$2$F$$20221024$20200505$20221026$PER$$US-PFIZER INC-2020177839$PFIZER$$64$YR$$F$Y$$$20221026$$CN$US$US
1774417517$17744175$17$F$$20221003$20200504$20221012$EXP$$CA-JNJFOC-20200436815$JOHNSON AND JOHNSON$$58$YR$A$M$Y$$$20221010$$CN$CA$CA
1774447831$17744478$31$F$20210323$20221130$20200505$20221206$EXP$$US-SHIRE-US202015186$TAKEDA$$81$YR$$F$Y$64$KG$20221206$$HP$US$US
177448025$17744802$5$F$$20221101$20200505$20221104$PER$$US-PFIZER INC-2020177164$PFIZER$$71$YR$$F$Y$88$KG$20221104$$CN$US$US
177448374$17744837$4$F$20220101$20221123$20200505$20221124$EXP$$US-PFIZER INC-2020178272$PFIZER$$57$YR$$F$Y$$$20221124$$HP$US$US
177455458$17745545$8$F$20190401$20221018$20200505$20221024$EXP$$NVSC2020CO043962$NOVARTIS$$57$YR$$F$Y$48$KG$20221024$$CN$CO$CO
1774681810$17746818$10$F$20191201$20221220$20200505$20221222$EXP$$BE-ROCHE-2576038$ROCHE$$47$YR$$M$Y$96.6$KG$20221222$$MD$BE$
177470035$17747003$5$F$20200301$20221122$20200505$20221201$EXP$$GB-EUSA PHARMA (UK) LIMITED-2020GB000052$EUSA PHARMA$$$$$$Y$$$20221201$$PH$GB$GB
1774705113$17747051$13$F$20170904$20221116$20200505$20221120$EXP$$PHHY2017CA133035$NOVARTIS$$68$YR$$F$Y$$$20221121$$HP$CA$CA
177472536$17747253$6$F$$20221012$20200505$20221014$EXP$$US-PFIZER INC-2020179815$PFIZER$$89$YR$$F$Y$$$20221014$$CN$US$US
177475323$17747532$3$F$$20221130$20200505$20221130$EXP$$CA-BAUSCH-BL-2020-012898$BAUSCH AND LOMB$$73$YR$$F$Y$$$20221130$$CN$CA$CA
177476404$17747640$4$F$$20220722$20200505$20221130$EXP$$GB-JNJFOC-20200435585$JOHNSON AND JOHNSON$$$$$M$Y$$$20221130$$CN$GB$GB
177482418$17748241$8$F$$20221018$20200505$20221021$EXP$$CA-TAKEDA-2020TUS021156$TAKEDA$$33$YR$$F$Y$$$20221021$$MD$CA$CA
177483126$17748312$6$F$20050101$20221004$20200505$20221007$EXP$$US-GILEAD-2020-0464102$GILEAD$$$$E$F$Y$$$20221006$$LW$US$US
1774835017$17748350$17$F$20170101$20221103$20200506$20221110$EXP$$CA-ROCHE-2012928$ROCHE$$26$YR$$F$Y$$$20221110$$CN$CA$CA
177483832$17748383$2$F$$20221027$20200506$20221101$PER$$US-SHIRE-US202015488$TAKEDA$$$$$F$Y$$$20221101$$CN$US$US
177484227$17748422$7$F$20200328$20221201$20200505$20221209$EXP$$CA-TOLMAR, INC.-20CA020888$TOLMAR$$78$YR$$M$Y$$$20221209$$CN$CA$CA
177484334$17748433$4$F$20150101$20221111$20200506$20221117$EXP$$DE-BIOGEN-2020BI00869290$BIOGEN$$$$$F$Y$$$20221117$$CN$DE$DE
177492577$17749257$7$F$20181023$20221111$20200506$20221121$EXP$$CY-ROCHE-2282547$ROCHE$$81$YR$$F$Y$47$KG$20221121$$MD$CY$CY
177494772$17749477$2$F$$20221201$20200505$20221216$EXP$$IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-245554$RANBAXY$Bhanuda S, Ravanagomagan, Jagadeeswari, Sundari S. Acute phenytoin intoxication in a 4-year old mimicking viral Meningo-encephalitis. Indian J Public Health Res Dev. 2019;Nov; 10(11):3979-3981$4$YR$$F$Y$$$20221216$$MD$IN$IN
177496433$17749643$3$F$$20221106$20200506$20221111$PER$$DK-AMGEN-DNKSP2020069748$AMGEN$Vestergaard P.; Leere J. S.; Majgaard J. et al.. Withdrawal of Denosumab in Patients with Primary Hyperparathyroidism: A Follow-up Report of the DENOCINA- Study. Endocrine Practice. 2022$$$$$Y$$$20221111$$HP$DK$DK
177498914$17749891$4$F$20200420$20220912$20200506$20221221$PER$$NVSC2020US122918$NOVARTIS$$47$YR$$F$Y$$$20221221$$CN$US$US
177502392$17750239$2$F$$20221206$20200506$20221209$PER$$US-PFIZER INC-2017273854$PFIZER$$80$YR$$F$Y$$$20221209$$CN$US$US
177502425$17750242$5$F$$20221219$20200506$20221222$PER$$US-PFIZER INC-2020180874$PFIZER$$72$YR$$F$Y$$$20221222$$CN$US$US
1775027010$17750270$10$F$20100101$20221019$20200506$20221024$EXP$$US-PFIZER INC-2019281552$PFIZER$$50$YR$$F$Y$$$20221024$$CN$US$US
177504775$17750477$5$F$$20221025$20200506$20221107$PER$$AU-TOLMAR, INC.-2019AU004115$TOLMAR$$$$$M$Y$$$20221107$$HP$AU$AU
177504894$17750489$4$F$20150101$20221111$20200506$20221115$EXP$$US-GILEAD-2020-0463835$GILEAD$$$$A$M$Y$$$20221115$$LW$US$US
1775125435$17751254$35$F$20190101$20221222$20200506$20221226$EXP$$CA-ROCHE-2256002$ROCHE$$$$$F$Y$71$KG$20221226$$CN$CA$
177516154$17751615$4$F$$20221004$20200506$20221011$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-15098$SAMSUNG BIOEPIS$$40$YR$A$M$Y$77$KG$20221011$$HP$CA$CA
177516422$17751642$2$F$20200101$20221221$20200506$20221227$EXP$$US-PFIZER INC-2020179576$PFIZER$$56$YR$$F$Y$$$20221227$$HP$US$US
177517237$17751723$7$F$$20221114$20200506$20221116$EXP$$NVSC2020FR122259$NOVARTIS$Laloui K, Tafat A, Razafimbelo H, Goby-Ribemont AC, Rabus MT, Rwabihama JP. A case report of microscopic colitis under lansoprazole. SOINS GERONTOLOGIE. 2020;25(141):47-8$86$YR$$F$Y$43.8$KG$20221116$$HP$FR$FR
177519732$17751973$2$F$20191015$20221017$20200506$20221019$EXP$$NVSC2020FR121441$NOVARTIS$$73$YR$$F$Y$55$KG$20221019$$MD$FR$FR
177523373$17752337$3$F$20200101$20200602$20200506$20221227$PER$$US-AMGEN-USASP2020071283$AMGEN$$70$YR$E$F$Y$$$20221227$$CN$US$US
177526532$17752653$2$F$20190921$20221213$20200506$20221215$EXP$$US-ROCHE-2423202$ROCHE$$$$$F$Y$$$20221215$$CN$US$
177526893$17752689$3$F$20150101$20221205$20200506$20221213$EXP$$US-AstraZeneca-2020SE58593$ASTRAZENECA$$79$YR$$F$Y$$$20221213$$LW$US$
177529562$17752956$2$F$20190601$20221202$20200506$20221209$EXP$$DE-MYLANLABS-2020M1045167$MYLAN$$44$YR$$F$Y$68$KG$20221209$$MD$DE$DE
177532188$17753218$8$F$20190509$20221116$20200506$20221119$EXP$$PHHY2019CA009798$NOVARTIS$$65$YR$$F$Y$$$20221119$$MD$CA$CA
177544092$17754409$2$F$$20221031$20200506$20221110$EXP$$CA-PFIZER INC-2020175762$MYLAN$$59$YR$$F$Y$$$20221110$$HP$CA$CA
177544464$17754446$4$F$20200401$20221208$20200507$20221221$PER$$US-ELI_LILLY_AND_COMPANY-US202004007487$ELI LILLY AND CO$$48$YR$$F$Y$$$20221221$$CN$US$US
177546804$17754680$4$F$$20221222$20200506$20221228$PER$$US-AMGEN-USASP2020073544$AMGEN$$59$YR$A$F$Y$$$20221227$$HP$US$US
1775475327$17754753$27$F$20191001$20221128$20200507$20221207$EXP$$CA-CELLTRION INC.-2019CA025271$CELLTRION$$$$$$Y$$$20221207$$HP$CA$CA
1775492612$17754926$12$F$20200301$20221213$20200507$20221221$EXP$$CA-CELLTRION INC.-2020CA022108$CELLTRION$$$$$$Y$$$20221221$$CN$CA$CA
177553818$17755381$8$F$20200413$20221215$20200507$20221223$EXP$$AR-ASTELLAS-2020US013793$ASTELLAS$$64$YR$$M$Y$$$20221223$$CN$US$AR
177562829$17756282$9$F$20220609$20221006$20200507$20221011$EXP$$US-SHIRE-US202015556$TAKEDA$$69$YR$$F$Y$$$20221011$$MD$US$US
177566522$17756652$2$F$$20221010$20200507$20221017$EXP$DE-ADRED-04335-01$NVSC2020DE123110$NOVARTIS$$71$YR$$F$Y$$$20221017$$MD$DE$DE
177567015$17756701$5$F$$20221117$20200507$20221125$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-15192$SAMSUNG BIOEPIS$$64$YR$A$M$Y$$$20221125$$HP$CA$CA
1775698720$17756987$20$F$20211028$20221208$20200507$20221215$EXP$$US-SHIRE-US202015227$TAKEDA$$73$YR$$F$Y$63$KG$20221215$$MD$US$US
177569985$17756998$5$F$$20220718$20200507$20221201$EXP$$CA-BAUSCH-BL-2020-013031$BAUSCH AND LOMB$$58$YR$$M$Y$$$20221201$$HP$CA$CA
177570047$17757004$7$F$20200504$20221202$20200507$20221209$EXP$$US-SHIRE-US202015434$TAKEDA$$19$YR$$M$Y$$$20221209$$CN$US$US
177571115$17757111$5$F$20200401$20221025$20200507$20221029$PER$$NVSC2020US122672$NOVARTIS$$50$YR$$M$Y$$$20221029$$HP$US$US
177571392$17757139$2$F$20190601$20221119$20200507$20221202$EXP$DE-BFARM-20004670$DE-Accord-180986$ACCORD$$44$YR$A$F$Y$68$KG$20221202$$MD$DE$DE
177572914$17757291$4$F$20170101$20221026$20200507$20221028$EXP$$US-GILEAD-2020-0463708$GILEAD$$44$YR$A$M$Y$$$20221028$$LW$US$US
177576669$17757666$9$F$$20221114$20200507$20221117$EXP$$US-SHIRE-US202015570$TAKEDA$$$$$F$Y$81.633$KG$20221117$$HP$US$US
1775777619$17757776$19$F$20200428$20221117$20200507$20221125$EXP$$NVSC2020CA122648$NOVARTIS$$33$YR$$F$Y$116.1$KG$20221125$$MD$CA$CA
177579922$17757992$2$F$20191020$20221010$20200507$20221017$EXP$$NVSC2020DE123117$NOVARTIS$$70$YR$$F$Y$$$20221017$$MD$DE$DE
177581485$17758148$5$F$$20221111$20200507$20221117$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-15103$SAMSUNG BIOEPIS$$31$YR$A$M$Y$124$KG$20221117$$HP$CA$CA
1775829614$17758296$14$F$20170116$20221101$20200507$20221107$EXP$$PHHY2017CA007047$NOVARTIS$$63$YR$$F$Y$$$20221107$$CN$CA$CA
177585694$17758569$4$F$20130123$20221003$20200508$20221011$EXP$$US-AstraZeneca-2020SE58422$ASTRAZENECA$$25520$DY$$M$Y$63.5$KG$20221011$$LW$US$
177588184$17758818$4$F$$20221202$20200508$20221211$PER$$US-JNJFOC-20200429519$JOHNSON AND JOHNSON$$86$YR$E$M$Y$79.904$KG$20221212$$CN$US$GB
177588535$17758853$5$F$20200319$20221128$20200508$20221207$EXP$$CA-ROCHE-2595577$ROCHE$$29$YR$$F$Y$$$20221207$$CN$CA$CA
177594393$17759439$3$F$$20221108$20200508$20221122$EXP$$DE-AUROBINDO-AUR-APL-2020-022354$AUROBINDO$$$$$M$Y$$$20221122$$CN$DE$DE
1775947612$17759476$12$F$20200615$20221004$20200508$20221013$EXP$$CA-ROCHE-2593756$ROCHE$$68$YR$$F$Y$$$20221012$$CN$CA$
1775949916$17759499$16$F$20200312$20221221$20200508$20221230$EXP$$CA-CELLTRION INC.-2020CA020779$CELLTRION$$$$$$Y$$$20221230$$HP$CA$CA
177595353$17759535$3$F$20190101$20221219$20200508$20221226$EXP$$PHHY2019CA123757$NOVARTIS$$53$YR$$F$Y$$$20221226$$CN$CA$CA
177595474$17759547$4$F$20200211$20221005$20200508$20221011$EXP$$NVSC2020CA043965$NOVARTIS$$67$YR$$F$Y$$$20221011$$CN$CA$CA
177596099$17759609$9$F$$20221108$20200508$20221114$EXP$ES-AEMPS-626506$ES-009507513-2005ESP001225$MERCK$Lambea-Gil A, Sancho-Saldana A, Caldu-Agud R, Garcia-Rubio S. Posterior reversible encephalopathy associated with pembrolizumab. neurologia. 2020;36(7):548-50$56$YR$$F$Y$$$20221114$$HP$ES$ES
177597574$17759757$4$F$$20220907$20200508$20221124$EXP$$AU-PFIZER INC-2020183264$PFIZER$Brown, J.. Morbidity and mortality review of methotrexate: The many lessons learnt. Clinical Toxicology. 2019;57 (12):1209$77$YR$$M$Y$$$20221124$$HP$AU$AU
1776004715$17760047$15$F$20210202$20221212$20200508$20221219$EXP$$US-SHIRE-US202015692$TAKEDA$$70$YR$$M$Y$103$KG$20221219$$CN$US$US
177601073$17760107$3$F$$20221019$20200508$20221022$EXP$$US-SHIRE-US202015750$TAKEDA$$$$$F$Y$58.95$KG$20221022$$HP$US$US
177603648$17760364$8$F$20200130$20221215$20200508$20221222$EXP$$US-VERTEX PHARMACEUTICALS-2020-001124$VERTEX$$74$YR$$F$Y$$$20221222$$MD$US$US
1776066818$17760668$18$F$$20220927$20200508$20221004$EXP$$US-BIOVITRUM-2020US2124$BIOVITRUM$$$$$M$Y$$$20221004$$CN$US$US
177609635$17760963$5$F$20200101$20221114$20200508$20221117$PER$$US-PFIZER INC-2020170475$PFIZER$$88$YR$$F$Y$55.79$KG$20221117$$MD$US$US
177609655$17760965$5$F$20200101$20221018$20200508$20221020$EXP$$US-PFIZER INC-2020183025$PFIZER$$65$YR$$F$Y$79.32$KG$20221020$$CN$US$US
177609824$17760982$4$F$$20221108$20200508$20221110$PER$$US-PFIZER INC-2020184855$PFIZER$$65$YR$$M$Y$$$20221110$$CN$US$US
1776136018$17761360$18$F$20150311$20221019$20200508$20221021$EXP$$PHHY2014CA125377$NOVARTIS$$51$YR$$F$Y$$$20221021$$MD$CA$CA
177613625$17761362$5$F$20090101$20221026$20200508$20221028$EXP$$US-GILEAD-2020-0465067$GILEAD$$$$A$M$Y$$$20221028$$LW$US$US
177615957$17761595$7$F$20190829$20221013$20200508$20221019$EXP$$DE-PFIZER INC-2020182148$PFIZER$$$$E$F$Y$52$KG$20221019$$MD$DE$DE
1776178413$17761784$13$F$20160801$20221114$20200508$20221117$EXP$$PHHY2016CA123269$NOVARTIS$$50$YR$$M$Y$$$20221117$$CN$CA$CA
177620925$17762092$5$F$$20221110$20200508$20221116$EXP$$NVSC2020GR110694$NOVARTIS$$$$A$F$Y$60$KG$20221116$$MD$GR$GR
177621322$17762132$2$F$$20180515$20200508$20221101$EXP$$NVSC2018CO003718$NOVARTIS$$$$$F$Y$$$20221101$$CN$CO$CO
177628394$17762839$4$F$$20221221$20200509$20221227$EXP$$CA-TAKEDA-2020TUS021617$TAKEDA$$68$YR$$F$Y$$$20221227$$CN$CA$CA
177629132$17762913$2$F$$20221010$20200508$20221012$EXP$$NVSC2020DE123058$NOVARTIS$$89$YR$$F$Y$$$20221012$$PH$DE$DE
1776313110$17763131$10$F$20151218$20221221$20200508$20221229$EXP$$PHHY2015CA169370$NOVARTIS$$71$YR$$F$Y$$$20221229$$CN$CA$CA
177635563$17763556$3$F$20190816$20221013$20200509$20221022$EXP$$BE-TEVA-2020-BE-1231762$TEVA$$$$A$M$Y$96.7$KG$20221022$$MD$BE$BE
177636397$17763639$7$F$20190617$20220923$20200509$20221011$EXP$$FR-ABBVIE-20K-056-3253720-00$ABBVIE$$72$YR$$M$Y$71$KG$20221011$$MD$FR$FR
177638072$17763807$2$F$$20221208$20200510$20221227$PER$$US-ELI_LILLY_AND_COMPANY-US202005000972$ELI LILLY AND CO$$$$$F$Y$$$20221227$$CN$US$US
177639242$17763924$2$F$$20221219$20200510$20221220$EXP$$CA-ROCHE-2595043$ROCHE$$60$YR$$F$Y$81$KG$20221220$$HP$CA$
1776416430$17764164$30$F$20200303$20221018$20200511$20221027$EXP$$CA-CELLTRION INC.-2019CA027063$CELLTRION$$$$$$Y$$$20221027$$CN$CA$CA
1776421818$17764218$18$F$20200331$20221209$20200511$20221219$EXP$$CA-CELLTRION INC.-2020CA019808$CELLTRION$$$$$$Y$$$20221219$$MD$CA$CA
177642607$17764260$7$F$20191216$20221206$20200511$20221209$EXP$$US-ROCHE-2594767$ROCHE$$84$YR$$M$Y$78$KG$20221209$$MD$US$
177644155$17764415$5$F$20200320$20221128$20200511$20221208$PER$$US-LUPIN PHARMACEUTICALS INC.-2020-01989$LUPIN$$$$$$Y$$$20221208$$CN$US$US
177644788$17764478$8$F$20200401$20221215$20200511$20221223$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-001450$ACADIA PHARMACEUTICALS$$80$YR$$M$Y$61$KG$20221223$$CN$US$US
177646727$17764672$7$F$$20221216$20200511$20221222$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-15238$SAMSUNG BIOEPIS$$65$YR$E$F$Y$103$KG$20221222$$MD$CA$CA
177647227$17764722$7$F$20200101$20221123$20200511$20221124$EXP$$US-BIOGEN-2020BI00871344$BIOGEN$$58$YR$$F$Y$$$20221124$$CN$US$US
177648442$17764844$2$F$$20221129$20200511$20221206$EXP$$DE-drreddys-GER/GER/20/0122593$DR REDDYS$$$$$M$Y$$$20221207$$CN$DE$DE
1776488626$17764886$26$F$20170323$20221214$20200511$20221221$EXP$$PHHY2016CA037687$NOVARTIS$$51$YR$$F$Y$$$20221221$$CN$CA$CA
177651124$17765112$4$F$20200101$20221006$20200511$20221011$EXP$$NVSC2020CA126067$NOVARTIS$$$$$M$Y$$$20221011$$CN$CA$CA
177652192$17765219$2$F$20200211$20221012$20200511$20221019$EXP$DE-ADRED-04794-01$DE-TORRENT-00017533$TORRENT$$20$YR$A$F$Y$$$20221019$$MD$DE$DE
177652652$17765265$2$F$20191201$20221011$20200511$20221013$PER$$US-PFIZER INC-2020186197$PFIZER$$67$YR$$F$Y$72.57$KG$20221013$$CN$US$US
177653074$17765307$4$F$20220118$20221209$20200511$20221215$PER$$US-PFIZER INC-2020186370$PFIZER$$54$YR$$F$Y$$$20221215$$HP$US$US
177653269$17765326$9$F$$20220930$20200511$20221004$EXP$$US-PFIZER INC-2020187358$PFIZER$$79$YR$$F$Y$$$20221004$$CN$US$US
177653802$17765380$2$F$$20221104$20200511$20221108$PER$$US-PFIZER INC-2020187214$PFIZER$$34$YR$$F$Y$$$20221108$$MD$US$US
177657792$17765779$2$F$$20221010$20200511$20221017$EXP$$NVSC2020DE121295$NOVARTIS$$81$YR$$M$Y$$$20221017$$MD$DE$DE
1776615025$17766150$25$F$$20221207$20200511$20221216$EXP$$US-SHIRE-US202015863$TAKEDA$$$$$F$Y$75$KG$20221216$$HP$US$US
177662548$17766254$8$F$$20221011$20200511$20221018$EXP$$ALC2020CA003398$ALCON$$89$YR$$F$Y$$$20221018$$HP$CA$CA
177663953$17766395$3$F$$20221005$20200511$20221010$PER$$US-PFIZER INC-2020187279$PFIZER$$55$YR$$F$Y$$$20221010$$HP$US$US
177664356$17766435$6$F$20200312$20221007$20200511$20221011$EXP$$NVSC2020AU125748$NOVARTIS$$45$YR$$F$Y$53.3$KG$20221011$$MD$AU$AU
177667629$17766762$9$F$$20221109$20200511$20221114$EXP$$US-SHIRE-US202015540$TAKEDA$$$$$F$Y$100$KG$20221114$$CN$US$US
1776678919$17766789$19$F$20210107$20221216$20200511$20221223$EXP$$US-SHIRE-US202015722$TAKEDA$$58$YR$$F$Y$47$KG$20221223$$MD$US$US
177667919$17766791$9$F$20200301$20221021$20200511$20221025$EXP$$US-SHIRE-US202015698$TAKEDA$$53$YR$$M$Y$$$20221025$$CN$US$US
177669896$17766989$6$F$$20221108$20200511$20221116$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-15255$SAMSUNG BIOEPIS$$20$YR$A$F$Y$62$KG$20221116$$MD$CA$CA
1776714613$17767146$13$F$20220110$20221208$20200511$20221214$EXP$$US-SHIRE-US202015827$TAKEDA$$17$YR$$M$Y$88$KG$20221214$$HP$US$US
177672505$17767250$5$F$20200201$20221010$20200511$20221024$EXP$$BR-ELI_LILLY_AND_COMPANY-BR202003003947$ELI LILLY AND CO$$32$YR$$M$Y$$$20221024$$CN$DE$BR
177675857$17767585$7$F$20200224$20221213$20200511$20221220$EXP$$US-BAYER-2020-040634$BAYER$$28$YR$A$F$Y$71.7$KG$20221220$$MD$US$US
1776767611$17767676$11$F$20190607$20221005$20200511$20221010$EXP$$CA-TAKEDA-2019TUS073516$TAKEDA$$82$YR$$M$Y$$$20221010$$CN$CA$CA
177676826$17767682$6$F$20171222$20221103$20200511$20221110$EXP$$NVSC2020CA123554$NOVARTIS$$48$YR$$F$Y$$$20221110$$MD$CA$CA
177680604$17768060$4$F$20200101$20221027$20200511$20221102$EXP$$CA-TAKEDA-2019TUS059089$TAKEDA$$64$YR$$M$Y$$$20221102$$MD$CA$CA
1776830319$17768303$19$F$20221025$20221206$20200511$20221214$EXP$$US-SHIRE-US202015919$TAKEDA$$38$YR$$M$Y$66$KG$20221214$$CN$US$US
177684072$17768407$2$F$$20220926$20200512$20221010$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-246031$RANBAXY$Oguni H, Hirano Y, Nagata S. Encephalopathy related to status epilepticus during slow sleep (ESES) as atypical evolution of Panayiotopoulos syndrome: an EEG and neuropsychological study. Epileptic Disord. 2020;Feb; 22(1):67-72$$$T$M$Y$$$20221010$$HP$JP$JP
177684092$17768409$2$F$$20220926$20200512$20221010$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-246030$RANBAXY$Oguni H, Hirano Y, Nagata S. Encephalopathy related to status epilepticus during slow sleep (ESES) as atypical evolution of Panayiotopoulos syndrome: an EEG and neuropsychological study. Epileptic Disord. 2020;Feb; 22(1):67-72$$$T$F$Y$$$20221010$$HP$JP$JP
177687065$17768706$5$F$20200202$20221206$20200512$20221212$EXP$$US-ROCHE-2550922$ROCHE$$51$YR$$F$Y$78.5$KG$20221212$$MD$US$
177688904$17768890$4$F$20200421$20221215$20200512$20221219$EXP$$BR-SA-2020SA105686$SANOFI AVENTIS$$$$A$F$Y$82$KG$20221219$$CN$BR$BR
177689949$17768994$9$F$20200101$20221018$20200512$20221020$EXP$$US-PFIZER INC-2020188417$PFIZER$$61$YR$$F$Y$$$20221020$$CN$US$US
1776952911$17769529$11$F$20200408$20220930$20200512$20221006$EXP$$NVSC2020CA121877$NOVARTIS$$18$YR$$F$Y$71.6$KG$20221006$$MD$CA$CA
1776955010$17769550$10$F$$20221202$20200512$20221209$EXP$$US-SHIRE-US202015958$TAKEDA$$$$$F$Y$73$KG$20221209$$HP$US$US
177697242$17769724$2$F$$20221102$20200512$20221104$PER$$US-PFIZER INC-2020188893$PFIZER$$72$YR$$F$Y$$$20221104$$CN$US$US
177703156$17770315$6$F$20180801$20220214$20200512$20221227$EXP$$US-GILEAD-2020-0466061$GILEAD$$58$YR$A$F$Y$$$20221227$$LW$US$US
177703272$17770327$2$F$$20221119$20200512$20221202$EXP$DE-BFARM-20004763$DE-Accord-181320$ACCORD$$89$YR$E$F$Y$53$KG$20221202$$MD$DE$DE
1777038813$17770388$13$F$$20221121$20200512$20221130$EXP$$US-SHIRE-US202015448$TAKEDA$$$$$F$Y$$$20221130$$CN$US$US
177704044$17770404$4$F$20150201$20221115$20200512$20221227$EXP$$US-GILEAD-2020-0465692$GILEAD$$38$YR$A$M$Y$$$20221227$$LW$US$US
177709302$17770930$2$F$$20191016$20200512$20221102$EXP$$NVSC2019CO090991$NOVARTIS$$$$$F$Y$$$20221102$$CN$CO$CO
177710362$17771036$2$F$$20221108$20200512$20221111$EXP$$DE-MYLANLABS-2020M1045643$MYLAN$Alter M, Satzger I, Schrem H, Kaltenborn A, Kapp A, Gutzmer R.. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients. J-Dtsch-Dermatol-Ges. 2014;12(6):480-488$$$A$$Y$$$20221111$$MD$DE$DE
177710552$17771055$2$F$$20221010$20200512$20221017$EXP$$NVSC2020DE123187$NOVARTIS$$80$YR$$M$Y$70$KG$20221017$$PH$DE$DE
1777138713$17771387$13$F$20220524$20221124$20200512$20221130$EXP$$CA-TAKEDA-2020TUS021885$TAKEDA$$46$YR$$M$Y$$$20221130$$HP$CA$CA
1777160110$17771601$10$F$20200428$20221114$20200512$20221121$EXP$$DE-EXELIXIS-XL18420029761$EXELIXIS$$$$$$Y$$$20221121$$MD$DE$DE
177717686$17771768$6$F$20200502$20221222$20200512$20221227$EXP$$US-PFIZER INC-2020188776$PFIZER$$86$YR$$F$Y$68.95$KG$20221227$$CN$US$US
177719313$17771931$3$F$20220101$20221109$20200512$20221118$EXP$$BR-JNJFOC-20200505551$JOHNSON AND JOHNSON$$$$$M$Y$67$KG$20221118$$CN$BR$BR
177719566$17771956$6$F$20150601$20221101$20200512$20221107$EXP$$US-GILEAD-2020-0465914$GILEAD$$60$YR$A$M$Y$$$20221107$$LW$US$US
1777236930$17772369$30$F$20181002$20221122$20200512$20221129$EXP$$PHHY2018CA119921$NOVARTIS$$73$YR$$F$Y$$$20221129$$PH$CA$CA
177724248$17772424$8$F$20200323$20221214$20200512$20221227$EXP$$IN-INCYTE CORPORATION-2020IN004254$INCYTE$$$$$$Y$$$20221227$$CN$IN$IN
177724335$17772433$5$F$20150101$20221024$20200512$20221027$EXP$$US-GILEAD-2020-0466272$GILEAD$$52$YR$A$M$Y$$$20221026$$LW$US$US
177726365$17772636$5$F$20110407$20221005$20200512$20221012$EXP$$US-GILEAD-2020-0466102$GILEAD$$40$YR$A$F$Y$$$20221011$$LW$US$US
1777283823$17772838$23$F$$20221216$20200512$20221219$EXP$$NVSC2020CO128552$NOVARTIS$$$$$M$Y$70$KG$20221219$$CN$CO$CO
1777290319$17772903$19$F$20190301$20221012$20200512$20221017$EXP$$PHHY2019CA060714$NOVARTIS$$72$YR$$F$Y$$$20221017$$CN$CA$CA
177729404$17772940$4$F$20170101$20221017$20200512$20221021$EXP$$US-GILEAD-2020-0466349$GILEAD$$$$A$F$Y$$$20221020$$LW$US$US
177729615$17772961$5$F$20151201$20221010$20200512$20221012$EXP$$US-GILEAD-2020-0466387$GILEAD$$59$YR$A$M$Y$$$20221011$$LW$US$US
177729783$17772978$3$F$20190501$20221101$20200512$20221107$EXP$$US-GILEAD-2020-0466071$GILEAD$$46$YR$A$F$Y$$$20221107$$LW$US$US
177731136$17773113$6$F$20100101$20221007$20200512$20221010$EXP$$US-GILEAD-2020-0465763$GILEAD$$58$YR$A$M$Y$$$20221010$$LW$US$US
177731952$17773195$2$F$20200508$20220919$20200512$20221003$EXP$$US-ELI_LILLY_AND_COMPANY-US202005003393$ELI LILLY AND CO$$77$YR$$M$Y$$$20221003$$HP$US$US
177735852$17773585$2$F$$20221011$20200512$20221013$EXP$$GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-037359$BRISTOL MYERS SQUIBB$$80$YR$E$F$Y$$$20221013$$CN$GB$GB
177741932$17774193$2$F$$20221209$20200513$20221223$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-246145$RANBAXY$Dasgupta K, Nielson S. Coma and Respiratory Failure in a 2-Year-Old Child After Accidental Overdose of Baclofen. S D Med. 2020;73(3):106-110$24$MON$$F$Y$11.9$KG$20221223$$MD$US$US
177745605$17774560$5$F$20191101$20221118$20200513$20221213$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-015069$ACADIA PHARMACEUTICALS$$69$YR$$M$Y$$$20221213$$CN$US$US
177745732$17774573$2$F$20221117$20221129$20200513$20221208$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-015075$ACADIA PHARMACEUTICALS$$70$YR$$M$Y$$$20221209$$CN$US$US
177745912$17774591$2$F$20221024$20221102$20200513$20221111$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-015098$ACADIA PHARMACEUTICALS$$92$YR$$M$Y$$$20221111$$CN$US$US
177746017$17774601$7$F$20191102$20221219$20200513$20221228$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-015106$ACADIA PHARMACEUTICALS$$73$YR$$F$Y$$$20221229$$CN$US$US
1777464810$17774648$10$F$20201118$20220917$20200513$20221011$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-015221$ACADIA PHARMACEUTICALS$$84$YR$$F$Y$$$20221012$$CN$US$US
177747814$17774781$4$F$20191201$20221109$20200513$20221117$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000135$ACADIA PHARMACEUTICALS$$68$YR$$M$Y$$$20221118$$CN$US$US
177747843$17774784$3$F$$20221128$20200513$20221222$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000088$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221223$$MD$US$US
177748656$17774865$6$F$20211111$20221118$20200513$20221213$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000200$ACADIA PHARMACEUTICALS$$86$YR$$F$Y$$$20221213$$CN$US$US
177749636$17774963$6$F$20211123$20221003$20200513$20221011$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000300$ACADIA PHARMACEUTICALS$$70$YR$$M$Y$$$20221012$$CN$US$US
177750542$17775054$2$F$$20221207$20200513$20221229$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000365$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221230$$CN$US$US
177750706$17775070$6$F$20200101$20220915$20200513$20221010$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000389$ACADIA PHARMACEUTICALS$$82$YR$$M$Y$72$KG$20221010$$CN$US$US
177752872$17775287$2$F$20200201$20221031$20200513$20221124$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000639$ACADIA PHARMACEUTICALS$$75$YR$$M$Y$109$KG$20221125$$CN$US$US
177753085$17775308$5$F$20221003$20221003$20200513$20221011$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000655$ACADIA PHARMACEUTICALS$$69$YR$$M$Y$$$20221012$$CN$US$US
177753245$17775324$5$F$20201230$20221221$20200513$20221229$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000707$ACADIA PHARMACEUTICALS$$81$YR$$F$Y$$$20221230$$CN$US$US
177754403$17775440$3$F$20190901$20221029$20200513$20221107$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000872$ACADIA PHARMACEUTICALS$$75$YR$$F$Y$$$20221107$$CN$US$US
177755044$17775504$4$F$20170101$20221026$20200513$20221028$EXP$$US-GILEAD-2020-0466678$GILEAD$$32$YR$A$M$Y$$$20221028$$LW$US$US
177755077$17775507$7$F$20191101$20221107$20200513$20221117$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000922$ACADIA PHARMACEUTICALS$$57$YR$$M$Y$$$20221117$$CN$US$US
177755217$17775521$7$F$20200201$20220926$20200513$20221020$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000934$ACADIA PHARMACEUTICALS$$70$YR$$F$Y$$$20221021$$CN$US$US
177755388$17775538$8$F$20200301$20221203$20200513$20221227$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000974$ACADIA PHARMACEUTICALS$$75$YR$$M$Y$$$20221228$$CN$US$US
1777555910$17775559$10$F$20200101$20221128$20200513$20221222$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-001005$ACADIA PHARMACEUTICALS$$67$YR$$M$Y$$$20221223$$CN$US$US
177755904$17775590$4$F$20200101$20221212$20200513$20221222$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-001046$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221222$$CN$US$US
177755972$17775597$2$F$$20221026$20200513$20221117$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-001018$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221118$$CN$US$US
177757522$17775752$2$F$$20221205$20200513$20221229$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-001283$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221230$$CN$US$US
177757726$17775772$6$F$$20221202$20200513$20221206$EXP$$CA-ROCHE-2593600$ROCHE$$49$YR$$F$Y$73$KG$20221206$$HP$CA$
177758568$17775856$8$F$20190101$20221111$20200513$20221121$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-012792$ACADIA PHARMACEUTICALS$$$$$F$Y$54$KG$20221121$$CN$US$US
177758903$17775890$3$F$$20221115$20200513$20221209$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-012966$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221209$$CN$US$US
177761105$17776110$5$F$20200101$20221017$20200513$20221020$PER$$US-PFIZER INC-2020189008$PFIZER$$65$YR$$F$Y$89$KG$20221020$$CN$US$US
177761474$17776147$4$F$$20221116$20200513$20221121$PER$$US-PFIZER INC-2020190766$PFIZER$$56$YR$$F$Y$$$20221121$$CN$US$US
177763683$17776368$3$F$$20221018$20200513$20221021$EXP$$US-GILEAD-2020-0466582$GILEAD$$48$YR$A$F$Y$$$20221021$$LW$US$US
177765093$17776509$3$F$20220505$20221103$20200513$20221128$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-013646$ACADIA PHARMACEUTICALS$$80$YR$$M$Y$$$20221128$$CN$US$US
177767062$17776706$2$F$20190801$20221108$20200513$20221117$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-013941$ACADIA PHARMACEUTICALS$$62$YR$$M$Y$$$20221118$$CN$US$US
177767584$17776758$4$F$20221010$20221123$20200513$20221202$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-013985$ACADIA PHARMACEUTICALS$$71$YR$$M$Y$$$20221202$$CN$US$US
177767922$17776792$2$F$$20221013$20200513$20221019$EXP$$NVSC2020US128820$NOVARTIS$$$$$M$Y$$$20221019$$CN$US$US
177768693$17776869$3$F$20190101$20221006$20200513$20221031$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-013750$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221031$$CN$US$US
177768712$17776871$2$F$$20221024$20200513$20221117$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014115$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221118$$CN$US$US
177769652$17776965$2$F$20221107$20221107$20200513$20221117$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014227$ACADIA PHARMACEUTICALS$$63$YR$$M$Y$$$20221117$$CN$US$US
177770653$17777065$3$F$$20221205$20200513$20221214$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014317$ACADIA PHARMACEUTICALS$$$$$M$Y$91$KG$20221215$$CN$US$US
177772057$17777205$7$F$20190701$20221107$20200513$20221117$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-013603$ACADIA PHARMACEUTICALS$$85$YR$$F$Y$$$20221117$$CN$US$US
1777736116$17777361$16$F$20190901$20221209$20200513$20221219$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014598$ACADIA PHARMACEUTICALS$$76$YR$$M$Y$$$20221219$$CN$US$US
177773634$17777363$4$F$20190923$20221012$20200513$20221103$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014204$ACADIA PHARMACEUTICALS$$85$YR$$M$Y$$$20221104$$CN$US$US
177773893$17777389$3$F$20191001$20221010$20200513$20221020$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014618$ACADIA PHARMACEUTICALS$$77$YR$$F$Y$$$20221020$$CN$US$US
177774164$17777416$4$F$20190201$20221011$20200513$20221014$EXP$$US-GILEAD-2020-0466543$GILEAD$$56$YR$A$M$Y$$$20221013$$LW$US$US
177774325$17777432$5$F$20190101$20221101$20200513$20221110$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014282$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221111$$CN$US$US
177775505$17777550$5$F$20190601$20221128$20200513$20221208$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-013351$ACADIA PHARMACEUTICALS$$73$YR$$F$Y$$$20221208$$CN$US$US
177775685$17777568$5$F$20191001$20221118$20200513$20221128$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014937$ACADIA PHARMACEUTICALS$$68$YR$$M$Y$$$20221128$$CN$US$US
177777152$17777715$2$F$20190101$20221003$20200513$20221027$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014831$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221028$$CN$US$US
177777522$17777752$2$F$20190801$20220912$20200513$20221006$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014715$ACADIA PHARMACEUTICALS$$80$YR$$M$Y$$$20221007$$CN$US$US
1777776521$17777765$21$F$20191101$20221129$20200513$20221208$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014867$ACADIA PHARMACEUTICALS$$81$YR$$M$Y$$$20221209$$CN$US$US
177777842$17777784$2$F$$20221017$20200513$20221027$EXP$$DE-MICRO LABS LIMITED-ML2020-01518$MICRO LABS$$71$YR$E$F$Y$69$KG$20221027$$PH$DE$DE
177777975$17777797$5$F$20190901$20221130$20200513$20221223$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014836$ACADIA PHARMACEUTICALS$$75$YR$$F$Y$$$20221223$$CN$US$US
177780423$17778042$3$F$$20221114$20200513$20221128$EXP$$US-PFIZER INC-2020183688$PFIZER$Hoogenboom, L.. Sequential transplantation and implications for clinical management: OLT followed by HCT and consequent RT in a pediatric patient.. Pediatric Transplantation. 2019;23(3):e13370$13$YR$$M$Y$$$20221128$$MD$US$US
177781757$17778175$7$F$$20221123$20200513$20221130$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-15763$SAMSUNG BIOEPIS$$74$YR$E$M$Y$100$KG$20221130$$MD$CA$CA
177781773$17778177$3$F$$20221122$20200513$20221128$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-15804$SAMSUNG BIOEPIS$$33$YR$A$M$Y$64$KG$20221128$$MD$CA$CA
1777840720$17778407$20$F$20200202$20221111$20200514$20221125$EXP$$DE-AUROBINDO-AUR-APL-2020-024386$AUROBINDO$$$$E$F$Y$64$KG$20221125$$MD$DE$DE
177790263$17779026$3$F$20200501$20221123$20200513$20221220$PER$$AU-TOLMAR, INC.-20AU021231$TOLMAR$$72$YR$$M$Y$$$20221220$$PH$AU$AU
177790862$17779086$2$F$$20221202$20200514$20221210$PER$$US-JNJFOC-20200419059$JOHNSON AND JOHNSON$$$$$F$Y$$$20221210$$CN$US$US
177791722$17779172$2$F$$20221010$20200513$20221017$EXP$$NVSC2020DE127973$NOVARTIS$$70$YR$$M$Y$72$KG$20221017$$PH$DE$DE
1777929612$17779296$12$F$20200508$20221128$20200513$20221201$EXP$$PL-EXELIXIS-XL18420029753$EXELIXIS$$60$YR$$F$Y$77$KG$20221201$$MD$PL$PL
177794527$17779452$7$F$20180301$20221026$20200514$20221102$EXP$$CA-ROCHE-2089229$ROCHE$$49$YR$$M$Y$$$20221102$$CN$CA$
177801633$17780163$3$F$$20221017$20200514$20221018$PER$$US-BIOGEN-2019BI00812748$BIOGEN$$$$$F$Y$$$20221018$$CN$US$US
1778046911$17780469$11$F$$20221205$20200514$20221212$EXP$$US-ROCHE-2600576$ROCHE$$$$A$M$Y$$$20221212$$CN$US$
177808043$17780804$3$F$20190101$20221221$20200513$20221229$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-013942$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221230$$CN$US$US
177809498$17780949$8$F$$20221212$20200514$20221214$EXP$$NVSC2020PT124292$NOVARTIS$Palhinha A, Lobato M, Romeira AM, Leiria-Pinto P. Anaphylaxis to beta-lactams - when tolerance does not exclude allergy. REVISTA PORTUGUESA DE IMUNOALERGOLOGIA. 2019;27(1):55$49$YR$$M$Y$$$20221214$$HP$PT$PT
177809713$17780971$3$F$20191001$20221110$20200513$20221117$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014584$ACADIA PHARMACEUTICALS$$64$YR$$M$Y$$$20221118$$CN$US$US
177809793$17780979$3$F$$20221212$20200514$20221217$EXP$$NVSC2020GB102723$NOVARTIS$$53$YR$$F$Y$$$20221217$$CN$GB$GB
177810988$17781098$8$F$20200504$20221024$20200514$20221027$EXP$$IL-ABBVIE-20K-082-3394394-00$ABBVIE$$72$YR$$M$Y$99$KG$20221027$$MD$IL$IL
177816203$17781620$3$F$$20221103$20200514$20221107$EXP$$US-PFIZER INC-2020191121$PFIZER$Pikman, Y.. Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. Blood Advances. 2020;4 (7):1265-1269$15$YR$$F$Y$$$20221107$$HP$US$US
177816746$17781674$6$F$20191101$20221004$20200513$20221027$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014951$ACADIA PHARMACEUTICALS$$77$YR$$F$Y$$$20221028$$CN$US$US
177818152$17781815$2$F$20190101$20220915$20200513$20221010$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-012929$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221010$$CN$US$US
177819404$17781940$4$F$20191227$20221202$20200513$20221212$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-013640$ACADIA PHARMACEUTICALS$$84$YR$$M$Y$$$20221212$$CN$US$US
177820853$17782085$3$F$20200301$20221027$20200513$20221104$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000418$ACADIA PHARMACEUTICALS$$78$YR$$M$Y$$$20221104$$HP$US$US
1778227311$17782273$11$F$20200301$20221205$20200513$20221229$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-000918$ACADIA PHARMACEUTICALS$$87$YR$$M$Y$57$KG$20221230$$CN$US$US
177823154$17782315$4$F$20200326$20221020$20200513$20221114$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-001061$ACADIA PHARMACEUTICALS$$68$YR$$M$Y$106$KG$20221114$$CN$US$US
177823882$17782388$2$F$20221115$20221118$20200513$20221213$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-001242$ACADIA PHARMACEUTICALS$$82$YR$$F$Y$$$20221213$$HP$US$US
1778263921$17782639$21$F$20201030$20221014$20200513$20221018$EXP$$US-SHIRE-US202016134$TAKEDA$$67$YR$$F$Y$55$KG$20221018$$HP$US$US
177830376$17783037$6$F$20200101$20221117$20200513$20221122$EXP$$BR-BIOMARINAP-BR-2020-130103$BIOMARIN$$$$$$Y$$$20221122$$CN$BR$BR
177835392$17783539$2$F$$20220928$20200514$20221005$EXP$$US-KYOWAKIRIN-2020BKK007562$KYOWA$$$$$$Y$$$20221005$$HP$US$US
177835697$17783569$7$F$20200501$20221205$20200514$20221209$EXP$$US-PFIZER INC-2020192004$PFIZER$$81$YR$$F$Y$78.02$KG$20221209$$CN$US$US
177837027$17783702$7$F$20170901$20221024$20200513$20221027$EXP$$CA-TAKEDA-2017TUS019738$TAKEDA$$78$YR$$F$Y$$$20221027$$MD$CA$CA
177838104$17783810$4$F$$20221011$20200514$20221019$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-15794$SAMSUNG BIOEPIS$$25$YR$A$F$Y$91$KG$20221019$$HP$CA$CA
1778533732$17785337$32$F$20180902$20221211$20200514$20221219$EXP$$IL-PFIZER INC-2018347010$PFIZER$$60$YR$$M$Y$$$20221219$$HP$IL$IL
177855724$17785572$4$F$20180101$20220324$20200513$20221130$EXP$$US-GILEAD-2020-0465829$GILEAD$$$$A$M$Y$$$20221130$$LW$US$US
177856916$17785691$6$F$20181201$20221223$20200513$20221229$EXP$$NVSC2020DE118596$NOVARTIS$$75$YR$$F$Y$71.7$KG$20221229$$CN$DE$DE
177856923$17785692$3$F$20190601$20221209$20200514$20221215$EXP$$AT-ELI_LILLY_AND_COMPANY-AT202005002618$ELI LILLY AND CO$$72$YR$$F$Y$$$20221215$$CN$AT$AT
177857629$17785762$9$F$20220721$20221122$20200514$20221128$EXP$$US-SHIRE-US202016257$TAKEDA$$18$YR$$M$Y$63.49$KG$20221128$$CN$US$US
1778596711$17785967$11$F$20200508$20221128$20200513$20221202$EXP$$PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-038089$BRISTOL MYERS SQUIBB$$60$YR$A$F$Y$77$KG$20221202$$HP$PL$PL
1778621622$17786216$22$F$20190301$20221208$20200513$20221229$EXP$$CA-CELLTRION INC.-2019CA019905$CELLTRION$$$$$$Y$$$20221229$$CN$CA$CA
177871014$17787101$4$F$$20221018$20200514$20221021$EXP$$US-SHIRE-US202015959$TAKEDA$$$$$F$Y$47.62$KG$20221021$$CN$US$US
177871172$17787117$2$F$20200508$20221213$20200514$20221216$EXP$$US-SHIRE-US202016100$TAKEDA$$15$YR$$M$Y$$$20221216$$CN$US$US
177871306$17787130$6$F$$20221019$20200514$20221028$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-15892$SAMSUNG BIOEPIS$$45$YR$A$M$Y$84$KG$20221028$$HP$CA$CA
177874296$17787429$6$F$$20221102$20200515$20221111$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-15806$SAMSUNG BIOEPIS$$61$YR$A$F$Y$54$KG$20221111$$HP$CA$CA
177875423$17787542$3$F$20130605$20221128$20200514$20221201$EXP$$US-GILEAD-2020-0466908$GILEAD$$45$YR$A$M$Y$$$20221130$$LW$US$US
177878758$17787875$8$F$20180424$20221103$20200514$20221110$EXP$$CA-ROCHE-2593854$ROCHE$$37$YR$$M$Y$$$20221110$$CN$CA$
1778801012$17788010$12$F$20190528$20221012$20200514$20221014$EXP$$CA-TAKEDA-2020TUS021977$TAKEDA$$51$YR$$M$Y$$$20221014$$CN$CA$CA
1778911719$17789117$19$F$20200428$20221121$20200515$20221129$EXP$$CA-CELLTRION INC.-2019CA028195$CELLTRION$$$$$$Y$$$20221129$$HP$CA$CA
177894212$17789421$2$F$$20221204$20200515$20221207$EXP$$CA-ROCHE-2596530$ROCHE$$$$A$F$Y$95$KG$20221207$$HP$CA$
177898882$17789888$2$F$20221030$20221121$20200515$20221125$PER$$US-SHIRE-US202016284$TAKEDA$$70$YR$$F$Y$110$KG$20221125$$HP$US$US
1779139611$17791396$11$F$20220422$20221021$20200515$20221031$EXP$$US-SHIRE-US202016386$TAKEDA$$60$YR$$F$Y$54$KG$20221031$$MD$US$US
177914604$17791460$4$F$$20220927$20200515$20221003$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-15800$SAMSUNG BIOEPIS$$18$YR$A$M$Y$44$KG$20221003$$HP$CA$CA
1779148812$17791488$12$F$20200401$20221116$20200515$20221121$EXP$$US-ROCHE-2598539$ROCHE$$82$YR$$F$Y$44.492$KG$20221121$$MD$US$
177916413$17791641$3$F$$20221228$20200515$20221230$EXP$$NVSC2020PT130926$NOVARTIS$Valido R, Frias P, Caldas F, Ferreira P. Severe catatonia following quetiapine abrupt withdrawal. EUROPEAN PSYCHIATRY. 2020;63:S663$66$YR$$F$Y$$$20221230$$HP$PT$PT
177917683$17791768$3$F$$20221017$20200515$20221025$EXP$$JP-AstraZeneca-2020SE63252$ASTRAZENECA$$76$YR$$F$Y$$$20221025$$MD$JP$
177920779$17792077$9$F$20191210$20221021$20200515$20221031$EXP$$DE-ROCHE-2530920$ROCHE$$34$YR$$F$Y$$$20221031$$CN$DE$
177921017$17792101$7$F$20200421$20221019$20200515$20221021$EXP$$NVSC2020FR121197$NOVARTIS$$46$YR$$F$Y$87$KG$20221021$$MD$FR$FR
177921205$17792120$5$F$20190501$20221021$20200515$20221225$EXP$$IT-JNJFOC-20200512501$JOHNSON AND JOHNSON$$65$YR$E$F$Y$$$20221226$$HP$IT$IT
177923212$17792321$2$F$$20221017$20200515$20221021$EXP$$CA-GLAXOSMITHKLINE-CA2018GSK133194$GLAXOSMITHKLINE$$$$$$Y$$$20221021$$MD$CA$CA
1779249411$17792494$11$F$$20221222$20200515$20221229$EXP$$US-SHIRE-US202016141$TAKEDA$$$$$M$Y$96.15$KG$20221229$$HP$US$US
177929637$17792963$7$F$20190615$20220930$20200515$20221005$EXP$$BE-TAKEDA-2020TUS011319$TAKEDA$$56$YR$$M$Y$$$20221005$$HP$BE$BE
177936814$17793681$4$F$20220628$20221212$20200515$20221217$EXP$$NVSC2020CA132782$NOVARTIS$$58$YR$$M$Y$$$20221217$$CN$CA$CA
177937794$17793779$4$F$20180101$20221024$20200515$20221101$EXP$$GB-BIOGEN-2020BI00873992$BIOGEN$$50$YR$$M$Y$$$20221101$$CN$GB$GB
177938364$17793836$4$F$20200301$20221121$20200515$20221125$EXP$$NVSC2020CA025294$NOVARTIS$$55$YR$$M$Y$$$20221125$$MD$CA$CA
177940082$17794008$2$F$$20221207$20200516$20221222$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247316$RANBAXY$Roy S, Mieczkowski PA, Weida C, Huo J, Roehrs P, Singh HK, et al. BK polyomavirus nephropathy with systemic viral spread: Whole genome sequencing data from a fatal case of BKPyV infection. Transpl Infect Dis. 2020;22(2):e13269(1-8)$23$YR$$F$Y$$$20221222$$HP$US$US
177948883$17794888$3$F$$20221216$20200516$20221230$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247044$RANBAXY$Powel JE , Rosenthal E , Roman A , Chasen ST , Berghella V. Preeclampsia and low sodium (PALS): A case and systematic review. Eur J Obstet Gynecol Reprod Biol.. 2020;249:14-20$$$N$$Y$1.943$KG$20221230$$HP$US$US
1779502510$17795025$10$F$20200108$20221221$20200516$20221228$EXP$$CA-ROCHE-2601863$ROCHE$$71$YR$$M$Y$$$20221228$$CN$CA$CA
177954215$17795421$5$F$$20221214$20200515$20221221$EXP$$US-INCYTE CORPORATION-2020IN003421$INCYTE$$$$$$Y$$$20221221$$CN$US$US
177957417$17795741$7$F$20180101$20221116$20200516$20221122$EXP$$PHHY2019CA025241$NOVARTIS$$$$$M$Y$74.5$KG$20221122$$CN$CA$CA
177958745$17795874$5$F$$20221020$20200516$20221028$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-11274$SAMSUNG BIOEPIS$$18$YR$A$M$Y$50$KG$20221028$$CN$CA$CA
177959877$17795987$7$F$20200319$20221005$20200516$20221006$PER$$NVSC2020US134456$NOVARTIS$$53$YR$$M$Y$$$20221006$$CN$US$US
1779622512$17796225$12$F$20181030$20221024$20200517$20221027$EXP$$PHHY2018CA083116$NOVARTIS$$39$YR$$F$Y$$$20221027$$CN$CA$CA
177962852$17796285$2$F$20181130$20221003$20200517$20221006$EXP$$NVSC2020DE133546$NOVARTIS$$85$YR$$M$Y$$$20221006$$MD$DE$DE
177963557$17796355$7$F$20200421$20221222$20200517$20221229$EXP$$US-Blueprint Medicines Corporation-SP-US-2020-000587$BLUEPRINT MEDICINES$$84$YR$E$F$Y$$$20221229$$CN$US$US
177965083$17796508$3$F$$20221216$20200518$20221230$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247039$RANBAXY$Powel JE , Rosenthal E , Roman A , Chasen ST , Berghella V. Preeclampsia and low sodium (PALS): A case and systematic review. Eur J Obstet Gynecol Reprod Biol. 2020;249:14-20$45$YR$$F$Y$$$20221230$$HP$US$US
177965092$17796509$2$F$$20221205$20200518$20221220$EXP$$IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-246335$RANBAXY$Bagal B, Kumar R, Gaur T, Talreja V, Bonda A, Patkar N, et al. Characterization of therapy related acute leukemia in hereditary breast-ovarian carcinoma patients role of BRCA1 mutation and topoisomerase II-directed therapy. Med Oncol. 2020;37(5):48$38$YR$$F$Y$$$20221220$$HP$IN$IN
177965102$17796510$2$F$$20221205$20200518$20221220$EXP$$IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-246336$RANBAXY$Bagal B, Kumar R, Gaur T, Talreja V, Bonda A, Patkar N, et al.. Characterization of therapy related acute leukemia in hereditary breast-ovarian carcinoma patients. Med Oncol. 2020;37(5):48$47$YR$$F$Y$$$20221220$$HP$IN$IN
1779652410$17796524$10$F$$20221129$20200518$20221202$EXP$$US-SHIRE-US202016427$TAKEDA$$$$$F$Y$61$KG$20221202$$HP$US$US
177966205$17796620$5$F$20210702$20221222$20200518$20221230$EXP$$US-SHIRE-US202016406$TAKEDA$$65$YR$$F$Y$90$KG$20221230$$HP$US$US
1779664926$17796649$26$F$20200101$20221006$20200518$20221018$EXP$$CA-CELLTRION INC.-2020CA019873$CELLTRION$$$$$$Y$$$20221018$$MD$CA$CA
177973216$17797321$6$F$20200506$20221021$20200518$20221025$EXP$$NVSC2020CA097237$NOVARTIS$$56$YR$$M$Y$$$20221025$$MD$CA$CA
177976272$17797627$2$F$20200401$20221115$20200518$20221123$PER$$AU-TOLMAR, INC.-20AU021256$TOLMAR$$79$YR$$M$Y$$$20221123$$HP$AU$AU
177979073$17797907$3$F$$20221122$20200518$20221128$PER$$US-PFIZER INC-2020194198$PFIZER$$67$YR$$M$Y$$$20221128$$HP$US$US
177979522$17797952$2$F$20200514$20221209$20200518$20221215$PER$$US-PFIZER INC-2020195630$PFIZER$$68$YR$$M$Y$$$20221215$$HP$US$US
1779834612$17798346$12$F$20190705$20221108$20200518$20221121$EXP$$IT-ROCHE-2598043$ROCHE$$51$YR$$F$Y$81$KG$20221121$$MD$IT$
177989623$17798962$3$F$20170101$20221108$20200518$20221114$EXP$$AU-JNJFOC-20171202386$JOHNSON AND JOHNSON$$35$YR$A$F$Y$$$20221115$$HP$AU$AU
177992292$17799229$2$F$$20221205$20200518$20221215$EXP$$DE-MYLANLABS-2020M1048536$MYLAN$$86$YR$$F$Y$$$20221215$$PH$DE$DE
177994092$17799409$2$F$$20221123$20200518$20221125$PER$$US-SHIRE-US202016536$TAKEDA$$$$$F$Y$58.05$KG$20221125$$CN$US$US
1779961329$17799613$29$F$20200507$20221205$20200518$20221213$EXP$$GB-MYLANLABS-2020M1048584$MYLAN$$93$YR$$F$Y$$$20221213$$MD$GB$GB
177996356$17799635$6$F$20191201$20221025$20200518$20221031$EXP$$NVSC2020CO052266$NOVARTIS$$45$YR$$F$Y$$$20221031$$CN$CO$CO
177996635$17799663$5$F$$20221019$20200518$20221026$PER$$CA-TOLMAR, INC.-20CA021305$TOLMAR$$$$$M$Y$$$20221026$$CN$CA$CA
177999034$17799903$4$F$20190912$20221110$20200518$20221118$EXP$$JP-ELI_LILLY_AND_COMPANY-JP202005005733$ELI LILLY AND CO$$$$I$M$Y$8.3$KG$20221118$$CN$JP$JP
1780045517$17800455$17$F$20200101$20221220$20200519$20221229$EXP$$CA-CELLTRION INC.-2020CA019088$CELLTRION$$$$$$Y$$$20221229$$MD$CA$CA
178005546$17800554$6$F$20200506$20221017$20200518$20221031$EXP$$PL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-038787$BRISTOL MYERS SQUIBB$$60$YR$A$M$Y$87$KG$20221031$$HP$PL$PL
178006395$17800639$5$F$20071215$20221005$20200518$20221006$EXP$$US-NAPPMUNDI-USA-2020-0153181$PURDUE$$52$YR$$M$Y$$$20221006$$CN$US$US
178007632$17800763$2$F$$20220204$20200518$20221026$PER$$US-JAZZ-2018-US-010694$JAZZ$$$$$F$Y$$$20221026$$MD$US$US
178007652$17800765$2$F$$20221101$20200518$20221109$EXP$$US-JAZZ-2020-US-006525$JAZZ$$$$$F$Y$$$20221109$$CN$US$US
1780092824$17800928$24$F$20190101$20220927$20200518$20221009$EXP$$CA-CELLTRION INC.-2019CA025473$CELLTRION$$$$$$Y$$$20221010$$MD$CA$CA
178009568$17800956$8$F$20200301$20220928$20200518$20221003$EXP$$US-BIOGEN-2020BI00869803$BIOGEN$$64$YR$$F$Y$56.75$KG$20221003$$CN$US$US
178011402$17801140$2$F$$20221103$20200519$20221108$EXP$$US-Orion Corporation ORION PHARMA-20_00009093$ORION$Pikman Y, Conway A. Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. Blood Advances. 2020;4(7):1265-9.$15$YR$T$F$Y$$$20221108$$MD$US$
178011553$17801155$3$F$$20221221$20200519$20221224$EXP$$GB-ROCHE-2128769$ROCHE$$80$YR$$F$Y$$$20221224$$CN$GB$
1780120516$17801205$16$F$20180305$20221209$20200519$20221219$EXP$$CA-CELLTRION INC.-2019CA019200$CELLTRION$$$$$$Y$$$20221219$$CN$CA$CA
178014335$17801433$5$F$20200705$20221003$20200519$20221005$PER$$NVSC2020US136065$NOVARTIS$$3$YR$$M$Y$15.4$KG$20221005$$HP$US$US
178015838$17801583$8$F$20190103$20221116$20200519$20221121$EXP$$PHHY2019CA068983$NOVARTIS$$71$YR$$M$Y$$$20221121$$CN$CA$CA
178016332$17801633$2$F$$20221109$20200519$20221116$EXP$$DE-IPCA LABORATORIES LIMITED-IPC-2020-DE-001460$IPCA$$$$$$Y$$$20221116$$CN$DE$DE
178035522$17803552$2$F$$20221109$20200519$20221114$EXP$$CA-PFIZER INC-2020193975$PFIZER$$50$YR$$F$Y$$$20221114$$CN$CA$CA
178035605$17803560$5$F$20210601$20221104$20200519$20221108$EXP$$US-SHIRE-US202016265$TAKEDA$$6$YR$$M$Y$$$20221108$$CN$US$US
1780358625$17803586$25$F$$20221216$20200519$20221223$EXP$$US-SHIRE-US202015966$TAKEDA$$$$$F$Y$65$KG$20221223$$HP$US$US
178035908$17803590$8$F$$20221207$20200519$20221215$EXP$$US-SHIRE-US202016390$TAKEDA$$$$$M$Y$15$KG$20221215$$CN$US$US
178041713$17804171$3$F$$20221011$20200519$20221014$EXP$$CA-GLAXOSMITHKLINE-CA2020AMR082304$GLAXOSMITHKLINE$$$$$$Y$$$20221014$$MD$CA$CA
178043223$17804322$3$F$$20221013$20200519$20221020$EXP$$NVSC2020DE136057$NOVARTIS$$71$YR$$F$Y$69$KG$20221020$$PH$DE$DE
178049175$17804917$5$F$20200424$20221202$20200520$20221216$EXP$$GB-AUROBINDO-AUR-APL-2020-024743$AUROBINDO$$67$YR$$F$Y$82.55$KG$20221217$$CN$GB$GB
1780504320$17805043$20$F$20190416$20221129$20200520$20221208$EXP$$CA-CELLTRION INC.-2018CA024552$CELLTRION$$$$$$Y$$$20221208$$CN$CA$CA
1780643325$17806433$25$F$20190801$20221101$20200520$20221107$EXP$$AR-MYLANLABS-2019M1078025$MYLAN$$45$YR$$F$Y$$$20221107$$CN$AR$AR
178068344$17806834$4$F$$20221215$20200520$20221220$EXP$$CA-ROCHE-2598918$ROCHE$$54$YR$$F$Y$56$KG$20221220$$MD$CA$
178068675$17806867$5$F$20200101$20221004$20200520$20221006$PER$$US-PFIZER INC-2020199767$PFIZER$$55$YR$$F$Y$$$20221006$$CN$US$US
178068822$17806882$2$F$$20221202$20200520$20221206$PER$$US-PFIZER INC-2020199828$PFIZER$$68$YR$$F$Y$$$20221206$$MD$US$US
178069464$17806946$4$F$$20221128$20200520$20221129$PER$$US-PFIZER INC-2020199899$PFIZER$$52$YR$$F$Y$$$20221129$$MD$US$US
178070792$17807079$2$F$20160101$20221128$20200520$20221213$PER$$US-TOLMAR, INC.-20US021012$TOLMAR$$$$E$M$Y$$$20221213$$CN$US$US
178072073$17807207$3$F$20200501$20200604$20200520$20221031$EXP$$NVSC2020LB138351$NOVARTIS$$73$YR$$M$Y$100$KG$20221031$$CN$LB$LB
1780723910$17807239$10$F$20200515$20221011$20200520$20221014$PER$$DE-AMGEN-DEUCT2020080334$AMGEN$$60$YR$A$M$Y$100$KG$20221014$$MD$DE$DE
178078015$17807801$5$F$20200511$20221017$20200520$20221027$EXP$$CA-ROCHE-2604872$ROCHE$$45$YR$$F$Y$$$20221027$$CN$CA$CA
178079322$17807932$2$F$$20221010$20200520$20221011$EXP$$NVSC2020DE137487$NOVARTIS$$79$YR$$F$Y$$$20221011$$MD$DE$DE
178083172$17808317$2$F$20200506$20221102$20200520$20221104$EXP$$CA-ROCHE-2598177$ROCHE$$46$YR$$F$Y$$$20221104$$CN$CA$
178085846$17808584$6$F$20190801$20221021$20200520$20221026$EXP$$NVSC2020CZ138041$NOVARTIS$Pastor Z, Novackova M, Chmel R, Cekal M, Chmel R. Delivery of first child after uterine transplantation in the czech republic - sexual, reproductive and ethical consequences. SEXUOLOGIA. 2019;19(2):15-20$33$YR$$F$Y$$$20221026$$HP$CZ$CZ
1780930515$17809305$15$F$20150604$20221103$20200520$20221109$EXP$$PHHY2015CA064470$NOVARTIS$$70$YR$$F$Y$$$20221109$$CN$CA$CA
178093954$17809395$4$F$$20221019$20200520$20221027$EXP$$NVSC2020CA134094$NOVARTIS$$$$$F$Y$$$20221027$$MD$CA$CA
178095252$17809525$2$F$$20221209$20200521$20221223$EXP$$GR-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247161$RANBAXY$Mosa E, Manouvelou S, Tolia M, Tsoukalas N, Ardavanis A, Stasinopoulou M, et al. Acute leriche syndrome in pancreatic adenocarcinoma: A case report. Curr Med Imaging Rev. 2020;16(5):622-624$57$YR$$M$Y$$$20221223$$HP$GR$GR
1780963712$17809637$12$F$20200201$20221129$20200520$20221205$EXP$$NVSC2020CA051416$NOVARTIS$$31$YR$$M$Y$$$20221205$$CN$CA$CA
1780997525$17809975$25$F$20200101$20221212$20200521$20221219$EXP$$CA-CELLTRION INC.-2020CA021347$CELLTRION$$$$$$Y$$$20221219$$CN$CA$CA
178100984$17810098$4$F$$20221121$20200521$20221123$EXP$$CA-ROCHE-2599567$ROCHE$$58$YR$$F$Y$$$20221123$$HP$CA$
1781020622$17810206$22$F$20200101$20221128$20200521$20221207$EXP$$CA-CELLTRION INC.-2020CA022044$CELLTRION$$$$$$Y$$$20221207$$HP$CA$CA
1781033222$17810332$22$F$20200121$20221207$20200520$20221215$EXP$$CA-CELLTRION INC.-2020CA018310$CELLTRION$$$$$$Y$$$20221216$$HP$CA$CA
178104654$17810465$4$F$20190117$20221103$20200521$20221111$EXP$$BE-ABBVIE-19K-013-3144751-00$ABBVIE$$76$YR$$M$Y$$$20221111$$MD$BE$BE
178114282$17811428$2$F$20200101$20221221$20200521$20221227$PER$$US-PFIZER INC-2020200283$PFIZER$$54$YR$$F$Y$$$20221227$$HP$US$US
178119142$17811914$2$F$$20221114$20200521$20221121$EXP$$JP-PFIZER INC-2020018962$PFIZER$Muto, Y.. A case of methotrexate sodium-associated lymphoproliferative disorder with diffuse large B-cell lymphoma of the lower leg and rapid outcome. The 94th Yamanashi Regional Meeting of the Japanese Dermatological Association. 2019;94th$81$YR$$M$Y$$$20221121$$MD$JP$JP
178120202$17812020$2$F$$20221201$20200521$20221212$EXP$$CN-ROCHE-2603415$ROCHE$PRIVACY P, Wang C Zeng Z, Yang Y and Guo S Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour. DOI: 10.1016/j.jns.2017.04.007. Journal of the Neurological Sciences 2017 Jun 15;377:127-32.$20$YR$$F$Y$$$20221212$$PH$CN$
178120768$17812076$8$F$20190101$20221109$20200521$20221110$EXP$$PHHY2018BR193463$NOVARTIS$$32$YR$$M$Y$90$KG$20221110$$CN$BR$BR
178120947$17812094$7$F$20200228$20221205$20200521$20221208$EXP$$JP-ROCHE-2605687$ROCHE$$56$YR$$M$Y$64$KG$20221208$$MD$JP$JP
1781217311$17812173$11$F$20090101$20220923$20200521$20221007$EXP$$US-PERRIGO-18US016170$PERRIGO$$$$$F$Y$220$KG$20221007$$CN$US$US
178124272$17812427$2$F$20191126$20221128$20200521$20221203$EXP$FR-AFSSAPS-NT20200243$NVSC2020FR138778$NOVARTIS$$44$YR$$F$Y$$$20221203$$PH$FR$FR
1781268513$17812685$13$F$$20221019$20200521$20221028$EXP$$CA-JNJFOC-20200517496$JOHNSON AND JOHNSON$$61$YR$A$M$Y$$$20221028$$HP$CA$CA
1781328815$17813288$15$F$20221205$20221222$20200521$20221229$EXP$$US-SHIRE-US202016961$TAKEDA$$79$YR$$F$Y$45$KG$20221229$$CN$US$US
178134224$17813422$4$F$20220101$20221130$20200521$20221205$EXP$$US-PFIZER INC-2020202017$PFIZER$$68$YR$$F$Y$$$20221205$$CN$US$US
178137922$17813792$2$F$$20220930$20200521$20221010$PER$$US-BIOGEN-2020BI00877769$BIOGEN$$$$$F$Y$$$20221010$$CN$US$US
1781385516$17813855$16$F$20170825$20221020$20200521$20221026$EXP$$PHHY2017CO135492$NOVARTIS$$56$YR$$M$Y$78$KG$20221026$$CN$CO$CO
178143273$17814327$3$F$$20221125$20200522$20221129$PER$$AR-AMGEN-ARGSP2020079479$AMGEN$$24$YR$A$M$Y$$$20221129$$CN$AR$AR
1781442812$17814428$12$F$20200514$20221011$20200522$20221021$EXP$$DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-039282$BRISTOL MYERS SQUIBB$$60$YR$A$M$Y$100$KG$20221021$$HP$DE$DE
178151154$17815115$4$F$$20221124$20200522$20221128$EXP$$AT-ROCHE-2604475$ROCHE$Bohn J. Multiple drugs:Lack of efficacy and off-label use case report. Reactions. 1905;. ;:9999-.$76$YR$$F$Y$$$20221129$$MD$AT$AT
178152332$17815233$2$F$$20221103$20200522$20221116$EXP$$US-Accord-182657$ACCORD$Pikman Y, Conway AS, Robichaud AL, Kitara S, Church AJ, Kennedy AL et al. Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. Blood Advances. 2020;4(7):1265 - 1269.$15$YR$T$F$Y$$$20221116$$MD$US$US
1781525411$17815254$11$F$20200414$20221004$20200522$20221010$EXP$$US-SHIRE-US202016947$TAKEDA$$42$YR$$M$Y$$$20221010$$MD$US$US
1781575611$17815756$11$F$$20221124$20200522$20221129$EXP$$CA-BIOVITRUM-2018CA0739$BIOVITRUM$$40$YR$$M$Y$$$20221129$$MD$CA$CA
178159162$17815916$2$F$$20221031$20200522$20221116$PER$$US-TEVA-2020-US-1238846$TEVA$$$$$M$Y$$$20221115$$CN$US$US
178164913$17816491$3$F$$20221202$20200522$20221202$PER$$US-PFIZER INC-2020201390$PFIZER$$73$YR$$F$Y$$$20221202$$CN$US$US
1781655314$17816553$14$F$20180101$20221018$20200522$20221020$EXP$$US-PFIZER INC-2018175310$PFIZER$$32$YR$$M$Y$$$20221020$$MD$US$US
1781682514$17816825$14$F$20200417$20221003$20200522$20221010$PER$$KR-Eisai Medical Research-EC-2020-074992$EISAI$$77$YR$E$M$Y$63.5$KG$20221010$$MD$KR$
1781686213$17816862$13$F$20200513$20221212$20200522$20221219$EXP$$US-SHIRE-US202016864$TAKEDA$$11$YR$$M$Y$$$20221219$$CN$US$US
178171323$17817132$3$F$$20221207$20200522$20221213$EXP$$US-PFIZER INC-2020201998$PFIZER$$91$YR$$M$Y$$$20221213$$CN$US$US
178171809$17817180$9$F$20200210$20221130$20200522$20221212$EXP$$CA-TAKEDA-2020TUS009512$TAKEDA$$59$YR$$F$Y$$$20221212$$CN$CA$CA
178175152$17817515$2$F$$20221215$20200522$20221222$EXP$$NVSC2020DE135536$NOVARTIS$Schmidt E, Herzog S, Brocker EB, Zillikens D, Goebeler M. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. BRITISH JOURNAL OF DERMATOLOGY. 2005;153(2):449-51$14$YR$$M$Y$40$KG$20221222$$HP$DE$DE
1781814112$17818141$12$F$$20221215$20200522$20221223$EXP$$US-SHIRE-US202016981$TAKEDA$$$$$F$Y$58$KG$20221223$$CN$US$US
1781823510$17818235$10$F$20150527$20220803$20200522$20221013$EXP$$CO-BIOGEN-2020BI00875573$BIOGEN$$44$YR$$F$Y$60$KG$20221013$$CN$CO$CO
178183564$17818356$4$F$20191101$20221219$20200523$20221228$EXP$$IT-TAKEDA-2020TUS023359$TAKEDA$$62$YR$$F$Y$$$20221228$$HP$IT$IT
178183963$17818396$3$F$20191001$20221116$20200522$20221121$EXP$$NVSC2019CA036618$NOVARTIS$$60$YR$$F$Y$$$20221121$$CN$CA$CA
178190492$17819049$2$F$20200201$20221213$20200523$20221223$EXP$FR-AFSSAPS-LL20200663$FR-TEVA-2020-FR-1238594$TEVA$$53$YR$A$F$Y$$$20221223$$MD$FR$FR
1781944761$17819447$61$F$20151101$20221028$20200523$20221103$EXP$$NVSC2019GB056626$NOVARTIS$$59$YR$$M$Y$62$KG$20221103$$MD$GB$GB
178195482$17819548$2$F$$20221010$20200523$20221013$EXP$$NVSC2020DE137051$NOVARTIS$$57$YR$$F$Y$$$20221013$$MD$DE$DE
1781962930$17819629$30$F$20171127$20221223$20200523$20221230$EXP$$PHHY2016CA129250$NOVARTIS$$70$YR$$F$Y$$$20221230$$CN$CA$CA
1781972522$17819725$22$F$20200504$20221122$20200524$20221130$EXP$$US-SHIRE-US202017119$TAKEDA$$69$YR$$F$Y$58$KG$20221130$$HP$US$US
178197563$17819756$3$F$$20201116$20200524$20221208$PER$$US-AMGEN-USASP2020082350$AMGEN$$$$$F$Y$$$20221208$$CN$US$US
178198873$17819887$3$F$$20221117$20200524$20221128$EXP$$DE-TEVA-2020-DE-1234944$TEVA$$$$$M$Y$$$20221126$$CN$DE$DE
178199472$17819947$2$F$$20221214$20200525$20221227$EXP$$IT-AUROBINDO-AUR-APL-2020-019652$AUROBINDO$Crescioli G, Lombardi N, Bettiol A, Menniti-Ippolito F, Da Cas R, Parrilli M, et al.. Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database. Br-J-Clin-Pharmacol. 2020;86(1):106-120$55$YR$$F$Y$$$20221228$$HP$IT$IT
1782028120$17820281$20$F$$20221207$20200525$20221214$EXP$$US-SHIRE-US202017132$TAKEDA$$$$$F$Y$58$KG$20221214$$CN$US$US
178203626$17820362$6$F$$20221227$20200525$20221230$EXP$$US-BIOGEN-2020BI00879102$BIOGEN$$$$$F$Y$$$20221230$$CN$US$US
178204689$17820468$9$F$20170301$20221221$20200525$20221226$EXP$$JP-VIIV HEALTHCARE LIMITED-JP2018JPN232159$VIIV$$$$$$Y$$$20221226$$MD$JP$JP
178206628$17820662$8$F$20200421$20221019$20200525$20221025$EXP$$IL-ABBVIE-20K-082-3413237-00$ABBVIE$$69$YR$$F$Y$64$KG$20221025$$MD$IL$IL
178213725$17821372$5$F$$20221202$20200525$20221208$EXP$$US-SHIRE-US202016950$TAKEDA$$$$$F$Y$82$KG$20221208$$CN$US$US
178215553$17821555$3$F$$20221208$20200525$20221223$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247051$RANBAXY$Pattnaik P, Levin T, Gagne S, Angert R. Case 2: Rapidly Growing Neck Mass in an Extremely Preterm Infant with Pulmonary Hypertension. Neoreviews. 2019;20(4):e226-e228$27$YR$$F$Y$$$20221223$$MD$US$US
1782181422$17821814$22$F$20190320$20220927$20200525$20221007$EXP$$CA-CELLTRION INC.-2019CA020011$CELLTRION$$$$$$Y$$$20221008$$CN$CA$CA
178218464$17821846$4$F$20190418$20221116$20200525$20221123$EXP$$FR-ABBVIE-19K-056-2828363-00$ABBVIE$$$$A$M$Y$122$KG$20221123$$MD$FR$FR
178220966$17822096$6$F$20200520$20221222$20200526$20221227$EXP$$NVSC2020MX142224$NOVARTIS$$36$YR$$F$Y$107$KG$20221227$$CN$MX$MX
178225632$17822563$2$F$20190718$20200519$20200526$20221006$EXP$$CN-SA-2020SA131960$SANOFI AVENTIS$$50$YR$A$M$Y$50$KG$20221006$$HP$CN$CN
178226386$17822638$6$F$$20221114$20200526$20221118$EXP$$CA-AstraZeneca-2020SE67936$ASTRAZENECA$$65$YR$$F$Y$$$20221118$$MD$CA$
178231014$17823101$4$F$$20221021$20200526$20221025$EXP$$CA-ROCHE-2599694$ROCHE$$67$YR$$F$Y$$$20221025$$HP$CA$
178231105$17823110$5$F$$20221220$20200526$20221227$PER$$US-PFIZER INC-2019014153$PFIZER$$29$YR$$F$Y$$$20221227$$CN$US$US
1782332410$17823324$10$F$20200119$20221227$20200526$20221227$EXP$$NVSC2020ES028429$NOVARTIS$$61$YR$$M$Y$95.4$KG$20221227$$MD$ES$ES
178233322$17823332$2$F$$20221208$20200526$20221223$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247053$RANBAXY$Pattnaik P, Levin T, Gagne S, Angert R. Case 2: Rapidly Growing Neck Mass in an Extremely Preterm Infant with Pulmonary Hypertension. Neoreviews. 2019;Apr;20(4):e226-e228$$$I$M$Y$$$20221223$$MD$US$US
178234176$17823417$6$F$20151114$20221027$20200526$20221102$EXP$$CA-ROCHE-1766067$ROCHE$$74$YR$$M$Y$$$20221102$$CN$CA$CA
178235033$17823503$3$F$$20221228$20200526$20221229$EXP$$CA-ROCHE-2607778$ROCHE$$33$YR$$F$Y$$$20221229$$HP$CA$
178235523$17823552$3$F$20200101$20221025$20200526$20221027$PER$$US-PFIZER INC-2020184680$PFIZER$$63$YR$$F$Y$86.168$KG$20221027$$CN$US$US
178240859$17824085$9$F$20200922$20221109$20200526$20221114$EXP$$US-SHIRE-US202017345$TAKEDA$$25$YR$$F$Y$61$KG$20221114$$CN$US$US
178242424$17824242$4$F$20200430$20221102$20200526$20221107$EXP$$US-ASTELLAS-2020US017746$ASTELLAS$$70$YR$$M$Y$$$20221107$$CN$US$US
178248577$17824857$7$F$20200516$20221206$20200526$20221208$EXP$$US-SHIRE-US202016968$TAKEDA$$20$YR$$M$Y$$$20221208$$PH$US$US
1782487511$17824875$11$F$20200518$20221201$20200526$20221208$EXP$$US-SHIRE-US202017237$TAKEDA$$68$YR$$F$Y$47$KG$20221208$$HP$US$US
1782488015$17824880$15$F$20200512$20221115$20200526$20221116$EXP$$US-SHIRE-US202017219$TAKEDA$$29$YR$$M$Y$$$20221116$$CN$US$US
1782539314$17825393$14$F$$20221205$20200526$20221208$PER$$US-PFIZER INC-2020135338$PFIZER$$66$YR$$F$Y$108.84$KG$20221208$$MD$US$US
178257422$17825742$2$F$$20200512$20200526$20221111$EXP$$CA-JNJFOC-20200515682$JOHNSON AND JOHNSON$$72$YR$E$M$Y$$$20221111$$HP$CA$CA
178261565$17826156$5$F$20200514$20221122$20200526$20221129$EXP$$CA-TAKEDA-2020TUS023632$TAKEDA$$65$YR$$M$Y$61.2$KG$20221129$$HP$CA$CA
178263142$17826314$2$F$$20221004$20200527$20221018$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247770$RANBAXY$Terlecki M, Symons YT, Singh I, McConachie I.. Anesthetic management of patients post heart transplant having cesarean delivery: Case study and literature review.. Can J Anesth. 2019;66 (Suppl.)(2):S268-S269 (638130)$36$YR$$F$Y$$$20221018$$HP$US$CA
178263733$17826373$3$F$$20210408$20200526$20221008$PER$$US-NAPPMUNDI-USA-2020-0152540$PURDUE$$$$$M$Y$$$20221008$$CN$US$US
1782663528$17826635$28$F$20180101$20221222$20200527$20221230$EXP$$CA-CELLTRION INC.-2018CA021352$CELLTRION$$$$$$Y$$$20221231$$CN$CA$CA
178269245$17826924$5$F$$20221021$20200526$20221102$EXP$$NVSC2020GB104703$NOVARTIS$$$$A$F$Y$$$20221102$$CN$GB$GB
1782698512$17826985$12$F$20150101$20221129$20200526$20221209$EXP$$NVSC2019DE087107$NOVARTIS$$$$E$F$Y$78$KG$20221209$$MD$DE$DE
178271097$17827109$7$F$20181207$20221026$20200527$20221105$EXP$$AT-CELLTRION INC.-2020AT022577$CELLTRION$$$$$$Y$$$20221105$$MD$AT$AT
178276183$17827618$3$F$20190101$20221004$20200527$20221111$EXP$$DE-AstraZeneca-2020SE68067$ASTRAZENECA$$$$$M$Y$$$20221111$$MD$DE$
178276725$17827672$5$F$$20221213$20200527$20221218$EXP$$CA-ROCHE-2603342$ROCHE$$64$YR$$F$Y$69$KG$20221219$$HP$CA$
178276943$17827694$3$F$20200520$20221006$20200527$20221013$EXP$$DE-EMD Serono-9165327$EMD SERONO INC$$13$YR$T$M$Y$43$KG$20221013$$CN$DE$
178278618$17827861$8$F$20200101$20221103$20200527$20221111$PER$$US-SA-2020SA133894$SANOFI AVENTIS$$25$YR$A$F$Y$$$20221111$$MD$US$US
178281092$17828109$2$F$$20221215$20200527$20221219$EXP$$CA-ROCHE-2605388$ROCHE$$28$YR$$F$Y$68$KG$20221219$$HP$CA$
178283069$17828306$9$F$20181109$20221209$20200527$20221214$EXP$$US-ROCHE-2255442$ROCHE$$54$YR$$F$Y$70.824$KG$20221214$$CN$US$
178284667$17828466$7$F$20200601$20221125$20200527$20221129$EXP$$US-PFIZER INC-2020207835$PFIZER$$73$YR$$F$Y$108.86$KG$20221129$$CN$US$US
178285066$17828506$6$F$$20221219$20200527$20221229$EXP$$US-PFIZER INC-2020208353$MYLAN$$$$$F$Y$$$20221229$$CN$US$US
1782912019$17829120$19$F$$20221209$20200527$20221216$EXP$$US-SHIRE-US202017476$TAKEDA$$$$$M$Y$73$KG$20221216$$HP$US$US
178301127$17830112$7$F$20200519$20221214$20200527$20221220$EXP$$US-PFIZER INC-2020207462$PFIZER$$77$YR$$F$Y$44.91$KG$20221220$$CN$US$US
178306264$17830626$4$F$$20221003$20200527$20221006$PER$$US-PFIZER INC-2020207851$PFIZER$$67$YR$$F$Y$63.5$KG$20221006$$HP$US$US
178306645$17830664$5$F$20181211$20221014$20200527$20221109$PER$$CA-TOLMAR, INC.-20CA021447$TOLMAR$$72$YR$$M$Y$$$20221109$$CN$CA$CA
178309305$17830930$5$F$20200408$20221208$20200527$20221219$EXP$$US-AMNEAL PHARMACEUTICALS-2020-AMRX-01485$AMNEAL$$51$YR$$F$Y$96$KG$20221219$$MD$US$US
178309603$17830960$3$F$20190626$20221207$20200527$20221213$EXP$$CA-JNJFOC-20200519933$JOHNSON AND JOHNSON$$30$YR$A$F$Y$54.5$KG$20221213$$HP$CA$CA
178318836$17831883$6$F$20200101$20221028$20200527$20221102$EXP$$US-ROCHE-2553214$ROCHE$$48$YR$$F$Y$64.922$KG$20221102$$CN$US$US
1783192629$17831926$29$F$20200507$20221122$20200528$20221206$EXP$$GB-AUROBINDO-AUR-APL-2020-026127$AUROBINDO$$93$YR$$F$Y$$$20221206$$MD$GB$GB
1783231631$17832316$31$F$20200415$20221213$20200528$20221221$EXP$$CA-CELLTRION INC.-2019CA025906$CELLTRION$$$$$$Y$$$20221222$$MD$CA$CA
1783240912$17832409$12$F$20201101$20221010$20200528$20221015$EXP$$US-SHIRE-US202017512$TAKEDA$$66$YR$$M$Y$90$KG$20221015$$HP$US$US
178335874$17833587$4$F$$20221220$20200528$20221221$EXP$$CA-ROCHE-2607176$ROCHE$$9$YR$$M$Y$$$20221221$$HP$CA$
178336702$17833670$2$F$$20221212$20200528$20221227$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247795$RANBAXY$Nasomyont N, Hornung LN, Wasserman H.. Intravenous bisphosphonate therapy in children with spinal muscular atrophy. Osteoporos Int. 2020;31(5):995-1000$$$C$M$Y$$$20221227$$HP$US$US
178337443$17833744$3$F$20190827$20221031$20200528$20221104$EXP$$KR-ROCHE-2416417$ROCHE$$68$YR$$F$Y$39$KG$20221103$$MD$KR$
178344716$17834471$6$F$20200101$20221019$20200528$20221026$EXP$$US-ACORDA-ACO_157826_2019$ACORDA$$41$YR$$F$Y$$$20221026$$HP$US$US
178345164$17834516$4$F$$20221209$20200528$20221215$PER$$US-PFIZER INC-2020209227$PFIZER$$74$YR$$F$Y$$$20221215$$HP$US$US
178353592$17835359$2$F$20180701$20221206$20200528$20221214$EXP$$NL-JNJFOC-20190738021$JOHNSON AND JOHNSON$$48$YR$A$M$Y$88$KG$20221214$$CN$NL$NL
178359448$17835944$8$F$20200301$20221218$20200528$20221227$EXP$$GB-BAUSCH-BL-2020-015222$BAUSCH AND LOMB$$66$YR$$F$Y$$$20221227$$PH$GB$GB
1783645013$17836450$13$F$20200103$20221104$20200529$20221115$EXP$$CA-CELLTRION INC.-2019CA028119$CELLTRION$$$$$$Y$$$20221115$$HP$CA$CA
178365352$17836535$2$F$$20221102$20200529$20221107$EXP$$CA-ROCHE-2605054$ROCHE$$$$$F$Y$$$20221107$$CN$CA$
178365533$17836553$3$F$$20200603$20200528$20221125$EXP$$NVSC2020US146246$NOVARTIS$$$$$F$Y$$$20221125$$CN$US$US
178365794$17836579$4$F$20191201$20221011$20200529$20221020$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2019-014973$ACADIA PHARMACEUTICALS$$67$YR$$F$Y$$$20221021$$CN$US$US
178369263$17836926$3$F$$20221202$20200529$20221207$EXP$$CA-ROCHE-2607346$ROCHE$$73$YR$$F$Y$$$20221207$$HP$CA$
178374242$17837424$2$F$$20221017$20200529$20221019$EXP$$CA-ROCHE-2605111$ROCHE$$58$YR$$M$Y$88$KG$20221019$$HP$CA$
1783755411$17837554$11$F$20150201$20221204$20200528$20221207$EXP$$GB-BAUSCH-BL-2020-015423$BAUSCH AND LOMB$$80$YR$$M$Y$77$KG$20221207$$MD$GB$GB
1783805724$17838057$24$F$20190502$20221130$20200528$20221209$EXP$$CA-CELLTRION INC.-2019CA021088$CELLTRION$$$$$$Y$$$20221210$$MD$CA$CA
1783814714$17838147$14$F$20200319$20221118$20200528$20221127$EXP$$CA-CELLTRION INC.-2020CA022087$CELLTRION$$$$$$Y$$$20221128$$CN$CA$CA
1783822718$17838227$18$F$20200522$20221014$20200528$20221024$EXP$$CA-CELLTRION INC.-2020CA022639$CELLTRION$$$$$$Y$$$20221024$$HP$CA$CA
178383239$17838323$9$F$$20221128$20200528$20221202$EXP$$NVSC2020US145789$NOVARTIS$$$$$F$Y$72$KG$20221202$$CN$US$US
178384559$17838455$9$F$20200424$20221025$20200528$20221029$EXP$$NVSC2020PA143954$NOVARTIS$$72$YR$$F$Y$71$KG$20221029$$CN$PA$PA
1783851321$17838513$21$F$20190101$20221220$20200528$20221227$EXP$$NVSC2020CO055412$NOVARTIS$$$$$F$Y$56$KG$20221227$$CN$CO$CO
178385402$17838540$2$F$$20221215$20200529$20221219$EXP$$CA-ROCHE-2605169$ROCHE$$50$YR$$F$Y$118$KG$20221219$$HP$CA$
178385502$17838550$2$F$$20221222$20200528$20221228$EXP$$NVSC2020CA143748$NOVARTIS$$48$YR$$F$Y$$$20221228$$CN$CA$CA
1783855216$17838552$16$F$20190101$20221011$20200528$20221017$EXP$$PHHY2019CA075268$NOVARTIS$$52$YR$$F$Y$$$20221017$$CN$CA$CA
178385859$17838585$9$F$$20221130$20200528$20221203$EXP$$NVSC2020CA142466$NOVARTIS$$$$$M$Y$$$20221203$$CN$CA$CA
178393545$17839354$5$F$20200504$20221206$20200529$20221209$EXP$$NVSC2020US144147$NOVARTIS$$22$YR$$M$Y$80$KG$20221209$$MD$US$US
178394343$17839434$3$F$20200514$20200528$20200529$20221231$PER$$DE-AMGEN-DEUSP2020080600$AMGEN$$$$$$Y$$$20221231$$PH$DE$DE
178394722$17839472$2$F$$20221212$20200529$20221227$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247984$RANBAXY$Barone H, Brockman R, Johnson L, Al-Uzri A, Wright M, Mengden-Koon S, et al.. Trichodysplasia spinulosa mimicking lichen nitidus in a renal transplant patient. Pediatr Transplant. 2019;23(4):e13394$9$YR$$F$Y$$$20221227$$HP$US$US
178394844$17839484$4$F$20200101$20221114$20200529$20221208$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-001485$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221209$$CN$US$US
1783975510$17839755$10$F$20170202$20221213$20200529$20221220$EXP$$CA-ROCHE-2047662$ROCHE$$47$YR$$F$Y$$$20221220$$CN$CA$CA
178403623$17840362$3$F$$20221121$20200529$20221122$EXP$$CA-ROCHE-2605078$ROCHE$$61$YR$$F$Y$72$KG$20221122$$HP$CA$
178403903$17840390$3$F$$20221125$20200529$20221130$EXP$$AU-PFIZER INC-2020208831$PFIZER$Kallukaran, A.. Pneumocystis jiroveci pneumonitis in an infant. Internal Medicine Journal. 2019;49 (Suppl 4):40-41$7$MON$$F$Y$$$20221130$$HP$AU$AU
1784062049$17840620$49$F$20140101$20221227$20200529$20221230$EXP$$CA-PFIZER INC-2020211017$PFIZER$$46$YR$$M$Y$$$20221230$$MD$CA$CA
178407096$17840709$6$F$$20221215$20200529$20221219$EXP$$CA-GLAXOSMITHKLINE-CA2020AMR089325$GLAXOSMITHKLINE$$$$$$Y$$$20221219$$MD$CA$CA
1784071320$17840713$20$F$20151101$20221107$20200529$20221111$EXP$$GB-OTSUKA-2020_013018$OTSUKA$$59$YR$$M$Y$62$KG$20221111$$MD$GB$GB
178407963$17840796$3$F$$20221201$20200529$20221206$EXP$$US-JNJFOC-20200525578$JOHNSON AND JOHNSON$$9$DEC$E$M$Y$$$20221207$$CN$US$US
178409667$17840966$7$F$20200808$20221126$20200529$20221213$PER$$CA-TOLMAR, INC.-20CA021433$TOLMAR$$60$YR$$M$Y$$$20221213$$CN$CA$CA
178410544$17841054$4$F$$20221013$20200529$20221017$PER$$US-PFIZER INC-2020210374$PFIZER$$85$YR$$M$Y$$$20221017$$CN$US$US
178410565$17841056$5$F$$20221201$20200529$20221206$EXP$$US-PFIZER INC-2020210367$PFIZER$$58$YR$$F$Y$$$20221206$$CN$US$US
178410959$17841095$9$F$20200101$20221206$20200529$20221209$PER$$US-PFIZER INC-2020211716$PFIZER$$61$YR$$F$Y$$$20221209$$HP$US$US
178411026$17841102$6$F$$20221205$20200529$20221208$PER$$US-PFIZER INC-2020210182$PFIZER$$58$YR$$F$Y$$$20221208$$CN$US$US
1784124413$17841244$13$F$20200224$20221219$20200529$20221220$EXP$$NVSC2020GB137093$NOVARTIS$$76$YR$$F$Y$$$20221220$$HP$GB$GB
1784127026$17841270$26$F$20200507$20220927$20200529$20221007$EXP$$GB-ELI_LILLY_AND_COMPANY-GB202005007626$ELI LILLY AND CO$$93$YR$$F$Y$$$20221007$$HP$NL$GB
178413425$17841342$5$F$20220831$20221017$20200529$20221019$EXP$$NVSC2020US147828$NOVARTIS$$79$YR$$M$Y$$$20221019$$HP$US$US
178414152$17841415$2$F$$20221215$20200529$20221216$EXP$$CA-ROCHE-2604994$ROCHE$$53$YR$$F$Y$67$KG$20221216$$HP$CA$
178414798$17841479$8$F$20211227$20221205$20200529$20221209$EXP$$US-PFIZER INC-2020211128$PFIZER$$74$YR$$F$Y$68$KG$20221209$$CN$US$US
1784155420$17841554$20$F$20111101$20221224$20200529$20221231$EXP$$GB-BAUSCH-BL-2020-015418$BAUSCH AND LOMB$$59$YR$$M$Y$62$KG$20230101$$MD$GB$GB
178416148$17841614$8$F$$20221118$20200529$20221124$EXP$$US-SHIRE-US202017697$TAKEDA$$$$$M$Y$88$KG$20221124$$CN$US$US
178417524$17841752$4$F$20211115$20221014$20200529$20221031$EXP$$NVSC2020CA147969$NOVARTIS$$69$YR$$M$Y$$$20221031$$CN$CA$CA
178417858$17841785$8$F$20220701$20221028$20200529$20221102$EXP$$NVSC2020CR148516$NOVARTIS$$69$YR$$F$Y$70$KG$20221102$$CN$CR$CR
1784180021$17841800$21$F$20190101$20221024$20200529$20221101$EXP$$US-PFIZER INC-2014130743$PFIZER$$60$YR$$F$Y$62.8$KG$20221101$$CN$US$US
178418063$17841806$3$F$$20221207$20200529$20221207$EXP$$CA-ROCHE-2608326$ROCHE$$59$YR$$F$Y$77$KG$20221207$$HP$CA$
178418192$17841819$2$F$$20221122$20200529$20221123$EXP$$CA-ROCHE-2605286$ROCHE$$83$YR$$F$Y$88$KG$20221123$$HP$CA$
178425775$17842577$5$F$$20221129$20200529$20221216$EXP$$CA-AUROBINDO-AUR-APL-2020-025889$AUROBINDO$Terlecki M, Symons YT, Singh I, McConachie I.. Anesthetic management of patients post heart transplant having cesarean delivery: Case study and literature review.. Can-J-Anesth.. 2019;66 (Suppl. 2):S268-69$36$YR$$F$Y$$$20221214$$HP$CA$CA
178432083$17843208$3$F$20160101$20221130$20200530$20221203$PER$$US-ABBVIE-20K-163-3423621-00$ABBVIE$$$$$F$Y$$$20221203$$CN$US$US
178432094$17843209$4$F$20200713$20221129$20200530$20221205$EXP$$US-ABBVIE-20K-163-3424724-00$ABBVIE$$81$YR$$F$Y$48.988$KG$20221205$$CN$US$US
1784337012$17843370$12$F$$20221214$20200530$20221215$EXP$$CA-ROCHE-2606054$ROCHE$$66$YR$$F$Y$95$KG$20221215$$HP$CA$
178434064$17843406$4$F$$20221216$20200530$20221220$EXP$$CA-ROCHE-2607077$ROCHE$$69$YR$$M$Y$75$KG$20221220$$HP$CA$
178435684$17843568$4$F$$20221130$20200531$20221205$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-026829$BOEHRINGER INGELHEIM$$81$YR$E$M$Y$$$20221205$$MD$ES$ES
1784370116$17843701$16$F$20181211$20221024$20200531$20221101$EXP$$CA-CELLTRION INC.-2018CA024955$CELLTRION$$$$$$Y$$$20221101$$CN$CA$CA
1784381123$17843811$23$F$20191029$20221128$20200531$20221207$EXP$$CA-CELLTRION INC.-2019CA026450$CELLTRION$$$$$$Y$$$20221207$$CN$CA$CA
1784390718$17843907$18$F$20180704$20221027$20200601$20221105$EXP$$CA-CELLTRION INC.-2018CA025315$CELLTRION$$$$$$Y$$$20221105$$HP$CA$CA
178439242$17843924$2$F$$20221004$20200601$20221018$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-248489$RANBAXY$Chin AJ, Rashid S, Gharibeh TR, Kibbe PS, Wynbrandt JH. Interstitial lung disease secondary to long-term nitrofurantoin use. Am J Case Rep. 2020;21:e920386$88$YR$$M$Y$$$20221018$$HP$US$US
178439272$17843927$2$F$$20221212$20200601$20221227$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247964$RANBAXY$Ichikawa S, Fukuhara N, Saito K, Onodera K, Shirai T, Onishi Y, et al. Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series. Int J Hematol. 2020;111(5):667-672$40$YR$$F$Y$$$20221227$$HP$JP$JP
178440912$17844091$2$F$$20200528$20200601$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-042281$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20221222$$HP$CA$CA
178445822$17844582$2$F$$20221212$20200601$20221227$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247962$RANBAXY$Ichikawa S, Fukuhara N, Saito K, Onodera K, Shirai T, Onishi Y, et al. Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series. Int J Hematol. 2020;111(5):667-672$56$YR$$F$Y$$$20221227$$HP$JP$JP
178445862$17844586$2$F$$20221004$20200601$20221018$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247986$RANBAXY$Noor A, Bindal P, Ramirez M, Vredenburgh J.. Chordoma: A case report and review of literature. Am J Case Rep. 2020;Jan 23; 21:e918927$68$YR$$F$Y$$$20221018$$HP$US$US
178445932$17844593$2$F$$20221212$20200601$20221226$EXP$$ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-248121$RANBAXY$Munoz Morales A, Sanchez-Vicente JL, Franco Ruedas C, de Las Morenas Iglesias J, Espineira Perinan MA, Lopez-Herrero F. Macular neurosensory retinal detachment associated with topiramate use. Arch Soc Esp Oftalmol. 2019;Dec; 94(12):614-618$36$YR$$F$Y$$$20221227$$HP$ES$ES
178448742$17844874$2$F$$20221004$20200601$20221018$EXP$$IE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-248221$RANBAXY$McCabe E, Tormey V, Doran JP. Polyethylene glycol: An underrecognized compound in certolizumab pegol and Movicol that may cause anaphylaxis. Rheumatol. 2020;59(4):908-910$37$YR$$F$Y$$$20221018$$HP$IE$IE
1784492818$17844928$18$F$20190510$20221219$20200601$20221227$EXP$$CA-CELLTRION INC.-2019CA018449$CELLTRION$$$$$$Y$$$20221227$$MD$CA$CA
178449513$17844951$3$F$$20221020$20200601$20221021$EXP$$CA-ROCHE-2608944$ROCHE$$53$YR$$F$Y$53$KG$20221021$$HP$CA$
178451769$17845176$9$F$20211009$20221121$20200601$20221129$EXP$$US-SHIRE-US202006457$TAKEDA$$57$YR$$F$Y$114$KG$20221129$$HP$US$US
1784523010$17845230$10$F$$20221102$20200601$20221109$EXP$$US-SHIRE-US202017679$TAKEDA$$$$$F$Y$104.76$KG$20221109$$CN$US$US
178452353$17845235$3$F$$20221122$20200601$20221128$EXP$$NVSC2020CA011545$NOVARTIS$$$$$M$Y$$$20221128$$MD$CA$CA
1784534312$17845343$12$F$$20221010$20200601$20221015$EXP$$US-SHIRE-US202017801$TAKEDA$$$$$F$Y$113$KG$20221015$$HP$US$US
178453472$17845347$2$F$$20221212$20200601$20221227$EXP$$JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-247963$RANBAXY$Ichikawa S, Fukuhara N, Saito K, Onodera K, Shirai T, Onishi Y, et al. Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series. Int J Hematol. 2020;111(5):667-672$45$YR$$F$Y$$$20221227$$HP$JP$JP
178460722$17846072$2$F$$20200524$20200601$20221031$PER$$US-UCBSA-2020021968$UCB$Hussain SA, Asilnejad B, Heesch J, Navarro M, Ji M, Shrey DW, et al. Felbamate in the treatment of refractory epileptic spasms. Epilepsy Research. 2020;161$12$MON$$$Y$$$20221031$$MD$US$US
1784611311$17846113$11$F$20200101$20221130$20200601$20221202$EXP$$US-PFIZER INC-2020213588$PFIZER$$69$YR$$F$Y$$$20221202$$CN$US$US
178462322$17846232$2$F$20220901$20221219$20200601$20221226$EXP$$NVSC2020GB150834$NOVARTIS$$$$A$M$Y$$$20221226$$CN$GB$GB
1784635819$17846358$19$F$20091128$20221116$20200601$20221122$EXP$$PHHY2016CA114707$NOVARTIS$$43$YR$$F$Y$$$20221122$$MD$CA$CA
178469999$17846999$9$F$$20221010$20200601$20221012$PER$$US-PFIZER INC-2020213427$PFIZER$$83$YR$$$Y$$$20221012$$HP$US$US
178470706$17847070$6$F$20171030$20221121$20200601$20221125$EXP$$US-SHIRE-US202017856$TAKEDA$$50$YR$$F$Y$68$KG$20221125$$HP$US$US
178473608$17847360$8$F$$20221220$20200601$20221223$EXP$$CA-ROCHE-2609237$ROCHE$$23$MON$$F$Y$$$20221223$$HP$CA$
1784736411$17847364$11$F$20190723$20221005$20200601$20221013$EXP$$DE-ROCHE-2577243$ROCHE$$$$A$F$Y$125$KG$20221012$$CN$DE$
178474397$17847439$7$F$$20221223$20200601$20221228$EXP$$JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-042667$BRISTOL MYERS SQUIBB$Ogawa K, et al. Experience of ipilimumab/nivolumab combination therapy for metastatic renal cancer in a patient under hemodialysis. The West Japan Urological Association. 2020;82(1):167.$68$YR$E$M$Y$$$20221228$$MD$JP$JP
1784768323$17847683$23$F$20210814$20221206$20200601$20221212$EXP$$US-SHIRE-US202017774$TAKEDA$$50$YR$$F$Y$71$KG$20221212$$MD$US$US
1784782917$17847829$17$F$20200801$20221110$20200601$20221117$EXP$$US-SHIRE-US202017940$TAKEDA$$77$YR$$F$Y$121$KG$20221117$$HP$US$US
178479445$17847944$5$F$20200515$20221129$20200601$20221206$EXP$$ES-SEATTLE GENETICS-2020SGN02372$SEATTLE GENETICS$$28$YR$$M$Y$107$KG$20221206$$MD$ES$ES
178481769$17848176$9$F$20200505$20221202$20200601$20221208$EXP$$US-TAKEDA-2020TUS024317$TAKEDA$$63$YR$$F$Y$68$KG$20221208$$MD$US$US
178484412$17848441$2$F$$20221212$20200602$20221227$EXP$$TH-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-248794$RANBAXY$Patntirapong S, Techanunt C, Limsuvan P. Post-herpetic osteonecrosis of the jaw in a patient on oral ibandronate therapy: A case report. J Med Assoc Thai. 2020;103(4):106-110$58$YR$$F$Y$$$20221227$$HP$TH$TH
178486095$17848609$5$F$$20221103$20200602$20221110$EXP$$CA-ROCHE-2606875$ROCHE$$$$$F$Y$$$20221110$$HP$CA$
1784867011$17848670$11$F$20200101$20221207$20200602$20221214$EXP$$CA-CELLTRION INC.-2020CA021491$CELLTRION$$$$$$Y$$$20221214$$MD$CA$CA
178487182$17848718$2$F$$20221212$20200602$20221227$EXP$$IE-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-248747$RANBAXY$Moloney PB, Hutchinson S, Heskin J, Mulcahy F, Langan Y, Conlon NP, et al. Possible N-methyl-D-aspartate receptor antibody-mediated encephalitis in the setting of HIV cerebrospinal fluid escape. J Neurol. 2020;267(5):1348-1352$41$YR$$M$Y$$$20221227$$HP$IE$IE
178487754$17848775$4$F$20080101$20220417$20200602$20221018$EXP$$NVSC2020DE150363$NOVARTIS$$$$A$F$Y$$$20221018$$MD$DE$DE
178492346$17849234$6$F$20210101$20221027$20200602$20221121$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-001541$ACADIA PHARMACEUTICALS$$$$$F$Y$$$20221121$$CN$US$US
178493757$17849375$7$F$20200101$20221111$20200602$20221206$PER$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-001549$ACADIA PHARMACEUTICALS$$$$$M$Y$89$KG$20221206$$CN$US$US
178494189$17849418$9$F$20200512$20221212$20200602$20221223$PER$$JP-AMGEN-JPNSP2020085522$AMGEN$$82$YR$E$F$Y$41.5$KG$20221223$$MD$JP$JP
178495106$17849510$6$F$20200414$20221012$20200602$20221018$EXP$$NVSC2020CO150715$NOVARTIS$$52$YR$$F$Y$68$KG$20221018$$CN$CO$CO
178497154$17849715$4$F$$20221222$20200602$20221227$EXP$$US-PFIZER INC-2020213541$PFIZER$$61$YR$$F$Y$$$20221227$$HP$US$US
178497336$17849733$6$F$$20221017$20200602$20221019$PER$$US-PFIZER INC-2020214637$PFIZER$$65$YR$$M$Y$74.83$KG$20221019$$CN$US$US
178497653$17849765$3$F$$20221011$20200602$20221013$PER$$US-PFIZER INC-2020214474$PFIZER$$66$YR$$F$Y$90.72$KG$20221013$$CN$US$US
178500697$17850069$7$F$20220922$20221004$20200602$20221011$EXP$$CA-TAKEDA-2020TUS024386$TAKEDA$$38$YR$$M$Y$$$20221011$$CN$CA$CA
178504229$17850422$9$F$20150715$20221110$20200602$20221118$EXP$$PHHY2015CA086396$NOVARTIS$$7$YR$$F$Y$$$20221118$$MD$CA$CA
178506664$17850666$4$F$20200101$20221006$20200602$20221012$EXP$$CA-GLAXOSMITHKLINE-CA2020091418$GLAXOSMITHKLINE$$$$$$Y$$$20221012$$MD$CA$CA
178507452$17850745$2$F$$20221026$20200602$20221107$PER$$US-SA-2020SA138317$SANOFI AVENTIS$$$$A$F$Y$$$20221108$$MD$US$US
178508286$17850828$6$F$$20221013$20200602$20221020$PER$$US-SA-2020SA139585$SANOFI AVENTIS$$76$YR$E$M$Y$$$20221020$$HP$US$US
1785089818$17850898$18$F$20210707$20221216$20200602$20221223$EXP$$US-SHIRE-US202018053$TAKEDA$$54$YR$$F$Y$145$KG$20221223$$HP$US$US
178509904$17850990$4$F$20190616$20221122$20200602$20221124$EXP$$US-SHIRE-US202008152$TAKEDA$$20$YR$$F$Y$55.782$KG$20221124$$HP$US$US
1785140912$17851409$12$F$20210824$20221205$20200602$20221209$EXP$$US-SHIRE-US202018051$TAKEDA$$72$YR$$F$Y$108$KG$20221209$$HP$US$US
178514844$17851484$4$F$20200328$20221021$20200602$20221102$EXP$$FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-248664$RANBAXY$$73$YR$$M$Y$80.6$KG$20221102$$MD$FR$FR
178515022$17851502$2$F$$20200524$20200602$20221031$PER$$US-UCBSA-2020021436$UCB$Garris J, Aungaroon G, Peariso K. Ictal Bradyarrhythmia in a 2-Year-Old Male with Brainstem Embryonal Tumor. Journal of Pediatric Epilepsy. 2020;9(1):18-21$2$YR$$M$Y$$$20221031$$MD$US$US
1785156021$17851560$21$F$20210801$20221220$20200602$20221222$EXP$$US-GLAXOSMITHKLINE-US2020AMR090962$GLAXOSMITHKLINE$$$$$$Y$$$20221222$$HP$US$US
178517594$17851759$4$F$20200101$20221106$20200602$20221110$EXP$$CA-JNJFOC-20190619553$JOHNSON AND JOHNSON$$52$YR$A$F$Y$84.4$KG$20221110$$HP$CA$CA
178522529$17852252$9$F$$20221013$20200602$20221020$EXP$$NVSC2020CL110654$NOVARTIS$$$$$M$Y$$$20221020$$CN$CL$CL
178523272$17852327$2$F$$20200529$20200602$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-042945$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20221222$$HP$CA$CA
178524559$17852455$9$F$20200101$20221025$20200602$20221101$EXP$$US-PFIZER INC-2020215234$PFIZER$$66$YR$$F$Y$$$20221101$$CN$US$US
178525732$17852573$2$F$$20200528$20200603$20221222$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-042290$BRISTOL MYERS SQUIBB$$$$$F$Y$$$20221222$$HP$CA$CA
1785263511$17852635$11$F$$20221019$20200603$20221122$EXP$$CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-042391$BRISTOL MYERS SQUIBB$$67$YR$E$M$Y$70$KG$20221122$$HP$CA$CA
178536357$17853635$7$F$$20221110$20200602$20221115$EXP$$US-SHIRE-US202018027$TAKEDA$$$$$F$Y$69$KG$20221115$$HP$US$US
178537743$17853774$3$F$$20221130$20200603$20221207$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-026980$BOEHRINGER INGELHEIM$$64$YR$A$$Y$$$20221208$$MD$ES$ES
178541502$17854150$2$F$20190101$20221011$20200603$20221014$EXP$$CA-009507513-2006CAN000605$MERCK$$71$YR$$M$Y$$$20221014$$PH$CA$CA
178543757$17854375$7$F$20200501$20221129$20200603$20221202$30DAY$$US-PFIZER INC-2020211892$PFIZER$$5$YR$$M$Y$$$20221202$$CN$US$US
178548243$17854824$3$F$$20221108$20200603$20221110$PER$$US-PFIZER INC-2020215714$PFIZER$$45$YR$$F$Y$$$20221110$$MD$US$US
178548549$17854854$9$F$$20221025$20200603$20221101$EXP$$US-PFIZER INC-2020215175$PFIZER$$66$YR$$F$Y$$$20221101$$CN$US$US
1785486814$17854868$14$F$20150101$20221107$20200603$20221110$PER$$US-PFIZER INC-2020215330$PFIZER$$72$YR$$F$Y$58.97$KG$20221110$$CN$US$US
178549182$17854918$2$F$$20221130$20200603$20221202$PER$$US-PFIZER INC-2020217139$PFIZER$$67$YR$$F$Y$$$20221202$$CN$US$US
178549485$17854948$5$F$20221001$20221117$20200603$20221118$EXP$$US-PFIZER INC-2020217154$PFIZER$$73$YR$$F$Y$$$20221118$$HP$US$US
178551163$17855116$3$F$20180326$20221003$20200603$20221006$PER$$US-GILEAD-2020-0469441$GILEAD$$64$YR$A$M$Y$$$20221005$$LW$US$US
178554346$17855434$6$F$$20221130$20200603$20221206$PER$$US-PFIZER INC-2020217047$PFIZER$$71$YR$$F$Y$$$20221206$$PH$US$US
178554354$17855435$4$F$20191001$20221108$20200603$20221114$EXP$$US-PFIZER INC-2020216910$PFIZER$$59$YR$$M$Y$$$20221114$$HP$US$US
178554403$17855440$3$F$20200301$20221129$20200603$20221205$EXP$FR-AFSSAPS-TS20200425$FR-009507513-2006FRA000313$MERCK$$73$YR$$F$Y$$$20221205$$MD$FR$FR
178554808$17855480$8$F$20191201$20221010$20200603$20221019$PER$$US-VERTEX PHARMACEUTICALS-2020-007346$VERTEX$$32$YR$$F$Y$50$KG$20221019$$PH$US$US
178557584$17855758$4$F$20170101$20221003$20200603$20221004$EXP$$US-TAKEDA-2020TUS024751$TAKEDA$$$$$$Y$$$20221004$$LW$US$US
178557695$17855769$5$F$$20221130$20200603$20221208$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2019-BI-023483$BOEHRINGER INGELHEIM$$64$YR$A$M$Y$$$20221208$$MD$ES$ES
1785603317$17856033$17$F$20200401$20221006$20200603$20221017$EXP$$GB-MYLANLABS-2020M1053583$MYLAN$$57$YR$$M$Y$$$20221017$$HP$GB$GB
178560563$17856056$3$F$$20221130$20200603$20221207$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-027006$BOEHRINGER INGELHEIM$$$$$$Y$$$20221207$$MD$ES$ES
178566092$17856609$2$F$$20221109$20200603$20221116$EXP$$NVSC2020CA154669$NOVARTIS$$39$YR$$M$Y$$$20221116$$CN$CA$CA
178569034$17856903$4$F$20171227$20221019$20200603$20221026$EXP$$PHHY2018CA000716$NOVARTIS$$46$YR$$F$Y$$$20221026$$CN$CA$CA
178571363$17857136$3$F$$20221215$20200603$20221219$EXP$$CA-ROCHE-2606319$ROCHE$$67$YR$$F$Y$68$KG$20221219$$HP$CA$
1785768721$17857687$21$F$20190901$20221020$20200604$20221030$EXP$$CA-CELLTRION INC.-2019CA023780$CELLTRION$$$$$$Y$$$20221030$$MD$CA$CA
178579845$17857984$5$F$20191001$20221010$20200604$20221013$EXP$$US-SA-2020SA140390$SANOFI AVENTIS$$72$YR$E$F$Y$99.773$KG$20221013$$MD$US$US
178580217$17858021$7$F$$20221201$20200604$20221205$EXP$$CA-ROCHE-2606496$ROCHE$$58$YR$$F$Y$$$20221205$$CN$CA$
1785802963$17858029$63$F$20151101$20221127$20200604$20221212$EXP$$GB-AUROBINDO-AUR-APL-2020-026911$AUROBINDO$$59$YR$$M$Y$62$KG$20221212$$MD$GB$GB
178581488$17858148$8$F$20200601$20221221$20200604$20221227$EXP$$CA-TAKEDA-2020TUS007860$TAKEDA$$55$YR$$M$Y$$$20221227$$CN$CA$CA
1785815213$17858152$13$F$20200517$20221112$20200604$20221117$EXP$$US-ROCHE-2603956$ROCHE$$19$YR$$M$Y$116.8$KG$20221117$$MD$US$
178581917$17858191$7$F$20170101$20221014$20200604$20221021$EXP$$PHHY2017CA126536$NOVARTIS$$$$$F$Y$$$20221021$$CN$CA$CA
1785889610$17858896$10$F$$20221219$20200604$20221227$EXP$$US-SHIRE-US202018368$TAKEDA$$$$$F$Y$54$KG$20221227$$HP$US$US
1785901511$17859015$11$F$20200520$20221130$20200604$20221206$EXP$$CA-ROCHE-2496099$ROCHE$$47$YR$$F$Y$$$20221206$$CN$CA$
1785908216$17859082$16$F$$20221216$20200604$20221222$EXP$$CA-ROCHE-2606894$ROCHE$$43$YR$$F$Y$97$KG$20221222$$HP$CA$
178593322$17859332$2$F$$20221212$20200604$20221227$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-248932$RANBAXY$Berman DJ. A case of local anesthetic toxicity that wasn^t: lipid rescue from self-administered benzodiazepine overdose in labor. Int J Obstet Anesth. 2020;May; 42:109-111$32$YR$$F$Y$$$20221227$$HP$US$US
178593342$17859334$2$F$$20221004$20200604$20221018$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-248933$RANBAXY$Koslow M, Bennji SM, Griffith-Richards S, Ahmad K, Johnson GB, Ryu JH, et al. A 48-Year-Old South African Woman with Rheumatoid Arthritis and Lung Nodules. Chest. 2020;May; 157(5):e151-e155$48$YR$$F$Y$$$20221018$$MD$US$ZA
178593482$17859348$2$F$$20221004$20200604$20221018$EXP$$BR-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-248796$RANBAXY$Cafezeiro CRF, Lopes MP, Silva CT, Avila MS, Seguro LFBC, Mangini S, et al. Epipericardial fat necrosis as cause of chest pain in patient after heart transplantation. Am J Transplant. 2020;20(5):1451-1453$39$YR$$F$Y$$$20221018$$HP$BR$BR
178594353$17859435$3$F$20200429$20221111$20200604$20221116$EXP$FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-042899$FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-042899$BRISTOL MYERS SQUIBB$$61$YR$A$F$Y$76.9$KG$20221116$$MD$FR$FR
178597233$17859723$3$F$$20221021$20200604$20221025$EXP$$US-PFIZER INC-2020218336$PFIZER$$77$YR$$F$Y$$$20221025$$CN$US$US
178597685$17859768$5$F$$20221123$20200604$20221128$PER$$US-PFIZER INC-2020218858$PFIZER$$46$YR$$F$Y$$$20221128$$CN$US$US
178598058$17859805$8$F$20220801$20221124$20200604$20221130$PER$$US-PFIZER INC-2020218372$PFIZER$$60$YR$$F$Y$59.87$KG$20221130$$CN$US$US
1785983312$17859833$12$F$$20221206$20200604$20221210$EXP$$CA-ROCHE-2606396$ROCHE$$58$YR$$F$Y$$$20221210$$HP$CA$
178601543$17860154$3$F$$20221129$20200604$20221207$EXP$RO-FMX-PRM-05-LIT$RO-drreddys-GER/ROM/20/0123515$DR REDDYS$S?ndulescu O, Streinu-Cercel A, Oan? AA, Streinu-Cercel A.Repeated systemic infections unveiling a silent colon cancer. Romanian Archives of Microbiology and Immunology. 2018;77(4):301-304.$72$YR$E$F$Y$$$20221208$$MD$RO$RO
178601973$17860197$3$F$$20221111$20200604$20221125$EXP$$RO-MACLEODS PHARMACEUTICALS US LTD-MAC2020026671$MACLEODS$$$$$$Y$$$20221124$$MD$RO$RO
178603574$17860357$4$F$20170101$20221011$20200604$20221014$EXP$$US-PFIZER INC-2020218250$PFIZER$$48$YR$$F$Y$$$20221014$$LW$US$US
178604722$17860472$2$F$$20221011$20200604$20221014$EXP$$CA-009507513-2006CAN000624$MERCK$$$$$$Y$$$20221014$$CN$CA$CA
178607263$17860726$3$F$20200101$20221013$20200604$20221019$PER$$US-SA-2020SA143098$SANOFI AVENTIS$$49$YR$A$F$Y$$$20221019$$MD$US$US
178611805$17861180$5$F$$20221111$20200604$20221116$EXP$$US-PFIZER INC-2020216505$PFIZER$Eudaley, S.. Case report: Successful treatment of suspected kratom-induced serotonin syndrome. Journal of the American College of Clinical Pharmacy. 2020;3(1):347$63$YR$$M$Y$102$KG$20221116$$PH$US$US
178613274$17861327$4$F$20221217$20221223$20200604$20221227$EXP$$US-PFIZER INC-2020218374$PFIZER$$83$YR$$M$Y$$$20221227$$CN$US$US
178613693$17861369$3$F$$20221130$20200604$20221208$EXP$$ES-B.I. Pharmaceuticals,Inc./Ridgefield-2020-BI-026962$BOEHRINGER INGELHEIM$Calvo J, Rebollo M, Amarilla I, Fernandez N, Sancho L. Real world use of idarucizumab for dabigatran reversal in Aragon (Spain). Journal of Cardiology + Current Research. 2020 Dec 19;13:6154-161.$54$YR$A$$Y$$$20221208$$MD$ES$ES
178617113$17861711$3$F$$20221031$20200604$20221110$EXP$DE-ADRED-04558-01$DE-ABBVIE-20K-062-3431630-00$ABBVIE$$67$YR$$F$Y$63$KG$20221110$$PH$DE$DE
178618354$17861835$4$F$20190730$20221213$20200604$20221219$EXP$$CA-TAKEDA-2019TUS046356$TAKEDA$$58$YR$$M$Y$$$20221219$$CN$CA$CA
1786194339$17861943$39$F$20151101$20221002$20200604$20221017$EXP$$GB-ELI_LILLY_AND_COMPANY-GB202005010189$ELI LILLY AND CO$$59$YR$$M$Y$62$KG$20221017$$CN$GB$GB
178620233$17862023$3$F$20200519$20221025$20200604$20221027$EXP$$CA-JNJFOC-20200536457$JOHNSON AND JOHNSON$$39$YR$A$F$Y$69$KG$20221027$$HP$CA$CA
1786205918$17862059$18$F$20220912$20221114$20200604$20221118$EXP$$US-SHIRE-US202018022$TAKEDA$$73$YR$$F$Y$56.689$KG$20221118$$CN$US$US
178621882$17862188$2$F$20191121$20221013$20200604$20221017$EXP$DE-ADRED-04580-01$DE-BAUSCH-BL-2020-015989$BAUSCH AND LOMB$$73$YR$$F$Y$74$KG$20221018$$PH$DE$DE
178626128$17862612$8$F$20200101$20221006$20200605$20221019$EXP$$JP-ABBVIE-20K-087-3378110-00$ABBVIE$$75$YR$$M$Y$43$KG$20221019$$CN$JP$JP
178632417$17863241$7$F$$20221017$20200604$20221027$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-18315$SAMSUNG BIOEPIS$$45$YR$A$F$Y$83$KG$20221027$$HP$CA$CA
178635785$17863578$5$F$20200501$20221012$20200604$20221021$EXP$$US-SHIRE-US202018221$TAKEDA$$26$YR$$F$Y$68$KG$20221021$$HP$US$US
178636882$17863688$2$F$20200530$20200601$20200605$20221228$PER$$US-AMGEN INC.-USASP2020087609$AMGEN$$40$YR$A$F$Y$$$20221228$$PH$US$US
178637716$17863771$6$F$20171130$20221004$20200605$20221012$EXP$$US-AstraZeneca-2020SE70677$ASTRAZENECA$$20532$DY$$M$Y$111.1$KG$20221012$$LW$US$
178638562$17863856$2$F$$20221216$20200605$20221230$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-249262$RANBAXY$Woolum JA, Hays WB, Patel KH. Use of fomepizole, n-acetylcysteine, and hemodialysis for massive acetaminophen overdose. Am J Emerg Med. 2020;Mar38(3):P692.E5-692.E7$55$YR$$M$Y$$$20221230$$HP$US$US
178641677$17864167$7$F$20210801$20221212$20200605$20221219$EXP$$BR-GLAXOSMITHKLINE-BR2020AMR093371$GLAXOSMITHKLINE$$$$$$Y$$$20221214$$MD$BR$BR
178646813$17864681$3$F$20220901$20221031$20200605$20221109$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-001605$ACADIA PHARMACEUTICALS$$84$YR$$M$Y$$$20221110$$CN$US$US
178648364$17864836$4$F$$20221116$20200605$20221118$EXP$$US-KYOWAKIRIN-2020BKK009142$KYOWA$$$$$$Y$$$20221118$$CN$US$US
178648453$17864845$3$F$20200529$20221021$20200605$20221026$EXP$$US-SHIRE-US202018480$TAKEDA$$18$YR$$M$Y$$$20221026$$MD$US$US
178655584$17865558$4$F$$20221215$20200605$20221221$EXP$$US-PFIZER INC-2020220414$PFIZER$$76$YR$$F$Y$$$20221221$$CN$US$US
178657652$17865765$2$F$20200429$20221121$20200605$20221201$EXP$FR-AFSSAPS-NY20200802$FR-TEVA-2020-FR-1244761$TEVA$$61$YR$A$F$Y$$$20221201$$MD$FR$FR
178657735$17865773$5$F$20200221$20221220$20200605$20221227$EXP$$DE-PFIZER INC-2020217797$PFIZER$$81$YR$$F$Y$55$KG$20221227$$MD$DE$DE
178658176$17865817$6$F$20200101$20221201$20200605$20221206$PER$$US-PFIZER INC-2019209339$PFIZER$$78$YR$$M$Y$104$KG$20221206$$MD$US$US
178658925$17865892$5$F$$20221201$20200605$20221208$30DAY$$US-PFIZER INC-2020219776$PFIZER$$78$YR$$F$Y$$$20221208$$MD$US$US
178659026$17865902$6$F$$20221110$20200605$20221115$PER$$US-PFIZER INC-2020219952$PFIZER$$81$YR$$F$Y$$$20221115$$MD$US$US
178659322$17865932$2$F$20220603$20221025$20200605$20221028$PER$$US-PFIZER INC-2020220160$PFIZER$$69$YR$$F$Y$$$20221028$$CN$US$US
178659406$17865940$6$F$20200401$20221110$20200605$20221114$EXP$$US-PFIZER INC-2020220493$PFIZER$$68$YR$$F$Y$63.5$KG$20221114$$HP$US$US
1786605712$17866057$12$F$20210115$20221208$20200605$20221212$EXP$$CA-TAKEDA-2020TUS024971$TAKEDA$$55$YR$$F$Y$$$20221212$$HP$CA$CA
178662303$17866230$3$F$20160601$20221010$20200605$20221014$EXP$$US-SA-2020SA144112$SANOFI AVENTIS$$70$YR$E$F$Y$$$20221014$$MD$US$US
178662853$17866285$3$F$20200115$20221010$20200605$20221013$EXP$$US-SA-2020SA144104$SANOFI AVENTIS$$73$YR$E$F$Y$$$20221013$$MD$US$US
178663445$17866344$5$F$20210726$20221019$20200605$20221021$EXP$$US-SHIRE-US202017959$TAKEDA$$8$YR$$M$Y$$$20221021$$CN$US$US
178669635$17866963$5$F$$20221012$20200605$20221020$EXP$$CA-SAMSUNG BIOEPIS-SB-2020-18324$SAMSUNG BIOEPIS$$22$YR$A$F$Y$119$KG$20221020$$CN$CA$CA
178671395$17867139$5$F$$20200804$20200605$20221013$EXP$$US-GILEAD-2020-0469805$GILEAD$$51$YR$A$F$Y$$$20221013$$HP$US$US
178671533$17867153$3$F$20200301$20221010$20200605$20221013$EXP$$US-SA-2020SA144102$SANOFI AVENTIS$$87$YR$E$F$Y$$$20221013$$MD$US$US
178674765$17867476$5$F$20200405$20221024$20200605$20221031$EXP$$JP-ELI_LILLY_AND_COMPANY-JP202005011576$ELI LILLY AND CO$$34$YR$$M$Y$$$20221031$$CN$JP$JP
178681452$17868145$2$F$$20221101$20200605$20221102$PER$$NVSC2020US033207$NOVARTIS$$$$$M$Y$$$20221102$$CN$US$US
178681557$17868155$7$F$$20221124$20200605$20221218$EXP$$CA-ROCHE-2607024$ROCHE$$41$YR$$M$Y$90$KG$20221219$$HP$CA$
178683858$17868385$8$F$20200512$20221219$20200606$20221223$EXP$$IL-ABBVIE-20K-082-3430808-00$ABBVIE$$73$YR$$M$Y$83.3$KG$20221223$$MD$IL$IL
1786845915$17868459$15$F$20100629$20221005$20200606$20221018$EXP$$GB-MACLEODS PHARMACEUTICALS US LTD-MAC2020026669$MACLEODS$$$$$$Y$$$20221017$$HP$GB$GB
1786846352$17868463$52$F$$20221024$20200606$20221027$EXP$$GB-ABBVIE-20K-167-3433813-00$ABBVIE$$57$YR$$M$Y$$$20221027$$HP$GB$GB
178685563$17868556$3$F$20200429$20221130$20200606$20221212$EXP$FR-AFSSAPS-NY20200802$FR-Accord-184284$ACCORD$$61$YR$A$F$Y$76.9$KG$20221212$$MD$FR$FR
178686253$17868625$3$F$$20221011$20200606$20221014$EXP$$ES-009507513-2006ESP001139$MERCK$Fuentes-Antras J, Peinado P, Guevara-Hoyer K, Diaz C, Sanchez-Ramon S, Agudo C. Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: A case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma. Hematology/ Oncology and Stem Cell Therapy. 2020$75$YR$$M$Y$$$20221014$$HP$ES$ES
1786903028$17869030$28$F$20200312$20221129$20200608$20221208$EXP$$CA-CELLTRION INC.-2019CA022639$CELLTRION$$$$$$Y$$$20221209$$MD$CA$CA
178692644$17869264$4$F$20140901$20221121$20200608$20221123$PER$$US-GILEAD-2020-0470220$GILEAD$$27$YR$T$M$Y$$$20221123$$LW$US$US
178695714$17869571$4$F$20190923$20221003$20200608$20221007$EXP$$US-SA-2020SA145162$SANOFI AVENTIS$$72$YR$E$F$Y$$$20221007$$MD$US$US
178699326$17869932$6$F$$20221119$20200608$20221203$EXP$DE-BFARM-20005981$DE-Accord-184434$ACCORD$$64$YR$A$F$Y$$$20221203$$MD$DE$DE
178700286$17870028$6$F$20200101$20221006$20200608$20221014$EXP$$US-ACADIA PHARMACEUTICALS INC.-ACA-2020-PIM-001610$ACADIA PHARMACEUTICALS$$$$$M$Y$$$20221014$$CN$US$US
178703122$17870312$2$F$$20221008$20200608$20221013$EXP$$CA-ROCHE-2615099$ROCHE$$45$YR$$F$Y$$$20221011$$HP$CA$
178705205$17870520$5$F$20200101$20221209$20200608$20221216$PER$$US-PFIZER INC-2020221868$PFIZER$$63$YR$$F$Y$54.43$KG$20221216$$HP$US$US
178705626$17870562$6$F$$20221012$20200608$20221014$EXP$$US-PFIZER INC-2020222350$PFIZER$$72$YR$$F$Y$$$20221014$$CN$US$US
1787068910$17870689$10$F$20200429$20221226$20200608$20221229$EXP$$NVSC2019CL079097$NOVARTIS$$54$YR$$F$Y$$$20221229$$CN$CL$CL
178709072$17870907$2$F$$20221216$20200608$20221230$EXP$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-249401$RANBAXY$Helal A, Graffeo CS, Perry A, Cheville JC, Link MJ, Pollock BE. Capicua Transcriptional Repressor-Rearranged Undifferentiated Round Cell Sarcoma Metastatic to the Brain Treated with Surgery and Stereotactic Radiosurgery. World Neurosurg. 2020;139:12-19$56$YR$$F$Y$$$20221230$$MD$US$US
178710533$17871053$3$F$$20221108$20200608$20221115$EXP$$NVSC2020CL093221$NOVARTIS$$$$$F$Y$$$20221115$$CN$CL$CL
178710882$17871088$2$F$20200603$20221114$20200608$20221117$PER$$US-TAKEDA-2020TUS025413$TAKEDA$$66$YR$$F$Y$104$KG$20221117$$MD$US$US
178713953$17871395$3$F$20200528$20221207$20200608$20221209$EXP$$US-SHIRE-US202018098$TAKEDA$$14$YR$$M$Y$$$20221209$$PH$US$US
1787157318$17871573$18$F$20180925$20221129$20200608$20221208$EXP$$PHHY2018CA111609$NOVARTIS$$78$YR$$F$Y$$$20221208$$CN$CA$CA
1787161613$17871616$13$F$20210714$20221020$20200608$20221025$EXP$$US-GLAXOSMITHKLINE-US2020AMR092292$GLAXOSMITHKLINE$$$$$$Y$$$20221025$$HP$US$US
178720522$17872052$2$F$$20200218$20200608$20221006$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-237865$RANBAXY$$$$E$F$Y$$$20221006$$CN$US$US
178720552$17872055$2$F$$20200304$20200608$20221006$PER$$US-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-239633$RANBAXY$$$$A$F$Y$$$20221006$$CN$US$US
1787207012$17872070$12$F$$20221121$20200608$20221124$EXP$$US-PFIZER INC-2020222188$PFIZER$$63$YR$$M$Y$108.86$KG$20221124$$CN$US$US
178720954$17872095$4$F$20191001$20221114$20200608$20221117$EXP$$US-SA-2020SA145168$SANOFI AVENTIS$$52$YR$A$M$Y$$$20221117$$LW$US$US
178721563$17872156$3$F$$20221213$20200608$20221218$EXP$$CN-ROCHE-2617076$ROCHE$$29$YR$$F$Y$$$20221219$$MD$CN$
178721794$17872179$4$F$20170101$20221018$20200608$20221020$EXP$$US-GILEAD-2020-0469729$GILEAD$$$$A$M$Y$$$20221019$$LW$US$US
178722826$17872282$6$F$20190501$20200929$20200608$20221104$PER$$NVSC2020US153774$NOVARTIS$$79$YR$$F$Y$$$20221104$$CN$US$US
178723194$17872319$4$F$20200111$20221114$20200608$20221115$EXP$$NVSC2020DE153619$NOVARTIS$$$$A$M$Y$$$20221115$$CN$DE$DE
178726444$17872644$4$F$20190101$20220928$20200608$20221002$EXP$$US-SA-2020SA145755$SANOFI AVENTIS$$80$YR$E$F$Y$$$20221003$$MD$US$US
178729914$17872991$4$F$20200120$20221025$20200608$20221027$EXP$$BE-GILEAD-2020-0448581$GILEAD$$$$A$F$Y$73.3$KG$20221027$$HP$BE$BE
178731137$17873113$7$F$$20221017$20200608$20221021$EXP$$US-SHIRE-US202018899$TAKEDA$$$$$F$Y$77$KG$20221021$$CN$US$US
178734703$17873470$3$F$20200429$20221111$20200609$20221125$EXP$$FR-AUROBINDO-AUR-APL-2020-027299$AUROBINDO$$61$YR$$F$Y$76.9$KG$20221125$$MD$FR$FR
178736357$17873635$7$F$20191231$20221018$20200609$20221031$EXP$$IL-ABBVIE-20K-082-3342541-00$ABBVIE$$84$YR$$F$Y$$$20221031$$MD$IL$IL
178737382$17873738$2$F$$20221202$20200609$20221212$PER$$US-JNJFOC-20200607487$JOHNSON AND JOHNSON$$$$$$Y$$$20221213$$CN$US$US
1787386616$17873866$16$F$$20220919$20200609$20221003$EXP$$CA-UCBSA-2020021854$UCB$$59$YR$$F$Y$68$KG$20221003$$HP$CA$CA
178740824$17874082$4$F$20140526$20210712$20200609$20221104$EXP$$US-GILEAD-2020-0469972$GILEAD$$58$YR$A$M$Y$$$20221104$$LW$US$US
178742074$17874207$4$F$$20221111$20200609$20221123$EXP$$US-LUPIN PHARMACEUTICALS INC.-2020-02668$LUPIN$Eudaley ST, Hamilton LA. Case report: Successful treatment of suspected kratom induced serotonin syndrome. Journal of the American College of Clinical Pharmacy. 2020;3:347$63$YR$$M$Y$102.5$KG$20221123$$PH$US$US
178742965$17874296$5$F$20190701$20221005$20200609$20221007$EXP$$US-SA-2020SA145506$SANOFI AVENTIS$$66$YR$E$F$Y$$$20221007$$MD$US$US
178742983$17874298$3$F$20181001$20221010$20200609$20221013$EXP$$US-SA-2020SA145674$SANOFI AVENTIS$$78$YR$E$F$Y$$$20221013$$MD$US$US
178744653$17874465$3$F$20191121$20221205$20200609$20221213$EXP$$DE-MYLANLABS-2020M1054826$MYLAN$$73$YR$$F$Y$74$KG$20221213$$PH$DE$DE
178749317$17874931$7$F$20200401$20221108$20200609$20221110$PER$$US-PFIZER INC-2020134378$PFIZER$$15$YR$$M$Y$57.15$KG$20221110$$CN$US$US
1787494813$17874948$13$F$$20221024$20200609$20221026$PER$$US-PFIZER INC-2020223718$PFIZER$$67$YR$$M$Y$87.09$KG$20221026$$CN$US$US
178751012$17875101$2$F$20191121$20221119$20200609$20221202$EXP$DE-BFARM-20005984$DE-Accord-184404$ACCORD$$73$YR$E$F$Y$74$KG$20221202$$PH$DE$DE
